PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Huang, SS; Tang, FM; Huang, YH; Liu, IH; Hsu, SC; Chen, ST; Huang, JS				Huang, SS; Tang, FM; Huang, YH; Liu, IH; Hsu, SC; Chen, ST; Huang, JS			Cloning, expression, characterization, and role in autocrine cell growth of cell surface retention sequence binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIS GENE-PRODUCT; V-SIS; EXTRACELLULAR-MATRIX; TRANSFORMED CELLS; ONCOGENE PRODUCT; MICE LACKING; FACTOR VEGF; IN-VIVO; B-CHAIN; RECEPTOR	Cell surface retention sequence binding protein-1 (CRSBP-1) is a cell surface binding protein for the cell surface retention sequence (CRS) motif of the v-sis gene product (platelet-derived growth factor-BB). It has been shown to be responsible for cell surface retention of the v-sis gene product in v-sis-transformed cells ( fibroblasts) and has been hypothesized to play a role in autocrine growth and transformation of these cells. Here we demonstrate that the CRSBP-1 cDNA cloned from bovine liver libraries encodes a 322-residue type I membrane protein containing a 23-residue signal peptide, a 215-residue cell surface domain, a 21-residue transmembrane domain, and a 63-residue cytoplasmic domain. CRSBP-1 expressed in transfected cells is an similar to 120-kDa disulfide-linked homodimeric glycoprotein and exhibits dual ligand (CRS-containing growth regulators (v-sis gene product and insulin-like growth factor binding protein-3, IGFBP-3) and hyaluronic acid) binding activity. CRSBP-1 overexpression (by stable transfection of cells with CRSBP-1 cDNA) enhances autocrine loop signaling, cell growth, and tumorigenicity ( in mice) of v-sis-transformed cells. CRSBP-1 expression also enhances autocrine cell growth mediated by IGFBP-3 in human lung carcinoma cells (H1299 cells), which express very little, if any, endogenous CRSBP-1 and exhibits a mitogenic response to exogenous IGFBP-3, stably transfected with IGFBP-3 cDNA. However, CRSBP-1 overexpression does not affect growth of normal and transformed cells that do not produce these CRS-containing growth regulators. These results suggest that CRSBP-1 plays a role in autocrine regulation of cell growth mediated by growth regulators containing CRS.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Taipei Med Univ, Dept Biochem, Taipei 110, Taiwan	Saint Louis University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Medical University	Huang, SS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangss@slu.edu; huangjs@slu.edu			NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Assmann V, 1998, J CELL SCI, V111, P1685; BACH LA, 1992, DIABETES METAB REV, V8, P229, DOI 10.1002/dmr.5610080304; Baghdiguian S, 1996, EUR J CANCER, V32A, P525, DOI 10.1016/0959-8049(95)00588-9; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; Boensch C, 1999, J BIOL CHEM, V274, P10582, DOI 10.1074/jbc.274.15.10582; BOENSCH C, 1995, J BIOL CHEM, V270, P1807, DOI 10.1074/jbc.270.4.1807; BOENSCH C, 1998, THESIS ST LOUIS U ST; BOWENPOPE DF, 1984, BLOOD, V64, P458; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carreira CM, 2001, CANCER RES, V61, P8079; COHICK WS, 1992, ENDOCRINOLOGY, V130, P1508, DOI 10.1210/en.130.3.1508; DAVIS SR, 1992, J ENDOCRINOL, V132, P339, DOI 10.1677/joe.0.1320339; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DEUEL TF, 1984, BLOOD, V64, P951; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; Devi GR, 2000, ENDOCRINOLOGY, V141, P4171, DOI 10.1210/en.141.11.4171; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GARGOSKY SE, 1990, J ENDOCRINOL, V127, P391, DOI 10.1677/joe.0.1270391; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; HELDIN CH, 1985, J CELL SCI, P65; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hofmann M, 1998, J CELL SCI, V111, P1673; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; Huang SS, 1997, FEBS LETT, V416, P297, DOI 10.1016/S0014-5793(97)01213-1; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUANG SS, 2003, IN PRESS FASEB J; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; LEAL SM, 1999, THESIS ST LOUIS U ST; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; Robinson CJ, 2001, J CELL SCI, V114, P853; Schryver B, 1996, ONCOGENE, V13, P333; Sleeman JP, 1997, J BIOL CHEM, V272, P31837, DOI 10.1074/jbc.272.50.31837; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1991, CANCER RES, V51, P5087	72	18	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43855	43869		10.1074/jbc.M306411200	http://dx.doi.org/10.1074/jbc.M306411200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912978	hybrid			2022-12-25	WOS:000186157000136
J	Li, BL; Dedman, JR; Kaetzel, MA				Li, BL; Dedman, JR; Kaetzel, MA			Intron disruption of the annexin IV gene reveals novel transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; FOLATE CARRIER GENE; OPEN READING FRAME; TRANSLATIONAL CONTROL; EXPRESSION; PROTEIN; PROMOTERS; IDENTIFICATION; VARIANTS; SEQUENCE	Annexin IV (AIV), a Ca2+-dependent membrane-binding protein, is expressed in many epithelia. Annexin IV modifies membrane bilayers by increasing rigidity, reducing water and H+ permeability, promoting vesicle aggregation, and regulating ion conductances, all in a Ca2+-dependent manner. We have characterized a mouse in which a gene trap has been inserted into the first intron of annexin IV. Processing of the primary transcript is disrupted. Northern blot and immunoblot data indicated that annexin IV expression was eliminated in many but not all tissues. Immunohistochemical analysis, however, demonstrated that annexin IV expression was eliminated in some cell types, but was unaltered in others. 5'-Rapid amplification of cDNA ends analysis of intestinal and kidney RNA revealed three transcripts, AIVa, AIVb, and AIVc. AIVa is widely distributed. AIVb is expressed only in the digestive tract. AIVc expression is very restricted. A selected number of epithelial cells of unique morphology demonstrate high concentrations. All three transcripts produce an identical annexin IV protein. The different tissue and cell-specific expression profiles of the three transcripts suggest that regulation of both the annexin IV gene expression and the cellular role of the protein are complex. The AIVa(-/-) mouse may become a valuable model to further study transcription and the physiological role of annexin IV.	Univ Cincinnati, Coll Med, Genome Res Inst, Dept Genome Sci, Cincinnati, OH 45237 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45237 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Kaetzel, MA (corresponding author), Univ Cincinnati, Coll Med, Genome Res Inst, Dept Genome Sci, 2180 E Galbraith Rd, Cincinnati, OH 45237 USA.	Marcia.Kaetzel@uc.edu						Bances P, 2000, GENOMICS, V69, P95, DOI 10.1006/geno.2000.6309; Beck CW, 1999, MECH DEVELOP, V88, P221, DOI 10.1016/S0925-4773(99)00217-8; Breslin MB, 2001, MOL ENDOCRINOL, V15, P1381, DOI 10.1210/me.15.8.1381; Carcedo MT, 2001, BIOCHEM J, V356, P571, DOI 10.1042/0264-6021:3560571; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Farber SA, 2003, GENOME RES, V13, P1082, DOI 10.1101/gr.479603; Fukuoka SI, 2002, BBA-GENE STRUCT EXPR, V1575, P148, DOI 10.1016/S0167-4781(02)00299-3; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; HAMMAN HC, 1998, BIOCH BIOPHYS COMMUN, V156, P660; Hanfrey C, 2002, J BIOL CHEM, V277, P44131, DOI 10.1074/jbc.M206161200; Hill WG, 2003, J GEN PHYSIOL, V121, P413, DOI 10.1085/jgp.200308803; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; IMAI Y, 1995, EUR J BIOCHEM, V232, P327, DOI 10.1111/j.1432-1033.1995.tb20815.x; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; KAETZEL MA, 1994, J BIOL CHEM, V269, P5297; Kaetzel MA, 2001, BIOCHEMISTRY-US, V40, P4192, DOI 10.1021/bi002507s; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAETZEL MA, 2002, WILEY ENCY MOL MED, V5, P208; Kos M, 2002, J BIOL CHEM, V277, P37131, DOI 10.1074/jbc.M206325200; KOWN HS, 2001, ARCH BIOCHEM BIOPHYS, V386, P163; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lee J, 2002, NUCLEIC ACIDS RES, V30, P5110, DOI 10.1093/nar/gkf664; Munch C, 2002, J NEUROCHEM, V82, P594, DOI 10.1046/j.1471-4159.2002.01012.x; Sable CL, 1999, BIOCHEM BIOPH RES CO, V258, P162, DOI 10.1006/bbrc.1999.0544; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Seville RA, 2002, DEVELOPMENT, V129, P1693; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; SUAR D, 2002, AM J PHYSIOL, V282, pG349; TAIT JF, 1992, GENOMICS, V12, P313, DOI 10.1016/0888-7543(92)90379-7; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; Whetstine JR, 2002, J BIOL CHEM, V277, P43873, DOI 10.1074/jbc.M208296200; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	36	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43276	43283		10.1074/jbc.M306361200	http://dx.doi.org/10.1074/jbc.M306361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912993	hybrid			2022-12-25	WOS:000186157000070
J	Brewer, L; Corzett, M; Lau, EY; Balhorn, R				Brewer, L; Corzett, M; Lau, EY; Balhorn, R			Dynamics of protamine 1 binding to single DNA molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-AMINO ACIDS; NUCLEIC-ACIDS; CHAIN LENGTHS; SPERM; IDENTIFICATION; CONDENSATION; COMPLEXES; PEPTIDES; PROTEINS; RESIDUES	Protamine molecules bind to and condense DNA in the sperm of most vertebrates, packaging the sperm genome in an inactive state until it can be reactivated following fertilization. By using methods that enable the analysis of protamine binding to individual DNA molecules, we have monitored the kinetics of DNA condensation and decondensation by protamine 1 (P1) and synthetic peptides corresponding to specific segments of the bull P1 DNA binding domain. Our results show that the number of clustered arginine residues present in the DNA binding domain is the most important factor affecting the condensation and stability of the DNA-protamine complex prior to the formation of inter-protamine disulfide cross-links. The high affinity of P1 for DNA is achieved by the coordinated binding of three anchoring domains, which together in bull P1 contain 19 Arg residues. The single DNA molecule experiments show that sequences containing two or more anchoring domains have an off-rate that is at least 3 orders of magnitude slower than those containing a single domain. The use of Arg, rather than Lys residues, and the inclusion of Tyr or Phe residues in the hinge regions between anchoring domains provide additional stability to the complex.	Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Balhorn, R (corresponding author), Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, POB 5508, Livermore, CA 94550 USA.	balhorn2@llnl.gov	Brewer, Laurence/G-4056-2012	Lau, Edmond/0000-0003-0619-7249	NICHD NIH HHS [1K25 HD 01387-03] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K25HD001387] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; BALHORN R, 1992, ARCH BIOCHEM BIOPHYS, V296, P384, DOI 10.1016/0003-9861(92)90588-N; Balhorn R., 1989, P366; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; Balhorn R, 2000, MOL REPROD DEV, V56, P230, DOI 10.1002/(SICI)1098-2795(200006)56:2+<230::AID-MRD3>3.3.CO;2-M; BALHORN R, 1991, BIOCHEMISTRY-US, V30, P175, DOI 10.1021/bi00215a026; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; Brewer L, 2002, J BIOL CHEM, V277, P38895, DOI 10.1074/jbc.M204755200; Brewer LR, 1999, SCIENCE, V286, P120, DOI 10.1126/science.286.5437.120; BRUN F, 1975, BIOCHEMISTRY-US, V14, P558, DOI 10.1021/bi00674a015; BUCK F, 1983, EUR J BIOCHEM, V132, P321, DOI 10.1111/j.1432-1033.1983.tb07365.x; CHIRAT F, 1993, BIOCHIM BIOPHYS ACTA, V1203, P109, DOI 10.1016/0167-4838(93)90043-Q; COLEMAN JE, 1978, BIOCHEMISTRY-US, V17, P5038, DOI 10.1021/bi00616a028; COREY RB, 1953, REV SCI INSTRUM, V24, P621, DOI 10.1063/1.1770803; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Corzett M, 2002, MOL REPROD DEV, V61, P519, DOI 10.1002/mrd.10105; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FEUGHELMAN M, 1955, NATURE, V175, P834, DOI 10.1038/175834a0; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; HUANG XF, 1994, BIOCHEM BIOPH RES CO, V198, P712, DOI 10.1006/bbrc.1994.1103; HUD NV, 1993, BIOCHEM BIOPH RES CO, V193, P1347, DOI 10.1006/bbrc.1993.1773; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KAWASHIMA S, 1978, J BIOCHEM-TOKYO, V84, P343, DOI 10.1093/oxfordjournals.jbchem.a132134; KAWASHIMA S, 1969, BIOCHIM BIOPHYS ACTA, V186, P145, DOI 10.1016/0005-2787(69)90497-3; Kelley LA, 1997, PROTEIN ENG, V10, P737, DOI 10.1093/protein/10.6.737; LOUIE AJ, 1972, J BIOL CHEM, V247, P7962; Mascotti DP, 1997, BIOCHEMISTRY-US, V36, P7272, DOI 10.1021/bi970272n; MAZRIMAS JA, 1986, BIOCHIM BIOPHYS ACTA, V872, P11, DOI 10.1016/0167-4838(86)90141-X; Meistrich M., 1989, HISTONES OTHER BASIC, P165; NAKANO M, 1989, J BIOCHEM-TOKYO, V105, P133, DOI 10.1093/oxfordjournals.jbchem.a122607; OLINS DE, 1967, J MOL BIOL, V24, P157, DOI 10.1016/0022-2836(67)90324-5; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PIRHONEN A, 1994, EUR J BIOCHEM, V223, P165, DOI 10.1111/j.1432-1033.1994.tb18979.x; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; PORSCHKE D, 1978, EUR J BIOCHEM, V86, P291, DOI 10.1111/j.1432-1033.1978.tb12310.x; Prieto MC, 1997, BIOCHEMISTRY-US, V36, P11944, DOI 10.1021/bi971061l; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; SAUTIERE P, 1984, EUR J BIOCHEM, V144, P121, DOI 10.1111/j.1432-1033.1984.tb08439.x; SRIDHARAN S, 1992, FASEB J, V6, pA174; STANDKE KH, 1975, NUCLEIC ACIDS RES, V2, P1839, DOI 10.1093/nar/2.10.1839; TOBITA T, 1988, BIOCHEM INT, V16, P163; Toth G, 2001, PROTEINS, V43, P373, DOI 10.1002/prot.1050; Ward WS, 1996, CRIT REV EUKAR GENE, V6, P139, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.30; WEHLING K, 1975, NUCLEIC ACIDS RES, V2, P799, DOI 10.1093/nar/2.6.799; Wong B, 2002, BIOCHEMISTRY-US, V41, P5404, DOI 10.1021/bi012077l; WORTH GA, 1995, J PHYS CHEM-US, V99, P17473, DOI 10.1021/j100048a025; Zhang XD, 1996, J STRUCT BIOL, V116, P335, DOI 10.1006/jsbi.1996.0051	49	60	67	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42403	42408		10.1074/jbc.M303610200	http://dx.doi.org/10.1074/jbc.M303610200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912999	hybrid			2022-12-25	WOS:000185989500103
J	Deng, XB; Ewton, DZ; Pawlikowski, B; Maimone, M; Friedman, E				Deng, XB; Ewton, DZ; Pawlikowski, B; Maimone, M; Friedman, E			Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIRK PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATOR; TERMINAL DIFFERENTIATION; COLON-CANCER; DYRK FAMILY; MAP KINASE; CELL-CYCLE; SPECIFICITY; MYOD; EXPRESSION	The Rho family of small GTPases regulates numerous signaling pathways that control the organization of the cytoskeleton, transcription factor activity, and many aspects of the differentiation of skeletal myoblasts. We now demonstrate that the kinase Mirk (minibrain-related kinase)/dyrk1B is induced by members of the Rho-family in myoblasts and that Mirk is active in skeletal muscle differentiation. Mirk is an arginine-directed serine/ threonine kinase which is expressed at elevated levels in skeletal muscle compared with other normal tissues. A Mirk promoter construct was activated when C2C12 myoblasts were switched from growth to differentiation medium and was also activated by the Rho family members RhoA, Cdc42, and to a lesser degree Rac1, but not by MyoD or Myf5. Mirk protein levels increased following transient expression of constitutively active Cdc42-QL, RhoA-QL, or Rac1-QL in C2C12 cells. High concentrations of serum mitogens down-regulated Mirk through activation of the Ras-MEK-Erk pathway. As a result, Mirk transcription was induced by the MEK1 inhibitor PD98059 and by the switch from growth to differentiation medium. Mirk was induced with similar kinetics to another Rho-induced differentiation gene, myogenin. Mirk protein levels increased 10-fold within 24 - 48 h after primary cultured muscle cells; C2C12 mouse myoblasts or L6 rat myoblasts were induced to differentiate. Thus Mirk was induced following the commitment stage of myogenesis. Stable overexpression of Mirk enabled myoblasts to fuse more rapidly when placed in differentiation medium. The function of Mirk in muscle differentiation was established by depletion of endogenous Mirk by small interfering RNA, which prevented myoblast fusion into myotubes and inhibited induction of markers of differentiation, including myogenin, fast twitch troponin T, and muscle myosin heavy chain. Other members of the dyrk/minibrain/HIPK family of kinases in lower organisms have been shown to regulate the transition from growth to differentiation, and Mirk is now shown to participate in skeletal muscle development.	SUNY, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA; SUNY, Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College	Friedman, E (corresponding author), SUNY, Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.	friedmae@mail.upstate.edu			NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [CA67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Cabane C, 2003, AM J PHYSIOL-CELL PH, V284, pC658, DOI 10.1152/ajpcell.00078.2002; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Eskinazi R, 1999, AM J PATHOL, V155, P1105, DOI 10.1016/S0002-9440(10)65213-3; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Leder S, 2003, BIOCHEM J, V372, P881, DOI 10.1042/BJ20030182; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 2000, CANCER RES, V60, P3631; Lim S, 2002, J BIOL CHEM, V277, P49438, DOI 10.1074/jbc.M206840200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; Mullen AJ, 2000, GENE, V242, P313, DOI 10.1016/S0378-1119(99)00519-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Neufeld B, 2000, J BIOL CHEM, V275, P20239, DOI 10.1074/jbc.C901040199; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Rhee KH, 1997, J MOL BIOL, V265, P20, DOI 10.1006/jmbi.1996.0708; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Taminato A, 2002, MOL BIOL CELL, V13, P2266, DOI 10.1091/mbc.01-11-0555; Yan ZF, 2002, J BIOL CHEM, V277, P9870, DOI 10.1074/jbc.M107646200	32	65	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41347	41354		10.1074/jbc.M306780200	http://dx.doi.org/10.1074/jbc.M306780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902328	hybrid			2022-12-25	WOS:000185847200115
J	Mana-Capelli, S; Mandal, AK; Arguello, JM				Mana-Capelli, S; Mandal, AK; Arguello, JM			Archaeoglobus fulgidus CopB is a thermophilic Cu2+-ATPase - Functional role of its histidine-rich N-terminal metal binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; WILSONS-DISEASE PROTEIN; MEMBRANE-VESICLES; ESCHERICHIA-COLI; TRANSPORTING ATPASES; COPPER TRANSPORT; CADA; ZNTA; PUMP; METALLOCHAPERONE	P-1B-type ATPases transport heavy metal ions across cellular membranes. Archaeoglobus fulgidus CopB is a member of this subfamily. We have cloned, expressed in Escherichia coli, and functionally characterized this enzyme. CopB and its homologs are distinguished by a metal binding sequence Cys-Pro-His in their sixth transmembrane segment (H6) and a His-rich N-terminal metal binding domain (His-N-MBD). CopB is a thermophilic protein active at 75 degreesC and high ionic strength. It is activated by Cu2+ with high apparent affinity (K-1/2 = 0.28 muM) and partially by Cu+ and Ag+ ( 22 and 55%, respectively). The higher turnover was associated with a faster phosphorylation rate in the presence of Cu2+. A truncated CopB lacking the first 54 amino acids was constructed to characterize the His-N-MBD. This enzyme showed reduced ATPase activity (50% of wild type) but no changes in metal selectivity, ATP dependence, or phosphorylation levels. However, a slower rate of dephosphorylation of the E2P(Cu2+) form was observed for truncated CopB. The data suggest that the presence of the His residue in the putative transmembrane metal binding site of CopB determines a selectivity for this enzyme that is different for that observed in Cu+/Ag+-ATPases carrying a Cys-Pro-Cys sequence. The His-N-MBD appears to have a regulatory role affecting the metal transport rate by controlling the metal release/ dephosphorylation rates.	Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA	Worcester Polytechnic Institute	Arguello, JM (corresponding author), Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA.	arguello@wpi.edu	Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297				Arguello JM, 2003, ANN NY ACAD SCI, V986, P212, DOI 10.1111/j.1749-6632.2003.tb07162.x; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; BLOSTEIN R, 1983, J BIOL CHEM, V258, P7948; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; da Silva J. J. R. Frausto, 2001, BIOL CHEM ELEMENTS; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Fatemi N, 2002, J BIOENERG BIOMEMBR, V34, P339, DOI 10.1023/A:1021245902195; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Okkeri J, 1999, BIOCHEMISTRY-US, V38, P14109, DOI 10.1021/bi9913956; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Scarborough GA, 2002, J BIOENERG BIOMEMBR, V34, P235, DOI 10.1023/A:1020211016696; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tsai KJ, 2002, J BIOENERG BIOMEMBR, V34, P147, DOI 10.1023/A:1016085301323; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258	42	82	84	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40534	40541		10.1074/jbc.M306907200	http://dx.doi.org/10.1074/jbc.M306907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12876283	hybrid			2022-12-25	WOS:000185847200015
J	Yang, YS; Sharma, A; Sharma, R; Patrick, B; Singhal, SS; Zimniak, P; Awasthi, S; Awasthi, YC				Yang, YS; Sharma, A; Sharma, R; Patrick, B; Singhal, SS; Zimniak, P; Awasthi, S; Awasthi, YC			Cells preconditioned with mild, transient UVA irradiation acquire resistance to oxidative stress and UVA-induced apoptosis - Role of 4-hydroxynonenal in UVA-mediated signaling for apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCT; GLUTATHIONE S-TRANSFERASES; TERMINAL KINASE JNK; NF-KAPPA-B; ANTIOXIDANT ENZYMES; HUMAN KERATINOCYTES; SKIN FIBROBLASTS; HUMAN TISSUES; ACTIVATION; PATHWAYS	Because 4-hydroxynonenal (4-HNE) has been suggested to be involved in oxidative stress-mediated apoptosis (Cheng, J.Z., Sharma, R., Yang, Y., Singhal, S. S., Sharma, A., Saini, M. K., Singh, S. V., Zimniak, P., Awasthi, S., and Awasthi, Y. C. ( 2001) J. Biol. Chem. 276, 41213 - 41223) and UVA irradiation also causes lipid peroxidation, we have examined the role of 4-HNE in UVA-mediated apoptosis. K562 cells irradiated with UVA (3.0 milliwatts/cm(2)) for 5, 15, and 30 min showed a time dependent increase in 4-HNE levels. As judged by the activation of caspases, apoptosis was observed only in cells irradiated for 30 min. Within 2 h of recovery in normal medium, 4-HNE levels in 5 and 15 min UVA, irradiated cells returned to the basal or even lower levels but in cells irradiated for 30 min, 4-HNE levels remained consistently higher. The cells irradiated with UVA for 5 min and allowed to recover for 2 h in normal medium (UVA-preconditioned cells) showed a remarkable induction of hGST5.8, which catalyzes conjugation of 4-HNE to glutathione (GSH), and RLIP76 (Ral BP-1), which mediates the transport of the conjugate, GS-HNE. In cells irradiated with UVA for 30 min the induction of RLIP76 or hGST5.8 was not observed. The preconditioned cells transported GS-HNE into the medium at a rate about 2-fold higher than the controls and the transport was inhibited (65%) by coating the cells with anti-RLIP76 IgG. Upon treatment with xanthine/ xanthine oxidase (XA/XO), 4-HNE, or prolonged UVA exposure, the control cells showed a sustained activation of c-Jun N-terminal kinase (JNK) and apoptosis. However, in the UVA-preconditioned cells, apoptosis was not observed, and JNK activation was inhibited. This resistance of preconditioned cells to XA/ XO-, 4-HNE-, or UVA-induced apoptosis could be abrogated when these cells were coated with anti-RLIP76 IgG to block the efflux of GS-HNE. These studies strongly suggest a role of 4-HNE in UVA-mediated apoptosis.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Dept Chem & Biochem, Arlington, TX 76019 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Arlington; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Awasthi, YC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 551 Basic Sci Bldg, Galveston, TX 77555 USA.		Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717	NATIONAL CANCER INSTITUTE [R01CA077495] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004396, R55EY004396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032304] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77495] Funding Source: Medline; NEI NIH HHS [EY 04396] Funding Source: Medline; NIEHS NIH HHS [ES 07804] Funding Source: Medline; NIGMS NIH HHS [GM 32304] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; Awasthi S, 2002, DRUG METAB DISPOS, V30, P1300, DOI 10.1124/dmd.30.12.1300; BEERS RF, 1952, J BIOL CHEM, V195, P133; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P29, DOI 10.1006/abbi.1999.1479; Cheng JZ, 2001, J BIOL CHEM, V276, P41213, DOI 10.1074/jbc.M106838200; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; Cheng JZ, 2001, BIOCHEM BIOPH RES CO, V282, P1268, DOI 10.1006/bbrc.2001.4707; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HATCHARD CG, 1956, PROC R SOC LON SER-A, V235, P518, DOI 10.1098/rspa.1956.0102; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Hu YZ, 2003, J BIOL CHEM, V278, P17299, DOI 10.1074/jbc.M300788200; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kruman I, 1997, J NEUROSCI, V17, P5089; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORLIERE P, 1991, BIOCHIM BIOPHYS ACTA, V1084, P261, DOI 10.1016/0005-2760(91)90068-S; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; Pourzand C, 1999, P NATL ACAD SCI USA, V96, P6751, DOI 10.1073/pnas.96.12.6751; Pourzand C, 1997, CANCER RES, V57, P1405; PUNNONEN K, 1991, J INVEST DERMATOL, V96, P255, DOI 10.1111/1523-1747.ep12462271; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071; Sharutin VV, 2001, RUSS J GEN CHEM+, V71, P79, DOI 10.1023/A:1012385524010; SINGHAL SS, 1994, BBA-PROTEIN STRUCT M, V1204, P279, DOI 10.1016/0167-4838(94)90019-1; Singhal SS, 1999, BIOCHEM ARCH, V15, P163; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VILE GF, 1995, PHOTOCHEM PHOTOBIOL, V62, P463, DOI 10.1111/j.1751-1097.1995.tb02369.x; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yang YS, 2002, TOXICOL APPL PHARM, V182, P105, DOI 10.1006/taap.2002.9450; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200	45	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41380	41388		10.1074/jbc.M305766200	http://dx.doi.org/10.1074/jbc.M305766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888579	hybrid			2022-12-25	WOS:000185847200118
J	Hryciw, DH; Wang, YH; Devuyst, O; Pollock, CA; Poronnik, P; Guggino, WB				Hryciw, DH; Wang, YH; Devuyst, O; Pollock, CA; Poronnik, P; Guggino, WB			Cofilin interacts with ClC-5 and regulates albumin uptake in proximal tubule cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; CHLORIDE CHANNEL; IMPAIRS ENDOCYTOSIS; DENTS-DISEASE; H+-ATPASE; ACTIN; NHE3; PROTEINS; INHIBITION; TRANSPORT	Receptor-mediated endocytosis is a constitutive high capacity pathway for the reabsorption of proteins from the glomerular filtrate by the renal proximal tubule. ClC-5 is a voltage-gated chloride channel found in the proximal tubule where it has been shown to be essential for protein uptake, based on evidence from patients with Dent's disease and studies in ClC-5 knockout mice. To further delineate the role of ClC-5 in albumin uptake, we performed a yeast two-hybrid screen with the C-terminal tail of ClC-5 to identify any interactions of the channel with proteins involved in endocytosis. We found that the C-terminal tail of ClC-5 bound the actin depolymerizing protein, cofilin, a result that was confirmed by GST-fusion pulldown assays. In cultured proximal tubule cells, cofilin was distributed in nuclear, cytoplasmic, and microsomal fractions and co-localized with ClC-5. Phosphorylation of cofilin by overexpressing LIM kinase 1 resulted in a stabilization of the actin cytoskeleton. Phosphorylation of cofilin in two proximal tubule cell models (porcine renal proximal tubule and opossum kidney) was also accompanied by a pronounced inhibition of albumin uptake. This study identifies a novel interaction between the C-terminal tail of ClC-5 and cofilin, an actin-associated protein that is crucial in the regulation of albumin uptake by the proximal tubule.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Catholic Univ Louvain, Sch Med, Div Nephrol, B-1200 Brussels, Belgium; Univ Sydney, Royal N Shore Hosp, Dept Med, St Leonards, NSW 2065, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia	Johns Hopkins University; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Royal North Shore Hospital; University of Sydney; University of Queensland	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.	wguggino@jhmi.edu	Hryciw, Deanne/P-2642-2019	Hryciw, Deanne/0000-0003-1697-8890; Devuyst, Olivier/0000-0003-3744-4767; Poronnik, Philip/0000-0002-6246-528X	NHLBI NIH HHS [HL47122] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Ashworth SL, 2003, AM J PHYSIOL-RENAL, V284, pF852, DOI 10.1152/ajprenal.00210.2002; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; Brown D, 2000, KIDNEY INT, V57, P816, DOI 10.1046/j.1523-1755.2000.00920.x; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; Christensen EI, 2003, P NATL ACAD SCI USA, V100, P8472, DOI 10.1073/pnas.1432873100; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Drumm K, 2001, EUR J MED RES, V6, P422; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gekle M, 2002, AM J PHYSIOL-RENAL, V283, pF549, DOI 10.1152/ajprenal.00206.2001; Gekle M, 1997, AM J PHYSIOL-RENAL, V272, pF668, DOI 10.1152/ajprenal.1997.272.5.F668; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Jung JH, 2002, J BIOL CHEM, V277, P48931, DOI 10.1074/jbc.M208806200; Khurana S, 2000, J MEMBRANE BIOL, V178, P73, DOI 10.1007/s002320010016; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Kim M, 2002, BIOCHIMIE, V84, P1021, DOI 10.1016/S0300-9084(02)00004-4; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Lawler S, 1999, CURR BIOL, V9, pR800, DOI 10.1016/S0960-9822(99)80493-X; Lee K, 2001, BIOCHEM J, V353, P377, DOI 10.1042/0264-6021:3530377; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moulin P, 2003, KIDNEY INT, V63, P1285, DOI 10.1046/j.1523-1755.2003.00851.x; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; NEGOESCU A, 1994, J HISTOCHEM CYTOCHEM, V42, P433, DOI 10.1177/42.3.7508473; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Ponting CP, 1997, J MOL MED-JMM, V75, P160; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rueckschloss U, 2001, J PHYSIOL-LONDON, V537, P363, DOI 10.1111/j.1469-7793.2001.00363.x; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; SCHWEGLER JS, 1991, PFLUG ARCH EUR J PHY, V418, P383, DOI 10.1007/BF00550876; Shabahang S, 2002, BIOCHEM BIOPH RES CO, V298, P408, DOI 10.1016/S0006-291X(02)02483-X; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; Wang SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/hmg/9.20.2937; Weinman EJ, 2001, KIDNEY INT, V60, P450, DOI 10.1046/j.1523-1755.2001.060002450.x; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Wohlfarth V, 2003, KIDNEY INT, V63, pS103, DOI 10.1046/j.1523-1755.63.s84.13.x; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Zhai XY, 2000, KIDNEY INT, V58, P1523, DOI 10.1046/j.1523-1755.2000.00314.x	47	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40169	40176		10.1074/jbc.M307890200	http://dx.doi.org/10.1074/jbc.M307890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12904289	hybrid			2022-12-25	WOS:000185713800110
J	Liu, XW; Bernardo, MM; Fridman, R; Kim, HRC				Liu, XW; Bernardo, MM; Fridman, R; Kim, HRC			Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; MEDIATED GENE DELIVERY; MATRIX METALLOPROTEINASES; PHOSPHATIDYLINOSITOL 3-KINASE; EXTRACELLULAR-MATRIX; MELANOMA-CELLS; IN-VITRO; LIVER FIBROSIS; B-CELLS; KINASE	Tissue inhibitor of metalloproteinase (TIMP-1) is a natural protease inhibitor of matrix metalloproteinases ( MMPs). Recent studies revealed a novel function of TIMP-1 as a potent inhibitor of apoptosis in mammalian cells. However, the mechanisms by which TIMP-1 exerts its anti-apoptotic effect are not understood. Here we show that TIMP-1 activates cell survival signaling pathways involving focal adhesion kinase, phosphatidylinositol 3-kinase, and ERKs in human breast epithelial cells to TIMP-1. TIMP-1-activated cell survival signaling down-regulates caspase-mediated classical apoptotic pathways induced by a variety of stimuli including anoikis, staurosporine exposure, and growth factor withdrawal. Consistently, down-regulation of TIMP-1 expression greatly enhances apoptotic cell death. In a previous study, substitution of the second amino acid residue threonine for glycine in TIMP-1, which confers selective MMP inhibition, was shown to obliterate its anti-apoptotic activity in activated hepatic stellate cells suggesting that the anti-apoptotic activity of TIMP-1 is dependent on MMP inhibition. Here we show that the same mutant inhibits apoptosis of human breast epithelial cells, suggesting different mechanisms of TIMP-1 regulation of apoptosis depending on cell types. Neither TIMP-2 nor a synthetic MMP inhibitor protects breast epithelial cells from intrinsic apoptotic cell death. Furthermore, TIMP-1 enhances cell survival in the presence of the synthetic MMP inhibitor. Taken together, the present study unveils some of the mechanisms mediating the anti-apoptotic effects of TIMP-1 in human breast epithelial cells through TIMP-1-specific signal transduction pathways.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NCI NIH HHS [CA-82298, CA89113] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089113, R01CA082298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Ahonen M, 1998, CANCER RES, V58, P2310; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Barasch J, 1999, J CLIN INVEST, V103, P1299, DOI 10.1172/JCI4586; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; Guedez L, 2001, BLOOD, V97, P1796, DOI 10.1182/blood.V97.6.1796; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; Jiang YF, 2001, CANCER RES, V61, P2365; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kadri Z, 2000, CELL GROWTH DIFFER, V11, P573; Kim HRC, 1999, CANCER RES, V59, P4148; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAMBERT E, 2003, BIOCH J; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; Li GY, 1999, CANCER RES, V59, P6267; Lim MS, 1999, ANN NY ACAD SCI, V878, P522, DOI 10.1111/j.1749-6632.1999.tb07715.x; Lin HL, 2002, KIDNEY INT, V62, P60, DOI 10.1046/j.1523-1755.2002.00403.x; Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8; Majid MA, 2002, BRIT J OPHTHALMOL, V86, P97, DOI 10.1136/bjo.86.1.97; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Petitfrere E, 2000, FEBS LETT, V485, P117, DOI 10.1016/S0014-5793(00)02210-9; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Ree AH, 1997, CLIN CANCER RES, V3, P1623; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Tummalapalli CM, 2001, J CELL BIOCHEM, V80, P512, DOI 10.1002/1097-4644(20010315)80:4<512::AID-JCB1005>3.0.CO;2-N; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; Yamashita K, 1996, FEBS LETT, V396, P103, DOI 10.1016/0014-5793(96)01066-6; Yoshiji H, 2002, HEPATOLOGY, V36, P850, DOI 10.1053/jhep.2002.35625; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	63	144	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40364	40372		10.1074/jbc.M302999200	http://dx.doi.org/10.1074/jbc.M302999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12904305	hybrid			2022-12-25	WOS:000185713800130
J	Ding, Y; Xu, MQ; Ghosh, I; Chen, XH; Ferrandon, S; Lesage, G; Rao, ZH				Ding, Y; Xu, MQ; Ghosh, I; Chen, XH; Ferrandon, S; Lesage, G; Rao, ZH			Crystal structure of a mini-intein reveals a conserved catalytic module involved in side chain cyclization of asparagine during protein splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; ELECTRON-DENSITY MAPS; CEREVISIAE VMA INTEIN; SACCHAROMYCES-CEREVISIAE; SPLIT INTEIN; ADENOSINE-TRIPHOSPHATASE; BRANCHED INTERMEDIATE; PHENOTYPIC SELECTION; INTERVENING SEQUENCE; HOMING ENDONUCLEASE	We have determined the crystal structure of a 154-residue intein derived from the dnaB gene of Synechocystis sp. strain PCC6803 and refined it to a 2.0-Angstrom resolution. The x-ray structure suggests that this intein possesses two catalytic sites that appear to be separately responsible for splicing and cleavage of the Nand C-terminal scissile bonds. The conserved intein block F residues are the important components of a catalytic site for side chain cyclization of the last intein residue, Asn-154. The data suggest that the imidazole ring of His-143 is involved in the activation of the side chain Ndelta atom of Asn-154, leading to a nucleophilic attack on the carbonyl carbon of Asn-154. Substitution of His-143 with Ala or Gln resulted in the inhibition of C-terminal cleavage. His-153, Asp-136, and a water molecule appear to constitute an oxyanion binding site by contacting the carbonyl oxygen of Asn-154 to stabilize the transition state. The structure and mutagenesis data also support that the close contact between the hydroxyl groups of Thr-138 and Ser-155, whose side chain participates in an S --> O acyl shift, plays an important role in the nucleophile orientation. Our structural modeling suggests that this catalytic module is conserved in the C-terminal subdomains of inteins from diverse organisms.	New England Biolabs Inc, Beverly, MA 01915 USA; Tsing Hua Univ, Sch Life Sci & Engn, Struct Biol Lab, Beijing 100084, Peoples R China; Tsing Hua Univ, Sch Life Sci & Engn, Minist Educ Lab Prot Sci, Beijing 100084, Peoples R China; Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China	Tsinghua University; Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Xu, MQ (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.							BRUICE TC, 1966, BIOORGANIC MECH; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen LX, 2000, J BIOL CHEM, V275, P20431, DOI 10.1074/jbc.M000178200; Chen XH, 2002, ACTA CRYSTALLOGR D, V58, P1201, DOI 10.1107/S0907444902006583; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; Chong SR, 1997, J BIOL CHEM, V272, P15587, DOI 10.1074/jbc.272.25.15587; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Evans TC, 2002, CHEM REV, V102, P4869, DOI 10.1021/cr9601369; Evans TC, 1999, BIOPOLYMERS, V51, P333, DOI 10.1002/(SICI)1097-0282(1999)51:5<333::AID-BIP3>3.3.CO;2-R; Ghosh I, 2001, J BIOL CHEM, V276, P24051, DOI 10.1074/jbc.M011049200; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Hu DL, 2000, J BIOL CHEM, V275, P2705, DOI 10.1074/jbc.275.4.2705; Ichiyanagi K, 2000, J MOL BIOL, V300, P889, DOI 10.1006/jmbi.2000.3873; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizutani R, 2002, J MOL BIOL, V316, P919, DOI 10.1006/jmbi.2001.5357; Muir TW, 2003, ANNU REV BIOCHEM, V72, P249, DOI 10.1146/annurev.biochem.72.121801.161900; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 2000, NUCLEIC ACIDS RES, V28, P344, DOI 10.1093/nar/28.1.344; Pietrokovski S, 1996, TRENDS GENET, V12, P287, DOI 10.1016/0168-9525(96)20005-8; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Poland BW, 2000, J BIOL CHEM, V275, P16408, DOI 10.1074/jbc.275.22.16408; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; Shingledecker K, 1998, GENE, V207, P187, DOI 10.1016/S0378-1119(97)00624-0; Southworth MW, 2000, EMBO J, V19, P5019, DOI 10.1093/emboj/19.18.5019; Wang SL, 1997, J BIOL CHEM, V272, P11869, DOI 10.1074/jbc.272.18.11869; Wood DW, 1999, NAT BIOTECHNOL, V17, P889, DOI 10.1038/12879; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187	49	116	129	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39133	39142		10.1074/jbc.M306197200	http://dx.doi.org/10.1074/jbc.M306197200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878593	hybrid			2022-12-25	WOS:000185575100127
J	Chung, JH; Han, JH; Hwang, EJ; Seo, JY; Cho, KH; Kim, KH; Youn, JI; Eun, HC				Chung, JH; Han, JH; Hwang, EJ; Seo, JY; Cho, KH; Kim, KH; Youn, JI; Eun, HC			Dual mechanisms of green tea extract-induced cell survival in human epidermal keratinocytes	FASEB JOURNAL			English	Article						EGCG; keratinocytes; proliferation; apoptosis	HAIRLESS MICE; GROWTH; INDUCTION; APOPTOSIS; PHOSPHORYLATION; PROTECTION; DEATH; SKIN; BAD; (-)-EPIGALLOCATECHIN-3-GALLATE	Beneficial effects attributed to green tea, such as its anticancer and antioxidant properties, may be mediated by (-)-epigallocatechin-3-gallate ( EGCG). In this study, the effects of EGCG on cell proliferation and UV-induced apoptosis were investigated in normal epidermal keratinocytes. When topically applied to aged human skin, EGCG stimulated the proliferation of epidermal keratinocytes, which increased the epidermal thickness. In addition, this topical application also inhibited the UV-induced apoptosis of epidermal keratinocytes. EGCG was found to increase the phosphorylation of Bad protein at the Ser112 and Ser136. Moreover, EGCG-induced Erk phosphorylation was found to be critical for the phosphorylation of Ser112 in Bad protein, and the EGCG-induced activation of the Akt pathway was found to be involved in the phosphorylation of Ser136. Furthermore, EGCG increased Bcl-2 expression but decreased Bax expression, causing an increase in the Bcl-2-to-Bax ratio. In addition, we demonstrate the differential growth inhibitory effects of EGCG on cancer cells. In conclusion, this study demonstrates that EGCG promotes keratinocyte survival and inhibits the UV-induced apoptosis via two mechanisms: by phosphorylating Ser112 and Ser136 of Bad protein through Erk and Akt pathways, respectively, and by increasing the Bcl-2-to-Bax ratio. Moreover, these two proposed mechanisms of EGCG-induced cell proliferation may differ kinetically to promote keratinocyte survival.	Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Lab Cutaneous Aging Res, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Eun, HC (corresponding author), Seoul Natl Univ, Coll Med, Dept Dermatol, 28 Yongon Dong, Seoul 110744, South Korea.	hceun@snu.ac.kr	Chung, Jin Ho/C-3604-2011; Kim, Kyu Han/E-7814-2012; Eun, Hee Chul/J-5568-2012; Cho, Kwang Hyun/J-5661-2012					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AGARWAL R, 1993, PHOTOCHEM PHOTOBIOL, V58, P695, DOI 10.1111/j.1751-1097.1993.tb04954.x; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Blot WJ, 1997, CRIT REV FOOD SCI, V37, P739, DOI 10.1080/10408399709527800; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; Bushman JL, 1998, NUTR CANCER, V31, P151, DOI 10.1080/01635589809514697; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Chung JH, 2000, J INVEST DERMATOL, V115, P177, DOI 10.1046/j.1523-1747.2000.00009.x; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; delPeso L, 1997, SCIENCE, V278, P687; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Isoherranen K, 1999, ARCH DERMATOL RES, V291, P212, DOI 10.1007/s004030050396; KATIYAR SK, 1995, PHOTOCHEM PHOTOBIOL, V62, P855; Katiyar SK, 1999, PHOTOCHEM PHOTOBIOL, V69, P148, DOI 10.1111/j.1751-1097.1999.tb03267.x; Kim YG, 2000, PIGM CELL RES, V13, P352, DOI 10.1034/j.1600-0749.2000.130508.x; Kohlmeier L, 1997, NUTR CANCER, V27, P1, DOI 10.1080/01635589709514494; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LEE MJ, 1995, CANCER EPIDEM BIOMAR, V4, P393; Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Seo JY, 2001, J INVEST DERMATOL, V116, P915, DOI 10.1046/j.1523-1747.2001.01358.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011; WANG ZY, 1991, CARCINOGENESIS, V12, P1527, DOI 10.1093/carcin/12.8.1527; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	40	124	138	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1913	+		10.1096/fj.02-0914fje	http://dx.doi.org/10.1096/fj.02-0914fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897059				2022-12-25	WOS:000185345100017
J	Damy, T; Ratajczak, P; Robidel, E; Bendall, JK; Oliviero, P; Boczkowski, J; Ebrahimian, T; Marotte, F; Samuel, JL; Heymes, C				Damy, T; Ratajczak, P; Robidel, E; Bendall, JK; Oliviero, P; Boczkowski, J; Ebrahimian, T; Marotte, F; Samuel, JL; Heymes, C			Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats	FASEB JOURNAL			English	Article						NOS1; caveolin; aging; cardiac dysfunction	HUMAN HEART-FAILURE; SKELETAL-MUSCLE; VENTRICULAR MYOCYTES; CALCIUM CURRENT; IN-VIVO; EXPRESSION; DYSFUNCTION; CAVEOLIN-3; RELEASE; BASAL	Nitric oxide ( NO) has been implicated in the development of heart failure, although the source, significance, and functional role of the different NO synthase (NOS) isoforms in this pathology are controversial. The presence of a neuronal-type NOS isoform (NOS1) in the cardiac sarcoplasmic reticulum has been recently discovered, leading to the hypothesis that NOS1-derived NO may notably alter myocardial inotropy. However, the regulation and role(s) of NOS1 in cardiac diseases remain to be determined. Using an experimental model of myocardial infarction (MI) in senescent rats, we demonstrated a significant increase in cardiac NOS1 expression and activity in MI, coupled with the translocation of this enzyme to the sarcolemma through interactions with caveolin-3. The enhanced NOS1 activity counteracts the decrease in cardiac NOS3 expression and activity observed in heart failure. We demonstrated an increased interaction between NOS1 and its regulatory protein HSP90 in post-MI hearts, a potential mechanism for the higher NOS1 activity in this setting. Finally, preferential in vivo inhibition of NOS1 activity enhanced basal post-MI left ventricular dysfunction in senescent rats. These results provide the first evidence that increased NOS1-derived NO production may play a significant role in the autocrine regulation of myocardial contractility after MI in aging rats.	Univ Paris 07, Hop Lariboisiere, INSERM, U572,IFR J Marrey, F-75475 Paris 10, France; Hop Bichat Claude Bernard, INSERM, U408, F-75877 Paris, France; Univ Paris 07, Hop Lariboisiere, INSERM, U541,IFR J Marrey, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Heymes, C (corresponding author), Univ Paris 07, Hop Lariboisiere, INSERM, U572,IFR J Marrey, 41 Blvd Chapelle, F-75475 Paris 10, France.	Christophe.Heymes@larib.inserm.fr	Boczkowski, Jorge/S-7474-2018; Ratajczak, Philippe/H-5398-2012; Heymes, Christophe/Y-9368-2019	Boczkowski, Jorge/0000-0001-6619-5785; Heymes, Christophe/0000-0002-6666-6193				Andries LJ, 1998, CIRC RES, V82, P195; Ashley EA, 2002, CIRCULATION, V105, P3011, DOI 10.1161/01.CIR.0000019516.31040.2D; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Bing RJ, 1996, MOL CELL BIOCHEM, V161, P303, DOI 10.1007/BF00240063; Brahmajothi MV, 1999, CIRC RES, V85, P575, DOI 10.1161/01.RES.85.7.575; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Dittrich M, 2001, J PHYSIOL-LONDON, V534, P109, DOI 10.1111/j.1469-7793.2001.00109.x; Drexler H, 1999, J MOL CELL CARDIOL, V31, P51, DOI 10.1006/jmcc.1998.0843; DUDEK RR, 1994, BIOCHEM BIOPH RES CO, V205, P1671, DOI 10.1006/bbrc.1994.2860; FINKEL MS, 1995, J PHARMACOL EXP THER, V272, P945; Gallo MP, 2001, PFLUG ARCH EUR J PHY, V441, P621, DOI 10.1007/s004240000475; GROCOTTMASON R, 1994, AM J PHYSIOL-HEART C, V267, pH1804, DOI 10.1152/ajpheart.1994.267.5.H1804; Gyurko R, 2000, AM J PHYSIOL-HEART C, V278, pH971, DOI 10.1152/ajpheart.2000.278.3.H971; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Heymes C, 1999, CIRCULATION, V99, P3009, DOI 10.1161/01.CIR.99.23.3009; Kaye DM, 2002, CIRC RES, V91, P1198, DOI 10.1161/01.RES.0000047506.52381.90; Keita H, 2000, BRAIN RES, V881, P237, DOI 10.1016/S0006-8993(00)02820-1; Kelm M, 1997, CARDIOVASC RES, V36, P185, DOI 10.1016/S0008-6363(97)00149-1; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Lanone S, 2001, CRIT CARE MED, V29, P1720, DOI 10.1097/00003246-200109000-00011; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Mohri M, 1997, HYPERTENSION, V30, P50, DOI 10.1161/01.HYP.30.1.50; Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265; Paulus W J, 2001, Heart Fail Rev, V6, P105; PAULUS WJ, 1995, CIRCULATION, V92, P2119, DOI 10.1161/01.CIR.92.8.2119; Paulus WJ, 2001, CIRCULATION, V104, P2260, DOI 10.1161/circ.104.19.2260; PAULUS WJ, 1994, CIRCULATION, V89, P2070, DOI 10.1161/01.CIR.89.5.2070; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; Piech A, 2002, AM J PHYSIOL-HEART C, V282, pH219, DOI 10.1152/ajpheart.2002.282.1.H219; Prabhu SD, 2000, CIRCULATION, V101, P2103, DOI 10.1161/01.CIR.101.17.2103; Ratajczak P, 2003, CARDIOVASC RES, V57, P358, DOI 10.1016/S0008-6363(02)00660-0; Raya TE, 1997, AM J PHYSIOL-HEART C, V273, pH2652, DOI 10.1152/ajpheart.1997.273.6.H2652; Sears CE, 2003, CIRC RES, V92, pE52, DOI 10.1161/01.RES.0000064585.95749.6D; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; Shah AM, 1999, CARDIOVASC RES, V43, P507, DOI 10.1016/S0008-6363(99)00181-9; Shah AM, 2000, PHARMACOL THERAPEUT, V86, P49, DOI 10.1016/S0163-7258(99)00072-8; SHAH VP, 1991, PHARMACEUT RES, V8, P55, DOI 10.1023/A:1015826205930; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Silvestre JS, 1999, CIRCULATION, V99, P2694, DOI 10.1161/01.CIR.99.20.2694; Smith CJ, 1996, CIRC RES, V78, P58, DOI 10.1161/01.RES.78.1.58; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; Sunada Y, 2001, HUM MOL GENET, V10, P173, DOI 10.1093/hmg/10.3.173; Vandecasteele G, 1999, NAT MED, V5, P331, DOI 10.1038/6553; Vejlstrup NG, 1998, J MOL CELL CARDIOL, V30, P1215, DOI 10.1006/jmcc.1998.0686; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	54	97	98	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1934	+		10.1096/fj.02-1208fje	http://dx.doi.org/10.1096/fj.02-1208fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897062				2022-12-25	WOS:000185345100020
J	Merker, K; Ullrich, O; Schmidt, H; Sitte, N; Grune, T				Merker, K; Ullrich, O; Schmidt, H; Sitte, N; Grune, T			Stability of the nuclear protein turnover during cellular senescence of human fibroblasts	FASEB JOURNAL			English	Article						protein oxidation; proteasome; proliferative senescence; nucleus; cytosol	HUMAN BJ FIBROBLASTS; GLUTAMINE-SYNTHETASE; OXIDIZED PROTEINS; OXIDATION; DEGRADATION; PROTEASOME; PROTEOLYSIS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; INHIBITION; COMPLEX	The accumulation of oxidized proteins is one of the highlights of age-related changes of cellular metabolism and happens at least partially as a result of a decline in the activity of intracellular proteases (e.g., the proteasome). Because the proteasome is located in numerous cellular compartments, we tested whether and to which extent the proteasome and the protein turnover changes in the cytosolic compartment and in the nucleus of proliferating fibroblasts. We demonstrated that the activity of the proteasomal system declines during proliferative senescence of human fibroblasts in the cytosol dramatically, whereas it is stable within the nucleus. It could be demonstrated in both compartments that an accumulation of oxidized proteins occurs. After oxidative stress, a short timed activation of the proteasomal system in the nucleus occurs. This activation was accompanied by an increase in the protein turnover in response to oxidative stress, which was also present in the nucleus of senescent cells. Taking into account that the nuclear/cytosol ratio of the proteasome content declines during proliferative senescence, we postulated that the senescence-related changes in the cytosolic proteasomal system are more pronounced and that the nuclear proteasomal system is only marginally affected by the senescence process.	Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, D-10117 Berlin, Germany; Humboldt Univ, Fac Med Charite, Inst Anat, D-10117 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Gastroenterol & Hepatol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Grune, T (corresponding author), Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, Schumannstr 20-21, D-10117 Berlin, Germany.	tilman.grune@charite.de		Grune, Tilman/0000-0003-4775-9973				AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; Burkle A, 2000, BIOGERONTOLOGY, V1, P41, DOI 10.1023/A:1010089924898; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 2001, J GERONTOL A-BIOL, V56, pB459, DOI 10.1093/gerona/56.11.B459; GRUNE T, 2001, HDB BIOL AGING, P25; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HOLLIDAY R, 1972, NATURE, V238, P26, DOI 10.1038/238026a0; Lasch P, 2001, J BIOL CHEM, V276, P9492, DOI 10.1074/jbc.M008528200; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Sitte N, 2000, FREE RADICAL BIO MED, V28, P701, DOI 10.1016/S0891-5849(99)00279-8; Stadtman E R, 1988, Basic Life Sci, V49, P331; Stadtman E R, 1992, EXS, V62, P64; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Waterborg JH, 2001, BIOCHEMISTRY-US, V40, P2599, DOI 10.1021/bi002480c; Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X	36	29	29	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1963	+		10.1096/fj.03-0177fje	http://dx.doi.org/10.1096/fj.03-0177fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897070				2022-12-25	WOS:000185345100028
J	Harmon, FG; Brockman, JP; Kowalczykowski, SC				Harmon, FG; Brockman, JP; Kowalczykowski, SC			RecQ helicase stimulates both DNA catenation and changes in DNA topology by topoisomerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; SYNDROME GENE-PRODUCT; BLOOM-SYNDROME; SGS1; INTERACTS; HOMOLOG; CLONING; RECOMBINATION; PROTEIN; FAMILY	Together, RecQ helicase and topoisomerase III (Topo III) of Escherichia coli comprise a potent DNA strand passage activity that can catenate covalently closed DNA (Harmon, F. G., DiGate, R. J., and Kowalczykowski, S. C. (1999) Mol. Cell 3, 611-620). Here we directly assessed the structure of the catenated DNA species formed by RecQ helicase and Topo III using atomic force microscopy. The images show complex catenated DNA species involving crossovers between multiple double-stranded DNA molecules that are consistent with full catenanes. E. coli single-stranded DNA-binding protein significantly stimulated both the topoisomerase activity of Topo III alone and the DNA strand passage activity of RecQ helicase and Topo III. Titration data suggest that an intermediate of the RecQ helicase unwinding process, perhaps a RecQ helicase-DNA fork, is the target for Topo III action. Catenated DNA is the predominant product under conditions of molecular crowding; however, we also discovered that RecQ helicase and single-stranded DNA-binding protein greatly stimulated the intramolecular strand passage ("supercoiling") activity of Topo III, as revealed by changes in the linking number of uncatenated DNA. Together our results demonstrate that RecQ helicase and Topo III function together to comprise a potent and concerted single-strand DNA passage activity that can mediate both catenation-decatenation processes and changes in DNA topology.	Univ Calif Davis, Ctr Genet & Dev, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Div Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Ctr Genet & Dev, Div Biol Sci, Microbiol Sect, Briggs Hall,1 Shields Ave, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu						Bennett RJ, 2000, J BIOL CHEM, V275, P26898; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Hanai R, 1999, METH MOL B, V94, P19; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; HIASA H, 1994, J BIOL CHEM, V269, P32655; IRINO N, 1986, MOL GEN GENET, V205, P298, DOI 10.1007/BF00430442; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIM RA, 1992, J BIOL CHEM, V267, P17178; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KRASNOW MA, 1983, NATURE, V304, P559, DOI 10.1038/304559a0; Kusano K, 1999, GENETICS, V151, P1027; LEBOWITZ J, 1985, THESIS J HOPKINS U B; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; Nurse P, 2003, J BIOL CHEM, V278, P8653, DOI 10.1074/jbc.M211211200; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WHORISKEY SK, 1991, GENETICS, V127, P21; Wilson-Sali T, 2002, J BIOL CHEM, V277, P26865, DOI 10.1074/jbc.M204641200; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zerbib D, 1997, J MOL BIOL, V270, P663, DOI 10.1006/jmbi.1997.1157; Zhu Q, 2001, P NATL ACAD SCI USA, V98, P9766, DOI 10.1073/pnas.171579898	53	64	66	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42668	42678		10.1074/jbc.M302994200	http://dx.doi.org/10.1074/jbc.M302994200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909639	Green Published, hybrid			2022-12-25	WOS:000185989500133
J	Heller, MJ; Nili, M; Homsher, E; Tobacman, LS				Heller, MJ; Nili, M; Homsher, E; Tobacman, LS			Cardiomyopathic tropomyosin mutations that increase thin filament Ca2+ sensitivity and tropomyosin N-domain flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; RABBIT SKELETAL-MUSCLE; TROPONIN-T MUTATIONS; MYOSIN SUBFRAGMENT 1; VITRO MOTILITY ASSAY; ALPHA-TROPOMYOSIN; CARDIAC TROPONIN; MUTANT TROPOMYOSIN; 3-DIMENSIONAL RECONSTRUCTION; REGULATORY PROPERTIES	The relationship between tropomyosin thermal stability and thin filament activation was explored using two N-domain mutants of alpha-striated muscle tropomyosin, A63V and K70T, each previously implicated in familial hypertrophic cardiomyopathy. Both mutations had prominent effects on tropomyosin thermal stability as monitored by circular dichroism. Wild type tropomyosin unfolded in two transitions, separated by 10degreesC. The A63V and K70T mutations decreased the melting temperature of the more stable of these transitions by 4 and 10degreesC, respectively, indicating destabilization of the N-domain in both cases. Global analysis of all three proteins indicated that the tropomyosin N-domain and C-domain fold with a cooperative free energy of 1.0-1.5 kcal/mol. The two mutations increased the apparent affinity of the regulatory Ca2+ binding sites of thin filament in two settings: Ca2+-dependent sliding speed of unloaded thin filaments in vitro (at both pH 7.4 and 6.3), and Ca2+ activation of the thin filament-myosin S1 ATPase rate. Neither mutation had more than small effects on the maximal ATPase rate in the presence of saturating Ca2+ or on the maximal sliding speed. Despite the increased tropomyosin flexibility implied by destabilization of the N-domain, neither the cooperativity of thin filament activation by Ca2+ nor the cooperative binding of myosin S1-ADP to the thin filament was altered by the mutations. The combined results suggest that a more dynamic tropomyosin N-domain influences interactions with actin and/or troponin that modulate Ca2+ sensitivity, but has an unexpectedly small effect on cooperative changes in tropomyosin position on actin.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90025 USA	University of Iowa; University of Iowa; University of California System; University of California Los Angeles	Tobacman, LS (corresponding author), Univ Illinois, Dept Med, MC 787,840 W Wood St,Rm 317F CSN, Chicago, IL 60612 USA.							Bacchiocchi C, 2002, BIOPHYS J, V82, P1524, DOI 10.1016/S0006-3495(02)75505-7; Bing W, 2000, J MOL CELL CARDIOL, V32, P1489, DOI 10.1006/jmcc.2000.1182; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Butters CA, 1997, J BIOL CHEM, V272, P13196, DOI 10.1074/jbc.272.20.13196; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CLARK ID, 1990, BIOCHEMISTRY-US, V29, P10842, DOI 10.1021/bi00500a018; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; Evans CC, 2000, AM J PHYSIOL-HEART C, V279, pH2414, DOI 10.1152/ajpheart.2000.279.5.H2414; Fujita H, 2002, J PHYSIOL-LONDON, V539, P267, DOI 10.1113/jphysiol.2001.013220; Fukuda N, 2001, J PHYSIOL-LONDON, V536, P153, DOI 10.1111/j.1469-7793.2001.00153.x; GODT RE, 1989, J PHYSIOL-LONDON, V412, P155, DOI 10.1113/jphysiol.1989.sp017609; Golitsina N, 1997, BIOCHEMISTRY-US, V36, P4637, DOI 10.1021/bi962970y; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Graceffa P, 2000, J BIOL CHEM, V275, P17143, DOI 10.1074/jbc.M001979200; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hill T. L., 1985, COOPERATIVITY THEORY; HOLMES KC, 1995, BIOPHYS J S, V68, P2; Holtzer ME, 2001, BIOPOLYMERS, V59, P257, DOI 10.1002/1097-0282(20011005)59:4<257::AID-BIP1022>3.0.CO;2-7; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; Homsher E, 2000, J PHYSIOL-LONDON, V524, P233, DOI 10.1111/j.1469-7793.2000.00233.x; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; INGRAHAM RH, 1985, BIOCHEMISTRY-US, V24, P5221, DOI 10.1021/bi00340a040; ISHII Y, 1991, J BIOL CHEM, V266, P6894; Karibe A, 2001, CIRCULATION, V103, P65; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Luque I, 2002, ANNU REV BIOPH BIOM, V31, P235, DOI 10.1146/annurev.biophys.31.082901.134215; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Michele DE, 1999, NAT MED, V5, P1413; Michele DE, 2002, CIRC RES, V91, P255, DOI 10.1161/01.RES.0000027530.58419.82; Michele DE, 2002, PHYSIOL GENOMICS, V9, P103, DOI 10.1152/physiolgenomics.00099.2001; Miki M, 1998, J BIOCHEM-TOKYO, V123, P1104; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MO JM, 1992, BIOPOLYMERS, V32, P751, DOI 10.1002/bip.360320704; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Morris CA, 2001, J BIOL CHEM, V276, P20245, DOI 10.1074/jbc.M007371200; MOSS RL, 1986, J PHYSIOL-LONDON, V377, P487, DOI 10.1113/jphysiol.1986.sp016199; Mukherjea P, 1999, BIOCHEMISTRY-US, V38, P13296, DOI 10.1021/bi9906120; Muthuchamy M, 1999, CIRC RES, V85, P47; NAKAJIMATANIGUCHI C, 1995, J MOL CELL CARDIOL, V27, P2053, DOI 10.1016/0022-2828(95)90026-8; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PATO MD, 1981, J BIOL CHEM, V256, P593; Paulucci AA, 2002, J BIOL CHEM, V277, P39574, DOI 10.1074/jbc.M204749200; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Resetar AM, 2002, BIOPHYS J, V83, P1039, DOI 10.1016/S0006-3495(02)75229-6; RICCIARDI L, 1994, J MOL CELL CARDIOL, V26, P601, DOI 10.1006/jmcc.1994.1072; Rosol M, 2000, BIOPHYS J, V78, P908, DOI 10.1016/S0006-3495(00)76648-3; Smith DA, 2001, J PHYS A-MATH GEN, V34, P4507, DOI 10.1088/0305-4470/34/21/307; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Strand J, 2001, J BIOL CHEM, V276, P34832, DOI 10.1074/jbc.M104750200; Suarez MC, 2001, BIOCHEMISTRY-US, V40, P1300, DOI 10.1021/bi0020978; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; Tobacman LS, 2002, J BIOL CHEM, V277, P27636, DOI 10.1074/jbc.M201768200; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; YamauchiTakihara K, 1996, HEART, V76, P63, DOI 10.1136/hrt.76.1.63; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806	71	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41742	41748		10.1074/jbc.M303408200	http://dx.doi.org/10.1074/jbc.M303408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12900417	hybrid			2022-12-25	WOS:000185989500025
J	Muhlenhoff, U; Stadler, JA; Richhardt, N; Seubert, A; Eickhorst, T; Schweyen, RJ; Lill, R; Wiesenberger, G				Muhlenhoff, U; Stadler, JA; Richhardt, N; Seubert, A; Eickhorst, T; Schweyen, RJ; Lill, R; Wiesenberger, G			A specific role of the yeast mitochondrial carriers Mrs3/4p in mitochondrial iron acquisition under iron-limiting conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; FRATAXIN-DEFICIENT STRAIN; CYTOSOLIC FE/S PROTEINS; SACCHAROMYCES-CEREVISIAE; PUTATIVE HOMOLOG; SPLICING DEFECTS; SULFUR PROTEINS; GENE-EXPRESSION; NULL MUTATION; DNA-BINDING	The yeast genes MRS3 and MRS4 encode two members of the mitochondrial carrier family with high sequence similarity. To elucidate their function we utilized genome-wide expression profiling and found that both deletion and overexpression of MRS3/4 lead to up-regulation of several genes of the "iron regulon." We therefore analyzed the two major iron-utilizing processes, heme formation and Fe/S protein biosynthesis in vivo, in organello ( intact mitochondria), and in vitro ( mitochondrial extracts). Radiolabeling of yeast cells with Fe-55 revealed a clear correlation between MRS3/4 expression levels and the efficiency of these biosynthetic reactions indicating a role of the carriers in utilization and/or transport of iron in vivo. Similar effects on both heme formation and Fe/S protein biosynthesis were seen in organello using mitochondria isolated from cells grown under iron-limiting conditions. The correlation between MRS3/4 expression levels and the efficiency of the two iron-utilizing processes was lost upon detergent lysis of mitochondria. As no significant changes in the mitochondrial membrane potential were observed upon overexpression or deletion of MRS3/4, our results suggest that Mrs3/4p carriers are directly involved in mitochondrial iron uptake. Mrs3/4p function in mitochondrial iron transport becomes evident under iron-limiting conditions only, indicating that the two carriers do not represent the sole system for mitochondrial iron acquisition.	Univ Vienna, Dept Genet & Microbiol, Max F Perutz Labs, A-1030 Vienna, Austria; Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Marburg, Fachbereich Chem, D-35032 Marburg, Germany	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Philipps University Marburg; Philipps University Marburg	Wiesenberger, G (corresponding author), Univ Vienna, Dept Genet & Microbiol, Max F Perutz Labs, Dr Bohrgasse 9, A-1030 Vienna, Austria.	gerlinde@gem.univie.ac.at		Lill, Roland/0000-0002-8345-6518; Wiesenberger, Gerlinde/0000-0002-3788-7974				AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Belenkiy R, 2000, BBA-BIOMEMBRANES, V1467, P207, DOI 10.1016/S0005-2736(00)00222-4; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Cho JH, 1998, MOL CELL BIOL, V18, P5712, DOI 10.1128/MCB.18.10.5712; DAUM G, 1982, J BIOL CHEM, V257, P3028; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gerber J, 2002, MITOCHONDRION, V2, P71, DOI 10.1016/S1567-7249(02)00041-7; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gregan J, 2001, GENE DEV, V15, P2229, DOI 10.1101/gad.201301; Harlow E., 1988, ANTIBODIES LAB MANUA; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Kao LR, 1996, YEAST, V12, P1239, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1239::AID-YEA17>3.0.CO;2-8; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KISPAL G, 1988, J BIOL CHEM, V263, P11145; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; Labbe-Bois Rosine, 1994, V11, P413; LALO D, 1994, YEAST, V10, P523, DOI 10.1002/yea.320100412; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; MUHLENHOFF U, 2003, IN PRESS EMBO J, V22; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nyhus KJ, 2002, MED MYCOL, V40, P581, DOI 10.1080/mmy.40.6.581.591; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri L, 2000, J BIOENERG BIOMEMBR, V32, P67, DOI 10.1023/A:1005564429242; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Palmieri L, 2001, J BIOL CHEM, V276, P1916, DOI 10.1074/jbc.M004332200; Prohl C, 2001, MOL CELL BIOL, V21, P1089, DOI 10.1128/MCB.21.4.1089-1097.2001; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Sambrook J, 2001, MOL CLONING LAB MANU; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Tzagoloff A, 1996, J BIOL CHEM, V271, P7392, DOI 10.1074/jbc.271.13.7392; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; VANDYCK E, 1995, MOL GEN GENET, V246, P426, DOI 10.1007/BF00290446; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wach A, 1998, METHOD MICROBIOL, V26, P67; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	72	154	159	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40612	40620		10.1074/jbc.M307847200	http://dx.doi.org/10.1074/jbc.M307847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902335	hybrid			2022-12-25	WOS:000185847200025
J	Paromov, VM; Morton, RE				Paromov, VM; Morton, RE			Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN-PLASMA-LIPOPROTEINS; DEFICIENT PLASMA; MASS-TRANSFER; NORMOLIPIDEMIC SUBJECTS; HDL METABOLISM; HEPATIC LIPASE; HUMAN-SERUM; ACYLTRANSFERASE; TRIGLYCERIDE	Cholesterol ester transfer protein ( CETP) moves triglyceride (TG) and cholesteryl ester (CE) between lipoproteins. CETP has no apparent preference for high (HDL) or low (LDL) density lipoprotein as lipid donor to very low density lipoprotein ( VLDL), and the preference for HDL observed in plasma is due to suppression of LDL transfers by lipid transfer inhibitor protein ( LTIP). Given the heterogeneity of HDL, and a demonstrated ability of HDL subfractions to bind LTIP, we examined whether LTIP might also control CETP-facilitated lipid flux among HDL subfractions. CETP-mediated CE transfers from [H-3] CE VLDL to various lipoproteins, combined on an equal phospholipid basis, ranged 2-fold and followed the order: HDL3 > LDL > HDL2. LTIP inhibited VLDL to HDL2 transfer at one-half the rate of VLDL to LDL. In contrast, VLDL to HDL3 transfer was stimulated, resulting in a CETP preference for HDL3 that was 3-fold greater than that for LDL or HDL2. Long-term mass transfer experiments confirmed these findings and further established that the previously observed stimulation of CETP activity on HDL by LTIP is due solely to its stimulation of transfer activity on HDL3. TG enrichment of HDL2, which occurs during the HDL cycle, inhibited CETP activity by similar to2-fold and LTIP activity was blocked almost completely. This suggests that LTIP keeps lipid transfer activity on HDL2 low and constant regardless of its TG enrichment status. Overall, these results show that LTIP tailors CETP-mediated remodeling of HDL3 and HDL2 particles in subclass-specific ways, strongly implicating LTIP as a regulator of HDL metabolism.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NC 10, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Morton, RE (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NC 10, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL60934] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CHAIT A, 1984, BIOCHIM BIOPHYS ACTA, V795, P314, DOI 10.1016/0005-2760(84)90081-X; Curtiss LK, 2000, BIOCHEMISTRY-US, V39, P5712, DOI 10.1021/bi992902m; de Beer MC, 2001, J LIPID RES, V42, P309; de Grooth GJ, 2002, CIRCULATION, V105, P2159, DOI 10.1161/01.CIR.0000015857.31889.7B; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DECKELBAUM RJ, 1988, BIOCHIM BIOPHYS ACTA, V961, P223, DOI 10.1016/0005-2760(88)90117-8; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; DECKELBAUM RJ, 1986, J BIOL CHEM, V261, P5201; DECKELBAUM RJ, 1979, J BIOL CHEM, V254, P6079; DOBIASOVA M, 1992, J LIPID RES, V33, P1411; Edelstein C., 1986, BIOCH BIOL PLASMA LI, P495; FIELDING CJ, 1981, J BIOL CHEM, V256, P2102; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KO KWS, 1994, J BIOL CHEM, V269, P28206; Kosek AB, 1999, BIOCHEM BIOPH RES CO, V258, P548, DOI 10.1006/bbrc.1999.0690; LAGROST L, 1994, ARTERIOSCLER THROMB, V14, P1327, DOI 10.1161/01.ATV.14.8.1327; Lamarche B, 1999, CLIN CHIM ACTA, V286, P145, DOI 10.1016/S0009-8981(99)00098-4; Lamarche B, 1999, J CLIN INVEST, V103, P1191, DOI 10.1172/JCI5286; LASUNCION MA, 1990, BIOCHEM J, V270, P441, DOI 10.1042/bj2700441; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LIANG HQ, 1994, J LIPID RES, V35, P1187; Liu XQ, 1995, J LIPID RES, V36, P2574; LOPEZMIRANDA J, 1994, BBA-LIPID LIPID MET, V1214, P143, DOI 10.1016/0005-2760(94)90038-8; Morton RE, 1999, CURR OPIN LIPIDOL, V10, P321, DOI 10.1097/00041433-199908000-00006; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1994, J LIPID RES, V35, P836; MORTON RE, 1990, J LIPID RES, V31, P1559; MORTON RE, 1982, J LIPID RES, V23, P1058; MORTON RE, 1994, J LIPID RES, V35, P2094; MORTON RE, 1993, ARTERIOSCLER THROMB, V13, P1843, DOI 10.1161/01.ATV.13.12.1843; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MORTON RE, 1990, EXPERIENTIA, V46, P552, DOI 10.1007/BF01939693; Morton RE, 2000, BBA-MOL CELL BIOL L, V1486, P275, DOI 10.1016/S1388-1981(00)00064-0; MORTON RE, 1983, J BIOL CHEM, V258, P1751; MORTON RE, 1988, J LIPID RES, V29, P1367; Mowri HO, 1996, ARTERIOSCL THROM VAS, V16, P755, DOI 10.1161/01.ATV.16.6.755; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119; Oliveira HCF, 1997, ARTERIOSCL THROM VAS, V17, P1045, DOI 10.1161/01.ATV.17.6.1045; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rittershaus CW, 2000, ARTERIOSCL THROM VAS, V20, P2106, DOI 10.1161/01.ATV.20.9.2106; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; SCHECTMAN G, 1992, ARTERIOSCLER THROMB, V12, P1053, DOI 10.1161/01.ATV.12.9.1053; Serdyuk AP, 1999, ARTERIOSCL THROM VAS, V19, P718, DOI 10.1161/01.ATV.19.3.718; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SON YSC, 1984, BIOCHIM BIOPHYS ACTA, V795, P473; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Tall AR, 1999, ATHEROSCLEROSIS, V146, pS10, DOI 10.1016/S0021-9150(99)00229-4; TALL AR, 1986, J LIPID RES, V27, P361; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; VANTOL A, 1991, ARTERIOSCLER THROMB, V11, P55, DOI 10.1161/01.ATV.11.1.55; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019; Wang XX, 1999, J BIOL CHEM, V274, P1814, DOI 10.1074/jbc.274.3.1814; WEINBERG RB, 1994, J BIOL CHEM, V269, P29588; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112; Yoshikawa M, 1997, CLIN BIOCHEM, V30, P221, DOI 10.1016/S0009-9120(97)00031-3; ZECHNER R, 1987, BIOCHIM BIOPHYS ACTA, V918, P27, DOI 10.1016/0005-2760(87)90005-1	61	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40859	40866		10.1074/jbc.M306580200	http://dx.doi.org/10.1074/jbc.M306580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907677	hybrid			2022-12-25	WOS:000185847200055
J	Zito, CR; Oliver, D				Zito, CR; Oliver, D			Two-stage binding of SecA to the bacterial translocon regulates ribosome-translocon interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; DISTINCT ATP-BINDING; ESCHERICHIA-COLI; PROTEIN-TRANSLOCATION; PREPROTEIN TRANSLOCATION; MEMBRANE-PROTEIN; TARGETING PATHWAYS; CHANNEL; SECYEG; COMPONENTS	The bacterial translocon interacts with both SecA-bound preproteins and nascent chain-ribosome complexes during Sec and signal recognition particle-dependent protein translocation, respectively. In their inactive state, translocons are saturated with ribosomes and SecA protein, reflecting the inherent affinity of these components for one another. We found that SecA and ribosomes are bound simultaneously and noncompetitively to a common set of inactive translocons. Furthermore, we demonstrate that at a later stage in binding, SecA possesses a ribosome-translocon dissociation activity that is coupled to its ATP-dependent membrane insertion and retraction cycle that drives protein translocation. This novel activity is presumably important in the commitment of the translocon to the Sec-dependent pathway. These results also provide a rationale for the compatibility and regulation of multiple protein translocation pathways that each makes distinct demands on a common translocon core.	Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA	Wesleyan University	Oliver, D (corresponding author), Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA.	doliver@wesleyan.edu			NIGMS NIH HHS [GM42033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, BIOCH CHARACTERIZATI, P255; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; denBlaauwen T, 1997, FEBS LETT, V416, P35, DOI 10.1016/S0014-5793(97)01142-3; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIMURA E, 1991, J BIOL CHEM, V266, P6600; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Neidhardt F.C., 1996, ESCHERICHIA COLI SAL, Vvol. 1; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; Schmidt MO, 2001, J BIOL CHEM, V276, P37076, DOI 10.1074/jbc.M104584200; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Voorst F, 2000, FEBS LETT, V486, P57, DOI 10.1016/S0014-5793(00)02209-2; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577	57	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40640	40646		10.1074/jbc.M308025200	http://dx.doi.org/10.1074/jbc.M308025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907673	hybrid			2022-12-25	WOS:000185847200028
J	Huynh, TT; Huynh, VT; Harmon, MA; Phillips, MA				Huynh, TT; Huynh, VT; Harmon, MA; Phillips, MA			Gene knockdown of gamma-glutamylcysteine synthetase by RNA(i) in the parasitic protozoa Trypanosoma brucei demonstrates that it is an essential enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN TRYPANOSOMIASIS; TRANSFERASE TRANSPEPTIDASE; TRYPANOTHIONE REDUCTASE; BUTHIONINE SULFOXIMINE; CRITHIDIA-FASCICULATA; BINDING DETERMINANTS; LEISHMANIA-DONOVANI; SLEEPING SICKNESS; OXIDATIVE STRESS; AMINO-ACIDS	The parasitic protozoa Trypanosoma brucei utilizes a novel cofactor (trypanothione, T(SH)(2)), which is a conjugate of GSH and spermidine, to maintain cellular redox balance. gamma-Glutamylcysteine synthetase (gamma-GCS) catalyzes the first step in the biosynthesis of GSH. To evaluate the importance of thiol metabolism to the parasite, RNA(i) methods were used to knock down gene expression of gamma-GCS in procyclic T. brucei cells. Induction of gamma-GCS RNA(i) with tetracycline led to cell death within 4-6 days post-induction. Cell death was preceded by the depletion of the gamma-GCS protein and RNA and by the loss of the cellular pools of GSH and T(SH)(2). The addition of GSH (80 muM) to cell cultures rescued the RNA(i) cell death phenotype and restored the intracellular thiol pools to wild-type levels. Treatment of cells with buthionine sulfoximine (BSO), an enzyme-activated inhibitor of gamma-GCS, also resulted in cell death. However, the toxicity of the inhibitor was not reversed by GSH, suggesting that BSO has more than one cellular target. BSO depletes intracellular thiols to a similar extent as gamma-GCS RNA(i); however, addition of GSH did not restore the pools of GSH and T( SH) 2. These data suggest that BSO also acts to inhibit the transport of GSH or its peptide metabolites into the cell. The ability of BSO to inhibit both synthesis and transport of GSH likely makes it a more effective cytotoxic agent than an inhibitor with a single mode of action. Finally the potential for the T(SH)(2) biosynthetic enzymes to be regulated in response to reduced thiol levels was studied. The expression levels of ornithine decarboxylase and of S-adenosylmethionine decarboxylase, two essential enzymes in spermidine biosynthesis, remained constant in induced gamma-GCS RNA(i) cell lines.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	margaret.phillips@utsouthwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34432] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbott JJ, 2002, BIOCHEMISTRY-US, V41, P2741, DOI 10.1021/bi0159128; Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; ARRICK BA, 1981, J EXP MED, V153, P720, DOI 10.1084/jem.153.3.720; Augustyns K, 2001, CURR PHARM DESIGN, V7, P1117, DOI 10.2174/1381612013397564; BELLOFATTO V, 1987, MOL BIOCHEM PARASIT, V25, P227, DOI 10.1016/0166-6851(87)90086-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; BRUN R, 1979, ACTA TROP, V36, P289; Burchmore RJS, 2002, CURR PHARM DESIGN, V8, P257, DOI 10.2174/1381612023396159; Carter KC, 2003, ANTIMICROB AGENTS CH, V47, P1529, DOI 10.1128/AAC.47.5.1529-1535.2003; Cottrell TR, 2003, TRENDS MICROBIOL, V11, P37, DOI 10.1016/S0966-842X(02)00004-5; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Fairlamb Alan H., 1997, P149; Fries D.S., 2003, BURGERS MED CHEM DRU, P1033; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P6319, DOI 10.1073/pnas.76.12.6319; GRIFFITH OW, 1981, P NATL ACAD SCI-BIOL, V78, P2777, DOI 10.1073/pnas.78.5.2777; GRIFFITH OW, 1978, P NATL ACAD SCI USA, V75, P5405, DOI 10.1073/pnas.75.11.5405; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; KANG YJ, 1994, TOXICOLOGY, V88, P177, DOI 10.1016/0300-483X(94)90119-8; Karp DR, 2001, J BIOL CHEM, V276, P3798, DOI 10.1074/jbc.M008484200; Kinch LN, 2000, BIOCHEMISTRY-US, V39, P3336, DOI 10.1021/bi991493r; KIRCHHOFF LV, 1994, CURR OPIN INFECT DIS, V7, P542, DOI 10.1097/00001432-199410000-00004; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; Luersen K, 2000, BIOCHEM J, V346, P545, DOI 10.1042/0264-6021:3460545; Matovu E, 2001, MICROBES INFECT, V3, P763, DOI 10.1016/S1286-4579(01)01432-0; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; Meister A., 1989, METABOLISM FUNCTIONS, P367; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Mulenga C, 2001, NEUROPATH APPL NEURO, V27, P77, DOI 10.1046/j.0305-1846.2001.00306.x; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Oza SL, 2002, J BIOL CHEM, V277, P35853, DOI 10.1074/jbc.M204403200; PEGG AE, 1995, J CELL BIOCHEM, P132; PEPIN J, 2000, HUNTERS TROPICAL MED, P643; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; REED SG, 2000, HUNTERS TROPICAL MED, P653; REPETTO Y, 1987, COMP BIOCHEM PHYS B, V87, P73, DOI 10.1016/0305-0491(87)90472-X; Sagerstrom Charles G., 1996, P83; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt Armin, 2002, Current Topics in Medicinal Chemistry, V2, P1239, DOI 10.2174/1568026023393048; SEED JR, 1989, J PROTOZOOL, V36, P572, DOI 10.1111/j.1550-7408.1989.tb01099.x; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; Tetaud E, 1998, J BIOL CHEM, V273, P19383, DOI 10.1074/jbc.273.31.19383; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Weldrick DP, 1999, FEMS MICROBIOL LETT, V173, P139, DOI 10.1111/j.1574-6968.1999.tb13495.x; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887	54	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39794	39800		10.1074/jbc.M306306200	http://dx.doi.org/10.1074/jbc.M306306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888552	hybrid			2022-12-25	WOS:000185713800065
J	Price, LS; Langeslag, M; ten Klooster, JP; Hordijk, PL; Jalink, K; Collard, JG				Price, LS; Langeslag, M; ten Klooster, JP; Hordijk, PL; Jalink, K; Collard, JG			Calcium signaling regulates translocation and activation of Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; RHO FAMILY GTPASES; DISSOCIATION INHIBITOR; ACTIN CYTOSKELETON; MAST-CELLS; NEUTROPHILS; HOMOLOGY; COMPLEX; TIAM1	Rac is activated in response to various stimuli including growth factors and by adhesion to the extracellular matrix. However, how these stimuli ultimately result in Rac activation is poorly understood. The increase in intracellular calcium [Ca2+](i) represents a ubiquitous second messenger system in cells, linking receptor activation to downstream signaling pathways. Here we show that elevation of [Ca2+](i), either artificially or by thrombin receptor activation, potently induces Rac activation. Lamellipodia formation induced by artificial elevation of [Ca2+](i) is blocked by inhibition of Rac signaling, indicating that calcium-induced cytoskeletal changes are controlled by the activation of Rac. Calcium-dependent Rac activation was dependent on the activation of a conventional protein kinase C. Furthermore, both increased [Ca2+](i) and protein kinase C activation induce phosphorylation of RhoGDIalpha and induce the translocation of cytosolic Rac to the plasma membrane. Intracellular calcium signaling may thus contribute to the intracellular localization and activation of Rac to regulate the cytoskeletal changes in response to receptor stimulation.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands; CLB, Sanquin Res, Dept Expt Immunohematol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Collard, JG (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Jalink, Kees/0000-0001-7019-3440; ten Klooster, Jean Paul/0000-0002-4979-7482; Hordijk, Peter/0000-0002-3348-078X; Langeslag, Michiel/0000-0003-4883-7339				Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ho A, 2001, CANCER RES, V61, P474; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Meacci E, 2000, FEBS LETT, V482, P97, DOI 10.1016/S0014-5793(00)02039-1; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Michiels F, 2000, METHOD ENZYMOL, V325, P295; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORTON RA, 1993, CANCER RES, V53, P3585; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; Pierini LM, 2000, BLOOD, V95, P2471; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, DEV CELL, V1, P160, DOI 10.1016/S1534-5807(01)00029-6; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scaife RM, 2003, J CELL SCI, V116, P463, DOI 10.1242/jcs.00244; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Scherberich A, 2000, J CELL SCI, V113, P653; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Soulet C, 2001, FEBS LETT, V507, P253, DOI 10.1016/S0014-5793(01)02984-2; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; van Rheenen J, 2002, MOL BIOL CELL, V13, P3257, DOI 10.1091/mbc.E02-04-0231; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; WILLIAMS DA, 1990, CELL CALCIUM, V11, P589, DOI 10.1016/0143-4160(90)90013-K; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	56	165	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39413	39421		10.1074/jbc.M302083200	http://dx.doi.org/10.1074/jbc.M302083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888567	hybrid			2022-12-25	WOS:000185713800018
J	Chen, Y; Balakrishnan, M; Roques, BP; Bambara, RA				Chen, Y; Balakrishnan, M; Roques, BP; Bambara, RA			Steps of the acceptor invasion mechanism for HIV-1 minus strand strong stop transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; RNASE-H ACTIVITY; NUCLEOCAPSID PROTEIN NCP7; REVERSE-TRANSCRIPTASE; DNA-SYNTHESIS; IN-VITRO; RETROVIRAL REPLICATION; SECONDARY STRUCTURE; INTERNAL REGIONS	Minus strand strong stop transfer is obligatory for completion of HIV-1 minus strand synthesis. We previously showed evidence for an acceptor invasion-initiated mechanism for minus strand transfer. In the present study, we examined the major acceptor invasion initiation site using a minus strand transfer system in vitro, containing the 97-nucleotide full-length R region. A series of DNA oligonucleotides complementary to different regions of the cDNA was designed to interfere with transfer. Oligomers covering the region around the base of the TAR hairpin were most effective in inhibiting transfer, suggesting that the hairpin base is a preferred site for acceptor invasion. The strong pausing of reverse transcriptase at the base of the TAR and the concomitant RNase H cleavages 10-19 nucleotides behind the pause site correlated with the location of the invasion site. Oligomers closer to the 5'-end of R also inhibited transfer, though less effectively, presumably by blocking strand exchange and branch migration. We propose that pausing of reverse transcriptase at the base of TAR increases RNase H cleavages, creating gaps for acceptor invasion and transfer initiation. Strand exchange then propagates by branch migration, displacing the fragmented donor RNA, including the fragment at the 5' terminus. The primer terminus switches to the acceptor, completing the transfer. Nucleocapsid (NC) protein stimulated transfer efficiency by 5-7-fold. NC enhanced RNase H cleavages close to the TAR base, creating more effective invasion sites for efficient transfer. Most likely, NC also stimulates transfer by promoting strand exchange invasion and branch migration.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; UER Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, URA D1500,INSERM,U266, F-75270 Paris, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				PHS HHS [49573] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allain B, 1998, J MOL BIOL, V277, P225, DOI 10.1006/jmbi.1997.1596; ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; BERKHOUT B, 1995, J MOL BIOL, V252, P59, DOI 10.1006/jmbi.1994.0475; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Berkhout B, 1998, VIROLOGY, V249, P211, DOI 10.1006/viro.1998.9321; Brule F, 2000, NUCLEIC ACIDS RES, V28, P634, DOI 10.1093/nar/28.2.634; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Chen Y, 2003, J BIOL CHEM, V278, P8006, DOI 10.1074/jbc.M210959200; Cheslock SR, 2000, J VIROL, V74, P9571, DOI 10.1128/JVI.74.20.9571-9579.2000; Dang Q, 2001, J VIROL, V75, P809, DOI 10.1128/JVI.75.2.809-820.2001; Derebail SS, 2003, J BIOL CHEM, V278, P15702, DOI 10.1074/jbc.M211701200; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; Golinelli MP, 2001, VIROLOGY, V285, P278, DOI 10.1006/viro.2001.0970; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Guo JH, 1998, J VIROL, V72, P6716, DOI 10.1128/JVI.72.8.6716-6724.1998; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Hsu M, 2000, NUCLEIC ACIDS RES, V28, P1724, DOI 10.1093/nar/28.8.1724; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; JONES JS, 1994, J VIROL, V68, P207, DOI 10.1128/JVI.68.1.207-216.1994; KHAN R, 1992, J BIOL CHEM, V267, P6689; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KLAVER B, 1994, NUCLEIC ACIDS RES, V22, P137, DOI 10.1093/nar/22.2.137; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; LOBEL LI, 1985, J VIROL, V53, P447, DOI 10.1128/JVI.53.2.447-455.1985; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; Ohi Y, 2000, J VIROL, V74, P8324, DOI 10.1128/JVI.74.18.8324-8334.2000; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Pfeiffer JK, 2001, J VIROL, V75, P11263, DOI 10.1128/JVI.75.23.11263-11274.2001; RAMSEY CA, 1993, J VIROL, V67, P4114, DOI 10.1128/JVI.67.7.4114-4121.1993; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1992, J VIROL, V66, P615, DOI 10.1128/JVI.66.2.615-622.1992; Telesnitsky A., 1997, P121; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; Topping R, 1998, J MOL BIOL, V281, P1, DOI 10.1006/jmbi.1998.1929; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; van Wamel JLB, 1998, VIROLOGY, V244, P245, DOI 10.1006/viro.1998.9096; VARMUS HE, 1978, J MOL BIOL, V120, P55, DOI 10.1016/0022-2836(78)90295-4; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Yin PD, 1997, J VIROL, V71, P2487, DOI 10.1128/JVI.71.3.2487-2494.1997; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491	65	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38368	38375		10.1074/jbc.M305700200	http://dx.doi.org/10.1074/jbc.M305700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878597	hybrid			2022-12-25	WOS:000185575100036
J	Miura-Shimura, Y; Duan, L; Rao, NL; Reddi, AL; Shimura, H; Rottapel, R; Druker, BJ; Tsygankov, AY; Band, V; Band, H				Miura-Shimura, Y; Duan, L; Rao, NL; Reddi, AL; Shimura, H; Rottapel, R; Druker, BJ; Tsygankov, AY; Band, V; Band, H			Cbl-mediated ubiquitinylation and negative regulation of Vav	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; T-CELL-RECEPTOR; SYK TYROSINE KINASE; C-CBL; SIGNAL-TRANSDUCTION; PROTOONCOGENE PRODUCT; RING FINGER; PHOSPHORYLATION SITE; DOWN-MODULATION	The Cbl ubiquitin ligase has emerged as a negative regulator of receptor and non-receptor tyrosine kinases. Cbl is known to associate with the proto-oncogene product Vav, a hematopoietic-restricted Rac guanine nucleotide exchange factor, but the consequences of this interaction remain to be elucidated. Using immortalized T cell lines from Cbl(+/+) and Cbl(-/-) mice, and transfection analyses in 293T cells, we demonstrate that Vav undergoes Cbl-dependent ubiquitinylation under conditions that promote Cbl and Vav phosphorylation. Interaction with Cbl also induced the loss of phosphorylated Vav. In addition, we show that an activated Vav mutant (Vav-Y174F) is more sensitive to Cbl-dependent ubiquitinylation. We demonstrate that the Cbl-dependent ubiquitinylation of Vav requires Cbl/Vav association through phosphorylated Tyr-700 on Cbl, and also requires an intact Cbl RING finger domain. Finally, using transfection analyses in the Jurkat T cell line, we show that Cbl, but not its ubiquitin ligase mutant, can inhibit Vav-dependent signaling. Thus, our findings strongly support the role of Cbl, via its ubiquitin ligase activity, as a negative regulator of activated Vav.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Ctr Neurol Dis, Boston, MA 02115 USA; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Oregon Hlth & Sci Univ, Portland, OR 97239 USA; Tufts Univ, New England Med Ctr, Dept Radiat & Canc Biol, Boston, MA 02111 USA; Temple Univ, Sch Med, Dept Microbiol Immunol, Philadelphia, PA 19140 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Oregon Health & Science University; Tufts Medical Center; Tufts University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Band, H (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, ENH Res Inst,Div Mol Oncol, 1001 Univ Pl, Evanston, IL 60201 USA.	h-band@northwestern.edu	shimura, hideki/AAA-2864-2020; Tsygankov, Alexander Y/K-6205-2017	Druker, Brian/0000-0001-8331-8206; Rottapel, Robert/0000-0002-6024-5558	NCI NIH HHS [CA76118, CA75075, CA70195, CA99900, CA99163, CA87986, CA81076] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070195, R01CA099900, R01CA087986, R01CA099163, R01CA081076, R01CA076118, R01CA075075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; Germani A, 1999, MOL CELL BIOL, V19, P3798; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hawash IY, 2002, J BIOL CHEM, V277, P5683, DOI 10.1074/jbc.M110002200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 2002, TRENDS IMMUNOL, V23, P140, DOI 10.1016/S1471-4906(01)02157-3; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; RAO N, 2002, SIGNAL TRANSDUCTION, V1, P29; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Schuebel KE, 1996, ONCOGENE, V13, P363; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2003, J EXP MED, V197, P503, DOI 10.1084/jem.20021498; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WU J, 1995, MOL CELL BIOL, V15, P4337; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	67	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38495	38504		10.1074/jbc.M305656200	http://dx.doi.org/10.1074/jbc.M305656200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12881521	hybrid			2022-12-25	WOS:000185575100051
J	Livingstone-Zatchej, M; Marcionelli, R; Moller, K; de Pril, R; Thoma, F				Livingstone-Zatchej, M; Marcionelli, R; Moller, K; de Pril, R; Thoma, F			Repair of UV lesions in silenced chromatin provides in vivo evidence for a compact chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE-PYRIMIDINE DIMERS; NUCLEASE-SENSITIVE REGIONS; NUCLEOSOME CORE PARTICLE; INDUCED DNA LESIONS; SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; NONTRANSCRIBED STRAND; DIFFERENTIAL REPAIR; HISTONE ACETYLATION	Genes positioned close to telomeres in yeast are silenced by a heterochromatin-like structure containing Sir proteins. To investigate whether silencing also affects DNA repair, we studied removal of UV lesions by photolyase and nucleotide excision repair (NER) in strains containing the URA3 gene inserted 2 kilobases from a telomere. URA3 was transcriptionally active in sir3Delta mutants, partially silenced in SIR3 cells, or completely silenced by overexpression of SIR3 or deletion of RPD3. The active URA3 showed efficient repair by both pathways. Fast repair of the promoter and 3' end by photolyase reflected a non-nucleosomal structure. Partial silencing had no remarkable effect on photolyase but reduced repair by NER, indicating differential accessibility for the two repair reactions. Complete silencing inhibits NER and photolyase in the coding region as well as in the promoter and the 3'-end. Conventional nuclease footprinting analyses revealed subtle changes in the promoter proximal nucleosome under partially silenced conditions but a pronounced reorganization of chromatin extending over the whole gene in silenced chromatin. Thus, both repair systems are sensitive to chromatin changes associated with silencing and provide direct evidence for a compact structure of heterochromatin.	ETH Honggerberg, Inst Zellbiol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thoma, F (corresponding author), ETH Honggerberg, Inst Zellbiol, CH-8093 Zurich, Switzerland.							Aboussekhra A, 1998, GENE DEV, V12, P411, DOI 10.1101/gad.12.3.411; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; Conconi A, 2002, P NATL ACAD SCI USA, V99, P649, DOI 10.1073/pnas.022373099; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; DeRubertis F, 1996, NATURE, V384, P589; Dhillon N, 2002, CURR OPIN GENET DEV, V12, P188, DOI 10.1016/S0959-437X(02)00285-X; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gaillard H, 2003, J BIOL CHEM, V278, P17655, DOI 10.1074/jbc.M300770200; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Hara R, 2002, MOL CELL BIOL, V22, P6779, DOI 10.1128/MCB.22.19.6779-6787.2002; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HUANG JC, 1994, J BIOL CHEM, V269, P19034; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; LivingstoneZatchej M, 1997, NUCLEIC ACIDS RES, V25, P3795, DOI 10.1093/nar/25.19.3795; LOHR D, 1977, BIOCHEMISTRY-US, V16, P463, DOI 10.1021/bi00622a020; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Meier A, 2002, J BIOL CHEM, V277, P11845, DOI 10.1074/jbc.M110941200; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Park JH, 2002, NAT GENET, V32, P273, DOI 10.1038/ng982; Park Y, 2000, GENETICS, V154, P587; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Ravindra A, 1999, MOL CELL BIOL, V19, P7944; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Sancar A, 1996, SCIENCE, V272, P48, DOI 10.1126/science.272.5258.48; Sancar GB, 2000, MUTAT RES-FUND MOL M, V451, P25, DOI 10.1016/S0027-5107(00)00038-5; Schieferstein U, 1998, EMBO J, V17, P306, DOI 10.1093/emboj/17.1.306; Sekinger EA, 1999, EMBO J, V18, P7041, DOI 10.1093/emboj/18.24.7041; Singer MS, 1998, GENETICS, V150, P613; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Sun ZW, 1999, GENETICS, V152, P921; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Suter B, 2000, NUCLEIC ACIDS RES, V28, P4083, DOI 10.1093/nar/28.21.4083; Suter B, 2000, NUCLEIC ACIDS RES, V28, P2060, DOI 10.1093/nar/28.10.2060; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Suter B, 1999, METHOD ENZYMOL, V304, P447; Suter B, 2002, J MOL BIOL, V319, P395, DOI 10.1016/S0022-2836(02)00291-7; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tanaka S, 1996, J MOL BIOL, V257, P919, DOI 10.1006/jmbi.1996.0212; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; Tham WH, 2001, MOL CELL, V8, P189, DOI 10.1016/S1097-2765(01)00287-8; Tham WH, 2002, ONCOGENE, V21, P512, DOI 10.1038/sj.onc.1205078; THOMA F, 1986, J MOL BIOL, V190, P177, DOI 10.1016/0022-2836(86)90291-3; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; Thoma F, 1996, METHOD ENZYMOL, V274, P197; Tijsterman M, 1999, MOL CELL BIOL, V19, P934; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Vega-Palas MA, 1998, J BIOL CHEM, V273, P9388, DOI 10.1074/jbc.273.16.9388; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WATERS R, 1993, MOL GEN GENET, V239, P28, DOI 10.1007/BF00281597; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	85	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37471	37479		10.1074/jbc.M306335200	http://dx.doi.org/10.1074/jbc.M306335200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12882973	hybrid			2022-12-25	WOS:000185437200060
J	Sato, N; Fukushima, N; Maehara, N; Matsubayashi, H; Koopmann, J; Su, GH; Hruban, RH; Goggins, M				Sato, N; Fukushima, N; Maehara, N; Matsubayashi, H; Koopmann, J; Su, GH; Hruban, RH; Goggins, M			SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions	ONCOGENE			English	Article						SPARC; methylation; pancreatic cancer; tumor-stromal interaction	CELL-CYCLE PROGRESSION; SPARC-NULL MICE; GENE-EXPRESSION; NEOPLASTIC PROGRESSION; DUCTAL ADENOCARCINOMA; DESMOPLASTIC RESPONSE; CPG ISLANDS; CANCER; INVASION; PROTEIN	Deregulated expression of SPARC/osteonectin, a secreted glycoprotein with multiple biological functions, has been associated with the progression of various cancers. Using microarrays, we previously identified SPARC as one of the genes induced by treatment with a DNA methylation inhibitor in pancreatic cancer cells. We therefore analysed the expression pattern and methylation status of the SPARC gene in pancreatic cancer. Gene expression profiting by oligonucleotide microarray and reverse transcription-PCR analyses demonstrated that SPARC mRNA was expressed in non-neoplastic pancreatic ductal epithelial cells, but was not expressed in a majority of pancreatic cancer cell lines. The loss of SPARC expression was associated with aberrant hypermethylation of its CpG island. Immunohistochemical labeling revealed that the SPARC protein was overexpressed in the stromal fibroblasts immediately adjacent to the neoplastic epithelium in primary pancreatic cancers, but rarely expressed in the cancers themselves. Primary fibroblasts derived from pancreatic cancer strongly expressed SPARC mRNA and secreted SPARC protein into the conditioned media, and treatment of pancreatic cancer cells with exogenous SPARC resulted in growth suppression. SPARC expression in fibroblasts from noncancerous pancreatic tissue was augmented by coculture with pancreatic cancer cells. These findings suggest that SPARC is a frequent target for aberrant methylation in pancreatic cancer and that SPARC expression in fibroblasts adjacent to pancreatic cancer cells is regulated through tumor-stromal interactions.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu		Su, Gloria/0000-0002-5158-6019	NCI NIH HHS [CA62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Dhanesuan N, 2002, BREAST CANCER RES TR, V75, P73, DOI 10.1023/A:1016536725958; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Fukushima N, 2003, CANCER BIOL THER, V2, P78; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Goggins M, 2000, J SURG ONCOL, V74, P243, DOI 10.1002/1096-9098(200008)74:4<243::AID-JSO1>3.0.CO;2-C; HAHN SA, 1995, CANCER RES, V55, P4670; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2002, CANCER RES, V62, P5351; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P91, DOI 10.1016/S0002-9440(10)64353-2; Jacob K, 1999, CANCER RES, V59, P4453; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; Le Bail B, 1999, J PATHOL, V189, P46; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Maehara N, 2001, BRIT J CANCER, V84, P864, DOI 10.1054/bjoc.2000.1682; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446; Mok SC, 1996, ONCOGENE, V12, P1895; Paley PJ, 2000, GYNECOL ONCOL, V78, P336, DOI 10.1006/gyno.2000.5894; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Rempel SA, 1999, CLIN CANCER RES, V5, P237; Rosty C, 2002, CANCER RES, V62, P1868; Rosty C, 2002, HEMATOL ONCOL CLIN N, V16, P37, DOI 10.1016/S0889-8588(01)00007-7; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Ryu B, 2001, CANCER RES, V61, P1833; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2002, GASTROENTEROLOGY, V123, P365, DOI 10.1053/gast.2002.34160; SATO N, 2003, IN PRESS CANC RES; Schultz C, 2002, CANCER RES, V62, P6270; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Ueki T, 2001, CANCER RES, V61, P8540; WEWER UM, 1988, AM J PATHOL, V132, P345; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4	51	235	248	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5021	5030		10.1038/sj.onc.1206807	http://dx.doi.org/10.1038/sj.onc.1206807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902985				2022-12-25	WOS:000184578900010
J	Plenz, G; Eschert, H; Beissert, S; Arps, V; Sindermann, JR; Robenek, H; Volker, W				Plenz, G; Eschert, H; Beissert, S; Arps, V; Sindermann, JR; Robenek, H; Volker, W			Alterations in the vascular extracellular matrix of granulocyte macrophage colony-stimulating factor (GM-CSF)-deficient mice	FASEB JOURNAL			English	Article						GM-CSF deficiency; vascular collagens; remodeling; atherogenesis	SMOOTH-MUSCLE-CELLS; TUMOR-NECROSIS-FACTOR; COLLAGEN TYPES-I; VIII COLLAGEN; MESSENGER-RNA; GM-CSF; CHOLESTEROL; EXPRESSION; PROLIFERATION; INTERLEUKIN-1	GM-CSF takes part in the cytokine network regulating the metabolism of extracellular matrix (ECM) during atherogenesis. Since data also point to an effect of GM-CSF on the vascular ECM in general, the vascular collagenous matrix was studied in wild-type and GM-CSF-deficient mice. Histological examination revealed a disorganized vascular ECM in GM-CSF-deficient mice involving the collagenous matrix and elastic fiber system. As shown by electron microscopy, collagen bundles were disrupted and reduced. The diameter of fibrils varied widely. mRNA expression of collagens and related molecules was studied. Fibrillar collagens were markedly reduced, alpha1 (I) procollagen to 16.5% of control levels alpha1 (III) procollagen was abolished whereas the expression level of network-forming alpha1 (VIII) procollagen was not altered. As shown by in situ hybridization, the number of collagen-expressing cells was reduced. Matrix metalloproteinases and their inhibitor 1 were not affected by GM-CSF deficiency. Our studies demonstrate that GM-CSF plays a major role in the cytokine network regulating the metabolism of vascular collagens. GM-CSF deficiency leads to an altered composition of the vascular collagenous matrix, i.e., reduced amount of fibrillar collagen, altered ratio of fibrillar and network-forming collagen, and failures in the fibrillogenesis. We suggest that GM-CSF is a basic requirement for the maintenance of vessel wall integrity and resilience.	Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Hosp Munster, Dept Thorac & Cardiovasc Surg, D-48149 Munster, Germany; Univ Hosp Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Hosp Munster, Dept Cardiol & Angiol, D-48149 Munster, Germany	University of Munster; University of Munster; University of Munster	Plenz, G (corresponding author), Inst Arteriosclerosis Res, Domagkstr 3, D-48149 Munster, Germany.	plenz@uni-muenster.de						Brandt T, 2001, NEUROLOGY, V57, P24, DOI 10.1212/WNL.57.1.24; Canturk NZ, 1999, ENDOCR RES, V25, P105, DOI 10.3109/07435809909066133; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; FILONZI EL, 1993, ATHEROSCLEROSIS, V99, P241, DOI 10.1016/0021-9150(93)90026-Q; George SJ, 2000, EXPERT OPIN INV DRUG, V9, P993, DOI 10.1517/13543784.9.5.993; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHIBASHI T, 1995, ANN NY ACAD SCI, V748, P630; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993; MCCULLAGH KG, 1980, J PATHOL, V130, P45, DOI 10.1002/path.1711300107; METCALF D, 1985, CELL, V43, P5, DOI 10.1016/0092-8674(85)90004-2; METCALF D, 1993, CR ACAD SCI III-VIE, V316, P866; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; NAKAO K, 1995, J DENT RES, V74, P1072, DOI 10.1177/00220345950740040701; NAKATA K, 1991, J IMMUNOL, V147, P1266; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; NIMER SD, 1988, JAMA-J AM MED ASSOC, V260, P3297, DOI 10.1001/jama.260.22.3297; Ottani V, 2001, MICRON, V32, P251, DOI 10.1016/S0968-4328(00)00042-1; PIGUET PF, 1993, EXP LUNG RES, V19, P579, DOI 10.3109/01902149309031729; Plenz G, 1999, ARTERIOSCL THROM VAS, V19, P1658, DOI 10.1161/01.ATV.19.7.1658; Plenz G, 1997, ARTERIOSCL THROM VAS, V17, P2489, DOI 10.1161/01.ATV.17.11.2489; Plenz G, 1999, ARTERIOSCL THROM VAS, V19, P1201, DOI 10.1161/01.ATV.19.5.1201; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; SEELENTAG W, 1989, EUR J IMMUNOL, V19, P209, DOI 10.1002/eji.1830190135; Shindo J, 1999, CIRCULATION, V99, P2150, DOI 10.1161/01.CIR.99.16.2150; SIEFF CA, 1988, BLOOD, V72, P1316; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; Tomita T, 2000, CANCER LETT, V156, P83, DOI 10.1016/S0304-3835(00)00446-8; VOSS B, 1986, PATHOL RES PRACT, V181, P568, DOI 10.1016/S0344-0338(86)80151-0; WANG J, 1994, EXP MOL PATHOL, V61, P109, DOI 10.1006/exmp.1994.1030; Zhang YH, 1998, J IMMUNOL, V161, P3071	34	15	16	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1451	1457		10.1096/fj.02-1035com	http://dx.doi.org/10.1096/fj.02-1035com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890699				2022-12-25	WOS:000185345100038
J	Ma, Y; Koza-Taylor, PH; DiMattia, DA; Hames, L; Fu, HN; Dragnev, KH; Turi, T; Beebe, JS; Freemantle, SJ; Dmitrovsky, E				Ma, Y; Koza-Taylor, PH; DiMattia, DA; Hames, L; Fu, HN; Dragnev, KH; Turi, T; Beebe, JS; Freemantle, SJ; Dmitrovsky, E			Microarray analysis uncovers retinoid targets in human bronchial epithelial cells	ONCOGENE			English	Article						retinoic acid; bronchial epithelial cells; microarray analysis; retinoic acid resistance	TGF-BETA SUPERFAMILY; FACTOR BINDING PROTEIN-6; LOOP-HELIX PROTEINS; ACUTE PROMYELOCYTIC LEUKEMIA; ASPARAGINE SYNTHETASE GENE; PLACEBO-CONTROLLED TRIAL; TISSUE TRANSGLUTAMINASE; LUNG-CANCER; TRANSCRIPTION FACTOR; SIGNALING PATHWAY	Retinoids, the natural and synthetic derivatives of vitamin A, have a role in cancer treatment and prevention. There is a need to reveal mechanisms that account for retinoid response or resistance. This study identified candidate all-trans-retinoic acid (RA) target genes linked to growth suppression in BEAS-2B human bronchial epithelial cells. Microarray analyses were performed using Affymetrix arrays. A total of 11 RA-induced species were validated by reverse transcription polymerase chain reaction (RT-PCR), Western or Northern analyses. Three of these species were novel candidate RA-target genes in human bronchial epithelial cells. These included: placental bone morphogenetic protein (PLAB), polyamine oxidase isoform 1 (PAOh1) and E74-like factor 3 (ELF3). Expression patterns were studied in RA-resistant BEAS-2BR1 cells. In BEAS-2B-R1 cells, RA dysregulated the expression of the putative lymphocyte G0/G1 switch gene (G0S2), heme oxygenase 1 (HMOX1), tumor necrosis factor-alpha-induced protein 2 (TNFAIP2), inhibitor of DNA binding 1(Id1), fos-like antigen 1 (FOSL1), transglutaminase 2 (TGM2), asparagine synthetase (ASNS), PLAB, PAOh1 and ELF3, while prominent induction of insulin-like growth-factor-binding protein 6 (IGFBP6) still occurred. In summary, this study identified 11 candidate RA-target genes in human bronchial epithelial cells including three novel species. Expression studies in BEAS-2B-R1 cells indicated that several were directly implicated in RA signaling, since their aberrant expression was linked to RA resistance of human bronchial epithelial cells.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Pfizer Global Res & Dev, Groton, CT 06340 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Pfizer	Dmitrovsky, E (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [R01CA087546] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA87546] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; ARFIN SM, 1977, P NATL ACAD SCI USA, V74, P2367, DOI 10.1073/pnas.74.6.2367; Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Clarke PA, 2001, BIOCHEM PHARMACOL, V62, P1311, DOI 10.1016/S0006-2952(01)00785-7; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DELVA L, 1993, BLOOD, V82, P2175; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Ferry RJ, 1999, HORM METAB RES, V31, P192, DOI 10.1055/s-2007-978719; Freeman WM, 2000, BIOTECHNIQUES, V29, P1042, DOI 10.2144/00295rv01; Gabbitas B, 1996, J CELL PHYSIOL, V169, P15, DOI 10.1002/(SICI)1097-4652(199610)169:1<15::AID-JCP2>3.0.CO;2-H; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HONGO S, 1990, LEUKEMIA, V4, P708; Kaiser A, 1999, FEBS LETT, V448, P45, DOI 10.1016/S0014-5793(99)00326-9; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5; KITAREEWAN S, IN PRESS CANC CHEMOP, V1; Kizaki M, 1996, BLOOD, V87, P725, DOI 10.1182/blood.V87.2.725.bloodjournal872725; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Langenfeld J, 1996, ONCOGENE, V13, P1983; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605; Lonardo F, 1999, CANCER RES, V59, P2470; Lonardo F, 2002, CLIN CANCER RES, V8, P54; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Nagy L, 1996, J BIOL CHEM, V271, P4355; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Ou HS, 2000, CIRC RES, V87, P881, DOI 10.1161/01.RES.87.10.881; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; REDDEL RR, 1988, CANCER RES, V48, P1904; Rusiniak ME, 2000, CANCER RES, V60, P1824; RUSSELL L, 1991, DNA CELL BIOL, V10, P581, DOI 10.1089/dna.1991.10.581; SARMA V, 1992, J IMMUNOL, V148, P3302; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; SPORN MB, 1976, FED PROC, V35, P1332; Sueoka N, 2000, AM J RESP CELL MOL, V23, P297, DOI 10.1165/ajrcmb.23.3.4013; Sueoka N, 1999, CANCER RES, V59, P3838; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Yan ZH, 1996, MOL CELL ENDOCRINOL, V120, P203, DOI 10.1016/0303-7207(96)03826-9; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	59	44	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4924	4932		10.1038/sj.onc.1206728	http://dx.doi.org/10.1038/sj.onc.1206728			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894236				2022-12-25	WOS:000184344600018
J	Taylor, ER; Boner, W; Dornan, ES; Corr, EM; Morgan, IM				Taylor, ER; Boner, W; Dornan, ES; Corr, EM; Morgan, IM			UVB irradiation reduces the half-life and transactivation potential of the human papillomavirus 16 E2 protein	ONCOGENE			English	Article						HPV; E2; transcription; protein solubility; UV	HUMAN-PAPILLOMAVIRUS TYPE-18; E2 PROTEIN; DNA-DAMAGE; FUNCTIONAL INTERACTION; TRANSCRIPTIONAL ACTIVATOR; BINDING PROTEIN; P53; PROMOTER; CELLS; DEGRADATION	Human papillomaviruses (HPV) are causative agents of human cancers including those of the cervix and also of the head and neck; HPV16 is the most commonly found type in these diseases. The viral E2 protein regulates transcription from the viral genome by interacting with DNA-binding sequences in the HPV transcriptional control region; it also regulates replication by interacting with and recruiting the HPV replication factor El to the viral origin. Therefore, E2 is essential for the viral life cycle. The E2 protein interacts with several proteins involved in the cellular response to DNA damage including p53, TopBP1, and PARP. We therefore set out to establish whether DNA-damaging agents can regulate E2 activity. Here we show that UVB irradiation downregulates transcriptional activity of both HPV16 and HPV8 E2, while hydroxyurea and etoposide do not. This downregulation of E2 activity is independent of p53 function as it occurs in p53 wild type and null cell types as well as in the presence of functional HPV16 E6 that degrades p53. Using stable cell lines expressing E2 we show that this downregulation of E2 function by UVB is due to a reduction of the E2 protein half-life. The identification of the pathway(s) through which UVB downregulates E2 transcriptional activity and protein levels will present a novel target for the treatment of HPV-related diseases.	Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Morgan, IM (corresponding author), Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	i.morgan@vet.gla.ac.uk						Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; Beniston RG, 2001, CARCINOGENESIS, V22, P1069, DOI 10.1093/carcin/22.7.1069; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Boner W, 2002, J BIOL CHEM, V277, P22297, DOI 10.1074/jbc.M202163200; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Chao SF, 1999, BIOCHEMISTRY-US, V38, P4586, DOI 10.1021/bi982616v; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HIBMA MH, 1995, EUR J BIOCHEM, V229, P517, DOI 10.1111/j.1432-1033.1995.tb20493.x; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee D, 2002, ONCOGENE, V21, P5877, DOI 10.1038/sj.onc.1205723; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Mantovani F, 1999, SEMIN CANCER BIOL, V9, P387, DOI 10.1006/scbi.1999.0142; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165-4608(01)00575-1; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Penrose KJ, 2000, J VIROL, V74, P6031, DOI 10.1128/JVI.74.13.6031-6038.2000; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; Ruhland A, 2001, INT J CANCER, V91, P828, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1129&gt;3.0.CO;2-B; SANDERS CM, 1995, VIROLOGY, V211, P418, DOI 10.1006/viro.1995.1424; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; STUBENRAUCH F, 1994, J VIROL, V68, P6959, DOI 10.1128/JVI.68.11.6959-6966.1994; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Titolo S, 1999, J VIROL, V73, P5282, DOI 10.1128/JVI.73.7.5282-5293.1999; Vance KW, 1999, J BIOL CHEM, V274, P27839, DOI 10.1074/jbc.274.39.27839; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	47	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4469	4477		10.1038/sj.onc.1206746	http://dx.doi.org/10.1038/sj.onc.1206746			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881703				2022-12-25	WOS:000184054700002
J	Khadaroo, RG; Kapus, A; Powers, KA; Cybulsky, MI; Marshall, JC; Rotstein, OD				Khadaroo, RG; Kapus, A; Powers, KA; Cybulsky, MI; Marshall, JC; Rotstein, OD			Oxidative stress reprograms lipopolysaccharide signaling via Src kinase-dependent pathway in RAW 264.7 macrophage cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; FAMILY KINASES; CYTOKINE EXPRESSION; HEMORRHAGIC-SHOCK; ACTIVATION; LUNG; INHIBITOR; INJURY	Oxidative stress generated during ischemia/reperfusion injury has been shown to augment cellular responsiveness. Whereas oxidants are themselves known to induce several intracellular signaling cascades, their effect on signaling pathways initiated by other inflammatory stimuli remains poorly elucidated. Previous work has suggested that oxidants are able to prime alveolar macrophages for increased NF-kappaB translocation in response to treatment with lipopolysaccharide (LPS). Because oxidants are known to stimulate the Src family of tyrosine kinases, we hypothesized that the oxidants might contribute to augmented NF-kappaB translocation by LPS via the involvement of Src family kinases. To model macrophage priming in vitro, the murine macrophage cell line, RAW 264.7, was first incubated with various oxidants and then exposed to low dose LPS. These studies show that oxidant stress is able to augment macrophage responsiveness to LPS as evidenced by earlier and increased NF-kappaB translocation. Inhibition of the Src family kinases by either pharmacological inhibition using PP2 or through a molecular approach by cell transfection with Csk was found to prevent the augmented LPS-induced NF-kappaB translocation caused by oxidants. Interestingly, while Src kinase inhibition was able to prevent the LPS-induced NF-kappaB translocation in oxidant-treated macrophages, this strategy had no effect on NF-kappaB translocation caused by LPS in the absence of oxidants. These findings suggested that oxidative stress might divert LPS signaling along an alternative signaling pathway. Further studies demonstrated that the Src-dependent pathway induced by oxidant pretreatment involved the activation of phosphatidylinositol 3-kinase. Involvement of this pathway appeared to be independent of traditional LPS signaling. Together, these studies provide a novel potential mechanism whereby oxidants might prime alveolar macrophages for altered responsiveness to subsequent inflammatory stimuli and suggest different cellular targets for immunomodulation following ischemia/reperfusion.	Univ Toronto, Dept Surg, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2C4, Canada; Univ Hlth Network, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Rotstein, OD (corresponding author), Toronto Gen Hosp, 200 Elizabeth St,EN9-232, Toronto, ON M5G 2C4, Canada.		Cybulsky, Myron I./AAD-6539-2019	Cybulsky, Myron/0000-0002-1696-2867				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Blackwell TS, 1996, J IMMUNOL, V157, P1630; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fan J, 1998, J IMMUNOL, V161, P440; Giron-Calle J, 2002, J PHARMACOL EXP THER, V301, P87, DOI 10.1124/jpet.301.1.87; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Imbert V, 1996, J INFLAMM, V46, P65; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mallozzi C, 2001, FREE RADICAL BIO MED, V30, P1108, DOI 10.1016/S0891-5849(01)00509-3; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCUTCHAN HJ, 1990, AM J PHYSIOL, V258, pH1415, DOI 10.1152/ajpheart.1990.258.5.H1415; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Monick MM, 2001, J IMMUNOL, V167, P5977, DOI 10.4049/jimmunol.167.10.5977; MOORE FA, 1995, SURG CLIN N AM, V75, P257, DOI 10.1016/S0039-6109(16)46587-4; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Parat MO, 2002, BIOCHEM J, V361, P681, DOI 10.1042/0264-6021:3610681; RICE KL, 1992, AM J PHYSIOL, V263, pL430, DOI 10.1152/ajplung.1992.263.4.L430; SCHWARTZ MC, 1995, AM J RESP CELL MOL, V12, P434, DOI 10.1165/ajrcmb.12.4.7695923; Su XH, 1999, AM J PHYSIOL-GASTR L, V276, pG853, DOI 10.1152/ajpgi.1999.276.4.G853; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Triantafilou M, 2002, J CELL SCI, V115, P2603; Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601	33	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47834	47841		10.1074/jbc.M302660200	http://dx.doi.org/10.1074/jbc.M302660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12896983	hybrid			2022-12-25	WOS:000186731400060
J	Burkert, E; Arnold, C; Hammarberg, T; Radmark, O; Steinhilber, D; Werz, O				Burkert, E; Arnold, C; Hammarberg, T; Radmark, O; Steinhilber, D; Werz, O			The C2-like beta-barrel domain mediates the Ca2+-dependent resistance of 5-lipoxygenase activity against inhibition by glutathione peroxidase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED HUMAN 5-LIPOXYGENASE; EXTRACELLULAR CALCIUM; MEMBRANE; CELLS; LEUKOTRIENES; STIMULATION; ACTIVATION; MECHANISM; SELENIUM; PHOSPHATIDYLCHOLINE	Recently, we reported that in crude enzyme preparations, a monocyte-derived soluble protein (M-DSP) renders 5-lipoxygenase (5-LO) activity Ca2+-dependent. Here we provide evidence that this M-DSP is glutathione peroxidase (GPx)-1. Thus, the inhibitory effect of the M-DSP on 5-LO could be overcome by the GPx-1 inhibitor mercaptosuccinate and by the broad spectrum GPx inhibitor iodoacetate, as well as by addition of 13(S)-hydroperoxy-9Z,11E-octadecadienoic acid (13(S)-HPODE). Also, the chromatographic characteristics and the estimated molecular mass ( 80 - 100 kDa) of the M-DSP fit to GPx-1 (87 kDa), and GPx-1, isolated from bovine erythrocytes, mimicked the effects of the M-DSP. Intriguingly, only a trace amount of thiol (10 muM GSH) was required for reduction of 5-LO activity by GPx-1 or the M-DSP. Moreover, the requirement of Ca2+ allowing 5-LO product synthesis in various leukocytes correlated with the respective GPx-1 activities. Mutation of the Ca2+ binding sites within the C2-like domain of 5-LO resulted in strong reduction of 5-LO activity by M-DSP and GPx-1, also in the presence of Ca2+. In summary, our data suggest that interaction of Ca2+ at the C2-like domain of 5-LO protects the enzyme against the effect of GPx-1. Apparently, in the presence of Ca2+, a low lipid hydroperoxide level is sufficient for 5-LO activation.	Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60439 Frankfurt, Germany; Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol, S-17177 Stockholm, Sweden	Goethe University Frankfurt; Karolinska Institutet	Werz, O (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	o.werz@pharmchem.uni-frankfurt.de	Steinhilber, Dieter/J-3221-2012					AHARONY D, 1986, J BIOL CHEM, V261, P1512; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; BRYANT RW, 1982, J BIOL CHEM, V257, P4937; Burkert E, 2003, J LEUKOCYTE BIOL, V73, P191, DOI 10.1189/jlb.0702354; Burkert E, 2002, BIOCHEM BIOPH RES CO, V295, P985, DOI 10.1016/S0006-291X(02)00791-X; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; Coffey MJ, 1998, PROSTAG OTH LIPID M, V56, P113; EGAN RW, 1983, ADV PROSTAG THROMB L, V11, P151; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; Fischer L, 2003, FASEB J, V17, P949, DOI 10.1096/fj.02-0815fje; FLOHE L, 1971, H-S Z PHYSIOL CHEM, V352, P159, DOI 10.1515/bchm2.1971.352.1.159; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2001, BIOCHEMISTRY-US, V40, P6371, DOI 10.1021/bi001595d; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; HATZELMANN A, 1989, EUR J BIOCHEM, V180, P527, DOI 10.1111/j.1432-1033.1989.tb14678.x; HAURAND M, 1988, BIOL CHEM H-S, V369, P133, DOI 10.1515/bchm3.1988.369.1.133; Huang HS, 1998, FEBS LETT, V424, P22, DOI 10.1016/S0014-5793(98)00130-6; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; JAKOBSSON PJ, 1995, EUR J BIOCHEM, V232, P37, DOI 10.1111/j.1432-1033.1995.tb20778.x; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; MAIORINO M, 1991, J BIOL CHEM, V266, P7728; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Mogul R, 2000, BIOCHEMISTRY-US, V39, P4801, DOI 10.1021/bi992805t; NOGUCHI M, 1994, BBA-LIPID LIPID MET, V1215, P300, DOI 10.1016/0005-2760(94)90057-4; PERCIVAL MD, 1992, EUR J BIOCHEM, V210, P109, DOI 10.1111/j.1432-1033.1992.tb17397.x; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; RIENDEAU D, 1989, BIOCHEM J, V263, P565, DOI 10.1042/bj2630565; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1986, FEBS LETT, V204, P293, DOI 10.1016/0014-5793(86)80831-6; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; Sailer ER, 1998, EUR J BIOCHEM, V256, P364, DOI 10.1046/j.1432-1327.1998.2560364.x; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHATZMUNDING M, 1991, EUR J BIOCHEM, V197, P487, DOI 10.1111/j.1432-1033.1991.tb15936.x; SCHEWE C, 1994, BIOCHEM PHARMACOL, V48, P65, DOI 10.1016/0006-2952(94)90224-0; SIES H, 1994, METHOD ENZYMOL, V234, P476; STEINHILBER D, 1989, J CHROMATOGR-BIOMED, V493, P361, DOI 10.1016/S0378-4347(00)82742-5; Straif D, 2000, BIOCHEM J, V349, P455, DOI 10.1042/0264-6021:3490455; Tappel A L, 1978, Methods Enzymol, V52, P506; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; Wendel A, 1981, Methods Enzymol, V77, P325; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Werz O, 2000, EUR J BIOCHEM, V267, P1263, DOI 10.1046/j.1432-1327.2000.01000.x; Werz O, 1998, MOL PHARMACOL, V54, P445, DOI 10.1124/mol.54.2.445; Werz O, 1996, PHARMAZIE, V51, P893; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; ZHANG YY, 1994, ANAL BIOCHEM, V220, P28, DOI 10.1006/abio.1994.1294	56	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42846	42853		10.1074/jbc.M302471200	http://dx.doi.org/10.1074/jbc.M302471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12893830	hybrid			2022-12-25	WOS:000186157000016
J	Thoden, JB; Zhuang, ZH; Dunaway-Mariano, D; Holden, HM				Thoden, JB; Zhuang, ZH; Dunaway-Mariano, D; Holden, HM			The structure of 4-hydroxybenzoyl-CoA thioesterase from Arthrobacter sp strain SU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS SP; 4-CHLOROBENZOIC ACID; ACTIVE-SITE; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; DEHALOGENATION; BIOSYNTHESIS; DEGRADATION; BACTERIA; PROGRAM	The 4-chlorobenzoyl-CoA dehalogenation pathway in certain Arthrobacter and Pseudomonas bacterial species contains three enzymes: a ligase, a dehalogenase, and a thioesterase. Here we describe the high resolution x-ray crystallographic structure of the 4-hydroxybenzoyl-CoA thioesterase from Arthrobacter sp. strain SU. The tetrameric enzyme is a dimer of dimers with each subunit adopting the so-called "hot dog fold" composed of six strands of anti-parallel beta-sheet flanked on one side by a rather long alpha-helix. The dimers come together to form the tetramer with their alpha-helices facing outwards. This quaternary structure is in sharp contrast to that previously observed for the 4-hydroxybenzoyl-CoA thioesterase from Pseudomonas species strain CBS-3, whereby the dimers forming the tetramer pack with their alpha-helices projecting toward the interfacial region. In the Arthrobacter thioesterase, each of the four active sites is formed by three of the subunits of the tetramer. On the basis of both structural and kinetic data, it appears that Glu(73) is the active site base in the Arthrobacter thioesterase. Remarkably, this residue is located on the opposite side of the substrate-binding pocket compared with that observed for the Pseudomonas enzyme. Although these two bacterial thioesterases demonstrate equivalent catalytic efficiencies, substrate specificities, and metabolic functions, their quaternary structures, CoA-binding sites, and catalytic platforms are decidedly different.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of Wisconsin System; University of Wisconsin Madison; University of New Mexico	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28688, GM55513] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chae JC, 2000, GENE, V258, P109, DOI 10.1016/S0378-1119(00)00419-4; CORK DJ, 1991, ADV APPL MICROBIOL, V36, P1; Dunaway-Mariano Debra, 1994, Biodegradation, V5, P259, DOI 10.1007/BF00696464; Furukawa Kensuke, 1994, Biodegradation, V5, P289, DOI 10.1007/BF00696466; HAGGBLOM MM, 1992, FEMS MICROBIOL LETT, V103, P29; HIGSON FK, 1992, ADV APPL MICROBIOL, V37, P135, DOI 10.1016/S0065-2164(08)70254-5; Hisano T, 2003, J BIOL CHEM, V278, P617, DOI 10.1074/jbc.M205484200; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KLAGES U, 1980, ZBL BAKT MIK HYG I C, V1, P215, DOI 10.1016/S0172-5564(80)80002-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAYTON AC, 1992, APPL ENVIRON MICROB, V58, P399, DOI 10.1128/AEM.58.1.399-402.1992; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Li J, 2000, NAT STRUCT BIOL, V7, P555; Luo LS, 2001, BIOCHEMISTRY-US, V40, P15684, DOI 10.1021/bi011536f; MARKS TS, 1984, BIOCHEM BIOPH RES CO, V124, P669, DOI 10.1016/0006-291X(84)91607-3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ROUSSEL A, 1990, ACTA CRYSTALLOGR A, V4, P66; RUISINGER S, 1976, ARCH MICROBIOL, V110, P253, DOI 10.1007/BF00690235; SAVARD P, 1986, J BACTERIOL, V168, P81, DOI 10.1128/jb.168.1.81-85.1986; SCHOLTEN JD, 1991, SCIENCE, V253, P182, DOI 10.1126/science.1853203; Thoden JB, 2002, J BIOL CHEM, V277, P27468, DOI 10.1074/jbc.M203904200; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Yi HR, 2000, FEMS MICROBIOL ECOL, V31, P53, DOI 10.1111/j.1574-6941.2000.tb00671.x; Zhuang ZH, 2003, APPL ENVIRON MICROB, V69, P2707, DOI 10.1128/AEM.69.5.2707-2711.2003; Zhuang ZH, 2002, BIOCHEMISTRY-US, V41, P11152, DOI 10.1021/bi0262303	29	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43709	43716		10.1074/jbc.M308198200	http://dx.doi.org/10.1074/jbc.M308198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12907670	hybrid			2022-12-25	WOS:000186157000120
J	Yakovleva, L; Tian, LG; Sayer, JM; Kalena, GP; Kroth, H; Jerina, DM; Shuman, S				Yakovleva, L; Tian, LG; Sayer, JM; Kalena, GP; Kroth, H; Jerina, DM; Shuman, S			Site-specific DNA transesterification by vaccinia topoisomerase - Effects of benzo[a]pyrene-dA, 8-oxoguanine, 8-oxoadenine, and 2-aminopurine modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODON 61 SEQUENCE; DIOL EPOXIDE; VIRUS TOPOISOMERASE; COVALENT CATALYSIS; MINOR-GROOVE; MUTATIONAL ANALYSIS; IB TOPOISOMERASE; DUPLEX DNA; ADDUCT; MECHANISM	Vaccinia DNA topoisomerase forms a covalent DNA(3'-phosphotyrosyl)-enzyme intermediate at a specific target site 5'-C(+5)C(+4)C(+3)T(+2)T(+1)p down arrow N-1 in duplex DNA. Here we study the effects of base modifications on the rate and extent of single-turnover DNA transesterification. Chiral trans opened C-10 R and S adducts of benzo[a]pyrene (BP) 7,8-diol 9,10-epoxide were introduced at single N-6-deoxyadenosine (dA) positions within the 3'-G(+5)G(+4)G(+3)A(+2)A(+1)T(-1)A(-2) sequence of the nonscissile DNA strand. The R and S BPdA adducts intercalate from the major groove on the 5' and 3' sides of the modified base, respectively, and perturb local base stacking. We found that R and S BPdA modifications at +1A reduced the transesterification rate by a factor of 700-1000 without affecting the yield of the covalent topoisomerase-DNA complex. BPdA modifications at +2A reduced the extent of transesterification and elicited rate decrements of 200- and 7000-fold for the S and R diastereomers, respectively. In contrast, BPdA adducts at the -2 position had no effect on the extent of the reaction and relatively little impact on the rate of cleavage. A more subtle probe of major groove contacts entailed substituting each of the purines of the nonscissile strand with its 8-oxo analog. The +3 oxoG modification slowed transesterification 35-fold, whereas other 8-oxo modifications were benign. 8-Oxo substitutions at the -1 position in the scissile strand slowed single-turnover cleavage by a factor of six but had an even greater slowing effect on religation, which resulted in an increase in the cleavage equilibrium constant. 2-Aminopurine at positions +3, +4, or +5 in the nonscissile strand had no effect on transesterification per se but had synergistic effects when combined with 8-oxoA at position -1 in the scissile strand. These findings illuminate the functional interface of vaccinia topoisomerase with the DNA major groove.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; NIDDK, Bioorgan Chem Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.			Kroth, Heiko/0000-0002-6936-3921	NIAID NIH HHS [AI 053471] Funding Source: Medline; NIGMS NIH HHS [GM 46330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; CHRISTNER DF, 1994, BIOCHEMISTRY-US, V33, P14297, DOI 10.1021/bi00251a043; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Hwang Y, 1998, J VIROL, V72, P3401, DOI 10.1128/JVI.72.4.3401-3406.1998; Hwang Y, 1999, J BIOL CHEM, V274, P9160, DOI 10.1074/jbc.274.14.9160; Hwang Y, 1999, VIROLOGY, V262, P479, DOI 10.1006/viro.1999.9920; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P20907, DOI 10.1074/jbc.M102312200; Kwon K, 2002, J BIOL CHEM, V277, P345, DOI 10.1074/jbc.M109449200; Kwon K, 2002, J BIOL CHEM, V277, P353, DOI 10.1074/jbc.M109450200; LAKSHMAN MK, 1992, J ORG CHEM, V57, P4585, DOI 10.1021/jo00043a012; LAKSHMAN MK, 1991, J AM CHEM SOC, V113, P6589, DOI 10.1021/ja00017a034; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Mauro SA, 2003, J BIOL CHEM, V278, P12955, DOI 10.1074/jbc.M212667200; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pradhan P, 2001, BIOCHEMISTRY-US, V40, P5870, DOI 10.1021/bi002896q; Sayer JM, 1999, POLYCYCL AROMAT COMP, V17, P95, DOI 10.1080/10406639908020605; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; SCHURTER EJ, 1995, BIOCHEMISTRY-US, V34, P9009, DOI 10.1021/bi00028a009; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; Sekiguchi JA, 1996, J BIOL CHEM, V271, P2313, DOI 10.1074/jbc.271.4.2313; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; White S, 1998, NATURE, V391, P468, DOI 10.1038/35106; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Zegar IS, 1998, BIOCHEMISTRY-US, V37, P16516, DOI 10.1021/bi9817616; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P6212, DOI 10.1021/bi9524732; Zhang HL, 2001, P NATL ACAD SCI USA, V98, P10608, DOI 10.1073/pnas.191321998	54	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42170	42177		10.1074/jbc.M308079200	http://dx.doi.org/10.1074/jbc.M308079200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909623	hybrid			2022-12-25	WOS:000185989500075
J	Duan, HO; Simpson-Haidaris, PJ				Duan, HO; Simpson-Haidaris, PJ			Functional analysis of interleukin 6 response elements (IL-6REs) on the human gamma-fibrinogen promoter - Binding of hepatic Stat3 correlates negatively with transactivation potential of type IIIL-6REs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; 5-FLANKING REGION; GENE-EXPRESSION; C/EBP-DELTA; ACTIVATION; CHAIN; PROTEINS; CELLS	Several families of transcription factors play important roles in modulating liver-specific gene expression during an acute phase response (APR). Stat3/APR factor is the main transactivator of gene expression by the interleukin (IL)-6 family of cytokines signaling through gp130. During an APR, fibrinogen (FBG) genes are coordinately upregulated by IL-6 and glucocorticoids. Except for rat gammaFBG, attempts to demonstrate direct binding of IL-6-activated Stat3 to FBG CTGGGAA promoter elements have not been successful. Herein we show the presence of three functional type II IL-6 response elements (IL-6REs) on the human gammaFBG promoter and that the magnitude of Stat3 binding to these elements correlates negatively with their functional activity in reporter gene assays. Stat3-specific binding to gammaFBG IL-6REs was confirmed by cross-competition with alpha(2)-macroglobulin IL-6RE and specific interactions with anti-Stat3 in electrophoretic mobility shift assays. All type II IL-6REs contributed to full promoter activity; however, transactivation from Site II at - 306 to - 301 was strongest. In contrast to a previous report, IL-6 failed to induce activation of serum amyloid A-activating factor-1/c-Myc-associated zinc finger protein (SAF-1/MAZ), and mutation of the SAF-1RE had little effect on IL-6 induction of gammaFBG promoter activity. In the absence of a functional glucocorticoid receptor response element, dexamethasone potentiated IL-6-induced gammaFBG promoter activity 2-fold, requiring promoter-proximal Site I and Site II; the promoter-distal Site III had no effect on dexamethasone potentiation of IL-6-induced promoter activity. Notably the propensity for Stat3 binding to human gammaFBG IL-6REs was low compared with Stat3 binding to the alpha(2)-macroglobulin IL-6RE. Together these data suggest that Stat3 transactivation via IL-6REs on FBG promoters likely involves participation of additional transcription factors and/or coactivators to achieve optimal coordinated up-regulation during an APR.	Univ Rochester, Sch Med & Dent, Dept Med, Hematol Oncol Unit,Program Hemostasis & Thrombosi, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Simpson-Haidaris, PJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Hematol Oncol Unit,Program Hemostasis & Thrombosi, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.			, PJ/0000-0003-2778-2500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050615, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL50615, P01-HL30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 1995, IMMUNOL REV, V148, P221, DOI 10.1111/j.1600-065X.1995.tb00100.x; Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Alonzi T, 1997, IMMUNOBIOLOGY, V198, P144, DOI 10.1016/S0171-2985(97)80035-6; Alonzi T, 1998, CYTOKINE, V10, P13, DOI 10.1006/cyto.1997.0250; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Asselta R, 1998, THROMB HAEMOSTASIS, V79, P1144, DOI 10.1055/s-0037-1615031; BINI A, 2000, ENCY REFERENCE VASCU, P372; Bode JG, 2001, J IMMUNOL, V167, P1469, DOI 10.4049/jimmunol.167.3.1469; BROWN LF, 1993, AM J PATHOL, V142, P273; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Chan HM, 2001, J CELL SCI, V114, P2363; Chapman RS, 2000, ADV EXP MED BIOL, V480, P129; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; de Maat MPM, 2001, ANN NY ACAD SCI, V936, P509; deMaat MPM, 1997, THROMB HAEMOSTASIS, V77, P75; ESMON CT, 1993, ANNU REV CELL BIOL, V9, P1; FRANCIS CW, 1993, BLOOD CELLS, V19, P291; Fuller GM, 2001, ANN NY ACAD SCI, V936, P469; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Guadiz G, 1997, AM J RESP CELL MOL, V17, P60, DOI 10.1165/ajrcmb.17.1.2730; Guadiz G, 1997, BLOOD, V90, P2644, DOI 10.1182/blood.V90.7.2644.2644_2644_2653; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; He YZ, 2002, J BIOL CHEM, V277, P49256, DOI 10.1074/jbc.M205536200; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HU CH, 1995, J BIOL CHEM, V270, P28342; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; MIZUGUCHI J, 1995, J BIOL CHEM, V270, P28350; NAITO M, 1992, ATHEROSCLEROSIS, V96, P227, DOI 10.1016/0021-9150(92)90069-S; Odrljin TM, 1996, BBA-PROTEIN STRUCT M, V1298, P69, DOI 10.1016/S0167-4838(96)00090-8; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 2000, J IMMUNOL, V165, P3411, DOI 10.4049/jimmunol.165.6.3411; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray A, 1996, MOL CELL BIOL, V16, P1584; Redman CM, 2001, ANN NY ACAD SCI, V936, P480; SIMPSONHAIDARIS PJ, 1992, BLOOD, V79, P1218; SIMPSONHAIDARIS PJ, 1997, BLOOD, V89, P873; Song J, 1999, EUR J BIOCHEM, V259, P676, DOI 10.1046/j.1432-1327.1999.00081.x; Song J, 1998, J BIOL CHEM, V273, P20603, DOI 10.1074/jbc.273.32.20603; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; Zhang ZX, 1997, BIOCHEM BIOPH RES CO, V237, P90, DOI 10.1006/bbrc.1997.7082; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287	51	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41270	41281		10.1074/jbc.M304210200	http://dx.doi.org/10.1074/jbc.M304210200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900415	hybrid			2022-12-25	WOS:000185847200106
J	Mataraza, JM; Briggs, MW; Li, ZG; Entwistle, A; Ridley, AJ; Sacks, DB				Mataraza, JM; Briggs, MW; Li, ZG; Entwistle, A; Ridley, AJ; Sacks, DB			IQGAP1 promotes cell motility and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO FAMILY GTPASES; RNA INTERFERENCE; BINDING PROTEIN; CDC42; CALMODULIN; MIGRATION; RAC1; CYTOSKELETON; METASTASIS; FILOPODIA	The dynamic processes of cell migration and invasion are largely coordinated by Rho family GTPases. The scaffolding protein IQGAP1 binds to Cdc42, increasing the amount of active Cdc42 both in vitro and in cells. Here we show that overexpression of IQGAP1 in mammalian cells enhances cell migration in a Cdc42- and Rac1-dependent manner. Importantly, cell motility was significantly decreased both by knock down of endogenous IQGAP1 using small interfering RNA and by transfection of a dominant negative IQGAP1 construct, IQGAP1DeltaGRD. Cell invasion was similarly altered by manipulating intracellular IQGAP1 concentrations. Moreover, invasion mediated by constitutively active Cdc42 was attenuated by IQGAP1DeltaGRD. Thus, IQGAP1 has a fundamental role in cell motility and invasion.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Ridley, Anne/0000-0001-8186-5708; Sacks, David/0000-0003-3100-0735	NCI NIH HHS [CA75205] Funding Source: Medline; NHLBI NIH HHS [HL07627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA075205, R01CA075205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Brill S, 1996, MOL CELL BIOL, V16, P4869; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keely PJ, 2001, METHODS ENZYMOL, V333, P256; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; Mathew AC, 1997, CLIN EXP METASTAS, V15, P393, DOI 10.1023/A:1018498120910; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sokol SY, 2001, J BIOL CHEM, V276, P48425, DOI 10.1074/jbc.M107975200; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Wojciak-Stothard B, 2003, J CELL BIOL, V161, P429, DOI 10.1083/jcb.200210135; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	32	167	170	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41237	41245		10.1074/jbc.M304838200	http://dx.doi.org/10.1074/jbc.M304838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900413	hybrid			2022-12-25	WOS:000185847200102
J	Minic, Z; Herve, G				Minic, Z; Herve, G			Arginine metabolism in the deep sea tube worm Riftia pachyptila and its bacterial endosymbiont	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATABOLIC ORNITHINE CARBAMOYLTRANSFERASE; AUTOTROPHIC CARBON FIXATION; HYDROTHERMAL VENT ANIMALS; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; CHEMOAUTOTROPHIC SYMBIONTS; PYRIMIDINE NUCLEOTIDES; INORGANIC CARBON; KINETIC-ANALYSIS; BIOSYNTHESIS	The present study describes the distribution and properties of enzymes involved in arginine metabolism in Riftia pachyptila, a tubeworm living around deep sea hydrothermal vents and known to be engaged in a highly specific symbiotic association with a bacterium. The results obtained show that the arginine biosynthetic enzymes, carbamyl phosphate synthetase, ornithine transcarbamylase, and argininosuccinate synthetase are present in all of the tissues of the worm and in the bacteria. Thus, Riftia and its bacterial endosymbiont can assimilate nitrogen and carbon via this arginine biosynthetic pathway. The kinetic properties of ornithine transcarbamylase strongly suggest that neither Riftia nor the bacteria possess the catabolic form of this enzyme belonging to the arginine deiminase pathway, the absence of this pathway being confirmed by the lack of arginine deiminase activity. Arginine decarboxylase and ornithine decarboxylase are involved in the biosynthesis of polyamines such as putrescine and agmatine. These activities are present in the trophosome, the symbiont-harboring tissue, and are higher in the isolated bacteria than in the trophosome, indicating that these enzymes are of bacterial origin. This finding indicates that Riftia is dependent on its bacterial endosymbiont for the biosynthesis of polyamines that are important for its metabolism and physiology. These results emphasize a particular organization of the arginine metabolism and the exchanges of metabolites between the two partners of this symbiosis.	Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Herve, G (corresponding author), Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, 96 Blvd Raspail, F-75006 Paris, France.	gherve@ccr.jussieu.fr	Minic, Zoran/AAH-2091-2021					ABDELAL ATH, 1977, J BACTERIOL, V129, P1387, DOI 10.1128/JB.129.3.1387-1396.1977; ARP AJ, 1981, SCIENCE, V213, P342, DOI 10.1126/science.213.4505.342; ARP AJ, 1985, B BIOL SOC WASH, V6, P289; BELKIN S, 1986, BIOL BULL, V170, P110, DOI 10.2307/1541384; Bright M, 2000, MAR BIOL, V136, P621, DOI 10.1007/s002270050722; Cabella C, 2001, EUR J BIOCHEM, V268, P940, DOI 10.1046/j.1432-1327.2001.01955.x; CAVANAUGH CM, 1981, SCIENCE, V213, P340, DOI 10.1126/science.213.4505.340; CHILDRESS JJ, 1993, NATURE, V362, P147, DOI 10.1038/362147a0; CHILDRESS JJ, 1984, MAR BIOL, V83, P109, DOI 10.1007/BF00394718; CHILDRESS JJ, 1992, OCEANOGR MAR BIOL, V83, P109; CLARK JL, 1976, ANAL BIOCHEM, V74, P329, DOI 10.1016/0003-2697(76)90213-X; Cohen SS, 1988, GUIDE POLYAMINES; COOPER TG, 1969, J BIOL CHEM, V244, P1081; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; De Cian MC, 2000, J EXP BIOL, V203, P2907; De Cian MC, 2003, J EXP BIOL, V206, P399, DOI 10.1242/jeb.00074; DISTEL DL, 1988, J EXP ZOOL, V247, P1, DOI 10.1002/jez.1402470102; EISENSTEIN E, 1984, J BIOL CHEM, V259, P5139; FELBECK H, 1981, NATURE, V293, P291, DOI 10.1038/293291a0; FELBECK H, 1981, SCIENCE, V213, P336, DOI 10.1126/science.213.4505.336; Felbeck Horst, 1988, Oceanologica Acta Special Issue, V8, P131; FISHER CR, 1989, BIOL BULL, V177, P372, DOI 10.2307/1541597; FOX RM, 1971, ANAL BIOCHEM, V41, P578, DOI 10.1016/0003-2697(71)90180-1; GAILL F, 1993, FASEB J, V7, P558, DOI 10.1096/fasebj.7.6.8472894; Graham DE, 2002, J BIOL CHEM, V277, P23500, DOI 10.1074/jbc.M203467200; HAAS D, 1979, J BACTERIOL, V139, P713, DOI 10.1128/JB.139.3.713-720.1979; HENTSCHEL U, 1993, NATURE, V366, P338, DOI 10.1038/366338a0; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; Jones M.L., 1981, Proceedings of the Biological Society of Washington, V93, P1295; Jones Meredith L., 1988, Oceanologica Acta Special Issue, V8, P69; JOSEPH RL, 1963, BIOCHEM J, V87, P409, DOI 10.1042/bj0870409; Kandpal M, 1997, LIFE SCI, V60, P1793, DOI 10.1016/S0024-3205(97)00139-2; Kochevar Randall E., 1993, Molecular Marine Biology and Biotechnology, V2, P10; KUO LC, 1982, P NATL ACAD SCI-BIOL, V79, P2250, DOI 10.1073/pnas.79.7.2250; Lee RW, 1999, J EXP BIOL, V202, P289; LEE RW, 1996, BIOL BULL, V190, P367; LEE SJ, 1990, J MOL BIOL, V211, P255, DOI 10.1016/0022-2836(90)90025-H; LEGRAIN C, 1977, EUR J BIOCHEM, V80, P401, DOI 10.1111/j.1432-1033.1977.tb11895.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCENIER A, 1980, J GEN MICROBIOL, V116, P381; Minic Z, 2002, J BIOL CHEM, V277, P127, DOI 10.1074/jbc.M108035200; Minic Z, 2001, J BIOL CHEM, V276, P23777, DOI 10.1074/jbc.M102249200; Nakada Y, 2001, J BACTERIOL, V183, P6517, DOI 10.1128/JB.183.22.6517-6524.2001; Nelson D.C., 1995, DEEP SEA HYDROTHERMA, P125; POWELL MA, 1986, BIOL BULL, V171, P274, DOI 10.2307/1541923; PRIEUR D, 1995, PLANET SPACE SCI, V43, P115, DOI 10.1016/0032-0633(94)00143-F; Purcarea C, 2001, EXTREMOPHILES, V5, P229, DOI 10.1007/s007920100201; ROBIN JP, 1989, EUR J BIOCHEM, V183, P519, DOI 10.1111/j.1432-1033.1989.tb21080.x; ROCHOVANSKY O, 1977, J BIOL CHEM, V252, P5287; Satriano J, 2001, AM J PHYSIOL-CELL PH, V281, pC329, DOI 10.1152/ajpcell.2001.281.1.C329; SCHIMKE RT, 1966, J BIOL CHEM, V241, P2228; Schneider BL, 1998, J BACTERIOL, V180, P4278, DOI 10.1128/JB.180.16.4278-4286.1998; SCOTT KM, 1994, PHYSIOL ZOOL, V67, P617, DOI 10.1086/physzool.67.3.30163761; Simon V, 2000, MAR BIOL, V136, P115, DOI 10.1007/s002270050014; STALON V, 1987, J GEN MICROBIOL, V133, P2487; STALON V, 1977, EUR J BIOCHEM, V74, P319, DOI 10.1111/j.1432-1033.1977.tb11396.x; STALON V, 1967, BIOCHIM BIOPHYS ACTA, V139, P91, DOI 10.1016/0005-2744(67)90115-5; STALON V, 1972, EUR J BIOCHEM, V29, P25, DOI 10.1111/j.1432-1033.1972.tb01953.x; STEWART V, 1994, ANTON LEEUW INT J G, V66, P37, DOI 10.1007/BF00871631; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Tricot C, 1998, J MOL BIOL, V283, P695, DOI 10.1006/jmbi.1998.2133; TUNNICLIFFE V, 1992, AM SCI, V80, P336; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; VANDERWAUVEN C, 1984, J BACTERIOL, V160, P928, DOI 10.1128/JB.160.3.928-934.1984; WARGNIES B, 1978, EUR J BIOCHEM, V89, P203, DOI 10.1111/j.1432-1033.1978.tb20914.x; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEICKMANN JL, 1977, J BIOL CHEM, V252, P2615; WITTICH RM, 1987, MOL BIOCHEM PARASIT, V24, P155, DOI 10.1016/0166-6851(87)90102-2	68	16	16	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40527	40533		10.1074/jbc.M307835200	http://dx.doi.org/10.1074/jbc.M307835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882969	hybrid			2022-12-25	WOS:000185847200014
J	Pola, S; Cattaneo, MG; Vicentini, LM				Pola, S; Cattaneo, MG; Vicentini, LM			Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells - Involvement of Rac and MAP kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GENE-EXPRESSION; ACTIVATION; RECEPTORS; PROLIFERATION; CHEMOTAXIS; MECHANISMS; PATHWAY; BIOLOGY; ANALOGS	Cell motility and invasion are crucial events for the spread of cancer and, consequently, the metastatic process. Platelet-derived growth factor ( PDGF) is not only capable of stimulating the proliferation of SH-SY5Y human neuroblastoma cells, but also their migration and invasion through an extracellular matrix barrier. Experiments using wortmannin and PD98059, specific inhibitors of the phosphatidylinositol 3-kinase (PI3-K) and of the mitogen-activated protein kinases (ERK 1 and 2) signaling, respectively, show that the activation of both pathways is required for the PDGF-induced cell motility responses. We have previously shown that somatostatin inhibits cell division and ERK 1/2 and Ras activity in SH-SY5Y cells. We report here that it is also capable of potently and effectively inhibiting their PDGF-stimulated migration and invasion. The inhibitory effect of somatostatin is sensitive to pertussis toxin. Although somatostatin does not affect PI3-K, it inhibits ERK 1/2 and the small G-protein Rac activation and ruffle formation induced by PDGF. These results indicate that somatostatin can be considered an anti-migratory and antiinvasive agent that acts by inhibiting ERK 1/2 signaling and the PI3-K pathway via the inhibition of Rac in SH-SY5Y cells.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy	University of Milan	Vicentini, LM (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.		Cattaneo, Maria Grazia/H-3067-2017	Cattaneo, Maria Grazia/0000-0002-1582-9933; Vicentini, Lucia M./0000-0002-2446-1974				Albers AR, 2000, REGUL PEPTIDES, V88, P61, DOI 10.1016/S0167-0115(99)00121-4; Albini A, 1999, FASEB J, V13, P647, DOI 10.1096/fasebj.13.6.647; ALBINI A, 1987, CANCER RES, V47, P3239; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bousquet C, 2001, CHEMOTHERAPY, V47, P30, DOI 10.1159/000049159; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cattaneo MG, 1999, FEBS LETT, V459, P64, DOI 10.1016/S0014-5793(99)01218-1; Cattaneo MG, 2000, FEBS LETT, V481, P271, DOI 10.1016/S0014-5793(00)02012-3; Cattaneo MG, 1996, FEBS LETT, V397, P164, DOI 10.1016/S0014-5793(96)01159-3; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOUDHURY GG, 1997, AM J PHYSIOL, V273, P931; Csaba Z, 2001, NEUROPEPTIDES, V35, P1, DOI 10.1054/npep.2001.0848; de Herder WW, 2002, CURR OPIN ONCOL, V14, P53, DOI 10.1097/00001622-200201000-00010; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hinton DR, 1998, EXP CELL RES, V239, P11, DOI 10.1006/excr.1997.3873; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Kramer K, 2001, CANCER, V91, P1510, DOI 10.1002/1097-0142(20010415)91:8<1510::AID-CNCR1159>3.3.CO;2-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI T, 1993, J CLIN INVEST, V92, P1153, DOI 10.1172/JCI116684; Orlando C, 2001, MED PEDIATR ONCOL, V36, P224, DOI 10.1002/1096-911X(20010101)36:1<224::AID-MPO1054>3.0.CO;2-#; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; REUBI JC, 1995, TRENDS PHARMACOL SCI, V16, P110, DOI 10.1016/S0165-6147(00)88992-0; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; VANZOELEN EJJ, 1985, MOL CELL BIOL, V5, P2289, DOI 10.1128/MCB.5.9.2289	34	48	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40601	40606		10.1074/jbc.M306510200	http://dx.doi.org/10.1074/jbc.M306510200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902325	hybrid			2022-12-25	WOS:000185847200023
J	Schuh, K; Quaschning, T; Knauer, S; Hu, K; Kocak, S; Roethlein, N; Neyses, L				Schuh, K; Quaschning, T; Knauer, S; Hu, K; Kocak, S; Roethlein, N; Neyses, L			Regulation of vascular tone in animals overexpressing the sarcolemmal calcium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CA2+-ATPASE; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; NA+/CA2+ EXCHANGER; PROTEIN-KINASE; CA-2+ PUMP; ISOFORM 4B; CA2+ PUMP; PHOSPHORYLATION; EXPRESSION	The mechanisms governing vascular smooth muscle tone are incompletely understood. In particular, the role of the sarcolemmal calcium pump PMCA ( plasma membrane calmodulin-dependent calcium ATPase), which extrudes Ca2+ from the cytosol, and its importance compared with the sodium/calcium exchanger remain speculative. To test whether the PMCA is a regulator of vascular tone, we generated transgenic mice overexpressing the human PMCA4b under control of the arterial smooth muscle-specific SM22alpha promoter. This resulted in an elevated systolic blood pressure compared with littermate controls. In PMCA-overexpressing mice, endothelium-dependent relaxation of norepinephrine-preconstricted aortic rings to acetylcholine did not differ from wild type controls (76 +/- 8% versus 79 +/- 8% of maximum relaxation; n = 12, n.s.). De-endothelialized aortas of transgenic mice exhibited stronger maximum contraction to KCl (100 mmol/liter) compared with controls (86 +/- 6% versus 68 +/- 7% of reference KCl contraction at the beginning of the experiment; p < 0.05). Preincubation of de-endothelialized vessels with the nitric oxide synthase (NOS) inhibitor L-NAME (L-N(G)-nitroarginine methyl ester) (10(-5) mol/liter) resulted in a stronger contraction to KCl (p < 0.05 versus without L-NAME), thus unmasking vasodilatory effects of inherent NO production. Maximum contraction to KCl after preincubation with L-NAME did not differ between PMCA mice and controls. In analogy to the results in PMCA-overexpressing mice, contractions of de-endothelialized aortas of neuronal NOS-deficient mice to KCl were significantly increased compared with controls (151 +/- 5% versus 131 +/- 6% of reference KCl contraction; p < 0.05). In conclusion, our data suggest a model in which the sarcolemmal Ca2+ pump down-regulates activity of the vascular smooth muscle Ca2+/calmodulin-dependent neuronal NOS by a functionally relevant interaction. Therefore, the PMCA represents a novel regulator of vascular tone.	Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Inst Clin Biochem & Pathobiochem, D-97078 Wurzburg, Germany; Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany	University of Manchester; University of Wurzburg	Neyses, L (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Med, Oxford Rd, Manchester M13 9WL, Lancs, England.		Neyses, Ludwig/AGY-7446-2022					Barton M, 1998, HYPERTENSION, V31, P499, DOI 10.1161/01.HYP.31.1.499; Blaustein M. P., 1977, AM J PHYSIOL, V1, P165; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GROS R, 2003, IN PRESS CIRC RES, V93; Hammes A, 1998, CIRC RES, V83, P877; Hammes A, 1996, J BIOL CHEM, V271, P30816, DOI 10.1074/jbc.271.48.30816; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; Husain M, 1997, AM J PHYSIOL-CELL PH, V272, pC1947, DOI 10.1152/ajpcell.1997.272.6.C1947; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; Jaggar JH, 1998, ACTA PHYSIOL SCAND, V164, P577; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Lau KS, 2000, PHYSIOL GENOMICS, V2, P21, DOI 10.1152/physiolgenomics.2000.2.1.21; MOTLEY ED, 1993, AM J PHYSIOL, V264, pH1028, DOI 10.1152/ajpheart.1993.264.4.H1028; NEYSES L, 1985, J BIOL CHEM, V260, P283; Pfitzer G, 2001, J APPL PHYSIOL, V91, P497, DOI 10.1152/jappl.2001.91.1.497; Quaschning T, 2001, HYPERTENSION, V37, P1108, DOI 10.1161/01.HYP.37.4.1108; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Segal SS, 1999, AM J PHYSIOL-HEART C, V277, pH1167; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Strehler E E, 1990, Semin Cell Biol, V1, P283; Wakimoto K, 2000, J BIOL CHEM, V275, P36991, DOI 10.1074/jbc.M004035200; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; Wan TC, 2003, THROMB HAEMOSTASIS, V89, P122	33	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41246	41252		10.1074/jbc.M307606200	http://dx.doi.org/10.1074/jbc.M307606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900399	Green Published, hybrid			2022-12-25	WOS:000185847200103
J	Wang, WN; Lo, KWH; Kan, HM; Fan, JS; Zhang, MJ				Wang, WN; Lo, KWH; Kan, HM; Fan, JS; Zhang, MJ			Structure of the monomeric 8-kDa dynein light chain and mechanism of the domain-swapped dimer assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CYTOPLASMIC DYNEIN; PROTEIN INHIBITOR; MYOSIN-V; MOTOR COMPLEX; NMR; KDA; PROGRAM; DIMERIZATION; MUTATIONS	The 8-kDa light chain of dynein (DLC8) is ubiquitously expressed in various cell types. Other than serving as a light chain of the dynein complexes, this highly conserved protein has been shown to bind a larger number of proteins with diverse biological functions. DLC8 forms a homodimer via three-dimensional domain swapping of an internal beta-strand (the beta2-strand) at neutral pH. The protein undergoes non-reversible dimer-to-monomer dissociation when the pH value of the protein solution decreases. The three-dimensional structure of the DLC8 monomer determined by NMR spectroscopy at pH 3.0 showed that the protein is well folded. The major conformational change accompanied by dimer dissociation is in the beta2-strand of the protein, which undergoes transition from a beta-strand to a nascent alpha-helix. The monomer form of DLC8 is not capable of binding to target proteins. Insertion of two flexible amino acid residues in the tight beta1/beta2-loop dramatically stabilized the monomer conformation of the protein. NMR studies showed that the mutation altered the conformation as well as the three-dimensional domain swapping-mediated assembly of the DLC8 dimer. The mutant DLC8 was unable to bind to its targets even at physiological pH. The three-dimensional structure of the mutant protein in its monomeric form provides the structural basis of the mutation-induced stabilization of the monomer conformation. Based on the experimental data, we conclude that the formation of the beta2-strand swapping-mediated dimer is mandatory for the structure and function of DLC8. We further note that the DLC8 dimer represents a novel mode of three-dimensional domain swapping.	Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China	Hong Kong University of Science & Technology; Fudan University	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.			Zhang, Mingjie/0000-0001-9404-0190				Barbar E, 2001, BIOCHEMISTRY-US, V40, P1596, DOI 10.1021/bi002278+; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clore GM, 1997, NAT STRUCT BIOL, V4, P849; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dick T, 1996, MOL CELL BIOL, V16, P1966; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Fan JS, 2002, J BIOMOL NMR, V23, P103, DOI 10.1023/A:1016332918178; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HUGHES SM, 1995, J CELL SCI, V108, P17; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Newcomer ME, 2002, CURR OPIN STRUC BIOL, V12, P48, DOI 10.1016/S0959-440X(02)00288-9; Nicholls A., 1992, GRASP GRAPHICAL REPR; Phillis R, 1996, DEVELOPMENT, V122, P2955; PIPERNO G, 1979, J BIOL CHEM, V254, P3084; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rodriguez-Crespo I, 2001, FEBS LETT, V503, P135, DOI 10.1016/S0014-5793(01)02718-1; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Tochio H, 1998, NAT STRUCT BIOL, V5, P965, DOI 10.1038/2940; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Wuthrich K, 1986, NMR PROTEINS NUCL AC	45	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41491	41499		10.1074/jbc.M307118200	http://dx.doi.org/10.1074/jbc.M307118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904292	hybrid			2022-12-25	WOS:000185847200129
J	Hara, T; Matsuyama, S; Tokuda, H				Hara, T; Matsuyama, S; Tokuda, H			Mechanism underlying the inner membrane retention of Escherichia coli lipoproteins caused by Lol avoidance signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; CYTOPLASMIC MEMBRANE; SORTING SIGNALS; DEPENDENT RELEASE; LOCALIZATION; PROTEIN; TRANSLOCATION; TRANSPORTER; ACCUMULATION; VESICLES	Escherichia coli lipoproteins are localized to either the inner or outer membrane depending on the residue at position 2. The inner membrane retention signal, Asp at position 2 in combination with certain residues at position 3, functions as a Lol avoidance signal, i.e. the signal inhibits the recognition of lipoproteins by Lol-CDE that releases lipoproteins from the inner membrane. To understand the role of the residue at position 2, outer membrane-specific lipoproteins with Cys at position 2 were subjected to chemical modification followed by the release reaction in reconstituted proteoliposomes. Sulfhydryl-specific introduction of nonprotein molecules or a negative charge to Cys did not inhibit the LolCDE-dependent release. In contrast, oxidation of Cys to cysteic acid resulted in generation of the Lol avoidance signal, indicating that the Lol avoidance signal requires a critical length of negative charge at the second residue. Furthermore, not only modification of the carboxylic acid of Asp at position 2 but also that of the amine of phosphatidylethanolamine abolished the Lol avoidance function. Based on these results, the Lol avoidance mechanism is discussed.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fukuda A, 2002, J BIOL CHEM, V277, P43512, DOI 10.1074/jbc.M206816200; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Narita S, 2003, MOL MICROBIOL, V49, P167, DOI 10.1046/j.1365-2958.2003.03569.x; Narita S, 2002, J BACTERIOL, V184, P1417, DOI 10.1128/JB.184.5.1417-1422.2002; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Tanaka K, 2001, J BACTERIOL, V183, P6538, DOI 10.1128/JB.183.22.6538-6542.2001; TANI K, 1990, J BIOL CHEM, V265, P17341; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6	27	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40408	40414		10.1074/jbc.M307836200	http://dx.doi.org/10.1074/jbc.M307836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12896969	hybrid			2022-12-25	WOS:000185713800135
J	Szeto, TH; Rowland, SL; Habrukowich, CL; King, GF				Szeto, TH; Rowland, SL; Habrukowich, CL; King, GF			The MinD membrane targeting sequence is a transplantable lipid-binding helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL DIVISION; TO-POLE OSCILLATION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; TOPOLOGICAL REGULATION; NEISSERIA-GONORRHOEAE; DYNAMIC LOCALIZATION; CRYSTAL-STRUCTURE; INHIBITOR MINC; RAPID POLE	MinD is a ubiquitous ATPase that plays a crucial role in selection of the division site in eubacteria, chloroplasts, and probably also Archaea. It was recently demonstrated that membrane localization of MinD is mediated by an 8-12-residue C-terminal motif termed the membrane targeting sequence or MTS. In this study we show that the MinD MTS is a transplantable lipid-binding motif that can effectively target heterologous proteins to the cell membrane. We demonstrate that eubacterial MTSs interact directly with lipid bilayers as an amphipathic helix, with a distinct preference for anionic phospholipids. Moreover, we provide evidence that the phospholipid preference of each MTS, as well as its affinity for biological membranes, has been evolutionarily "tuned" to its specific role in different bacteria. We propose a model to describe how the MTS is coupled to ATP binding to regulate the reversible membrane association of Escherichia coli MinD during its pole-to-pole oscillation cycle.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA; Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06032 USA	University of Connecticut; University of Connecticut	King, GF (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, 263 Farmington Ave, Farmington, CT 06032 USA.	glenn@psel.uchc.edu	King, Glenn F/J-5059-2012; Rowland, Susan/M-1928-2016	King, Glenn F/0000-0002-2308-2200; Rowland, Susan/0000-0003-1926-7509	NIAID NIH HHS [AI-048583] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048583] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bains NPS, 1999, LETT PEPT SCI, V6, P381; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Buddelmeijer N, 2002, CURR OPIN MICROBIOL, V5, P553, DOI 10.1016/S1369-5274(02)00374-0; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Cordell SC, 2003, P NATL ACAD SCI USA, V100, P7889, DOI 10.1073/pnas.1330742100; Cordell SC, 2001, FEBS LETT, V492, P160, DOI 10.1016/S0014-5793(01)02216-5; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DEBOER PAJ, 1992, J BACTERIOL, V174, P63, DOI 10.1128/jb.174.1.63-70.1992; deKruijff B, 1997, CURR TOP MEMBR, V44, P477; Dowhan W, 1998, BBA-REV BIOMEMBRANES, V1376, P455, DOI 10.1016/S0304-4157(98)00013-6; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; Fu XL, 2001, P NATL ACAD SCI USA, V98, P980, DOI 10.1073/pnas.031549298; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hale CA, 2001, EMBO J, V20, P1563, DOI 10.1093/emboj/20.7.1563; Harry EJ, 2003, MOL MICROBIOL, V47, P37, DOI 10.1046/j.1365-2958.2003.03253.x; Harry EJ, 2001, MOL MICROBIOL, V40, P795, DOI 10.1046/j.1365-2958.2001.02370.x; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Hu ZL, 2003, MOL MICROBIOL, V47, P345, DOI 10.1046/j.1365-2958.2003.03321.x; Hu ZL, 2003, J BACTERIOL, V185, P196, DOI 10.1128/JB.185.1.196-203.2003; Hu ZL, 2002, P NATL ACAD SCI USA, V99, P6761, DOI 10.1073/pnas.102059099; Hu ZL, 1999, MOL MICROBIOL, V34, P82, DOI 10.1046/j.1365-2958.1999.01575.x; Hu ZL, 2001, MOL CELL, V7, P1337, DOI 10.1016/S1097-2765(01)00273-8; Huang H, 1999, BIOCHEMISTRY-US, V38, P13231, DOI 10.1021/bi990870x; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; Johnson JE, 2002, J BACTERIOL, V184, P2951, DOI 10.1128/JB.184.11.2951-2962.2002; Lutkenhaus J, 2003, MOL MICROBIOL, V48, P295, DOI 10.1046/j.1365-2958.2003.03427.x; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Marston AL, 1998, GENE DEV, V12, P3419, DOI 10.1101/gad.12.21.3419; Marston AL, 1999, MOL MICROBIOL, V33, P84, DOI 10.1046/j.1365-2958.1999.01450.x; Matsumoto K, 1998, J BACTERIOL, V180, P100, DOI 10.1128/JB.180.1.100-106.1998; Mileykovskaya E, 2003, J BIOL CHEM, V278, P22193, DOI 10.1074/jbc.M302603200; Ramirez-Arcos S, 2002, MOL MICROBIOL, V46, P493, DOI 10.1046/j.1365-2958.2002.03168.x; Raskin DM, 1999, J BACTERIOL, V181, P6419, DOI 10.1128/JB.181.20.6419-6424.1999; Raskin DM, 1999, P NATL ACAD SCI USA, V96, P4971, DOI 10.1073/pnas.96.9.4971; Rothfield LI, 2001, CELL, V106, P13, DOI 10.1016/S0092-8674(01)00432-9; Rowland SL, 2000, J BACTERIOL, V182, P613, DOI 10.1128/JB.182.3.613-619.2000; Shih YL, 2003, P NATL ACAD SCI USA, V100, P7865, DOI 10.1073/pnas.1232225100; Shih YL, 2002, EMBO J, V21, P3347, DOI 10.1093/emboj/cdf323; Shimada H, 2002, J BACTERIOL, V184, P556, DOI 10.1128/JB.184.2.556-563.2002; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; Suefuji K, 2002, P NATL ACAD SCI USA, V99, P16776, DOI 10.1073/pnas.262671699; Szeto J, 2001, J BACTERIOL, V183, P6253, DOI 10.1128/JB.183.21.6253-6264.2001; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; Wang GS, 2000, J BIOL CHEM, V275, P39811, DOI 10.1074/jbc.C000709200; Wieprecht T, 1999, J MOL BIOL, V294, P785, DOI 10.1006/jmbi.1999.3268; Yamaichi Y, 2000, P NATL ACAD SCI USA, V97, P14656, DOI 10.1073/pnas.97.26.14656; Yu XC, 1999, MOL MICROBIOL, V32, P315, DOI 10.1046/j.1365-2958.1999.01351.x	54	125	128	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40050	40056		10.1074/jbc.M306876200	http://dx.doi.org/10.1074/jbc.M306876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882967	hybrid			2022-12-25	WOS:000185713800095
J	Bock, HH; Jossin, Y; Liu, PS; Forster, E; May, P; Goffinet, AM; Herz, J				Bock, HH; Jossin, Y; Liu, PS; Forster, E; May, P; Goffinet, AM; Herz, J			Phosphatidylinositol 3-kinase interacts with the adaptor protein Dab1 in response to Reelin signaling and is required for normal cortical lamination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; INSULIN-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; DISABLED 1; LIPID RAFTS; BINDING; LOCALIZATION; PREDICTION; MOLECULES	Reelin is a large secreted signaling protein that binds to two members of the low density lipoprotein receptor family, the apolipoprotein E receptor 2 and the very low density lipoprotein receptor, and regulates neuronal positioning during brain development. Reelin signaling requires activation of Src family kinases as well as tyrosine phosphorylation of the intracellular adaptor protein Disabled-1 (Dab1). This results in activation of phosphatidylinositol 3-kinase (PI3K), the serine/threonine kinase Akt, and the inhibition of glycogen synthase kinase 3beta, a protein that is implicated in the regulation of axonal transport. Here we demonstrate that PI3K activation by Reelin requires Src family kinase activity and depends on the Reelin-triggered interaction of Dab1 with the PI3K regulatory subunit p85alpha. Because the Dab1 phosphotyrosine binding domain can interact simultaneously with membrane lipids and with the intracellular domains of apolipoprotein E receptor 2 and very low density lipoprotein receptor, Dab1 is preferentially recruited to the neuronal plasma membrane, where it is phosphorylated. Efficient Dab1 phosphorylation and activation of the Reelin signaling cascade is impaired by cholesterol depletion of the plasma membrane. Using a neuronal migration assay, we also show that PI3K signaling is required for the formation of a normal cortical plate, a step that is dependent upon Reelin signaling.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Catholic Univ Louvain, Dev Genet Unit, UCL 7382, B-1200 Brussels, Belgium; Univ Freiburg, Inst Anat, D-79104 Freiburg, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Freiburg	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Joachim.Herz@UTSouthwestern.edu	Bock, Hans/AAF-2635-2021	Jossin, Yves/0000-0001-8466-7432; Forster, Eckart/0000-0002-2478-5610	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, P01HL020948, R01HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, R37 HL063762, HL63762] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Buchdunger E, 2002, EUR J CANCER, V38, pS28, DOI 10.1016/S0959-8049(02)80600-1; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; Forster E, 2002, P NATL ACAD SCI USA, V99, P13178, DOI 10.1073/pnas.202035899; Foukas LC, 2003, ARCH BIOCHEM BIOPHYS, V414, P13, DOI 10.1016/S0003-9861(03)00177-2; Funaki M, 2000, CELL SIGNAL, V12, P135, DOI 10.1016/S0898-6568(99)00086-8; Hartfuss E, 2003, DEVELOPMENT, V130, P4597, DOI 10.1242/dev.00654; Herrick TM, 2002, DEVELOPMENT, V129, P787; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Jacobs AR, 2001, J BIOL CHEM, V276, P40795, DOI 10.1074/jbc.M105194200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kubo K, 2002, NEUROSCI RES, V43, P381, DOI 10.1016/S0168-0102(02)00068-8; Murata H, 2003, J BIOL CHEM, V278, P21607, DOI 10.1074/jbc.M302934200; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 1999, GENE DEV, V13, P2758, DOI 10.1101/gad.13.21.2758; Riddell DR, 2001, J LIPID RES, V42, P998; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vainshtein I, 2001, J BIOL CHEM, V276, P8073, DOI 10.1074/jbc.M008436200; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	47	149	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38772	38779		10.1074/jbc.M306416200	http://dx.doi.org/10.1074/jbc.M306416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882964	hybrid			2022-12-25	WOS:000185575100084
J	Gardocki, ME; Lopes, JM				Gardocki, ME; Lopes, JM			Expression of the yeast PIS1 gene requires multiple regulatory elements including a Rox1p binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAMES; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL SYNTHASE; PHOSPHOLIPID BIOSYNTHESIS; HYPOXIC GENES; CELL-WALL; FUNCTIONAL COMPLEMENTATION; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; PROMOTER ELEMENTS	The PIS1 gene is required for de novo synthesis of phosphatidylinositol ( PI), an essential phospholipid in Saccharomyces cerevisiae. PIS1 gene expression is unusual because it is uncoupled from the other phospholipid biosynthetic genes, which are regulated in response to inositol and choline. Relatively little is known about regulation of transcription of the PIS1 gene. We reported previously that PIS1 transcription is sensitive to carbon source. To further our understanding of the regulation of PIS1 transcription, we carried out a promoter deletion analysis that identified three regions required for PIS1 gene expression ( upstream activating sequence (UAS) elements 1-3). Deletion of either UAS1 or UAS2 resulted in an similar to 45% reduction in expression, whereas removal of UAS3 yielded an 84% decrease in expression. A comparison of promoters among several Saccharomyces species shows that these sequences are highly conserved. Curiously, the UAS3 element region ( - 149 to - 138) includes a Rox1p binding site. Rox1p is a repressor of hypoxic genes under aerobic growth conditions. Consistent with this, we have found that expression of a PIS1-cat reporter was repressed under aerobic conditions, and this repression was dependent on both Rox1p and its binding site. Furthermore, PI levels were elevated under anaerobic conditions. This is the first evidence that PI levels are affected by regulation of PIS1 transcription.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Lopes, JM (corresponding author), Wayne State Univ, Dept Biol Sci, 5047 Gullen Mall, Detroit, MI 48202 USA.							Abramova N, 2001, J BACTERIOL, V183, P2881, DOI 10.1128/JB.183.9.2881-2887.2001; Abramova NE, 2001, GENETICS, V157, P1169; Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ANDERSON MS, 1996, ANAL PISI GENE EXPRE; Antonsson B, 1997, BBA-LIPID LIPID MET, V1348, P179, DOI 10.1016/S0005-2760(97)00105-7; Antonsson BE, 1996, YEAST, V12, P449, DOI 10.1002/(SICI)1097-0061(199604)12:5<449::AID-YEA927>3.0.CO;2-P; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BARNETT JA, 1992, YEAST, V8, P1, DOI 10.1002/yea.320080102; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; COHEN R, 1986, MOL CELL BIOL, V6, P2287, DOI 10.1128/MCB.6.7.2287; Crowley JH, 1998, J BACTERIOL, V180, P4177, DOI 10.1128/JB.180.16.4177-4183.1998; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DECKERT J, 1995, MOL CELL BIOL, V15, P6109; Deckert J, 1999, NUCLEIC ACIDS RES, V27, P3518, DOI 10.1093/nar/27.17.3518; Deckert J, 1998, GENETICS, V150, P1429; Delbecq P, 2000, CURR GENET, V38, P105, DOI 10.1007/s002940000140; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Eiznhamer DA, 2001, MOL MICROBIOL, V39, P1395, DOI 10.1046/j.1365-2958.2001.02330.x; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Gonzalez CI, 2001, GENE, V274, P15, DOI 10.1016/S0378-1119(01)00552-2; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GRIGGS DW, 1993, MOL CELL BIOL, V13, P4999, DOI 10.1128/MCB.13.8.4999; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; Kastaniotis AJ, 2000, MOL CELL BIOL, V20, P7088, DOI 10.1128/MCB.20.19.7088-7098.2000; Kastaniotis AJ, 2000, ADV EXP MED BIOL, V475, P185; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLY BL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P144, DOI 10.1016/0005-2760(90)90181-V; KUMANO Y, 1995, FEMS MICROBIOL LETT, V126, P81, DOI 10.1111/j.1574-6968.1995.tb07394.x; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; LERAY C, 1987, J CHROMATOGR-BIOMED, V420, P411, DOI 10.1016/0378-4347(87)80198-6; LOWRY CV, 1984, P NATL ACAD SCI-BIOL, V81, P6129, DOI 10.1073/pnas.81.19.6129; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; Lykidis A, 1997, J BIOL CHEM, V272, P33402, DOI 10.1074/jbc.272.52.33402; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; Mead J, 2002, MOL CELL BIOL, V22, P4607, DOI 10.1128/MCB.22.13.4607-4621.2002; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKAWA JI, 1982, EUR J BIOCHEM, V125, P445, DOI 10.1111/j.1432-1033.1982.tb06703.x; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Seron K, 2000, EUR J BIOCHEM, V267, P6571, DOI 10.1046/j.1432-1327.2000.01749.x; Sertil O, 1997, GENE, V192, P199, DOI 10.1016/S0378-1119(97)00028-0; Shears SB, 2000, BIOESSAYS, V22, P786, DOI 10.1002/1521-1878(200009)22:9<786::AID-BIES3>3.3.CO;2-S; Shields D, 1999, CURR OPIN CELL BIOL, V11, P489, DOI 10.1016/S0955-0674(99)80070-2; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Tanaka S, 1996, FEBS LETT, V393, P89, DOI 10.1016/0014-5793(96)00858-7; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; Ter Linde JJM, 2002, YEAST, V19, P825, DOI 10.1002/yea.879; Vilela C, 1998, NUCLEIC ACIDS RES, V26, P1150, DOI 10.1093/nar/26.5.1150; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Xue HW, 2000, PLANT MOL BIOL, V42, P757, DOI 10.1023/A:1006308909105; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110	75	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38646	38652		10.1074/jbc.M305251200	http://dx.doi.org/10.1074/jbc.M305251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12890676	hybrid			2022-12-25	WOS:000185575100069
J	Yang, ML; Ito, T; May, WS				Yang, ML; Ito, T; May, WS			A novel role for RAX, the cellular activator of PKR, in synergistically stimulating SV40 large T antigen-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PKR; RNA-BINDING MOTIFS; DNA-REPLICATION; INDUCED APOPTOSIS; MAMMALIAN-CELLS; IN-VITRO; INTERFERON; ELEMENTS; ORIGIN; TRANSCRIPTION	The double-stranded (ds) RNA-binding protein RAX was discovered as a stress-induced cellular activator of the dsRNA-dependent protein kinase (PKR), a key regulator of protein synthesis in response to viral infection and cellular stress. We now report a novel function of RAX, independent of PKR, to enhance SV40 promoter (origin)/enhancer-dependent gene expression. Several mammalian cell lines including COS-7, CV-1, and HeLa cells were tested. Results reveal that the SV40 large T antigen is required for RAX-mediated, synergistic enhancement of gene expression. RAX augments SV40 regulatory element-dependent DNA replication and transcription. The mechanism requires the SV40 enhancer, a viral transcriptional element that is necessary for efficient SV40 DNA replication in vivo. Mutational analysis reveals that the dsRNA-binding domains of RAX are required for the gene expression enhancing function. Thus, in addition to stimulating PKR activity, RAX can positively regulate both SV40 large T antigen-dependent DNA replication and transcription in a mechanism that may alter the interaction of the cellular factor(s) with the SV40 enhancer via the dsRNA-binding domains of RAX. This novel function of RAX may have implications for regulation of mammalian DNA replication and transcription because of the many similarities between the viral and cellular processes.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	May, WS (corresponding author), Univ Florida, Shands Canc Ctr, POB 100232,1600 SW Archer Rd, Gainesville, FL 32610 USA.			Yang, Mingli/0000-0002-4781-690X	NHLBI NIH HHS [HL54083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; DAMNIA B, 1998, MOL CELL BIOL, V18, P1331; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HAAS MW, 1991, VIROLOGY, V180, P41, DOI 10.1016/0042-6822(91)90007-X; HERENDEEN D, 1996, EUKARYOTIC DNA REPLI, P29; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Milavetz BI, 2002, VIROLOGY, V294, P170, DOI 10.1006/viro.2001.1308; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; ROBERTSON HD, 1982, CELL, V30, P669, DOI 10.1016/0092-8674(82)90270-7; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Swaminathan S, 1996, VIROLOGY, V219, P321, DOI 10.1006/viro.1996.0255; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Turner WJ, 2001, J VIROL, V75, P5638, DOI 10.1128/JVI.75.12.5638-5645.2001; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Williams B.R., 2001, SCI STKE, V2001, pre2; Williams DD, 2001, J BIOL CHEM, V276, P3733, DOI 10.1074/jbc.M008041200; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451	50	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38325	38332		10.1074/jbc.M303420200	http://dx.doi.org/10.1074/jbc.M303420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874289	hybrid			2022-12-25	WOS:000185575100031
J	Zeiner, GM; Sturm, NR; Campbell, DA				Zeiner, GM; Sturm, NR; Campbell, DA			The Leishmania tarentolae spliced leader contains determinants for association with polysomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							18S RIBOSOMAL-RNA; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; CAENORHABDITIS-ELEGANS; MODIFIED NUCLEOTIDES; PROTEIN-SYNTHESIS; EUKARYOTIC CELLS; DOWNSTREAM BOX; CAP STRUCTURES; SL RNA	In kinetoplastids, every nuclear-derived mRNA contains an identical 39-nucleotide (nt) spliced leader at its 5'-terminus. The spliced leader is derived from substrate spliced leader RNA and joined to pre-mRNA by trans-splicing, thus providing mature mRNAs with an m(7)G cap and additional methylations referred to as cap 4. It was shown previously that mutations spanning nucleotides 10-39 of the spliced leader did not affect substrate spliced leader RNA transcription or trans-splicing in Leishmania tarentolae (Saito, R. M., Elgort, M. G., and Campbell, D. A. (1994) EMBO J. 13, 5460-5469). In this study we examined these sequences for a possible role in translation by assaying the association of mRNAs, which possess mutated spliced leaders, with polysomes. For the nt 28-39 mutated spliced leaders, both the substrate spliced leader RNA and the spliced leader demonstrated a wild-type methylation pattern; spliced nt 28-39 mRNA was found in polysomes. Thus, the nt 28-39 region conserved primary sequence is not a determinant of polysome association. An undermethylated cap 4 structure was present on substrate and mRNA spliced leaders in nt 20-29 mutated exons; nt 20-29 mRNA was not present in polysomes. A differential pattern of cap 4 methylation was seen between the nt 10-19 substrate spliced leader RNA and the nt 10-19 spliced leaders found in the poly(A)(+) population of RNA; the nt 10-19 mRNA was not seen in polysomes. Under-methylated spliced leaders did not associate efficiently with polysomes, suggesting a requirement for the cap 4 and/or primary sequence of the spliced leader in translation. This is the first report demonstrating that the spliced leader contains critical structural or sequence determinants for association with polysomes and, hence, translation.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Campbell, DA (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 609 Charles E Young Dr E, Los Angeles, CA 90095 USA.			Zeiner, Gusti/0000-0001-7815-5588	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034536, T32AI007323] Funding Source: NIH RePORTER; NIAID NIH HHS [2-T32-AI-07323, AI34536] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALINE RF, 1989, MOL BIOCHEM PARASIT, V32, P169, DOI 10.1016/0166-6851(89)90068-6; Avila AR, 2001, MOL BIOCHEM PARASIT, V117, P169, DOI 10.1016/S0166-6851(01)00346-2; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; Brecht M, 1998, MOL BIOCHEM PARASIT, V97, P189, DOI 10.1016/S0166-6851(98)00151-0; BRIONES MRS, 1992, MOL BIOCHEM PARASIT, V53, P121, DOI 10.1016/0166-6851(92)90014-B; CROSS GAM, 1970, BIOCHIM BIOPHYS ACTA, V204, P470, DOI 10.1016/0005-2787(70)90167-X; Djikeng A, 2003, RNA, V9, P802, DOI 10.1261/rna.5270203; FLEISCHMANN J, 1994, GENE, V144, P45, DOI 10.1016/0378-1119(94)90201-1; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; Gibson W, 2000, MOL BIOCHEM PARASIT, V107, P269, DOI 10.1016/S0166-6851(00)00193-6; Gu J, 1996, RNA, V2, P909; HAGENBUCHLE O, 1978, CELL, V13, P551, DOI 10.1016/0092-8674(78)90328-8; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; Keiper BD, 2000, J BIOL CHEM, V275, P10590, DOI 10.1074/jbc.275.14.10590; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; Lafontaine DLJ, 1998, MOL CELL BIOL, V18, P2360, DOI 10.1128/MCB.18.4.2360; LAIRD P, 1988, THESIS NETHERLANDS C; Lamontagne J, 1999, J BIOL CHEM, V274, P6602, DOI 10.1074/jbc.274.10.6602; LENARDO MJ, 1985, MOL CELL BIOL, V5, P2487, DOI 10.1128/MCB.5.9.2487; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; Londei P, 1998, BBA-GENE STRUCT EXPR, V1396, P169, DOI 10.1016/S0167-4781(97)00190-5; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Maden BEH, 1997, CHROMOSOMA, V105, P391, DOI 10.1007/s004120050200; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MAGA JA, 1995, MOL CELL BIOL, V15, P4884; Mandelboim M, 2002, J BIOL CHEM, V277, P35210, DOI 10.1074/jbc.M201910200; MARIN F, 1995, J MOL BIOL, V247, P49; MAROUN LE, 1986, J THEOR BIOL, V120, P85, DOI 10.1016/S0022-5193(86)80019-4; Miyoshi H, 2002, EMBO J, V21, P4680, DOI 10.1093/emboj/cdf473; O'Connor M, 1999, P NATL ACAD SCI USA, V96, P8973, DOI 10.1073/pnas.96.16.8973; Orlando TC, 2002, MEM I OSWALDO CRUZ, V97, P695, DOI 10.1590/S0074-02762002000500020; PELLE R, 1993, MOL BIOCHEM PARASIT, V59, P277, DOI 10.1016/0166-6851(93)90225-M; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; Santana DM, 2001, FEMS MICROBIOL LETT, V204, P233, DOI 10.1111/j.1574-6968.2001.tb10890.x; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; STUART KD, 1992, P NATL ACAD SCI USA, V89, P8596, DOI 10.1073/pnas.89.18.8596; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; Sturm NR, 1999, MOL CELL BIOL, V19, P1595; SUTTON RE, 1988, MOL CELL BIOL, V8, P494, DOI 10.1128/MCB.8.1.494; TESTA D, 1977, J VIROL, V24, P786, DOI 10.1128/JVI.24.3.786-793.1977; Tourriere H, 2002, BIOCHIMIE, V84, P821, DOI 10.1016/S0300-9084(02)01445-1; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P131, DOI 10.1016/0166-6851(96)02726-0; YOUNG JR, 1982, NUCLEIC ACIDS RES, V10, P803, DOI 10.1093/nar/10.3.803; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1; Yueh A, 2000, GENE DEV, V14, P414; Zeiner GM, 2003, EUKARYOT CELL, V2, P222, DOI 10.1128/EC.2.2.222-230.2003	54	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38269	38275		10.1074/jbc.M304295200	http://dx.doi.org/10.1074/jbc.M304295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878606	hybrid			2022-12-25	WOS:000185575100024
J	Bishop-Bailey, D; Warner, TD				Bishop-Bailey, D; Warner, TD			PPAR gamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist	FASEB JOURNAL			English	Article						restenosis; inflammation; nuclear receptor; NSAID	CYCLOOXYGENASE-2 EXPRESSION; PHOSPHOLIPASE A(2); ARACHIDONIC-ACID; APOPTOSIS; THERAPY; CYCLO-OXYGENASE-2; RELEASE; TARGET; GENE; RAT	Peroxisome proliferator-activated receptor (PPAR)gamma and inducible cyclooxygenase-2 (COX-2) are expressed in atherosclerotic lesions, particularly in the intimal monocytic and vascular smooth muscle cells. We have therefore studied the interaction between PPAR. and inducible cyclo-oxygenase (COX-2) in rat aortic vascular smooth muscle cells (RASMC)s. The synthetic PPARgamma ligand rosiglitazone induced prostaglandin (PG) release from RASMCs, including that of PGD(2), the precursor of the putative endogenous PPARgamma ligand 15-deoxy-Delta(12,14)-prostaglandin J(2). Moreover, rosiglitazone both synergized with IL-1beta to further induce prostaglandin release and affected the expression of phospholipase A(2) and COX-2. Rosiglitazone-induced prostaglandin release was inhibited by the PPARgamma partial agonist GW0072 and the PPARgamma antagonist GW9662. Rosiglitazone also induced RASMC apoptosis, an effect not explained as an autocrine effect of the induced-prostanoids, but on arachidonic acid release, as cell death was unaffected by either the nonselective COX inhibitor piroxicam or the selective COX-2 inhibitor DFP, but by inhibitors of either secretory or cytosolic phospholipase A(2). In contrast, indomethacin, an alternative inhibitor of cyclooxygenase activity, inhibited both rosiglitazone-induced cell death, and rosiglitazone-induced PPAR reporter gene activation.	Barts & London, Queen Marys Sch Med & Dent, Dept Cardiac Vasc & Inflammat Res, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London	Bishop-Bailey, D (corresponding author), Barts & London, Queen Marys Sch Med & Dent, Dept Cardiac Vasc & Inflammat Res, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	d.bishop-bailey@qmul.ac.uk	Warner, Timothy D/A-1980-2009	Warner, Timothy D/0000-0003-3988-4408; Bishop-Bailey, David/0000-0003-2455-596X				Adamson DJA, 2002, MOL PHARMACOL, V61, P7, DOI 10.1124/mol.61.1.7; Bishop-Bailey D, 1999, INT J MOL MED, V3, P41; Bishop-Bailey D, 2000, BRIT J PHARMACOL, V129, P823, DOI 10.1038/sj.bjp.0703149; Bishop-Bailey D, 2002, CIRC RES, V91, P210, DOI 10.1161/01.RES.0000029080.15742.85; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Bishop-Bailey D, 1998, ARTERIOSCL THROM VAS, V18, P1655, DOI 10.1161/01.ATV.18.10.1655; BishopBailey D, 1997, BRIT J PHARMACOL, V121, P125, DOI 10.1038/sj.bjp.0701100; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Dubois RN, 2000, ALIMENT PHARM THERAP, V14, P64, DOI 10.1046/j.1365-2036.2000.014s1064.x; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Inoue H, 2000, J BIOL CHEM, V275, P28028; INSEL PA, 1996, GOODMAN GILMANS PHAR, P633; Jiang YJ, 2001, J LIPID RES, V42, P716; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Leblanc Y, 1999, BIOORG MED CHEM LETT, V9, P2207, DOI 10.1016/S0960-894X(99)00365-0; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Levine L, 2003, FASEB J, V17, P800, DOI 10.1096/fj.02-0906hyp; Levine L, 2001, PROSTAG LEUKOTR ESS, V65, P229, DOI 10.1054/plef.2001.0316; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mitchell JA, 1999, BRIT J PHARMACOL, V128, P1121, DOI 10.1038/sj.bjp.0702897; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Taketo MM, 2002, BBA-MOL CELL BIOL L, V1585, P72, DOI 10.1016/S1388-1981(02)00326-8	29	62	67	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1925	+		10.1096/fj.02-1075fje	http://dx.doi.org/10.1096/fj.02-1075fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897060				2022-12-25	WOS:000185345100018
J	Gratzinger, D; Canosa, S; Engelhardt, B; Madri, JA				Gratzinger, D; Canosa, S; Engelhardt, B; Madri, JA			Platelet endothelial cell adhesion molecule-1 modulates endothelial cell motility through the small G-protein Rho	FASEB JOURNAL			English	Article						CD31; vascular endothelium; cell movement; small G-protein; sphingosine-1-phosphate	HETEROTRIMERIC G-PROTEINS; TYROSINE PHOSPHORYLATION; SPHINGOSINE 1-PHOSPHATE; LIPID RAFTS; IN-VITRO; C-SRC; CYTOPLASMIC DOMAIN; MIGRATORY BEHAVIOR; MEMBRANE DOMAINS; VASCULAR SYSTEM	Platelet endothelial cell adhesion molecule-1 (PECAM-1), an immunoglobulin family vascular adhesion molecule, is involved in endothelial cell migration and angiogenesis (1, 2). We found that endothelial cells lacking PECAM-1 exhibit increased single cell motility and extension formation but poor wound healing migration, reminiscent of cells in which Rho activity has been suppressed by overexpressing a GTPase-activating protein (3). The ability of PECAM-1 to restore wound healing migration to PECAM-1-deficient cells was independent of its extracellular domain or signaling via its immunoreceptor tyrosine-based inhibitory motif. PECAM-1-deficient endothelial cells had a selective defect in RhoGTP loading, and inhibition of Rho activity mimicked the PECAM-1-deficient phenotype of increased chemokinetic single cell motility at the expense of coordinated wound healing migration. The wound healing advantage of PECAM-1-positive endothelial cells was not only Rho mediated but pertussis toxin inhibitable, characteristic of migration mediated by heterotrimeric G-protein-linked seven-transmembrane receptor signaling such as signaling in response to the serum sphingolipid sphingosine-1-phosphate (S1P) (4, 5). Indeed, we found that the wound healing defect of PECAM-1 null endothelial cells is minimized in sphingolipid-depleted media; moreover, PECAM-1 null endothelial cells fail to increase their migration in response to S1P. We have also found that PECAM-1 localizes to rafts and that in its absence heterotrimeric G-protein components are differentially recruited to rafts, providing a potential mechanism for PECAM-1-mediated coordination of S1P signaling. PECAM-1 may thus support the effective S1P/RhoGTP signaling required for wound healing endothelial migration by allowing for the spatially directed, coordinated activation of Galpha signaling pathways.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Max Planck Inst Vasc Biol, Munster, Germany	Yale University; Max Planck Society	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, Lauder Hall 115, New Haven, CT 06510 USA.	joseph.madri@yale.edu	Engelhardt, Britta/K-7267-2014	Engelhardt, Britta/0000-0003-3059-9846; Gratzinger, Dita/0000-0002-9182-8123	NHLBI NIH HHS [R37-HL-28373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Amerongen GPV, 2001, ARTERIOSCL THROM VAS, V21, P300, DOI 10.1161/01.ATV.21.3.300; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; BERNANKE DH, 1982, DEV BIOL, V91, P235, DOI 10.1016/0012-1606(82)90030-6; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cao GY, 2002, AM J PHYSIOL-CELL PH, V282, pC1181, DOI 10.1152/ajpcell.00524.2001; Chiba R, 1999, BLOOD, V94, P1319, DOI 10.1182/blood.V94.4.1319.416k28_1319_1329; COTRAN RS, 1994, PATHOLOGIC BASIS DIS; DeLisser HM, 1997, AM J PATHOL, V151, P671; Duncan GS, 1999, J IMMUNOL, V162, P3022; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Enciso JM, 2003, J CELL BIOL, V160, P605, DOI 10.1083/jcb.200209014; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Haskell MD, 2001, J CELL SCI, V114, P1699; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kim CS, 1998, LAB INVEST, V78, P583; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kurz H, 1996, DEV BIOL, V173, P133, DOI 10.1006/dbio.1996.0012; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; MADRI JA, 1988, AM J PATHOL, V132, P18; Mahooti S, 2000, AM J PATHOL, V157, P75, DOI 10.1016/S0002-9440(10)64519-1; Maragoudakis ME, 2002, BIOCHEM SOC T, V30, P173, DOI 10.1042/bst0300173; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Murthy KS, 2000, J BIOL CHEM, V275, P30211, DOI 10.1074/jbc.M002194200; Nakamura K, 2000, J BIOL CHEM, V275, P27155; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Nusrat A, 2000, J CELL SCI, V113, P1771; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Osawa M, 1997, EUR J CELL BIOL, V72, P229; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Pinter E, 1997, AM J PATHOL, V150, P1523; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Solowiej A, 2003, AM J PATHOL, V162, P953, DOI 10.1016/S0002-9440(10)63890-4; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sun BW, 2001, CHEM LETT, P2, DOI 10.1246/cl.2001.2; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Uchida S, 2000, BIOCHEM BIOPH RES CO, V269, P633, DOI 10.1006/bbrc.2000.2315; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wong CWY, 2000, MOL BIOL CELL, V11, P3109, DOI 10.1091/mbc.11.9.3109; Yano Y, 1996, BIOCHEM BIOPH RES CO, V224, P508, DOI 10.1006/bbrc.1996.1057; Yatomi Y, 1997, J BIOCHEM, V121, P969	74	67	70	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1458	1469		10.1096/fj.02-1040com	http://dx.doi.org/10.1096/fj.02-1040com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890700				2022-12-25	WOS:000185345100039
J	Xin, H; Curry, J; Johnstone, RW; Nickoloff, BJ; Choubey, D				Xin, H; Curry, J; Johnstone, RW; Nickoloff, BJ; Choubey, D			Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence	ONCOGENE			English	Article						interferon-inducible IFI 16; prostate; senescence; p21(WAF1); E2F; Rb	NEGATIVE REGULATOR; RETINOBLASTOMA PROTEIN; GENE; EXPRESSION; CELLS; P202; TRANSCRIPTION; IDENTIFICATION; LOCALIZATION; INHIBITION	Recent studies have implicated interferon signaling in the regulation of cellular senescence. However, the role of specific interferon-inducible proteins in cellular senescence remains to be defined. Here we report that IFI 16, an interferon-inducible transcriptional modulator from the p200-protein family, contributes to cellular senescence of prostate epithelial cells. Normal human prostate epithelial cells (PrEC) in culture expressed detectable levels of IFI 16, and the levels increased more than fourfold when cells approached cellular senescence. Consistent with a role of IFI 16 in cellular senescence, human prostate cancer cell lines either did not express IFI 16 or expressed a variant form, which was primarily detected in the cytoplasm of prostate cancer cells and not in the nucleus. Moreover, overexpression of functional IFI 16 in human prostate cancer cell lines inhibited colony formation. Additionally, ectopic expression of IFI 16 in clonal prostate cancer cell lines was associated with a senescence-like phenotype, production of senescence-associated beta-galactosidase (a biochemical marker for cellular senescence), and reduction of S-phase cells in culture. Importantly, upregulation of p21(WAF1) and inhibition of E2F-stimulated transcription accompanied inhibition of cell growth by IFI 16 in prostate cancer cell lines. Collectively, our observations support the idea that increased levels of IFI 16 in PrECs contribute to senescence-associated irreversible cell growth arrest.	Loyola Univ, Stritch Sch Med, Dept Pathol, Med Ctr, Maywood, IL 60153 USA; Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, Med Ctr, Maywood, IL 60153 USA; Peter MacCallum Canc Inst, Canc Immunol Program, Trescowthick Res Labs, Melbourne, Vic 3002, Australia	Loyola University Chicago; Loyola University Chicago; Peter Maccallum Cancer Center	Choubey, D (corresponding author), Loyola Univ, Stritch Sch Med, Dept Pathol, Med Ctr, 2160 S 1st Ave,Mail Code 114B, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008; Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237	NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG022124] Funding Source: NIH RePORTER; NCI NIH HHS [CA69031] Funding Source: Medline; NIAMS NIH HHS [AR47307] Funding Source: Medline; NIA NIH HHS [AG022124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Castro P, 2003, PROSTATE, V55, P30, DOI 10.1002/pros.10204; Certa U, 2001, BRIT J CANCER, V85, P107, DOI 10.1054/bjoc.2001.1865; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Jarrard DF, 1999, CANCER RES, V59, P2957; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Karlsson C, 1996, CANCER RES, V56, P241; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Mori Y, 2001, CANCER RES, V61, P6046; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; SEN GC, 1992, J BIOL CHEM, V267, P5017; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Untergasser G, 2002, CANCER RES, V62, P6255; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Webber MM, 1997, PROSTATE, V30, P58; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844	51	97	100	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4831	4840		10.1038/sj.onc.1206754	http://dx.doi.org/10.1038/sj.onc.1206754			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894224				2022-12-25	WOS:000184344600006
J	Dallol, A; Krex, D; Hesson, L; Eng, C; Maher, ER; Latif, F				Dallol, A; Krex, D; Hesson, L; Eng, C; Maher, ER; Latif, F			Frequent epigenetic inactivation of the SLIT2 gene in gliomas	ONCOGENE			English	Article						SLIT2; glioma; methylation	TUMOR-SUPPRESSOR GENE; BREAST CANCERS; LATERAL POSITION; DNA METHYLATION; ROBO RECEPTORS; AXON GUIDANCE; HUMAN HOMOLOG; CPG ISLAND; RASSF1A; 3P21.3	The SLIT family of genes consists of large extracellular matrix-secreted and membrane-associated glycoproteins. The Slits (Slit1-3) are ligands for the repulsive guidance receptors, the roho gene family. The Slit-Robo interactions mediate the repulsive cues on axons and growth cones during neural development. In a recent report, we demonstrated that promoter region CpG island of human SLIT2 was frequently hypermethylated in lung, breast and colorectal tumours and the silenced gene transcript suppressed the malignant phenotype in in vitro assays. In this report we undertook epigenetic, genetic and expression analysis of SLIT2 gene in a large series of gliomas and glioma cell lines. Promoter region CpG island of SLIT2 was found to be methylated in 71% (5/7) of glioma cell lines and was unmethylated in five DNA samples from normal brain tissues. The hypermethylation of the SLIT2 promoter region in glioma cell lines correlated with loss of expression and treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivated SLIT2 gene expression. In primary gliomas, SLIT2 was methylated in 59% (37/63) of tumours analysed. In addition, SLIT2 expression was downregulated in methylated gliomas relative to unmethylated tumour samples, as demonstrated by quantitative real-time RT-PCR. Loss of heterozygosity analysis revealed that SLIT2 methylated gliomas retained both alleles of a microsatellite marker within 100 kb of the SLIT2 gene at 4p15.2. Exogenous expression of SLIT2 in a glioma cell tine that was heavily methylated for SLIT2 decreased in vitro colony formation. Our data indicate that SLIT2 is frequently inactivated by promoter region CpG island hypermethylation in gliomas and may be a good candidate for a glioma tumour suppressor gene (TSG) located at 4p15.2. Furthermore, our data suggest that a detailed analysis of both the cancer genome and epigenome will be required to identify key TSGs involved in glioma development.	Univ Birmingham, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England; Tech Univ Dresden, Dept Neurosurg, Univ Klinikum Carl Gustav Carus, D-01307 Dresden, Germany; Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Univ Birmingham, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TG, W Midlands, England	University of Birmingham; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England.		Krex, Dietmar/E-6833-2014; Hesson, Luke/HDM-0311-2022; Dallol, Ashraf/H-8661-2012; MAHER, EAMONN R/A-9507-2008	Dallol, Ashraf/0000-0002-8803-228X; MAHER, EAMONN R/0000-0002-6226-6918; Eng, Charis/0000-0002-3693-5145				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Burton EC, 2002, CANCER RES, V62, P6205; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; GREGER V, 1994, HUM GENET, V94, P491; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Lo KW, 2001, CANCER RES, V61, P3877; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Lusher ME, 2002, CANCER RES, V62, P5906; Morrissey C, 2001, CANCER RES, V61, P7277; Rajagopalan S, 2000, CELL, V103, P1033, DOI 10.1016/S0092-8674(00)00207-5; Simpson JH, 2000, CELL, V103, P1019, DOI 10.1016/S0092-8674(00)00206-3; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Yin D, 2002, ONCOGENE, V21, P8372, DOI 10.1038/sj.onc.1206031	28	108	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4611	4616		10.1038/sj.onc.1206687	http://dx.doi.org/10.1038/sj.onc.1206687			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881718				2022-12-25	WOS:000184054700017
J	Paruchuri, S; Sjolander, A				Paruchuri, S; Sjolander, A			Leukotriene D-4 mediates survival and proliferation via separate but parallel pathways in the human intestinal epithelial cell line int 407	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ELEMENT-BINDING PROTEIN; HUMAN-MELANOMA CELLS; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; S6 KINASE; RESPONSIVE ELEMENT; COLORECTAL-CANCER; RECEPTOR; GROWTH	We demonstrated previously that leukotriene D-4 (LTD4) regulates proliferation of intestinal epithelial cells through a CysLT receptor by protein kinase C (PKC)epsilon-dependent stimulation of the mitogen-activated protein kinase ERK1/2. Our current study provides the first evidence that LTD4 can activate 90-kDa ribosomal S6 kinase (p90(RSK)) and cAMP-responsive element-binding protein (CREB) via pertussis-toxin-sensitive G(i) protein pathways. Transfection and inhibitor experiments revealed that activation of p90(RSK), but not CREB, is a PKCepsilon/Raf-1/ERK1/2-dependent process. LTD4-mediated CREB activation was not affected by expression of kinase-dead p90(RSK) but was abolished by transfection with the regulatory domain of PKCalpha (a specific dominant-inhibitor of PKCalpha). Kinase-negative mutants of p90(RSK) and CREB (K(-)p90(RSK) and K-CREB) blocked the LTD4-induced increase in cell number and DNA synthesis (thymidine incorporation). Compatible with these results, flow cytometry showed that LTD4 caused transition from the G(0)/G(1) to the S+G(2)/M cell cycle phase, indicating increased proliferation. Similar treatment of cells transfected with K-p90(RSK) resulted in cell cycle arrest in the G(0)/G(1) phase, consistent with a role of p90(RSK) in LTD4-induced proliferation. On the other hand, expression of K-CREB caused a substantial buildup in the sub-G(0)/G(1) phase, suggesting a role for CREB in mediating LTD4-mediated survival in intestinal epithelial cells. Our results show that LTD4 regulates proliferation and survival via distinct intracellular signaling pathways in intestinal epithelial cells.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Expt Pathol, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Expt Pathol, SE-20502 Malmo, Sweden.							Apati A, 2003, J BIOL CHEM, V278, P9235, DOI 10.1074/jbc.M205528200; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Braccioni F, 2002, J ALLERGY CLIN IMMUN, V110, P96, DOI 10.1067/mai.2002.125000; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHAN CC, 1990, EUR J PHARMACOL, V191, P273; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Choe ES, 2002, NEUROSCIENCE, V114, P557, DOI 10.1016/S0306-4522(02)00318-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Gogal RM, 2000, CYTOMETRY, V39, P310, DOI 10.1002/(SICI)1097-0320(20000401)39:4<310::AID-CYTO10>3.0.CO;2-V; Gubina E, 2001, J IMMUNOL, V167, P4303, DOI 10.4049/jimmunol.167.8.4303; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HENLE G, 1957, J IMMUNOL, V79, P54; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lynch KR, 1999, NATURE, V399, P789; Massoumi R, 1998, EUR J CELL BIOL, V76, P185, DOI 10.1016/S0171-9335(98)80033-2; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Ohd JF, 2002, ADV EXP MED BIOL, V507, P193; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; Paruchuri S, 2002, J CELL SCI, V115, P1883; Pende M, 1997, J NEUROSCI, V17, P1291; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SADOSHIMA J, 1995, CIRC RES, V76, P1; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SJOLANDER A, 1990, J BIOL CHEM, V265, P20976; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Swart JM, 2000, J IMMUNOL, V164, P2311, DOI 10.4049/jimmunol.164.5.2311; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Thodeti CK, 2001, EXP CELL RES, V262, P95, DOI 10.1006/excr.2000.5077; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Wikstrom K, 2003, BIOCHEM BIOPH RES CO, V302, P330, DOI 10.1016/S0006-291X(03)00187-6; Yang YM, 1996, ONCOGENE, V12, P2223; Zeidman R, 1999, INT J CANCER, V81, P494, DOI 10.1002/(SICI)1097-0215(19990505)81:3<494::AID-IJC26>3.0.CO;2-L	55	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45577	45585		10.1074/jbc.M302881200	http://dx.doi.org/10.1074/jbc.M302881200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12912998	hybrid			2022-12-25	WOS:000186452300066
J	Jiang, XP; Newell, EW; Schlichter, LC				Jiang, XP; Newell, EW; Schlichter, LC			Regulation of a TRPM7-like current in rat brain microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC TYROSINE KINASE; T-LYMPHOCYTES; MIC CHANNELS; K+ CHANNELS; INTERMEDIATE CONDUCTANCE; CELLS; ACTIVATION; CRAC; TRP; PROTEIN	Non-excitable cells use Ca2+ influx for essential functions but usually lack voltage-gated Ca2+ channels. The main routes of Ca2+ entry appear to be store-operated channels or Ca2+-permeable non-selective cation channels, of which the magnesium-inhibited cation ( or magnesium-nucleotide-regulated metal cation) current has received considerable recent attention. This current appears to be produced by one of the recently cloned transient receptor potential (TRP) channels, TRPM7. In this study of rat microglia, we identified TRPM7 transcripts and a prevalent current with the hallmark biophysical and pharmacological features of TRPM7. This is the first identification of a TRPM7-like current in the brain. There is little known about how members of the TRPM sub-family normally become activated. Using whole-cell patch clamp recordings from rat microglia, we found that the TRPM7-like current activates spontaneously after break- in and that the current and its activation are inhibited by elevated intracellular Mg2+ but not affected by cell swelling or a wide range of intracellular Ca2+ concentrations. The TRPM7-like current in microglia appears to depend on tyrosine phosphorylation. It was inhibited by several tyrosine kinase inhibitors, including a peptide (Src 40 - 58) that was shown previously to inhibit Src actions, but not by inactive drugs or peptide analogues. The current did not depend on the cell activation state; i.e. it was the same in microglia recently removed from the brain or when cultured under a wide range of conditions that favor the resting or activated state. Because TRPM7 channels are permeable to Ca2+, this current may be important for microglia functions that depend on elevations in intracellular Ca2+.	Toronto Western Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Schlichter, LC (corresponding author), Toronto Western Inst, Div Cellular & Mol Biol, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Newell, Evan/F-9711-2012	Newell, Evan/0000-0002-2889-243X				Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Attali B, 1997, J NEUROSCI, V17, P8234; Aussel C, 1996, BIOCHEM J, V313, P909, DOI 10.1042/bj3130909; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; Cayabyab FS, 2002, J BIOL CHEM, V277, P13673, DOI 10.1074/jbc.M108211200; Chandy KG, 2001, TOXICON, V39, P1269, DOI 10.1016/S0041-0101(01)00120-9; Clapham DE, 2002, J GEN PHYSIOL, V120, P217, DOI 10.1085/jgp.20028618; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; COLTON CA, 1994, AM J PHYSIOL, V266, pC1650, DOI 10.1152/ajpcell.1994.266.6.C1650; Daeron M, 1997, Int Rev Immunol, V16, P1, DOI 10.3109/08830189709045701; Eder C, 1999, EUR J NEUROSCI, V11, P4251, DOI 10.1046/j.1460-9568.1999.00852.x; Fujishima H, 1998, INT J CANCER, V76, P423; Grubbs RD, 2002, BIOMETALS, V15, P251, DOI 10.1023/A:1016026831789; Hahn J, 2000, GLIA, V31, P118, DOI 10.1002/1098-1136(200008)31:2<118::AID-GLIA30>3.0.CO;2-0; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Illes P, 1996, NEUROCHEM INT, V29, P13; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 2001, CURR DRUG TARGETS, V2, P401, DOI 10.2174/1389450013348173; Kerschbaum HH, 2003, BIOPHYS J, V84, P2293, DOI 10.1016/S0006-3495(03)75035-8; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KODAMA I, 1987, J MOL CELL CARDIOL, V19, P367, DOI 10.1016/S0022-2828(87)80582-5; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Schilling T, 2000, AM J PHYSIOL-CELL PH, V279, pC1123, DOI 10.1152/ajpcell.2000.279.4.C1123; Schilling T, 2002, NEUROSCIENCE, V109, P827, DOI 10.1016/S0306-4522(01)00534-6; Schlichter LC, 1996, GLIA, V17, P225, DOI 10.1002/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#; SCHLICHTER LC, 2002, POTASSIUM CHANNELS P; SCHUMACHER PA, 1995, J MEMBRANE BIOL, V145, P217; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; WATSKY MA, 1995, AM J PHYSIOL-CELL PH, V268, pC1179, DOI 10.1152/ajpcell.1995.268.5.C1179; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	57	115	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42867	42876		10.1074/jbc.M304487200	http://dx.doi.org/10.1074/jbc.M304487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904301	hybrid			2022-12-25	WOS:000186157000018
J	McKallip, RJ; Fisher, M; Do, Y; Szakal, AK; Gunthert, U; Nagarkatti, PS; Nagarkatti, M				McKallip, RJ; Fisher, M; Do, Y; Szakal, AK; Gunthert, U; Nagarkatti, PS; Nagarkatti, M			Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT INTERLEUKIN-2; ADHESION MOLECULES; VARIANT ISOFORMS; HYALURONIC-ACID; T-CELLS; INVOLVEMENT; ACTIVATION; VASCULITIS; TOXICITY; RECEPTOR	In the current study, we investigated the nature and role of CD44 variant isoforms involved in endothelial cell (EC) injury and tumor cell cytotoxicity mediated by IL-2-activated killer (LAK) cells. Treatment of CD44 wild-type lymphocytes with IL-2 led to increased gene expression of CD44 v6 and v7 variant isoforms and to significant induction of vascular leak syndrome (VLS). CD44v6-v7 knockout (KO) and CD44v7 KO mice showed markedly reduced levels of IL-2-induced VLS. The decreased VLS in CD44v6-v7 KO and CD44v7 KO mice did not result from differential activation and expansion of CD8(+) T cells, NK, and NK-T cells or from altered degree of perivascular lymphocytic infiltration in the lungs. LAK cells from CD44v7 KO mice showed a significant decrease in their ability to adhere to and mediate lysis of EC but not lysis of P815 tumor cells in vitro. CD44v7-mediated lysis of EC by LAK cells was dependent on the activity of phosphatidylinositol 3-kinase and tyrosine kinases. Interestingly, IL-2-activated LAK cells expressing CD44(hi) but not CD44(lo) were responsible for EC lysis. Furthermore, lysis of EC targets could be blocked by addition of soluble or enzymatic cleavage of CD44v6-v7-binding glycosaminoglycans. Finally, anti-CD44v7 mAbs caused a significant reduction in the adherence to and killing of EC and led to suppression of IL-2-induced VLS. Together, this study suggests that the expression of CD44v7 on LAK cells plays a specific role in EC injury and that it may be possible to reduce EC injury but not tumor cell killing by specifically targeting CD44v7.	Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA; Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Basel	Nagarkatti, M (corresponding author), Virginia Commonwealth Univ, Dept Microbiol & Immunol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	mnagark@hsc.vcu.edu	Do, Yoonkyung/F-5231-2010	Do, Yoonkyung/0000-0001-7947-4767; Nagarkatti, Prakash/0000-0003-2663-0759	NCI NIH HHS [P30 CA 16059] Funding Source: Medline; NHLBI NIH HHS [R01 HL058641, F32 HL 10455] Funding Source: Medline; NIAID NIH HHS [R01AI053703] Funding Source: Medline; NIDA NIH HHS [R21 DA 014885, R01 DA016545] Funding Source: Medline; NIEHS NIH HHS [R01 ES09098, F32 ES011732] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010455, R01HL058641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES011732, R01ES009098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016545, R21DA014885] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Baluna R, 1997, IMMUNOPHARMACOLOGY, V37, P117, DOI 10.1016/S0162-3109(97)00041-6; Baluna R, 1999, P NATL ACAD SCI USA, V96, P3957, DOI 10.1073/pnas.96.7.3957; BECHARD DE, 1989, AM J MED SCI, V298, P28, DOI 10.1097/00000441-198907000-00005; Beekhuizen H, 1998, TRANSPL P, V30, P4251, DOI 10.1016/S0041-1345(98)01405-5; Chen DW, 2001, J IMMUNOL, V166, P5889, DOI 10.4049/jimmunol.166.10.5889; Christ O, 2001, J LEUKOCYTE BIOL, V69, P343; DAMLE NK, 1987, J IMMUNOL, V138, P1779; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DOHERTY PC, 1990, IMMUNOL TODAY, V11, P55; Estess P, 1999, J EXP MED, V190, P9, DOI 10.1084/jem.190.1.9; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; GALANDRINI R, 1994, J IMMUNOL, V153, P4399; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; HAMMOND DM, 1993, J EXP MED, V178, P2225, DOI 10.1084/jem.178.6.2225; HAMMONDMCKIBBEN DM, 1995, INT J CANCER, V60, P828, DOI 10.1002/ijc.2910600618; HEWICKER M, 1987, LAB ANIM, V21, P335, DOI 10.1258/002367787781363408; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; LESLEY J, 1992, EUR J IMMUNOL, V22, P2719, DOI 10.1002/eji.1830221036; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LI L, 1994, J IMMUNOL, V153, P3967; Liu DC, 1996, CELL IMMUNOL, V174, P73, DOI 10.1006/cimm.1996.0295; Malaguarnera M, 2001, EUR J CLIN PHARMACOL, V57, P267, DOI 10.1007/s002280100321; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Matsumoto G, 1998, J IMMUNOL, V160, P5781; MCCLUSKEY RT, 1983, HUM PATHOL, V14, P305, DOI 10.1016/S0046-8177(83)80116-6; McKallip RJ, 2002, INT IMMUNOL, V14, P1015, DOI 10.1093/intimm/dxf068; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; MOYER CF, 1984, AM J PATHOL, V117, P380; Nakajima T, 2002, CIRCULATION, V105, P570, DOI 10.1161/hc0502.103348; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; PEACE DJ, 1989, J EXP MED, V169, P161, DOI 10.1084/jem.169.1.161; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Rafi AQ, 1998, J IMMUNOL, V161, P3077; Rafi-Janajreh AQ, 1999, J IMMUNOL, V163, P1619; Rafi-Janajreh Asimah Q., 1998, Frontiers in Bioscience, V3, pD665; Robinson MJ, 2002, J BIOL CHEM, V277, P3658, DOI 10.1074/jbc.M102950200; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Sconocchia G, 1997, BLOOD, V90, P716, DOI 10.1182/blood.V90.2.716.716_716_725; Seiter S, 2000, INT IMMUNOL, V12, P37, DOI 10.1093/intimm/12.1.37; SETH A, 1991, P NATL ACAD SCI USA, V88, P7877, DOI 10.1073/pnas.88.17.7877; Sleeman JP, 1997, J BIOL CHEM, V272, P31837, DOI 10.1074/jbc.272.50.31837; TSUKADA N, 1993, J NEUROL SCI, V117, P140, DOI 10.1016/0022-510X(93)90166-V; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UDAKA K, 1970, P SOC EXP BIOL MED, V133, P1384; Van Driel M, 2002, LEUKEMIA, V16, P135, DOI 10.1038/sj.leu.2402336; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; VIAL T, 1995, DRUG SAFETY, V13, P371, DOI 10.2165/00002018-199513060-00006; Wittig B, 1998, J IMMUNOL, V161, P1069; Wittig BM, 2000, J EXP MED, V191, P2053, DOI 10.1084/jem.191.12.2053; Yoneda O, 2000, J IMMUNOL, V164, P4055, DOI 10.4049/jimmunol.164.8.4055	55	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43818	43830		10.1074/jbc.M304467200	http://dx.doi.org/10.1074/jbc.M304467200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904302	Green Accepted, hybrid			2022-12-25	WOS:000186157000132
J	Christian, SL; Lee, RL; McLeod, SJ; Burgess, AE; Li, AHY; Dang-Lawson, M; Lin, KBL; Gold, MR				Christian, SL; Lee, RL; McLeod, SJ; Burgess, AE; Li, AHY; Dang-Lawson, M; Lin, KBL; Gold, MR			Activation of the Rap GTPases in B lymphocytes modulates B cell antigen receptor-induced activation of Akt but has no effect on MAPK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE-3; NUCLEOTIDE EXCHANGE FACTOR; SIGNAL-REGULATED KINASE; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; T-CELL; PHOSPHOINOSITIDE 3-KINASE-GAMMA; PHOSPHOLIPASE C-GAMMA-2	Signaling by the B cell antigen receptor (BCR) activates the Rap1 and Rap2 GTPases, putative antagonists of Ras-mediated signaling. Because Ras can activate the Raf-1/ERK pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, we asked whether Rap activation limits the ability of the BCR to signal via these pathways. To do this, we blocked the activation of endogenous Rap1 and Rap2 by expressing the Rap-specific GTPase-activating protein RapGAPII. Preventing Rap activation had no effect on BCR-induced activation of ERK. In contrast, BCR-induced phosphorylation of Akt on critical activating sites was increased 2- to 3-fold when Rap activation was blocked. Preventing Rap activation also increased the ability of the BCR to stimulate Akt-dependent phosphorylation of the FKHR transcription factor on negative regulatory sites and decreased the levels of p27(Kip1), a pro-apoptotic factor whose transcription is enhanced by FKHR. Moreover, preventing Rap activation reduced BCR-induced cell death in the WEHI-231 B cell line. Thus activation of endogenous Rap by the BCR limits BCR-induced activation of the PI3K/Akt pathway, opposes the subsequent inhibition of the FKHR/p27(Kip1) pro-apoptotic module, and enhances BCR-induced cell death. Consistent with the idea that Rap-GTP is a negative regulator of the PI3K/Akt pathway, expressing constitutively active Rap2 (Rap2V12) reduced BCR-induced phosphorylation of Akt and FKHR. Finally, our finding that Rap2V12 can bind PI3K and inhibit its activity in a manner that depends upon BCR engagement provides a potential mechanism by which Rap-GTP limits activation of the PI3K/Akt pathway, a central regulator of B cell growth and survival.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Gold, MR (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	mgold@interchange.ubc.ca	Gold, Michael/AAF-2081-2021	Gold, Michael/0000-0003-1222-3191; Christian, Sherri/0000-0002-4289-4386				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buensuceso CS, 2000, J BIOL CHEM, V275, P13118, DOI 10.1074/jbc.275.17.13118; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; Carey GB, 2000, IMMUNOL REV, V176, P105; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Christian SL, 2002, J IMMUNOL, V169, P758, DOI 10.4049/jimmunol.169.2.758; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Czyzyk J, 2000, MOL CELL BIOL, V20, P8740, DOI 10.1128/MCB.20.23.8740-8747.2000; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Gold MR, 2002, TRENDS PHARMACOL SCI, V23, P316, DOI 10.1016/S0165-6147(02)02045-X; Gold MR, 1999, J IMMUNOL, V163, P1894; GOLD MR, 1992, J IMMUNOL, V148, P2012; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Jacob A, 2002, J BIOL CHEM, V277, P23420, DOI 10.1074/jbc.M202485200; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katner AL, 2002, PROSTATE, V53, P77, DOI 10.1002/pros.10124; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; King LB, 1999, J IMMUNOL, V162, P2655; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Krebs Danielle L., 1999, Methods in Cell Science, V21, P57, DOI 10.1023/A:1009843325770; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marshall AJ, 2000, IMMUNOL REV, V176, P30; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; Onishi M, 1996, EXP HEMATOL, V24, P324; Ozes ON, 1999, NATURE, V401, P82; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; SATO KY, 1994, CANCER RES, V54, P552; Sawada Y, 2001, J CELL SCI, V114, P1221; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shimizu Y, 2000, Immunol Today, V21, P597, DOI 10.1016/S0167-5699(00)01783-7; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Ting HC, 2002, IMMUNOL LETT, V82, P205, DOI 10.1016/S0165-2478(02)00044-5; TORDAI A, 1994, J BIOL CHEM, V269, P7538; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Wu M, 1999, J IMMUNOL, V163, P6530; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	84	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41756	41767		10.1074/jbc.M303180200	http://dx.doi.org/10.1074/jbc.M303180200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904304	hybrid			2022-12-25	WOS:000185989500027
J	Mantovani, F; Banks, L				Mantovani, F; Banks, L			Regulation of the discs large tumor suppressor by a phosphorylation-dependent interaction with the beta-TrCP ubiquitin ligase receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; HUMAN-PAPILLOMAVIRUS E6; F-BOX PROTEIN; P105 REQUIRES PHOSPHORYLATION; HUMAN HOMOLOG; MEDIATED DEGRADATION; EPITHELIAL-CELLS; RECRUITS SAP97; CATENIN; KINASE	The discs large (hDlg) tumor suppressor is intimately involved in the control of cell contact, polarity, and proliferation by interacting with several components of the epithelial junctional complex and with the APC tumor suppressor protein. In epithelial cells, hDlg protein stability is regulated through the ubiquitin-proteasome pathway: hDlg is actively degraded in isolated cells, whereas it accumulates upon cell-cell contact. During neoplastic transformation of epithelial cells, loss of the differentiated morphology and progression toward a metastatic phenotype correlate with down-regulation of hDlg levels and loss of contact-dependent stabilization. Here we show that upon hyperphosphorylation, hDlg interacts with the beta-TrCP ubiquitin ligase receptor through a DSGLPS motif within its Src homology 3 domain. As a consequence, overexpression of beta-TrCP enhances ubiquitination of Dlg protein and decreases its stability, whereas a dominant negative beta-TrCP mutant inhibits this process. Furthermore, a mutant Dlg protein that is unable to bind beta-TrCP displays a higher protein stability and is insensitive to beta-TrCP. Using RNA interference, we also demonstrate that endogenous beta-TrCP regulates hDlg protein levels in epithelial cells. Finally, we show that beta-TrCP selectively induces the degradation of the membrane-cytoplasmic pool, without affecting the nuclear pool of hDlg.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Mantovani, F (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	mantovani@area.trieste.it; banks@icgeb.org						Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mantovani F, 2001, J CELL SCI, V114, P4285; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Reuver SM, 1998, J CELL SCI, V111, P1071; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	55	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42477	42486		10.1074/jbc.M302799200	http://dx.doi.org/10.1074/jbc.M302799200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902344	hybrid			2022-12-25	WOS:000185989500112
J	Zannini, L; Lecis, D; Lisanti, S; Benetti, R; Buscemi, G; Schneider, C; Delia, D				Zannini, L; Lecis, D; Lisanti, S; Benetti, R; Buscemi, G; Schneider, C; Delia, D			Karyopherin-alpha 2 protein interacts with Chk2 and contributes to its nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; RESPONSE PATHWAYS; KINASE; ALPHA; ACTIVATION; P53; PHOSPHORYLATION; DOMAIN; 53BP1; RCH1	Chk2 is a nuclear protein kinase involved in the DNA damage-induced ataxia telangiectasia mutated-dependent checkpoint arrest at multiple cell cycle phases. Searching for Chk2-binding proteins by a yeast two-hybrid system, we identified a strong interaction with karyopherin-alpha2 (KPNA-2), a gene product involved in active nuclear import of proteins bearing a nuclear localization signal (NLS). This finding was confirmed by glutathione S-transferase pull-down and co-immunoprecipitation assays. Of the three predicted Chk2 NLSs, located at amino acids 179-182 (NLS-1), 240-256 (NLS-2), and 515-522 (NLS-3), only the latter mediated the interaction with KPNA-2 in the yeast two-hybrid system, and in particular with its C terminus. Unlike mutations in NLS-1 or NLS-2, which left the nuclear localization of Chk2 unaffected, mutations in NLS-3 caused a cytoplasmic relocalization, indicating that the NLS-3 motif acts indeed as NLS for Chk2 in vivo. Finally, co-transfection experiments with green fluorescent protein (GFP)-Chk2 and wild type or mutant KPNA-2 confirmed the role of KPNA-2 in nuclear import of Chk2.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; AREA Sci Pk, Consorzio Interuniv Biotecnol, Lab Nazl, I-34012 Trieste, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Buscemi, Giacomo/ABI-1170-2020; Zannini, Laura/N-5646-2015; Lecis, Daniele/C-2113-2017	Buscemi, Giacomo/0000-0002-8404-7142; Lecis, Daniele/0000-0002-0564-0563; BENETTI, Roberta/0000-0001-8863-0821; Zannini, Laura/0000-0001-8731-6507	Telethon [GP0205Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahn JY, 2000, CANCER RES, V60, P5934; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Perez-Villar JJ, 2001, INT IMMUNOL, V13, P1265, DOI 10.1093/intimm/13.10.1265; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Shieh SY, 2000, GENE DEV, V14, P289; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	37	64	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42346	42351		10.1074/jbc.M303304200	http://dx.doi.org/10.1074/jbc.M303304200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909615	hybrid			2022-12-25	WOS:000185989500096
J	Zhou, YX; Zhao, MR; Li, D; Shimazu, K; Sakata, K; Deng, CX; Lu, B				Zhou, YX; Zhao, MR; Li, D; Shimazu, K; Sakata, K; Deng, CX; Lu, B			Cerebellar deficits and hyperactivity in mice lacking Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; RAT HIPPOCAMPAL-NEURONS; BONE MORPHOGENETIC PROTEINS; LONG-TERM POTENTIATION; MAD-RELATED PROTEIN; NERVOUS-SYSTEM; TUMOR-SUPPRESSOR; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNAL-TRANSDUCTION	Smad4 is a central mediator of TGF-beta signals, which are known to play essential roles in many biological processes. Using a Cre-loxP approach to overcome early embryonic lethality, we have studied functions of TGFbeta/Smad4 signals in the central nervous system (CNS). No obvious deficits were detected in mice carrying the targeted disruption of Smad4 in the CNS. The overall morphology of the hippocampus appeared normal. There was no change in the proliferation of neuronal precursor cells, nor in several forms of synaptic plasticity. In contrast, deletion of Smad4 resulted in a marked decrease in the number of cerebellar Purkinje cells and parvalbumin-positive interneurons. Accompanied by the abnormality in the cerebellum, mutant mice also exhibited significantly increased vertical activity. Thus, our study reveals an unexpected role for Smad4 in cerebellar development and in the control of motor function.	NIDDK, Mammalian Genet Sect, NIH, Bethesda, MD 20892 USA; NICHD, Sect Neural Dev & Plast, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Lu, B (corresponding author), NIDDK, Mammalian Genet Sect, NIH, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; Lu, Bai/A-4018-2012; Sakata, Kazuko/I-2351-2017	Lu, Bai/0000-0001-5418-9759				Abe K, 1996, BRAIN RES, V723, P206, DOI 10.1016/0006-8993(96)00253-3; Alder J, 1999, NAT NEUROSCI, V2, P535, DOI 10.1038/9189; Angley C, 2003, J NEUROSCI, V23, P260; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Bates B, 1999, NAT NEUROSCI, V2, P115, DOI 10.1038/5669; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; COLINO A, 1993, J NEUROPHYSIOL, V69, P1150, DOI 10.1152/jn.1993.69.4.1150; Combs SE, 2000, J NEUROSCI RES, V59, P379, DOI 10.1002/(SICI)1097-4547(20000201)59:3<379::AID-JNR12>3.0.CO;2-5; CONSTAM DB, 1994, EUR J NEUROSCI, V6, P766, DOI 10.1111/j.1460-9568.1994.tb00988.x; Crone SA, 2003, NEURON, V37, P29, DOI 10.1016/S0896-6273(02)01128-5; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAHL D, 1989, P NATL ACAD SCI USA, V86, P4776, DOI 10.1073/pnas.86.12.4776; deLuca A, 1996, J NEUROSCI, V16, P4174; DENNENBERG VH, 1969, ANN NY ACAD SCI, V159, P852; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dunker N, 2000, EUR J BIOCHEM, V267, P6982, DOI 10.1046/j.1432-1327.2000.01825.x; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; GAGELIN C, 1995, GLIA, V13, P283, DOI 10.1002/glia.440130405; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Harris-White ME, 1998, J NEUROSCI, V18, P10366; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; Ikegaya Y, 1997, JPN J PHARMACOL, V75, P87, DOI 10.1254/jjp.75.87; ISHIHARA A, 1994, BRAIN RES, V639, P21, DOI 10.1016/0006-8993(94)91759-0; Iwahori Y, 1997, BRAIN RES, V760, P52, DOI 10.1016/S0006-8993(97)00275-8; Kane CJM, 1996, DEV BRAIN RES, V96, P46, DOI 10.1016/S0165-3806(96)00092-2; Kim ES, 1998, MOL BRAIN RES, V62, P122, DOI 10.1016/S0169-328X(98)00217-4; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meucci O, 1996, J NEUROSCI, V16, P4080; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, DEVELOPMENT, V125, P857; PLETNIKOV MV, 1999, PHYSIOL BEHAV, V66, DOI UNSP 8230831; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Prehn JHM, 1996, NEUROPHARMACOLOGY, V35, P249, DOI 10.1016/0028-3908(96)00001-9; Ren RF, 1996, BRAIN RES, V732, P16, DOI 10.1016/0006-8993(96)00458-1; SAUREZ SD, 1981, LEARN MOTIV, V12, P342; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; TORUDELBAUFFE D, 1990, J NEUROCHEM, V54, P1056, DOI 10.1111/j.1471-4159.1990.tb02357.x; Trumpp A, 1999, GENE DEV, V13, P3136, DOI 10.1101/gad.13.23.3136; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; Unsicker K, 2000, EUR J BIOCHEM, V267, P6972, DOI 10.1046/j.1432-1327.2000.01824.x; VERGELLI M, 1995, J NEUROSCI RES, V40, P127, DOI 10.1002/jnr.490400114; Waite JJ, 1999, NEUROBIOL LEARN MEM, V71, P325, DOI 10.1006/nlme.1998.3884; Weinstein DC, 1997, CURR OPIN NEUROBIOL, V7, P7, DOI 10.1016/S0959-4388(97)80114-6; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Withers GS, 2000, EUR J NEUROSCI, V12, P106, DOI 10.1046/j.1460-9568.2000.00889.x; Wolf N, 1999, NEUROSCIENCE, V90, P629, DOI 10.1016/S0306-4522(98)00456-4; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	70	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42313	42320		10.1074/jbc.M308287200	http://dx.doi.org/10.1074/jbc.M308287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12896967	hybrid			2022-12-25	WOS:000185989500092
J	Dixelius, J; Makinen, T; Wirzenius, M; Karkkainen, MJ; Wernstedt, C; Alitalo, K; Claesson-Welsh, L				Dixelius, J; Makinen, T; Wirzenius, M; Karkkainen, MJ; Wernstedt, C; Alitalo, K; Claesson-Welsh, L			Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLT4 RECEPTOR; TUMOR LYMPHANGIOGENESIS; SIGNALING PROPERTIES; BREAST-CANCER; HUMAN TISSUES; EXPRESSION; ANGIOGENESIS; LYMPHEDEMA; PROMOTES; GENE	Vascular endothelial growth factors (VEGFs) regulate the development and growth of the blood and lymphatic vascular systems. Of the three VEGF receptors ( VEGFR), VEGFR-1 and -2 are expressed on blood vessels; VEGFR-2 is found also on lymphatic vessels. VEGFR-3 is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Although VEGFR-3 is essential for proper lymphatic development, its signal transduction mechanisms are still incompletely understood. Trans-phosphorylation of activated, dimerized receptor tyrosine kinases is known to be critical for the regulation of kinase activity and for receptor interaction with signal transduction molecules. In this study, we have identified five tyrosyl phosphorylation sites in the VEGFR-3 carboxyl-terminal tail. These sites were used both in VEGFR-3 overexpressed in 293 cells and when the endogenous VEGFR-3 was activated in lymphatic endothelial cells. Interestingly, VEGF-C stimulation of lymphatic endothelial cells also induced the formation of VEGFR-3/VEGFR-2 heterodimers, in which VEGFR-3 was phosphorylated only at three of the five sites while the two most carboxyl-terminal tyrosine residues appeared not to be accessible for the VEGFR-2 kinase. Our data suggest that the carboxyl-terminal tail of VEGFR-3 provides important regulatory tyrosine phosphorylation sites with potential signal transduction capacity and that these sites are differentially used in ligand-induced homo- and heterodimeric receptor complexes.	Univ Uppsala, Dept Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden; Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Uppsala Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Uppsala University; University of Helsinki; Ludwig Institute for Cancer Research	Claesson-Welsh, L (corresponding author), Univ Uppsala, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskjolds Vag 20, S-75185 Uppsala, Sweden.		Makinen, Taija/CAI-2233-2022; Makinen, Taija/C-5765-2014; Alitalo, Kari K/J-5013-2014	Makinen, Taija/0000-0002-9338-1257; Makinen, Taija/0000-0002-9338-1257; Alitalo, Kari K/0000-0002-7331-0902; Claesson-Welsh, Lena/0000-0003-4275-2000				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Enholm B, 2001, CIRC RES, V88, P623, DOI 10.1161/01.RES.88.6.623; FOURNIER E, 1995, ONCOGENE, V11, P921; GALLAND F, 1993, ONCOGENE, V8, P1233; Huang K, 2001, INT J BIOCHEM CELL B, V33, P315, DOI 10.1016/S1357-2725(01)00019-X; Hughes DC, 2001, J MOL EVOL, V53, P77, DOI 10.1007/s002390010195; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V251, P77, DOI 10.1006/bbrc.1998.9442; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Jussila L, 1998, CANCER RES, V58, P1599; Karkkainen MJ, 2002, SEMIN CELL DEV BIOL, V13, P9, DOI 10.1006/scdb.2001.0286; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karpanen T, 2001, CANCER RES, V61, P1786; Kubo H, 2000, BLOOD, V96, P546; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; MATSUMOTO T, 2001, SCI STKE 2001; Matsumura K, 2003, BLOOD, V101, P1367, DOI 10.1182/blood-2002-05-1329; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Witmer AN, 2001, J PATHOL, V195, P490, DOI 10.1002/path.969	35	176	188	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40973	40979		10.1074/jbc.M304499200	http://dx.doi.org/10.1074/jbc.M304499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12881528	hybrid			2022-12-25	WOS:000185847200070
J	Driscoll, HC; Matson, SW; Sayer, JM; Kroth, H; Jerina, DM; Brosh, RM				Driscoll, HC; Matson, SW; Sayer, JM; Kroth, H; Jerina, DM; Brosh, RM			Inhibition of Werner syndrome helicase activity by benzo[c]phenanthrene diol epoxide dA adducts in DNA is both strand- and stereoisomer-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; SYNDROME PROTEIN; SYNDROME CELLS; ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; DEOXYADENOSINE ADDUCTS; SUBSTRATE-SPECIFICITY; SOLUTION CONFORMATION	Helicases are among the first enzymes to encounter DNA damage during DNA processing within the cell and thus are likely to be targets for the adverse effects of DNA lesions induced by environmental chemicals. Here we examined the effect of cis- and trans-opened 3,4-diol 1,2-epoxide (DE) DNA adducts of benzo[c] phenanthrene (BcPh) at N-6 of adenine on helicase activity. These adducts are derived from the highly tumorigenic (-)( 1R, 2S, 3S, 4R)- DE as well as its less carcinogenic (+)( 1S, 2R, 3R, 4S)-DE enantiomer in both of which the benzylic 4-hydroxyl group and epoxide oxygen are trans. The hydrocarbon portions of these adducts intercalate into DNA on the 3' or the 5' side of the adducted deoxyadenosine for the 1S- and 1R-adducts, respectively. These adducts inhibited the human Werner (WRN) syndrome helicase activity in a strand-specific and stereospecific manner. In the strand along which WRN translocates, cis- opened adducts were significantly more effective inhibitors than trans-opened isomers, indicating that WRN unwinding is sensitive to adduct stereochemistry. WRN helicase activity was also inhibited but to a lesser extent by cis- opened BcPh DE adducts in the displaced strand independent of their direction of intercalation, whereas inhibition by the trans-opened stereoisomers in the displaced strand depended on their orientation, such that only adducts oriented toward the advancing helicase inhibited WRN activity. A BcPh DE adduct positioned in the helicase-translocating strand did not sequester WRN, nor affect the rate of ATP hydrolysis relative to an unadducted control. Although the Bloom (BLM) syndrome helicase was also inhibited by a cis- opened adduct in a strand-specific manner, this helicase was not as severely affected as WRN. Because BcPh DEs form substantial amounts of deoxyadenosine adducts at dA, their adverse effects on helicases could contribute to genetic damage and cell transformation induced by these DEs. Thus, the unwinding activity of RecQ helicases is sensitive to the strand, orientation, and stereochemistry of intercalated polycyclic aromatic hydrocarbon adducts.	NIA, Lab Mol Gerontol, NIH, DHHS, Baltimore, MD 21224 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA; NIDDK, Bioorgan Chem Lab, NIH, DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, DHHS, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Brosh, Robert/AAR-6124-2020	Kroth, Heiko/0000-0002-6936-3921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000741, Z01AG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agarwal R, 1996, CHEM RES TOXICOL, V9, P586, DOI 10.1021/tx950148+; AGARWAL SK, 1987, J AM CHEM SOC, V109, P2497, DOI 10.1021/ja00242a040; [Anonymous], 1985, BIOACTIVATION FOREIG; Baum M, 2001, CHEM RES TOXICOL, V14, P686, DOI 10.1021/tx000240s; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; BIGGER CAH, 1992, P NATL ACAD SCI USA, V89, P368, DOI 10.1073/pnas.89.1.368; BJORSETH A, 1979, 3 INT S CHEM BIOL CA, P371; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; BROWN WC, 1989, J BIOL CHEM, V264, P6748; Buterin T, 2000, CANCER RES, V60, P1849; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P12488, DOI 10.1021/bi00097a029; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P1295, DOI 10.1021/bi00004a024; DEVOS RH, 1990, FOOD CHEM TOXICOL, V28, P263, DOI 10.1016/0278-6915(90)90038-O; DIPPLE A, 1987, NATURE, V327, P535, DOI 10.1038/327535a0; Einolf HJ, 1996, CARCINOGENESIS, V17, P2237, DOI 10.1093/carcin/17.10.2237; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Huber MD, 2002, NUCLEIC ACIDS RES, V30, P3954, DOI 10.1093/nar/gkf530; Ilankumaran P, 2001, CHEM RES TOXICOL, V14, P1330, DOI 10.1021/tx010092l; *INT AG RES COUNC, 1983, IARC MON EV CARC RIS; International Agency for Research on Cancer, 1985, IARC MON EV CARC RIS; Jerina D M, 1986, Adv Exp Med Biol, V197, P11; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; LEVIN W, 1986, CANCER RES, V46, P2257; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOWN JW, 1985, BIOCHEMISTRY-US, V24, P4028, DOI 10.1021/bi00336a034; LUNDE G, 1977, NATURE, V268, P518, DOI 10.1038/268518a0; Marians KJ, 2000, STRUCTURE, V8, pR227, DOI 10.1016/S0969-2126(00)00539-6; MATSON SW, 1983, J BIOL CHEM, V258, P4009; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAEGELI H, 1993, J BIOL CHEM, V268, P10386; NAEGELI H, 1993, BIOCHEMISTRY-US, V32, P613, DOI 10.1021/bi00053a029; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; Ponten I, 1999, BIOCHEMISTRY-US, V38, P1144, DOI 10.1021/bi982436l; Ponten I, 2000, BIOCHEMISTRY-US, V39, P4136, DOI 10.1021/bi991719q; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; PRUESSSCHWARTZ D, 1987, CANCER RES, V47, P4032; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1985, ADV EXP MED BIOL, V190, P305; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; VILLANI G, 1994, J BIOL CHEM, V269, P21676; Villani G, 2000, J BIOL CHEM, V275, P33185, DOI 10.1074/jbc.R000011200; Wei SJC, 1996, CANCER RES, V56, P3695; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7; Yong YQ, 1996, CHEM RES TOXICOL, V9, P179, DOI 10.1021/tx950112h; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	66	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41126	41135		10.1074/jbc.M304798200	http://dx.doi.org/10.1074/jbc.M304798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12881525	hybrid, Green Published			2022-12-25	WOS:000185847200088
J	Flintoff, WF; Williams, FMR; Sadlish, H				Flintoff, WF; Williams, FMR; Sadlish, H			The region between transmembrane domains 1 and 2 of the reduced folate carrier forms part of the substrate-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMAGGLUTININ EPITOPE INSERTION; MURINE LEUKEMIA-CELLS; HAMSTER OVARY CELLS; METHOTREXATE UPTAKE; ANTIFOLATE RESISTANCE; SCANNING MUTAGENESIS; MEMBRANE TOPOLOGY; PLASMA-MEMBRANE; N-GLYCOSYLATION; ANION-EXCHANGER	A functional cysteine-less form of the hamster reduced folate carrier protein was generated by alanine replacement of the 14 cysteine residues. The predicted 12-transmembrane topology was examined by replacing selected amino acids, predicted to be exposed to the extracellular or cytosolic environments, with cysteines. The location of these cysteines was defined by their accessibility to biotin maleimide in the presence or absence of specific blocking agents. Amino acids predicted to be exposed to the extracellular environment (S46C, S179C, L300C, Y355C, and K430C) could be labeled with biotin maleimide; this modification could be blocked by prior treatment with nonpermeable reagents. Amino acids predicted to be within the cytosol (S152C, Cys(224), and L475C) could be labeled only after streptolysin O permeabilization. In addition, the cysteine-less reduced folate carrier was exploited to evaluate a potential substrate-binding domain as suggested by previous studies. Nineteen cysteine replacements were generated between residues 39 and 75, a region located between the first and second transmembrane segments. From the biotinylation of these sites and the ability of various reagents to block this labeling, it appears that L41C, E45C, S46C, T49C, I66C, and L70C are exposed to the extracellular environment, whereas Q54C, Q61C, and T63C are slightly less accessible. Cysteines 39, 42, 44, 47, 51, and 73 were inefficiently biotinylated, suggesting that these sites are located in the membrane or within a tightly folded domain of the protein. Furthermore, biotinylation of cysteines 41, 46, 49, 70, and 71 could be prevented by prior treatment with either methotrexate or folinic acid, indicating that these sites form part of a substrate-binding pocket.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Flintoff, WF (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, Dent Sci Bldg,Rm 3006B, London, ON N6A 5C1, Canada.							CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; Frillingos S, 1997, PROTEIN SCI, V6, P431; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rothem L, 2002, BIOCHEM J, V367, P741, DOI 10.1042/BJ20020801; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; Sadlish H, 2000, BIOCHEM J, V346, P509, DOI 10.1042/0264-6021:3460509; Sadlish H, 2002, BIOCHEM J, V364, P777, DOI 10.1042/BJ20011361; Sadlish H, 2002, J BIOL CHEM, V277, P42105, DOI 10.1074/jbc.M206459200; SAMBROOK J, 1989, MOL CLONING, V2, P9; Sharina IG, 2002, BIOCHEM PHARMACOL, V63, P1717, DOI 10.1016/S0006-2952(02)00955-3; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SIROTNAK FM, 1985, CANCER RES, V45, P3992; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; Wang YH, 2001, BBA-BIOMEMBRANES, V1513, P49, DOI 10.1016/S0005-2736(01)00340-6; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; Wong SC, 1998, BBA-BIOMEMBRANES, V1375, P6, DOI 10.1016/S0005-2736(98)00118-7; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 2000, BBA-BIOMEMBRANES, V1466, P7, DOI 10.1016/S0005-2736(00)00190-5; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68	33	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40867	40876		10.1074/jbc.M302102200	http://dx.doi.org/10.1074/jbc.M302102200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909642	hybrid			2022-12-25	WOS:000185847200056
J	Horie, C; Suzuki, H; Sakaguchi, M; Mihara, K				Horie, C; Suzuki, H; Sakaguchi, M; Mihara, K			Targeting and assembly of mitochondrial tail-anchored protein Tom5 to the TOM complex depend on a signal distinct from that of tail-anchored proteins dispersed in the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL IMPORT PORE; OUTER-MEMBRANE; RECEPTOR COMPLEX; ENDOPLASMIC-RETICULUM; PREPROTEIN TRANSLOCASE; YEAST MITOCHONDRIA; INSERTION PORE; AMINO-ACIDS; CHANNEL; COMPONENT	Mitochondrial outer membrane proteins are synthesized without a cleavable presequence but instead contain segments responsible for mitochondrial targeting and membrane integration within the molecule: the transmembrane segment (TMS) and N- or C-terminal flanking segment. We analyzed targeting and integration of Tom5, a C-tail anchor protein associated with the preprotein translocase of the outer membrane, to the yeast mitochondrial outer membrane in vivo using green fluorescent protein as the reporter and compared the signal with other signals for proteins dispersed in the membrane. The functional assembly of Tom5 into the TOM complex was assessed by blue native PAGE and complementation of temperature-sensitive Deltatom5 cells. Correct targeting and assembly required (i) an appropriate length TMS rather than hydrophobicity, (ii) a proline residue located at correct position in the TMS and specific residues near the proline, and (iii) that, in contrast to proteins dispersed in the outer membrane, the positive C-terminal segment was dispensable. Based on these findings, we constructed green fluorescent protein fusions with a C-terminal TMS in which the deduced sequences ( minimum: Ser-Pro-Met) were inserted at an appropriate position within artificial Leu-Ala repeats. They were targeted to mitochondria and complemented the temperature-sensitive growth phenotype of Deltatom5 yeast cells. The membrane-targeting mechanism of Tom5 appears to be distinct from that for proteins that are dispersed in the outer membrane.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan.							Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; Borgese N, 2001, MOL BIOL CELL, V12, P2482, DOI 10.1091/mbc.12.8.2482; CAO W, 1995, J BIOL CHEM, V270, P5674, DOI 10.1074/jbc.270.10.5674; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Egan B, 1999, FEBS LETT, V451, P243, DOI 10.1016/S0014-5793(99)00581-5; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Horie C, 2002, MOL BIOL CELL, V13, P1615, DOI 10.1091/mbc.01-12-0570; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; Miyazaki E, 2001, J BIOL CHEM, V276, P49221, DOI 10.1074/jbc.M106267200; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Motz C, 2002, J MOL BIOL, V323, P729, DOI 10.1016/S0022-2836(02)00995-6; Nemoto Y, 1999, EMBO J, V18, P2991, DOI 10.1093/emboj/18.11.2991; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	43	47	49	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41462	41471		10.1074/jbc.M307047200	http://dx.doi.org/10.1074/jbc.M307047200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896971	hybrid			2022-12-25	WOS:000185847200126
J	Matsumoto, K; Shionyu, M; Go, M; Shimizu, K; Shinomura, T; Kimata, K; Watanabe, H				Matsumoto, K; Shionyu, M; Go, M; Shimizu, K; Shinomura, T; Kimata, K; Watanabe, H			Distinct interaction of versican/PG-M with hyaluronan and link protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; LARGE AGGREGATING PROTEOGLYCAN; BINDING-SITE; CARTILAGE PROTEOGLYCAN; CELL-MIGRATION; CDNA CLONING; TISSUES; DOMAINS; BRAIN; AGGRECAN	The proteoglycan aggregate is the major structural component of the cartilage matrix, comprising hyaluronan (HA), link protein (LP), and a large chondroitin sulfate (CS) proteoglycan, aggrecan. Here, we found that another member of aggrecan family, versican, biochemically binds to both HA and LP. Functional analyses of recombinant looped domains (subdomains) A, B, and B' of the N-terminal G(1) domain revealed that the B-B' segment of versican is adequate for binding to HA and LP, whereas A and B-B' of aggrecan bound to LP and HA, respectively. BIAcore(TM) analyses showed that the A subdomain of versican G(1) enhances HA binding but has a negligible effect on LP binding. Overlay sensorgrams demonstrated that versican G(1) or its B-B' segment forms a complex with both HA and LP. We generated a molecular model of the B-B' segment, in which a deletion and an insertion of B' and B are critical for stable structure and HA binding. These results provide important insights into the mechanisms of formation of the proteoglycan aggregate and HA binding of molecules containing the link module.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan; Gifu Univ, Sch Med, Dept Orthopaed Surg, Gifu 5008705, Japan	Aichi Medical University; Nagoya University; Gifu University	Watanabe, H (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Karimata 21, Nagakute, Aichi 4801195, Japan.			Watanabe, Hideto/0000-0001-5291-0696; Shionyu, Masafumi/0000-0002-0431-3456				Almond A, 1998, J MOL BIOL, V284, P1425, DOI 10.1006/jmbi.1998.2245; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; Hascall V.C, 1991, PROTEOGLYCANS CELL B, P149, DOI 10.1007/978-1-4615-3770-0_6; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; Kishimoto J, 1999, P NATL ACAD SCI USA, V96, P7336, DOI 10.1073/pnas.96.13.7336; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; Nishida Y, 1994, Osteoarthritis Cartilage, V2, P43, DOI 10.1016/S1063-4584(05)80005-6; Ogata K, 2000, J MOL GRAPH MODEL, V18, P258, DOI 10.1016/S1093-3263(00)00037-1; PERKINS SJ, 1992, BIOCHEM J, V285, P263, DOI 10.1042/bj2850263; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; RAUCH U, 1992, J BIOL CHEM, V267, P19536; ROSENBERG L, 1988, J BIOL CHEM, V263, P18071; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, J CELL SCI, V106, P55; YU Q, 1995, BIOTECHNIQUES, V19, P122; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	35	107	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41205	41212		10.1074/jbc.M305060200	http://dx.doi.org/10.1074/jbc.M305060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888576	hybrid			2022-12-25	WOS:000185847200098
J	Moreno, H; Serrano, AL; Santalucia, T; Guma, A; Canto, C; Brand, NJ; Palacin, M; Schiaffino, S; Zorzano, A				Moreno, H; Serrano, AL; Santalucia, T; Guma, A; Canto, C; Brand, NJ; Palacin, M; Schiaffino, S; Zorzano, A			Differential regulation of the muscle-specific GLUT4 enhancer in regenerating and adult skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER EXPRESSION; BROWN ADIPOSE-TISSUE; GENE-EXPRESSION; THYROID-HORMONE; TRANSGENIC MICE; TRANSCRIPTIONAL REGULATION; SATELLITE CELLS; BINDING-SITE; FACTOR-I; INSULIN	We have reported a novel functional co-operation among MyoD, myocyte enhancer factor-2 (MEF2), and the thyroid hormone receptor in a muscle-specific enhancer of the rat GLUT4 gene in muscle cells. Here, we demonstrate that the muscle-specific enhancer of the GLUT4 gene operates in skeletal muscle and is muscle fiber-dependent and innervation-independent. Under normal conditions, both in soleus and in extensor digitorum longus muscles, the activity of the enhancer required the integrity of the MEF2-binding site. Cancellation of the binding site of thyroid hormone receptor enhanced its activity, suggesting an inhibitory role. Muscle regeneration of the soleus and extensor digitorum longus muscles caused a marked induction of GLUT4 and stimulation of the enhancer activity, which was independent of innervation. During muscle regeneration, the enhancer activity was markedly inhibited by cancellation of the binding sites of MEF2, MyoD, or thyroid hormone receptors. Different MEF2 isoforms expressed in skeletal muscle (MEF2A, MEF2C, and MEF2D) and all members of the MyoD family had the capacity to participate in the activity of the GLUT4 enhancer as assessed by transient transfection in cultured cells. Our data indicate that the GLUT4 enhancer operates in muscle fibers and its activity contributes to the differences in GLUT4 gene expression between oxidative and glycolytic muscle fibers and to the GLUT4 up-regulation that occurs during muscle regeneration. The activity of the enhancer is maintained in adult muscle by MEF2, whereas during regeneration the operation of the enhancer depends on MEF2, myogenic transcription factors of the MyoD family, and thyroid hormone receptors.	Univ Barcelona, Fac Biol, Parc Cient Barcelona, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Padua, Dept Biomed Sci, CNR, Inst Neurosci, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiothorac Surg, London SW3 6LY, England	University of Barcelona; University of Barcelona; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine; Imperial College London	Zorzano, A (corresponding author), Univ Barcelona, Fac Biol, Parc Cient Barcelona, Avda Diagonal 645, E-08028 Barcelona, Spain.	azorzano@porthos.bio.ub.es	Palacín, Manuel/G-9786-2015; Santalucia, Tomas/B-6140-2012; Serrano, A/I-9198-2014; Gumà, Anna/C-5165-2017; Zorzano, Antonio/R-5479-2018; Santalucia, Tomas/I-7411-2012	Santalucia, Tomas/0000-0003-4604-9195; Gumà, Anna/0000-0001-9390-5252; Santalucia, Tomas/0000-0003-4604-9195; Canto, Carles/0000-0002-5167-7922; Palacin, Manuel/0000-0002-8670-293X; Schiaffino, Stefano/0000-0002-5607-6421				Akkila WM, 1997, BIOCHEM J, V325, P87, DOI 10.1042/bj3250087; BANERJEE SS, 2002, J BIOL CHEM, V277, P34322; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; Buhl ES, 2001, DIABETES, V50, P12, DOI 10.2337/diabetes.50.1.12; CAMPBELL C, 1992, AM J PHYSIOL, V263, pE102; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; Escobar-Morreale HF, 1999, BIOCHIMIE, V81, P453, DOI 10.1016/S0300-9084(99)80095-9; GosteliPeter MA, 1996, J CLIN INVEST, V98, P1737, DOI 10.1172/JCI118972; Jones JP, 1998, J APPL PHYSIOL, V84, P1661, DOI 10.1152/jappl.1998.84.5.1661; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KOISHI K, 1995, DEV DYNAM, V202, P244, DOI 10.1002/aja.1002020304; LIU ML, 1994, J BIOL CHEM, V269, P28514; LIU ML, 1992, J BIOL CHEM, V267, P11673; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Mora S, 2000, J BIOL CHEM, V275, P16323, DOI 10.1074/jbc.M910259199; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; OLSON AL, 1995, J BIOL CHEM, V270, P23491, DOI 10.1074/jbc.270.40.23491; Oshel KM, 2000, J BIOL CHEM, V275, P23666, DOI 10.1074/jbc.M001452200; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; Santalucia T, 2001, J MOL BIOL, V314, P195, DOI 10.1006/jmbi.2001.5091; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SLIEKER LJ, 1992, DIABETES, V41, P187, DOI 10.2337/diabetes.41.2.187; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; Torrance CJ, 1997, ENDOCRINOLOGY, V138, P1204, DOI 10.1210/en.138.3.1204; Torrance CJ, 1997, ENDOCRINOLOGY, V138, P1215, DOI 10.1210/en.138.3.1215; Tsunoda N, 2000, BIOCHEM BIOPH RES CO, V267, P744, DOI 10.1006/bbrc.1999.2031; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; Vinals F, 1997, ENDOCRINOLOGY, V138, P2521, DOI 10.1210/en.138.6.2521; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; Yokomori N, 1999, DIABETES, V48, P2471, DOI 10.2337/diabetes.48.12.2471; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073; Zhou Z, 2001, J MUSCLE RES CELL M, V22, P311, DOI 10.1023/A:1013133616449	44	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40557	40564		10.1074/jbc.M306609200	http://dx.doi.org/10.1074/jbc.M306609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893821	hybrid, Green Published			2022-12-25	WOS:000185847200018
J	Akhavan, A; Atanasiu, R; Shrier, A				Akhavan, A; Atanasiu, R; Shrier, A			Identification of a COOH-terminal segment involved in maturation and stability of human ether-a-go-go-related gene potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT-SYNDROME; TRANSMEMBRANE CONDUCTANCE REGULATOR; INTRACELLULAR-TRANSPORT; CARDIAC-ARRHYTHMIA; RETENTION SIGNAL; HERG MUTATIONS; WILD-TYPE; PROTEIN; DOMAIN; TRAFFICKING	Mutations in the potassium channel encoded by the human ether-a-go-go-related gene (HERG) have been linked to the congenital long QT syndrome (LQTS), a cardiac disease associated with an increased preponderance of ventricular arrhythmias and sudden death. The COOH terminus of HERG harbors a large number of LQTS mutations and its removal prevents functional expression for reasons that remain unknown. In this study, we show that the COOH terminus of HERG is required for normal trafficking of the ion channel. We have identified a region critical for trafficking between residues 860 and 899 that includes a novel missense mutation at amino acid 861 (HERG(N861I)). Truncations or deletion of residues 860-899, characterized in six different expression systems including a cardiac cell line, resulted in decreased expression levels and an absence of the mature glycosylated form of the HERG protein. Deletion of this region did not interfere with the formation of tetramers but caused retention of the assembled ion channels within the endoplasmic reticulum. Consequently, removal of residues 860-899 resulted in the absence of the ion channels from the cell surface and a more rapid turnover rate than the wild type channels, which was evident very early in biogenesis. This study reveals a novel role of the COOH terminus in the normal biogenesis of HERG channels and suggests defective trafficking as a common mechanism for abnormal channel function resulting from mutations of critical COOH-terminal residues, including the LQTS mutant HERG(N861I).	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Shrier, A (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	alvin.shrier@mcgill.ca						Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Berthet M, 1999, CIRCULATION, V99, P1464, DOI 10.1161/01.CIR.99.11.1464; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Delisle BP, 2003, J BIOL CHEM, V278, P35749, DOI 10.1074/jbc.M305787200; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Eertmoed AL, 1999, J NEUROSCI, V19, P6298; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Kupershmidt S, 2002, J BIOL CHEM, V277, P27442, DOI 10.1074/jbc.M112375200; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Manganas LN, 2001, P NATL ACAD SCI USA, V98, P14055, DOI 10.1073/pnas.241403898; Moss AJ, 2002, CIRCULATION, V105, P794, DOI 10.1161/hc0702.105124; Nufer O, 2002, J CELL SCI, V115, P619; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; Wang JL, 2000, J GEN PHYSIOL, V115, P749, DOI 10.1085/jgp.115.6.749; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WHITE SH, 1994, ANNU REV BIOPH BIOM, V23, P407, DOI 10.1146/annurev.bb.23.060194.002203; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zimmerman CC, 1999, MOL VIS, V5	48	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40105	40112		10.1074/jbc.M307837200	http://dx.doi.org/10.1074/jbc.M307837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885765	hybrid			2022-12-25	WOS:000185713800102
J	Brown, K; Chen, Y; Underhill, TM; Mymryk, JS; Torchia, J				Brown, K; Chen, Y; Underhill, TM; Mymryk, JS; Torchia, J			The coactivator p/CIP/SRC-3 facilitates retinoic acid receptor signaling via recruitment of GCN5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HISTONE ACETYLTRANSFERASE ACTIVITY; YEAST PUTATIVE ADAPTERS; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; ESTROGEN-RECEPTOR; BINDING-PROTEIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; MUSCLE DIFFERENTIATION	p/CIP/SRC-3 is a member of a family of steroid receptor coactivators/nuclear receptor coactivators (SRC/NCoA) proteins that mediate the transcriptional effects of nuclear hormone receptors (NRs). Using deletion analysis we have mapped the location of two distinct activation domains in p/CIP (AD1 and AD2) capable of activating transcription in mammalian cells when fused to the Gal4-DNA binding domain. In addition to AD1 being coincident with the interaction domain for CBP, we demonstrate a novel in vivo interaction between the AD1 and GCN5. Overexpression of a Gal4-AD1 fusion protein in yeast leads to growth arrest that is relieved by mutation of genes encoding components of the SAGA complex including GCN5, ADA3, and SPT7. In addition, the AD1 of p/CIP and the ADA3 gene are shown to be essential for retinoic acid receptor alpha-dependent transcription in yeast. Transient transfection assays in mammalian cells indicate that GCN5 cooperates with p/CIP as a coactivator of RARalpha-dependent transcription. Down-regulation of GCN5 using small interfering RNA in mammalian cells indicates that the AD1 domain and the RARbeta promoter activity are dependent, in part, on GCN5. Mutational analysis of AD1 has identified two helical motifs that are required for interactions with GCN5 and CBP. Taken together, these results support a model by which p/CIP functions as a ligand-dependent adapter, through specific protein-protein interactions with AD1, to recruit members from at least two distinct families of acetyltransferase proteins to NRs.	London Reg Canc Ctr, Canc Res Labs, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Torchia, J (corresponding author), London Reg Canc Ctr, Canc Res Labs, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.							Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, J BIOL CHEM, V271, P5237; Candau R, 1996, MOL CELL BIOL, V16, P593; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2000, GENE DEV, V14, P1209; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Ikeda M, 1999, MOL CELL ENDOCRINOL, V147, P103, DOI 10.1016/S0303-7207(98)00211-1; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Ma H, 1999, MOL CELL BIOL, V19, P6164; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roberts SM, 1997, GENETICS, V147, P451; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wei LN, 2003, ANNU REV PHARMACOL, V43, P47, DOI 10.1146/annurev.pharmtox.43.100901.140301; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	78	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39402	39412		10.1074/jbc.M307832200	http://dx.doi.org/10.1074/jbc.M307832200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885766	hybrid			2022-12-25	WOS:000185713800017
J	Ding, Q; Stewart, J; Olman, MA; Klobe, MR; Gladson, CL				Ding, Q; Stewart, J; Olman, MA; Klobe, MR; Gladson, CL			The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MALIGNANT ASTROCYTOMA; TYROSINE KINASES; MIGRATION; PDGF; RECEPTOR; FYN; ASSOCIATION; ACTIVATION; EXPRESSION	Enhanced expression of both integrin alpha(v)beta(3) and platelet-derived growth factor receptor (PDGFr) has been described in glioblastoma tumors. We therefore explored the possibility that integrin alpha(v)beta(3) cooperates with PDGFr to promote cell migration in glioblastoma cells, and extended the study to identify the Src family members that are activated on PDGF stimulation. Glioblastoma cells utilize integrins alpha(v)beta(3) and alpha(v)beta(5) to mediate vitronectin attachment. We found that physiologic PDGF stimulation (83 pM, 10 min) of vitronectin-adherent cells promoted the specific recruitment of integrin alpha(v)beta(3)-containing focal adhesions to the cell cortex and alpha(v)beta(3)-mediated cell motility. Analysis of PDGFr immunoprecipitates indicated an association of the PDGFr beta with integrin alpha(v)beta(3), but not integrin alpha(v)beta(5). Cells plated onto collagen or laminin, which engage different integrins, exhibited significantly less migration on PDGF stimulation, indicating a cooperation of alpha(v)beta(3) and the PDGFr beta in glioblastoma cells that promotes migration. Further analysis of the cells plated onto vitronectin indicated that PDGF stimulation caused an increase in Src kinase activity, which was associated with integrin alpha(v)beta(3). In the vitronectin-adherent cells, Lyn was associated preferentially with alpha(v)beta(3) both in the presence and absence of PDGF stimulation. In contrast, Fyn was associated with both alpha(v)beta(3) and alpha(v)beta(5). Moreover, PDGF stimulation increased the activity of Lyn, but not Fyn, in vitronectin-adherent cells, and the activity of Fyn, but not Lyn, in laminin-adherent cells. Using cells attached to mAb anti-alpha(v)beta(3) or mAb anti-integrin alpha(6), we confirmed the activation of specific members of the Src kinase family with PDGF stimulation. Down-regulation of Lyn expression by siRNA significantly inhibited the cell migration mediated by integrin alpha(v)beta(3) in PDGF-stimulated cells, demonstrating the PDGFr beta cooperates with integrin alpha(v)beta(3) in promoting the motility of vitronectin-adherent glioblastoma cells through a Lyn kinase-mediated pathway. Notably, the data indicate that engagement of different integrins alters the identity of the Src family members that are activated on stimulation with PDGF.	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Pulm & Crit Care Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Gladson, CL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, LHRB 567,701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu			NATIONAL CANCER INSTITUTE [R01CA059958, R01CA097110] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058655] Funding Source: NIH RePORTER; NCI NIH HHS [CA97110, CA59958] Funding Source: Medline; NHLBI NIH HHS [HL58655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Baron W, 2002, EMBO J, V21, P1957, DOI 10.1093/emboj/21.8.1957; Bertagnolli ME, 1999, BIOCHEM BIOPH RES CO, V260, P790, DOI 10.1006/bbrc.1999.0985; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Cary LA, 1996, J CELL SCI, V109, P1787; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Ding Q, 2000, GROWTH FACTORS, V18, P93, DOI 10.3109/08977190009003236; Ding Q, 2002, CANCER RES, V62, P5336; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; GLADSON CL, 1995, J CELL SCI, V108, P947; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Han NM, 1996, CLIN CANCER RES, V2, P1397; Han XS, 2001, ONCOGENE, V20, P7976, DOI 10.1038/sj.onc.1204996; Hansen K, 1997, BIOCHEM BIOPH RES CO, V241, P355, DOI 10.1006/bbrc.1997.7743; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hecker TP, 2002, CANCER RES, V62, P2699; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HERMANSON M, 1992, CANCER RES, V52, P3213; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kralisz U, 1998, BIOCHEM MOL BIOL INT, V45, P735; Ling LX, 1999, J CELL BIOCHEM, V73, P533; Lokker NA, 2002, CANCER RES, V62, P3729; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Martin S, 2003, J NEUROSCI, V23, P1198, DOI 10.1523/JNEUROSCI.23-04-01198.2003; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; PijuanThompson V, 1997, J BIOL CHEM, V272, P2736, DOI 10.1074/jbc.272.5.2736; Rabinowich H, 1996, J IMMUNOL, V157, P3860; Rozen S, 2000, Methods Mol Biol, V132, P365; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Vines CM, 2001, IMMUNITY, V15, P507, DOI 10.1016/S1074-7613(01)00221-7; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang DY, 2000, J CELL SCI, V113, P4221; Woodard AS, 1998, J CELL SCI, V111, P469; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049	49	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39882	39891		10.1074/jbc.M304685200	http://dx.doi.org/10.1074/jbc.M304685200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881526	hybrid			2022-12-25	WOS:000185713800075
J	Liang, W; Austin, S; Hoang, Q; Fishman, PH				Liang, W; Austin, S; Hoang, Q; Fishman, PH			Resistance of the human beta(1)-adrenergic receptor to agonist-mediated down-regulation - Role of the C terminus in determining beta-subtype degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; CARDIAC MYOCYTES; BETA-1-ADRENERGIC RECEPTOR; DIFFERENTIAL REGULATION; ACTIVATED RECEPTOR-1; HEART-FAILURE; RAT-HEART	Prolonged agonist stimulation results in down-regulation of most G protein-coupled receptors. When we exposed baby hamster kidney cells stably expressing the human beta(1)-adrenergic receptor (beta(1)AR) to agonist over a 24-h period, we instead observed an increase of similar to30% in both beta(1)AR binding activity and immune-detected receptors. In contrast, beta(2)AR expressed in these cells exhibited a decrease of greater than or equal to50%. We determined that the basal turnover rates of the two subtypes were similar (t1/2 similar to 7 h) and that agonist stimulation increased beta(2)AR but not beta(1)AR turnover. Blocking receptor trafficking to lysosomes with bafilomycin A(1) had no effect on basal turnover of either subtype but blocked agonist-stimulated beta(2)AR turnover. As beta(1)AR mRNA levels increased in agonist-stimulated cells, beta(1)AR up-regulation appeared to result from increased synthesis with no change in degradation. To explore the basis for the subtype differences, we expressed chimeras in which the C termini had been exchanged. Each chimera responded to persistent agonist stimulation based on the source of its C-tail; beta(1)AR with a beta(2)AR C-tail underwent down-regulation, and beta(2)AR with a beta(1)AR C-tail underwent up-regulation. The C-tails had a corresponding effect on agonist-stimulated receptor phosphorylation and internalization with the order being beta(2)AR > beta(1)AR with beta(2)AR C-tail > beta(2)AR with a beta(1)AR C-tail > beta(1)AR. As internalization may be a prerequisite for down-regulation, we addressed this possibility by co-expressing each subtype with arrestin-2. Although beta(1)AR internalization was increased to that of beta(2)AR, down-regulation still did not occur. Instead, beta(1)AR accumulated inside the cells. We conclude that in unstimulated cells, both subtypes appear to be turned over by the same mechanism. Upon agonist stimulation, both subtypes are internalized, and beta(2)AR but not beta(1)AR undergoes lysosomal degradation, the fate of each subtype being regulated by determinants in its C-tail.	NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Fishman, PH (corresponding author), NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bldg 49,Rm 2A28,49 Convent Dr,MSC4440, Bethesda, MD 20892 USA.	fishmanp@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002366] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Blaxall BC, 2000, J BIOL CHEM, V275, P4290, DOI 10.1074/jbc.275.6.4290; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Curran PK, 1996, CELL SIGNAL, V8, P355, DOI 10.1016/0898-6568(96)00068-X; Dangel V, 1996, BIOCHEM J, V317, P925, DOI 10.1042/bj3170925; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; Devic E, 2001, MOL PHARMACOL, V60, P577; Dunigan CD, 2000, METH MOL B, V136, P329; Dunigan CD, 2002, BIOCHEMISTRY-US, V41, P8019, DOI 10.1021/bi025538r; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FISHMAN PH, 1994, J RECEPTOR RES, V14, P281, DOI 10.3109/10799899409066037; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1994, J BIOL CHEM, V269, P26215; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; JASPER JR, 1990, AM J PHYSIOL, V259, pC41, DOI 10.1152/ajpcell.1990.259.1.C41; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; MAHAN LC, 1987, ANNU REV PHARMACOL, V27, P215; McLean AJ, 2000, BRIT J PHARMACOL, V130, P1825, DOI 10.1038/sj.bjp.0703506; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Moore RH, 1999, J CELL SCI, V112, P329; NEVE KA, 1986, MOL PHARMACOL, V30, P104; NEVE KA, 1985, J PHARMACOL EXP THER, V235, P657; PORT JD, 1992, J BIOL CHEM, V267, P24103; Port JD, 2001, J MOL CELL CARDIOL, V33, P887, DOI 10.1006/jmcc.2001.1358; Rathz DA, 2002, J CARDIOVASC PHARM, V39, P155, DOI 10.1097/00005344-200202000-00001; Rousseau G, 1996, MOL PHARMACOL, V49, P752; Santini F, 2000, J CELL SCI, V113, P2463; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; VALET P, 1989, J PHARMACOL EXP THER, V249, P271; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Williams BR, 2000, MOL PHARMACOL, V58, P421, DOI 10.1124/mol.58.2.421; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; Xiao RP, 2000, CIRC RES, V87, P635, DOI 10.1161/01.RES.87.8.635; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; ZHANG LJ, 1994, MOL PHARMACOL, V45, P878; Zhao MM, 1996, AM J PHYSIOL-HEART C, V271, pH1762, DOI 10.1152/ajpheart.1996.271.5.H1762; ZHOU XM, 1995, CELL SIGNAL, V7, P207, DOI 10.1016/0898-6568(94)00091-O; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	58	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39773	39781		10.1074/jbc.M304482200	http://dx.doi.org/10.1074/jbc.M304482200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888573	hybrid			2022-12-25	WOS:000185713800063
J	Whitley, P; Reaves, BJ; Hashimoto, M; Riley, AM; Potter, BVL; Holman, GD				Whitley, P; Reaves, BJ; Hashimoto, M; Riley, AM; Potter, BVL; Holman, GD			Identification of mammalian Vps24p as an effector of phosphatidylinositol 3,5-bisphosphate-dependent endosome compartmentalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSG101 PROTEIN; FYVE FINGER; PX DOMAINS; CLONING; BINDING; 3-PHOSPHATE; EXPRESSION; DISPLAY; TRAFFICKING; FAB1P	Phosphatidylinositol 3,5-bisphosphate is a membrane lipid found in all eukaryotes so far studied but down-stream effector proteins of this lipid have yet to be identified. Here we report the use of cDNA phage libraries in conjunction with synthetic biotinylated derivatives of phosphatidylinositol 3,5-bisphosphate in the identification of a mammalian phosphatidylinositol 3,5-bisphosphate-binding protein, mVps24p. This protein is orthologous to the Saccharomyces cerevisiae protein, Vps24p, a class-E vacuolar protein-sorting protein. Using in vitro liposome binding and competition assays, we demonstrate that mVps24p selectively binds to phosphatidylinositol 3,5-bisphosphate and phosphatidylinositol 3,4-bisphosphate in preference to other phosphoinositides tested. When expressed in cultured mammalian cells, full-length mVps24p is cytosolic. However, when cells expressing the full-length mVps24p are co-transfected with a mutated form of mVps4p (which is defective in ATP hydrolysis), or when a N-terminal construct of mVps24p is expressed, the class-E cellular phenotype with swollen vacuoles is induced and mVps24p is membrane-associated. Furthermore, the accumulation of the N-terminal mVps24p construct on the swollen endosomal membranes is abrogated when phosphatidylinositol 3,5-bisphosphate synthesis is blocked with wortmannin. These data provide the first direct link between phosphatidylinositol 3,5-bisphosphate and the protein machinery involved in the production of the class-E cellular phenotype. We hypothesize that accumulation of Vps24 on membranes occurs when membrane association (dependent on interaction of phosphatidylinositol 3,5-bisphosphate with the N-terminal domain of the protein) is uncoupled from membrane disassociation (driven by Vps4p).	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England	University of Bath; University of Bath	Whitley, P (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	bssprw@bath.ac.uk	Riley, Andrew M/F-3526-2013; Potter, Barry VL/A-1845-2012; Potter, Barry/AAX-4781-2020; Hashimoto, Makoto/B-7837-2012	Riley, Andrew M/0000-0001-9003-3540; Hashimoto, Makoto/0000-0002-5526-8835; Holman, Geoffrey/0000-0001-7045-1358				Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cozier GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Danner S, 2001, P NATL ACAD SCI USA, V98, P12954, DOI 10.1073/pnas.211439598; Dove SK, 2002, CURR BIOL, V12, P885, DOI 10.1016/S0960-9822(02)00891-6; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Howard TL, 2001, J CELL SCI, V114, P2395; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Lindborg M, 1999, J INVEST DERMATOL, V113, P156, DOI 10.1046/j.1523-1747.1999.00661.x; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Rao VR, 1999, J BIOL CHEM, V274, P37893, DOI 10.1074/jbc.274.53.37893; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reaves BJ, 2000, J CELL SCI, V113, P4099; RILEY AM, 1988, TETRAHEDRON LETT, V30, P6769; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Sbrissa D, 2001, MOL CELL ENDOCRINOL, V181, P35, DOI 10.1016/S0303-7207(01)00539-1; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; Shaw JD, 2003, TRAFFIC, V4, P479, DOI 10.1034/j.1600-0854.2003.t01-1-00106.x; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stauffer DR, 2001, J CELL SCI, V114, P2383; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zhong Q, 1998, CANCER RES, V58, P2699	47	123	126	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38786	38795		10.1074/jbc.M306864200	http://dx.doi.org/10.1074/jbc.M306864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878588	hybrid			2022-12-25	WOS:000185575100086
J	Yim, S; Choi, SM; Choi, YY; Lee, N; Chung, J; Park, H				Yim, S; Choi, SM; Choi, YY; Lee, N; Chung, J; Park, H			Insulin and hypoxia share common target genes but not the hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIN-1 GENE; HIF-ALPHA; FACTOR-I; EXPRESSION; TRANSCRIPTION; ACTIVATION; PROTEIN; KINASE	Both hypoxia and insulin induce common target genes, including vascular endothelial growth factors and several glycolytic enzymes. However, these two signals eventually trigger quite different metabolic pathways. Hypoxia induces glycolysis, resulting in anaerobic ATP production, while insulin increases glycolysis for energy storage. Hypoxia-induced gene expression is mediated by the hypoxia-inducible factor-1 (HIF-1) that consists of HIF-1alpha and the aromatic hydrocarbon nuclear translocator (Arnt). Hypoxia-induced gene expression is initiated by the stabilization of the HIF-1alpha subunit. Here we investigated whether insulin-induced gene expression also requires stabilization of HIF-1alpha. Our results indicate that hypoxia but not insulin stabilizes HIF-1alpha protein levels, whereas both insulin- and hypoxia-induced gene expression require the presence of the Arnt protein. Insulin treatment fails to inactivate proline hydroxylation of HIF-1alpha, which triggers recruitment of the von Hippel-Lindau protein and oxygen-dependent degradation of HIF-1alpha. Insulin-induced gene expression is inhibited by the presence of the phosphoinositide (PI) 3-kinase inhibitor LY294002 and the dominant negative mutant of the p85 subunit of PI 3-kinase, whereas hypoxia-induced gene expression is not. Pyrrolidine dithiocarbamate, a scavenger of H2O2, reduces insulin- induced gene expression but not hypoxia-induced gene expression. Although both hypoxia and insulin induce the expression of common target genes through a hypoxia-responsive element- and Arnt-dependent mechanism, insulin cannot stabilize the HIF-1alpha protein. We believe that insulin activates other putative partner proteins for Arnt in PI 3-kinase- and H2O2-dependent pathways.	Univ Seoul, Dept Life Sci, Seoul 130743, South Korea	University of Seoul	Park, H (corresponding author), Univ Seoul, Dept Life Sci, 90 Cheonnong Dong, Seoul 130743, South Korea.							Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FERNYHOUGH P, 1994, NEUROSCIENCE, V62, P337, DOI 10.1016/0306-4522(94)90368-9; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Ko HSP, 1996, MOL CELL BIOL, V16, P430; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Masuda S, 1997, BRAIN RES, V746, P63, DOI 10.1016/S0006-8993(96)01186-9; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Okino ST, 1998, J BIOL CHEM, V273, P23837, DOI 10.1074/jbc.273.37.23837; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2000, GENE DEV, V14, P1983; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	45	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38260	38268		10.1074/jbc.M306016200	http://dx.doi.org/10.1074/jbc.M306016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876287	hybrid			2022-12-25	WOS:000185575100023
J	Mahmmoud, YA; Cramb, G; Maunsbach, AB; Cutler, CP; Meischke, L; Cornelius, F				Mahmmoud, YA; Cramb, G; Maunsbach, AB; Cutler, CP; Meischke, L; Cornelius, F			Regulation of Na,K-ATPase by PLMS, the phospholemman-like protein from shark - Molecular cloning, sequence, expression, cellular distribution, and functional effects of PLMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; NA+,K+-ATPASE PUMP CYCLE; C-TERMINAL DOMAIN; GAMMA-SUBUNIT; SQUALUS-ACANTHIAS; RENAL NA,K-ATPASE; RECTAL GLAND; KINASE-C; INHIBITORY FUNCTION; CHANNEL ACTIVITY	In Na, K-ATPase membrane preparations from shark rectal glands, we have previously identified an FXYD domain-containing protein, phospholemman-like protein from shark, PLMS. This protein was shown to associate and modulate shark Na, K-ATPase activity in vitro. Here we describe the complete coding sequence, expression, and cellular localization of PLMS in the rectal gland of the shark Squalus acanthias. The mature protein contained 74 amino acids, including the N-terminal FXYD motif and a C-terminal protein kinase multisite phosphorylation motif. The sequence is preceded by a 20 amino acid candidate cleavable signal sequence. Immunogold labeling of the Na, K-ATPase alpha-subunit and PLMS showed the presence of alpha and PLMS in the basolateral membranes of the rectal gland cells and suggested their partial colocalization. Furthermore, through controlled proteolysis, the C terminus of PLMS containing the protein kinase phosphorylation domain can be specifically cleaved. Removal of this domain resulted in stimulation of maximal Na, K-ATPase activity, as well as several partial reactions. Both the E-1 similar to P --> E-2-P reaction, which is partially rate-limiting in shark, and the K+ deocclusion reaction, E-2(K) --> E-1, are accelerated. The latter may explain the finding that the apparent Na+ affinity was increased by the specific C-terminal PLMS truncation. Thus, these data are consistent with a model where interaction of the phosphorylation domain of PLMS with the Na, K-ATPase alpha-subunit is important for the modulation of shark Na, K-ATPase activity.	Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark; Aarhus Univ, Inst Anat, Dept Cell Biol, Water & Salt Res Ctr, DK-8000 Aarhus C, Denmark; Univ St Andrews, Sch Biol, St Andrews KY16 9TS, Fife, Scotland	Aarhus University; Aarhus University; University of St Andrews	Cornelius, F (corresponding author), Aarhus Univ, Dept Biophys, Ole Worms Alle 185, DK-8000 Aarhus C, Denmark.	fc@biophys.au.dk	Cornelius, Flemming/C-1912-2019	Cornelius, Flemming/0000-0003-1566-0020; Cramb, Gordon/0000-0003-4929-951X				Aizman R, 2002, AM J PHYSIOL-RENAL, V283, pF569, DOI 10.1152/ajprenal.00376.2001; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2002, J BIOL CHEM, V277, P10162, DOI 10.1074/jbc.M111552200; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; BULGER RE, 1963, ANAT REC, V147, P95, DOI 10.1002/ar.1091470108; Chen LSK, 1997, GENOMICS, V41, P435, DOI 10.1006/geno.1997.4665; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CORNELIUS F, 1992, BIOCHIM BIOPHYS ACTA, V1108, P190, DOI 10.1016/0005-2736(92)90025-H; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1067, P227, DOI 10.1016/0005-2736(91)90048-D; Cornelius F, 2003, ANN NY ACAD SCI, V986, P579, DOI 10.1111/j.1749-6632.2003.tb07256.x; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Cornelius F, 2001, J BIOENERG BIOMEMBR, V33, P415, DOI 10.1023/A:1010671607911; Cornelius F, 1999, BIOPHYS J, V77, P934, DOI 10.1016/S0006-3495(99)76944-4; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE; Cutler CP, 2000, AM J PHYSIOL-REG I, V279, pR222, DOI 10.1152/ajpregu.2000.279.1.R222; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; EVELOFF J, 1979, J CELL BIOL, V83, P16, DOI 10.1083/jcb.83.1.16; Fedosova NU, 1995, BIOCHEMISTRY-US, V34, P16806, DOI 10.1021/bi00051a031; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GOERTEMILLER CC, 1976, CELL TISSUE RES, V175, P101; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Humphrey PA, 2002, BIOCHEMISTRY-US, V41, P9496, DOI 10.1021/bi025836o; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Kruger A, 2003, ANN NY ACAD SCI, V986, P541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; Lupfert C, 2001, BIOPHYS J, V81, P2069, DOI 10.1016/S0006-3495(01)75856-0; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2002, BIOPHYS J, V82, P1907, DOI 10.1016/S0006-3495(02)75540-9; MANUSBACH AB, 1998, CELL BIOL LAB HDB, V3, P268; MAUNSBACH AB, 1984, AM J PHYSIOL, V246, pF710, DOI 10.1152/ajprenal.1984.246.5.F710; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLESNER IW, 1986, BIOCHEM J, V239, P175, DOI 10.1042/bj2390175; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; SAMBROOK J, 1989, NATURE, V342, P224, DOI 10.1038/342224a0; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; Silva P, 1996, KIDNEY INT, V49, P1552, DOI 10.1038/ki.1996.223; SKOU JC, 1979, BIOCHIM BIOPHYS ACTA, V567, P436, DOI 10.1016/0005-2744(79)90129-3; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313	69	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37427	37438		10.1074/jbc.M305126200	http://dx.doi.org/10.1074/jbc.M305126200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12874284	hybrid			2022-12-25	WOS:000185437200055
J	Cutress, RI; Townsend, PA; Sharp, A; Maison, A; Wood, L; Lee, R; Brimmell, M; Mullee, MA; Johnson, PWM; Royle, GT; Bateman, AC; Packham, G				Cutress, RI; Townsend, PA; Sharp, A; Maison, A; Wood, L; Lee, R; Brimmell, M; Mullee, MA; Johnson, PWM; Royle, GT; Bateman, AC; Packham, G			The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription	ONCOGENE			English	Article						BAG-1; breast cancer; oestrogen; receptor; hormone therapy; survival	HUMAN BREAST-CANCER; APOPTOTIC PROTEIN BAG-1; GENE BAG-1; CELL-LINES; RECEPTOR; EXPRESSION; SURVIVAL; HSC70; BINDS; OVEREXPRESSION	BAG-1 is a multifunctional protein that interacts with a wide range of cellular targets including heat-shock proteins and some nuclear hormone receptors. BAG-1 exists as three major isoforms, BAG-1L, BAG-1M and BAG-1S. BAG-1L contains a nuclear localization signal, which is not present in the other isoforms, and is predominantly localized in the cell nucleus. Here we have investigated the effects of BAG-1 on function of the oestrogen receptor (ER), a key growth control molecule and target for hormonal therapy in breast cancer. We demonstrate that BAG-1L, but not BAG-1S or BAG-1M increased oestrogen-dependent transcription in breast cancer cells. BAG-1L interacted with and stimulated the activity of both ER alpha and beta. Although BAG-1L and ERs colocalize to the nucleus, fusing BAG-1S to an heterologous nuclear localization sequence was not sufficient to stimulate transcription. Consistent with an important effect on receptor function, nuclear BAG-I expression in breast cancers was associated with expression of the progesterone receptor, a transcriptional target of ER(x, and was associated with improved survival in patients treated with hormonal therapy. These data suggest that BAG-1L is an important determinant of ER function in vitro and in human breast cancer.	Univ Southampton, Canc Res UK,Southampton Gen Hosp, Oncol Unit, Canc Sci Div,Sch Med, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Royal S Hants Hosp, Southampton Breast Unit, Southampton SO14 0YG, Hants, England; Southampton Gen Hosp, Dept Pathol, Southampton SO16 6YD, Hants, England	Cancer Research UK; University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton	Packham, G (corresponding author), Univ Southampton, Canc Res UK,Southampton Gen Hosp, Oncol Unit, Canc Sci Div,Sch Med, Somers Canc Sci Bldg,Mail Point 824, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018; Townsend, Paul/AAF-8234-2020	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Sharp, Adam/0000-0002-3740-1612; Packham, Graham/0000-0002-9232-5691; Sharp, Adam/0000-0002-3902-0135; Bateman, Adrian/0000-0003-2222-4104; Townsend, Paul/0000-0001-8956-9508	Breast Cancer Now [2001:180] Funding Source: Medline	Breast Cancer Now		*AJM SOC CLIN ONC, 1996, J CLIN ONCOL, V14, P2843; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Cato ACB, 2001, J STEROID BIOCHEM, V78, P379, DOI 10.1016/S0960-0760(01)00114-5; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Clarke M, 1998, LANCET, V351, P1451; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cutress RI, 2002, BRIT J CANCER, V87, P834, DOI 10.1038/sj.bjc.6600538; Cutress RI, 2001, J CLIN ONCOL, V19, P3706, DOI 10.1200/JCO.2001.19.16.3706; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Guzey M, 2000, J BIOL CHEM, V275, P40749, DOI 10.1074/jbc.M004977200; Hague A, 2002, J PATHOL, V197, P60, DOI 10.1002/path.1076; Hohfeld J, 1998, BIOL CHEM, V379, P269; HORWITZ KB, 1975, SCIENCE, V189, P726, DOI 10.1126/science.168640; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; KINSEL LB, 1989, CANCER RES, V49, P1052; Knee DA, 2001, J BIOL CHEM, V276, P12718, DOI 10.1074/jbc.M010841200; Kudoh M, 2002, CANCER RES, V62, P1904; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Niyaz Y, 2001, J CELL SCI, V114, P1839; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rorke S, 2001, INT J CANCER, V95, P317, DOI 10.1002/1097-0215(20010920)95:5<317::AID-IJC1055>3.0.CO;2-J; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Shindoh M, 2000, ORAL ONCOL, V36, P444, DOI 10.1016/S1368-8375(00)00025-7; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1998, CANCER RES, V58, P3116; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Witcher M, 2001, EXP CELL RES, V265, P167, DOI 10.1006/excr.2001.5176; Yamauchi H, 2001, CANCER LETT, V165, P103, DOI 10.1016/S0304-3835(01)00397-4; Yang XL, 1999, CLIN CANCER RES, V5, P1816; Yang XL, 1999, EXP CELL RES, V247, P200, DOI 10.1006/excr.1998.4349; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	52	60	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4973	4982		10.1038/sj.onc.1206688	http://dx.doi.org/10.1038/sj.onc.1206688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902980				2022-12-25	WOS:000184578900005
J	Russell, JP; Shinohara, S; Melillo, RM; Castellone, MD; Santoro, M; Rothstein, JL				Russell, JP; Shinohara, S; Melillo, RM; Castellone, MD; Santoro, M; Rothstein, JL			Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors	ONCOGENE			English	Article						autoimmunity; inflammation; inflammatory cytokines; oncogene; RET/PTC; tumor antigen	PAPILLARY THYROID-CARCINOMA; NF-KAPPA-B; CHRONIC LYMPHOCYTIC THYROIDITIS; TUMOR-NECROSIS-FACTOR; CELL-LINE; IMMUNOCYTOCHEMICAL LOCALIZATION; TARGETED EXPRESSION; ONCOGENE ACTIVATION; RET PROTOONCOGENE; TRANSGENIC MICE	Differentiated thyroid carcinomas are the most frequent endocrine neoplasms, but account for few cancer-related deaths. Although the indolent growth of these cancers correlates well with longevity, the biological basis for this good prognosis is not known. In contrast, two of the most frequent autoimmune diseases involve the thyroid suggesting a high propensity for this organ to invoke destructive immunity. Unfortunately, the mechanism linking malignancy and autoimmunity is not clear, although the expression of the oncogenic fusion protein RET/PTC3 (RP3) in both of these disorders may provide a clue. Interestingly, the signaling caused by activated RET kinase involves overlapping pathways and some common to the inflammatory response. Accordingly, we analyzed the function of RP3 and a mutant RP3 molecule to induce proinflammatory pathways in thyroid epithelial cells. Indeed, we find that RP3 alone causes increases in nuclear NF-kappaB activity and secretion of MCP-1 and GM-CSF. Finally, transfer of RP3-expressing thyrocytes into mice in vivo attracted dense macrophage infiltrates, which lead to rapid thyroid cell death. Further, cytokine synthesis and inflammation was largely abrogated by mutation of RP3 Tyr(588); an important protein-binding site for downstream signaling. Together, these studies implicate oncogene-induced cytokine-signaling pathways in a new mechanism linking inflammation with cancer.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Rothstein Kimmel Canc Inst, Philadelphia, PA 19107 USA; Univ Naples Federico II, Fac Med & Chirurg 2, Ctr Endocrinol & Oncol Sperimentale, CNR,Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Thomas Jefferson Univ, Dept Otolaryngol Head & Neck Surg, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Rothstein Kimmel Canc Inst, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.	Jay.Rothstein@jefferson.edu	melillo, rosa marina/O-5255-2015; Shinohara, Shogo/H-8976-2019	Shinohara, Shogo/0000-0002-1794-2091; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; MELILLO, Rosa Marina/0000-0002-9233-5275	NCI NIH HHS [T32-CA09678, CA-76259] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009678, P01CA076259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asakawa H, 1999, ANTICANCER RES, V19, P761; Aust G, 1996, CLIN EXP IMMUNOL, V105, P148, DOI 10.1046/j.1365-2249.1996.d01-726.x; Aust G, 2001, J ENDOCRINOL, V170, P513, DOI 10.1677/joe.0.1700513; Basolo F, 1998, CLIN CANCER RES, V4, P381; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Biswas SK, 2002, J INTERF CYTOK RES, V22, P527, DOI 10.1089/10799900252982007; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Borrello I, 2002, CYTOKINE GROWTH F R, V13, P185, DOI 10.1016/S1359-6101(01)00034-X; BRAVERMAN LE, 1995, THYROID FUNDAMENTAL; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CRILE G, 1953, CANCER-AM CANCER SOC, V6, P57, DOI 10.1002/1097-0142(195301)6:1<57::AID-CNCR2820060104>3.0.CO;2-D; DAILEY ME, 1955, ARCH SURG-CHICAGO, V70, P291, DOI 10.1001/archsurg.1955.01270080137023; Daniel D, 2003, J EXP MED, V197, P1017, DOI 10.1084/jem.20021047; Di Pasquale M, 2001, HUM PATHOL, V32, P24, DOI 10.1053/hupa.2001.21138; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENOMOTO T, 1990, CANCER, V65, P1971, DOI 10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; Fleischmann A, 1999, SCHWEIZ MED WSCHR, V129, P873; Foo SY, 1999, TRENDS GENET, V15, P229; Fusco A, 2002, AM J PATHOL, V160, P2157, DOI 10.1016/S0002-9440(10)61164-9; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; KABEL PJ, 1987, ACTA ENDOCRINOL-COP, V115, P42; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kayser L, 1996, AUTOIMMUNITY, V23, P91, DOI 10.3109/08916939608995332; KAYSER L, 1995, AUTOIMMUNITY, V20, P75, DOI 10.3109/08916939509001930; Kebebew E, 2001, WORLD J SURG, V25, P632, DOI 10.1007/s002680020165; KENNEDY RL, 1992, J ENDOCRINOL, V133, P477, DOI 10.1677/joe.0.1330477; Kurebayashi J, 2000, J CLIN ENDOCR METAB, V85, P2889, DOI 10.1210/jc.85.8.2889; Loh KC, 1999, J CLIN ENDOCR METAB, V84, P458, DOI 10.1210/jc.84.2.458; Ludwig L, 2001, CANCER RES, V61, P4526; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; MATSUBAYASHI S, 1995, J CLIN ENDOCR METAB, V80, P3421, DOI 10.1210/jc.80.12.3421; Mechler C, 2001, BRIT J CANCER, V85, P1831, DOI 10.1054/bjoc.2001.2187; Nakada T, 1996, INTERNAL MED, V35, P815, DOI 10.2169/internalmedicine.35.815; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Powell DJ, 2001, ONCOGENE, V20, P3235, DOI 10.1038/sj.onc.1204425; Sagartz JE, 1997, LAB INVEST, V76, P307; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Tamimi DM, 2002, INT J SURG PATHOL, V10, P141, DOI 10.1177/106689690201000207; TOHYAMA K, 1992, JPN J CANCER RES, V83, P153, DOI 10.1111/j.1349-7006.1992.tb00080.x; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; YOSHIDA A, 1994, J SURG ONCOL, V55, P104, DOI 10.1002/jso.2930550209; YOSHIDA M, 1992, CANCER RES, V52, P464	59	62	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4569	4577		10.1038/sj.onc.1206759	http://dx.doi.org/10.1038/sj.onc.1206759			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881713				2022-12-25	WOS:000184054700012
J	Jones, P; Messner, B; Nakajima, JI; Schaffner, AR; Saito, K				Jones, P; Messner, B; Nakajima, JI; Schaffner, AR; Saito, K			UGT73C6 and UGT78D1, glycosyltransferases involved in flavonol glycoside biosynthesis in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PETUNIA-HYBRIDA; UDP-GLUCOSE; BIOCHEMICAL-CHARACTERIZATION; HETEROLOGOUS EXPRESSION; MOLECULAR-CLONING; OXIDATIVE STRESS; GLUCOSYLTRANSFERASE; ANTHOCYANIN; FAMILY; GENES	Flavonol glycosides constitute one of the most prominent plant natural product classes that accumulate in the model plant Arabidopsis thaliana. To date there are no reports of functionally characterized flavonoid glycosyltransferases in Arabidopsis, despite intensive research efforts aimed at both flavonoids and Arabidopsis. In this study, flavonol glycosyltransferases were considered in a functional genomics approach aimed at revealing genes involved in determining the flavonol-glycoside profile. Candidate glycosyltransferase-encoding genes were selected based on homology to other known flavonoid glycosyltransferases and two T-DNA knockout lines lacking flavonol-3-O-rhamnoside-7-O-rhamnosides (ugt78D1) and quercetin-3-O-rhamnoside-7-O-glucoside (ugt73C6 and ugt78D1) were identified. To confirm the in planta results, cDNAs encoding both UGT78D1 and UGT73C6 were expressed in vitro and analyzed for their qualitative substrate specificity. UGT78D1 catalyzed the transfer of rhamnose from UDP-rhamnose to the 3-OH position of quercetin and kaempferol, whereas UGT73C6 catalyzed the transfer of glucose from UDPglucose to the 7-OH position of kaempferol-3-O-rhamnoside and quercetin-3-O-rhamnoside, respectively. The present results suggest that UGT78D1 and UGT73C6 should be classified as UDP-rhamnose:flavonol-3-O-rhamnosyltransferase and UDP-glucose:flavonol-3-O-glycoside-7-O-glucosyltransferase, respectively.	Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, JST,Core Res Evolut Sci & Techol,Inage Ku, Chiba 2638522, Japan; GSF, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, D-85764 Neuherberg, Germany	Chiba University; Japan Science & Technology Agency (JST); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Saito, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, JST,Core Res Evolut Sci & Techol,Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.		Saito, Kazuki/D-2670-2009	Saito, Kazuki/0000-0001-6310-5342				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARPELED M, 1991, J BIOL CHEM, V266, P20953; Bloor SJ, 2002, PHYTOCHEMISTRY, V59, P343, DOI 10.1016/S0031-9422(01)00460-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG S, 1993, PLANT MOL BIOL REP, V11; Chong J, 2002, PLANT CELL, V14, P1093, DOI 10.1105/tpc.010436; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; Gibeaut DM, 1997, PLANT PHYSIOL, V115, P317, DOI 10.1104/pp.115.2.317; Harborne J., 1999, HDB NATURAL FLAVONOI, P297; Hirotani M, 2000, PLANTA, V210, P1006, DOI 10.1007/s004250050710; Hollman PCH, 1999, FREE RADICAL RES, V31, P569, DOI 10.1080/10715769900301141; Jackson RG, 2001, J BIOL CHEM, V276, P4350, DOI 10.1074/jbc.M006185200; Jones P, 2001, PLANTA, V213, P164, DOI 10.1007/s004250000492; Jones PR, 2003, J BIOL CHEM, V278, P10291, DOI 10.1074/jbc.M212207200; KAMSTEEG J, 1979, ANAL BIOCHEM, V9, P457; Knekt P, 2002, AM J CLIN NUTR, V76, P560, DOI 10.1093/ajcn/76.3.560; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 2002, J BIOL CHEM, V277, P586, DOI 10.1074/jbc.M109287200; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; Liu CJ, 2002, P NATL ACAD SCI USA, V99, P14578, DOI 10.1073/pnas.212522099; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Martin RC, 1999, PLANT PHYSIOL, V120, P553, DOI 10.1104/pp.120.2.553; McElver J, 2001, GENETICS, V159, P1751; Milbury PE, 2002, MECH AGEING DEV, V123, P997, DOI 10.1016/S0047-6374(01)00383-9; Milkowski C, 2000, PLANTA, V211, P883, DOI 10.1007/s004250000411; Miller KD, 1999, J BIOL CHEM, V274, P34011, DOI 10.1074/jbc.274.48.34011; Olthof MR, 2000, J NUTR, V130, P1200, DOI 10.1093/jn/130.5.1200; Paquette S, 2003, PHYTOCHEMISTRY, V62, P399, DOI 10.1016/S0031-9422(02)00558-7; Quiel JA, 2003, J BIOL CHEM, V278, P6275, DOI 10.1074/jbc.M211822200; Richards KD, 1998, PLANT PHYSIOL, V116, P409, DOI 10.1104/pp.116.1.409; SESSION A, 2003, PLANT CELL, V14, P2985; Tattersall DB, 2001, SCIENCE, V293, P1826, DOI 10.1126/science.1062249; Tolstikov VV, 2002, ANAL BIOCHEM, V301, P298, DOI 10.1006/abio.2001.5513; Veit M, 1999, J NAT PROD, V62, P1301, DOI 10.1021/np990080o; Vogt T, 2000, TRENDS PLANT SCI, V5, P380, DOI 10.1016/S1360-1385(00)01720-9; Weig A, 1997, PLANT PHYSIOL, V114, P1347, DOI 10.1104/pp.114.4.1347; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405; Yamazaki M, 2003, PHYTOCHEMISTRY, V62, P987, DOI 10.1016/S0031-9422(02)00721-5; Yamazaki M, 2002, PLANT MOL BIOL, V48, P401, DOI 10.1023/A:1014043214943	41	248	280	8	73	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43910	43918		10.1074/jbc.M303523200	http://dx.doi.org/10.1074/jbc.M303523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12900416	hybrid			2022-12-25	WOS:000186306700006
J	Sivaraman, J; Li, YG; Banks, J; Cane, DE; Matte, A; Cygler, M				Sivaraman, J; Li, YG; Banks, J; Cane, DE; Matte, A; Cygler, M			Crystal structure of Escherichia coli PdxA, an enzyme involved in the pyridoxal phosphate biosynthesis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; 3-ISOPROPYLMALATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE; THREONINE DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; VITAMIN-B-6 PYRIDOXINE; 5'-PHOSPHATE SYNTHASE; PROTEIN; COMPLEX; 1-DEOXY-D-XYLULOSE-5-PHOSPHATE	Pyridoxal 5'-phosphate is an essential cofactor for many enzymes responsible for the metabolic conversions of amino acids. Two pathways for its de novo synthesis are known. The pathway utilized by Escherichia coli consists of six enzymatic steps catalyzed by six different enzymes. The fourth step is catalyzed by 4-hydroxythreonine-4-phosphate dehydrogenase (PdxA, E.C. 1.1.1.262), which converts 4-hydroxy-L-threonine phosphate (HTP) to 3-amino-2-oxopropyl phosphate. This divalent metal ion-dependent enzyme has a strict requirement for the phosphate ester form of the substrate HTP, but can utilize either NADP(+) or NAD(+) as redox cofactor. We report the crystal structure of E. coli PdxA and its complex with HTP and Zn2+. The protein forms tightly bound dimers. Each monomer has an alpha/beta/alpha-fold and can be divided into two subdomains. The active site is located at the dimer interface, within a cleft between the two subdomains and involves residues from both monomers. A Zn2+ ion is bound within each active site, coordinated by three conserved histidine residues from both monomers. In addition two conserved amino acids, Asp(247) and Asp(267), play a role in maintaining integrity of the active site. The substrate is anchored to the enzyme by the interactions of its phospho group and by coordination of the amino and hydroxyl groups by the Zn2+ ion. PdxA is structurally similar to, but limited in sequence similarity with isocitrate dehydrogenase and isopropylmalate dehydrogenase. These structural similarities and the comparison with a NADP-bound isocitrate dehydrogenase suggest that the cofactor binding mode of PdxA is very similar to that of the other two enzymes and that PdxA catalyzes a stepwise oxidative decarboxylation of the substrate HTP.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; Brown Univ, Dept Chem, Providence, RI 02912 USA	National Research Council Canada; Brown University	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	Sivaraman, J/H-8028-2012	J, Sivaraman/0000-0001-9781-5326	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030301, R01GM030301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30301, GM20096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cane DE, 1998, J AM CHEM SOC, V120, P1936, DOI 10.1021/ja9742085; Cane DE, 1999, J AM CHEM SOC, V121, P7722, DOI 10.1021/ja9914947; Cane DE, 2000, J AM CHEM SOC, V122, P4213, DOI 10.1021/ja000224h; Doyle SA, 2001, BIOCHEMISTRY-US, V40, P4234, DOI 10.1021/bi002533q; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 1999, CURR GENET, V34, P478, DOI 10.1007/s002940050423; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Franco MG, 2001, STRUCTURE, V9, P245, DOI 10.1016/S0969-2126(01)00584-6; Garrido-Franco M, 2002, J BIOL CHEM, V277, P12396, DOI 10.1074/jbc.M108734200; GRISSOM CB, 1988, BIOCHEMISTRY-US, V27, P2934, DOI 10.1021/bi00408a040; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HILL RE, 1996, ESCHERICHIA COLI SAL, P695; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; Imada K, 1998, STRUCTURE, V6, P971, DOI 10.1016/S0969-2126(98)00099-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laber B, 1999, FEBS LETT, V449, P45, DOI 10.1016/S0014-5793(99)00393-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; MARCUS JP, 1993, J BACTERIOL, V175, P6505, DOI 10.1128/jb.175.20.6505-6511.1993; MARCUS JP, 1993, BIOCHEM BIOPH RES CO, V190, P1066, DOI 10.1006/bbrc.1993.1157; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Yang Y, 1998, J BACTERIOL, V180, P4294, DOI 10.1128/JB.180.16.4294-4299.1998; Yeh JI, 2002, BIOCHEMISTRY-US, V41, P11649, DOI 10.1021/bi026292t	36	31	35	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43682	43690		10.1074/jbc.M306344200	http://dx.doi.org/10.1074/jbc.M306344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12896974	hybrid			2022-12-25	WOS:000186157000117
J	Bouma, B; Kroon-Batenburg, LMJ; Wu, YP; Brunjes, B; Posthuma, G; Kranenburg, O; de Groot, PG; Voest, EE; Gebbink, MFBG				Bouma, B; Kroon-Batenburg, LMJ; Wu, YP; Brunjes, B; Posthuma, G; Kranenburg, O; de Groot, PG; Voest, EE; Gebbink, MFBG			Glycation induces formation of amyloid cross-beta structure in albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CULTURED CORTICAL-NEURONS; B SCAVENGER RECEPTOR; HUMAN-SERUM-ALBUMIN; END-PRODUCTS AGE; ENDOTHELIAL-CELLS; FIBRIL FORMATION; ADVANCED GLYCOSYLATION; PLASMINOGEN-ACTIVATOR; ALZHEIMERS-DISEASE	Amyloid fibrils are components of proteinaceous plaques that are associated with conformational diseases such as Alzheimer's disease, transmissible spongiform encephalopathies, and familial amyloidosis. Amyloid polypeptides share a specific quarternary structure element known as cross-beta structure. Commonly, fibrillar aggregates are modified by advanced glycation end products (AGE). In addition, AGE formation itself induces protein aggregation. Both amyloid proteins and protein-AGE adducts bind multiligand receptors, such as receptor for AGE, CD36, and scavenger receptors A and B type I, and the serine protease tissue-type plasminogen activator (tPA). Based on these observations, we hypothesized that glycation induces refolding of globular proteins, accompanied by formation of cross-beta structure. Using transmission electron microscopy, we demonstrate here that glycated albumin condensates into fibrous or amorphous aggregates. These aggregates bind to amyloid-specific dyes Congo red and thioflavin T and to tPA. In contrast to globular albumin, glycated albumin contains amino acid residues in beta-sheet conformation, as measured with circular dichroism spectropolarimetry. Moreover, it displays cross-beta structure, as determined with x-ray fiber diffraction. We conclude that glycation induces refolding of initially globular albumin into amyloid fibrils comprising cross-beta structure. This would explain how glycated ligands and amyloid ligands can bind to the same multiligand "cross-beta structure" receptors and to tPA.	Univ Med Ctr Utrecht, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Med Oncol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Crystal & Struct Chem, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Cell Biol, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University Medical Center	Gebbink, MFBG (corresponding author), Univ Med Ctr Utrecht, Dept Haematol, Thrombosis & Haemostasis Lab, G-03-647,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Kranenburg, Onno/K-4115-2015; Kroon-Batenburg, Loes/J-9058-2016	Kranenburg, Onno/0000-0002-2112-4390; 				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; Bellotti V, 2000, J STRUCT BIOL, V130, P280, DOI 10.1006/jsbi.2000.4248; Bobbink IWG, 1997, DIABETES, V46, P87, DOI 10.2337/diabetes.46.1.87; Bobbink IWG, 1997, BIOCHEM BIOPH RES CO, V240, P595, DOI 10.1006/bbrc.1997.7718; Bornemann KD, 2001, AM J PATHOL, V158, P63, DOI 10.1016/S0002-9440(10)63945-4; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Cohen G, 2001, J AM SOC NEPHROL, V12, P1264, DOI 10.1681/ASN.V1261264; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; Cribbs DH, 2000, BIOCHEMISTRY-US, V39, P5988, DOI 10.1021/bi000029f; Crowther DC, 2002, HUM MUTAT, V20, P1, DOI 10.1002/humu.10100; Damas AM, 2000, J STRUCT BIOL, V130, P290, DOI 10.1006/jsbi.2000.4273; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; FRASER PE, 1991, J NEUROSCI RES, V28, P474, DOI 10.1002/jnr.490280404; GARLICK RL, 1983, J BIOL CHEM, V258, P6142; Gasic-Milenkovic J, 2001, Z GERONTOL GERIATR, V34, P457, DOI 10.1007/s003910170018; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Greten J, 1996, NEPHROL DIAL TRANSPL, V11, P786, DOI 10.1093/oxfordjournals.ndt.a027399; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Hoppener JWM, 2000, NEW ENGL J MED, V343, P411; Husemann J, 2001, J NEUROIMMUNOL, V114, P142, DOI 10.1016/S0165-5728(01)00239-9; Inouye H, 2000, J MOL BIOL, V300, P1283, DOI 10.1006/jmbi.2000.3926; Jackson GS, 2000, CURR OPIN STRUC BIOL, V10, P69, DOI 10.1016/S0959-440X(99)00051-2; Jaroniec CP, 2002, P NATL ACAD SCI USA, V99, P16748, DOI 10.1073/pnas.252625999; Kapurniotu A, 1998, EUR J BIOCHEM, V251, P208, DOI 10.1046/j.1432-1327.1998.2510208.x; Kikuchi S, 1999, J NEUROSCI RES, V57, P280, DOI 10.1002/(SICI)1097-4547(19990715)57:2<280::AID-JNR14>3.0.CO;2-U; Kirpichnikov D, 2001, TRENDS ENDOCRIN MET, V12, P225, DOI 10.1016/S1043-2760(01)00391-5; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; Krieger M, 2001, J CLIN INVEST, V108, P645, DOI 10.1172/JCI13932; KUME S, 1995, AM J PATHOL, V147, P654; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Loske C, 1998, J NEURAL TRANSM, V105, P1005, DOI 10.1007/s007020050108; Lyons TJ, 2000, INVEST OPHTH VIS SCI, V41, P1176; MARSH RE, 1955, ACTA CRYSTALLOGR, V8, P710, DOI 10.1107/S0365110X5500217X; MARSH RE, 1955, BIOCHIM BIOPHYS ACTA, V16, P1, DOI 10.1016/0006-3002(55)90178-5; Matsumoto K, 2000, BIOCHEM J, V352, P233, DOI 10.1042/0264-6021:3520233; Min C, 1999, DIABETES RES CLIN PR, V46, P197, DOI 10.1016/S0168-8227(99)00094-7; Munch G, 1997, BBA-MOL BASIS DIS, V1360, P17, DOI 10.1016/S0925-4439(96)00062-2; NGUYEN JT, 1995, J MOL BIOL, V252, P412, DOI 10.1006/jmbi.1995.0507; Nieuwenhuizen W, 2001, ANN NY ACAD SCI, V936, P237; Niwa T, 2001, SEMIN DIALYSIS, V14, P123, DOI 10.1046/j.1525-139x.2001.00031.x; Ohgami N, 2001, ANN NY ACAD SCI, V947, P350; Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2; Sakata N, 1999, ATHEROSCLEROSIS, V142, P67, DOI 10.1016/S0021-9150(98)00192-0; Sasaki N, 2002, NEUROSCI LETT, V326, P117, DOI 10.1016/S0304-3940(02)00310-5; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; Schmidt AM, 2000, SEMIN THROMB HEMOST, V26, P485, DOI 10.1055/s-2000-13204; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Symmons MF, 1997, FEBS LETT, V412, P397, DOI 10.1016/S0014-5793(97)00809-0; Takeuchi M, 2000, J NEUROPATH EXP NEUR, V59, P1094, DOI 10.1093/jnen/59.12.1094; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; TRUEB B, 1984, COLLAGEN REL RES, V4, P239; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; VLASSARA H, 1994, LAB INVEST, V70, P138; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; Westwood ME, 1997, BBA-MOL CELL RES, V1356, P84, DOI 10.1016/S0167-4889(96)00154-1; Yamagishi S, 2002, J BIOL CHEM, V277, P20309, DOI 10.1074/jbc.M202634200; YAN SD, 1994, J BIOL CHEM, V269, P9889	71	206	219	4	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41810	41819		10.1074/jbc.M303925200	http://dx.doi.org/10.1074/jbc.M303925200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909637	hybrid			2022-12-25	WOS:000185989500033
J	Falcon, AA; Aris, JP				Falcon, AA; Aris, JP			Plasmid accumulation reduces life span in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK BARRIER; RIBOSOMAL DNA; METABOLIC-CONTROL; CHROMATIN-STRUCTURE; SHUTTLE VECTORS; DAUGHTER CELLS; YEAST RDNA; GENES; RECOMBINATION; PROTEIN	Aging in the yeast Saccharomyces cerevisiae is under the control of multiple pathways. The production and accumulation of extrachromosomal rDNA circles (ERCs) is one pathway that has been proposed to bring about aging in yeast. To test this proposal, we have developed a plasmid-based model system to study the role of DNA episomes in reduction of yeast life span. Recombinant plasmids containing different replication origins, cis-acting partitioning elements, and selectable marker genes were constructed and analyzed for their effects on yeast replicative life span. Plasmids containing the ARS1 replication origin reduce life span to the greatest extent of the plasmids analyzed. This reduction in life span is partially suppressed by a CEN4 centromeric element on ARS1 plasmids. Plasmids containing a replication origin from the endogenous yeast 2 mu circle also reduce life span, but to a lesser extent than ARS1 plasmids. Consistent with this, ARS1 and 2 mu origin plasmids accumulate in similar to7-generation-old cells, but ARS1/CEN4 plasmids do not. Importantly, ARS1 plasmids accumulate to higher levels in old cells than 2 mu origin plasmids, suggesting a correlation between plasmid accumulation and life span reduction. Reduction in life span is neither an indirect effect of increased ERC levels nor the result of stochastic cessation of growth. The presence of a fully functional 9.1-kb rDNA repeat on plasmids is not required for, and does not augment, reduction in life span. These findings support the view that accumulation of DNA episomes, including episomes such as ERCs, cause cell senescence in yeast.	Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Aris, JP (corresponding author), Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.	johnaris@ufl.edu		Aris, John/0000-0002-6475-064X	NATIONAL INSTITUTE ON AGING [R21AG023719] Funding Source: NIH RePORTER; NIA NIH HHS [R21 AG023719-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Benguria A, 2003, NUCLEIC ACIDS RES, V31, P893, DOI 10.1093/nar/gkg188; Bielinsky AK, 2001, J CELL SCI, V114, P643; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROACH JR, 1991, MOL CELLULAR BIOL YE, V1, P297; CARBON J, 1990, New Biologist, V2, P10; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Coelho PSR, 2002, GENE DEV, V16, P2755, DOI 10.1101/gad.1035002; CONRADWEBB H, 1995, MOL CELL BIOL, V15, P2420; Costa Vitor, 2001, Molecular Aspects of Medicine, V22, P217, DOI 10.1016/S0098-2997(01)00012-7; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; FUTCHER B, 1988, GENETICS, V118, P411; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; HOLM C, 1982, CELL, V29, P585, DOI 10.1016/0092-8674(82)90174-X; Hoopes LLM, 2002, MOL CELL BIOL, V22, P4136, DOI 10.1128/MCB.22.12.4136-4146.2002; Jazwinski SM, 2002, ANNU REV MICROBIOL, V56, P769, DOI 10.1146/annurev.micro.56.012302.160830; Jazwinski SM, 2000, TRENDS GENET, V16, P506, DOI 10.1016/S0168-9525(00)02119-3; Jazwinski SM, 2000, ANN NY ACAD SCI, V908, P21; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Kirchman PA, 1999, GENETICS, V152, P179; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; McVey M, 2001, GENETICS, V157, P1531; Merker RJ, 2002, MOL CELL BIOL, V22, P421, DOI 10.1128/MCB.22.2.421-429.2002; Miller CA, 1999, NUCLEIC ACIDS RES, V27, P3921, DOI 10.1093/nar/27.19.3921; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; Park PU, 2002, METHOD ENZYMOL, V351, P468; Park PU, 1999, MOL CELL BIOL, V19, P3848; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair D, 1998, ANNU REV MICROBIOL, V52, P533, DOI 10.1146/annurev.micro.52.1.533; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; Smith JS, 1998, GENETICS, V149, P1205; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; Ward TR, 2000, MOL CELL BIOL, V20, P4948, DOI 10.1128/MCB.20.13.4948-4957.2000; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221	51	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41607	41617		10.1074/jbc.M307025200	http://dx.doi.org/10.1074/jbc.M307025200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904293	Green Accepted, hybrid			2022-12-25	WOS:000185989500008
J	Fiordalisi, JJ; Johnson, RL; Weinbaum, CA; Sakabe, K; Chen, Z; Casey, PJ; Cox, AD				Fiordalisi, JJ; Johnson, RL; Weinbaum, CA; Sakabe, K; Chen, Z; Casey, PJ; Cox, AD			High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-PROTEIN TRANSFERASE; K-RAS; N-RAS; H-RAS; PHOSPHOINOSITIDE 3-KINASE; ISOPRENOID MODIFICATION; MAMMALIAN-CELLS; PLASMA-MEMBRANE; CANCER-CELLS; IN-VITRO	Farnesyltransferase inhibitors (FTIs) block Ras farnesylation, subcellular localization and activity, and inhibit the growth of Ras-transformed cells. Although FTIs are ineffective against K-Ras4B, the Ras isoform most commonly mutated in human cancers, they can inhibit the growth of tumors containing oncogenic K-Ras4B, implicating other farnesylated proteins or suggesting distinct functions for farnesylated and for geranylgeranylated K-Ras, which is generated when farnesyltransferase is inhibited. In addition to bypassing FTI blockade through geranylgeranylation, K-Ras4B resistance to FTIs may also result from its higher affinity for farnesyltransferase. Using chimeric Ras proteins containing all combinations of Ras background, CAAX motif, and K-Ras polybasic domain, we show that either a polybasic domain or an alternatively prenylated CAAX renders Ras prenylation, Ras-induced Elk-1 activation, and anchorage-independent cell growth FTI-resistant. The polybasic domain alone increases the affinity of Ras for farnesyltransferase, implying independent roles for each K-Ras4B sequence element in FTI resistance. Using microarray analysis and colony formation assays, we confirm that K-Ras function is independent of the identity of the prenyl group and, therefore, that FTI inhibition of K-Ras transformed cells is likely to be independent of K-Ras inhibition. Our results imply that relevant FTI targets will lack both polybasic and potentially geranylgeranylated methionine-CAAX motifs.	Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Duke Univ, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Dept Biochem, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University	Fiordalisi, JJ (corresponding author), Univ N Carolina, Dept Radiat Oncol, CB 7512, Chapel Hill, NC 27599 USA.	fiordali@med.unc.edu		Casey, Patrick/0000-0002-7366-9309; Cox, Adrienne D./0000-0002-4901-2454				Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Baum Charles, 2003, Curr Oncol Rep, V5, P99, DOI 10.1007/s11912-003-0096-5; BOS JL, 1989, CANCER RES, V49, P4682; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark GJ, 1997, J BIOL CHEM, V272, P10608; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; COX AD, 1994, J BIOL CHEM, V269, P19203; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Crespo NC, 2001, J BIOL CHEM, V276, P16161, DOI 10.1074/jbc.M006213200; Du W, 1999, CANCER RES, V59, P5492; Fiordalis JJ, 2002, J BIOL CHEM, V277, P10813, DOI 10.1074/jbc.M107684200; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Ganguly AK, 2001, CURR MED CHEM, V8, P1419, DOI 10.2174/0929867013372021; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Gotoh T, 2001, J BIOL CHEM, V276, P38029; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Ohkanda Junko, 2002, Current Topics in Medicinal Chemistry, V2, P303, DOI 10.2174/1568026023394281; Prendergast GC, 2001, EXPERT OPIN INV DRUG, V10, P2105, DOI 10.1517/13543784.10.12.2105; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, J CELL SCI, V114, P1603; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; SASSEVILLE AMJ, 1995, J CELL SCI, V108, P273; SEBTI SM, 2003, IN PRESS NAT REV CAN; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P10499, DOI 10.1073/pnas.95.18.10499; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Tamanoi F, 2001, J CELL BIOCHEM, V84, P64, DOI 10.1002/jcb.10067; Tamanoi F, 2001, CELL MOL LIFE SCI, V58, P1636, DOI 10.1007/PL00000802; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zhang FL, 1997, J BIOL CHEM, V272, P10232	55	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41718	41727		10.1074/jbc.M305733200	http://dx.doi.org/10.1074/jbc.M305733200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12882980	Green Published, hybrid			2022-12-25	WOS:000185989500022
J	Truglio, JJ; Theis, K; Feng, YG; Gajda, R; Machutta, C; Tonge, PJ; Kisker, C				Truglio, JJ; Theis, K; Feng, YG; Gajda, R; Machutta, C; Tonge, PJ; Kisker, C			Crystal structure of Mycobacterium tuberculosis MenB, a key enzyme in vitamin K-2 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORTHO-SUCCINYLBENZOIC ACID; ENOYL-COA HYDRATASE; NICOTINAMIDE-ADENINE DINUCLEOTIDE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; MENAQUINONE VITAMIN-K-2; ISOPRENOID BIOSYNTHESIS; CROTONASE SUPERFAMILY; O-SUCCINYLBENZOATE; 1,4-DIHYDROXY-2-NAPHTHOIC ACID	Bacterial enzymes of the menaquinone (Vitamin K-2) pathway are potential drug targets because they lack human homologs. MenB, 1,4-dihydroxy-2-naphthoyl-CoA synthase, the fourth enzyme in the biosynthetic pathway leading from chorismate to menaquinone, catalyzes the conversion of O-succinylbenzoyl-CoA ( OSB-CoA) to 1,4-dihydroxy-2-naphthoyl-CoA (DHNA-CoA). Based on our interest in developing novel tuberculosis chemotherapeutics, we have solved the structures of MenB from Mycobacterium tuberculosis and its complex with acetoacetyl-coenzyme A at 1.8 and 2.3 Angstrom resolution, respectively. Like other members of the crotonase superfamily, MenB folds as an (alpha(3))(2) hexamer, but its fold is distinct in that the C terminus crosses the trimer-trimer interface, forming a flexible part of the active site within the opposing trimer. The highly conserved active site of MenB contains a deep pocket lined by Asp-192, Tyr-287, and hydrophobic residues. Mutagenesis shows that Asp-192 and Tyr-287 are essential for enzymatic catalysis. We postulate a catalytic mechanism in which MenB enables proton transfer within the substrate to yield an oxyanion as the initial step in catalysis. Knowledge of the active site geometry and characterization of the catalytic mechanism of MenB will aid in identifying new inhibitors for this potential drug target.	SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Ctr Struct Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kisker, C (corresponding author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.		Kisker, Caroline/T-1724-2019; Tonge, Peter J/A-7443-2009	Tonge, Peter J/0000-0003-1606-3471; Kisker, Caroline/0000-0002-0216-6026; Theis, Karsten/0000-0003-2697-6143	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044639, R21AI044639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM058190] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44639] Funding Source: Medline; NIGMS NIH HHS [GM 58190] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZERAD R, 1967, BIOCHEM BIOPH RES CO, V27, P253, DOI 10.1016/S0006-291X(67)80070-6; Bahnson BJ, 2002, BIOCHEMISTRY-US, V41, P2621, DOI 10.1021/bi015844p; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Begley TP, 1998, TOP CURR CHEM, V195, P93; Bell AF, 2002, CHEM BIOL, V9, P1247, DOI 10.1016/S1074-5521(02)00263-6; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; BISHOP DHL, 1962, BIOCHEM J, V83, P606, DOI 10.1042/bj0830606; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUNGER AT, 1992, XPLOR VERSION 3 1; CATALA F, 1970, INT Z VITAMINFORSCH, V40, P363; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COLLINS MD, 1977, J GEN MICROBIOL, V100, P221, DOI 10.1099/00221287-100-2-221; DANSETTE P, 1970, BIOCHEM BIOPH RES CO, V40, P1090, DOI 10.1016/0006-291X(70)90906-X; Daruwala R, 1996, FEMS MICROBIOL LETT, V140, P159, DOI 10.1016/0378-1097(96)00173-5; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P14733, DOI 10.1021/bi00253a011; DOWD P, 1995, ANNU REV NUTR, V15, P419, DOI 10.1146/annurev.nu.15.070195.002223; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; HEIDE L, 1982, J BIOL CHEM, V257, P7396; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; IGBAVBOA U, 1990, EUR J BIOCHEM, V192, P441, DOI 10.1111/j.1432-1033.1990.tb19246.x; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kemp LE, 2002, P NATL ACAD SCI USA, V99, P6591, DOI 10.1073/pnas.102679799; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurimoto K, 2001, STRUCTURE, V9, P1253, DOI 10.1016/S0969-2126(01)00686-4; KUSUNOSE E, 1963, BIOCHIM BIOPHYS ACTA, V73, P391; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDUC MM, 1970, EUR J BIOCHEM, V15, P428, DOI 10.1111/j.1432-1033.1970.tb01025.x; LESTER RL, 1959, J BIOL CHEM, V234, P2169; Lichtenthaler HK, 2000, Z NATURFORSCH C, V55, P305; MCGOVERN EP, 1978, ARCH BIOCHEM BIOPHYS, V188, P56, DOI 10.1016/0003-9861(78)90355-7; MEGANATHAN R, 1981, BIOCHEMISTRY-US, V20, P5336, DOI 10.1021/bi00521a038; MEGANATHAN R, 1981, J BIOL CHEM, V256, P9386; MEGANATHAN R, 1981, J BACTERIOL, V145, P328, DOI 10.1128/JB.145.1.328-332.1981; MEGANATHAN R, 1979, FED PROC, V38, P315; MEGANATHAN R, 1980, BIOCHEMISTRY-US, V19, P785, DOI 10.1021/bi00545a026; MEGANATHAN R, 1983, J BACTERIOL, V153, P739, DOI 10.1128/JB.153.2.739-746.1983; MEGANATHAN R, 1979, J BACTERIOL, V140, P92, DOI 10.1128/JB.140.1.92-98.1979; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; Meganathan R, 2001, VITAM HORM, V61, P173; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mursula AM, 2001, J MOL BIOL, V309, P845, DOI 10.1006/jmbi.2001.4671; NOLL H, 1958, J BIOL CHEM, V232, P919; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALANIAPPAN C, 1992, J BACTERIOL, V174, P8111, DOI 10.1128/JB.174.24.8111-8118.1992; Palmer DRJ, 1999, BIOCHEMISTRY-US, V38, P4252, DOI 10.1021/bi990140p; Pelletier DA, 1998, J BACTERIOL, V180, P2330, DOI 10.1128/JB.180.9.2330-2336.1998; Perlman DC, 1997, AIDS, V11, pS173; Putra SR, 1998, FEMS MICROBIOL LETT, V164, P169; Rattan A, 1998, EMERG INFECT DIS, V4, P195, DOI 10.3201/eid0402.980207; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Rowland B, 1995, GENE, V167, P105, DOI 10.1016/0378-1119(95)00662-1; Rowland BM, 1996, GENE, V178, P119, DOI 10.1016/0378-1119(96)00349-6; Rowland BM, 1996, J BACTERIOL, V178, P854, DOI 10.1128/jb.178.3.854-861.1996; Schwender J, 1996, BIOCHEM J, V316, P73, DOI 10.1042/bj3160073; SEGEL WP, 1963, BIOCHIM BIOPHYS ACTA, V73, P380, DOI 10.1016/0926-6569(63)90127-5; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; Sharma V, 1996, GENE, V168, P43, DOI 10.1016/0378-1119(95)00721-0; SHARMA V, 1993, J BACTERIOL, V175, P4917, DOI 10.1128/JB.175.15.4917-4921.1993; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; Thompson TB, 2000, BIOCHEMISTRY-US, V39, P10662, DOI 10.1021/bi000855o; Whittingham JL, 2003, J BIOL CHEM, V278, P1744, DOI 10.1074/jbc.M211188200; Wu WJ, 1997, BIOCHEMISTRY-US, V36, P2211, DOI 10.1021/bi962549+	73	79	84	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42352	42360		10.1074/jbc.M307399200	http://dx.doi.org/10.1074/jbc.M307399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909628	hybrid			2022-12-25	WOS:000185989500097
J	Watanabe, J; Miyazaki, Y; Zimmerman, GA; Albertine, KH; McIntyre, TM				Watanabe, J; Miyazaki, Y; Zimmerman, GA; Albertine, KH; McIntyre, TM			Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; TOLL-LIKE RECEPTOR-2; BACTERIAL LIPOPOLYSACCHARIDE; ESCHERICHIA-COLI; ALLERGIC-ASTHMA; KAPPA-B; MICE; HYPERRESPONSIVENESS; INFLAMMATION; EXPOSURE	The reversible airway hyper-reactivity (AHR) of asthma is modeled by sensitizing and challenging mice with aerosolized ovalbumin. However, the C57BL/6 murine strain does not display the large increase in circulating IgG and IgE antibodies found in human atopy and asthma. We found that commercial ovalbumin was contaminated with lipopolysaccharide (LPS) in amounts sufficient to fully activate endothelial cells in an in vitro assay of the first step of inflammation. Desensitization of TLR4 by LPS pretreatment suppressed the inflammatory effect of ovalbumin. The presence of LPS was occult, because it does not require serum presentation and, like the LPS of Salmonella minnesota, was not suppressed by polymyxin B. Purified ovalbumin did not activate endothelial cells in vitro; however, endotoxin-free ovalbumin was far more effective than commercial material in stimulating IgE production and respiratory dysfunction in a C57BL/6 murine model of AHR. Moreover, endotoxin-free ovalbumin induced lung inflammation with alveolar enlargement and destruction in a histologic pattern that differed from the changes caused by commercial, endotoxin-contaminated ovalbumin. Reconstitution of purified ovalbumin with S. minnesota LPS decreased lung inflammation, decreased changes in lung function, and suppressed anti-ovalbumin antibody production. We conclude endotoxin contaminates ovalbumin preparations and that endotoxin co-administration with the ovalbumin antigen creates a state of tolerance in a murine model of AHR. Co-exposure to endotoxin and antigen occurs in humans through organic dusts, so murine models of AHR may reflect the clinical situation, but models based on commercial ovalbumin do not accurately reflect the effect of protein antigen alone on animal physiology.	Univ Utah, Eccles Inst Human Genet 4130, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntyre, TM (corresponding author), Univ Utah, Eccles Inst Human Genet 4130, Dept Pathol, Salt Lake City, UT 84112 USA.			Albertine, Kurt/0000-0001-8497-0861	NHLBI NIH HHS [HL 44513, P50 HL 50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153, R01HL044513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albertine KH, 2002, AM J PHYSIOL-LUNG C, V283, pL219, DOI 10.1152/ajplung.00324.2001; AWADE AC, 1994, J CHROMATOGR A, V677, P279, DOI 10.1016/0021-9673(94)80156-8; Brass DM, 2003, AM J PHYSIOL-LUNG C, V285, pL755, DOI 10.1152/ajplung.00001.2003; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150, DOI 10.1164/ajrccm.160.4.9806034; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; CAVAILLON JM, 1986, MOL IMMUNOL, V23, P965, DOI 10.1016/0161-5890(86)90127-6; Drazen JM, 1999, CLIN EXP ALLERGY, V29, P37; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; FOTHERGI.LA, 1970, BIOCHEM J, V116, P555, DOI 10.1042/bj1160555; Gleich GJ, 1997, P NATL ACAD SCI USA, V94, P2101, DOI 10.1073/pnas.94.6.2101; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; HEGG PO, 1979, BIOCHIM BIOPHYS ACTA, V579, P73, DOI 10.1016/0005-2795(79)90088-6; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; JOHNSON JR, 1992, INFECT IMMUN, V60, P578, DOI 10.1128/IAI.60.2.578-583.1992; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Manthey CL, 1994, J ENDOTOXIN RES, V1, P84; McIntyre TM, 2003, CURR OPIN HEMATOL, V10, P150, DOI 10.1097/00062752-200303000-00009; Neilsen PO, 2001, J IMMUNOL, V167, P5231, DOI 10.4049/jimmunol.167.9.5231; Nightingale JA, 1998, THORAX, V53, P563, DOI 10.1136/thx.53.7.563; O'Byrne PM, 1999, AM J RESP CRIT CARE, V159, pS41; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591, DOI 10.1164/ajrccm.163.7.2009111; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Rylander R, 2002, J ENDOTOXIN RES, V8, P241, DOI 10.1179/096805102125000452; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305, DOI 10.1164/ajrccm.163.2.ed2000a; Strohmeier GR, 2001, J IMMUNOL, V166, P2063, DOI 10.4049/jimmunol.166.3.2063; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394, DOI 10.1152/ajplung.2001.281.2.L394; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; VACHIER MC, 1995, J CHROMATOGR B, V664, P201, DOI 10.1016/0378-4347(94)00411-W; Vasquez Y R, 2000, Respir Res, V1, P82; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Wilder JA, 1999, AM J RESP CELL MOL, V20, P1326, DOI 10.1165/ajrcmb.20.6.3561; Wooten RM, 1996, J IMMUNOL, V157, P4584; Zimmerman GA, 1997, J CLIN INVEST, V100, pS3; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	42	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42361	42368		10.1074/jbc.M307752200	http://dx.doi.org/10.1074/jbc.M307752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909619	hybrid			2022-12-25	WOS:000185989500098
J	Xu, KY; Kuppusamy, SP; Wang, JQ; Li, HQ; Cui, HM; Dawson, TM; Huang, PL; Burnett, AL; Kuppusamy, P; Becker, LC				Xu, KY; Kuppusamy, SP; Wang, JQ; Li, HQ; Cui, HM; Dawson, TM; Huang, PL; Burnett, AL; Kuppusamy, P; Becker, LC			Nitric oxide protects cardiac sarcolemmal membrane enzyme function and ion active transport against ischemia-induced inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; FREE-RADICALS; SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; MYOCARDIAL-ISCHEMIA; ENDOTHELIAL-CELLS; HYDROXYL RADICALS; SYNTHASE; ISOFORMS	Nitric oxide (NO.) generated from nitric oxide synthase (NOS) isoforms bound to cellular membranes may serve to modulate oxidative stresses in cardiac muscle and thereby regulate the function of key membrane-associated enzymes. Ischemia is known to inhibit the function of sarcolemmal enzymes, including the (Na+ + K+)-ATPase, but it is unknown whether concomitant injury to sarcolemma (SL)-associated NOS isoforms may contribute to this process by reducing the availability of locally generated NO.. Here we report that nNOS, as well as eNOS (SL NOSs), are tightly associated with cardiac SL membranes in several different species. In isolated perfused rat hearts, global ischemia caused a time-dependent irreversible injury to cardiac SL NOSs and a disruption of SL NO. generation. Pretreatment with low concentrations of the NO. donor 1-hydroxy-2-oxo-3-(N-3-methyl- aminopropyl)-3-methyl-1-triazene (NOC-7) markedly protected both SL NOS and (Na+ + K+)-ATPase functions against ischemia-induced inactivation. Moreover, ischemia impaired SL Na+/K+ binding, and NOC-7 significantly prevented ischemic injury to the ion binding sites on (Na+ + K+)-ATPase. These novel findings indicate that NO. can protect cardiac SL NOSs and (Na+ + K+)-ATPase against ischemia-induced inactivation and suggest that locally generated NO. may serve to regulate SL Na+/ K+ ion active transport in the heart.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Neurosci, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Inst Cell Engn, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21224 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02129 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02129 USA; Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University System of Ohio; Ohio State University	Xu, KY (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Rm 308,108 N Greene St, Baltimore, MD 21201 USA.			Huang, Paul/0000-0002-5436-8658	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052175, R01HL033360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52175, HL 33360] Funding Source: Medline; NIDDK NIH HHS [DK 02568] Funding Source: Medline; NINDS NIH HHS [NS 378090] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; HESS ML, 1995, ANN THORAC SURG, V60, P760, DOI 10.1016/0003-4975(95)00574-5; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Huang PL, 1998, PROG BRAIN RES, V118, P13; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Jennings R B, 1995, Monogr Pathol, V37, P47; JENNINGS RB, 1989, HOSP PRACT, V24, P89; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KIM MS, 1987, AM J PHYSIOL, V252, pH252, DOI 10.1152/ajpheart.1987.252.2.H252; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; KUKREJA RC, 1990, AM J PHYSIOL, V259, pH1330, DOI 10.1152/ajpheart.1990.259.5.H1330; KUKREJA RC, 1991, CIRC RES, V69, P1003, DOI 10.1161/01.RES.69.4.1003; KYTE J, 1971, J BIOL CHEM, V246, P4157; KYTE J, 1987, BIOCHEMISTRY-US, V26, P8350, DOI 10.1021/bi00399a049; Li HQ, 2000, J PHARMACOL EXP THER, V295, P563; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miethke A, 2003, ACTA HISTOCHEM, V105, P43, DOI 10.1078/0065-1281-00692; MURPHY JG, 1987, CIRCULATION, V75, P15; Nandagopal K, 2001, J PHARMACOL EXP THER, V297, P474; ONeill CA, 1996, AM J PHYSIOL-HEART C, V271, pH660, DOI 10.1152/ajpheart.1996.271.2.H660; ROSKAMS AJ, 1994, NEURON, V13, P289; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Skou JC, 1998, BIOSCIENCE REP, V18, P155, DOI 10.1023/A:1020196612909; SUN JZ, 1993, CIRC RES, V73, P534, DOI 10.1161/01.RES.73.3.534; Xu KY, 2000, BBA-PROTEIN STRUCT M, V1481, P156, DOI 10.1016/S0167-4838(00)00113-8; Xu KY, 1997, ANN NY ACAD SCI, V834, P680, DOI 10.1111/j.1749-6632.1997.tb52349.x; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Zhang P, 1996, CIRCULATION, V94, P2235, DOI 10.1161/01.CIR.94.9.2235	35	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41798	41803		10.1074/jbc.M306865200	http://dx.doi.org/10.1074/jbc.M306865200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904295	hybrid			2022-12-25	WOS:000185989500031
J	Dadke, S; Chernoff, J				Dadke, S; Chernoff, J			Protein-tyrosine phosphatase 1B mediates the effects of insulin on the actin cytoskeleton in immortalized fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATOR; RHO-GTPASES; PTP 1B; C-SRC; CELL; ACTIVATION; RECEPTOR	Insulin regulates diverse cellular responses including actin reorganization. The mechanism by which insulin induces formation of lamellipodia in cultured cells is not known but is likely to involve activation of Src family protein-tyrosine kinases. Here we show that protein-tyrosine phosphatase 1B (PTPIB) activates Src, thereby initiating the activation of a Rac-dependent pathway leading to cytoskeletal remodeling. Conversely, expression of a proline to alanine (P309,310A) PTP1B mutant, which cannot activate Src, fails to activate Rho GTPases or cause changes in actin organization. Rat fibroblasts lacking PTP1B expression do not activate Src or Rac in response to insulin and cannot reorganize actin. These results show that PTP1B, best known as a negative regulator of the metabolic effects of insulin, is required for the effects of insulin on actin organization in immortalized fibroblasts.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [CA-06927, CA-58836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058836, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; AHMAD F, 1995, J BIOL CHEM, V270, P20502; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Buckley DA, 2002, MOL CELL BIOL, V22, P1998, DOI 10.1128/MCB.22.7.1998-2010.2002; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Dadke S, 2002, BIOCHEM J, V364, P377, DOI 10.1042/BJ20011372; Dadke S, 2001, MOL CELL BIOCHEM, V221, P147, DOI 10.1023/A:1010909031310; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fincham VJ, 1999, J CELL SCI, V112, P947; Goldstein Barry J., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P265, DOI 10.2174/1568008013341163; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hassid A, 1999, AM J PHYSIOL-HEART C, V277, pH192, DOI 10.1152/ajpheart.1999.277.1.H192; Johnson TO, 2002, NAT REV DRUG DISCOV, V1, P696, DOI 10.1038/nrd895; KENNER KA, 1993, J BIOL CHEM, V268, P25455; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; MIYATA Y, 1988, EXP CELL RES, V175, P286, DOI 10.1016/0014-4827(88)90193-0; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; NOBES CD, 1995, J CELL SCI, V108, P225; Pathre P, 2001, J NEUROSCI RES, V63, P143, DOI 10.1002/1097-4547(20010115)63:2<143::AID-JNR1006>3.0.CO;2-1; REN XD, 2000, METHODS ENZYMOL, V325; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Tao JC, 2001, J BIOL CHEM, V276, P29520, DOI 10.1074/jbc.M103721200; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; WIENER JR, 1994, AM J OBSTET GYNECOL, V170, P1177, DOI 10.1016/S0002-9378(94)70118-0; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372	50	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40607	40611		10.1074/jbc.M306772200	http://dx.doi.org/10.1074/jbc.M306772200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902327	hybrid			2022-12-25	WOS:000185847200024
J	Kingsbury, TJ; Murray, PD; Bambrick, LL; Krueger, BK				Kingsbury, TJ; Murray, PD; Bambrick, LL; Krueger, BK			Ca2+-dependent regulation of TrkB expression in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIC FACTOR; TRANSCRIPTION FACTOR; FULL-LENGTH; HIPPOCAMPAL-NEURONS; SURFACE EXPRESSION; TYROSINE KINASE; CALCIUM INFLUX; MESSENGER-RNAS; RECEPTOR; BDNF	The neurotrophin brain-derived neurotrophic factor ( BDNF), via activation of its receptor, tyrosine receptor kinase B ( trkB), regulates a wide variety of cellular processes in the nervous system, including neuron survival and synaptic plasticity. Although the expression of BDNF is known to be Ca2+-dependent, the regulation of trkB expression has not been extensively studied. Here we report that depolarization of cultured mouse cortical neurons increased the expression of the full-length, catalytically active isoform of trkB without affecting expression of the truncated isoform. This increase in protein expression was accompanied by increased levels of transcripts encoding full-length, but not truncated, trkB. Depolarization also regulated transcription of the gene, TRKB, via entry of Ca2+ through voltage-gated Ca2+ channels and subsequent activation of Ca2+-responsive elements in the two TRKB promoters. Using transient transfection of neurons with TRKB promoter-luciferase constructs, we found that Ca2+ inhibited the upstream promoter P1 but activated the downstream promoter P2. Ca2+-dependent stimulation of TRKB expression requires two adjacent, non-identical CRE sites located within P2. The coordinated regulation of BDNF and trkB by Ca2+ may play a role in activity-dependent survival and synaptic plasticity by enhancing BDNF signaling in electrically active neurons.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Kingsbury, TJ (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.	tking001@umaryland.edu			NIA NIH HHS [AG10686] Funding Source: Medline; NIGMS NIH HHS [2T32GM08181] Funding Source: Medline; NINDS NIH HHS [5T32NS07375, NS40492] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007375, R01NS040492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010686] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balkowiec A, 2002, J NEUROSCI, V22, P10399; Barettino D, 1999, BBA-GENE STRUCT EXPR, V1446, P24, DOI 10.1016/S0167-4781(99)00056-1; Dorsey SG, 2002, J NEUROSCI, V22, P2571, DOI 10.1523/JNEUROSCI.22-07-02571.2002; Du J, 2000, J CELL BIOL, V150, P1423, DOI 10.1083/jcb.150.6.1423; Eide FF, 1996, J NEUROSCI, V16, P3123; ESCANDON E, 1994, J NEUROSCI, V14, P2054; Ferrer I, 1999, J NEUROPATH EXP NEUR, V58, P729, DOI 10.1097/00005072-199907000-00007; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; Gartner AG, 2002, P NATL ACAD SCI USA, V99, P6386, DOI 10.1073/pnas.092129699; Gonzalez M, 1999, NEURON, V24, P567, DOI 10.1016/S0896-6273(00)81113-7; Haapasalo A, 2002, J BIOL CHEM, V277, P43160, DOI 10.1074/jbc.M205202200; Hartmann M, 2001, EMBO J, V20, P5887, DOI 10.1093/emboj/20.21.5887; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Li YX, 1998, P NATL ACAD SCI USA, V95, P10884, DOI 10.1073/pnas.95.18.10884; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Righi M, 2000, J NEUROSCI, V20, P3165, DOI 10.1523/JNEUROSCI.20-09-03165.2000; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Schinder AF, 2000, TRENDS NEUROSCI, V23, P639, DOI 10.1016/S0166-2236(00)01672-6; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Stoilov P, 2002, BIOCHEM BIOPH RES CO, V290, P1054, DOI 10.1006/bbrc.2001.6301; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; Xia ZG, 1996, J NEUROSCI, V16, P5425	32	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40744	40748		10.1074/jbc.M303082200	http://dx.doi.org/10.1074/jbc.M303082200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900419	hybrid			2022-12-25	WOS:000185847200041
J	Serrano-Heras, G; Salas, M; Bravo, A				Serrano-Heras, G; Salas, M; Bravo, A			In vivo assembly of phage phi 29 replication protein p1 into membrane-associated multimeric structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR-SENSITIVE MUTANTS; BACTERIAL-CELL DIVISION; SUBTILIS PHAGE PHI-29; DNA-REPLICATION; BACILLUS-SUBTILIS; NUCLEAR-MATRIX; TERMINAL PROTEIN; ADENOVIRUS DNA; PROTOFILAMENT SHEETS; INFECTED-CELLS	The mechanisms underlying compartmentalization of prokaryotic DNA replication are largely unknown. In the case of the Bacillus subtilis phage phi29, the viral protein p1 enhances the rate of in vivo viral DNA replication. Previous work showed that p1 generates highly ordered structures in vitro. We now show that protein p1, like integral membrane proteins, has an amphiphilic nature. Furthermore, immunoelectron microscopy studies reveal that p1 has a peripheral subcellular location. By combining in vivo chemical cross-linking and cell fractionation techniques, we also demonstrate that p1 assembles in infected cells into multimeric structures that are associated with the bacterial membrane. These structures exist both during viral DNA replication and when phi29 DNA synthesis is blocked due to the lack of viral replisome components. In addition, protein p1 encoded by plasmid generates membrane-associated multimers and supports DNA replication of a p1-lacking mutant phage, suggesting that the pre-assembled structures are functional. We propose that a phage structure assembled on the cell membrane provides a specific site for phi29 DNA replication.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain.		Bravo, Alicia/Y-5060-2019; Salas, Margarita/J-9873-2014; Garcia, Pedro/L-2808-2017	Bravo, Alicia/0000-0002-4410-3584; Salas, Margarita/0000-0001-5939-3441; Garcia, Pedro/0000-0001-6717-8717; Serrano-Heras, Gemma/0000-0001-9368-4832	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01 GM27242-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Ahola T, 1999, EMBO J, V18, P3164, DOI 10.1093/emboj/18.11.3164; Angeletti PC, 1998, J VIROL, V72, P2896, DOI 10.1128/JVI.72.4.2896-2904.1998; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bravo A, 1997, J MOL BIOL, V269, P102, DOI 10.1006/jmbi.1997.1032; Bravo A, 1998, EMBO J, V17, P6096, DOI 10.1093/emboj/17.20.6096; Bravo A, 2000, EMBO J, V19, P5575, DOI 10.1093/emboj/19.20.5575; BRAVO A, 1994, MOL GEN GENET, V245, P529, DOI 10.1007/BF00282215; Bravo A, 2001, J BIOL CHEM, V276, P21250, DOI 10.1074/jbc.M011296200; Bridge E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P99; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; FREDMAN JN, 1993, J VIROL, V67, P3384, DOI 10.1128/JVI.67.6.3384-3395.1993; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; IVARIE RD, 1973, VIROLOGY, V52, P351, DOI 10.1016/0042-6822(73)90330-9; KONINGS WN, 1973, J BACTERIOL, V116, P1456, DOI 10.1128/JB.116.3.1456-1465.1973; Koppes LJH, 1999, BIOCHIMIE, V81, P803, DOI 10.1016/S0300-9084(00)87163-1; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lampio A, 2000, J BIOL CHEM, V275, P37853, DOI 10.1074/jbc.M004865200; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; Moir RD, 2000, J STRUCT BIOL, V129, P324, DOI 10.1006/jsbi.2000.4251; MORENO F, 1974, VIROLOGY, V62, P1, DOI 10.1016/0042-6822(74)90298-0; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; POMBO A, 1994, EMBO J, V13, P5075, DOI 10.1002/j.1460-2075.1994.tb06837.x; REILLY BE, 1973, J VIROL, V11, P756, DOI 10.1128/JVI.11.5.756-760.1973; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; SALAS M, 1996, DNA REPLICATION EUKA, P131; Salas Margarita, 1993, P843; Sambrook J., 1989, MOL CLONING, pA1; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; Schaad MC, 1997, EMBO J, V16, P4049, DOI 10.1093/emboj/16.13.4049; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; VERHEIJEN R, 1988, J CELL SCI, V90, P11; Yamanaka T, 2000, P NATL ACAD SCI USA, V97, P10107, DOI 10.1073/pnas.170295097; YOSHIKAWA H, 1982, GENE, V17, P323; YOUNGHUSBAND HB, 1982, J VIROL, V43, P705, DOI 10.1128/JVI.43.2.705-713.1982	44	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40771	40777		10.1074/jbc.M306935200	http://dx.doi.org/10.1074/jbc.M306935200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904294	hybrid, Green Published			2022-12-25	WOS:000185847200045
J	Smith, JL; Collins, I; Chandramouli, GVR; Butscher, WG; Zaitseva, E; Freebern, WJ; Haggerty, CM; Doseeva, V; Gardner, K				Smith, JL; Collins, I; Chandramouli, GVR; Butscher, WG; Zaitseva, E; Freebern, WJ; Haggerty, CM; Doseeva, V; Gardner, K			Targeting combinatorial transcriptional complex assembly at specific modules within the interleukin-2 promoter by the immunosuppressant SB203580	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; T-CELL ACTIVATION; P38 MAP KINASE; IL-2 GENE-EXPRESSION; C-REL; LYMPHOCYTE-PROLIFERATION; SELECTIVE-INHIBITION; HISTONE DEACETYLASE	The proximal promoter sequence of the interleukin-2 (IL-2) gene contains a series of composite sites or modules that controls much of its responsiveness to environmental stimuli. The integrated targeting of these modules is therefore a major mode of regulation. This report describes how multiple functional hierarchies, required for the recruitment of the p300 co-activator to the CD28RE/AP1 (TRE) module of the IL-2 promoter, are selectively disrupted in human T-cells by the immunosuppressive and anti-inflammatory actions of the p38 mitogen-activated protein kinase inhibitor ( MAPK), SB203580. The molecular hierarchies targeted by SB203580 include the combinatorial interaction of NF-kappaB and CREB at the CD28RE/AP1 element coupled with the subsequent dynamic co-assembly and activation of p300. Several aspects of this targeting are linked to the ability of SB203580 to inhibit p38 MAPK-controlled pathways. Together, these results provide the molecular basis through which the combinatorial structure and context of the composite elements of the IL-2 promoter dictates mitogen responsiveness and drug susceptibility that are quantitatively and qualitatively distinct from the isolated action of single consensus sequences and/or transcriptional motifs.	NCI, Ctr Adv Technol, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gardner, K (corresponding author), NCI, Ctr Adv Technol, Lab Receptor Biol & Gene Express, NIH, Rm 134C,8717 Grovemont Circle, Bethesda, MD 20892 USA.			Haggerty, Cynthia/0000-0002-6019-2724				Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Attema JL, 2002, J IMMUNOL, V169, P2466, DOI 10.4049/jimmunol.169.5.2466; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Butscher WG, 2001, J BIOL CHEM, V276, P27647, DOI 10.1074/jbc.M009614200; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chaudhry S, 2002, J IMMUNOL, V169, P6767, DOI 10.4049/jimmunol.169.12.6767; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Freebern WJ, 2003, J BIOL CHEM, V278, P2249, DOI 10.1074/jbc.M208517200; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; IHM P, 1965, METHOD INFORM MED, V4, P107; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lehner MD, 2002, J IMMUNOL, V168, P4667, DOI 10.4049/jimmunol.168.9.4667; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; Nambiar MP, 2002, J CELL BIOCHEM, V85, P459, DOI 10.1002/jcb.10160; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nebl G, 1998, J IMMUNOL, V161, P1803; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; PETRAK D, 1994, J IMMUNOL, V153, P2046; Powell JD, 1999, J IMMUNOL, V163, P6631; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; SANG N, 2003, J BIOL CHEM; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Solomou EE, 2001, J IMMUNOL, V166, P5665, DOI 10.4049/jimmunol.166.9.5665; Takahashi I, 1996, J ANTIBIOT, V49, P453, DOI 10.7164/antibiotics.49.453; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tenbrock K, 2003, J IMMUNOL, V170, P2971, DOI 10.4049/jimmunol.170.6.2971; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Ward SG, 1997, BIOCHEM SOC T, V25, pS304, DOI 10.1042/bst025304s; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wyrick JJ, 2002, CURR OPIN GENET DEV, V12, P130, DOI 10.1016/S0959-437X(02)00277-0; Yasui H, 1997, J BIOL CHEM, V272, P28762, DOI 10.1074/jbc.272.45.28762; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu CT, 2002, MOL CELL BIOL, V22, P4556, DOI 10.1128/MCB.22.13.4556-4566.2002; Yu CT, 2001, J IMMUNOL, V166, P284, DOI 10.4049/jimmunol.166.1.284; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	86	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41034	41046		10.1074/jbc.M305615200	http://dx.doi.org/10.1074/jbc.M305615200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896977	hybrid			2022-12-25	WOS:000185847200078
J	Suliman, HB; Carraway, MS; Welty-Wolf, KE; Whorton, AR; Piantadosi, CA				Suliman, HB; Carraway, MS; Welty-Wolf, KE; Whorton, AR; Piantadosi, CA			Lipopolysaccharide stimulates mitochondrial biogenesis via activation of nuclear respiratory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR-A; KAPPA-B ACTIVATION; REACTIVE OXYGEN; FACTOR-ALPHA; LIVER-MITOCHONDRIA; REDOX REGULATION; MAMMALIAN-CELLS; GENE-EXPRESSION; GROWTH-FACTOR	Exposure to bacterial lipopolysaccharide (LPS) in vivo damages mitochondrial DNA ( mtDNA) and interferes with mitochondrial transcription and oxidative phosphorylation (OXPHOS). Because this damage accompanies oxidative stress and is reversible, we postulated that LPS stimulates mtDNA replication and mitochondrial biogenesis via expression of factors responsive to reactive oxygen species, i.e. nuclear respiratory factor-1 (NRF-1) and mitochondrial transcription factor-A. In testing this hypothesis in rat liver, we found that LPS induces NRF-1 protein expression and activity accompanied by mRNA expression for mitochondrial transcription factor-A, mtDNA polymerase gamma, NRF-2, and single-stranded DNA-binding protein. These events restored the loss in mtDNA copy number and OXPHOS gene expression caused by LPS and increased hepatocyte mitotic index, nuclear cyclin D1 translocation, and phosphorylation of pro-survival kinase, Akt. Thus, NRF-1 was implicated in oxidant-mediated mitochondrial biogenesis to provide OXPHOS for proliferation. This implication was tested in novel mtDNA-deficient cells generated from rat hepatoma cells that overexpress NRF-1. Depletion of mtDNA (rho(o) clones) diminished oxidant production and caused loss of NRF-1 expression and growth delay. NRF-1 expression and growth were restored by exogenous oxidant exposure indicating that oxidative stress stimulates biogenesis in part via NRF-1 activation and corresponding to recovery events after LPS-induced liver damage.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Piantadosi, CA (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3315,Rm 0590,CRII Bldg, Durham, NC 27710 USA.							Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Arai T, 1998, BIOCHEM J, V331, P853, DOI 10.1042/bj3310853; ASUNCION JG, 1996, FASEB J, V10, P333; Au HC, 1998, EUR J BIOCHEM, V251, P164, DOI 10.1046/j.1432-1327.1998.2510164.x; BEYER HS, 1990, BIOCHEM INT, V22, P405; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Cunningham PN, 2002, J IMMUNOL, V168, P5817, DOI 10.4049/jimmunol.168.11.5817; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Enriquez JA, 1999, MOL CELL BIOL, V19, P657; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FAIRMAN MP, 1990, J CELL SCI, V95, P1; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Gao CH, 1999, HEPATOLOGY, V30, P1405, DOI 10.1002/hep.510300602; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kantrow SP, 1997, ARCH BIOCHEM BIOPHYS, V345, P278, DOI 10.1006/abbi.1997.0264; Kato A, 1998, BIOCHEM BIOPH RES CO, V245, P70, DOI 10.1006/bbrc.1998.8377; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kinnula VL, 1998, CANCER LETT, V125, P191, DOI 10.1016/S0304-3835(97)00511-9; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603; LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Moraes CT, 1999, MOL BIOL CELL, V10, P3345, DOI 10.1091/mbc.10.10.3345; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; Ozes ON, 1999, NATURE, V401, P82; PARAIDATHATHU T, 1992, FREE RADICAL BIO MED, V13, P289, DOI 10.1016/0891-5849(92)90176-H; Ramljak D, 2000, CARCINOGENESIS, V21, P1537, DOI 10.1093/carcin/21.8.1537; ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SIMONSON SG, 1994, CIRC SHOCK, V43, P34; Suliman HB, 2002, FREE RADICAL BIO MED, V32, P246, DOI 10.1016/S0891-5849(01)00797-3; Suliman HB, 2003, AM J RESP CRIT CARE, V167, P570, DOI 10.1164/rccm.200206-518OC; Suliman HB, 1996, GENE, V171, P275, DOI 10.1016/0378-1119(95)00895-0; Taylor DE, 1998, AM J PHYSIOL-LUNG C, V275, pL139, DOI 10.1152/ajplung.1998.275.1.L139; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Turpaev KT, 2002, BIOCHEMISTRY-MOSCOW+, V67, P281, DOI 10.1023/A:1014819832003; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WIESNER RJ, 1994, AM J PHYSIOL, V267, pC229, DOI 10.1152/ajpcell.1994.267.1.C229; WOLF HK, 1992, HEPATOLOGY, V15, P707, DOI 10.1002/hep.1840150426; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	58	144	156	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41510	41518		10.1074/jbc.M304719200	http://dx.doi.org/10.1074/jbc.M304719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902348	hybrid			2022-12-25	WOS:000185847200131
J	Tatsumi, Y; Ohta, S; Kimura, H; Tsurimoto, T; Obuse, C				Tatsumi, Y; Ohta, S; Kimura, H; Tsurimoto, T; Obuse, C			The ORC1 cycle in human cells - I. Cell cycle-regulated oscillation of human ORC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; MCM PROTEINS; S-PHASE; FISSION YEAST; CHROMATIN; ASSOCIATION; INITIATION; XENOPUS	Components of ORC ( the origin recognition complex) are highly conserved among eukaryotes and are thought to play an essential role in the initiation of DNA replication. The level of the largest subunit of human ORC (ORC1) during the cell cycle was studied in several human cell lines with a specific antibody. In all cell lines, ORC1 levels oscillate: ORC1 starts to accumulate in mid-G(1) phase, reaches a peak at the G(1)/S boundary, and decreases to a basal level in S phase. In contrast, the levels of other ORC subunits (ORCs 2 - 5) remain constant throughout the cell cycle. The oscillation of ORC1, or the ORC1 cycle, also occurs in cells expressing ORC1 ectopically from a constitutive promoter. Furthermore, the 26 S proteasome inhibitor MG132 blocks the decrease in ORC1, suggesting that the ORC1 cycle is mainly due to 26 S proteasome- dependent degradation. Arrest of the cell cycle in early S phase by hydroxyurea, aphidicolin, or thymidine treatment is associated with basal levels of ORC1, indicating that ORC1 proteolysis starts in early S phase and is independent of S phase progression. These observations indicate that the ORC1 cycle in human cells is highly linked with cell cycle progression, allowing the initiation of replication to be coordinated with the cell cycle and preventing origins from refiring.	Nara Inst Sci & Technol, Nara 6300101, Japan; Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138510, Japan	Nara Institute of Science & Technology; Tokyo Medical & Dental University (TMDU)	Obuse, C (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068502, Japan.		Kimura, Hiroshi/B-9524-2015; Obuse, Chikashi/F-5273-2011	Kimura, Hiroshi/0000-0003-0854-083X; Tsurimoto, Toshiki/0000-0001-7597-2216; Tatsumi, Yasutoshi/0000-0003-2646-7410				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; DEPAMPHILIS ML, 2003, GENE, V22, P1; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Fujita M, 1998, GENES CELLS, V3, P737, DOI 10.1046/j.1365-2443.1998.00226.x; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Hori Y, 1996, MOL BIOL CELL, V7, P409, DOI 10.1091/mbc.7.3.409; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lygerou Z, 1999, J CELL SCI, V112, P3703; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Ohta S, 2003, J BIOL CHEM, V278, P41535, DOI 10.1074/jbc.M307535200; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Romanowski P, 2000, J BIOL CHEM, V275, P4239, DOI 10.1074/jbc.275.6.4239; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sun WH, 2002, EMBO J, V21, P1437, DOI 10.1093/emboj/21.6.1437; Tadokoro R, 2002, J BIOL CHEM, V277, P15881, DOI 10.1074/jbc.M200322200; Takahashi T, 2003, EMBO J, V22, P964, DOI 10.1093/emboj/cdg079; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200	40	81	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41528	41534		10.1074/jbc.M307534200	http://dx.doi.org/10.1074/jbc.M307534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909627	hybrid			2022-12-25	WOS:000185847200133
J	Duval, DL; Jean, A; Gutierrez-Hartmann, A				Duval, DL; Jean, A; Gutierrez-Hartmann, A			Ras signaling and transcriptional synergy at a flexible Ets-1/Pit-1 composite DNA element is defined by the assembly of selective activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN PROMOTER; HOMEODOMAIN FACTOR; GENE-EXPRESSION; BINDING-SITES; MURINE ETS-1; FACTOR GHF-1; PIT-1; PROTEINS; BETA; PHOSPHORYLATION	Pit-1 and Ets-1 binding to a composite element synergistically activates and targets Ras-mitogen-activated protein kinase signaling to the rat prolactin promoter. These transcriptional responses appear to depend on three molecular features: organization of the Ets-1/Pit-1 composite element, physical interaction of these two factors via the Pit-1 homeodomain (amino acids 199 291) and the Ets-1 regulatory III domain (amino acids 190-257), and assembly of their transcriptional activation domains (TADs). Here we show that the organization of the Ets-1/Pit-1 composite element tolerates significant flexibility with regard to Ras stimulation and synergy. Specifically, the putative monomeric Pit-1 binding site can be substituted with bona fide binding sites for either a Pit-1 monomer or dimer, and these sites tolerated a separation of 28 bp. Additionally, we show that the physical interaction of Ets-1 and Pit-1 is not required for Ras responsiveness or synergy because block mutations of the Pit-1 interaction surface in Ets-1, which reduced Ets-1/Pit-1 binding in vitro, did not significantly affect Ets-1 stimulation of Ras responsiveness or synergy. We also show differential use of distinct TAD subtypes and Pit-1 TAD subregions to mediate either synergy or Ras responsiveness. Specifically, TADs from Gal4, VP16, or Ets-2 regulatory III domain linked to Ets-1 DNA binding domain constructs restored synergy to these TAD/Ets-1 DNA binding domain fusions. Conversely, deletion of the defined Pit-1 TAD (amino acids 2-80) retained synergy, but not Ras responsiveness. Consequently, we further defined the Pit-1 amino-terminal TAD into region 1 (R1, amino acids 2-45) and region 2 (R2, amino acids 46-80). R1 appears to regulate basal and synergistic responses, whereas the Ras response was mapped to R2. In summary, Ras responsiveness and Pit-1/Ets-1 synergy are mediated through the assembly of distinct TADs at a flexible composite element, indicating that different mechanisms underlie these two transcriptional responses and that the Pit-1 R2 subregion represents a novel, tissue-specific Ras-responsive TAD.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Duval, DL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011		NIDDK NIH HHS [DK46868, DK02946, K01 DK002946] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046868, R01DK046868, K01DK002946] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Augustijn KD, 2002, P NATL ACAD SCI USA, V99, P12657, DOI 10.1073/pnas.192693499; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; Budworth PR, 1997, MOL ENDOCRINOL, V11, P1669, DOI 10.1210/me.11.11.1669; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; CONRAD KE, 1992, ONCOGENE, V7, P1279; Courey AJ, 2001, CURR BIOL, V11, pR250, DOI 10.1016/S0960-9822(01)00130-0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diamond SE, 1996, J BIOL CHEM, V271, P28925, DOI 10.1074/jbc.271.46.28925; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Farrow KN, 1996, J BIOL CHEM, V271, P17139, DOI 10.1074/jbc.271.29.17139; GALANG CK, 1994, ONCOGENE, V9, P2913; Gordon DF, 2002, MOL CELL ENDOCRINOL, V196, P53, DOI 10.1016/S0303-7207(02)00223-X; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; Kel-Margoulis OV, 2002, NUCLEIC ACIDS RES, V30, P332, DOI 10.1093/nar/30.1.332; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kishimoto M, 2002, J BIOL CHEM, V277, P45141, DOI 10.1074/jbc.M202991200; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; NOWAKOWSKI BE, 1994, MOL ENDOCRINOL, V8, P1742, DOI 10.1210/me.8.12.1742; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Remenyi A, 2002, BIOCHEM PHARMACOL, V64, P979, DOI 10.1016/S0006-2952(02)01164-4; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P251; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270	48	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39684	39696		10.1074/jbc.M302433200	http://dx.doi.org/10.1074/jbc.M302433200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902343	hybrid			2022-12-25	WOS:000185713800054
J	Fenton, MS; Gralla, JD				Fenton, MS; Gralla, JD			Roles for inhibitory interactions in the use of the-10 promoter element by sigma 70 holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; AROMATIC-AMINO-ACIDS; SINGLE-STRANDED-DNA; NONTEMPLATE STRAND; CONSERVED REGION-2; BACILLUS-SUBTILIS; OPEN COMPLEX; RECOGNITION; BINDING; TRANSCRIPTION	A panel of seven -10 region DNA mutants was tested for holoenzyme binding against a panel of 13 region 2 mutants of sigma70. No patterns were noticed that would indicate unique interactions between individual amino acids and individual -10 region bases. Instead, certain amino acid substitutions led to increased holoenzyme binding to DNA, implying that the wild type interactions are associated with an inhibitory component. These inhibitory interactions were stronger on DNA containing non-consensus sequences, like those of typical promoters. In addition, the DNA segment downstream from the -10 element was also inhibitory to binding when in duplex form but stimulated binding when in single strand form. Overall, the data suggest that -10 region duplex recognition and melting have a large component of overcoming unfavorable protein: DNA base interactions, particularly when the bases are non-consensus, and that this contributes to setting physiologically appropriate variations in transcription rate.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buckle M, 1999, J MOL BIOL, V285, P955, DOI 10.1006/jmbi.1998.2391; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Fenton MS, 2001, P NATL ACAD SCI USA, V98, P9020, DOI 10.1073/pnas.161085798; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Fenton MS, 2003, NUCLEIC ACIDS RES, V31, P2745, DOI 10.1093/nar/gkg400; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GOPAL V, 1994, J MOL BIOL, V242, P9, DOI 10.1006/jmbi.1994.1553; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; Lee SJ, 2003, J MOL BIOL, V329, P941, DOI 10.1016/S0022-2836(03)00369-3; Lee SJ, 2002, J BIOL CHEM, V277, P47420, DOI 10.1074/jbc.M208363200; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MEIKLEJOHN AL, 1989, J MOL BIOL, V207, P661, DOI 10.1016/0022-2836(89)90236-2; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; STEFANO JE, 1980, J BIOL CHEM, V255, P423; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; Wang L, 1999, J BACTERIOL, V181, P7558, DOI 10.1128/JB.181.24.7558-7565.1999; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; ZILLIG W, 1971, COLD SPRING HARB SYM, V35, P47	32	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39669	39674		10.1074/jbc.M307412200	http://dx.doi.org/10.1074/jbc.M307412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902332	hybrid			2022-12-25	WOS:000185713800052
J	Gitan, RS; Shababi, M; Kramer, M; Eide, DJ				Gitan, RS; Shababi, M; Kramer, M; Eide, DJ			A cytosolic domain of the yeast Zrt1 zinc transporter is required for its post-translational inactivation in response to zinc and cadmium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DEPENDENT PHOSPHORYLATION; A-FACTOR RECEPTOR; SACCHAROMYCES-CEREVISIAE; URACIL PERMEASE; UBIQUITIN CONJUGATION; VACUOLAR DEGRADATION; MALTOSE PERMEASE; GENE ENCODES; ENDOCYTOSIS; PROTEIN	Nutrient metals such as zinc are both essential to life and potentially toxic if overaccumulated by cells. Nonessential toxic metals like cadmium can enter cells through the uptake transporters responsible for nutrient metal acquisition. Therefore, in the face of ever changing extracellular metal levels, organisms tightly control their intracellular levels of nutrient metals and prevent accumulation of toxic metals. We show here that post-translational inactivation of the yeast Zrt1 zinc uptake transporter is important for zinc homeostasis. During the transition from zinc-limiting to zinc-replete growth conditions (i.e. zinc shock), the Zrt1 transporter is ubiquitinated, endocytosed, and subsequently degraded in the vacuole. To further understand this process at a molecular level, we mapped a region of Zrt1 required for ubiquitination and endocytosis in response to zinc to a domain located on the intracellular surface of the plasma membrane. This domain is a critical cis-acting component of the metal signaling pathway that controls Zrt1 protein trafficking. Using mutant alleles defective for metal-responsive inactivation, we also show that Zrt1 inactivation may be an important mechanism for preventing cadmium uptake and toxicity in zinc-limited cells.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Colwell R R, 2000, J Infect Chemother, V6, P121, DOI 10.1007/PL00012151; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; EIDE D, 1992, J BIOL CHEM, V267, P20774; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Gomes DS, 2002, BBA-GEN SUBJECTS, V1573, P21, DOI 10.1016/S0304-4165(02)00324-0; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Koch AL, 1997, MICROBIOL MOL BIOL R, V61, P305, DOI 10.1128/.61.3.305-318.1997; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Mason B., 1982, PRINCIPLES GEOCHEMIS; Medintz I, 1998, J BIOL CHEM, V273, P34454, DOI 10.1074/jbc.273.51.34454; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sherman F., 1986, METHODS YEAST GENETI; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WERTMAN KF, 1992, GENETICS, V132, P337; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	37	60	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39558	39564		10.1074/jbc.M302760200	http://dx.doi.org/10.1074/jbc.M302760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893829	hybrid			2022-12-25	WOS:000185713800037
J	Kanaji, S; Kanaji, T; Furihata, K; Kato, K; Ware, JL; Kunicki, TJ				Kanaji, S; Kanaji, T; Furihata, K; Kato, K; Ware, JL; Kunicki, TJ			Convulxin binds to native, human glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; RECEPTOR-GAMMA-CHAIN; C-TYPE LECTIN; PLATELET-AGGREGATING PROTEIN; IX-V COMPLEX; ALPHA(2)BETA(1) INTEGRIN; ACTIVATES PLATELETS; TYROSINE SULFATION; COLLAGEN; VENOM	Convulxin (CVX), a C-type snake protein from Crotalus durissus terrificus venom, is the quintessential agonist for studies of the collagen receptor, glycoprotein VI ( GPVI) and its role in platelet adhesion to collagens. In this study, CVX, purified from venom, behaves as expected, i.e. it binds to platelet GPVI and recombinant human GPVI, induces platelet aggregation and platelet prothrombinase activity, and binds uniquely to GPVI in ligand blots of SDS-denatured proteins. Nonetheless, we find that CVX has a dual specificity for both GPVI and native but not denatured human GPIbalpha. First, CVX binds to human GPIbalpha expressed on the surface of CHO cells. Second, CVX binds weakly to murine platelet GPIbalpha but more strongly to human platelet GPIbalpha, as evidenced by comparative binding to wild-type, GPVI(-/-), FcRgamma (-/-), and human GPIb transgenic mice. Third, the binding of CVX to human GPIbalpha is inhibited by soluble, recombinant human GPVI. Fourth, CVX binding to GPIbalpha is disrupted by phenylalanine substitutions at GPIbalpha tyrosine-276, tyrosine-278, and tyrosine-279, which also disrupts von Willebrand factor and alpha-thrombin binding to GPIbalpha. Fifth, CVX binding to GPIbalpha on Chinese hamster ovary cell transfectants is inhibited by function-blocking murine monoclonal anti-GPIbalpha antibodies. Lastly, CVX fails to bind to denatured GPIbalpha in detergent extracts of platelets. Three separate preparations of CVX (two purified by the authors; one obtained commercially) produced equivalent results. These results indicate that CVX exhibits dual specificity for both native GPIbalpha and GPVI. Furthermore, the binding site on GPIbalpha for CVX may be close to that for von Willebrand factor. Therefore, a contribution of GPIbalpha to CVX-induced platelet responses needs to be carefully re-evaluated.	Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA	Scripps Research Institute	Kunicki, TJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, 10550 N Torrey Pines Rd,Maildrop MEM150, La Jolla, CA 92037 USA.	tomk@scripps.edu	Kanaji, Taisuke/AAN-1458-2021	Kanaji, Taisuke/0000-0002-3588-6038	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050545, R01HL046979] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050545, HL50545, R01 HL050545-12, HL46979] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews RK, 2001, HAEMOSTASIS, V31, P155; Bergmeier W, 2001, J BIOL CHEM, V276, P25121, DOI 10.1074/jbc.M103892200; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Du XY, 2002, THROMB HAEMOSTASIS, V87, P692, DOI 10.1055/s-0037-1613067; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Furihata K, 2001, ARTERIOSCL THROM VAS, V21, P1857, DOI 10.1161/hq1001.096643; Goto S, 1998, J CLIN INVEST, V101, P479, DOI 10.1172/JCI973; HANDA M, 1986, J BIOL CHEM, V261, P2579; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; Leduc M, 1998, BIOCHEM J, V333, P389, DOI 10.1042/bj3330389; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Niedergang F, 2000, BIOCHEM BIOPH RES CO, V273, P246, DOI 10.1006/bbrc.2000.2940; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; TENG CM, 1993, THROMB HAEMOSTASIS, V69, P286; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Ware J, 1997, BLOOD CELL MOL DIS, V23, P292, DOI 10.1006/bcmd.1997.0146; Ware J, 2000, P NATL ACAD SCI USA, V97, P2803, DOI 10.1073/pnas.050582097; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836	27	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39452	39460		10.1074/jbc.M300199200	http://dx.doi.org/10.1074/jbc.M300199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881531	hybrid			2022-12-25	WOS:000185713800023
J	Kowanetz, K; Szymkiewicz, I; Haglund, K; Kowanetz, M; Husnjak, K; Taylor, JD; Soubeyran, P; Engstrom, U; Ladbury, JE; Dikic, I				Kowanetz, K; Szymkiewicz, I; Haglund, K; Kowanetz, M; Husnjak, K; Taylor, JD; Soubeyran, P; Engstrom, U; Ladbury, JE; Dikic, I			Identification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; SH3 DOMAIN; C-CBL; BINDING MOTIF; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; LIGAND; CIN85; WW	CIN85 is a multidomain adaptor protein implicated in Cbl-mediated down-regulation of receptor tyrosine kinases. CIN85 binding to Cbl is increased after growth factor stimulation and is critical for targeting receptor tyrosine kinases to clathrin-mediated endocytosis. Here we report the identification of a novel polyproline-arginine motif (PXXXPR), specifically recognized by the SH3 domains of CIN85 and its homologue CMS/CD2AP. This motif was indispensable for CIN85 binding to Cbl/Cbl-b, to other CIN85 SH3 domains' effectors, and for mediating an intramolecular interaction between the SH3-A domain and the proline-rich region of CIN85. Individual SH3 domains of CIN85 bound to PXXXPR peptides of Cbl/Cbl-b with micromolar affinities, whereas an extended structure of two or three SH3 domains bound with higher stoichiometry and increased affinity to the same peptides. This enabled full size CIN85 to simultaneously interact with multiple Cbl molecules, promoting their clustering in mammalian cells. The ability of CIN85 to cluster Cbl was important for ligand-induced stabilization of CIN85.Cbl.epidermal growth factor receptor complexes, as well as for epidermal growth factor receptor degradation in the lysosome. Thus, specific interactions of CIN85 SH3 domains with the PXXXPR motif in Cbl play multiple roles in down-regulation of receptor tyrosine kinases.	Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Rudjer Boskovic Inst, Div Mol Med, Zagreb 10000, Croatia; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Goethe University Frankfurt; Ludwig Institute for Cancer Research; Rudjer Boskovic Institute; University of London; University College London	Dikic, I (corresponding author), Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Ivan.Dikic@biochem2.de	Pilecka, Iwona/AAT-9114-2021; Soubeyran, Philippe/P-1758-2018; Haglund, Kaisa/B-3927-2017; Taylor, Jonathan/A-1416-2013; Dikic, Ivan/O-4650-2015; Husnjak, Koraljka/C-3717-2015; Soubeyran, Pierre-Louis/F-4523-2012	Pilecka, Iwona/0000-0002-5057-346X; Haglund, Kaisa/0000-0002-7946-3299; Taylor, Jonathan/0000-0003-0119-433X; Dikic, Ivan/0000-0001-8156-9511; Husnjak, Koraljka/0000-0003-0573-6239; Soubeyran, Pierre-Louis/0000-0003-3244-7299; Taylor, Jonathan/0000-0002-9797-3989; Soubeyran, Philippe/0000-0002-5876-3217; Ladbury, John/0000-0002-6328-7200				Bogler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; de Melker AA, 2001, J CELL SCI, V114, P2167; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mayer BJ, 2001, J CELL SCI, V114, P1253; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; O'Brien R, 1998, J MOL BIOL, V279, P117, DOI 10.1006/jmbi.1998.1743; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Tibaldi EV, 2003, INT IMMUNOL, V15, P313, DOI 10.1093/intimm/dxg032; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2	44	102	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39735	39746		10.1074/jbc.M304541200	http://dx.doi.org/10.1074/jbc.M304541200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874286	hybrid			2022-12-25	WOS:000185713800059
J	Sharpe, IA; Palant, E; Schroeder, CI; Kaye, DM; Adams, DJ; Alewood, PF; Lewis, RJ				Sharpe, IA; Palant, E; Schroeder, CI; Kaye, DM; Adams, DJ; Alewood, PF; Lewis, RJ			Inhibition of the norepinephrine transporter by the venom peptide x-MrIA - Site of action, Na+ dependence, and structure-activity relationship	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NORADRENALINE CARRIER; BIOGENIC-AMINE TRANSPORTERS; DOPAMINE TRANSPORTER; MOLECULAR-CLONING; NMR-SPECTROSCOPY; OMEGA-CONOTOXINS; RAT; EXPRESSION; BINDING; CELLS	chi-Conopeptide MrIA (chi-MrIA) is a 13-residue peptide contained in the venom of the predatory marine snail Conus marmoreus that has been found to inhibit the norepinephrine transporter (NET). We investigated whether chi-MrIA targeted the other members of the monoamine transporter family and found no effect of the peptide (100 muM) on the activity of the dopamine transporter and the serotonin transporter, indicating a high specificity of action. The binding of the NET inhibitors, [H-3] nisoxetine and [H-3] mazindol, to the expressed rat and human NET was inhibited by chi-MrIA with the conopeptide displaying a slight preference toward the rat isoform. For both radioligands, saturation binding studies showed that the inhibition by chi-MrIA was competitive in nature. It has previously been demonstrated that chi-MrIA does not compete with norepinephrine, unlike classically described NET inhibitors such as nisoxetine and mazindol that do. This pattern of behavior implies that the binding site for chi-MrIA on the NET overlaps the antidepressant binding site and is wholly distinct from the substrate binding site. The inhibitory effect of chi-MrIA was found to be dependent on Na+ with the conopeptide becoming a less effective blocker of [H-3] norepinephrine by the NET under the conditions of reduced extracellular Na+. In this respect, chi-MrIA is similar to the antidepressant inhibitors of the NET. The structure-activity relationship of chi-MrIA was investigated by alanine scanning. Four residues in the first cysteine-bracketed loop of chi-MrIA and a His in loop 2 played a dominant role in the interaction between chi-MrIA and the NET. Halpha chemical shift comparisons indicated that side-chain interactions at these key positions were structurally perturbed by the replacement of Gly-6. From these data, we present a model of the structure of chi-MrIA that shows the relative orientation of the key binding residues. This model provides a new molecular caliper for probing the structure of the NET.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Xenome Ltd, Indooroopilly, Qld 4068, Australia; Baker Heart Res Inst, Prahran, Vic 3181, Australia	University of Queensland; University of Queensland; Baker Heart and Diabetes Institute	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Schroeder, Cristina I./K-2042-2014; Lewis, Richard J/E-8674-2013; Lewis, Richard/T-8763-2019; Kaye, David/AAF-1202-2021; Adams, David/J-9125-2014; Adams, David John/K-3578-2019	Schroeder, Cristina I./0000-0002-6737-6374; Lewis, Richard J/0000-0003-3470-923X; Lewis, Richard/0000-0003-3470-923X; Adams, David/0000-0002-7030-2288; Adams, David John/0000-0002-7030-2288; Kaye, David/0000-0003-4058-0372				*ACC INC, 2001, INS 2 MOD ENV VERS 9; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BONISCH H, 1994, ANN NY ACAD SCI, V733, P193, DOI 10.1111/j.1749-6632.1994.tb17269.x; Bonisch H, 1999, J AUTON PHARMACOL, V19, P327; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bruss M, 1997, MOL BRAIN RES, V52, P257, DOI 10.1016/S0169-328X(97)00267-2; Bryan-Lluka LJ, 2003, J BIOL CHEM, V278, P40324, DOI 10.1074/jbc.M213101200; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; Burgess KSD, 1999, J NEUROCHEM, V73, P656, DOI 10.1046/j.1471-4159.1999.0730656.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Eisenhofer G, 1996, CIRCULATION, V93, P1667, DOI 10.1161/01.CIR.93.9.1667; Eshleman AJ, 1999, J PHARMACOL EXP THER, V289, P877; FRIEDRICH U, 1986, N-S ARCH PHARMACOL, V333, P246, DOI 10.1007/BF00512937; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; GIROS B, 1992, MOL PHARMACOL, V42, P383; GRAEFE KH, 1988, HDB EXP PHARM, V90, P193; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Klimek V, 1997, J NEUROSCI, V17, P8451; KOPPEL G, 1995, CHEM BIOL, V2, P483, DOI 10.1016/1074-5521(95)90265-1; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEEDHAM JA, 1985, ARCH INT PHARMACOD T, V277, P39; Lewis RJ, 2000, J BIOL CHEM, V275, P35335, DOI 10.1074/jbc.M002252200; MACK F, 1979, N-S ARCH PHARMACOL, V310, P1, DOI 10.1007/BF00499868; McIntosh JM, 2000, J BIOL CHEM, V275, P32391, DOI 10.1074/jbc.M003619200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen KJ, 1999, J MED CHEM, V42, P415, DOI 10.1021/jm981052q; Nielsen KJ, 2000, J MOL RECOGNIT, V13, P55, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O; NIELSON C, 2002, 10 WORLD C PAIN SAN, P278; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Paczkowski FA, 2001, MOL BRAIN RES, V97, P32, DOI 10.1016/S0169-328X(01)00295-9; Paczkowski FA, 2002, N-S ARCH PHARMACOL, V365, P312, DOI 10.1007/s00210-002-0528-z; Paczkowski FA, 1999, J PHARMACOL EXP THER, V290, P761; Percy E, 1999, BRIT J PHARMACOL, V128, P774, DOI 10.1038/sj.bjp.0702831; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Rothman RB, 1999, SYNAPSE, V33, P239, DOI 10.1002/(SICI)1098-2396(19990901)33:3<239::AID-SYN8>3.0.CO;2-R; Roubert C, 2001, J BIOL CHEM, V276, P8254, DOI 10.1074/jbc.M009798200; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SCHOMIG E, 1988, N-S ARCH PHARMACOL, V337, P626; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; SILVERTHORN ML, 1995, J PHARMACOL EXP THER, V273, P213; Singer A, 1999, J PHARMACOL EXP THER, V290, P1363; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Sucic S, 2002, MOL BRAIN RES, V108, P40, DOI 10.1016/S0169-328X(02)00512-0; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZEITNER CJ, 1986, N-S ARCH PHARMACOL, V334, P397, DOI 10.1007/BF00569377	53	63	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40317	40323		10.1074/jbc.M213030200	http://dx.doi.org/10.1074/jbc.M213030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885787	Green Submitted, hybrid			2022-12-25	WOS:000185713800124
J	Sheng, ST; Gao, Y; Khromov, AS; Somlyo, AV; Somlyo, AP; Shao, ZF				Sheng, ST; Gao, Y; Khromov, AS; Somlyo, AV; Somlyo, AP; Shao, ZF			Cryo-atomic force microscopy of unphosphorylated and thiophosphorylated single smooth muscle myosin molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; PHOSPHORYLATION-DEPENDENT REGULATION; HEAVY-MEROMYOSIN; IMAGE-RECONSTRUCTION; 2-HEADED STRUCTURE; SCALLOP MYOSIN; CROSS-BRIDGES; MOTOR DOMAIN; 2 HEADS; ACTIN	The purpose of this study was to determine whether steric blockage of one head by the second head of native two-headed myosin was responsible for the inactivity of nonphosphorylated two-headed myosin compared with the high activity of single-headed myosin, as suggested on the basis of electron microscopy of two-dimensional crystals of heavy meromyosin (Wendt, T., Taylor, D., Messier, T., Trybus, K. M., and Taylor, K. A. (1999) J. Cell Biol. 147, 1385-1390; and Wendt, T., Taylor, D., Trybus, K. M., and Taylor, K. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 4361-4366). Our earlier cryo-atomic force microscopy (cryo-AFM) (Zhang, Y., Shao, Z., Somlyo, A. P., and Somlyo, A. V. (1997) Biophys. J. 72, 1308-1318) indicates that thiophosphorylation of the regulatory light chain increases the separation of the two heads of a single myosin molecule, but the thermodynamic probability of steric hindrance by strong binding between the two heads was not determined. We now report this probability determined by cryo-AFM of single whole myosin molecules shown to have normal low ATPase activity (0.007 s(-1)). We found that the thermodynamic probability of the relative head positions of nonphosphorylated myosin was approximately equal between separated heads as compared with closely apposed heads (energy difference of 0.24 kT (where k is a Boltzman constant and T is the absolute temperature)), and thiophosphorylation increased the number of molecules having separated heads (energy advantage of -1.2 kT (where k is a Boltzman constant and I is the absolute temperature)). Our results do not support the suggestion that strong binding of one head to the other stabilizes the blocked conformation against thermal fluctuations resulting in steric blockage that can account for the low activity of nonphosphorylated two-headed myosin.	Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Shao, ZF (corresponding author), Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, POB 800736,Jordan Hall, Charlottesville, VA 22908 USA.	zs9q@virginia.edu	Shao, Zhifeng/B-6075-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002017] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48807] Funding Source: Medline; NIBIB NIH HHS [EB002017] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Baker JE, 2002, BIOPHYS J, V82, P2134, DOI 10.1016/S0006-3495(02)75560-4; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DREW JS, 1993, CELL MOTIL CYTOSKEL, V26, P291, DOI 10.1002/cm.970260404; Ellison PA, 2003, J BIOL CHEM, V278, P4410, DOI 10.1074/jbc.M211016200; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; HAN WH, 1995, BIOCHEMISTRY-US, V34, P8215, DOI 10.1021/bi00026a001; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; IKEBE M, 1986, J BIOL CHEM, V261, P8249; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; Katoh T, 1996, J BIOL CHEM, V271, P9992, DOI 10.1074/jbc.271.17.9992; Khromov AS, 1998, J PHYSIOL-LONDON, V512, P345, DOI 10.1111/j.1469-7793.1998.345be.x; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P17810, DOI 10.1021/bi981656w; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Liu J, 2003, J MOL BIOL, V329, P963, DOI 10.1016/S0022-2836(03)00516-3; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Matthew JD, 1998, J BIOL CHEM, V273, P31289, DOI 10.1074/jbc.273.47.31289; MOU JX, 1993, REV SCI INSTRUM, V64, P1483, DOI 10.1063/1.1144454; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; Sheng ST, 1998, JPN J APPL PHYS 1, V37, P3828, DOI 10.1143/JJAP.37.3828; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; TRYBUS KM, 1991, J CELL SCI, P87; Wahlstrom JL, 2003, J BIOL CHEM, V278, P5123, DOI 10.1074/jbc.M206963200; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; Wu XD, 1999, J BIOL CHEM, V274, P20328, DOI 10.1074/jbc.274.29.20328; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Zhang YY, 1997, BIOPHYS J, V72, P1308, DOI 10.1016/S0006-3495(97)78777-0; Zhang YY, 1996, BIOPHYS J, V71, P2168, DOI 10.1016/S0006-3495(96)79418-3	42	23	23	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39892	39896		10.1074/jbc.M306094200	http://dx.doi.org/10.1074/jbc.M306094200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12907680	hybrid			2022-12-25	WOS:000185713800076
J	Zhu, C; Rao, K; Xiong, HB; Gagnidze, K; Li, FL; Horvath, C; Plevy, S				Zhu, C; Rao, K; Xiong, HB; Gagnidze, K; Li, FL; Horvath, C; Plevy, S			Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; CELLULAR PHOSPHATASE CALCINEURIN; INTERFERON REGULATORY FACTORS; GENE PROMOTER; IFN-GAMMA; TRANSCRIPTIONAL ACTIVATION; PERITONEAL-MACROPHAGES; MONOCYTIC CELLS; FACTOR-I; T-CELLS	Interleukin (IL)-12 is a heterodimeric cytokine that is critical for the development of a T-helper-1 immune response and immunity against intracellular pathogens. The IL-12 p40 gene product, expressed specifically in macrophages and dendritic cells, heterodimerizes with p35 to form bioactive IL-12, and heterodimerizes with p19 to comprise the cytokine IL-23. Regulation of the murine IL-12 p40 promoter is complex. Multiple cis-acting elements have been characterized that are involved in activation by bacterial products. However, molecular mechanisms through which interferon (IFN)-gamma and bacterial products synergistically activate IL-12 p40 gene expression are less clear. In this study, a composite NFAT/ICSBP binding site at -68 to -54 is identified that is functionally important for p40 promoter activation by lipopolysaccharide (LPS) and LPS plus IFN-gamma. DNA binding of NFAT and ICSBP is demonstrated on the endogenous promoter by chromatin immunoprecipitation. NFAT is required for ICSBP binding to this region. Overexpression of NFAT and ICSBP synergistically activates the p40 promoter. A dominant negative NFAT molecule attenuates LPS- and IFN-gamma-activated endogenous IL-12 p40 mRNA expression. A physical association between NFAT and ICSBP in the absence of DNA is detected by co-immunoprecipitation of endogenous proteins. Three NFAT domains are required for ICSBP interaction. Finally, in LPS- and IFN-gamma-activated RAW-264.7 cells, the association between NFAT and ICSBP is abrogated by IL-10 priming.	Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15261 USA; CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Plevy, S (corresponding author), Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Scaife Hall,Rm S857,3550 Terrace St, Pittsburgh, PA 15261 USA.							Adorini L, 1999, CELL MOL LIFE SCI, V55, P1610, DOI 10.1007/s000180050400; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Cappiello MG, 2001, J IMMUNOL, V166, P4498, DOI 10.4049/jimmunol.166.7.4498; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Cooper AM, 2002, J IMMUNOL, V168, P1322, DOI 10.4049/jimmunol.168.3.1322; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Kim YM, 1999, J IMMUNOL, V163, P2000; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Luo C, 1996, MOL CELL BIOL, V16, P3955; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Ma XJ, 1996, ANN NY ACAD SCI, V795, P357, DOI 10.1111/j.1749-6632.1996.tb52692.x; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Maruyama S, 2003, J IMMUNOL, V170, P997, DOI 10.4049/jimmunol.170.2.997; Masumi A, 2002, FEBS LETT, V531, P348, DOI 10.1016/S0014-5793(02)03556-1; McElligott DL, 1997, J IMMUNOL, V159, P4180; Meraro D, 1999, J IMMUNOL, V163, P6468; Miskin JE, 2000, J VIROL, V74, P9412, DOI 10.1128/JVI.74.20.9412-9420.2000; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; POLITIS AD, 1992, J IMMUNOL, V148, P801; POLITIS AD, 1994, J IMMUNOL, V152, P2270; RADDASSI K, 1994, CELL IMMUNOL, V153, P443, DOI 10.1006/cimm.1994.1041; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Salkowski CA, 1999, J IMMUNOL, V163, P1529; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Sharf R, 1997, J BIOL CHEM, V272, P9785; Sherman MA, 1999, J IMMUNOL, V162, P2820; Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; West MA, 1996, J TRAUMA, V41, P647, DOI 10.1097/00005373-199610000-00009; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wu CY, 1999, J IMMUNOL, V162, P807; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	49	91	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39372	39382		10.1074/jbc.M306441200	http://dx.doi.org/10.1074/jbc.M306441200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12876285	hybrid			2022-12-25	WOS:000185713800014
J	Zhu, M; Li, J; Fink, AL				Zhu, M; Li, J; Fink, AL			The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; VESICLE PERMEABILIZATION; FATTY-ACIDS; BINDING; PROTEIN; PHOSPHOLIPIDS; MODEL; AGGREGATION; MUTATION; GROWTH	The aggregation of alpha-synuclein is believed to be a critical factor in the etiology of Parkinson's disease. alpha-Synuclein is an abundant neuronal protein of unknown function, which is enriched in the presynaptic terminals of neurons. Although alpha-synuclein is found predominantly in the cytosolic fractions, membrane-bound alpha-synuclein has been suggested to play an important role in fibril formation. The effects of alpha-synuclein on lipid bilayers of different compositions were determined using fluorescent environment-specific probes located at various depths. alpha-Synuclein-membrane interactions were found to affect both protein and membrane properties. Our results indicate that in addition to electrostatic interactions, hydrophobic interactions are important in the association of the protein with the bilayer, and lead to disruption of the membrane. The latter was observed by atomic force microscopy and fluorescent dye leakage from vesicles. The kinetics of alpha-synuclein fibril formation were significantly affected by the protein association and subsequent membrane disruption, and reflected the conformation of alpha-synuclein. The ability of alpha-synuclein to disrupt membranes correlated with the binding affinity of alpha-synuclein for the particular membrane composition, and to the induced helical conformation of alpha-synuclein. Protofibrillar or fibrillar alpha-synuclein caused a much more rapid destruction of the membrane than soluble monomeric alpha-synuclein, indicating that protofibrils (oligomers) or fibrils are likely to be significantly neurotoxic.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039985] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39985] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagatolli LA, 1999, PHOTOCHEM PHOTOBIOL, V70, P557, DOI 10.1562/0031-8655(1999)070<0557:AMFTIO>2.3.CO;2; Balasubramanian SV, 2000, PHARMACEUT RES, V17, P344, DOI 10.1023/A:1007561308498; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Epand RM, 1999, CHEM PHYS LIPIDS, V101, P57, DOI 10.1016/S0009-3084(99)00055-9; Fang Y, 1997, BBA-BIOMEMBRANES, V1324, P309, DOI 10.1016/S0005-2736(96)00236-2; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lee JCM, 2001, LANGMUIR, V17, P3592, DOI 10.1021/la001678v; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Reviakine I, 2000, LANGMUIR, V16, P1806, DOI 10.1021/la9903043; RIGAUD JL, 1977, BIOCHIM BIOPHYS ACTA, V469, P246, DOI 10.1016/0005-2736(77)90160-2; SEMBLE SC, 2001, J BIOPHYS ACTA, V1510, P152; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Tang ZY, 2000, LANGMUIR, V16, P1696, DOI 10.1021/la981491s; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Walde P, 2001, BIOMOL ENG, V18, P143, DOI 10.1016/S1389-0344(01)00088-0; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yang ZH, 1999, LANGMUIR, V15, P1731, DOI 10.1021/la980839g; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200	41	264	274	0	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40186	40197		10.1074/jbc.M305326200	http://dx.doi.org/10.1074/jbc.M305326200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885775	hybrid			2022-12-25	WOS:000185713800112
J	Ziouzenkova, O; Asatryan, L; Sahady, D; Orasanu, G; Perrey, S; Cutak, B; Hassell, T; Akiyama, TE; Berger, JP; Sevanian, A; Plutzky, J				Ziouzenkova, O; Asatryan, L; Sahady, D; Orasanu, G; Perrey, S; Cutak, B; Hassell, T; Akiyama, TE; Berger, JP; Sevanian, A; Plutzky, J			Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; PPAR-ALPHA; KAPPA-B; ADHESION MOLECULE; CORONARY EVENTS; GENE-EXPRESSION; GAMMA LIGANDS; OXIDIZED LDL; LIPASE; CIII	Low density lipoprotein (LDL) exists in various forms that possess unique characteristics, including particle content and metabolism. One circulating subfraction, electronegative LDL (LDL(-)), which is increased in familial hypercholesterolemia and diabetes, is implicated in accelerated atherosclerosis. Cellular responses to LDL(-) remain poorly described. Here we demonstrate that LDL(-) increases tumor necrosis factor alpha (TNFalpha)-induced inflammatory responses through NFkappaB and AP-1 activation with corresponding increases in vascular cell adhesion molecule-1 (VCAM1) expression. LDL receptor overexpression increased these effects. In contrast, exposing LDL(-) to the key lipolytic enzyme lipoprotein lipase (LPL) reversed these responses, inhibiting VCAM1 below levels seen with TNFalpha alone. LPL is known to act on lipoproteins to generate endogenous peroxisomal proliferator-activated receptor alpha (PPARalpha) ligand, thus limiting inflammation. These responses varied according to the lipoprotein substrate triglyceride content (very low density lipoprotein >> LDL > high density lipoprotein). The PPARalpha activation seen with LDL, however, was disproportionately high. We show here that MUT LDL activates PPARalpha to an extent proportional to its LDL(-) content. As compared with LDL(-) alone, LPL-treated LDL(-) increased PPARalpha activation 20-fold in either cell-based transfection or radioligand displacement assays. LPL-treated LDL(-) suppressed NFkappaB and AP-1 activation, increasing expression of the PPARalpha target gene IkappaBalpha, although only in the genetic presence of PPARalpha and with intact LPL hydrolysis. Mass spectrometry reveals that LPL-treatment of either LDL or LDL(-) releases hydroxy-octadecadienoic acids (HODEs), potent PPARalpha activators. These findings suggest LPL-mediated PPARalpha activation as an alternative catabolic pathway that may limit inflammatory responses to LDL(-).	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Sigma Aldrich, St Louis, MO 63103 USA; Merck Res Labs, Rahway, NJ 07065 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Southern California; Merck KGaA; MilliporeSigma; Merck & Company	Plutzky, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, 77 Av Louis Pasteur,NRB 740, Boston, MA 02115 USA.	jplutzky@rics.bwh.harvard.edu	perrey, stephane/B-7483-2008; Ziouzenkova, Ouliana/B-3690-2012; Plutzky, Jorge/V-3410-2019; Ziouzenkova, Ouliana/AAM-1971-2020	perrey, stephane/0000-0002-8741-629X; Ziouzenkova, Ouliana/0000-0003-2449-2591; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050350] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050350, HL50350] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; CAZZOLATO G, 1991, FREE RADICAL BIO MED, V11, P247, DOI 10.1016/0891-5849(91)90120-R; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Delerive P, 2000, J BIOL CHEM, V275, P36703, DOI 10.1074/jbc.M004045200; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; HODIS HN, 1994, J LIPID RES, V35, P669; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; Lee H, 2000, CIRC RES, V87, P516; Lee SJ, 2003, ARTERIOSCL THROM VAS, V23, P853, DOI 10.1161/01.ATV.0000066131.01313.EB; Lee SST, 1996, ANN NY ACAD SCI, V804, P524, DOI 10.1111/j.1749-6632.1996.tb18642.x; Li DY, 2002, J PHARMACOL EXP THER, V302, P601, DOI 10.1124/jpet.102.034959; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Maziere C, 1997, FEBS LETT, V409, P351, DOI 10.1016/S0014-5793(97)00545-0; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; PEDERSEN TR, 1994, LANCET, V344, P1383; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; Sacks FM, 2000, CIRCULATION, V102, P1886, DOI 10.1161/01.CIR.102.16.1886; Sanchez-Quesada JL, 2003, ATHEROSCLEROSIS, V166, P261, DOI 10.1016/S0021-9150(02)00374-X; Sanchez-Quesada JL, 2002, J LIPID RES, V43, P699; SanchezQuesada JL, 1996, DIABETOLOGIA, V39, P1469, DOI 10.1007/s001250050600; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; Steinberg D, 1997, CIRCULATION, V95, P1062; Sugiyama S, 1998, ARTERIOSCL THROM VAS, V18, P568, DOI 10.1161/01.ATV.18.4.568; Vedie B, 1998, ARTERIOSCL THROM VAS, V18, P1780, DOI 10.1161/01.ATV.18.11.1780; Wang XS, 1999, BIOCHEM J, V343, P347, DOI 10.1042/0264-6021:3430347; Ziouzenkova O, 1999, J BIOL CHEM, V274, P18916, DOI 10.1074/jbc.274.27.18916; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100; Ziouzenkova O, 2000, BLOOD PURIFICAT, V18, P169, DOI 10.1159/000014415	39	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39874	39881		10.1074/jbc.M306786200	http://dx.doi.org/10.1074/jbc.M306786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878589	Green Accepted, hybrid			2022-12-25	WOS:000185713800074
J	Caspi, M; Coquelle, FM; Koifman, C; Levy, T; Arai, H; Aoki, J; De Mey, JR; Reiner, O				Caspi, M; Coquelle, FM; Koifman, C; Levy, T; Arai, H; Aoki, J; De Mey, JR; Reiner, O			LIS1 missense mutations - Variable phenotypes result from unpredictable alterations in biochemical and cellular properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; ACETYLHYDROLASE CATALYTIC SUBUNITS; LISSENCEPHALY GENE-PRODUCT; PROTEIN BETA-SUBUNIT; CYTOPLASMIC DYNEIN; ASPERGILLUS-NIDULANS; NUCLEAR MIGRATION; NEURONAL MIGRATION; BAND HETEROTOPIA; BRAIN	Mutations in one allele of the human LIS1 gene cause a severe brain malformation, lissencephaly. Although most LIS1 mutations involve deletions, several point mutations with a single amino acid alteration were described. Patients carrying these mutations reveal variable phenotypic manifestations. We have analyzed the functional importance of these point mutations by examining protein stability, folding, intracellular localization, and protein-protein interactions. Our data suggest that the mutated proteins were affected at different levels, and no single assay could be used to predict the lissencephaly phenotype. Most interesting are those mutant proteins that retain partial folding and interactions. In the case of LIS1 mutated in F31S, the cellular phenotype may be modified by overexpression of specific interacting proteins. Overexpression of the PAF-AH alpha1 subunit dissolved aggregates induced by this mutant protein and increased its half-life. Overexpression of NudE or NudEL localized this mutant protein to spindle poles and kinetochores but had no effect on protein stability. Our results implicate that there are probably different biochemical and cellular mechanisms obstructed in each patient yielding the varied lissencephaly phenotypes.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Ctr Univ Orsay, CNRS, UMR 146, Inst Curie,Sect Rech, F-91405 Orsay, France; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Tokyo	Reiner, O (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Reiner, Orly/E-9455-2010	Reiner, Orly/0000-0001-7560-9599; Aoki, Junken/0000-0001-9435-1896; COQUELLE, Frederic/0000-0002-5483-8787				Aumais JP, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0002.2001; BARKOVICH AJ, 1994, ANN NEUROL, V36, P609, DOI 10.1002/ana.410360409; Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; BONIFACINO JS, 1999, CURRENT PROTOCOLS CE; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Cahana A, 2001, P NATL ACAD SCI USA, V98, P6429, DOI 10.1073/pnas.101122598; Cardoso C, 2002, HUM MUTAT, V19, P4, DOI 10.1002/humu.10028; Cardoso C, 2000, HUM MOL GENET, V9, P3019, DOI 10.1093/hmg/9.20.3019; Caspi M, 2000, HUM MOL GENET, V9, P2205, DOI 10.1093/oxfordjournals.hmg.a018911; Coquelle FM, 2002, MOL CELL BIOL, V22, P3089, DOI 10.1128/MCB.22.9.3089-3102.2002; des Portes V, 1998, CELL, V92, P51; Dobyns WB, 1999, NEUROLOGY, V53, P270, DOI 10.1212/WNL.53.2.270; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; Emes RD, 2001, HUM MOL GENET, V10, P2813, DOI 10.1093/hmg/10.24.2813; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Fogli A, 1999, ANN NEUROL, V45, P154, DOI 10.1002/1531-8249(199902)45:2<154::AID-ANA4>3.0.CO;2-P; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HOFFMANN B, 2001, J BIOL CHEM, V16, P16; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Kitagawa M, 2000, FEBS LETT, V479, P57, DOI 10.1016/S0014-5793(00)01856-1; Koizumi H, 2003, J BIOL CHEM, V278, P12489, DOI 10.1074/jbc.M211836200; Leventer RJ, 2001, NEUROLOGY, V57, P416, DOI 10.1212/WNL.57.3.416; LO NC, 1997, HUM MOL GENET, V6, P157; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Morris NR, 1998, TRENDS CELL BIOL, V8, P467, DOI 10.1016/S0962-8924(98)01389-0; Morris SM, 1998, CURR BIOL, V8, P603, DOI 10.1016/S0960-9822(98)70232-5; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Pilz DT, 1999, HUM MOL GENET, V8, P1757, DOI 10.1093/hmg/8.9.1757; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; Pilz DT, 1998, GENET MED, V1, P29; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Reiner O, 2000, NEURON, V28, P633, DOI 10.1016/S0896-6273(00)00142-2; Sapir T, 1999, EUR J BIOCHEM, V266, P1011, DOI 10.1046/j.1432-1327.1999.00942.x; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sheffield PJ, 2000, PROTEINS, V39, P1, DOI 10.1002/(SICI)1097-0134(20000401)39:1<1::AID-PROT1>3.0.CO;2-N; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Sweeney KJ, 2001, MECH DEVELOP, V101, P21, DOI 10.1016/S0925-4773(00)00543-8; Sweeney KJ, 2000, MECH DEVELOP, V92, P263, DOI 10.1016/S0925-4773(00)00242-2; TAI CY, 2002, J CELL BIOL, V11, P11; Xiang X, 2000, CURR BIOL, V10, P603, DOI 10.1016/S0960-9822(00)00488-7; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	48	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38740	38748		10.1074/jbc.M301147200	http://dx.doi.org/10.1074/jbc.M301147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885786	hybrid			2022-12-25	WOS:000185575100080
J	Ishikawa, T; Jiang, C; Stutts, MJ; Marunaka, Y; Rotin, D				Ishikawa, T; Jiang, C; Stutts, MJ; Marunaka, Y; Rotin, D			Regulation of the epithelial Na+ channel by cytosolic ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; TOAD URINARY-BLADDER; SODIUM-CHANNEL; PSEUDOHYPOALDOSTERONISM TYPE-1; LIDDLE-SYNDROME; XENOPUS OOCYTES; DOWN-REGULATION; GAMMA-SUBUNIT; BETA-SUBUNIT; CELLS	The epithelial Na+ channel (ENaC), composed of three subunits (alphabetagamma), is expressed in various Na+-absorbing epithelia and plays a critical role in salt and water balance and in the regulation of blood pressure. By using patch clamp techniques, we have examined the effect of cytosolic ATP on the activity of the rat alphabetagammaENaC (rENaC) stably expressed in NIH-3T3 cells and in Madin-Darby canine kidney epithelial cells. The inward whole-cell current attributable to rENaC activity ran down when these cells were dialyzed with an ATP-free pipette solution in the conventional whole-cell voltage-clamping technique. This run down was prevented by 2 mM ATP (but not by AMP or ADP) in the pipette solution or by the poorly or non-hydrolyzable analogues of ATP (adenosine 5'-O-(thiotriphosphate) and adenosine 5'-(beta,gamma-imino)triphosphate) in both cell lines, suggesting that protection from run down was mediated through non-hydrolytic nucleotide binding. Accordingly, we demonstrate binding of ATP (but not AMP) to alpharENaC expressed in Madin-Darby canine kidney cells, which was inhibited upon mutation of the two putative nucleotide-binding motifs of alpharENaC. Single channel analyses indicated that the run down of currents observed in the whole-cell recording was attributable to run down of channel activity, defined as NPo (the product of the number of channels and open probability). We propose that this novel ATP regulation of ENaC may be, at least in part, involved in the fine-tuning of ENaC activity under physiologic and pathophysiologic conditions.	Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Physiol Lab, Sapporo, Hokkaido 0600818, Japan; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Cell Physiol, Kyoto 6020841, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Resp Mol Med, Kyoto 6020841, Japan; Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	Hokkaido University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Ishikawa, T (corresponding author), Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Physiol Lab, Sapporo, Hokkaido 0600818, Japan.			Marunaka, Yoshinori/0000-0003-3846-0937				Abriel H, 1999, J PHYSIOL-LONDON, V516, P31, DOI 10.1111/j.1469-7793.1999.031aa.x; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; Awayda MS, 1999, AM J PHYSIOL-CELL PH, V277, pC216, DOI 10.1152/ajpcell.1999.277.2.C216; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; Bond T, 1999, J GEN PHYSIOL, V113, P441, DOI 10.1085/jgp.113.3.441; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chraibi A, 2001, CELL PHYSIOL BIOCHEM, V11, P115, DOI 10.1159/000047799; Chraibi A, 1999, J PHARMACOL EXP THER, V290, P341; FRINDT G, 1995, AM J PHYSIOL-RENAL, V268, pF480, DOI 10.1152/ajprenal.1995.268.3.F480; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1983, J MEMBRANE BIOL, V74, P15, DOI 10.1007/BF01870591; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; JORGENSEN PL, 1980, PHYSIOL REV, V60, P864; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Mirshahi M, 2001, OPHTHALMIC RES, V33, P7, DOI 10.1159/000055635; PALMER LG, 1980, J MEMBRANE BIOL, V57, P59, DOI 10.1007/BF01868986; Palmer LG, 1998, J PHYSIOL-LONDON, V509, P151, DOI 10.1111/j.1469-7793.1998.151bo.x; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RINDT G, 1996, AM J PHYSIOL, V271, pF1086; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; STUTTS MJ, 1988, J APPL PHYSIOL, V64, P253, DOI 10.1152/jappl.1988.64.1.253; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037	40	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38276	38286		10.1074/jbc.M307216200	http://dx.doi.org/10.1074/jbc.M307216200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876281	Green Published, hybrid			2022-12-25	WOS:000185575100025
J	Ng, HH; Dole, S; Struhl, K				Ng, HH; Dole, S; Struhl, K			The Rtf1 component of the Paf1 transcriptional elongation complex is required for ubiquitination of histone H2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; REGULATES H3 METHYLATION; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; ACTIVE GENES; SET DOMAIN; IN-VIVO; YEAST; METHYLTRANSFERASE; RAD6	In yeast cells, the Rtf1 and Paf1 components of the Paf1 transcriptional elongation complex are important for recruitment of Set1, the histone H3-lysine 4 (H3-Lys(4)) methylase, to a highly localized domain at the 5' portion of active mRNA coding regions. Here, we show that Rtf1 is essential for global methylation of H3-Lys(4) and H3-Lys(79), but not H3-Lys(36). This role of Rtf1 resembles that of Rad6, which mediates ubiquitination of histone H2B at lysine 123. Indeed, Rtf1 is required for H2B ubiquitination, suggesting that its effects on H3-Lys(4) and H3-Lys(79) methylation are an indirect consequence of its effect on H2B ubiquitination. Rtf1 is important for telomeric silencing, with loss of H3-Lys(4) and H3-Lys(79) methylation synergistically reducing Sir2 association with telomeric DNA. Dot1, the H3-Lys(79) methylase, associates with transcriptionally active genes, but unlike the association of Set1 and Set2 (the H3-Lys(36) methylase), this association is largely independent of Rtf1. We suggest that Rtf1 affects genome-wide ubiquitination of H2B by a mechanism that is distinct from its function as a transcriptional elongation factor.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Genome Inst Singapore, Singapore 117528, Singapore	Harvard University; Harvard Medical School; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, C2-315,240 Longwood Ave, Boston, MA 02115 USA.	kevin@hms.harvard.edu	Ng, Huck Hui/A-1135-2009		NIGMS NIH HHS [GM 53720, GM 30186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030186, R01GM030186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Costa PJ, 2000, GENETICS, V156, P535; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	38	215	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33625	33628		10.1074/jbc.C300270200	http://dx.doi.org/10.1074/jbc.C300270200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12876293	hybrid			2022-12-25	WOS:000185047500005
J	Johnson, TR; Stone, K; Nikrad, M; Yeh, T; Zong, WX; Thompson, CB; Nesterov, A; Kraft, AS				Johnson, TR; Stone, K; Nikrad, M; Yeh, T; Zong, WX; Thompson, CB; Nesterov, A; Kraft, AS			The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells	ONCOGENE			English	Article						PS-341; TRAIL; Bax; Bcl-2; apoptosis	CYTOCHROME-C RELEASE; FACTOR-KAPPA-B; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; TUMOR-CELLS; DRUG-RESISTANCE; LIGAND TRAIL; DEATH; ACTIVATION; RECEPTOR	We demonstrate that PS-341, a small molecule inhibitor of the proteasome, markedly sensitizes resistant prostate, colon, and bladder cancer cells to TNF-like apoptosis-inducing ligand (TRAIL)-induced apoptosis irrespective of Bcl-xL overexpression. PS-341 treatment by itself does not affect the levels of Bax, Bak, caspases 3 and 8, c-Flip or FADD, but elevates levels of TRAIL receptors DR4 and DR5. This increase in receptor protein levels is associated with the ubiquitination of the DR5 protein. When PS-341 is combined with TRAIL, the levels of activated caspase 8 and cleaved Bid are substantially increased. In Bax-negative TRAIL-resistant HC-4 colon cancer cells, the combination of PS-341 and TRAIL overcomes the block to activation of the mitochondrial pathway and causes SMAC and cytochrome c release followed by apoptosis. Similarly, murine embryonic fibroblasts lacking Bax undergo apoptosis when exposed to the combination of PS-341 and TRAIL; however, fibroblasts lacking Bak are significantly resistant. Taken together, these findings indicate that PS-341 enhances TRAIL-induced apoptosis by increasing the cleavage of caspase 8, causing Bak-dependent release of mitochondrial proapoptotic proteins.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Penn, Dept Med Canc Biol & Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Pennsylvania; Pennsylvania Medicine	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.	Andrew.Kraft@UCHSC.edu	高, 雨莉/HGU-8187-2022					Adams J, 1999, CANCER RES, V59, P2615; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Cusack JC, 2001, CANCER RES, V61, P3535; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hao CH, 2001, CANCER RES, V61, P1162; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Hideshima T, 2001, CANCER RES, V61, P3071; Hietakangas V, 2003, MOL CELL BIOL, V23, P1278, DOI 10.1128/MCB.23.4.1278-1291.2003; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lacour S, 2001, CANCER RES, V61, P1645; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2000, CANCER RES, V60, P847; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Pawlowski JE, 2000, ANTICANCER RES, V20, P4243; Racke MM, 2002, J NEUROCHEM, V80, P1039, DOI 10.1046/j.0022-3042.2002.00787.x; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; van Bokhoven A, 2001, CANCER RES, V61, P6340; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; van Kerkhof P, 2001, BIOCHEM SOC T, V29, P488, DOI 10.1042/BST0290488; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	56	161	165	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4953	4963		10.1038/sj.onc.1206656	http://dx.doi.org/10.1038/sj.onc.1206656			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902978				2022-12-25	WOS:000184578900003
J	Buckley, KA; Golding, SL; Rice, JM; Dillon, JP; Gallagher, JA				Buckley, KA; Golding, SL; Rice, JM; Dillon, JP; Gallagher, JA			Release and interconversion of P2 receptor agonists by human osteoblast-like cells	FASEB JOURNAL			English	Article						ATP; ADP; bone; ecto-nucleoside diphosphokinase; ecto-NDPK	NUCLEOSIDE DIPHOSPHATE KINASE; ATP RELEASE; ENDOTHELIAL-CELLS; BONE-CELLS; OSTEOCLASTS; ACTIVATION; NUCLEOTIDES; DIPHOSPHOKINASE; IDENTIFICATION; TRANSDUCTION	Nucleotides, acting as agonists at P2 receptors, are important extracellular signaling molecules in many tissues. In bone they affect both bone-forming osteoblast and bone-resorbing osteoclast cell activity. The presence of nucleotides in the extracellular microenvironment is largely determined by their release from cells and metabolism by ecto-enzymes, both of which have scarcely been studied in bone. We have investigated adenosine 5'-triphosphate (ATP) release from SaOS-2 osteoblastic cells and the activities of cell surface ecto-enzymes on ATP metabolism. ATP, but not LDH, was detected in SaOS-2 cell conditioned medium, suggesting these cells were actively releasing ATP. Introduction of ADP resulted in increased ATP concentrations in the medium, which was found not to be receptor mediated. Nucleotide inhibition and substrate specificity studies revealed an ecto-nucleoside diphosphokinase (ecto-NDPK) was responsible for the ADP-->ATP conversion; PCR and immunocytochemistry confirmed its presence. Analysis of ATP metabolism over time demonstrated overall ATP degradation was increased by inhibiting ecto-NDPK activity; confirming that the combined action of multiple osteoblast-expressed ecto-enzymes affected extracellular nucleotide concentration. The data establish the coexistence of ATP-consuming, and for the first time, ATP-generating activities on the osteoblast cell surface, the discovery of which has significant implications for studies involving P2 receptor subtypes in bone.	Univ Liverpool, Dept Human Anat & Cell Biol, Human Bone Cell Res Grp, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Clin Engn, Liverpool L69 3GA, Merseyside, England; UK Ctr Tissue Engn, Liverpool L69 3GA, Merseyside, England	University of Liverpool; University of Liverpool; University of Liverpool	Buckley, KA (corresponding author), Univ Liverpool, Dept Human Anat & Cell Biol, Human Bone Cell Res Grp, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	buckleyk@liv.ac.uk		Buckley, Katherine/0000-0002-6585-8943				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; BOWLER WB, 1995, J BONE MINER RES, V10, P1137; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; BOWLER WB, 1998, J BONE MINER RES, V13, P524; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; Buckley KA, 2002, BONE, V31, P582, DOI 10.1016/S8756-3282(02)00877-3; Buckley KA, 2001, J BIOL CHEM, V276, P9565, DOI 10.1074/jbc.M005672200; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; CASWELL AM, 1988, BIOCHIM BIOPHYS ACTA, V966, P310, DOI 10.1016/0304-4165(88)90080-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; FUKUCHI T, 1994, BBA-PROTEIN STRUCT M, V1205, P113, DOI 10.1016/0167-4838(94)90099-X; Gallagher James A., 1996, P233; Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846; GARTLAND A, 2003, IN PRESS CALCIF TISS; Guidotti G, 1996, CHEM BIOL, V3, P703, DOI 10.1016/S1074-5521(96)90244-6; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; HILLARP NA, 1959, ACTA PHYSIOL SCAND, V45, P328, DOI 10.1111/j.1748-1716.1959.tb01705.x; Hoebertz A, 2001, FASEB J, V15, P1139, DOI 10.1096/fj.00-0395com; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200; Jorgensen NR, 2000, J BONE MINER RES, V15, P1024, DOI 10.1359/jbmr.2000.15.6.1024; KAPLAN N, 1995, COMPUTER MEDIATED CO, V2, P3; KIMURA N, 1990, J BIOL CHEM, V265, P15744; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LEW MJ, 1987, BRIT J PHARMACOL, V92, P349, DOI 10.1111/j.1476-5381.1987.tb11330.x; Maier R, 1997, BIOCHEM BIOPH RES CO, V237, P297, DOI 10.1006/bbrc.1997.7135; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Morrison MS, 1998, J PHYSIOL-LONDON, V511, P495, DOI 10.1111/j.1469-7793.1998.495bh.x; Nakamura E, 2000, AM J PHYSIOL-CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; REIMER WJ, 1992, AM J PHYSIOL, V263, pC1040, DOI 10.1152/ajpcell.1992.263.5.C1040; Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732; SONNEMANN J, 1995, BIOCHEM BIOPH RES CO, V209, P490, DOI 10.1006/bbrc.1995.1528; Todorov LD, 1996, J PHYSIOL-LONDON, V496, P731, DOI 10.1113/jphysiol.1996.sp021723; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Wiebe SH, 1999, CELL PHYSIOL BIOCHEM, V9, P323, DOI 10.1159/000016326; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; YU HH, 1993, FEBS LETT, V328, P209, DOI 10.1016/0014-5793(93)80994-6; YU HS, 1994, CELL SIGNAL, V6, P905, DOI 10.1016/0898-6568(94)90023-X; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	51	56	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1401	1410		10.1096/fj.02-0940com	http://dx.doi.org/10.1096/fj.02-0940com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890693				2022-12-25	WOS:000185345100032
J	Procino, G; Carmosino, M; Marin, O; Brunanti, AM; Contri, A; Pinna, LA; Mannucci, R; Nielsen, S; Kwon, TH; Svelto, M; Valenti, G				Procino, G; Carmosino, M; Marin, O; Brunanti, AM; Contri, A; Pinna, LA; Mannucci, R; Nielsen, S; Kwon, TH; Svelto, M; Valenti, G			Ser-256 phosphorylation dynamics of aquaporin 2 during maturation from the endoplasmic reticulum to the vesicular compartment in renal cells	FASEB JOURNAL			English	Article						Golgi casein kinase; PKA; NDI; phosphorylation	NEPHROGENIC DIABETES-INSIPIDUS; TRANS-GOLGI NETWORK; SUBSTRATE-SPECIFICITY DETERMINANTS; LACTATING MAMMARY-GLAND; KINASE-A ACTIVITY; WATER CHANNEL; CASEIN KINASE; BREFELDIN-A; PROTEIN-KINASES; AQP2 TRANSLOCATION	Aquaporin 2 (AQP2) phosphorylation at Ser-256 by protein kinase A (PKA) is a key signal for vasopressin-stimulated AQP2 insertion into the plasma membrane in renal cells. This study underscores the possible role of phosphorylation at Ser-256 in regulating AQP2 maturation. AQP2-transfected renal CD8 cells were incubated with brefeldin A (BFA) to accumulate newly synthesized AQP2 in the endoplasmic reticulum ( ER), and AQP2 flow from ER to the vesicular compartment was analyzed after BFA washout. We found that a) in the ER, AQP2 is weakly phosphorylated; b) the amount of phosphorylated AQP2 (p-AQP2) at Ser-256 increased significantly during transit in the Golgi, even in the presence of the PKA inhibitor H89; and c) AQP2 transport from the Golgi to the vasopressin-regulated vesicular compartment occurred with a concomitant decrease in p-AQP2 at Ser-256. These results support the hypothesis that AQP2 transition in the Golgi apparatus is associated with a PKA-independent increase in AQP2 phosphorylation at Ser-256. Conversely, impaired constitutive phosphorylation in a Golgi-associated compartment occurring in cells expressing mutated S256A-AQP2 or E258K-AQP2 causes phosphorylation-defective AQP2 routing to lysosomes. This result might explain the molecular basis of the dominant form of nephrogenic diabetes insipidus caused by the mutation E258K-AQP2, in which the phenotype is caused by an impaired routing of AQP2.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Perugia, Dipartimento Med Clin & Sperimentale, I-06100 Perugia, Italy; Univ Aarhus, Dept Cell Biol, Inst Anat, DK-8000 Aarhus, Denmark; Dongguk Univ, Dept Physiol, Sch Med, Kyungju 780714, South Korea; Univ Bari, Ctr Eccellenza Genom Comparata, I-70121 Bari, Italy	Universita degli Studi di Bari Aldo Moro; University of Padua; University of Perugia; Aarhus University; Dongguk University; Universita degli Studi di Bari Aldo Moro	Valenti, G (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	g.valenti@biologia.uniba.it	Carmosino, Monica/O-2594-2014; Svelto, Maria/P-6186-2014; Kwon, Tae-Hwan/ABA-1981-2020	Carmosino, Monica/0000-0001-7600-8816; VALENTI, GIOVANNA/0000-0003-0233-0778; Svelto, Maria/0000-0002-5584-9541; Procino, Giuseppe/0000-0002-0043-7523				Brunati AM, 2000, FEBS LETT, V471, P151, DOI 10.1016/S0014-5793(00)01378-8; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Christensen BM, 2000, AM J PHYSIOL-RENAL, V278, pF29, DOI 10.1152/ajprenal.2000.278.1.F29; DEMATTIA F, 2002, ASN 35 ANN M PENNS C; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Fiedler K, 1997, ELECTROPHORESIS, V18, P2613, DOI 10.1002/elps.1150181417; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; Hirano K, 2002, HISTOCHEM CELL BIOL, V117, P41, DOI 10.1007/s00418-001-0370-2; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Kamsteeg EJ, 2000, J CELL BIOL, V151, P919, DOI 10.1083/jcb.151.4.919; Katsura T, 1997, Am J Physiol, V272, pF817; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Lasa M, 1997, EUR J BIOCHEM, V243, P719, DOI 10.1111/j.1432-1033.1997.00719.x; LasaBenito M, 1996, FEBS LETT, V382, P149, DOI 10.1016/0014-5793(96)00136-6; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Martin ME, 2000, J BIOL CHEM, V275, P19050, DOI 10.1074/jbc.275.25.19050; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MEGGIO F, 1988, EUR J BIOCHEM, V177, P281, DOI 10.1111/j.1432-1033.1988.tb14374.x; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Nishimoto G, 1999, AM J PHYSIOL-RENAL, V276, pF254, DOI 10.1152/ajprenal.1999.276.2.F254; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; Orzech E, 2000, J BIOL CHEM, V275, P15207, DOI 10.1074/jbc.275.20.15207; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PERKEL VS, 1989, P SOC EXP BIOL MED, V190, P286; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; PRICE PA, 1994, PROTEIN SCI, V3, P822; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; Valenti G, 2000, J CELL SCI, V113, P1985; Valenti G, 1996, J BIOL CHEM, V271, P24365, DOI 10.1074/jbc.271.40.24365; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; VANDEWALLE A, 1989, J CELL PHYSIOL, V141, P203, DOI 10.1002/jcp.1041410128	42	67	69	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1886	+		10.1096/fj.02-0870fje	http://dx.doi.org/10.1096/fj.02-0870fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897058				2022-12-25	WOS:000185345100016
J	Liao, GX; Sun, SC				Liao, GX; Sun, SC			Regulation of NF-kappa B2/p100 processing by its nuclear shuttling	ONCOGENE			English	Article						NF-kappa B; p100; protein processing; nuclear localization signal; leptomycin B	NF-KAPPA-B; TRCP UBIQUITIN LIGASE; MICE LACKING; P105; PROTEINS; SIGNAL; PHOSPHORYLATION; PRECURSOR; KINASE; DOMAIN	Processing of the NF-kappaB2 precursor protein p100 to generate p52 is an important step of NF-kappaB regulation. This proteolytic event is tightly regulated by sequences located at the C-terminal portion of p100. Constitutive processing of p100 occurs in certain lymphoma cells due to the loss of its C-terminal regulatory domain, although the underlying mechanisms remain unknown. We show here that the constitutive processing of C-terminal truncation mutants of p100 is associated with their active nuclear translocation. Deletion of the C-terminal death domain of p100 triggers a low, but significant, level of nuclear translocation and processing. Disruption of the ankyrin-repeat domain of p100 further enhances its nuclear shuttling activity, which is again associated with elevated level of processing. More importantly, mutation of the nuclear localization signal (NLS) of p100 abolishes its processing, and this defect can be rescued by fusion of a heterologous NLS to the amino- or carboxyl-terminus of the p100 mutant. These results suggest that nuclear shuttling is a mechanism regulating the processing of NF-kappaB2/p100.	Penn State Univ Hosp, Dept Microbiol & Immunol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ Hosp, Dept Microbiol & Immunol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NCI NIH HHS [1R01 CA94922] Funding Source: Medline; NIAID NIH HHS [1R01 AI45045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Harhaj EW, 1996, ONCOGENE, V12, P2385; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980	37	34	38	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4868	4874		10.1038/sj.onc.1206761	http://dx.doi.org/10.1038/sj.onc.1206761			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894228				2022-12-25	WOS:000184344600010
J	Napolitano, G; Mazzocco, A; Fraldi, A; Majello, B; Lania, L				Napolitano, G; Mazzocco, A; Fraldi, A; Majello, B; Lania, L			Functional inactivation of Cdk9 through oligomerization chain reaction	ONCOGENE			English	Article						Cdk9; OCR; P-TEFb; coiled-coil domain; PML	P-TEFB KINASE; C-TERMINAL DOMAIN; HUMAN CYCLIN T1; HIV-1 TAT; IN-VIVO; TRANSCRIPTIONAL ELONGATION; DEPENDENT TRANSCRIPTION; TAK/P-TEFB; ACTIVATION; RECRUITMENT	The oligomerization chain reaction (OCR) strategy is a recently described technique for inactivation of target proteins that function as homoassociate complexes. This novel strategy is based on the fusion of self-associating coiled-coil (CC) domain of the nuclear factor promyelocytic leukemia (PML) to target proteins. Here, we present the successful application of the OCR strategy for inactivation of the heterodimeric Cdk9/cyclin T1 complex. Cyclin T1/Cdk9 (P-TEFb) complex is a positive regulator of gene transcription, whose function is underlined by the ability to phosphorylate the carboxyl-terminal domain (CTD) of the RNA polymerase II conferring productive transcript elongation. Fusion of the CC domain to Cdk9 leads to the formation of high molecular complexes to which the endogenous cyclin T1 is recruited. The CC-Cdk9 chimera effectively inhibits HIV-1 Tat activation, whose transcription activity is exquisitely dependent upon cyclin T1/Cdk9 function. Furthermore, expression of CC-Cdk9 protein inhibits cell proliferation, as shown by colony-formation assay. Collectively, our findings add further support to the OCR strategy for functional inactivation of hetero-associated factors such as the Cdk9/cyclin T1 complex, and highlight a putative function of Cdk9 in cell growth control.	Univ Naples Federico II, Dept Genet Mol & Gen Biol, I-80134 Naples, Italy	University of Naples Federico II	Lania, L (corresponding author), Univ Naples Federico II, Dept Genet Mol & Gen Biol, Via Mezzocannone 8, I-80134 Naples, Italy.	lania@unina.it	Fraldi, Alessandro/AAB-2243-2021	Fraldi, Alessandro/0000-0002-7795-0720; Majello, Barbara/0000-0003-2789-3585; Napolitano, Giuliana/0000-0002-1637-6016				ALONSO A, 1992, J VIROL, V66, P4617, DOI 10.1128/JVI.66.7.4617-4621.1992; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Contegno F, 2002, P NATL ACAD SCI USA, V99, P1865, DOI 10.1073/pnas.042460299; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Herrmann CH, 2001, J CELL SCI, V114, P1491; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lis JT, 2000, GENE DEV, V14, P792; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marcello A, 2001, J BIOL CHEM, V276, P39220, DOI 10.1074/jbc.M104830200; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Napolitano G, 2002, J CELL PHYSIOL, V192, P209, DOI 10.1002/jcp.10130; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sausville EA, 2002, TRENDS MOL MED, V8, pS32, DOI 10.1016/S1471-4914(02)02308-0; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	34	12	12	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4882	4888		10.1038/sj.onc.1206785	http://dx.doi.org/10.1038/sj.onc.1206785			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894230	Bronze			2022-12-25	WOS:000184344600012
J	Span, PN; Tjan-Heijnen, VCG; Manders, P; Beex, LVAM; Sweep, CGJ				Span, PN; Tjan-Heijnen, VCG; Manders, P; Beex, LVAM; Sweep, CGJ			Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer	ONCOGENE			English	Article						cell cycle; prognosis; multivariate study; treatment interaction; tamoxifen	PROGNOSTIC FACTORS; E OVEREXPRESSION; CELL-CYCLE; EXPRESSION; DEREGULATION; SURVIVAL; PROTEIN; KINASE; PROLIFERATION; RISK	Recently, cyclin-E was reported to be the most prominent prognostic factor for breast cancer outcome described so far, even surpassing axillary nodal involvement. Earlier studies on the prognostic value of cyclin-E in breast cancer, however, yielded heterogeneous results. Therefore, we set out to confirm and extend these results by quantitative Taqman RT-PCR of cyclin-E levels in 277 resectable breast cancers. Cyclin-E levels were not associated with relapse-free survival (RFS) or overall survival (OS) in the total cohort of patients, or in the subset of patients without involved lymph nodes that were not treated with adjuvant systemic therapy. Besides several classical clinicopathological factors, the interaction between cyclin-E and adjuvant endocrine therapy (P = 0.01, HR = 3.04, 95% CI: 1.30-7.09) was found to contribute significantly in multivariate analyses. Cyclin-E levels were associated with poor RFS specifically in patients treated with adjuvant endocrine therapy (n = 108, P = 0.001, HR = 4.01, 95% CI: 1.76-9.12), independent of estrogen receptor status. In conclusion, cyclin-E is not a pure prognostic factor in breast cancer, but rather a predictor of failure of endocrine therapy. Differences in literature on the presumed prognostic value of cyclin-E may be due to differences in treatment. Assessment of cyclin-E levels can aid in improving adjuvant treatment selection.	Univ Med Ctr Nijmegen, Dept Chem Endocrinol 530, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Span, PN (corresponding author), Univ Med Ctr Nijmegen, Dept Chem Endocrinol 530, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Span, Paul/G-4710-2012; Sweep, C.G.J./H-8096-2014; Manders, P./L-4501-2015; Span, Paul N./A-3143-2009	Span, Paul/0000-0002-1930-6638; Sweep, C.G.J./0000-0003-1103-3070; 				ALTMAN DG, 1994, J NATL CANCER I, V86, P829, DOI 10.1093/jnci/86.11.829; Altman DG, 1998, BREAST CANCER RES TR, V52, P289, DOI 10.1023/A:1006193704132; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; COX DR, 1972, J R STAT SOC B, V34, P187; Dhillon NK, 2002, ONCOGENE, V21, P4626, DOI 10.1038/sj.onc.1205576; Donnellan R, 2001, HUM PATHOL, V32, P89, DOI 10.1053/hupa.2001.21141; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Foekens JA, 2003, CANCER RES, V63, P337; Harbeck N, 2002, CANCER RES, V62, P4617; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kim HK, 2001, EUR J SURG ONCOL, V27, P464, DOI 10.1053/ejso.2001.1137; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kuhling H, 2003, J PATHOL, V199, P424, DOI 10.1002/path.1322; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Payton M, 2002, ONCOGENE, V21, P8529, DOI 10.1038/sj.onc.1206035; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076	25	70	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4898	4904		10.1038/sj.onc.1206818	http://dx.doi.org/10.1038/sj.onc.1206818			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894232				2022-12-25	WOS:000184344600014
J	Ko, J; Lee, YH; Hwang, SY; Lee, YS; Shin, SM; Hwang, JH; Kim, J; Kim, YW; Jang, SW; Ryoo, ZY; Kim, IK; Namkoong, SE; Kim, JW				Ko, J; Lee, YH; Hwang, SY; Lee, YS; Shin, SM; Hwang, JH; Kim, J; Kim, YW; Jang, SW; Ryoo, ZY; Kim, IK; Namkoong, SE; Kim, JW			Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization	ONCOGENE			English	Article						HCCR-2; cervical cancer; p53; oncogene	TUMOR-SUPPRESSOR GENES; CELLS; ASSOCIATION; MICROSCOPY; PROTEINS; INVITRO	Basic studies of oncogenesis have demonstrated that either the elevated production of particular oncogene proteins or the occurrence of qualitative abnormalities in oncogenes can contribute to neoplastic cellular transformation. The purpose of this study was to identify unique oncogenes that are differentially expressed in human cancers and characterize their functions in tumorigenesis. To discover new putative oncogenes, the differential display RT-PCR method was applied using normal cervical tissues, cervical cancer cell lines, cervical cancer tissues, and metastatic tissues. We identified a new human cervical cancer oncogene HCCR-2 that was overexpressed in various human tumors including leukemia, lymphoma, and carcinomas of the breast, kidney, ovary, stomach, colon, and uterine cervix. Ectopic expression of HCCR-2 resulted in direct tumorigenic conversions of NIH/3T3 and Rat1 fibroblasts. Nude mice injected with NIH/3T3 cells stably transfected with HCCR-2 formed tumors in 4 weeks. The resultant tumors display characteristics of an epithelial carcinoma. In HCCR-2 transfected NCI-H460 cells and RKO cells, stabilization of the p53 tumor suppressor occurred without genetic mutation and correlated with functional impairment, as indicated by the defective induction of p53-induced p21(WAF1), MDM2, and bax. These results indicate. that HCCR-2 probably represents a new oncogene that is related to tumorigenesis, functioning as a negative regulator of the p53 tumor suppressor.	Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Hanyang Univ, Dept Biochem & Mol Biol, Ansan 425791, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Anat, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Lab Anim Sci, Seoul 137040, South Korea	Catholic University of Korea; University of Ulsan; Yeungnam University; Hanyang University; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Kim, JW (corresponding author), Catholic Univ Korea, Coll Med, Mol Genet Lab, 505 Banpo Dong, Seoul 137040, South Korea.	jinwoo@cmc.cu-k.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020					AARONSON SA, 1970, P NATL ACAD SCI USA, V66, P1236, DOI 10.1073/pnas.66.4.1236; AHN KY, 1991, AM J PHYSIOL, V265, pF792; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUICK RN, 1980, CANCER, V45, P1238, DOI 10.1002/1097-0142(19800315)45:5+<1238::AID-CNCR2820451333>3.0.CO;2-R; BUSBYEARLE RMC, 1994, BRIT J CANCER, V69, P732, DOI 10.1038/bjc.1994.138; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; Cooper G.M., 1995, ONCOGENES; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; HUBERT WG, 1993, J VIROL, V67, P2932, DOI 10.1128/JVI.67.5.2932-2937.1993; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; Kim J, 1996, AM J PHYSIOL-RENAL, V270, pF575, DOI 10.1152/ajprenal.1996.270.4.F575; Kim JW, 1996, GYNECOL ONCOL, V62, P230, DOI 10.1006/gyno.1996.0221; Leonard C J, 1995, Important Adv Oncol, P33; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PUCHTLER H, 1978, HISTOCHEMISTRY, V57, P177, DOI 10.1007/BF00492078; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; WEINBERG RA, 1994, CA-CANCER J CLIN, V44, P160, DOI 10.3322/canjclin.44.3.160; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	48	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4679	4689		10.1038/sj.onc.1206624	http://dx.doi.org/10.1038/sj.onc.1206624			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879013				2022-12-25	WOS:000184157000009
J	Syken, J; Macian, F; Agarwal, S; Rao, A; Munger, K				Syken, J; Macian, F; Agarwal, S; Rao, A; Munger, K			TID1, a mammalian homologue of the drosophila tumor suppressor lethal(2) tumorous imaginal discs, regulates activation-induced cell death in Th2 cells	ONCOGENE			English	Article						tumor suppressor; apoptosis; DnaJ protein; T cells	ESCHERICHIA-COLI DNAJ; T-CELL; MOLECULAR CHAPERONES; ATPASE ACTIVITY; UP-REGULATION; EXPRESSION; APOPTOSIS; PROTEIN; GENE; SUBSETS	We previously described two human DnaJ proteins, hTid-1(L) and hTid-1(S), which are derived from alternative splicing of the TID1 gene, the human homologue of the Drosophila tumor suppressor lethal(2) tumorous imaginal discs, and showed that hTid-1(L) promoted while hTid-1(S) antagonized apoptosis. There are two subsets of helper T cells, Th1 and Th2, of which Th2 cells are significantly less prone to apoptosis induced by stimulation through the T-cell receptor. This apoptotic process is known as activation-induced cell death (AICD). The molecular basis for the differential susceptibility of Th1 and Th2 cells to AICD is not known. Here we show that the antiapoptotic variant, Tid-1(S), is selectively induced in murine Th2 cells following activation. Expression of a dominant-negative mutant of hTid-1(S) in a Th2 cell line strikingly enhanced activation of caspase 3 in response to CD3 stimulation, and caused the cells to become sensitive to AICD. Hence, the accumulation of Tid-1(S) in Th2 cells following activation represents a novel mechanism that may contribute to the induction of apoptosis resistance during the activation of Th2 cells.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave,D2-544A, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Macian, Fernando/0000-0003-2666-035X; Munger, Karl/0000-0003-3288-9935				Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; Carter LL, 1998, J IMMUNOTHER, V21, P181, DOI 10.1097/00002371-199805000-00003; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Li-Weber M, 2002, CELL DEATH DIFFER, V9, P1256, DOI 10.1038/sj.cdd.4401102; Li-Weber M, 2002, CELL DEATH DIFFER, V9, P101, DOI 10.1038/sj.cdd.4400984; Li-Weber M, 2002, J CLIN INVEST, V110, P681, DOI [10.1172/JCI0215073, 10.1172/JCI200215073]; Lohman BL, 1998, J VIROL, V72, P7815, DOI 10.1128/JVI.72.10.7815-7821.1998; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; WALL D, 1994, J BIOL CHEM, V269, P5446; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	41	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4636	4641		10.1038/sj.onc.1206569	http://dx.doi.org/10.1038/sj.onc.1206569			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879007				2022-12-25	WOS:000184157000003
J	Edwards, SJ; Hananeia, L; Eccles, MR; Zhang, YF; Braithwaite, AW				Edwards, SJ; Hananeia, L; Eccles, MR; Zhang, YF; Braithwaite, AW			The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions	ONCOGENE			English	Article						p53; proline domain; apoptosis	WILD-TYPE P53; DNA-DAMAGE; TUMOR-SUPPRESSOR; DROSOPHILA P53; GROWTH ARREST; CELLS; HOMOLOG; IDENTIFICATION; TRANSCRIPTION; PROMOTERS	The N-terminal proline-rich domain of human p53 has been shown to be important for the induction of apoptosis. However, the corresponding region in mouse and other species is not highly conserved and has been less well studied. In this paper, we have characterized mutants with deletions in this region of mouse p53. Our results demonstrate that deletions in the proline-rich domain have varying effects on function ranging from no effect to severe impairment of cell death activity, depending on precisely which residues are deleted. We also show that the mutants differ in their ability to transactivate different p53 target promoters. Although we have been able to obtain mutants selectively impaired for apoptosis, our data are not generally consistent with this region being a functional domain. The data are more consistent with the interpretation that the region influences function by altering local protein structure which may affect promoter discrimination.	Univ Otago, Dept Pathol, Dunedin Sch Med, Dunedin, New Zealand	University of Otago	Edwards, SJ (corresponding author), Univ Otago, Dept Pathol, Dunedin Sch Med, Box 913, Dunedin, New Zealand.		Eccles, Michael Roger/AAF-7878-2020	Eccles, Michael Roger/0000-0002-6824-8761; Edwards, Sara/0000-0002-3468-1217				Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hansen RS, 1996, ONCOGENE, V13, P995; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; JACKSON P, 1993, ONCOGENE, V8, P589; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; PERREM K, 1995, ONCOGENE, V11, P1299; Prives C, 1999, J PATHOL, V187, P112; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SOUSSI T, 1990, ONCOGENE, V5, P945; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	24	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4517	4523		10.1038/sj.onc.1206726	http://dx.doi.org/10.1038/sj.onc.1206726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881708				2022-12-25	WOS:000184054700007
J	Pylypenko, O; Vitali, F; Zerbe, K; Robinson, JA; Schlichting, I				Pylypenko, O; Vitali, F; Zerbe, K; Robinson, JA; Schlichting, I			Crystal structure of OxyC, a cytochrome P450 implicated in an oxidative C-C coupling reaction during vancomycin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPEPTIDE ANTIBIOTICS; PEPTIDE DEFORMYLASE; CYCLIZATION STEPS; IDENTIFICATION; REFINEMENT; RESOLUTION; MOLSCRIPT; MECHANISM; REDUCTASE; P450BM-3	Gene inactivation studies point to the involvement of OxyC in catalyzing the last oxidative phenol coupling reaction during glycopeptide antibiotic biosynthesis. Presently, the substrate and exact timing of the OxyC reaction are unknown. The substrate might be the bicyclic heptapeptide or a thioester derivative bound to a protein carrier domain. OxyC from the vancomycin producer Amycolatopsis orientalis was produced in Escherichia coli and crystallized, and its structure was determined to 1.9 Angstrom resolution. OxyC gave UV-visible spectra characteristic of a P450-like hemoprotein in the low spin ferric state. After reduction to the ferrous state by dithionite the CO-ligated form gave a 450-nm peak in a UV-difference spectrum. The addition of vancomycin aglycone to OxyC produced type I changes to the UV spectrum. OxyC exhibits the typical P450-fold, with the Cys ligand loop containing the signature sequence FGHGX-HXCLG and Cys-356 being the proximal axial thiolate ligand of the heme iron. The observation of a water molecule bound to the heme iron is consistent with the UV-visible spectra of OxyC indicating a low spin heme. A polyethylene glycol molecule occupying the active site might mimic the bicyclic heptapeptide substrate. Analysis of the structure of Oxy-proteins and other P450s indicates regions that might be involved in binding of the redox partner and possibly the protein carrier domain.	Univ Zurich, Inst Organ Chem, CH-8057 Zurich, Switzerland; Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany	University of Zurich; Max Planck Society; Max Planck Society	Schlichting, I (corresponding author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	ilme.schlichting@mpimf-heidelberg.mpg.de	Schlichting, Ilme/I-1339-2013	Pylypenko, Olena/0000-0001-7073-5238				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Becker A, 1998, J BIOL CHEM, V273, P11413, DOI 10.1074/jbc.273.19.11413; Becker A, 1998, NAT STRUCT BIOL, V5, P1053, DOI 10.1038/4162; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P4688, DOI 10.1002/1521-3773(20011217)40:24<4688::AID-ANIE4688>3.0.CO;2-M; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P1693, DOI 10.1002/1521-3773(20010504)40:9<1693::AID-ANIE16930>3.0.CO;2-8; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen HW, 2001, CHEM BIOL, V8, P301, DOI 10.1016/S1074-5521(01)00009-6; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kim JJP, 1996, METHOD ENZYMOL, V272, P368, DOI 10.1016/S0076-6879(96)72042-6; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUS PFX, 1995, P NATL ACAD SCI USA, V92, P2071, DOI 10.1073/pnas.92.6.2071; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nicolaou KC, 1999, ANGEW CHEM INT EDIT, V38, P2096, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F; Pelzer S, 1999, ANTIMICROB AGENTS CH, V43, P1565, DOI 10.1128/AAC.43.7.1565; Pootoolal J, 2002, P NATL ACAD SCI USA, V99, P8962, DOI 10.1073/pnas.102285099; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C; Zerbe K, 2002, J BIOL CHEM, V277, P47476, DOI 10.1074/jbc.M206342200	33	77	80	3	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46727	46733		10.1074/jbc.M306486200	http://dx.doi.org/10.1074/jbc.M306486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12888556	hybrid			2022-12-25	WOS:000186569400063
J	Wynn, RM; Machius, M; Chuang, JL; Li, J; Tomchick, DR; Chuang, DT				Wynn, RM; Machius, M; Chuang, JL; Li, J; Tomchick, DR; Chuang, DT			Roles of His(291)-alpha and His(146)-beta ' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase - Refined phosphorylation loop structure in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; SYRUP-URINE-DISEASE; ESCHERICHIA-COLI; MULTIENZYME COMPLEXES; THIAMINE DIPHOSPHATE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; E1 COMPONENT; LIPOIC ACID; TRANSKETOLASE	We report here that alterations of either His(291)-alpha or His(146)-beta' in the active site of human branched-chain alpha-ketoacid dehydrogenase (E1b) impede both the decarboxylation and the reductive acylation reactions catalyzed by E1b as well as the binding of cofactor thiamin diphosphate (ThDP). In a refined human E1b active-site structure, His(291)-alpha, which aligns with His(407) in Escherichia coli pyruvate dehydrogenase and His(263) in yeast transketolase, is on a largely ordered phosphorylation loop. The imidazole ring of His(291)-alpha in E1b coordinates to the terminal phosphate oxygen atoms of bound ThDP. The N3 atom of wild-type His(146)-beta', which can be protonated, binds a water molecule and points toward the aminopyrimidine ring of ThDP. Remarkably, the H291A-alpha mutation results in a complete order-to-disorder transition of the loop region, which precludes the binding of the substrate lipoyl-bearing domain to E1b. The H146A-beta' mutation, on the other hand, does not alter the loop structure, but nullifies the reductive acylation activity of E1b. Our results suggest that: 1) His(291)-alpha plays a structural rather than a catalytic role in the binding of cofactor ThDP and the lipoyl-bearing domain to E1b, and 2) His(146)-beta' is an essential catalytic residue, probably functioning as a proton donor in the reductive acylation of lipoamide on the lipoyl-bearing domain.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	david.chuang@utsouthwestern.edu	Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643; Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK62306, DK26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062306, R01DK062306, R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; ARJUNAN P, 1999, BIOCHEMISTRY-US, V41, P5213; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Chuang JL, 2002, J BIOL CHEM, V277, P36905, DOI 10.1074/jbc.C200430200; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fiedler E, 2001, J BIOL CHEM, V276, P16051, DOI 10.1074/jbc.M007936200; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; Hawes JW, 1995, J BIOL CHEM, V270, P31071, DOI 10.1074/jbc.270.52.31071; HENNIG J, 1966, BIOCH PHYSL THIAMIN, P243; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KICE JL, 1968, ACCOUNTS CHEM RES, V1, P58, DOI 10.1021/ar50002a004; LAKOWICZ JR, 1983, BIOCHEMISTRY-US, V22, P1741, DOI 10.1021/bi00277a001; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan K, 1998, BIOCHEMISTRY-US, V37, P1357, DOI 10.1021/bi971835y; Wynn RM, 2000, METHOD ENZYMOL, V324, P179; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200	24	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43402	43410		10.1074/jbc.M306204200	http://dx.doi.org/10.1074/jbc.M306204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12902323	hybrid			2022-12-25	WOS:000186157000084
J	Chao, C; Hergenhahn, M; Kaeser, MD; Wu, ZQ; Saito, S; Iggo, R; Hollstein, M; Appella, E; Xu, Y				Chao, C; Hergenhahn, M; Kaeser, MD; Wu, ZQ; Saito, S; Iggo, R; Hollstein, M; Appella, E; Xu, Y			Cell type- and promoter-specific roles of Ser(18) phosphorylation in regulating p53 responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; IN-VIVO; APOPTOSIS; MDM2; RECRUITMENT; DEGRADATION; EXPRESSION; SERINE-15; PATHWAYS	Phosphorylation of mouse p53 at Ser(18) occurs after DNA damage. To determine the physiological roles of this phosphorylation event in p53-dependent DNA damage responses, a Ser(18) to Ala missense mutation was introduced into the germline of mice. Thymocytes and fibroblasts from the knock-in mice show reduced transactivation of many p53 target genes following DNA damage. p53 protein stabilization and DNA binding are similar in knock-in and wild type mice, but C-terminal acetylation was defective, consistent with a role for Ser(18) in the recruitment of transcriptional co-activators. The apoptotic response of knock-in thymocytes to ionizing radiation is intermediate between that of wild type and p53 null thymocytes. Despite impaired transcriptional and apoptotic responses, the knock-in mice are not prone to spontaneous tumorigenesis. This indicates that neither phosphorylation of p53 on Ser(18) by ATM nor a full transcriptional response is essential to prevent spontaneous tumor formation in mice.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA; Deutsch Krebsforschungszentrum, Dept Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany; Swiss Inst Expt Canc Res, Oncogene Grp, CH-1066 Epalinges, Switzerland; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Diego; Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Institute Experimental Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Iggo, Richard/G-3546-2014	Xu, Yang/0000-0001-5574-921X; Kaeser, Matthias/0000-0003-0050-9408	NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER; NCI NIH HHS [CA94254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Boley SE, 2002, TOXICOL SCI, V66, P209, DOI 10.1093/toxsci/66.2.209; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	30	110	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41028	41033		10.1074/jbc.M306938200	http://dx.doi.org/10.1074/jbc.M306938200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909629	hybrid			2022-12-25	WOS:000185847200077
J	Filipek, R; Rzychon, M; Oleksy, A; Gruca, M; Dubin, A; Potempa, J; Bochtler, M				Filipek, R; Rzychon, M; Oleksy, A; Gruca, M; Dubin, A; Potempa, J; Bochtler, M			The staphostatin-staphopain complex - A forward binding inhibitor in complex with its target cysteine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; CRYSTAL-STRUCTURE; QUINUPRISTIN-DALFOPRISTIN; PROTEINASE-INHIBITORS; MOLECULAR-BASIS; ACTIVE-SITE; PAPAIN; VIRULENCE; SPECIFICITY; RESISTANCE	Staphostatins are the endogenous inhibitors of the major secreted cysteine proteases of Staphylococcus aureus, the staphopains. Our recent crystal structure of staphostatin B has shown that this inhibitor forms a mixed, eight-stranded beta-barrel with statistically significant similarity to lipocalins, but not to cystatins. We now present the 1.8-Angstrom crystal structure of staphostatin B in complex with an inactive mutant of its target protease. The complex is held together through extensive interactions and buries a total surface area of 2300 Angstrom(2). Unexpectedly for a cysteine protease inhibitor, staphostatin B binds to staphopain B in an almost substrate-like manner. The inhibitor polypeptide chain runs through the protease active site cleft in the forward direction, with residues IG-TS in P2 to P2' positions. Both in the free and complexed forms, the P1 glycine residue of the inhibitor is in a main chain conformation only accessible to glycines. Mutations in this residue lead to a loss of affinity of the inhibitor for protease and convert the inhibitor into a substrate.	Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Max Planck Inst Mol Cell Biol & Genet, D-01309 Dresden, Germany; Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Max Planck Society; Jagiellonian University; University System of Georgia; University of Georgia	Bochtler, M (corresponding author), Int Inst Mol & Cell Biol, Ul Trojdena 4, PL-02109 Warsaw, Poland.		Bochtler, Matthias/A-4514-2010	Bochtler, Matthias/0000-0001-7884-4463				BAILEY CJ, 1995, MED MICROBIOL IMMUN, V184, P53; BERTHOLD H, 1992, BIOTECHNOL LETT, V14, P245, DOI 10.1007/BF01022318; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; CHAVIRA R, 1984, ANAL BIOCHEM, V136, P446, DOI 10.1016/0003-2697(84)90242-2; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Coulter SN, 1998, MOL MICROBIOL, V30, P393, DOI 10.1046/j.1365-2958.1998.01075.x; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P750, DOI 10.1107/S0907444997016247; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; Delgado G, 2000, PHARMACOTHERAPY, V20, P1469, DOI 10.1592/phco.20.19.1469.34858; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Evans Gerald A., 2002, Curr Infect Dis Rep, V4, P17, DOI 10.1007/s11908-002-0063-6; GEMMELL CG, 1995, J MED MICROBIOL, V43, P318, DOI 10.1099/00222615-43-5-318; Goldstein EJC, 2003, ANTIMICROB AGENTS CH, V47, P337, DOI 10.1128/AAC.47.1.337-341.2003; Harrison MJ, 1997, J AM CHEM SOC, V119, P12285, DOI 10.1021/ja9711472; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; Hoffman B., 1993, ACTA CRYSTALLOGR S, P102; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Kagawa TF, 2000, P NATL ACAD SCI USA, V97, P2235, DOI 10.1073/pnas.040549997; Lee LY, 2002, J CLIN INVEST, V110, P1461, DOI 10.1172/JC1200216318; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; Maskalyk J, 2002, CAN MED ASSOC J, V167, P375; Massimi I, 2002, J BIOL CHEM, V277, P41770, DOI 10.1074/jbc.M207162200; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; Moise PA, 2002, J ANTIMICROB CHEMOTH, V50, P1017, DOI 10.1093/jac/dkf215; Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999; Pearson H, 2002, NATURE, V418, P469, DOI 10.1038/418469b; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rice K, 2001, INFECT IMMUN, V69, P159, DOI 10.1128/IAI.69.1.159-169.2001; Rzychon M, 2003, MOL MICROBIOL, V49, P1051, DOI 10.1046/j.1365-2958.2003.03613.x; RZYCHON M, 2003, IN PRESS PROTEIN SCI, V12; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VASSEUR C, 1991, J BIOCHEM BIOPH METH, V22, P195, DOI 10.1016/0165-022X(91)90068-8; Viale P, 2002, J CHEMOTHERAPY, V14, P526, DOI 10.1179/joc.2002.14.5.526; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604	44	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40959	40966		10.1074/jbc.M302926200	http://dx.doi.org/10.1074/jbc.M302926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12874290	hybrid			2022-12-25	WOS:000185847200068
J	Leao-Helder, AN; Krikken, AM; van der Klei, IJ; Kiel, JAKW; Veenhuis, M				Leao-Helder, AN; Krikken, AM; van der Klei, IJ; Kiel, JAKW; Veenhuis, M			Transcriptional down-regulation of peroxisome numbers affects selective peroxisome degradation in Hansenula polymorpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NITRATE ASSIMILATION; ALCOHOL OXIDASE; BETA-OXIDATION; MATRIX PROTEIN; GENE ENCODES; IMPORT; INDUCTION; MEMBRANE; PEX3P	We have isolated and characterized a novel transcription factor of Hansenula polymorpha that is involved in the regulation of peroxisomal protein levels. This protein, designated Mpp1p, belongs to the family of Zn(II)(2)Cys(6) proteins. In cells deleted for the function of Mpp1p the levels of various proteins involved in peroxisome biogenesis (peroxins) and function ( enzymes) are reduced compared with wild type or, in the case of the matrix protein dihydroxyacetone synthase, fully absent. Also, upon induction of mpp1 cells on methanol, the number of peroxisomes was strongly reduced relative to wild type cells and generally amounted to one organelle per cell. Remarkably, this single organelle was not susceptible to selective peroxisome degradation (pexophagy) and remained unaffected during exposure of methanol-induced cells to excess glucose conditions. We show that this mechanism is a general phenomenon in H. polymorpha in the case of cells that contain only a single peroxisome.	Univ Groningen, GBB, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	University of Groningen	Veenhuis, M (corresponding author), Univ Groningen, GBB, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.	M.Veenhuis@biol.rug.nl	van der Klei, Ida J/D-1919-2012; Leao-Helder, Adriana Nivea/J-2086-2014	Leao-Helder, Adriana Nivea/0000-0002-0664-1533; Van der Klei, Ida J./0000-0001-7165-9679; krikken, arjen/0000-0002-6684-6303				Akache B, 2001, NUCLEIC ACIDS RES, V29, P2181, DOI 10.1093/nar/29.10.2181; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Avila J, 2002, YEAST, V19, P537, DOI 10.1002/yea.847; Avila J, 1998, BIOCHEM J, V335, P647, DOI 10.1042/bj3350647; Baerends RJS, 1997, YEAST, V13, P1437; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Baumgartner U, 1999, J BIOL CHEM, V274, P22208, DOI 10.1074/jbc.274.32.22208; Bellu AR, 2003, MICROSC RES TECHNIQ, V61, P161, DOI 10.1002/jemt.10325; Bellu AR, 2002, J BIOL CHEM, V277, P42875, DOI 10.1074/jbc.M205437200; Bellu AR, 2001, J BIOL CHEM, V276, P44570, DOI 10.1074/jbc.M107599200; BRUINENBERG PG, 1990, YEAST, V6, P245, DOI 10.1002/yea.320060309; DISTEL B, 1988, J CELL BIOL, V107, P1669, DOI 10.1083/jcb.107.5.1669; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; Faber KN, 2002, BBA-MOL CELL RES, V1591, P157, DOI 10.1016/S0167-4889(02)00274-4; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; Marshall PA, 1996, J CELL BIOL, V135, P123, DOI 10.1083/jcb.135.1.123; MERCKELBACH A, 1993, APPL MICROBIOL BIOT, V40, P361, DOI 10.1007/BF00170393; Nikolaev I, 1999, J BIOL CHEM, V274, P9795, DOI 10.1074/jbc.274.14.9795; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TITORENKO VI, 1995, J BACTERIOL, V177, P357, DOI 10.1128/jb.177.2.357-363.1995; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; van Dijk R, 2001, MOL GENET GENOMICS, V266, P646, DOI 10.1007/s004380100584; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; VEENHUIS M, 1989, ARCH MICROBIOL, V151, P105, DOI 10.1007/BF00414422; VEENHUIS M, 1979, ARCH MICROBIOL, V120, P167, DOI 10.1007/BF00409104; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; WATERHAM HR, 1992, YEAST, V8, P961, DOI 10.1002/yea.320081106	44	61	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40749	40756		10.1074/jbc.M304029200	http://dx.doi.org/10.1074/jbc.M304029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902346	hybrid			2022-12-25	WOS:000185847200042
J	Rieckhof, GE; Yoshihara, M; Guan, Z; Littleton, JT				Rieckhof, GE; Yoshihara, M; Guan, Z; Littleton, JT			Presynaptic N-type calcium channels regulate synaptic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DROSOPHILA MEMORY; ALPHA-1 SUBUNIT; ION CHANNELS; II RECEPTOR; TERM-MEMORY; PLASTICITY; GENE; MUTANTS; ACTIVATION	Voltage-gated calcium channels couple changes in membrane potential to neuronal functions regulated by calcium, including neurotransmitter release. Here we report that presynaptic N-type calcium channels not only control neurotransmitter release but also regulate synaptic growth at Drosophila neuromuscular junctions. In a screen for behavioral mutants that disrupt synaptic transmission, an allele of the N-type calcium channel locus (Dmca1A) was identified that caused synaptic undergrowth. The underlying molecular defect was identified as a neutralization of a charged residue in the third S4 voltage sensor. RNA interference reduction of N-type calcium channel expression also reduced synaptic growth. Hypomorphic mutations in syntaxin-1A or n-synaptobrevin, which also disrupt neurotransmitter release, did not affect synapse proliferation at the neuromuscular junction, suggesting calcium entry through presynaptic N-type calcium channels, not neurotransmitter release per se, is important for synaptic growth. The reduced synapse proliferation in Dmca1A mutants is not due to increased synapse retraction but instead reflects a role for calcium influx in synaptic growth mechanisms. These results suggest N-type channels participate in synaptic growth through signaling pathways that are distinct from those that mediate neurotransmitter release. Linking presynaptic voltage-gated calcium entry to downstream calcium-sensitive synaptic growth regulators provides an efficient activity-dependent mechanism for modifying synaptic strength.	MIT, Dept Biol, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Littleton, JT (corresponding author), MIT, Dept Biol, Picower Ctr Learning & Memory, E18-672,50 Ames St, Cambridge, MA 02139 USA.	troy@mit.edu		Littleton, J. Troy/0000-0001-5576-2887	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043244, R01NS040296] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS043244, R01 NS040296, R01 NS040296-03, R01 NS043244-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aberle H, 2002, NEURON, V33, P545, DOI 10.1016/S0896-6273(02)00589-5; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Beumer K, 2002, DEVELOPMENT, V129, P3381; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; BUDNIK V, 1990, J NEUROSCI, V10, P3754; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Eaton BA, 2002, NEURON, V34, P729, DOI 10.1016/S0896-6273(02)00721-3; Eberl DF, 1998, GENETICS, V148, P1159; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; Jarecki J, 1995, J NEUROSCI, V15, P8177; Jen J, 1999, CURR OPIN NEUROBIOL, V9, P274, DOI 10.1016/S0959-4388(99)80040-3; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; Kawasaki F, 2002, J NEUROSCI, V22, P5856; Kawasaki F, 2000, J NEUROSCI, V20, P4885; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; Lichtman JW, 2000, NEURON, V25, P269, DOI 10.1016/S0896-6273(00)80893-4; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; Littleton JT, 2001, P NATL ACAD SCI USA, V98, P12233, DOI 10.1073/pnas.221450198; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Marques G, 2002, NEURON, V33, P529, DOI 10.1016/S0896-6273(02)00595-0; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Mori Y, 2000, J NEUROSCI, V20, P5654, DOI 10.1523/JNEUROSCI.20-15-05654.2000; Pennetta G, 2002, NEURON, V35, P291, DOI 10.1016/S0896-6273(02)00769-9; RAISMAN G, 1969, BRAIN RES, V14, P25, DOI 10.1016/0006-8993(69)90029-8; Ren DJ, 1998, J NEUROSCI, V18, P2335; Roos J, 2000, NEURON, V26, P371, DOI 10.1016/S0896-6273(00)81170-8; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SCHWABE U, 1977, J PHARMACOL EXP THER, V202, P134; SHAO XM, 1993, NEURON, V11, P343, DOI 10.1016/0896-6273(93)90189-X; Smith LA, 1998, GENETICS, V149, P1407; Smith LA, 1996, J NEUROSCI, V16, P7868; Steinlein OK, 2000, CURR OPIN GENET DEV, V10, P286, DOI 10.1016/S0959-437X(00)00079-4; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; TSUKAHARA N, 1975, J NEUROPHYSIOL, V38, P1359, DOI 10.1152/jn.1975.38.6.1359; TYTGAT J, 1993, J BIOL CHEM, V268, P23777; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; WANG J, 1994, NEURON, V13, P1373, DOI 10.1016/0896-6273(94)90422-7; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200; Yoshihara M, 1997, J NEUROSCI, V17, P8408; Zhang N, 2002, J NEUROSCI, V22, P7065; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X; ZHONG Y, 1991, SCIENCE, V251, P198, DOI 10.1126/science.1670967; ZHONG Y, 1992, J NEUROSCI, V12, P644; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; Zito K, 1999, NEURON, V22, P719, DOI 10.1016/S0896-6273(00)80731-X; Zwingman TA, 2001, J NEUROSCI, V21, P1169	64	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41099	41108		10.1074/jbc.M306417200	http://dx.doi.org/10.1074/jbc.M306417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896973	hybrid			2022-12-25	WOS:000185847200085
J	Tannert, A; Wustner, D; Bechstein, J; Muller, P; Devaux, PF; Herrmann, A				Tannert, A; Wustner, D; Bechstein, J; Muller, P; Devaux, PF; Herrmann, A			Aminophospholipids have no access to the luminal side of the biliary canaliculus - Implications for the specific lipid composition of the bile fluid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-LABELED PHOSPHOLIPIDS; MDR1 P-GLYCOPROTEIN; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; HUMAN-ERYTHROCYTES; TRANSPORT; FLUORESCENT; HEPG2; TRANSLOCATION; ASYMMETRY	About 95% of the bile phospholipids are phosphatidylcholine. Although the fractions of phosphatidylcholine and of both aminophospholipids phosphatidylserine and phosphatidylethanolamine in the canalicular membrane are in the same order of about 35% of total lipids, both aminophospholipids are almost absent from the bile. To rationalize this observation, we studied the intracellular uptake of various fluorescent phospholipid analogues and their subsequent enrichment in the bile canaliculus (BC) of HepG2 cells. Diacylaminophospholipid analogues but not phosphatidylcholine analogues became rapidly internalized by an aminophospholipid translocase (APLT) activity in the plasma membrane of HepG2 cells. We observed only low labeling of BC by diacylaminophospholipids but extensive staining by phosphatidylcholine analogues. In the presence of suramin, known to inhibit APLT, a strong labeling of BC by diacylaminophospholipid analogues was found that declined to a level observed for control cells after removal of suramin. Unlike diacylphosphatidylserine, diether phosphatidylserine analogue, which is not an appropriate substrate of APLT, accumulated in the BC. The correlation between low labeling of BC and an APLT-mediated transbilayer movement suggests the presence of an APLT activity in the canalicular membrane that prevents exposure of aminophospholipids to the bile.	Humboldt Univ, Math Nat Wissensch Fak 1, Inst Biol, D-10115 Berlin, Germany; Max Delbruck Zentrum Mol Med, D-13125 Berlin, Germany; Inst Biol Physicochim, Lab Physicochim Mol Membranes Biol, Unite Mixte Rech 7099, F-75005 Paris, France	Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; UDICE-French Research Universities; Universite Paris Cite	Herrmann, A (corresponding author), Humboldt Univ, Math Nat Wissensch Fak 1, Inst Biol, Invalidenstr 43, D-10115 Berlin, Germany.	andreas.herrmann@rz.hu-berlin.de		Tannert, Astrid/0000-0003-4115-2564; Wustner, Daniel/0000-0003-4995-9709				Beleznay Z, 1997, EUR J BIOCHEM, V243, P58, DOI 10.1111/j.1432-1033.1997.58_1a.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOHME M, 1993, FEBS LETT, V333, P193, DOI 10.1016/0014-5793(93)80403-H; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Buton X, 2002, BIOCHEMISTRY-US, V41, P13106, DOI 10.1021/bi020385t; Cantz T, 2000, AM J PHYSIOL-GASTR L, V278, pG522, DOI 10.1152/ajpgi.2000.278.4.G522; COLEMAN R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P113, DOI 10.1016/0005-2760(92)90036-U; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; CONNOR J, 1992, J BIOL CHEM, V267, P19412; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; Daleke DL, 2000, BBA-MOL CELL BIOL L, V1486, P108, DOI 10.1016/S1388-1981(00)00052-4; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; Devaux PF, 2002, CHEM PHYS LIPIDS, V116, P115, DOI 10.1016/S0009-3084(02)00023-3; DRAGSTEN PR, 1982, FED PROC, V41, P48; Elferink RPJO, 1997, FASEB J, V11, P19, DOI 10.1096/fasebj.11.1.9034162; Ernest S, 1999, J AM SOC NEPHROL, V10, P2306; Fellmann P, 2000, BIOCHEMISTRY-US, V39, P4994, DOI 10.1021/bi992649q; Kipp H, 2002, ANNU REV PHYSIOL, V64, P595, DOI 10.1146/annurev.physiol.64.081501.155793; KullakUblick GA, 1996, HEPATOLOGY, V23, P1053; Lian WN, 1999, HEPATOLOGY, V30, P748, DOI 10.1002/hep.510300302; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; Muller P, 1996, HEPATOLOGY, V24, P1497; OKA JA, 1989, BIOCHEM BIOPH RES CO, V159, P488, DOI 10.1016/0006-291X(89)90019-3; Pohl A, 2002, BIOCHEM J, V365, P259, DOI 10.1042/BJ20011880; Pomorski T, 1996, J CELL SCI, V109, P687; RIGOTTI A, 1994, CURR TOP MEMBR, V40, P579, DOI 10.1016/S0070-2161(08)60997-1; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; SMIT JJM, 1994, LAB INVEST, V71, P638; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TILLEY L, 1986, FEBS LETT, V194, P21, DOI 10.1016/0014-5793(86)80044-8; Ujhazy P, 2001, HEPATOLOGY, V34, P768, DOI 10.1053/jhep.2001.27663; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; vanIjzendoorn SCD, 1997, J CELL BIOL, V137, P347, DOI 10.1083/jcb.137.2.347; Wustner D, 2001, TRAFFIC, V2, P277, DOI 10.1034/j.1600-0854.2001.9o135.x; Wustner D, 2000, J LIPID RES, V41, P395; Wustner D, 1998, BIOCHEMISTRY-US, V37, P17093, DOI 10.1021/bi981608b; YOUSEF IM, 1976, CAN J BIOCHEM CELL B, V54, P1040, DOI 10.1139/o76-152; Zegers MMP, 1997, J CELL BIOL, V138, P307, DOI 10.1083/jcb.138.2.307	43	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40631	40639		10.1074/jbc.M302131200	http://dx.doi.org/10.1074/jbc.M302131200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904307	hybrid			2022-12-25	WOS:000185847200027
J	Cozier, GE; Bouyoucef, D; Cullen, PJ				Cozier, GE; Bouyoucef, D; Cullen, PJ			Engineering the phosphoinositide-binding profile of a class I Pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; GUANINE-NUCLEOTIDE-EXCHANGE; PH-DOMAIN; CRYSTAL-STRUCTURE; INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; PLASMA-MEMBRANE; HIGH-AFFINITY; STRUCTURAL BASIS; BETA-SPECTRIN; PROTEIN	Pleckstrin homology (PH) domains are protein modules that bind with varying degrees of affinity and specificity membrane phosphoinositides. Previously we have shown that although the PH domains of the Ras GTPase-activating proteins GAP1(m) and GAP1(IP4BP) are 63% identical at the amino acid level they possess distinct phosphoinositide-binding profiles. The GAP1(m) PH domain binds phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5) P-3), whereas the domain from GAP1(IP4BP) binds PtdIns(3,4,5) P-3 and phosphatidylinositol 4,5-bisphosphate ( PtdIns(4,5) P-2) equally well. These phosphoinositide specificities are translated into distinct subcellular localizations. GAP1(m) is cytosolic and undergoes a rapid PtdIns(3,4,5) P-3-dependent association with the plasma membrane following growth factor stimulation. In contrast, GAP1(IP4BP) is constitutively associated, in a PtdIns(4,5) P-2-dependent manner, with the plasma membrane (Cozier, G. E., Lockyer, P. J., Reynolds, J. S., Kupzig, S., Bottomley, J. R., Millard, T., Banting, G., and Cullen, P. J. (2000) J. Biol. Chem. 275, 28261 - 28268). In the present study, we have used molecular modeling to identify residues in the GAP1(IP4BP) PH domain predicted to be required for high affinity binding to PtdIns( 4,5) P2. This has allowed the isolation of a mutant, GAP1(IP4BP)( K591T), which while retaining high affinity for PtdIns( 3,4,5) P-3 has a 6-fold reduction in its affinity for PtdIns( 4,5) P-2. Importantly, GAP1(IP4BP)-(K591T) is predominantly localized to the cytosol and undergoes a PtdIns( 3,4,5) P-3- dependent association with the plasma membrane following growth factor stimulation. We have therefore engineered the phosphoinositide-binding profile of the GAP1(IP4BP) PH domain, thereby emphasizing that subtle changes in PH domain structure can have a pronounced effect on phosphoinositide binding and the subcellular localization of GAP1(IP4BP).	Univ Bristol, Sch Med Sci, Dept Biochem,Inositide Grp, Henry Wellcome Integrated Signalling Labs, Bristol BS8 1TD, Avon, England	University of Bristol	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem,Inositide Grp, Henry Wellcome Integrated Signalling Labs, Bristol BS8 1TD, Avon, England.		Cozier, Gyles/A-5891-2009	Cozier, Gyles/0000-0003-2851-0902; Cullen, Peter/0000-0002-9070-8349				Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Blomberg N, 2000, STRUCTURE, V8, P1079, DOI 10.1016/S0969-2126(00)00509-8; Cozier G, 2000, BIOCHEM J, V349, P333, DOI 10.1042/0264-6021:3490333; Cozier GE, 2000, J BIOL CHEM, V275, P28261; Cullen PJ, 2000, CURR BIOL, V10, pR876, DOI 10.1016/S0960-9822(00)00818-6; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Jogl G, 2002, EMBO J, V21, P4785, DOI 10.1093/emboj/cdf502; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Ogasawara M, 2000, J BIOL CHEM, V275, P3221, DOI 10.1074/jbc.275.5.3221; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Thomas CC, 2001, BIOCHEM J, V358, P287, DOI 10.1042/0264-6021:3580287; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Walker SA, 2002, J BIOL CHEM, V277, P48779, DOI 10.1074/jbc.M204839200; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHANG P, 1995, STRUCTURE, V3, P1185, DOI 10.1016/S0969-2126(01)00254-4; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340	43	16	16	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39489	39496		10.1074/jbc.M307785200	http://dx.doi.org/10.1074/jbc.M307785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885767	hybrid			2022-12-25	WOS:000185713800028
J	Howes, AL; Arthur, JF; Zhang, T; Miyamoto, S; Adams, JW; Dorn, GW; Woodcock, EA; Brown, JH				Howes, AL; Arthur, JF; Zhang, T; Miyamoto, S; Adams, JW; Dorn, GW; Woodcock, EA; Brown, JH			Akt-mediated cardiomyocyte survival pathways are compromised by G alpha(q)-induced phosphoinositide 4,5-bisphosphate depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; PROTEIN-KINASE B; HEART-FAILURE; CARDIAC MYOCYTES; PHOSPHOLIPASE-C; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSGENIC MICE; MYOCARDIAL HYPERTROPHY; CELL-SURVIVAL	Expression of the wild type alpha subunit of G(q) (G(q)WT) in cardiomyocytes induces hypertrophy, whereas a constitutively active Galpha(q) subunit (G(q)Q209L) induces apoptosis. Akt phosphorylation increases with G(q)WT expression but is markedly attenuated in cardiomyocytes expressing G(q)Q209L or in those expressing G(q)WT and treated with agonist. A membrane-targeted Akt rescues G(q)Q209L-expressing cardiomyocytes from apoptotic cell death. In contrast, leukemia inhibitory factor fails to activate Akt or promote cell survival in these cells. Association of Akt and PDK-1 with the membrane is also diminished in G(q)Q209L-expressing cardiomyocytes. Phosphatidylinositol 3,4,5-trisphosphate (PIP3), the primary regulator of Akt, increases significantly in G(q)WT-expressing cells but not in cardiomyocytes expressing G(q)Q209L. Levels of phosphatidylinositol 4,5-bisphosphate (PIP2), the immediate precursor of PIP3, are also markedly lower in G(q)Q209L-expressing compared to control cells. Expression of a G(q)Q209L mutant that has diminished capacity to activate phospholipase C does not decrease PIP2 or Akt or induce apoptosis. In transgenic mice with cardiac Galpha(q) overexpression, heart failure and increased cardiomyocyte apoptosis develop during the peripartal period. Akt phosphorylation and PIP2 levels decrease concomitantly. Our findings suggest that an Akt-mediated cell survival pathway is compromised by the diminished availability of PIP2 elicited by pathological levels of G(q) activity.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Arena Pharmaceut, San Diego, CA 92121 USA; Baker Heart Res Inst, Cellular Biochem Lab, Melbourne, Vic, Australia; Univ Cincinnati, Med Ctr, Dept Internal Med, Div Cardiol, Cincinnati, OH 45267 USA	University of California System; University of California San Diego; Baker Heart and Diabetes Institute; University System of Ohio; University of Cincinnati	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,Mail Code 0636, La Jolla, CA 92093 USA.		ARTHUR, JANE/AAW-9983-2020		NHLBI NIH HHS [HL28143, HL46345, HL59888] Funding Source: Medline; NIGMS NIH HHS [T32 GM007752, GM-07752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL059888, R37HL028143, R01HL028143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Clerk A, 1999, AM J CARDIOL, V83, p64H; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; HAYAKAWA Y, 2003, IN PRESS CIRCULATION; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Ju HS, 1998, CIRCULATION, V97, P892, DOI 10.1161/01.CIR.97.9.892; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Kuwahara K, 2000, J MOL CELL CARDIOL, V32, P1385, DOI 10.1006/jmcc.2000.1177; Kuwahara K, 1999, CIRCULATION, V100, P1116, DOI 10.1161/01.CIR.100.10.1116; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Miao WF, 2000, J MOL CELL CARDIOL, V32, P2397, DOI 10.1006/jmcc.2000.1283; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MONACO ME, 1987, J BIOL CHEM, V262, P147; Negoro S, 2001, CIRCULATION, V103, P555, DOI 10.1161/01.CIR.103.4.555; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sakata Y, 1998, CIRCULATION, V97, P1488; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Speed CJ, 2000, J CELL SCI, V113, P2631; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Taniyama Y, 2002, J MOL CELL CARDIOL, V34, P1241, DOI 10.1006/jmcc.2002.2068; Tappia PS, 1999, AM J PHYSIOL-HEART C, V277, pH40, DOI 10.1152/ajpheart.1999.277.1.H40; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Woodcock EA, 1997, MOL CELL BIOCHEM, V172, P121, DOI 10.1023/A:1006871722652; WOODCOCK EA, 1995, CIRC RES, V76, P252, DOI 10.1161/01.RES.76.2.252; Ziegelhoffer A, 2001, CARDIOVASC RES, V49, P118, DOI 10.1016/S0008-6363(00)00209-1	50	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40343	40351		10.1074/jbc.M305964200	http://dx.doi.org/10.1074/jbc.M305964200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900409	hybrid			2022-12-25	WOS:000185713800128
J	Popescu, A; Miron, S; Blouquit, Y; Duchambon, P; Christova, P; Craescu, CT				Popescu, A; Miron, S; Blouquit, Y; Duchambon, P; Christova, P; Craescu, CT			Xeroderma pigmentosum group C protein possesses a high affinity binding site to human centrin 2 and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; NUCLEOTIDE EXCISION-REPAIR; MICROTUBULE-ORGANIZING CENTER; TARGET PEPTIDE RECOGNITION; YEAST CALMODULIN; TROPONIN-C; SACCHAROMYCES-CEREVISIAE; CENTROSOME DUPLICATION; MOLECULAR RECOGNITION; REGULATORY DOMAIN	Human centrin 2 (HsCen2), a member of the EF-hand superfamily of Ca2+-binding proteins, is commonly associated with centrosome-related structures. The protein is organized in two domains, each containing two EF-hand motifs, but only the C-terminal half exhibits Ca2+ sensor properties. A significant fraction of HsCen2 is localized in the nucleus, where it was recently found associated with the xeroderma pigmentosum group C protein (XPC), a component of the nuclear excision repair pathway. Analysis of the XPC sequence (940 residues), using a calmodulin target recognition software, enabled us to predict two putative binding sites. The binding properties of the two corresponding peptides were investigated by isothermal titration calorimetry. Only one of the peptides (P1-XPC) interacts strongly (K-a = 2.2 x 10(8) M-1, stoichiometry 1:1) with HsCen2 in a Ca2+-dependent manner. This peptide also binds, with a similar affinity (K-a = 1.1 x 10(8) M-1) to a C-terminal construct of HsCen2, indicating that the interaction with the integral protein is mainly the result of the contribution of the C-terminal half. The second peptide (P2-XPC) failed to show any detectable binding either to HsCen2 or to its C-terminal lobe. The two peptides interact with different affinities and mechanisms with calmodulin. Circular dichroism and nuclear magnetic resonance were used to structurally characterize the complex formed by the C-terminal domain of HsCen2 with P1-XPC.	Ctr Univ, INSERM, U350, F-91405 Orsay, France; Ctr Univ, Inst Curie Rech, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Craescu, CT (corresponding author), Ctr Univ, INSERM, U350, Batiments 110-112, F-91405 Orsay, France.		Miron, Simona/M-9223-2018					Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; Benhamou S, 2000, MUTAT RES-REV MUTAT, V462, P149, DOI 10.1016/S1383-5742(00)00032-6; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Brokx RD, 2001, J BIOL CHEM, V276, P14083, DOI 10.1074/jbc.M011026200; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Censarek P, 2002, BIOCHEMISTRY-US, V41, P8598, DOI 10.1021/bi025681k; Chavanne F, 2000, CANCER RES, V60, P1974; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Durussel I, 2000, FEBS LETT, V472, P208, DOI 10.1016/S0014-5793(00)01452-6; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; ERRABOLU R, 1994, J CELL SCI, V107, P9; Flory MR, 2000, P NATL ACAD SCI USA, V97, P5919, DOI 10.1073/pnas.97.11.5919; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Geier BM, 1996, J BIOL CHEM, V271, P28366, DOI 10.1074/jbc.271.45.28366; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Ivanovska I, 2001, GENETICS, V157, P503; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; Li CJ, 1999, J CELL SCI, V112, P1567; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; Luque I, 1998, BIOCHEMISTRY-US, V37, P5791, DOI 10.1021/bi9802521; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Matei E, 2003, BIOCHEMISTRY-US, V42, P1439, DOI 10.1021/bi0269714; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1995, NAT STRUCT BIOL, V2, P943, DOI 10.1038/nsb1195-943; Middendorp S, 1997, P NATL ACAD SCI USA, V94, P9141, DOI 10.1073/pnas.94.17.9141; Moisoi N, 2002, J CELL SCI, V115, P2367; Moorthy AK, 1999, FEBS LETT, V461, P19, DOI 10.1016/S0014-5793(99)01380-0; Moser MJ, 1997, J CELL SCI, V110, P1805; Murase T, 2002, BIOCHEMISTRY-US, V41, P1618, DOI 10.1021/bi011782r; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Osawa M, 1998, J MOL BIOL, V276, P165, DOI 10.1006/jmbi.1997.1524; Paoletti A, 1996, J CELL SCI, V109, P3089; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; Uchida A, 2002, DNA REPAIR, V1, P449, DOI 10.1016/S1568-7864(02)00031-9; VALLEN EA, 1994, GENETICS, V137, P407; Veeraraghavan S, 2002, J BIOL CHEM, V277, P28564, DOI 10.1074/jbc.M112232200; Wang EZ, 1997, BIOCHEMISTRY-US, V36, P15026, DOI 10.1021/bi963075h; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; Wolfrum U, 1998, EXP CELL RES, V242, P10, DOI 10.1006/excr.1998.4038; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YAP KL, 2001, J STRUCT FUNCT GENOM, V1, P8	65	74	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40252	40261		10.1074/jbc.M302546200	http://dx.doi.org/10.1074/jbc.M302546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890685	hybrid			2022-12-25	WOS:000185713800118
J	Tonello, F; Ascenzi, P; Montecucco, C				Tonello, F; Ascenzi, P; Montecucco, C			The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; DEPENDENT PROCESS; FACTOR CLEAVES; KINASE-KINASE; TOXIN; MACROPHAGES; RECEPTOR; INACTIVATION; PROTEOLYSIS; PATHWAYS	The anthrax lethal factor (LF) is a Zn2+ endopeptidase specific for mitogen-activated protein kinase kinases (MAPKKs), which are cleaved within their N termini. Here, the proteolytic activity of LF has been investigated using novel chromogenic MAPKK-derived peptide substrates, which allowed us to determine the kinetic parameters of the reaction. LF displayed maximal proteolytic activity at the pH and temperature values of the cell cytosol, which is its site of action. LF undergoes substrate inhibition, in keeping with the non-productive binding geometry of the MAPPK-2 N terminus to LF.	CNR, Ist Neurosci, I-35121 Padua, Italy; Univ Roma Tre, Dipartimento Biol, I-00146 Rome, Italy; Univ Roma Tre, Lab Interdipartimentale Microscopia Elettron, I-00146 Rome, Italy; Univ Padua, Dipartimento Sci Biomed, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); Roma Tre University; Roma Tre University; University of Padua	Tonello, F (corresponding author), CNR, Ist Neurosci, Via G Colombo 3, I-35121 Padua, Italy.		Tonello, Fiorella/G-8957-2013; Tonello, Fiorella/AAM-6737-2021	Tonello, Fiorella/0000-0001-8935-8938; Tonello, Fiorella/0000-0001-8935-8938				Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Ascenzi P, 2002, FEBS LETT, V531, P384, DOI 10.1016/S0014-5793(02)03609-8; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Chopra AP, 2003, J BIOL CHEM, V278, P9402, DOI 10.1074/jbc.M211262200; Cleland W W, 1979, Methods Enzymol, V63, P500; DiBella EE, 1996, BIOCHEMISTRY-US, V35, P4427, DOI 10.1021/bi952617c; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Friedlander AM, 2002, CURR TOP MICROBIOL, V271, P33; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GLADSTONE GP, 1946, BR J EXP PATHOL, V27, P349; HANNA PC, 1994, MOL MED, V1, P7; Johansson A, 2000, J COMB CHEM, V2, P496, DOI 10.1021/cc000022h; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kim SO, 2003, J BIOL CHEM, V278, P7413, DOI 10.1074/jbc.M209279200; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; Lacy DB, 2002, CURR TOP MICROBIOL, V271, P61; Leppla SH, 1999, J APPL MICROBIOL, V87, P284, DOI 10.1046/j.1365-2672.1999.00890.x; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Menard A, 1996, BIOCHEM J, V320, P687, DOI 10.1042/bj3200687; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Mock M, 2003, CELL MICROBIOL, V5, P15, DOI 10.1046/j.1462-5822.2003.00253.x; MORGAN G, 1978, BIOCHEMISTRY-US, V17, P3562, DOI 10.1021/bi00610a022; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Salvati L, 2001, EUR J BIOCHEM, V268, P3253, DOI 10.1046/j.1432-1327.2001.02223.x; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Tonello F, 2002, NATURE, V418, P386, DOI 10.1038/418386a; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; ZIMMERMAN M, 1976, ANAL BIOCHEM, V70, P258, DOI 10.1016/S0003-2697(76)80066-8	34	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40075	40078		10.1074/jbc.M306466200	http://dx.doi.org/10.1074/jbc.M306466200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888555	hybrid			2022-12-25	WOS:000185713800098
J	Zhang, YX; Manning, LR; Falcone, J; Platt, O; Manning, JM				Zhang, YX; Manning, LR; Falcone, J; Platt, O; Manning, JM			Human erythrocyte membrane band 3 protein influences hemoglobin cooperativity - Possible effect on oxygen transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; BINDING-SITES; 2,3-DIPHOSPHOGLYCERATE; CHLORIDE; POLYMERIZATION; ASSOCIATION; AFFINITY; FRAGMENT; MUTANT; ANIONS	Hemoglobin function can be modulated by the red cell membrane but some mechanistic details are incomplete. For example, the 43-kDa chymotryptic fragment of the cytoplasmic portion of red cell membrane Band 3 protein and its corresponding N-terminal 11-residue synthetic peptide lower the oxygen affinity of hemoglobin but effects on cooperativity are unclear. Using highly purified preparations, we also find a lowered Hill coefficient (n values < 2) at subequivalent ratios of Band 3 fragment or of synthetic peptide to Hb, resulting in an oxygen affinity that is moderately decreased and a partially hyperbolic shape for the O-2 binding curve. Both normal HbA and sickle HbS display this property. Thus, the determinant responsible for the Hb cooperativity decreases by the 43-kDa fragment resides within its first 11 N-terminal residues. This effect is observed in the absence of chloride and is reversed by its addition. As effector to Hb ratios approach equivalence or with saturating chloride normal cooperativity is restored, and oxygen affinity is further lowered because the shape of the oxygen binding curve becomes completely sigmoidal. The relative efficiencies of 2,3-diphosphoglycerate (DPG), the 43-kDa Band 3 fragment, and the 11-residue synthetic peptide in lowering cooperativity are very similar. The findings are explained based on the stereochemical mechanism of cooperativity because of two populations of T-state hemoglobin tetramers, one with bound effector and the other with free (Perutz, M. F. ( 1989) Q. Rev. Biophys. 22, 139 - 237). As a result of this property, hemoglobin at the membrane inner surface in contact with the N-terminal region of Band 3 could preferentially bind O-2 at low oxygen tension and then release it upon saturation with 2,3-diphosphoglycerate in the interior of the red cell. Membrane modulation of hemoglobin oxygen affinity has particularly interesting implications for the polymerization of hemoglobin S in the sickle red cell.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Northeastern University; Harvard University; Boston Children's Hospital	Manning, JM (corresponding author), Northeastern Univ, Dept Biol, Mugar Life Sci Bldg,360 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL-18819, HL-15157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018819, P60HL015157, R01HL018819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONINI E, 1970, ANNU REV BIOCHEM, V39, P977, DOI 10.1146/annurev.bi.39.070170.004553; APPELL KC, 1981, J BIOL CHEM, V256, P1104; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; Baldwin J.M., 1975, Progress Biophys Molec Biol, V29, P225; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BERGER RL, 1973, ANAL LETT, V6, P125; BONAVENTURA J, 1976, J BIOL CHEM, V251, P7563; CASSOLY R, 1983, J BIOL CHEM, V258, P3859; Chen WH, 2000, BIOCHEMISTRY-US, V39, P3774, DOI 10.1021/bi992691l; CHETRITE G, 1985, J MOL BIOL, V185, P639, DOI 10.1016/0022-2836(85)90076-2; DANISH EH, 1994, AM J HEMATOL, V47, P106, DOI 10.1002/ajh.2830470208; Dumoulin A, 1998, J BIOL CHEM, V273, P35032, DOI 10.1074/jbc.273.52.35032; Eaton WA, 1999, NAT STRUCT BIOL, V6, P351, DOI 10.1038/7586; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Himanen JP, 1996, J BIOL CHEM, V271, P25152, DOI 10.1074/jbc.271.41.25152; KISTER J, 1987, J BIOL CHEM, V262, P12085; LOW PS, 1989, RED BLOOD CELL MEMBR, P237; NIGEN AM, 1975, J BIOL CHEM, V250, P8248; NIGEN AM, 1980, J BIOL CHEM, V255, P5525; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; Platt Orah S., 1994, P125; SALHANY JM, 1980, BIOCHEMISTRY-US, V19, P1447, DOI 10.1021/bi00548a028; SALHANY JM, 1994, BIOCHEMISTRY-US, V33, P11909, DOI 10.1021/bi00205a029; TSUNESHIGE A, 1987, J BIOCHEM-TOKYO, V101, P695, DOI 10.1093/jb/101.3.695; UENO H, 1992, J PROTEIN CHEM, V11, P177, DOI 10.1007/BF01025223; WALDER JA, 1984, J BIOL CHEM, V259, P238; Wyman J, 1968, Q Rev Biophys, V1, P35; Zhang DC, 2000, BLOOD, V96, P2925	30	18	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39565	39571		10.1074/jbc.M303352200	http://dx.doi.org/10.1074/jbc.M303352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893828	hybrid			2022-12-25	WOS:000185713800038
J	Emiliani, C; Urbanelli, L; Racanicchi, L; Orlacchio, A; Pelicci, G; Sorbi, S; Bernardi, G; Orlacchio, A				Emiliani, C; Urbanelli, L; Racanicchi, L; Orlacchio, A; Pelicci, G; Sorbi, S; Bernardi, G; Orlacchio, A			Up-regulation of glycohydrolases in Alzheimer's Disease fibroblasts correlates with Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ENDOSOMAL-LYSOSOMAL SYSTEM; BETA-PROTEIN; CATHEPSIN-D; MEMBRANE ASSOCIATION; TAU PHOSPHORYLATION; OXIDATIVE STRESS; GENE-EXPRESSION; KINASE CASCADE; GLIAL-CELLS	The lysosomal system is up-regulated in the brain of patients with Alzheimer's Disease (AD), as demonstrated by previous experiments carried out in postmortem samples of brain patients. In this paper we provide evidence that an up-regulation of lysosomal glycohydrolases (alpha-D-mannosidase, beta-D-hexosaminidase, and beta-D-galactosidase) takes place in skin fibroblasts from AD patients affected either by sporadic or familial forms and is detectable also in presymptomatic subjects carrying the above mutations but healthy at the time of skin biopsy. This increase of enzyme activity is consequent to a transcriptional up-regulation. The oncogene Ras appears to be involved in the regulation of enzymatic activity. A parallel increase of Ras transcript and Ras protein, without an increase of p44/p42 MAPK activation was revealed in the same AD fibroblasts. An activation of p38 MAPK already described to occur in neurodegenerative diseases such as Alzheimer's, was also found in fibroblasts derived from AD patients. High levels of expression of the constitutively active form of Ras in normal or AD fibroblasts induced glycohydrolases up-regulation. Overall results demonstrated that glycohydrolases up-regulation, as well as Ras up-regulation, are early markers of AD, detectable at peripheral level, and good candidates to be exploited for diagnostic purposes. These data also provide the first proof for a role of Ras in regulating lysosomal glycohydrolases expression.	Univ Perugia, Dipartimento Sci Biochim & Biotecnol Mol, I-06122 Perugia, Italy; IRCCS Santa Lucia, Neurogenet Lab, I-00179 Rome, Italy; Univ Roma Tor Vergata, Policlin Tor Vergata, Dipartimento Neurosci, I-00133 Rome, Italy; Ist Europeo Oncol, Dipartimento Oncol Sperimentale, I-20141 Milan, Italy; Univ Florence, Dipartimento Sci Neurol & Psichiatr, I-50134 Florence, Italy	University of Perugia; IRCCS Santa Lucia; University of Rome Tor Vergata; Policlin Tor Vergata; IRCCS European Institute of Oncology (IEO); University of Florence	Orlacchio, A (corresponding author), Univ Perugia, Dipartimento Sci Biochim & Biotecnol Mol, Via Giochetto, I-06122 Perugia, Italy.	orly@unipg.it	Orlacchio, Antonio/AAO-5124-2021; Orlacchio, Antonio/A-1968-2014; Urbanelli, Lorena/G-4936-2010; Pelicci, Giuliana/AAA-8921-2022; Emiliani, Carla/G-3738-2010	Orlacchio, Antonio/0000-0002-2602-3281; Orlacchio, Antonio/0000-0002-2602-3281; Pelicci, Giuliana/0000-0003-0986-8255; Emiliani, Carla/0000-0002-6368-1515; Urbanelli, Lorena/0000-0003-0621-8476; sorbi, sandro/0000-0002-0380-6670	Telethon [E.0980] Funding Source: Medline	Telethon(Fondazione Telethon)		Adamec E, 2000, NEUROSCIENCE, V100, P663, DOI 10.1016/S0306-4522(00)00281-5; Atzori C, 2001, J NEUROPATH EXP NEUR, V60, P1190, DOI 10.1093/jnen/60.12.1190; Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cataldo AM, 1996, J NEUROSCI, V16, P186; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; Connolly GP, 1998, TRENDS PHARMACOL SCI, V19, P171, DOI 10.1016/S0165-6147(98)01202-4; Cosgaya JM, 1996, J NEUROCHEM, V67, P98; CRUTCHER KA, 1993, J NEUROSCI, V13, P2540, DOI 10.1523/JNEUROSCI.13-06-02540.1993; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; Demoz M, 1999, J CELL BIOCHEM, V73, P370, DOI 10.1002/(SICI)1097-4644(19990601)73:3<370::AID-JCB8>3.0.CO;2-N; EMILIANI C, 1995, BIOCHEM J, V305, P363, DOI 10.1042/bj3050363; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; Ferrer I, 2001, J NEURAL TRANSM, V108, P1397, DOI 10.1007/s007020100016; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Fraser PE, 2000, BBA-MOL BASIS DIS, V1502, P1, DOI 10.1016/S0925-4439(00)00028-4; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; GARTNER U, 1995, NEUROREPORT, V6, P1441; Gartner U, 1999, NEUROSCIENCE, V91, P1, DOI 10.1016/S0306-4522(99)00059-7; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Gomez-Pinilla F, 1990, Neuroreport, V1, P211; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; JIANG LW, 1990, J BIOL CHEM, V265, P4775; KOO EH, 1994, J BIOL CHEM, V269, P17386; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Mathews PM, 2002, J BIOL CHEM, V277, P5299, DOI 10.1074/jbc.M108161200; McFarlane I, 1999, NEUROSCIENCE, V90, P15, DOI 10.1016/S0306-4522(98)00361-3; Nixon RA, 2001, J ALZHEIMERS DIS, V3, P97, DOI 10.3233/JAD-2001-3114; ORLACCHIO A, 2000, REC RES DEV NEUROCHE, V3, P205; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sadot E, 1998, J NEUROCHEM, V70, P428; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Skaper SD, 1998, MOL CELL NEUROSCI, V12, P179, DOI 10.1006/mcne.1998.0714; SLOANE BF, 1994, J CELL SCI, V107, P373; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880; Zhu XW, 2001, J NEUROCHEM, V79, P311, DOI 10.1046/j.1471-4159.2001.00597.x	49	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38453	38460		10.1074/jbc.M303030200	http://dx.doi.org/10.1074/jbc.M303030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878600	hybrid			2022-12-25	WOS:000185575100046
J	Maier, HJ; Marienfeld, R; Wirth, T; Baumann, B				Maier, HJ; Marienfeld, R; Wirth, T; Baumann, B			Critical role of RelB serine 368 for dimerization and p100 stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; DIFFERENTIAL REGULATION; SIGNALING PATHWAY; NF-KAPPA-B2 P100; IMMUNE-RESPONSES; B/REL FAMILY; I-REL; ACTIVATION	In mature B cells RelB-containing complexes are constitutively present in the nucleus, and they are less susceptible to inhibitory kappaB proteins. In most other cell types inhibitory kappaB proteins prevent nuclear translocation and activation of NFkappaB. We reasoned that this characteristic might be because of post-translational modifications of RelB. In Drosophila, signal-dependent phosphorylation of the Rel homologue Dorsal at serine 317 has been shown to be critical for nuclear import. The evolutionary conservation of this serine prompted us to analyze the function of the corresponding site in RelB. As a model system we used the murine S107 plasmacytoma cell line, which lacks endogenous RelB expression. Analysis of S107 cells expressing wild type RelB and serine 368 mutants reveals that serine 368 is not required for nuclear import but that it is critical for RelB dimerization with other members of the NFkappaB family. Similar effects were obtained when the conserved serine in RelA was mutated. We further demonstrate that expression of functional RelB, but not of serine 368 mutants, severely reduces p52 generation and strongly increases expression of the p52 precursor, p100. Wild type RelB, but not mutant RelB, prolonged p100 half-life. We therefore suggest an inhibitory effect of RelB on p100 processing, which is possibly regulated in a signal-dependent manner.	Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Ulm University; Howard Hughes Medical Institute; Yale University	Wirth, T (corresponding author), Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany.		Wirth, Thomas/X-7172-2019					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baumann B, 1998, J BIOL CHEM, V273, P11448, DOI 10.1074/jbc.273.19.11448; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BAUMANN B, 2002, J BIOL CHEM, V16, P16; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BOURS V, 1994, ONCOGENE, V9, P1699; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Kistler B, 1998, J IMMUNOL, V160, P2308; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1995, MOL CELL BIOL, V15, P3100; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Weih F, 1997, J IMMUNOL, V158, P5211; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004	58	44	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39242	39250		10.1074/jbc.M301521200	http://dx.doi.org/10.1074/jbc.M301521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874295	hybrid			2022-12-25	WOS:000185575100139
J	Chen, Y; Kramer, DL; Li, FZ; Porter, CW				Chen, Y; Kramer, DL; Li, FZ; Porter, CW			Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells	ONCOGENE			English	Article						survivin; apoptosis; DENSPM; IAP; ML-IAP; polyamines; siRNA	CYTOCHROME-C; BACULOVIRAL-INHIBITOR; CANCER-CELLS; IAP PROTEINS; LUNG-CANCER; PHASE-I; SURVIVIN; FAMILY; IDENTIFICATION; EXPRESSION	We have previously shown that the clinically relevant polyamine analog N-1,N-11-diethylnorspermine (DENSPM) causes rapid apoptosis in human melanoma SK-MEL-28 cells via a series of events that include mitochondrial release of cytochrome c and activation of the caspase cascade. Upstream to these events, DENSPM downregulates polyamine biosynthesis and potently upregulates polyamine catabolism at the level of spermidine/spermine All-acetyltransferase (SSAT). In searching for downstream effectors that either contribute to or abrogate the apoptotic response, we observed that DENSPM treatment of SK-MEL-28 cells for 30 h led to cytosolic release of Smac/Diablo, a mitochondrial protein known to bind and inhibit the function of inhibitor of apoptosis proteins (IAPs). Subsequently, we found that DENSPM markedly lowered survivin and ML-IAP protein (but not XIAP) levels by 18 h via an apparently Smac/Diablo-independent pathway. Proteasome inhibitors fully prevented survivin and ML-IAP protein loss as well as apoptosis, suggesting that the proteasome-mediated degradation of survivin and ML-IAP is causally linked to the cellular outcome. We also observed that structural analogs of DENSPM which differentially induced SSAT and apoptosis lowered survivin and ML-IAP levels in a manner that correlated with enzyme activity. The linkage between IAPs and SSAT was more directly established by the finding that selective prevention of SSAT induction by small interfering RNA prevented survivin and ML-IAP loss as well as apoptosis during DENSPM treatment. Among the melanoma cell lines (SK-MEL-28, MALME-3M, A375 and LOX), survivin degradation correlated temporally with the onset of DENSPM induced apoptosis or growth inhibition. By contrast, ML-IAP degradation occurred only during rapid apoptosis seen in SK-MEL-28 cells. These data suggest a sequence of events whereby DENSPM induction of SSAT leads to loss of IAP proteins and a more fulminate apoptotic response. The findings implicate survivin and ML-IAP as important determinants of polyamine analog drug action in melanoma cells.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Porter, CW (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	carl.porter@roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056, R01CA022153] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-22153, CA-16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Chen Y, 2001, CANCER RES, V61, P6437; CHEN Y, 2003, IN PRESS CANC RES; CHEN Y, 2003, UNPUB MOL PHARM; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Creaven PJ, 1997, INVEST NEW DRUG, V15, P227, DOI 10.1023/A:1005827231849; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; Hahm HA, 2002, CLIN CANCER RES, V8, P684; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kramer DL, 2001, CANCER RES, V61, P7754; Kramer DL, 1999, CANCER RES, V59, P1278; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Olie RA, 2000, CANCER RES, V60, P2805; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1988, ADV ENZYME REGUL, V27, P57; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Streiff RR, 2001, INVEST NEW DRUG, V19, P29, DOI 10.1023/A:1006448516938; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Tamm I, 1998, CANCER RES, V58, P5315; Tanaka K, 2000, CLIN CANCER RES, V6, P127; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhao J, 2000, J CELL SCI, V113, P4363	39	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4964	4972		10.1038/sj.onc.1206725	http://dx.doi.org/10.1038/sj.onc.1206725			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902979				2022-12-25	WOS:000184578900004
J	Garcia, MC; Lopez, M; Gualillo, O; Seoane, LM; Dieguez, C; Senaris, RM				Garcia, MC; Lopez, M; Gualillo, O; Seoane, LM; Dieguez, C; Senaris, RM			Hypothalamic levels of NPY, MCH, and prepro-orexin mRNA during pregnancy and lactation in the rat: role of prolactin	FASEB JOURNAL			English	Article						hypothalamus; gestation; orexigenic peptides; lactogenic hormones	MELANIN-CONCENTRATING HORMONE; STIMULATES FOOD-INTAKE; AGOUTI-RELATED PEPTIDE; NEUROPEPTIDE-Y NPY; GENE-EXPRESSION; PARAVENTRICULAR NUCLEUS; SUCKLING STIMULUS; HYPOCRETIN OREXIN; LEPTIN REGULATION; RIBONUCLEIC-ACID	Pregnancy and lactation provide excellent models of physiological hyperphagia and hyper-prolactinemia. To identify possible factors associated with the increased feeding in these situations, we measured hypothalamic mRNA levels of three orexigenic neuropeptides - NPY, MCH, and orexins - in nonpregnant, pregnant, and lactating rats by in situ hybridization. NPY mRNA content in the arcuate nucleus was significantly increased during pregnancy and lactation. However, MCH and prepro-orexin expression was decreased in both states. 48 or 72 h of fasting in pregnant and lactating rats further elevated NPY mRNA levels and increased the low MCH mRNA content. Surprisingly, no effect was observed in preproorexin mRNA levels. Finally, we investigated the possible effect of high PRL levels on these orexigenic signals using a model of hyperprolactinemia induced by pituitary graft. NPY mRNA content was unchanged, but MCH and prepro-orexin mRNA levels were significantly decreased. Our results suggest that the increased NPY expression might be partly responsible for the hyperphagia observed during pregnancy and lactation. MCH and prepro-orexin may be involved in the adaptation of other homeostatic mechanisms and their decreased levels in these physiological settings could be mediated by the elevated circulating PRL levels.	Univ Santiago de Compostela, Fac Med, Dept Physiol, Santiago De Compostela 15782, Spain	Universidade de Santiago de Compostela	Senaris, RM (corresponding author), Univ Santiago de Compostela, Fac Med, Dept Physiol, R San Francisco S-N, Santiago De Compostela 15782, Spain.	fsrsr@usc.es	seoane, luisa M/E-6570-2013; García, María C/A-7565-2014; López, Miguel/ABF-4844-2021; Gualillo, Oreste/B-8223-2008	García, María C/0000-0001-5672-1366; López, Miguel/0000-0002-7823-1648; Gualillo, Oreste/0000-0002-7154-1328; dieguez, carlos/0000-0002-0919-4337; Senaris, Rosa/0000-0002-4536-2609				BAI FL, 1985, BRAIN RES, V331, P172, DOI 10.1016/0006-8993(85)90730-9; Beck B, 1999, BIOCHEM BIOPH RES CO, V258, P119, DOI 10.1006/bbrc.1999.0605; BLUETPAJOT MT, 1995, J NEUROENDOCRINOL, V7, P297, DOI 10.1111/j.1365-2826.1995.tb00761.x; Broberger C, 1999, BRAIN RES, V848, P101, DOI 10.1016/S0006-8993(99)01977-0; Brogan RS, 1999, ENDOCRINOLOGY, V140, P2621, DOI 10.1210/en.140.6.2621; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Coya R, 1999, J NEUROENDOCRINOL, V11, P351; CRIPPS AW, 1975, BRIT J NUTR, V33, P17, DOI 10.1079/BJN19750005; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dhillon H, 2000, REGUL PEPTIDES, V92, P97, DOI 10.1016/S0167-0115(00)00155-5; Garcia MD, 2000, BIOL REPROD, V62, P698, DOI 10.1095/biolreprod62.3.698; GERARDOGETTENS T, 1989, AM J PHYSIOL, V256, pR276, DOI 10.1152/ajpregu.1989.256.1.R276; GERARDOGETTENS T, 1989, AM J PHYSIOL, V256, pR701, DOI 10.1152/ajpregu.1989.256.3.R701; Grattan D R, 2001, Prog Brain Res, V133, P153; Griffond B, 1997, J CHEM NEUROANAT, V12, P183, DOI 10.1016/S0891-0618(96)00200-1; Gualillo O, 1999, ENDOCRINOLOGY, V140, P5149, DOI 10.1210/en.140.11.5149; Gualillo O, 2002, OBES RES, V10, P682, DOI 10.1038/oby.2002.92; Jaszberenyi M, 2000, J NEUROENDOCRINOL, V12, P1174, DOI 10.1046/j.1365-2826.2000.00572.x; Kesterson RA, 1997, MOL ENDOCRINOL, V11, P630, DOI 10.1210/me.11.5.630; Kimura M, 1996, AM J PHYSIOL-REG I, V271, pR1063, DOI 10.1152/ajpregu.1996.271.4.R1063; Korner J, 2001, J NEUROENDOCRINOL, V13, P959, DOI 10.1046/j.1365-2826.2001.00716.x; LEWIS DE, 1993, AM J PHYSIOL, V264, pE279, DOI 10.1152/ajpendo.1993.264.2.E279; Li C, 1999, ENDOCRINOLOGY, V140, P118, DOI 10.1210/en.140.1.118; Li C, 1998, REGUL PEPTIDES, V75-6, P93, DOI 10.1016/S0167-0115(98)00057-3; Li C, 1998, ENDOCRINOLOGY, V139, P1645, DOI 10.1210/en.139.4.1645; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Lopez M, 2000, BIOCHEM BIOPH RES CO, V269, P41, DOI 10.1006/bbrc.2000.2245; Lopez M, 2002, NEUROENDOCRINOLOGY, V75, P34, DOI 10.1159/000048219; MARKS JL, 1993, DIABETOLOGIA, V36, P497, DOI 10.1007/BF02743264; Mondal MS, 1999, BIOCHEM BIOPH RES CO, V256, P495, DOI 10.1006/bbrc.1999.0362; Murray JF, 2000, J NEUROENDOCRINOL, V12, P217; Nishino S, 2001, ANN NEUROL, V50, P381, DOI 10.1002/ana.1130; Pi XJ, 1999, J MOL ENDOCRINOL, V23, P13, DOI 10.1677/jme.0.0230013; Pinilla L, 1999, EUR J ENDOCRINOL, V140, P468, DOI 10.1530/eje.0.1400468; Presse F, 1996, NEUROSCIENCE, V71, P735, DOI 10.1016/0306-4522(95)00481-5; Pu S, 1998, REGUL PEPTIDES, V78, P133; RICHARD D, 1985, J NUTR, V115, P593, DOI 10.1093/jn/115.5.593; ROBERTS SB, 1984, J NUTR, V114, P2193, DOI 10.1093/jn/114.12.2193; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Santiago JR, 2001, ANN INTERN MED, V134, P396, DOI 10.7326/0003-4819-134-5-200103060-00012; Sauve D, 1996, BRAIN RES, V729, P75; SCHWARTZ MW, 1993, BRAIN RES BULL, V31, P361, DOI 10.1016/0361-9230(93)90228-4; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Senaris RM, 1996, ENDOCRINOLOGY, V137, P5236, DOI 10.1210/en.137.12.5236; Seoane LM, 2003, ENDOCRINOLOGY, V144, P544, DOI 10.1210/en.2002-220795; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SMITH MS, 1981, BIOL REPROD, V24, P967, DOI 10.1095/biolreprod24.5.967; STANLEY BG, 1986, PEPTIDES, V7, P1189; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; SUGIYAMA T, 1994, J ENDOCRINOL, V141, P325, DOI 10.1677/joe.0.1410325; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takekawa S, 2002, EUR J PHARMACOL, V438, P129, DOI 10.1016/S0014-2999(02)01314-6; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; TRAYHURN P, 1989, CAN J PHYSIOL PHARM, V67, P370, DOI 10.1139/y89-060; VOLOSCHIN LM, 1979, ENDOCRINOLOGY, V105, P1202, DOI 10.1210/endo-105-5-1202; Whitelegge T., 1890, REC AUST MUS, V1, P41, DOI DOI 10.3853/J.0067-1975.1.1890.1224; Wilding JPH, 1997, J ENDOCRINOL, V152, P365, DOI 10.1677/joe.0.1520365; Xu M, 2000, NEUROENDOCRINOLOGY, V72, P263, DOI 10.1159/000054595; Zhang SQ, 1999, PSYCHIAT CLIN NEUROS, V53, P101, DOI 10.1046/j.1440-1819.1999.00504.x	61	87	91	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1392	1400		10.1096/fj.02-0933com	http://dx.doi.org/10.1096/fj.02-0933com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890692				2022-12-25	WOS:000185345100031
J	Georget, M; Mateo, P; Vandecasteele, G; Lipskaia, L; Defer, N; Hanoune, J; Hoerter, J; Lugnier, C; Fischmeister, R				Georget, M; Mateo, P; Vandecasteele, G; Lipskaia, L; Defer, N; Hanoune, J; Hoerter, J; Lugnier, C; Fischmeister, R			Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8)	FASEB JOURNAL			English	Article						transgenic mouse; cAMP; isolated heart; L-type Ca2+ current; beta-adrenoceptors; muscarinic receptors; phosphodiesterase; compartmentation	PROTEIN-KINASE; NUCLEOTIDE PHOSPHODIESTERASES; MUSCARINIC RECEPTORS; CALCIUM CURRENT; PHOSPHORYLATION; CONTRACTILITY; ACTIVATION; SUBTYPES; CLONING; CANINE	Hearts from AC8TG mice develop a higher contractility (LVSP) and larger Ca2+ transients than NTG mice, with (surprisingly) no modification in L-type Ca2+ channel current (I-Ca,I-L) (1). In this study, we examined the cardiac response of AC8TG mice to beta-adrenergic and muscarinic agonists and IBMX, a cyclic nucleotide phosphodiesterase (PDE) inhibitor. Stimulation of LVSP and I-Ca,I-L by isoprenaline (ISO, 100 nM) was twofold smaller in AC8TG vs. NTG mice. In contrast, IBMX (100 muM) produced a twofold higher stimulation of ICa, L in AC8TG vs. NTG mice. IBMX (10 muM) increased LVSP by 40% in both types of mice, but contraction and relaxation were hastened in AC8TG mice only. Carbachol (10 muM) had no effect on basal contractility in NTG hearts but decreased LVSP by 50% in AC8TG mice. PDE assays demonstrated an increase in cAMP-PDE activity in AC8TG hearts, mainly due to an increase in the hydrolytic activity of PDE4 and PDE1 toward cAMP and a decrease in the activity of PDE1 and PDE2 toward cGMP. We conclude that cardiac expression of AC8 is accompanied by a rearrangement of PDE isoforms, leading to a strong compartmentation of the cAMP signal that shields L-type Ca2+ channels and protects the cardiomyocytes from Ca2+ overload.	Univ Paris Sud, Fac Pharm, INSERM, U446,Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France; Hop Henri Mondor, INSERM, U99, Lab Regulat Genes & Signalisat Cellulaire, F-94010 Creteil, France; Univ Strasbourg, CNRS, UMR 7034, Lab Pharmacol & Physicochim Interact Cellulaires, F-67401 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Fischmeister, R (corresponding author), Univ Paris Sud, Fac Pharm, INSERM, U446,Lab Cardiol Cellulaire & Mol, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	Fisch@vjf.inserm.fr	Lipskaia, Larissa/AAK-9322-2020; lugnier, claire/AAF-3911-2020; Fischmeister, Rodolphe/L-6061-2018; Vandecasteele, Gregoire/M-2922-2018	Fischmeister, Rodolphe/0000-0003-2086-9865; Vandecasteele, Gregoire/0000-0002-4046-4171				BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bers DM, 2001, CIRC RES, V89, P373, DOI 10.1161/res.89.5.373; Boknik P, 1997, J CARDIOVASC PHARM, V30, P750, DOI 10.1097/00005344-199712000-00009; Brodde OE, 1999, PHARMACOL REV, V51, P651; BRUNTON LL, 1979, NATURE, V280, P78, DOI 10.1038/280078a0; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; DEFER N, 1994, FEBS LETT, V351, P109, DOI 10.1016/0014-5793(94)00836-1; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Dhein S, 2001, PHARMACOL RES, V44, P161, DOI 10.1006/phrs.2001.0835; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; EcklyMichel A, 1997, BRIT J PHARMACOL, V122, P158, DOI 10.1038/sj.bjp.0701339; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; GEORGET M, 2002, FASEB J, DOI DOI 10.1096/F4.02-0292F4E; HAYES JS, 1979, P NATL ACAD SCI USA, V76, P1570, DOI 10.1073/pnas.76.4.1570; HOHL CM, 1991, CIRC RES, V69, P1369, DOI 10.1161/01.RES.69.5.1369; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Jiang Xin, 1998, Cell Biochemistry and Biophysics, V28, P135, DOI 10.1007/BF02737809; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KERAVIS TM, 1980, BIOCHIM BIOPHYS ACTA, V613, P116, DOI 10.1016/0005-2744(80)90198-9; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Lipskaia L, 2000, CIRC RES, V86, P795, DOI 10.1161/01.RES.86.7.795; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lugnier C, 1999, BBA-GEN SUBJECTS, V1472, P431, DOI 10.1016/S0304-4165(99)00145-2; LUGNIER C, 1993, J PHARMACOL EXP THER, V265, P1142; MERY PF, 1995, MOL PHARMACOL, V48, P121; Mery PF, 1997, LIFE SCI, V60, P1113, DOI 10.1016/S0024-3205(97)00055-6; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; Okruhlicova L, 1996, HISTOCHEM J, V28, P165, DOI 10.1007/BF02331440; OKRUHLICOVA L, 1998, EXP CLIN CARDIOL, V3, P188; Petroff MGV, 2001, CIRC RES, V89, P445, DOI 10.1161/hh1701.095716; Rapundalo ST, 1998, CARDIOVASC RES, V38, P559, DOI 10.1016/S0008-6363(98)00063-7; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991; Sonnenburg WK, 1998, METHODS, V14, P3, DOI 10.1006/meth.1997.0561; Steinberg SF, 1999, CIRC RES, V85, P1101; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Stoclet J.C., 1995, EXPERT OPIN INV DRUG, V4, P1081; Vandecasteele G, 1999, NAT MED, V5, P331, DOI 10.1038/6553; Verde I, 1999, BRIT J PHARMACOL, V127, P65, DOI 10.1038/sj.bjp.0702506; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; Xiao RP, 1999, CIRC RES, V85, P1092; XIAO RP, 1994, J BIOL CHEM, V269, P19151	48	54	57	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1380	1391		10.1096/fj.02-0784com	http://dx.doi.org/10.1096/fj.02-0784com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890691	Green Submitted			2022-12-25	WOS:000185345100030
J	Walker, GA; Thompson, FJ; Brawley, A; Scanlon, T; Devaney, E				Walker, GA; Thompson, FJ; Brawley, A; Scanlon, T; Devaney, E			Heat shock factor functions at the convergence of the stress response and developmental pathways in Caenorhabditis elegans	FASEB JOURNAL			English	Article						dauer pathway; thermotolerance; life span	DAUER FORMATION; TRANSCRIPTION FACTORS; GENETIC-ANALYSIS; EXPRESSION; AGE; THERMOTOLERANCE; THERMOTAXIS; PARALLEL; RECEPTOR; MUTANT	Heat shock factor (HSF) is best characterized as the transcriptional regulator of heat shock protein genes, required by all cells to survive periods of stress. Recent evidence suggests that HSF also functions to regulate the expression of genes involved in growth and development under normal physiological conditions. In this study, we used RNA interference (RNAi) assays to investigate the role of HSF in Caenorhabditis elegans. Exposure of wild-type worms to hsf dsRNAi constructs caused a temperature-sensitive developmental arrest at the L2/L3 stage. At normal growth temperatures, hsf(RNAi) worms that developed to adults were small and scrawny, largely infertile, and showed a significant reduction in life span. These results demonstrate that HSF is required for normal postembryonic development under physiological conditions. Following heat shock, hsf(RNAi) worms were thermosensitive and displayed a significant reduction of hsp16 expression. When hsf(RNAi) was carried out in various dauer-constitutive mutant backgrounds, a dramatic reversal of dauer formation was observed, indicating that HSF is also required in the dauer pathway. In its natural habitat of the soil, where C. elegans is exposed to a constantly fluctuating environment; the ability to integrate the stress response with development may be an essential element of its ecology.	Univ Glasgow, Inst Comparat Med, Glasgow, Lanark, Scotland	University of Glasgow	Devaney, E (corresponding author), Univ Glasgow, Inst Comparat Med, Bearsden Rd, Glasgow, Lanark, Scotland.	e.devaney@vet.gla.ac.uk		Devaney, Eileen/0000-0002-1935-834X				Ailion M, 2000, GENETICS, V156, P1047; Antebi A, 2000, GENE DEV, V14, P1512; Antebi A, 1998, DEVELOPMENT, V125, P1191; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Garigan D, 2002, GENETICS, V161, P1101; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; HEDGECOCK EM, 1975, P NATL ACAD SCI USA, V72, P4061, DOI 10.1073/pnas.72.10.4061; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; Koga M, 1999, DEVELOPMENT, V126, P5387; LARSEN PL, 1995, GENETICS, V139, P1567; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; MORI I, 1995, NATURE, V376, P344, DOI 10.1038/376344a0; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Riddle DL, 1997, C ELEGANS, P739; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Sulston J., 1988, NEMATODE CAENORHABDI, P587; THOMAS JH, 1993, GENETICS, V134, P1105; Thompson FJ, 2001, EUR J BIOCHEM, V268, P5808, DOI 10.1046/j.0014-2956.2001.02525.x; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; VOWELS JJ, 1992, GENETICS, V130, P105; Walker GA, 2003, AGING CELL, V2, P131, DOI 10.1046/j.1474-9728.2003.00045.x; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5	35	54	64	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1960	+		10.1096/fj.03-0164fje	http://dx.doi.org/10.1096/fj.03-0164fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897069				2022-12-25	WOS:000185345100027
J	Molton, SA; Todd, DE; Cook, SJ				Molton, SA; Todd, DE; Cook, SJ			Selective activation of the c-Jun N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3 '-kinase (PI3K) pathway is inhibited	ONCOGENE			English	Article						apoptosis; Bcl-2; JNK; MEKK1; PI3K; PKB	KAPPA-B KINASE; FORKHEAD TRANSCRIPTION FACTOR; PROGRAMMED CELL-DEATH; BCL-2 FAMILY MEMBER; PROTEIN-KINASE; FAS LIGAND; SIGNAL-TRANSDUCTION; MAP KINASES; MEK KINASE; NH2-TERMINAL KINASE	c-Jun N-terminal kinase (JNK) is activated when cells are exposed to noxious stimuli. The role of JNK in apoptosis is subject to considerable debate; for example, JNK activation may promote or inhibit apoptosis depending on the cell type and stimulus involved. These conflicting results have arisen in part because few studies have successfully separated JNK activation from the primary stress-induced damage or from other stress-induced signalling pathways. Here we describe a conditional mutant, DeltaMEKK1:ER*, which allows selective activation of the JNK cascade in the absence of any cellular stress. Activation of DeltaMEKK1:ER* in CC139 fibroblasts resulted in the rapid and sustained activation of JNK without activating ERK or p38 or promoting IkappaBalpha phosphorylation. Activation of AMEKK1:ER* caused a reversible halt in cell growth but failed to induce apoptosis. In contrast, treatment of cells with LY294002, to inhibit phosphoinositide 3-kinase (PI3K), caused downregulation of Bcl-2 and Mcl-1 and allowed AMEKK1:ER* to elicit a robust apoptotic response characterized by activation of Bax and caspases. This PI3K-inhibitable, JNK-induced death response was not impeded, but actually accelerated, by cycloheximide. This suggests that JNK-induced activation of Bax and cell death does not require the upregulation of pro-death genes such as Bim or FasL, but rather proceeds through preexisting components. However, if the PI3K cell survival pathway is not inhibited, even sustained activation of JNK exerts no overt proapoptotic effect in CC139 cells.	Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England.				Biotechnology and Biological Sciences Research Council [BBS/E/B/0000H457, BBS/E/B/0000C199] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ADLER V, 1992, J BIOL CHEM, V267, P17001; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Levresse V, 2000, J NEUROSCI RES, V62, P799; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YAN MH, 1994, NATURE, V372, P798; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	62	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4690	4701		10.1038/sj.onc.1206692	http://dx.doi.org/10.1038/sj.onc.1206692			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879014				2022-12-25	WOS:000184157000010
J	Konduri, SD; Srivenugopal, KS; Yanamandra, N; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Ali-Osman, F; Kondraganti, S; Lakka, SS; Rao, JS				Konduri, SD; Srivenugopal, KS; Yanamandra, N; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Ali-Osman, F; Kondraganti, S; Lakka, SS; Rao, JS			Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), in human glioma cells	ONCOGENE			English	Article						TFPI-2; 5 '-CpG methylation; gliomas; methyl CpG-group binding protein; historic deacetylation; gene silencing; epigenetic mechanisms; proteinase inhibitor	HISTONE DEACETYLASE INHIBITION; IN-VITRO; TRANSCRIPTIONAL REPRESSOR; PROTEASE INHIBITOR; CANCER-CELLS; CDNA CLONING; GENE; DNA; MATRIX; EXPRESSION	We have shown previously that the tissue factor pathway inhibitor-2 (TFPI-2), a broad range proteinase inhibitor, is highly expressed in low-grade gliomas, but, minimally expressed or undetectable in glioblastomas, and that enforced expression of this gene reduces the invasive properties of brain tumor cells. Here, we examined the role of promoter methylation as a mechanism of TFPI-2 gene silencing. In SNB19 glioblastoma cells, which have no detectable TFPI-2 expression, 5-aza-2'-deoxycytidine (5aC), an inhibitor of DNA methyltransferase, induced TFPI-2 mRNA in a dose-dependent manner. Trichostatin A (TSA), the histone deacetylase (HDAC) inhibitor, by itself, was more efficient than 5aC in inducing TFPI-2 transcripts, and the 5aC + TSA combination resulted in highly synergistic reactivation of the gene, both at the transcript and protein levels. In Hs683 glioma cells, which express the TFPI-2 gene at high levels, transfection of the in vitro methylated TFPI-2 promoter constructs resulted in a drastic decrease of promoter activity compared to the unmethylated promoter. Further, the methylation-specific PCR in SNB19 and Hs683 cells showed that TFPI-2 gene repression was closely linked with methylation of the CpG islands in the promoter. Finally, the chromatin immunoprecipitation assays in SNB19 cells showed that the methylated and repressed TFPI-2 promoter was associated with the methyl-CpG binding protein 2 (MeCP2), and that gene reactivation resulted in the loss of MeCP2 from this site. These studies establish that TFPI-2 is transcriptionally silenced through promoter methylation in SNB19 cells.	Univ Illinois, Coll Med, Program Canc Biol, Peoria, IL 61656 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Neuropathol, Peoria, IL USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Illinois System; University of Illinois Peoria; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Zymogenet Inc.; University of New Mexico; University of New Mexico's Health Sciences Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.ed						BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; Esteller M, 2001, CANCER RES, V61, P3225; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; McQueen HA, 1998, GENOME RES, V8, P621, DOI 10.1101/gr.8.6.621; Miyagi Y, 1996, DNA CELL BIOL, V15, P947, DOI 10.1089/dna.1996.15.947; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; RAO JS, 1993, CANCER RES, V53, P2208; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Yang XW, 2001, CANCER RES, V61, P7025	31	61	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4509	4516		10.1038/sj.onc.1206695	http://dx.doi.org/10.1038/sj.onc.1206695			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881707				2022-12-25	WOS:000184054700006
J	Soares, P; Trovisco, V; Rocha, AS; Lima, J; Castro, P; Preto, A; Maximo, V; Botelho, T; Seruca, R; Sobrinho-Simoes, M				Soares, P; Trovisco, V; Rocha, AS; Lima, J; Castro, P; Preto, A; Maximo, V; Botelho, T; Seruca, R; Sobrinho-Simoes, M			BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC	ONCOGENE			English	Article						BRAF; RET/PTC; thyroid; papillary carcinoma	THYROID-TUMORS; CARCINOMA; CANCER; GENE; ONCOGENES; MELANOMA	Rearrangement of RET proto-oncogene is the major event in the etiopathogenesis of papillary thyroid carcinoma (PTC). We report a high prevalence of BRAF(V599E) mutation in sporadic PTC and in PTC-derived cell lines. The BRAF(V599E) mutation was detected in 23 of 50 PTC (46%) and in three of four PTC-derived cell lines. The prevalence of the BRAF(V599E) mutation in PTC is the highest reported to date in human carcinomas, being only exceeded by melanoma. PTC with RET/PTC rearrangement as well as the TPC-1 cell line (the only one harboring RET/PTC rearrangement) did not show the BRAF(V599E) mutation. BRAF(V599E) mutation was not detected in any of 23 nodular goiters, 51 follicular adenomas and 18 follicular carcinomas. A distinct mutation in BRAF (codon K600E) was detected in a follicular adenoma. Activating mutations in RAS genes were detected in 15% of FA, 33% of FTC and 7% of PTC. BRAF(V599E) mutation did not coexist with alterations in any of the RAS genes in any of the tumors. These results suggest that BRAF(V599E) mutation is frequent in the etiopathogenesis of PTC. The BRAF(V599E) mutation appears to be an alternative event to RET/PTC rearrangement rather than to RAS mutations, which are rare in PTC. BRAF(V599E) may represent an alternative pathway to oncogenic MAPK activation in PTCs without RET/PTC activation.	IPATIMUP, P-4200465 Oporto, Portugal; Hosp Sao Joao, Dept Pathol, Oporto, Portugal; Fac Med Porto, Dept Pathol, Oporto, Portugal	Sao Joao Hospital; Universidade do Porto	Sobrinho-Simoes, M (corresponding author), IPATIMUP, Rua Roberto Frias S-N, P-4200465 Oporto, Portugal.		Preto, Ana/H-8112-2012; Sobrinho-Simões, Manuel/J-8290-2013; Lima, Jorge/J-5975-2013; seruca, raquel/F-8187-2011; Castro, Patricia/J-8537-2013; Maximo, Valdemar/E-7480-2011; Soares, Paula/B-6054-2008	Preto, Ana/0000-0002-7302-0630; Lima, Jorge/0000-0001-7780-0901; Maximo, Valdemar/0000-0002-8631-8356; Soares, Paula/0000-0001-9607-6998; Castro, Patricia/0000-0001-9588-9065; Sobrinho-Simoes, Manuel/0000-0003-1613-1235; Oliveira Botelho, Tiago/0000-0002-2456-8421; Seruca, Raquel/0000-0002-8851-4166				Brose MS, 2002, CANCER RES, V62, P6997; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; KOVACS K, 1991, FUNCTIONAL ENDOCRINE; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Ludwig L, 2001, CANCER RES, V61, P4526; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Naoki K, 2002, CANCER RES, V62, P7001; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, NATURE, V417, P906, DOI 10.1038/417906a; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; ROSAI J, 1992, TUMORS THYROID GLAND; Soares P, 1998, J PATHOL, V185, P71; Soares P, 1997, EUR J CANCER, V33, P293, DOI 10.1016/S0959-8049(96)00457-1; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; Yuen ST, 2002, CANCER RES, V62, P6451	20	498	522	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4578	4580		10.1038/sj.onc.1206706	http://dx.doi.org/10.1038/sj.onc.1206706			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881714				2022-12-25	WOS:000184054700013
J	Alter-Koltunoff, M; Ehrlich, S; Dror, N; Azriel, A; Eilers, M; Hauser, H; Bowen, H; Barton, CH; Tamura, T; Ozato, K; Levi, BZ				Alter-Koltunoff, M; Ehrlich, S; Dror, N; Azriel, A; Eilers, M; Hauser, H; Bowen, H; Barton, CH; Tamura, T; Ozato, K; Levi, BZ			Nramp1-mediated innate resistance to intraphagosomal pathogens is regulated by IRF-8, PU.1, and Miz-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; IL-18 GENE-EXPRESSION; TRANSCRIPTION FACTOR; GP91(PHOX) EXPRESSION; NATURAL-RESISTANCE; COMPLEX-FORMATION; MYC REPRESSES; C-MYC; MACROPHAGES; ICSBP	Natural resistance-associated macrophage protein 1 (Nramp1) is a proton/divalent cation antiporter exclusively expressed in monocyte/macrophage cells with a unique role in innate resistance to intraphagosomal pathogens. In humans, it is linked to several infectious diseases, including leprosy, pulmonary tuberculosis, visceral leishmaniasis, meningococcal meningitis, and human immunodeficiency virus as well as to autoimmune diseases such as rheumatoid arthritis and Crohn's disease. Here we demonstrate that the restricted expression of Nramp1 is mediated by the macrophage-specific transcription factor IRF-8. This factor exerts its activity via protein-protein interaction, which facilitates its binding to target DNA. Using yeast two-hybrid screen we identified Myc Interacting Zinc finger protein 1 (Miz-1) as new interacting partner. This interaction is restricted to immune cells and takes place on the promoter Nramp1 in association with PU.1, a transcription factor essential for myelopoiesis. Consistent with these data, IRF-8 knockout mice are sensitive to a repertoire of intracellular pathogens. Accordingly, IRF-8(-/-) mice express low levels of Nramp1 that can not be induced any further. Thus, our results explain in molecular terms the role of IRF-8 in conferring innate resistance to intracellular pathogens and point to its possible involvement in autoimmune diseases.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Univ Marburg, Inst Mol Biol & Tumour Res, D-35033 Marburg, Germany; GBF, Gesell Biotechnol Forsch GmbH, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany; Univ Southampton, Dept Biochem & Mol Biol, Southampton S016 7PX, Hants, England; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Technion Israel Institute of Technology; Philipps University Marburg; Gesellschaft fur Biotechnologische Forschung mbH; Helmholtz Association; Helmholtz-Center for Infection Research; University of Southampton; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Levi, BZ (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.			Eilers, Martin/0000-0002-0376-6533	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001310] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akira S, 2000, CURR OPIN IMMUNOL, V12, P59, DOI 10.1016/S0952-7915(99)00051-5; BARBER SA, 1995, INFECT IMMUN, V63, P601, DOI 10.1128/IAI.63.2.601-608.1995; Barton CH, 1999, J LEUKOCYTE BIOL, V66, P757, DOI 10.1002/jlb.66.5.757; Blackwell JM, 2003, IMMUNOL LETT, V85, P197, DOI 10.1016/S0165-2478(02)00231-6; Bowen H, 2002, J BIOL CHEM, V277, P34997, DOI 10.1074/jbc.M204232200; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; BRITTON W, 2001, IMMUNOLOGY, P371; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen H, 2000, J BIOL CHEM, V275, P39081, DOI 10.1074/jbc.M004900200; Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Giese NA, 1997, J EXP MED, V186, P1535, DOI 10.1084/jem.186.9.1535; Hashmueli S, 2003, INT IMMUNOL, V15, P807, DOI 10.1093/intimm/dxg077; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Kantakamalakul W, 1999, J IMMUNOL, V162, P7417; Kautz B, 2001, J BIOL CHEM, V276, P37868; Kim YM, 1999, J IMMUNOL, V163, P2000; Kim YM, 2000, J IMMUNOL, V165, P3198, DOI 10.4049/jimmunol.165.6.3198; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; Levi BZ, 2002, J INTERF CYTOK RES, V22, P153, DOI 10.1089/107999002753452764; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Masumi A, 2002, FEBS LETT, V531, P348, DOI 10.1016/S0014-5793(02)03556-1; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Meraro D, 1999, J IMMUNOL, V163, P6468; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; Perkel JM, 1998, J IMMUNOL, V160, P241; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schaper F, 1998, BIOCHEM J, V335, P147, DOI 10.1042/bj3350147; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; Sharf R, 1997, J BIOL CHEM, V272, P9785; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Wyllie S, 2002, MICROBES INFECT, V4, P351, DOI 10.1016/S1286-4579(02)01548-4; Xiong HB, 2003, J BIOL CHEM, V278, P2271, DOI 10.1074/jbc.M209583200	52	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44025	44032		10.1074/jbc.M307954200	http://dx.doi.org/10.1074/jbc.M307954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12904288	hybrid			2022-12-25	WOS:000186306700018
J	Li, GY; Wang, SF; Gelehrter, TD				Li, GY; Wang, SF; Gelehrter, TD			Identification of glucocorticoid receptor domains involved in transrepression of transforming growth factor-beta action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; STEROID-HORMONE RECEPTORS; DEPENDENT TRANSCRIPTIONAL ACTIVATION; NEGATIVE CROSS-TALK; TGF-BETA; SMAD PROTEINS; DNA-BINDING; GENE-EXPRESSION; ANTIINFLAMMATORY ACTION; INHIBITOR-1 PROMOTER	The transforming growth factor-beta (TGF-beta) and glucocorticoid signaling pathways interact both positively and negatively in regulating a variety of physiological and pathologic processes. We previously reported that liganded glucocorticoid receptor (GR) repressed TGF-beta induction of human plasminogen activator inhibitor-1 gene transcription by directly targeting the transcriptional activation function of Smad3. To identify the domain( s) in the glucocorticoid receptor involved in this repression, we have examined the ability of various GR truncation, deletion, and substitution mutants to repress TGF-beta transactivation in Hep3B human hepatoma cells that lack functional endogenous GR. Partial deletions in the ligand-binding domain (LBD), including the tau2 and tauc regions, greatly reduced or eliminated GR repression, whereas deletion of the N-terminal AF1 (tau1) domain and substitution mutations in the DNA-binding domain had little or no effect. Liganded androgen receptor repressed TGF-beta transactivation, whereas mineralocorticoid receptor did not, and studies with rat GR-mineralocorticoid receptor chimeras confirmed that the GR C-terminal domains were required for repression. RU486, a strong antagonist of transactivation by GR, partially reversed repression by wild type GR. Co-immunoprecipitation experiments in Hep3B cells indicated that physical interaction between GR and Smad3 is necessary but not sufficient for repression. Physical interaction required activation of Smad3 by TGF-beta but not dexamethasone binding to GR. Glutathione S-transferase pull-down assays demonstrated that several regions of the LBD could mediate GR-Smad3 physical interaction. We conclude that the LBD of GR, but not the DNA-binding domain or the N-terminal activation domain, is required for GR-mediated transrepression of TGF-beta transactivation.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Gelehrter, TD (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, 4909 Buhl Bldg,Box 0618,1241 E Catherine St, Ann Arbor, MI 48109 USA.				NIAMS NIH HHS [P60 AR 20557] Funding Source: Medline; NIDDK NIH HHS [P60 DK 20572] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Chou WC, 2003, MOL BIOL CELL, V14, P1279, DOI 10.1091/mbc.E02-07-0375; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GULLER S, 1995, J CLIN ENDOCR METAB, V80, P3273, DOI 10.1210/jc.80.11.3273; Hayes SA, 2001, CANCER RES, V61, P2112; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; JOHNSON BH, 1993, CELL GROWTH DIFFER, V4, P25; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kanatani Y, 1996, CELL GROWTH DIFFER, V7, P187; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Milhon J, 1997, MOL ENDOCRINOL, V11, P1795, DOI 10.1210/me.11.12.1795; Miyazono K, 2000, J CELL SCI, V113, P1101; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; ONATE SA, 1995, SCIENCE, V270, P1354; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROBERTS AB, 1990, PHILOS T R SOC B, V327, P145, DOI 10.1098/rstb.1990.0050; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SLAVIN J, 1994, GROWTH FACTORS, V11, P205, DOI 10.3109/08977199409046918; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Su SM, 1996, DNA CELL BIOL, V15, P1039, DOI 10.1089/dna.1996.15.1039; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	73	21	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41779	41788		10.1074/jbc.M305350200	http://dx.doi.org/10.1074/jbc.M305350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902338	hybrid			2022-12-25	WOS:000185989500029
J	Lodhi, KM; Ozdener, MH; Shayiq, RM				Lodhi, KM; Ozdener, MH; Shayiq, RM			The upstream open reading frame mediates constitutive effects on translation of cytochrome P-450c27 from the seventh in-frame AUG codon in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL RIBOSOME ENTRY; DECARBOXYLASE MESSENGER-RNA; SERINE-PROTEASE INHIBITOR; VITAMIN-D; INITIATION; CHOLESTEROL; GENE; REINITIATION; EXPRESSION; MECHANISM	The 2.3-kb mRNA that codes for cytochrome P-450c27 (CYP27) has an unexpectedly long 5'-untranslated region (UTR) that holds six AUGs, leading to several upstream open reading frames (uORFs). The initiation of translation from the seventh AUG forms a putative 55-kDa precursor, which is processed in mitochondria to form a 52-kDa mature protein. The first three AUGs form fully overlapping uORF1, uORF2, and uORF3 that are in-frame with the seventh AUG and next two form fully overlapping uORF4 and uORF5 that are out-of-frame with the seventh AUG. Although not recognized by the scanning ribosomes under normal conditions, the sixth in-frame AUG forms a putative 57-kDa extension of the main open reading frame. The purpose of this study was to identify the elements in the 5'-UTR that direct CYP27 mRNA translation exclusively from the seventh AUG. Expression of 5' deletion mutants in COS cells reveal that the intact 5'-UTR not only directs the initiation of translation from the seventh AUG but also acts as a negative regulator. A 2-kb deletion mutant that lacks uORF1 initiates translation equally from the sixth and the seventh AUGs, forming both 57- and 55-kDa precursor proteins with a 2-fold increase in rate of translation. However, induction in translation does not affect the levels of the mature 52-kDa form in mitochondria but causes accumulation of the precursor form in cytosol not seen in COS cells transfected with wild-type cDNA. Mutation of the stop codon that terminates uORF1 completely shifts the initiation of translation from the seventh to the first AUG, forming a 67-kDa precursor that is processed into a 52-kDa mature protein in mitochondria. Confirmation of the bicistronic nature of CYP27 mRNA by epitope mapping of uORF1 suggests that translation of CYP27 mRNA from the seventh AUG is directed and regulated by uORF1 expression.	Thomas Jefferson Univ, Dept Med, Div Clin Pharmacol, Philadelphia, PA 19107 USA	Jefferson University	Shayiq, RM (corresponding author), Thomas Jefferson Univ, Dept Med, Div Clin Pharmacol, Philadelphia, PA 19107 USA.	rmshayiq@hotmail.com	Ozdener, Mehmet Hakan/I-4097-2019		NIGMS NIH HHS [GM50290] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1991, BIOCHEMISTRY-US, V30, P19947; ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BJORKHEM J, 1985, STEROLS BILE ACIDS, P231; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; CANCELA L, 1988, HORMONES THEIR ACT 1, P269; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; Cao JH, 1996, MOL CELL BIOL, V16, P603; CARTER G, 1993, BRIT J CANCER, V67, P869, DOI 10.1038/bjc.1993.164; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGNIN CR, 1993, J VIROL, V67, P5514, DOI 10.1128/JVI.67.9.5514-5521.1993; DELUCA HF, 1981, HARVEY LECT, V75, P333; DELUCA HF, 1976, ANNU REV BIOCHEM, V45, P631, DOI 10.1146/annurev.bi.45.070176.003215; FRIEDLANDER EJ, 1975, ARCH BIOCHEM BIOPHYS, V170, P731, DOI 10.1016/0003-9861(75)90171-X; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; GRANT CM, 1994, MOL CELL BIOL, V14, P606, DOI 10.1128/MCB.14.1.606; GRANT CM, 1995, NUCLEIC ACIDS RES, V23, P3980, DOI 10.1093/nar/23.19.3980; HENERY HL, 1980, VITAMIN D MOL BIOL C, P127; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HILL JR, 1993, J BIOL CHEM, V268, P726; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; MORITA T, 1982, J BIOL CHEM, V257, P547; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; NIRANJAN BG, 1988, J BIOL CHEM, V263, P575; NISHIKURA K, 1992, ANN NY ACAD SCI, V660, P240, DOI 10.1111/j.1749-6632.1992.tb21076.x; Oumard A, 2000, MOL CELL BIOL, V20, P2755, DOI 10.1128/MCB.20.8.2755-2759.2000; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; Ritchie H, 1997, BIOCHEM BIOPH RES CO, V231, P425, DOI 10.1006/bbrc.1997.6126; ROSSI V, 1992, NUCLEIC ACIDS RES, V20, P1061, DOI 10.1093/nar/20.5.1061; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; SAKAKI T, 1992, J BIOL CHEM, V267, P16497; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAYIQ RM, 1989, BIOCHEMISTRY-US, V28, P7546, DOI 10.1021/bi00445a008; SHAYIQ RM, 1994, ANAL BIOCHEM, V221, P206, DOI 10.1006/abio.1994.1400; SHAYIQ RM, 1990, BIOCHEMISTRY-US, V29, P866, DOI 10.1021/bi00456a003; SHAYIQ RM, 1992, J BIOL CHEM, V267, P2421; Shayiq RM, 1997, J BIOL CHEM, V272, P4050; Sloan J, 1999, NUCLEIC ACIDS RES, V27, P854, DOI 10.1093/nar/27.3.854; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; USUI E, 1990, FEBS LETT, V274, P175, DOI 10.1016/0014-5793(90)81357-T; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vilela C, 1999, EMBO J, V18, P3139, DOI 10.1093/emboj/18.11.3139; Wang LJ, 1998, PLANT CELL, V10, P1733, DOI 10.1105/tpc.10.10.1733; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; Wikvall K, 2001, INT J MOL MED, V7, P201; Wu HJ, 1998, J BIOL CHEM, V273, P2532, DOI 10.1074/jbc.273.5.2532; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; YOON JB, 1990, J BIOL CHEM, V265, P19947	83	2	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40647	40657		10.1074/jbc.M302081200	http://dx.doi.org/10.1074/jbc.M302081200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909643	hybrid			2022-12-25	WOS:000185847200029
J	Miyanoiri, Y; Kobayashi, H; Imai, T; Watanabe, M; Nagata, T; Uesugi, S; Okano, H; Katahira, M				Miyanoiri, Y; Kobayashi, H; Imai, T; Watanabe, M; Nagata, T; Uesugi, S; Okano, H; Katahira, M			Origin of higher affinity to RNA of the N-terminal RNA-binding domain than that of the C-terminal one of a mouse neural protein, Musashi1, as revealed by comparison of their structures, modes of interaction, surface electrostatic potentials, and backbone dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASYMMETRIC CELL-DIVISION; MESSENGER-RNA; STEM-CELLS; HNRNP D0; CNS; RECOGNITION; MOUSE-MUSASHI-1; DETERMINANTS; SPECIFICITY; REPRESSION	Musashi1 is an RNA-binding protein abundantly expressed in the developing mouse central nervous system. Its restricted expression in neural precursor cells suggests that it is involved in maintenance of the character of progenitor cells. Musashi1 contains two ribonucleoprotein-type RNA-binding domains (RBDs), RBD1 and RBD2, the affinity to RNA of RBD1 being much higher than that of RBD2. We previously reported the structure and mode of interaction with RNA of RBD2. Here, we have determined the structure and mode of interaction with RNA of RBD1. We have also analyzed the surface electrostatic potential and backbone dynamics of both RBDs. The two RBDs exhibit the same ribonucleoprotein-type fold and commonly make contact with RNA on the beta-sheet side. On the other hand, there is a remarkable difference in surface electrostatic potential, the beta-sheet of RBD1 being positively charged, which is favorable for binding negatively charged RNA, but that of RBD2 being almost neutral. There is also a difference in backbone dynamics, the central portion of the beta-sheet of RBD1 being flexible, but that of RBD2 not being flexible. The flexibility of RBD1 may be utilized in the recognition process to facilitate an induced fit. Thus, comparative studies have revealed the origin of the higher affinity of RBD1 than that of RBD2 and indicated that the affinity of an RBD to RNA is not governed by its fold alone but is also determined by its surface electrostatic potential and/or backbone dynamics. The biological role of RBD2 with lower affinity is also discussed.	Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan; Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan	Yokohama National University; Keio University	Katahira, M (corresponding author), Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodogaya Ku, 79-7 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.		Nagata, Takashi/D-4547-2018; Imai, Takao/L-1232-2013; Okano, Hideyuki/I-7584-2019	Nagata, Takashi/0000-0002-3733-2709; Miyanoiri, Yohei/0000-0001-6889-5160				Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Giesen K, 1997, DEVELOPMENT, V124, P2307; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kurihara Y, 1997, GENE, V186, P21, DOI 10.1016/S0378-1119(96)00673-7; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; Mittermaier A, 1999, J MOL BIOL, V294, P967, DOI 10.1006/jmbi.1999.3311; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nagata T, 1999, J MOL BIOL, V287, P221, DOI 10.1006/jmbi.1999.2616; Nagata T, 1999, J MOL BIOL, V287, P315, DOI 10.1006/jmbi.1999.2596; NAKAMURA H, 1994, J LOW FREQ NOISE VIB, V13, P1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okabe M, 2001, NATURE, V411, P94, DOI 10.1038/35075094; Okano H, 2002, J CELL SCI, V115, P1355; Okano HJ, 1997, J NEUROSCI, V17, P3024; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Sakakibara S, 2002, P NATL ACAD SCI USA, V99, P15194, DOI 10.1073/pnas.232087499; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; Sakakibara S, 1997, J NEUROSCI, V17, P8300; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931	38	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41309	41315		10.1074/jbc.M306210200	http://dx.doi.org/10.1074/jbc.M306210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907678	hybrid			2022-12-25	WOS:000185847200110
J	Lahlou, H; Saint-Laurent, N; Esteve, JP; Eychene, A; Pradayrol, L; Pyronnet, S; Susini, C				Lahlou, H; Saint-Laurent, N; Esteve, JP; Eychene, A; Pradayrol, L; Pyronnet, S; Susini, C			sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; SIGNAL-REGULATED KINASE; NERVE GROWTH-FACTOR; G-BETA-GAMMA; PROTEIN-COUPLED RECEPTORS; MAP KINASE; PHOSPHOINOSITIDE 3-KINASE; LYSOPHOSPHATIDIC ACID; SUSTAINED ACTIVATION; MEDIATED ACTIVATION	The G protein-coupled sst2 somatostatin receptor is a critical negative regulator of cell proliferation. sstII prevents growth factor-induced cell proliferation through activation of the tyrosine phosphatase SHP-1 leading to induction of the cyclin-dependent kinase inhibitor p27(Kip1). Here, we investigate the signaling molecules linking sst2 to p27(Kip1). In Chinese hamster ovary-DG-44 cells stably expressing sst2 (CHO/sst2), the somatostatin analogue RC-160 transiently stimulates ERK2 activity and potentiates insulin-stimulated ERK2 activity. RC-160 also stimulates ERK2 activity in pancreatic acini isolated from normal mice, which endogenously express sst2, but has no effect in pancreatic acini derived from sst2 knock-out mice. RC-160-induced p27(Kip1) up-regulation and inhibition of insulin-dependent cell proliferation are both prevented by pretreatment of CHO/sst2 cells with the MEK1/2 inhibitor PD98059. In addition, using dominant negative mutants, we show that sst2-mediated ERK2 stimulation is dependent on the pertussis toxin-sensitive G(i/o) protein, the tyrosine kinase Src, both small G proteins Ras and Rap1, and the MEK kinase B-Raf but is independent of Raf-1. Phosphatidylinositol 3-kinase (PI3K) and both tyrosine phosphatases, SHP-1 and SHP-2, are required upstream of Ras and Rap1. Taken together, our results identify a novel mechanism whereby a G(i/o) protein-coupled receptor inhibits cell proliferation by stimulating ERK signaling via a SHP-1-SHP-2-PI3K/Ras-Rap1/B-Raf/MEK pathway.	CHU Rangueil, IFR31, INSERM, U531, F-31403 Toulouse, France; Ctr Univ, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Susini, C (corresponding author), CHU Rangueil, IFR31, INSERM, U531, 1 Ave Jean Poulhes, F-31403 Toulouse, France.	susinich@toulouse.inserm.fr	Pyronnet, Stéphane/P-2419-2014; Eychene, Alain/M-8838-2017; Nathalie, Saint-Laurent/G-5487-2017	EYCHENE, Alain/0000-0002-6818-7225				Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Antonelli V, 2000, MOL BIOL CELL, V11, P1129, DOI 10.1091/mbc.11.4.1129; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Auer KL, 1998, FEBS LETT, V436, P131, DOI 10.1016/S0014-5793(98)01074-6; Benali N, 2000, P NATL ACAD SCI USA, V97, P9180, DOI 10.1073/pnas.130196697; Bisotto S, 2001, BIOCHEM J, V360, P77, DOI 10.1042/0264-6021:3600077; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bouschet T, 2003, J BIOL CHEM, V278, P4778, DOI 10.1074/jbc.M204652200; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; Brasselet S, 2002, FEBS LETT, V516, P124, DOI 10.1016/S0014-5793(02)02517-6; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Cattaneo MG, 2000, FEBS LETT, V481, P271, DOI 10.1016/S0014-5793(00)02012-3; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Cordelier P, 1997, P NATL ACAD SCI USA, V94, P9343, DOI 10.1073/pnas.94.17.9343; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Cui TX, 2001, CARDIOVASC RES, V49, P863, DOI 10.1016/S0008-6363(00)00299-6; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dixon BS, 2002, AM J PHYSIOL-CELL PH, V283, pC193, DOI 10.1152/ajpcell.00289.2001; FERJOUX G, 2003, IN PRESS MOL BIOL CE; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Florio T, 2000, J PHYSIOL-PARIS, V94, P239, DOI 10.1016/S0928-4257(00)00214-X; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; Guillemot L, 2000, J BIOL CHEM, V275, P26349, DOI 10.1074/jbc.M001614200; Held-Feindt J, 2001, MOL BRAIN RES, V87, P12, DOI 10.1016/S0169-328X(00)00225-4; HULLEY P, 2003, EUR J BIOCH S1, V270, P58; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; LAW SF, 1995, CELL SIGNAL, V7, P1, DOI 10.1016/0898-6568(94)00064-I; Lopez F, 2001, FASEB J, V15, P2300, DOI 10.1096/fj.00-0867fje; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2002, CELL MOL LIFE SCI, V59, P456, DOI 10.1007/s00018-002-8438-2; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Okada T, 1999, MOL CELL BIOL, V19, P6057; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; Paruchuri S, 2002, J CELL SCI, V115, P1883; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pollak MN, 1998, P SOC EXP BIOL MED, V217, P143; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Schmitt JM, 2002, J BIOL CHEM, V277, P43024, DOI 10.1074/jbc.M204006200; Sellers LA, 2000, MOL CELL BIOL, V20, P5974, DOI 10.1128/MCB.20.16.5974-5985.2000; Sellers LA, 1999, J BIOL CHEM, V274, P24280, DOI 10.1074/jbc.274.34.24280; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zheng H, 1997, MOL ENDOCRINOL, V11, P1709, DOI 10.1210/me.11.11.1709; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	76	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39356	39371		10.1074/jbc.M304524200	http://dx.doi.org/10.1074/jbc.M304524200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878607	hybrid			2022-12-25	WOS:000185713800013
J	Merlot, S; Meili, R; Pagliarini, DJ; Maehama, T; Dixon, JE; Firtel, RA				Merlot, S; Meili, R; Pagliarini, DJ; Maehama, T; Dixon, JE; Firtel, RA			A PTEN-related 5-phosphatidylinositol phosphatase localized in the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PROTEIN-KINASE-B; DICTYOSTELIUM-DISCOIDEUM; TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PHOSPHOINOSITIDE PHOSPHATASES; LIPID 2ND-MESSENGER; MYOTUBULAR MYOPATHY; MAMMALIAN-CELLS; PATHWAY	Phosphoinositides play important roles as signaling molecules in different cell compartments by regulating the localization and activity of proteins through their interaction with specific domains. The activity of these lipids depends on which sites on the inositol ring are phosphorylated. Signaling pathways dependent on phosphoinositides phosphorylated at the D3 position of this ring (3-phosphoinositides) are negatively regulated by 3-phosphoinositide-specific phosphatases that include PTEN and myotubularin. Using the conserved PTEN catalytic core motif, we have identified a new protein in the Dictyostelium genome called phospholipid-inositol phosphatase ( PLIP), which defines a new subfamily of phosphoinositide phosphatases clearly distinct from PTEN or other closely related proteins. We show that PLIP is able to dephosphorylate a broad spectrum of phosphoinositides, including 3-phosphoinositides. In contrast to previously characterized phosphoinositide phosphatases, PLIP has a preference for phosphatidylinositol 5-phosphate, a newly discovered phosphoinositide. We found that PLIP is localized in the Golgi, with its phosphatase domain facing the cytoplasmic compartment. PLIP null cells created via homologous recombination are unable to effectively aggregate to form multicellular organisms at low cell densities. The presence of PLIP in the Golgi suggests that it may be involved in membrane trafficking.	Univ Calif San Diego, Ctr Mol Genet, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Firtel, RA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Div Biol Sci, Sect Cell & Dev Biol, Rm 225,9500 Gilman Dr, La Jolla, CA 92093 USA.	rafirtel@ucsd.edu	Maehama, Tomohiko/AAX-8926-2020; Maehama, Tomohiko/HGB-4896-2022	Maehama, Tomohiko/0000-0002-9685-2317; Merlot, Sylvain/0000-0002-9352-1184; Pagliarini, David J./0000-0002-0001-0087	NIGMS NIH HHS [2 T32 GM07752-25] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CARDELLI JA, 1986, ARCH BIOCHEM BIOPHYS, V244, P338, DOI 10.1016/0003-9861(86)90122-0; Chabin-Brion K, 2001, MOL BIOL CELL, V12, P2047, DOI 10.1091/mbc.12.7.2047; Chiang CF, 2001, ARCH BIOCHEM BIOPHYS, V394, P229, DOI 10.1006/abbi.2001.2537; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gaskins C, 1996, GENE DEV, V10, P118, DOI 10.1101/gad.10.1.118; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Graf R, 1999, BIOL CELL, V91, P471, DOI 10.1016/S0248-4900(99)80088-4; Guipponi M, 2001, HUM GENET, V109, P569, DOI 10.1007/s004390100607; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Loovers HM, 2003, J BIOL CHEM, V278, P5652, DOI 10.1074/jbc.M208396200; Ma S, 1999, J CELL BIOL, V147, P1261, DOI 10.1083/jcb.147.6.1261; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Meijer HJG, 2001, BIOCHEM J, V360, P491, DOI 10.1042/0264-6021:3600491; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Sbrissa D, 2002, J BIOL CHEM, V277, P47276, DOI 10.1074/jbc.M207576200; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Schneider N, 2000, BIOL CELL, V92, P495, DOI 10.1016/S0248-4900(00)01102-3; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Temesvari LA, 1996, J CELL SCI, V109, P1479; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; WEINER OH, 1993, J CELL BIOL, V123, P23, DOI 10.1083/jcb.123.1.23; Wu Y, 2001, J BIOL CHEM, V276, P21745, DOI 10.1074/jbc.M101480200; WUESTEHUBE LJ, 1989, CELL MOTIL CYTOSKEL, V13, P245, DOI 10.1002/cm.970130404; ZHU QL, 1993, J CELL SCI, V104, P1119	52	26	27	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39866	39873		10.1074/jbc.M306318200	http://dx.doi.org/10.1074/jbc.M306318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878591	hybrid			2022-12-25	WOS:000185713800073
J	Chattopadhyay, K; Banerjee, KK				Chattopadhyay, K; Banerjee, KK			Unfolding of Vibrio cholerae hemolysin induces oligomerization of the toxin monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EL-TOR; ALPHA-HEMOLYSIN; MEMBRANE; CYTOLYSIN; PORE; PROTEINS; CHOLESTEROL; ACTIVATION; HLYA	Vibrio cholerae hemolysin (HlyA) is a pore-forming toxin that exists in two stable forms: a hemolytically active water-soluble monomer with a native molecular weight of 65,000 and a hemolytically inactive SDS-stable heptamer with the configuration of a transmembrane diffusion channel. Transformation of the monomer into the oligomer is spontaneous but very slow in the absence of interaction with specific membrane components like cholesterol and sphingolipids. In this report, we show that mild disruption of the native tertiary structure of HlyA by 1.75 M urea triggered rapid and quantitative conversion of the monomer to an oligomer. Furthermore, the HlyA monomer when unfolded in 8 M urea refolded and reconstituted on renaturation into the oligomer biochemically and functionally similar to the heptamer formed in target lipid bilayer, suggesting that the HlyA polypeptide had a strong propensity to adopt the oligomer as the stable native state in preference to the monomer. On the basis of our results, we propose that (a) the hemolytically active HlyA monomer represents a quasi-stable conformation corresponding to a local free energy minimum and the transmembrane heptameric pore represents a stable conformation corresponding to an absolute free energy minimum and (b) any perturbation of the native tertiary structure of the HlyA monomer causing relaxation of conformational constraints tends to promote self-assembly to the oligomer with membrane components playing at most an accessory role.	Natl Inst Cholera & Enter Dis, Div Immunol & Vaccine Dev, Kolkata 700010, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED)	Banerjee, KK (corresponding author), Natl Inst Cholera & Enter Dis, Div Immunol & Vaccine Dev, Kolkata 700010, India.		Chattopadhyay, Kausik/H-5044-2015	Chattopadhyay, Kausik/0000-0001-8529-9475				BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bychkova V. E., 1993, CHEMTRACTS BIOCH MOL, V4, P133; Cantor C. R., 1982, PROTEINS, VV, P145; Chattopadhyay K, 2002, EUR J BIOCHEM, V269, P4351, DOI 10.1046/j.1432-1033.2002.03137.x; Creighton T E, 1986, Methods Enzymol, V131, P156; GOLDBERG SL, 1984, J BACTERIOL, V160, P239, DOI 10.1128/JB.160.1.239-244.1984; Harris JR, 2002, J STRUCT BIOL, V139, P122; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; IKIGAI H, 1987, J BIOL CHEM, V262, P2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lesieur C, 1999, J BIOL CHEM, V274, P36722, DOI 10.1074/jbc.274.51.36722; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Nagamune K, 1996, INFECT IMMUN, V64, P4655, DOI 10.1128/IAI.64.11.4655-4658.1996; Nagamune K, 1997, J BIOL CHEM, V272, P1338, DOI 10.1074/jbc.272.2.1338; Olson R, 2003, PROTEIN SCI, V12, P379, DOI 10.1110/ps.0231703; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PTITSYN OB, 1995, PHILOS T ROY SOC B, V348, P35, DOI 10.1098/rstb.1995.0043; Saha N, 1997, J BIOL CHEM, V272, P162, DOI 10.1074/jbc.272.1.162; Schmid F. Z., 1997, PROTEIN STRUCTURE PR, P261; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Der Goot Francoise G., 1992, Trends in Cell Biology, V2, P343; WILSON M, 2002, BACTERIAL DIS MECH I, P466; YAMAMOTO K, 1990, INFECT IMMUN, V58, P4106, DOI 10.1128/IAI.58.12.4106-4116.1990; YAMAMOTO K, 1984, INFECT IMMUN, V45, P192, DOI 10.1128/IAI.45.1.192-196.1984; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375	27	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38470	38475		10.1074/jbc.M305965200	http://dx.doi.org/10.1074/jbc.M305965200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878594	hybrid			2022-12-25	WOS:000185575100048
J	Pettus, BJ; Bielawski, J; Porcelli, AM; Reames, DL; Johnson, KR; Morrow, J; Chalfant, CE; Obeid, LM; Hannun, YA				Pettus, BJ; Bielawski, J; Porcelli, AM; Reames, DL; Johnson, KR; Morrow, J; Chalfant, CE; Obeid, LM; Hannun, YA			The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE(2) production in response to TNF-alpha	FASEB JOURNAL			English	Article						prostaglandin E-2; inflammation; ceramide; sphingosine; RNA interference; tumor necrosis factor	TUMOR-NECROSIS-FACTOR; CYTOSOLIC PHOSPHOLIPASE A(2); PROGRAMMED CELL-DEATH; FC-GAMMA-RI; NF-KAPPA-B; EPITHELIAL-CELLS; SPHINGOLIPID METABOLISM; INTESTINAL POLYPOSIS; INHIBITS APOPTOSIS; TYROSINE KINASE	In this study we addressed the role of sphingolipid metabolism in the inflammatory response. In a L929 fibroblast model, tumor necrosis factor-alpha (TNF) induced prostaglandin E-2 (PGE(2)) production by 4 h and cyclooxygenase-2 (COX-2) induction as early as 2 h. This TNF-induced PGE(2) production was inhibited by NS398, a COX-2 selective inhibitor. GC-MS analysis revealed that only COX-2-generated prostanoids were produced in response to TNF, thus providing further evidence of COX-2 selectivity. As sphingolipids have been implicated in mediating several actions of TNF, their role in COX-2 induction and PGE(2) production was evaluated. Sphingosine-1-phosphate (S1P) induced both COX-2 and PGE(2) in a dose-responsive manner with an apparent ED50 of 100-300 nM. The related sphingolipid sphingosine also induced PGE(2), though with much less efficacy. TNF induced a 3.5-fold increase in sphingosine-1-phosphate levels at 10 min that rapidly returned to baseline by 40 min. Small interfering RNAs (siRNAs) directed against mouse SK1 decreased (typically by 80%) SK1 protein and inhibited TNF-induced SK activity. Treatment of cells with RNAi to SK1 but not SK2 almost completely abolished the ability of TNF to induce COX-2 or generate PGE(2). By contrast, cells treated with RNAi to S1P lyase or S1P phosphatase enhanced COX-2 induction leading to enhanced generation of PGE(2). Treatment with SK1 RNAi also abolished the effects of exogenous sphingosine and ceramide on PGE(2), revealing that the action of sphingosine and ceramide are due to intracellular metabolism into S1P. Collectively, these results provide novel evidence that SK1 and S1P are necessary for TNF to induce COX-2 and PGE(2) production. Based on these findings, this study indicates that SK1 and S1P could be implicated in pathological inflammatory disorders and cancer.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA; Univ Bologna, Dept Biol, I-40126 Bologna, Italy; Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Nashville, TN 37212 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; University of Bologna; Vanderbilt University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Room 501,Basic Sci Bldg,173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu		obeid, lina/0000-0002-0734-0847; Porcelli, Anna Maria/0000-0002-6209-0692	NATIONAL CANCER INSTITUTE [R01CA087584, P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM062887, P50GM015431, P01GM015431, R01GM043825] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839, CA87584] Funding Source: Medline; NHLBI NIH HHS [HL 07260] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM08716, GM62887, GM43825, GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKARASEREENONT P, 1995, BRIT J PHARMACOL, V115, P401, DOI 10.1111/j.1476-5381.1995.tb16347.x; Altman D.G., 1991, PRACTICAL STATISTIC; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; Chang HC, 2001, ONCOL REP, V8, P1321; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V220, P681, DOI 10.1006/bbrc.1996.0464; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; KARIM SMM, 1968, EUR J PHARMACOL, V4, P416, DOI 10.1016/0014-2999(68)90028-9; Kato M, 2001, J PHARM PHARMACOL, V53, P1679, DOI 10.1211/0022357011778070; Kawa S, 1997, FEBS LETT, V420, P196, DOI 10.1016/S0014-5793(97)01516-0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mifflin RC, 2002, AM J PHYSIOL-CELL PH, V282, pC824, DOI 10.1152/ajpcell.00388.2001; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; Newton R, 2000, BIOCHEM BIOPH RES CO, V277, P675, DOI 10.1006/bbrc.2000.3722; Niwa M, 1999, LIFE SCI, V66, P245, DOI 10.1016/S0024-3205(99)00587-1; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Plo I, 1999, NEUROREPORT, V10, P2373, DOI 10.1097/00001756-199908020-00028; POLLARD JK, 1993, PROSTAGLANDINS, V46, P499, DOI 10.1016/0090-6980(93)90069-J; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; RIEGELMAN RPH, 1992, STT 1 AID INTERPRETA; Siehler S, 2001, J BIOL CHEM, V276, P48733, DOI 10.1074/jbc.M011072200; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Takeshita A, 2000, J BIOL CHEM, V275, P32220, DOI 10.1074/jbc.M002569200; Vann LR, 2002, J BIOL CHEM, V277, P12649, DOI 10.1074/jbc.M109111200; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499	58	274	304	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1411	1421		10.1096/fj.02-1038com	http://dx.doi.org/10.1096/fj.02-1038com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890694				2022-12-25	WOS:000185345100033
J	Rodrigues, S; Attoub, S; Nguyen, QD; Bruyneel, E; Rodrigue, CM; Westley, BR; May, FEB; Thim, L; Mareel, M; Emami, S; Gespach, C				Rodrigues, S; Attoub, S; Nguyen, QD; Bruyneel, E; Rodrigue, CM; Westley, BR; May, FEB; Thim, L; Mareel, M; Emami, S; Gespach, C			Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells	ONCOGENE			English	Article						HER-CD533; EGFRvIIl; Iressa; src; TXA2-R; bile acids	EPIDERMAL-GROWTH-FACTOR; PLATELET-ACTIVATING-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR INVASION; EPITHELIAL-CELLS; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER	Trefoil peptides (TFFs) are now considered as scatter factors, proinvasive and angiogenic agents acting through cyclooxygenase-2 (COX-2)- and thromboxane A2 receptor (TXA2-R)-dependent signaling pathways. As expression and activation levels of the epidermal growth factor receptor (EGFR) predict the metastatic potential of human colorectal cancers, the purpose of this study was to establish whether the EGF receptor tyrosine kinase (EGFR-TK) contributes to cellular invasion induced by TFFs in kidney and colonic cancer cells. Both the dominant negative form of the EGFR (HER-CD533) and the EGFR-TK inhibitor ZD1839 (Iressa) abrogated cellular invasion induced by pS2, spasmolytic polypeptide (SP) and the src oncogene, but not by ITF and the TXA2-R. Similarly, EGFR-TK inhibition by ZD1839 reversed the invasive phenotype promoted by the constitutively activated form of the EGFR (EGFRvIII) and the EGFR agonists transforming growth factor alpha (TGFalpha), amphiregulin and EGF. We also provide evidence that TFFs, EGFRvIII, and TGFalpha trigger common proinvasive pathways using the P13'-kinase and Rho/Rho- kinase cascades. These findings identify the EGFR-TK as a key signaling element for pS2- and SP-mediated cellular invasion. It is concluded that although pS2, SP and ITF belong to the same family of inflammation- and cancer-associated regulatory peptides, they do not control identical signaling networks.	Hop St Antoine, INSERM, U482, Signal Transduct & Cellular Funct Diabet & Digest, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Newcastle Univ, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Newcastle University - UK; Novo Nordisk	Gespach, C (corresponding author), Hop St Antoine, INSERM, U482, Signal Transduct & Cellular Funct Diabet & Digest, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	Attoub, Samir/N-6852-2018					Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; CHINERY R, 1995, FEBS LETT, V357, P50, DOI 10.1016/0014-5793(94)01297-E; CHINERY R, 1995, CLIN SCI, V88, P401, DOI 10.1042/cs0880401; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DANTE R, 1994, LAB INVEST, V71, P188; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Debruyne PR, 2002, ONCOGENE, V21, P6740, DOI 10.1038/sj.onc.1205729; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; Hoffmann W, 2002, INT REV CYTOL, V213, P147; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jacoby RF, 1996, CANCER RES, V56, P710; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Lal A, 2002, CANCER RES, V62, P3335; Lalani EN, 1999, LAB INVEST, V79, P537; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Maurizi M, 1996, BRIT J CANCER, V74, P1253, DOI 10.1038/bjc.1996.525; May FEB, 1997, J PATHOL, V182, P404; Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595; Moasser MM, 2001, CANCER RES, V61, P7184; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozgul C, 1997, Acta Physiol Hung, V85, P121; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Regnauld K, 2002, ONCOGENE, V21, P4020, DOI 10.1038/sj.onc.1205498; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; ROSAM AC, 1986, NATURE, V319, P54, DOI 10.1038/319054a0; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SAITO Y, 1997, BACTERIAL TOXINS TOO, P85; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Taupin D, 1996, LAB INVEST, V75, P25; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; THEISINGER B, 1991, EUR J CANCER, V27, P770, DOI 10.1016/0277-5379(91)90186-H; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Tong WM, 1998, BRIT J CANCER, V77, P1792, DOI 10.1038/bjc.1998.298; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; VAN BT, 1995, NATURE, V376, P781; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wakeling AE, 2002, CANCER RES, V62, P5749; Wang DG, 1998, J CELL PHYSIOL, V177, P387, DOI 10.1002/(SICI)1097-4652(199812)177:3<387::AID-JCP2>3.3.CO;2-C; Wheeler M, 2001, MOL CELL BIOL, V21, P6660, DOI 10.1128/MCB.21.19.6660-6667.2001; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Williams R, 1996, J CELL SCI, V109, P63; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; Xie H, 1998, J CELL SCI, V111, P615; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YANG LJ, 1993, J BIOL CHEM, V268, P3739; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yoon JH, 2002, GASTROENTEROLOGY, V122, P985, DOI 10.1053/gast.2002.32410; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	98	50	50	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4488	4497		10.1038/sj.onc.1206685	http://dx.doi.org/10.1038/sj.onc.1206685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881705				2022-12-25	WOS:000184054700004
J	Alves-Guerra, MC; Rousset, S; Pecqueur, C; Mallat, Z; Blanc, J; Tedgui, A; Bouillaud, F; Cassard-Doulcier, AM; Ricquier, D; Miroux, B				Alves-Guerra, MC; Rousset, S; Pecqueur, C; Mallat, Z; Blanc, J; Tedgui, A; Bouillaud, F; Cassard-Doulcier, AM; Ricquier, D; Miroux, B			Bone marrow transplantation reveals the in vivo expression of the mitochondrial uncoupling protein 2 in immune and nonimmune cells during inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; UP-REGULATION; N-ACETYLCYSTEINE; GENE-EXPRESSION; PROTON LEAK; OBESITY; ENDOTOXIN; OXYGEN; UCP2	The mitochondrial uncoupling protein 2 (UCP2) is expressed in spleen, lung, intestine, white adipose tissue, and immune cells. Bone marrow transplantation in mice was used to assess the contribution of immune cells to the expression of UCP2 in basal condition and during inflammation. Immune cells accounted for the total amount of UCP2 expression in the spleen, one-third of its expression in the lung, and did not participate in its expression in the intestine. LPS injection stimulated UCP2 expression in lung, spleen, and intestine in both immune and non-immune cells. Successive injections of LPS and dexamethasone or N-acetyl-cysteine prevented the induction of UCP2 in all three tissues, suggesting that oxygen free radical generation plays a role in UCP2 regulation. Finally, both previous studies and our data show that there is down-regulation of UCP2 in immune cells during their activation in the early stages of the LPS response followed by an up-regulation in UCP2 during the later stages to protect all cells against oxidative stress.	Fac Med Necker Enfants Malad, CNRS, UPR 9078, F-75730 Paris 15, France; Hop Lariboisiere, INSERM, F-75475 Paris 10, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Miroux, B (corresponding author), Fac Med Necker Enfants Malad, CNRS, UPR 9078, 156 Rue Vaugirard, F-75730 Paris 15, France.	miroux@necker.fr	Pecqueur, Claire/L-3073-2015; CASSARD, Anne-Marie/B-6095-2019; Alves-Guerra, Marie-Clotilde/P-4356-2017; Mallat, Ziad/D-4041-2012; Bouillaud, Frédéric R/L-3238-2017; Miroux, Bruno/E-9267-2017	Pecqueur, Claire/0000-0002-7612-1672; CASSARD, Anne-Marie/0000-0002-1813-5128; Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; Mallat, Ziad/0000-0003-0443-7878; Bouillaud, Frédéric R/0000-0002-7518-9237; Miroux, Bruno/0000-0002-3066-4700				ALVESGUERRA MC, 2002, CELL MOL RESPONSES S, V3, P257; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BERNARD GR, 1984, J CLIN INVEST, V73, P1772, DOI 10.1172/JCI111386; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Chen Z, 2002, BIOCHEM BIOPH RES CO, V290, P66, DOI 10.1006/bbrc.2001.6147; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Faggioni R, 1998, BIOCHEM BIOPH RES CO, V244, P75, DOI 10.1006/bbrc.1998.8219; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; GATTI S, 1993, CLIN EXP IMMUNOL, V91, P456; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; Lefort J, 1998, J IMMUNOL, V161, P474; Mallat Z, 2002, CIRC RES, V91, P441, DOI 10.1161/01.RES.0000033592.11674.D8; Memon RA, 2000, BBA-MOL CELL BIOL L, V1484, P41, DOI 10.1016/S1388-1981(99)00195-X; Nakata K, 1999, BLOOD, V93, P667, DOI 10.1182/blood.V93.2.667.402k25_667_673; Nakatani T, 2002, J BIOL CHEM, V277, P9562, DOI 10.1074/jbc.M110132200; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Rashid A, 1999, HEPATOLOGY, V29, P1131, DOI 10.1002/hep.510290428; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rocksen D, 2000, CLIN EXP IMMUNOL, V122, P249, DOI 10.1046/j.1365-2249.2000.01373.x; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	36	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42307	42312		10.1074/jbc.M306951200	http://dx.doi.org/10.1074/jbc.M306951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907675	hybrid			2022-12-25	WOS:000185989500091
J	Dong, WJ; Robinson, JM; Xing, J; Cheung, HC				Dong, WJ; Robinson, JM; Xing, J; Cheung, HC			Kinetics of conformational transitions in cardiac troponin induced by Ca2+ dissociation determined by Forster resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; REGULATORY DOMAIN; EXTENDED CONFORMATION; TROPOMYOSIN COMPLEX; INHIBITORY REGION; CALCIUM-BINDING; THIN-FILAMENTS; ACTIN	Upon Ca2+ activation of cardiac muscle, several structural changes occur in the troponin subunits. These changes include the opening of the cardiac troponin C (cTnC) N-domain, the change of secondary structure of the inhibitory region of cardiac troponin I (cTnI), and the change in the separation between these two proteins in the cTnC-cTnI interface. We have used Forster resonance energy transfer in Ca2+ titration and stopped-flow experiments to delineate these transitions using a reconstituted cardiac troponin. Energy transfer results were quantified to yield time-dependent profiles of changes in intersite distances during Ca2+ dissociation. The closing of the cTnC N-domain induced by release of regulatory Ca2+ from cTnC occurs in one step (t(1/2) similar to 5 ms), and this transition is not affected by Ca2+ release from the C-domain. The other two transitions triggered by Ca2+ dissociation are biphasic with the fast phase (t(1/2) similar to 5 ms) correlated with Ca2+ release from the cTnC N-domain. These transitions are slower than the release of bound regulatory Ca2+ (t(1/2) 3.6 ms) and are coupled to one another in a cooperative manner in restoring their conformations in the deactivated state. The kinetic results define the magnitudes of structural changes relevant in Ca2+ switching between activation and deactivation of cardiac muscle contraction.	Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Dong, WJ (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	wdong@uab.edu; hccheung@uab.edu	Dong, Wenji/A-8579-2011		NHLBI NIH HHS [HL 52508, R01 HL080186] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052508, R01HL080186] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; Dong WJ, 2003, J BIOL CHEM, V278, P8686, DOI 10.1074/jbc.M212886200; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; Dong WJ, 2001, J MOL BIOL, V314, P51, DOI 10.1006/jmbi.2001.5118; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GARLAND F, 1988, J BIOL CHEM, V263, P11621; Hernandez G, 1999, BIOCHEMISTRY-US, V38, P6911, DOI 10.1021/bi990150q; Kobayashi T, 2000, BIOCHEMISTRY-US, V39, P86, DOI 10.1021/bi991903b; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Luo Y, 2002, BIOCHEMISTRY-US, V41, P12891, DOI 10.1021/bi020396m; Luo Y, 2002, J MOL BIOL, V316, P429, DOI 10.1006/jmbi.2001.5358; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; She MD, 1998, J MOL BIOL, V281, P445, DOI 10.1006/jmbi.1998.1933; SMITH SJ, 1990, BRIT J PHARMACOL, V100, P779, DOI 10.1111/j.1476-5381.1990.tb14092.x; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356	24	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42394	42402		10.1074/jbc.M304858200	http://dx.doi.org/10.1074/jbc.M304858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909617	hybrid			2022-12-25	WOS:000185989500102
J	Myers, JC; Moore, SA; Shamoo, Y				Myers, JC; Moore, SA; Shamoo, Y			Structure-based incorporation of 6-methyl-8-(2-deoxy-beta-ribofuranosyl)isoxanthopteridine into the human telomeric repeat DNA as a probe for UP1 binding and destabilization of G-tetrad structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; PTERIDINE NUCLEOSIDE ANALOGS; 3' SPLICE-SITE; G-RICH STRAND; HNRNP A1; RNA-BINDING; CRYSTAL-STRUCTURE; IN-VITRO; PROTEIN; QUADRUPLEX	Heterogeneous ribonucleoprotein A1 ( hnRNP A1) is an abundant nuclear protein that participates in RNA processing, alternative splicing, and chromosome maintenance. hnRNP A1 can be proteolyzed to unwinding protein (UP1), a 22.1-kDa protein that retains a high affinity for purine-rich single-stranded nucleic acids, including the human telomeric repeat (hTR) d(TTAGGG)n. Using the structure of UP1 bound to hTR as a guide, we have incorporated the fluorescent guanine analog 6-MI at one of two positions within the DNA to facilitate binding studies. One is where 6-MI remains stacked with an adjacent purine, and another is where it becomes fully unstacked upon UP1 binding. The structures of both modified oligonucleotides complexed to UP1 were determined by x-ray crystallography to validate the efficacy of our design, and 6-MI has proven to be an excellent reporter molecule for single-stranded nucleic acid interactions in positions where there is a change in stacking environment upon complex formation. We have shown that UP1 affinity for d( TTAGGG) 2 is similar to5 nM at 100 mM NaCl, pH 6.0, and our binding studies with d(TTAGG(6-MI)TTAGGG) show that binding is only modestly sensitive to salt and pH. UP1 also has a potent G-tetrad destabilizing activity that reduces the T-m of the hTR sequence d(TAGGGT)(4) from 67.0degreesC to 36.1degreesC at physiological conditions (150 mM KCl, pH 7.0). Consistent with the structures determined by x-ray crystallography, UP1 is able to bind the hTR sequence in solution as a dimer and supports a model for hnRNP A1 binding to nucleic acids in arrays that may make a contiguous set of anti-parallel single-stranded nucleic acid binding clefts. These data suggest that seemingly disparate roles for hnRNP A1 in alternative splice site selection, RNA processing, RNA transport, and chromosome maintenance reflect its ability to bind a purine-rich consensus sequence (nYAGGn) and destabilize potentially deleterious G-tetrad structures.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Rice University	Shamoo, Y (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS-140,6100 S Main St, Houston, TX 77005 USA.			Shamoo, Yousif/0000-0001-9241-8962	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R41HD036958] Funding Source: NIH RePORTER; NICHD NIH HHS [R03 HD 36958-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AbdulManan N, 1996, NUCLEIC ACIDS RES, V24, P4063, DOI 10.1093/nar/24.20.4063; Allers J, 2001, J MOL BIOL, V311, P75, DOI 10.1006/jmbi.2001.4857; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Blanchette M, 1997, RNA, V3, P405; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Fukuda H, 2002, P NATL ACAD SCI USA, V99, P12685, DOI 10.1073/pnas.152456899; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Hawkins ME, 1997, ANAL BIOCHEM, V244, P86, DOI 10.1006/abio.1996.9879; Hawkins ME, 2001, CELL BIOCHEM BIOPHYS, V34, P257, DOI 10.1385/CBB:34:2:257; Hutchison S, 2002, J BIOL CHEM, V277, P29745, DOI 10.1074/jbc.M203633200; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Katahira M, 1999, BIOCHEM BIOPH RES CO, V264, P327, DOI 10.1006/bbrc.1999.1521; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MERRILL BM, 1987, INT J PEPT PROT RES, V29, P21; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; Nasim FUH, 2002, RNA, V8, P1078, DOI 10.1017/S1355838202024056; Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Phan AT, 2002, NUCLEIC ACIDS RES, V30, P4618, DOI 10.1093/nar/gkf597; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RECORD MT, 1976, BIOPOLYMERS, V15, P893, DOI 10.1002/bip.1976.360150507; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; Simard MJ, 2000, MOL CELL BIOL, V20, P7353, DOI 10.1128/MCB.20.19.7353-7362.2000; Sun SY, 2003, J BIOL CHEM, V278, P3876, DOI 10.1074/jbc.M210497200; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740	50	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42300	42306		10.1074/jbc.M306147200	http://dx.doi.org/10.1074/jbc.M306147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904298	hybrid			2022-12-25	WOS:000185989500090
J	Villa, JP; Bertenshaw, GP; Bond, JS				Villa, JP; Bertenshaw, GP; Bond, JS			Critical amino acids in the active site of meprin metalloproteinases for substrate and peptide bond specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTACIN FAMILY; MOUSE KIDNEY; BETA-GENE; EXPRESSION; ALPHA; METALLOENDOPEPTIDASE; ACTIVATION; SECRETION; SUBUNITS; CANCER	The protease domains of the evolutionarily related alpha and beta subunits of meprin metalloproteases are similar to 55% identical at the amino acid level; however, their substrate and peptide bond specificities differ markedly. The meprin beta subunit favors acidic residues proximal to the scissile bond, while the alpha subunit prefers small or aromatic amino acids flanking the scissile bond. Thus gastrin, a peptide that contains a string of five Glu residues, is an excellent substrate for meprin beta, while it is not hydrolyzed by meprin alpha. Work herein aimed to identify critical amino acids in the meprin active sites that determine the substrate specificity differences. Sequence alignments and homology models, based on the crystal structure of the crayfish astacin, showed electrostatic differences within the meprin active sites. Site-directed mutagenesis of active site residues demonstrated that replacement of a hydrophobic residue by a basic amino acid enabled the meprin alpha protease to cleave gastrin. The meprin alphaY199K mutant was most effective; the corresponding mutation of meprin betaK185Y resulted in decreased activity toward gastrin. Peptide cleavage site determinations and kinetic analyses using a variety of peptides extended evidence that meprin alphaTyr-199/betaLys-185 are substrate specificity determinants in meprin active sites. These studies shed light on the molecular basis for the substrate specificity differences of astacin metalloproteinases.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Bond, JS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171, Hershey, PA 17033 USA.	jbond@psu.edu		Bertenshaw, Greg/0000-0003-4903-3412	NIDDK NIH HHS [R01 DK019691, DK 19691, R56 DK019691, R01 DK019691-27, DK 54625] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R01DK019691, R37DK019691, R01DK054625] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Bertenshaw GP, 2003, J BIOL CHEM, V278, P2522, DOI 10.1074/jbc.M208808200; Bertenshaw GP, 2002, BIOL CHEM, V383, P1175, DOI 10.1515/BC.2002.129; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, GENOMICS, V25, P300, DOI 10.1016/0888-7543(95)80142-9; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; Carmago S, 2002, KIDNEY INT, V61, P959, DOI 10.1046/j.1523-1755.2002.00209.x; Doll BA, 2002, BIOL CHEM, V383, P1167, DOI 10.1515/BC.2002.128; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Johnson G.S., 1998, HDB PROTEOLYTIC ENZY, P1222; Kumar JM, 2001, BBA-GENE STRUCT EXPR, V1518, P106, DOI 10.1016/S0167-4781(01)00188-9; LEE KS, 1994, FEBS LETT, V339, P281, DOI 10.1016/0014-5793(94)80431-1; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Norman LP, 2003, CURR TOP DEV BIOL, V54, P145, DOI 10.1016/S0070-2153(03)54008-X; Norman LP, 2003, MOL CELL BIOL, V23, P1221, DOI 10.1128/MCB.23.4.1221-1230.2003; Rosmann S, 2002, J BIOL CHEM, V277, P40650, DOI 10.1074/jbc.M206203200; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; STOCKER W, 1995, METHOD ENZYMOL, V248, P305; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V319, P281, DOI 10.1006/abbi.1995.1293; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; TRACHTMAN H, 1995, BIOCHEM BIOPH RES CO, V208, P498, DOI 10.1006/bbrc.1995.1366; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; WOLZ RL, 1994, ARCH BIOCHEM BIOPHYS, V310, P144, DOI 10.1006/abbi.1994.1150; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; Yiallouros I, 2000, FEBS LETT, V484, P224, DOI 10.1016/S0014-5793(00)02163-3	32	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42545	42550		10.1074/jbc.M303718200	http://dx.doi.org/10.1074/jbc.M303718200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888571	Green Accepted, hybrid			2022-12-25	WOS:000185989500119
J	Gronholm, M; Vossebein, L; Carlson, CR; Kuja-Panula, J; Teesalu, T; Alfthan, K; Vaheri, A; Rauvala, H; Herberg, FW; Tasken, K; Carpen, O				Gronholm, M; Vossebein, L; Carlson, CR; Kuja-Panula, J; Teesalu, T; Alfthan, K; Vaheri, A; Rauvala, H; Herberg, FW; Tasken, K; Carpen, O			Merlin links to the cAMP neuronal signaling pathway by anchoring the RI Chi subunit of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I REGULATORY SUBUNIT; TUMOR-SUPPRESSOR; MOLECULAR-CLONING; TERMINAL DOMAIN; EXPRESSION; GENE; EZRIN; NEUROFIBROMATOSIS-2; MEMBRANE; BETA	The cAMP-protein kinase A (PKA) pathway, important in neuronal signaling, is regulated by molecules that bind and target PKA regulatory subunits. Of four regulatory subunits, RIbeta is most abundantly expressed in brain. The RIbeta knockout mouse has defects in hippocampal synaptic plasticity, suggesting a role for RIbeta in learning and memory-related functions. Molecules that interact with or regulate RIbeta are still unknown. We identified the neurofibromatosis 2 tumor suppressor protein merlin (schwannomin), a molecule related to the ezrin-radixin-moesin family of membrane-cytoskeleton linker proteins, as a binding partner for RIbeta. Merlin and RIbeta demonstrated a similar expression pattern in central nervous system neurons and an overlapping subcellular localization in cultured hippocampal neurons and transfected cells. The proteins were coprecipitated from brain lysates by cAMP-agarose and coimmunoprecipited from cellular lysates with specific antibodies. In vitro binding studies verified that the interaction is direct. The interaction appeared to be under conformational regulation and was mediated via the alpha-helical region of merlin. Sequence comparison between merlin and known PKA anchoring proteins identified a conserved alpha-helical PKA anchoring protein motif in merlin. These results identify merlin as the first neuronal binding partner for PKA-RIbeta and suggest a novel function for merlin in connecting neuronal cytoskeleton to PKA signaling.	Univ Helsinki, Biomedicum Helsinki, Dept Pathol, Neurosci Program, FIN-00014 Helsinki, Finland; Univ Helsinki, Ctr Neurosci, Inst Biotechnol, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki 00014, Finland; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; Univ Oslo, Dept Med Biochem, N-0317 Oslo, Norway; Tartu Cent Hosp, EE-50406 Tartu, Estonia; Univ Kassel, Inst Biochem, D-34109 Kassel, Germany	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Ruhr University Bochum; University of Oslo; Universitat Kassel	Gronholm, M (corresponding author), Univ Helsinki, Biomedicum Helsinki, Dept Pathol, Neurosci Program, PB 63,Haartmanink 8, FIN-00014 Helsinki, Finland.	mikaela.gronholm@helsinki.fi	Herberg, Friedrich W/B-5572-2015; Vaheri, Antti/AAV-1523-2020; Gronholm, Mikaela/B-4225-2010; Teesalu, Tambet/J-1802-2015	Herberg, Friedrich W/0000-0001-7117-7653; Gronholm, Mikaela/0000-0002-2378-8924; Rauvala, Heikki/0000-0001-7809-9811				Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Bagorda A, 2002, J BIOL CHEM, V277, P21480, DOI 10.1074/jbc.M112245200; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Bohling T, 1996, AM J PATHOL, V148, P367; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CARR DW, 1991, J BIOL CHEM, V266, P14188; CLAUDIO JO, 1995, NEUROREPORT, V6, P1942, DOI 10.1097/00001756-199510020-00028; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; den Bakker MA, 1999, J HISTOCHEM CYTOCHEM, V47, P1471; DENBAKKER MA, 1995, ONCOGENE, V10, P757; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 1999, J CELL SCI, V112, P895; GUTMANN DH, 1995, HUM MOL GENET, V4, P471, DOI 10.1093/hmg/4.3.471; HARA T, 1994, CANCER RES, V54, P330; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Shaw RJ, 1998, CELL GROWTH DIFFER, V9, P287; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; StemmerRachamimov AO, 1997, J NEUROPATH EXP NEUR, V56, P735; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; TASKEN K, 1993, J BIOL CHEM, V268, P21276; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Weinman EJ, 2001, J BIOL CHEM, V276, P42339, DOI 10.1074/jbc.M106153200; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	43	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41167	41172		10.1074/jbc.M306149200	http://dx.doi.org/10.1074/jbc.M306149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896975	hybrid			2022-12-25	WOS:000185847200093
J	Kinoshita, A; Shah, T; Tangredi, MM; Strickland, DK; Hyman, BT				Kinoshita, A; Shah, T; Tangredi, MM; Strickland, DK; Hyman, BT			The intracellular domain of the low density lipoprotein receptor-related protein modulates transactivation mediated by amyloid precursor protein and Fe65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFETIME IMAGING MICROSCOPY; RESONANCE ENERGY-TRANSFER; CARBOXYL-TERMINAL DOMAIN; METHYL-D-ASPARTATE; ALZHEIMERS-DISEASE; ADAPTER PROTEIN; APOE RECEPTOR; BETA-PROTEIN; LRP; COMPLEX	Low density lipoprotein-related protein (LRP) is a transmembrane receptor, localized mainly in hepatocytes, fibroblasts, and neurons. It is implicated in diverse biological processes both as an endocytic receptor and as a signaling molecule. Recent reports show that LRP undergoes sequential proteolytic cleavage in the ectodomain and transmembrane domain. The latter cleavage, mediated by the Alzheimer-related gamma-secretase activity that also cleaves amyloid precursor protein (APP) and Notch, results in the release of the LRP cytoplasmic domain (LRPICD) fragment. This relatively small cytoplasmic fragment has several motifs by which LRP interacts with various intracellular adaptor and scaffold proteins. However, the function of this fragment is largely unknown. Here we show that the LRPICD is translocated to the nucleus, where it colocalizes in the nucleus with a transcription modulator, Tip60, which is known to interact with Fe65 and with the APP-derived intracellular domain. LRPICD dramatically inhibits APP-derived intracellular domain/Fe65 transactivation mediated by Tip60. LRPICD has a close interaction with Tip60 in the nucleus, as shown by a fluorescence resonance energy transfer assay. These observations suggest that LRPICD has a novel signaling function, negatively impacting transcriptional activity of the APP, Fe65, and Tip60 complex in the nucleus, and shed new light on the function of LRP in transcriptional modulation.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimer Dis Res Lab, Charlestown, MA 02129 USA; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA	Harvard University; Massachusetts General Hospital; American Red Cross	Hyman, BT (corresponding author), Dept Neurol, Alzheimer Unit, 114 16th St,CAGN 2009, Charlestown, MA 02129 USA.				NIA NIH HHS [AG15379, AG12406, P01AG05134] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG012406, R01AG012406, P01AG015379] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; Berezovska O, 2003, J NEUROSCI, V23, P4560; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Guenette SY, 2002, J NEUROCHEM, V82, P755, DOI 10.1046/j.1471-4159.2002.01009.x; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Li YH, 2001, MOL NEUROBIOL, V23, P53; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Narita M, 1997, J NEUROCHEM, V69, P1904; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Zhao Q, 2003, BIOCHEMISTRY-US, V42, P3627, DOI 10.1021/bi027117f	36	96	100	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41182	41188		10.1074/jbc.M306403200	http://dx.doi.org/10.1074/jbc.M306403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888553	hybrid			2022-12-25	WOS:000185847200095
J	Mukherjee, A; Arnaud, L; Cooper, JA				Mukherjee, A; Arnaud, L; Cooper, JA			Lipid-dependent recruitment of neuronal Src to lipid rafts in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; ROUS-SARCOMA VIRUS; T-CELL-ACTIVATION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; FAMILY KINASES; C-SRC; FOCAL ADHESIONS; SH2 DOMAIN; PHOSPHORYLATION	Although most Src family tyrosine kinases are modified by palmitoylation as well as myristoylation, Src itself is only myristoylated. Dual acylation is important for attachment to liquid-ordered microdomains or lipid rafts. Accordingly, Src is excluded from lipid rafts in fibroblasts. Evidence of partial genetic redundancy between Src and Fyn for brain-specific targets suggests that these two kinases may occupy overlapping subcellular locations. Neuronal Src (NSrc), an alternative isoform of Src with a 6-amino acid insert in the Src homology 3 domain, is highly expressed in neurons. We investigated whether this structural difference in NSrc allows it to associate with lipid rafts. We found that perinatal mouse brains express predominantly NSrc, which is partly (10 - 20%) in a lipid raft fraction from brain but not fibroblasts. The association of Src with brain lipid rafts does not depend on the NSrc insert but depends on the amino-terminal myristoylation signal. A crude lipid fraction from brain promotes NSrc entry into rafts in vitro. Moreover, lipid raft-localized NSrc is more catalytically active than NSrc from the soluble fraction, possibly because raft localization alters access to other tyrosine kinases and phosphatases. These findings suggest that NSrc may be involved in signaling from lipid rafts in mouse brain.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Cooper, JA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,Mailstop A2-025, Seattle, WA 98109 USA.	jcooper@fhcrc.org			NCI NIH HHS [R37-CA41072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; BROWN DJ, 1984, J BIOL CHEM, V259, P9580; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kalka D, 2001, BIOCHEM BIOPH RES CO, V283, P989, DOI 10.1006/bbrc.2001.4864; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MAGEE AI, 1989, J CELL SCI, P149; MARIECARDINE A, 1992, J IMMUNOL, V148, P3879; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Prior IA, 2001, J CELL SCI, V114, P1603; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; Sheets ED, 1999, CURR OPIN CHEM BIOL, V3, P95, DOI 10.1016/S1367-5931(99)80017-9; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; Stehr M, 2003, J UROLOGY, V169, P1165, DOI 10.1097/01.ju.0000041501.01323.b9; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905; Young RM, 2003, J BIOL CHEM, V278, P20746, DOI 10.1074/jbc.M211402200; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914	71	83	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40806	40814		10.1074/jbc.M306440200	http://dx.doi.org/10.1074/jbc.M306440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912979	hybrid			2022-12-25	WOS:000185847200049
J	Shern, JF; Sharer, JD; Pallas, DC; Bartolini, F; Cowan, NJ; Reed, MS; Pohl, J; Kahn, RA				Shern, JF; Sharer, JD; Pallas, DC; Bartolini, F; Cowan, NJ; Reed, MS; Pohl, J; Kahn, RA			Cytosolic Arl2 is complexed with cofactor D and protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYOMAVIRUS MIDDLE-T; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; TUMOR-ANTIGEN; BETA-TUBULIN; CELL-GROWTH; 2A; MICROTUBULES; FAMILY; STATE	Arl2 is a member of the ADP-ribosylation factor family of 20-kDa GTPases that is highly conserved in eukaryotes. Recent results revealed that a portion of cellular Arl2 and its binding partner, BART, localize to mitochondria. Because similar to 90% of cellular Arl2 is cytosolic, we investigated properties of the soluble protein and found that it is stably bound in a complex that migrates in gel filtration medium with a predicted molecular mass of similar to 300 kDa. This complex was purified similar to 500-fold from the soluble fraction of bovine brain. Protein components were identified by mass spectroscopy and revealed the presence of four other proteins that include the tubulin folding cochaperone cofactor D and all three subunits of at least two protein phosphatase 2A ( PP2A) protein phosphatase trimers. The presence of more than one PP2A B-type subunit and the low stoichiometry of Arl2 indicate that the purified preparation still contains a mixture of complexes that cannot currently be completely resolved. Thus, although all the soluble Arl2 in bovine brain is in high molecular mass complexes, only a portion of the total cellular cofactor D and PP2A are associated with the Arl2. We further show that the Arl2 in the complex cannot bind GTP and that complexed cofactor D does not efficiently participate in tubulin refolding reactions in a manner comparable with free cofactor D. Our data suggest functional roles for the cytosolic Arl2 complex in modulating tubulin and microtubule behavior as well as a possible role in apoptosis.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Microchem Facil, Atlanta, GA 30322 USA; NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA	Emory University; Emory University; New York University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Shern, Jack/V-4002-2019; Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NCI NIH HHS [R01 CA057327, CA57327] Funding Source: Medline; NIGMS NIH HHS [GM68209] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartolini F, 2002, J BIOL CHEM, V277, P14629, DOI 10.1074/jbc.M200128200; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Carre M, 2002, J BIOL CHEM, V277, P33664, DOI 10.1074/jbc.M203834200; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hiraga A, 2000, BIOCHEM J, V346, P433, DOI 10.1042/0264-6021:3460433; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Hoyt MA, 1997, GENETICS, V146, P849; Hubalek F, 2002, ANAL BIOCHEM, V306, P124, DOI 10.1006/abio.2002.5693; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kobayashi A, 2003, FEBS LETT, V534, P26, DOI 10.1016/S0014-5793(02)03766-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Price NE, 1999, MOL BRAIN RES, V73, P68, DOI 10.1016/S0169-328X(99)00237-5; Radcliffe PA, 2000, FEBS LETT, V468, P84, DOI 10.1016/S0014-5793(00)01202-3; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; SCHONTHAL AH, 1998, FRONT BIOSCI, V3, P1262; Sharer JD, 1999, J BIOL CHEM, V274, P27553, DOI 10.1074/jbc.274.39.27553; SHARER JD, 2001, MOL BIOL CELL, P71; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Spengler B, 1997, J MASS SPECTROM, V32, P1019, DOI 10.1002/(SICI)1096-9888(199711)32:10<1019::AID-JMS595>3.0.CO;2-G; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Van Valkenburgh HA, 2002, METHOD ENZYMOL, V344, P186; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185	43	43	52	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40829	40836		10.1074/jbc.M308678200	http://dx.doi.org/10.1074/jbc.M308678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912990	hybrid			2022-12-25	WOS:000185847200051
J	Tsunenari, T; Sun, H; Williams, J; Cahill, H; Smallwood, P; Yau, KW; Nathans, J				Tsunenari, T; Sun, H; Williams, J; Cahill, H; Smallwood, P; Yau, KW; Nathans, J			Structure-function analysis of the bestrophin family of anion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; MEMBRANE TOPOLOGY; BEST-DISEASE; PROTEIN; DYSTROPHY; GENE; VMD2; IDENTIFICATION; PREDICTION; MUTATIONS	The bestrophins are a newly described family of anion channels unrelated in primary sequence to any previously characterized channel proteins. The human genome codes for four bestrophins, each of which confers a distinctive plasma membrane conductance on transfected 293 cells. Extracellular treatment with methanethiosulfonate ethyltrimethylammonium (MTSET) of a series of substitution mutants that eliminate one or more cysteines from human bestrophin1 demonstrates that cysteine 69 is the single endogenous cysteine responsible for MTSET inhibition of whole-cell current. Cysteines introduced between positions 78-99 and 223-226 are also accessible to external MTSET, with MTSET modification at positions 79, 80, 83, and 90 producing a 2-6-fold increase in whole-cell current. The latter set of four cysteine-substitution mutants define a region that appears to mediate allosteric control of channel activity. Mapping of transmembrane topography by insertion of N-linked glycosylation sites and tobacco etch virus protease cleavage sites provides evidence for cytosolic N and C termini and an unexpected transmembrane topography with at least three extracellular loops that include positions 60-63, 212-227, and 261-267. These experiments provide the first structural analysis of the bestrophin channel family.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Yau, KW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	kwyau@mail.jhmi.edu; jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460	NATIONAL EYE INSTITUTE [R37EY006837, R01EY006837, R01EY014596] Funding Source: NIH RePORTER; NEI NIH HHS [R37 EY006837, R01 EY006837, R01 EY014596, R37 EY006837-15, R01 EY006837-16A1, R37 EY006837-15S1, R01 EY014596-01, R37 EY006837-14, R37 EY006837-13] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bakall B, 1999, HUM GENET, V104, P383, DOI 10.1007/s004390050972; Betz H, 1999, ANN NY ACAD SCI, V868, P667, DOI 10.1111/j.1749-6632.1999.tb11343.x; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; DEUTMAN AF, 1969, ARCH OPHTHALMOL-CHIC, V81, P305, DOI 10.1001/archopht.1969.00990010307001; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Faber KN, 2001, J BIOL CHEM, V276, P36501, DOI 10.1074/jbc.M105828200; FRANCOIS J, 1967, ARCH OPHTHALMOL-CHIC, V77, P726; FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115; GALLEMORE RP, 1998, RETINAL PIGMENT EPIT, P175; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; George AL, 2001, CURR BIOL, V11, pR620, DOI 10.1016/S0960-9822(01)00368-2; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Iyer R, 2002, NATURE, V419, P715, DOI 10.1038/nature01000; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leahy DJ, 2000, PROTEIN EXPRES PURIF, V20, P500, DOI 10.1006/prep.2000.1331; Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; MACKE JP, 1993, AM J HUM GENET, V53, P80; Marchant D, 2001, Hum Mutat, V17, P235, DOI 10.1002/humu.9; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; Marmorstein LY, 2002, J BIOL CHEM, V277, P30591, DOI 10.1074/jbc.M204269200; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; MOHLER CW, 1981, OPHTHALMOLOGY, V88, P688; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Steinberg R. H., 1985, PROGR RETINAL RES, P33, DOI 10.1016/0278-4327(85)90004-5; Stohr H, 2002, EUR J HUM GENET, V10, P281, DOI 10.1038/sj.ejhg.5200796; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Urabe M, 1999, BIOCHEM BIOPH RES CO, V266, P92, DOI 10.1006/bbrc.1999.1788; WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108; White K, 2000, HUM MUTAT, V15, P301, DOI 10.1002/(SICI)1098-1004(200004)15:4<301::AID-HUMU1>3.0.CO;2-N; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	52	182	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41114	41125		10.1074/jbc.M306150200	http://dx.doi.org/10.1074/jbc.M306150200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907679	hybrid, Green Accepted			2022-12-25	WOS:000185847200087
J	Fraser, DJ; Zumsteg, A; Meyer, UA				Fraser, DJ; Zumsteg, A; Meyer, UA			Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR; SIGNALING PATHWAY; HEME METABOLISM; INDUCTION; CAR; PXR; PROTEIN; CXR; ELEMENTS	Nuclear receptors have been implicated in the transcriptional regulation of expression of a growing number of genes, including cytochromes P450 and 5-aminolevulinate synthase (ALAS1), the first and rate-limiting enzyme in the heme biosynthesis pathway. Although drugs that induce cytochromes P450 also induce ALAS1, the regulatory mechanisms governing these pathways have not been fully elucidated. We have identified a drug-responsive enhancer in the murine ALAS1 gene. This sequence mediates transcriptional activation by a wide range of compounds including typical cytochrome P450 pan-inducers phenobarbital and metyrapone, as well as specific activators of the pregnane X receptor and the constitutive androstane receptor. ALAS1 drug-responsive enhancer sequences were identified by transient transfection of reporter gene constructs in the drug-responsive leghorn male hepatoma cell line. Using the NUBIScan algorithm, DR4 nuclear receptor binding sites were identified within the elements and their roles in mediating transcriptional activation of ALAS1 were confirmed by site-directed mutagenesis. Electrophoretic mobility shift assays demonstrate clear interactions of mouse pregnane X receptor and constitutive androstane receptor on the ADRES. Transactivation assays in CV-1 cells implicate the nuclear receptors as major contributors to transcriptional activation of ALAS1. Moreover, in vivo studies in knock-out animals confirm the induction of ALAS1 is mediated at least in part by nuclear receptors. These studies are the first to explain drug induction via drug response elements for mammalian ALAS1.	Univ Basel, Bioctr, Dept Pharmacol Neurobiol, Div Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Basel	Meyer, UA (corresponding author), Univ Basel, Bioctr, Dept Pharmacol Neurobiol, Div Pharmacol Neurobiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.							Akiyama TE, 2003, BBA-GEN SUBJECTS, V1619, P223, DOI 10.1016/S0304-4165(02)00480-4; Anderson K. E., 2001, METABOLIC BASIS INHE; Baader M, 2002, J BIOL CHEM, V277, P15647, DOI 10.1074/jbc.M109882200; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Cable EE, 2002, DNA CELL BIOL, V21, P323, DOI 10.1089/104454902753759735; Cable EE, 2000, ARCH BIOCHEM BIOPHYS, V384, P280, DOI 10.1006/abbi.2000.2117; Ferguson SS, 2002, MOL PHARMACOL, V62, P737, DOI 10.1124/mol.62.3.737; Fraser DJ, 2002, J BIOL CHEM, V277, P34717, DOI 10.1074/jbc.M204699200; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; GRANICK S, 1975, J BIOL CHEM, V250, P9215; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jones SA, 2002, METHOD ENZYMOL, V357, P161; Jover R, 1996, BIOCHEM BIOPH RES CO, V226, P152, DOI 10.1006/bbrc.1996.1325; Kakizaki S, 2003, BBA-GEN SUBJECTS, V1619, P239, DOI 10.1016/S0304-4165(02)00482-8; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Lindberg RLP, 1996, NAT GENET, V12, P195, DOI 10.1038/ng0296-195; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; Paquet Y, 2000, J BIOL CHEM, V275, P38427, DOI 10.1074/jbc.M005776200; Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269; Sassa S, 2002, PHOTODERMATOL PHOTO, V18, P56, DOI 10.1034/j.1600-0781.2002.180202.x; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; WANG H, 2003, J BIOL CHEM, V5, P5; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753	37	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39392	39401		10.1074/jbc.M306148200	http://dx.doi.org/10.1074/jbc.M306148200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881517	hybrid			2022-12-25	WOS:000185713800016
J	Torres, AM; Wong, HY; Desai, M; Moochhala, S; Kuchel, PW; Kini, RM				Torres, AM; Wong, HY; Desai, M; Moochhala, S; Kuchel, PW; Kini, RM			Identification of a novel family of proteins in snake venoms - Purification and structural characterization of nawaprin from Naja nigricollis snake venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEY ACIDIC PROTEIN; TRANSGLUTAMINASE SUBSTRATE DOMAIN; ELASTASE-SPECIFIC INHIBITOR; ACCELERATED EVOLUTION; CRYSTAL-STRUCTURE; GENE FAMILY; SEQUENCE; ELAFIN; EPIDIDYMIS; SPECTROSCOPY	The three-dimensional structure of nawaprin has been determined by nuclear magnetic resonance spectroscopy. This 51-amino acid residue peptide was isolated from the venom of the spitting cobra, Naja nigricollis, and is the first member of a new family of snake venom proteins referred to as waprins. Nawaprin is relatively flat and disc-like in shape, characterized by a spiral backbone configuration that forms outer and inner circular segments. The two circular segments are held together by four disulfide bonds, three of which are clustered at the base of the molecule. The inner segment contains a short antiparallel beta-sheet, whereas the outer segment is devoid of secondary structures except for a small turn or 3(10) helix. The structure of nawaprin is very similar to elafin, a human leukocyte elastase-specific inhibitor. Although substantial parts of the nawaprin molecule are well defined, the tips of the outer and inner circular segments, which are hypothesized to be critical for binding interactions, are apparently disordered, similar to that found in elafin. The amino acid residues in these important regions in nawaprin are different from those in elafin, suggesting that nawaprin is not an elastase-specific inhibitor and therefore has a different function in the snake venom.	Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 119260, Singapore; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Def Sci & Technol Agcy, Def Med Res Inst, Singapore 117597, Singapore	National University of Singapore; National University of Singapore; University of Sydney; Agency for Science Technology & Research (A*STAR)	Kini, RM (corresponding author), Natl Univ Singapore, Fac Sci, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.	dbskinim@nus.edu.sg	Torres, Allan/GSN-4624-2022; Kini, Manjunatha/H-8029-2012	Kini, Manjunatha/0000-0002-6100-3251; MOOCHHALA, SHABBIR/0000-0003-4521-3192; Kuchel, Philip/0000-0003-4100-7332				ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; BAILEY GS, 1998, ENZYMES SNAKE VENOM; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEG OU, 1986, EUR J BIOCHEM, V159, P195, DOI 10.1111/j.1432-1033.1986.tb09852.x; BRAGANCA BM, 1967, NATURE, V216, P1210, DOI 10.1038/2161210a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; Clauss A, 2002, BIOCHEM J, V368, P233, DOI 10.1042/BJ20020869; CORONEL CE, 1990, J BIOL CHEM, V265, P6854; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; EISENBERG SP, 1988, BIOL CHEM H-S      S, V369, P79; ELLERBROCK K, 1994, INT J ANDROL, V17, P314, DOI 10.1111/j.1365-2605.1994.tb01262.x; Fan HY, 1999, ARCH ANDROLOGY, V42, P63, DOI 10.1080/014850199262896; Francart C, 1997, J MOL BIOL, V268, P666, DOI 10.1006/jmbi.1997.0983; Furukawa M, 1996, J BIOL CHEM, V271, P29517, DOI 10.1074/jbc.271.47.29517; Furutani Y, 1998, J BIOCHEM-TOKYO, V124, P491, DOI 10.1093/oxfordjournals.jbchem.a022140; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; Hagiwara K, 2003, J IMMUNOL, V170, P1973, DOI 10.4049/jimmunol.170.4.1973; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; Joseph JS, 1999, BLOOD, V94, P621, DOI 10.1182/blood.V94.2.621.414k25_621_631; Kini R.M., 1997, VENOM PHOSPHOLIPASE; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; KIRCHLOFF C, 1990, INT J ANDROL, V13, P155, DOI 10.1111/j.1365-2605.1990.tb00972.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOZAKI T, 1994, PEPT CHEM, P405; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Mebs D., 1991, SNAKE TOXINS, P425; NAKASHIMA K, 1993, P NATL ACAD SCI USA, V90, P5964, DOI 10.1073/pnas.90.13.5964; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; OGAWA T, 1992, P NATL ACAD SCI USA, V89, P8557, DOI 10.1073/pnas.89.18.8557; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RENFREE MB, 1981, BIOL NEONATE, V40, P29, DOI 10.1159/000241469; Schalkwijk J, 1999, BIOCHEM J, V340, P569, DOI 10.1042/0264-6021:3400569; SCHALKWIJK J, 1990, BRIT J DERMATOL, V122, P631, DOI 10.1111/j.1365-2133.1990.tb07285.x; Si-Tahar M, 2000, GASTROENTEROLOGY, V118, P1061, DOI 10.1016/S0016-5085(00)70359-3; Simpson KJ, 2000, J BIOL CHEM, V275, P23074, DOI 10.1074/jbc.M002161200; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; TAKASAKI C, 1990, TOXICON, V28, P319, DOI 10.1016/0041-0101(90)90067-H; Tamechika I, 1996, J BIOL CHEM, V271, P7012, DOI 10.1074/jbc.271.12.7012; Tomee JFC, 1998, THORAX, V53, P114, DOI 10.1136/thx.53.2.114; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; TU AT, 1991, REPTILE VENOMS TOXIN; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; Yamazaki Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P133, DOI 10.1016/S0003-9861(03)00028-6; Zeeuwen PLJM, 1997, J BIOL CHEM, V272, P20471, DOI 10.1074/jbc.272.33.20471; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8; [No title captured]	57	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40097	40104		10.1074/jbc.M305322200	http://dx.doi.org/10.1074/jbc.M305322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878611	hybrid			2022-12-25	WOS:000185713800101
J	Amraei, M; Jia, ZJ; Reboul, P; Nabi, IR				Amraei, M; Jia, ZJ; Reboul, P; Nabi, IR			Acid-induced conformational changes in phosphoglucose isomerase result in its increased cell surface association and deposition on fibronectin fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOCRINE MOTILITY FACTOR; RHEUMATOID KNEE-JOINTS; FACTOR-RECEPTOR; CRYSTAL-STRUCTURE; ENDOPLASMIC-RETICULUM; GLUCOSE-6-PHOSPHATE ISOMERASE; MONOCLONAL-ANTIBODIES; MEDIATED ENDOCYTOSIS; FACTOR NEUROLEUKIN; GLYCOLYTIC ENZYME	Phosphoglucose isomerase (PGI) is a glycolytic enzyme that exhibits extracellular cytokine activity as autocrine motility factor, neuroleukin, and maturation factor and that has been recently implicated as an autoantigen in rheumatoid arthritis. In contrast to its receptor-mediated endocytosis at neutral pH, addition of 25 mug/ml of either Alexa 568- or FITC-conjugated PGI to NIH-3T3 cells at progressively acid pH results in its quantitatively increased association with cell surface fibrillar structures that is particularly evident at pH 5. A similar pH-dependent cell surface association of PGI is observed for first passage human chondrocytes obtained from osteoarthritic joints. At acid pH, PGI colocalizes with fibronectin fibrils, and this association occurs directly upon addition of PGI to the cells. In contrast to the receptor-mediated endocytosis of PGI, fibril association of 25 mug/ml PGI at pH 5 is not competed with an excess (2 mg/ml) of unlabeled PGI. PGI binding at acid pH is therefore neither saturable nor mediated by its receptor. PGI is enzymatically active as a dimer and we show here by non-denaturing gel electrophoresis as well as by glutaraldehyde cross-linking that it exists at neutral pH in a tetrameric form. Increasingly acid pH results in the appearance of PGI monomers that correlates directly with its enhanced cell surface association. However, glutaraldehyde cross-linked PGI is endocytosed at neutral pH and still exhibits enhanced cell surface binding at pH 5. Circular dichroism analysis revealed pH-dependent changes in the near but not the far UV spectra indicating that the tertiary structure of the protein is specifically altered at pH 5. Conformational changes of PGI and exposure of the monomer-monomer interface under acidic conditions, such as those encountered in the synovial fluid of arthritic joints, could therefore result in its deposition on the surface of joints and the induction of an autoimmune response.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Ctr Hosp, Hop Notre Dame, Osteoarthrit Res Unit, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Nabi, IR (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, CP 6128,Succursale A, Montreal, PQ H3C 3J7, Canada.		REBOUL, Pascal/ABA-3774-2021; Nabi, Ivan R/C-5493-2009; Nabi, Ivan/GWZ-5144-2022	REBOUL, Pascal/0000-0003-3546-2152; Nabi, Ivan/0000-0002-0670-0513				ACCOLA MA, 2002, J BIOL CHEM, DOI UNSP M201641200; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Amraei M, 2002, FEBS LETT, V525, P151, DOI 10.1016/S0014-5793(02)03072-7; Arsenieva D, 2002, P NATL ACAD SCI USA, V99, P5872, DOI 10.1073/pnas.052131799; Barilla ML, 2000, SEMIN ARTHRITIS RHEU, V29, P252, DOI 10.1016/S0049-0172(00)80012-8; BENLIMAME N, 1995, J CELL BIOL, V129, P459, DOI 10.1083/jcb.129.2.459; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; BLACKBURN MN, 1972, J BIOL CHEM, V247, P5668; BODANSKY O, 1954, CANCER, V7, P1200, DOI 10.1002/1097-0142(195411)7:6<1200::AID-CNCR2820070612>3.0.CO;2-9; BRUCH P, 1976, EUR J BIOCHEM, V68, P153, DOI 10.1111/j.1432-1033.1976.tb10773.x; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; Chou CC, 2000, J BIOL CHEM, V275, P23154, DOI 10.1074/jbc.M002017200; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DYSON JED, 1968, J BIOL CHEM, V243, P1401; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; Funasaka T, 2001, BIOCHEM BIOPH RES CO, V285, P118, DOI 10.1006/bbrc.2001.5135; GOLDIE I, 1970, ACTA ORTHOP SCAND, V41, P354, DOI 10.3109/17453677008991521; GOLDIE I, 1969, ACTA ORTHOP SCAND, V40, P634, DOI 10.3109/17453676908989529; GURNEY ME, 1986, SCIENCE, V234, P574, DOI 10.1126/science.3020690; GURNEY ME, 1986, J CELL BIOL, V102, P2264, DOI 10.1083/jcb.102.6.2264; HERVE CA, 2003, RHEUMATOLOGY, V212, P986; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; Hirono Y, 1996, BRIT J CANCER, V74, P2003, DOI 10.1038/bjc.1996.667; Jeffery CJ, 2000, BIOCHEMISTRY-US, V39, P955, DOI 10.1021/bi991604m; Jeffery CJ, 2001, BIOCHEMISTRY-US, V40, P1560, DOI 10.1021/bi0018483; Kassahn D, 2002, NAT IMMUNOL, V3, P411, DOI 10.1038/ni0502-411b; Konttinen YT, 2002, ARTHRITIS RHEUM, V46, P953, DOI 10.1002/art.10185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le PU, 2000, J CELL SCI, V113, P3227; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Leclerc N, 2000, J NEUROSCI RES, V60, P602, DOI 10.1002/(SICI)1097-4547(20000601)60:5<602::AID-JNR5>3.0.CO;2-F; LU HS, 1981, J BIOL CHEM, V256, P785; Lui KEH, 2002, J CELL PHYSIOL, V192, P102, DOI 10.1002/jcp.10120; Luo YQ, 2002, J NEUROCHEM, V80, P354, DOI 10.1046/j.0022-3042.2001.00707.x; Maccioni M, 2002, J EXP MED, V195, P1071, DOI 10.1084/jem.20011941; Mandik-Nayak L, 2002, P NATL ACAD SCI USA, V99, P14368, DOI 10.1073/pnas.182549099; MARUYAMA K, 1995, INT J CANCER, V64, P316, DOI 10.1002/ijc.2910640506; MASTERS CJ, 1984, J CELL BIOL, V99, P222; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; Matsumoto I, 2002, NAT IMMUNOL, V3, P360, DOI 10.1038/ni772; Matsumoto I, 2003, ARTHRITIS RHEUM-US, V48, P944, DOI 10.1002/art.10898; Menkin V, 1937, AM J PATHOL, V13, P25; NABI IR, 1990, CANCER RES, V50, P409; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nagai Y, 1996, DERMATOLOGY, V192, P8, DOI 10.1159/000246304; NAKAMORI S, 1994, CANCER-AM CANCER SOC, V74, P1855, DOI 10.1002/1097-0142(19941001)74:7<1855::AID-CNCR2820740705>3.0.CO;2-1; Niinaka Y, 2002, ORAL ONCOL, V38, P49, DOI 10.1016/S1368-8375(01)00022-7; OTTO T, 1994, CANCER RES, V54, P3120; PON NG, 1970, BIOCHEMISTRY-US, V9, P1506, DOI 10.1021/bi00809a005; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; Schaller M, 2001, NAT IMMUNOL, V2, P746, DOI 10.1038/90696; Schubert D, 2002, NAT IMMUNOL, V3, P411, DOI 10.1038/ni0502-411a; SCHWARTZ MK, 1973, CLIN CHEM, V19, P10; Shimizu K, 1999, FEBS LETT, V456, P295, DOI 10.1016/S0014-5793(99)00966-7; Silletti S., 1991, CANCER RES, V51, P3301; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P5412, DOI 10.1073/pnas.96.10.5412; Takanami I, 1998, TUMOR BIOL, V19, P384, DOI 10.1159/000030031; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; Tardif G, 1999, ARTHRITIS RHEUM, V42, P1147, DOI 10.1002/1529-0131(199906)42:6<1147::AID-ANR11>3.0.CO;2-Y; TREUHAFT PS, 1971, ARTHRITIS RHEUM, V14, P475, DOI 10.1002/art.1780140407; Tsutsumi S, 2003, FEBS LETT, V534, P49, DOI 10.1016/S0014-6793(02)03773-0; Tsutsumi S, 2003, CANCER RES, V63, P242; Wang HJ, 2000, J CELL BIOL, V150, P1489, DOI 10.1083/jcb.150.6.1489; Wang HJ, 1997, J CELL SCI, V110, P3043; WATANABE H, 1994, J RHEUMATOL, V21, P37; Watanabe H, 1996, CANCER RES, V56, P2960; Wipke BT, 2002, NAT IMMUNOL, V3, P366, DOI 10.1038/ni775; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867; Zhi J, 2001, J BONE MINER RES, V16, P1994, DOI 10.1359/jbmr.2001.16.11.1994	71	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38935	38941		10.1074/jbc.M304778200	http://dx.doi.org/10.1074/jbc.M304778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12888574	hybrid			2022-12-25	WOS:000185575100103
J	Giese, B; Au-Yeung, CK; Herrmann, A; Diefenbach, S; Haan, C; Kuster, A; Wortmann, SB; Roderburg, C; Heinrich, PC; Behrmann, I; Muller-Newen, G				Giese, B; Au-Yeung, CK; Herrmann, A; Diefenbach, S; Haan, C; Kuster, A; Wortmann, SB; Roderburg, C; Heinrich, PC; Behrmann, I; Muller-Newen, G			Long term association of the cytokine receptor gp130 and the janus kinase Jak1 revealed by FRAP analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; FLUORESCENCE PHOTOBLEACHING RECOVERY; CELL-SURFACE EXPRESSION; MONOCLONAL-ANTIBODIES; HUMAN-ERYTHROCYTES; TYROSINE KINASES; PROTEIN-KINASE; FERM DOMAIN; INTERLEUKIN-6; REGION	Signal transduction through cytokine receptors is mediated mainly by non-covalently associated Jak tyrosine kinases. By confocal microscopy, the cytokine receptor gp130 and Jak1, fused with either yellow (YFP) or cyan (CFP) fluorescent protein, were found to be colocalized predominantly at intracellular vesicular structures and at the plasma membrane. Quantitative fluorescence recovery after photobleaching (FRAP) analysis at the plasma membrane revealed equal mobilities for gp130-YFP and Jak1-YFP. Thus, Jak1-YFP diffuses like a transmembrane protein indicating that membrane-bound Jak1 does not exchange rapidly with cytosolic Jaks. Applying a novel dual-color FRAP approach we found that immobilization of gp130-CFP by a pair of monoclonal antibodies led to a corresponding immobilization of co-transfected Jak1-YFP. We conclude from these findings that Jak1, once bound to a gp130 molecule, does not exchange between different receptors at the plasma membrane neither via the cytoplasmic compartment nor via a membrane-associated state.	Univ Klinikum RWTH Aachen, Inst Biochem, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Muller-Newen, G (corresponding author), Univ Klinikum RWTH Aachen, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.		Wortmann, Saskia/E-6125-2010; Roderburg, Christoph/AAR-3051-2021; Roderburg, Christoph/AHC-8101-2022	Roderburg, Christoph/0000-0002-1409-7697; Behrmann, Iris/0000-0003-3688-3645				AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2000, BIOCHEM J, V349, P261, DOI 10.1042/0264-6021:3490261; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; KATZIR Z, 1989, BIOCHEMISTRY-US, V28, P6400, DOI 10.1021/bi00441a036; Klonis N, 2002, EUR BIOPHYS J BIOPHY, V31, P36, DOI 10.1007/s00249-001-0202-2; KNOWLES DW, 1994, BIOPHYS J, V66, P1726, DOI 10.1016/S0006-3495(94)80965-8; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Muller-Newen G, 2000, J BIOL CHEM, V275, P4579, DOI 10.1074/jbc.275.7.4579; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmitz J, 2000, J IMMUNOL, V164, P848, DOI 10.4049/jimmunol.164.2.848; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; Sloan-Lancaster J, 1998, J CELL BIOL, V143, P613, DOI 10.1083/jcb.143.3.613; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	41	45	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39205	39213		10.1074/jbc.M303347200	http://dx.doi.org/10.1074/jbc.M303347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878601	hybrid			2022-12-25	WOS:000185575100135
J	Shao, GZ; Zhou, RL; Zhang, QY; Zhang, Y; Liu, JJ; Rui, JA; Wei, X; Ye, DX				Shao, GZ; Zhou, RL; Zhang, QY; Zhang, Y; Liu, JJ; Rui, JA; Wei, X; Ye, DX			Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma	ONCOGENE			English	Article						LAPTM4B; hepatocellular carcinoma; differential expression; promoter analysis	HEPATITIS-B-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; MESSENGER-RNA OVEREXPRESSION; CYCLIN D1 OVEREXPRESSION; MEMBRANE-PROTEIN; C-MET; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; P53 MUTATION; CELL-LINES	Lysosomal-associated protein transmembrane-4 beta (LAPTM4B), a novel gene upregulated in hepatocellular carcinoma (HCC), was cloned using fluorescence differential display, RACE, and RT-PCR. It contains seven exons and encodes a 35-kDa protein with four putative transmembrane regions. Both the N- and C-termini of the protein are proline-rich, and may serve as potential ligands for the SH3 domain. Immunohistochemical analysis localized the protein predominantly to intracellular membranes. Northern blot showed that the LAPTM4B mRNAs were remarkably upregulated in HCC (87.3%) and correlated inversely with differentiation status. LAPTM4B was also overexpressed in many HCC-derived cell tines. It was also highly expressed in fetal livers and certain adult normal tissues including the heart, skeletal muscle, testis, and ovary. Promoter function assays showed a distinct difference in the gene's activities between BEL7402 and HLE cell lines, suggesting that the transcription factors responsible for regulation of the gene in the two cell lines are different, and that possible negative regulatory cis-elements may exist upstream of the promoter region. It was demonstrated that the N-terminus of LAPTM4B was essential for survival of the cells. Cells harboring the full-length LAPTM4B cDNA expression clone displayed a slightly increased efficiency in colony formation. These results suggest that LAPTM4B is a potential protooncogene, whose overexpression is involved in carcinogenesis and progression of HCC. In normal cells, it may also play important roles such as regulation of cell proliferation and survival.	Peking Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, Beijing 100083, Peoples R China; Beijing Union Med Coll Hosp, Dept Basic Surg, Beijing 100032, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Zhou, RL (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	rlzhou@mail.bjmu.edu.cn						Adra CN, 1996, GENOMICS, V35, P328, DOI 10.1006/geno.1996.0364; Anthony PP, 2001, HISTOPATHOLOGY, V39, P109, DOI 10.1046/j.1365-2559.2001.01188.x; Arii S, 1996, HEPATOLOGY, V24, P316; BEGUM NA, 1995, HEPATOLOGY, V22, P1447, DOI 10.1002/hep.1840220518; BOIX L, 1994, HEPATOLOGY, V19, P88, DOI 10.1016/0270-9139(94)90057-4; Cabrita MA, 1999, CANCER RES, V59, P4890; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; Deane NG, 2001, CANCER RES, V61, P5389; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Fujimoto Y, 1998, J GASTROENTEROL, V33, P368, DOI 10.1007/s005350050098; GRAZIANO P, 2001, GENE, V276, P73; GRIGIONI WF, 1995, HEPATOLOGY, V21, P1543, DOI 10.1016/0270-9139(95)90457-3; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; HE J, 2003, IN PRESS J PEKING U, V35; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hogue DL, 2002, BIOCHEM J, V365, P721, DOI 10.1042/BJ20020205; Hogue DL, 1999, J BIOL CHEM, V274, P12877, DOI 10.1074/jbc.274.18.12877; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; KENMOCHI K, 1987, LIVER, V7, P18; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; Lin YW, 1999, EUR J CANCER, V35, P652, DOI 10.1016/S0959-8049(98)00430-4; Liu JJ, 2000, CHINESE MED J-PEKING, V113, P881; Liu JJ, 2000, J BEIJING MED U, V32, P411; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Masumoto N, 2002, GENE, V291, P169, DOI 10.1016/S0378-1119(02)00593-0; Nakakura EK, 2000, ONCOLOGY-NY, V14, P1085; Ozaki I, 2000, CANCER RES, V60, P6519; Peng SY, 1998, J HEPATOL, V29, P281, DOI 10.1016/S0168-8278(98)80014-7; Pineau P, 2000, J HEPATOL, V33, P152, DOI 10.1016/S0168-8278(00)80172-5; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; Radford KJ, 1997, J IMMUNOL, V158, P3353; TANG ZY, 1995, CHINESE MED J-PEKING, V108, P568; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wu BY, 1996, CHINESE MED J-PEKING, V109, P922; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; YEH FS, 1989, CANCER RES, V49, P2506; Zeng JZ, 2002, ONCOGENE, V21, P4932, DOI 10.1038/sj.onc.1205652	49	136	153	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5060	5069		10.1038/sj.onc.1206832	http://dx.doi.org/10.1038/sj.onc.1206832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902989				2022-12-25	WOS:000184578900014
J	Guo, RF; Riedemann, NC; Bernacki, KD; Sarma, VJ; Laudes, IJ; Reuben, JS; Younkin, EM; Neff, TA; Paulauskis, JD; Zetoune, FS; Ward, PA				Guo, RF; Riedemann, NC; Bernacki, KD; Sarma, VJ; Laudes, IJ; Reuben, JS; Younkin, EM; Neff, TA; Paulauskis, JD; Zetoune, FS; Ward, PA			Neutrophil C5a receptor and the outcome in a rat model of sepsis	FASEB JOURNAL			English	Article						innate immunity; polymorphonuclear cells; complement	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTOR; FORMYL PEPTIDE; IMMUNE-COMPLEX; ANAPHYLATOXIN; EXPRESSION; ACTIVATION; ANTI-C5A; INTERNALIZATION; BINDING	Complement fragment 5a (C5a)-C5a receptor (C5aR) signaling plays an essential role in neutrophil innate immunity. Blockade of either the ligand or the receptor improves survival rates in experimental sepsis. In the current study, sepsis was induced in rats by cecal ligation/puncture. Early in sepsis C5aR content on neutrophils significantly dropped, reached the nadir at 24 h after onset of sepsis, and progressively elevated thereafter. Western-blot, RT-PCR, and confocal microscopy analyses revealed that the loss and re-expression of C5aR during sepsis might be due, at least in part, to the receptor internalization and reconstitution. The reduction and reconstitution of C5aR correlate with the loss and restoration of innate immune functions of blood neutrophils (chemotaxis and reactive oxygen species production), respectively. Quantitative measurements of C5aR on blood neutrophils are highly predictive of survival or death during sepsis. These data suggest that neutrophil C5aR content represents an essential component of an efficient defense system in sepsis and may serve as a prognostic marker for the outcome.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Pfizer Global Res & Dev, Dept Drug Safety Evaluat, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; Pfizer	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Riedemann, Niels C/C-1633-2010; Reuben, Jayne/GWQ-6664-2022					AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BENGTSON A, 1988, ARCH SURG-CHICAGO, V123, P645; Bock D, 1997, EUR J IMMUNOL, V27, P1522, DOI 10.1002/eji.1830270631; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; BOTHA AJ, 1995, SURGERY, V118, P358, DOI 10.1016/S0039-6060(05)80345-9; BOTHA AJ, 1995, SHOCK, V3, P157, DOI 10.1097/00024382-199503000-00001; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; Cohen J, 2001, CRIT CARE MED, V29, P880, DOI 10.1097/00003246-200104000-00039; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; DARVILLE T, 1993, INFECTION, V21, P279, DOI 10.1007/BF01712446; DEBOER JP, 1993, INFECT IMMUN, V61, P4293, DOI 10.1128/IAI.61.10.4293-4301.1993; Faist E, 1996, WORLD J SURG, V20, P454, DOI 10.1007/s002689900071; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; GOLDMAN DW, 1986, J IMMUNOL, V137, P1971; GOYA T, 1994, SURGERY, V115, P145; Guo RF, 2000, J CLIN INVEST, V106, P1271, DOI 10.1172/JCI10793; Guo RF, 1999, GENOMICS, V58, P313, DOI 10.1006/geno.1999.5837; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; HU MH, 1999, BLOOD, V93, P3241; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2001, FASEB J, V15, P568; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; Koch T, 1997, SHOCK, V7, P42, DOI 10.1097/00024382-199701000-00005; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; Laudes IJ, 2002, AM J PATHOL, V160, P1867, DOI 10.1016/S0002-9440(10)61133-9; Meddows-Taylor S, 2001, J INFECT DIS, V183, P662, DOI 10.1086/318532; Mollnes TE, 2002, BLOOD, V100, P1869; Naik N, 1997, J CELL SCI, V110, P2381; NAKAE H, 1994, RES COMMUN CHEM PATH, V84, P189; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; OPPERMANN M, 1994, IMMUNOLOGY, V82, P516; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Schieferdecker HL, 2001, INT IMMUNOPHARMACOL, V1, P469, DOI 10.1016/S1567-5769(00)00038-2; Seely AJE, 2002, ANN SURG, V235, P550, DOI 10.1097/00000658-200204000-00014; SHIRATO M, 1988, FEBS LETT, V234, P231, DOI 10.1016/0014-5793(88)81341-3; SHUM JK, 1995, BIOCHEM BIOPH RES CO, V208, P223, DOI 10.1006/bbrc.1995.1327; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SMEDEGARD G, 1989, AM J PATHOL, V135, P489; SOLOMKIN JS, 1984, J SURG RES, V36, P407, DOI 10.1016/0022-4804(84)90119-7; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; Strachan AJ, 2000, J IMMUNOL, V164, P6560, DOI 10.4049/jimmunol.164.12.6560; Strachan AJ, 2001, BRIT J PHARMACOL, V134, P1778, DOI 10.1038/sj.bjp.0704417; TELLADO JM, 1993, CRIT CARE MED, V21, P1496, DOI 10.1097/00003246-199310000-00017; TENNENBERG SD, 1988, ARCH SURG-CHICAGO, V123, P171; VANEPPS DE, 1990, J LEUKOCYTE BIOL, V47, P519; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; WERFEL T, 1992, BLOOD, V79, P152, DOI 10.1182/blood.V79.1.152.bloodjournal791152; ZIMMERMAN JJ, 1985, CRIT CARE MED, V13, P143, DOI 10.1097/00003246-198503000-00001	51	64	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1889	+		10.1096/fj.03-0009fje	http://dx.doi.org/10.1096/fj.03-0009fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897064	Green Submitted			2022-12-25	WOS:000185345100022
J	Mulholland, NM; Soeth, E; Smith, CL				Mulholland, NM; Soeth, E; Smith, CL			Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation	ONCOGENE			English	Article						histone deacetylase; transcription; chromatin; mouse mammary tumor virus	TUMOR VIRUS PROMOTER; LONG TERMINAL REPEAT; GLUCOCORTICOID-RECEPTOR; DEACETYLASE INHIBITORS; GENE-EXPRESSION; IN-VIVO; SACCHAROMYCES-CEREVISIAE; SODIUM-BUTYRATE; N-COR; ACTIVATION	Increased histone acetylation has been associated with activated gene transcription and decreased acetylation with repression. However, there is a growing number of genes known, which are downregulated by histone deacetylase (HDAC) inhibitors through unknown mechanisms. This study examines the mechanism by which the mouse mammary tumor virus (MMTV) promoter is repressed by the HDAC inhibitor, trichostatin A (TSA). We find that this repression is transcriptional in nature and that it occurs in the presence and absence of glucocorticoids. TSA decreases MMTV transcription at a rapid rate, reaching maximum in 30-60 min. In contrast with previous reports, the repression does not correlate with an inhibition of glucocorticoid-induced nuclease hypersensitivity or NF1-binding at the MMTV promoter. Surprisingly, TSA does not induce sizable increases in histone acetylation at the MMTV promoter nor does it inhibit histone deacetylation, which accompanies deactivation of the glucocorticoid-activated MMTV promoter. Repression of MMTV transcription by TSA does not depend on the chromatin organization of the promoter because a transiently transfected MMTV promoter construct with a disorganized nucleoprotein structure was also repressed by TSA treatment. Mutational analysis of the MMTV promoter indicates that repression by TSA is mediated through the TATA box region. These results suggest a novel mechanism that involves acetylation of nonhistone proteins necessary for basal transcription.	NCI, Signal Transduct Grp, Lab Receptor Biol & Gene Express, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; George Washington Univ, Dept Genet, Washington, DC 20052 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University	Smith, CL (corresponding author), NCI, Signal Transduct Grp, Lab Receptor Biol & Gene Express, Ctr Canc Res,NIH, Bldg 41,Room B608,41 Library Dr,MSC 5055, Bethesda, MD 20892 USA.	smithcat@exchange.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DeRubertis F, 1996, NATURE, V384, P589; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HONG L, 1993, J BIOL CHEM, V268, P305; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Kim SY, 2003, J VIROL, V77, P3394, DOI 10.1128/JVI.77.6.3394-3401.2003; Koyama Y, 2000, BLOOD, V96, P1490, DOI 10.1182/blood.V96.4.1490.h8001490_1490_1495; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Lambert JR, 1998, J BIOL CHEM, V273, P32708, DOI 10.1074/jbc.273.49.32708; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MCKNIGHT SL, 1982, COLD SPRING HARB SYM, V47, P945; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOYER ML, 1993, J BIOL CHEM, V268, P22933; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Myers CA, 1998, MOL CELL BIOL, V18, P2184, DOI 10.1128/MCB.18.4.2184; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PIERCE J, 1993, J VIROL, V67, P415, DOI 10.1128/JVI.67.1.415-424.1993; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; VanLint C, 1996, GENE EXPRESSION, V5, P245; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200	61	46	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4807	4818		10.1038/sj.onc.1206722	http://dx.doi.org/10.1038/sj.onc.1206722			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894222				2022-12-25	WOS:000184344600004
J	Miething, C; Grundler, R; Fend, F; Hoepfl, J; Mugler, C; von Schilling, C; Morris, SW; Peschel, C; Duyster, J				Miething, C; Grundler, R; Fend, F; Hoepfl, J; Mugler, C; von Schilling, C; Morris, SW; Peschel, C; Duyster, J			The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model	ONCOGENE			English	Article						NPM-ALK; mouse model; tyrosine kinase; lymphoma	LARGE-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; MYELOPROLIFERATIVE DISEASE; MULTIPLE-MYELOMA; RAPID INDUCTION; TYROSINE KINASE; V-MYC; MICE	A t(2;5) (p23;q35) chromosomal translocation can be found in a high percentage of anaplastic large-cell lymphomas (ALCL). This genetic abnormality leads to the expression of the NPM-ALK fusion protein, which encodes a constitutively active tyrosine kinase that plays a causative role in lymphomagenesis. Employing a modified infection/transplantation protocol utilizing an MSCV-based vector, we were able to reproducibly induce two phenotypically different lymphoma-like diseases dependent on the retroviral titers used. The first phenotype presented as a polyclonal histiocytic malignancy of myeloid/macrophage origin with a short latency period of 3-4 weeks. Clinically, the diseased mice showed rapidly progressive wasting, lymphadenopathy and pancytopenia. Mice displaying the second phenotype developed monoclonal B-lymphoid tumors with a longer latency of approximately 12-16 weeks, primarily involving the spleen and the bone marrow, with less extensive lymph node but also histologically evident extranodal organ infiltration by large immature plasmoblastic cells. The described retroviral mouse model will be useful to analyse the role of NPM-ALK in lymphomagenesis in vivo and may contribute to the development of new treatment options for NPM-ALK induced malignancies.	Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany; Tech Univ Munich, Dept Pathol, D-8000 Munich, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	Technical University of Munich; University of Munich; Technical University of Munich; St Jude Children's Research Hospital	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Trogerstr 32, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de	Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA069129] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA69129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Cheuk W, 2000, AM J SURG PATHOL, V24, P1537, DOI 10.1097/00000478-200011000-00010; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Falini B, 1999, BLOOD, V93, P2697; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; HAWLEY RG, 1994, GENE THER, V1, P136; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Mason DY, 1998, CANCER RES, V58, P1057; Million RP, 2000, BLOOD, V96, P664; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Parker JR, 2001, PEDIATR DEVEL PATHOL, V4, P397, DOI 10.1007/s10024001-0004-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Potter M, 1999, INT IMMUNOL, V11, P1059, DOI 10.1093/intimm/11.7.1059; POTTER M, 1986, CURR TOP MICROBIOL, V132, P40; Rawat R, 2000, BLOOD, V96, P3514; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Stein H, 2000, BLOOD, V96, P3681; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; Tu YP, 2000, CANCER RES, V60, P6763; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang W, 2001, IEEE CONTR SYST MAG, V21, P84, DOI 10.1109/37.898794; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	38	40	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4642	4647		10.1038/sj.onc.1206575	http://dx.doi.org/10.1038/sj.onc.1206575			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879008				2022-12-25	WOS:000184157000004
J	Persson, T; Cuzic, S; Hartmann, RK				Persson, T; Cuzic, S; Hartmann, RK			Catalysis by RNase P RNA - Unique features and unprecedented active site plasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS RIBONUCLEASE-P; PRECURSOR-TRANSFER-RNA; GROUP-I RIBOZYME; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; CLEAVAGE SITE; M1 RNA; 5' LEADER; MAGNESIUM-IONS; ACCEPTOR STEM	Metal ions are essential cofactors for precursor tRNA (ptRNA) processing by bacterial RNase P. The ribose 2'-OH at nucleotide (nt) - 1 of ptRNAs is known to contribute to positioning of catalytic Me2+. To investigate the catalytic process, we used ptRNAs with single 2'-deoxy (2'-H), 2'-amino (2'-N), or 2'-fluoro (2'-F) modifications at the cleavage site (nt - 1). 2' modifications had small (2.4 - 7.7- fold) effects on ptRNA binding to E. coli RNase P RNA in the ground state, decreasing substrate affinity in the order 2'-OH > 2'-F > 2'-N > 2'-H. Effects on the rate of the chemical step (about 10-fold for 2'-F, almost 150-fold for 2'-H and 2'-N) were much stronger, and, except for the 2'-N modification, resembled strikingly those observed in the Tetrahymena ribozyme-catalyzed reaction at corresponding position. Mn2+ rescued cleavage of the 2'-N but also the 2'-H-modified ptRNA, arguing against a direct metal ion coordination at this location. Miscleavage between nt - 1 and - 2 was observed for the 2'-N- ptRNA at low pH ( further influenced by the base identities at nt - 1 and + 73), suggesting repulsion of a catalytic metal ion due to protonation of the amino group. Effects caused by the 2'-N modification at nt - 1 of the substrate allowed us to substantiate a mechanistic difference in phosphodiester hydrolysis catalyzed by Escherichia coli RNase P RNA and the Tetrahymena ribozyme: a metal ion binds next to the 2' substituent at nt - 1 in the reaction catalyzed by RNase P RNA, but not at the corresponding location in the Tetrahymena ribozyme reaction.	Med Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany	University of Lubeck	Hartmann, RK (corresponding author), Univ Marburg, Inst Pharmazeut Chem, Marbacher Weg 6, D-35037 Marburg, Germany.							Altman S., 1999, RNA WORLD, P351; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; Berger I, 1998, NUCLEIC ACIDS RES, V26, P2473, DOI 10.1093/nar/26.10.2473; Blanchard SC, 2001, P NATL ACAD SCI USA, V98, P3720, DOI 10.1073/pnas.051608498; Brannvall M, 2003, J MOL BIOL, V325, P697, DOI 10.1016/S0022-2836(02)01195-6; Brannvall M, 2002, BIOCHIMIE, V84, P693, DOI 10.1016/S0300-9084(02)01462-1; Brannvall M, 1999, J MOL BIOL, V292, P53, DOI 10.1006/jmbi.1999.3048; Brannvall M, 2001, P NATL ACAD SCI USA, V98, P12943, DOI 10.1073/pnas.221456598; Brown JW, 1998, NUCLEIC ACIDS RES, V26, P351, DOI 10.1093/nar/26.1.351; BURKARD U, 1988, NUCLEIC ACIDS RES, V16, P11617, DOI 10.1093/nar/16.24.11617; Busch S, 2000, J MOL BIOL, V299, P941, DOI 10.1006/jmbi.2000.3789; Chen Y, 1997, BIOCHEMISTRY-US, V36, P2425; Christian EL, 1998, BIOCHEMISTRY-US, V37, P17618, DOI 10.1021/bi982050a; Christian EL, 2002, EMBO J, V21, P2253, DOI 10.1093/emboj/21.9.2253; Crary SM, 1998, BIOCHEMISTRY-US, V37, P9409, DOI 10.1021/bi980613c; Eckstein F, 2002, BIOCHIMIE, V84, P841, DOI 10.1016/S0300-9084(02)01459-1; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1993, BIOCHEMISTRY-US, V32, P7152, DOI 10.1021/bi00079a012; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Hansen A, 2001, MOL MICROBIOL, V41, P131, DOI 10.1046/j.1365-2958.2001.02467.x; HARDT WD, 1995, J MOL BIOL, V247, P161, DOI 10.1006/jmbi.1994.0130; Hartmann R K, 1995, Biotechnol Annu Rev, V1, P215, DOI 10.1016/S1387-2656(08)70053-X; Heide C, 1999, RNA, V5, P102, DOI 10.1017/S1355838299981499; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; Juneau K, 2001, STRUCTURE, V9, P221, DOI 10.1016/S0969-2126(01)00579-2; KIRSEBOM LA, 1994, EMBO J, V13, P4870, DOI 10.1002/j.1460-2075.1994.tb06814.x; Kufel J, 1996, P NATL ACAD SCI USA, V93, P6085, DOI 10.1073/pnas.93.12.6085; Kufel J, 1998, RNA, V4, P777, DOI 10.1017/S1355838298970923; Kurz JC, 2002, BIOCHEMISTRY-US, V41, P9545, DOI 10.1021/bi025553w; Loria A, 1997, BIOCHEMISTRY-US, V36, P6317, DOI 10.1021/bi970115o; Loria A, 1998, BIOCHEMISTRY-US, V37, P10126, DOI 10.1021/bi980220d; MILLER PS, 1993, NUCLEOS NUCLEOT, V12, P785, DOI 10.1080/07328319308018549; ORELLANA O, 1986, MOL CELL BIOL, V6, P525, DOI 10.1128/MCB.6.2.525; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PERREAULT JP, 1993, J MOL BIOL, V230, P750, DOI 10.1006/jmbi.1993.1197; Persson T, 2002, CHEMBIOCHEM, V3, P1066, DOI 10.1002/1439-7633(20021104)3:11<1066::AID-CBIC1066>3.0.CO;2-G; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P55; Schon A, 1999, FEMS MICROBIOL REV, V23, P391, DOI 10.1016/S0168-6445(99)00014-5; Sigel H, 1996, MET IONS BIOL SYST, V32, P135; Sjogren AS, 1997, NUCLEIC ACIDS RES, V25, P648, DOI 10.1093/nar/25.3.648; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; Sreedhara A, 2002, BIOMETALS, V15, P211, DOI 10.1023/A:1016070614042; Strobel SA, 1999, CHEM BIOL, V6, P153, DOI 10.1016/S1074-5521(99)89007-3; Thomson JB, 1996, J ORG CHEM, V61, P6273, DOI 10.1021/jo960795l; Warnecke JM, 1999, J MOL BIOL, V290, P433, DOI 10.1006/jmbi.1999.2890; Warnecke JM, 1996, P NATL ACAD SCI USA, V93, P8924, DOI 10.1073/pnas.93.17.8924; Warnecke JM, 2000, NUCLEIC ACIDS RES, V28, P720, DOI 10.1093/nar/28.3.720; Willkomm DK, 2002, BIOCHIMIE, V84, P713, DOI 10.1016/S0300-9084(02)01447-5; Yoshida A, 2000, CHEM BIOL, V7, P85, DOI 10.1016/S1074-5521(00)00074-0; Zahler NH, 2003, RNA, V9, P734, DOI 10.1261/rna.5220703; Zuleeg T, 2001, J MOL BIOL, V305, P181, DOI 10.1006/jmbi.2000.4299	54	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43394	43401		10.1074/jbc.M305939200	http://dx.doi.org/10.1074/jbc.M305939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904300	hybrid			2022-12-25	WOS:000186157000083
J	Lim, IJ; Phan, TT; Tan, EK; Nguyen, TTT; Tran, E; Longaker, MT; Song, C; Lee, ST; Huynh, HT				Lim, IJ; Phan, TT; Tan, EK; Nguyen, TTT; Tran, E; Longaker, MT; Song, C; Lee, ST; Huynh, HT			Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; HYPERTROPHIC SCARS; IN-VITRO; FIBROBLASTS; KERATINOCYTES; PROLIFERATION; BETA(1); CELLS; GENE; CONTRACTION	Keloid fibroproliferation appears to be influenced by epithelial-mesenchymal interactions between keloid keratinocytes (KKs) and keloid fibroblasts (KFs). Keloid and normal fibroblasts exhibit accelerated proliferation and collagen I and III production in co-culture with KKs compared with single cell culture or co-culture with normal keratinocytes. ERK and phosphatidylinositol 3-kinase (PI3K) pathway activation has been observed in excessively proliferating KFs in co-culture with KKs. We hypothesized that ERK and PI3K pathways might be involved in collagen and extracellular matrix production in KFs. To test our hypothesis, four samples of KFs were co-cultured in defined serum-free medium with KKs for 2-5 days. KF cell lysate was subjected to Western blot analysis. Compared with KF single cell culture, phospho-ERK1/2 and downstream phospho-Elk-1 showed up-regulation in the co-culture groups, as did phospho-PI3K and phospho-Akt-1, indicating ERK and PI3K pathway activation. Western blotting of the conditioned medium demonstrated increased collagen I-III, laminin beta2, and fibronectin levels. Addition of the MEK1/2-specific inhibitor U0126 or the PI3K-specific inhibitor LY294002 (but not p38 kinase and JNK inhibitors) completely nullified collagen I-III production and significantly decreased laminin beta2 and fibronectin secretion. In the presence of the MEK1/2 or PI3K inhibitor, fibronectin demonstrated changes in molecular mass reflected by faster in-gel migration. These data strongly suggest that synchronous activation of both the ERK and PI3K pathways is essential for collagen I - III and laminin beta2 production. These pathways additionally appear to affect the side chain attachments of fibronectin. Modulation of these pathways may suggest a direction for keloid therapy.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Natl Univ Singapore, Dept Surg, Singapore 119074, Singapore; Natl Univ Singapore, Dept Orthopaed Surg, Singapore 119074, Singapore; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Singapore Gen Hosp, Burns Ctr, Dept Plast Surg, Singapore 169608, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore; Stanford University; Singapore General Hospital	Huynh, HT (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore.	cmrhth@nccs.com.sg	Phan, Toan Thang/A-5527-2009					Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; Bayat A, 2003, PLAST RECONSTR SURG, V111, P535, DOI 10.1097/01.PRS.0000041536.02524.A3; BOYCE ST, 1994, J INVEST DERMATOL, V102, P8, DOI 10.1111/1523-1747.ep12371721; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chen H, 1998, CELL GROWTH DIFFER, V9, P939; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; COHEN IK, 1990, KELOIDS HYPERTROPHIC, P732; D'Addario M, 2002, J BIOL CHEM, V277, P47541, DOI 10.1074/jbc.M207681200; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; EHRLICH HP, 1994, AM J PATHOL, V145, P105; FUSENIG NE, 1994, KERATINOCYTE HDB, P71; Garner WL, 1998, PLAST RECONSTR SURG, V102, P135, DOI 10.1097/00006534-199807000-00021; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hirano S, 2002, J SURG RES, V102, P77, DOI 10.1006/jsre.2001.6315; Ivarsson M, 1998, MATRIX BIOL, V16, P409, DOI 10.1016/S0945-053X(98)90014-2; Katz AB, 1999, J INVEST DERMATOL, V112, P818, DOI 10.1046/j.1523-1747.1999.00572.x; Lim IJ, 2002, AM J PHYSIOL-CELL PH, V283, pC212, DOI 10.1152/ajpcell.00555.2001; Lim IJ, 2001, PLAST RECONSTR SURG, V107, P797, DOI 10.1097/00006534-200103000-00022; Maas-Szabowski N, 1999, J CELL SCI, V112, P1843; MACKENZIE IC, 1994, KERATINOCYTE HDB, P243; Marneros AG, 2001, ARCH DERMATOL, V137, P1429; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Niessen FB, 1999, PLAST RECONSTR SURG, V104, P1435, DOI 10.1097/00006534-199910000-00031; NODA M, 1989, CONNECT TISSUE RES, V21, P401, DOI 10.3109/03008208909049997; Omo-Dare P, 1975, J Natl Med Assoc, V67, P428; Palcy S, 1999, BIOCHEM J, V343, P21, DOI 10.1042/0264-6021:3430021; Phan TT, 2003, AM J PHYSIOL-CELL PH, V284, pC860, DOI 10.1152/ajpcell.00350.2002; Ricupero DA, 2001, AM J PHYSIOL-CELL PH, V281, pC99, DOI 10.1152/ajpcell.2001.281.1.C99; ROCKWELL WB, 1989, PLAST RECONSTR SURG, V84, P827, DOI 10.1097/00006534-198911000-00021; Sato M, 2002, J INVEST DERMATOL, V118, P704, DOI 10.1046/j.1523-1747.2002.01719.x; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130, DOI 10.1053/jhep.2001.23788; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Urioste SS, 1999, SEMIN CUTAN MED SURG, V18, P159, DOI 10.1016/S1085-5629(99)80040-6; Xue H, 2000, J SURG RES, V89, P74, DOI 10.1006/jsre.1999.5805	38	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40851	40858		10.1074/jbc.M305759200	http://dx.doi.org/10.1074/jbc.M305759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907681	hybrid			2022-12-25	WOS:000185847200054
J	Trettel, F; Di Bartolomeo, S; Lauro, C; Catalano, M; Ciotti, MT; Limatola, C				Trettel, F; Di Bartolomeo, S; Lauro, C; Catalano, M; Ciotti, MT; Limatola, C			Ligand-independent CXCR2 dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR2; DELTA-OPIOID RECEPTORS; GLUTAMATE RECEPTORS; GRANULE CELLS; HETERODIMERIZATION; DOPAMINE; HOMODIMERIZATION; OLIGOMERIZATION; INTERNALIZATION; SOMATOSTATIN	Homo- and hetero-oligomerization have been reported for several G protein-coupled receptors (GPCRs). The CXCR2 is a GPCR that is activated, among the others, by the chemokines CXCL8 (interleukin-8) and CXCL2 (growth-related gene product beta) to induce cell chemotaxis. We have investigated the oligomerization of CXCR2 receptors expressed in human embryonic kidney cells and generated a series of truncated mutants to determine whether they could negatively regulate the wild-type (wt) receptor functions. CXCR2 receptor oligomerization was also studied by coimmunoprecipitation of green fluorescent protein- and V5-tagged CXCR2. Truncated CXCR2 receptors retained their ability to form oligomers only if the region between the amino acids Ala-106 and Lys-163 was present. In contrast, all of the deletion mutants analyzed were able to form heterodimers with the wt CXCR2 receptor, albeit with different efficiency, competing for wt/wt dimer formation. The truncated CXCR2 mutants were not functional and, when coexpressed with wt CXCR2, interfered with receptor functions, impairing cell signaling and chemotaxis. When CXCR2 was expressed with the AMPA-type glutamate receptor GluR1, CXCR2 dimerization was again impaired in a dose-dependent way, and receptor functions were prejudiced. In contrast, CXCR1, a chemokine receptor that shares many similarities with CXCR2, did not dimerize alone or with CXCR2 and when coexpressed with CXCR2 did not impair receptor signaling and chemotaxis. The formation of CXCR2 dimers was also confirmed in cerebellar neuron cells. Taken together, we conclude from these studies that CXCR2 functions as a dimer and that truncated receptors negatively modulate receptor activities competing for the formation of wt/wt dimers.	Univ Roma La Sapienza, Dipartimento Fisiol Umana & Farmacol, I-00185 Rome, Italy; San Rafaele Pisana, Dipartimento Sci Internist, I-00163 Rome, Italy; CNR, Ist Neurobiol, I-00137 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)	Limatola, C (corresponding author), Univ Roma La Sapienza, Dipartimento Fisiol Umana & Farmacol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	cristina.limatola@uniroma1.it	Di+Bartolomeo, Sabrina/AAB-9791-2019; Lauro, Clotilde/Q-6110-2016	limatola, cristina/0000-0001-7504-8197; trettel, flavia/0000-0002-7983-2955; DI BARTOLOMEO, Sabrina/0000-0002-5748-1541; Catalano, Myriam/0000-0003-4638-9202	Telethon [E.0912] Funding Source: Medline	Telethon(Fondazione Telethon)		AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERBERG JT, 1984, J BIOL CHEM, V259, P9285; Horcher M, 1998, CYTOKINE, V10, P1, DOI 10.1006/cyto.1997.0251; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Ji IH, 2002, MOL ENDOCRINOL, V16, P1299, DOI 10.1210/me.16.6.1299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Lax P, 2002, J NEUROIMMUNOL, V129, P66, DOI 10.1016/S0165-5728(02)00178-9; Leong SR, 1997, PROTEIN SCI, V6, P609; Limatola C, 2003, J NEUROIMMUNOL, V134, P61, DOI 10.1016/S0165-5728(02)00401-0; Limatola C, 2002, J NEUROIMMUNOL, V123, P9, DOI 10.1016/S0165-5728(01)00472-6; Limatola C, 1999, J BIOL CHEM, V274, P36537, DOI 10.1074/jbc.274.51.36537; Limatola C, 2000, P NATL ACAD SCI USA, V97, P6197, DOI 10.1073/pnas.090105997; Lowman HB, 1997, PROTEIN SCI, V6, P598; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Shibata F, 2002, BIOL PHARM BULL, V25, P1217, DOI 10.1248/bpb.25.1217; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Van Brocklyn JR, 2002, BBA-MOL CELL BIOL L, V1582, P89, DOI 10.1016/S1388-1981(02)00141-5; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xu JG, 2003, J BIOL CHEM, V278, P10770, DOI 10.1074/jbc.M207968200; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	48	88	89	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40980	40988		10.1074/jbc.M306815200	http://dx.doi.org/10.1074/jbc.M306815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888558	hybrid, Green Published			2022-12-25	WOS:000185847200071
J	Zouzoulas, A; Therien, AG; Scanzano, R; Deber, CM; Blostein, R				Zouzoulas, A; Therien, AG; Scanzano, R; Deber, CM; Blostein, R			Modulation of Na,K-ATPase by the gamma subunit - Studies with transfected cells and transmembrane mimetic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SODIUM-PUMP; FUNCTIONAL-ROLE; ION-TRANSPORT; EXPRESSION; FAMILY; OLIGOMERIZATION; IDENTIFICATION; ACTIVATION; POTASSIUM	The enzymatic activity of the Na,K-ATPase, or sodium pump, is modulated by members of the so- called FXYD family of transmembrane proteins. The best characterized member, FXYD2, also referred to as the gamma subunit, has been shown to decrease the apparent Na+ affinity and increase the apparent ATP affinity of the pump. The effect on ATP affinity had been ascribed to the cytoplasmic C-terminal end of the protein, whereas recent observations suggest that the transmembrane (TM) segment of gamma mediates the Na+ affinity effect. Here we use a novel approach involving synthetic transmembrane mimetic peptides to demonstrate unequivocally that the TM domain of gamma effects the shift in apparent Na+ affinity. Specifically, we show that incubation of these peptides with membranes containing alphabeta pumps modulates Na+ affinity in a manner similar to transfected full-length gamma subunit. Using mutated gamma peptides and transfected proteins, we also show that a specific glycine residue, Gly-41, which is associated with a form of familial renal hypomagnesemia when mutated to Arg, is important for this kinetic effect, whereas Gly-35, located on an alternate face of the transmembrane helix, is not. The peptide approach allows for the analysis of mutants that fail to be expressed in a transfected system.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Blostein, R (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada.	rhoda.blostein@mcgill.ca	Therien, Alex/AAS-8437-2021					Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Partridge AW, 2003, J BIOL CHEM, V278, P22056, DOI 10.1074/jbc.M210685200; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SACHS JR, 1986, J PHYSIOL-LONDON, V374, P221, DOI 10.1113/jphysiol.1986.sp016076; Scheiner-Bobis G, 2002, EUR J BIOCHEM, V269, P2424, DOI 10.1046/j.1432-1033.2002.02909.x; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Tarasova NI, 1999, J BIOL CHEM, V274, P34911, DOI 10.1074/jbc.274.49.34911; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2002, J MOL BIOL, V322, P583, DOI 10.1016/S0022-2836(02)00781-7; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Xie HB, 2000, BIOCHEMISTRY-US, V39, P15462, DOI 10.1021/bi001432p	29	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40437	40441		10.1074/jbc.M308610200	http://dx.doi.org/10.1074/jbc.M308610200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907667	hybrid			2022-12-25	WOS:000185847200004
J	Bar, D; Golbik, R; Hubner, G; Lilie, H; Muller, EC; Naumann, M; Otto, A; Reuter, R; Breunig, KD; Kriegel, TM				Bar, D; Golbik, R; Hubner, G; Lilie, H; Muller, EC; Naumann, M; Otto, A; Reuter, R; Breunig, KD; Kriegel, TM			The unique hexokinase of Kluyveromyces lactis - Molecular and functional characterization and evaluation of a role in glucose signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; IN-VIVO PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; YEAST HEXOKINASE; TRANSCRIPTIONAL REGULATION; GENE; PII; SUGAR; EXPRESSION; MUTANTS	The Crabtree-negative yeast Kluyveromyces lactis is capable of adjusting its glycolytic flux to the requirements of respiration by tightly regulating glucose uptake. RAG5 encoding the only glucose and fructose phosphorylating enzyme present in K. lactis is required for the up-regulation of glucose transport and also for glucose repression. To understand the significance of the molecular identity and specific function(s) of the corresponding kinase to glucose signaling, RAG5 was overexpressed and its gene product KlHxk1 (Rag5p) isolated and characterized. Stopped-flow kinetics and sedimentation analysis indicated a monomer-homodimer equilibrium of KlHxk1 in a condition of catalysis, i.e. in the presence of substrates and products. The kinetic constants of ATP-dependent glucose phosphorylation identified a 53-kDa monomer as the high affinity/high activity form of the novel enzyme for both glycolytic substrates suggesting a control of glucose phosphorylation at the level of dimer formation and dissociation. In contrast to the highly homologous hexokinase isoenzyme 2 of Saccharomyces cerevisiae (ScHxk2), KlHxk1 was not inhibited by free ATP in a physiological range of nucleotide concentration. Mass spectrometric sequencing of tryptic peptides of KlHxk1 identified unmodified serine at amino acid position 156. The corresponding amino acid in ScHxk2 is serine 157, which represents the autophosphorylation-inactivation site. KlHxk1 did not display, however, the typical pattern of inactivation under the respective in vitro conditions and maintained a high residual glucose phosphorylating activity. The biophysical and functional data are discussed with respect to a possible regulatory role of KlHxk1 in glucose metabolism and signaling in K. lactis.	Tech Univ Dresden, Med Fak Carl Gustav Carus, Inst Physiol Chem, D-01307 Dresden, Germany; Univ Halle Wittenberg, Inst Biochem, D-06120 Halle Saale, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle Saale, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Leipzig, Fak Med, Inst Biochem, D-04103 Leipzig, Germany; Univ Halle Wittenberg, Inst Genet, D-06120 Halle Saale, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Leipzig University; Martin Luther University Halle Wittenberg	Kriegel, TM (corresponding author), Tech Univ Dresden, Med Fak Carl Gustav Carus, Inst Physiol Chem, Fetscherstr 74, D-01307 Dresden, Germany.							Behlke J, 1998, BIOCHEMISTRY-US, V37, P11989, DOI 10.1021/bi980914m; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; Bianchi MM, 1996, MOL MICROBIOL, V19, P27, DOI 10.1046/j.1365-2958.1996.346875.x; Billard P, 1996, J BACTERIOL, V178, P5860, DOI 10.1128/jb.178.20.5860-5866.1996; Bolotin-Fukuhara M, 2000, FEBS LETT, V487, P66, DOI 10.1016/S0014-5793(00)02282-1; Breunig KD, 2000, ENZYME MICROB TECH, V26, P771, DOI 10.1016/S0141-0229(00)00170-8; BREUNIG KD, 1987, MOL CELL BIOL, V7, P4400, DOI 10.1128/MCB.7.12.4400; BREUNIG KD, 1989, MOL GEN GENET, V216, P422, DOI 10.1007/BF00334386; Bui DM, 1996, APPL MICROBIOL BIOT, V45, P102, DOI 10.1007/s002530050655; CARLSON M, 1987, J BACTERIOL, V169, P4873, DOI 10.1128/jb.169.11.4873-4877.1987; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; ENTIAN KD, 1984, J BACTERIOL, V158, P29, DOI 10.1128/JB.158.1.29-35.1984; Ernandes JR, 1998, YEAST, V14, P255, DOI 10.1002/(SICI)1097-0061(199802)14:3<255::AID-YEA228>3.0.CO;2-N; FERRERO I, 1978, BIOCHEM BIOPH RES CO, V80, P340, DOI 10.1016/0006-291X(78)90682-4; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GANCEDO JM, 1977, J BIOL CHEM, V252, P4443; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOFFRINI P, 1989, YEAST, V5, P99, DOI 10.1002/yea.320050205; GOFFRINI P, 1995, MICROBIOL-SGM, V141, P441, DOI 10.1099/13500872-141-2-441; Golbik R, 2001, BIOCHEMISTRY-US, V40, P1083, DOI 10.1021/bi001745k; Heidrich K, 1997, BIOCHEMISTRY-US, V36, P1960, DOI 10.1021/bi9623643; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; HERRERO P, 1995, YEAST, V11, P137, DOI 10.1002/yea.320110205; Herrero P, 1999, BIOCHEM J, V343, P319, DOI 10.1042/0264-6021:3430319; Hohmann S, 1999, MICROBIOL-UK, V145, P703, DOI 10.1099/13500872-145-3-703; Kiers J, 1998, YEAST, V14, P459, DOI 10.1002/(SICI)1097-0061(19980330)14:5<459::AID-YEA248>3.0.CO;2-O; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; KRIEGEL TM, 1994, BIOCHEMISTRY-US, V33, P148, DOI 10.1021/bi00167a019; Larsson C, 2000, YEAST, V16, P797, DOI 10.1002/1097-0061(20000630)16:9<797::AID-YEA553>3.3.CO;2-X; LOBO Z, 1977, ARCH BIOCHEM BIOPHYS, V182, P639, DOI 10.1016/0003-9861(77)90544-6; Meijer MMC, 1998, J BIOL CHEM, V273, P24102, DOI 10.1074/jbc.273.37.24102; Milkowski C, 2001, J BACTERIOL, V183, P5223, DOI 10.1128/JB.183.18.5223-5229.2001; Moreno F, 2002, FEMS MICROBIOL REV, V26, P83, DOI 10.1111/j.1574-6976.2002.tb00600.x; MORENO F, 1986, EUR J BIOCHEM, V161, P565, DOI 10.1111/j.1432-1033.1986.tb10479.x; ORENTLICHER M, 1977, AM J PHYSIOL, V233, pC127, DOI 10.1152/ajpcell.1977.233.5.C127; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; PRIOR C, 1993, MOL CELL BIOL, V13, P3882, DOI 10.1128/MCB.13.7.3882; Randez-Gil F, 1998, FEBS LETT, V425, P475, DOI 10.1016/S0014-5793(98)00289-0; Randez-Gil F, 1998, MOL CELL BIOL, V18, P2940, DOI 10.1128/MCB.18.5.2940; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Schaffrath R, 2000, FUNGAL GENET BIOL, V30, P173, DOI 10.1006/fgbi.2000.1221; SHERMAN F, 1990, METHOD ENZYMOL, V194, P3; Versele M, 2001, EMBO REP, V2, P574, DOI 10.1093/embo-reports/kve132; VOJTEK AB, 1990, EUR J BIOCHEM, V190, P371, DOI 10.1111/j.1432-1033.1990.tb15585.x; WALSH RB, 1991, GENETICS, V128, P521; Weirich J, 1997, EUR J BIOCHEM, V249, P248, DOI 10.1111/j.1432-1033.1997.t01-1-00248.x; WESOLOWSKI M, 1982, CURR GENET, V150, P137; WESOLOWSKILOUVEL M, 1988, YEAST, V4, P71, DOI 10.1002/yea.320040108; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Xiao WY, 2000, PLANT MOL BIOL, V44, P451, DOI 10.1023/A:1026501430422; XU LZ, 1995, BIOCHEMISTRY-US, V34, P6083, DOI 10.1021/bi00018a011; ZACHARIAE W, 1993, NUCLEIC ACIDS RES, V21, P69, DOI 10.1093/nar/21.1.69; ZACHARIAE W, 1994, THESIS H HEINE U DUS; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662	56	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39280	39286		10.1074/jbc.M305706200	http://dx.doi.org/10.1074/jbc.M305706200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882981	hybrid			2022-12-25	WOS:000185713800004
J	Hui, DJ; Bhasker, CR; Merrick, WC; Sen, GC				Hui, DJ; Bhasker, CR; Merrick, WC; Sen, GC			Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2 center dot GTP center dot Met-tRNA(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; HEPATITIS-C VIRUS; INITIATION-FACTOR (EIF)-4F; FACTOR 4G EIF4G; INTERFERON; BINDING; RNA; DOMAINS; DISTINCT; SUBUNIT	Viral stress-inducible protein p56 is produced in response to viral stress-inducing agents such as double-stranded RNA and interferon, as well as other poorly understood mechanisms of viral infection. It has been shown previously that p56 is able to bind the eukaryotic initiation factor 3e(eIF3e) (p48/Int-6) subunit of the eukaryotic translation initiation factor eIF3 and function as an inhibitor of translation in vitro and in vivo. The exact mechanism by which p56 is able to interfere with protein synthesis is not understood. Based on the known roles of eIF3 in the initiation pathway, we employed assays designed to individually look at specific functions of eIF3 and the effect of p56 on these eIF3-mediated functions. These assays examined the effect of p56 on ribosome dissociation, the eIF3.eIF4F interaction, and enhancement of the ternary complex eIF2.GTP.Met-tRNA(i) formation. Here we report that p56 is able to inhibit translation initiation specifically at the level of eIF3.ternary complex formation. The effect of p56-mediated inhibition was also examined in two different contexts, cap-mediated and encephalomyocarditis virus internal ribosomal entry site-mediated translation. Whereas cap-dependent initiation was severely inhibited by p56, internal ribosomal entry site-mediated translation appeared to be insensitive to p56.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Grad Program Mol Virol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org	Hui, Daniel J/H-8855-2013	Hui, Daniel J/0000-0003-0294-3582	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62220, CA-68782] Funding Source: Medline; NIGMS NIH HHS [GM-26796] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; ASANO K, 2000, METH MOL B, V177, P179; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BLUYSSEN HAR, 1994, GENOMICS, V24, P137, DOI 10.1006/geno.1994.1591; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; de Veer MJ, 1998, GENOMICS, V54, P267, DOI 10.1006/geno.1998.5555; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; GUPTA NK, 1990, POSTTRANSCRIPTIONAL, P521; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lytle JR, 2002, RNA, V8, P1045, DOI 10.1017/S1355838202029965; Lytle JR, 2001, J VIROL, V75, P7629, DOI 10.1128/JVI.75.16.7629-7636.2001; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1973, P NATL ACAD SCI USA, V70, P2220, DOI 10.1073/pnas.70.8.2220; Niikura T, 1997, BLOOD CELL MOL DIS, V23, P337, DOI 10.1006/bcmd.1997.0151; Olsen DS, 2003, EMBO J, V22, P193, DOI 10.1093/emboj/cdg030; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; Sarnow P, 2003, J VIROL, V77, P2801, DOI 10.1128/JVI.77.5.2801-2806.2003; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; VANDERVELDEN A, 1995, VIROLOGY, V214, P82, DOI 10.1006/viro.1995.9952; Wang CF, 2003, J VIROL, V77, P3898, DOI 10.1128/JVI.77.7.3898-3912.2003; WATHELET MG, 1988, FEBS LETT, V231, P164, DOI 10.1016/0014-5793(88)80724-5; YARUS M, 1969, J MOL BIOL, V42, P171, DOI 10.1016/0022-2836(69)90037-0; YODERHILL J, 1993, J BIOL CHEM, V268, P5566; Yu M, 1997, P NATL ACAD SCI USA, V94, P7406, DOI 10.1073/pnas.94.14.7406	36	121	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39477	39482		10.1074/jbc.M305038200	http://dx.doi.org/10.1074/jbc.M305038200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885778	hybrid			2022-12-25	WOS:000185713800026
J	Yang, SZ; Abdulkadir, SA				Yang, SZ; Abdulkadir, SA			Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGR1 TARGET GENES; CANCER CELLS; EXPRESSION; TRANSCRIPTION; ACTIVATION; MECHANISM; ENCODES; PROTEIN; MOUSE; IDENTIFICATION	The transcription factor early growth response gene 1 (EGR1) has been implicated in diverse roles in the regulation of cell growth, apoptosis, and differentiation. Previous studies suggest that the effects of EGR1 on tumorigenesis are critically dependent on the cellular context. In a majority of prostate cancers, EGR1 is overexpressed and promotes prostate tumor progression. In contrast, in other tumor types such as breast cancers and glioblastomas, EGR1 is expressed at low levels and when overexpressed can inhibit tumor growth. To explore the role of EGR1 in prostate tumorigenesis, we examined the impact of EGR1 expression on the androgen receptor (AR) signaling pathway. We show here that EGR1 binds to the AR in prostate carcinoma cells, and an EGR1-AR complex can be detected by chromatin immunoprecipitation at the enhancer of an endogenous AR target gene. Overexpression of EGR1 enhanced AR-mediated transactivation, whereas EGR1 knockdown by small interfering RNA inhibited AR signaling pathway activity. Furthermore, Western blot and immunocytochemical analyses showed that constitutive overexpression of EGR1 promotes the translocation of AR from the cytoplasm to the nucleus. These results indicate that EGR1 may promote prostate cancer development by modulating the androgen receptor signaling pathway.	Univ Alabama, Sch Med, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Abdulkadir, SA (corresponding author), Univ Alabama, Sch Med, Dept Pathol, 701 19th St S, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [F32CA007901] Funding Source: NIH RePORTER; NCI NIH HHS [CA7901] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Calogero A, 2001, CLIN CANCER RES, V7, P2788; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1995, EUR UROL, V27, P45; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eid MA, 1998, CANCER RES, V58, P2461; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Gregory CW, 2001, CANCER RES, V61, P4315; Hobisch A, 1998, CANCER RES, V58, P4640; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; LEVIN WJ, 1995, ONCOGENE, V11, P1261; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200	30	52	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39906	39911		10.1074/jbc.M307250200	http://dx.doi.org/10.1074/jbc.M307250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890669	hybrid			2022-12-25	WOS:000185713800078
J	Culbertson, SM; Vassilenko, EI; Morrison, LD; Ingold, KU				Culbertson, SM; Vassilenko, EI; Morrison, LD; Ingold, KU			Paradoxical impact of antioxidants on post-Amadori glycoxidation - Counterintuitive increase in the yields of pentosidine and N-epsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; MAILLARD CROSS-LINKS; PROTEIN GLYCATION; IN-VITRO; CHEMICAL MODIFICATION; FRUCTOSAMINE ASSAY; DIABETES-MELLITUS; MASS-SPECTROMETRY; OXIDATIVE STRESS; VASCULAR-DISEASE	The inhibition of post-Amadori advanced glycation end product (AGE) formation by three different classes of AGE inhibitors, carbonyl group traps, chelators, and radical-trapping antioxidants, challenge the current paradigms that: 1) AGE inhibitors will not increase the formation of any AGE product, 2) transition metal ions are required for oxidative formation of AGE, and 3) screening AGE inhibitors only in systems containing transition metal ions represents a valid estimate of potential in vivo mechanisms. This work also introduces a novel multifunctional AGE inhibitor, 6-dimethylaminopyridoxamine (dmaPM), designed to function as a combined carbonyl trap, metal ion chelator, and radical-trapping antioxidant. Other AGE inhibitors including pyridoxamine, aminoguanidine, o-phenylenediamine, dipyridoxylamine, and diethylenetriaminepentaacetic acid were also examined. The results during uninterrupted and interrupted ribose glycations show: 1) an unexpected increase in the yield of pentosidine in the presence of radical-trapping phenolic antioxidants such as Trolox and dmaPM, 2) significant formation of N-epsilon-carboxymethyllysine (CML) in the presence of strong chelators and phenolic antioxidants, which implies that there must be nonradical routes to CML, 3) prevention of intermolecular cross-links with radical-trapping inhibitors, and 4) that dmaPM shows excellent inhibition of AGE. Glucose glycations reveal the expected inhibition of pentosidine and CML with all compounds tested, but in a buffer free of trace metal ions the yield of CML in the presence of radical-trapping antioxidants was between the metal ion-free and metal ion-containing controls. Protein molecular weight analyses support the conclusion that Amadori decomposition pathways are constrained in the presence of metal ion chelators and radical traps.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada; National Research Council Canada	Culbertson, SM (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.							Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; BAKER JR, 1993, CLIN CHEM, V39, P2460; BAKER JR, 1994, CLIN CHEM, V40, P1950; Baynes J.W., 1996, MAILLARD REACTION CO, P55; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Biemel KM, 2003, BIOCONJUGATE CHEM, V14, P619, DOI 10.1021/bc025653e; Biemel KM, 2002, ANGEW CHEM INT EDIT, V41, P801, DOI 10.1002/1521-3773(20020301)41:5<801::AID-ANIE801>3.0.CO;2-I; Biemel KM, 2001, J BIOL CHEM, V276, P23405, DOI 10.1074/jbc.M102035200; Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200; Bierhaus A, 1998, CARDIOVASC RES, V37, P586, DOI 10.1016/S0008-6363(97)00233-2; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; Costantino L, 1999, MED RES REV, V19, P3, DOI 10.1002/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.3.CO;2-Z; Courderot-Masuyer C, 1999, FUND CLIN PHARMACOL, V13, P535, DOI 10.1111/j.1472-8206.1999.tb00358.x; Culbertson SM, 2003, ORG LETT, V5, P2659, DOI 10.1021/ol0348147; Degenhardt T. P., 1998, MAILLARD REACTION FO, P3; DELANGE RJ, 1989, ANAL BIOCHEM, V177, P300, DOI 10.1016/0003-2697(89)90056-0; Dickinson PJ, 2002, DIABETES-METAB RES, V18, P260, DOI 10.1002/dmrr.305; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; DYER DG, 1991, J BIOL CHEM, V266, P11654; Elgawish A, 1996, J BIOL CHEM, V271, P12964, DOI 10.1074/jbc.271.22.12964; Fu SL, 1998, BIOCHEM J, V330, P233, DOI 10.1042/bj3300233; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; IKAWA M, 1967, ARCH BIOCHEM BIOPHYS, V118, P497, DOI 10.1016/0003-9861(67)90378-5; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; KHALIFAH RG, 2000, Patent No. 0051987; Lapolla A, 2000, MASS SPECTROM REV, V19, P279; LAPOLLA A, 1993, BIOCHIM BIOPHYS ACTA, V1225, P33, DOI 10.1016/0925-4439(93)90118-K; Litchfield JE, 1999, INT J BIOCHEM CELL B, V31, P1297, DOI 10.1016/S1357-2725(99)00091-6; Miyata T, 2000, J AM SOC NEPHROL, V11, P1719, DOI 10.1681/ASN.V1191719; Miyata T, 2000, J AM SOC NEPHROL, V11, P1744, DOI 10.1681/ASN.V1191744; Miyata T, 2002, J AM SOC NEPHROL, V13, P2478, DOI 10.1097/01.ASN.0000032418.67267.F2; Monnier VM, 2001, J CLIN INVEST, V107, P799, DOI 10.1172/JCI12635; Mossine VV, 1999, CHEM RES TOXICOL, V12, P230, DOI 10.1021/tx980209e; Mowri HO, 2000, FREE RADICAL BIO MED, V29, P814, DOI 10.1016/S0891-5849(00)00379-8; Nagai R, 2002, DIABETES, V51, P2833, DOI 10.2337/diabetes.51.9.2833; Nagaraj RH, 2002, ARCH BIOCHEM BIOPHYS, V402, P110, DOI 10.1016/S0003-9861(02)00067-X; Nakagawa T, 2002, J AGR FOOD CHEM, V50, P2418, DOI 10.1021/jf011339n; ODETTI P, 1992, DIABETES, V41, P153, DOI 10.2337/diabetes.41.2.153; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pratt DA, 2001, J AM CHEM SOC, V123, P4625, DOI 10.1021/ja005679l; Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200; QUATTRUCCI E, 1992, FOOD ADDIT CONTAM, V9, P515, DOI 10.1080/02652039209374105; Saxena P, 2000, INVEST OPHTH VIS SCI, V41, P1473; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; Sobal G, 2000, FREE RADICAL RES, V32, P439, DOI 10.1080/10715760000300441; Thornalley PJ, 2000, BIOCHEM PHARMACOL, V60, P55, DOI 10.1016/S0006-2952(00)00287-2; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Vinson JA, 1996, J NUTR BIOCHEM, V7, P659, DOI 10.1016/S0955-2863(96)00128-3; Voziyan PA, 2002, J BIOL CHEM, V277, P3397, DOI 10.1074/jbc.M109935200; Weiss MF, 2000, KIDNEY INT, V57, P2571, DOI 10.1046/j.1523-1755.2000.00117.x; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; YIM HS, 1995, J BIOL CHEM, V270, P28228	59	45	45	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38384	38394		10.1074/jbc.M305099200	http://dx.doi.org/10.1074/jbc.M305099200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878609	hybrid			2022-12-25	WOS:000185575100038
J	Jansson, A; Niemi, J; Mantsala, P; Schneider, G				Jansson, A; Niemi, J; Mantsala, P; Schneider, G			Crystal structure of aclacinomycin methylesterase with bound product analogues - Implications for anthracycline recognition and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARMINOMYCIN 4-O-METHYLTRANSFERASE; STREPTOMYCES-PURPURASCENS; LATE STEPS; IN-VITRO; BIOSYNTHESIS; ANTIBIOTICS; GENES; DAUNOMYCIN; ACLACINOMYCIN-10-HYDROXYLASE; DAUNORUBICIN	Aclacinomycin methylesterase (RdmC) is one of the tailoring enzymes that modify the aklavinone skeleton in the biosynthesis of anthracyclines in Streptomyces species. The crystal structures of this enzyme from Streptomyces purpurascens in complex with the product analogues 10-decarboxymethylaclacinomycin T and 10-decarboxymethylaclacinomycin A were determined to nominal resolutions of 1.45 and 1.95 Angstrom, respectively. RdmC is built up of two domains. The larger alpha/beta domain shows the common alpha/beta hydrolase fold, whereas the smaller domain is alpha-helical. The active site and substrate binding pocket are located at the interface between the two domains. Decarboxymethylaclacinomycin T and decarboxymethylaclacinomycin A bind close to the catalytic triad (Ser(102)-His(276)-Asp(248)) in a hydrophobic pocket, with the sugar moieties located at the surface of the enzyme. The binding of the ligands is dominated by hydrophobic interactions, and specificity appears to be controlled mainly by the shape of the binding pocket rather than through specific hydrogen bonds. Mechanistic key features consistent with the structure of complexes of RdmC with product analogues are Ser(102) acting as nucleophile and transition state stabilization by an oxyanion hole formed by the backbone amides of residues Gly(32) and Met(103).	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland	Karolinska Institutet; University of Turku	Schneider, G (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	gunter@alfa.mbb.ki.se		Schneider, Gunter/0000-0003-0622-5713				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARORA SK, 1985, J ANTIBIOT, V38, P1788, DOI 10.7164/antibiotics.38.1788; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BOOSER DJ, 1994, DRUGS, V47, P223, DOI 10.2165/00003495-199447020-00002; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Callebaut I, 2000, ANN NY ACAD SCI, V923, P90; CONNORS NC, 1990, J GEN MICROBIOL, V136, P1895, DOI 10.1099/00221287-136-9-1895; Dickens ML, 1997, J BACTERIOL, V179, P2641, DOI 10.1128/jb.179.8.2641-2650.1997; DICKENS ML, 1995, J BACTERIOL, V177, P536, DOI 10.1128/jb.177.3.536-543.1995; DIMARCO A, 1964, NATURE, V201, P706, DOI 10.1038/201706a0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; Hofmann B, 1998, J MOL BIOL, V279, P889, DOI 10.1006/jmbi.1998.1802; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; Jansson A, 2003, ACTA CRYSTALLOGR D, V59, P1637, DOI 10.1107/S0907444903014100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRASSILNIKOV NA, 1939, MIKROBIOLOGIYA, P673; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MADDURI K, 1995, J BACTERIOL, V177, P3879, DOI 10.1128/jb.177.13.3879-3884.1995; MADDURI K, 1993, J BACTERIOL, V175, P3900, DOI 10.1128/JB.175.12.3900-3904.1993; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myers CE, 1988, ANTHRACYCLINE ANTHRA, P527; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niemi J, 1999, BBA-PROTEIN STRUCT M, V1430, P57, DOI 10.1016/S0167-4838(98)00265-9; NIEMI J, 1995, J BACTERIOL, V177, P2942, DOI 10.1128/jb.177.10.2942-2945.1995; NIEMI J, 1994, MICROBIOL-UK, V140, P1351, DOI 10.1099/00221287-140-6-1351; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; TANAKA H, 1983, J ANTIBIOT, V36, P601, DOI 10.7164/antibiotics.36.601; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Walczak RJ, 1999, J BACTERIOL, V181, P298, DOI 10.1128/JB.181.1.298-304.1999; Wang YL, 2000, BBA-PROTEIN STRUCT M, V1480, P191, DOI 10.1016/S0167-4838(00)00089-3; Wang YL, 2002, FEMS MICROBIOL LETT, V208, P117, DOI 10.1016/S0378-1097(01)00591-2; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994	44	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39006	39013		10.1074/jbc.M304008200	http://dx.doi.org/10.1074/jbc.M304008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878604	hybrid			2022-12-25	WOS:000185575100112
J	Kaiser, FJ; Moroy, T; Chang, GTG; Horsthemke, B; Ludecke, HJ				Kaiser, FJ; Moroy, T; Chang, GTG; Horsthemke, B; Ludecke, HJ			The RING finger protein RNF4, a co-regulator of transcription, interacts with the TRPS1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-I; GENE; IDENTIFICATION; REPRESSION; MECHANISMS; APOPTOSIS	The TRPS1 gene encodes a repressor of GATA-mediated transcription. Mutations in this gene cause the tricho-rhino-phalangeal syndromes, but the affected pathways are unknown. In a yeast two-hybrid screen with the C-terminal part of the murine Trps1 protein as bait, we obtained three yeast clones encoding two overlapping fragments of the 194 amino acids RING finger protein 4 (Rnf4). The overlap narrows down the Trps1-binding region within Rnf4 to amino acids 6-65. This region in Rnf4 is also known to interact with several proteins including steroid receptors. By using truncated Trps1 constructs, the Rnf4-binding region in Trps1 could be assigned to amino acids 985-1184 of 1281. This 200 amino acid region of Trps1 does not contain any predicted protein-protein interacting motif. Complex formation between the human proteins TRPS1 and RNF4 was verified by co-immunoprecipitation from transfected and native mammalian cells. Confocal laser-scanning microscopy revealed that the endogenous proteins are located in distinct structures of the nucleus. Using a luciferase reporter assay, we could demonstrate that the repressional function of TRPS1 is inhibited by RNF4. This finding suggests that RNF4 is a negative regulator of TRPS1 activity.	Univ Klinikum, Inst Humangenet, D-45122 Essen, Germany; Univ Klinikum, Inst Zellbiol, D-45122 Essen, Germany; Erasmus Med Ctr, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	University of Duisburg Essen; University of Duisburg Essen; Erasmus University Rotterdam; Erasmus MC	Ludecke, HJ (corresponding author), Univ Klinikum, Inst Humangenet, Hufelandstr 55, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011					Chang GTG, 2000, J NATL CANCER I, V92, P1414, DOI 10.1093/jnci/92.17.1414; Chang GTG, 1997, CANCER RES, V57, P4075; Chang GTG, 2002, APOPTOSIS, V7, P13, DOI 10.1023/A:1013504710343; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Galili N, 2000, DEV DYNAM, V218, P102, DOI 10.1002/(SICI)1097-0177(200005)218:1<102::AID-DVDY9>3.3.CO;2-1; Kaiser FJ, 2003, HUM MOL GENET, V12, P1349, DOI 10.1093/hmg/ddg145; Kunath Melanie, 2002, Gene Expression Patterns, V2, P119, DOI 10.1016/S0925-4773(02)00300-3; Ludecke HJ, 2001, AM J HUM GENET, V68, P81, DOI 10.1086/316926; Lyngso C, 2000, J BIOL CHEM, V275, P26144, DOI 10.1074/jbc.M003405200; Malik TH, 2001, EMBO J, V20, P1715, DOI 10.1093/emboj/20.7.1715; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Momeni P, 2000, NAT GENET, V24, P71, DOI 10.1038/71717; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; REYNOLDS A, 1989, CURRENT PROTOCOLS MO; Shoichet SA, 2000, P NATL ACAD SCI USA, V97, P4076, DOI 10.1073/pnas.97.8.4076	17	37	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38780	38785		10.1074/jbc.M306259200	http://dx.doi.org/10.1074/jbc.M306259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885770	hybrid			2022-12-25	WOS:000185575100085
J	Song, K; Cornelius, SC; Reiss, M; Danielpour, D				Song, K; Cornelius, SC; Reiss, M; Danielpour, D			Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; PROGRAMMED CELL-DEATH; PROTEIN-KINASE B/AKT; FYVE DOMAIN PROTEIN; TGF-BETA; EPITHELIAL-CELLS; SIGNALING PATHWAY; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; CANCER-CELLS	Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta (TGF-beta) have been shown to be oncogenic and tumor suppressive, respectively, on prostate epithelial cells. Here we show that IGF-I inhibits the ability of TGF-beta to regulate expression of several genes in the non-tumorigenic rat prostatic epithelial line, NRP-152. In these cells, IGF-I also inhibits TGF-beta-induced transcriptional responses, as shown by several promoter reporter constructs, suggesting that IGF-I intercepts an early step in TGF-beta signaling. We show that IGF-I does not down-regulate TGF-beta receptor levels, as determined by both receptor cross-linking and Western blot analyses. However, Western blot analysis reveals that IGF-I selectively inhibits the TGF-beta-triggered activation Smad3 but not Smad2, while not altering expression of total Smads 2, 3, or 4. The phosphatidylinositol 3-kinase (PI3K) inhibitor, LY29004 reverses the ability of IGF-I to inhibit TGF-beta-induced transcriptional responses and the activation of Smad3, suggesting that the suppression of TGF-beta signaling by IGF-I is mediated through activation of PI3K. Moreover, we show that enforced expression of dominant-negative PI3K (DN-p85alpha) or phosphatidylinositol 3-phosphate-phosphatase, PTEN, also reverse the suppressive effect of IGF-I on TGF-beta-induced 3TP-luciferase reporter activity, whereas constitutively active PI3K (p110alphaCAAX) completely blocks TGF-beta-induced 3TP-luciferase reporter activity. Further transfection experiments including expression of constitutively active and dominant-negative Akt and rapamycin treatment suggest that suppression of TGF-beta signaling/ Smad3 activation by IGF-I occurs downstream of Akt and through mammalian target of rapamycin activation. In summary, our data suggest that IGF-I inhibits TGF-beta transcriptional responses through selective suppression of Smad3 activation via a PI3K/Akt-dependent pathway.	Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs,Lab 3, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Danielpour, D (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs,Lab 3, Samuel Gerber Bldg,Ste 200,11001 Cedar Ave, Cleveland, OH 44106 USA.	dxd49@po.cwru.edu	Reiss, Michael/A-8314-2009	Reiss, Michael/0000-0001-8543-8092	NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA3069-01, P30CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 1999, J CELL BIOCHEM, P68; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brodin G, 1999, CANCER RES, V59, P2731; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; CULIG Z, 1994, CANCER RES, V54, P5474; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; Danielpour D, 1999, J CELL SCI, V112, P169; Danielpour D, 2000, METH MOL B, V142, P29; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Giovannucci E, 1999, HORM RES, V51, P34, DOI 10.1159/000053160; Goto D, 2001, BIOCHEM BIOPH RES CO, V281, P1100, DOI 10.1006/bbrc.2001.4489; Grammer TC, 1996, CANCER SURV, V27, P271; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Guo YP, 1999, CANCER RES, V59, P1366; Hayward SW, 1999, PROSTATE, V39, P205; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hsing AY, 1996, CANCER RES, V56, P5146; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaplan PJ, 1999, CANCER RES, V59, P2203; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; Kunzmann S, 2003, FASEB J, V17, P194, DOI 10.1096/fj.02-0550com; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Li DM, 1997, CANCER RES, V57, P2124; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; LORD APD, 1994, J ENDOCRINOL, V141, P505, DOI 10.1677/joe.0.1410505; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Pearson R B, 1995, Prog Cell Cycle Res, V1, P21; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stattin P, 2000, J NATL CANCER I, V92, P1910, DOI 10.1093/jnci/92.23.1910; Stewart LMV, 2003, EXP CELL RES, V284, P303, DOI 10.1016/S0014(02)00037-X; Tang BW, 1999, CANCER RES, V59, P4834; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wen Y, 2000, CANCER RES, V60, P6841; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200	72	80	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38342	38351		10.1074/jbc.M304583200	http://dx.doi.org/10.1074/jbc.M304583200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876289	hybrid			2022-12-25	WOS:000185575100033
J	Kunji, ERS; Harding, M				Kunji, ERS; Harding, M			Projection structure of the atractyloside-inhibited mitochondrial ADP/ATP carrier of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; ESCHERICHIA-COLI; UNCOUPLING PROTEIN; ANGSTROM RESOLUTION; MEMBRANE; TRANSPORTER; TRANSLOCATION; ARCHITECTURE; RHODOPSIN; CRYSTALS	carriers in the inner mitochondrial membrane catalyze the exchange of cytosolic ADP for ATP synthesized in the mitochondrial matrix by ATP synthase and thereby replenish the eukaryotic cell with metabolic energy. The yeast ADP/ATP carrier (AAC3) was overexpressed, inhibited by atractyloside, purified, and reconstituted into two-dimensional crystals. Images of frozen hydrated crystals were recorded by electron microscopy, and a projection structure was calculated to 8-Angstrom resolution. The AAC3 molecule has pseudo 3-fold symmetry in agreement with the 3-fold sequence repeats that are typical of members of the mitochondrial carrier family. The density distribution is consistent with a bundle of six transmembrane alpha-helices with two or three short alpha-helical extensions closing the central pore on the matrix side. The AAC3 molecules in the crystal are arranged in symmetrical homo-dimers, but the translocation pore for adenine nucleotides lies in the center of the molecule and not along the dyad axis of the dimer.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Kunji, ERS (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Kunji, Edmund/AAH-2362-2020	Kunji, Edmund/0000-0002-0610-4500	MRC [MC_U105663139] Funding Source: UKRI; Medical Research Council [MC_U105663139] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; Bisaccia F, 1996, BBA-PROTEIN STRUCT M, V1292, P281, DOI 10.1016/0167-4838(95)00215-4; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; Hacksell I, 2002, EMBO J, V21, P3569, DOI 10.1093/emboj/cdf378; Hatanaka T, 1999, BIOCHEM BIOPH RES CO, V262, P726, DOI 10.1006/bbrc.1999.1283; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; Huang SG, 2001, ARCH BIOCHEM BIOPHYS, V394, P67, DOI 10.1006/abbi.2001.2520; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; Kotaria R, 1999, J BIOENERG BIOMEMBR, V31, P543, DOI 10.1023/A:1005460810527; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; Kunji ERS, 2001, J MOL BIOL, V308, P279, DOI 10.1006/jmbi.2001.4565; LIN CS, 1980, FEBS LETT, V113, P304, DOI 10.1016/0014-5793(80)80614-4; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Majima E, 1998, BIOCHEMISTRY-US, V37, P424, DOI 10.1021/bi9710683; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MIROUX B, 1993, EMBO J, V12, P3739, DOI 10.1002/j.1460-2075.1993.tb06051.x; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHOERS A, 1998, J BIOL CHEM, V273, P14269; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Trezeguet V, 2000, BBA-BIOENERGETICS, V1457, P81, DOI 10.1016/S0005-2728(99)00115-2; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; van der Giezen M, 2002, EMBO J, V21, P572, DOI 10.1093/emboj/21.4.572; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558	33	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36985	36988		10.1074/jbc.C300304200	http://dx.doi.org/10.1074/jbc.C300304200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12893834	hybrid			2022-12-25	WOS:000185437200002
J	Nakamura, K; Johnson, GL				Nakamura, K; Johnson, GL			PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL-GROWTH-FACTOR; N-TERMINAL KINASE; NADPH OXIDASE; SIGNALING PATHWAY; GENE-EXPRESSION; MAST-CELLS; PC MOTIF; 1 BMK1; P62	MEKK2 and MEKK3 are MAPK kinase kinases that activate the ERK5 pathway by phosphorylating and activating the MAPK kinase, MEK5. Activated MEK5 then phosphorylates and activates ERK5. PB1 domains were first defined in the p67(phox) and Bem1p proteins and have been shown to mediate protein-protein heterodimerization. A PB1 domain is encoded within the N-terminal portion of MEKK2, MEKK3, and MEK5. Herein, we analyze the functional role of MEKK2, MEKK3, and MEK5 PB1 domains in the ERK5 activation pathway. The PB1 domains of MEKK2 and MEKK3 bind the PB1 domain of MEK5 but do not significantly homo- or heterodimerize with one another in vitro. Furthermore, co-immunoprecipitation of MEKK2 and MEK5 from cell lysates shows that they form a complex in vivo. Deletion or mutation of the MEKK2 PB1 domain abolishes MEKK2-MEK5 complexes, demonstrating that the PB1 domain interaction is required for MEKK2-MEK5 interactions. Expression in cells of the MEKK2 or MEKK3 PB1 domain inhibits ERK5 activation, whereas expression of a mutant MEKK2 unable to bind the MEK5 PB1 domain or expression of the p67phox PB1 domain has no effect on ERK5 activation. These findings demonstrate that the PB1 domain mediates the association of MEKK2 and MEKK3 with MEK5 and that the respective PB1 domains of these kinases are critical for regulation of the ERK5 pathway. The free PB1 domain of MEKK2 or MEKK3 functions effectively to inhibit the ERK5 pathway but not the p38 or JNK pathways, demonstrating the specific and unique requirement of the MEKK2 and MEKK3 PB1 domain in regulating ERK5 activation.	Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Johnson, GL (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, 1108 Mary Ellen Jones Bldg,CB 7365, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068820] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM068820] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Geetha T, 2003, J BIOL CHEM, V278, P4730, DOI 10.1074/jbc.M208468200; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	26	68	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36989	36992		10.1074/jbc.C300313200	http://dx.doi.org/10.1074/jbc.C300313200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12912994	hybrid, Green Published			2022-12-25	WOS:000185437200003
J	Torres, JM; Ortega, E				Torres, JM; Ortega, E			Differential regulation of steroid 5 alpha-reductase isozymes expression by androgens in the adult rat brain	FASEB JOURNAL			English	Article						transcriptional regulation; prefrontal cortex	GABA(A) RECEPTOR FUNCTION; CENTRAL-NERVOUS-SYSTEM; NEUROACTIVE STEROIDS; A RECEPTOR; SEX-DIFFERENCES; NEUROSTEROIDS; STRESS; PLASMA; ALLOPREGNANOLONE; AROMATASE	The enzyme 5alpha-reductase (5alpha-R) is present in many mammalian tissues, including the brain. The physiological importance of 5alpha-R in the brain derives from its capability to convert testosterone ( T) to a more potent androgen, dihydrotestosterone (DHT), and to convert progesterone and deoxycorticosterone (DOC) to their respective 5alpha-reduced derivatives, precursors of allopregnanolone and tetrahydroDOC, potent allosteric modulators of the gamma-aminobutyric acid receptor (GABA(A)-R). 5alpha-R occurs as two isoforms, 5alpha-R type 1 (5alpha-R1) and 5alpha-R type 2 (5alpha-R2). We studied the effects of T and DHT on the mRNA levels of both 5alpha-R isozymes in the prefrontal cortex of the adult rat, using an accurate and precise method that combines the high specificity of one-step quantitative RT-PCR with the sensitivity of capillary electrophoresis. Our results demonstrate that both isozymes of 5alpha-R are expressed in the cerebral cortex of adult rats. The gene expression of 5alpha-R type 2 is under the positive control of T and DHT. The gene that codes for 5alpha-R type 1 is not constitutive, because its expression is negatively regulated by T and DHT. These results open up a new research line that may lead to a better understanding of the role of 5alpha-R isozymes in the physiology of the central nervous system.	Univ Granada, Fac Med, Dept Biochem & Mol Biol, Granada 18012, Spain; Univ Granada, Inst Neurosci, Granada 18012, Spain	University of Granada; University of Granada	Ortega, E (corresponding author), Univ Granada, Fac Med, Dept Biochem & Mol Biol, Avda Madrid S-N, Granada 18012, Spain.	esortega@ugr.es	Torres, Jesus M/B-3634-2011					Barbaccia ML, 1997, BRIT J PHARMACOL, V120, P1582, DOI 10.1038/sj.bjp.0701046; Barbaccia ML, 1996, NEUROENDOCRINOLOGY, V63, P166, DOI 10.1159/000126953; Barbaccia ML, 2001, INT REV NEUROBIOL, V46, P243; BIGGIO G, 1999, GABA NERVOUS SYSTEM; CELOTTI F, 1992, FRONT NEUROENDOCRIN, V13, P163; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; EINARSSON K, 1973, J BIOL CHEM, V248, P4987; FINN DA, 1994, J PHARMACOL EXP THER, V271, P164; GEORGE FW, 1991, P NATL ACAD SCI USA, V88, P8044, DOI 10.1073/pnas.88.18.8044; LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165-6147(00)89058-6; Lauber ME, 1996, ENDOCRINOLOGY, V137, P2718, DOI 10.1210/en.137.7.2718; Lephart ED, 1996, BRAIN RES REV, V22, P1; Li XD, 1997, J STEROID BIOCHEM, V60, P311, DOI 10.1016/S0960-0760(96)00195-1; Mahendroo MS, 1997, MOL ENDOCRINOL, V11, P917, DOI 10.1210/me.11.7.917; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Matsui D, 2002, NUCLEIC ACIDS RES, V30, P1387, DOI 10.1093/nar/30.6.1387; Melcangi RC, 1998, J STEROID BIOCHEM, V65, P295, DOI 10.1016/S0960-0760(98)00030-2; Mellon SH, 2002, TRENDS ENDOCRIN MET, V13, P35, DOI 10.1016/S1043-2760(01)00503-3; NegriCesi P, 1996, J STEROID BIOCHEM, V58, P455, DOI 10.1016/0960-0760(96)00083-0; NORMINGTON K, 1992, J BIOL CHEM, V267, P19548; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Poletti A, 1998, STEROIDS, V63, P246, DOI 10.1016/S0039-128X(98)00018-X; Poletti A, 1998, ENDOCRINOLOGY, V139, P2171, DOI 10.1210/en.139.4.2171; Poletti A, 1997, MOL CELL ENDOCRINOL, V129, P181, DOI 10.1016/S0303-7207(97)04056-2; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; Segovia S, 1999, BEHAV BRAIN RES, V105, P69, DOI 10.1016/S0166-4328(99)00083-2; Segovia S, 1996, NEUROREPORT, V7, P2553, DOI 10.1097/00001756-199611040-00030; Serra M, 2000, J NEUROCHEM, V75, P732, DOI 10.1046/j.1471-4159.2000.0750732.x; Torres JM, 2002, ANAL BIOCHEM, V307, P177, DOI 10.1016/S0003-2697(02)00023-4; Torres JM, 2001, NEUROCHEM RES, V26, P555, DOI 10.1023/A:1010925331768; TORRES JM, 2002, IN PRESS NEUROPSYCHO; TORRES JM, 2002, IN PRESS PROSTATE; VALENCIA A, 1992, DEV BRAIN RES, V8, P132	37	75	76	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1428	1433		10.1096/fj.02-1119com	http://dx.doi.org/10.1096/fj.02-1119com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890696				2022-12-25	WOS:000185345100035
J	Hastak, K; Gupta, S; Ahmad, N; Agarwal, MK; Agarwal, ML; Mukhtar, H				Hastak, K; Gupta, S; Ahmad, N; Agarwal, MK; Agarwal, ML; Mukhtar, H			Role of p53 and NF-kappa B in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells	ONCOGENE			English	Article						epigallocatechin-3-gallate; prostate cancer; p53; NF-kappa B; Bax; Bcl-2; caspases; apoptosis	TEA CONSTITUENT (-)-EPIGALLOCATECHIN-3-GALLATE; CYCLE ARREST; GROWTH-INHIBITION; GREEN; ACTIVATION; EXPRESSION; PHOSPHORYLATION; GALLATE; FAMILY; GENES	We have recently shown that oral consumption of green tea polyphenols inhibits prostate carcinogenesis in transgenic mouse model of prostate cancer and suggested that induction of apoptosis in prostate cancer cells is responsible for these effects. Much of the chemopreventive effects of green tea are attributed to its major polyphenolic constituent (-) epigallocatechin-3-gallate (EGCG). In the present study, we report that EGCG-induced apoptosis in human prostate carcinoma LNCaP cells is mediated via modulation of two related pathways: (a) stabilization of p53 by phosphorylation on critical serine residues and p14(ARF)-mediated downregulation of murine double minute 2(MDM2) protein, and (b) negative regulation of NF-kappaB activity, thereby decreasing the expression of the proapoptotic protein Bcl-2. EGCG-induced stabilization of p53 caused an upregulation in its transcriptional activity, thereby resulting in activation of its downstream targets p21/WAF1 and Bax. Thus, EGCG had a concurrent effect on two important transcription factors p53 and NF-kappaB, causing a change in the ratio of Bax/Bcl-2 in a manner that favors apoptosis. This altered expression of Bcl-2 family members triggered the activation of initiator capsases 9 and 8 followed by activation of effector caspase 3. Activation of the caspases was followed by poly (ADP-ribose) polymerase cleavage and induction of apoptosis. Taken together, the data indicate that EGCG induces apoptosis in human prostate carcinoma cells by shifting the balance between pro- and antiapoptotic proteins in favor of apoptosis.	Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Cleveland Clin, Dept Mol Biol, Learner Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Jim & Eillen Dicke Res Lab, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Inst Res, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; University Hospitals of Cleveland	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Gupta, Sanjay/0000-0002-9492-3249	NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Conney AH, 1999, P SOC EXP BIOL MED, V220, P229, DOI 10.1046/j.1525-1373.1999.d01-39.x; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9; Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159/000068711; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Otsuka T, 1998, LIFE SCI, V63, P1397, DOI 10.1016/S0024-3205(98)00406-8; Pianetti S, 2002, CANCER RES, V62, P652; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TOHYAMA M, 1999, BIOL CHEM, V274, P8531; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2001, NATURE, V412, P865, DOI 10.1038/35091170; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weisburger JH, 1999, P SOC EXP BIOL MED, V220, P271, DOI 10.1046/j.1525-1373.1999.d01-46.x; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	44	254	279	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4851	4859		10.1038/sj.onc.1206708	http://dx.doi.org/10.1038/sj.onc.1206708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894226				2022-12-25	WOS:000184344600008
J	Rosner, M; Hofer, K; Kubista, M; Hengstschlager, M				Rosner, M; Hofer, K; Kubista, M; Hengstschlager, M			Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38	ONCOGENE			English	Article						TSC1; TSC2; tuberin; hamartin; tuberous sclerosis; cell cycle; cell size	SCLEROSIS GENE-2 PRODUCT; C-MYC; EMBRYONIC LETHALITY; GENETIC-CONTROL; KINASE-ACTIVITY; TUBERIN; HAMARTIN; GROWTH; IDENTIFICATION; ACTIVATION	TSC1 and TSC2 are responsible for the tumor suppressor gene syndrome tuberous sclerosis (TSC). Mammalian TSC genes have been shown to be involved in cell cycle regulation. Recently, in Drosophila, these data have been confirmed and TSC genes have further been demonstrated to affect cell size control. Here we provide supporting data for the fact that the latter function is conserved in mammals. Human TSC1 and TSC2 trigger mammalian cell size reduction and a dominant-negative TSC2 mutant induces increased size. These effects occur in all cell cycle phases, are dependent on the activity of the phosphoinositide-3-kinase and are abolished by co-overexpression of a dominant-negative Akt mutant. Two independent naturally occurring and disease-causing mutations within the TSC2 gene eliminate tuberin's capacity to affect cell size control, emphasizing the relevance of this function for the development of the disease. The same mutations have earlier been shown not to affect tuberin's antiproliferative capacity. That the consequences of modulated TSC gene expression on cell proliferation and on cell size can be assigned to separable functions is further supported by two findings: A mutation within the TSC1 gene, earlier shown to still harbor anti-proliferative effects, was found to eliminate the cell size regulating functions. An important mammalian cell size regulator, c-Myc, was found to inhibit tuberin's antiproliferative capacity, but to have no effects on tuberin-dependent cell size control. To obtain further mechanistical insights, microarray screens for genes involved in TSC1- or TSC2-mediated cell size effects were performed. Antisense experiments revealed that the so observed regulation of the FK506-binding protein, FKBP38, plays a role in TSC gene-dependent cell size regulation. These data provide new insights into mammalian cell size regulation and allow a better understanding of the function of human TSC genes.	Univ Vienna, A-1090 Vienna, Austria	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@akh-wien.ac.at	Kubista, Mikael/A-5689-2008	Kubista, Mikael/0000-0002-2940-352X				Aghdasi B, 2001, P NATL ACAD SCI USA, V98, P2425, DOI 10.1073/pnas.041614198; Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Klettner A, 2001, MOL BRAIN RES, V97, P21, DOI 10.1016/S0169-328X(01)00286-8; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwan KM, 2002, GENESIS, V32, P49, DOI 10.1002/gene.10068; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Mak BC, 2003, J BIOL CHEM, V278, P5947, DOI 10.1074/jbc.C200473200; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2002, J NEUROPATH EXP NEUR, V61, P154, DOI 10.1093/jnen/61.2.154; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Montagne J, 2001, Sci STKE, V2001, ppe36, DOI 10.1126/stke.2001.105.pe36; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 2001, ONCOGENE, V20, P4904, DOI 10.1038/sj.onc.1204627; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Tsuchiya H, 1996, CANCER RES, V56, P429; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	66	85	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4786	4798		10.1038/sj.onc.1206776	http://dx.doi.org/10.1038/sj.onc.1206776			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894220				2022-12-25	WOS:000184344600002
J	Blom, AM; Villoutreix, BO; Dahlback, B				Blom, AM; Villoutreix, BO; Dahlback, B			Mutations in alpha-chain of C4BP that selectively affect its factor I cofactor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4B-BINDING PROTEIN; HUMAN FACTOR-H; COMPLEMENT REGULATORY DOMAINS; CONFORMATIONAL-CHANGES; C3B INACTIVATOR; STRUCTURAL REQUIREMENTS; NEISSERIA-GONORRHOEAE; C3B/C4B RECEPTOR; SERUM RESISTANCE; BINDING-PROTEIN	C4b-binding protein (C4BP) inhibits all pathways of complement activation, acting as a cofactor to the serine protease factor I (FI) in the degradation of activated complement factors C4b and C3b. C4BP is a disulfide-linked polymer of seven alpha-chains and a unique beta-chain, the alpha- and beta-chains being composed of eight and three complement control protein (CCP) domains, respectively. In previous studies we have localized cofactor activity and binding of C4b to alpha-chain CCP1-3 of C4BP, whereas the binding of C3b required additionally CCP4. Likewise, introduced point mutations that decreased binding of C4b/C3b caused a decrease in cofactor activity. In the present study, we describe two mutants of C4BP, K126Q/K128Q and F144S/F149S, clustered on alpha-chain CCP3, which selectively lost their ability to act as cofactors in the cleavage of both C4b and C3b. Both mutants show the same binding affinity for C4b/C3b as measured by surface plasmon resonance and have the same inhibitory effect on formation and decay of the classical pathway C3-convertase as the wild type C4BP. It appears that C4b and C3b do not undergo the same conformational changes upon binding to the C4BP mutants as during the interaction with the wild type C4BP, which then results in the observed loss of the cofactor activity.	Lund Univ, Dept Clin Chem, Malmo Univ Hosp, Wallenberg Lab, S-20502 Malmo, Sweden; Univ Paris 06, INSERM, U428, F-75006 Paris, France	Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Blom, AM (corresponding author), Lund Univ, Dept Clin Chem, Malmo Univ Hosp, Wallenberg Lab, Entrance 46,Floor 6, S-20502 Malmo, Sweden.		Blom, Anna/B-9607-2009; Villoutreix, Bruno/I-4565-2015; Blom, Anna/AFS-7369-2022	Blom, Anna/0000-0002-1348-1734; Villoutreix, Bruno/0000-0002-6456-7730; Dahlback, Bjorn/0000-0003-1546-0328				ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; Berggard K, 2001, EUR J IMMUNOL, V31, P2771, DOI 10.1002/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO;2-0; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Blom AM, 2001, J IMMUNOL, V166, P6764, DOI 10.4049/jimmunol.166.11.6764; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; COOPER NR, 1975, J EXP MED, V141, P890; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; EKDAHL KN, 1990, J IMMUNOL, V144, P4269; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; GORDON DL, 1995, J IMMUNOL, V155, P348; HESSING M, 1990, J IMMUNOL, V144, P204; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1983, J BIOL CHEM, V258, P4238; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Kask L, 2002, BIOCHEMISTRY-US, V41, P9349, DOI 10.1021/bi025980+; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; Oran AE, 1999, J BIOL CHEM, V274, P5120, DOI 10.1074/jbc.274.8.5120; Prasadarao NV, 2002, J IMMUNOL, V169, P6352, DOI 10.4049/jimmunol.169.11.6352; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; RUDDY S, 1971, J IMMUNOL, V107, P742; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; THERN A, 1995, J IMMUNOL, V154, P375; Villoutreix BO, 1998, PROTEINS, V31, P391, DOI 10.1002/(SICI)1097-0134(19980601)31:4<391::AID-PROT6>3.0.CO;2-L; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	44	27	27	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43437	43442		10.1074/jbc.M306620200	http://dx.doi.org/10.1074/jbc.M306620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12893820	hybrid			2022-12-25	WOS:000186157000088
J	Smyth, SS; Sciorra, VA; Sigal, YJ; Pamuklar, Z; Wang, ZC; Xu, Y; Prestwich, GD; Morris, AJ				Smyth, SS; Sciorra, VA; Sigal, YJ; Pamuklar, Z; Wang, ZC; Xu, Y; Prestwich, GD; Morris, AJ			Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets - Studies using chemical inhibitors of lipid phosphate phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATING GERM-CELLS; LYSOPHOSPHOLIPID RECEPTORS; IDENTIFICATION; ANALOGS; PHOSPHOHYDROLASES; CLONING; SURFACE; ISOFORM; GROWTH; WUNEN	Blood platelets play an essential role in ischemic heart disease and stroke contributing to acute thrombotic events by release of potent inflammatory agents within the vasculature. Lysophosphatidic acid (LPA) is a bioactive lipid mediator produced by platelets and found in the blood and atherosclerotic plaques. LPA receptors on platelets, leukocytes, endothelial cells, and smooth muscle cells regulate growth, differentiation, survival, motility, and contractile activity. Definition of the opposing pathways of synthesis and degradation that control extracellular LPA levels is critical to understanding how LPA bioactivity is regulated. We show that intact platelets and platelet membranes actively dephosphorylate LPA and identify the major enzyme responsible as lipid phosphate phosphatase 1 (LPP1). Localization of LPP1 to the platelet surface is increased by exposure to LPA. A novel receptor-inactive sn-3-substituted difluoromethylenephosphonate analog of phosphatidic acid that is a potent competitive inhibitor of LPP1 activity potentiates platelet aggregation and shape change responses to LPA and amplifies LPA production by agonist-stimulated platelets. Our results identify LPP1 as a pivotal regulator of LPA signaling in the cardiovascular system. These findings are consistent with genetic and cell biological evidence implicating LPPs as negative regulators of lysophospholipid signaling and suggest that the mechanisms involve both attenuation of lysophospholipid actions at cell surface receptors and opposition of lysophospholipid production.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA; Univ N Carolina, Dept Med, Div Cardiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; University of California System; University of California San Diego; Utah System of Higher Education; University of Utah; University of North Carolina; University of North Carolina Chapel Hill	Morris, AJ (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.		Morris, Andrew/B-7869-2010		NCI NIH HHS [CA12451, K22 CA124517] Funding Source: Medline; NHLBI NIH HHS [K08 HL070304, HL070304] Funding Source: Medline; NIDDK NIH HHS [R21 DK064183, DK064183] Funding Source: Medline; NIGMS NIH HHS [GM 50388, R01 GM050388] Funding Source: Medline; NINDS NIH HHS [R01 NS029632, NS029632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL070304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alderton F, 2001, J BIOL CHEM, V276, P13452, DOI 10.1074/jbc.M006582200; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; BROEKMAN MJ, 1992, METHOD ENZYMOL, V215, P21; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Humtsoe JO, 2003, EMBO J, V22, P1539, DOI 10.1093/emboj/cdg165; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; Luquain C, 2003, TRENDS BIOCHEM SCI, V28, P377, DOI 10.1016/S0968-0004(03)00139-7; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P289, DOI 10.1016/S1388-1981(02)00183-X; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Olorundare OE, 2001, BLOOD, V98, P117, DOI 10.1182/blood.V98.1.117; Pilquil C, 2001, PROSTAG OTH LIPID M, V64, P83, DOI 10.1016/S0090-6980(01)00101-0; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Roberts RZ, 2000, BBA-MOL CELL BIOL L, V1487, P33, DOI 10.1016/S1388-1981(00)00081-0; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Sciorra VA, 1999, MOL BIOL CELL, V10, P3863, DOI 10.1091/mbc.10.11.3863; Siess W, 2002, BBA-MOL CELL BIOL L, V1582, P204, DOI 10.1016/S1388-1981(02)00173-7; Starz-Gaiano M, 2001, DEVELOPMENT, V128, P983; Tanyi JL, 2003, CANCER RES, V63, P1073; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; TOKUMURA A, 1981, J PHARMACOL EXP THER, V219, P219; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xu J, 2000, J BIOL CHEM, V275, P27520; Xu Y, 2002, ORG LETT, V4, P4021, DOI 10.1021/ol026684s; Xu Y, 2002, J ORG CHEM, V67, P7158, DOI 10.1021/jo0203037; Yang AH, 2002, BBA-MOL CELL BIOL L, V1582, P197, DOI 10.1016/S1388-1981(02)00172-5; Zhang N, 2000, GENESIS, V27, P137, DOI 10.1002/1526-968X(200008)27:4<137::AID-GENE10>3.0.CO;2-4; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	41	63	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43214	43223		10.1074/jbc.M306709200	http://dx.doi.org/10.1074/jbc.M306709200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12909631	hybrid			2022-12-25	WOS:000186157000062
J	von Roepenack-Lahaye, E; Newman, MA; Schornack, S; Hammond-Kosack, KE; Lahaye, T; Jones, JDG; Daniels, MJ; Dow, JM				von Roepenack-Lahaye, E; Newman, MA; Schornack, S; Hammond-Kosack, KE; Lahaye, T; Jones, JDG; Daniels, MJ; Dow, JM			p-coumaroylnoradrenaline, a novel plant metabolite implicated in tomato defense against pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; COA-TYRAMINE N-(HYDROXYCINNAMOYL)TRANSFERASE; WALL-BOUND PHENOLICS; DISEASE RESISTANCE; CLADOSPORIUM-FULVUM; HYDROXYCINNAMOYL-COA; SOLANUM-TUBEROSUM; NICOTIANA-TABACUM; GENE FAMILY; OPIUM POPPY	The Avr9 peptide elicitor from the fungus Cladosporium fulvum, the bacterial pathogen Pseudomonas syringae pathovar tomato carrying the avirulence gene avrPto (Pst (avrPto)), and the organophosphorous insecticide fenitrothion induce resistance-related responses in tomato lines carrying the Cf-9, Pto, and Fen genes, respectively. These responses were associated with synthesis of p-coumaroyloctopamine and p-coumaroyl-noradrenaline, a novel compound for plants. In susceptible near isogenic tomato lines (Cf-0, pto, fen) and wounded tomato leaves, the levels of these compounds were reduced or undetectable. The elevated levels of p-coumaroyloctopamine and p-coumaroylnoradrenaline were accompanied by elevated mRNA levels of genes encoding phenylalanine ammonia lyase, p-coumarate CoA ligase, and hydroxycinnamoyl-CoA: tyramine N-(hydroxycinnamoyl) transferase (THT), enzymes that are involved in the hydroxycinnamic acid amide biosynthesis. Southern hybridization indicated that THT is encoded by a multigene family in tomato. Four different THT full-length cDNAs were derived by reverse transcriptase-PCR using degenerate primers based on potato and tobacco THT sequences. Transcripts for all four homologs were present in unchallenged tomato leaves, but only tomTHT1-3 was highly expressed following challenge with Pst ( avrPto). Furthermore, tomTHT1-3 showed a more substantial and rapid induction in the incompatible interaction than in the compatible interaction. The cDNAs tomTHT1-3, tomTHT7-1, and tomTHT7-8 encoded proteins with a high degree of amino acid sequence homology, although the recombinant proteins had different preferences for octopamine and noradrenaline. The fourth cDNA, tomTHT1-4, directed synthesis of a truncated enzymatically inactive protein due to the presence of a premature stop codon.	Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Univ Halle Wittenberg, Inst Genet, D-06120 Halle Saale, Saale, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Martin Luther University Halle Wittenberg	von Roepenack-Lahaye, E (corresponding author), Inst Pflanzenbioch, D-06120 Halle Saale, Saale, Germany.		Schornack, Sebastian/AAE-4897-2020; Schornack, Sebastian/A-3650-2011; Newman, Mari-Anne/M-1550-2013; Jones, Jonathan DG/J-5129-2012	Schornack, Sebastian/0000-0002-7836-5881; Schornack, Sebastian/0000-0002-7836-5881; Newman, Mari-Anne/0000-0001-5782-6071; Jones, Jonathan DG/0000-0002-4953-261X				AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; Back K, 2001, PLANT CELL PHYSIOL, V42, P475, DOI 10.1093/pcp/pce060; Bonas U, 2002, CURR OPIN MICROBIOL, V5, P44, DOI 10.1016/S1369-5274(02)00284-9; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Dixon RA, 2002, MOL PLANT PATHOL, V3, P371, DOI 10.1046/j.1364-3703.2002.00131.x; Facchini PJ, 1998, PHYTOCHEMISTRY, V49, P481, DOI 10.1016/S0031-9422(98)00136-8; Farmer MJ, 1999, EUR J BIOCHEM, V263, P686, DOI 10.1046/j.1432-1327.1999.00538.x; Fouts DE, 2002, P NATL ACAD SCI USA, V99, P2275, DOI 10.1073/pnas.032514099; GRANDMAISON J, 1993, MYCORRHIZA, V3, P155, DOI 10.1007/BF00203609; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HammondKosack KE, 1996, PLANT PHYSIOL, V110, P1381, DOI 10.1104/pp.110.4.1381; Hohlfeld H, 1996, PLANTA, V199, P166, DOI 10.1007/BF00196893; Joosten MHAJ, 1999, ANNU REV PHYTOPATHOL, V37, P335, DOI 10.1146/annurev.phyto.37.1.335; Karsai A, 2002, BIOTECHNIQUES, V32, P790, DOI 10.2144/02324st05; Keller H, 1996, PHYTOCHEMISTRY, V42, P389, DOI 10.1016/0031-9422(95)00866-7; KING EO, 1954, J LAB CLIN MED, V44, P301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahaye T, 1996, BIOTECHNIQUES, V21, P1067; Laterrot H., 1985, TOMATO GENET COOP RE, V35, P6; Lee D, 1996, PLANT PHYSIOL, V112, P193, DOI 10.1104/pp.112.1.193; LEE SW, 1992, PLANT MOL BIOL, V18, P345, DOI 10.1007/BF00034961; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; McLusky SR, 1999, PLANT J, V17, P523, DOI 10.1046/j.1365-313X.1999.00403.x; Meng HB, 1997, PHYTOCHEMISTRY, V44, P605, DOI 10.1016/S0031-9422(96)00594-8; Muhlenbeck U, 1996, PHYTOCHEMISTRY, V42, P1573, DOI 10.1016/0031-9422(96)00173-2; NEGREL J, 1987, PHYTOCHEMISTRY, V26, P2185, DOI 10.1016/S0031-9422(00)84681-6; Negrel J, 1997, EUR J BIOCHEM, V247, P1127, DOI 10.1111/j.1432-1033.1997.01127.x; NEGREL J, 1984, PHYTOCHEMISTRY, V23, P2797, DOI 10.1016/0031-9422(84)83018-6; Newman MA, 2002, PLANT J, V29, P487, DOI 10.1046/j.0960-7412.2001.00233.x; Newman MA, 2001, MOL PLANT MICROBE IN, V14, P785, DOI 10.1094/MPMI.2001.14.6.785; Nurnberger T, 1999, CELL MOL LIFE SCI, V55, P167, DOI 10.1007/s000180050283; Oldroyd GED, 1998, P NATL ACAD SCI USA, V95, P10300, DOI 10.1073/pnas.95.17.10300; Pearce G, 1998, PHYTOCHEMISTRY, V47, P659, DOI 10.1016/S0031-9422(97)00620-1; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Scheel D, 1998, CURR OPIN PLANT BIOL, V1, P305, DOI 10.1016/1369-5266(88)80051-7; Schmidt A, 1999, J BIOL CHEM, V274, P4273, DOI 10.1074/jbc.274.7.4273; Schmidt A, 1998, PLANTA, V205, P51, DOI 10.1007/s004250050295; SIEDLER H, 1991, MOL GEN GENET, V226, P177, DOI 10.1007/BF00273601; SMITH TA, 1983, ADV POLYAMINE RES, V4, P347; THOMAS CM, 1995, PLANT J, V8, P785, DOI 10.1046/j.1365-313X.1995.08050785.x; von Ropenack E, 1998, J BIOL CHEM, V273, P9013, DOI 10.1074/jbc.273.15.9013; Yu M, 1999, PLANTA, V209, P33, DOI 10.1007/s004250050604	44	74	75	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43373	43383		10.1074/jbc.M305084200	http://dx.doi.org/10.1074/jbc.M305084200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12900412	hybrid			2022-12-25	WOS:000186157000081
J	Kittendorf, JD; Sgraja, T; Reuter, K; Klebe, G; Garcia, GA				Kittendorf, JD; Sgraja, T; Reuter, K; Klebe, G; Garcia, GA			An essential role for aspartate 264 in catalysis by tRNA-guanine transglycosylase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; COVALENT INTERMEDIATE; ACID/BASE CATALYST; SHIGELLA-FLEXNERI; CRYSTAL-STRUCTURE; IDENTIFICATION; NUCLEOPHILE; MECHANISM; RECOGNITION; AMIDOTRANSFERASE	tRNA-guanine transglycosylase (TGT) catalyzes a post-transcriptional base-exchange reaction involved in the incorporation of the modified base queuine (Q) into the wobble position of certain tRNAs. Catalysis by TGT occurs through a double-displacement mechanism that involves the formation of a covalent enzyme-RNA intermediate (Kittendorf, J. D., Barcomb, L. M., Nonekowski, S. T., and Garcia, G. A. (2001) Biochemistry 40, 14123 14133). The TGT chemical mechanism requires the protonation of the displaced guanine and the deprotonation of the incoming heterocyclic base. Based on its position in the active site, it is likely that aspartate 264 is involved in these proton transfer events. To investigate this possibility, site-directed mutagenesis was employed to convert aspartate 264 to alanine, asparagine, glutamate, glutamine, lysine, and histidine. Biochemical characterization of these TGT mutants revealed that only the conservative glutamate mutant retained catalytic activity, with K-m values for both tRNA and guanine 3-fold greater than those for wild-type, whereas the k(cat) was depressed by an order of magnitude. Furthermore, of these six TGT mutants, only the TGT(D264E) was capable of forming a TGT.RNA covalent intermediate; however, unlike wild-type TGT, only hydroxylamine is capable of cleaving the TGT(D264E).RNA covalent complex. In an effort to better understand the unique biochemical properties of the D264E TGT mutant, we solved the crystal structure of the Zymomonas mobilis TGT with the analogous mutation (D280E). The results of these studies support two roles for aspartate 264 in catalysis by TGT, protonation of the leaving guanine and deprotonation of the incoming preQ(1).	Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Marburg, Inst Pharmazeut Chem, D-35037 Marburg, Germany	University of Michigan System; University of Michigan; Philipps University Marburg	Garcia, GA (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.			Reuter, Klaus/0000-0003-3673-7971	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007767, GM 07767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai Y, 2000, J BIOL CHEM, V275, P28731, DOI 10.1074/jbc.M002174200; Brenk R, 2003, J MED CHEM, V46, P1133, DOI 10.1021/jm0209937; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; Durand JMB, 1997, J BACTERIOL, V179, P5777, DOI 10.1128/jb.179.18.5777-5782.1997; FREY B, 1988, J BACTERIOL, V170, P2078, DOI 10.1128/jb.170.5.2078-2082.1988; Garcia GA, 1997, J PROTEIN CHEM, V16, P11, DOI 10.1023/A:1026334726357; Goodenough-Lashua DM, 2003, BIOORG CHEM, V31, P331, DOI 10.1016/S0045-2068(03)00069-5; Gradler U, 1999, FEBS LETT, V454, P142, DOI 10.1016/S0014-5793(99)00793-0; Gradler U, 2001, J MOL BIOL, V306, P455, DOI 10.1006/jmbi.2000.4256; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; Hoops GC, 1996, J HETEROCYCLIC CHEM, V33, P767, DOI 10.1002/jhet.5570330341; HOOPS GC, 1995, BIOCHEMISTRY-US, V34, P15381, DOI 10.1021/bi00046a047; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kittendorf JD, 2001, BIOCHEMISTRY-US, V40, P14123, DOI 10.1021/bi0110589; Kung FL, 2000, RNA, V6, P233, DOI 10.1017/S135583820099191X; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; MIAO S, 1994, BIOCHEMISTRY-US, V33, P7029; Nonekowski ST, 2002, J BIOL CHEM, V277, P7178, DOI 10.1074/jbc.M111077200; OKADA N, 1979, J BIOL CHEM, V254, P3067; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Romier C, 1996, BIOCHEMISTRY-US, V35, P15734, DOI 10.1021/bi962003n; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; Schnizer HG, 1999, BIOCHEMISTRY-US, V38, P3677, DOI 10.1021/bi981450v; Short SA, 1996, J BIOL CHEM, V271, P4978; SLANY RK, 1994, BIOCHIMIE, V76, P389, DOI 10.1016/0300-9084(94)90113-9; TSANG TH, 1983, BIOCHIM BIOPHYS ACTA, V741, P180, DOI 10.1016/0167-4781(83)90058-1; Vocadlo DJ, 1998, BIOCHEM J, V335, P449, DOI 10.1042/bj3350449; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; WANG Q, 1995, BIOCHEMISTRY-US, V34, P14554, DOI 10.1021/bi00044a034; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; Wong AW, 1998, J BIOL CHEM, V273, P34057, DOI 10.1074/jbc.273.51.34057; Xiong HS, 1999, J BIOL CHEM, V274, P35059, DOI 10.1074/jbc.274.49.35059; Xu YM, 1998, BIOCHEMISTRY-US, V37, P4114, DOI 10.1021/bi972519m; Zechel DL, 1998, BIOCHEM J, V336, P139, DOI 10.1042/bj3360139	41	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42369	42376		10.1074/jbc.M304323200	http://dx.doi.org/10.1074/jbc.M304323200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909636	hybrid			2022-12-25	WOS:000185989500099
J	Wu, H; Wang, ZX				Wu, H; Wang, ZX			The mechanism of p21-activated kinase 2 autoactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED ACTIVATION; DEPENDENT PROTEIN-KINASE; GAMMA-PAK; SUBSTRATE REACTION; IRREVERSIBLE MODIFICATION; CATALYTIC MECHANISM; KINETIC MECHANISM; ENZYME-ACTIVITY; CHAIN KINASE; ALPHA-PAK	The p21-activated kinases (PAKs) play an important role in diverse cellular processes. PAK2 is activated by autophosphorylation upon binding of small G proteins such as Cdc42 and Rac in the GTP-bound state. However, the mechanism of PAK2 autophosphorylation in vitro is unclear. In the present study, the kinetic theory of the substrate reaction during modification of enzyme activity has been applied to a study of the autoactivation of PAK2. On the basis of the kinetic equation of the substrate reaction during the autophosphorylation of PAK2, the activation rate constants for the free enzyme and enzyme-substrate complex have been determined. The results indicate that 1) in the presence of Cdc42, PAK2 autophosphorylation is a bipartite mechanism, with the regulatory domain autophosphorylated at multiple residues, whereas activation coincides with autophosphorylation of the catalytic domain at Thr-402; 2) the autophosphorylation reactions in regulatory domain are either a nonlimiting step or not required for activation of enzyme; 3) the autophosphorylation at site Thr-402 on the catalytic domain occurs by an intermolecular mechanism and is required for phosphorylation of exogenous substrates examined; 4) binding of the exogenous protein/ peptide substrates at the active site of PAK2 has little or no effect on the autoactivation of PAK2, suggesting that multiple regions of PAK2 are involved in the enzyme-substrate recognition. The present method also provides a novel approach for studying autophosphorylation reactions. Since the experimental conditions used resemble more closely the in vivo situation where the substrate is constantly being turned over while the enzyme is being modified, this new method would be particularly useful when the regulatory mechanisms of the reversible phosphorylation reaction toward certain enzymes are being assessed.	Acad Sinica, Inst Biophys, Ctr Mol Biol, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, ZX (corresponding author), Acad Sinica, Inst Biophys, Ctr Mol Biol, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	zxwang@sun5.ibp.ac.cn			FIC NIH HHS [R03 TW 01501] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001501] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; DUGGLEBY RG, 1986, J THEOR BIOL, V123, P67, DOI 10.1016/S0022-5193(86)80236-3; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; LAIDLER KJ, 1973, CHEM KINETICS ENZYME, P175; Lee SR, 2002, MOL ENDOCRINOL, V16, P85, DOI 10.1210/me.16.1.85; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TSOU CL, 1988, ADV ENZYMOL RAMB, V61, P381; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Waas WF, 2002, J BIOL CHEM, V277, P12532, DOI 10.1074/jbc.M110523200; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang MH, 1996, BIOCHEM J, V320, P187, DOI 10.1042/bj3200187; Wang ZX, 1999, BIOCHEM J, V341, P545, DOI 10.1042/0264-6021:3410545; Wang ZX, 2002, BIOCHEMISTRY-US, V41, P7849, DOI 10.1021/bi025776m; WANG ZX, 1987, J THEOR BIOL, V127, P253, DOI 10.1016/S0022-5193(87)80106-6; Wang ZX, 2002, BIOCHEM J, V368, P947, DOI 10.1042/BJ20020557; WANG ZX, 1990, J THEOR BIOL, V142, P531, DOI 10.1016/S0022-5193(05)80107-9; WANG ZX, 1995, BIOCHEMISTRY-US, V34, P6863, DOI 10.1021/bi00020a033; Wu H, 2003, BIOCHEMISTRY-US, V42, P1129, DOI 10.1021/bi026857l; Wu JW, 1998, BIOCHEM J, V335, P181, DOI 10.1042/bj3350181; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	63	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41768	41778		10.1074/jbc.M308196200	http://dx.doi.org/10.1074/jbc.M308196200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907671	hybrid			2022-12-25	WOS:000185989500028
J	Das, S; Gerwin, C; Sheng, ZH				Das, S; Gerwin, C; Sheng, ZH			Syntaphilin binds to dynamin-1 and inhibits dynamin-dependent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; VESICLE RELEASE; MEMBRANE; AMPHIPHYSIN-1; EXPRESSION; DOMAIN	Syntaphilin is a brain-specific syntaxin-binding partner first characterized as an inhibitor of SNARE complex formation and neurotransmitter release. Here we show that syntaphilin also binds to dynamin-1 and through this interaction inhibits dynamin-mediated endocytosis. Immunoprecipitation studies from crosslinked rat synaptosomes demonstrate that an endogenous syntaphilin-dynamin-1 complex exists independently of dynamin-1 binding to amphiphysin. Functionally, syntaphilin expression inhibits transferrin internalization in COS-7 cells. These data reveal that syntaphilin is an inhibitor of both SNARE-based fusion and dynamin-mediated endocytosis.	NINDS, Synapt Funct Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Sheng, ZH (corresponding author), NINDS, Synapt Funct Unit, NIH, Bethesda, MD 20892 USA.	shengz@ninds.nih.gov	Das, Sunit/J-3903-2015	Das, Sunit/0000-0002-2146-4168				Atwood HL, 2002, NAT REV NEUROSCI, V3, P497, DOI 10.1038/nrn876; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; Das S, 2003, MOL BRAIN RES, V116, P38, DOI 10.1016/S0169-328X(03)00212-2; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Lai MM, 2000, J BIOL CHEM, V275, P34017, DOI 10.1074/jbc.C000429200; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Liu JP, 1997, MOL CELL ENDOCRINOL, V132, P61, DOI 10.1016/S0303-7207(97)00120-2; Ma L, 1999, NAT NEUROSCI, V2, P24, DOI 10.1038/4525; Markram H, 1998, NEUROPHARMACOLOGY, V37, P489, DOI 10.1016/S0028-3908(98)00049-5; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Martin TFJ, 2002, NEURON, V34, P9, DOI 10.1016/S0896-6273(02)00651-7; Park JS, 2001, FASEB J, V15, P1625, DOI 10.1096/fj.00-0723fje; Ryan TA, 2003, P NATL ACAD SCI USA, V100, P2171, DOI 10.1073/pnas.0530260100; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Zakharenko SS, 2002, NEURON, V35, P1099, DOI 10.1016/S0896-6273(02)00898-X	28	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41221	41226		10.1074/jbc.M304851200	http://dx.doi.org/10.1074/jbc.M304851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896979	hybrid			2022-12-25	WOS:000185847200100
J	Chattopadhyay, S; Sun, P; Wang, PC; Abonyo, B; Cross, NL; Liu, L				Chattopadhyay, S; Sun, P; Wang, PC; Abonyo, B; Cross, NL; Liu, L			Fusion of lamellar body with plasma membrane is driven by the dual action of annexin II tetramer and arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SURFACTANT SECRETION; PHOSPHOLIPID-BINDING; FLUORESCENCE ASSAY; CHROMAFFIN CELLS; PORE EXPANSION; VESICLE FUSION; AGGREGATION; CALCIUM; EXOCYTOSIS	Annexin II has been implicated in membrane fusion during the exocytosis of lamellar bodies from alveolar epithelial type II cells. Most previous studies were based on the fusion assays by using model membranes. In the present study, we investigated annexin II-mediated membrane fusion by using isolated lamellar bodies and plasma membrane as determined by the relief of octadecyl rhodamine B (R18) self-quenching. Immunodepletion of annexin II from type II cell cytosol reduced its fusion activity. Purified annexin II tetramer (AIIt) induced the fusion of lamellar bodies with the plasma membrane in a dose-dependent manner. This fusion is Ca2+-dependent and is highly specific to AIIt because other annexins (I and II monomer, III, IV, V, and VI) were unable to induce the fusion. Modification of the different functional residues of AIIt by N-ethylmaleimide, nitric oxide, or peroxynitrite abolished AIIt-mediated fusion. Arachidonic acid enhanced AIIt-mediated fusion and reduced its Ca2+ requirement to an intracellularly achievable level. This effect is due to membrane-bound arachidonic acid, not free arachidonic acid. Other fatty acids including linolenic acid, palmitoleic acid, myristoleic acid, stearic acid, palmitic acid, and myristic acid had little effect. AIIt-mediated fusion was suppressed by the removal of arachidonic acid from lamellar body and plasma membrane using bovine serum albumin. The addition of arachidonic acid back to the arachidonic acid-depleted membranes restored its fusion activity. Our results suggest that the fusion between lamellar bodies with the plasma membrane is driven by the synergistic action of AIIt and arachidonic acid.	Oklahoma State Univ, Dept Physiol Sci, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Liu, L (corresponding author), Oklahoma State Univ, Dept Physiol Sci, 264 McElroy Hall, Stillwater, OK 74078 USA.		Wang, Pa-Chun/AAD-4094-2019		NHLBI NIH HHS [HL-52146] Funding Source: Medline; NICHD NIH HHS [HD30763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030763] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052146, R01HL052146] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Arrastua L, 2003, BIOCHEM J, V370, P641, DOI 10.1042/BJ20021736; Ayala-Sanmartin J, 2001, BIOCHEM BIOPH RES CO, V283, P72, DOI 10.1006/bbrc.2001.4748; Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER KNJ, 1990, EXPERIENTIA, V46, P631, DOI 10.1007/BF01939702; Caohuy H, 2002, J BIOL CHEM, V277, P25217, DOI 10.1074/jbc.M202452200; Chander A, 2001, AM J PHYSIOL-LUNG C, V280, pL991, DOI 10.1152/ajplung.2001.280.5.L991; CHANDER A, 1983, BIOCHIM BIOPHYS ACTA, V753, P119, DOI 10.1016/0005-2760(83)90105-4; CHANDER A, 1990, AM J PHYSIOL, V258, P241; CHERNOMORDIK L, 1995, BIOPHYS J, V69, P922, DOI 10.1016/S0006-3495(95)79966-0; CHERNOMORDIK L, 1995, J VIROL, V69, P3049, DOI 10.1128/JVI.69.5.3049-3058.1995; COBALEDA C, 1994, BIOCHEM J, V300, P347, DOI 10.1042/bj3000347; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Della Gaspera B, 2001, DEV DYNAM, V222, P206, DOI 10.1002/dvdy.1183; DOBBS LG, 1985, BIOCHIM BIOPHYS ACTA, V846, P155, DOI 10.1016/0167-4889(85)90121-1; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EDWARDS HC, 1991, EUR J BIOCHEM, V198, P121, DOI 10.1111/j.1432-1033.1991.tb15994.x; Faure AV, 2002, EXP CELL RES, V276, P79, DOI 10.1006/excr.2002.5512; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GILFILLAN AM, 1985, BIOCHIM BIOPHYS ACTA, V833, P336, DOI 10.1016/0005-2760(85)90207-3; Haller T, 2001, J CELL BIOL, V155, P279, DOI 10.1083/jcb.200102106; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HONG K, 1982, P NATL ACAD SCI-BIOL, V79, P4642, DOI 10.1073/pnas.79.15.4642; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; JOBE A, 1977, BIOCHIM BIOPHYS ACTA, V489, P440, DOI 10.1016/0005-2760(77)90165-5; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; KARLI UO, 1990, P NATL ACAD SCI USA, V87, P5912, DOI 10.1073/pnas.87.15.5912; KENDALL DA, 1982, J BIOL CHEM, V257, P3892; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KLIEWER M, 1985, EXP LUNG RES, V9, P351, DOI 10.3109/01902148509057533; LIEBICH HM, 1991, J CHROMATOGR-BIOMED, V572, P1, DOI 10.1016/0378-4347(91)80468-R; LIU L, 1995, BBA-LIPID LIPID MET, V1259, P166, DOI 10.1016/0005-2760(95)00159-A; Liu L, 1996, AM J PHYSIOL-LUNG C, V270, pL668, DOI 10.1152/ajplung.1996.270.4.L668; Liu L, 1999, CELL SIGNAL, V11, P317, DOI 10.1016/S0898-6568(98)00047-3; Liu L, 1997, CELL SIGNAL, V9, P299, DOI 10.1016/S0898-6568(97)89891-9; Liu L, 2002, EUR J BIOCHEM, V269, P4277, DOI 10.1046/j.1432-1033.2002.03118.x; LIU L, 1995, BBA-LIPID LIPID MET, V1254, P274, DOI 10.1016/0005-2760(94)00188-5; MACLEAN CM, 1992, BIOCHEM J, V286, P747, DOI 10.1042/bj2860747; MARSHALL BC, 1988, BIOCHIM BIOPHYS ACTA, V966, P403, DOI 10.1016/0304-4165(88)90091-8; Mason RJ, 1998, BBA-MOL BASIS DIS, V1408, P226, DOI 10.1016/S0925-4439(98)00070-2; Massey-Harroche D, 1998, J CELL SCI, V111, P3007; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; McIntosh TJ, 1999, BIOPHYS J, V76, P2090, DOI 10.1016/S0006-3495(99)77365-0; Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Nunes-Correia I, 2002, BBA-BIOMEMBRANES, V1561, P65, DOI 10.1016/S0005-2736(01)00457-6; Ohki S, 1998, BIOCHEMISTRY-US, V37, P7496, DOI 10.1021/bi972016g; Pecheur EI, 2002, BIOCHEMISTRY-US, V41, P9813, DOI 10.1021/bi0259195; Puisieux A, 1996, BIOCHEM J, V313, P51, DOI 10.1042/bj3130051; PURI A, 1993, VIROLOGY, V195, P855, DOI 10.1006/viro.1993.1444; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; Rooney SA, 2001, COMP BIOCHEM PHYS A, V129, P233, DOI 10.1016/S1095-6433(01)00320-8; Rowan WH, 2002, BIOCHEMISTRY-US, V41, P1409, DOI 10.1021/bi0119767; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Singh TK, 2000, ARCH BIOCHEM BIOPHYS, V381, P235, DOI 10.1006/abbi.2000.1994; STEGMANN T, 1995, BIOCHEM J, V307, P875, DOI 10.1042/bj3070875; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Troyer KP, 2002, J BIOL CHEM, V277, P29101, DOI 10.1074/jbc.M202856200; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WEINMAN JS, 1994, CELL TISSUE RES, V278, P389, DOI 10.1007/BF00414181; Yamane T, 2002, BBA-PROTEIN STRUCT M, V1596, P108, DOI 10.1016/S0167-4838(02)00209-1; Zarkik S, 1997, J VIROL, V71, P738, DOI 10.1128/JVI.71.1.738-740.1997	69	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39675	39683		10.1074/jbc.M212594200	http://dx.doi.org/10.1074/jbc.M212594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902340	hybrid			2022-12-25	WOS:000185713800053
J	Dutta, PR; Sui, BQ; Nataro, JP				Dutta, PR; Sui, BQ; Nataro, JP			Structure-function analysis of the enteroaggregative Escherichia coli plasmid-encoded toxin autotransporter using scanning linker mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYLORI VACUOLATING TOXIN; SERINE-PROTEASE; DIARRHEA; IDENTIFICATION; PROTEINS; CELLS; PET; ENTEROTOXIN; INVOLVEMENT; SECRETION	The plasmid-encoded toxin (Pet) from enteroaggregative Escherichia coli is a cytopathic serine protease, which is prototypical of a large family of bacterial autotransporter toxins. To further elucidate the structure-function relationships of this toxin, we employed transposon-based scanning linker mutagenesis. A subset of insertions throughout the Pet mature toxin (passenger) domain reduced secretion to the extracellular space. Many of these mutants were undetectable, but secretion of a subset of mutants with insertions in the N-terminal half of the toxin could be restored to wild type secretion levels if cultured in the presence of 0.1% Triton X-100. Secretion of two mutants with insertions at the extreme C terminus was partially restored when co-expressed with a minimal clone of EspP, a related autotransporter protein. Several well secreted mutants with insertions in the N-terminal third of the molecule reduced protease activity over 20-fold, suggesting that the protease domain is located within this N-terminal region of Pet. We have also identified two insertional mutants in the middle of the passenger domain that were proteolytic but no longer cytopathic; these mutants displayed decreased binding and internalization upon incubation with HEp-2 cells. Our data suggest the existence of separate functional domains mediating Pet proteolysis, secretion, and cell interaction.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Nataro, JP (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, HSF 480,685 W Baltimore St, Baltimore, MD 21201 USA.				NIAID NIH HHS [5 T32 AI07540-04, AI 43615] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043615, T32AI007540, R56AI043615] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BHAN MK, 1989, J INFECT DIS, V159, P1061, DOI 10.1093/infdis/159.6.1061; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CRAVIOTO A, 1991, LANCET, V337, P262, DOI 10.1016/0140-6736(91)90868-P; DALESSIO JM, 1990, FOCUS, V12, P47; Dutta PR, 2002, INFECT IMMUN, V70, P7105, DOI 10.1128/IAI.70.12.7105-7113.2002; Eslava C, 1998, INFECT IMMUN, V66, P3155, DOI 10.1128/IAI.66.7.3155-3163.1998; ESLAVA C, 1993, GEN M AM SOC MICR AT, pB105; Fink DL, 2001, J BIOL CHEM, V276, P39492, DOI 10.1074/jbc.M106913200; Hayes F, 2000, TRENDS MICROBIOL, V8, P571, DOI 10.1016/S0966-842X(00)01857-6; Henderson IR, 1999, INFECT IMMUN, V67, P5338, DOI 10.1128/IAI.67.10.5338-5344.1999; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; Knutton S, 2001, J PEDIATR GASTR NUTR, V33, P32, DOI 10.1097/00005176-200107000-00006; Maurer J, 1999, J BACTERIOL, V181, P7014, DOI 10.1128/JB.181.22.7014-7020.1999; Nataro JP, 1996, INFECT IMMUN, V64, P4761, DOI 10.1128/IAI.64.11.4761-4768.1996; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; Navarro-Garcia F, 2001, INFECT IMMUN, V69, P1053, DOI 10.1128/IAI.69.2.1053-1060.2001; Navarro-Garcia F, 1999, INFECT IMMUN, V67, P2184; NOLAN CM, 1992, PROTEIN TARGETING PR, P1; OHNISHI Y, 1994, J BIOL CHEM, V269, P32800; OLIVER D, 2001, GEN M AM SOC MICR OR; Oliver DC, 2003, MOL MICROBIOL, V47, P1367, DOI 10.1046/j.1365-2958.2003.03377.x; Oliver DC, 2003, J BACTERIOL, V185, P489, DOI 10.1128/JB.185.2.489-495.2003; Presterl E, 1999, EUR J CLIN MICROBIOL, V18, P209, DOI 10.1007/s100960050261; Sheikh J, 2001, MOL MICROBIOL, V41, P983, DOI 10.1046/j.1365-2958.2001.02512.x; TZIPORI S, 1992, INFECT IMMUN, V60, P5302, DOI 10.1128/IAI.60.12.5302-5306.1992; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; VELARDE J, 2002, GEN M AM SOC MICR SA; Villaseca JM, 2000, INFECT IMMUN, V68, P5920, DOI 10.1128/IAI.68.10.5920-5927.2000; Wanke CA, 1998, J INFECT DIS, V178, P185, DOI 10.1086/515595; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	33	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39912	39920		10.1074/jbc.M303595200	http://dx.doi.org/10.1074/jbc.M303595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878602	hybrid			2022-12-25	WOS:000185713800079
J	Miyake, T; Hiraishi, H; Sammoto, H; Ono, BI				Miyake, T; Hiraishi, H; Sammoto, H; Ono, BI			Involvement of the VDE homing endonuclease and rapamycin in regulation of the Saccharomyces cerevisiae GSH11 gene encoding the high affinity glutathione transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; SULFUR SOURCE; YEAST; DEATH; GENERATION; PATHWAY; ELEMENT; FAMILY; TARGET; DNA	The Saccharomyces cerevisiae gene HGT1/GSH11 encodes the high affinity glutathione transporter and is repressed by cysteine added to the culture medium. It has been found previously that a 5'-upstream cis-element, CCGCCACAC, is responsible for regulating GSH11 expression and that several proteins bind to this element (Miyake, T., Kanayama, M., Sammoto, H., and Ono, B. (2002) Mol. Genet. Genomics 266, 1004 - 1011). In this report we present evidence that the most prominent of these proteins is VDE, known previously as the homing endonuclease encoded by VMA1. We show also that GSH11 is not expressed in a VDE-deleted strain and that inability to express the GSH11 of this strain is overcome by introduction of the coding region of VDE or the entire VMA1 gene. It is also found that VDE does not cut DNA in the vicinity of the GSH11 cis-element. Rapamycin, an inhibitor of the target of rapamycin (TOR) signal-transduction system, is found to enhance expression of GSH11 in a VDE-dependent manner under conditions of sulfur starvation. These results indicate that GSH11 is regulated by a system sensitive to sulfur starvation ( presumably via cysteine depletion) and a more general system involving the nutritional starvation signal mediated by the TOR system. Both systems need to be operational ( inhibition of TOR and sulfur starvation) for full expression of GSH11.	Ind Technol Ctr, Okayama 7011296, Japan; Ritsumeikan Univ, Fac Sci & Engn, Dept Biotechnol, Shiga 5258577, Japan	Ritsumeikan University	Miyake, T (corresponding author), Ind Technol Ctr, 5301 Haga, Okayama 7011296, Japan.	tsuyoshi_miyake@pref.okayama.jp						Anraku Y, 1997, GENES CELLS, V2, P359, DOI 10.1046/j.1365-2443.1997.1270325.x; Aoshima H, 1999, BIOSCI BIOTECH BIOCH, V63, P1025, DOI 10.1271/bbb.63.1025; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; DESCHAVANNE PJ, 1981, BRIT J RADIOL, V54, P361, DOI 10.1259/0007-1285-54-640-361; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; Gimble FS, 2001, NUCLEIC ACIDS RES, V29, P4215, DOI 10.1093/nar/29.20.4215; Goddard MR, 2001, P ROY SOC B-BIOL SCI, V268, P2537, DOI 10.1098/rspb.2001.1830; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Hauser M, 2000, J BIOL CHEM, V275, P3037, DOI 10.1074/jbc.275.5.3037; HIRATA R, 1990, J BIOL CHEM, V265, P6726; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Koh S, 2002, PLANT PHYSIOL, V128, P21, DOI 10.1104/pp.010332; Lubkowitz MA, 1998, MOL MICROBIOL, V28, P729, DOI 10.1046/j.1365-2958.1998.00827.x; MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Miyake T, 1999, YEAST, V15, P1449, DOI 10.1002/(SICI)1097-0061(199910)15:14<1449::AID-YEA469>3.0.CO;2-S; Miyake T, 1998, BIOSCI BIOTECH BIOCH, V62, P1858, DOI 10.1271/bbb.62.1858; Miyake T, 2002, MOL GENET GENOMICS, V266, P1004, DOI 10.1007/s00438-001-0625-6; Nagai Y, 2003, MOL CELL BIOL, V23, P1726, DOI 10.1128/MCB.23.5.1726-1736.2003; Nogami S, 2002, YEAST, V19, P773, DOI 10.1002/yea.872; ONO BI, 1991, YEAST, V7, P843, DOI 10.1002/yea.320070809; PENNINCKX MJ, 1982, B I PASTEUR, V80, P291; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; RENNENBERG H, 1982, PHYTOCHEMISTRY, V21, P2771, DOI 10.1016/0031-9422(80)85045-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman F, 1986, LAB COURSE MANUAL ME; Stephen DWS, 1996, FEMS MICROBIOL LETT, V141, P207, DOI 10.1111/j.1574-6968.1996.tb08386.x; Sugiyama K, 2000, BIOCHEM J, V352, P71, DOI 10.1042/0264-6021:3520071; Taniguchi N, 1988, Tanpakushitsu Kakusan Koso, V33, P1397; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946	37	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39632	39636		10.1074/jbc.M302084200	http://dx.doi.org/10.1074/jbc.M302084200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900422	hybrid			2022-12-25	WOS:000185713800047
J	Galvez, AS; Ulloa, JA; Chiong, M; Criollo, A; Eisner, V; Barros, LF; Lavandero, S				Galvez, AS; Ulloa, JA; Chiong, M; Criollo, A; Eisner, V; Barros, LF; Lavandero, S			Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis - Differential effects of sorbitol and mannitol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; VOLUME REGULATORY MECHANISMS; MUSCLE-CELL-GROWTH; VENTRICULAR MYOCYTES; GENE-EXPRESSION; PROTEIN-KINASE; OSMOTIC-STRESS; ISCHEMIC-INJURY; MAMMALIAN-CELLS; HUMAN-TISSUES	Cells adapt to hyperosmotic conditions by several mechanisms, including accumulation of sorbitol via induction of the polyol pathway. Failure to adapt to osmotic stress can result in apoptotic cell death. In the present study, we assessed the role of aldose reductase, the key enzyme of the polyol pathway, in cardiac myocyte apoptosis. Hyperosmotic stress, elicited by exposure of cultured rat cardiac myocytes to the nonpermeant solutes sorbitol and mannitol, caused identical cell shrinkage and adaptive hexose uptake stimulation. In contrast, only sorbitol induced the polyol pathway and triggered stress pathways as well as apoptosis-related signaling events. Sorbitol resulted in activation of the extracellular signal-regulated kinase (ERK), p54 c-Jun N-terminal kinase (JNK), and protein kinase B. Furthermore, sorbitol treatment resulting in induction and activation of aldose reductase, decreased expression of the antiapoptotic protein Bcl-xL, increased DNA fragmentation, and glutathione depletion. Apoptosis was attenuated by aldose reductase inhibition with zopolrestat and also by glutathione replenishment with N-acetylcysteine. In conclusion, our data show that hypertonic shrinkage of cardiac myocytes alone is not sufficient to induce cardiac myocyte apoptosis. Hyperosmolarity-induced cell death is sensitive to the nature of the osmolyte and requires induction of aldose reductase as well as a decrease in intracellular glutathione levels.	Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Bioquim & Biol Mol, Ctr FONDAP Estudios Mol Celula, Santiago 6640750, Chile; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 6640750, Chile; Ctr Estudios Cient, Valdivia, Chile	Universidad de Chile; Universidad de Chile	Lavandero, S (corresponding author), Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Bioquim & Biol Mol, Ctr FONDAP Estudios Mol Celula, Olivos 1007, Santiago 6640750, Chile.	slavander@uchile.cl	Lavandero, Sergio/B-6001-2013; Chiong, M./ABH-5784-2020; Chiong, Mario/I-1043-2013	Lavandero, Sergio/0000-0003-4258-1483; Chiong, M./0000-0002-5174-6545; Chiong, Mario/0000-0002-5174-6545; Criollo, Alfredo/0000-0002-2737-7751				Aida K, 1999, ENDOCRINOLOGY, V140, P609, DOI 10.1210/en.140.2.609; ANDERSON ME, 1980, J BIOL CHEM, V255, P9530; Barros LF, 1999, PFLUG ARCH EUR J PHY, V437, P763, DOI 10.1007/s004240050843; Barros LF, 2001, PFLUG ARCH EUR J PHY, V442, P614; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Better OS, 1997, KIDNEY INT, V52, P886, DOI 10.1038/ki.1997.409; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Castella M, 2003, ANN THORAC SURG, V75, P1238, DOI 10.1016/S0003-4975(02)04499-5; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Cigola E, 1997, EXP CELL RES, V231, P363, DOI 10.1006/excr.1997.3477; Clemo HF, 1997, J GEN PHYSIOL, V110, P297, DOI 10.1085/jgp.110.3.297; COHEN MP, 1986, METABOLISM, V35, P55, DOI 10.1016/0026-0495(86)90188-5; DAS B, 1985, DIABETES, V34, P1145, DOI 10.2337/diabetes.34.11.1145; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; Galvez A, 2001, CELL TISSUE RES, V304, P279, DOI 10.1007/s004410100358; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GONZALEZ AM, 1986, DIABETES, V35, P1200, DOI 10.2337/diabetes.35.11.1200; Gual P, 2002, J BIOL CHEM, V277, P43980, DOI 10.1074/jbc.M203042200; Hamaoka R, 1999, J BIOCHEM-TOKYO, V126, P41, DOI 10.1093/oxfordjournals.jbchem.a022434; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARADA K, 1994, CIRC RES, V74, P1197, DOI 10.1161/01.RES.74.6.1197; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; HEMPLING HG, 1987, J CELL PHYSL, V93, P293; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; JEFFERY J, 1988, ADV ENZYMOL RAMB, V61, P47; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; Kajstura J, 1996, LAB INVEST, V74, P86; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRACKE GR, 1994, AM J PHYSIOL, V266, pC343, DOI 10.1152/ajpcell.1994.266.2.C343; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Leu M, 2001, ANAT EMBRYOL, V204, P217, DOI 10.1007/s004290100206; Libioulle C, 1996, J CELL PHYSIOL, V168, P147, DOI 10.1002/(SICI)1097-4652(199607)168:1<147::AID-JCP18>3.0.CO;2-4; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MAGOVERN GJ, 1984, CIRCULATION, V70, P91; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; MALONE JI, 1980, DIABETES, V29, P861, DOI 10.2337/diabetes.29.11.861; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Michea L, 2002, AM J PHYSIOL-RENAL, V282, pF981, DOI 10.1152/ajprenal.00301.2001; MIKA K, 2003, DIABETES RES CLIN PR, V60, P1; Mizisin AP, 1996, AM J PHYSIOL-RENAL, V270, pF90, DOI 10.1152/ajprenal.1996.270.1.F90; Moor AN, 2000, J MOL CELL CARDIOL, V32, P925, DOI 10.1006/jmcc.2000.1133; Morales MP, 2000, BIOCHEM BIOPH RES CO, V270, P1029, DOI 10.1006/bbrc.2000.2550; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; Murata M, 2001, CHEM-BIOL INTERACT, V130, P617, DOI 10.1016/S0009-2797(00)00289-1; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; *NIH, 1985, GUID CAR US LAB AN; Paczynski RP, 1997, STROKE, V28, P1437, DOI 10.1161/01.STR.28.7.1437; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Pulkki KJ, 1997, ANN MED, V29, P339, DOI 10.3109/07853899708999358; Ramasamy R, 2001, AM J PHYSIOL-HEART C, V281, pH515, DOI 10.1152/ajpheart.2001.281.2.H515; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; RAMASAMY R, 1988, AM J PHYSIOL, V275, pH195; ROTIROTI LW, 1973, EXP CELL RES, V79, P295, DOI 10.1016/0014-4827(73)90448-5; RUBIN LJ, 1993, J MOL CELL CARDIOL, V25, P721, DOI 10.1006/jmcc.1993.1084; Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; Sajan MP, 2002, BIOCHEM J, V362, P665, DOI 10.1042/0264-6021:3620665; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; SRIVASTAVA SK, 1984, BIOCHIM BIOPHYS ACTA, V800, P220, DOI 10.1016/0304-4165(84)90399-4; STAHL B, 1989, J NEUROCHEM, V53, P665, DOI 10.1111/j.1471-4159.1989.tb11755.x; STEVENS MJ, 1993, AM J PHYSIOL, V265, pE428, DOI 10.1152/ajpendo.1993.265.3.E428; SURGES R, 1993, PROG DRUG RES, V40, P99; TAKAHASHI M, 1995, INT J CANCER, V62, P749, DOI 10.1002/ijc.2910620617; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; Terada Y, 2001, KIDNEY INT, V60, P553, DOI 10.1046/j.1523-1755.2001.060002553.x; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; Wright AR, 1998, PHARMACOL THERAPEUT, V80, P89, DOI 10.1016/S0163-7258(98)00025-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; ZHIQING Z, 2000, CARDIOVASC RES, V45, P651	88	80	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38484	38494		10.1074/jbc.M211824200	http://dx.doi.org/10.1074/jbc.M211824200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12881532	hybrid			2022-12-25	WOS:000185575100050
J	Rehmann, H; Schwede, F; Doskeland, SO; Wittinghofer, A; Bos, JL				Rehmann, H; Schwede, F; Doskeland, SO; Wittinghofer, A; Bos, JL			Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CGMP-BINDING-SITES; REGULATORY SUBUNIT; FACTOR CDC25(MM); RAP1; RAS; DOMAINS; ANTAGONISTS; MECHANISM; ANALOGS	Epac is a cAMP-dependent exchange factor for the small GTP-binding protein Rap. The activity of Epac is inhibited by a direct interaction between the C-terminal helical part of the cAMP-binding domain, called the lid, and the catalytic region, which is released after binding of cAMP. Herein, we show that the activation properties are very sensitive to modifications of the cyclic nucleotide. Some analogues are inhibitory and others are stimulatory; some are characterized by a much higher activation potential than normal cAMP. Mutational analysis of Epac allows insights into a network of interactions between the cyclic nucleotides and Epac. Mutations in the lid region are able to amplify or to attenuate selectively the activation potency of cAMP analogues. The properties of cAMP analogues previously used for the activation of the cAMP responsive protein kinase A and of 8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclicmonophosphate, an analogue highly selective for activation of Epac were investigated in detail.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; BIOLOG Life Sci Inst, D-28071 Bremen, Germany; Univ Bergen, Dept Anat & Cell Biol, Fac Med, N-5009 Bergen, Norway	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Max Planck Society; University of Bergen	Bos, JL (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.			Doskeland, Stein Ove/0000-0002-4009-4756				Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Huang LJS, 1998, J BIOL CHEM, V273, P26739, DOI 10.1074/jbc.273.41.26739; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; OGREID D, 1983, J BIOL CHEM, V258, P1041; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; Rehmann H, 2003, J BIOL CHEM, V278, P23508, DOI 10.1074/jbc.M301680200; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; SHABB JB, 1991, J BIOL CHEM, V266, P24320; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; YAGURA TS, 1981, BIOCHEMISTRY-US, V20, P879, DOI 10.1021/bi00507a035	27	127	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38548	38556		10.1074/jbc.M306292200	http://dx.doi.org/10.1074/jbc.M306292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12888551	hybrid			2022-12-25	WOS:000185575100057
J	Yang, LK; Manithody, C; Walston, TD; Cooper, ST; Rezaie, AR				Yang, LK; Manithody, C; Walston, TD; Cooper, ST; Rezaie, AR			Thrombomodulin enhances the reactivity of thrombin with protein C inhibitor by providing both a binding site for the serpin and allosterically modulating the activity of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; HEPARIN-BINDING; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; FACTOR XA; SPECIFICITY; ANTITHROMBIN; RESIDUES; DOMAIN; COAGULATION	Thrombomodulin (TM), or its epidermal growth factor-like domains 456 (TM456), enhances the catalytic efficiency of thrombin toward both protein C and protein C inhibitor (PCI) by 2-3 orders of magnitude. Structural and mutagenesis data have indicated that the interaction of basic residues of the heparin-binding exosite of protein C with the acidic residues of TM4 is partially responsible for the efficient activation of the substrate by the thrombin-TM456 complex. Similar to protein C, PCI has a basic exosite (H-helix) that constitutes the heparin-binding site of the serpin. To determine whether TM accelerates the reactivity of thrombin with PCI by providing a binding site for the H-helix of the serpin, an antithrombin (AT) mutant was constructed in which the H-helix of the serpin was replaced with the same region of PCI (AT-PCIH-helix). Unlike PCI, the H-helix of AT is negatively charged. It was discovered that TM456 slightly (<2-fold) impaired the reactivity of AT with thrombin; however, it enhanced the reactivity of AT-PCIH-helix with the protease by an order of magnitude. Further studies revealed that the substitution of Arg(35) of thrombin with an Ala also resulted in an order of magnitude enhancement in reactivity of the protease with both PCI and AT-PCIH-helix independent of TM. We conclude that TM enhances the reactivity of PCI with thrombin by providing both a binding site for the serpin and a conformational modulation of the extended binding pocket of thrombin.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Wisconsin, La Crosse, WI 54601 USA	Saint Louis University; University of Wisconsin System	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R15HL058222] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62565, HL58222] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; COOPER ST, 1995, BIOCHEMISTRY-US, V34, P12991, DOI 10.1021/bi00040a009; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; HEEB MJ, 1989, BLOOD, V73, P446; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, J BIOL CHEM, V275, P15377, DOI 10.1074/jbc.275.20.15377; Huntington JA, 2003, STRUCTURE, V11, P205, DOI 10.1016/S0969-2126(02)00944-9; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; Liu Z, 2000, J BIOL CHEM, V275, P25641, DOI 10.1074/jbc.M003353200; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; Mosnier LO, 2001, THROMB HAEMOSTASIS, V86, P1057; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; PRATT CW, 1992, J BIOL CHEM, V267, P8795; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P7437, DOI 10.1021/bi962965u; Rezaie AR, 1998, BIOCHEMISTRY-US, V37, P13138, DOI 10.1021/bi9808518; Rezaie AR, 1998, PROTEIN SCI, V7, P349; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; Rezaie AR, 2002, J BIOL CHEM, V277, P1235, DOI 10.1074/jbc.M108544200; Rezaie AR, 1998, BLOOD, V91, P4572, DOI 10.1182/blood.V91.12.4572.412k13_4572_4580; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; REZAIE AR, 1998, TRENDS CARDIOVAS MED, V13, P8; SUZUKI K, 1987, J BIOL CHEM, V262, P611; TSIANG M, 1992, J BIOL CHEM, V267, P6164; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; Yang LK, 2003, J BIOL CHEM, V278, P10484, DOI 10.1074/jbc.M211797200; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37465	37470		10.1074/jbc.M307243200	http://dx.doi.org/10.1074/jbc.M307243200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12878585	hybrid			2022-12-25	WOS:000185437200059
J	Tkach, V; Tulchinsky, E; Lukanidin, E; Vinson, C; Bock, E; Berezin, V				Tkach, V; Tulchinsky, E; Lukanidin, E; Vinson, C; Bock, E; Berezin, V			Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility	ONCOGENE			English	Article						c-Fos; Fra-1; Fra-2; cell locomotion	TRANSCRIPTION FACTOR AP-1; DNA-BINDING; TRANSFORMATION; ACTIVATION; MIGRATION; INTERACTS; INVASION; GENE; JUN; AP1	The AP-1 transcription factor is composed of members of the Fos, Jun and ATF families, and plays a key role in tumor progression. We investigated whether Fos proteins regulate cell motility, and if so, whether this capacity is related to their transactivation potential. Two cell tines with different expression profiles of AP-1 were employed focusing on the Fos-family members c-Fos, Fra-1 and Fra-2. Transactivation motifs are found in c-Fos, but not in Fra-1 or Fra-2. The adenocarcinoma CSML0 cells display a low motility and do not express Fra-1 or Fra-2, and only very little c-Fos. In contrast, the fibroblastoid L929 cells express both Fra-1 and Fra-2, but no c-Fos, and these cells display a high motility. Transfection with Fra-1 or c-Fos, but not with Fra-2, strongly enhanced the motility of CSML0 cells. The effect of Fra-1 required the presence of the N-terminal domain of this protein. Conversely, transfection with a Fos dominant-negative mutant or with anti-sense fra-1 or fra-2, strongly reduced the motility of L929 cells. Changes in cell motility correlated with the morphological appearance and the degree of contact with the substratum. We conclude that Fos proteins have distinct roles in the regulation of cell motility.	Univ Copenhagen, Panum Inst, Prot Lab,Inst Mol Pathol, Sch Med, DK-2200 Copenhagen N, Denmark; Danish Canc Soc, Dept Mol Cell Biol, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; NCI, Met Lab, NIH, Bethesda, MD 20892 USA	University of Copenhagen; Danish Cancer Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Berezin, V (corresponding author), Univ Copenhagen, Panum Inst, Prot Lab,Inst Mol Pathol, Sch Med, Blegdamsvej 3C,Bld 6-2, DK-2200 Copenhagen N, Denmark.	berezin@plab.ku.dk	Tulchinsky, Eugene/ABD-7070-2021		NATIONAL CANCER INSTITUTE [Z01BC005271, ZIABC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrektsen T, 2001, MOL PHARMACOL, V59, P567, DOI 10.1124/mol.59.3.567; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Dunn G A, 1983, Agents Actions Suppl, V12, P14; Funk M, 1997, MOL CELL BIOL, V17, P537, DOI 10.1128/MCB.17.2.537; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P236; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lepekhin EA, 2001, METH MOL B, V161, P85; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; SENIN VM, 1984, VESTN AKAD MED NAUK+, P85; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Walmod PS, 1998, CELL MOTIL CYTOSKEL, V40, P220; Walmod PS, 2001, METH MOL B, V161, P59; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429	29	60	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5045	5054		10.1038/sj.onc.1206570	http://dx.doi.org/10.1038/sj.onc.1206570			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902987				2022-12-25	WOS:000184578900012
J	Charvet, C; Alberti, I; Luciano, F; Jacquel, A; Bernard, A; Auberger, P; Deckert, M				Charvet, C; Alberti, I; Luciano, F; Jacquel, A; Bernard, A; Auberger, P; Deckert, M			Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases	ONCOGENE			English	Article						FOXO3a; transcription; cleavage; caspase; Fas; apoptosis	SERUM RESPONSE FACTOR; RECEPTOR-INDUCED APOPTOSIS; INDUCED CELL-DEATH; SIGNALING COMPLEX; FACTOR FKHR-L1; FACTOR FKHRL1; FAS LIGAND; T-CELLS; PROTEIN; DOWNSTREAM	Forkhead family transcription factors are critical regulators of cell cycle progression and apoptosis in hematopoietic cells. Here, we show that FOXO3a (also known as FKHRL1) is a new substrate of caspase-3-like proteases during apoptosis in T lymphocytes. FOXO3a was cleaved in vivo by caspases in leukemic Jurkat cells following engagement of Fas (CD95) receptor, staurosporine, and etoposide treatment, but not following engagement of CD99, a caspase-independent cell death inducer. Caspase-mediated cleavage of FOXO3a was also observed in CD4 +. peripheral T cells subjected to activation-induced cell death. The expression of the death adapter FADD and caspase-8 was required for Fas-induced FOXO3a cleavage, but activation of survival pathways by overexpression of FLICE-inhibitory protein or phorbol myristate acetate treatment prevented it. FOXO3a was cleaved in vitro by caspase-3-like proteases at the consensus sequence DELD(304)A, releasing the N-terminal DNA-binding domain of FOXO3a from its C-terminal transactivating domain. Whereas full-length FOXO3a enhanced Forkhead response element-dependent transcription and apoptosis in Jurkat cells, both fragments were inactive to promote gene activation and cell death. In contrast, a caspase-resistant FOXO3a mutant exhibited enhanced transcriptional and proapoptotic activities. Together, these results indicate that the proteolytic cleavage of FOXO3a by caspases may represent a novel regulatory mechanism of FOXO3a activity during death receptors signaling.	Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France; Fac Med Nice, INSERM, U526, IFR50, F-06107 Nice, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Deckert, M (corresponding author), Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France.		luciano, frederic/P-6264-2016; Deckert, Marcel/T-3566-2019; Jacquel, Arnaud/O-1928-2017; AUBERGER, Patrick/G-1491-2013; Jacquel, Arnaud/AAJ-4760-2021; Deckert, Marcel/M-4998-2016	luciano, frederic/0000-0001-9253-4998; Deckert, Marcel/0000-0003-2094-559X; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; Jacquel, Arnaud/0000-0001-5062-8048; 				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Baumann Sven, 2002, Current Molecular Medicine (Hilversum), V2, P257, DOI 10.2174/1566524024605671; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Charvet C, 2002, J BIOL CHEM, V277, P15376, DOI 10.1074/jbc.M111627200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Noraz N, 2000, J BIOL CHEM, V275, P15832, DOI 10.1074/jbc.M908568199; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Ravi R, 1998, CANCER RES, V58, P882; Ricci JE, 2001, EUR CYTOKINE NETW, V12, P126; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tanaka M, 2001, J BIOL CHEM, V276, P15082, DOI 10.1074/jbc.M007958200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141	41	61	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4557	4568		10.1038/sj.onc.1206778	http://dx.doi.org/10.1038/sj.onc.1206778			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881712				2022-12-25	WOS:000184054700011
J	Torres, AM; Bansal, PS; Sunde, M; Clarke, CE; Bursill, JA; Smith, DJ; Bauskin, A; Breit, SN; Campbell, TJ; Alewood, PF; Kuchel, PW; Vandenberg, JI				Torres, AM; Bansal, PS; Sunde, M; Clarke, CE; Bursill, JA; Smith, DJ; Bauskin, A; Breit, SN; Campbell, TJ; Alewood, PF; Kuchel, PW; Vandenberg, JI			Structure of the HERG K+ channel S5P extracellular linker - Role of an amphipathic alpha-helix in C-type inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; I-KR; MOLECULAR DETERMINANTS; SECONDARY STRUCTURE; CARDIAC-ARRHYTHMIA; CRYSTAL-STRUCTURE; NMR; PROGRAM; MUTATIONS; BLOCK	The HERG K+ channel has very unusual kinetic behavior that includes slow activation but rapid inactivation. These features are critical for normal cardiac repolarization as well as in preventing lethal ventricular arrhythmias. Mutagenesis studies have shown that the extracellular peptide linker joining the fifth transmembrane domain to the pore helix is critical for rapid inactivation of the HERG K+ channel. This peptide linker is also considerably longer in HERG K+ channels, 40 amino acids, than in most other voltage-gated K+ channels. In this study we show that a synthetic 42-residue peptide corresponding to this linker region of the HERG K+ channel does not have defined structural elements in aqueous solution; however, it displays two well defined helical regions when in the presence of SDS micelles. The helices correspond to Trp(585)-Ile(593) and Gly(604)-Tyr(611) of the channel. The Trp(585)-Ile(593) helix has distinct hydrophilic and hydrophobic surfaces. The Gly(604)-Tyr(611) helix corresponds to an N-terminal extension of the pore helix. Electrophysiological studies of HERG currents following application of exogenous S5P peptides show that the amphipathic helix in the S5P linker interacts with the pore region of the channel in a voltage-dependent manner.	Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Univ New S Wales, Dept Med, St Lucia, Qld 4072, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Sydney, NSW 2010, Australia	Victor Chang Cardiac Research Institute; University of Sydney; University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Vandenberg, JI (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	j.vandenberg@victorchang.unsw.edu.au	Vandenberg, Jamie I/B-6608-2013; Torres, Allan/GSN-4624-2022; Sunde, Margaret/A-5186-2016; Sunde, Margaret/ABH-2584-2020	Vandenberg, Jamie I/0000-0002-3859-3716; Sunde, Margaret/0000-0002-0150-3203; Sunde, Margaret/0000-0002-0150-3203; Campbell, Terry/0000-0003-0055-4137; Gregory, Catherine/0000-0002-3100-2741; Kuchel, Philip/0000-0003-4100-7332				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chiang CE, 2000, J AM COLL CARDIOL, V36, P1, DOI 10.1016/S0735-1097(00)00716-6; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; Fan JS, 1999, BIOPHYS J, V76, P3128, DOI 10.1016/S0006-3495(99)77464-3; FERSHT A, 1999, STRUCTURE MECH PROTE, P527; Ficker E, 1998, CIRC RES, V82, P386, DOI 10.1161/01.RES.82.3.386; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; Halsall A, 1999, J MOL BIOL, V293, P901, DOI 10.1006/jmbi.1999.3194; Hancox JC, 1998, PFLUG ARCH EUR J PHY, V436, P843, DOI 10.1007/s004240050713; Haverkamp W, 2000, EUR HEART J, V21, P1216, DOI 10.1053/euhj.2000.2249; Herzberg IM, 1998, J PHYSIOL-LONDON, V511, P3, DOI 10.1111/j.1469-7793.1998.003bi.x; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korolkova Y, 2003, BIOPHYS J, V84, p8A; Korolkova YV, 2001, J BIOL CHEM, V276, P9868, DOI 10.1074/jbc.M005973200; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Liu J, 2002, J GEN PHYSIOL, V120, P723, DOI 10.1085/jgp.20028687; Lu Y, 2001, J PHYSIOL-LONDON, V537, P843, DOI 10.1113/jphysiol.2001.012690; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Mullins FM, 2002, J GEN PHYSIOL, V120, P517, DOI 10.1085/jgp.20028589; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Pardo-Lopez L, 2002, J BIOL CHEM, V277, P16403, DOI 10.1074/jbc.M200460200; PeledZehavi H, 1996, BIOCHEMISTRY-US, V35, P6828, DOI 10.1021/bi952988t; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rosenbusch JP, 2001, J STRUCT BIOL, V136, P144, DOI 10.1006/jsbi.2001.4431; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Tseng GN, 2001, J MOL CELL CARDIOL, V33, P835, DOI 10.1006/jmcc.2000.1317; Vandenberg JI, 2001, TRENDS PHARMACOL SCI, V22, P240, DOI 10.1016/S0165-6147(00)01662-X; Walker BD, 1999, BRIT J PHARMACOL, V127, P243, DOI 10.1038/sj.bjp.0702502; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Weerapura M, 2000, J PHYSIOL-LONDON, V526, P265, DOI 10.1111/j.1469-7793.2000.t01-1-00265.x; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	54	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42136	42148		10.1074/jbc.M212824200	http://dx.doi.org/10.1074/jbc.M212824200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902341	hybrid			2022-12-25	WOS:000185989500072
J	Calzada, MJ; Sipes, JM; Krutzsch, HC; Yurchenco, PD; Annis, DS; Mosher, DF; Roberts, DD				Calzada, MJ; Sipes, JM; Krutzsch, HC; Yurchenco, PD; Annis, DS; Mosher, DF; Roberts, DD			Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha(6)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; VEIN ENDOTHELIAL-CELLS; IN-VITRO; ALPHA(3)BETA(1) INTEGRIN; PROMOTES ANGIOGENESIS; SYNTHETIC PEPTIDES; TYPE-1 REPEATS; BINDING SITES; TUMOR-GROWTH; CYR61 CCN1	In addition to its recognition by alpha(3)beta(1) and alpha(4)beta(1) integrins, the N-terminal pentraxin module of thrombospondin-1 is a ligand for alpha(6)beta(1) integrin. alpha(6)beta(1) integrin mediates adhesion of human microvascular endothelial and HT-1080 fibrosarcoma cells to immobilized thrombospondin-1 and recombinant N-terminal regions of thrombospondin-1 and thrombospondin-2. alpha(6)beta(1) also mediates chemotaxis of microvascular cells to thrombospondin-1 and thrombospondin-2. Using synthetic peptides, LALERKDHSG was identified as an alpha(6)beta(1)-binding sequence in thrombospondin-1. This peptide inhibited alpha(6)beta(1)-dependent cell adhesion to thrombospondin-1, thrombospondin-2, and the E8 fragment of murine laminin-1. The Glu residue in this peptide was required for activity, and the corresponding residue (Glu(90)) in the N-terminal module of thrombospondin-1 was required for its recognition by alpha(6)beta(1), but not by alpha(4)beta(1). alpha(6)beta(1) was also expressed in human umbilical vein endothelial cells; but in these cells, only certain agonists could activate the integrin to recognize thrombospondins. Selective activation of alpha(6)beta(1) integrin in microvascular endothelial cells by the anti-beta(1) antibody TS2/16 therefore accounts for their adhesion responses to thrombospondins and explains the distinct functions of alpha(4)beta(1) and alpha(6)beta(1) integrins as thrombospondin receptors in microvascular and large vessel endothelial cells.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Wisconsin System; University of Wisconsin Madison	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.		Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Yurchenco, Peter/0000-0003-0387-2317	NATIONAL CANCER INSTITUTE [Z01SC009172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Davis TL, 2001, J BIOL CHEM, V276, P26099, DOI 10.1074/jbc.M102811200; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Le Bellego F, 2002, J ENDOCRINOL, V172, P45, DOI 10.1677/joe.0.1720045; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Murayama O, 1996, J BIOCHEM-TOKYO, V120, P445; Nath D, 2000, J CELL SCI, V113, P2319; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; SWERLICK RA, 1992, J IMMUNOL, V148, P78; Taraboletti G, 2000, FASEB J, V14, P1674; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yoon CS, 2001, BIOCHEM BIOPH RES CO, V283, P668, DOI 10.1006/bbrc.2001.4838; Yu HN, 2000, ARCH BIOCHEM BIOPHYS, V374, P13, DOI 10.1006/abbi.1999.1597; YURCHENCO PD, 1994, METHOD ENZYMOL, V245, P489; Zhu XL, 2000, J BIOL CHEM, V275, P7677, DOI 10.1074/jbc.275.11.7677	55	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40679	40687		10.1074/jbc.M302014200	http://dx.doi.org/10.1074/jbc.M302014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909644	hybrid			2022-12-25	WOS:000185847200032
J	Ohta, S; Tatsumi, Y; Fujita, M; Tsurimoto, T; Obuse, C				Ohta, S; Tatsumi, Y; Fujita, M; Tsurimoto, T; Obuse, C			The ORC1 cycle in human cells - II. Dynamic changes in the human ORC complex during the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; CHROMOSOMAL REPLICATION ORIGINS; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; NUCLEAR MATRIX; HOMOLOG; PROTEIN; IDENTIFICATION; ASSOCIATION; DROSOPHILA	The origin recognition complex (ORC) plays a central role in regulating the initiation of DNA replication in eukaryotes. The level of the ORC1 subunit oscillates throughout the cell cycle, defining an ORC1 cycle. ORC1 accumulates in G(1) and is degraded in S phase, although other ORC subunits (ORCs 2 - 5) remain at almost constant levels. The behavior of ORC components in human cell nuclei with respect to the ORC1 cycle demonstrates that ORCs 2 - 5 form a complex that is present throughout the cell cycle and that associates with ORC1 when it accumulates in G(1) nuclei. ORCs 2 - 5 are found in both nuclease-insoluble and - soluble fractions. The appearance of nuclease-insoluble ORCs 2 - 5 parallels the increase in the level of ORC1 associating with nuclease-insoluble, non-chromatin nuclear structures. Thus, ORCs 2 - 5 are temporally recruited to nuclease-insoluble structures by formation of the ORC1 - 5 complex. An artificial reduction in the level of ORC1 in human cells by RNA interference results in a shift of ORC2 to the nuclease-soluble fraction, and the association of MCM proteins with chromatin fractions is also blocked by this treatment. These results indicate that ORC1 regulates the status of the ORC complex in human nuclei by tethering ORCs 2 - 5 to nuclear structures. This dynamic shift is further required for the loading of MCM proteins onto chromatin. Thus, the pre-replication complex in human cells may be regulated by the temporal accumulation of ORC1 in G(1) nuclei.	Nara Inst Sci & Technol, Nara 6300101, Japan; Natl Canc Ctr, Res Inst, Chuoh Ku, Tokyo 1040045, Japan	Nara Institute of Science & Technology; National Cancer Center - Japan	Obuse, C (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068502, Japan.		Obuse, Chikashi/F-5273-2011	Tsurimoto, Toshiki/0000-0001-7597-2216; Fujita, Masatoshi/0000-0001-6617-2452; Tatsumi, Yasutoshi/0000-0003-2646-7410				Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; DePamphilis ML, 2003, GENE, V310, P1, DOI 10.1016/S0378-1119(03)00546-8; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dijkwel PA, 1995, INT REV CYTOL, V162A, P455; Djeliova V, 2001, NUCLEIC ACIDS RES, V29, P3181, DOI 10.1093/nar/29.15.3181; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fujita M, 1998, GENES CELLS, V3, P737, DOI 10.1046/j.1365-2443.1998.00226.x; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 1996, J BIOL CHEM, V271, P4349; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MICHELLE FP, 2001, DEVELOPMENT, V128, P1697; Ogawa Y, 1999, MOL CELL BIOL, V19, P7228; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Tadokoro R, 2002, J BIOL CHEM, V277, P15881, DOI 10.1074/jbc.M200322200; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; TATSUMI Y, UNPUB; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200	42	64	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41535	41540		10.1074/jbc.M307535200	http://dx.doi.org/10.1074/jbc.M307535200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909626	hybrid			2022-12-25	WOS:000185847200134
J	Chen, K; Albano, A; Ho, A; Keaney, JF				Chen, K; Albano, A; Ho, A; Keaney, JF			Activation of p53 by oxidative stress involves platelet-derived growth factor-beta receptor-mediated ataxia telangiectasia mutated (ATM) kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; PROTEIN-TYROSINE PHOSPHATASES; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; REVERSIBLE INACTIVATION; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; CELLS; H2O2; TRANSACTIVATION	Phosphorylation of the p53 tumor suppressor protein is a critical event in the up-regulation and activation of p53 during cellular stress. In this study, we characterized the signaling pathway linking oxidative stress to p53 through the platelet-derived growth factor beta (PDGFbeta) receptor and the ataxia telangiectasia mutated (ATM) kinase. In response to H2O2, we observed phosphorylation of p53 specifically at serine 15, but not serine 9, 20, or 392. Phosphorylation of Ser-15 was correlated with enhanced induction and functional activation of p53 manifest as transcription of the p53 target p21(CIP/WAF). We found that H2O2 induced phosphorylation of the PDGFbeta receptor and increased ATM kinase activity, two events integral to p53 activation as either AG1433 (a PDGFbeta receptor inhibitor) or caffeine (an ATM kinase inhibitor) inhibited Ser-15 phosphorylation. Similarly, p53 activation by H2O2 was inhibited by kinase-inactive forms of the PDGFbeta receptor or ATM. Inhibition of ATM kinase had no effect on H2O2-induced PDGFbeta receptor tyrosine phosphorylation, whereas PDGFbeta receptor suppression with RNA interference impaired H2O2-induced ATM activation, indicating that ATM lies downstream to the PDGFbeta receptor in this signaling cascade. Functionally, inhibition of the PDGFbeta receptor abrogated the inhibition of cell proliferation, and promotion of apoptosis due to H2O2 treatment. Thus, these data link PDGFbeta receptor transactivation to H2O2-induced p53 phosphorylation and suggest a functional role for growth factor receptors in modulation of p53 function.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Mem Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Keaney, JF (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,Rm W507, Boston, MA 02118 USA.			Keaney, John/0000-0002-0866-1837	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60886] Funding Source: Medline; NIDDK NIH HHS [DK55656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cartel NJ, 2001, AM J PHYSIOL-LUNG C, V281, pL786, DOI 10.1152/ajplung.2001.281.4.L786; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Chen K, 1996, BIOCHEM BIOPH RES CO, V224, P703, DOI 10.1006/bbrc.1996.1087; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; Green MHL, 1997, FREE RADICAL BIO MED, V22, P343, DOI 10.1016/S0891-5849(96)00336-X; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin WC, 2001, GENE DEV, V15, P1833; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MAYR GA, 1995, CANCER RES, V55, P2410; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; NGHIEM P, 2001, J BIOL CHEM; PRYOR WA, 1994, NATURAL ANTIOXIDANTS, P1; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Vile GF, 1997, FEBS LETT, V412, P70, DOI 10.1016/S0014-5793(97)00748-5; VUILLAUME M, 1989, CARCINOGENESIS, V10, P1375, DOI 10.1093/carcin/10.8.1375; WANG RJ, 1980, RADIAT RES, V82, P269, DOI 10.2307/3575378; WARD AJ, 1994, ENVIRON MOL MUTAGEN, V24, P103, DOI 10.1002/em.2850240205; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	46	83	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39527	39533		10.1074/jbc.M304423200	http://dx.doi.org/10.1074/jbc.M304423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890678	hybrid			2022-12-25	WOS:000185713800033
J	Emerson, JP; Coulter, ED; Phillips, RS; Kurtz, DM				Emerson, JP; Coulter, ED; Phillips, RS; Kurtz, DM			Kinetics of the superoxide reductase catalytic cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; OXIDATIVE STRESS PROTECTION; RBO GENE-PRODUCT; DESULFOARCULUS-BAARSII; ESCHERICHIA-COLI; RUBREDOXIN OXIDOREDUCTASE; TREPONEMA-PALLIDUM; ACTIVE-SITE; OXYGEN DETOXIFICATION; PYROCOCCUS-FURIOSUS	The steady state kinetics of a Desulfovibrio ( D.) vulgaris superoxide reductase (SOR) turnover cycle, in which superoxide is catalytically reduced to hydrogen peroxide at a [Fe( His)(4)(Cys)] active site, are reported. A proximal electron donor, rubredoxin, was used to supply reducing equivalents from NADPH via ferredoxin: NADP(+) oxidoreductase, and xanthine/xanthine oxidase was used to provide a calibrated flux of superoxide. SOR turnover in this system was well coupled, i.e. similar to 2O(2)(radical anion) reduced: NADPH oxidized over a 10-fold range of superoxide flux. The reduction of the ferric SOR active site by reduced rubredoxin was independently measured to have a second-order rate constant of similar to 1 x 10(6) M-1 s(-1). Analysis of the kinetics showed that: ( i) 1 muM SOR can convert a 10 muM/min superoxide flux to a steady state superoxide concentration of 10(-10) M, during which SOR turns over about once every 6 s, (ii) the diffusion-controlled reaction of reduced SOR with superoxide is the slowest process during turnover, and (iii) neither ligation nor deligation of the active site carboxylate of SOR limits the turnover rate. An intracellular SOR concentration on the order of 10 muM is estimated to be the minimum required for lowering superoxide to sublethal levels in aerobically growing SOD knockout mutants of Escherichia coli. SORs from Desulfovibrio gigas and Treponema pallidum showed similar turnover rates when substituted for the D. vulgaris SOR, whereas superoxide dismutases showed no SOR activity in our assay. These results provide quantitative support for previous suggestions that, in times of oxidative stress, SORs efficiently divert intracellular reducing equivalents to superoxide.	Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Kurtz, DM (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.			Phillips, Robert/0000-0001-8710-562X; Emerson, Joseph/0000-0002-7556-1393				Abreu IA, 2002, J BIOL INORG CHEM, V7, P668, DOI 10.1007/s00775-002-0363-1; Abreu IA, 2001, J BIOL CHEM, V276, P38995, DOI 10.1074/jbc.M103232200; Baumgarten A, 2001, ARCH MICROBIOL, V176, P306, DOI 10.1007/s002030100329; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Clay MD, 2002, J AM CHEM SOC, V124, P788, DOI 10.1021/ja016889g; COEHLO AV, 1997, J BIOL INORG CHEM, V2, P680; Coulter ED, 2001, ARCH BIOCHEM BIOPHYS, V394, P76, DOI 10.1006/abbi.2001.2531; Coulter ED, 2000, J AM CHEM SOC, V122, P11555, DOI 10.1021/ja005583r; Cypionka H, 2000, ANNU REV MICROBIOL, V54, P827, DOI 10.1146/annurev.micro.54.1.827; Das A, 2001, J BACTERIOL, V183, P1560, DOI 10.1128/JB.183.5.1560-1567.2001; Eidsness MK, 1999, BIOCHEMISTRY-US, V38, P14803, DOI 10.1021/bi991661f; Emerson JP, 2003, P NATL ACAD SCI USA, V100, P3802, DOI 10.1073/pnas.0537177100; Emerson JP, 2002, BIOCHEMISTRY-US, V41, P4348, DOI 10.1021/bi0119159; Eschemann A, 1999, ENVIRON MICROBIOL, V1, P489, DOI 10.1046/j.1462-2920.1999.00057.x; Fournier M, 2003, J BACTERIOL, V185, P71, DOI 10.1128/JB.185.1.71-79.2003; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; Imlay JA, 2002, J BIOL INORG CHEM, V7, P659, DOI 10.1007/s00775-002-0361-3; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Johnson MS, 1997, J BACTERIOL, V179, P5598, DOI 10.1128/jb.179.17.5598-5601.1997; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; Kurtz DM, 2002, J BIOL INORG CHEM, V7, P653, DOI 10.1007/s00775-002-0360-4; KURTZ DM, 2001, CHEMTRACTS INORG CHE, V14, P407; Lemos RS, 2001, FEBS LETT, V496, P40, DOI 10.1016/S0014-5793(01)02399-7; Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; Lombard M, 2000, J BIOL CHEM, V275, P27021; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; Lombard M, 2001, BIOCHEMISTRY-US, V40, P5032, DOI 10.1021/bi0023908; Lovenberg W, 1978, Methods Enzymol, V53, P340; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; Mathe C, 2002, J AM CHEM SOC, V124, P4966, DOI 10.1021/ja025707v; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Niviere V, 2001, FEBS LETT, V497, P171, DOI 10.1016/S0014-5793(01)02468-1; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Richie KA, 1996, PROTEIN SCI, V5, P883; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; Shearer J, 2003, P NATL ACAD SCI USA, V100, P3671, DOI 10.1073/pnas.0637029100; Silaghi-Dumitrescu R, 2003, INORG CHEM, V42, P446, DOI 10.1021/ic025684l; Silva G, 1999, EUR J BIOCHEM, V259, P235, DOI 10.1046/j.1432-1327.1999.00025.x; Silva G, 2001, J BACTERIOL, V183, P4413, DOI 10.1128/JB.183.4.4413-4420.2001; WALEY SG, 1992, BIOCHEM J, V286, P357, DOI 10.1042/bj2860357; Yeh AP, 2000, BIOCHEMISTRY-US, V39, P2499, DOI 10.1021/bi992428k	48	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39662	39668		10.1074/jbc.M306488200	http://dx.doi.org/10.1074/jbc.M306488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900405	hybrid			2022-12-25	WOS:000185713800051
J	Giraudo, CG; Maccioni, HJF				Giraudo, CG; Maccioni, HJF			Ganglioside glycosyltransferases organize in distinct multienzyme complexes in CHO-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL RETINA CELLS; GOLGI-APPARATUS; BREFELDIN-A; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MANNOSYLTRANSFERASE COMPLEX; MICROTUBULE DISRUPTION; GA2/GM2/GD2 SYNTHASE; HEPARAN-SULFATE; RAT-LIVER	The synthesis of gangliosides is compartmentalized in the Golgi complex. In most cells, glycosylation of LacCer, GM3, and GD3 to form higher order species (GA2, GM2, GD2, GM1, GD1b) is displaced toward the most distal aspects of the Golgi and the trans-Golgi network, where the involved transferases (GalNAcT and GalT2) form physical and functional associations. Glycosylation of the simple species LacCer, GM3, and GD3, on the other hand, is displaced toward more proximal Golgi compartments, and we investigate here whether the involved transferases (GalT1, SialT1, and SialT2) share the property of forming physical associations. Co-immunoprecipitation experiments from membranes of CHO-K1 cells expressing epitope-tagged versions of these enzymes indicate that GalT1, SialT1, and SialT2 associate physically in a SialT1-dependent manner and that their N-terminal domains participate in these interactions. Microscopic fluorescence resonance energy transfer and fluorescence recovery after photobleaching in living cells confirmed the interactions, and in addition to showing a Golgi apparatus localization of the complexes, mapped their formation to the endoplasmic reticulum. Neither co-immunoprecipitation nor fluorescence resonance energy transfer detected interactions between either GalT2 or GalNAcT and GalT1 or SialT1 or SialT2. These results, and triple color imaging of Golgi-derived microvesicles in nocodazole-treated cells, suggest that ganglioside synthesis is organized in distinct units each formed by associations of particular glycosyltransferases, which concentrate in different sub-Golgi compartments.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CONICET,CIQUIBIC, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Maccioni, HJF (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CONICET,CIQUIBIC, Ciudad Univ, RA-5000 Cordoba, Argentina.							Allende ML, 2000, GLYCOBIOLOGY, V10, P1025, DOI 10.1093/glycob/10.10.1025; Bieberich E, 2002, BIOCHEMISTRY-US, V41, P11479, DOI 10.1021/bi0259958; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; FRITZ VMR, 1995, J NEUROCHEM, V65, P1859; Fritz VMR, 1996, J NEUROCHEM, V67, P1393; Giraudo CG, 1999, BIOCHEM J, V342, P633, DOI 10.1042/0264-6021:3420633; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; KEENAN TW, 1974, J BIOL CHEM, V249, P310; Lannert H, 1998, J BIOL CHEM, V273, P2939, DOI 10.1074/jbc.273.5.2939; Maccioni HJF, 1999, BBA-MOL CELL BIOL L, V1437, P101, DOI 10.1016/S1388-1981(99)00002-5; Maccioni HJF, 2002, NEUROCHEM RES, V27, P629, DOI 10.1023/A:1020271932760; Maxzud MK, 2000, NEUROCHEM RES, V25, P145, DOI 10.1023/A:1007555903335; MAXZUD MK, 1995, J BIOL CHEM, V270, P20207, DOI 10.1074/jbc.270.34.20207; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; MILLERPRODRAZA H, 1984, BIOCHIM BIOPHYS ACTA, V804, P44, DOI 10.1016/0167-4889(84)90097-1; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; NORES GA, 1986, NEUROCHEM INT, V8, P501, DOI 10.1016/0197-0186(86)90183-X; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Stolz J, 2002, J BIOL CHEM, V277, P44801, DOI 10.1074/jbc.M208023200; Todorow Z, 2000, P NATL ACAD SCI USA, V97, P13643, DOI 10.1073/pnas.250472397; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yang W, 1998, MOL BIOL CELL, V9, P191, DOI 10.1091/mbc.9.1.191; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; Yu R K, 1980, Adv Exp Med Biol, V125, P33	35	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40262	40271		10.1074/jbc.M305455200	http://dx.doi.org/10.1074/jbc.M305455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900410	hybrid			2022-12-25	WOS:000185713800119
J	Oak, SA; Zhou, YW; Jarrett, HW				Oak, SA; Zhou, YW; Jarrett, HW			Skeletal muscle signaling pathway through the dystrophin glycoprotein complex and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; BETA-DYSTROGLYCAN; GUANOSINE TRIPHOSPHATASES; MOUSE ALPHA-1-SYNTROPHIN; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; MUSCULAR-DYSTROPHIES; ALPHA-DYSTROGLYCAN; BINDING-SITES; SMOOTH-MUSCLE	The dystrophin glycoprotein complex has been proposed to be involved in signal transduction. Here we have shown that laminin binding causes syntrophin to recruit Rac1 from the rabbit skeletal muscle. Laminin-Sepharose and syntrophin-Sepharose bind a protein complex containing Rac1 from the muscle membranes. The presence of heparin, which inhibits laminin interactions, prevents recruitment of Rac1. The dystrophin glycoprotein complex recruits Rac1 via syntrophin through a Grb2.Sos1 complex. A syntrophin antibody also prevents recruitment of Rac1, suggesting that the signaling complex requires syntrophin. PAK1 is in turn bound by Rac1. c-Jun NH2-terminal kinase-p46 is phosphorylated and activated only when laminin is present, and the p54 isoform is activated when laminin is depleted or binding is inhibited with heparin. In the presence of laminin, c-Jun is activated in both skeletal muscle microsomes and in C2C12 myoblasts, and proliferation increases in C2C12 myoblasts. We postulate that this pathway signals muscle homeostasis and hypertrophy.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Jarrett, HW (corresponding author), Univ Tennessee, Dept Biochem, 858 Madison Ave, Memphis, TN 38163 USA.							Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Cavaldesi M, 1999, J NEUROCHEM, V72, P1648, DOI 10.1046/j.1471-4159.1999.721648.x; Chockalingam PS, 2002, AM J PHYSIOL-CELL PH, V283, pC500, DOI 10.1152/ajpcell.00529.2001; Colledge M, 1997, J NEUROSCI, V17, P5038; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Gee SH, 1998, J NEUROSCI, V18, P128; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; Howard PL, 1999, MUSCLE NERVE, V22, P16, DOI 10.1002/(SICI)1097-4598(199901)22:1<16::AID-MUS5>3.0.CO;2-R; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Iwata Y, 1998, FEBS LETT, V423, P173, DOI 10.1016/S0014-5793(98)00085-4; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; KOSTROMINOVA TY, 1995, J CELL BIOCHEM, V58, P527, DOI 10.1002/jcb.240580416; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; MADHAVAN R, 1992, BIOCHEM BIOPH RES CO, V185, P753, DOI 10.1016/0006-291X(92)91690-R; Mayer U, 2003, J BIOL CHEM, V278, P14587, DOI 10.1074/jbc.R200022200; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; Newbell BJ, 1997, BIOCHEMISTRY-US, V36, P1295, DOI 10.1021/bi962452n; Nguyen HT, 2000, AM J PHYSIOL-CELL PH, V279, pC1155, DOI 10.1152/ajpcell.2000.279.4.C1155; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Oak SA, 2001, BIOCHEMISTRY-US, V40, P11270, DOI 10.1021/bi010490n; Oak SA, 2000, BIOCHEMISTRY-US, V39, P8870, DOI 10.1021/bi0000824; Pall EA, 1996, J BIOL CHEM, V271, P3817; PELICCI G, 1995, ONCOGENE, V11, P899; Rosa G, 1996, BIOCHEM BIOPH RES CO, V223, P272, DOI 10.1006/bbrc.1996.0883; Rowley JA, 2002, J BIOMED MATER RES, V60, P217, DOI 10.1002/jbm.1287; Sasaki T, 2001, FEBS LETT, V509, P181, DOI 10.1016/S0014-5793(01)03167-2; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sotgia F, 2003, BIOCHEMISTRY-US, V42, P7110, DOI 10.1021/bi0271289; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; Spofford CM, 2001, AM J PHYSIOL-HEART C, V280, pH1354, DOI 10.1152/ajpheart.2001.280.3.H1354; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUNADA Y, 1995, CURR OPIN NEUROL, V8, P379, DOI 10.1097/00019052-199510000-00010; Thibault G, 2000, MOL PHARMACOL, V58, P1137, DOI 10.1124/mol.58.5.1137; Tiger CF, 1997, J BIOL CHEM, V272, P28590, DOI 10.1074/jbc.272.45.28590; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Weston C, 2000, J CELL BIOL, V150, P205, DOI 10.1083/jcb.150.1.205; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; Zhang BL, 2001, J BIOL CHEM, V276, P8958, DOI 10.1074/jbc.M008720200; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	52	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39287	39295		10.1074/jbc.M305551200	http://dx.doi.org/10.1074/jbc.M305551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885773	hybrid			2022-12-25	WOS:000185713800005
J	Saito, Y; Yoshida, Y; Akazawa, T; Takahashi, K; Niki, E				Saito, Y; Yoshida, Y; Akazawa, T; Takahashi, K; Niki, E			Cell death caused by selenium deficiency and protective effect of antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; HUMAN SELENOPROTEIN P; VITAMIN-E-DEFICIENCY; LIPID-PEROXIDATION; THIOREDOXIN REDUCTASE; FLUORESCENT-PROBE; ALPHA-TOCOTRIENOL; PROSTATE-CANCER; APOPTOTIC DEATH; HUMAN-PLASMA	Selenium is an essential trace element and it is well known that selenium is necessary for cell culture. However, the mechanism underlying the role of selenium in cellular proliferation and survival is still unknown. The present study using Jurkat cells showed that selenium deficiency in a serum-free medium decreased the selenium-dependent enzyme activity (glutathione peroxidases and thioredoxin reductase) within cells and cell viability. To understand the mechanism of this effect of selenium, we examined the effect of other antioxidants, which act by different mechanisms. Vitamin E, a lipid-soluble radical-scavenging antioxidant, completely blocked selenium deficiency-induced cell death, although alpha-tocopherol (biologically the most active form of vitamin E) could not preserve selenium-dependent enzyme activity. Other antioxidants, such as different isoforms and derivatives of vitamin E, BO-653 and deferoxamine mesylate, also exerted an inhibitory effect. However, the water-soluble antioxidants, such as ascorbic acid, N-acetyl cysteine, and glutathione, displayed no such effect. Dichlorodihydrofluorescein (DCF) assay revealed that cellular reactive oxygen species (ROS) increased before cell death, and sodium selenite and alpha-tocopherol inhibited ROS increase in a dose-dependent manner. The generation of lipid hydroperoxides was observed by fluorescence probe diphenyl-1-pyrenylphosphine (DPPP) and HPLC chemiluminescence only in selenium-deficient cells. These results suggest that the ROS, especially lipid hydroperoxides, are involved in the cell death caused by selenium deficiency and that selenium and vitamin E cooperate in the defense against oxidative stress upon cells by detoxifying and inhibiting the formation of lipid hydroperoxides.	Natl Inst Adv Ind Sci & Technol, HSSRC, Osaka 5638577, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Hokkaido University	Saito, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, HSSRC, 1-8-31 Midorigaoka, Osaka 5638577, Japan.		Saito, Yoshiro/H-4597-2019; Yoshida, Yasukazu/H-8510-2016	Saito, Yoshiro/0000-0002-0559-5889; Yoshida, Yasukazu/0000-0001-6034-2502				Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Beck MA, 2003, FREE RADICAL BIO MED, V34, P1263, DOI 10.1016/S0891-5849(03)00101-1; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Duffield-Lillico AJ, 2003, BJU INT, V91, P608, DOI 10.1046/j.1464-410X.2003.04167.x; Field CJ, 2002, J LEUKOCYTE BIOL, V71, P16; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2001, J NUTR, V131, P1798, DOI 10.1093/jn/131.6.1798; Hurst R, 2001, FREE RADICAL BIO MED, V31, P1051, DOI 10.1016/S0891-5849(01)00685-2; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Keaney JF, 1999, FASEB J, V13, P965, DOI 10.1096/fasebj.13.9.965; Knekt P, 1998, AM J EPIDEMIOL, V148, P975, DOI 10.1093/oxfordjournals.aje.a009574; Lewin MH, 2001, BBA-GEN SUBJECTS, V1526, P237, DOI 10.1016/S0304-4165(01)00133-7; Matot I, 2003, FREE RADICAL BIO MED, V34, P785, DOI 10.1016/S0891-5849(02)01435-1; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; McKenzie RC, 1998, IMMUNOL TODAY, V19, P342, DOI 10.1016/S0167-5699(98)01294-8; Meydani SN, 1998, NUTR REV, V56, pS49; MIYAZAWA T, 1994, METHOD ENZYMOL, V233, P324; Navarro F, 1998, FASEB J, V12, P1665, DOI 10.1096/fasebj.12.15.1665; Noguchi N, 2003, FREE RADICAL BIO MED, V34, P1614, DOI 10.1016/S0891-5849(03)00216-8; Noguchi N, 1997, ARCH BIOCHEM BIOPHYS, V342, P236, DOI 10.1006/abbi.1997.9994; Okimoto Y, 2000, FEBS LETT, V474, P137, DOI 10.1016/S0014-5793(00)01587-8; Packer L, 2001, J NUTR, V131, p369S, DOI 10.1093/jn/131.2.369S; Persson HL, 2003, FREE RADICAL BIO MED, V34, P1295, DOI 10.1016/S0891-5849(03)00106-0; PIGAULT C, 1994, J MOL BIOL, V236, P199, DOI 10.1006/jmbi.1994.1129; Ricciarelli R, 2001, FASEB J, V15, P2314, DOI 10.1096/fj.01-0258rev; Saito Y, 2000, J HEALTH SCI, V46, P409; Saito Y, 1999, J BIOL CHEM, V274, P2866, DOI 10.1074/jbc.274.5.2866; Saito Y, 2002, EUR J BIOCHEM, V269, P5746, DOI 10.1046/j.1432-1033.2002.03298.x; Saito Y, 2001, J HEALTH SCI, V47, P346, DOI 10.1248/jhs.47.346; SALONEN JT, 1991, BRIT MED J, V302, P756, DOI 10.1136/bmj.302.6779.756; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; SUADICANI P, 1992, ATHEROSCLEROSIS, V96, P33, DOI 10.1016/0021-9150(92)90035-F; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Takahashi M, 2001, FREE RADICAL BIO MED, V31, P164, DOI 10.1016/S0891-5849(01)00575-5; Takebe G, 2002, J BIOL CHEM, V277, P41254, DOI 10.1074/jbc.M202773200; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Yarimizu J, 2000, ANTIOXID REDOX SIGN, V2, P643, DOI 10.1089/ars.2000.2.4-643; Yoshida Y, 2003, FREE RADICAL RES, V37, P861, DOI 10.1080/1071576031000148736; Yoshida Y, 2003, BIOCHEM BIOPH RES CO, V305, P747, DOI 10.1016/S0006-291X(03)00813-1; Yoshida Y, 2003, CHEM PHYS LIPIDS, V123, P63, DOI 10.1016/S0009-3084(02)00164-0; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6; Zeng HW, 2002, J NUTR, V132, P674, DOI 10.1093/jn/132.4.674	52	187	203	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39428	39434		10.1074/jbc.M305542200	http://dx.doi.org/10.1074/jbc.M305542200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888577	hybrid			2022-12-25	WOS:000185713800020
J	McMullen, MR; Cocuzzi, E; Hatzoglou, M; Nagy, LE				McMullen, MR; Cocuzzi, E; Hatzoglou, M; Nagy, LE			Chronic ethanol exposure increases the binding of HuR to the TNF alpha 3 '-untranslated region in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA STABILITY; AU-RICH ELEMENTS; NF-KAPPA-B; LIVER-DISEASE; PLASMA ENDOTOXIN; PROTEIN LIGANDS; IN-VIVO; C-JUN; EXPRESSION	Tumor necrosis factor alpha (TNFalpha) expression is a key mediator of ethanol-induced liver disease. Increased lipopolysaccharide (LPS)-stimulated TNFalpha expression in macrophages after chronic ethanol feeding is associated with a stabilization of TNFalpha mRNA (Kishore, R., McMullen, M. R., and Nagy, L. E. ( 2001) J. Biol. Chem. 276, 41930-41937). Here we show that the 3'-UTR of murine TNFalpha mRNA was sufficient to mediate increased LPS-stimulated expression of a luciferase reporter in RAW 264.7 macrophages after chronic ethanol exposure. Further, we show that HuR, a nuclear/cytoplasmic shuttling protein, which binds to TNFalpha mRNA, is required for increased expression of TNFalpha after chronic ethanol. In Kupffer cells, HuR was primarily localized to the nucleus and then translocated to the cytosol in response to LPS in both pair- and ethanol-fed rats. After chronic ethanol feeding, HuR quantity in the cytosol was greater, both at baseline and in response to LPS, compared with pair- fed controls. Using RNA gel shift assays, we found that LPS treatment increased HuR binding to the 65-nucleotide A + U-rich element of the TNFalpha 3'-UTR by 2-fold over baseline in Kupffer cells from pair- fed rats. After chronic ethanol feeding, HuR binding to the TNFalpha A + U-rich element was increased by more than 5-fold at baseline and in response to LPS, compared with pair- fed controls. Down-regulation of HuR expression by RNA interference prevented the chronic ethanol-induced increase in expression of luciferase reporters containing the TNFalpha 3'-UTR. Taken together, these data demonstrate that increased binding of HuR to the TNFalpha 3'-UTR contributes to increased LPS-stimulated TNFalpha expression in macrophages after chronic ethanol exposure.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Case Western Reserve University	Nagy, LE (corresponding author), Case Western Reserve Univ, Dept Nutr, 2123 Abington Rd,Rm 201, Cleveland, OH 44106 USA.	len2@po.cwru.edu			NIAAA NIH HHS [R56 AA011975, AA 11975, R01 AA011975-10, R01 AA011975] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA011975, R01AA011975] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aldred A, 1999, AM J PHYSIOL-GASTR L, V276, pG98, DOI 10.1152/ajpgi.1999.276.1.G98; BEUTLER B, 1995, J INVEST MED, V43, P227; BODE C, 1987, J HEPATOL, V4, P8, DOI 10.1016/S0168-8278(87)80003-X; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FUKUI H, 1991, J HEPATOL, V12, P162, DOI 10.1016/0168-8278(91)90933-3; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Han J, 1990, Eur Cytokine Netw, V1, P71; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hel Z, 1996, MOL CELL BIOL, V16, P5579; HONCHEL R, 1992, ALCOHOL CLIN EXP RES, V16, P665, DOI 10.1111/j.1530-0277.1992.tb00656.x; Jacob CO, 1996, J IMMUNOL, V156, P3043; JACOB CO, 1992, IMMUNOL TODAY, V13, P122, DOI 10.1016/0167-5699(92)90107-I; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1016/0270-9139(91)92439-F; Kishore R, 2002, AM J PHYSIOL-GASTR L, V282, pG6, DOI 10.1152/ajpgi.00328.2001; Kishore R, 2001, J BIOL CHEM, V276, P41930, DOI 10.1074/jbc.M107181200; KISHORE R, 2003, IN PRESS COMP HEPATO; Kloss S, 2003, J BIOL CHEM, V278, P2377, DOI 10.1074/jbc.M206453200; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lee WY, 2000, J BIOL CHEM, V275, P33998, DOI 10.1074/jbc.M005040200; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Loflin P, 2001, FEBS LETT, V509, P267, DOI 10.1016/S0014-5793(01)03176-3; Marchant A, 1996, J INFLAMM, V46, P114; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; NANJI AA, 1993, AM J PATHOL, V142, P367; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Reimund JM, 1996, J CLIN IMMUNOL, V16, P144, DOI 10.1007/BF01540912; Ron D, 2000, FASEB J, V14, P2303, DOI 10.1096/fj.00-0143com; Sakai K, 1999, FEBS LETT, V446, P157, DOI 10.1016/S0014-5793(99)00206-9; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; SHALABY MR, 1989, TRANSPLANTATION, V47, P1057, DOI 10.1097/00007890-198906000-00028; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Thurman RG, 1998, AM J PHYSIOL-GASTR L, V275, pG605, DOI 10.1152/ajpgi.1998.275.4.G605; Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9	57	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38333	38341		10.1074/jbc.M304566200	http://dx.doi.org/10.1074/jbc.M304566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876290	hybrid, Green Accepted			2022-12-25	WOS:000185575100032
J	Tobaben, S; Varoqueaux, F; Brose, N; Stahl, B; Meyer, G				Tobaben, S; Varoqueaux, F; Brose, N; Stahl, B; Meyer, G			A brain-specific isoform of small glutamine-rich tetratricopeptide repeat-containing protein binds to Hsc70 and the cysteine string protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; UBIQUITIN LIGASE; DOMAIN; IDENTIFICATION; INTERACTS; COCHAPERONE; PEPTIDE; COMPLEX; FAMILY; HSP90	Small glutamine-rich tetratricopeptide repeat-containing protein (SGT) is a ubiquitously expressed cochaperone of heat shock cognate protein of 70 kDa (Hsc70). SGT binds to the C terminus of Hsc70, a site used by several tetratricopeptide repeat-containing binding partners to recruit Hsc70 into complexes of diverse function. We describe here an isoform of SGT with 60% amino acid sequence identity that we name betaSGT. In contrast to the previously published alphaSGT, betaSGT is almost exclusively expressed in brain. Both isoforms of SGT possess similar binding properties toward Hsc70 and cysteine string protein, a synaptic vesicle-associated J-domain-containing protein. In addition, SGTs oligomerize without preferences among isoforms. The distribution of protein binding motifs on SGTs reveals a modular structure. The N-terminal domains mediate oligomerization. Binding to Hsc70 is impaired by mutations of basic residues within the central tetratricopeptide repeat domain of betaSGT, indicating a two-carboxylate clamp as the binding mode. The tetratricopeptide repeats are also necessary for binding to the cysteine string protein. However, this binding mode is distinct from the two-carboxylate clamp that is involved in Hsc70 binding. The C-terminal regions of SGTs might constitute independent protein interaction domains. We conclude that betaSGT is likely to cooperate with alphaSGT as co-chaperone of Hsc70 in the brain. The modular structure of SGTs allows them to recruit client proteins to Hsc70 and to direct the resulting complex toward downstream proteins that take over the respective client proteins.	Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; Deutsch Forsch Gemeinschaft Ctr Mol Physiol Brain, D-37075 Gottingen, Germany	Max Planck Society	Meyer, G (corresponding author), Max Planck Inst Expt Med, Dept Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.	gmeyer@em.mpg.de	Varoqueaux, Frederique/AAC-1834-2021	Varoqueaux, Frederique/0000-0002-3614-3121				Angeletti PC, 2002, CELL STRESS CHAPERON, V7, P258, DOI 10.1379/1466-1268(2002)007<0258:SGRPVP>2.0.CO;2; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Betz A, 1997, J BIOL CHEM, V272, P2520; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; Callahan MA, 1998, J VIROL, V72, P5189, DOI 10.1128/JVI.72.6.5189-5197.1998; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Cziepluch C, 1998, J VIROL, V72, P4149, DOI 10.1128/JVI.72.5.4149-4156.1998; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Irmer H, 1997, J BIOL CHEM, V272, P2230; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kaye FJ, 2000, FEBS LETT, V467, P348, DOI 10.1016/S0014-5793(00)01135-2; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Kordes E, 1998, GENOMICS, V52, P90, DOI 10.1006/geno.1998.5385; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Muchowskil PJ, 2002, NEURON, V35, P9, DOI 10.1016/S0896-6273(02)00761-4; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; Ohtsuka K, 2000, BRAIN RES BULL, V53, P141, DOI 10.1016/S0361-9230(00)00325-7; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Smith DF, 1998, BIOL CHEM, V379, P283; Stahl B, 1999, EUR J CELL BIOL, V78, P375, DOI 10.1016/S0171-9335(99)80079-X; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Velten M, 2002, J BIOL CHEM, V277, P259, DOI 10.1074/jbc.M106881200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wu SJ, 2001, BIOCHEM J, V359, P419, DOI 10.1042/0264-6021:3590419; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zinsmaier KE, 2001, BIOCHEM PHARMACOL, V62, P1, DOI 10.1016/S0006-2952(01)00648-7	43	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38376	38383		10.1074/jbc.M301558200	http://dx.doi.org/10.1074/jbc.M301558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878599	hybrid			2022-12-25	WOS:000185575100037
J	Panka, DJ; Mier, JW				Panka, DJ; Mier, JW			Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT ANTITUMOR PROPERTIES; BASEMENT-MEMBRANE COLLAGEN; TRAIL-INDUCED APOPTOSIS; C-FLIP; CYTOCHROME-C; ALPHA(V)BETA(3) INTEGRIN; MEDIATED APOPTOSIS; CELLULAR FLIP; TUMOR-GROWTH; PROTEIN	Canstatin, a 24-kDa peptide derived from the C-terminal globular non-collagenous (NC1) domain of the alpha2 chain of type IV collagen, was previously shown to induce apoptosis in cultured endothelial cells and to inhibit angiogenesis in vitro and in vivo. In this report, we demonstrate that canstatin inhibits the phosphorylation of Akt, focal adhesion kinase, mammalian target of rapamycin, eukaryotic initiation factor-4E-binding protein-1, and ribosomal S6 kinase in cultured human umbilical vein endothelial cells. It also induces Fas ligand expression, activates procaspases 8 and 9 cleavage, reduces mitochondrial membrane potential, and increases cell death ( as determined by propidium iodide staining). Canstatin-induced activation of procaspases 8 and 9 as well as the induced reduction in mitochondrial membrane potential and cell viability were attenuated by the forced expression of FLICE-inhibitory protein. Canstatin-induced procaspase 8 activation and cell death were also inhibited by a neutralizing anti-Fas antibody. Collectively, these data indicate that canstatin-induced apoptosis is associated with phosphatidylinositol 3-kinase/ Akt inhibition and is dependent upon signaling events transduced through membrane death receptors.	Beth Israel Deaconess Med Ctr, Div Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mier, JW (corresponding author), Beth Israel Deaconess Med Ctr, Div Oncol, Kirstein 158,330 Brookline Ave, Boston, MA 02215 USA.				NCI NIH HHS [CA93683, CA92954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA093683, R21CA092954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Burns TF, 2001, J BIOL CHEM, V276, P37879; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Colorado PC, 2000, CANCER RES, V60, P2520; Dancey JE, 2002, HEMATOL ONCOL CLIN N, V16, P1101, DOI 10.1016/S0889-8588(02)00051-5; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Dhanabal M, 1999, CANCER RES, V59, P189; Dixelius J, 2002, CANCER RES, V62, P1944; Djerbi M, 2001, SCAND J IMMUNOL, V54, P180, DOI 10.1046/j.1365-3083.2001.00941.x; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Griffith TS, 1998, J IMMUNOL, V161, P2833; HARALABOPOULOS GC, 1994, LAB INVEST, V71, P575; Hyer ML, 2002, CANCER BIOL THER, V1, P401, DOI 10.4161/cbt.1.4.15; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JEFFRIES H, 1996, TRANSLATIONAL CONTRO; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kandasamy K, 2003, CANCER RES, V63, P1712; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	37	94	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37632	37636		10.1074/jbc.M307339200	http://dx.doi.org/10.1074/jbc.M307339200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12876280	hybrid			2022-12-25	WOS:000185437200078
J	Sharpless, NE; Kannan, K; Xu, J; Bosenberg, MW; Chin, LD				Sharpless, NE; Kannan, K; Xu, J; Bosenberg, MW; Chin, LD			Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo	ONCOGENE			English	Article						melanoma; RAS	GERMLINE MUTATION; TUMOR SUPPRESSION; RAS; P16(INK4A); P53; P19(ARF); GENE; SUSCEPTIBILITY; INACTIVATION; FIBROBLASTS	Deletion of the INK4a/ARF locus at 9p21 is detected with high frequency in human melanoma. Within a short genomic distance, this locus encodes several proteins with established tumor-suppressor roles in a broad spectrum of cancer types. Several lines of evidence support the view that p10(INKa4) and p19(ARF) exert the tumor-suppressor activities of this locus, although their relative importance in specific cancer types such as melanoma has been less rigorously documented on the genetic level. Here, we exploit a well-defined mouse model of RAS-induced melanomas to examine the impact of germline p16(INK4a) or p19(ARF) nullizygosity on melanoma formation. We demonstrate that loss of either Ink4a/Arf product can cooperate with RAS activation to produce clinically indistinguishable melanomas. In line with the common phenotypic end point, we further show that RAS+ p16(INK4a)-/- melanomas sustain somatic inactivation of p19(ARF)-p53 and, correspondingly, that RAS+ p19(ARF)-/- melanomas experience high-frequency loss of p16(INK4a). These genetic studies provide definitive proof that p16(INK4a), and p19(ARF) cooperate to suppress the development of melanoma in vivo.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Dermatol, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Chin, LD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	Lynda_Chin@dfci.harvard.edu		Sharpless, Norman/0000-0001-7078-9455				Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Flores JF, 1996, CANCER RES, V56, P5023; GLENDENING JM, 1995, CANCER RES, V55, P5531; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Groth A, 2000, J BIOL CHEM, V275, P27473; Herlyn M, 1996, AM J PATHOL, V149, P739; HERMAN JG, 1995, CANCER RES, V55, P4525; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N	29	70	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5055	5059		10.1038/sj.onc.1206809	http://dx.doi.org/10.1038/sj.onc.1206809			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902988				2022-12-25	WOS:000184578900013
J	Higuchi, E; Chandraratna, RAS; Hong, WK; Lotan, R				Higuchi, E; Chandraratna, RAS; Hong, WK; Lotan, R			Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype	ONCOGENE			English	Article						ALL-trans retinoic acid; tazarotene-induced gene 3; head and neck cancer; lung cancer	RECEPTOR-SELECTIVE RETINOIDS; INDUCIBLE GENE; RAS MUTATIONS; CANCER CELLS; EXPRESSION; DIFFERENTIATION; CLONING; GROWTH; ALPHA; BETA	Retinoids can regulate the proliferation and differentiation of various tumor cells. It is thought that nuclear retinoid receptors mediate these effects by regulating gene transcription. The identity of specific retinoid target genes is only beginning to be unraveled. One candidate for mediating retinoid-induced growth suppression is the novel class II tumor suppressor gene tazarotene-induced gene 3 (TIG3). We examined the constitutive and all-trans retinoic acid (ATRA)-inducible expression of TIG3 mRNA in five head and neck squamous cell carcinoma (HNSCC) and five nonsmall cell lung carcinoma (NSCLC) cell tines to determine whether it is associated with their responsiveness to ATRA. The expression patterns of retinoic acid receptor beta (RARbeta), another putative retinoid-inducible tumor suppressor gene, were also examined. The constitutive TIG3 expression was high in one HNSCC cell line and two NSCLC cell tines, and moderate to very low in the other cells. Some RARbeta-expressing cells had either low or undetectable TIG3 levels and vice versa. ATRA (1 mum; 48 h) increased TIG3 mRNA in 4/5 HNSCCs and 3/5 NSCLCs and RARbeta mRNA in some of the same cell lines, but also in cells that did not show TIG3 induction. TIG3 mRNA was induced by ATRA between 6 and 12 h in most of the responsive cells. ATRA concentrations required for TIG3 induction ranged from 1 to 500 nM depending on the cell line. The pan-RAR antagonists AGN193109 and the RARalpha antagonist Ro 41-5253 blocked TIG3 induction by ATRA. ATRA suppressed anchorage-independent colony formation in most cells that had a high or moderate constitutive or induced TIG3 expression level. In contrast, RARbeta mRNA expression pattern was not correlated with sensitivity to ATRA. These results suggest that TIG3 is regulated by ATRA via retinoid receptors in certain aerodigestive tract cancer cells, and its induction by ATRA is associated with the suppression of anchorage-independent growth.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Allergan Pharmaceut Inc, Irvine, CA 92623 USA	University of Texas System; UTMD Anderson Cancer Center; AbbVie; Allergan	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA16672, P01 CA52051, U19 CA68437] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA068437, P30CA016672, P01CA052051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; AOUDJIT F, 1995, CELL GROWTH DIFFER, V6, P515; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Casanova B, 2001, LEUKEMIA, V15, P1521, DOI 10.1038/sj.leu.2402243; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Deucher A, 2000, INT J ONCOL, V17, P1195; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Dressler D, 2002, INT J ONCOL, V20, P897; Duvic M, 2000, CLIN CANCER RES, V6, P3249; Gudas Lorraine J., 1994, P443; HAJNAL A, 1994, ONCOGENE, V9, P479; Hong Waun Ki, 1994, P597; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Huang SL, 2002, ANTICANCER RES, V22, P799; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Mangelsdorf David J., 1994, P319; Mao M, 1996, P NATL ACAD SCI USA, V93, P5910, DOI 10.1073/pnas.93.12.5910; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moon Richard C., 1994, P573; MORONI MC, 1993, MECH DEVELOP, V44, P139, DOI 10.1016/0925-4773(93)90063-4; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; Oridate N, 1996, ONCOGENE, V12, P2019; Oridate N, 1996, IN VITRO CELL DEV-AN, V32, P192; REISS M, 1992, ONCOL RES, V4, P349; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Sun SY, 1997, CANCER RES, V57, P4931; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942; Wan HS, 2001, CANCER RES, V61, P556; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	40	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4627	4635		10.1038/sj.onc.1206235	http://dx.doi.org/10.1038/sj.onc.1206235			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879006				2022-12-25	WOS:000184157000002
J	Nienhaus, K; Deng, PC; Olson, JS; Warren, JJ; Nienhaus, GU				Nienhaus, K; Deng, PC; Olson, JS; Warren, JJ; Nienhaus, GU			Structural dynamics of myoglobin - Ligand migration and binding in valine 68 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; DISTAL POCKET POLARITY; CARBON-MONOXIDE; HEME-PROTEINS; CRYSTAL-STRUCTURES; CONFORMATIONAL RELAXATION; VIBRATIONAL FREQUENCIES; DERIVATIVE SPECTROSCOPY; GEMINATE RECOMBINATION	We have combined Fourier transform infrared/temperature derivative (FTIR-TDS) spectroscopy at cryogenic temperatures and flash photolysis at ambient temperature to examine the effects of polar and bulky amino acid replacements of the highly conserved distal valine 68 in sperm whale myoglobin. In FTIR-TDS experiments, the CO ligand can serve as an internal voltmeter that monitors the local electrostatic field not only at the active site but also at intermediate ligand docking sites. Mutations of residue 68 alter size, shape, and electric field of the distal pocket, especially in the vicinity of the primary docking site ( state B). As a consequence, the infrared bands associated with the ligand at site B are shifted. The effect is most pronounced in mutants with large aromatic side chains. Polar side chains ( threonine or serine) have only little effect on the peak frequencies. Ligands that migrate toward more remote sites C and D give rise to IR bands with altered frequencies. TDS experiments separate the photoproducts according to their recombination temperatures. The rates and extent of ligand migration among internal cavities at cryogenic temperatures can be used to interpret geminate and bimolecular O-2 and CO recombination at room temperature. The kinetics of geminate recombination can be explained by steric arguments alone, whereas both the polarity and size of the position 68 side chain play major roles in regulating bimolecular ligand binding from the solvent.	Univ Ulm, Dept Biophys, D-89081 Ulm, Germany; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	Ulm University; Rice University; University of Illinois System; University of Illinois Urbana-Champaign	Nienhaus, GU (corresponding author), Univ Ulm, Dept Biophys, Albert Einstein Allee 11, D-89081 Ulm, Germany.		Nienhaus, Gerd Ulrich/G-8698-2012	Nienhaus, Gerd Ulrich/0000-0002-5027-3192; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BERENDZEN J, 1990, P NATL ACAD SCI USA, V87, P1, DOI 10.1073/pnas.87.1.1; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BRUNORI M, 1972, P NATL ACAD SCI USA, V69, P868, DOI 10.1073/pnas.69.4.868; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CAUGHEY WS, 1970, ANN NY ACAD SCI, V174, P148, DOI 10.1111/j.1749-6632.1970.tb49781.x; Christian JF, 1997, BIOCHEMISTRY-US, V36, P11198, DOI 10.1021/bi9710075; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; Dantsker D, 2002, J MOL BIOL, V315, P239, DOI 10.1006/jmbi.2001.5218; Dou Y, 2002, BIOPHYS CHEM, V98, P127, DOI 10.1016/S0301-4622(02)00090-X; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; Franzen S, 2002, J AM CHEM SOC, V124, P13271, DOI 10.1021/ja017708d; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; FRONTICELLI C, 1993, BIOCHEMISTRY-US, V32, P1235, DOI 10.1021/bi00056a006; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HONG MK, 1990, BIOPHYS J, V58, P429, DOI 10.1016/S0006-3495(90)82388-2; Ishikawa H, 2001, BIOPHYS J, V80, P1507, DOI 10.1016/S0006-3495(01)76123-1; Johnson JB, 1996, BIOPHYS J, V71, P1563, DOI 10.1016/S0006-3495(96)79359-1; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; Kriegl JM, 2003, P NATL ACAD SCI USA, V100, P7069, DOI 10.1073/pnas.1231856100; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; MILLER LM, 1996, J AM CHEM SOC, V34, P10170; MOURANT JR, 1993, BIOPHYS J, V65, P1496, DOI 10.1016/S0006-3495(93)81218-9; Muller JD, 1999, BIOPHYS J, V77, P1036, DOI 10.1016/S0006-3495(99)76954-7; NIENHAUS GU, 1992, P NATL ACAD SCI USA, V89, P2902, DOI 10.1073/pnas.89.7.2902; NIENHAUS GU, 1994, BIOCHEMISTRY-US, V33, P13413, DOI 10.1021/bi00249a030; Nienhaus GU, 2002, J BIOL PHYS, V28, P163, DOI 10.1023/A:1019990522433; Nienhaus GU, 1998, BIOCHEMISTRY-US, V37, P6819, DOI 10.1021/bi972843h; NIENHAUS GU, 1996, PROTEIN DYNAMICS, P163; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9633, DOI 10.1021/bi034787s; Nienhaus K, 2002, BIOPHYS J, V82, P1059, DOI 10.1016/S0006-3495(02)75465-9; NIENHAUS K, 2003, SPECTROSCOPIC STUDIE; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Park ES, 1999, J PHYS CHEM B, V103, P9813, DOI 10.1021/jp992329g; Park ES, 2002, J PHYS CHEM B, V106, P5800, DOI 10.1021/jp0203043; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; Pechik I, 1996, BIOCHEMISTRY-US, V35, P1935, DOI 10.1021/bi9519967; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; POWERS L, 1987, BIOCHEMISTRY-US, V26, P4785, DOI 10.1021/bi00389a028; POWERS LS, 1988, BIOPHYS J, V54, P181, DOI 10.1016/S0006-3495(88)82943-6; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPIRO TG, 1995, SCIENCE, V270, P221; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P4886, DOI 10.1021/bi00234a008; Sugimoto T, 1998, BIOPHYS J, V75, P2188, DOI 10.1016/S0006-3495(98)77662-3; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; Ye X, 2002, J AM CHEM SOC, V124, P5914, DOI 10.1021/ja017359n	78	65	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42532	42544		10.1074/jbc.M306888200	http://dx.doi.org/10.1074/jbc.M306888200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907676	hybrid			2022-12-25	WOS:000185989500118
J	Linseman, DA; Bartley, CM; Le, SS; Laessig, TA; Bouchard, RJ; Meintzer, MK; Li, MT; Heidenreich, KA				Linseman, DA; Bartley, CM; Le, SS; Laessig, TA; Bouchard, RJ; Meintzer, MK; Li, MT; Heidenreich, KA			Inactivation of the myocyte enhancer factor-2 repressor histone deacetylase-5 by endogenous Ca2+/calmodulin-dependent kinase II promotes depolarization-mediated cerebellar granule neuron survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MEF2 TRANSCRIPTION FACTOR; CULTURED HIPPOCAMPAL-NEURONS; INDUCED NEURITE-OUTGROWTH; CENTRAL-NERVOUS-SYSTEM; FACTOR 2C EXPRESSION; MUSCLE FIBER-TYPE; GROWTH-FACTOR-I; CARDIAC-HYPERTROPHY; BRAIN-DEVELOPMENT	Cerebellar granule neuron (CGN) survival depends on activity of the myocyte enhancer factor-2 (MEF2) transcription factors. Neuronal MEF2 activity is regulated by depolarization via a mechanism that is presently unclear. Here, we show that depolarization-mediated MEF2 activity and CGN survival are compromised by overexpression of the MEF2 repressor histone deacetylase-5 (HDAC5). Furthermore, removal of depolarization induced rapid cytoplasm-to-nuclear translocation of endogenous HDAC5. This effect was mimicked by addition of the calcium/calmodulin-dependent kinase ( CaMK) inhibitor KN93 to depolarizing medium. Removal of depolarization or KN93 addition resulted in dephosphorylation of HDAC5 and its co-precipitation with MEF2D. HDAC5 nuclear translocation triggered by KN93 induced a marked loss of MEF2 activity and subsequent apoptosis. To selectively decrease CaMKII, CGNs were incubated with an antisense oligonucleotide to CaMKIIalpha. This antisense decreased CaMKIIalpha expression and induced nuclear shuttling of HDAC5 in CGNs maintained in depolarizing medium. Selectivity of the CaMKIIalpha antisense was demonstrated by its lack of effect on CaMKIV-mediated CREB phosphorylation. Finally, antisense to CaMKIIalpha induced caspase-3 activation and apoptosis, whereas a missense control oligonucleotide had no effect on CGN survival. These results indicate that depolarization-mediated calcium influx acts through CaMKII to inhibit HDAC5, thereby sustaining high MEF2 activity in CGNs maintained under depolarizing conditions.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Heidenreich, KA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol C236, 4200 E 9th Ave, Denver, CO 80262 USA.		Linseman, Daniel/L-3846-2019; Bartley, Christopher/G-4226-2012	Bartley, Christopher/0000-0002-1391-4130	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007205] Funding Source: Medline; NINDS NIH HHS [NS38619-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babcock AM, 1999, J NEUROSCI RES, V56, P36, DOI 10.1002/(SICI)1097-4547(19990401)56:1<36::AID-JNR5>3.0.CO;2-4; Babcock AM, 2002, J NEUROSCI RES, V67, P804, DOI 10.1002/jnr.10169; BEAMANHALL CM, 1992, J NEUROCHEM, V58, P1259, DOI 10.1111/j.1471-4159.1992.tb11337.x; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Borodinsky LN, 2002, J NEUROCHEM, V80, P1062, DOI 10.1046/j.1471-4159.2002.00795.x; Borodinsky LN, 2003, J NEUROCHEM, V84, P1411, DOI 10.1046/j.1471-4159.2003.01638.x; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BURGIN KE, 1990, J NEUROSCI, V10, P1788; Chawla S, 2003, J NEUROCHEM, V85, P151, DOI 10.1046/j.1471-4159.2003.01648.x; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Churn SB, 2000, P NATL ACAD SCI USA, V97, P5604, DOI 10.1073/pnas.080071697; CHURN SB, 1995, J NEUROSCI, V15, P3200; Condon JC, 2002, ENDOCRINOLOGY, V143, P3651, DOI 10.1210/en.2001-211359; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kato T, 2000, CIRC RES, V87, P937, DOI 10.1161/01.RES.87.10.937; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; Leifer D, 1997, J MOL NEUROSCI, V8, P131, DOI 10.1007/BF02736778; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Linseman DA, 2002, J NEUROSCI, V22, P9287; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; SHACKELFORD DA, 1995, J CEREBR BLOOD F MET, V15, P450, DOI 10.1038/jcbfm.1995.56; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	59	104	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41472	41481		10.1074/jbc.M307245200	http://dx.doi.org/10.1074/jbc.M307245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896970	hybrid			2022-12-25	WOS:000185847200127
J	Okuno, T; Ago, H; Terawaki, K; Miyano, M; Shimizu, T; Yokomizo, T				Okuno, T; Ago, H; Terawaki, K; Miyano, M; Shimizu, T; Yokomizo, T			Helix 8 of the leukotriene B-4 receptor is required for the conformational change to the low affinity state after G-protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT CHANGES; COUPLED RECEPTOR; CYTOPLASMIC TAIL; C-TERMINUS; PHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; GABA(B) RECEPTORS; RHODOPSIN; KINASE; DESENSITIZATION	Recent studies have revealed that G-protein-coupled receptors contain a putative cytoplasmic helical domain, helix 8. Leukotriene B-4 (LTB4) receptor 1 derivatives with truncated or mutated helix 8 showed much higher LTB4 binding than wild-type (WT) receptors. Similar to the WT receptor, LTB4 promoted guanosine 5'-3-O-(thio) triphosphate (GTPgammaS) binding in these mutants. Unlike the WT receptor, however, the addition of GTPgammaS did not inhibit LTB4 binding to the mutant receptors. Scatchard analyses revealed that mutants maintained high affinity for LTB4, even in the presence of excess GTPgammaS. Consistently, mutant receptors showed a more prolonged Ca2+ mobilization and cellular metabolic activation than the WT receptor. From mutational studies and three-dimensional modeling based on the structure of bovine rhodopsin, we conclude that the helix 8 of LTB4 receptor 1 plays an important role in the conformational change of the receptor to the low affinity state after G-protein activation, possibly by sensing the status of coupling Galpha subunits as GTP-bound.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, PRESTO, CREST, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Harima Inst SPring 8, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan	University of Tokyo; Japan Science & Technology Agency (JST); RIKEN	Yokomizo, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Miyano, Masashi/R-2785-2016; Shimizu, Takao/AAV-7052-2021; Yokomizo, Takehiko/P-5673-2016	Miyano, Masashi/0000-0003-2253-6175; Yokomizo, Takehiko/0000-0002-5219-1553; Ago, Hideo/0000-0002-9040-488X				Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bohm SK, 1997, BIOCHEM J, V322, P1; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen ZG, 2002, J BIOL CHEM, V277, P7356, DOI 10.1074/jbc.M110058200; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; DRYDEN P, 1992, PROSTAGLANDINS, V44, P11, DOI 10.1016/0090-6980(92)90103-Z; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gaudreau R, 2002, J BIOL CHEM, V277, P31567, DOI 10.1074/jbc.M202723200; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Masuda K, 1999, BIOCHEM J, V342, P79, DOI 10.1042/0264-6021:3420079; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Moepps Barbara, 2003, EMBO Reports, V4, P237, DOI 10.1038/sj.embor.embor777; OFLAHERTY JT, 1986, FEBS LETT, V206, P279, DOI 10.1016/0014-5793(86)80996-6; Ohshima N, 2002, J BIOL CHEM, V277, P9722, DOI 10.1074/jbc.M112406200; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Pagano A, 2001, J NEUROSCI, V21, P1189; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Sambrook J., 2001, MOL CLONING; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SHOWELL HJ, 1982, J IMMUNOL, V128, P811; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Tager AM, 2000, J EXP MED, V192, P439, DOI 10.1084/jem.192.3.439; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Toda A, 1999, BIOCHEM BIOPH RES CO, V262, P806, DOI 10.1006/bbrc.1999.1284; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yokomizo T, 2000, AM J RESP CRIT CARE, V161, pS51, DOI 10.1164/ajrccm.161.supplement_1.ltta-11; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	54	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41500	41509		10.1074/jbc.M307335200	http://dx.doi.org/10.1074/jbc.M307335200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902330	hybrid			2022-12-25	WOS:000185847200130
J	Tuli, R; Tuli, S; Nandi, S; Huang, XX; Manner, PA; Hozack, WJ; Danielson, KG; Hall, DJ; Tuan, RS				Tuli, R; Tuli, S; Nandi, S; Huang, XX; Manner, PA; Hozack, WJ; Danielson, KG; Hall, DJ; Tuan, RS			Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogenactivated protein kinase and Wnt signaling cross-talk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRABECULAR BONE; HUMAN ADIPOSE-TISSUE; CHICK LIMB BUD; STEM-CELLS; IN-VITRO; MORPHOGENETIC PROTEIN-2; GENE-EXPRESSION; ATDC5 CELLS; DIFFERENTIATION; MARROW	The multilineage differentiation potential of adult tissue-derived mesenchymal progenitor cells (MPCs), such as those from bone marrow and trabecular bone, makes them a useful model to investigate mechanisms regulating tissue development and regeneration, such as cartilage. Treatment with transforming growth factor-beta( TGF-beta) superfamily members is a key requirement for the in vitro chondrogenic differentiation of MPCs. Intracellular signaling cascades, particularly those involving the mitogen-activated protein ( MAP) kinases, p38, ERK-1, and JNK, have been shown to be activated by TGF-betas in promoting cartilage-specific gene expression. MPC chondrogenesis in vitro also requires high cell seeding density, reminiscent of the cellular condensation requirements for embryonic mesenchymal chondrogenesis, suggesting common chondro-regulatory mechanisms. Prompted by recent findings of the crucial role of the cell adhesion protein, N-cadherin, and Wnt signaling in condensation and chondrogenesis, we have examined here their involvement, as well as MAP kinase signaling, in TGF-beta1-induced chondrogenesis of trabecular bone-derived MPCs. Our results showed that TGF-beta1 treatment initiates and maintains chondrogenesis of MPCs through the differential chondro-stimulatory activities of p38, ERK-1, and to a lesser extent, JNK. This regulation of MPC chondrogenic differentiation by the MAP kinases involves the modulation of N-cadherin expression levels, thereby likely controlling condensation-like cell-cell interaction and progression to chondrogenic differentiation, by the sequential up-regulation and progressive down-regulation of N-cadherin. TGF-beta1-mediated MAP kinase activation also controls WNT-7A gene expression and Wnt-mediated signaling through the intracellular beta-catenin-TCF pathway, which likely regulates N-cadherin expression and subsequent N-cadherin-mediated cell-adhesion complexes during the early steps of MPC chondrogenesis.	NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; George Washington Univ, Dept Orthopaed Surg, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Jefferson University; George Washington University	Tuan, RS (corresponding author), NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Dept Hlth & Human Serv, Bldg 50,Rm 1503,50 South Dr,MSC 8022, Bethesda, MD 20892 USA.	Tuanr@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041141, ZIAAR041131, Z01AR041141, Z01AR041131] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi N, 2002, J RHEUMATOL, V29, P1920; ANTONIO JDS, 1986, DEV BIOL, V115, P313, DOI 10.1016/0012-1606(86)90252-6; Barry F, 2001, EXP CELL RES, V268, P189, DOI 10.1006/excr.2001.5278; Behrens J, 2000, J CELL SCI, V113, P911; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Bosch P, 2000, J ORTHOP RES, V18, P933, DOI 10.1002/jor.1100180613; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429; Caterson E, 2002, MOL BIOTECHNOL, V20, P245, DOI 10.1385/MB:20:3:245; De Bari C, 2001, ARTHRITIS RHEUM, V44, P85, DOI 10.1002/1529-0131(200101)44:1<85::AID-ANR12>3.0.CO;2-6; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; DeLise AM, 2002, J CELL BIOCHEM, V87, P342, DOI 10.1002/jcb.10308; Delise AM, 2002, DEV DYNAM, V225, P195, DOI 10.1002/dvdy.10151; Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432-0436.1999.6420067.x; Fischer L, 2002, J CELL BIOCHEM, V84, P816, DOI 10.1002/jcb.10091; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138; Haas AR, 1999, DIFFERENTIATION, V64, P77, DOI 10.1046/j.1432-0436.1999.6420077.x; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Horner A, 1998, BONE, V23, P95, DOI 10.1016/S8756-3282(98)00080-5; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; Majumdar MK, 2001, J CELL PHYSIOL, V189, P275, DOI 10.1002/jcp.10025; NAKAHARA H, 1991, J ORTHOP RES, V9, P465, DOI 10.1002/jor.1100090402; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Noth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736-0266(02)00018-9; OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Osyczka AM, 2002, ANN NY ACAD SCI, V961, P73, DOI 10.1111/j.1749-6632.2002.tb03054.x; Osyczka AM, 2002, CALCIFIED TISSUE INT, V71, P447, DOI 10.1007/s00223-001-1090-2; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; Sekiya I, 2001, BIOCHEM BIOPH RES CO, V284, P411, DOI 10.1006/bbrc.2001.4898; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Stott NS, 1999, J CELL PHYSIOL, V180, P314, DOI 10.1002/(SICI)1097-4652(199909)180:3<314::AID-JCP2>3.3.CO;2-P; Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614; Tufan AC, 2002, EXP CELL RES, V273, P197, DOI 10.1006/excr.2001.5448; Tufan AC, 2001, FASEB J, V15, P1436, DOI 10.1096/fj.00-0784fje; Tuli R, 2003, MOL BIOTECHNOL, V23, P37, DOI 10.1385/MB:23:1:37; Tuli R, 2002, ANN NY ACAD SCI, V961, P172, DOI 10.1111/j.1749-6632.2002.tb03077.x; Wada MR, 2002, DEVELOPMENT, V129, P2987; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	54	374	406	0	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41227	41236		10.1074/jbc.M305312200	http://dx.doi.org/10.1074/jbc.M305312200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893825	hybrid			2022-12-25	WOS:000185847200101
J	van der Slot, AJ; Zuurmond, AM; Bardoel, AFJ; Wijmenga, C; Pruijs, HEH; Sillence, DO; Brinckmann, J; Abraham, DJ; Black, CM; Verzijl, N; DeGroot, J; Hanemaaijer, R; TeKoppele, JM; Huizinga, TWJ; Bank, RA				van der Slot, AJ; Zuurmond, AM; Bardoel, AFJ; Wijmenga, C; Pruijs, HEH; Sillence, DO; Brinckmann, J; Abraham, DJ; Black, CM; Verzijl, N; DeGroot, J; Hanemaaijer, R; TeKoppele, JM; Huizinga, TWJ; Bank, RA			Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; SYNDROME TYPE-VI; CONGENITAL JOINT CONTRACTURES; COLLAGEN CROSS-LINKING; BRUCK-SYNDROME; POSTTRANSLATIONAL MODIFICATIONS; OSTEOGENESIS IMPERFECTA; FIBROTIC COLLAGEN; GENE PLOD; PYRIDINOLINE	The hallmark of fibrotic processes is an excessive accumulation of collagen. The deposited collagen shows an increase in pyridinoline cross-links, which are derived from hydroxylated lysine residues within the telopeptides. This change in cross-linking is related to irreversible accumulation of collagen in fibrotic tissues. The increase in pyridinoline cross-links is likely to be the result of increased activity of the enzyme responsible for the hydroxylation of the telopeptides ( telopeptide lysyl hydroxylase, or TLH). Although the existence of TLH has been postulated, the gene encoding TLH has not been identified. By analyzing the genetic defect of Bruck syndrome, which is characterized by a pyridinoline deficiency in bone collagen, we found two missense mutations in exon 17 of PLOD2, thereby identifying PLOD2 as a putative TLH gene. Subsequently, we investigated fibroblasts derived from fibrotic skin of systemic sclerosis (SSc) patients and found that PLOD2 mRNA is highly increased indeed. Furthermore, increased pyridinoline cross-link levels were found in the matrix deposited by SSc fibroblasts, demonstrating a clear link between mRNA levels of the putative TLH gene ( PLOD2) and the hydroxylation of lysine residues within the telopeptides. These data underscore the significance of PLOD2 in fibrotic processes.	TNO Prevent & Hlth, Div Biomed Res, Dept Tissue Repair, NL-2301 CE Leiden, Netherlands; Univ Med Ctr Utrecht, Dept Med Genet, NL-3584 EA Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Pediat Orthoped, NL-3501 CA Utrecht, Netherlands; Childrens Hosp, Dept Pediat & Child Hlth, Westmead, NSW 2145, Australia; Univ Lubeck, Dept Dermatol, D-235552 Lubeck, Germany; UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, London NW3 2PF, England; Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands	Netherlands Organization Applied Science Research; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Sydney; University of Lubeck; University of London; University College London; UCL Medical School; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bank, RA (corresponding author), TNO Prevent & Hlth, Div Biomed Res, Dept Tissue Repair, POB 2215, NL-2301 CE Leiden, Netherlands.	RA.Bank@pg.tno.nl	Wijmenga, Cisca/D-2173-2009; Wijmenga, Cisca/AAE-7719-2019; DeGroot, Jeroen/C-4585-2012	Wijmenga, Cisca/0000-0002-5635-1614; 				BAILEY AJ, 1985, CIBA F SYMP, V114, P80; BAILEY AJ, 1975, BIOCHIM BIOPHYS ACTA, V405, P412, DOI 10.1016/0005-2795(75)90106-3; Bank RA, 1997, J CHROMATOGR B, V703, P37, DOI 10.1016/S0378-4347(97)00391-5; Bank RA, 1999, P NATL ACAD SCI USA, V96, P1054, DOI 10.1073/pnas.96.3.1054; Bilezikian, 1999, DYNAMICS BONE CARTIL, P3; BRENNER RE, 1993, EUR J PEDIATR, V152, P505, DOI 10.1007/BF01955060; Breslau-Siderius EJ, 1998, J PEDIATR ORTHOP B, V7, P35, DOI 10.1097/01202412-199801000-00006; Brinckmann J, 2001, J INVEST DERMATOL, V117, P269, DOI 10.1046/j.0022-202x.2001.01414.x; Brinckmann J, 1999, J INVEST DERMATOL, V113, P617, DOI 10.1046/j.1523-1747.1999.00735.x; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HEIKKINEN J, 1994, GENOMICS, V24, P464, DOI 10.1006/geno.1994.1654; Heikkinen J, 1997, AM J HUM GENET, V60, P48; HERBAGE D, 1985, FRONT MATRIX BIOL, V10, P59; Istok R, 2001, CLIN EXP DERMATOL, V26, P545, DOI 10.1046/j.1365-2230.2001.00886.x; LAST JA, 1990, AM REV RESPIR DIS, V141, P307, DOI 10.1164/ajrccm/141.2.307; LEROY EC, 1974, J CLIN INVEST, V54, P880, DOI 10.1172/JCI107827; Leroy JG, 1998, PEDIATR RADIOL, V28, P781, DOI 10.1007/s002470050465; McPherson E, 1997, AM J MED GENET, V70, P28, DOI 10.1002/(SICI)1096-8628(19970502)70:1<28::AID-AJMG6>3.3.CO;2-N; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; PELTONEN L, 1985, J INVEST DERMATOL, V84, P14, DOI 10.1111/1523-1747.ep12274596; Rautavuoma K, 2000, MATRIX BIOL, V19, P73, DOI 10.1016/S0945-053X(99)00058-X; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; RICARDBLUM S, 1993, CELL MOL BIOL, V39, P723; RICARDBLUM S, 1992, HEPATOLOGY, V15, P599, DOI 10.1002/hep.1840150408; Robins S P, 1982, Methods Biochem Anal, V28, P329, DOI 10.1002/9780470110485.ch8; Robins SP, 1996, CLIN CHEM, V42, P1621; ROBINS SP, 1999, DYNAMICS BONE CARTIL, P31; STEINMANN B, 1995, AM J HUM GENET, V57, P1505; Szpirer C, 1997, MAMM GENOME, V8, P707, DOI 10.1007/s003359900549; Uzawa K, 1998, BIOCHEM BIOPH RES CO, V249, P652, DOI 10.1006/bbrc.1998.8955; Uzawa K, 1999, J BONE MINER RES, V14, P1272, DOI 10.1359/jbmr.1999.14.8.1272; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X; Yeowell HN, 1997, P ASSOC AM PHYSICIAN, V109, P383; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	38	278	288	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40967	40972		10.1074/jbc.M307380200	http://dx.doi.org/10.1074/jbc.M307380200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12881513	Green Published, hybrid			2022-12-25	WOS:000185847200069
J	Yu, SSF; Wu, LY; Chen, KHC; Luo, WI; Huang, DS; Chan, SI				Yu, SSF; Wu, LY; Chen, KHC; Luo, WI; Huang, DS; Chan, SI			The stereospecific hydroxylation of [2,2-H-2(2)]butane and chiral dideuteriobutanes by the particulate methane monooxygenase from Methylococcus capsulatus (bath)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXYGEN ACTIVATION; COPPER IONS; OXIDATION; CATALYSTS; MECHANISM; ALCOHOLS; ENZYMES; SYSTEM	Experiments on cryptically chiral ethanes have indicated that the particulate methane monooxygenase ( pMMO) from Methylococcus capsulatus ( Bath) catalyzes the hydroxylation of ethane with total retention of configuration at the carbon center attacked. This result would seem to rule out a radical mechanism for the hydroxylation chemistry, at least as mediated by this enzyme. The interpretation of subsequent experiments on n-propane, n-butane, and n-pentane has been complicated by hydroxylation at both the pro-R and pro-S secondary C - H bonds, where the hydroxylation takes place. It has been suggested that these results merely reflect presentation of both the pro-R and pro-S C - H bonds to the hot "oxygen atom" species generated at the active site, and that the oxo-transfer chemistry, in fact, proceeds concertedly with retention of configuration. In the present work, we have augmented these earlier studies with experiments on [2,2-H-2(2)] butane and designed d,l form chiral dideuteriobutanes. Essentially equal amounts of (2R)-[3,3-H-2(2)] butan-2-ol and (2R)-[2-H-2(1)] butan-2-ol are produced upon hydroxylation of [2,2(2)H(2)] butane. The chemistry is stereospecific with full retention of configuration at the secondary carbon oxidized. In the case of the various chiral deuterated butanes, the extent of configurational inversion has been shown to be negligible for all the chiral butanes examined. Thus, the hydroxylation of butane takes place with full retention of configuration in butane as well as in the case of ethane. These results are interpreted in terms of an oxo-transfer mechanism based on side-on singlet oxene insertion across the C - H bond similar to that previously noted for singlet carbene insertion (Kirmse, W., and Ozkir, I. S. ( 1992) J. Am. Chem. Soc. 114, 7590 - 7591). Finally, we discuss how even the oxene insertion mechanism, with "spin crossover" in the transition state, could lead to small amounts of radical rearrangement products, if and when such products are observed. A scheme is described that unifies the two extreme mechanistic limits, namely the concerted oxene insertion and the hydrogen abstraction radical rebound mechanism within the same over-arching framework.	Acad Sinica, Inst Chem, Taipei 115, Taiwan; Natl Cheng Kung Univ, Dept Chem, Tainan 701, Taiwan	Academia Sinica - Taiwan; National Cheng Kung University	Chan, SI (corresponding author), Acad Sinica, Inst Chem, Taipei 115, Taiwan.	chans@chem.sinica.edu.tw	Yu, Steve Sheng-Fa/E-4866-2015	Yu, Steve Sheng-Fa/0000-0002-3462-065X				Baik MH, 2003, CHEM REV, V103, P2385, DOI 10.1021/cr950244f; Choi SY, 1996, J AM CHEM SOC, V118, P6547, DOI 10.1021/ja952226l; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; de Visser SP, 2001, ANGEW CHEM INT EDIT, V40, P2871, DOI 10.1002/1521-3773(20010803)40:15<2871::AID-ANIE2871>3.0.CO;2-R; Elliott SJ, 1997, J AM CHEM SOC, V119, P9949, DOI 10.1021/ja971049g; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; FORLANI O, 1992, MATER CHEM PHYS, V31, P155, DOI 10.1016/0254-0584(92)90169-9; GETZ E, 1987, J AM CHEM SOC, V109, P8109; HELMKAMP GK, 1957, J ORG CHEM, V22, P479, DOI 10.1021/jo01356a001; Huang DS, 2002, CHEMBIOCHEM, V3, P760, DOI 10.1002/1439-7633(20020802)3:8<760::AID-CBIC760>3.0.CO;2-K; KIRMSE W, 1992, J AM CHEM SOC, V114, P7590, DOI 10.1021/ja00045a057; KRISHNAMURTHY S, 1976, J ORG CHEM, V41, P3064, DOI 10.1021/jo00880a045; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; MAITRA AM, 1993, APPL CATAL A-GEN, V104, P11, DOI 10.1016/0926-860X(93)80209-9; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; Newcomb M, 2002, J AM CHEM SOC, V124, P6879, DOI 10.1021/ja017858o; Nguyen HHAT, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P150; Nguyen HHT, 1998, J BIOL CHEM, V273, P7957, DOI 10.1074/jbc.273.14.7957; NGUYEN HHT, 1994, J BIOL CHEM, V269, P14995; Nguyen HHT, 1996, J AM CHEM SOC, V118, P12766, DOI 10.1021/ja961778g; OLAH GA, 1987, ACCOUNTS CHEM RES, V20, P422, DOI 10.1021/ar00143a006; PARKER D, 1983, J CHEM SOC PERK T 2, P83, DOI 10.1039/p29830000083; Periana RA, 1998, SCIENCE, V280, P560, DOI 10.1126/science.280.5363.560; PERIANA RA, 1993, SCIENCE, V259, P340, DOI 10.1126/science.259.5093.340; PRIESTLEY ND, 1992, J AM CHEM SOC, V114, P7561, DOI 10.1021/ja00045a037; RAJA R, 1997, APPL CATAL A-GEN, V158, P7; Valentine AM, 1997, J AM CHEM SOC, V119, P1818, DOI 10.1021/ja963971g; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Wilkinson B, 1996, J AM CHEM SOC, V118, P921, DOI 10.1021/ja953407q; Wolf D, 1998, ANGEW CHEM INT EDIT, V37, P3351, DOI 10.1002/(SICI)1521-3773(19981231)37:24<3351::AID-ANIE3351>3.0.CO;2-U; YU SSF, 2003, IN PRESS J BACTERIOL, V185	32	36	37	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40658	40669		10.1074/jbc.M301018200	http://dx.doi.org/10.1074/jbc.M301018200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909646	hybrid			2022-12-25	WOS:000185847200030
J	He, JQ; Xu, HG; Xu, XX; Hall, RA				He, JQ; Xu, HG; Xu, XX; Hall, RA			Cell cycle-dependent phosphorylation of Disabled-2 by cdc2	ONCOGENE			English	Article						tumor suppressor; cdk; receptor; cancer; kinase; phosphatase	EPITHELIAL OVARIAN-CANCER; TUMOR-SUPPRESSOR GENE; PROTEIN-PHOSPHORYLATION; BINDING PARTNER; PROSTATE-CANCER; OKADAIC ACID; MYOSIN-VI; DOC-2/DAB2; KINASE; MOUSE	Disabled-2 (Dab2; also known as p96 and DOC-2) is a signal transduction protein that has been implicated in the control of cell growth. Dab2 is known to be a phosphoprotein, but little is known about the kinases that phosphorylate Dab2. We have found that Dab2 phosphorylation is markedly increased during the mitosis phase of the cell cycle. This phosphorylation is blocked by roscovitine, a selective inhibitor of cyclin-dependent kinases. Dab2 robustly coimmunoprecipitates from cells with the cyclin-dependent kinase cdc2, and purified cdc2 can phosphorylate purified Dab2 fusion proteins in vitro on multiple sites. Cellular phosphorylation of Dab2 by cdc2 promotes the association of Dab2 with Pir1 a peptidylprolyl isomerase that regulates the rate of Dab2 dephosphorylation. These findings reveal that Dab2 is differentially phosphorylated during the cell cycle by cdc2 and provide a potential feedback mechanism by which Dab2 inhibition of cell growth and proliferation may be regulated.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Fox Chase Canc Ctr, Ovarian Canc Program, Div Med Sci, Philadelphia, PA 19111 USA	Emory University; Fox Chase Cancer Center	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5113 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.			Hall, Randy/0000-0002-8318-8728	NCI NIH HHS [R01-CA-75389, R01-CA-79716] Funding Source: Medline; NHLBI NIH HHS [R01-HL-64713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079716, R01CA075389] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Inoue A, 2002, BIOCHEM BIOPH RES CO, V292, P300, DOI 10.1006/bbrc.2002.6636; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; SHETTY KTV, 1995, J NEUROCHEM, V64, P2681; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; SUGANUMA M, 1990, CANCER RES, V50, P3521; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wang SC, 2001, ONCOGENE, V20, P6960, DOI 10.1038/sj.onc.1204873; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	38	31	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4524	4530		10.1038/sj.onc.1206767	http://dx.doi.org/10.1038/sj.onc.1206767			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881709				2022-12-25	WOS:000184054700008
J	Kurosu, T; Fukuda, T; Miki, T; Miura, O				Kurosu, T; Fukuda, T; Miki, T; Miura, O			BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells	ONCOGENE			English	Article						BCL6; apoptosis; chemotherapeutic reagents; reactive oxygen species; etoposide	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; TRANSCRIPTIONAL REPRESSOR; PROTOONCOGENE BCL-6; EXPRESSION; DEATH; LAZ3; DIFFERENTIATION; TRANSLOCATIONS	Chromosomal translocations and somatic mutations occurring in the 5' noncoding region of the BCL6 gene, encoding a transcriptional repressor, are most frequent genetic abnormalities associated with non-Hodgkin B-cell lymphoma and result in deregulated expression of BCL6. However, the significance of deregulated expression of BCL6 in lymphomagenesis and its effect on clinical outcomes of lymphoma patients have remained elusive. In the present study, we established Daudi and Raji B-cell lymphoma cell lines that overexpress BCL6 or its mutant, BCL6-Ala333/343, in which serine residues required for degradation through the proteasome pathway in B-cell receptor-stimulated cells are mutated. BCL6 overexpression did not have any significant effect on cell proliferation, but significantly inhibited apoptosis caused by etoposide, which induced a proteasome-dependent degradation of BCL6. BCL6-Ala333/343 was not degraded after etoposide treatment and strongly inhibited apoptosis. In these lymphoma cell lines, etoposide increased the generation of reactive oxygen species (ROS) and reduced mitochondria membrane potential, both of which were inhibited by the antioxidant N-acetyl-L-cysteine (NAC). NAC also inhibited apoptosis. Furthermore, BCL6 overexpression was found to inhibit the increase in ROS levels and apoptosis in response to etoposide and other chemotherapeutic reagents. These results raise the possibility that deregulated expression of BCL6 may endow lymphoma cells with resistance to chemotherapeutic reagents, most likely by enhancing the antioxidant defense systems.	Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.			Miura, Osamu/0000-0002-0981-3054				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Barrans SL, 2002, BRIT J HAEMATOL, V117, P322, DOI 10.1046/j.1365-2141.2002.03435.x; BASTARD C, 1994, BLOOD, V83, P2423; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chabner B.A., 2001, CANC CHEMOTHERAPY BI, V3rd; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dvorakova K, 2001, BLOOD, V97, P3544, DOI 10.1182/blood.V97.11.3544; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kojima S, 2001, DEVELOPMENT, V128, P57; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 2000, LEUKEMIA LYMPHOMA, V38, P505, DOI 10.3109/10428190009059269; Niu HF, 2002, HEMATOL ONCOL, V20, P155, DOI 10.1002/hon.689; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	39	82	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4459	4468		10.1038/sj.onc.1206755	http://dx.doi.org/10.1038/sj.onc.1206755			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881702				2022-12-25	WOS:000184054700001
J	Peng, YH; Li, CG; Chen, LH; Sebti, S; Chen, JD				Peng, YH; Li, CG; Chen, LH; Sebti, S; Chen, JD			Rescue of mutant p53 transcription function by ellipticine	ONCOGENE			English	Article						p53; ellipticine; rescue; conformation; mutant	ELLIPTINIUM ACETATE; ACTIVATION FUNCTION; MDM2; CANCER; PHASE; DNA; RESTORATION; MUTATIONS; STABILITY; DATABASE	The p53 tumor suppressor is frequently inactivated in tumors by point mutations in the DNA-binding domain, resulting in loss of sequence-specific DNA binding and transcription function. We present evidence that ellipticine can restore the transactivation function of several transfected p53 mutants (175 H, 248W, 249S, 273 H, 281G), resulting in the induction of p53-responsive genes (p21(WAF1), MDM2) and activation of a p53-responsive luciferase reporter. Ellipticine also activates mutant p53 function in tumor cells expressing endogenous 194F, 233L, 241F, and 273C mutants. Treatment with ellipticine alters mutant p53 reactivity to conformation-sensitive Pab1620 and Pab240 antibodies and increases its sequence-specific DNA-binding activity in vivo. Finally, ellipticine activates mutant p53 and induces p21(WAF1) and MDM2 expression in nude mouse tumor xenografts. These results demonstrate that ellipticine can restore transcription function to mutant p53. This property may contribute to the selectivity of ellipticine-derived compounds against tumor cell lines expressing mutant p53.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu						ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; BUZDAR AU, 1990, ONCOLOGY, V47, P101; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GOUYETTE A, 1982, EUR J CANCER CLIN ON, V18, P1285, DOI 10.1016/0277-5379(82)90130-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KATTAN J, 1994, AM J CLIN ONCOL-CANC, V17, P242, DOI 10.1097/00000421-199406000-00013; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Ohnishi T, 1999, RADIAT RES, V151, P498, DOI 10.2307/3579838; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; ROUESSE J, 1993, EUR J CANCER, V29A, P856, DOI 10.1016/S0959-8049(05)80424-1; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shi LM, 1998, MOL PHARMACOL, V53, P241, DOI 10.1124/mol.53.2.241; Soong R, 1996, HUM PATHOL, V27, P1050, DOI 10.1016/S0046-8177(96)90282-8; Sugikawa E, 2001, ANTICANCER RES, V21, P2671; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	35	119	126	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4478	4487		10.1038/sj.onc.1206777	http://dx.doi.org/10.1038/sj.onc.1206777			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881704				2022-12-25	WOS:000184054700003
J	Renou, JP; Bierie, B; Miyoshi, K; Cui, YZ; Djiane, J; Reichenstein, M; Shani, M; Hennighausen, L				Renou, JP; Bierie, B; Miyoshi, K; Cui, YZ; Djiane, J; Reichenstein, M; Shani, M; Hennighausen, L			Identification of genes differentially expressed in mouse mammary epithelium transformed by an activated beta-catenin	ONCOGENE			English	Article						mammary gland; beta-catenin; transdifferentiation; metaplasia; microarrays Mammochip	LYSOSOMAL CYSTEINE PROTEASES; CRE RECOMBINASE; DEPENDENT EXPRESSION; GLAND INVOLUTION; BREAST-CANCER; HAMSTER CELLS; CATHEPSIN-L; PROTEIN; SPECIFICITY; ADIPOCYTES	beta-Catenin is an executor of Wnt signaling and it can control cell fate and specification. Deletion of exon 3 from the endogenous beta-catenin gene in differentiating mammary alveolar epithelium of the mouse results in the generation of an activated protein that lacks amino acids 5-80. This is accompanied by a loss of mammary epithelial differentiation and a transdifferentiation process to squamous metaplasias. To further understand the molecular process of transdifferentiation, the expression of genes in mammary tissue was profiled in the absence and presence of activated of beta-catenin. Microarrays were generated that carry about 8500 cDNA clones with approximately 6000 obtained from mammary tissue. Mutant tissues, which had undergone either partial (TD1) or complete (TD2) squamous transdifferentiation, were compared with wild-type mammary tissue. Four groups of genes were identified. Group I contained genes whose expression was induced in both mutant tissues. Groups 2 and 3 contained genes that were active preferentially in TD2 and TD1, respectively. Group 4 contained genes suppressed in both samples. Using this approach, known and unknown genes activated in the transdifferentiation process were identified. A new 20 kDa protein (PANE1) induced upon transdifferentiation was nuclear in nonconfluent cells and cytoplasmic in confluent or dividing cells. Lastly, stabilization of beta-catenin resulted in the retention of differentiated epithelium upon involution and altered activities of several proteases in transdifferentiated mammary epithelium.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; INRA, Jouy En Josas, France; Univ Tokushima, Dept Biochem, Sch Dent, Tokushima 770, Japan; Agr Res Org, Volcani Ctr, IL-50250 Bet Dagan, Israel	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Tokushima University; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.			Miyoshi, Keiko/0000-0001-6910-4172; Hennighausen, Lothar/0000-0001-8319-9841; Reichenstein, Moshe/0000-0003-4957-004X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; CALABRO MA, 1982, LIPIDS, V17, P397, DOI 10.1007/BF02535218; Campana WM, 1999, BBA-GEN SUBJECTS, V1427, P392, DOI 10.1016/S0304-4165(99)00036-7; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DUFOUR E, 1988, BIOSCIENCE REP, V8, P185, DOI 10.1007/BF01116463; Humphreys RC, 2002, ENDOCRINOLOGY, V143, P3641, DOI 10.1210/en.2002-220224; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Larsen LB, 1996, J DAIRY RES, V63, P119, DOI 10.1017/S0022029900031599; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; LYNCH CJ, 1993, AM J PHYSIOL, V265, pC234, DOI 10.1152/ajpcell.1993.265.1.C234; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; McMurtrie EB, 1997, GENOMICS, V45, P623, DOI 10.1006/geno.1997.4959; McTernan PG, 2002, J CLIN ENDOCR METAB, V87, P2407, DOI 10.1210/jc.87.5.2407; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Park DS, 2001, J BIOL CHEM, V276, P48389, DOI 10.1074/jbc.M108210200; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; Polakis P, 2000, GENE DEV, V14, P1837; Rossman TG, 1997, MUTAT RES-REV MUTAT, V386, P307, DOI 10.1016/S1383-5742(97)00013-6; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Sol-Church K, 2000, BBA-GENE STRUCT EXPR, V1491, P289, DOI 10.1016/S0167-4781(00)00030-0; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097	33	28	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4594	4610		10.1038/sj.onc.1206596	http://dx.doi.org/10.1038/sj.onc.1206596			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881717				2022-12-25	WOS:000184054700016
J	Iwamura, K; Furukawa, K; Uchikawa, M; Sojka, BN; Kojima, Y; Wiels, J; Shiku, H; Urano, T; Furukawa, K				Iwamura, K; Furukawa, K; Uchikawa, M; Sojka, BN; Kojima, Y; Wiels, J; Shiku, H; Urano, T; Furukawa, K			The blood group P1 synthase gene is identical to the Gb3/CD77 synthase gene - A clue to the solution of the P1/P2/p puzzle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA-ASSOCIATED ANTIGEN; GDP-L-FUCOSE; MONOCLONAL-ANTIBODY; DETERMINES EXPRESSION; MOLECULAR-CLONING; TRANSFECTED CELLS; BURKITT-LYMPHOMA; GROUP SYSTEM; GROUP LOCUS; LEWIS	Blood group P1/P2 is a glycolipid antigen system for which the genetic mechanism has not yet been clarified. We analyzed the potential of the cloned Gb3/CD77 synthase to synthesize P1 antigen, because Gb3/CD77 and P1 share a common structure, Galalpha1,4Galbeta1,4Glc (NAc)-. L cell transfectants with Gb3/CD77 synthase cDNA expressed marginal levels of P1 on the cell surface but contained high levels of P1 in the cytoplasm. P2-type erythrocytes, which were serotyped as P2, also contained definite P1 antigen inside cells, although the amounts were lower than those of P1 cells. Only p erythrocytes lacked P1 antigen corresponding with function-losing mutations in the Gb3/CD77 synthase gene. Synthesis of P1 antigen from paragloboside in vitro was demonstrated using membrane fraction of the transfectants and a fusion enzyme with protein A. These results strongly suggested that P1 synthase is identical to Gb3/CD77 synthase and appear to propose a clue for the solution of the long-pending P1/P2/p puzzle. The P1/P2 difference might result from the difference in P1 quantity based on either different enzyme activity or the presence/absence of other enzyme modulators. Because P2 erythrocytes showed lower levels of Gb3/CD77 synthase mRNA than P1, 5'-upstream promoter regions were analyzed, resulting in the identification of two P2-specific homozygous mutations. Differences in the transcriptional regulation in erythrocytes might be a major factor determining P1/P2.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Japanese Red Cross, Tokyo Blood Ctr, Shibuya Ku, Tokyo 1500012, Japan; Mie Univ, Sch Med, Dept Internal Med 2, Tsu, Mie 5148507, Japan; Umea Univ Hosp, Dept Transfus Med, S-90185 Umea, Sweden; Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France	Nagoya University; Japanese Red Cross Medical Center; Mie University; Umea University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Iwamura, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.		Wiels, Joëlle/AGL-2319-2022	Wiels, Joëlle/0000-0002-3313-2937; Urano, Takeshi/0000-0003-3383-3554; Shiku, Hiroshi/0000-0002-0362-755X				BAILLY P, 1992, CARBOHYD RES, V228, P277, DOI 10.1016/S0008-6215(00)90565-2; BAILLY P, 1987, MOL IMMUNOL, V24, P171, DOI 10.1016/0161-5890(87)90089-7; DAHR W, 1974, VOX SANG, V27, P29, DOI 10.1111/j.1423-0410.1974.tb02386.x; Daniels GL, 1999, VOX SANG, V77, P52, DOI 10.1159/000031074; FEIZI T, 1978, BIOCHEM J, V173, P245, DOI 10.1042/bj1730245; FLETCHER KS, 1979, J BIOL CHEM, V254, P1196; Furukawa K, 2000, J BIOL CHEM, V275, P37752, DOI 10.1074/jbc.C000625200; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; Furukawa K, 2002, J BIOL CHEM, V277, P11247, DOI 10.1074/jbc.M109519200; Ishikawa D, 2000, METHOD ENZYMOL, V312, P157; Kaneko M, 1997, BLOOD, V90, P839, DOI 10.1182/blood.V90.2.839.839_839_849; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Kudo T, 1996, J BIOL CHEM, V271, P9830, DOI 10.1074/jbc.271.16.9830; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Landsteiner K, 1927, P SOC EXP BIOL MED, V24, P941; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LOMBERG H, 1981, LANCET, V1, P551; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcus D M, 1989, Immunol Ser, V43, P701; MCALPINE PJ, 1978, CYTOGENET CELL GENET, V22, P629, DOI 10.1159/000131040; MYOGA A, 1988, CANCER RES, V48, P1512; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; REARDEN A, 1981, VOX SANG, V41, P160, DOI 10.1111/j.1423-0410.1981.tb01030.x; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; Watkins W M, 1980, Adv Hum Genet, V10, P1; WATKINS WM, 1976, J IMMUNOGENET, V3, P15; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; WIELS J, 1984, J BIOL CHEM, V259, P4783; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149	35	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44429	44438		10.1074/jbc.M301609200	http://dx.doi.org/10.1074/jbc.M301609200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12888565	hybrid			2022-12-25	WOS:000186306700070
J	Bergantino, E; Brunetta, A; Touloupakis, E; Segalla, A; Szabo, I; Giacometti, GM				Bergantino, E; Brunetta, A; Touloupakis, E; Segalla, A; Szabo, I; Giacometti, GM			Role of the PSII-H subunit in photoprotection - Novel aspects of D1 turnover in Synechocystis 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERBICIDE-RESISTANT MUTANTS; PHOTOSYSTEM-II COMPLEX; SP PCC-6803; CHLAMYDOMONAS-REINHARDTII; PROTEIN-PHOSPHORYLATION; 9-KDA PHOSPHOPROTEIN; STRUCTURAL-CHANGES; ELECTRON-TRANSFER; PSBA TRANSCRIPT; ACCEPTOR-SIDE	Photosystem I-less Synechocystis 6803 mutants carrying modified PsbH proteins, derived from different combinations of wild-type cyanobacterial and maize genes, were constructed. The mutants were analyzed in order to determine the relative importance of the intra- and extramembrane domains of the PsbH subunit in the functioning of photosystem ( PS) II, by a combination of biochemical, biophysical, and physiological approaches. The results confirmed and extended previously published data showing that, besides D1, the whole PsbH protein is necessary to determine the correct structure of a Q(B)/herbicide-binding site. The different turnover of the D1 protein and chlorophyll photobleaching displayed by mutant cells in response to photoinhibitory treatment revealed for the first time the actual role of the PsbH subunit in photoprotection. A functional PsbH protein is necessary for (i) rapid degradation of photodamaged D1 molecules, which is essential to avoid further oxidative damage to the PSII core, and (ii) insertion of newly synthesized D1 molecules into the thylakoid membrane. PsbH is thus required for both initiation and completion of the repair cycle of the PSII complex in cyanobacteria.	Univ Padua, Dept Biol, I-35121 Padua, Italy	University of Padua	Giacometti, GM (corresponding author), Univ Padua, Dept Biol, Viale G Colombo 3, I-35121 Padua, Italy.		Touloupakis, Eleftherios/AAA-1902-2019; Szabo, Ildiko/AAW-5972-2021; Padova, Ildiko/K-5344-2016	Touloupakis, Eleftherios/0000-0002-5133-0849; Szabo, Ildiko/0000-0002-3637-3947; 				Alfonso M, 1999, J PHOTOCH PHOTOBIO B, V48, P104, DOI 10.1016/S1011-1344(99)00038-X; Alfonso M, 2000, PLANT PHYSIOL, V122, P505, DOI 10.1104/pp.122.2.505; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Bailey S, 2001, BIOCHEM SOC T, V29, P455, DOI 10.1042/BST0290455; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNOUN P, 1994, BBA-BIOENERGETICS, V1186, P59, DOI 10.1016/0005-2728(94)90135-X; Bergantino E, 2002, FUNCT PLANT BIOL, V29, P1181, DOI 10.1071/FP02021; Buchel C, 2001, J MOL BIOL, V312, P371, DOI 10.1006/jmbi.2001.4951; Chiaramonte S, 1999, EUR J BIOCHEM, V260, P833, DOI 10.1046/j.1432-1327.1999.00226.x; Constant S, 2000, BIOCHEMISTRY-US, V39, P2032, DOI 10.1021/bi9914154; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; DallaChiesa M, 1997, EUR J BIOCHEM, V248, P731, DOI 10.1111/j.1432-1033.1997.00731.x; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; ERICKSON JM, 1989, PLANT CELL, V1, P361, DOI 10.1105/tpc.1.3.361; Funk C, 2000, PLANT MOL BIOL, V44, P815, DOI 10.1023/A:1026764728846; Golden S. S., 1994, MOL BIOL CYANOBACTER, P693; He QF, 1998, P NATL ACAD SCI USA, V95, P5830, DOI 10.1073/pnas.95.10.5830; Inagaki N, 2001, FEBS LETT, V509, P197, DOI 10.1016/S0014-5793(01)03180-5; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; Jansen T, 2002, J PLANT PHYSIOL, V159, P1205, DOI 10.1078/0176-1617-00829; KLEINFELD D, 1984, BIOCHEMISTRY-US, V23, P5780, DOI 10.1021/bi00319a017; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; Komenda J, 1999, J PHOTOCH PHOTOBIO B, V48, P114, DOI 10.1016/S1011-1344(99)00025-1; KOMENDA J, 1995, EUR J BIOCHEM, V233, P677, DOI 10.1111/j.1432-1033.1995.677_2.x; Komenda J, 2000, PLANT MOL BIOL, V42, P635, DOI 10.1023/A:1006305308196; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; KUHN M, 1988, Z NATURFORSCH C, V43, P413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; MAYES SR, 1991, PLANT MOL BIOL, V17, P289, DOI 10.1007/BF00039508; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; O'Connor HE, 1998, BBA-BIOENERGETICS, V1364, P63, DOI 10.1016/S0005-2728(98)00013-9; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; Summer EJ, 1997, PLANT PHYSIOL, V113, P1359, DOI 10.1104/pp.113.4.1359; Szabo I, 2001, J BIOL CHEM, V276, P13784, DOI 10.1074/jbc.M008081200; Tyystjarvi T, 1998, FEBS LETT, V436, P483, DOI 10.1016/S0014-5793(98)01181-8; Tyystjarvi T, 2001, MOL MICROBIOL, V40, P476, DOI 10.1046/j.1365-2958.2001.02402.x; Vass I, 1999, BIOCHEMISTRY-US, V38, P12786, DOI 10.1021/bi991094w; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Westphal S, 2001, P NATL ACAD SCI USA, V98, P4243, DOI 10.1073/pnas.061501198; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	46	23	26	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41820	41829		10.1074/jbc.M303096200	http://dx.doi.org/10.1074/jbc.M303096200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909614	hybrid			2022-12-25	WOS:000185989500034
J	Kim, TG; Kraus, JC; Chen, JQ; Lee, Y				Kim, TG; Kraus, JC; Chen, JQ; Lee, Y			JUMONJI, a critical factor for cardiac development, functions as a transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNALS; HEART TUBE FORMATION; HOLT-ORAM-SYNDROME; VENTRAL MORPHOGENESIS; HISTONE DEACETYLASE; ENHANCER FACTOR-2; BINDING-PROTEINS; GENETIC-BASIS; MUTANT MICE; DNA	JUMONJI (JMJ) is a nuclear factor that is critical for normal cardiovascular development, evidenced by the analysis of jmj homozygous mutant mice. However, the molecular function of JMJ remains to be elucidated. In the present study, we investigated whether JMJ is a transcriptional modulator. Reporter gene assays using the GAL4-DNA binding domain fused to JMJ and a reporter gene consisting of the GAL4 binding sites upstream of a luciferase reporter gene indicated that JMJ functions as a powerful transcriptional repressor. The DNA binding motif of JMJ was determined using CAST-ing experiments by incubating a random oligonucleotide library with the GST-JMJ fusion protein coupled to agarose beads. Among the selected binding oligonucleotides, the high affinity DNA binding sequences were identified by gel retardation assays. JMJ repressed expression of the reporter genes containing the high affinity JMJ binding sequences, indicating that JMJ is a DNA-binding transcriptional repressor. The domains for transcriptional repression, DNA binding, and nuclear localization signal were mapped by mutational analyses using reporter gene assays, gel retardation assays, and immunostaining experiments, respectively. The present data demonstrate for the first time that JMJ functions as a DNA-binding transcriptional repressor. Therefore, JMJ may play a critical role in transcription factor cascade to regulate expression of heart-specific genes and normal cardiac development.	Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Cardiovasc Res Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lee, Y (corresponding author), Univ Wisconsin, Sch Med, Dept Anat, 1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067050] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67050] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amendt BA, 1999, J BIOL CHEM, V274, P11635, DOI 10.1074/jbc.274.17.11635; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; Gregory SL, 1996, MOL CELL BIOL, V16, P792; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Kim YB, 1999, ANN NY ACAD SCI, V886, P200, DOI 10.1111/j.1749-6632.1999.tb09416.x; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEE Y, 1993, J BIOL CHEM, V268, P2021; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lee Y, 2000, CIRC RES, V86, P932, DOI 10.1161/01.RES.86.9.932; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Lyons GE, 1996, CURR OPIN GENET DEV, V6, P454, DOI 10.1016/S0959-437X(96)80067-0; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Motoyama J, 1997, MECH DEVELOP, V66, P27, DOI 10.1016/S0925-4773(97)00082-8; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Rao S, 1999, J BIOL CHEM, V274, P11115, DOI 10.1074/jbc.274.16.11115; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TAKEUCHI T, 1995, GENE DEV, V9, P1211, DOI 10.1101/gad.9.10.1211; Toyoda M, 2000, BIOCHEM BIOPH RES CO, V274, P332, DOI 10.1006/bbrc.2000.3138; WANG GF, 1999, HEART DEV, P357; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yamagishi H, 1999, SCIENCE, V283, P1158, DOI 10.1126/science.283.5405.1158; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Zaffran S, 2002, CIRC RES, V91, P457, DOI 10.1161/01.RES.0000034152.74523.A8; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	50	76	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42247	42255		10.1074/jbc.M307386200	http://dx.doi.org/10.1074/jbc.M307386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12890668	hybrid			2022-12-25	WOS:000185989500084
J	Li, MX; Zhou, JY; Ge, YB; Matherly, LH; Wu, GS				Li, MX; Zhou, JY; Ge, YB; Matherly, LH; Wu, GS			The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR P53; IMMEDIATE-EARLY GENE; WILD-TYPE P53; MAP KINASE; P53-DEPENDENT APOPTOSIS; TYROSINE-PHOSPHATASE; UV-RADIATION; CONDITIONAL EXPRESSION; P53-INDUCED APOPTOSIS	The tumor suppressor p53 protein suppresses cell growth by inducing cell cycle arrest or apoptosis. Despite the fact that p53-dependent p21-mediated G(1) arrest induced by DNA damage is well defined, the role of p53 in the cell cycle in response to the MAKP signaling remains to be determined. Here we show that MKP1, a member of the dual specificity protein phosphatase family capable of inactivating MAPKs, is a transcriptional target of p53. MKP1 mRNA and protein levels were increased upon p53 activation in several well defined p53-regulated cell systems. p53 bound to a consensus p53 binding site located in the second intron of the MKP1 gene and transactivated MKP1 in reporter gene assays. Inhibition of phosphatase activity impaired p53-mediated G(1) arrest in arrested human glioblastoma GM cells in response to growth factor stimuli. Importantly conditional expression of MKP1 prevented arrested human cancer cells from entering into the cell cycle. Thus, these results provide a novel mechanism by which p53 controls the cell cycle in response to the MAPK signaling in the absence of DNA damage and suggest that p53 may negatively control the MAKP pathway via MKP1.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pharmacol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Wu, GS (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.			Ge, Yubin/0000-0002-8748-716X				Attardi LD, 2000, GENE DEV, V14, P704; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHARLES CH, 1992, ONCOGENE, V7, P187; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Ge YB, 2001, J BIOL CHEM, V276, P43570, DOI 10.1074/jbc.M104930200; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xu QH, 2002, J BIOL CHEM, V277, P41693, DOI 10.1074/jbc.M207095200; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhao RB, 2000, GENE DEV, V14, P981	71	88	89	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41059	41068		10.1074/jbc.M307149200	http://dx.doi.org/10.1074/jbc.M307149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890671	hybrid			2022-12-25	WOS:000185847200080
J	Ose, T; Fujino, A; Yao, M; Watanabe, N; Honma, M; Tanaka, I				Ose, T; Fujino, A; Yao, M; Watanabe, N; Honma, M; Tanaka, I			Reaction intermediate structures of 1-aminocyclopropane-1-carboxylate deaminase - Insight into PLP-dependent cyclopropane ring-opening reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE BINDING-SITE; TRYPTOPHAN SYNTHASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; SEMIEMPIRICAL CALCULATIONS; 3-DIMENSIONAL STRUCTURE; ACTIVE-SITE; AMINO-ACID; ENZYME	The pyridoxal 5'-phosphate-dependent enzymes have been evolved to catalyze diverse substrates and to cause the reaction to vary. 1-Aminocyclopropane-1-carboxylate deaminase catalyzes the cyclopropane ring-opening reaction followed by deamination specifically. Since it was discovered in 1978, the enzyme has been widely investigated from the mechanistic and physiological viewpoints because the substrate is a precursor of the plant hormone ethylene and the enzymatic reaction includes a cyclopropane ring-opening. We have previously reported the crystal structure of the native enzyme. Here we report the crystal structures of the two reaction intermediates created by the mutagenesis complexed with the substrate. The substrate was validated in the active site of two forms: 1) covalent-bonded external aldimine with the coenzyme in the K51T form and 2) the non-covalent interaction around the coenzyme in the Y295F form. The orientations of the substrate in both structures were quite different form each other. In concert with other site-specific mutation experiments, this experiment revealed the ingenious and unique strategies that are used to achieve the specific activity. The substrate incorporated into the active site is reactivated by a two-phenol charge relay system to lead to the formation of a Schiff base with the coenzyme. The catalytic Lys(51) residue may play a novel role to abstract the methylene proton from the substrate in cooperation with other factors, the carboxylate group of the substrate and the electron-adjusting apparatuses of the coenzyme.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan	Hokkaido University; Hokkaido University	Tanaka, I (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.	tanaka@castor.sci.hokudai.ac.jp	yao, min/F-5287-2011; Fujino, Asa/AAG-4722-2020; Watanabe, Nobuhisa/B-1187-2008	yao, min/0000-0003-1687-5904; Fujino, Asa/0000-0003-0652-5222; Watanabe, Nobuhisa/0000-0002-0118-5815				ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; BURROUGHS LF, 1957, NATURE, V179, P360, DOI 10.1038/179360a0; Campbell BG, 1996, FEMS MICROBIOL LETT, V138, P207, DOI 10.1016/0378-1097(96)00108-5; CLARK PA, 1993, J AM CHEM SOC, V115, P9789, DOI 10.1021/ja00074a053; CLARK PA, 1993, J AM CHEM SOC, V115, P1894, DOI 10.1021/ja00058a039; Clausen T, 1996, J MOL BIOL, V262, P202, DOI 10.1006/jmbi.1996.0508; Denesyuk AI, 2002, J MOL BIOL, V316, P155, DOI 10.1006/jmbi.2001.5310; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Glick BR, 1998, J THEOR BIOL, V190, P63, DOI 10.1006/jtbi.1997.0532; GLICK BR, 1994, CAN J MICROBIOL, V40, P911, DOI 10.1139/m94-146; Hayashi H, 1997, BIOCHEMISTRY-US, V36, P13558, DOI 10.1021/bi971638z; HONMA M, 1985, AGR BIOL CHEM TOKYO, V49, P567, DOI 10.1080/00021369.1985.10866774; HONMA M, 1993, BIOSCI BIOTECH BIOCH, V57, P2090, DOI 10.1271/bbb.57.2090; HONMA M, 1978, AGR BIOL CHEM TOKYO, V42, P1825, DOI 10.1080/00021369.1978.10863261; HONMA M, 1986, AGR BIOL CHEM TOKYO, V50, P3189; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACOBSON CB, 1994, CAN J MICROBIOL, V40, P1019, DOI 10.1139/m94-162; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; Jhee KH, 1998, J BIOL CHEM, V273, P11417, DOI 10.1074/jbc.273.19.11417; Jia YJ, 1999, BIOSCI BIOTECH BIOCH, V63, P542, DOI 10.1271/bbb.63.542; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; Li KQ, 1996, J AM CHEM SOC, V118, P8763, DOI 10.1021/ja960822p; LIU HW, 1984, J AM CHEM SOC, V106, P5335, DOI 10.1021/ja00330a050; LU ZC, 1993, J BIOL CHEM, V268, P8727; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; Minami R, 1998, J BIOCHEM, V123, P1112; Murakami T, 1997, BIOSCI BIOTECH BIOCH, V61, P506, DOI 10.1271/bbb.61.506; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Reed AJ, 1996, J AGR FOOD CHEM, V44, P388, DOI 10.1021/jf9504071; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; SHEEHY RE, 1991, J BACTERIOL, V173, P5260, DOI 10.1128/jb.173.17.5260-5265.1991; Thomazeau K, 2001, PROTEIN SCI, V10, P638, DOI 10.1110/ps.44301; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; WALSH C, 1981, BIOCHEMISTRY-US, V20, P7509, DOI 10.1021/bi00529a028; WEBER IT, 1978, NATURE, V274, P433, DOI 10.1038/274433a0; Yao M, 2000, J BIOL CHEM, V275, P34557, DOI 10.1074/jbc.M004681200; YU YB, 1979, ARCH BIOCHEM BIOPHYS, V198, P280, DOI 10.1016/0003-9861(79)90420-X; Zhang ZH, 1997, BIOCHEMISTRY-US, V36, P15999, DOI 10.1021/bi971823c	47	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41069	41076		10.1074/jbc.M305865200	http://dx.doi.org/10.1074/jbc.M305865200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882962	hybrid			2022-12-25	WOS:000185847200081
J	Salas, TR; Reddy, SA; Clifford, JL; Davis, RJ; Kikuchi, A; Lippman, SM; Menter, DG				Salas, TR; Reddy, SA; Clifford, JL; Davis, RJ; Kikuchi, A; Lippman, SM; Menter, DG			Alleviating the suppression of glycogen synthase kinase-3 beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN MUTATIONS; PROSTATE-CANCER CELLS; KINASE 3-BETA; SUBSTRATE-SPECIFICITY; SIGNAL-TRANSDUCTION; PATHWAY; INSULIN; CREB; ACTIVATION; TUMORIGENESIS	Glycogen synthase kinase-3beta (GSK-3beta) activity is suppressed when it becomes phosphorylated on serine 9 by protein kinase B (Akt). To determine how GSK-3beta activity opposes Akt function we used various methods to alleviate GSK-3beta suppression in prostate carcinoma cells. In some experiments, LY294002, a specific inhibitor of phosphatidylinositol 3-kinase ( a kinase involved in activating Akt) and tumor necrosis factor-alpha (TNF-alpha) were used to activate GSK-3beta. In other experiments mutant forms of GSK-3beta, GSK-3beta(Delta9) (a constitutively active deletion mutant of GSK-3beta) and GSK-3beta(Y216F) ( an inactive point mutant of GSK-3beta) were used to alter GSK-3beta activity. LY294002, TNF-alpha, and overexpression of wild-type GSK-3beta or of GSK-3beta(Delta9), but not GSK-3beta(Y216F), alleviated the suppression of GSK-3beta activity in prostate carcinoma cells and enhanced the turnover of beta-catenin. Forced expression of wild-type GSK-3beta or of GSK-3beta(Delta9), but not GSK-3beta(Y216F), suppressed cell growth and showed that the phosphorylation status of GSK-3beta can affect its intracellular distribution. When transcription factors activator protein-1 and cyclic AMP-response element (CRE)-binding protein were analyzed as targets of GSK-3beta activity, overexpression of wild-type GSK-3beta suppressed AP1-mediated transcription and activated CRE-mediated transcription. Overexpression of GSK-3beta(Delta9) caused an (80-fold) increase in CRE-mediated transcription, which was further amplified ( up to 130-fold) by combining GSK-3betaDelta9 overexpression with the suppression of Jun activity. This study also demonstrated for the first time that expression of constitutively active GSK-3beta(Delta9) results in the phosphorylation of CRE-binding protein on serine 129 and enhancement of CRE-mediated transcription in intact cell nuclei.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Massachusetts, Sch Med, Program Mol Med, Howard Hughes Med Inst,Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Hiroshima University	Menter, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Box 236,1515 Holcombe Blvd, Houston, TX 77030 USA.	dmenter@mdanderson.org			NATIONAL CANCER INSTITUTE [R25CA057730] Funding Source: NIH RePORTER; NCI NIH HHS [R25 CA57730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angelloz-Nicoud P, 1998, GROWTH HORM IGF RES, V8, P71, DOI 10.1016/S1096-6374(98)80324-9; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Beresford SA, 2001, J INTERF CYTOK RES, V21, P313, DOI 10.1089/107999001300177501; Bevan P, 2001, J CELL SCI, V114, P1429; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Dupont J, 2001, J CLIN PATHOL-MOL PA, V54, P149, DOI 10.1136/mp.54.3.149; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huynh H, 1998, INT J ONCOL, V13, P137; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kimura G, 1996, Int J Urol, V3, P39; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P1163, DOI 10.1093/nar/21.5.1163; Menter DG, 2000, CANCER EPIDEM BIOMAR, V9, P1171; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; Rosenberg D, 2002, ANN NY ACAD SCI, V968, P65, DOI 10.1111/j.1749-6632.2002.tb04327.x; SASSONECORSI P, 1990, ONCOGENE, V5, P427; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Scheid MP, 2001, J MAMMARY GLAND BIOL, V6, P83, DOI 10.1023/A:1009520616247; Son H, 2001, NEUROSCI LETT, V308, P37, DOI 10.1016/S0304-3940(01)01984-X; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; Voeller HJ, 1998, CANCER RES, V58, P2520; Walczak J, 2001, UROLOGY, V57, P81, DOI 10.1016/S0090-4295(00)00947-X; WANG QM, 1994, ANAL BIOCHEM, V220, P397, DOI 10.1006/abio.1994.1356; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; WOODGETT JR, 2001, SCI STKE; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	48	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41338	41346		10.1074/jbc.M302972200	http://dx.doi.org/10.1074/jbc.M302972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900420	hybrid			2022-12-25	WOS:000185847200114
J	Ahn, JH; Beharry, S; Molday, LL; Molday, RS				Ahn, JH; Beharry, S; Molday, LL; Molday, RS			Functional interaction between the two halves of the photoreceptor-specific ATP binding cassette protein ABCR (ABCA4) - Evidence for a non-exchangeable ADP in the first nucleotide binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; STARGARDT MACULAR DYSTROPHY; ESCHERICHIA-COLI F1-ATPASE; HUMAN P-GLYCOPROTEIN; ROD OUTER SEGMENTS; DISEASE GENE ABCR; ADENINE-NUCLEOTIDE; ADENOSINE-TRIPHOSPHATASE; RETINITIS-PIGMENTOSA; DIMETHYL-SULFOXIDE	ABCR, also known as ABCA4, is a member of the superfamily of ATP binding cassette transporters that is believed to transport retinal or retinylidene-phosphatidylethanolamine across photoreceptor disk membranes. Mutations in the ABCR gene are responsible for Stargardt macular dystrophy and related retinal dystrophies that cause severe loss in vision. ABCR consists of two tandemly arranged halves each containing a membrane spanning segment followed by a large extracellular/ lumen domain, a multi-spanning membrane domain, and a nucleotide binding domain (NBD). To define the role of each NBD, we examined the nucleotide binding and ATPase activities of the N and C halves of ABCR individually and co-expressed in COS-1 cells and derived from trypsin-cleaved ABCR in disk membranes. When disk membranes or membranes from co-transfected cells were photoaffinity labeled with 8-azido-ATP and 8-azido-ADP, only the NBD2 in the C-half bound and trapped the nucleotide. Co-expressed half-molecules displayed basal and retinal-stimulated ATPase activity similar to full-length ABCR. The individually expressed N-half displayed weak 8-azido-ATP labeling and low basal ATPase activity that was not stimulated by retinal, whereas the C-half did not bind ATP and exhibited little if any ATPase activity. Purified ABCR contained one tightly bound ADP, presumably in NBD1. Our results indicate that only NBD2 of ABCR binds and hydrolyzes ATP in the presence or absence of retinal. NBD1, containing a bound ADP, associates with NBD2 to play a crucial, non-catalytic role in ABCR function.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.				NEI NIH HHS [EY 02422] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Ahn J, 2000, METHOD ENZYMOL, V315, P864; Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Beharry S, 1996, EUR J BIOCHEM, V240, P165, DOI 10.1111/j.1432-1033.1996.0165h.x; BEHARRY S, 1992, BIOCHEM BIOPH RES CO, V182, P697, DOI 10.1016/0006-291X(92)91788-R; BEHARRY S, 1992, BIOCHEM J, V286, P603, DOI 10.1042/bj2860603; BEHARRY S, 1991, BIOCHEM CELL BIOL, V69, P291, DOI 10.1139/o91-044; Biswas EE, 2001, BIOCHEMISTRY-US, V40, P8181, DOI 10.1021/bi0106686; Biswas EE, 2000, BIOCHEMISTRY-US, V39, P15879, DOI 10.1021/bi0015966; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GARRETT NE, 1975, J SUPRAMOL STR CELL, V3, P469, DOI 10.1002/jss.400030507; HAMPP R, 1984, METHOD ENZYMAT AN, V2, P370; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Muller M, 1996, J BIOL CHEM, V271, P1877; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; PAPERMASTER DS, 1982, VISION RES, V22, P1417, DOI 10.1016/0042-6989(82)90204-8; Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, METHOD ENZYMOL, V292, P514; Souied EH, 1999, INVEST OPHTH VIS SCI, V40, P2740; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	50	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39600	39608		10.1074/jbc.M304236200	http://dx.doi.org/10.1074/jbc.M304236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888572	hybrid			2022-12-25	WOS:000185713800043
J	Chadjichristos, C; Ghayor, C; Kypriotou, M; Martin, G; Renard, E; Ala-Kokko, L; Suske, G; de Crombrugghe, B; Pujol, JP; Galera, P				Chadjichristos, C; Ghayor, C; Kypriotou, M; Martin, G; Renard, E; Ala-Kokko, L; Suske, G; de Crombrugghe, B; Pujol, JP; Galera, P			Sp1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HUMAN COL2A1 GENE; TRANSFORMING GROWTH-FACTOR-BETA-1 TGF-BETA-1; MESSENGER-RNA LEVELS; NF-KAPPA-B; INTERFERON-GAMMA; INDUCED ARTHRITIS; BINDING-PROTEINS; UP-REGULATION; SOX9 GENE	Interleukin-1beta (IL-1beta) is a pleiotropic cytokine that was shown to inhibit the biosynthesis of articular cartilage components. Here we demonstrate that IL-1beta inhibits the production of newly synthesized collagens in proliferating rabbit articular chondrocytes and that this effect is accompanied by a decrease in the steady-state levels of type II collagen mRNA. IL-1beta down-regulates COL2A1 gene transcription through a -41/-33 bp sequence that binds a multimeric complex including Sp1 and Sp3 transcription factors. Specificity of IL-1beta effects on COL2A1 promoter activity was demonstrated in experiments in which transfection of a wild type -50/+1 sequence of COL2A1 promoter as a decoy oligonucleotide abolished the IL-1beta inhibition of a -63/+47 COL2A1-mediated transcription. By contrast, transfection of the related oligonucleotide harboring a targeted mutation in the -41/-33 sequence did not modify the negative effect the cytokine. Because we demonstrated previously that Sp1 was a strong activator of COL2A1 gene expression via the -63/+1 promoter region, whereas Sp3 overexpression blocked Sp1-induced promoter activity and inhibited COL2A1 gene transcription, we conclude that IL-1beta down-regulation of that gene, as we found previously for transforming growth factor-beta1, is mediated by an increase in the Sp3/Sp1 ratio. Moreover, IL-1beta increased steady-state levels of Sp1 and Sp3 mRNAs, whereas it enhanced Sp3 protein expression and inhibited Sp1 protein biosynthesis. Nevertheless, IL-1beta decreased the binding activity of both Sp1 and Sp3 to the 63-bp short COL2A1 promoter, suggesting that the cytokine exerts a post-transcriptional regulatory mechanism on Sp1 and Sp3 gene expressions. Altogether, these data indicate that modulation of Sp3/Sp1 ratio in cartilage could be a potential target to prevent or limit the tissue degradation.	CHU Niveau, Fac Med, Lab Biochim Tissu Conjonct, F-14032 Caen, France; Div Malad Osseuses, CH-1211 Geneva 14, Switzerland; Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem, SF-90220 Oulu, Finland; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	CHU de Caen NORMANDIE; Universite de Caen Normandie; University of Geneva; University of Oulu; University of Oulu; Philipps University Marburg; University of Texas System; UTMD Anderson Cancer Center	Galera, P (corresponding author), CHU Niveau, Fac Med, Lab Biochim Tissu Conjonct, 3 Ave Cote Nacre, F-14032 Caen, France.		Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Ghayor, Chafik/0000-0002-3016-3412; Martin, Gregoire/0000-0001-8240-6108; Suske, Guntram/0000-0002-4807-0513				ANDREWS HJ, 1989, BIOCHIM BIOPHYS ACTA, V1012, P128, DOI 10.1016/0167-4889(89)90085-2; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P105, DOI 10.1016/0014-4827(90)90042-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; GALERA P, 1992, J CELL PHYSIOL, V153, P596, DOI 10.1002/jcp.1041530322; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; INAGAKI Y, 1995, HEPATOLOGY, V22, P573, DOI 10.1016/0270-9139(95)90582-0; Inagaki Y, 2001, J BIOL CHEM, V276, P16573, DOI 10.1074/jbc.M010485200; Joosten LAB, 1996, ARTHRITIS RHEUM, V39, P797, DOI 10.1002/art.1780390513; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Kypriotou M, 2003, DNA CELL BIOL, V22, P119, DOI 10.1089/104454903321515922; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; Mayne R. u. M. H. I., 1986, ARTICULAR CARTILAGE, P23; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Osaki M, 2003, BIOCHEM J, V369, P103, DOI 10.1042/BJ20020928; Peterkofsky B, 1999, J CELL BIOCHEM, V73, P408, DOI 10.1002/(SICI)1097-4644(19990601)73:3<408::AID-JCB12>3.3.CO;2-4; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PUJOL JP, 1987, LIFE SCI, V41, P1187, DOI 10.1016/0024-3205(87)90196-2; PUJOL JP, 1984, BIOCHEM BIOPH RES CO, V119, P499, DOI 10.1016/S0006-291X(84)80276-4; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Robbins JR, 2000, ARTHRITIS RHEUM, V43, P2189, DOI 10.1002/1529-0131(200010)43:10<2189::AID-ANR6>3.0.CO;2-S; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; VANDELOO FAJ, 1995, ARTHRITIS RHEUM, V38, P164; Xu SC, 2001, DNA CELL BIOL, V20, P359, DOI 10.1089/10445490152122479; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	44	105	109	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39762	39772		10.1074/jbc.M303541200	http://dx.doi.org/10.1074/jbc.M303541200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888570	hybrid			2022-12-25	WOS:000185713800062
J	Kovacic, S; Soltys, CLM; Barr, AJ; Shiojima, I; Walsh, K; Dyck, JRB				Kovacic, S; Soltys, CLM; Barr, AJ; Shiojima, I; Walsh, K; Dyck, JRB			Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; INSULIN-RESISTANCE; RAT HEARTS; GLUCOSE-OXIDATION; MAMMALIAN TARGET; MICE LACKING; IN-VITRO; ISCHEMIA; TRANSLOCATION; INHIBITION	In the heart, insulin stimulates a variety of kinase cascades and controls glucose utilization. Because insulin is able to activate Akt and inactivate AMP-activated protein kinase (AMPK) in the heart, we hypothesized that Akt can regulate the activity of AMPK. To address the potential existence of this novel signaling pathway, we used a number of experimental protocols to activate Akt in cardiac myocytes and monitored the activation status of AMPK. Mouse hearts perfused in the presence of insulin demonstrated accelerated glycolysis and glucose oxidation rates as compared with non-insulin-perfused hearts. In addition, insulin caused an increase in Akt phosphorylation and a decrease in AMPK phosphorylation at its major regulatory site (threonine 172 of the alpha catalytic subunit). Transgenic mice overexpressing a constitutively active mutant form of Akt1 displayed decreased phosphorylation of cardiac alpha-AMPK. Isolated neonatal cardiac myocytes infected with an adenovirus expressing constitutively active mutant forms of either Akt1 or Akt2 also suppressed AMPK phosphorylation. However, Akt-dependent depression of alpha-AMPK phosphorylation could be overcome in the presence of the AMPK activator, metformin, suggesting that an override mechanism exists that can restore AMPK activity. Taken together, this study suggests that there is crosstalk between the AMPK and Akt pathways and that Akt activation can lead to decreased AMPK activity. In addition, our data suggest that the ability of insulin to inhibit AMPK may be controlled via an Akt-mediated mechanism.	Univ Alberta, Fac Med, Dept Pediat, Cardiovasc Res Grp,Heritage Med Res Ctr 474, Edmonton, AB T6G 2S2, Canada; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Univ Alberta, Fac Med, Dept Pharmacol, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada	University of Alberta; Boston University; University of Alberta	Dyck, JRB (corresponding author), Univ Alberta, Fac Med, Dept Pediat, Cardiovasc Res Grp,Heritage Med Res Ctr 474, Edmonton, AB T6G 2S2, Canada.			Dyck, Jason/0000-0002-7045-2884				Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; Beauloye C, 2001, CIRC RES, V88, P513, DOI 10.1161/01.RES.88.5.513; Belke DD, 2001, AM J PHYSIOL-ENDOC M, V280, pE420, DOI 10.1152/ajpendo.2001.280.3.E420; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Campbell FM, 2002, J BIOL CHEM, V277, P4098, DOI 10.1074/jbc.M106054200; Carvalho E, 2000, MOL CELL BIOCHEM, V206, P7, DOI 10.1023/A:1007009723616; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clarke B, 1996, J MOL CELL CARDIOL, V28, P341, DOI 10.1006/jmcc.1996.0032; Depre C, 1998, EUR J BIOCHEM, V258, P277, DOI 10.1046/j.1432-1327.1998.2580277.x; FANTINI E, 1994, J MOL CELL CARDIOL, V26, P949, DOI 10.1006/jmcc.1994.1116; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 2001, CELL DEATH DIFFER, V8, P1207, DOI 10.1038/sj.cdd.4400919; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; GOODWIN GW, 1995, J BIOL CHEM, V270, P9234, DOI 10.1074/jbc.270.16.9234; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; JESSEN N, 2002, J APPL PHYSIOL, V4, P1373; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; LAUGHLIN MR, 1992, AM J PHYSIOL, V262, pE875, DOI 10.1152/ajpendo.1992.262.6.E875; LOPASCHUK GD, 1990, CIRC RES, V66, P546, DOI 10.1161/01.RES.66.2.546; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Proud CG, 1997, BIOCHEM J, V328, P329; ROSEN P, 1984, BASIC RES CARDIOL, V79, P307; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; SCHONEKESS BO, 1995, CIRC RES, V77, P726, DOI 10.1161/01.RES.77.4.726; Scott JW, 2002, J MOL BIOL, V317, P309, DOI 10.1006/jmbi.2001.5316; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Soltys CLM, 2002, AM J PHYSIOL-HEART C, V283, pH1056, DOI 10.1152/ajpheart.00275.2002; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; VANOVERSCHELDE JL, 1994, AM J PHYSIOL, V267, pH1785; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	47	314	329	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39422	39427		10.1074/jbc.M305371200	http://dx.doi.org/10.1074/jbc.M305371200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890675	hybrid			2022-12-25	WOS:000185713800019
J	Park-Lee, S; Kim, S; Laird-Offringa, IA				Park-Lee, S; Kim, S; Laird-Offringa, IA			Characterization of the interaction between neuronal RNA-binding protein HuD and AU-rich RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; IN-VIVO STABILITY; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; 3-UNTRANSLATED REGION; GENE-EXPRESSION; POLY(A) TAIL; ELAV; SEQUENCE; ELEMENTS	Hu proteins have been shown to bind to AU-rich elements (AREs) in the 3'-untranslated region of unstable mRNAs. They can thereby inhibit the decay of labile transcripts by antagonizing destabilizing proteins that target these AU-rich sequences. Here we examine the sequence preferences of HuD to elucidate its possible role in counteracting mRNA decay. Using repeats of the prototype destabilizing sequence UU(AUUU)(n)AUU, we show that all three HuD RNA-binding domains participate in binding to AU-tracts that can be as short as 13 residues, depending on the position of the remaining As. Removal of the A residues, resulting in a poly(U)-tract, increased the affinity of HuD for RNA, suggesting that the presence of As in destabilizing elements might favor the recruitment of other proteins and/or prevent HuD from binding too tightly to AREs. In vitro selection experiments with randomized RNAs confirmed the preference of HuD for poly(U). RNA binding analysis of the related protein HuB showed a similar preference for poly(U). In contrast, tristetraprolin, an mRNA destabilizing protein, strongly prefers AU-rich RNA. Many labile mRNAs contain U-tracts in or near their AREs. Individual AREs may thus differentially affect mRNA half-life by recruiting a unique complement of stabilizing and destabilizing factors.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Surg, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Laird-Offringa, IA (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.	ilaird@usc.edu	Offringa, Ite/R-4101-2019		NCI NIH HHS [R29CA78407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Beckel-Mitchener AC, 2002, J BIOL CHEM, V277, P27996, DOI 10.1074/jbc.M201982200; Bernasconi NL, 2000, AM J RESP CELL MOL, V23, P560, DOI 10.1165/ajrcmb.23.4.4233; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chagnovich D, 1997, EUR J CANCER, V33, P2064, DOI 10.1016/S0959-8049(97)00208-6; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Cuadrado A, 2002, NUCLEIC ACIDS RES, V30, P2202, DOI 10.1093/nar/30.10.2202; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Jain R G, 1995, Nucleic Acids Symp Ser, P209; Katsamba PS, 2002, METHODS, V26, P95, DOI 10.1016/S1046-2023(02)00012-9; Kenan DJ, 1999, METH MOL B, V118, P217; Kwon YS, 1999, J BIOL CHEM, V274, P29149, DOI 10.1074/jbc.274.41.29149; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; Malter JS, 2001, J NEUROSCI RES, V66, P311, DOI 10.1002/jnr.10021; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Okano HJ, 1997, J NEUROSCI, V17, P3024; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335; Quattrone A, 2001, P NATL ACAD SCI USA, V98, P11668, DOI 10.1073/pnas.191388398; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Ross RA, 1997, EUR J CANCER, V33, P2071, DOI 10.1016/S0959-8049(97)00331-6; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; van Hoof A, 2002, CURR BIOL, V12, pR285, DOI 10.1016/S0960-9822(02)00802-3; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Zarudnaya MI, 1999, IUBMB LIFE, V48, P581; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	68	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39801	39808		10.1074/jbc.M307105200	http://dx.doi.org/10.1074/jbc.M307105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900401	hybrid			2022-12-25	WOS:000185713800066
J	Morishima, A; Ohkubo, N; Maeda, N; Miki, T; Mitsuda, N				Morishima, A; Ohkubo, N; Maeda, N; Miki, T; Mitsuda, N			NF kappa B regulates plasma apolipoprotein A-I and high density lipoprotein cholesterol through inhibition of peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INNOCENT BYSTANDER; APOA-I; EXPRESSION; GENE; TRANSCRIPTION; MICE; SIGNAL; ATHEROSCLEROSIS; ATHEROGENESIS	The levels of plasma HDL cholesterol and apoA-I in NFkappaB p50 subunit-deficient mice were significantly higher than those in wild-type mice under regular and high fat diets, without any significant difference in the level of total cholesterol. To examine the role of NFkappaB in lipid metabolism, we studied its effect on the regulation of apoA-I secretion from human hepatoma HepG2 cells. Lipopolysaccharide-induced activation of NFkappaB reduced the expression of apoA-I mRNA and protein, whereas adenovirus-mediated expression of IkappaBalpha super-repressor ameliorated the reduction. This IkappaBalpha-induced apoA-I increase was blocked by preincubation with MK886, a selective inhibitor of peroxisome proliferator-activated receptor alpha (PPARalpha), suggesting that NFkappaB inactivation induces apoA-I through activation of PPARalpha. To further support this idea, the expression of IkappaBalpha increased apoA-I promoter activity, and this increase was blocked by preincubation with MK886. Mutations in the putative PPARalpha-binding site in the apoA-I promoter or lack of the site abrogated these changes. Taking these results together, inhibition of NFkappaB increases apoA-I and HDL cholesterol through activation of PPARalpha in vivo and in vitro. Our data suggest a new aspect of lipid metabolism and may lead to a new paradigm for prevention and treatment of atherosclerotic disease.	Ehime Univ, Sch Med, Dept Physiol, Shigenobu, Ehime 7910295, Japan; Ehime Univ, Sch Med, Dept Geriatr Med, Shigenobu, Ehime 7910295, Japan	Ehime University; Ehime University	Mitsuda, N (corresponding author), Ehime Univ, Sch Med, Dept Physiol, Shigenobu, Ehime 7910295, Japan.	mitsuda@m.ehime-u.ac.jp						BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baroukh N, 2001, FEBS LETT, V502, P16, DOI 10.1016/S0014-5793(01)02621-7; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; Bisgaier CL, 1998, J LIPID RES, V39, P17; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; BRESLOW JL, 1993, CIRCULATION, V87, P16; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; DeGeest B, 1997, CIRCULATION, V96, P4349; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Jobin C, 1998, J IMMUNOL, V160, P410; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kehrer JP, 2001, BIOCHEM J, V356, P899, DOI 10.1042/0264-6021:3560899; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9; MALMENDIER CL, 1985, ATHEROSCLEROSIS, V43, P557; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; MILLER GJ, 1975, LANCET, V1, P16; Mitsuda N, 2001, J BIOL CHEM, V276, P9688, DOI 10.1074/jbc.M006153200; NARAYAN KA, 1965, NATURE, V205, P246, DOI 10.1038/205246a0; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; NG DS, 1995, ARTERIOSCL THROM VAS, V15, P2157, DOI 10.1161/01.ATV.15.12.2157; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; She MP, 1999, CLIN EXP PHARMACOL P, V26, P833, DOI 10.1046/j.1440-1681.1999.03139.x; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; Srivastava R, 2000, MOL CELL BIOCHEM, V209, P131, DOI 10.1023/A:1007111830472; SRIVASTAVA RAK, 1992, BIOCHIM BIOPHYS ACTA, V1125, P251, DOI 10.1016/0005-2760(92)90053-X; Srivastava RAK, 1998, METH MOL B, V86, P103; Staels B, 1998, ATHEROSCLEROSIS, V137, pS19, DOI 10.1016/S0021-9150(97)00313-4; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Stein O, 1997, P NATL ACAD SCI USA, V94, P9820, DOI 10.1073/pnas.94.18.9820; Sumida A, 2000, BIOCHEM BIOPH RES CO, V267, P756, DOI 10.1006/bbrc.1999.2029; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Voyiaziakis E, 1998, J LIPID RES, V39, P313; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	52	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38188	38193		10.1074/jbc.M306336200	http://dx.doi.org/10.1074/jbc.M306336200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882972	hybrid			2022-12-25	WOS:000185575100014
J	Pratta, MA; Yao, WQ; Decicco, C; Tortorella, MD; Liu, RQ; Copeland, RA; Magolda, R; Newton, RC; Trzaskos, JM; Arner, EC				Pratta, MA; Yao, WQ; Decicco, C; Tortorella, MD; Liu, RQ; Copeland, RA; Magolda, R; Newton, RC; Trzaskos, JM; Arner, EC			Aggrecan protects cartilage collagen from proteolytic cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOARTHRITIC ARTICULAR-CARTILAGE; BOVINE NASAL CARTILAGE; II COLLAGEN; MATRIX METALLOPROTEINASE-13; PROTEOGLYCAN DEGRADATION; INTERGLOBULAR DOMAIN; SYNTHETIC INHIBITOR; ADAMTS FAMILY; CHONDROCYTES; CLONING	The matrix components responsible for cartilage mechanical properties, type II collagen and aggrecan, are degraded in osteoarthritis through proteolytic cleavage by matrix metalloproteinases (MMPs) and aggrecanases, respectively. We now show that aggrecan may serve to protect cartilage collagen from degradation. Although collagen in freeze-thawed cartilage depleted of aggrecan was completely degraded following incubation with MMP-1, collagen in cartilage with intact aggrecan was not. Using interleukin-1-stimulated bovine nasal cartilage explants where aggrecan depletion occurs during the first week of culture, followed by collagen loss during the second week, we evaluated the effect of selective MMP and aggrecanase inhibitors on degradation. A selective MMP inhibitor did not block aggrecan degradation but caused complete inhibition of collagen breakdown. Similar inhibition was seen with inhibitor addition following aggrecan depletion on day 6-8, suggesting that MMPs are not causing significant collagen degradation prior to the second week of culture. Inclusion of a selective aggrecanase inhibitor blocked aggrecan degradation, and, in addition, inhibited collagen degradation. When the inhibitor was introduced following aggrecan depletion, it had no effect on collagen breakdown, ruling out a direct effect through inhibition of collagenase. These data suggest that aggrecan plays a protective role in preventing degradation of collagen fibrils, and that an aggrecanase inhibitor may impart overall cartilage protection.	Bristol Myers Squibb Pharmaceut Co, Wilmington, DE 19898 USA	Bristol-Myers Squibb	Pratta, MA (corresponding author), GlaxoSmithKline, UP1340 1250 S Collegeville Rd,POB 5089, Collegeville, PA 19426 USA.	michael_a_pratta@gsk.com						Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1999, ANN NY ACAD SCI, V878, P92, DOI 10.1111/j.1749-6632.1999.tb07676.x; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; ARNER EC, 1989, ARTHRITIS RHEUM, V32, P288, DOI 10.1002/anr.1780320310; Beekman B, 1998, OSTEOARTHR CARTILAGE, V6, P330, DOI 10.1053/joca.1998.0132; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Bottomley KM, 1997, BIOCHEM J, V323, P483, DOI 10.1042/bj3230483; Creemers LB, 1997, BIOTECHNIQUES, V22, P656, DOI 10.2144/97224bm19; Dahlberg L, 2000, ARTHRITIS RHEUM, V43, P673, DOI 10.1002/1529-0131(200003)43:3<673::AID-ANR25>3.0.CO;2-8; ELLIS AJ, 1994, BIOCHEM BIOPH RES CO, V201, P94, DOI 10.1006/bbrc.1994.1673; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; HARDINGHAM TE, 1995, J RHEUMATOL, V22, P86; Hedlund H, 1999, J BIOL CHEM, V274, P5777, DOI 10.1074/jbc.274.9.5777; Hollander AP, 1995, J CLIN INVEST, V96, P2859, DOI 10.1172/JCI118357; HOLLANDER AP, 1994, J CLIN INVEST, V93, P1722, DOI 10.1172/JCI117156; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kozaci LD, 1997, ARTHRITIS RHEUM-US, V40, P164, DOI 10.1002/art.1780400121; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945-053X(02)00004-5; Little CB, 2002, ARTHRITIS RHEUM-US, V46, P124, DOI 10.1002/1529-0131(200201)46:1<124::AID-ART10121>3.0.CO;2-X; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MAROUDAS A, 1976, NATURE, V260, P808, DOI 10.1038/260808a0; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; NAGASE H, 2001, CONNECT TISSUE, V33, P27; ORFORD CR, 1984, CONNECT TISSUE RES, V12, P345, DOI 10.3109/03008208409013696; PRATTA MA, 1998, T ORTHOP RES SOC, V23, P81; SCOTT JE, 1991, INT J BIOL MACROMOL, V13, P157, DOI 10.1016/0141-8130(91)90041-R; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Taylor P. C., 1997, Arthritis and Rheumatism, V40, pS80; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TORTORELLA MD, 1995, T ORTHOP RES SOC, V20, P341; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; VISCO DM, 1993, ARTHRITIS RHEUM, V36, P1718, DOI 10.1002/art.1780361211; XUE CB, 1997, Patent No. 97182072; YAO W, 2001, J MED CHEM, V11, P3317; Yasuda T, 2002, ARTHRITIS RHEUM, V46, P138, DOI 10.1002/1529-0131(200201)46:1<138::AID-ART10051>3.0.CO;2-K	39	215	223	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45539	45545		10.1074/jbc.M303737200	http://dx.doi.org/10.1074/jbc.M303737200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12890681	hybrid			2022-12-25	WOS:000186452300061
J	Takada, T; Katagiri, T; Ifuku, M; Morimura, N; Kobayashi, M; Hasegawa, K; Ogamo, A; Kamijo, R				Takada, T; Katagiri, T; Ifuku, M; Morimura, N; Kobayashi, M; Hasegawa, K; Ogamo, A; Kamijo, R			Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; FIBROBLAST-GROWTH; CRYSTAL-STRUCTURE; BMP; PROTEOGLYCANS; RECEPTORS; BINDING; MEMBERS	Bone morphogenetic proteins (BMPs), which have been shown to be heparin-binding proteins, induce osteoblast differentiation in mesenchymal cells. In the present study, we examined the effects of heparin on the BMP activities in C2C12 myoblasts. Heparin dose dependently enhanced the osteoblast differentiation induced by not only homodimers of BMP-2 or BMP-4 but also heterodimers of BMP-2/6 or BMP-2/7. However, the osteoblast differentiation induced by the constitutively active BMPR-IA, a functional BMP type I receptor, was not affected by heparin. Heparan sulfate and dextran sulfate also enhanced the BMP-2 activity, although the chemically desulfated heparin-derivatives have lost this stimulatory capacity. Heparin dose-dependently suppressed the accumulation of BMP-2 from the culture media into the cell layer or BMPR-IA, and retained a large amount of BMP-2 in the culture media. The biological activity of BMP-2, which was evaluated using a BMP-responsive reporter gene expression, was prolonged in the presence of heparin. Taken together, these results suggest that sulfated polysaccharides enhance the biological activity of both homodimers and heterodimers of BMPs by continuously serving the ligands to their signaling receptors expressed on cell membranes.	Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Dent, Dept Periodontol, Tokyo 1428515, Japan; Kitasato Univ, Tokyo 1088641, Japan	Showa University; Showa University; Kitasato University	Katagiri, T (corresponding author), Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	katagiri@dent.showa-u.ac.jp						Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; BARROWCLIFFE TW, 1978, BRIT MED BULL, V34, P143, DOI 10.1093/oxfordjournals.bmb.a071484; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DODGSON KS, 1962, BIOCHEM J, V84, P106, DOI 10.1042/bj0840106; Dudley AT, 1997, DEV DYNAM, V208, P349; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601-0825.2002.01829.x; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P575, DOI 10.1006/bbrc.1997.7497; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; Ohkawara B, 2002, CURR BIOL, V12, P205, DOI 10.1016/S0960-9822(01)00684-4; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rauch C, 2002, AM J PHYSIOL-CELL PH, V283, pC235, DOI 10.1152/ajpcell.00234.2001; Reddi AH, 2001, J BONE JOINT SURG AM, V83A, pS1, DOI 10.2106/00004623-200100001-00001; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; Storm EE, 1996, DEVELOPMENT, V122, P3969; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	51	225	230	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43229	43235		10.1074/jbc.M300937200	http://dx.doi.org/10.1074/jbc.M300937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912996	hybrid			2022-12-25	WOS:000186157000064
J	Ignatovich, IA; Dizhe, EB; Pavlotskaya, AV; Akifiev, BN; Burov, SV; Orlov, SV; Perevozchikov, AP				Ignatovich, IA; Dizhe, EB; Pavlotskaya, AV; Akifiev, BN; Burov, SV; Orlov, SV; Perevozchikov, AP			Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY MODIFIED ALBUMINS; ARGININE-RICH PEPTIDES; IN-VIVO; INTRACELLULAR DELIVERY; GENE DELIVERY; POLYELECTROLYTE COMPLEXES; METABOLIC-INHIBITORS; PENETRATING PEPTIDES; BINDING PROTEINS; CELLULAR UPTAKE	Arginine-rich peptides, penetratins, as part of a number of cellular and viral proteins, can penetrate across plasma membrane directly, without participation of endocytosis. We show that one of penetratins, the basic domain 47-57 of human immunodeficiency virus, type 1, transcription factor Tat (Tat peptide), is able to interact with plasmid DNA electrostatically. These interactions result in formation of polyelectrolytic complexes at various negative/positive charge ratios of plasmid DNA and Tat peptide. Plasmid DNA is capable of binding to Tat peptide up to 1.7-fold excess of the complex positive charge. The DNA-Tat complexes can be used for delivery of plasmid DNA into mammalian cells. Transfection efficacy of cultured cells by DNA-Tat complexes is stimulated by free Tat peptide, most likely because it protects DNA-Tat complexes from disruption by anionic proteoglycans of cellular surface. Our data strongly argue in favor of the endocytosis-dependent mechanism of DNA-Tat complex uptake by mammalian cells similarly to internalization of complexes of plasmid DNA with other polycationic carriers. Moreover, different cell lines use different endocytosis-mediated pathways for DNA-Tat complex internalization. Intravenous injections to mice of DNA-Tat complexes in comparison with injections of naked DNA showed an inhibitory effect of DNA-Tat complex positive charge on expression of transferred gene. A low level of foreign gene expression in the liver of mice injected intravenously with positively charged DNA-Tat complexes is accounted for by inactivation of DNA-Tat complexes in the bloodstream due to their interactions with serum albumin. These data should be taken into account in an attempt to develop versatile gene delivery systems based on penetratin application for human disease therapy.	Russian Acad Med Sci, Dept Biochem, Inst Expt Med, St Petersburg 197376, Russia; St Petersburg State Univ, Dept Cell Biol, St Petersburg 199034, Russia; Russian Acad Sci, Inst Macromol Cpds, Lab Peptide Synth, St Petersburg 199004, Russia; St Petersburg State Univ, Dept Embryol, St Petersburg 199034, Russia	Institute of Experimental Medicine; Russian Academy of Medical Sciences; Saint Petersburg State University; Russian Academy of Sciences; Institute of Macromolecular Compounds of the Russian Academy of Sciences; Saint Petersburg State University	Orlov, SV (corresponding author), Russian Acad Med Sci, Dept Biochem, Inst Expt Med, Acad Pavlov St 12, St Petersburg 197376, Russia.		Perevozchikov, Andrej/M-9744-2015; Orlov, Sergey V./N-6823-2014; Burov, Sergey V/P-7225-2015; Dizhe, Ella B./N-6842-2014	Perevozchikov, Andrej/0000-0001-7049-3224; Orlov, Sergey V./0000-0002-3134-1989; Burov, Sergey V/0000-0003-3607-5680; Dizhe, Ella/0000-0001-5147-4749				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; *APPL BIOS INC, 1990, INTR CLEAV TECHN; BERLOSE JP, 1996, EUR J BIOCHEM, V271, P18188; BUROV SV, 2002, J PEPT SCI, V8, P188; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dash PR, 1999, GENE THER, V6, P643, DOI 10.1038/sj.gt.3300843; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dizhe EB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P55, DOI 10.1023/A:1002881612906; DIZHE EB, 2001, RUS J HIV AIDS RELAT, V5, P112; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l; Gottschalk S, 1996, GENE THER, V3, P448; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haines AMR, 2001, GENE THER, V8, P99, DOI 10.1038/sj.gt.3301314; Ignatovich I A, 2002, Tsitologiia, V44, P455; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Kobayashi N, 2001, J PHARMACOL EXP THER, V297, P853; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Niidome T, 1999, BIOCONJUGATE CHEM, V10, P773, DOI 10.1021/bc990012d; Osaka G, 1996, J PHARM SCI, V85, P612, DOI 10.1021/js9504494; Perevozchikov A. P., 1997, Molekulyarnaya Biologiya (Moscow), V31, P216; Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/jbc.M211891200; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; Schaffer DV, 1998, J BIOL CHEM, V273, P28004, DOI 10.1074/jbc.273.43.28004; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Sobolev AS, 1998, J BIOL CHEM, V273, P7928, DOI 10.1074/jbc.273.14.7928; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Weber PJA, 1998, BIOORG MED CHEM LETT, V8, P597, DOI 10.1016/S0960-894X(98)00084-5; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wolfert MA, 1996, GENE THER, V3, P269; Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200	46	172	186	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42625	42636		10.1074/jbc.M301431200	http://dx.doi.org/10.1074/jbc.M301431200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12882958	hybrid			2022-12-25	WOS:000185989500128
J	Okajima, T; Xu, AG; Irvine, KD				Okajima, T; Xu, AG; Irvine, KD			Modulation of Notch-ligand binding by protein O-Fucosyltransferase 1 and Fringe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE REPEATS; SIGNALING PATHWAY; O-FUCOSE; SERRATE; DELTA; GLYCOSYLTRANSFERASE; GLYCOSYLATION; GENES	Notch receptors are glycoproteins that mediate a wide range of developmental processes. Notch is modified in its epidermal growth factor-like domains by the addition of fucose to serine or threonine residues. O-Fucosylation is mediated by protein O-fucosyltransferase 1, and down-regulation of this enzyme by RNA interference or mutation of the Ofut1 gene in Drosophila or by mutation of the Pofut1 gene in mouse prevents Notch signaling. To investigate the molecular basis for the requirement for O-linked fucose on Notch, we assayed the ability of tagged, soluble forms of the Notch extracellular domain to bind to its ligands, Delta and Serrate. Down-regulation of OFUT1 by RNA interference in Notch-secreting cells inhibits both Delta-Notch and Serrate-Notch binding, demonstrating a requirement for O-linked fucose for efficient binding of Notch to its ligands. Conversely, overexpression of OFUT1 in cultured cells increases Serrate-Notch binding but inhibits Delta-Notch binding. These effects of OFUT1 are consistent with the consequences of OFUT1 overexpression on Notch signaling in vivo. Intriguingly, they are also opposite to, and are suppressed by, expression of the glycosyltransferase Fringe, which specifically modifies O-linked fucose. Thus, Notch-ligand interactions are dependent upon both the presence and the type of O-fucose glycans.	Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, POB 759, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054594] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 54594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES DA, 1991, J BIOL CHEM, V266, P14277; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Duvic B, 2002, CURR BIOL, V12, P1923, DOI 10.1016/S0960-9822(02)01297-6; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; HAINES N, 2003, IN PRESS NAT REV MOL; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Klein T, 1998, DEVELOPMENT, V125, P2951; Klueg KM, 1999, J CELL SCI, V112, P3289; Lebestky T, 2003, GENE DEV, V17, P348, DOI 10.1101/gad.1052803; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Oh SW, 2003, GENETICS, V163, P195; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Shimizu K, 2001, J BIOL CHEM, V276, P25753, DOI 10.1074/jbc.M103473200; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; XU T, 1993, DEVELOPMENT, V117, P1223; Zeng CY, 1998, GENE DEV, V12, P1086, DOI 10.1101/gad.12.8.1086	31	155	159	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42340	42345		10.1074/jbc.M308687200	http://dx.doi.org/10.1074/jbc.M308687200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909620	hybrid			2022-12-25	WOS:000185989500095
J	Busch, A; Engemann, S; Lurz, R; Okazawa, H; Lehrach, H; Wanker, EE				Busch, A; Engemann, S; Lurz, R; Okazawa, H; Lehrach, H; Wanker, EE			Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin - A potential mechanism for loss of huntingtin function in Huntington's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE TRACT-BINDING; AMYLOID-LIKE FIBRILS; MAMMALIAN-CELLS; IN-VIVO; PROTEIN; TRANSCRIPTION; MICE; GENE; AGGREGATION	Aggregation of huntingtin (htt) in neuronal inclusions is associated with the development of Huntington's disease (HD). Previously, we have shown that mutant htt fragments with polyglutamine ( polyQ) tracts in the pathological range (> 37 glutamines) form SDS-resistant aggregates with a fibrillar morphology, whereas wildtype htt fragments with normal polyQ domains do not aggregate. In this study we have investigated the coaggregation of mutant and wild-type htt fragments. We found that mutant htt promotes the aggregation of wildtype htt, causing the formation of SDS-resistant co-aggregates with a fibrillar morphology. Conversely, mutant htt does not promote the fibrillogenesis of the polyQ-containing protein NOCT3 or the polyQ-binding protein PQBP1, although these proteins are recruited into inclusions containing mutant htt aggregates in mammalian cells. The formation of mixed htt fibrils is a highly selective process that not only depends on polyQ tract length but also on the surrounding amino acid sequence. Our data suggest that mutant and wild-type htt fragments may also co-aggregate in neurons of HD patients and that a loss of wild-type htt function may contribute to HD pathogenesis.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Tokyo Metropolitan Inst Neurosci, Dept Mol Therapeut, Tokyo 1838526, Japan	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Wanker, EE (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		busch, anne/AAB-9805-2022	busch, anne/0000-0001-9560-0057; Wanker, Erich/0000-0001-8072-1630				Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; HARPER PS, 1991, MAJOR PROBLEMS NEURO; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kim M, 1999, J NEUROSCI, V19, P964; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Maniatis T., 1982, MOL CLONING LAB MANU; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; O'Kusky JR, 1999, BRAIN RES, V818, P468, DOI 10.1016/S0006-8993(98)01312-2; Okazawa H, 2001, BRAIN RES BULL, V56, P273, DOI 10.1016/S0361-9230(01)00579-2; Okazawa H, 2002, NEURON, V34, P701, DOI 10.1016/S0896-6273(02)00697-9; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wanker EE, 1999, METHOD ENZYMOL, V309, P375; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	47	90	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41452	41461		10.1074/jbc.M303354200	http://dx.doi.org/10.1074/jbc.M303354200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888569	hybrid			2022-12-25	WOS:000185847200125
J	Price, NJ; Pinheiro, C; Soares, CM; Ashford, DA; Ricardo, CP; Jackson, PA				Price, NJ; Pinheiro, C; Soares, CM; Ashford, DA; Ricardo, CP; Jackson, PA			A biochemical and molecular characterization of LEP1, an extensin peroxidase from lupin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYPROLINE-RICH GLYCOPROTEINS; OXIDATIVE CROSS-LINKING; HORSERADISH-PEROXIDASE; SUSPENSION-CULTURES; CRYSTAL-STRUCTURE; PLANT PEROXIDASE; CELL-DIVISION; FERULIC ACID; AMINO-ACID; IN-VITRO	An analysis of apoplastic extensin cross-linking activity in vegetative organs of Lupinus albus indicated that leaves contained the highest specific activity. Assays of peroxidases fractionated from this material demonstrated that this activity could be largely attributed to a soluble and apoplastic 51-kDa peroxidase, denoted LEP1. Relative to other purified peroxidases, LEP1 demonstrates high extensin cross-linking activity and can be classified as an extensin peroxidase (EP). Optimal conditions for the in vitro oxidation of other phenolic substrates included 1.5-3.0 mM peroxide at pH 5.0. EP activity of LEP1 was low under these conditions but optimal and substantially higher with 100 muM peroxide and neutral pH, suggesting that physiological changes in pH and peroxide in muro could heavily influence the extensin cross-linking activity of LEP1 in vivo. Analysis of LEP1 glycans indicated 11-12 N-linked glycans, predominantly the heptasaccharide Man(3)XylFucGlcNAc(2), but also larger structures showing substantial heterogeneity. Comparative assays with horseradish peroxidase isoform C and peanut peroxidases suggested the high level of glycosylation in LEP1 may be responsible for the high solubility of this EP in the apoplastic space. A full-length cDNA corresponding to LEP1 was cloned. Quantitative reverse transcriptase-PCR demonstrated LEP1 induction in apical portions of etiolated hypocotyls 30 - 60 min after exposure to white light, prior to the onset of growth inhibition. Comparative modeling of the translated sequence indicated an unusually unobstructed equatorial cleft across the substrate access channel, which might facilitate interaction with extensin and confer higher EP activity.	Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Inst Agron, P-1349017 Lisbon, Portugal	University of York - UK; Universidade de Lisboa	Jackson, PA (corresponding author), Inst Tecnol Quim & Biol, Apartado 127, P-2781901 Oeiras, Portugal.	Phil@itqb.unl.pt	Pinheiro, Carla/A-4053-2008; Jackson, Phil A. P./N-8128-2019; Soares, Claudio M/E-2675-2012; Jackson, Phil A P/I-4925-2014; Ricardo, Cândido P P/B-7891-2008	Pinheiro, Carla/0000-0002-7799-0183; Jackson, Phil A. P./0000-0002-4564-784X; Soares, Claudio M/0000-0003-1154-556X; Ricardo, Cândido P P/0000-0003-4905-1274				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BILES CL, 1991, PLANT PHYSIOL, V96, P597, DOI 10.1104/pp.96.2.597; Bolwell GP, 1998, PLANT PHYSIOL, V116, P1379, DOI 10.1104/pp.116.4.1379; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BRISSON LF, 1994, PLANT CELL, V6, P1703, DOI 10.1105/tpc.6.12.1703; BROWNLEADER MD, 1995, PLANT PHYSIOL, V109, P1115, DOI 10.1104/pp.109.3.1115; Brownleader MD, 2000, PLANTA, V210, P668, DOI 10.1007/s004250050058; Brownleader MD, 1996, BIOCHEM J, V320, P577, DOI 10.1042/bj3200577; Cano A, 1996, J PLANT PHYSIOL, V147, P721, DOI 10.1016/S0176-1617(11)81484-7; Carpin S, 2001, PLANT CELL, V13, P511, DOI 10.1105/tpc.13.3.511; Carpin S, 1999, PLANT PHYSIOL, V120, P799, DOI 10.1104/pp.120.3.799; CASSAB GI, 1987, J CELL BIOL, V105, P2581, DOI 10.1083/jcb.105.6.2581; Cassab GI, 1998, ANNU REV PLANT PHYS, V49, P281, DOI 10.1146/annurev.arplant.49.1.281; COOPER JB, 1994, PLANT PHYSIOL, V104, P747, DOI 10.1104/pp.104.2.747; COOPER JB, 1984, PLANT PHYSIOL, V76, P414, DOI 10.1104/pp.76.2.414; COOPER JB, 1987, TRENDS BIOCHEM SCI, V12, P24, DOI 10.1016/0968-0004(87)90012-0; Costa J, 1997, EUR J BIOCHEM, V243, P695, DOI 10.1111/j.1432-1033.1997.t01-1-00695.x; De Tullio MC, 1999, PLANTA, V209, P424, DOI 10.1007/s004250050745; DEITS T, 1984, J BIOL CHEM, V259, P3525; Ender F, 2002, PLANT CELL, V14, P1147, DOI 10.1105/tpc.000711; ESQUERRETUGAYE MT, 1979, PLANT PHYSIOL, V64, P320, DOI 10.1104/pp.64.2.320; EVERDEEN DS, 1988, PLANT PHYSIOL, V87, P616, DOI 10.1104/pp.87.3.616; FERRER MA, 1991, J PLANT GROWTH REGUL, V10, P139, DOI 10.1007/BF02279325; Fitchette-Laine AC, 1997, PLANT J, V12, P1411, DOI 10.1046/j.1365-313x.1997.12061411.x; FUJIYAMA K, 1988, EUR J BIOCHEM, V173, P681, DOI 10.1111/j.1432-1033.1988.tb14052.x; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Gray JSS, 1996, GLYCOBIOLOGY, V6, P23, DOI 10.1093/glycob/6.1.23; Hall Q, 2002, PLANT CELL, V14, P1161, DOI 10.1105/tpc.010477; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; Henriksen A, 2001, PROTEIN SCI, V10, P108, DOI 10.1110/ps.37301; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; Hernandez-Ruiz J, 2000, BBA-PROTEIN STRUCT M, V1478, P78, DOI 10.1016/S0167-4838(00)00017-0; JACKSON P, 1994, PLANTA, V194, P311, DOI 10.1007/BF00197530; Jackson P, 1998, AUST J PLANT PHYSIOL, V25, P261, DOI 10.1071/PP97083; JACKSON P, 1996, PLANT PEROXIDASES BI, P255; JACKSON P, 1999, AUST J PLANT PHYSL, V26, P313; Jackson PAP, 2001, PLANT PHYSIOL, V127, P1065, DOI 10.1104/pp.010192; JOHANSSON A, 1992, PLANT MOL BIOL, V18, P1151, DOI 10.1007/BF00047718; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kjaersgard IVH, 1997, PLANT MOL BIOL, V33, P699, DOI 10.1023/A:1005707813801; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunze I, 1998, PLANTA, V205, P92, DOI 10.1007/s004250050300; Kutschera U, 1996, J EXP BOT, V47, P1387, DOI 10.1093/jxb/47.9.1387; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Magliano TMA, 1998, J EXP BOT, V49, P1491, DOI 10.1093/jexbot/49.326.1491; MCCANN MC, 1990, J CELL SCI, V96, P323; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; Melo NS, 1997, FEBS LETT, V415, P186, DOI 10.1016/S0014-5793(97)01121-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mirza O, 2000, ACTA CRYSTALLOGR D, V56, P372, DOI 10.1107/S0907444999016340; NAKAJIMA R, 1979, J BIOL CHEM, V254, P872; NAKAMURA K, 1993, PLANT PHYSIOL, V101, P1, DOI 10.1104/pp.101.1.1; NEUHAUS JM, 1994, PLANT J, V5, P45, DOI 10.1046/j.1365-313X.1994.5010045.x; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nunan KJ, 1998, PLANT PHYSIOL, V118, P783, DOI 10.1104/pp.118.3.783; Omann F, 1996, AUST J PLANT PHYSIOL, V23, P773, DOI 10.1071/PP9960773; Ostergaard L, 2000, PLANT MOL BIOL, V44, P231, DOI 10.1023/A:1006442618860; QI XY, 1995, PLANT PHYSIOL, V108, P1691, DOI 10.1104/pp.108.4.1691; RASMUSSEN SK, 1991, PLANT MOL BIOL, V16, P317, DOI 10.1007/BF00020562; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salva I, 2001, PLANT BIOLOGY, V3, P32, DOI 10.1055/s-2001-11746; Schnabelrauch LS, 1996, PLANT J, V9, P477, DOI 10.1046/j.1365-313X.1996.09040477.x; SCHOPFER P, 1994, PLANT PHYSIOL, V104, P1269, DOI 10.1104/pp.104.4.1269; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SWORDS KMM, 1993, PLANT PHYSIOL, V102, P891, DOI 10.1104/pp.102.3.891; TAKAHAMA U, 1993, PLANT CELL PHYSIOL, V34, P809; THEILADE B, 1992, GENE, V118, P261, DOI 10.1016/0378-1119(92)90197-W; THEILADE B, 1993, PLANT PEROXIDASES BI, P321; TIRE C, 1994, PLANTA, V195, P175, DOI 10.1007/BF00199676; Veitch NC, 1997, BIOCHEMISTRY-US, V36, P14751, DOI 10.1021/bi9718402; WAN LG, 1994, BIOCHEM CELL BIOL, V72, P411, DOI 10.1139/o94-055; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; Wojtaszek P, 1997, FEBS LETT, V405, P95, DOI 10.1016/S0014-5793(97)00166-X; Yang BY, 1996, CARBOHYD RES, V287, P203, DOI 10.1016/0008-6215(96)00073-0; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; ZIMMERLIN A, 1994, BIOCHEM J, V299, P747, DOI 10.1042/bj2990747	77	47	48	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41389	41399		10.1074/jbc.M304519200	http://dx.doi.org/10.1074/jbc.M304519200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882982	hybrid			2022-12-25	WOS:000185847200119
J	Rathore, D; Hrstka, SCL; Sacci, JB; De la Vega, P; Linhardt, RJ; Kumar, S; McCutchan, TF				Rathore, D; Hrstka, SCL; Sacci, JB; De la Vega, P; Linhardt, RJ; Kumar, S; McCutchan, TF			Molecular mechanism of host specificity in Plasmodium falciparum infection - Role of circumsporozoite protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA SPOROZOITES; HEPARIN; GENE; THROMBOSPONDIN; DNA; GLYCOSAMINOGLYCANS; MITOCHONDRIAL; PARASITES; MEMBRANE; INVASION	Plasmodium falciparum sporozoites invade liver cells in humans and set the stage for malaria infection. Circumsporozoite protein ( CSP), a predominant surface antigen on sporozoite surface, has been associated with the binding and invasion of liver cells by the sporozoites. Although CSP across the Plasmodium genus has homology and conserved structural organization, infection of a non-natural host by a species is rare. We investigated the role of CSP in providing the host specificity in P. falciparum infection. CSP from P. falciparum, P. gallinaceum, P. knowlesi, and P. yoelii species representing human, avian, simian, and rodent malaria species were recombinantly expressed, and the proteins were purified to homogeneity. The recombinant proteins were evaluated for their capacity to bind to human liver cell line HepG2 and to prevent P. falciparum sporozoites from invading these cells. The proteins showed significant differences in the binding and sporozoite invasion inhibition activity. Differences among proteins directly correlate with changes in the binding affinity to the sporozoite receptor on liver cells. P. knowlesi CSP (PkCSP) and P. yoelii CSP (PyCSP) had 4,790- and 17,800-fold lower affinity for heparin in comparison to P. falciparum CSP (PfCSP). We suggest that a difference in the binding affinity for the liver cell receptor is a mechanism involved in maintaining the host specificity by the malaria parasite.	NIAID, Growth & Dev Sect, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; US FDA, Bacterial & Parasit Dis Sect, Div Emerging TRansfus & Transmitted Dis, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Virginia Polytechnic Institute & State University; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University System of Maryland; University of Maryland Baltimore; United States Department of Defense; United States Navy; US Food & Drug Administration (FDA)	McCutchan, TF (corresponding author), NIAID, Growth & Dev Sect, Lab Malaria & Vector Res, NIH, Rm 126,Bldg 4,4 Ctr Dr,MSC 0425, Bethesda, MD 20892 USA.	tmccutchan@niaid.nih.gov		Hrstka, Sybil/0000-0003-1442-5707	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000208, ZIAAI000208] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; COLLINS WE, 1973, J PARASITOL, V59, P855, DOI 10.2307/3278423; COLLINS WE, 1994, AM J TROP MED HYG, V51, P224, DOI 10.4269/ajtmh.1994.51.224; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; Escalante AA, 1998, P NATL ACAD SCI USA, V95, P8124, DOI 10.1073/pnas.95.14.8124; FASMAN GD, 1990, BIOPOLYMERS, V29, P123, DOI 10.1002/bip.360290117; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; GOMES PB, 1982, COMP BIOCHEM PHYS B, V73, P857, DOI 10.1016/0305-0491(82)90329-7; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; Naitza S, 1998, PARASITOL TODAY, V14, P479, DOI 10.1016/S0169-4758(98)01346-5; Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; Rathore D, 2000, INFECT IMMUN, V68, P740, DOI 10.1128/IAI.68.2.740-743.2000; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Rathore D, 1996, FEBS LETT, V392, P259, DOI 10.1016/0014-5793(96)00825-3; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; Rathore D, 2001, MOL BIOCHEM PARASIT, V114, P89, DOI 10.1016/S0166-6851(01)00241-9; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Rogers WO, 2002, INFECT IMMUN, V70, P4329, DOI 10.1128/IAI.70.8.4329-4335.2002; Roggero MA, 1995, MOL IMMUNOL, V32, P1301, DOI 10.1016/0161-5890(95)00136-0; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHMIDT LH, 1978, AM J TROP MED HYG, V27, P671, DOI 10.4269/ajtmh.1978.27.671; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Templeton TJ, 1997, MOL BIOCHEM PARASIT, V84, P13, DOI 10.1016/S0166-6851(96)02775-2; Tewari R, 2002, J BIOL CHEM, V277, P47613, DOI 10.1074/jbc.M208453200; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WATERS AP, 1991, P NATL ACAD SCI USA, V88, P3140, DOI 10.1073/pnas.88.8.3140; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhang FM, 2002, ANAL BIOCHEM, V304, P271, DOI 10.1006/abio.2002.5617	33	39	49	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40905	40910		10.1074/jbc.M306250200	http://dx.doi.org/10.1074/jbc.M306250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904297	hybrid			2022-12-25	WOS:000185847200061
J	Richardt, A; Kemme, T; Wagner, S; Schwarzer, D; Marahiel, MA; Hovemann, BT				Richardt, A; Kemme, T; Wagner, S; Schwarzer, D; Marahiel, MA; Hovemann, BT			Ebony, a novel nonribosomal peptide synthetase for beta-alanine conjugation with biogenic amines in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; VISUAL MUTANTS; NERVOUS-SYSTEM; HISTAMINE; PROTEIN; BIOSYNTHESIS; LOCUS; EXPRESSION; DOMAINS; PCP	Using Ebony protein either expressed in Escherichia coli or in Schneider S2 cells, we provide evidence for its substrate specificity and reaction mechanism. Ebony activates beta-alanine to aminoacyladenylate by an adenylation domain and covalently attaches it as a thioester to a thiolation domain in a nonribosomal peptide synthetase (NRPS) related mechanism. In a second reaction, biogenic amines act as external nucleophiles on beta-alanyl-S-pantetheine- Ebony, thereby releasing in a fast reaction the dipeptide (peptidoamine) in a process that is novel in higher eucaryotes. Therefore, we define Ebony as a beta-alanyl-biogenic amine synthetase. Insight into the reaction mechanism stems from mutational analysis of an invariant serine that disclosed Ebony as a multienzyme with functional analogy to the starting modules of NRPSs. In light of a putative biogenic amine-deactivating capacity, Ebony function in the nervous system must be reconsidered. We propose that in the Drosophila eye Ebony is involved in the transmission process by inactivation of histamine through beta-alanyl conjugation.	Ruhr Univ Bochum, Fak Chem, AG Mol Zellbiochem, D-44780 Bochum, Germany; Univ Marburg, Fachbereich Chem Biochem, D-35032 Marburg, Germany	Ruhr University Bochum; Philipps University Marburg	Hovemann, BT (corresponding author), Ruhr Univ Bochum, Fak Chem, AG Mol Zellbiochem, Univ Str 150, D-44780 Bochum, Germany.	bernhard.hovemann@rub.de		Schwarzer, Dirk/0000-0002-7477-3319; Kemme, Tobias/0000-0002-5595-160X				BENZER S, 1967, P NATL ACAD SCI USA, V58, P1112, DOI 10.1073/pnas.58.3.1112; BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; Borycz J, 2002, J NEUROSCI, V22, P10549; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRIDGES CB, 1923, PUBL CARNEGIE I, V327, P50; CAIZZI R, 1987, MOL GEN GENET, V206, P66, DOI 10.1007/BF00326537; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; FLANCBAUM L, 1990, LIFE SCI, V47, P1587, DOI 10.1016/0024-3205(90)90188-W; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HEISENBERG M, 1971, J EXP BIOL, V55, P85; HEISENBERG M, 1972, J COMP PHYSIOL, V80, P119, DOI 10.1007/BF00696485; HOTTA Y, 1969, NATURE, V222, P354, DOI 10.1038/222354a0; Hovemann BT, 1998, GENE, V221, P1, DOI 10.1016/S0378-1119(98)00440-5; KYRIACOU CP, 1978, ANIM BEHAV, V26, P1195, DOI 10.1016/0003-3472(78)90109-4; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Melzig J, 1998, J NEUROSCI, V18, P7160; Morgan JR, 1999, J NEUROSCI, V19, P1217; Nassel D.R., 1988, Journal of Chemical Neuroanatomy, V1, P311; NEWBY LM, 1991, J NEUROGENET, V7, P85, DOI 10.3109/01677069109066213; Perez M, 2002, INSECT BIOCHEM MOLEC, V32, P617, DOI 10.1016/S0965-1748(01)00140-0; PFEIFER E, 1995, BIOCHEMISTRY-US, V34, P7450, DOI 10.1021/bi00022a019; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Richardt A, 2002, J COMP NEUROL, V452, P93, DOI 10.1002/cne.10360; SARTHY PV, 1991, J NEUROCHEM, V57, P1757, DOI 10.1111/j.1471-4159.1991.tb06378.x; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; Stuart AE, 1996, J NEUROSCI, V16, P3178; TURGAY K, 1992, MOL MICROBIOL, V6, P2743, DOI 10.1111/j.1365-2958.1992.tb01451.x; VOLLENBROICH D, 1993, FEBS LETT, V325, P220, DOI 10.1016/0014-5793(93)81077-D; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5	35	98	108	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41160	41166		10.1074/jbc.M304303200	http://dx.doi.org/10.1074/jbc.M304303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900414	hybrid			2022-12-25	WOS:000185847200092
J	Mucenski, ML; Wert, SE; Nation, JM; Loudy, DE; Huelsken, J; Birchmeier, W; Morrisey, EE; Whitsett, JA				Mucenski, ML; Wert, SE; Nation, JM; Loudy, DE; Huelsken, J; Birchmeier, W; Morrisey, EE; Whitsett, JA			beta-catenin is required for specification of proximal/distal cell fate during lung morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; DEVELOPING MOUSE LUNG; SURFACTANT PROTEIN-B; GROWTH-FACTOR; CHROMOSOMAL LOCALIZATION; BRANCHING MORPHOGENESIS; RESPIRATORY EPITHELIUM; EXPRESSION; GENE; MICE	The lungs are divided, both structurally and functionally, into two distinct components, the proximal airways, which conduct air, and the peripheral airways, which mediate gas exchange. The mechanisms that control the specification of these two structures during lung development are currently unknown. Here we show that beta-catenin signaling is required for the formation of the distal, but not the proximal, airways. When the gene for beta-catenin was conditionally excised in epithelial cells of the developing mouse lung prior to embryonic day 14.5, the proximal lung tubules grew and differentiated appropriately. The mice, however, died at birth because of respiratory failure. Analysis of the lungs by in situ hybridization and immunohistochemistry, using molecular markers of the epithelial and mesenchymal components of both proximal and peripheral airways, showed that the lungs were composed primarily of proximal airways. These observations establish, for the first time, both the sites and timing of specification of the proximal and peripheral airways in the developing lung, and that beta-catenin is one of the essential components of this specification.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Max Delbrueck Ctr Mol Med, D-13125 Berlin, Germany; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Cincinnati Children's Hospital Medical Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Pennsylvania	Mucenski, ML (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Huelsken, Joerg/AAC-9581-2021	Huelsken, Joerg/0000-0003-3105-9606	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, P50HL056387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bellusci S, 1997, DEVELOPMENT, V124, P53; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DasGupta R, 2002, J CELL BIOL, V158, P331, DOI 10.1083/jcb.200204134; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Greenberg JM, 2002, DEV DYNAM, V224, P144, DOI 10.1002/dvdy.10095; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Katoh M, 1996, ONCOGENE, V13, P873; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Li CG, 2002, DEV BIOL, V248, P68, DOI 10.1006/dbio.2002.0729; Lu MM, 2001, DEV DYNAM, V222, P667, DOI 10.1002/dvdy.1231; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Malik TH, 2000, BIOCHEM J, V349, P829, DOI 10.1042/bj3490829; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012-1606(03)00106-4; Quaggin SE, 1999, DEVELOPMENT, V126, P5771; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Shiratori M, 1996, AM J RESP CELL MOL, V15, P328, DOI 10.1165/ajrcmb.15.3.8810636; Shu WG, 2002, DEVELOPMENT, V129, P4831; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Tebar M, 2001, MECH DEVELOP, V109, P437, DOI 10.1016/S0925-4773(01)00556-1; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Weaver M, 2000, DEVELOPMENT, V127, P2695; Weaver M, 1999, DEVELOPMENT, V126, P4005; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WILKINSON DG, 1992, WHOLE MOUNT IN SITU; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	50	238	242	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40231	40238		10.1074/jbc.M305892200	http://dx.doi.org/10.1074/jbc.M305892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885771	hybrid			2022-12-25	WOS:000185713800116
J	Oliveira, ME; Gouveia, AM; Pinto, RA; Sa-Miranda, C; Azevedo, JE				Oliveira, ME; Gouveia, AM; Pinto, RA; Sa-Miranda, C; Azevedo, JE			The energetics of Pex5p-mediated peroxisomal protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; TARGETING SIGNAL 1; ACYL-COA OXIDASE; SACCHAROMYCES-CEREVISIAE; IN-VITRO; FIREFLY LUCIFERASE; PTS1 RECEPTOR; YARROWIA-LIPOLYTICA; CYCLING RECEPTOR; PEX5P	Most newly synthesized peroxisomal matrix proteins are targeted to the organelle by Pex5p, the peroxisomal cycling receptor. According to current models of peroxisomal biogenesis, Pex5p interacts with cargo proteins in the cytosol and transports them to the peroxisomal membrane. After delivering the passenger protein into the peroxisomal matrix, Pex5p returns to the cytosol to catalyze additional rounds of transportation. Obviously, such cyclic pathway must require energy, and indeed, data confirming this need are already available. However, the exact step(s) of this cycle where energy input is necessary remains unclear. Here, we present data suggesting that insertion of Pex5p into the peroxisomal membrane does not require ATP hydrolysis. This observation raises the possibility that at the peroxisomal membrane ATP is needed predominantly (if not exclusively) downstream of the protein translocation step to reset the Pex5p-mediated transport system.	Inst Biol Mol & Celular, P-4150180 Oporto, Portugal; Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal; Inst Genet Med Jacinto de Magalhaes, P-4050466 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Azevedo, JE (corresponding author), Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.		Azevedo, Jorge E/A-4113-2008; Gouveia, Alexandra/P-3525-2016; sá Miranda, Maria Clara/K-3920-2013	Azevedo, Jorge E/0000-0001-7714-5302; Gouveia, Alexandra/0000-0001-8784-4246; sá Miranda, Maria Clara/0000-0003-0123-5525; Oliveira, Marcia/0000-0003-2437-2004				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; BEHARI R, 1993, J BIOL CHEM, V268, P7315; BELLION E, 1987, CELL, V48, P165, DOI 10.1016/0092-8674(87)90367-9; Brickner DG, 1997, PLANT PHYSIOL, V113, P1213, DOI 10.1104/pp.113.4.1213; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Crookes WJ, 1998, J BIOL CHEM, V273, P17236, DOI 10.1074/jbc.273.27.17236; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dodt G, 2001, J BIOL CHEM, V276, P41769, DOI 10.1074/jbc.M106932200; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gatto GJ, 2003, BIOCHEMISTRY-US, V42, P1660, DOI 10.1021/bi027034z; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; Gouveia AM, 2003, J BIOL CHEM, V278, P4389, DOI 10.1074/jbc.C200650200; Gouveia AMM, 1999, ANAL BIOCHEM, V274, P270, DOI 10.1006/abio.1999.4281; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; HARTL FU, 1985, ARCH BIOCHEM BIOPHYS, V237, P124, DOI 10.1016/0003-9861(85)90261-9; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; HORNG JT, 1995, EUR J BIOCHEM, V230, P157, DOI 10.1111/j.1432-1033.1995.tb20546.x; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; LEIGHTON F, 1969, J CELL BIOL, V41, P521, DOI 10.1083/jcb.41.2.521; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Pool MR, 1998, EMBO J, V17, P6854, DOI 10.1093/emboj/17.23.6854; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; RAPP S, 1993, EXP CELL RES, V205, P59, DOI 10.1006/excr.1993.1058; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Saidowsky J, 2001, J BIOL CHEM, V276, P34524, DOI 10.1074/jbc.M104647200; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SOTO U, 1993, EXP CELL RES, V205, P66, DOI 10.1006/excr.1993.1059; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Terlecky SR, 2001, EXP CELL RES, V263, P98, DOI 10.1006/excr.2000.5111; Titorenko VI, 2002, J CELL BIOL, V156, P481, DOI 10.1083/jcb.200111075; Titorenko VI, 1998, J CELL BIOL, V142, P403, DOI 10.1083/jcb.142.2.403; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WALTON PA, 1994, J CELL BIOL, V125, P1037, DOI 10.1083/jcb.125.5.1037; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Will GK, 1999, MOL CELL BIOL, V19, P2265	59	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39483	39488		10.1074/jbc.M305089200	http://dx.doi.org/10.1074/jbc.M305089200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885776	hybrid			2022-12-25	WOS:000185713800027
J	Shen, MR; Chou, CY; Hsu, KF; Hsu, YM; Chiu, WT; Tang, MJ; Alper, SL; Ellory, JC				Shen, MR; Chou, CY; Hsu, KF; Hsu, YM; Chiu, WT; Tang, MJ; Alper, SL; Ellory, JC			KCl cotransport is an important modulator of human cervical cancer growth and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELLS; CL-COTRANSPORTER; VOLUME; EXPRESSION; CHLORIDE; ACTIVATION; SYSTEM; INTEGRINS; CARCINOMA; BETA(2)	Cervical cancer is a major world health problem for women, but the pathophysiology of this disease has received scant attention. Here we show that the growth and invasion of cervical cancer cells are strongly linked the expression and activity of the KCl cotransporter (KCC), an important regulator of the ionic and cellular osmotic homeostasis. Functional assays of KCl cotransport activation by osmotic swelling, staurosporine, and N-ethylmaleimide indicate that removal of the N-terminal 117 amino acids from KCC1 produces a dominant-negative loss-of-function phenotype for KCl cotransport in human cervical cancer cells. The capability for regulatory volume decrease is much attenuated in the loss-of-function KCC mutant cervical cancer cells. The lossoffunction KCC mutant cervical cancer cells exhibit inhibited cell growth accompanied by decreased activity of the cell cycle gene products retinoblastoma and cdc2 kinase. Reduced cellular invasiveness is in parallel by reduced expression of alpha(v)beta(3) and alpha(6)beta(4) integrins, accompanied by decreased activity of matrix metalloproteinase 2 and 9. Inhibition of tumor growth in SCID mice confirms the crucial role of KCC in promoting cervical cancer growth and invasion. Thus, blockade of KCl cotransport may be a useful therapeutic adjunctive strategy to retard or prevent cervical cancer invasion.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 704, Taiwan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Mol Med & Renal Unit, Boston, MA 02215 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; University of Oxford; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Shen, MR (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.	mrshen@mail.ncku.edu.tw	Hsu, Keng-Fu/C-1441-2009	Tang, Ming-Jer/0000-0002-0883-4363				ALBINI A, 1987, CANCER RES, V47, P3239; Aplin JD, 1996, BRIT J CANCER, V74, P240, DOI 10.1038/bjc.1996.344; Casula S, 2001, J BIOL CHEM, V276, P41870, DOI 10.1074/jbc.M107155200; Chattopadhyay N, 1999, GYNECOL ONCOL, V75, P215, DOI 10.1006/gyno.1999.5574; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Ellory JC, 1998, CONTRIB NEPHROL, V123, P220, DOI 10.1159/000059915; GARAY RP, 1988, MOL PHARMACOL, V33, P696; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Jeffers MD, 1997, GYNECOL ONCOL, V64, P481, DOI 10.1006/gyno.1996.4578; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; LEE YC, 1995, AM J PHYSIOL-RENAL, V268, pF862, DOI 10.1152/ajprenal.1995.268.5.F862; Menegazzi R, 1999, J IMMUNOL, V162, P423; Menegazzi R, 2000, J IMMUNOL, V165, P4606, DOI 10.4049/jimmunol.165.8.4606; Mercado A, 2000, J BIOL CHEM, V275, P30326, DOI 10.1074/jbc.M003112200; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; ROUSSA E, 2001, CELL BIOL, V117, P335; Saga Y, 2001, ONCOLOGY-BASEL, V60, P367, DOI 10.1159/000058534; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Shen MR, 2000, PFLUG ARCH EUR J PHY, V440, P751, DOI 10.1007/s004240000338; Shen MR, 2001, P NATL ACAD SCI USA, V98, P14714, DOI 10.1073/pnas.251388798; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; Yamani MH, 2002, CIRCULATION, V105, P1955, DOI 10.1161/01.CIR.0000014971.09169.BC	31	58	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39941	39950		10.1074/jbc.M308232200	http://dx.doi.org/10.1074/jbc.M308232200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902337	hybrid			2022-12-25	WOS:000185713800082
J	El-Azami-El-Idrissi, M; Bauche, C; Loucka, J; Osicka, R; Sebo, P; Ladant, D; Leclerc, C				El-Azami-El-Idrissi, M; Bauche, C; Loucka, J; Osicka, R; Sebo, P; Ladant, D; Leclerc, C			Interaction of Bordetella pertussis adenylate cyclase with CD11b/CD18 - Role of toxin acylation and identification of the main integrin interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL EPITOPES; ANTIGEN-PRESENTING CELLS; IN-VIVO; MACROPHAGE APOPTOSIS; HEMOLYTIC ACTIVITIES; COMPLEMENT RECEPTOR; PROTECTIVE ACTIVITY; LETHAL INFECTION; DENDRITIC CELLS; TARGET-CELLS	Adenylate cyclase toxin (CyaA) is one of the major virulence factors produced by Bordetella pertussis, the whooping cough agent. CyaA belongs to the repeat in toxin protein family and requires a post-translational fatty acylation to form cation-selective channels in target cell membranes and to penetrate into cytosol. We have demonstrated recently that CyaA uses the alpha(M)beta(2) integrin (CD11b/CD18) as a specific cellular receptor. Here we show that the acylation of CyaA is required for a productive and tight interaction of the toxin with cells expressing CD11b. In addition, we demonstrate that the catalytic domain is not required for binding of CyaA to CD11b and that the main integrin interacting domain of CyaA is located in its glycine/aspartate-rich repeat region. These data decipher, for the first time, the interaction of CyaA with CD11b-positive cells and open new prospects for understanding the interaction of Bordetella pertussis with innate and adaptive immune systems.	Inst Pasteur, INSERM, E0352, Unite Biol Regulat Immunitaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2185, Unite Biochim Interact Macromol, F-75724 Paris, France; Acad Sci Czech Republ, Prague 14220 4, Czech Republic	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Czech Academy of Sciences	Leclerc, C (corresponding author), Inst Pasteur, INSERM, E0352, Unite Biol Regulat Immunitaires, 25 Rue Dr Roux, F-75724 Paris 15, France.		SEBO, Peter/N-2043-2019; SEBO, Peter/F-7423-2011; Osicka, Radim/H-6776-2014; Kovářová, Jiřina/R-4129-2017	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; Osicka, Radim/0000-0003-2626-5456; LADANT, Daniel/0000-0003-1955-548X	PHS HHS [55000334] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ARCINIEGA JL, 1991, J INFECT DIS, V163, P135, DOI 10.1093/infdis/163.1.135; ARNAOUT MA, 1990, BLOOD, V75, P1037; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 2001, J BIOL CHEM, V276, P348, DOI 10.1074/jbc.M006463200; Bell D, 1999, ADV IMMUNOL, V72, P255, DOI 10.1016/S0065-2776(08)60023-1; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BETSOU F, 1995, INFECT IMMUN, V63, P3309, DOI 10.1128/IAI.63.9.3309-3315.1995; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Fayolle C, 1996, J IMMUNOL, V156, P4697; FRIEDMAN RL, 1987, INFECT IMMUN, V55, P135, DOI 10.1128/IAI.55.1.135-140.1987; Gmira S, 2001, RES MICROBIOL, V152, P889, DOI 10.1016/S0923-2508(01)01272-4; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; Gray MC, 1999, INFECT IMMUN, V67, P4393, DOI 10.1128/IAI.67.9.4393-4399.1999; Gueirard P, 1998, INFECT IMMUN, V66, P1718, DOI 10.1128/IAI.66.4.1718-1725.1998; Guermonprez P, 2000, METHOD ENZYMOL, V326, P527; Guermonprez P, 2002, EUR J IMMUNOL, V32, P3071, DOI 10.1002/1521-4141(200211)32:11<3071::AID-IMMU3071>3.0.CO;2-A; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; GUISO N, 1989, MICROB PATHOGENESIS, V7, P373, DOI 10.1016/0882-4010(89)90040-5; GUISO N, 1993, EUR J CLIN MICROBIOL, V12, P596, DOI 10.1007/BF01973637; GUISO N, 1991, MICROB PATHOGENESIS, V11, P423, DOI 10.1016/0882-4010(91)90038-C; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; Harvill ET, 1999, INFECT IMMUN, V67, P1493, DOI 10.1128/IAI.67.3.1493-1500.1999; Hormozi K, 1999, FEMS IMMUNOL MED MIC, V23, P273, DOI 10.1016/S0928-8244(98)00146-1; Ingalls RR, 1998, PROG CLIN BIOL RES, V397, P107; Karimova G, 1998, P NATL ACAD SCI USA, V95, P12532, DOI 10.1073/pnas.95.21.12532; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; KHELEF N, 1994, INFECT IMMUN, V62, P2893, DOI 10.1128/IAI.62.7.2893-2900.1994; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LADANT D, 1992, J BIOL CHEM, V267, P2244; Njamkepo E, 2000, J CELL PHYSIOL, V183, P91, DOI 10.1002/(SICI)1097-4652(200004)183:1<91::AID-JCP11>3.0.CO;2-S; Osicka R, 2000, INFECT IMMUN, V68, P247; PEARSON RD, 1987, J IMMUNOL, V139, P2749; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; Sambrook J., 2002, MOL CLONING LAB MANU; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; WEISS AA, 1989, INFECT IMMUN, V57, P3757, DOI 10.1128/IAI.57.12.3757-3764.1989; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734	46	99	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38514	38521		10.1074/jbc.M304387200	http://dx.doi.org/10.1074/jbc.M304387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885782	hybrid			2022-12-25	WOS:000185575100053
J	Le Bras, M; Bensaad, K; Soussi, T				Le Bras, M; Bensaad, K; Soussi, T			Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway	ONCOGENE			English	Article						p53 tumour suppressor gene; p53 gene family; apoptosis; phylogenetic studies; fugu rubripes; data mining	TUMOR-SUPPRESSOR; DNA-DAMAGE; CELL-CYCLE; MDM2; GENE; IDENTIFICATION; P73; EXPRESSION; HOMOLOG; PROTEIN	The p53 tumour suppressor gene belongs to a small family of related proteins that includes two other members, p63 and p73. Phylogenetic and functional studies suggest that p63 and p73 are ancient genes that have essential roles in normal development, whereas p53 seems to have evolved more recently to prevent cell transformation. In mammalian cells, a plethora of proteins have been found to specifically regulate p53 activity. The genome of the fish Fugu rubripes has been recently published. It is the second vertebrate genome for which the entire sequence is now available. Phylogenetic studies are essential in order to analyse and define signalling pathways important for cell cycle regulation. The presence or absence of a critical member in any pathway can shed light about the evolution of these pathways. The Fugu genome databank has been analysed for several members of the p53 network, including p53, p63 and p73. A good conservation of the network that regulates p53 stability and apoptosis has been found. We also discovered that some cofactors that cooperate with p53 for apoptosis are also well conserved and belong to multigene families not detected in the human genome.	Inst Curie, Lab Genotoxciol Tumeurs, F-75005 Paris, France; Univ Paris 06, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite	Soussi, T (corresponding author), Inst Curie, 26 Rue Ulm, F-75248 Paris 05, France.	Thierry.Soussi@curie.fr		soussi, thierry/0000-0001-8184-3293; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Cachot J, 1998, COMP BIOCHEM PHYS C, V120, P351, DOI 10.1016/S0742-8413(98)00039-5; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; DEFROMENTEL CC, 1992, GENE, V112, P241, DOI 10.1016/0378-1119(92)90383-Z; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gilley J, 2001, ONCOGENE, V20, P7447, DOI 10.1038/sj.onc.1204933; Goodman RH, 2000, GENE DEV, V14, P1553; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HARDYBESSARD AC, 1998, ONCOGENE, V16, P883; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kostic C, 2000, ONCOGENE, V19, P3978, DOI 10.1038/sj.onc.1203747; Krause MK, 1997, GENE, V189, P101, DOI 10.1016/S0378-1119(96)00841-4; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; VERGAMASCHI D, 2003, NAT GENET, V33, P162; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu WP, 2001, ONCOGENE, V20, P5554, DOI 10.1038/sj.onc.1204679; Zhao RB, 2000, GENE DEV, V14, P981	61	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5082	5090		10.1038/sj.onc.1206424	http://dx.doi.org/10.1038/sj.onc.1206424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902991				2022-12-25	WOS:000184578900016
J	Mathur, M; Das, S; Samuels, HH				Mathur, M; Das, S; Samuels, HH			PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration	ONCOGENE			English	Article						PSF-TFE3; TFE3; PSF-A; renal cell carcinoma; endosomes; cell transformation	SPLICING FACTOR PSF; HISTONE DEACETYLASE COMPLEX; NUCLEAR HORMONE-RECEPTORS; LOOP-HELIX PROTEINS; GENE-EXPRESSION; BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; RNA INTERFERENCE; FUSION PARTNER; BREAST-CANCER	Papillary renal cell carcinomas are associated with chromosomal translocations involving the helix-loop-helix leucine-zipper region of the TFE3 gene on the X chromosome. These translocations lead to the expression of TFE3 chimeras of PRCC, RCC17, NonO and PSF (PTB-associated splicing factor). In this study, we explored the role of PSF-TFE3 fusion protein in mediating cell transformation. Unlike wild-type TFE3 or PSF, which are nuclear proteins, PSF-TFE3 is not a nuclear protein and is targeted to the endosomal compartment. Although PSF-TFE3 has no effect on the nuclear localization of wild-type PSF, it sequesters wildtype TFE3 as well as p53 in the extranuclear compartment leading to functionally null p53 and TFE3 cells. In UOK-145 papillary renal carcinoma cells, which endogenously express PSF-TFE3, siRNA complementary to the PSF-TFE3 fusion junction leads to a reduction in PSF-TFE3 and redistribution of endogenous TFE3 and p53 from the cytoplasmic compartment to the nucleus. Our results indicate that PSF-TFE3 acts through a novel mechanism, and exports TFE3, p53 and possibly other factors from the nucleus to the cytoplasm for degradation leading to the transformed phenotype. Thus, PSF-TFE3 is a promising target for the treatment for a subset of renal cell carcinomas.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University; New York University	Samuels, HH (corresponding author), NYU, Sch Med, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.				NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R01DK016636, R37DK016636] Funding Source: NIH RePORTER; NCI NIH HHS [CA16087] Funding Source: Medline; NIAMS NIH HHS [AR02083] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Akhmedov AT, 2000, NUCLEIC ACIDS RES, V28, P3022, DOI 10.1093/nar/28.16.3022; Angelo LS, 2002, CANCER RES, V62, P932; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glukhova L, 1998, GENE CHROMOSOME CANC, V22, P171, DOI 10.1002/(SICI)1098-2264(199807)22:3<171::AID-GCC2>3.3.CO;2-K; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Heimann P, 2001, CANCER RES, V61, P4130; Hsueh C, 2002, MODERN PATHOL, V15, P606, DOI 10.1038/modpathol.3880573; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Li DS, 1999, MOL CELL BIOL, V19, P7191; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mahajan MA, 2002, MOL CELL BIOL, V22, P6883, DOI 10.1128/MCB.22.19.6883-6894.2002; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; ODA H, 1995, CANCER RES, V55, P658; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Qi JS, 1999, MOL CELL BIOL, V19, P864; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; REITER RE, 1993, CANCER RES, V53, P3092; Rosenberger U, 2002, J CELL BIOCHEM, V86, P394, DOI 10.1002/jcb.10233; Sewer MB, 2002, ENDOCRINOLOGY, V143, P1280, DOI 10.1210/en.143.4.1280; Simon JP, 2000, METHODS, V20, P437, DOI 10.1006/meth.2000.0957; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Tian G, 1999, MOL CELL BIOL, V19, P2946; Urban RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE794, DOI 10.1152/ajpendo.00174.2002; vandenBerg E, 1997, CANCER GENET CYTOGEN, V95, P103, DOI 10.1016/S0165-4608(96)00289-0; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	46	26	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5031	5044		10.1038/sj.onc.1206643	http://dx.doi.org/10.1038/sj.onc.1206643			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902986				2022-12-25	WOS:000184578900011
J	Perl, O; Ilani, T; Strous, RD; Lapidus, R; Fuchs, S				Perl, O; Ilani, T; Strous, RD; Lapidus, R; Fuchs, S			The alpha 7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes	FASEB JOURNAL			English	Article						human blood lymphocytes; RT-PCR; smoking	CIGARETTE-SMOKING; EXPRESSION; DONEPEZIL; PATHOLOGY; SUBUNIT; GENE	Recent studies have suggested that the alpha7 nicotinic acetylcholine receptor (alpha AChR) may play a role in the pathogenesis of schizophrenia. In search for peripheral biological markers for schizophrenia we have investigated alpha7 mRNA levels in peripheral blood lymphocytes (PBLs) of schizophrenic patients and healthy controls. Peripheral blood samples were collected from medicated and non-medicated (drug naive) schizophrenic patients as well as from healthy (non-mentally ill) smokers and non-smokers. RNA was prepared from isolated lymphocytes. Polymerase chain reaction products specific for human alpha7 AChR were quantified by densitometry using Scion image-analysis (shared NIH software). We observed a significant decrease of alpha7 mRNA levels on PBLs of schizophrenic patients compared with controls. The decrease in alpha7 mRNA levels was not a result of medication management, because non-medicated schizophrenic patients displayed the same level of reduction in alpha7 mRNA as did patients receiving medication. In addition, we exclude the possibility that the observed decrease in alpha7 mRNA levels resulted from nicotine consumption in smoking, because healthy smokers exhibited the same levels of alpha7 mRNA as non-smokers. We propose that alpha7 AChR may be involved in the pathophysiology of the disease and may serve as a reliable peripheral biological marker in schizophrenia.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Beer Yaakov Mental Hlth Ctr, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Fuchs, S (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	sara.fuchs@weizmann.ac.il		Ilani, Tal/0000-0003-2806-4455				Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; American Psychiatric Association, 1994, DSM 4 DIAGNOSTIC STA; Baron M, 2001, AM J HUM GENET, V68, P299, DOI 10.1086/318212; Court J, 1999, J NEUROCHEM, V73, P1590, DOI 10.1046/j.1471-4159.1999.0731590.x; Dalack GW, 1998, AM J PSYCHIAT, V155, P1490, DOI 10.1176/ajp.155.11.1490; Freedman R, 2000, J CHEM NEUROANAT, V20, P299, DOI 10.1016/S0891-0618(00)00109-5; Friedman JI, 2002, BIOL PSYCHIAT, V51, P349, DOI 10.1016/S0006-3223(01)01342-7; Gault J, 1998, GENOMICS, V52, P173, DOI 10.1006/geno.1998.5363; Guan ZZ, 1999, NEUROREPORT, V10, P1779, DOI 10.1097/00001756-199906030-00028; Hellstrom-Lindahl E, 1999, MOL BRAIN RES, V66, P94, DOI 10.1016/S0169-328X(99)00030-3; Hyde TM, 2001, J CHEM NEUROANAT, V22, P53, DOI 10.1016/S0891-0618(01)00101-6; Ilani T, 2001, P NATL ACAD SCI USA, V98, P625, DOI 10.1073/pnas.021535398; Leonard S, 2000, EUR J PHARMACOL, V393, P237, DOI 10.1016/S0014-2999(00)00035-2; Leonard S, 2002, ARCH GEN PSYCHIAT, V59, P1085, DOI 10.1001/archpsyc.59.12.1085; LEONARD S, 2000, PHARM BIOCH BEHAV, V70, P561; Lieberman JA, 1999, J CLIN PSYCHIAT, V60, P9; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; Olincy A, 1998, NEUROPSYCHOPHARMACOL, V18, P175, DOI 10.1016/S0893-133X(97)00095-X; Olincy A, 1997, BIOL PSYCHIAT, V42, P1, DOI 10.1016/S0006-3223(96)00302-2; Olincy A, 1999, NEUROPSYCHOPHARMACOL, V20, P52, DOI 10.1016/S0893-133X(98)00053-0; Risch SC, 2001, NEUROCASE, V7, P105, DOI 10.1076/neur.7.2.105.16262; Sato KZ, 1999, NEUROSCI LETT, V266, P17, DOI 10.1016/S0304-3940(99)00259-1; Stassen HH, 2000, AM J MED GENET, V96, P173, DOI 10.1002/(SICI)1096-8628(20000403)96:2<173::AID-AJMG10>3.0.CO;2-U; TRINA BA, 2002, AM J PSYCHIAT, V159, P1244	24	50	54	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1948	+		10.1096/fj.03-0104fje	http://dx.doi.org/10.1096/fj.03-0104fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897067				2022-12-25	WOS:000185345100025
J	Salvatori, L; Pallante, P; Ravenna, L; Chinzari, P; Frati, L; Russo, MA; Petrangeli, E				Salvatori, L; Pallante, P; Ravenna, L; Chinzari, P; Frati, L; Russo, MA; Petrangeli, E			Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER alpha and beta subtypes via an Sp1 site	ONCOGENE			English	Article						oestrogens; SERMs; oestrogen receptor; Sp1; EGF receptor; gene expression	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; DEOXYRIBONUCLEIC-ACID; THYROID-HORMONE; ACTIVATION; PROMOTER; ANTIESTROGENS; IDENTIFICATION; TRANSCRIPTION; PHYTOESTROGENS	Through the analysis of the transient expression of the luciferase reporter gene in HeLa cells, an evaluation has been made of the transcriptional activity of oestrogens and of selective oestrogen receptor (ER) modulators (SERMs), mediated by the alpha and beta isoforms of the ER, on the epidermal growth factor receptor gene promoter. Oestrogen-activated ERbeta presents a lower transcriptional activity compared with ERalpha, probably due to structural differences in the AF-1 regions of the receptors. Also SERMs induce different responses depending on the receptor isoform bound. Indeed, the phyto-oestrogens, genistein and daidzein, act as weak agonists of the oestrogenic activity via ERalpha, but as full agonists when bound to ERbeta. The synthetic SERM 40H-tamoxifen, on the other hand, displays an opposite behaviour since it exerts a full agonist action through ERalpha, but acts as a full antagonist via ERbeta. As we have previously shown for ERalpha, an ERbeta/Sp1 functional synergism has also been highlighted, by means of gel mobility shift assays. Moreover, our results show that the sensitivity of target tissues to oestrogens and SERMs can be affected by coexpression of ERs, depending on the formation of appropriate levels of homo- and heterodimers, thus providing a useful approach to predict the effects of hormonal treatment.	CNR, Ist Biol & Patol Mol, I-00137 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Neuromed Inst, I-86077 Pozzilli, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; IRCCS Neuromed	Salvatori, L (corresponding author), CNR, Ist Biol & Patol Mol, Viale Marx N 43, I-00137 Rome, Italy.	luisa.salvatori@ibpm.cnr.it	Salvatori, Luisa/AAK-9365-2021; Frati, Luigi/ABI-7437-2020; Pallante, Pierlorenzo/AAX-8758-2020					BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Cosman F, 1999, ENDOCR REV, V20, P418, DOI 10.1210/er.20.3.418; deGraffenried LA, 2002, J STEROID BIOCHEM, V82, P7, DOI 10.1016/S0960-0760(02)00151-6; DEWET JR, 1987, CELL, V54, P313; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; LINGHAM RB, 1988, MOL ENDOCRINOL, V2, P230, DOI 10.1210/mend-2-3-230; Maniatis T., 1982, MOL CLONING LAB MANU; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Moore DD, 1995, GLOB MOB SURV; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; NEAL DE, 1985, LANCET, V1, P366; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Salvatori L, 2000, ENDOCRINOLOGY, V141, P2266, DOI 10.1210/en.141.6.2266; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; van den Wijngaard A, 2000, MOL ENDOCRINOL, V14, P623, DOI 10.1210/me.14.5.623; Yarden RI, 1996, ENDOCRINOLOGY, V137, P2739, DOI 10.1210/en.137.7.2739; YASUI W, 1988, INT J CANCER, V41, P211, DOI 10.1002/ijc.2910410209; Zhang WH, 2000, P NATL ACAD SCI USA, V97, P5936, DOI 10.1073/pnas.97.11.5936	36	40	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4875	4881		10.1038/sj.onc.1206784	http://dx.doi.org/10.1038/sj.onc.1206784			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894229				2022-12-25	WOS:000184344600011
J	Malygin, EG; Lindstrom, WM; Zinoviev, VV; Evdokimov, AA; Schlagman, SL; Reich, NO; Hattman, S				Malygin, EG; Lindstrom, WM; Zinoviev, VV; Evdokimov, AA; Schlagman, SL; Reich, NO; Hattman, S			Bacteriophage T4Dam (DNA-(adenine-N-6)-methyltransferase) - Evidence for two distinct stages of methylation under single turnover conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORI DNA METHYLTRANSFERASE; DAM DNA-<N-6-ADENINE> METHYLTRANSFERASE; ADENOSYL-L-METHIONINE; CRYSTAL-STRUCTURE; S-ADENOSYLMETHIONINE; OLIGONUCLEOTIDE DUPLEXES; RECOGNITION SITES; STATE KINETICS; TARGET BASE; MOTIF-IV	We compared the (pre) steady-state and single turnover methylation kinetics of bacteriophage T4Dam (DNA-(adenine-N-6)-methyltransferase)-mediated methyl group transfer from S-adenosyl-L-methionine (AdoMet) to oligodeoxynucleotide duplexes containing a single recognition site (palindrome 5'-GATC/5'-GATC) or some modified variant. T4Dam-AdoMet functions as a monomer under steady-state conditions (enzyme/DNA << 1), whereas under single turnover conditions (enzyme/DNA > 1), a catalytically active complex containing two Dam-AdoMet molecules is formed initially, and two methyl groups are transferred per duplex (to produce a methylated duplex and S-adenosyl-L-homocysteine (AdoHcy)). We propose that the single turnover reaction proceeds in two stages. First, two preformed T4Dam-AdoMet complexes bind opposite strands of the unmodified target site, and one enzyme molecule catalyzes the rapid transfer of the AdoMet-methyl group (k(meth1) = 0.21 s(-1)); this is 2.5-fold slower than the rate observed with monomeric T4Dam-AdoMet bound under pre-steady-state conditions for burst determination. In the second stage, methyl transfer to adenine in GATC on the complementary strand occurs at a rate that is 1 order of magnitude slower (k(meth2) = 0.023 s(-1)). We suggest that under single turnover conditions, methylation of the second strand is rate-limited by Dam-AdoHcy dissociation or its clearance from the methylated complementary strand. The hemimethylated duplex 5'-GATC/5'-GMTC also interacts with T4Dam-AdoMet complexes in two stages under single turnover reaction conditions. The first stage (kmeth1) reflects methylation by dimeric T4Dam-AdoMet productively oriented to the strand with the adenine residue capable of methylation. The slower second stage (kmeth2) reflects methylation by enzyme molecules non-productively oriented to the GMTC chain, which then have to re-orient to the opposite productive chain. Substitutions of bases and deletions in the recognition site affect the kinetic parameters in different fashions. When the GAT portion of GATC was disrupted, the proportion of the initial productive enzyme-substrate complexes was sharply reduced.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; State Res Ctr Virol & Biotechnol Vector, Inst Mol Biol, Koltsov 630559, Novosibirsk Reg, Russia; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93103 USA	University of Rochester; State Research Center of Virology & Biotechnology VECTOR; University of California System; University of California Santa Barbara	Hattman, S (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.		Ernst, Malygin/A-6741-2014; Evdokimov, Alexey/A-6485-2014		FOGARTY INTERNATIONAL CENTER [R03TW005755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046333] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW 05755] Funding Source: Medline; NIGMS NIH HHS [GM 46333 3, GM 29227] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVNOV MG, 1995, GENE, V157, P149, DOI 10.1016/0378-1119(94)00738-E; BURYANOV YI, 1988, GENE, V74, P67, DOI 10.1016/0378-1119(88)90253-3; CHENG X, 1993, COLD SPRING HARB SYM, V58, P331, DOI 10.1101/SQB.1993.058.01.039; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; FERSHT A, 1985, ENZYME STRUCTURE MEC, P133; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Gromova ES, 1995, BIOCHEM MOL BIOL INT, V36, P247; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Jeltsch A, 1999, J MOL BIOL, V285, P1121, DOI 10.1006/jmbi.1998.2389; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOSSYKH VG, 1995, J BIOL CHEM, V270, P14389, DOI 10.1074/jbc.270.24.14389; KOSSYKH VG, 1995, FEBS LETT, V370, P75, DOI 10.1016/0014-5793(95)00795-B; KURGANOV BI, 1982, ALLOSTERIC ENZYMES K, P151; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Malygin EG, 1999, NUCLEIC ACIDS RES, V27, P1135, DOI 10.1093/nar/27.4.1135; Malygin EG, 1997, NUCLEIC ACIDS RES, V25, P4393, DOI 10.1093/nar/25.21.4393; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; Malygin EG, 2001, NUCLEIC ACIDS RES, V29, P2361, DOI 10.1093/nar/29.11.2361; NARDONE G, 1984, J BIOL CHEM, V259, P357; Pues H, 1999, BIOCHEMISTRY-US, V38, P1426, DOI 10.1021/bi9818016; REICH NO, 1991, NUCLEIC ACIDS RES, V19, P6587, DOI 10.1093/nar/19.23.6587; REICH NO, 1993, J BIOL CHEM, V268, P9191; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Scavetta R, 2000, NUCLEIC ACIDS RES, V28, P3950, DOI 10.1093/nar/28.20.3950; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1998, BIOL CHEM, V379, P389; Thielking V, 1997, BIOL CHEM, V378, P407, DOI 10.1515/bchm.1997.378.5.407; Tran PH, 1998, STRUCT FOLD DES, V6, P1563, DOI 10.1016/S0969-2126(98)00154-3; WU JC, 1987, J BIOL CHEM, V262, P4778; YANG Z, 2003, IN PRESS NAT STRUCT, V10; Zinov'ev V. V., 1996, Molekulyarnaya Biologiya (Moscow), V30, P1203; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41749	41755		10.1074/jbc.M306397200	http://dx.doi.org/10.1074/jbc.M306397200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12893823	hybrid			2022-12-25	WOS:000185989500026
J	Sugawara, T; Shimizu, H; Hoshi, N; Nakajima, A; Fujimoto, S				Sugawara, T; Shimizu, H; Hoshi, N; Nakajima, A; Fujimoto, S			Steroidogenic acute regulatory protein-binding protein cloned by a yeast two-hybrid system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; LIPOID ADRENAL-HYPERPLASIA; STAR GENE; MOLECULAR-CLONING; MOLTEN GLOBULE; TUMOR-CELLS; FACTOR-I; CHOLESTEROL; EXPRESSION; PROMOTER	Steroidogenic acute regulatory ( StAR) protein plays a key role in the transport of cholesterol from the outer mitochondrial membrane to the inner membrane. A StAR mutant protein lacking the first 62 amino acids (N-62 StAR protein) has been reported to be as effective as wild-type StAR protein. In the present study, we examined the mechanism by which StAR protein stimulates steroidogenesis. A Gal4-based yeast two-hybrid system was used to identify proteins interacting with N-62 StAR protein. Nine positive clones were obtained from screening 1 x 10(6) clones. The results of pull-down assays and mammalian two-hybrid assays confirmed interaction between N-62 StAR protein and the clone 4 translated product. The clone 4 translated product was named StAR-binding protein (SBP). We prepared an expression plasmid (pSBP) by inserting SBP cDNA into the pTarget vector. After cotransfection with the human cytochrome P450scc system, StAR expression vector, and pSBP, the amount of pregnenolone produced by COS-1 cells was increased. The amount of steroid hormones produced by steroidogenic cells subjected to small interfering RNA treatment was less than that produced by control cells. In conclusion, SBP binds StAR protein in cells and enhances the ability of StAR protein to promote syntheses of steroid hormones.	Hokkaido Univ, Grad Sch Med, Dept Biochem, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido 0608638, Japan; Kitasato Univ, Sch Vet Med & Anim Sci, Lab Expt Anim Sci, Towada, Aomori 0348628, Japan	Hokkaido University; Hokkaido University; Kitasato University	Sugawara, T (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Biochem, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.							Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; Balasubramanian K, 1997, ENDOCRINOLOGY, V138, P433, DOI 10.1210/en.138.1.433; BARNIKOLWATANABE S, 1994, BIOL CHEM H-S, V375, P497, DOI 10.1515/bchm3.1994.375.8.497; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Brand C, 1998, J BIOL CHEM, V273, P6410, DOI 10.1074/jbc.273.11.6410; Budnik LT, 1999, MOL CELL ENDOCRINOL, V150, P39, DOI 10.1016/S0303-7207(99)00029-5; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; Christenson LK, 2001, ENDOCRINOLOGY, V142, P28, DOI 10.1210/endo.142.1.7867; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hall PF, 1997, STEROIDS, V62, P185, DOI 10.1016/S0039-128X(96)00179-1; Hardwick M, 1999, CANCER RES, V59, P831; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; Hemenway CS, 1999, ANAL BIOCHEM, V268, P161, DOI 10.1006/abio.1998.3034; Ishii T, 2002, MOL ENDOCRINOL, V16, P2297, DOI 10.1210/me.2001-0320; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Oka A, 1999, HUM MOL GENET, V8, P2165, DOI 10.1093/hmg/8.12.2165; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; SHIVER TM, 1992, ENDOCRINOLOGY, V131, P201, DOI 10.1210/en.131.1.201; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 2001, BBA-MOL CELL BIOL L, V1533, P277, DOI 10.1016/S1388-1981(01)00160-3; Sugawara T, 2001, ENDOCRINOLOGY, V142, P3570, DOI 10.1210/en.142.8.3570; Takemori H, 2002, J BIOL CHEM, V277, P42334, DOI 10.1074/jbc.M204602200; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	51	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42487	42494		10.1074/jbc.M302291200	http://dx.doi.org/10.1074/jbc.M302291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909641	hybrid			2022-12-25	WOS:000185989500113
J	Yeh, TS; Lin, YM; Hsieh, RH; Tseng, MJ				Yeh, TS; Lin, YM; Hsieh, RH; Tseng, MJ			Association of transcription factor YY1 with the high molecular weight notch complex suppresses the transactivation activity of notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR-VIRUS EBNA2; SIGNALING PATHWAY; ANKYRIN REPEATS; INTRACELLULAR DOMAIN; PHYSICAL INTERACTION; BINDING-PROTEIN; HUMAN HOMOLOG; GENE; DIFFERENTIATION; COACTIVATOR	Notch receptors are evolutionarily conserved from Drosophila to human and play important roles in cell fate decisions. After ligand binding, Notch receptors are cleaved to release their intracellular domains. The intracellular domains, the activated form of Notch receptors, are then translocated into the nucleus where they interact with other transcriptional machinery to regulate the expression of cellular genes. To dissect the molecular mechanisms of Notch signaling, the cellular targets that interact with Notch1 receptor intracellular domain (N1IC) were screened. In this study, we found that endogenous transcription factor Ying Yang 1 (YY1) was associated with exogenous N1IC in human K562 erythroleukemic cells. The ankyrin (ANK) domain of N1IC and zinc finger domains of YY1 were essential for the association of N1IC and YY1 according to the pull-down assay of glutathione S-transferase fusion proteins. Furthermore, both YY1 and N1IC were present in a large complex of the nucleus to suppress the luciferase reporter activity transactivated by Notch signaling. The transcription factor YY1 indirectly regulated the transcriptional activity of the wild-type CBF1-response elements via the direct interaction of N1IC and CBF1. We also demonstrated the association between endogenous N1IC and intrinsic YY1 in human acute T-cell lymphoblastic leukemia cell lines. Taken together, these results indicate that transcription factor YY1 may modulate Notch signaling via association with the high molecular weight Notch complex.	Taipei Med Univ, Grad Inst Cell & Mol Biol, Taipei 110, Taiwan; Taipei Med Univ, Wan Fang Hosp, Ctr Stem Cells Res, Taipei 110, Taiwan; Taipei Med Univ, Grad Inst Nutr & Hlth Sci, Taipei 110, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University	Yeh, TS (corresponding author), Taipei Med Univ, Grad Inst Cell & Mol Biol, Taipei 110, Taiwan.	cmbtsyeh@tmu.edu.tw; cmbtseng@tmu.edu.tw						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chan HM, 2001, J CELL SCI, V114, P2363; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen HW, 2000, BIOCHEMISTRY-US, V39, P1675, DOI 10.1021/bi991786k; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jehn BM, 1999, J IMMUNOL, V162, P635; Kopan R, 2002, J CELL SCI, V115, P1095; Krebs LT, 2001, DEV BIOL, V238, P110, DOI 10.1006/dbio.2001.0408; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; LARSSON C, 1994, GENOMICS, V24, P253, DOI 10.1006/geno.1994.1613; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nekrep N, 2001, MOL CELL BIOL, V21, P5566, DOI 10.1128/MCB.21.16.5566-5576.2001; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; OTSUKA F, 1994, J BIOL CHEM, V269, P23700; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Reizis B, 2002, GENE DEV, V16, P295, DOI 10.1101/gad.960702; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Sugaya K, 1997, GENE, V189, P235, DOI 10.1016/S0378-1119(96)00857-8; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yan B, 2002, J BIOL CHEM, V277, P29760, DOI 10.1074/jbc.M204721200; Yeh TS, 1996, J VIROL, V70, P6190, DOI 10.1128/JVI.70.9.6190-6198.1996; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	57	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41963	41969		10.1074/jbc.M304353200	http://dx.doi.org/10.1074/jbc.M304353200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913000	hybrid			2022-12-25	WOS:000185989500051
J	Hihi, AK; Kebir, H; Hekimi, S				Hihi, AK; Kebir, H; Hekimi, S			Sensitivity of Caenorhabditis elegans clk-1 mutants to ubiquinone side-chain length reveals multiple ubiquinone-dependent processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVED CLK-1 MUTANTS; COENZYME-Q; SACCHAROMYCES-CEREVISIAE; CARBOXYLATE PROTEINS; ALTERNATIVE OXIDASE; GENETIC-EVIDENCE; ACTIVE-SITE; ELEGANS; MITOCHONDRIAL; BIOSYNTHESIS	Ubiquinone ( coenzyme Q, or Q) is a membrane constituent, whose head group is capable of accepting and donating electrons and whose lipidic side chain is composed of a variable number of isoprene subunits. A possible role for Q as a dietary antioxidant for treating conditions that involve altered cellular redox states is being intensely studied. Mutations in the clk-1 gene of the nematode Caenorhabditis elegans affect numerous physiological rates including behavioral rates, developmental rates, reproduction, and life span. clk-1 encodes a protein associated with the inner mitochondrial membrane that is necessary for Q biosynthesis in C. elegans. clk-1 mutants do not synthesize Q but accumulate demethoxyubiquinone, a Q synthesis intermediate that is able to partially sustain mitochondrial respiration in worms as well as in mammals. Recently, we and others have found that exogenous Q is necessary for the fertility and development of clk-1 mutants. Here, we take advantage of the clk-1 genetic model to identify structural features of Q that are functionally important in vivo. We show that clk-1 mutants are exquisitely sensitive to the length of the side chain of the Q they consume. We also identified differential sensitivity to Q side-chain length between null alleles of clk-1 (qm30 and qm51) and the weaker allele e2519. This allows us to propose a model where we distinguish several types of Q-dependent processes in vivo: processes that are very sensitive to Q side-chain length and processes that are permissive to Q with shorter chains.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Dr Penfield, Montreal, PQ H3A 1B1, Canada.			Kebir, Hania/0000-0001-6174-8846				Ajayi WU, 2002, J BIOL CHEM, V277, P8187, DOI 10.1074/jbc.M111477200; Albury MS, 2002, J BIOL CHEM, V277, P1190, DOI 10.1074/jbc.M109853200; Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891-5849(00)00307-5; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; EDLUND C, 1994, J NEUROCHEM, V63, P634; Ernster L., 1993, CLIN INVESTIGATOR, V71, P60; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; FORSMARK P, 1991, FEBS LETT, V285, P39, DOI 10.1016/0014-5793(91)80720-N; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kainou T, 2001, J BIOL CHEM, V276, P7876, DOI 10.1074/jbc.M007472200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Miyadera H, 2002, FEBS LETT, V512, P33, DOI 10.1016/S0014-5793(02)02282-2; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Nakai D, 2001, BIOCHEM BIOPH RES CO, V289, P463, DOI 10.1006/bbrc.2001.5977; Nohl H, 1998, ANN NY ACAD SCI, V854, P394, DOI 10.1111/j.1749-6632.1998.tb09919.x; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; Okada K, 1996, BBA-LIPID LIPID MET, V1302, P217, DOI 10.1016/0005-2760(96)00064-1; Okada K, 1998, FEBS LETT, V431, P241, DOI 10.1016/S0014-5793(98)00753-4; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; WONG A, 1995, GENETICS, V139, P1247	30	29	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41013	41018		10.1074/jbc.M305034200	http://dx.doi.org/10.1074/jbc.M305034200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893826	hybrid			2022-12-25	WOS:000185847200075
J	Shouldice, SR; Dougan, DR; Williams, PA; Skene, RJ; Snell, G; Scheibe, D; Kirby, S; Hosfield, DJ; McRee, DE; Schryvers, AB; Tari, LW				Shouldice, SR; Dougan, DR; Williams, PA; Skene, RJ; Snell, G; Scheibe, D; Kirby, S; Hosfield, DJ; McRee, DE; Schryvers, AB; Tari, LW			Crystal structure of Pasteurella haemolytica ferric ion-binding protein a reveals a novel class of bacterial iron-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN; N-LOBE; ACTIVE-TRANSPORT; LACTOFERRIN; ANGSTROM; OVOTRANSFERRIN; ACQUISITION; REFINEMENT; CHALLENGE; RECEPTORS	Pasteurellosis caused by the Gram-negative pathogen Pasteurella haemolytica is a serious disease leading to death in cattle. To scavenge growth-limiting iron from the host, the pathogen utilizes the periplasmic ferric ion-binding protein A (PhFbpA) as a component of an ATP-binding cassette transport pathway. We report the 1.2-Angstrom structure of the iron-free (apo) form of PhFbpA, which is a member of the transferrin structural superfamily. The protein structure adopts a closed conformation, allowing us to reliably assign putative iron-coordinating residues. Based on our analysis, PhFbpA utilizes a unique constellation of binding site residues and anions to octahedrally coordinate an iron atom. A surprising finding in the structure is the presence of two formate anions on opposite sides of the iron-binding pocket. The formate ions tether the N- and C-terminal domains of the protein and stabilize the closed structure, also providing clues as to probable candidates for synergistic anions in the iron-loaded state. PhFbpA represents a new class of bacterial iron-binding proteins.	Syrrx Inc, Crystallog, San Diego, CA 92121 USA; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Astex Technol, Cambridge CB4 0QA, England	University of Calgary	Tari, LW (corresponding author), Syrrx Inc, Crystallog, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.	ltari@syrrx.com	Schryvers, Anthony B./AAF-3417-2020	Skene, Robert/0000-0002-1482-6546; Williams, Pamela/0000-0002-1257-2351				ADHIKARI P, 1995, J BIOL CHEM, V270, P25142, DOI 10.1074/jbc.270.42.25142; AMES TR, 1985, CAN J COMP MED, V49, P395; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker HM, 2001, BIOCHEMISTRY-US, V40, P11670, DOI 10.1021/bi010907p; BROWN MPS, 1999, NUCLEIC ACIDS RES, V25, P3389; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; CONLON JA, 1991, INFECT IMMUN, V59, P587, DOI 10.1128/IAI.59.2.587-591.1991; CROSA JH, 1984, ANNU REV MICROBIOL, V38, P69, DOI 10.1146/annurev.mi.38.100184.000441; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dhungana S, 2003, P NATL ACAD SCI USA, V100, P3659, DOI 10.1073/pnas.0536897100; GILMOUR NJL, 1983, RES VET SCI, V35, P80, DOI 10.1016/S0034-5288(18)32208-2; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JAROSIK GP, 1995, INFECT IMMUN, V63, P710, DOI 10.1128/IAI.63.2.710-713.1995; Kirby SD, 1998, MICROBIOL-UK, V144, P3425, DOI 10.1099/00221287-144-12-3425; Kirby SD, 1997, MOL MICROBIOL, V25, P979, DOI 10.1111/j.1365-2958.1997.mmi535.x; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; Marchart J, 2003, VACCINE, V21, P1415, DOI 10.1016/S0264-410X(02)00635-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MIETZNER TA, 1994, ANNU REV NUTR, V14, P471, DOI 10.1146/annurev.nu.14.070194.002351; Mizutani K, 2001, J MOL BIOL, V309, P937, DOI 10.1006/jmbi.2001.4719; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peterson NA, 2002, BIOCHEMISTRY-US, V41, P14167, DOI 10.1021/bi020443a; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Shouldice SR, 2003, J BIOL CHEM, V278, P11513, DOI 10.1074/jbc.M211780200; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; WHITELEY LO, 1992, J VET INTERN MED, V6, P11, DOI 10.1111/j.1939-1676.1992.tb00980.x; Yang AHW, 2000, PROTEIN SCI, V9, P49	40	23	23	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41093	41098		10.1074/jbc.M306821200	http://dx.doi.org/10.1074/jbc.M306821200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882966	hybrid			2022-12-25	WOS:000185847200084
J	Caroppo, R; Colella, M; Colasuonno, A; DeLuisi, A; Debellis, L; Curci, S; Hofer, AM				Caroppo, R; Colella, M; Colasuonno, A; DeLuisi, A; Debellis, L; Curci, S; Hofer, AM			A reassessment of the effects of luminal [Ca2+] on inositol 1,4,5-trisphosphate-induced Ca2+ release from internal stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE-SENSITIVE STORES; ENDOPLASMIC-RETICULUM CA2+; STEADY-STATE MECHANISM; CALCIUM-RELEASE; CYTOSOLIC CA2+; INTRALUMINAL CA2+; INTACT-CELLS; IN-SITU; RECEPTOR; CHANNELS	Inositol 1,4,5-trisphosphate (InsP(3))-induced Ca2+ release from intracellular stores displays complex kinetic behavior. While it well established that cytosolic [Ca2+] can modulate release by acting on the InsP(3) receptor directly, the role of the filling state of internal Ca2+ stores in modulating Ca2+ release remains unclear. Here we have reevaluated this topic using a technique that permits rapid and reversible changes in free [Ca2+] in internal stores of living intact cells without altering cytoplasmic [Ca2+], InsP(3) receptors, or sarcoendoplasmic reticulum Ca2+ ATPases (SERCAs). N, N, N', N'-Tetrakis( 2-pyridylmethyl) ethylene diamine (TPEN), a membrane-permeant, low affinity Ca2+ chelator was used to manipulate [Ca2+] in intracellular stores, while [Ca2+] changes within the store were monitored directly with the low-affinity Ca2+ indicator, mag-fura-2, in intact BHK-21 cells. 200 muM TPEN caused a rapid drop in luminal free [Ca2+] and significantly reduced the extent of the response to stimulation with 100 nM bradykinin, a calcium-mobilizing agonist. The same effect was observed when intact cells were pretreated with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid(acetoxymethyl ester) (BAPTA-AM) to buffer cytoplasmic [Ca2+] changes. Although inhibition of Ca2+ uptake using the SERCA inhibitor tBHQ permitted significantly larger release of Ca2+ from stores, TPEN still attenuated the release in the presence of tBHQ in BAPTA-AM-loaded cells. These results demonstrate that the filling state of stores modulates the magnitude of InsP(3)-induced Ca2+ release by additional mechanism(s) that are independent of regulation by cytoplasmic [Ca2+] or effects on SERCA pumps.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, W Roxbury, MA 02132 USA; Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Boston Vet Affairs Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Universita degli Studi di Bari Aldo Moro	Hofer, AM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.		Colella, Matilde/G-9246-2011	Colella, Matilde/0000-0002-9584-7030; Debellis, Lucantonio/0000-0002-7571-0969; CAROPPO, Rosa/0000-0002-8773-8985	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34854] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; Hofer AM, 1999, METH MOL B, V114, P249; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; HOFER AM, 2001, CALCIUM SIGNALLING P, P111; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Meldolesi J, 2001, PROG NEUROBIOL, V65, P309, DOI 10.1016/S0301-0082(01)00004-1; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARYS JB, 1993, J BIOL CHEM, V268, P25206; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RAJU B, 1989, AM J PHYSIOL, V256, P540; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SHUTTLEWORTH TJ, 1995, CELL CALCIUM, V17, P393, DOI 10.1016/0143-4160(95)90085-3; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Snitsarev VA, 1996, BIOPHYS J, V71, P1048, DOI 10.1016/S0006-3495(96)79305-0; Steenbergen JF, 1996, J BIOL CHEM, V271, P1821, DOI 10.1074/jbc.271.4.1821; Tanimura A, 2000, J BIOL CHEM, V275, P27488; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200; Yule DI, 2001, J GEN PHYSIOL, V117, P431, DOI 10.1085/jgp.117.5.431	60	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39503	39508		10.1074/jbc.M305823200	http://dx.doi.org/10.1074/jbc.M305823200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888563	hybrid			2022-12-25	WOS:000185713800030
J	Deeds, L; Teodorescu, S; Chu, M; Yu, Q; Chen, CY				Deeds, L; Teodorescu, S; Chu, M; Yu, Q; Chen, CY			A p53-independent G(1) cell cycle checkpoint induced by the suppression of protein kinase C alpha and theta isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTING PHORBOL ESTERS; DEPENDENT KINASES; DOWN-REGULATION; TUMOR-SUPPRESSOR; DNA-REPLICATION; CDK-INHIBITOR; GROWTH; P21; ARREST; EXPRESSION	The protein kinase C (PKC) family consists of multiple isoforms that are involved in the regulation of diverse cellular responses. Suppression of PKC induces growth arrest in various types of cells. However, the underlying molecular mechanisms have not been thoroughly investigated. In this report, we demonstrated that the concurrent inhibition, rather than separate inhibition, of phorbol ester-dependent PKC alpha and theta isoforms is crucial for the induction of G(1) cell cycle arrest and that this negative cell cycle regulation is via p53-independent mechanisms. PKC suppression-mediated growth arrest is associated with the induction of cell cycle inhibitor p21(WAF1/CIP1) and the occurrence of hypophosphorylated Rb. The G(1) checkpoint induced by the suppression of PKC occurs not only in murine Swiss3T3 but also in p53-deficient cells and human lung cancer cells containing mutated p53. Luciferase and nuclear run-off assays demonstrated that p21(WAF1/CIP1) is, in part, transcriptionally regulated in response to the suppression of PKC alpha and theta. However, the stability of p21 mRNA is also augmented after the addition of PKC alpha and theta antisense oligonucleotides, indicating the involvement of post-transcriptional mechanisms in p21(WAF1/CIP1) expression. These data suggest the existence of a cell cycle checkpoint pathway regulated by PKC alpha and theta isoforms. Furthermore, our findings support the notion that G(1) checkpoint control can be restored in tumor cells containing abnormal p53, by targeting the PKC-regulated p21(WAF1/CIP1) induction.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Chen, CY (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 80 E Concord St,K522, Boston, MA 02118 USA.	yanyan@bu.edu						AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1990, J CELL PHYSIOL, V145, P381, DOI 10.1002/jcp.1041450225; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; GRANA X, 1995, ONCOGENE, V11, P211; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kiley SC, 1996, J MAMMARY GLAND BIOL, V1, P177, DOI 10.1007/BF02013641; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Loignon M, 1997, CANCER RES, V57, P3390; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1989, CANCER RES, V49, P3215; PHILLIPS MA, 1983, J BIOL CHEM, V258, P2875; RAVIPRAKASH K, 1995, J VIROL, V69, P69, DOI 10.1128/JVI.69.1.69-74.1995; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; STEVE C, 1996, SCIENCE, V272, P877; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Weiss RH, 1996, AM J PHYSIOL-CELL PH, V270, pC619, DOI 10.1152/ajpcell.1996.270.2.C619; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	64	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39782	39793		10.1074/jbc.M306854200	http://dx.doi.org/10.1074/jbc.M306854200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12896972	hybrid			2022-12-25	WOS:000185713800064
J	Santilli, G; Aronow, BJ; Sala, A				Santilli, G; Aronow, BJ; Sala, A			Essential requirement of apolipoprotein J (clusterin) signaling for I kappa B expression and regulation of NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CANCER-CELLS; AUTOIMMUNE MYOCARDITIS; DEGRADATION; ACTIVATION; PHOSPHORYLATION; UBIQUITINATION; MIGRATION; DEATH	Apolipoprotein J/clusterin is an enigmatic protein highly regulated in inflammation, apoptosis, and cancer. Despite extensive studies, its biological function has remained obscure. Here we show that apolipoprotein J inhibits neuroblastoma cell invasion. Since this function can be regulated by NF-kappaB, we explored the possibility that apolipoprotein J might interfere with NF-kappaB signaling. Ectopic apolipoprotein J expression strongly inhibited NF-kappaB activity in human neuroblastoma cells and murine embryonic fibroblasts by stabilizing inhibitors of NF-kappaB (IkappaBs). Steady state levels of IkappaB proteins are drastically reduced in mouse embryo fibroblasts after disruption of the apolipoprotein J gene. Absence of apolipoprotein J causes reduction of IkappaB stability, a tumor necrosis factor-dependent increase in NF-kappaB activity, increased transcription of the NF-kappaB target gene c-IAP and down-modulation of p53 protein. These results suggest that an unexpected physiological role of apolipoprotein J is to inhibit NF-kappaB signaling through stabilization of IkappaBs and that this activity may result in suppression of tumor cell motility.	UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; Univ G DAnnunzio, Sez Oncol Med, Dipartimento Oncol & Neurosci, I-66100 Chieti, Italy; Childrens Hosp, Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA	University of London; University College London; G d'Annunzio University of Chieti-Pescara; Cincinnati Children's Hospital Medical Center	Sala, A (corresponding author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England.	a.sala@ich.ucl.ac.uk	sala, arturo/C-4959-2008; Aronow, Bruce J/F-8438-2012	Sala, Arturo/0000-0002-2841-7866				Behrens P, 2001, PATHOBIOLOGY, V69, P19, DOI 10.1159/000048753; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Huber MA, 2002, J BIOL CHEM, V277, P1268, DOI 10.1074/jbc.M109358200; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; Miyake H, 2000, CLIN CANCER RES, V6, P1655; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SEEGER RC, 1982, J IMMUNOL, V128, P983; SENSIBAR JA, 1995, CANCER RES, V55, P2431; Sintich SM, 1999, PROSTATE, V39, P87; Sivamurthy N, 2001, J VASC SURG, V34, P716, DOI 10.1067/mva.2001.116301; Spalding AC, 2002, ONCOGENE, V21, P260, DOI 10.1038/sj.onc.1205048; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZB, 2001, FEBS LETT, V508, P360, DOI 10.1016/S0014-5793(01)03109-X; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yokoseki O, 2001, CIRC RES, V89, P899, DOI 10.1161/hh2201.099373	27	111	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38214	38219		10.1074/jbc.C300252200	http://dx.doi.org/10.1074/jbc.C300252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882985	hybrid			2022-12-25	WOS:000185575100017
J	Tuinstra, RL; Miziorko, HM				Tuinstra, RL; Miziorko, HM			Investigation of conserved acidic residues in 3-Hydroxy-3-methylglutaryl-CoA lyase - Implications for human disease and for functional roles in a family of related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HMG-COA LYASE; COENZYME-A; MALATE SYNTHASE; ESCHERICHIA-COLI; CATION ACTIVATOR; ENZYME-ACTIVITY; DEFICIENCY; MECHANISM; BINDING	Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase catalyzes the divalent cation-dependent cleavage of HMG-CoA to form acetyl-CoA and acetoacetate. In metal-dependent aldol and Claisen reactions, acidic residues often function either as cation ligands or as participants in general acid/base catalysis. Site-directed mutagenesis was used to produce conservative substitutions for the conserved acidic residues Glu-37, Asp-42, Glu-72, Asp-204, Glu-279, and Asp-280. HMG-CoA lyase deficiency results from a human mutation that substitutes lysine for glutamate 279. The E279K mutation has also been engineered; expression in Escherichia coli produces an unstable protein. Substitution of alanine for glutamate 279 produces a protein that is sufficiently stable for isolation and retains substantial catalytic activity. However, thermal inactivation experiments demonstrate that E279A is much less stable than wild-type enzyme. HMG-CoA lyase deficiency also results from mutations at aspartate 42. Substitutions that eliminate a carboxyl group at residue 42 perturb cation binding and substantially lower catalytic efficiency (10(4)-10(5)-fold decreases in specific activity for D42A, D42G, or D42H versus wildtype). Substitutions of alanine for the other conserved acidic residues indicate the importance of glutamate 72. E72A exhibits a 200-fold decrease in k(cat) and >10(3)-fold decrease in k(cat)/K-m. E72A is also characterized by inflation in the K-m for activator cation (26-fold for Mg2+; >200-fold for Mn2+). Similar, but less pronounced, effects are measured for the D204A mutant. E72A and D204A mutant proteins both bind stoichiometric amounts of Mn2+, but D204A exhibits only a 2-fold inflation in K-D for Mn2+, whereas E72A exhibits a 12-fold inflation in K-D (23 muM) in comparison with wild-type enzyme (K-D = 1.9 muM). Acidic residues corresponding to HMG-CoA lyase Asp-42 and Glu-72 are conserved in the HMG-CoA lyase protein family, which includes proteins that utilize acetyl-CoA in aldol condensations. These related reactions may require an activator cation that binds to the corresponding acidic residues in this protein family.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Miziorko, HM (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NCRR NIH HHS [RR01008] Funding Source: Medline; NIDDK NIH HHS [DK21491] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Ilan A, 2001, BIOCHEMISTRY-US, V40, P11946, DOI 10.1021/bi0104524; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COON MJ, 1955, AMINO ACID METABOLIS, P431; Dreyer MK, 1996, J MOL BIOL, V259, P458, DOI 10.1006/jmbi.1996.0332; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; Goh LL, 2001, APPL MICROBIOL BIOT, V57, P363, DOI 10.1007/s002530100785; GOLDFARB S, 1971, J LIPID RES, V12, P512; Higgins M. J. P., 1972, ENZYMES, VVII, P407; Howard BR, 2000, BIOCHEMISTRY-US, V39, P3156, DOI 10.1021/bi992519h; HRUZ PW, 1993, BIOCHIM BIOPHYS ACTA, V1162, P149, DOI 10.1016/0167-4838(93)90141-D; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; JENKINS J, 1992, BIOCHEMISTRY-US, V31, P5449, DOI 10.1021/bi00139a005; Jia Y, 1999, BIOCHEMISTRY-US, V38, P14165, DOI 10.1021/bi990771j; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; KRAMER PR, 1983, BIOCHEMISTRY-US, V22, P2353, DOI 10.1021/bi00279a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mitchell GA, 1998, AM J HUM GENET, V62, P295, DOI 10.1086/301730; Muroi J, 2000, HUM GENET, V107, P320, DOI 10.1007/s004390000363; REED WD, 1975, J BIOL CHEM, V250, P3117; Roberts JR, 1997, BIOCHEMISTRY-US, V36, P7594, DOI 10.1021/bi970207d; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; Roberts JR, 1996, J BIOL CHEM, V271, P24604, DOI 10.1074/jbc.271.40.24604; ROBERTS JR, 1995, J BIOL CHEM, V270, P17311, DOI 10.1074/jbc.270.29.17311; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; Smith CV, 2003, J BIOL CHEM, V278, P1735, DOI 10.1074/jbc.M209248200; STEGINK LD, 1968, J BIOL CHEM, V243, P5272; Tuinstra RL, 2002, BIOCHEMISTRY-US, V41, P8971; Vinarov DA, 2000, BIOCHEMISTRY-US, V39, P3360, DOI 10.1021/bi9922897	30	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37092	37098		10.1074/jbc.M304472200	http://dx.doi.org/10.1074/jbc.M304472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12874287	hybrid			2022-12-25	WOS:000185437200015
J	Montigiani, S; Muller, R; Kontermann, RE				Montigiani, S; Muller, R; Kontermann, RE			Inhibition of cell proliferation and induction of apoptosis by novel tetravalent peptides inhibiting DNA binding of E2F	ONCOGENE			English	Article						E2F; phage display; inhibitor of DNA binding; peptidomimetics; tat; cell cycle; apoptosis	RETINOBLASTOMA GENE-PRODUCT; MULTIPLE ANTIGEN PEPTIDE; TRANSCRIPTION FACTOR; FUNCTIONALLY ANTAGONIZE; CYCLE REGULATION; MAMMALIAN-CELLS; FAMILY MEMBERS; PROTEIN; REPRESSOR; DP-1	We have isolated several peptides from random peptide phage display libraries that specifically recognize the cell cycle regulatory transcription factor E2F and inhibit DNA binding of E2F/DP heterodimers (E2F-1, E2F-2, E2F-3, E2F-4 or EM-5, and DP-1). The inhibitory efficiency could be strongly enhanced by generating branched tetravalent molecules. To analyse the biological consequences of peptide-mediated E2F inhibition, we fused two of these branched molecules to a cell-penetrating peptide derived from the HTV-Tat protein. Incubation of human tumor cells with these branched Tat-containing peptides led to an inhibition of cell proliferation and induction of apoptosis. These results provide new insights into the function of E2F and further validate E2F as a potential therapeutic target in proliferative diseases.	Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res IMT, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Kontermann, Roland E./F-9263-2014; Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				AHLBORG N, 1995, J IMMUNOL METHODS, V179, P269, DOI 10.1016/0022-1759(94)00328-T; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCK V, 1995, ONCOGENE, V11, P31; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOORBAR J, 1994, J MOL BIOL, V244, P361, DOI 10.1006/jmbi.1994.1736; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Fan JG, 1997, ONCOGENE, V14, P1191, DOI 10.1038/sj.onc.1200940; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FURUKAWA Y, 2002, J BIOL CHEM, V30, P30; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Loughran O, 2002, CURR BIOL, V12, pR377, DOI 10.1016/S0960-9822(02)00876-X; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Santoni-Rugiu E, 2002, ONCOGENE, V21, P6498, DOI 10.1038/sj.onc.1205828; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; TAM JP, 1989, J IMMUNOL METHODS, V124, P53, DOI 10.1016/0022-1759(89)90185-3; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zwicker J, 1995, Prog Cell Cycle Res, V1, P91; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4943	4952		10.1038/sj.onc.1206495	http://dx.doi.org/10.1038/sj.onc.1206495			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902977				2022-12-25	WOS:000184578900002
J	Lee, H; Kim, YO; Kim, H; Kim, SY; Noh, HS; Kang, SS; Cho, GJ; Choi, WS; Suk, K				Lee, H; Kim, YO; Kim, H; Kim, SY; Noh, HS; Kang, SS; Cho, GJ; Choi, WS; Suk, K			Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia	FASEB JOURNAL			English	Article						nitric oxide; Scutellaria baicalensis; inflammation; neurodegenerative diseases	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SCUTELLARIA-BAICALENSIS-GEORGI; NITRIC-OXIDE PRODUCTION; REGULATORY FACTOR-I; PROSTAGLANDIN E-2; OXIDATIVE STRESS; INTERFERON-GAMMA; PLANT FLAVONOIDS; ALPHA SYNERGISM	Wogonin (5,7-dihydroxy-8-methoxyflavone), a flavonoid originated from the root of a medicinal herb Scutellaria baicalensis Georgi, has been previously shown to have anti-inflammatory activities in various cell types including macrophages. In this work, we have found that wogonin is a potent neuroprotector from natural source. Wogonin inhibited inflammatory activation of cultured brain microglia by diminishing lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta, and nitric oxide ( NO) production. Wogonin inhibited NO production by suppressing inducible NO synthase (iNOS) induction and NF-kappaB activation in microglia. Inhibition of inflammatory activation of microglia by wogonin led to the reduction in microglial cytotoxicity toward cocultured PC12 cells, supporting a neuroprotective role for wogonin in vitro. The neuroprotective effect of wogonin was further demonstrated in vivo using two experimental brain injury models; transient global ischemia by four-vessel occlusion and excitotoxic injury by systemic kainate injection. In both animal models, wogonin conferred neuroprotection by attenuating the death of hippocampal neurons, and the neuroprotective effect was associated with inhibition of the inflammatory activation of microglia. Hippocampal induction of inflammatory mediators such as iNOS and TNF-alpha was reduced by wogonin in the global ischemia model, and microglial activation was markedly down-regulated by wogonin in the kainate injection model as judged by microglia-specific isolectin B4 staining. Taken together, our results indicate that wogonin exerts its neuroprotective effect by inhibiting microglial activation, which is a critical component of pathogenic inflammatory responses in neurodegenerative diseases. The current study emphasizes the importance of medicinal herbs and their constituents as an invaluable source for the development of novel neuroprotective drugs.	Gyeongsang Natl Univ, Coll Med, Dept Anat & Neurobiol, Res Inst Nat Sci, Jinju 660751, Kyungnam, South Korea; Gyeongsang Natl Univ, Coll Med, Inst Hlth Sci, Jinju 660751, South Korea; Kyung Hee Univ, Grad Sch EW Med Sci, Dept Herbal Pharmacol, Seoul 130701, South Korea	Gyeongsang National University; Gyeongsang National University; Kyung Hee University	Suk, K (corresponding author), Gyeongsang Natl Univ, Coll Med, Dept Anat & Neurobiol, Res Inst Nat Sci, 92 Chilam Dong, Jinju 660751, Kyungnam, South Korea.	ksuk@nongae.gsnu.ac.kr						Aloisi F, 1999, J NEUROSCI RES, V56, P571; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Chang YL, 2001, MOL PHARMACOL, V60, P507; Chen XY, 2002, J CHROMATOGR B, V775, P169, DOI 10.1016/S1570-0232(02)00288-X; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Gao ZH, 2001, PHARMACOL RES, V43, P173, DOI 10.1006/phrs.2000.0761; Gao ZH, 1999, BBA-GEN SUBJECTS, V1472, P643, DOI 10.1016/S0304-4165(99)00152-X; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gong XD, 1999, TRENDS PHARMACOL SCI, V20, P191, DOI 10.1016/S0165-6147(98)01276-0; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HAMADA H, 1993, ARCH BIOCHEM BIOPHYS, V306, P261, DOI 10.1006/abbi.1993.1509; KANDASWAMI C, 1994, ADV EXP MED BIOL, V366, P351; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim H, 2001, NEUROSCI LETT, V309, P67, DOI 10.1016/S0304-3940(01)02028-6; Kim HK, 1999, BIOCHEM PHARMACOL, V58, P759, DOI 10.1016/S0006-2952(99)00160-4; Kim YO, 2001, J ETHNOPHARMACOL, V77, P183, DOI 10.1016/S0378-8741(01)00283-5; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lee J, 2001, J BIOL CHEM, V276, P32956, DOI 10.1074/jbc.M104700200; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lee P, 2001, BRAIN RES, V892, P380, DOI 10.1016/S0006-8993(00)03257-1; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li YK, 2001, J NEUROSCI RES, V66, P163, DOI 10.1002/jnr.1208; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Middleton E, 2000, PHARMACOL REV, V52, P673; MIDDLETON E, 1992, BIOCHEM PHARMACOL, V43, P1167, DOI 10.1016/0006-2952(92)90489-6; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park BK, 2001, EUR J PHARMACOL, V425, P153, DOI 10.1016/S0014-2999(01)01187-6; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shieh DE, 2000, ANTICANCER RES, V20, P2861; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; SUK K, 1993, IMMUNOLOGY, V80, P617; Suk K, 2002, LIFE SCI, V70, P2467, DOI 10.1016/S0024-3205(02)01534-5; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Suk K, 2001, J IMMUNOL, V166, P4481, DOI 10.4049/jimmunol.166.7.4481; SUK KH, 1995, P NATL ACAD SCI USA, V92, P4269, DOI 10.1073/pnas.92.10.4269; Wakabayashi I, 1999, PHARMACOL TOXICOL, V84, P288, DOI 10.1111/j.1600-0773.1999.tb01496.x; Wakabayashi I, 2000, EUR J PHARMACOL, V406, P477, DOI 10.1016/S0014-2999(00)00695-6; WOOLLEY DE, 1962, AM J PHYSIOL, V202, P379, DOI 10.1152/ajplegacy.1962.202.2.379; Zhang YY, 1998, BIOMED CHROMATOGR, V12, P31, DOI 10.1002/(SICI)1099-0801(199801/02)12:1<31::AID-BMC716>3.3.CO;2-J	47	234	245	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1943	+		10.1096/fj.03-0057fje	http://dx.doi.org/10.1096/fj.03-0057fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897065				2022-12-25	WOS:000185345100023
J	Ling, MT; Wang, XH; Ouyang, XS; Xu, KX; Tsao, SW; Wong, YC				Ling, MT; Wang, XH; Ouyang, XS; Xu, KX; Tsao, SW; Wong, YC			Id-1 expression promotes cell survival through activation of NF-kappa B signalling pathway in prostate cancer cells	ONCOGENE			English	Article						Id-1; prostate cancer; NF-kappa B; TNF alpha; apoptosis	LOOP-HELIX PROTEIN; CHEMOTHERAPY-INDUCED APOPTOSIS; SENESCENT HUMAN FIBROBLASTS; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; PANCREATIC-CANCER; EPITHELIAL-CELLS; GROWTH; CARCINOMA; INDUCTION	The growth-promoting effect of Id-1 (inhibitor of differentiation/DNA binding) has been demonstrated in a number of human cancers. However, the mechanisms responsible for its action are not clear. In this study, we report that in prostate cancer cells, Id-1 promotes cell survival through activation of nuclear factor-kappaB (NF-kappaB) signalling pathway. After stable expression of Id-1 protein in LNCaP cells, we found that the Id-1 transfectants showed increased resistance to apoptosis induced by TNFalpha through inactivation of Bax and caspase 3. In addition, in the LNCaP cells expressing ectopic Id-1 protein, we also observed increased NF-kappaB transactivation activity and nuclear translocation of the p65 and p50 proteins, which was accompanied by upregulation of their downstream effectors Bcl-xL and ICAM-1. These results indicate that the Id-1-induced antiapoptotic effect may be via NF-kappaB signalling transduction pathway in these cells. In addition, inactivation of Id-1 by its antisense oligonucleotide and retroviral construct in DU145 cells resulted in the decrease of nuclear level of p65 and p50 proteins, which was associated with increased sensitivity to TNFalpha-induced apoptosis. Our results strongly suggest that Id-1 may be one of the upstream regulators of NF-kappaB and activation of NF-kappaB signalling pathway, may be essential for Id-1 induced cell proliferation through protection against apoptosis. Our findings also suggest a potential therapeutic strategy in which inactivation of Id-1 may lead to sensitization of prostate cancer cells to chemotherapeutic drug-induced apoptosis.	Univ Hong Kong, Canc Biol Grp, Dept Anat, Lab Block,Fac Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, Cent Lab, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Wong, YC (corresponding author), Univ Hong Kong, Canc Biol Grp, Dept Anat, Lab Block,Fac Med, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.		Tsao, George/C-4422-2009					Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Hara E, 1996, DEV GENET, V18, P161; HARA E, 1994, J BIOL CHEM, V269, P2139; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kim BY, 2002, ONCOGENE, V21, P4490, DOI 10.1038/sj.onc.1205547; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kleeff J, 1998, CANCER RES, V58, P3769; Langlands K, 2000, CANCER RES, V60, P5929; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Lin CQ, 2000, CANCER RES, V60, P1332; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Polsky D, 2001, CANCER RES, V61, P6008; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; Schindl M, 2001, CANCER RES, V61, P5703; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wilson JW, 2001, CANCER RES, V61, P8803; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	52	142	147	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4498	4508		10.1038/sj.onc.1206693	http://dx.doi.org/10.1038/sj.onc.1206693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881706				2022-12-25	WOS:000184054700005
J	Panaretakis, T; Pokrovskaja, K; Shoshan, MC; Grander, D				Panaretakis, T; Pokrovskaja, K; Shoshan, MC; Grander, D			Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax	ONCOGENE			English	Article						apoptosis; IFN alpha; Bak; Bax; Bcl-2	CHRONIC LYMPHOCYTIC-LEUKEMIA; DRUG-INDUCED APOPTOSIS; MULTIPLE-MYELOMA; CYTOCHROME-C; CONFORMATIONAL-CHANGES; BH3-ONLY PROTEINS; OLIGOMERIZES BAK; UP-REGULATION; DEATH; MITOCHONDRIA	We have recently reported that the cytokine interferon-alpha (IFNalpha), commonly used in the treatment of cancer, induced a caspase-dependent apoptosis in tumor cell lines. The signaling mechanisms involved have not been defined. Here, we show that both proapoptotic Bcl-2 family members Bak and Bax were activated by IFNalpha, strictly in correlation with the induction of apoptosis. Using double stainings, we demonstrated that Bak was activated prior to cytochrome c (cyt c) release and caspase-3 activation, whereas activated Bax was only found in cells with released cyt c, mitochondrial depolarization, as well as activated caspase-3. Furthermore, IFNalpha-induced activation of Bak, and to a large extent also of Bax, was dependent on caspase activity. With the use of a panel of specific caspase inhibitors we found, however, that none of caspases-1 to -10 were responsible for this activation. Neither was the Ca2+-dependent protease calpain nor the stress-activated p38 SAPK pathway significantly involved. Overexpression of Bcl-2 blocked apoptosis induced by IFNalpha totally abolished Bak activation, as well as decreased the amount of activated Bax. We conclude that IFNalpha induces Bak and Bax activation via distinct mechanisms involving an unknown protease, and that their activation is regulated by Bcl-2.	Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, CCK, R8-03, S-17176 Stockholm, Sweden.			Panaretakis, Theocharis/0000-0001-5754-6950; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bradbury DA, 1997, LEUKEMIA LYMPHOMA, V24, P221, DOI 10.3109/10428199709039010; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Consoli U, 2002, BRIT J HAEMATOL, V116, P774, DOI 10.1046/j.0007-1048.2002.03344.x; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Grander D, 2000, ACTA ONCOL, V39, P801, DOI 10.1080/028418600750063532; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Ludwig H, 2000, ACTA ONCOL, V39, P815; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; Raza A, 2000, LEUKEMIA RES, V24, P63, DOI 10.1016/S0145-2126(99)00152-6; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; SANGFELT O, 1995, INT J CANCER, V63, P190, DOI 10.1002/ijc.2910630207; Smalley RV, 2001, LEUKEMIA, V15, P1118, DOI 10.1038/sj.leu.2402161; Strander H, 1996, BIOTHERAPY, V8, P213, DOI 10.1007/BF01877207; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060	37	69	72	4	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4543	4556		10.1038/sj.onc.1206503	http://dx.doi.org/10.1038/sj.onc.1206503			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881711				2022-12-25	WOS:000184054700010
J	Szynal, M; Cleuter, Y; Beskorwayne, T; Bagnis, C; Van Lint, C; Kerkhofs, P; Burny, A; Martiat, P; Griebel, P; Van den Broeke, A				Szynal, M; Cleuter, Y; Beskorwayne, T; Bagnis, C; Van Lint, C; Kerkhofs, P; Burny, A; Martiat, P; Griebel, P; Van den Broeke, A			Disruption of B-cell homeostatic control mediated by the BLV-Tax oncoprotein: association with the upregulation of Bcl-2 and signaling through NF-kappa B	ONCOGENE			English	Article						B-cell transformation; tax; complex retrovirus; BLV; Bcl-2; NF-kappa B	BOVINE LEUKEMIA-VIRUS; HTLV-I TAX; TYPE-1 TAX; GENE-EXPRESSION; GERMINAL CENTER; RAS ONCOGENE; PROTEIN; APOPTOSIS; ACTIVATION; TRANSCRIPTION	Transactivating proteins associated with complex oncoretroviruses including human T-cell leukemia virus-1 (HTLV-1) and bovine leukemia virus (BLV) mediate transformation using poorly understood mechanisms. To gain insight into the processes that govern tumor onset and progression, we have examined the impact of BLV-Tax expression on ovine B-cells, the targets of BLV in experimentally infected sheep, using B-cell clones that are dependent on CD154 and gamma(c)-common cytokines. Tax was capable of mediating progression of B-cells from cytokine dependence to cytokine independence, indicating that the transactivator can over-ride signaling pathways typically controlled by cytokine receptor activation in B-cells. When examined in the presence of both CD154 and interleukin-4, Tax had a clear supportive role on B-cell growth, with an impact on B-cell proliferation, cell cycle phase distribution, and survival. Apoptotic B-cell death mediated by growth factor withdrawal, physical insult, and NF-kappaB inhibition was dramatically reduced in the presence of Tax. Furthermore, the expression of Tax was associated with higher Bcl-2 protein levels, providing rationale for the rescue signals mediated by the transactivator. Finally, Tax expression in B-cells led to a dramatic increase of nuclear RelB/p50 and p50/p50 NF-kappaB dimers, indicating that cellular signaling through NF-kappaB is a major contributory mechanism in the disruption of B-cell homeostasis. Although Tax is involved in aspects of pathogenesis that are unique to complex retroviruses, the viral strategies associated with this transactivating oncoprotein may have wide-ranging effects that are relevant to other B-cell malignancies.	Inst Jules Bordet, Lab Expt Hematol, B-1000 Brussels, Belgium; Vet Infect Dis Org, Saskatoon, SK S7H 5E3, Canada; Etab Francais Sang, F-13009 Marseille, France; IBMM, B-6041 Gosselies, Belgium; Coda Cerva, B-1180 Brussels, Belgium	Institut Jules Bordet; University of Saskatchewan; Universite Libre de Bruxelles	Van den Broeke, A (corresponding author), Inst Jules Bordet, Lab Expt Hematol, 121 Blvd Waterloo, B-1000 Brussels, Belgium.	anne_vandenbroeke@compuserve.com						Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Badran BM, 2002, J BIOL CHEM, V277, P47136, DOI 10.1074/jbc.M206330200; Bagnis C, 1997, CANCER GENE THER, V4, P5; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BURNY A, 1994, SYMP SOC GEN MICROBI, V51, P213; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; Feinman R, 1999, BLOOD, V93, P3044; FELBER B K, 1989, New Biologist, V1, P318; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Griebel P, 1999, INT IMMUNOL, V11, P1139, DOI 10.1093/intimm/11.7.1139; Griebel PJ, 2000, J IMMUNOL METHODS, V237, P19, DOI 10.1016/S0022-1759(99)00247-1; HAAS L, 1992, J VIROL, V66, P6223, DOI 10.1128/JVI.66.10.6223-6225.1992; HAURY M, 1993, ONCOGENE, V8, P1257; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Horwitz BH, 1999, J IMMUNOL, V162, P1941; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Keller SA, 2000, BLOOD, V96, P2537; Kerkhofs P, 1998, J VIROL, V72, P2554, DOI 10.1128/JVI.72.3.2554-2559.1998; Kettmann R., 1994, The retroviridae: Volume 3, P39; Kirshenbaum LA, 2000, CLIN INVEST MED, V23, P322; Kistler B, 1998, J IMMUNOL, V160, P2308; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MAMMERICKX M, 1988, LEUKEMIA, V2, P103; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; MOTYKA B, 1995, IMMUNOLOGY, V84, P383; MURAKAMI K, 1994, AM J VET RES, V55, P72; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Porter LA, 2000, BLOOD, V95, P2645; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Reyes RA, 1998, VIROLOGY, V242, P184, DOI 10.1006/viro.1998.9029; Richardson JH, 1997, BLOOD, V89, P3303, DOI 10.1182/blood.V89.9.3303; Rovnak J, 1999, J VIROL, V73, P8890, DOI 10.1128/JVI.73.10.8890-8897.1999; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmaltz B, 2000, GNOMON, V72, P633; SchwartzCornil I, 1997, J GEN VIROL, V78, P153, DOI 10.1099/0022-1317-78-1-153; Semmes OJ, 1996, J BIOL CHEM, V271, P9730, DOI 10.1074/jbc.271.16.9730; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Stone DM, 2000, J GEN VIROL, V81, P971, DOI 10.1099/0022-1317-81-4-971; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Twizere JC, 2000, J VIROL, V74, P9895, DOI 10.1128/JVI.74.21.9895-9902.2000; Van den Broeke A, 1999, J VIROL, V73, P1054, DOI 10.1128/JVI.73.2.1054-1065.1999; Van den Broeke A, 2001, J VIROL, V75, P1095, DOI 10.1128/JVI.75.3.1095-1103.2001; Van Den Broeke Anne, 1997, P2127; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; VANDENBROEKE A, 1988, P NATL ACAD SCI USA, V85, P9263, DOI 10.1073/pnas.85.23.9263; Vernau W, 1997, VET PATHOL, V34, P222, DOI 10.1177/030098589703400307; Wagner EF, 1998, J IMMUNOL, V161, P1123; Warren WD, 1999, MOL IMMUNOL, V36, P31, DOI 10.1016/S0161-5890(98)00114-X; Watanabe T, 1997, INT J HEMATOL, V66, P257; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; WILLEMS L, 1987, EMBO J, V6, P3385, DOI 10.1002/j.1460-2075.1987.tb02661.x; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993; WILLEMS L, 1994, P NATL ACAD SCI USA, V91, P11532, DOI 10.1073/pnas.91.24.11532; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	75	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4531	4542		10.1038/sj.onc.1206546	http://dx.doi.org/10.1038/sj.onc.1206546			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881710	Bronze			2022-12-25	WOS:000184054700009
J	David, G; Blondeau, K; Schiltz, M; Penel, S; Lewit-Bentley, A				David, G; Blondeau, K; Schiltz, M; Penel, S; Lewit-Bentley, A			YodA from Escherichia coli is a metal-binding, lipocalin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FED-BATCH; CADMIUM; REFINEMENT; SITE; INDUCTION; IDENTIFICATION; INHIBITION; EXPRESSION; CULTURES	We have determined the crystal structure of YodA, an Escherichia coli protein of unknown function. YodA had been identified under conditions of cadmium stress, and we confirm that it binds metals such as cadmium and zinc. We have also found nickel bound in one of the crystal forms. YodA is composed of two domains: a main lipocalin/calycin-like domain and a helical domain. The principal metal-binding site lies on one side of the calycin domain, thus making YodA the first metal-binding lipocalin known. Our experiments suggest that YodA expression may be part of a more general stress response. From sequence analogy with the C-terminal domain of a metal-binding receptor of a member of bacterial ATP-binding cassette transporters, we propose a three-dimensional model for this receptor and suggest that YodA may have a receptor-type partner in E. coli.	CNRS, CEA, MdR, Lab Utilisat Rayonnement Electromagnet, F-91898 Orsay, France; Ctr Sci Paris Sud, Inst Genet & Microbiol, F-91405 Orsay, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lewit-Bentley, A (corresponding author), CNRS, CEA, MdR, Lab Utilisat Rayonnement Electromagnet, BP 34, F-91898 Orsay, France.	Anita.Bentley@lure.u-psud.fr		Schiltz, Marc/0000-0003-3529-0223				Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; Andersson L, 1996, J BIOTECHNOL, V46, P255, DOI 10.1016/0168-1656(96)00004-1; Babai R, 1998, FEMS MICROBIOL LETT, V167, P107, DOI 10.1111/j.1574-6968.1998.tb13215.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEARD SJ, 1995, FEMS MICROBIOL LETT, V131, P205, DOI 10.1111/j.1574-6968.1995.tb07778.x; Binet MRB, 2000, FEBS LETT, V473, P67, DOI 10.1016/S0014-5793(00)01509-X; Birch RM, 2003, PROTEOMICS, V3, P764, DOI 10.1002/pmic.200300397; BISHOP RE, 1995, J BIOL CHEM, V270, P23097, DOI 10.1074/jbc.270.39.23097; Bishop RE, 2000, BBA-PROTEIN STRUCT M, V1482, P73, DOI 10.1016/S0167-4838(00)00138-2; Blindauer CA, 2002, MOL MICROBIOL, V45, P1421, DOI 10.1046/j.1365-2958.2002.03109.x; BOLLAG DM, 1996, PROTEIN METHODS, P195; BRISSAUD I, 1989, J RADIOAN NUCL CH AR, V131, P399, DOI 10.1007/BF02060606; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; David G, 2002, ACTA CRYSTALLOGR D, V58, P1243, DOI 10.1107/S0907444902008326; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL, 2002, PYMOL USERS MANUAL; DeLisa MP, 2001, RECOMBINANT PROTEIN PRODUCTION WITH PROKARYOTIC AND EUKARYOTIC CELLS: A COMPARATIVE VIEW ON HOST PHYSIOLOGY, P43; Dintilhac A, 1997, MOL MICROBIOL, V25, P727, DOI 10.1046/j.1365-2958.1997.5111879.x; Ferianc P, 1998, MICROBIOL-UK, V144, P1045, DOI 10.1099/00221287-144-4-1045; Ferianc P, 2000, BIOLOGIA, V55, P653; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; FURRSCHMID K, 2003, ELECTROPHORESIS, V24, P303; Gomes DS, 2002, BBA-GEN SUBJECTS, V1573, P21, DOI 10.1016/S0304-4165(02)00324-0; Hieber AD, 2000, BBA-PROTEIN STRUCT M, V1482, P84, DOI 10.1016/S0167-4838(00)00141-2; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huang KF, 2002, ACTA CRYSTALLOGR D, V58, P1118, DOI 10.1107/S090744490200656X; INBAR O, 1993, FEMS MICROBIOL LETT, V113, P197, DOI 10.1016/0378-1097(93)90268-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAR H, 1991, J MOL BIOL, V218, P427, DOI 10.1016/0022-2836(91)90723-J; Neubauer P, 2001, RECOMBINANT PROTEIN PRODUCTION WITH PROKARYOTIC AND EUKARYOTIC CELLS: A COMPARATIVE VIEW ON HOST PHYSIOLOGY, P195; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nystrom T, 2003, MOL MICROBIOL, V48, P17, DOI 10.1046/j.1365-2958.2003.03385.x; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; Petering DH, 2000, MAR ENVIRON RES, V50, P89, DOI 10.1016/S0141-1136(00)00099-4; Puskarova A, 2002, MICROBIOL-SGM, V148, P3801, DOI 10.1099/00221287-148-12-3801; Puskarova A, 2001, BIOLOGIA, V56, P337; Rosen BP, 1999, ESSAYS BIOCHEM, V34, P1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Skerra A, 2000, BBA-PROTEIN STRUCT M, V1482, P337, DOI 10.1016/S0167-4838(00)00145-X; Stark A, 2003, J MOL BIOL, V326, P1307, DOI 10.1016/S0022-2836(03)00045-7; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Teich A, 1999, BIOTECHNOL PROGR, V15, P123, DOI 10.1021/bp980102h; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; VANYSEK P, 1997, CRC HDB CHEM PHYSICS, V77, P8; VANYSEK P, 1997, CRC HDB CHEM PHYSICS, V77, P30; VANYSEK P, 1997, CRC HDB CHEM PHYSICS, V77, P20; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200	62	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43728	43735		10.1074/jbc.M304484200	http://dx.doi.org/10.1074/jbc.M304484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12909634	hybrid			2022-12-25	WOS:000186157000122
J	Gagliardi, M; Maynard, S; Miyake, T; Rodrigues, N; Tjew, SL; Cabannes, E; Bedard, PA				Gagliardi, M; Maynard, S; Miyake, T; Rodrigues, N; Tjew, SL; Cabannes, E; Bedard, PA			Opposing roles of C/EBP beta and AP-1 in the control of fibroblast proliferation and growth arrest-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-BETA; CHICKEN-EMBRYO FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; CEF-4/9E3 CYTOKINE GENE; ROUS-SARCOMA VIRUS; C-JUN; TRANSCRIPTIONAL ACTIVATION; HEPATOCYTE PROLIFERATION; INHIBITORY PROTEIN; CYCLE PROGRESSION	Chicken embryo fibroblasts (CEF) express several growth arrest-specific (GAS) gene products in G(0). In contact-inhibited cells, the expression of the most abundant of these proteins, the p20K lipocalin, is activated at the transcriptional level by C/EBPbeta. In this report, we describe the role of C/EBPbeta in CEF proliferation. We show that the expression of a dominant negative mutant of C/EBPbeta (designated Delta184-C/EBPbeta) completely inhibited p20K expression at confluence and stimulated the proliferation of CEF without inducing transformation. Mouse embryo fibroblasts nullizygous for C/EBPbeta had a proliferative advantage over cells with one or two functional copies of this gene. C/EBP inhibition enhanced the expression of the three major components of AP-1 in cycling CEF, namely c-Jun, JunD, and Fra-2, and stimulated AP-1 activity. In contrast, the over-expression of C/EBPbeta caused a dramatic reduction in the levels of AP-1 proteins. Therefore, C/EBPbeta is a negative regulator of AP-1 expression and activity in CEF. The expression of cyclin D1 and cell proliferation were stimulated by the dominant negative mutant of C/EBPbeta but not in the presence of TAM67, a dominant negative mutant of c-Jun and AP-1. CEF over-expressing c-Jun, and to a lesser extent JunD and Fra-2, did not growth arrest at high cell density and did not express p20K. Therefore, AP-1 interfered with the action of C/EBPbeta at high cell density, indicating that these factors play opposing roles in the control of GAS gene expression and CEF proliferation.	McMaster Univ, Dept Biol, Hamilton, ON L8S 1K4, Canada; York Univ, Dept Biol, N York, ON M3J 1P3, Canada	McMaster University; York University - Canada	Bedard, PA (corresponding author), McMaster Univ, Dept Biol, Hamilton, ON L8S 1K4, Canada.			Maynard, Scott/0000-0001-5625-936X				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; Bojovic B, 1996, J BIOL CHEM, V271, P22528, DOI 10.1074/jbc.271.37.22528; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cancedda FD, 1996, J BIOL CHEM, V271, P20163, DOI 10.1074/jbc.271.33.20163; Casado FJ, 1996, MECH DEVELOP, V54, P237, DOI 10.1016/0925-4773(95)00482-3; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Gagliardi M, 2001, ONCOGENE, V20, P2301, DOI 10.1038/sj.onc.1204354; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim S, 1999, MOL CELL BIOL, V19, P5718; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; MAO PL, 1993, J BIOL CHEM, V268, P8131; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SONOBE MH, 1995, ONCOGENE, V10, P689; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zahnow CA, 2001, CANCER RES, V61, P261; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	54	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43846	43854		10.1074/jbc.M304085200	http://dx.doi.org/10.1074/jbc.M304085200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12896981	hybrid			2022-12-25	WOS:000186157000135
J	Riebeling, C; Allegood, JC; Wang, E; Merrill, AH; Futerman, AH				Riebeling, C; Allegood, JC; Wang, E; Merrill, AH; Futerman, AH			Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; SPHINGANINE N-ACYLTRANSFERASE; F-SP LYCOPERSICI; CERAMIDE SYNTHESIS; FUMONISIN B-1; SERINE PALMITOYLTRANSFERASE; ENDOPLASMIC-RETICULUM; CELL-DEATH; SPHINGOSINE; SYNTHASE	Overexpression of upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene (LAG1), selectively induces the synthesis of stearoyl-containing sphingolipids in mammalian cells ( Venkataraman, K., Riebeling, C., Bodennec, J., Riezman, H., Allegood, J. C., Sullards, M. C., Merrill, A. H. Jr., and Futerman, A. H. (2002) J. Biol. Chem. 277, 35642 - 35649). Gene data base analysis subsequently revealed a new subfamily of proteins containing the Lag1p motif, previously characterized as translocating chain-associating membrane ( TRAM) protein homologs (TRH). We now report that two additional members of this family regulate the synthesis of ( dihydro) ceramides with specific fatty acid(s) when overexpressed in human embryonic kidney 293T cells. TRH1 or TRH4-overexpression elevated [H-3]( dihydro) ceramide synthesis from L-[3-H-3] serine and the increase was not blocked by the ( dihydro) ceramide synthase inhibitor, fumonisin B-1 (FB1). Analysis of sphingolipids by liquid chromatography-electrospray tandem mass spectrometry revealed that TRH4-overexpression elevated mainly palmitic acid-containing sphingolipids whereas TRH1 overexpression increased mainly stearic acid and arachidic acid, which in both cases were further elevated upon incubation with FB1. A similar fatty acid specificity was obtained upon analysis of ( dihydro) ceramide synthase activity in vitro using various fatty acyl-CoA substrates, although in a FB1-sensitive manner. Moreover, in homogenates from TRH4-overexpressing cells, sphinganine, rather than sphingosine was the preferred substrate, whereas no preference was seen in homogenates from TRH1-overexpressing cells. These findings lend support to our hypothesis ( Venkataraman, K., and Futerman, A. H. (2002) FEBS Lett. 528, 3 - 4) that Lag1p family members regulate ( dihydro) ceramide synthases responsible for production of sphingolipids containing different fatty acids.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	Weizmann Institute of Science; University System of Georgia; Georgia Institute of Technology	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.			Riebeling, Christian/0000-0003-1991-0170; Futerman, Anthony/0000-0003-0013-0115; Merrill, Alfred/0000-0002-6673-968X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodennec J, 2000, J LIPID RES, V41, P1524; Brandwagt BF, 2000, P NATL ACAD SCI USA, V97, P4961, DOI 10.1073/pnas.97.9.4961; Brandwagt BF, 2002, MOL PLANT MICROBE IN, V15, P35, DOI 10.1094/MPMI.2002.15.1.35; Cai XF, 2003, DNA SEQUENCE, V14, P79, DOI 10.1080/1042517021000041831; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUTERMAN AH, 2003, CERAMIDE SIGNALING; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; HAREL R, 1993, J BIOL CHEM, V268, P14476; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Koyanagi S, 2003, INT J CANCER, V105, P1, DOI 10.1002/ijc.11024; Linn SC, 2001, BIOCHEM SOC T, V29, P831, DOI 10.1042/0300-5127:0290831; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 2003, CERAMIDE SIGNALING, P1; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MORELL P, 1970, J BIOL CHEM, V245, P342; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NURMINEN T, 1971, BIOCHEM J, V125, P963, DOI 10.1042/bj1250963; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Pelled D, 2003, J BIOL CHEM, V278, P29496, DOI 10.1074/jbc.M302964200; RIEBELING C, 2003, CERAMIDE SIGNALING, P101; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Sullards M C, 2001, Sci STKE, V2001, ppl1; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; van der Bijl P, 1996, BIOCHEM J, V317, P589, DOI 10.1042/bj3170589; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Venkataraman K, 2001, BBA-MOL CELL BIOL L, V1530, P219, DOI 10.1016/S1388-1981(01)00085-3; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; WAGNER H, 1966, BIOCHEM Z, V344, P314; Wang E, 2000, METHOD ENZYMOL, V311, P15; WANG E, 1991, J BIOL CHEM, V266, P14486; Wang E, 1999, J NUTR, V129, P214, DOI 10.1093/jn/129.1.214; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0	46	232	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43452	43459		10.1074/jbc.M307104200	http://dx.doi.org/10.1074/jbc.M307104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912983	hybrid			2022-12-25	WOS:000186157000090
J	Veeraraghavan, J; Rossi, ML; Bambara, RA				Veeraraghavan, J; Rossi, ML; Bambara, RA			Analysis of DNA replication intermediates suggests mechanisms of repeat sequence expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY-DISEASE GENES; TRINUCLEOTIDE REPEAT; SACCHAROMYCES-CEREVISIAE; TRIPLET REPEAT; IN-VITRO; SECONDARY STRUCTURE; CTG REPEATS; ESCHERICHIA-COLI; CAG REPEATS; INSTABILITY	We previously developed a system to investigate the mechanism of repeat sequence expansion during eukaryotic Okazaki fragment processing. Upstream and downstream primers were annealed to a complementary template to overlap across a CAG repeat region. Annealing by the competing primers lead to structural intermediates that ligated to expand the repeat segment. When an equal number of repeats overlapped on the upstream and downstream primers, a 2-fold expansion was expected, but no expansion occurred. We show here that such substrates do not expand irrespective of their repeat length. To reveal mechanism, we tested different hairpin loop intermediates expected to form and facilitate ligation. Substrates configured to form large loops in either the upstream or downstream primer alone allowed expansion. Large or small fixed position single loops allowed expansion when located at least six nucleotides up- or downstream of the nick. Fixed loops in both primers, simulating a double loop intermediate, allowed expansion as long as each loop was nine nucleotides from the nick. Thus, neither the double loop configuration required to form with equal length overlaps nor the large single loop configuration are fundamental structural impediments to expansion. We propose a model for the expansion mechanism based on the relative stabilities of single loop, double loop, hairpin, and flap intermediates that is consistent with the observed expansion efficiency of equal and unequal overlap substrates. The model suggests that the equilibrium concentration of double loop intermediates is so vanishingly small that they are not likely contributors to sequence expansion.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14624 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bennett P, 2000, J CLIN PATHOL-MOL PA, V53, P177; Chastain PD, 1998, J MOL BIOL, V275, P405, DOI 10.1006/jmbi.1997.1502; Cleary JD, 2002, NAT GENET, V31, P37, DOI 10.1038/ng870; Debrauwere H, 2001, P NATL ACAD SCI USA, V98, P8263, DOI 10.1073/pnas.121075598; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gacy AM, 1998, BIOCHEMISTRY-US, V37, P9426, DOI 10.1021/bi980157s; GACY AM, 1995, CELL, V81, P533; Goellner GM, 1997, AM J HUM GENET, V60, P879; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Hartenstine MJ, 2000, J BIOL CHEM, V275, P18382, DOI 10.1074/jbc.275.24.18382; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Henricksen LA, 2002, J BIOL CHEM, V277, P22361, DOI 10.1074/jbc.M201765200; Ireland MJ, 2000, GENETICS, V155, P1657; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jakupciak JP, 2000, IUBMB LIFE, V50, P355, DOI 10.1080/152165400300089358; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Nichol K, 2002, GENOME RES, V12, P1246, DOI 10.1101/gr.74502; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Panigrahi GB, 2002, J BIOL CHEM, V277, P13926, DOI 10.1074/jbc.M109761200; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 2002, NUCLEIC ACIDS RES, V30, P4534, DOI 10.1093/nar/gkf572; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Rolfsmeier ML, 2000, MOL CELL BIOL, V20, P173, DOI 10.1128/MCB.20.1.173-180.2000; Rolfsmeier ML, 2001, GENETICS, V157, P1569; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; Usdin K, 2000, CELL MOL LIFE SCI, V57, P914, DOI 10.1007/PL00000734; Volker J, 2002, P NATL ACAD SCI USA, V99, P14700, DOI 10.1073/pnas.222519799; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Zuker M, 2000, CURR OPIN STRUC BIOL, V10, P303, DOI 10.1016/S0959-440X(00)00088-9	45	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42854	42866		10.1074/jbc.M305137200	http://dx.doi.org/10.1074/jbc.M305137200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12902352	hybrid			2022-12-25	WOS:000186157000017
J	Ono, M; Shimizugawa, T; Shimamura, M; Yoshida, K; Noji-Sakikawa, C; Ando, Y; Koishi, R; Furukawa, H				Ono, M; Shimizugawa, T; Shimamura, M; Yoshida, K; Noji-Sakikawa, C; Ando, Y; Koishi, R; Furukawa, H			Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3) - ANGPTL3 is cleaved and activated in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-LIPASE; MICE; ADENOVIRUS; LIGAND; TIE2	Angiopoietin-like 3 (ANGPTL3) is a secreted protein that is mainly expressed in the liver and regulates lipid metabolism by inhibiting the lipolysis of triglyceride-rich lipoproteins. Using deletion mutants of human ANGPTL3, we demonstrated that the N-terminal coiled-coil domain-containing fragment-(17-207) and not the C-terminal fibrinogen-like domain-containing fragment( 207 - 460) increased the plasma triglyceride levels in mice. We also found that the N-terminal region 17 - 165 was required to increase plasma triglyceride levels in mice and that a substitution of basic amino acid residues in the region 61 - 66 of the fragment showed no increase in the plasma triglyceride levels and no inhibition of lipolysis by lipoprotein lipase. In addition, when we analyzed ANGPTL3 in human plasma, we detected cleaved fragments of ANGPTL3. By analyzing recombinant ANGPTL3 in mouse plasma, we found that it was cleaved at two sites, Arg(221)down arrowAla(222) and Arg(224)down arrowThr(225), which are located in the linker region between the coiled-coil domain and the fibrinogen-like domain. Furthermore, a cleavage-resistant mutant of ANGPTL3 was determined to be less active than wild-type ANGPTL3 in increasing mouse plasma triglyceride levels but not in inhibiting lipoprotein lipase activity. These findings suggest that the cleavage of ANGPTL3 is important for the activation of ANGPTL3 in vivo.	Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Med Safety Res Labs, Shizuoka 4370065, Japan	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Ono, M (corresponding author), Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1408710, Japan.			Ando, Yukio/0000-0001-7115-9105				Camenisch G, 2002, J BIOL CHEM, V277, P17281, DOI 10.1074/jbc.M109768200; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Fowlkes JL, 2002, CYTOKINE GROWTH F R, V13, P277, DOI 10.1016/S1359-6101(02)00005-9; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; LITHELL H, 1977, SCAND J CLIN LAB INV, V37, P551, DOI 10.3109/00365517709101845; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Naoumova RP, 2002, LANCET, V359, P2215, DOI 10.1016/S0140-6736(02)09315-7; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Rossetti L, 2002, NAT MED, V8, P112, DOI 10.1038/nm0202-112; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V301, P604, DOI 10.1016/S0006-291X(02)03058-9; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; SHIRAKI T, 1993, DIABETES FRONTIER, V4, P641; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Yoshida K, 2002, J LIPID RES, V43, P1770, DOI 10.1194/jlr.C200010-JLR200	20	165	192	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41804	41809		10.1074/jbc.M302861200	http://dx.doi.org/10.1074/jbc.M302861200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909640	hybrid			2022-12-25	WOS:000185989500032
J	Chow, JPH; Siu, WY; Ho, HTB; Ma, KHT; Ho, CC; Poon, RYC				Chow, JPH; Siu, WY; Ho, HTB; Ma, KHT; Ho, CC; Poon, RYC			Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE 2; S-PHASE; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; HUMAN MYT1; B1 GENE; ULTRAVIOLET-IRRADIATION; G(1)/S TRANSITION; DAMAGE CHECKPOINT; PROTEIN-KINASE	Inhibition of cyclin-dependent kinases (CDKs) by Thr(14)/Tyr(15) phosphorylation is critical for normal cell cycle progression and is a converging event for several cell cycle checkpoints. In this study, we compared the relative contribution of inhibitory phosphorylation for cyclin A/B1-CDC2 and cyclin A/E-CDK2 complexes. We found that inhibitory phosphorylation plays a major role in the regulation of CDC2 but only a minor role for CDK2 during the unperturbed cell cycle of HeLa cells. The relative importance of inhibitory phosphorylation of CDC2 and CDK2 may reflect their distinct cellular functions. Despite this, expression of nonphosphorylation mutants of both CDC2 and CDK2 triggered unscheduled histone H3 phosphorylation early in the cell cycle and was cytotoxic. DNA damage by a radiomimetic drug or replication block by hydroxyurea stimulated a buildup of cyclin B1 but was accompanied by an increase of inhibitory phosphorylation of CDC2. After DNA damage and replication block, all cyclin-CDK pairs that control S phase and mitosis were to different degrees inhibited by phosphorylation. Ectopic expression of nonphosphorylated CDC2 stimulated DNA replication, histone H3 phosphorylation, and cell division even after DNA damage. Similarly, a nonphosphorylation mutant of CDK2, but not CDK4, disrupted the G(2) DNA damage checkpoint. Finally, CDC25A, CDC25B, a dominant-negative CHK1, but not CDC25C or a dominant-negative WEE1, stimulated histone H3 phosphorylation after DNA damage. These data suggest differential contributions for the various regulators of Thr(14)/Tyr(15) phosphorylation in normal cell cycle and during the DNA damage checkpoint.	Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.			Poon, Randy/0000-0001-5571-6231; MA, Hoi Tang/0000-0001-5876-0107				AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; CHOW JPH, 2003, IN PRESS MOL BIOL CE; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Coverley D, 2000, J CELL SCI, V113, P1929; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Farina A, 1996, ONCOGENE, V13, P1287; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jiang W, 1998, BIOTECHNIQUES, V24, P349; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Lane ME, 2000, GENETICS, V155, P233; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Li KKW, 2002, LIVER, V22, P259, DOI 10.1046/j.0106-9543.2002.01629.x; Liu F, 1999, MOL CELL BIOL, V19, P5113; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 2002, ENCY CANC, P393; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wells NJ, 1999, J CELL SCI, V112, P3361; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yam CH, 1999, CANCER RES, V59, P5075; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	71	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40815	40828		10.1074/jbc.M306683200	http://dx.doi.org/10.1074/jbc.M306683200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912980	hybrid			2022-12-25	WOS:000185847200050
J	Das, S; Rafter, JD; Kim, KP; Gygi, SP; Cho, WH				Das, S; Rafter, JD; Kim, KP; Gygi, SP; Cho, WH			Mechanism of group IVA cytosolic phospholipase A(2) activation by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; LIPID-BINDING DOMAIN; PROTEIN-KINASE-C; MEMBRANE-DOCKING; INTERFACIAL CATALYSIS; HUMAN PLATELETS; CALCIUM; IDENTIFICATION; SPECIFICITY; MACROPHAGES	Group IVA cytosolic phospholipase A(2) (cPLA(2)) has been shown to play a critical role in the agonist-induced release of arachidonic acid. To understand the mechanism by which phosphorylation of Ser(505) and Ser(727) activates cPLA(2), we systematically analyzed the effects of S505A, S505E, S727A, S727E, S505A/S727A, S505A/S727E, and S505E/S727E mutations on its enzyme activity and membrane affinity. In vitro membrane binding measurements showed that S505A has lower affinity than the wild type or S505E for phosphatidylcholine membranes, which is exclusively due to faster desorption of the membrane-bound S505A. In contrast, neither S727A nor S727E mutation had a significant effect on the phosphatidylcholine vesicle binding affinity of cPLA(2). The difference in in vitro membrane affinity between wild type ( or S505E) and S505A increased with the decrease in Ca2+ concentration, reaching > 60-fold at 2.5 muM Ca2+. When HEK293 cells transfected with cPLA(2) and mutants were stimulated with ionomycin, the wild type and S505E translocated to the perinuclear region and caused the arachidonic acid release at 0.4 muM Ca2+, whereas S505A showed no membrane translocation and little activity to release arachidonic acid. Further mutational analysis of hydrophobic residues in the active site rim (Ile(399), Leu(400), and Leu(552)) indicate that a main role of the Ser(505) phosphorylation is to promote membrane penetration of these residues, presumably by inducing a conformational change of the protein. These enhanced hydrophobic interactions allow the sustained membrane interaction of cPLA(2) in response to transient calcium increases. On the basis of these results, we propose a mechanism for cPLA(2) activation by calcium and phosphorylation.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Harvard Medical School	Cho, WH (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.			Kim, Kwang Pyo/0000-0003-0095-3787	NIGMS NIH HHS [GM52598, GM53987] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; BERS DM, 1982, AM J PHYSIOL, V242, P404; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Buschbeck M, 1999, BIOCHEM J, V344, P359, DOI 10.1042/0264-6021:3440359; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haugland R.P., 1996, HDB FLUORESCENT PROB, P503; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; Johnson LN, 2001, CHEM REV, V101, P2209, DOI 10.1021/cr000225s; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; McMurray W. C., 1973, FORM FUNCTION PHOSPH, P205; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622	47	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41431	41442		10.1074/jbc.M304897200	http://dx.doi.org/10.1074/jbc.M304897200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12885780	hybrid			2022-12-25	WOS:000185847200123
J	Fernandez, CA; Butterfield, C; Jackson, G; Moses, MA				Fernandez, CA; Butterfield, C; Jackson, G; Moses, MA			Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2) - Loop 6 is a novel angiogenesis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; GROWTH-PROMOTING ACTIVITY; N-TERMINAL DOMAIN; MATRIX-METALLOPROTEINASE; CELL-DEATH; PICHIA-PASTORIS; B-CELLS; BINDING; NEOVASCULARIZATION; APOPTOSIS	Tissue inhibitors of metalloproteinases (TIMPs) regulate tumor growth, progression, and angiogenesis in a variety of experimental cancer models and in human malignancies. Results from numerous studies have revealed important differences between TIMP family members in their ability to inhibit angiogenic processes in vitro and angiogenesis in vivo despite their universal ability to inhibit matrix metalloproteinase (MMP) activity. To address these differences, a series of structure-function studies were conducted to identify and to characterize the anti-angiogenic domains of TIMP-2, the endogenous MMP inhibitor that uniquely inhibits capillary endothelial cell (EC) proliferation as well as angiogenesis in vivo. We demonstrate that the COOH-terminal domain of TIMP-2 (T2C) inhibits the proliferation of capillary EC at molar concentrations comparable with those previously reported for intact TIMP-2, while the NH2-terminal domain (T2N), which inhibits MMP activity, has no significant anti-proliferative effect. Interestingly, although both T2N and T2C inhibited embryonic angiogenesis, only T2C resulted in the potent inhibition of angiogenesis driven by the exogenous addition of angiogenic mitogen, suggesting that MMP inhibition alone may not be sufficient to inhibit the aggressive neovascularization characteristic of aberrant angiogenesis. We further mapped the anti-proliferative activity of T2C to a 24-amino acid peptide corresponding to Loop 6 of TIMP-2 and show that Loop 6 is a potent inhibitor of both embryonic and mitogen-stimulated angiogenesis in vivo. These findings demonstrate that TIMP-2 possesses two distinct types of anti-angiogenic activities which can be uncoupled from each other, the first represented by its MMP-dependent inhibitory activity which can inhibit only embryonic neovascularization and the second represented by an MMP-independent activity which inhibits both normal angiogenesis and mitogen-driven angiogenesis in vivo. In addition, we report, for the first time, the discovery of Loop 6 as a novel and potent inhibitor of angiogenesis.	Childrens Hosp, Surg Res Lab, Vasc Biol Program, Boston, MA 02115 USA; MIT, Div Biol Engn, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Moses, MA (corresponding author), Childrens Hosp, Surg Res Lab, Vasc Biol Program, Enders 1009,320 Longwood Ave, Boston, MA 02115 USA.				NCI NIH HHS [2P01CA455] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Brand K, 2000, CANCER RES, V60, P5723; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; BURT HM, 1995, CANCER LETT, V88, P73, DOI 10.1016/0304-3835(94)03614-O; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Ikegaya K, 1997, ANAL CHEM, V69, P1986, DOI 10.1021/ac961316l; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Li GY, 1999, CANCER RES, V59, P6267; Lim MS, 1999, ANN NY ACAD SCI, V878, P522, DOI 10.1111/j.1749-6632.1999.tb07715.x; MONSKY WL, 1993, CANCER RES, V53, P3159; MOSES MA, 1992, J CELL BIOL, V119, P475, DOI 10.1083/jcb.119.2.475; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; Moses MA, 1999, P NATL ACAD SCI USA, V96, P2645, DOI 10.1073/pnas.96.6.2645; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MOSES MA, 1991, BIO-TECHNOL, V9, P630, DOI 10.1038/nbt0791-630; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Sun JR, 1997, BIOCHEM BIOPH RES CO, V238, P920, DOI 10.1006/bbrc.1997.7370; TOLLEY S, 1993, J MOL BIOL, V229, P1163, DOI 10.1006/jmbi.1993.1114; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200	53	84	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40989	40995		10.1074/jbc.M306176200	http://dx.doi.org/10.1074/jbc.M306176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900406	hybrid			2022-12-25	WOS:000185847200072
J	Mutze, S; Hebling, U; Stremmel, W; Wang, J; Arnhold, J; Pantopoulos, K; Mueller, S				Mutze, S; Hebling, U; Stremmel, W; Wang, J; Arnhold, J; Pantopoulos, K; Mueller, S			Myeloperoxidase-derived hypochlorous acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; CHEMI-LUMINESCENCE; TYROSINE NITRATION; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; NITRIC-OXIDE; COMPOUNDS I; DNA-DAMAGE; LUMINOL; MECHANISM	Hypochlorous acid (HOCl) is a highly reactive product generated by the myeloperoxidase reaction during the oxidative burst of activated neutrophils, which is implicated in many bactericidal and cytotoxic responses. Recent evidence suggests that HOCl may also play a role in the modulation of redox sensitive signaling pathways. The short half-life of HOCl and the requirement for a continuous presence of H2O2 as a substrate for its myeloperoxidase-catalyzed generation make the study of HOCl-mediated responses very difficult. We describe here an enzymatic model consisting of glucose/glucose oxidase, catalase, and myeloperoxidase (GOX/CAT/ MPO) that allows the controlled generation of both HOCl and H2O2 and thus, mimics the oxidative burst of activated neutrophils. By employing this model we show that HOCl prevents the H2O2-mediated activation of iron regulatory protein 1 (IRP1), a central post-transcriptional regulator of mammalian iron metabolism. Activated IRP1 binds to "iron-responsive elements" (IREs) within the mRNAs encoding proteins of iron metabolism and thereby controls their translation or stability. The inhibitory effect of HOCl is not a result of a direct modification of IRP1 by this oxidant. Kinetics experiments provide evidence that HOCl intervenes with the signaling cascade, which results in the activation of IRP1. We further demonstrate that HOCl antagonizes the H2O2-mediated increase in the levels of transferrin receptor, which is a downstream target of IRP1. Our findings suggest that HOCl can modulate signaling pathways in a concerted action with H2O2. The GOX/CAT/ MPO system provides a valuable tool for studying the regulatory function of HOCl.	Univ Heidelberg, Dept Internal Med 4, D-69115 Heidelberg, Germany; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Univ Leipzig, Inst Med Phys & Biophys, D-04103 Leipzig, Germany; McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada	Ruprecht Karls University Heidelberg; Lady Davis Institute; McGill University; Leipzig University; McGill University	Mueller, S (corresponding author), Univ Heidelberg, Dept Internal Med 4, Bergheimer Str 58, D-69115 Heidelberg, Germany.		Pantopoulos, Kostas/A-9668-2008	Pantopoulos, Kostas/0000-0002-2305-0057; Stremmel, Wolfgang/0000-0002-8545-1753				ALBRECHT D, 1993, J LEUKOCYTE BIOL, V54, P300, DOI 10.1002/jlb.54.4.300; ARNHOLD J, 1990, BIOMED BIOCHIM ACTA, V49, P991; BAGGIOLINI M, 1991, OXIDATIVE STRESS OXI; Baldus S, 2001, J CLIN INVEST, V108, P1759; Baldus S, 2002, FREE RADICAL BIO MED, V33, P1010, DOI 10.1016/S0891-5849(02)00993-0; BEERS RF, 1952, J BIOL CHEM, V195, P133; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; Burner U, 1999, FEBS LETT, V443, P290, DOI 10.1016/S0014-5793(98)01727-X; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; CALTAGIRONE A, 2001, J BIOL CHEM, V22, P22; Capeillere-Blandin C, 1998, BIOCHEM J, V336, P395, DOI 10.1042/bj3360395; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; Chapman ALP, 2002, J BIOL CHEM, V277, P9757, DOI 10.1074/jbc.M106134200; CORMIER MJ, 1968, J BIOL CHEM, V243, P4706; DAHLGREN C, 1983, INFECT IMMUN, V39, P736, DOI 10.1128/IAI.39.2.736-741.1983; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; ELEY DW, 1991, CAN J PHYSIOL PHARM, V69, P1677, DOI 10.1139/y91-249; Engelmann I, 2000, REDOX REP, V5, P207, DOI 10.1179/135100000101535762; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MASHINO T, 1988, BIOCHIM BIOPHYS ACTA, V956, P63, DOI 10.1016/0167-4838(88)90298-1; McKenzie SJ, 1996, J CLIN INVEST, V98, P136, DOI 10.1172/JCI118757; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Midwinter RG, 2001, ARCH BIOCHEM BIOPHYS, V394, P13, DOI 10.1006/abbi.2001.2530; MISRA HP, 1982, ARCH BIOCHEM BIOPHYS, V215, P59, DOI 10.1016/0003-9861(82)90278-8; MORRIS JC, 1966, J PHYS CHEM-US, V70, P2798; Mueller S, 1997, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P338; Mueller S, 1997, ANAL BIOCHEM, V245, P55, DOI 10.1006/abio.1996.9939; Mueller S, 2000, FREE RADICAL BIO MED, V29, P410, DOI 10.1016/S0891-5849(00)00261-6; MUELLER S, 1995, J BIOLUM CHEMILUM, V10, P229, DOI 10.1002/bio.1170100406; Mueller S, 1997, BLOOD, V90, P4973, DOI 10.1182/blood.V90.12.4973.4973_4973_4978; Mueller S, 2002, METHOD ENZYMOL, V348, P324, DOI 10.1016/S0076-6879(02)48651-X; Mueller S, 2001, J BIOL CHEM, V276, P23192, DOI 10.1074/jbc.M100654200; Nakamura M, 1998, FREE RADICAL BIO MED, V24, P537, DOI 10.1016/S0891-5849(97)00326-2; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Pullar JM, 2002, ANTIOXID REDOX SIGN, V4, P5, DOI 10.1089/152308602753625807; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; Vile GF, 1998, ARCH BIOCHEM BIOPHYS, V359, P51, DOI 10.1006/abbi.1998.0881; Vissers MCM, 1998, BIOCHEM J, V330, P131; VISSERS MCM, 1995, BIOCHEM J, V307, P57, DOI 10.1042/bj3070057; Vissers MCM, 1997, FREE RADICAL BIO MED, V23, P401, DOI 10.1016/S0891-5849(96)00619-3; VOGT W, 1994, IMMUNOBIOLOGY, V192, P1; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5	56	61	65	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40542	40549		10.1074/jbc.M307159200	http://dx.doi.org/10.1074/jbc.M307159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888561	hybrid			2022-12-25	WOS:000185847200016
J	Dean, JLE; Sarsfield, SJ; Tsounakou, E; Saklatvala, J				Dean, JLE; Sarsfield, SJ; Tsounakou, E; Saklatvala, J			p38 mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; 3'-UNTRANSLATED REGION; SEQUENCE FEATURES; MAMMALIAN EXOSOME; GENE-EXPRESSION; POLY(A); DEGRADATION; YEAST; PATHWAY; HUR	AU-rich elements (AREs) in 3'-untranslated regions of mRNAs confer instability. They target mRNAs for rapid deadenylation and degradation and may enhance decapping. The p38 MAPK pathway stabilizes many otherwise unstable ARE-containing mRNAs encoding proteins involved in inflammation; however, the mRNA decay step(s) regulated by the signaling pathway are unknown. To investigate whether it regulates deadenylation or the decay of the mRNA body, we used a tetracycline-regulated beta-globin mRNA reporter system to transcribe pulses of mRNA of uniform length. We measured on Northern gels the migration of reporter mRNAs isolated from cells transfected only with reporter plasmid or co-transfected with an active mutant of MAPK kinase-6, and treated either with or without the p38 MAPK inhibitor SB 203580. Differences in migration were shown by RNase H mapping with oligo(dT) to be due to poly(A) shortening. Insertion of an ARE into the beta-globin reporter mRNA promoted rapid deadenylation and decay of hypo-adenylated reporter mRNA. p38 MAPK activation inhibited the deadenylation of reporter mRNAs containing either the cyclooxygenase-2 or tumor necrosis factor AREs. The regulation of deadenylation by p38 MAPK was found to be specific because deadenylation of the beta-globin reporter mRNA either lacking an ARE or containing the c-Myc 3'-untranslated region (which is not p38 MAPK-responsive) was unaffected by p38 MAPK. It was concluded that the p38 MAPK pathway predominantly regulates deadenylation, rather than decay of the mRNA body, and this provides an explanation for why p38 MAPK regulates mRNA stability in some situations and translation in others.	Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England	Imperial College London; University of Oxford	Dean, JLE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, 1 Aspenlea Rd, London W6 8LH, England.	jonathan.dean@imperial.ac.uk		Dean, Jonathan/0000-0002-0703-2756				Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Bollig F, 2003, BIOCHEM BIOPH RES CO, V301, P665, DOI 10.1016/S0006-291X(03)00015-9; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Clark AR, 2003, FEBS LETT, V546, P37, DOI 10.1016/S0014-5793(03)00439-3; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Korner CG, 1997, J BIOL CHEM, V272, P10448; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; PRICHETT W, 1995, J INFLAMM, V45, P97; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; Wang SW, 1999, INFLAMM RES, V48, P533, DOI 10.1007/s000110050499; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558	52	82	85	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39470	39476		10.1074/jbc.M306345200	http://dx.doi.org/10.1074/jbc.M306345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882963	hybrid			2022-12-25	WOS:000185713800025
J	Garcia-Castellanos, R; Marrero, A; Mallorqui-Fernandez, G; Potempa, J; Coll, M; Gomis-Ruth, FX				Garcia-Castellanos, R; Marrero, A; Mallorqui-Fernandez, G; Potempa, J; Coll, M; Gomis-Ruth, FX			Three-dimensional structure of MecI - Molecular basis for transcriptional regulation of staphylococcal methicillin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAMASE SYNTHESIS; BACILLUS-LICHENIFORMIS; CRYSTAL-STRUCTURE; SIGNALING PATHWAY; DNA-RECOGNITION; REPRESSOR BLAL; AUREUS; GENE; TRANSDUCER; STRAINS	Methicillin-resistant Staphylococcus aureus is the main cause of nosocomial and community-onset infections that affect millions of people worldwide. Some methicillin-resistant Staphylococcus aureus infections have become essentially untreatable by beta-lactams because of acquired molecular machineries enabling antibiotic resistance. Evasion from methicillin challenge is mainly achieved by the synthesis of a penicillin-binding protein of low affinity for antibiotics, MecA, that replaces regular penicillin-binding proteins in cell wall turnover when these have been inactivated by antibiotics. MecA synthesis is regulated by a signal transduction system consisting of the sensor/transducer MecR1 and the 14-kDa transcriptional repressor MecI (also known as methicillin repressor) that constitutively blocks mecA transcription. The three-dimensional structure of MecI reveals a dimer of two independent winged helix domains, each of which binds a palindromic DNA-operator half site, and two intimately intertwining dimerization domains of novel spiral staircase architecture, held together by a hydrophobic core. Limited proteolytic cleavage by cognate MecR1 within the dimerization domains results in loss of dimer interaction surface, dissociation, and repressor release, which triggers MecA synthesis. Structural information on components of the MecA regulatory pathway, in particular on methicillin repressor, the ultimate transcriptional trigger of mecA-encoded methicillin resistance, is expected to lead to the development of new antimicrobial drugs.	CSIC, Ctr Invest & Desenvolupament, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; Jagiellonian Univ, Fac Biotechnol, Dept Microbiol, Krakow, Poland; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Jagiellonian University; University System of Georgia; University of Georgia	Gomis-Ruth, FX (corresponding author), CSIC, Ctr Invest & Desenvolupament, Inst Biol Mol Barcelona, C Jordi Girona 18-26, ES-08034 Barcelona, Spain.	xgrcri@ibmb.csic.es	Coll, Miquel/L-5999-2014	Coll, Miquel/0000-0003-4471-8674; Garcia-Castellanos, Raquel/0000-0001-6225-5373; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; Ayliffe GAJ, 1997, CLIN INFECT DIS, V24, pS74, DOI 10.1093/clinids/24.Supplement_1.S74; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chambers HF, 2003, TRENDS MICROBIOL, V11, P145, DOI 10.1016/S0966-842X(03)00046-5; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clarke SR, 2001, MICROBIOL-UK, V147, P803, DOI 10.1099/00221287-147-4-803; Clarke SR, 2001, J ANTIMICROB CHEMOTH, V47, P377, DOI 10.1093/jac/47.4.377; COHEN S, 1968, J BACTERIOL, V95, P1368, DOI 10.1128/JB.95.4.1368-1374.1968; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; Crisostomo MI, 2001, P NATL ACAD SCI USA, V98, P9865, DOI 10.1073/pnas.161272898; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Filee P, 2003, J BIOL CHEM, V278, P16482, DOI 10.1074/jbc.M210887200; Filee P, 2002, MOL MICROBIOL, V44, P685, DOI 10.1046/j.1365-2958.2002.02888.x; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Ghuysen Jean-Marie, 1994, Trends in Microbiology, V2, P372, DOI 10.1016/0966-842X(94)90614-9; Giesbrecht P, 1998, MICROBIOL MOL BIOL R, V62, P1371, DOI 10.1128/MMBR.62.4.1371-1414.1998; Golemi-Kotra D, 2003, J BIOL CHEM, V278, P18419, DOI 10.1074/jbc.M300611200; Gregory PD, 1997, MOL MICROBIOL, V24, P1025, DOI 10.1046/j.1365-2958.1997.4051770.x; GROSSMAN MJ, 1989, FEBS LETT, V246, P83, DOI 10.1016/0014-5793(89)80258-3; HACKBARTH CJ, 1993, ANTIMICROB AGENTS CH, V37, P1144, DOI 10.1128/AAC.37.5.1144; Hardt K, 1997, MOL MICROBIOL, V23, P935, DOI 10.1046/j.1365-2958.1997.2761642.x; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; HIRAMATSU K, 1992, FEBS LETT, V298, P133, DOI 10.1016/0014-5793(92)80039-J; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a; Katayama Y, 2000, ANTIMICROB AGENTS CH, V44, P1549, DOI 10.1128/AAC.44.6.1549-1555.2000; Kirby WMM, 1944, SCIENCE, V99, P452, DOI 10.1126/science.99.2579.452; Lewis RA, 2000, J ANTIMICROB CHEMOTH, V45, P139, DOI 10.1093/jac/45.2.139; Lewis RA, 1999, FEMS MICROBIOL LETT, V178, P271, DOI 10.1016/S0378-1097(99)00366-3; LOPEZ P, 1980, J BACTERIOL, V143, P50; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McKinney TK, 2001, J BACTERIOL, V183, P6862, DOI 10.1128/JB.183.23.6862-6868.2001; Murchan S, 2003, J CLIN MICROBIOL, V41, P1574, DOI 10.1128/JCM.41.4.1574-1585.2003; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; RICHMOND MH, 1965, J BACTERIOL, V90, P370, DOI 10.1128/JB.90.2.370-374.1965; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; RYFFEL C, 1992, ANTIMICROB AGENTS CH, V36, P25, DOI 10.1128/AAC.36.1.25; Schmitz FJ, 1997, INT J ANTIMICROB AG, V9, P1, DOI 10.1016/S0924-8579(97)00027-7; Sharma VK, 1998, J BACTERIOL, V180, P2160, DOI 10.1128/JB.180.8.2160-2166.1998; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; White A, 1998, NATURE, V394, P502, DOI 10.1038/28893; WITTMAN V, 1993, J BACTERIOL, V175, P7383, DOI 10.1128/JB.175.22.7383-7390.1993; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144; ZHU YF, 1992, J BACTERIOL, V174, P6171, DOI 10.1128/JB.174.19.6171-6178.1992	51	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39897	39905		10.1074/jbc.M307199200	http://dx.doi.org/10.1074/jbc.M307199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881514	hybrid			2022-12-25	WOS:000185713800077
J	Leonard, MO; Cottell, DC; Godson, C; Brady, HR; Taylor, CT				Leonard, MO; Cottell, DC; Godson, C; Brady, HR; Taylor, CT			The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; NECROSIS-FACTOR-ALPHA; ELEMENT-BINDING PROTEIN; VHL TUMOR-SUPPRESSOR; GENE-EXPRESSION; MICROARRAY ANALYSIS; MESSENGER-RNA; HIF-ALPHA; IDENTIFICATION; GROWTH	Epithelial cells of the kidney represent a primary target for hypoxic injury in ischemic acute renal failure (ARF); however, the underlying transcriptional mechanism(s) remain undefined. In this study, human proximal tubular epithelial cells (HK-2) exposed to hypoxia in vitro demonstrated a non-lethal but dysfunctional phenotype, closely reflective of the epithelial pathobiology of ARF. HK-2 cells exposed to hypoxia demonstrated increased paracellular permeability, decreased proliferation, loss of tight junctional integrity, and significant actin disassembly in the absence of cell death. Microarray analysis of transcriptomic changes underlying this response identified a distinct cohort of 48 genes with a closely shared hypoxia-dependent expression profile. Within this hypoxia-sensitive cluster were genes identified previously as hypoxia-inducible factor-1 (HIF-1)-dependent ( e. g. vascular endothelial growth factor and adrenomedullin) as well as genes not previously known to be hypoxia-responsive ( e. g. stanniocalcin 2). In hypoxia, HIF-1 bound to evolutionarily conserved hypoxia-response elements (HRE) in the promoters of these genes as well as to the HRE consensus motif. A further subset of these genes, not associated with transcriptional regulation by HIF-1, was also present, suggesting alternative HIF-1-independent pathways. Overexpression of HIF-1alpha in normoxia induced the expression of a significant number of the hypoxia-dependent genes; however, it did not induce the pathophysiologic epithelial response. In summary, hypoxia-elicited alterations in renal proximal tubular epithelial cells in vitro closely resemble the epithelial pathophysiology of ARF. Our data indicate that although this event may rely heavily on HIF-1-dependent gene transcription, it is likely that separate hypoxia-dependent transcriptional regulators also play a role.	Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Natl Univ Ireland Univ Coll Dublin, Dublin Mol Med Ctr, Dublin 4, Ireland	University College Dublin; Trinity College Dublin; University College Dublin	Taylor, CT (corresponding author), Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland.		Leonard, Martin/AAI-2223-2020	Godson, Catherine/0000-0003-0655-1041; Taylor, Cormac/0000-0002-0946-1247				Bonventre JV, 2002, CURR OPIN NEPHROL HY, V11, P43, DOI 10.1097/00041552-200201000-00007; BRADY HR, 2000, KIDNEY, P1201; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fessele S, 2002, TRENDS GENET, V18, P60, DOI 10.1016/S0168-9525(02)02591-X; Fink T, 2002, BLOOD, V99, P2077, DOI 10.1182/blood.V99.6.2077; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jenq W, 1996, BIOCHEM BIOPH RES CO, V218, P444, DOI 10.1006/bbrc.1996.0079; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Matejuk A, 2002, ENDOCRINOLOGY, V143, P313, DOI 10.1210/en.143.1.313; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Millhorn DE, 1997, KIDNEY INT, V51, P527, DOI 10.1038/ki.1997.73; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Molin WT, 1999, WEED TECHNOL, V13, P1; ORourke JF, 1996, EUR J BIOCHEM, V241, P403, DOI 10.1111/j.1432-1033.1996.00403.x; Prince LS, 2001, PHYSIOL GENOMICS, V6, P81, DOI 10.1152/physiolgenomics.2001.6.2.81; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Schipani E, 2001, GENE DEV, V15, P2865; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Taylor CT, 1999, PHARM RES-DORDR, V16, P1498, DOI 10.1023/A:1011936016833; Taylor CT, 1999, J BIOL CHEM, V274, P19447, DOI 10.1074/jbc.274.27.19447; Taylor CT, 1998, GASTROENTEROLOGY, V114, P657, DOI 10.1016/S0016-5085(98)70579-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298	51	126	131	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40296	40304		10.1074/jbc.M302560200	http://dx.doi.org/10.1074/jbc.M302560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885785	hybrid			2022-12-25	WOS:000185713800122
J	Louneva, N; Saitta, B; Herrick, DJ; Jimenez, SA				Louneva, N; Saitta, B; Herrick, DJ; Jimenez, SA			Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN GENE; DERMAL FIBROBLASTS; INCREASED BINDING; CBF/NF-Y; PROMOTER; ACTIVATION; ELEMENTS; COL1A1; ADDUCTS; BASAL	We previously showed that COL1A1 expression is upregulated at the transcriptional level in systemic sclerosis (SSc) fibroblasts and that the CCAAT-binding factor (CBF) is involved in this increased expression. Ecteinascidin 743 (ET-743) is a chemotherapeutic agent that binds with sequence specificity to the minor groove of DNA and inhibits CBF-mediated transcriptional activation of numerous genes. Therefore, we examined the effects of ET-743 on the increased COL1A1 expression in SSc fibroblasts. The drug caused a potent and dose-dependent inhibition of type I collagen biosynthesis, which reached 70 - 90% at 700 pM without affecting cell viability. The same drug concentration caused 60 - 80% reduction in COL1A1 mRNA levels. The stability of the corresponding transcripts was not affected. In vitro nuclear transcription assays demonstrated a 54% downregulation of COL1A1 transcription. Transient transfections with COL1A1 promoter constructs containing the specific CBF binding sequence into SSc cells previously treated with 700 pM ET-743 failed to show an effect on COL1A1 promoter activity. Furthermore, ET-743 did not affect the binding of CBF or Sp1 transcription factors to their cognate COL1A1 elements. However, treatment with 700 pM ET-743 of stably transfected NIH 3T3 cells expressing a human type II procollagen gene under the control of the human COL1A1 promoter caused a greater than 50% reduction in the production of type II procollagen and a similar decrease in the corresponding type II procollagen transcripts. These results indicate that ET-743 is a potent inhibitor of COL1A1 transcription. However, this effect cannot be explained by a direct effect on CBF binding to the COL1A1 promoter. Although the exact mechanisms responsible for the transcriptional inhibition of COL1A1 by ET-743 are not apparent, our observations suggest that the drug may be an effective agent to decrease collagen overproduction in SSc and other fibrotic diseases.	Thomas Jefferson Univ, Dept Med, Div Rheumatol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Jimenez, SA (corresponding author), Thomas Jefferson Univ, Dept Med, Div Rheumatol, 233 S 10th St,Rm 509 BLSB, Philadelphia, PA 19107 USA.	Sergio.Jimenez@jefferson.edu		Jimenez, Sergio/0000-0001-5213-1203	NIAMS NIH HHS [AR19616] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019616] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; Artlett CM, 1998, MATRIX BIOL, V17, P425, DOI 10.1016/S0945-053X(98)90102-0; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; Finch JS, 2001, GENE, V267, P135, DOI 10.1016/S0378-1119(01)00398-5; Gaidarova S, 2002, J BIOL CHEM, V277, P38737, DOI 10.1074/jbc.M201742200; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Hitraya EG, 1996, ARTHRITIS RHEUM-US, V39, P1347, DOI 10.1002/art.1780390812; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Hurley LH, 2001, ADV EXP MED BIOL, V500, P289; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jimenez SA, 1996, RHEUM DIS CLIN N AM, V22, P647, DOI 10.1016/S0889-857X(05)70294-5; Jimenez SA, 2001, J CLIN INVEST, V108, P1395, DOI 10.1172/JCI200112347; Jimenez SA, 1997, MATRIX BIOL, V16, P29, DOI 10.1016/S0945-053X(97)90114-1; Jimenez SA, 1999, SPRINGER SEMIN IMMUN, V21, P397; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Peterkofsky B, 1999, J CELL BIOCHEM, V73, P408, DOI 10.1002/(SICI)1097-4644(19990601)73:3<408::AID-JCB12>3.3.CO;2-4; Saitta B, 2000, ARTHRITIS RHEUM-US, V43, P2219, DOI 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N; SIERON AL, 1993, J BIOL CHEM, V268, P21232; Trojanowska M, 2002, FRONT BIOSCI-LANDMRK, V7, pD608, DOI 10.2741/trojan; Valoti G, 1998, CLIN CANCER RES, V4, P1977; Zewail-Foote M, 2001, J AM CHEM SOC, V123, P6485, DOI 10.1021/ja004023p	28	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40400	40407		10.1074/jbc.M301964200	http://dx.doi.org/10.1074/jbc.M301964200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881530	hybrid, Green Published			2022-12-25	WOS:000185713800134
J	Sugiura, N; Adams, SM; Corriveau, RA				Sugiura, N; Adams, SM; Corriveau, RA			An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC NEURODEGENERATION; SACCHAROMYCES-CEREVISIAE; ALPHA-ACETYLTRANSFERASE; DEVELOPING BRAIN; RECEPTOR GENES; ARD1 GENE; EXPRESSION; YEAST; CELLS; MICE	We previously identified mNAT1 (murine N-terminal acetyltransferase 1) as an embryonic gene that is expressed in the developing brain and subsequently down-regulated, in part, by the onset of N-methyl-D-aspartate (NMDA) receptor function. By searching the data base we discovered a second closely related gene, mNAT2. mNAT1 and mNAT2 are highly homologous to yeast NAT1, a gene known to regulate entry into the G(0) phase of the cell cycle. However, in the absence of further characterization, including evidence that mammalian homologues of NAT1 encode functional acetyltransferases, the significance of this relationship has been unclear. Here we focus on mNAT1. Biochemical analysis demonstrated that mNAT1 and its evolutionarily conserved co-subunit, mARD1, assemble to form a functional acetyltransferase. Transfection of mammalian cells with mNAT1 and mARD1 followed by immunofluorescent staining revealed that these proteins localize to the cytoplasm in both overlapping and separate compartments. In situ hybridization demonstrated that throughout brain development mNAT1 and mARD1 are highly expressed in areas of cell division and migration and are down-regulated as neurons differentiate. Finally, mNAT1 and mARD1 are expressed in proliferating mouse P19 embryonic carcinoma cells; treatment of these cells with retinoic acid initiates exit from the cell cycle, neuronal differentiation, and down-regulation of mNAT1 and mARD1 as the NMOA receptor 1 gene is induced. The results provide the first direct evidence that vertebrate homologues of NAT1 and ARD1 form an evolutionarily conserved N-terminal acetyltransferase and suggest that expression and down-regulation of this enzyme complex plays an important role in the generation and differentiation of neurons.	Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Corriveau, RA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, 1901 Perdido St, New Orleans, LA 70112 USA.							BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; Choi SC, 2001, BIOCHEM BIOPH RES CO, V285, P1338, DOI 10.1006/bbrc.2001.5300; Constantine-Paton M, 1998, CURR OPIN NEUROBIOL, V8, P139, DOI 10.1016/S0959-4388(98)80017-2; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Gould E, 1997, BEHAV NEUROSCI, V111, P49; HUSMANN M, 1989, DEV BIOL, V136, P194, DOI 10.1016/0012-1606(89)90141-3; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Komuro H, 1998, J NEUROBIOL, V37, P110, DOI 10.1002/(SICI)1097-4695(199810)37:1<110::AID-NEU9>3.3.CO;2-Q; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MacPherson PA, 1997, NEUROSCIENCE, V80, P487, DOI 10.1016/S0306-4522(97)00102-4; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NEY RL, 1964, P INT C END, V2, P1184; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Poon CS, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-09-j0003.2000; Poser S, 2001, INT J DEV NEUROSCI, V19, P387, DOI 10.1016/S0736-5748(00)00094-0; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Sugiura N, 2001, J BIOL CHEM, V276, P14257, DOI 10.1074/jbc.M100011200; SYMTH DG, 1979, NATURE, V279, P252; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1010, DOI 10.1021/bi00218a018	35	65	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40113	40120		10.1074/jbc.M301218200	http://dx.doi.org/10.1074/jbc.M301218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888564	hybrid			2022-12-25	WOS:000185713800103
J	Breslin, MB; Zhu, M; Lan, MS				Breslin, MB; Zhu, M; Lan, MS			NeuroD1/E47 regulates the e-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROENDOCRINE DIFFERENTIATION; MOTOR NEURONS; BHLH PROTEIN; GENE; CELLS; EXPRESSION; ELEGANS; IDENTIFICATION; BETA2/NEUROD; NEUROGENIN	IA-1 is a novel zinc finger transcription factor with a restricted tissue distribution in the embryonic nervous system and tumors of neuroendocrine origin. The 1.7-kilobase 5'-upstream DNA sequence of the human IA-1 gene directed transgene expression predominantly in the developing nervous system including forebrain, midbrain, hindbrain, spinal cord, retina, olfactory bulb, and cerebellum, which recapitulated the expression patterns of neuroendocrine tissues and childhood brain tumors. The IA-1 promoter deletion reporter gene constructs revealed that the sequence between -426 and -65 bp containing three putative E-boxes (similar to361 bp) upstream of the transcription start site was sufficient to confer tissue-specific transcriptional activity. Further mutation analysis revealed that the proximal E-box (E3) closest to the start site is critical to confer transcriptional activity. Electrophoretic mobility shift assay and transient transfection studies demonstrated that the NeuroD1 and E47 heterodimer are the key transcription factors that regulate the proximal E-box of the IA-1 promoter. Therefore, we concluded that the IA-1 gene is developmentally expressed in the nervous system and the NeuroD1/E47 transcription factors up-regulate IA-1 gene expression through the proximal E-box element of the IA-1 promoter.	Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Childrens Hosp,Res Inst Children, New Orleans, LA 70118 USA	Children's Hospital of New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lan, MS (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Childrens Hosp,Res Inst Children, 200 Henry Clay Ave,Res & Educ Bldg,Rm 2211, New Orleans, LA 70118 USA.	mlan@chnola-research.org	Lan, Michael/CAF-1839-2022		NIDDK NIH HHS [R01 DK061436, DK61436] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061436] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Breslin MB, 2002, NUCLEIC ACIDS RES, V30, P1038, DOI 10.1093/nar/30.4.1038; Castanon I, 2001, DEVELOPMENT, V128, P3145; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Dumonteil E, 1998, J BIOL CHEM, V273, P19945, DOI 10.1074/jbc.273.32.19945; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Heremans Y, 2002, J CELL BIOL, V159, P303, DOI 10.1083/jcb.200203074; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Ito T, 2000, DEVELOPMENT, V127, P3913; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; LAN MS, 1993, CANCER RES, V53, P4169; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Li Q, 1997, BIOCHEM BIOPH RES CO, V236, P776, DOI 10.1006/bbrc.1997.7054; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Morrow EM, 1999, DEVELOPMENT, V126, P23; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PEARSE AGE, 1978, GUT HORM, P33; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; Rostomily RC, 1997, CANCER RES, V57, P3526; Stivers C, 2000, MECH DEVELOP, V97, P205, DOI 10.1016/S0925-4773(00)00409-3; Verzi MP, 2002, DEV BIOL, V249, P174, DOI 10.1006/dbio.2002.0753; Wu J, 2001, GENE DEV, V15, P789, DOI 10.1101/gad.857401; Xie JP, 2002, GENOMICS, V80, P54, DOI 10.1006/geno.2002.6800; Zhu M, 2002, PANCREAS, V24, P139, DOI 10.1097/00006676-200203000-00004	35	78	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38991	38997		10.1074/jbc.M306795200	http://dx.doi.org/10.1074/jbc.M306795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12890672	hybrid, Green Accepted			2022-12-25	WOS:000185575100110
J	Payen, LF; Gao, M; Westlake, CJ; Cole, SPC; Deeley, RG				Payen, LF; Gao, M; Westlake, CJ; Cole, SPC; Deeley, RG			Role of carboxylate residues adjacent to the conserved core walker B motifs in the catalytic cycle of multidrug resistance protein 1 (ABCC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; HUMAN P-GLYCOPROTEIN; ATP-BINDING; LEUKOTRIENE C-4; MONOCLONAL-ANTIBODIES; SULFONYLUREA RECEPTOR; MEMBRANE TOPOLOGY; TUMOR-CELLS; MRP1 ABCC1; 2ND DOMAIN	MRP1 belongs to subfamily "C" of the ABC transporter superfamily. The nucleotide-binding domains (NBDs) of the C family members are relatively divergent compared with many ABC proteins. They also differ in their ability to bind and hydrolyze ATP. In MRP1, NBD1 binds ATP with high affinity, whereas NBD2 is hydrolytically more active. Furthermore, ATP binding and/or hydrolysis by NBD2 of MRP1, but not NBD1, is required for MRP1 to shift from a high to low affinity substrate binding state. Little is known of the structural basis for these functional differences. One minor structural difference between NBDs is the presence of Asp COOH-terminal to the conserved core Walker B motif in NBD1, rather than the more commonly found Glu present in NBD2. We show that the presence of Asp or Glu following the Walker B motif profoundly affects the ability of the NBDs to bind, hydrolyze, and release nucleotide. An Asp to Glu mutation in NBD1 enhances its hydrolytic capacity and affinity for ADP but markedly decreases transport activity. In contrast, mutations that eliminate the negative charge of the Asp side chain have little effect. The decrease in transport caused by the Asp to Glu mutation in NBD1 is associated with an inability of MRP1 to shift from high to low affinity substrate binding states. In contrast, mutation of Glu to Asp markedly increases the affinity of NBD2 for ATP while decreasing its ability to hydrolyze ATP and to release ADP. This mutation eliminates transport activity but potentiates the conversion from a high to low affinity binding state in the presence of nucleotide. These observations are discussed in the context of catalytic models proposed for MRP1 and other ABC drug transport proteins.	Queens Univ, Canc Res Inst, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Inst, Canc Res Labs, Kingston, ON K7L 3N6, Canada.		Westlake, Christopher/AAG-1150-2019; Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Westlake, Christopher/0000-0001-7476-2014; Cole, Susan P.C./0000-0001-6571-6884; 				Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Cole S P, 1996, Cancer Treat Res, V87, P39; COLE SPC, 1994, CANCER RES, V54, P5902; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Cui LY, 2001, ARCH BIOCHEM BIOPHYS, V392, P153, DOI 10.1006/abbi.2001.2441; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2003, J BIOL CHEM, V278, P3599, DOI 10.1074/jbc.M210480200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Kreimer DI, 2000, BIOCHEMISTRY-US, V39, P14183, DOI 10.1021/bi001066+; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Renes J, 2000, DRUG RESIST UPDATE, V3, P289, DOI 10.1054/drup.2000.0156; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; WALKER JE, 1982, BIOCHEM SOC T, V10, P203, DOI 10.1042/bst0100203	45	64	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38537	38547		10.1074/jbc.M305786200	http://dx.doi.org/10.1074/jbc.M305786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882957	hybrid			2022-12-25	WOS:000185575100056
J	Worthington, EN; Kavakli, IH; Berrocal-Tito, G; Bondo, BE; Sancar, A				Worthington, EN; Kavakli, IH; Berrocal-Tito, G; Bondo, BE; Sancar, A			Purification and characterization of three members of the photolyase/cryptochrome family blue-light photoreceptors from Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; ACTION MECHANISM; 2ND CHROMOPHORE; CRYPTOCHROME; FLAVIN; GENES; IDENTIFICATION; REPAIR; RECEPTORS	The sequence of Vibrio cholerae genome revealed three genes belonging to the photolyase/cryptochrome blue-light photoreceptor family. The proteins encoded by the three genes were purified and characterized. All three proteins contain folate and flavin cofactors and have absorption peaks in the range of 350-500 nm. Only one of the three, VcPhr, is a photolyase specific for cyclobutane pyrimidine dimers. The other two are cryptochromes and were designated VcCry1 and VcCry2, respectively. Mutation of phr abolishes photoreactivation of UV-induced killing, whereas mutations in cry1 and cry2 do not affect photorepair activity. VcCry1 exhibits some unique features. Of all cryptochromes characterized to date, it is the only one that contains stoichiometric amounts of both chromophores and retains its flavin cofactor in the two-electron reduced FADH2 form. In addition, VcCry1 exhibits RNA binding activity and co-purifies with an RNA of 60-70 nucleotides in length.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Izmir Inst Technol, Dept Biol, TR-35437 Gulbahce Kampusu, Urla Izmir, Turkey	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Izmir Institute of Technology	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.	aziz_sancar@med.unc.edu	Kavakli, Ibrahim/AAF-5468-2020	Kavakli, Ibrahim/0000-0001-6624-3505	NIGMS NIH HHS [GM31082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031082, R01GM031082] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; CHANDA PK, 1976, CAN J MICROBIOL, V22, P1186, DOI 10.1139/m76-172; DAS G, 1981, BIOCHIM BIOPHYS ACTA, V655, P413, DOI 10.1016/0005-2787(81)90053-8; EKER APM, 1990, J BIOL CHEM, V265, P8009; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; Hitomi K, 2000, NUCLEIC ACIDS RES, V28, P2353, DOI 10.1093/nar/28.12.2353; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1987, J BIOL CHEM, V262, P486; KAVAKLI IH, 2002, MOL INTERV, V8, P484; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lin C., 1996, PLANT PHYSIOL, V110, P1047; Lin CT, 2002, PLANT CELL, V14, pS207, DOI 10.1105/tpc.000646; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Ng WO, 2000, ARCH MICROBIOL, V173, P412, DOI 10.1007/s002030000164; Ng WO, 2001, MOL GEN GENET, V264, P924, DOI 10.1007/s004380000383; Ozgur S, 2003, BIOCHEMISTRY-US, V42, P2926, DOI 10.1021/bi026963n; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, TRENDS BIOCHEM SCI, V12, P259, DOI 10.1016/0968-0004(87)90130-7; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SANCAR GB, 2000, MUTAT RES, V451, P7715; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Thompson CL, 2002, ONCOGENE, V21, P9043, DOI 10.1038/sj.onc.1205958; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Yildiz FH, 2001, J BACTERIOL, V183, P1716, DOI 10.1128/JB.183.5.1716-1726.2001; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	44	87	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39143	39154		10.1074/jbc.M305792200	http://dx.doi.org/10.1074/jbc.M305792200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878596	Green Published, hybrid			2022-12-25	WOS:000185575100128
J	Omoto, Y; Eguchi, H; Yamamoto-Yamaguchi, Y; Hayashi, S				Omoto, Y; Eguchi, H; Yamamoto-Yamaguchi, Y; Hayashi, S			Estrogen receptor (ER) beta 1 and ER beta cx/beta 2 inhibit ER alpha function differently in breast cancer cell line MCF7	ONCOGENE			English	Article						estrogen receptor alpha; estrogen receptor beta; estrogen receptor beta cx; breast cancer; cDNA microarray	FACTOR-BINDING-PROTEINS; MESSENGER-RNA; CATHEPSIN-D; EXPRESSION PATTERNS; WILD-TYPE; GROWTH; PROLIFERATION; GENE; ISOFORMS; CLONING	Estrogen receptor (ER) alpha plays an important role in the proliferation and progression of breast cancer. In order to explore the function of wild-type ERbeta (ERbeta1) and its variant form, ERbetacx/beta2, stable transformants of ERalpha-positive breast cancer MCF7 cells with ERbeta1 or ERbetacx/ beta2 expression vector were established. Constitutive expression of ERbeta1 or ERbetacx/beta2 reduced the S phase population of the cell cycle in dish culture and the number of colonies in an anchorage-independent assay. DNA-protein complexes of ERE with nuclear extracts from ERbeta1 transformants were observed in the electrophoretic mobility shift assay, while no complex was observed for ERbetacx/beta2 transformants. Reporter gene assay using estrogen-responsive element (ERE)-luciferase showed less responsiveness to estrogen in these transformants compared with parental cells. Endogenous mRNA expression of two known estrogen-responsive genes, cathepsin D and IGFBP4, was weakly induced by estrogen in ERbeta1 and ERbetacx/beta2 transformants compared with parental cells. A comprehensive gene expression analysis using our custom-made cDNA microarray showed that MCF7 and ERbeta1 transformants had a similar gene expression profile, whereas ERbetacx/beta2 showed a distinct profile from others. These results indicate that ERbeta1 and ERbetacx/beta2 inhibit ERalpha function differently in MCF7 cells.	Saitama Canc Ctr, Div Endocrinol, Res Inst, Ina, Saitama 3620806, Japan		Hayashi, S (corresponding author), Hiroshima Univ, Dept Mol Epidemiol, Grad Sch Biomed Sci, Minami Ku, 5-2 Hijiyama Pk, Hiroshima 7320815, Japan.							Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; BTIST G, 1986, J BIOL CHEM, V261, P15544; Chu S, 2000, J CLIN ENDOCR METAB, V85, P1200, DOI 10.1210/jc.85.3.1200; Clarke M, 1998, LANCET, V351, P1451; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Eguchi H, 2000, CELL DEATH DIFFER, V7, P439, DOI 10.1038/sj.cdd.4400675; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; FIGUEROA JA, 1993, J CELL BIOCHEM, V52, P196, DOI 10.1002/jcb.240520211; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; Fujimura T, 2001, BIOCHEM BIOPH RES CO, V289, P692, DOI 10.1006/bbrc.2001.6038; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Honma Y, 1999, BRIT J CANCER, V80, P96, DOI 10.1038/sj.bjc.6690327; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; JENSEN EV, 1980, CANCER-AM CANCER SOC, V46, P2759, DOI 10.1002/1097-0142(19801215)46:12+<2759::AID-CNCR2820461402>3.0.CO;2-7; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leygue E, 1999, CANCER RES, V59, P1175; Leygue E, 1998, CANCER RES, V58, P3197; Locker GY, 1998, CANCER TREAT REV, V24, P221, DOI 10.1016/S0305-7372(98)90051-2; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Omoto Y, 2002, EUR J CANCER, V38, P380, DOI 10.1016/S0959-8049(01)00383-5; Omoto Y, 2000, Breast Cancer, V7, P27, DOI 10.1007/BF02967184; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Omoto Y, 2001, CANCER LETT, V163, P207, DOI 10.1016/S0304-3835(00)00680-7; OWENS PC, 1993, BIOCHEM BIOPH RES CO, V193, P467, DOI 10.1006/bbrc.1993.1647; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Peng B, 2003, J MOL ENDOCRINOL, V30, P13, DOI 10.1677/jme.0.0300013; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PRATT SE, 1993, CANCER RES, V53, P5193; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Saji S, 2002, CANCER RES, V62, P4849; Speirs V, 1999, CANCER RES, V59, P5421; Tanimoto K, 1999, NUCLEIC ACIDS RES, V27, P903, DOI 10.1093/nar/27.3.903; TOI M, 1992, CANCER RES, V52, P275; Tong D, 2002, BREAST CANCER RES TR, V71, P249, DOI 10.1023/A:1014465916473; VICKERS PJ, 1988, MOL ENDOCRINOL, V2, P886, DOI 10.1210/mend-2-10-886; Vladusic EA, 2000, ONCOL REP, V7, P157; Vladusic EA, 1998, CANCER RES, V58, P210	48	110	114	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5011	5020		10.1038/sj.onc.1206787	http://dx.doi.org/10.1038/sj.onc.1206787			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902984				2022-12-25	WOS:000184578900009
J	Bohm, M; Sawicka, K; Siebrasse, JP; Brehmer-Fastnacht, A; Peters, R; Klempnauer, KH				Bohm, M; Sawicka, K; Siebrasse, JP; Brehmer-Fastnacht, A; Peters, R; Klempnauer, KH			The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA	ONCOGENE			English	Article						Pdcd4; nuclear export signals; RNA-binding; Myb target gene	INITIATION-FACTOR 4G; EUKARYOTIC TRANSLATION; QUALITY-CONTROL; C-MYB; EXPORT; GENE; CRM1; IDENTIFICATION; PROMOTER; MESSAGE	The Pdcd4 gene has originally been isolated in a search for genes that are activated in cells undergoing apoptosis. Independent of these studies, the Pdcd4 gene has been implicated in the suppression of tumor-promoter-mediated transformation of keratinocytes and as a downstream target of Myb in hematopoietic cells. The Pdcd4 protein has weak homology to the eucaryotic translation initiation factor eIF4G and has been shown to interact with certain translation initiation factors. To explore the molecular function of the Pdcd4 protein, we have studied its subcellular localization. We show that the Pdcd4 protein is a predominantly nuclear protein under normal growth conditions and that it is exported from the nucleus by a leptomycin B-sensitive mechanism upon serum withdrawal. The protein contains two nuclear export signals, one of which is very potent. In addition, we demonstrate that the Pdcd4 protein has RNA-binding activity and that the sequences involved in RNA-binding are located in the amino-terminal part of the protein. Taken together, our data raise the possibility that Pdcd4 is involved in some aspect of nuclear RNA metabolism in addition to its suspected role in protein translation.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Univ Munster, Inst Med Biophys, D-48149 Munster, Germany	University of Munster; University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Peters, Reiner/E-7352-2011	Sawicka, Kirsty/0000-0003-4195-6327				Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Lykke-Andersen J, 2001, CURR BIOL, V11, pR88, DOI 10.1016/S0960-9822(01)00036-7; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NISHI K, 1994, J BIOL CHEM, V269, P6320; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; Schell T, 2002, GENOME BIOL, V3; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Wagner C, 1998, MAR BIOL, V131, P411, DOI 10.1007/s002270050334; Weiss MA, 1998, BIOPOLYMERS, V48, P167, DOI 10.1002/(SICI)1097-0282(1998)48:2<167::AID-BIP6>3.0.CO;2-8; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Westhof E, 1999, CURR OPIN STRUC BIOL, V9, P293, DOI 10.1016/S0959-440X(99)80039-6; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x	29	83	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4905	4910		10.1038/sj.onc.1206710	http://dx.doi.org/10.1038/sj.onc.1206710			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894233				2022-12-25	WOS:000184344600015
J	Hayes, SA; Huang, XK; Kambhampati, S; Platanias, LC; Bergan, RC				Hayes, SA; Huang, XK; Kambhampati, S; Platanias, LC; Bergan, RC			p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion	ONCOGENE			English	Article						p38 MAP kinase; transforming growth factor beta; Smad; cell adhesion; prostate cancer	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; TGF-BETA; SIGNAL-TRANSDUCTION; TRANSFORMING GROWTH-FACTOR-BETA-1; INDUCED PHOSPHORYLATION; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; CARCINOMA CELLS	Transforming growth factor beta (TGFbeta) regulates cell adhesion, proliferation, and differentiation in a variety of cells. Smad proteins are receptor-activated transcription factors that translocate to the nucleus in response to TGFbeta. We demonstrate here that TGFbeta increases cell adhesion in metastatic PC3-M prostate cancer cells. TGFbeta treatment of PC3-M cells leads to nuclear translocation of R-Smad proteins. We show that Smad proteins are necessary, but not sufficient, for TGFbeta-mediated cell adhesion. After showing that TGFbeta upregulated p38 MAP kinase activity in PC3-M cells, we show that inhibition of p38 MAP kinase partially blocked TGFbeta-mediated increase in cell adhesion, as well as nuclear translocation of Smad3. Finally, we show that Smad3 is phosphorylated by p38 MAP kinase in vitro. These findings implicate crosstalk between the MAP kinase and Smad signaling pathways in TGFbeta's regulation of cell adhesion in human prostate cells. This represents a mechanism by which the pleiotropic effects of TGFbeta may be channeled to modulate cell adhesion.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8524,710 N Fairbanks, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA077816, P50CA090386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000260] Funding Source: NIH RePORTER; NCI NIH HHS [CA9407, CA77816, CA90386] Funding Source: Medline; NIA NIH HHS [T32 AG00260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bakin AV, 2002, J CELL SCI, V115, P3193; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Brodin G, 1999, CANCER RES, V59, P2731; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.0.CO;2-V; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsing AY, 1996, CANCER RES, V56, P5146; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim IY, 1996, CANCER RES, V56, P44; Kostenuik PJ, 1997, CLIN EXP METASTAS, V15, P41; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Latil A, 1999, PROSTATE, V40, P225, DOI 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MOORADIAN DL, 1990, CANCER RES, V50, P273; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Olsson N, 2001, CELL SIGNAL, V13, P483, DOI 10.1016/S0898-6568(01)00176-0; Ozen M, 2000, ANTICANCER RES, V20, P1905; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Paul R, 1997, BRIT J UROL, V79, P37, DOI 10.1111/j.1464-410X.1997.tb00799.x; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schnaper HW, 1998, PEDIATR NEPHROL, V12, P790, DOI 10.1007/s004670050550; Sehgal I, 1996, CANCER RES, V56, P3359; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; VERMA A, 2001, J BIOL CHEM, V31, P31; Wagers AJ, 2000, J IMMUNOL, V165, P5011, DOI 10.4049/jimmunol.165.9.5011; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WILDING G, 1989, MOL CELL ENDOCRINOL, V62, P79, DOI 10.1016/0303-7207(89)90115-9; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Xiao BG, 1996, CLIN EXP IMMUNOL, V103, P475; Yamamoto T, 2001, J CELL BIOCHEM, V82, P591, DOI 10.1002/jcb.1179; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	72	48	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4841	4850		10.1038/sj.onc.1206730	http://dx.doi.org/10.1038/sj.onc.1206730			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894225				2022-12-25	WOS:000184344600007
J	Maliekal, TT; Antony, ML; Nair, A; Paulmurugan, R; Karunagaran, D				Maliekal, TT; Antony, ML; Nair, A; Paulmurugan, R; Karunagaran, D			Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer	ONCOGENE			English	Article						Smads; TGF-beta; cervical cancer; SQRT-PCR	GROWTH-FACTOR-BETA; SQUAMOUS-CELL CARCINOMA; TGF-BETA; TUMOR-SUPPRESSOR; JUVENILE POLYPOSIS; COLORECTAL-CANCER; PANCREATIC-CANCER; DPC4 EXPRESSION; II GENE; RECEPTOR	Mutations in Smads, intermediates of transforming growth factor-beta signaling, are known to contribute to the loss of sensitivity to transforming growth factor-beta, a common feature of many neoplastic cells. However, not much information is available on Smad alterations in cervical cancer and so we probed, for the first time, for alterations in Smad 2 and Smad 4 genes using human cervical cancer cell lines and human cervical tissue samples. Using PCR/reverse transcription-PCR, single-stranded conformation polymorphism analysis and DNA sequencing, we observed a deletion of 'G' in the L3 loop (crucial in Smad-receptor interaction) in C-33A cells, and an insertion of 'A' in codon 122 (loss of MH2 domain) from a cervical tumor sample, both of which caused frame shift and pretermination in Smad 2. In addition, a G/A transition at 31 bp upstream-nontranslated regions of exon 8 of Smad 4 was found in Bu 25TK cells. Smad 2 expression was less in some of the cervical tumor samples than that of nonmalignant samples and six cancer samples showed C-terminal deletions that abolish Smad 2 phosphorylation sites. The loss of expression of Smad 4 found in some cervical tumor samples was due to transcription loss rather than deletion of the gene. Our results highlight an important role for Smad 2 and Smad 4 in human cervical tumors.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.	dkarunagaran@hotmail.com	Antony, Marie Lue/AAB-3952-2019; Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Paulmurugan, Ramasamy/0000-0001-7155-4738; Maliekal, Tessy/0000-0002-7311-7950				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barabas E, 2001, BRAZ J MED BIOL RES, V34, P1271, DOI 10.1590/S0100-879X2001001000006; Barbera VM, 2000, BBA-MOL BASIS DIS, V1502, P283, DOI 10.1016/S0925-4439(00)00054-5; Bevan S, 1999, GUT, V45, P406, DOI 10.1136/gut.45.3.406; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; Cain JM, 2000, SCIENCE, V288, P1753, DOI 10.1126/science.288.5472.1753; Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.3.CO;2-5; Costentin L, 2002, PANCREATOLOGY, V2, P17, DOI 10.1159/000049443; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dellas A, 1999, CANCER RES, V59, P3475; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, CANCER RES, V56, P490; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hilgers W, 2000, GENE CHROMOSOME CANC, V27, P353, DOI 10.1002/(SICI)1098-2264(200004)27:4<353::AID-GCC3>3.3.CO;2-X; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kaneko H, 1998, ACTA HAEMATOL-BASEL, V99, P187, DOI 10.1159/000040837; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.3.CO;2-5; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; Lee SH, 2001, INT J CANCER, V94, P500, DOI 10.1002/ijc.1494; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Lohmann DR, 1996, AM J HUM GENET, V58, P940; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Muliokandov MR, 1996, CANCER RES, V56, P197; Muro-Cacho CA, 2001, CLIN CANCER RES, V7, P1618; Nguyen HN, 1999, SEMIN SURG ONCOL, V16, P217, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<217::AID-SSU4>3.0.CO;2-U; Osawa H, 2000, INT J ONCOL, V17, P723; Patel SA, 2002, AM J SURG PATHOL, V26, P1071, DOI 10.1097/00000478-200208000-00014; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Schutte M, 1996, CANCER RES, V56, P2527; Tanaka S, 2000, BRIT J CANCER, V82, P1557; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uchida K, 1996, CANCER RES, V56, P5583; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Xie W, 2002, CANCER RES, V62, P497	42	46	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4889	4897		10.1038/sj.onc.1206806	http://dx.doi.org/10.1038/sj.onc.1206806			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894231				2022-12-25	WOS:000184344600013
J	Dunfield, LD; Nachtigal, MW				Dunfield, LD; Nachtigal, MW			Inhibition of the antiproliferative effect of TGF beta by EGF in primary human ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; TGF beta; EGF; p15(INK4B)	GROWTH-FACTOR-BETA; SIGNAL-TRANSDUCTION; SURFACE EPITHELIUM; GENE-MUTATIONS; RECEPTOR; SMAD7; IDENTIFICATION; EPIDEMIOLOGY; ANTAGONIST; CARCINOMA	The majority of ovarian cancers (OCs) arise from the ovarian surface epithelium (OSE). Proliferation of the OSE can be regulated by a number of autocrine and paracrine factors, including transforming growth factor beta (TGFbeta). Defects in the TGFbeta signaling pathway have been implicated in a number of cancers, including ovarian. We previously found that the TGFbeta signaling pathway is intact and functional in primary human OC cells, and that these cells stop growing in response to TGFbeta. Ovarian cancer cells in vivo are exposed to TGFbeta, yet continue to proliferate, therefore, mechanisms must exist to inhibit TGFbeta signaling contributing to uncontrolled cellular proliferation. Numerous signaling pathways converge with the TGFbeta pathway to modulate its effects, including signaling induced by epidermal growth factor (EGF). We hypothesized that EGF can modulate TGFbeta signaling and contribute to uncontrolled cellular proliferation of OC cells. Our results show that EGF abrogates the antiproliferative effect of TGFbeta. EGF does not modulate TGFbeta signaling by inhibiting receptor-activated Smad (R-Smad) phosphorylation or nuclear translocation. Rather, EGF decreases TGFbeta-induced mRNA expression of the cell cycle regulator, p15(INK4B), contributing to decreased sensitivity of OC cells to the antiproliferative effect of TGFbeta.	Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 1X5, Canada	Dalhousie University	Nachtigal, MW (corresponding author), Dalhousie Univ, Dept Pharmacol, 5850 Coll St, Halifax, NS B3H 1X5, Canada.	Mark.Nachtigal@Dal.ca		Nachtigal, Mark/0000-0003-3291-8628				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; Chen T, 2001, CANCER RES, V61, P4679; Daly M, 1998, SEMIN ONCOL, V25, P255; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dunfield LD, 2002, ENDOCRINOLOGY, V143, P1174, DOI 10.1210/en.143.4.1174; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HURTEAU J, 1994, CANCER, V74, P93, DOI 10.1002/1097-0142(19940701)74:1<93::AID-CNCR2820740117>3.0.CO;2-P; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Lynch MA, 1998, CANCER RES, V58, P4227; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Riggins GJ, 1997, CANCER RES, V57, P2578; Scully RE, 1995, J CELL BIOCHEM, P208; Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; TORTOLEROLUNA G, 1994, OBSTET GYN CLIN N AM, V21, P1; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VIGNE JL, 1994, BIOL REPROD, V51, P1213, DOI 10.1095/biolreprod51.6.1213; Wang D, 2000, CANCER RES, V60, P4507; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	26	26	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4745	4751		10.1038/sj.onc.1206617	http://dx.doi.org/10.1038/sj.onc.1206617			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879019				2022-12-25	WOS:000184157000015
J	Soejima, K; Fang, WZ; Rollins, BJ				Soejima, K; Fang, WZ; Rollins, BJ			DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras	ONCOGENE			English	Article						DNA methyltransferase; tumor suppressor; lung cancer	TUMOR-SUPPRESSOR GENE; HISTONE DEACETYLASE COMPLEX; HUMAN CANCER-CELLS; CYTOSINE-5 METHYLTRANSFERASES; RENAL-CARCINOMA; LUNG-CANCER; IMMUNODEFICIENCY SYNDROME; HUMAN FIBROBLASTS; CPG METHYLATION; STEM-CELLS	Transcriptional silencing of tumor suppressor genes in association with DNA methylation contributes to malignant transformation. However, the specific DNA methyltransferases that initiate this process are unknown. Here we show that a de novo DNA methyltransferase, DNMT3b, substantially contributes to the oncogenic phenotype in a lung cancer model. Normal human bronchial epithelial (NHBE) cells expressing telomerase, SV40 large T antigen, and activated Ras were immortal, formed colonies in soft agar, and expressed DNMT3b. Antisense suppression of DNMT3b prevented soft agar growth. Furthermore, mouse embryo fibroblasts expressing T antigen and Ras formed soft agar colonies and large tumors, but fibroblasts from Dnmt3b(-/-) mice did not grow in soft agar and were much less tumorigenic in vivo. The tumor suppressor genes, FHIT, TSLC1, and RASSF1A were downregulated in transformed NHBE cells, and antisense DNMT3b treatment resulted in re-expression of FHIT and TSLC1. While expression of TSCL1 correlated with methylation of CpG dinucleotides in its promoter region, the expression of FHIT did not, suggesting that DNMT3b may silence genes by several mechanisms including direct DNA methylation or recruitment of proteins that modify chromatin. Regardless of mechanism, our data indicate that DNMT3b plays an important role in transformation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rollins, BJ (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, M430,44 Binney St, Boston, MA 02115 USA.	barrett_rollins@dfci.harvard.edu	Soejima, Kenzo/T-9878-2019	Soejima, Kenzo/0000-0001-9749-995X				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan MF, 2000, CURR TOP MICROBIOL, V249, P75; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GREGER V, 1994, HUM GENET, V94, P491; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Pradhan S, 1998, NUCLEIC ACIDS RES, V26, P1214, DOI 10.1093/nar/26.5.1214; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RIOS M, 1990, J CELL PHYSIOL, V145, P434, DOI 10.1002/jcp.1041450307; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SAKAI T, 1991, AM J HUM GENET, V48, P880; SHAPIRO GI, 1995, CANCER RES, V55, P505; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Tanaka H, 1998, CANCER RES, V58, P3429; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	57	80	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4723	4733		10.1038/sj.onc.1206510	http://dx.doi.org/10.1038/sj.onc.1206510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879017				2022-12-25	WOS:000184157000013
J	Ris, L; Dewachter, I; Reverse, D; Godaux, E; Van Leuven, F				Ris, L; Dewachter, I; Reverse, D; Godaux, E; Van Leuven, F			Capacitative calcium entry induces hippocampal long term potentiation in the absence of presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; TRANSGENIC MICE; LOCALIZATION; BRAIN; EXPRESSION; KINASE; STORES; GENE; APP	Presenilins, whose mutant forms are the most common cause of early onset familial Alzheimer's disease, are involved in two very distinct processes: (i) proteolytic activity as gamma-secretase acting on amyloid precursor protein to produce amyloid peptides and (ii) storage of Ca2+ in the endoplasmic reticulum (ER). In particular, absence of presenilin-1 (PS1) was claimed to potentiate capacitative calcium entry (CCE), i.e. the mechanism of replenishment of ER Ca2+ stores. However, until now, evidence in favor of the latter role has been obtained only in isolated or cultured cells and not on neurons in situ. Here, we studied the strength of the synapses between Schaffer's collaterals and CA1 neurons in hippocampal slices when they were submitted first to Ca2+-free medium containing thapsigargin and subsequently to normal artificial cerebrospinal fluid, a procedure known to trigger CCE. We demonstrate that Ca2+ influx via the CCE mechanism is sufficient to trigger robust long term potentiation of the synapses in hippocampal slices from transgenic mice with a postnatal, neuron-specific ablation of PS1, but remarkably not from wildtype mice. Our data establish for the first time in neurons confined in normal neuronal networks that PS1 acts on the refilling mechanism of ER Ca2+ stores.	Univ Mons, Neurosci Lab, B-7000 Mons, Belgium; Katholieke Univ Leuven, Dept Human Genet, Expt Genet Grp, B-3000 Louvain, Belgium	University of Mons; KU Leuven	Godaux, E (corresponding author), Univ Mons, Neurosci Lab, Pl Parc 20, B-7000 Mons, Belgium.			, Ilse Dewachter/0000-0001-7202-515X				Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DEADWYLER SA, 1987, SYNAPSE, V1, P90, DOI 10.1002/syn.890010112; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Dewachter I, 2002, J NEUROSCI, V22, P3445; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Emptage NJ, 2001, NEURON, V29, P197, DOI 10.1016/S0896-6273(01)00190-8; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Llano I, 2000, NAT NEUROSCI, V3, P1256, DOI 10.1038/81781; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; SHARP AH, 1993, J NEUROSCI, V13, P3051; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Van Leuven F, 2002, NEUROBIOL AGING, V23, pS243; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2	35	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44393	44399		10.1074/jbc.M300971200	http://dx.doi.org/10.1074/jbc.M300971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12902342	hybrid			2022-12-25	WOS:000186306700064
J	Delmas, D; Rebe, C; Lacour, S; Filomenko, R; Athias, A; Gambert, P; Cherkaoui-Malki, M; Jannin, B; Dubrez-Daloz, L; Latruffe, N; Solary, E				Delmas, D; Rebe, C; Lacour, S; Filomenko, R; Athias, A; Gambert, P; Cherkaoui-Malki, M; Jannin, B; Dubrez-Daloz, L; Latruffe, N; Solary, E			Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CHEMOPREVENTIVE AGENT; INDEPENDENT APOPTOSIS; INDUCED ACTIVATION; CARCINOMA CELLS; MEMBRANE RAFTS; KAPPA-B; BAX; PROTEIN; FADD	Resveratrol, a polyphenol found in grape skin and various other food products, may function as a cancer chemopreventive agent for colon and other malignant tumors and possesses a chemotherapeutic potential through its ability to trigger apoptosis in tumor cells. The present study analyses the molecular mechanisms of resveratrol-induced apoptosis in colon cancer cells, with special attention to the role of the death receptor Fas in this pathway. We show that, in the 10 - 100 muM range of concentrations, resveratrol activates various caspases and triggers apoptosis in SW480 human colon cancer cells. Caspase activation is associated with accumulation of the pro-apoptotic proteins Bax and Bak that undergo conformational changes and relocalization to the mitochondria. Resveratrol does not modulate the expression of Fas and Fas-ligand ( FasL) at the surface of cancer cells, and inhibition of the Fas/FasL interaction does not influence the apoptotic response to the molecule. Resveratrol induces the clustering of Fas and its redistribution in cholesterol and sphingolipid-rich fractions of SW480 cells, together with FADD and procaspase-8. This redistribution is associated with the formation of a death-inducing signaling complex ( DISC). Transient transfection of either a dominant-negative mutant of FADD, E8, or MC159 viral proteins that interfere with the DISC function, decreases the apoptotic response of SW480 cells to resveratrol and partially prevents resveratrol-induced Bax and Bak conformational changes. Altogether, these results indicate that the ability of resveratrol to induce the redistribution of Fas receptor in membrane rafts may contribute to the molecule's ability to trigger apoptosis in colon cancer cells.	INSERM, U517, Fac Med, F-21000 Dijon, France; CHU Bocage, INSERM, U498, F-21034 Dijon, France; CNRS, Fac Life Sci, Mol & Cellular Biol Lab, F-21000 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne	Solary, E (corresponding author), INSERM, U517, Fac Med, IFR100,7 Blvd Jeanne Arc, F-21000 Dijon, France.	esolary@u-bourgogne.fr	Cherkaoui-Malki, Mustapha/B-2412-2012; Delmas, Dominique/AAD-9749-2019; Dubrez, Laurence/I-4971-2016; REBE, Cédric/AAD-4316-2019; Laurence, Dubrez/P-9472-2019	Cherkaoui-Malki, Mustapha/0000-0001-5010-739X; Delmas, Dominique/0000-0003-3576-0248; Dubrez, Laurence/0000-0002-7030-2181; REBE, Cédric/0000-0001-8831-145X; Laurence, Dubrez/0000-0002-7030-2181; Solary, Eric/0000-0002-8629-1341; Delmas, Dominique/0000-0002-8911-8499				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Banerjee S, 2002, CANCER RES, V62, P4945; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Ciolino HP, 1999, MOL PHARMACOL, V56, P760; Clement MV, 1998, BLOOD, V92, P996; Delmas D, 2002, INT J MOL MED, V10, P193; Dorrie J, 2001, CANCER RES, V61, P4731; Dubrez L, 2001, J BIOL CHEM, V276, P38980, DOI 10.1074/jbc.M102683200; Ducoroy P, 2003, BLOOD, V101, P194, DOI 10.1182/blood-2002-02-0603; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fulda S, 1997, CANCER RES, V57, P3823; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gao XH, 2002, J NUTR, V132, P2076, DOI 10.1093/jn/132.7.2076; GOLDBERG DM, 1995, CLIN CHIM ACTA, V237, P155, DOI 10.1016/0009-8981(95)06069-P; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hsieh TC, 1999, INT J ONCOL, V15, P245; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jeandet P., 1993, J WINE RES, V4, P79, DOI [10.1080/09571269308717954, DOI 10.1080/09571269308717954]; LAMUELARAVENTOS RM, 1993, J AGR FOOD CHEM, V41, P521, DOI 10.1021/jf00028a001; Liang YC, 2003, BIOCHEM PHARMACOL, V65, P1053, DOI 10.1016/S0006-2952(03)00011-X; Lu JB, 2001, CARCINOGENESIS, V22, P321, DOI 10.1093/carcin/22.2.321; Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Martinez J, 2000, BIOCHEM PHARMACOL, V59, P865, DOI 10.1016/S0006-2952(99)00380-9; Memon SA, 1998, J IMMUNOL, V160, P2046; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Mutoh M, 2000, CARCINOGENESIS, V21, P959, DOI 10.1093/carcin/21.5.959; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; Renaud SC, 1998, EPIDEMIOLOGY, V9, P184, DOI 10.1097/00001648-199803000-00014; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Schneider Y, 2001, NUTR CANCER, V39, P102, DOI 10.1207/S15327914nc391_14; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; She QB, 2001, CANCER RES, V61, P1604; Solary E, 2003, LEUKEMIA LYMPHOMA, V44, P563, DOI 10.1080/1042819021000038001; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Tsan MF, 2000, BRIT J HAEMATOL, V109, P405, DOI 10.1046/j.1365-2141.2000.01980.x; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	54	243	260	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41482	41490		10.1074/jbc.M304896200	http://dx.doi.org/10.1074/jbc.M304896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902349	hybrid			2022-12-25	WOS:000185847200128
J	Li, K; Miller, C; Hegde, S; Wojchowski, D				Li, K; Miller, C; Hegde, S; Wojchowski, D			Roles for an Epo receptor Tyr-343 Stat5 pathway in proliferative co-signaling with Kit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL-FACTOR; PROTOONCOGENE C-KIT; ERYTHROPOIETIN RECEPTOR; TYROSINE KINASE; ACTIVATION; JAK2; IDENTIFICATION; PROTEIN; GENE; DOMAIN	Erythroid progenitor cell expansion depends upon cosignaling by Epo receptor (EpoR) and Kit, but underlying mechanisms are incompletely understood. To quantitatively analyze EpoR contributions to co-signaling, phosphotyrosine (Tyr(P)) mutants were expressed as human epidermal growth factor ( hEGF) receptor-mEpoR EE chimeras at matched and physiological levels in FDCW2 hematopoietic progenitor cells and were assayed for proliferative activities in the absence or presence of endogenous Kit stimulation. Two Tyr( P)-null ( but Jak2-coupled) EpoR forms each retained less than or equal to 25% of the wild-type activity, whereas the add-back of single Tyr( P) sites in the EpoR forms EE-T-Y343 (Stat5 binding site), EE-Y479 (p85/phosphatidylinositol 3-kinase binding site), or EE-Y464 (Src kinase binding site) significantly enhanced activities ( to 100, 95, and 50% of EE-WT ( wild type) levels, respectively). EE-Y343&Y401 and EE-F343& F401 double add-back and deletion constructs were also prepared and were shown to possess 90 and less than or equal to 50% of wild-type activity. In contrast, efficient Kit cosignaling activity was retained only by EE-T-Y343 and EE-Y343&Y401 EpoR forms. EE-T-Y343 together with EE-T-Y343F and EE-WT EpoR forms were also analyzed in embryonic stem cell-derived erythroid G1E-2 cells with highly comparable outcomes, including the ability of EE-T-Y343 ( but not EE-T-Y-343F) to synergize with Kit. Despite specific connection of EE-T-Y343 to Stat5, the contributions of Kit to EpoR-dependent proliferation did not involve Kit effects on Stat5 activation ( but was limited by the mutation of Kit Tyr( P)-567 and Tyr( P)-569 Src kinase recruitment sites). Instead, cosignaling appears to depend upon the downstream integration of Kit signals with the targets of an EpoR/Jak2/ Y343/Stat 5 response axis.	Penn State Univ, Program Immunol, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, D (corresponding author), Penn State Univ, Program Immunol, 115 Henning Bldg, University Pk, PA 16802 USA.	dmw1@psu.edu			NHLBI NIH HHS [R01 HL44491] Funding Source: Medline; NIDDK NIH HHS [R01 DK40242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Bittorf T, 2001, CELL SIGNAL, V13, P673, DOI 10.1016/S0898-6568(01)00189-9; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chin H, 1998, BLOOD, V91, P3734; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Divoky V, 2001, P NATL ACAD SCI USA, V98, P986, DOI 10.1073/pnas.98.3.986; Escribano L, 1998, LEUKEMIA LYMPHOMA, V30, P459, DOI 10.3109/10428199809057558; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Hao Z, 2002, BLOOD, V100, p718A; Hirota S, 2002, GASTROENTEROLOGY, V122, P1493, DOI 10.1053/gast.2002.33024; Hortner M, 2002, EUR J BIOCHEM, V269, P2516, DOI 10.1046/j.1432-1033.2002.02916.x; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; Jegalian AG, 2002, BLOOD, V99, P2603, DOI 10.1182/blood.V99.7.2603; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; LI K, 2003, IN PRESS BLOOD; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Miller CP, 2002, BLOOD, V99, P898, DOI 10.1182/blood.V99.3.898; MIURA O, 1994, BLOOD, V84, P1501; PACIFICI RE, 1994, J BIOL CHEM, V269, P1571; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pharr PN, 2000, INT J HEMATOL, V72, P178; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Tan BL, 2003, J BIOL CHEM, V278, P11686, DOI 10.1074/jbc.M207068200; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Tilbrook PA, 1999, GROWTH FACTORS, V17, P25, DOI 10.3109/08977199909001060; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V203, P1912, DOI 10.1006/bbrc.1994.2411; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WOGNUM AW, 1990, BLOOD, V76, P697; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156; Zhao SM, 2002, EMBO J, V21, P2159, DOI 10.1093/emboj/21.9.2159; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500	56	18	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40702	40709		10.1074/jbc.M307182200	http://dx.doi.org/10.1074/jbc.M307182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909618	hybrid			2022-12-25	WOS:000185847200035
J	Ubeda, M; Habener, JF				Ubeda, M; Habener, JF			CHOP transcription factor phosphorylation by casein kinase 2 inhibits transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GENE-TRANSCRIPTION; BUDDING YEAST; PROTEIN; CK2; CHECKPOINT; APOPTOSIS; CHOP/GADD153; CLEAVAGE; GADD153	The CAAT/enhancer binding protein homologous transcription factor CHOP, also known as GADD153, is involved in DNA damage, growth arrest, and the induction of apoptosis after endoplasmic reticulum stress and nutrient deprivation. CHOP dimerizes with and inhibits the binding of C/EBP-related transcription factors to their consensus DNA target sequences and also forms novel complexes with other transcriptional proteins ( e. g. c-Jun, c-Fos). The transcriptional activation of these complexes is modified by their phosphorylation. Phosphorylation of CHOP at serine 79 and serine 81 by p38-MAP kinase enhances its transcriptional activity. Here we show that an interactive association between CHOP and casein kinase II (CK2) results in the phosphorylation of its amino-terminal transactivation domain. Mapping of the functional domains of CHOP indicates that the region in CHOP required for association with CK2 differs from that required for its phosphorylation. Th binding of CK2 to CHOP requires only the carboxylterminal bZip domain of CHOP, whereas phosphorylation involves residues located in the amino-terminal domain. The presence of the bZip domain, however, facilitates the phosphorylation of CHOP. Analyses of the effect of point mutations of CHOP on its transcriptional activity and the effect of specific inhibitors of CK2 lead us to conclude that CK2-mediated phosphorylation of CHOP inhibits its transcriptional activity. Our findings suggest that inhibition of the proapoptotic functions of CHOP by CK2 may be a mechanism by which CK2 prevents apoptosis and promotes cellular proliferation.	Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Habener, JF (corresponding author), Massachusetts Gen Hosp, Mol Endocrinol Lab, WEL320,55 Fruit St, Boston, MA 02114 USA.		Ubeda, Mariano/ABB-2691-2021					BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sok J, 1999, MOL CELL BIOL, V19, P495; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; Yin XY, 2001, CELL COMMUN ADHES, V8, P373, DOI 10.3109/15419060109080756; YOI OKO, 1993, EMBO J, V12, P1621; Zhang Z, 1999, AM J PHYSIOL-RENAL, V276, pF786, DOI 10.1152/ajprenal.1999.276.5.F786; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	25	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40514	40520		10.1074/jbc.M306404200	http://dx.doi.org/10.1074/jbc.M306404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12876286	hybrid			2022-12-25	WOS:000185847200012
J	Witting, SR; Maiorano, JN; Davidson, WS				Witting, SR; Maiorano, JN; Davidson, WS			Ceramide enhances cholesterol efflux to apolipoprotein A-I by increasing the cell surface presence of ATP-binding cassette transporter A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; TANGIER-DISEASE; PLASMA-MEMBRANE; LIPID EFFLUX; INTRACELLULAR CHOLESTEROL; DOWN-REGULATION; APOA-I; ABCA1; STEROL; SPHINGOMYELIN	It is widely accepted that functional ATP-binding cassette transporter A1 (ABCA1) is critical for the formation of nascent high density lipoprotein particles. However, the cholesterol pool(s) and the cellular signaling processes utilized by the ABCA1-mediated pathway remain unclear. Sphingomyelin maintains a preferential interaction with cholesterol in membranes, and its catabolites, especially ceramide, are potent signaling molecules that could play a role in ABCA1 regulation or function. To study the potential role of ceramide in this process, we treated a variety of cell lines with 20 muM C-2-ceramide and examined apolipoprotein-mediated cholesterol efflux to lipid-free apoA-I. We found that cell lines expressing ABCA1 displayed 2-3-fold increases in cholesterol efflux to apoA-I. Cell lines not expressing ABCA1 were unaffected by ceramide. We further characterized the cholesterol efflux effect in Chinese hamster ovary cells. Ceramide treatment did not cause significant cytotoxicity or apoptosis and did not affect cholesterol efflux to non-apolipoprotein acceptors. Raising endogenous ceramide levels increased cholesterol efflux to apoA-I. Using a cell surface biotinylation method, we found that the total cellular ABCA1 and that at the plasma membrane were increased with ceramide treatment. Also ceramide enhanced the binding of fluorescently labeled apoA-I to Chinese hamster ovary cells. These data suggest that ceramide may increase the plasma membrane content of ABCA1, leading to increased apoA-I binding and cholesterol efflux.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067093, R01HL062542] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62542, HL67093] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arakawa R, 2000, J LIPID RES, V41, P1952; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; CLEJAN S, 1984, J BIOL CHEM, V259, P441; Costet P, 2000, J BIOL CHEM, V275, P28240; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FUGLER L, 1985, J BIOL CHEM, V260, P4098; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Haidar B, 2001, J LIPID RES, V42, P249; Hess KL, 2001, J LEUKOCYTE BIOL, V70, P405; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; Karasawa K, 1999, J BIOL CHEM, V274, P8655, DOI 10.1074/jbc.274.13.8655; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LADENSON RC, 1993, J BIOL CHEM, V268, P7650; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; Lin GR, 2000, ATHEROSCLEROSIS, V149, P359, DOI 10.1016/S0021-9150(99)00503-1; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PATTON S, 1970, J THEOR BIOL, V29, P489, DOI 10.1016/0022-5193(70)90111-6; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PORN MI, 1993, J LIPID RES, V34, P1385; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCHAEFER EJ, 1994, J LIPID RES, V35, P871; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Sviridov D, 2001, BIOCHEM J, V358, P79, DOI 10.1042/0264-6021:3580079; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Zha XH, 2003, J BIOL CHEM, V278, P10002, DOI 10.1074/jbc.C300024200	70	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40121	40127		10.1074/jbc.M305193200	http://dx.doi.org/10.1074/jbc.M305193200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890677	hybrid			2022-12-25	WOS:000185713800104
J	Praml, C; Savelyeva, L; Schwab, M				Praml, C; Savelyeva, L; Schwab, M			Aflatoxin B-1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cells	ONCOGENE			English	Article						AFAR; AKR7; 1p; aflatoxin B1 aldehyde reductase; detoxication; chemoprevention	ALDO-KETO REDUCTASE; HUMAN NEUROBLASTOMA-CELLS; RAT-LIVER; SUPERFAMILY; EXPRESSION; MEMBER; CANCER; CLONING; B-1; SELENIUM	Alterations of the distal portion of the short arm of chromosome 1 (1p) are among the earliest abnormalities of human colorectal tumours. Recently, we have cloned the Aflatoxin B, aldehyde reductase (AFAR) gene from a smallest region of overlapping deletion that is frequently (48%) hemizygously deleted in sporadic colorectal cancer. AFAR is expressed in a broad range of tissues. Its closely related rat protein is the major factor conferring resistance of rats towards aflatoxin B-1-induced liver carcinogenesis. Here, we have identified cDNAs covering two additional human AFAR-related genes localized in close proximity to the previously described AFAR at 1p35-36. We have analysed their structure and tissue-related expression. One of them, AFAR3, carries a Selenocysteine-Insertion Element (SECIS)-like structure that during translation may recode an in-frame TGA-stop codon to a selenocysteine. Two additional AFAR-pseudogenes are localized at Xq25 and 1p12, respectively. AFAR exon sequences share an identity of DNA and amino acids of more than 78%. Also large blocks of intronic sequences can be up to 98.6% identical. Knowledge of the AFAR genes and their structure will be essential in genetic and functional studies, where discrimination of the genes and proteins is a prerequisite for evaluating their individual functions.	Deutsch Krebsforschungszentrum, Div Tumour Genet B030, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Tumour Genet B030, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.schwab@dkfz.de						Almeida RMA, 1996, MYCOPATHOLOGIA, V133, P23, DOI 10.1007/BF00437095; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CHEN J, 1982, J NUTR, V112, P324, DOI 10.1093/jn/112.2.324; CLARK LC, 1995, J NATL CANCER I, V87, P473, DOI 10.1093/jnci/87.7.473; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; ELLIS EM, 1993, P NATL ACAD SCI USA, V90, P10350, DOI 10.1073/pnas.90.21.10350; ELLIS EM, 1995, BIOCHEM J, V312, P535, DOI 10.1042/bj3120535; GARLAND M, 1994, NATURAL ANTIOXIDANTS, P263; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Hengstler JG, 1999, DRUG METAB REV, V31, P917, DOI 10.1081/DMR-100101946; Hinshelwood A, 2002, FEBS LETT, V523, P213, DOI 10.1016/S0014-5793(02)02982-4; Houlston RS, 2000, J MED GENET, V37, P161, DOI 10.1136/jmg.37.3.161; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; JUDAH DJ, 1993, BIOCHEM J, V292, P13, DOI 10.1042/bj2920013; Kelly VP, 2002, BIOCHEM J, V366, P847, DOI 10.1042/BJ20020342; Kelly VP, 2000, BIOCHEM J, V348, P389, DOI 10.1042/0264-6021:3480389; Key SCS, 1997, VIROLOGY, V234, P147, DOI 10.1006/viro.1997.8647; Knight LP, 1999, CARCINOGENESIS, V20, P1215, DOI 10.1093/carcin/20.7.1215; Kozma E, 2002, J BIOL CHEM, V277, P16285, DOI 10.1074/jbc.M110808200; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MARNETT LJ, 1994, CANCER METAST REV, V13, P303, DOI 10.1007/BF00666100; McLeod R, 1997, CANCER RES, V57, P4257; NEWBERNE PM, 1969, CANCER RES, V29, P236; Nishi N, 2000, ENDOCRINOLOGY, V141, P3194, DOI 10.1210/en.141.9.3194; Praml C, 1998, CANCER RES, V58, P5014; PRAML C, 1995, ONCOGENE, V11, P1357; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; Schaller M, 1999, EUR J BIOCHEM, V265, P1056, DOI 10.1046/j.1432-1327.1999.00826.x; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; TUDEK B, 1989, CANCER RES, V49, P1236; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	35	11	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4765	4773		10.1038/sj.onc.1206684	http://dx.doi.org/10.1038/sj.onc.1206684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879023				2022-12-25	WOS:000184157000019
J	Rangatia, J; Vangala, RK; Singh, SM; Zada, AAP; Elsasser, A; Kohlmann, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G				Rangatia, J; Vangala, RK; Singh, SM; Zada, AAP; Elsasser, A; Kohlmann, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G			Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBP alpha DNA binding via leucine zipper domain interaction	ONCOGENE			English	Article						C/EBP alpha; c-Jun; AML	TRANSCRIPTION-FACTOR; PROTEIN-ALPHA; BCR-ABL; GRANULOCYTIC DIFFERENTIATION; LINEAGE COMMITMENT; DOWN-REGULATION; PU.1; MUTATIONS; REGULATOR; GENE	Transcription factor C/EBPalpha induces normal myeloid differentiation, inactivation of C/EBPalpha leads to a differentiation block in acute myeloid leukemias (AML), and overexpression of C/EBPalpha results in ANIL growth arrest and differentiation. Recent reports suggest that C/EBPalpha is activated or inactivated via protein-protein interactions. We previously reported that C/EBPalpha needs to inactivate the proto-oncogene c-Jun via leucine zipper domain interaction in order to induce granulocytic differentiation. We, therefore, hypothesized that c-Jun expression might be elevated in AML and subsequently inactivate C/EBPalpha. In fact, compared to normal bone marrow mononuclear cells, c-Jun expression is increased in AML patient samples (Affymetrix expression microarray analysis, n = 166). c-Jun binds to C/EBPalpha via the leucine zipper domains and prevents C/EBPalpha from DNA binding. Inactivation of C/EBPalpha by c-Jun is necessary for c-Jun to induce proliferation because c-Jun-induced proliferation can be prevented by ectopic overexpression of C/EBPalpha. The dominant-negative 30-kDa C/EBPalpha protein, found in AML, fails to downregulate c-Jun mRNA expression in AML patient samples. Thus, our data suggest a model for AML in which c-Jun promotes proliferation and prevents differentiation by inhibiting C/EBPalpha DNA binding via leucine zipper domain interaction. It might depend on the expression levels of C/EBPalpha and c-Jun, if inhibition of C/EBPalpha by c-Jun or if inhibition of c-Jun by C/EBPalpha is more predominant: proliferation versus differentiation; AML versus normal myeloid development.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany; GSF Res Ctr, Munich, Germany; Harvard Univ, Sch Med, Inst Med, Boston, MA USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.			Tenen, Daniel/0000-0002-6423-3888				Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; ELSAESSER A, 2003, IN PRESS ONCOGENE; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; MILLER M, 2003, J BIOL CHEM     0210; MIZUKI M, 2002, BLOOD           1205; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Preudhomme C, 2002, BLOOD, V100, P2717, DOI 10.1182/blood-2002-03-0990; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; van Waalwijk van Doorn-Khosravani SB, 2002, HEMATOL J, V3, P324; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	31	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4760	4764		10.1038/sj.onc.1206664	http://dx.doi.org/10.1038/sj.onc.1206664			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879022				2022-12-25	WOS:000184157000018
J	Modena, P; Testi, MA; Facchinetti, F; Mezzanzanica, D; Radice, MT; Pilotti, S; Sozzi, G				Modena, P; Testi, MA; Facchinetti, F; Mezzanzanica, D; Radice, MT; Pilotti, S; Sozzi, G			UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines	ONCOGENE			English	Article						EWS; sarcoma; ovarian carcinoma; hinge protein; mitochondrial complex III	CYTOCHROME-C OXIDOREDUCTASE; 17-KDA SUBUNIT-VI; YEAST UBIQUINOL; COMPLEX; EXPRESSION; MUTATIONS; DELETION; SITE	We previously reported the identification of a novel zinc-finger gene, designated ZSG, fused to Ewing sarcoma gene (EWS) by a submicroscopic paracentric inversion of 22q12 in a small round cell sarcoma presenting a translocation t(1;22)(p34;q12). We report here the molecular cloning and characterization of the breakpoint in 1p34, which encompasses the gene coding for mitochondrial Hinge protein ubiquinol-cytochrome C reductase hinge gene (UQCRH). All the three breakpoints, two on 22q12 and one in 1p34, interrupt different genes: EWS, ZSG and UQCRH. We determined the genomic structure of UQCRH, characterized its splicing variants and identified a transcribed processed pseudogene. The analysis of UQCRH expression in normal tissues and cancer cell lines revealed absent expression of UQCRH in two ovarian and one breast cancer cell lines and reduced expression in a further breast carcinoma cell line. CpG island methylation upstream exon 1 was detected in all the three cell lines with absent expression. Moreover, treatment with demethylating agent 5-azacytidine restored UQCRH expression in OAW42 ovarian cancer cells. These data provide preliminary evidence of the inactivation of UQCRH gene in cancer either by structural rearrangements or epigenetic mechanisms.	Ist Nazl Tumori, Unit Mol Cytogenet, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Unit Mol Therapies, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Sozzi, G (corresponding author), Ist Nazl Tumori, Unit Mol Cytogenet, Via G Venezian 1, I-20133 Milan, Italy.		Testi, Maria Adele/D-6994-2017; sozzi, gabriella/G-8259-2011; Mezzanzanica, Delia/C-2607-2017	Testi, Maria Adele/0000-0002-9462-0336; sozzi, gabriella/0000-0001-9360-6914; Mezzanzanica, Delia/0000-0002-9664-6871				Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jones DH, 1997, BIOTECHNIQUES, V23, P132, DOI 10.2144/97231rr01; KIM CH, 1983, J BIOL CHEM, V258, P3543; KIM CH, 1989, BIOCHEMISTRY-US, V28, P1439, DOI 10.1021/bi00430a002; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; LIU AY, 1993, CANCER RES, V53, P2460; Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; MUKAI K, 1985, J BIOCHEM-TOKYO, V98, P1417, DOI 10.1093/oxfordjournals.jbchem.a135409; OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2; Okazaki M, 1998, BIOCHEM BIOPH RES CO, V243, P131, DOI 10.1006/bbrc.1997.7979; Rustin P, 2002, NAT GENET, V30, P352, DOI 10.1038/ng0402-352; Santiard-Baron D, 1999, EXP NEUROL, V158, P206, DOI 10.1006/exnr.1999.7076; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849	20	15	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4586	4593		10.1038/sj.onc.1206472	http://dx.doi.org/10.1038/sj.onc.1206472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881716				2022-12-25	WOS:000184054700015
J	Suzuki, T; Murakami, T; Iino, R; Suzuki, J; Ono, S; Shirakihara, Y; Yoshida, M				Suzuki, T; Murakami, T; Iino, R; Suzuki, J; Ono, S; Shirakihara, Y; Yoshida, M			F0F1-ATPase/synthase is geared to the synthesis mode by conformational rearrangement of epsilon subunit in response to proton motive force and ADP/ATP balance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; CHLOROPLAST ATP SYNTHASE; DISULFIDE BOND FORMATION; CROSS-LINKING; GAMMA-SUBUNIT; BETA-SUBUNITS; F1F0-ATP SYNTHASE; TERMINAL DOMAIN; CATALYTIC SITES; ROTARY MOTOR	The epsilon subunit in F0F1-ATPase/synthase undergoes drastic conformational rearrangement, which involves the transition of two C-terminal helices between a hairpin "down"-state and an extended "up"-state, and the enzyme with the up-fixed epsilon cannot catalyze ATP hydrolysis but can catalyze ATP synthesis (Tsunoda, S. P., Rodgers, A. J. W., Aggeler, R., Wilce, M. C. J., Yoshida, M., and Capaldi, R. A. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 6560 - 6564). Here, using cross-linking between introduced cysteine residues as a probe, we have investigated the causes of the transition. Our findings are as follows. (i) In the up-state, the two helices of epsilon are fully extended to insert the C terminus into a deeper position in the central cavity of F-1 than was thought previously. (ii) Without a nucleotide, epsilon is in the up-state. ATP induces the transition to the down-state, and ADP counteracts the action of ATP. (iii) Conversely, the enzyme with the down-state epsilon can bind an ATP analogue, 2', 3'-O-( 2,4,6-trinitrophenyl)-ATP, much faster than the enzyme with the up-state epsilon. (iv) Proton motive force stabilizes the up-state. Thus, responding to the increase of proton motive force and ADP, F0F1-ATPase/synthase would transform the epsilon subunit into the up-state conformation and change gear to the mode for ATP synthesis.	Japan Sci & Technol Corp, ERATO, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Natl Inst Genet, Shizuoka 4118540, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Yoshida, M (corresponding author), Japan Sci & Technol Corp, ERATO, ATP Syst Project, Nagatsuta 5800-2, Yokohama, Kanagawa 2260026, Japan.		Iino, Ryota/B-7746-2011	Iino, Ryota/0000-0003-0110-5704				Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Alper S, 1996, J MOL BIOL, V260, P165, DOI 10.1006/jmbi.1996.0390; BAGNARA AS, 1973, EUR J BIOCHEM, V36, P422, DOI 10.1111/j.1432-1033.1973.tb02927.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; Hausrath AC, 2001, J BIOL CHEM, V276, P47227, DOI 10.1074/jbc.M107536200; Iida T, 2002, EXTREMOPHILES, V6, P369, DOI 10.1007/s00792-002-0266-7; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 2000, J BIOL CHEM, V275, P35746, DOI 10.1074/jbc.M006575200; KOMATSUTAKAKI M, 1993, EUR J BIOCHEM, V214, P587, DOI 10.1111/j.1432-1033.1993.tb17957.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nowak KF, 2002, BIOCHEMISTRY-US, V41, P15130, DOI 10.1021/bi026594v; Pedersen PL, 2002, J BIOENERG BIOMEMBR, V34, P327, DOI 10.1023/A:1021249701287; Ren HM, 2000, BBA-BIOENERGETICS, V1458, P221, DOI 10.1016/S0005-2728(00)00075-X; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SMITH RC, 1964, BIOCHIM BIOPHYS ACTA, V86, P229, DOI 10.1016/0304-4165(64)90047-9; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Suzuki T, 2002, J BIOL CHEM, V277, P13281, DOI 10.1074/jbc.M111210200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; XIE DL, 1993, BIOCHIM BIOPHYS ACTA, V1172, P267, DOI 10.1016/0167-4781(93)90213-W; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	45	128	139	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46840	46846		10.1074/jbc.M307165200	http://dx.doi.org/10.1074/jbc.M307165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12881515	hybrid			2022-12-25	WOS:000186569400076
J	Fiorani, P; Bruselles, A; Falconi, M; Chillemi, G; Desideri, A; Benedetti, P				Fiorani, P; Bruselles, A; Falconi, M; Chillemi, G; Desideri, A; Benedetti, P			Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICLE MESH EWALD; MOLECULAR-DYNAMICS; DNA TOPOISOMERASES; SENSITIVITY; EXPRESSION; MECHANISM; CATALYSIS; CELLS; COVALENT; ENZYMES	DNA topoisomerase I relaxes supercoiled DNA by the formation of a covalent intermediate in which the active-site tyrosine is transiently bound to the cleaved DNA strand. The antineoplastic agent camptothecin specifically targets DNA topoisomerase I, and several mutations have been isolated that render the enzyme camptothecin-resistant. The catalytic and structural dynamical properties of a human DNA topoisomerase I mutant in which Ala-653 in the linker domain was mutated into Pro have been investigated. The mutant is resistant to camptothecin and in the absence of the drug displays a cleavage-religation equilibrium strongly shifted toward religation. The shift is mainly because of an increase in the religation rate relative to the wild type enzyme, indicating that the unperturbed linker is involved in slowing religation. Molecular dynamics simulation indicates that the Ala to Pro mutation increases the linker flexibility allowing it to sample a wider conformational space. The increase in religation rate of the mutant, explained by means of the enhanced linker flexibility, provides an explanation for the mutant camptothecin resistance.	Univ Roma Tor Vergata, Natl Inst Phys Matter, I-00133 Rome, Italy; Univ Padua, Dept Biol, I-35131 Padua, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Consorzio Interuniv Applicaz Supercalculo Univ &, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; University of Padua; University of Rome Tor Vergata	Desideri, A (corresponding author), Univ Roma Tor Vergata, Natl Inst Phys Matter, Via Ric Sci, I-00133 Rome, Italy.	desideri@uniroma2.it	Chillemi, Giovanni/O-2825-2019; Bruselles, Alessandro/M-7908-2017; Bruselles, Alessandro/M-6012-2019; Chillemi, Giovanni/E-5201-2010; Bruselles, Alessandro/G-3251-2011	Chillemi, Giovanni/0000-0003-3901-6926; Bruselles, Alessandro/0000-0002-1556-4998; Bruselles, Alessandro/0000-0002-1556-4998; Chillemi, Giovanni/0000-0003-3901-6926; FALCONI, MATTIA/0000-0002-3990-4758; desideri, alessandro/0000-0003-1541-4217				BENEDETTI P, 1993, CANCER RES, V53, P4343; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Chang JY, 2002, CANCER RES, V62, P3716; CHEATHAM TE, 1995, J AM CHEM SOC, V117, P4193, DOI 10.1021/ja00119a045; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chillemi G, 2003, NUCLEIC ACIDS RES, V31, P1525, DOI 10.1093/nar/gkg242; Chillemi G, 2001, BIOPHYS J, V81, P490, DOI 10.1016/S0006-3495(01)75716-5; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2000, METH MOL B, V95, P291; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Ireton GC, 2000, J BIOL CHEM, V275, P25820, DOI 10.1074/jbc.M002144200; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200	35	72	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43268	43275		10.1074/jbc.M303899200	http://dx.doi.org/10.1074/jbc.M303899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904303	hybrid			2022-12-25	WOS:000186157000069
J	Pang, QS; Christianson, TA; Koretsky, T; Carlson, HQ; David, L; Keeble, W; Faulkner, GR; Speckhart, A; Bagby, GC				Pang, QS; Christianson, TA; Koretsky, T; Carlson, HQ; David, L; Keeble, W; Faulkner, GR; Speckhart, A; Bagby, GC			Nucleophosmin interacts with and inhibits the catalytic function of eukaryotic initiation factor 2 kinase PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; ENDOPLASMIC-RETICULUM STRESS; BUTYRATE-INDUCED APOPTOSIS; FANCONI-ANEMIA PROTEIN; LEUKEMIA HL-60 CELLS; MALIGNANT-TRANSFORMATION; INCREASED EXPRESSION; TELOMERASE ACTIVITY; INTERFERON	In normal cells the protein kinase PKR effects apoptosis in response to various extra and intracellular cues and can also function to suppress the neoplastic phenotype. Because most neoplastic cells are resistant to certain apoptotic cues, we reasoned that an early molecular event in carcinogenesis or leukemogenesis might be the inactivation of PKR by expression or activation of intracellular PKR inhibitors. Seeking novel PKR-modulating proteins we report here that nucleophosmin (NPM), a protein frequently overexpressed in a variety of human malignancies, binds to PKR, and inhibits its activation. Co-immunoprecipitation and in vitro binding experiments showed that NPM associated with PKR. Kinase assays demonstrated that recombinant NPM inhibited PKR activation in a dose-dependent manner. In addition, purified recombinant NPM was phosphorylated by activated PKR. Most importantly, overexpression of NPM suppressed PKR activity, enhanced protein synthesis, and inhibited apoptosis. Lymphoblasts from patients with Fanconi anemia ( FA) expressed low levels of NPM, which correlated with high ground-state activation of PKR and cellular hypersensitivity to apoptotic cues, but enforced expression of NPM in these mutant cells reduced aberrant apoptotic responses. Inhibition of PKR by NPM may be one mechanism by which neoplastic clones evolve in sporadic malignancies and in neoplastic cells arising in the context of the cancer predisposition syndrome, Fanconi anemia.	Oregon Hlth & Sci Univ, Inst Canc, Sch Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Inst Canc, Sch Dent, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR 97201 USA; Cincinnati Children Hosp Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Bagby, GC (corresponding author), Oregon Hlth & Sci Univ, Inst Canc, Sch Med, CR145, Portland, OR 97201 USA.	grover@ohsu.edu			NHLBI NIH HHS [HL 48546] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048546] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alter BP, 2002, PEDIATR CLIN N AM, V49, P973, DOI 10.1016/S0031-3955(02)00031-7; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; DANDREA AD, 2002, AM SOC HEMATOL ED PR, P58; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; Fagerlie S, 2001, EXP HEMATOL, V29, P1371, DOI 10.1016/S0301-472X(01)00755-X; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Kenmochi N, 2000, J HUM GENET, V45, P290, DOI 10.1007/s100380070018; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kowalczyk P, 2002, ACTA BIOCHIM POL, V49, P615; Kryndushkin DS, 2002, J BIOL CHEM, V277, P23702, DOI 10.1074/jbc.M111547200; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Lensch MW, 1999, LEUKEMIA, V13, P1784, DOI 10.1038/sj.leu.2401586; Li SY, 2001, J BIOL CHEM, V276, P13881, DOI 10.1074/jbc.M008140200; Liu WH, 1998, ONCOGENE, V17, P3055, DOI 10.1038/sj.onc.1202234; Liu WH, 1999, INT J CANCER, V83, P765, DOI 10.1002/(SICI)1097-0215(19991210)83:6<765::AID-IJC12>3.0.CO;2-J; Matsui T, 2001, BIOCHEM BIOPH RES CO, V284, P798, DOI 10.1006/bbrc.2001.5039; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; Naora H, 1999, IMMUNOL CELL BIOL, V77, P197, DOI 10.1046/j.1440-1711.1999.00816.x; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Pang QS, 2002, J BIOL CHEM, V277, P49638, DOI 10.1074/jbc.M209386200; Pang QS, 2001, BLOOD, V97, P1644, DOI 10.1182/blood.V97.6.1644; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; Peel AL, 2001, HUM MOL GENET, V10, P1531, DOI 10.1093/hmg/10.15.1531; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; Shields LBE, 1997, J SOC GYNECOL INVEST, V4, P298, DOI 10.1016/S1071-5576(97)00068-3; Sieff CA, 2000, BRIT J HAEMATOL, V111, P30, DOI 10.1046/j.1365-2141.2000.02263.x; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Subong ENP, 1999, PROSTATE, V39, P298; Szebeni A, 1999, PROTEIN SCI, V8, P905; VanBelzen N, 1995, EUR J BIOCHEM, V234, P843; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; You BJ, 1999, N-S ARCH PHARMACOL, V360, P683, DOI 10.1007/s002109900145; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200	54	40	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41709	41717		10.1074/jbc.M301392200	http://dx.doi.org/10.1074/jbc.M301392200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12882984	hybrid			2022-12-25	WOS:000185989500021
J	Beugnet, A; Wang, XM; Proud, CG				Beugnet, A; Wang, XM; Proud, CG			Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D1 MESSENGER-RNA; P70 S6 KINASE; PHAS-I; MTOR; TRANSLATION; REGULATORS; GROWTH; RAPTOR; 4E-BP1; IDENTIFICATION	The translational repressor protein eIF4E-binding protein 1 (4E-BP1, also termed PHAS-I) is regulated by phosphorylation through the rapamycin-sensitive mTOR ( mammalian target of rapamycin) pathway. Recent studies have identified two regulatory motifs in 4E-BP1, an mTOR-signaling (TOS) motif in the C terminus of 4E-BP1 and an RAIP motif ( named after its sequence) in the N terminus. Other recent work has shown that the protein raptor binds to mTOR and 4E-BP1. We show that raptor binds to full-length 4E-BP1 or a C-terminal fragment containing the TOS motif but not to an N-terminal fragment containing the RAIP motif. Mutation of several residues within the TOS motif abrogates binding to raptor, indicating that the TOS motif is required for this interaction. 4E-BP1 undergoes phosphorylation at multiple sites in intact cells. The effects of removal or mutation of the RAIP and TOS motifs differ. The RAIP motif is absolutely required for phosphorylation of sites in the N and C termini of 4E-BP1, whereas the TOS motif primarily affects phosphorylation of Ser-64/65, Thr-69/70, and also the rapamycin-insensitive site Ser-101. Phosphorylation of N-terminal sites that are dependent upon the RAIP motif is sensitive to rapamycin. The RAIP motif thus promotes the mTOR-dependent phosphorylation of multiple sites in 4E-BP1 independently of the 4E-BP1/raptor interaction.	Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk		Proud, Christopher/0000-0003-0704-6442				Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Gingras AC, 2001, PROG MOLEC, V27, P143; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball S R, 2001, Prog Mol Subcell Biol, V26, P155; Lai HK, 2000, ONCOGENE, V19, P1623, DOI 10.1038/sj.onc.1203473; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Wang XM, 2002, BIOCHEM J, V367, P475, DOI 10.1042/BJ20020677; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	38	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40717	40722		10.1074/jbc.M308573200	http://dx.doi.org/10.1074/jbc.M308573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912989	hybrid			2022-12-25	WOS:000185847200037
J	Mohanty, AK; Bishop, CM; Bishop, TC; Wimley, WC; Wiener, MC				Mohanty, AK; Bishop, CM; Bishop, TC; Wimley, WC; Wiener, MC			Enzymatic E-colicins bind to their target receptor BtuB by presentation of a small binding epitope on a coiled-coil scaffold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; COBALAMIN TRANSPORTER; CRYSTAL-STRUCTURE; PROTEIN; CELLS; VITAMIN-B12; ENVELOPE; DOMAINS; ENTRY	Toxins and viruses often initiate their attacks by binding to specific proteins on the surfaces of target cells. Bacterial toxins (e.g. bacteriocins) and viruses (bacteriophages) targeting Gram-negative bacteria typically bind to outer membrane proteins. Bacterial E-colicins target Escherichia coli by binding to the outer membrane cobalamin transporter BtuB. Colicins are tripartite molecules possessing receptor-binding, translocation, and toxin domains connected by long coiled-coil alpha-helices. Surprisingly, the crystal structure of colicin E3 does not possess a recognizable globular fold in its receptor-binding domain. We hypothesized that the binding epitope of enzymatic E-colicins is a short loop connecting the two alpha-helices that comprise the coiled-coil region and that this flanking coiled-coil region serves to present the loop in a binding-capable conformation. To test this hypothesis, we designed and synthesized a 34-residue peptide (E-peptide-1) corresponding to residues Ala(366)-Arg(399) of the helix-loop-helix region of colicin E3. Cysteines placed near the ends of the peptide (I372C and A393C) enabled crosslinking for reduction of conformational entropy and formation of a peptide structure that would present the loop epitope. A fluorescent analog was also made for characterization of binding by measurement of fluorescence polarization. Our analysis shows the following. (i) E-peptide-1 is predominantly random coil in aqueous solution, but disulfide bond formation increases its alpha-helical content in both aqueous buffer and solvents that promote helix formation. (ii) Fluorescein-labeled E-peptide-1 binds to purified BtuB in a calcium-dependent manner with a K-d of 43.6 +/- 4.9 nM or 2370 +/- 670 nM in the presence or absence of calcium, respectively. (iii) In the presence of calcium, cyanocobalamin (CN-Cbl) displaces E-peptide-1 with a nanomolar inhibition constant (K-i = 78.9 +/- 5.6 nM). We conclude that the BtuB binding sites for cobalamins and enzymatic E-colicins are overlapping but inequivalent and that the distal loop and (possibly) the short alpha-helical flanking regions are sufficient for high affinity binding.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA; Xavier Univ, Div Pharmaceut Sci, New Orleans, LA 70125 USA	University of Virginia; Tulane University; Xavier University of Louisiana	Wiener, MC (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.	mwiener@virginia.edu			NIDDK NIH HHS [DK59999] Funding Source: Medline; NIGMS NIH HHS [R01 GM060000, R01 GM060000-05, GM60000] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060000] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atherton E., 1990, SOLID PHASE PEPTIDE; Bano SF, 2002, BIOPHYS J, V82, p555A; Boetzel R, 2003, FARADAY DISCUSS, V122, P145, DOI 10.1039/b201127a; BRADBEER C, 1986, J BIOL CHEM, V261, P2520; BRAUN V, 1994, ARCH MICROBIOL, V161, P199, DOI 10.1007/s002030050042; BUDAVARI S, 1996, MERCK INDEX ENCY CHE, P1710; Cao Z, 2002, BIOCHIMIE, V84, P399, DOI 10.1016/S0300-9084(02)01455-4; CAVARD D, 1994, FEMS MICROBIOL LETT, V116, P37; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; Chimento DP, 2003, ACTA CRYSTALLOGR D, V59, P509, DOI 10.1107/S0907444903000052; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; DIMASI DR, 1973, J BACTERIOL, V115, P506, DOI 10.1128/JB.115.2.506-513.1973; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Grant G. A, 1992, SYNTHETIC PEPTIDES U; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HELLER K, 1985, J BACTERIOL, V161, P896, DOI 10.1128/JB.161.3.896-903.1985; Hocart SJ, 1999, J MED CHEM, V42, P1863, DOI 10.1021/jm9806289; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kenakin T., 1997, PHARM ANAL DRUG RECE, P242; Knodler LA, 2001, NAT REV MOL CELL BIO, V2, P578, DOI 10.1038/35085062; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; Penfold CN, 2000, MOL MICROBIOL, V38, P639, DOI 10.1046/j.1365-2958.2000.02160.x; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Smarda J, 2000, FOLIA MICROBIOL, V45, P379, DOI 10.1007/BF02817609; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Tam JP, 2000, EUR J BIOCHEM, V267, P3289, DOI 10.1046/j.1432-1327.2000.01359.x; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; Wimley WC, 1996, BIOCHEMISTRY-US, V35, P5109, DOI 10.1021/bi9600153; Zakharov SD, 2003, BIOPHYS J, V84, p324A	33	10	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40953	40958		10.1074/jbc.M308227200	http://dx.doi.org/10.1074/jbc.M308227200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902336	hybrid			2022-12-25	WOS:000185847200067
J	Numakawa, T; Nakayama, H; Suzuki, S; Kubo, T; Nara, F; Numakawa, Y; Yokomaku, D; Araki, T; Ishimoto, T; Ogura, A; Taguchi, T				Numakawa, T; Nakayama, H; Suzuki, S; Kubo, T; Nara, F; Numakawa, Y; Yokomaku, D; Araki, T; Ishimoto, T; Ogura, A; Taguchi, T			Nerve growth factor-induced glutamate release is via p75 receptor, ceramide, and Ca2+ from ryanodine receptor in developing cerebellar neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; AFFINITY NEUROTROPHIN RECEPTOR; PC12 CELLS; GRANULE NEURONS; NEUTRAL SPHINGOMYELINASE; RECOMBINANT ADENOVIRUS; SYNAPTIC-TRANSMISSION; INTRACELLULAR CA2+; INDUCED APOPTOSIS; CORTICAL-NEURONS	Very little is known about the contribution of a low affinity neurotrophin receptor, p75, to neurotransmitter release. Here we show that nerve growth factor (NGF) induced a rapid release of glutamate and an increase of Ca2+ in cerebellar neurons through a p75-dependent pathway. The NGF-induced release occurred even in the presence of the Trk inhibitor K252a. The release caused by NGF but not brain-derived neurotrophic factor was enhanced in neurons overexpressing p75. Further, after transfection of p75-small interfering RNA, which downregulated the endogenous p75 expression, the NGF-induced release was inhibited, suggesting that the NGF-induced glutamate release was through p75. We found that the NGF-increased Ca2+ was derived from the ryanodine-sensitive Ca2+ receptor and that the NGF-increased Ca2+ was essential for the NGF-induced glutamate release. Furthermore, scyphostatin, a sphingomyelinase inhibitor, blocked the NGF-dependent Ca2+ increase and glutamate release, suggesting that a ceramide produced by sphingomyelinase was required for the NGF-stimulated Ca2+ increase and glutamate release. This action of NGF only occurred in developing neurons whereas the brain-derived neurotrophic factor-mediated Ca2+ increase and glutamate release was observed at the mature neuronal stage. Thus, we demonstrate that NGF-mediated neurotransmitter release via the p75-dependent pathway has an important role in developing neurons.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Disorder Res, Kodaira, Tokyo 1878502, Japan; Natl Inst Adv Ind Sci & Technol, Neuron RG Special Div Human Life Technol, Osaka 5638577, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Nara Med Univ, Nara 6348521, Japan; Sankyo Co Ltd, Shinagawa Ku, Tokyo 1408710, Japan; AIST, Human Stress, Ikeda, Osaka 5638577, Japan; Osaka Univ, Fac Sci, Grad Sch Frontier Biosci, Osaka 4600043, Japan	National Center for Neurology & Psychiatry - Japan; National Institute of Advanced Industrial Science & Technology (AIST); Osaka University; Nara Medical University; Daiichi Sankyo Company Limited; National Institute of Advanced Industrial Science & Technology (AIST); Osaka University	Numakawa, T (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Disorder Res, 4-1-1 Ogawahigashicho, Kodaira, Tokyo 1878502, Japan.	numakawa@ncnp.go.jp		Araki, Toshiyuki/0000-0002-1179-4534				Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Blochl A, 1996, J BIOL CHEM, V271, P21100; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Bui NT, 2002, J NEUROCHEM, V81, P594, DOI 10.1046/j.1471-4159.2002.00841.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.0.CO;2-0; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DeFreitas MF, 2001, J NEUROSCI, V21, P5121, DOI 10.1523/JNEUROSCI.21-14-05121.2001; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Fagan AM, 1997, J NEUROSCI, V17, P7644; Frade JM, 1998, BIOESSAYS, V20, P137, DOI 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; FURUYA S, 1995, J NEUROCHEM, V65, P1551; GalveRoperh I, 1997, J NEUROSCI RES, V49, P569, DOI 10.1002/(SICI)1097-4547(19970901)49:5<569::AID-JNR7>3.0.CO;2-9; Halpain S, 1998, J NEUROSCI, V18, P9835; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HATANAKA H, 1988, DEV BRAIN RES, V39, P85, DOI 10.1016/0165-3806(88)90069-7; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Higuchi H, 2003, BIOCHEM BIOPH RES CO, V301, P804, DOI 10.1016/S0006-291X(03)00029-9; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HUBER LJ, 1995, DEV BIOL, V167, P227, DOI 10.1006/dbio.1995.1019; Hughes AL, 2001, J NEUROSCI RES, V63, P10, DOI 10.1002/1097-4547(20010101)63:1<10::AID-JNR2>3.0.CO;2-R; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; Korkotian E, 1999, P NATL ACAD SCI USA, V96, P12068, DOI 10.1073/pnas.96.21.12068; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Kurihara H, 1997, J NEUROSCI, V17, P9613; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LESSMANN V, 1994, NEUROREPORT, V6, P21; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MURAKAMI T, 1991, CHEMOTHERAPY, V37, P327, DOI 10.1159/000238875; Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525; Numakawa T, 1999, BRAIN RES, V842, P431, DOI 10.1016/S0006-8993(99)01867-3; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Numakawa T, 2002, J BIOL CHEM, V277, P28861, DOI 10.1074/jbc.M202927200; Numakawa T, 2001, J NEUROSCI RES, V66, P96, DOI 10.1002/jnr.1201; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wang SY, 2000, AM J PATHOL, V157, P1247, DOI 10.1016/S0002-9440(10)64640-8; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Xu AG, 2001, WORLD J GASTROENTERO, V7, P403; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Yang F, 2001, NAT NEUROSCI, V4, P19, DOI 10.1038/82858	65	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41259	41269		10.1074/jbc.M304409200	http://dx.doi.org/10.1074/jbc.M304409200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902347	hybrid			2022-12-25	WOS:000185847200105
J	Spinella, F; Rosano, L; Di Castro, V; Nicotra, MR; Natali, PG; Bagnato, A				Spinella, F; Rosano, L; Di Castro, V; Nicotra, MR; Natali, PG; Bagnato, A			Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; GROWTH-FACTOR; PROTEIN CONNEXIN-43; RECEPTOR BLOCKADE; EPITHELIAL-CELLS; CARDIAC MYOCYTES; A RECEPTOR; C-SRC; EXPRESSION; ACTIVATION	Endothelin-1 (ET-1) is overexpressed in ovarian carcinoma and acts as an autocrine factor selectively through the ETA receptor (ETAR) to promote tumor cell proliferation, survival, neovascularization, and invasiveness. Loss of gap junctional intercellular communication (GJIC) is critical for tumor progression by allowing the cells to escape growth control. Exposure of HEY and OVCA 433 ovarian carcinoma cell lines to ET-1 led to a 50 - 75% inhibition in intercellular communication and to a decrease in the connexin 43 (Cx43)- based gap junction plaques. To investigate the phosphorylation state of Cx43, ovarian carcinoma cell lysates were immunoprecipitated and transient tyrosine phosphorylation of Cx43 was detected in ET-1-treated cells. BQ 123, a selective ETAR antagonist, blocked the ET-1-induced Cx43 phosphorylation and cellular uncoupling. Gap junction closure was prevented by tyrphostin 25 and by the selective c-Src inhibitor, PP2. Furthermore, the increased Cx43 tyrosine phosphorylation was correlated with ET-1-induced increase of c-Src activity, and PP2 suppressed the ET-1-induced Cx43 tyrosine phosphorylation, indicating that inhibition of Cx43-based GJIC is mainly mediated by the Src tyrosine kinase pathway. In vivo, the inhibition of human ovarian tumor growth in nude mice induced by the potent ETAR antagonist, ABT-627, was associated with a reduction of Cx43 phosphorylation. These findings indicate that the signaling mechanisms involved in GJIC disruption on ovarian carcinoma cells depend on ETAR activation, which leads to the Cx43 tyrosine phosphorylation mediated by c-Src, suggesting that ETAR blockade may contribute to the control of ovarian carcinoma growth and progression also by preventing the loss of GJIC.	Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Dept Immunol, I-00158 Rome, Italy; CNR, Inst Mol Biol & Pathol, I-00137 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Bagnato, A (corresponding author), Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, Via Messi Oro 156, I-00158 Rome, Italy.	bagnato@ifo.it	Di Castro, Valeriana/H-8873-2017; ROSANO', Laura/AAK-1424-2020; spinella, francesca/AAZ-8982-2020; Bagnato, Anna/G-9747-2016; Rosanò, Laura/I-9266-2012; Rosanò, Laura/AAB-7821-2019; Rosanò, Laura/B-2863-2018	Di Castro, Valeriana/0000-0002-1899-3683; ROSANO', Laura/0000-0002-9962-6411; Bagnato, Anna/0000-0002-7269-9522; Rosanò, Laura/0000-0002-3981-8593; Rosanò, Laura/0000-0002-9962-6411				Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; Bagnato A, 2002, CANCER RES, V62, P6381; Bagnato A, 2001, AM J PATHOL, V158, P841, DOI 10.1016/S0002-9440(10)64032-1; BALEY PA, 1990, J CLIN INVEST, V85, P1320, DOI 10.1172/JCI114570; Blomstrand F, 1999, AM J PHYSIOL-CELL PH, V277, pC616, DOI 10.1152/ajpcell.1999.277.4.C616; Carducci MA, 2002, J CLIN ONCOL, V20, P2171, DOI 10.1200/JCO.2002.08.028; Carruba G, 2002, PROSTATE, V50, P73; Cruciani V, 2002, BIOL CELL, V94, P433, DOI 10.1016/S0248-4900(02)00014-X; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; ECONOMOS K, 1992, CANCER RES, V52, P554; Egidy G, 2000, AM J PATHOL, V157, P1863, DOI 10.1016/S0002-9440(10)64825-0; Fernstrom MJ, 2002, EXP MOL PATHOL, V73, P54, DOI 10.1006/exmp.2002.2436; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; Giepmans BNG, 2001, CURR BIOL, V11, P1364, DOI 10.1016/S0960-9822(01)00424-9; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Giusti AF, 2000, J BIOL CHEM, V275, P16788, DOI 10.1074/jbc.M001091200; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Govindarajan R, 2002, J BIOL CHEM, V277, P50087, DOI 10.1074/jbc.M202652200; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; Lahav R, 1999, P NATL ACAD SCI USA, V96, P11496, DOI 10.1073/pnas.96.20.11496; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laing JG, 2001, J BIOL CHEM, V276, P23051, DOI 10.1074/jbc.M100303200; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lidington D, 2002, J CELL PHYSIOL, V193, P373, DOI 10.1002/jcp.10179; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Polontchouk L, 2001, FASEB J, V15, P87, DOI 10.1096/fj.01-0381fje; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Rosano L, 2003, CANCER RES, V63, P2447; Rosano L, 2001, CANCER RES, V61, P8340; RUBANJI GM, 1999, PHARMACOL REV, V46, P325; Ruch RJ, 2001, J CELL BIOCHEM, V83, P163, DOI 10.1002/jcb.1227; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8; Salani D, 2002, CLIN SCI, V103, p318S, DOI 10.1042/CS103S318S; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; Spinella F, 2002, J BIOL CHEM, V277, P27850, DOI 10.1074/jbc.M202421200; Sumitomo M, 2001, CANCER RES, V61, P3294; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Trosko JE, 2001, MUTAT RES-FUND MOL M, V480, P219, DOI 10.1016/S0027-5107(01)00181-6; Umhauer S, 2000, AM J OBSTET GYNECOL, V182, P999, DOI 10.1016/S0002-9378(00)70135-9; van der Boon J, 2002, LANCET ONCOL, V3, P201, DOI 10.1016/S1470-2045(02)00704-0; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Venuti A, 2000, FASEB J, V14, P2277, DOI 10.1096/fj.00-0024com	51	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41294	41301		10.1074/jbc.M304785200	http://dx.doi.org/10.1074/jbc.M304785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907686	hybrid			2022-12-25	WOS:000185847200108
J	Torkko, JM; Koivuranta, KT; Kastaniotis, AJ; Airenne, TT; Glumoff, T; Ilves, M; Hartig, A; Gurvitz, A; Hiltunen, JK				Torkko, JM; Koivuranta, KT; Kastaniotis, AJ; Airenne, TT; Glumoff, T; Ilves, M; Hartig, A; Gurvitz, A; Hiltunen, JK			Candida tropicalis expresses two mitochondrial 2-enoyl thioester reductases that are able to form both homodimers and heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; ALKANE-ASSIMILATING YEAST; FATTY-ACID SYNTHESIS; SACCHAROMYCES-CEREVISIAE; HEMIASCOMYCETOUS YEASTS; GENOMIC EXPLORATION; GENETIC EVALUATION; NEUROSPORA-CRASSA; THIOLASE ISOZYMES; CREATINE-KINASE	Here we report on the cloning of a Candida tropicalis gene, ETR2, that is closely related to ETR1. Both genes encode enzymatically active 2-enoyl thioester reductases involved in mitochondrial synthesis of fatty acids ( fatty acid synthesis type II) and respiratory competence. The 5'- and 3'-flanking (coding) regions of ETR2 and ETR1 are about 90% (97%) identical, indicating that the genes have evolved via gene duplication. The gene products differ in three amino acid residues: Ile(67) (Val), Ala(92) (Thr), and Lys(251) (Arg) in Etr2p (Etr1p). Quantitative PCR analysis and reverse transcriptase-PCR indicated that both genes were expressed about equally in fermenting and ETR1 predominantly respiring yeast cells. Like the situation with ETR1, expression of ETR2 in respiration-deficient Saccharomyces cerevisiae mutant cells devoid of Ybr026p/Etr1p was able to restore growth on glycerol. Triclosan that is used as an antibacterial agent against fatty acid synthesis type II 2-enoyl thioester reductases inhibited growth of FabI overexpressing mutant yeast cells but was not able to inhibit respiratory growth of the ETR2- or ETR1-complemented mutant yeast cells. Resolving of crystal structures obtained via Etr2p and Etr1p co-crystallization indicated that all possible dimer variants occur in the same asymmetric unit, suggesting that similar dimer formation also takes place in vivo.	Univ Oulu, Dept Biochem, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Physiol, FIN-90014 Oulu, Finland; VTT Biotechnol, FIN-02044 Espoo, Finland; Univ Vienna, Dept Biochem & Mol Cell Biol, Vienna Bioctr, Univ Dept,Max F Perutz Labs, A-1030 Vienna, Austria	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; VTT Technical Research Center Finland; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, Bioctr Oulu, POB 3000, FIN-90014 Oulu, Finland.			Hartig, Andreas/0000-0003-3334-2763; Hiltunen, Kalervo/0000-0002-3073-9602; Kastaniotis, Alexander/0000-0003-3624-9214				Airenne TT, 2003, J MOL BIOL, V327, P47, DOI 10.1016/S0022-2836(03)00038-X; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; Blandin G, 2000, FEBS LETT, V487, P91, DOI 10.1016/S0014-5793(00)02287-0; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DODSON EJ, 1994, ACTA CRYSTALLOGR D, V50, P760; DOI M, 1992, J GEN MICROBIOL, V138, P2243, DOI 10.1099/00221287-138-10-2243; Glanz S, 1992, PRIMER BIOSTATISTICS; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARINGTON A, 1994, EMBO J, V13, P5531, DOI 10.1002/j.1460-2075.1994.tb06890.x; Heath RJ, 2000, J BIOL CHEM, V275, P40128, DOI 10.1074/jbc.M005611200; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; Johnston J.R., 1994, MOL GENETICS YEAST P; JONES EW, 1977, GENETICS, V85, P23; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; KAMIRYO T, 1991, YEAST, V7, P503, DOI 10.1002/yea.320070510; Kanayama N, 1998, J BACTERIOL, V180, P690, DOI 10.1128/JB.180.3.690-698.1998; KAWAMOTO S, 1978, EUR J BIOCHEM, V83, P609, DOI 10.1111/j.1432-1033.1978.tb12130.x; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Llorente B, 2000, FEBS LETT, V487, P122, DOI 10.1016/S0014-5793(00)02291-2; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; Nordling E, 2002, EUR J BIOCHEM, V269, P4267, DOI 10.1046/j.1432-1033.2002.03114.x; Nowak MA, 1997, NATURE, V388, P167, DOI 10.1038/40618; OCARRA P, 1990, BIOCHEM SOC T, V18, P272, DOI 10.1042/bst0180272; OKAZAKI K, 1987, GENE, V58, P37; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PICATAGGIO S, 1991, MOL CELL BIOL, V11, P4333, DOI 10.1128/MCB.11.9.4333; QUEST AFG, 1990, FEBS LETT, V262, P299, DOI 10.1016/0014-5793(90)80214-4; Rachubinski R. A., 1990, The genetics of Candida., P177; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; ROSENBERG UB, 1981, EUR J BIOCHEM, V116, P87, DOI 10.1111/j.1432-1033.1981.tb05304.x; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; Sugita T, 1999, SYST APPL MICROBIOL, V22, P79, DOI 10.1016/S0723-2020(99)80030-7; TANAKA A, 1993, MYCOL RES, V97, P1025, DOI 10.1016/S0953-7562(09)80504-2; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Ueda M, 1998, BBA-GENE STRUCT EXPR, V1397, P213, DOI 10.1016/S0167-4781(98)00009-8; Ueda M, 2000, CELL BIOCHEM BIOPHYS, V32, P285, DOI 10.1385/CBB:32:1-3:285; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; YAMAZOE M, 1994, J BIOL CHEM, V269, P15244; ZEELEN JP, 1992, J MOL BIOL, V224, P273, DOI 10.1016/0022-2836(92)90591-7; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F	52	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41213	41220		10.1074/jbc.M307664200	http://dx.doi.org/10.1074/jbc.M307664200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890667	hybrid			2022-12-25	WOS:000185847200099
J	Mohamed, MR; Niles, EG				Mohamed, MR; Niles, EG			UUUUUNU stimulation of vaccinia virus early gene transcription termination - Oligonucleotide sequence and structural requirements for stimulation of premature termination in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA POLYMERASE; TRIPHOSPHATE PHOSPHOHYDROLASE-I; TEMPERATURE-SENSITIVE MUTANTS; H4L SUBUNIT; CAPPING ENZYME; ESCHERICHIA-COLI; EXPRESSION; MUTATIONS; IDENTIFICATION; PURIFICATION	Vaccinia virus early genes are unique in that transcription terminates in a signal- and factor-dependent manner. Recent results from this laboratory demonstrated that a 22-mer RNA oligonucleotide containing a central U9 sequence exhibited sequence- and concentration-dependent stimulation of premature transcription termination and transcript release in trans. In an effort to better understand the different aspects of the U5NU stimulation of premature termination, we evaluated the activity of various oligonucleotides in vitro. Neither RNA containing a mutant U5NU signal nor single-stranded DNA containing T5NT was able to stimulate premature termination, demonstrating both sequence specificity and a requirement for ribose. Furthermore, neither oligonucleotide was able to compete with U5NU, demonstrating that each failed to bind to the U5NU recognition factor. Substitution of the U9 signal with either BrU9 or BrdU9 inhibited normal termination but did not stimulate premature termination. The addition of BrdU5NdU inhibited U5NU stimulation of premature termination, demonstrating that both oligonucleotides bind to the same site on the U5NU recognition factor. Finally, U5NU containing RNA as short as nine bases served as an effective stimulator of premature termination. These observations impact directly on the development of oligonucleotide based anti-poxvirus therapeutic agents.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Niles, EG (corresponding author), SUNY Buffalo, Sch Med, Dept Microbiol, 138 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	eniles@buffalo.edu	Mohamed, Mohamed Ragaa/V-9143-2019	Mohamed, Mohamed Ragaa/0000-0002-9269-3128	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043933] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI 43933] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1992, J VIROL, V66, P971, DOI 10.1128/JVI.66.2.971-982.1992; Christen LA, 1999, BIOCHEMISTRY-US, V38, P8072, DOI 10.1021/bi9903749; Christen LM, 1998, VIROLOGY, V245, P360, DOI 10.1006/viro.1998.9177; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; Condit RC, 1996, VIROLOGY, V220, P10, DOI 10.1006/viro.1996.0280; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; Deng L, 1997, J BIOL CHEM, V272, P695; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; Mohamed MR, 2000, J BIOL CHEM, V275, P25798, DOI 10.1074/jbc.M002250200; Mohamed MR, 2003, J BIOL CHEM, V278, P11794, DOI 10.1074/jbc.M213263200; Mohamed MR, 2002, VIROLOGY, V299, P142, DOI 10.1006/viro.2002.1498; Mohamed MR, 2001, J BIOL CHEM, V276, P20758, DOI 10.1074/jbc.M101641200; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; Moss B, 2001, FIELDS VIROLOGY, P2849; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; Piacente SC, 2003, VIROLOGY, V310, P109, DOI 10.1016/S0042-6822(03)00092-8; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSALES R, 1994, J BIOL CHEM, V269, P14260; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; Smith GL, 1997, IMMUNOL REV, V159, P137, DOI 10.1111/j.1600-065X.1997.tb01012.x; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998	35	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39534	39541		10.1074/jbc.M306048200	http://dx.doi.org/10.1074/jbc.M306048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890673	hybrid			2022-12-25	WOS:000185713800034
J	Sanchez-Pacheco, A; Aranda, A				Sanchez-Pacheco, A; Aranda, A			Binding of the thyroid hormone receptor to a negative element in the basal growth hormone promoter is associated with histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BOX; TRANSCRIPTIONAL ACTIVATION; LIGAND-BINDING; N-COR; GENE; REPRESSION; DEACETYLASE; BETA; TRANSACTIVATION; COREPRESSORS	Nuclear thyroid hormone receptors (TRs) act as ligand-dependent activators, but paradoxically unliganded TRs can increase transcription of promoters containing negative response elements (nTRE), and hormone binding represses this activation. The rat growth hormone (GH) promoter contains a positive TRE and a nTRE. Ligand-dependent negative regulation mediated by the nTRE could play an important physiological role in restricting GH gene expression in non-pituitary cells that express TRs. With chromatin immunoprecipitation assays, we show here that the nTRE is responsible for binding of TR to the promoter in non-pituitary HeLa cells and that this element also governs transactivation by the unoccupied receptor and repression by triiodothyronine. Occupancy of the promoter by TR is concomitant with appearance of acetylated histone H3, and triiodothyronine causes release of the receptor as well as disappearance of the acetylated histone from the promoter. Although the nTRE overlaps the TATA box, the receptor does not exclude binding of TATA-binding protein, but could rather facilitate formation of the preinitiation complex. Furthermore, the proximal GH promoter is synergistically stimulated by unliganded TR and TATA-binding protein, whereas the ligand represses this cooperation. Constitutive receptor activity and synergism with TATA-binding protein require binding of corepressors. Furthermore, inhibitors of histone deacetylases enhance promoter activation by the unliganded receptor and reduce triiodothyronine-dependent repression, whereas expression of HDAC1 reverses promoter stimulation. This suggests that partitioning of histone acetylases and deacetylases between the receptors and basal transcription factors could be involved in regulation of the basal GH promoter by TRs.	CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Univ Autonoma Madrid, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Aranda, A (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	aaranda@iib.uam.es	Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589; Sanchez Pacheco, Aurora/0000-0002-7776-2594				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CRONE DE, 1990, J BIOL CHEM, V265, P10851; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, MOL CELL BIOL, V16, P281; GarciaVillalba P, 1997, DNA CELL BIOL, V16, P421, DOI 10.1089/dna.1997.16.421; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; Glass CK, 2000, GENE DEV, V14, P121; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Helmer EB, 1996, ENDOCRINOLOGY, V137, P390, DOI 10.1210/en.137.2.390; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kao HY, 2000, GENE DEV, V14, P55; Kim MK, 1999, P NATL ACAD SCI USA, V96, P10092, DOI 10.1073/pnas.96.18.10092; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mendez-Pertuz M, 2003, EMBO J, V22, P3102, DOI 10.1093/emboj/cdg295; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Palomino T, 1998, FASEB J, V12, P1201, DOI 10.1096/fasebj.12.12.1201; Palomino T, 1998, J BIOL CHEM, V273, P27541, DOI 10.1074/jbc.273.42.27541; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Shibusawa N, 2003, J BIOL CHEM, V278, P732, DOI 10.1074/jbc.M207264200; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0	51	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39383	39391		10.1074/jbc.M306988200	http://dx.doi.org/10.1074/jbc.M306988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878587	hybrid			2022-12-25	WOS:000185713800015
J	Wang, LX; Cummings, R; Zhao, YT; Kazlauskas, A; Sham, JKS; Morris, A; Georas, S; Brindley, DN; Natarajan, V				Wang, LX; Cummings, R; Zhao, YT; Kazlauskas, A; Sham, JKS; Morris, A; Georas, S; Brindley, DN; Natarajan, V			Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; AIRWAY SMOOTH-MUSCLE; OVARIAN-CANCER CELLS; COUPLED RECEPTORS; TYROSINE PHOSPHORYLATION; SPHINGOSINE 1-PHOSPHATE; EGF RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; ENDOTHELIAL-CELLS; MEDIATED ACTIVATION	Lysophosphatidate (LPA) mediates multiple cellular responses via heterotrimeric G protein coupled LPA-1, LPA-2, and LPA-3 receptors. Many G protein-coupled receptors stimulate ERK following tyrosine phosphorylation of growth factor receptors; however, the mechanism(s) of transactivation of receptor tyrosine kinases are not well defined. Here, we provide evidence for the involvement of phospholipase D (PLD) in LPA-mediated transactivation of platelet-derived growth factor receptorbeta (PDGF-Rbeta). In primary cultures of human bronchial epithelial cells (HBEpCs), LPA stimulated tyrosine phosphorylation of PDGF-Rbeta and threonine/tyrosine phosphorylation of ERK1/2. The LPA-mediated activation of ERK and tyrosine phosphorylation of PDGF-Rbeta was attenuated by tyrphostin AG 1296, an inhibitor of PDGF-R kinase, suggesting transactivation of PDGF-R by LPA. Furthermore, LPA-, but not PDGF beta-chain homodimer-induced tyrosine phosphorylation of PDGF-Rbeta was partially blocked by pertussis toxin, indicating coupling of LPA-R(s) to G(i). Exposure of HBEpCs to LPA activated PLD. Butan-1-ol, which acts as an acceptor of phosphatidate generated by the PLD pathway, blocked LPA- mediated transactivation of PDGF-Rbeta. This effect was not seen with butan-3-ol, suggesting PLD involvement. The role of PLD1 and PLD2 in the PDGF-Rbeta transactivation by LPA was investigated by infection of cells with adenoviral constructs of wild type and catalytically inactive mutants of PLD. LPA activated both PLD1 and PLD2 in HBEpCs; however, infection of cells with cDNA for wild type PLD2, but not PLD1, increased the tyrosine phosphorylation of PDGF-Rbeta in response to LPA. Also, the LPA- mediated tyrosine phosphorylation of PDGF-Rbeta was attenuated by the catalytically inactive mutant mPLD2-K758R. Infection of HBEpCs with adenoviral constructs of wild type hPLD1, mPLD2, and the inactive mutants of hPLD1 and mPLD2 resulted in association of PLD2 wild type and inactive mutant proteins with the PDGF-Rbeta compared with PLD1. These results show for the first time that transactivation of PDGF-Rbeta by LPA in HBEpCs is regulated by PLD2.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care, Baltimore, MD 21224 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada	Johns Hopkins University; Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of North Carolina; University of North Carolina Chapel Hill; University of Alberta	Natarajan, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care, Mason F Lord Bldg,Rm 675,5200 Eastern Ave, Baltimore, MD 21224 USA.		wang, xl/Y-8251-2019; Wang, Lai-Xi/E-8755-2019					Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; BUCH S, 1994, AM J RESP CELL MOL, V11, P251, DOI 10.1165/ajrcmb.11.3.8086163; Cerutis DR, 1997, AM J PHYSIOL-LUNG C, V273, pL10, DOI 10.1152/ajplung.1997.273.1.L10; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fishman DA, 2001, CANCER RES, V61, P3194; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GSCHWIND A, 2000, CANCER RES, V62, P6329; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Kanda Y, 2001, BRIT J PHARMACOL, V132, P1657, DOI 10.1038/sj.bjp.0703952; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; Kim SN, 2000, J CELL BIOCHEM, V76, P386, DOI 10.1002/(SICI)1097-4644(20000301)76:3<386::AID-JCB6>3.0.CO;2-9; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; KOVALENKO M, 1994, CANCER RES, V54, P6106; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Kue PF, 2002, INT J CANCER, V102, P572, DOI 10.1002/ijc.10734; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Liebmann C, 2000, CURR MED CHEM, V7, P911, DOI 10.2174/0929867003374589; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; Min DS, 2001, MOL CELLS, V11, P369; Natarajan V, 1998, MOL CELL BIOCHEM, V183, P113, DOI 10.1023/A:1006872230910; NATARAJAN V, 1995, J LIPID RES, V36, P2005; Ohata H, 1997, LIFE SCI, V60, P1287, DOI 10.1016/S0024-3205(97)00072-6; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Parinandi NL, 2001, ARCH BIOCHEM BIOPHYS, V396, P231, DOI 10.1006/abbi.2001.2609; PIAZZA GA, 1995, EXP CELL RES, V216, P51, DOI 10.1006/excr.1995.1007; Pietruck F, 1997, N-S ARCH PHARMACOL, V355, P1; Qi C, 1998, J CELL PHYSIOL, V174, P261, DOI 10.1002/(SICI)1097-4652(199802)174:2<261::AID-JCP13>3.0.CO;2-F; Racke K, 2000, PULM PHARMACOL THER, V13, P99, DOI 10.1006/pupt.2000.0241; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Shimizu S, 2000, AM J PHYSIOL-LUNG C, V279, pL503, DOI 10.1152/ajplung.2000.279.3.L503; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Toews ML, 2002, BBA-MOL CELL BIOL L, V1582, P240, DOI 10.1016/S1388-1981(02)00177-4; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wang LX, 2002, BIOCHEM J, V367, P751, DOI 10.1042/BJ20020586; Wu J, 2002, BBA-MOL CELL BIOL L, V1582, P100, DOI 10.1016/S1388-1981(02)00143-9; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200	64	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39931	39940		10.1074/jbc.M302896200	http://dx.doi.org/10.1074/jbc.M302896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890682	Green Published, hybrid			2022-12-25	WOS:000185713800081
J	De, S; Chen, JH; Narizhneva, NV; Heston, W; Brainard, J; Sage, EH; Byzova, TV				De, S; Chen, JH; Narizhneva, NV; Heston, W; Brainard, J; Sage, EH; Byzova, TV			Molecular pathway for cancer metastasis to bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN PROSTATE-CANCER; IN-VITRO EXPRESSION; CELL-MIGRATION; TUMOR-CELLS; FACTOR VEGF; INTEGRIN; ADHESION; ANGIOGENESIS; PROGRESSION	The molecular mechanism leading to the cancer metastasis to bone is poorly understood but yet determines prognosis and therapy. Here, we define a new molecular pathway that may account for the extraordinarily high osteotropism of prostate cancer. By using SPARC (secreted protein, acidic and rich in cysteine)-deficient mice and recombinant SPARC, we demonstrated that SPARC selectively supports the migration of highly metastatic relative to less metastatic prostate cancer cell lines to bone. Increased migration to SPARC can be traced to the activation of integrins alphaVbeta3 and alphaVbeta5 on tumor cells. Such activation is induced by an autocrine vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-2 loop on the tumor cells, which also supports the growth and proliferation of prostate cancer cells. A consequence of SPARC recognition by alphaVbeta5 is enhanced VEGF production. Thus, prostate cancer cells expressing VEGF/VEGFR-2 will activate alphaVbeta3 and alphaVbeta5 on their surface and use these integrins to migrate toward SPARC in bone. Within the bone environment, SPARC engagement of these integrins will stimulate growth of the tumor and further production of VEGF to support neoangiogenesis, thereby favoring the development of the metastatic tumor. Supporting this model, activated integrins were found to colocalize with VEGFR-2 in tissue samples of metastatic prostate tumors from patients.	Cleveland Clin Fdn, Taussig Canc Ctr, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Taussig Canc Ctr, Dept Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44195 USA; Hope Heart Inst, Seattle, WA 98122 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin Fdn, Taussig Canc Ctr, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org		Byzova, Tatiana/0000-0002-2615-875X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60933, R01 DK060933] Funding Source: Medline; NIGMS NIH HHS [R01 GM040711, GM40711] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bradshaw Amy D., 2000, Molecular Cell Biology Research Communications, V3, P345, DOI 10.1006/mcbr.2000.0237; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039; Edlund M, 2001, CELL GROWTH DIFFER, V12, P99; Ferrer FA, 1999, UROLOGY, V54, P567, DOI 10.1016/S0090-4295(99)00156-9; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; Fontana A., 2000, Cancer, V88, P2952, DOI 10.1002/1097-0142(20000615)88:12+<2952::AID-CNCR11>3.0.CO;2-M; Gardiner EE, 1997, J BIOL CHEM, V272, P15474, DOI 10.1074/jbc.272.24.15474; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Jacob K, 1999, CANCER RES, V59, P4453; Jones A, 2000, BJU INT, V85, P276, DOI 10.1046/j.1464-410x.2000.00432.x; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lang SH, 1997, CLIN EXP METASTAS, V15, P218, DOI 10.1023/A:1018465213641; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; ROKHLIN OW, 1995, PROSTATE, V26, P205, DOI 10.1002/pros.2990260406; Sage EH, 1999, J HISTOCHEM CYTOCHEM, V47, P1643; Salih MA, 1999, MOL CELL ENDOCRINOL, V147, P149, DOI 10.1016/S0303-7207(98)00206-8; Smit JWA, 1998, THYROID, V8, P29, DOI 10.1089/thy.1998.8.29; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; Sokoloff MH, 1998, CANCER METAST REV, V17, P307, DOI 10.1023/A:1006170612253; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; vanderPluijm G, 1996, CANCER RES, V56, P1948; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WEIDNER N, 1993, AM J PATHOL, V143, P401; Zheng DQ, 1999, CANCER RES, V59, P1655; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	37	122	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39044	39050		10.1074/jbc.M304494200	http://dx.doi.org/10.1074/jbc.M304494200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885781	Green Accepted, hybrid			2022-12-25	WOS:000185575100117
J	Chun, ACS; Jin, DY				Chun, ACS; Jin, DY			Transcriptional regulation of mitotic checkpoint gene MAD1 by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; HUMAN HEPATOCELLULAR-CARCINOMA; HISTONE DEACETYLASE ACTIVITY; REPRESSION IN-VIVO; SPINDLE CHECKPOINT; CELL-CYCLE; MUTANT P53; MAMMALIAN-CELLS; DNA-BINDING; KINETOCHORE LOCALIZATION	p53 regulates a number of genes through transcriptional activation and repression. p53-dependent mitotic checkpoint has been described, but the underlying mechanism is still obscure. Here we examined the effect of p53 on the expression of a human mitotic checkpoint protein, Mitosis Arrest Deficiency 1 (MAD1), in cultured human cells. The expression of MAD1 was reduced when the cells were overexpressing exogenously introduced wild-type p53. The same reduction was also observed when the cells were treated with anticancer agents 5-fluorouracil and cisplatin or were irradiated with UV. Consistently, MAD1 promoter activity diminished in a dose-dependent manner when induced by p53, indicating that p53 repressed MAD1 at a transcriptional level. Intriguingly, several tumor hot spot mutations in p53 (V143A, R175H, R248W, and R273H) did not abolish the ability of p53 to repress MAD1 expression. By serial truncation of the MAD1 promoter, we confined the p53-responsive element to a 38-bp region that represents a novel sequence distinct from the known p53 consensus binding site. Trichostatin A, a histone deacetylase inhibitor, relieved the p53 transrepression activity on MAD1. Chromatin immunoprecipitation assay revealed that p53, histone deacetylase 1, and co-repressor mSin3a associated with the MAD1 promoter in vivo. Taken together, our findings suggest a regulatory mechanism for the mitotic checkpoint in which MAD1 is inhibited by p53.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Jin, DY (corresponding author), Univ Hong Kong, Dept Biochem, 3rd Floor,Lab Block,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.				FOGARTY INTERNATIONAL CENTER [R01TW006186] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW06186] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campbell MS, 2001, J CELL SCI, V114, P953; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARSHID M, 1992, J MED VIROL, V38, P235, DOI 10.1002/jmv.1890380402; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Haugwitz U, 2002, NUCLEIC ACIDS RES, V30, P1967, DOI 10.1093/nar/30.9.1967; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Ikui AE, 2002, J CELL SCI, V115, P1603; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Iouk T, 2002, J CELL BIOL, V159, P807, DOI 10.1083/jcb.200205068; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Iwanaga Y, 2002, CANCER RES, V62, P2618; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson CA, 2002, J BIOL CHEM, V277, P9590, DOI 10.1074/jbc.M107942200; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Patino WD, 2002, CIRC RES, V91, P565, DOI 10.1161/01.RES.0000036018.76903.18; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; SIMON D, 1985, CYTOGENET CELL GENET, V39, P116, DOI 10.1159/000132118; Sironi L, 2002, EMBO J, V21, P2496, DOI 10.1093/emboj/21.10.2496; Stahler F, 1998, ONCOGENE, V17, P3507, DOI 10.1038/sj.onc.1202245; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2003, ONCOGENE, V22, P109, DOI 10.1038/sj.onc.1206069; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yoshikawa R, 2001, CANCER RES, V61, P1029; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zhou HJ, 2001, J BIOL CHEM, V276, P28933, DOI 10.1074/jbc.M103893200; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	93	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37439	37450		10.1074/jbc.M307185200	http://dx.doi.org/10.1074/jbc.M307185200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12876282	hybrid			2022-12-25	WOS:000185437200056
J	Ghosh, M; Peterson, YK; Lanier, SM; Smrcka, AV				Ghosh, M; Peterson, YK; Lanier, SM; Smrcka, AV			Receptor- and nucleotide exchange-independent mechanisms for promoting G protein subunit dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; G-ALPHA SUBUNITS; REGULATORY MOTIF; BINDING; INHIBITION; TRANSDUCIN; PEPTIDE; ADENYLYL-CYCLASE-2; DETERMINANTS	Mechanisms for heterotrimeric G protein activation that do not rely on G protein coupled receptor activation are becoming increasingly apparent. We recently identified betagamma subunit-binding peptides that we proposed bound to a "hot spot" on betagamma subunits, stimulating G protein dissociation without stimulating nucleotide exchange and activating G protein signaling in intact cells. AGS3, a member of the activators of G protein signaling family of proteins, also activates G protein signaling in a nucleotide exchange-independent manner, and AGS3 homologues are involved in asymmetric cell division during development. Here we demonstrate that a consensus G protein regulatory (GPR) peptide from AGS3 and related proteins is sufficient to induce G protein subunit dissociation and that both the GPR and hot spot-binding peptides promote dissociation to extents comparable with a known G protein activator, AMF. Peptides derived from adenylyl cyclase 2 and GRK2 prevented formation of the heterotrimeric complex but did not alter the rate of alpha subunit dissociation from betagamma subunits. These data indicate that these nucleotide exchange-independent G protein activator peptides do not simply compete for alpha interactions with betagamma subunits, but actively promote subunit dissociation. Thus, we propose two novel mechanisms for nucleotide exchange independent activation of G protein signaling, one that involves conformational changes in the alpha subunit and one that involves conformational changes in the betagamma subunits.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	University of Rochester; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Smrcka, AV (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA.		Ghosh, Mousumi/D-3180-2011	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blumer JB, 2003, RECEPTOR CHANNEL, V9, P195, DOI 10.1080/10606820390203839; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Goubaeva F, 2003, J BIOL CHEM, V278, P19634, DOI 10.1074/jbc.M300052200; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KATADA T, 1984, J BIOL CHEM, V259, P3578; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445	28	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34747	34750		10.1074/jbc.C300271200	http://dx.doi.org/10.1074/jbc.C300271200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12881533	hybrid			2022-12-25	WOS:000185164400004
J	Nagano, H; Noguchi, T; Inagaki, K; Yoon, S; Matozaki, T; Itoh, H; Kasuga, M; Hayashi, Y				Nagano, H; Noguchi, T; Inagaki, K; Yoon, S; Matozaki, T; Itoh, H; Kasuga, M; Hayashi, Y			Downregulation of stomach cancer-associated protein tyrosine phosphatase-1 (SAP-1) in advanced human hepatocellular carcinoma	ONCOGENE			English	Article						tyrosine phosphatase; cell migration; dedifferentiation; hepatoma	FOCAL ADHESION KINASE; CELL INVASION; HUMAN LUNG; EXPRESSION; RECEPTOR; GROWTH; GENE; LIVER; OVEREXPRESSION; AMPLIFICATION	SAP-1 (stomach cancer-associated protein tyrosine phosphatase-1) is a transmembrane-type protein tyrosine phosphatase that has been implicated as a negative regulator of integrin-mediated signaling. The potential role of this enzyme in hepatocarcinogenesis has now been investigated by examining its expression in 32 surgically excised human hepatocellular carcinoma (HCC) specimens. Both immunohistochemical and immunoblot analyses revealed that normal liver tissue, as well as tissue affected by chronic hepatitis or cirrhosis, contained substantial amounts of SAP-1. The expression level of SAP-1 in 75% of well-differentiated HCCs was similar to or higher than that observed in the surrounding non-cancerous tissue. In contrast, the abundance of SAP-1 in 85.7% of moderately differentiated HCCs and in all poorly differentiated HCCs was greatly reduced compared with that in the adjacent tissue. Indeed, SAP-1 was almost undetectable in 83.3% of poorly differentiated HCCs. Furthermore, expression of recombinant SAP-1 in two highly motile human HCC cell lines resulted in a change in morphology and a marked reduction in both migratory activity and growth rate. In conclusion, these results indicate that SAP-1 expression is downregulated during the dedifferentiation of human HCC, and that this downregulation may play a causal role in disease progression.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Biomed Informat, Div Surg Pathol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan	Kobe University; Kobe University; Gunma University	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEVRIES L, 1991, FEBS LETT, V282, P285; DOI I, 1975, GANN, V66, P385; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKUTA S, 1994, J GASTROENTEROL, V29, P727, DOI 10.1007/BF02349278; Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; KAMEDA T, 1990, CANCER RES, V50, P8002; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Keane MM, 1996, CANCER RES, V56, P4236; KIM SR, 1995, J GASTROEN HEPATOL, V10, P498, DOI 10.1111/j.1440-1746.1995.tb01338.x; KITAMURA T, 1995, JPN J CANCER RES, V86, P811, DOI 10.1111/j.1349-7006.1995.tb03090.x; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; Morita Y, 1997, HEPATOLOGY, V25, P856, DOI 10.1002/hep.510250412; NISHIDA N, 1993, CANCER RES, V53, P368; Noguchi T, 2001, J BIOL CHEM, V276, P15216, DOI 10.1074/jbc.M007208200; Ojakian GK, 2001, J CELL SCI, V114, P941; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palmer HJ, 1999, J BIOL CHEM, V274, P11424, DOI 10.1074/jbc.274.16.11424; ROGLER CE, 1992, SEMIN LIVER DIS, V12, P265, DOI 10.1055/s-2007-1007398; Saito S, 1996, BIOCHEM BIOPH RES CO, V227, P406, DOI 10.1006/bbrc.1996.1520; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TAHARA H, 1995, CANCER RES, V55, P2734; Takada T, 2002, J BIOL CHEM, V277, P34359, DOI 10.1074/jbc.M206541200; Tamura M, 1999, CANCER RES, V59, P442; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101	41	23	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4656	4663		10.1038/sj.onc.1206588	http://dx.doi.org/10.1038/sj.onc.1206588			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879010				2022-12-25	WOS:000184157000006
J	Weber, A; Langhanki, L; Sommerer, F; Markwarth, A; Wittekind, C; Tannapfel, A				Weber, A; Langhanki, L; Sommerer, F; Markwarth, A; Wittekind, C; Tannapfel, A			Mutations of the BRAF gene in squamous cell carcinoma of the head and neck	ONCOGENE			English	Article						squamous cell carcinoma of the head and neck; BRAF; KRAS2	RAS MUTATIONS; ACTIVATION; TUMORIGENESIS; FREQUENCY; PATHWAY; CANCER; KINASE; LIVER; P53	The RAF/MEK/ERK (MAPK) signal transduction cascade is an important mediator of a number of cellular fates including growth, proliferation and survival. The BRAF gene, one of the human isoforms of RAF, is activated by oncogenic RAS, leading to cooperative effects in cells responding to growth factor signals. This study was performed to elucidate a possible function of BRAF in squamous cell carcinoma of the head and neck (HNSCC). Mutations of BRAF and KRAS2 were evaluated in 89 HNSCC and corresponding normal mucosa by direct DNA sequencing analyses after microdissection. The results obtained were correlated with histopathological variables. Activating BRAF missense mutations were identified in 3/89 HNSCC (3%). KRAS2 mutations were found in five out of 89 (6%) HNSCC examined. There were no mutations of KRAS2 and BRAF in non-neoplastic mucosa. We failed to observe a correlation between BRAF or KRAS2 mutations and histopathological factors. Our data indicate that BRAF gene mutations are relatively rare events in HNSCC. Although uncommon, BRAF mutations may identify a subset of patients with HNSCC sensitive to targeted therapy.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Univ Leipzig, Dept Otorhinolaryngol Head & Neck Surg, D-04103 Leipzig, Germany	Leipzig University; Leipzig University	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.							Brose MS, 2002, CANCER RES, V62, P6997; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hao D, 2002, CANCER INVEST, V20, P387, DOI 10.1081/CNV-120001184; Hoa M, 2002, CANCER RES, V62, P7154; Leder A, 2002, ONCOGENE, V21, P6657, DOI 10.1038/sj.onc.1205795; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Naoki K, 2002, CANCER RES, V62, P7001; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pindborg JJ, 1997, HISTOLOGICAL TYPING; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Shanmugaratnam K, 1991, HISTOLOGICAL TYPING; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 2001, EUR ARCH OTO-RHINO-L, V258, P83, DOI 10.1007/s004050000303; Tannapfel A, 2001, ONCOGENE, V20, P7104, DOI 10.1038/sj.onc.1204902; Weber CK, 2001, CANCER RES, V61, P3595; Xu J, 1998, CANCER-AM CANCER SOC, V83, P204, DOI 10.1002/(SICI)1097-0142(19980715)83:2<204::AID-CNCR2>3.0.CO;2-Q; Yuen ST, 2002, CANCER RES, V62, P6451	25	99	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4757	4759		10.1038/sj.onc.1206705	http://dx.doi.org/10.1038/sj.onc.1206705			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879021				2022-12-25	WOS:000184157000017
J	Stefanovic, D; Stanojcic, S; Vindigni, A; Ochem, A; Falaschi, A				Stefanovic, D; Stanojcic, S; Vindigni, A; Ochem, A; Falaschi, A			In vitro protein-DNA interactions at the human lamin B2 replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION COMPLEX; CELL-CYCLE; BINDING; GENE	The complexity of mammalian origins of DNA replication has prevented, so far, the in vitro studies of the modalities of initiator protein binding and origin selection. We approached this problem by utilizing the human lamin B2 origin, wherein the precise start sites of replication initiation have been identified and known to be bound in vivo by the origin recognition complex (ORC). In order to analyze the in vitro interactions occurring at this origin, we have compared the DNA binding requirements and patterns of the human recombinant Orc4 with those of preparations of HeLa nuclear proteins containing the ORC complex. Here we show that both HsOrc4 alone and HeLa nuclear proteins recognize multiple sites within a 241-bp DNA sequence encompassing the lamin B2 origin. The DNA binding activity of HeLa cells requires the presence of ORC and can be reproduced in the absence of all the other proteins known to be recruited to origins by ORC. Both HsOrc4 alone and HeLa nuclear proteins exhibit cooperative and ATP-independent binding. This binding covers nucleotides 3853 - 3953 and then spreads outward. Because this region contains the start sites of DNA synthesis as well as the area protected in vivo and preserves protein binding capacity in vitro after removal of a fraction of the protected region, we suggest that it could contain the primary binding site. Thus the in vitro approach points to the sequence requirements for ORC binding as a key element for origin recognition.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Falaschi, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; Abdurashidova G, 2003, EMBO J, V22, P4294, DOI 10.1093/emboj/cdg404; Abdurashidova G, 1998, EMBO J, V17, P2961, DOI 10.1093/emboj/17.10.2961; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BIAMONTI G, 1992, MOL CELL BIOL, V12, P3499, DOI 10.1128/MCB.12.8.3499; Bielinsky AK, 2001, CURR BIOL, V11, P1427, DOI 10.1016/S0960-9822(01)00444-4; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Chuang RY, 2002, J BIOL CHEM, V277, P16920, DOI 10.1074/jbc.M107710200; de Stanchina E, 2000, J MOL BIOL, V299, P667, DOI 10.1006/jmbi.2000.3782; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimitrova DS, 1996, P NATL ACAD SCI USA, V93, P1498, DOI 10.1073/pnas.93.4.1498; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kong DC, 2002, EMBO J, V21, P5567, DOI 10.1093/emboj/cdf546; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Kumar S, 1996, NUCLEIC ACIDS RES, V24, P3289, DOI 10.1093/nar/24.17.3289; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; Lee JK, 2001, P NATL ACAD SCI USA, V98, P13589, DOI 10.1073/pnas.251530398; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200	26	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42737	42743		10.1074/jbc.M307058200	http://dx.doi.org/10.1074/jbc.M307058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12902329	hybrid			2022-12-25	WOS:000186157000003
J	Zander, K; Sherman, MP; Tessmer, U; Bruns, K; Wray, V; Prechtel, AT; Schubert, E; Henklein, P; Luban, J; Neidleman, J; Greene, WC; Schubert, U				Zander, K; Sherman, MP; Tessmer, U; Bruns, K; Wray, V; Prechtel, AT; Schubert, E; Henklein, P; Luban, J; Neidleman, J; Greene, WC; Schubert, U			Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 VPR; VIRAL PROTEIN R; CYCLOSPORINE-A; CELL-CYCLE; TERMINAL DOMAIN; NMR STRUCTURE; SDZ NIM-811; IMMUNODEFICIENCY; REPLICATION; INFECTION	Viral protein R (Vpr) of human immunodeficiency virus, type 1 (HIV-1) is the major virion-associated accessory protein that affects a number of biological functions in the retroviral life cycle, including promotion of the transport of the preintegration complex into the nucleus and the induction of G(2) host cell cycle arrest. Our recent investigation of the conformational heterogeneity of the proline residues in the N terminus of Vpr suggested a functional interaction between Vpr and a host peptidylprolyl cis/trans isomerase (PPIase) that might regulate the cis/trans interconversion of the imidic bond within the conserved proline residues of Vpr in vivo. Using surface plasmon resonance spectroscopy, Far Western blot, and pulldown experiments a physical interaction of Vpr with the major host PPIase cyclophilin A (CypA) is now demonstrated. The interaction domain involves the N-terminal region of Vpr including an essential role for proline in position 35. The CypA inhibitor cyclosporin A and non-immunosuppressive PPIase inhibitors such as NIM811 and sanglifehrin A block expression of Vpr without affecting pre- or post-translational events such as transcription, intracellular transport, or virus incorporation of Vpr. Similarly to CypA inhibition, Vpr expression is also reduced in HIV-1 infected CypA(-/-) knock-out T cells. This study thus shows that in addition to the interaction between CypA and HIV-1 capsid occurring during early steps in virus replication, CypA is also important for the de novo synthesis of Vpr and that in the absence of CypA activity, the Vpr-mediated cell cycle arrest is completely lost in HIV-1-infected T cells.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94103 USA; Gesell Biotechnol Forsch mbH, Dept Mol Struct Res, D-38124 Braunschweig, Germany; Humboldt Univ, Inst Biochem, D-10115 Berlin, Germany; Columbia Univ, Dept Microbiol, New York, NY 10018 USA; Columbia Univ, Dept Med, New York, NY 10018 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	University of Erlangen Nuremberg; Heinrich Pette Institute; University of Hamburg; University of California System; University of California San Francisco; The J David Gladstone Institutes; Gesellschaft fur Biotechnologische Forschung mbH; Humboldt University of Berlin; Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schubert, U (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	ulrich.schubert@viro.med.uni-erlangen.de		Luban, Jeremy/0000-0001-5650-4054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059537] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI36199, R01 AI036199] Funding Source: Medline; NIDDK NIH HHS [R01 DK59537-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ANDRIEU JM, 1988, CLIN IMMUNOL IMMUNOP, V47, P181, DOI 10.1016/0090-1229(88)90071-2; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Bosco DA, 2002, P NATL ACAD SCI USA, V99, P5247, DOI 10.1073/pnas.082100499; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1997, J VIROL, V71, P2107, DOI 10.1128/JVI.71.3.2107-2113.1997; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; Bruns K, 2003, J BIOL CHEM, V278, P43188, DOI 10.1074/jbc.M305413200; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; BUSS WC, 1995, TOXICOLOGY, V100, P17, DOI 10.1016/0300-483X(95)03053-I; Conti L, 2000, J IMMUNOL, V165, P3293, DOI 10.4049/jimmunol.165.6.3293; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; de Rocquigny H, 2000, EUR J BIOCHEM, V267, P3654, DOI 10.1046/j.1432-1327.2000.01397.x; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; Dorfman T, 1997, J VIROL, V71, P7110, DOI 10.1128/JVI.71.9.7110-7113.1997; Dorfman T, 1996, J VIROL, V70, P5751, DOI 10.1128/JVI.70.9.5751-5757.1996; Eckstein DA, 2001, J EXP MED, V194, P1407, DOI 10.1084/jem.194.10.1407; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Engler A, 2002, EUR J BIOCHEM, V269, P3264, DOI 10.1046/j.1432-1033.2002.03005.x; Engler A, 2001, EUR J BIOCHEM, V268, P389, DOI 10.1046/j.1432-1327.2001.01895.x; Ferri KF, 2000, ANN NY ACAD SCI, V926, P149; Franke EK, 1996, VIROLOGY, V222, P279, DOI 10.1006/viro.1996.0421; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jenkins Y, 2001, J VIROL, V75, P10537, DOI 10.1128/JVI.75.21.10537-10542.2001; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Luban J, 1996, CELL, V87, P1157, DOI 10.1016/S0092-8674(00)81811-5; Luo ZW, 1998, BIOCHEM BIOPH RES CO, V244, P732, DOI 10.1006/bbrc.1998.8330; Mahalingam S, 2001, J VIROL, V75, P362, DOI 10.1128/JVI.75.1.362-374.2001; Martin LN, 1997, J INFECT DIS, V176, P374, DOI 10.1086/514054; Ott DE, 2002, REV MED VIROL, V12, P359, DOI 10.1002/rmv.367; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; Poon B, 1998, SCIENCE, V281, P266, DOI 10.1126/science.281.5374.266; Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198; Rizzardi GP, 2002, J BIOL REG HOMEOS AG, V16, P83; Rizzardi GP, 2002, J CLIN INVEST, V109, P681, DOI 10.1172/JCI200214522; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; Saphire ACS, 2002, J VIROL, V76, P2255, DOI 10.1128/JVI.76.5.2255-2262.2002; Saphire ACS, 2000, IMMUNOL RES, V21, P211, DOI 10.1385/IR:21:2-3:211; Sawaya BE, 1999, GENE THER, V6, P947, DOI 10.1038/sj.gt.3300907; SCHUBERT U, 1995, J VIROL, V69, P7699, DOI 10.1128/JVI.69.12.7699-7711.1995; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Sherman MP, 2000, J VIROL, V74, P8159, DOI 10.1128/JVI.74.17.8159-8165.2000; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; STEINKASSERER A, 1995, J VIROL, V69, P814, DOI 10.1128/JVI.69.2.814-824.1995; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Taylor P, 1997, PROG BIOPHYS MOL BIO, V67, P155, DOI 10.1016/S0079-6107(97)00014-X; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; VALENT P, 1991, P NATL ACAD SCI USA, V88, P3339, DOI 10.1073/pnas.88.8.3339; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; Wiegers K, 1999, VIROLOGY, V257, P261, DOI 10.1006/viro.1999.9669; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; Yao XJ, 2002, J BIOL CHEM, V277, P48816, DOI 10.1074/jbc.M207982200; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	71	74	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43202	43213		10.1074/jbc.M305414200	http://dx.doi.org/10.1074/jbc.M305414200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12881522	hybrid			2022-12-25	WOS:000186157000061
J	Csordas, G; Hajnoczky, G				Csordas, G; Hajnoczky, G			Plasticity of mitochondrial calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RYANODINE-RECEPTORS; CA2+ RELEASE; INOSITOL TRISPHOSPHATE; CYTOSOLIC CA2+; ACINAR-CELLS; CALMODULIN; PROPAGATION; ACTIVATION; LIVER	Evidence is emerging that a quasisynaptic local communication facilitates the calcium signaling between endoplasmic reticulum and mitochondria. However, it remains elusive whether the machinery of mitochondrial calcium signaling displays plasticity similar to the synaptic transmission. Here we studied the relationship between inositol 1,4,5-trisphosphate (IP3)-linked cytosolic [Ca2+] ([Ca2+](c)) oscillations and the associated rise in mitochondrial matrix [Ca2+] ([Ca2+](m)) in RBL-2H3 mast cells. We observed that the second [Ca2+](c) spike is often associated with a larger rise in the [Ca2+](m) than the first. It would appear that this phenomenon was not due to a change in the driving force for Ca2+ uptake and therefore must be due to an enhanced Ca2+ permeability of the mitochondrial Ca2+ uptake sites ( uniporter). To investigate the activation and deactivation kinetics of the uniporter during IP3 receptor-mediated Ca2+ mobilization, we established novel methods. Using these approaches, we demonstrated that the IP3-induced increase in the permeability of the uniporter lasted longer than the Ca2+ signal. The sustained increase in Ca2+ permeability was bidirectional. Furthermore, the addition of Ca2+ during the decay of the IP3 effect evoked a large further increase in the uniporter permeability. Calmodulin inhibitors did not interfere with the IP3-induced initial activation of the uniporter but inhibited the sustained phase. These results suggest that the uniporter displays a calmodulin-mediated facilitation. This plasticity may allow cooperation among sequential IP3 receptor-mediated [Ca2+] transients in the control of calcium signal propagation to the mitochondria.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Hajnoczky, G (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Suite 253 JAH, Philadelphia, PA 19107 USA.	Gyorgy.Hajnoczky@jefferson.edu		Csordas, Gyorgy/0000-0003-3156-1460				ALI H, 1990, J BIOL CHEM, V265, P745; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Csordas G, 2001, CELL CALCIUM, V29, P249, DOI 10.1054/ceca.2000.0191; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; David G, 1999, J NEUROSCI, V19, P7495, DOI 10.1523/JNEUROSCI.19-17-07495.1999; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Falcke M, 1999, BIOPHYS J, V77, P37, DOI 10.1016/S0006-3495(99)76870-0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 2001, IUBMB LIFE, V52, P237, DOI 10.1080/15216540152846055; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HIROSE K, 1994, NATURE, V372, P791; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; KWAN CY, 1990, J BIOL CHEM, V265, P678; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Marchant JS, 2002, AM J PHYSIOL-CELL PH, V282, pC1374, DOI 10.1152/ajpcell.00446.2001; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; Striggow F, 1996, J GEN PHYSIOL, V108, P115, DOI 10.1085/jgp.108.2.115; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; VINOGRADOV A, 1973, J BIOL CHEM, V248, P5527; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; Wang XD, 2001, GENE DEV, V15, P2922; Wilson BS, 1998, MOL BIOL CELL, V9, P1465, DOI 10.1091/mbc.9.6.1465	62	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42273	42282		10.1074/jbc.M305248200	http://dx.doi.org/10.1074/jbc.M305248200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907683				2022-12-25	WOS:000185989500087
J	Kim, BT; Kitagawa, H; Tanaka, J; Tamura, J; Sugahara, K				Kim, BT; Kitagawa, H; Tanaka, J; Tamura, J; Sugahara, K			In vitro heparan sulfate polymerization - Crucial roles of core protein moieties of primer substrates in addition to the EXT1-EXT2 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; EXT GENE FAMILY; TUMOR SUPPRESSORS EXT1; CAENORHABDITIS-ELEGANS; GOLGI-APPARATUS; LINKAGE REGION; TOUT-VELU; BIOSYNTHESIS; PROTEOGLYCANS; EXPRESSION	Heparan, the common unsulfated precursor of heparan sulfate (HS) and heparin, is synthesized on the glycosaminoglycan-protein linkage region tetrasaccharide GlcUA-Gal-Gal-Xyl attached to the respective core proteins presumably by HS co-polymerases encoded by EXT1 and EXT2, the genetic defects of which result in hereditary multiple exostoses in humans. Although both EXT1 and EXT2 exhibit GlcNAc transferase and GlcUA transferase activities required for the HS synthesis, no HS chain polymerization has been demonstrated in vitro using recombinant enzymes. Here we report in vitro HS polymerization. Recombinant soluble enzymes expressed by co-transfection of EXT1 and EXT2 synthesized heparan polymers with average molecular weights greater than 1.7 x 10(5) using UDP-[H-3]GlcNAc and UDP-GlcUA as donors on the recombinant glypican-1 core protein and also on the synthetic linkage region analog GlcUA-Gal-O-C2H4NH-benzyloxycarbonyl. Moreover, in our in vitro polymerization system, a part time proteoglycan, alpha-thrombomodulin, that is normally modified with chondroitin sulfate served as a polymerization primer for heparan chain. In contrast, no polymerization was achieved with a mixture of individually expressed EXT1 and EXT2 or with acceptor substrates such as N-acetylheparosan oligosaccharides or the linkage region tetrasaccharide-Ser, which are devoid of a hydrophobic aglycon, suggesting the critical requirement of core protein moieties in addition to the interaction between EXT1 and EXT2 for HS polymerization.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Tottori Univ, Fac Educ & Reg Sci, Dept Environm Sci, Tottori 6808551, Japan	Kobe Pharmaceutical University; Tottori University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; COOK A, 1993, AM J HUM GENET, V53, P71; Dong SC, 2003, J BIOL CHEM, V278, P1700, DOI 10.1074/jbc.M209276200; Francannet C, 2001, J MED GENET, V38, P430, DOI 10.1136/jmg.38.7.430; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HAN C, 2001, ANN DROS RES C WASH; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Hecht JT, 1997, AM J HUM GENET, V60, P80; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V268, P860, DOI 10.1006/bbrc.2000.2219; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LIN JH, 1994, J BIOL CHEM, V269, P25021; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; LINHARDT RJ, 1992, BIOCHEMISTRY-US, V31, P12441, DOI 10.1021/bi00164a020; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Morimoto K, 2002, BIOCHEM BIOPH RES CO, V292, P999, DOI 10.1006/bbrc.2002.6770; Morio H, 2003, BIOCHEM BIOPH RES CO, V301, P317, DOI 10.1016/S0006-291X(02)03031-0; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Neumann KW, 1995, BIOORGAN MED CHEM, V3, P1637, DOI 10.1016/0968-0896(95)00151-4; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; POOLE AR, 1986, BIOCHEM J, V236, P1; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Tamura J, 1996, LIEBIGS ANN, P1239; Tamura J, 2002, BIOORG MED CHEM LETT, V12, P1901, DOI 10.1016/S0960-894X(02)00327-X; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; ZHANG L, 1995, J BIOL CHEM, V270, P12557, DOI 10.1074/jbc.270.21.12557; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	51	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41618	41623		10.1074/jbc.M304831200	http://dx.doi.org/10.1074/jbc.M304831200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907685	hybrid			2022-12-25	WOS:000185989500009
J	McCarthy, KM; McDevit, D; Andreucci, A; Reeves, R; Nikolajczyk, BS				McCarthy, KM; McDevit, D; Andreucci, A; Reeves, R; Nikolajczyk, BS			HMGA1 co-activates transcription in B cells through indirect association with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN GENE ENHANCER; GROUP PROTEIN I(Y); IG-HEAVY-CHAIN; IFN-BETA GENE; INTRONIC ENHANCER; BINDING-FACTOR; ETS; EXPRESSION; PU.1; SEQUENCES	The immunoglobulin heavy chain enhancer, or mu enhancer, is required for B cell development. Only the appropriate combination of transcription factors results in B cell-specific enhancer activation. HMGA1 (formerly (HMG-I(Y)) is a proposed co-activator of the ETS transcription factors required for mu enhancer activity. HMGA1 associates with the ETS factor PU.1, resulting in changes in PU.1 structure, and enhanced transcriptional synergy with Ets-1 on the mu enhancer in nonlymphoid cells. New data show HMGA1 directly interacts with Ets-1 in addition to PU.1. In vitro HMGA1/Ets-1 interaction facilitates Ets-1/mu enhancer binding in the absence of an HMGA1.Ets-1.DNA complex. To address whether HMGA1 is present in the transcriptionally active mu nucleoprotein complex, we completed DNA pull-down assays to detect protein tethering in the context of protein/DNA interaction. Results show that HMGA1 is not tightly associated with mu enhancer DNA through PU.1 or Ets-1, despite strong associations between these proteins in solution. However, chromatin immunoprecipitation assays show HMGA1 associates with the endogenous enhancer in B cells. Furthermore, antisense HMGA1 substantially decreases mu enhancer activity in B cells. Taken together, these data suggest that HMGA1 functions as a transcriptional mu enhancer co-activator in B cells through indirect association with DNA.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Med Ctr, Evans Mem Dept Clin Res, Dept Med, Immunobiol Unit, Boston, MA 02118 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Boston University; Boston Medical Center; Washington State University	Nikolajczyk, BS (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.				NATIONAL CANCER INSTITUTE [T32CA064070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054611] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 64070] Funding Source: Medline; NIAID NIH HHS [AI 54611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreucci A, 2002, BIOCHEM BIOPH RES CO, V292, P427, DOI 10.1006/bbrc.2002.6672; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; Chowdhury D, 2003, IMMUNITY, V18, P229, DOI 10.1016/S1074-7613(03)00030-X; Chowdhury D, 2001, EMBO J, V20, P6394, DOI 10.1093/emboj/20.22.6394; Cowley DO, 2000, GENE DEV, V14, P366; Dang W, 1998, MOL CELL BIOL, V18, P6870, DOI 10.1128/MCB.18.11.6870; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FERNEX C, 1994, NUCLEIC ACIDS RES, V22, P792, DOI 10.1093/nar/22.5.792; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Lewis RT, 2001, J BIOL CHEM, V276, P9550, DOI 10.1074/jbc.M008726200; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Merrell K, 1997, MOL CELL BIOL, V17, P3335, DOI 10.1128/MCB.17.6.3335; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nikolajczyk BS, 1997, MOL CELL BIOL, V17, P3527, DOI 10.1128/MCB.17.7.3527; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; REIK W, 1987, EUR J IMMUNOL, V17, P465, DOI 10.1002/eji.1830170405; Sakai E, 1999, P NATL ACAD SCI USA, V96, P1526, DOI 10.1073/pnas.96.4.1526; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tian G, 1999, MOL CELL BIOL, V19, P2946; Wang DZ, 1997, J BIOL CHEM, V272, P25083, DOI 10.1074/jbc.272.40.25083; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649	49	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42106	42114		10.1074/jbc.M308586200	http://dx.doi.org/10.1074/jbc.M308586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907668	hybrid			2022-12-25	WOS:000185989500068
J	Gibson, KJC; Eggeling, L; Maughan, WN; Krumbach, K; Gurcha, SS; Nigou, J; Puzo, G; Sahm, H; Besra, GS				Gibson, KJC; Eggeling, L; Maughan, WN; Krumbach, K; Gurcha, SS; Nigou, J; Puzo, G; Sahm, H; Besra, GS			Disruption of Cg-Ppm1, a polyprenyl monophosphomannose synthase, and the generation of lipoglycan-less mutants in Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE MANNOSE SYNTHASE; BACILLUS-CALMETTE-GUERIN; MYCOBACTERIUM-TUBERCULOSIS; PHOSPHATIDYLINOSITOL MANNOSIDES; CORYNEFORM BACTERIA; MEDIATED ACTIVATION; ACYLATION STATE; LIPOARABINOMANNAN; BIOSYNTHESIS; PROTEIN	The glycosyl donor, polyprenyl monophosphomannose (PPM), has been shown to be involved in the biosynthesis of the mycobacterial lipoglycans: lipomannan and lipoarabinomannan. The mycobacterial PPM synthase (Mt-ppm1) catalyzes the transfer of mannose from GDP-mannose to polyprenyl phosphates. Based on sequence homology to Mt-ppm1, we have identified the PPM synthase from Corynebacterium glutamicum. In the present study, we demonstrate that the corynebacterial synthase is composed of two distinct domains; a catalytic domain (Cg-ppm1) and a membrane domain (Cg-ppm2). Through the inactivation of Cg-ppm1, we observed a complex phenotype that included altered cell growth rate and inability to synthesize PPM molecules and lipoglycans. When Cg-ppm2 was deleted, no observable phenotype was noted, indicating the clear organization of the two domains. The complementation of the inactivated Cg-ppm1 strain with the corresponding mycobacterial enzyme (Mt-Ppm1/D2) led to the restoration of a wild type phenotype. The present study illustrates, for the first time, the generation of a lipoglycan-less mutant based on a molecular strategy in a member of the Corynebacterianeae family. Lipoglycans are important immunomodulatory molecules involved in determining the outcome of infection, and so the generation of defined mutants and their subsequent immunological characterization is timely.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; REs Ctr Juelich, Inst Biotechnol 1, D-52425 Julich, Germany; CNRS, Inst Pharmacol & Biol Struct, Dept Mol Mech Mycobacterial Infect, UMR 5089, F-31077 Toulouse 4, France	University of Birmingham; Helmholtz Association; Research Center Julich; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Besra, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	g.besra@bham.ac.uk	Nigou, Jérôme/D-6802-2019	Nigou, Jérôme/0000-0002-6233-2487; Besra, Gurdyal/0000-0002-5605-0395				Baulard AR, 2003, J BIOL CHEM, V278, P2242, DOI 10.1074/jbc.M207922200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COYLE MB, 1990, CLIN MICROBIOL REV, V3, P227, DOI 10.1128/CMR.3.3.227-246.1990; Eggeling L, 2001, J BIOSCI BIOENG, V92, P201, DOI 10.1263/jbb.92.201; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Funke G, 1997, CLIN MICROBIOL REV, V10, P125, DOI 10.1128/CMR.10.1.125; Garton NJ, 2002, J BIOL CHEM, V277, P31722, DOI 10.1074/jbc.M203008200; Gibson KJC, 2003, BIOCHEM J, V372, P821, DOI 10.1042/BJ20030197; Gibson KJC, 2003, MICROBIOL-SGM, V149, P1437, DOI 10.1099/mic.0.26161-0; Gilleron M, 1997, J BIOL CHEM, V272, P117; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; Jakoby M, 1999, BIOTECHNOL TECH, V13, P437, DOI 10.1023/A:1008968419217; KEILHAUER C, 1993, J BACTERIOL, V175, P5595, DOI 10.1128/JB.175.17.5595-5603.1993; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Kordulakova J, 2003, J BIOL CHEM, V278, P36285, DOI 10.1074/jbc.M303639200; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; KRAMER R, 1994, FEMS MICROBIOL REV, V13, P74; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Means TK, 1999, J IMMUNOL, V163, P3920; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PITULLE C, 1992, INT J SYST BACTERIOL, V42, P337, DOI 10.1099/00207713-42-3-337; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; Puech V, 2000, MOL MICROBIOL, V35, P1026, DOI 10.1046/j.1365-2958.2000.01738.x; Salim K, 1997, APPL ENVIRON MICROB, V63, P4392, DOI 10.1128/AEM.63.11.4392-4400.1997; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SIBLEY LD, 1990, CLIN EXP IMMUNOL, V80, P141; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; Sutcliffe IC, 1995, ARCH ORAL BIOL, V40, P1119, DOI 10.1016/0003-9969(95)00086-0; VENISSE A, 1993, J BIOL CHEM, V268, P12401; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83	50	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40842	40850		10.1074/jbc.M307988200	http://dx.doi.org/10.1074/jbc.M307988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904287	hybrid			2022-12-25	WOS:000185847200053
J	Lee, MG; Pedersen, PL				Lee, MG; Pedersen, PL			Glucose metabolism in cancer - Importance of transcription factor-DNA interactions within a short segment of the proximal region of the type II hexokinase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; MITOCHONDRIAL BOUND HEXOKINASE; HEPATOMA-CELL LINE; RAT HEPATOMA; BREAST-CANCER; CYCLIC-AMP; GENE-TRANSCRIPTION; RESPONSE ELEMENTS; GLUCOKINASE GENE; BINDING ACTIVITY	A common signature of many cancers is a high glucose catabolic rate frequently dependent on the overexpression of Type II hexokinase (HKII), a mitochondrial bound enzyme that also suppresses cell death. As the tumor HKII promoter plays a significant role in HKII overexpression, studies reported here were undertaken to identify both the major regions and transcription factors involved under tumor-like conditions. Reporter gene assays following transfection of hepatoma cells with decreasing segments of the HKII promoter traced its known strength to the proximal region (- 281 to - 35). Mutational analyses showed that in this short region GC boxes 1, 2, 5, and 6, a CCAAT box, an inverted CCAAT box, and CRE are involved in promoter activation. Other studies demonstrated binding of transcription factors Sp1, Sp2, and Sp3 to GC boxes 1 and 6, Sp1 and Sp2 to GC boxes 2 and 5, NF-Y to CCAAT boxes, and CREB, ATF1, and CREM to CRE. In addition, transfection studies involving Sp1, Sp2, Sp3, CREB, and NFY ( dominant negative form) provided evidence that these proteins are promoter activators. Finally, alignment of available HK proximal promoters showed strong conservation only among HKII sequences. These findings implicate signaling pathways directed to a short segment of the proximal region of the HKII promoter as major contributors to HKII overexpression in many cancers.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.				NCI NIH HHS [CA80118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Aisenberg AC, 1961, GLYCOLYSIS RESP TUMO; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; ARORA KK, 1988, J BIOL CHEM, V263, P17422; BURK D, 1967, JNCI-J NATL CANCER I, V38, P839; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Dose J, 2002, NUCL MED COMMUN, V23, P857, DOI 10.1097/00006231-200209000-00009; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Heikkinen S, 2000, MAMM GENOME, V11, P91, DOI 10.1007/s003350010019; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Iynedjian PB, 1998, BIOCHEM J, V333, P705, DOI 10.1042/bj3330705; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHANSSON T, 1985, BIOCHEM BIOPH RES CO, V133, P608, DOI 10.1016/0006-291X(85)90948-9; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Liu WJ, 1997, ARCH BIOCHEM BIOPHYS, V346, P142, DOI 10.1006/abbi.1997.0295; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Malkki M, 1997, DIABETOLOGIA, V40, P1461, DOI 10.1007/s001250050850; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; NAKASHIMA RA, 1988, CANCER RES, V48, P913; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; PARRY DM, 1983, J BIOL CHEM, V258, P904; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; PATRONAS NJ, 1985, J NEUROSURG, V62, P816, DOI 10.3171/jns.1985.62.6.0816; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Rempel A, 1996, CANCER RES, V56, P2468; Rempel A, 1996, FEBS LETT, V385, P233, DOI 10.1016/0014-5793(96)00399-7; REMPEL A, 1994, BBA-GENE STRUCT EXPR, V1219, P660, DOI 10.1016/0167-4781(94)90225-9; Rose C, 2002, NUCL MED COMMUN, V23, P613, DOI 10.1097/00006231-200207000-00004; Rostom AY, 1999, BRIT J RADIOL, V72, P1064, DOI 10.1259/bjr.72.863.10700822; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Sebastian S, 1999, J BIOL CHEM, V274, P31700, DOI 10.1074/jbc.274.44.31700; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; SMITH DF, 1970, CANCER RES, V30, P2306; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAGNER HN, 1993, J NUCL MED, V34, pN13; WARBURG O, 1930, METABOLISM TUMORS; White JA, 1996, ARCH BIOCHEM BIOPHYS, V335, P161, DOI 10.1006/abbi.1996.0494	52	49	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41047	41058		10.1074/jbc.M307031200	http://dx.doi.org/10.1074/jbc.M307031200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893819				2022-12-25	WOS:000185847200079
J	Vassilaki, N; Mavromara, P				Vassilaki, N; Mavromara, P			Two alternative translation mechanisms are responsible for the expression of the HCV ARFP/F/Core+1 coding open reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS CORE PROTEIN; BICISTRONIC MESSENGER-RNA; HEPATITIS-C; CAP-POLY(A) SYNERGY; INITIATION; GENOME; IDENTIFICATION; REGION; GENE	HCV-1 produces a novel protein, known as ARFP, F, or core +1. This protein is encoded by an open reading frame (ORF) that overlaps the core gene in the +1 frame ( core +1 ORF). In vitro this protein is produced by a ribosomal frameshift mechanism. However, similar studies failed to detect the ARFP/F/core+1 protein in the HCV-1a ( H) isolate. To clarify this issue and to elucidate the functions of this protein, we examined the expression of the core +1 ORF by the HCV-1 and HCV-1a ( H) isolates in vivo, in transfected cells. For this purpose, we carried out luciferase (LUC) tagging experiments combined with site-directed mutagenesis studies. Our results showed that the core +1-LUC chimeric protein was efficiently produced in vivo by both isolates. More importantly, neither changes in the specific 10-A residue region of HCV-1 (codons 8 - 11), the proposed frameshift site for the production of the ARFP/F/core+1 protein in vitro, nor the alteration of the ATG start site of the HCV polyprotein to a stop codon significantly affected the in vivo expression of the core +1 ORF. Furthermore, we showed that efficient translation initiation of the core +1 ORF is mediated by internal initiation codon(s) within the core/core +1-coding sequence, located between nucleotides 583 and 606. Collectively, our data suggest the existence of an alternative translation initiation mechanism that may result in the synthesis of a shorter form of the core +1 protein in transfected cells.	Hellenic Pasteur Inst, Mol Virol Lab, Athens 11521, Greece		Mavromara, P (corresponding author), Hellenic Pasteur Inst, Mol Virol Lab, 127 Vas Sofias Ave, Athens 11521, Greece.							Borman AM, 2000, NUCLEIC ACIDS RES, V28, P4068, DOI 10.1093/nar/28.21.4068; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; Di Bisceglie AM, 2000, HEPATOLOGY, V31, P1014, DOI 10.1053/he.2000.5762; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Jayakar HR, 2002, J VIROL, V76, P8011, DOI 10.1128/JVI.76.16.8011-8018.2002; Kobayashi T, 2000, VIROLOGY, V277, P296, DOI 10.1006/viro.2000.0592; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; MURPHY FA, 1995, VIRUS TAXONOMY, P424; PAVLAKIS G N, 1990, New Biologist, V2, P20; Psaridi L, 1999, FEBS LETT, V453, P49, DOI 10.1016/S0014-5793(99)00662-6; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; Rumenapf T, 1998, J VIROL, V72, P2544; Ryabova LA, 2000, J BIOL CHEM, V275, P37278, DOI 10.1074/jbc.M004909200; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Stacey SN, 2000, J VIROL, V74, P7284, DOI 10.1128/JVI.74.16.7284-7297.2000; Varaklioti A, 2002, J BIOL CHEM, V277, P17713, DOI 10.1074/jbc.M201722200; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yamasaki K, 1999, J VIROL, V73, P8519, DOI 10.1128/JVI.73.10.8519-8526.1999; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P182, DOI 10.1046/j.1440-1746.2000.02066.x; Yueh A, 2000, GENE DEV, V14, P414	30	60	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40503	40513		10.1074/jbc.M305504200	http://dx.doi.org/10.1074/jbc.M305504200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12874283	hybrid			2022-12-25	WOS:000185847200011
J	Wing, MR; Snyder, JT; Sondek, J; Harden, TK				Wing, MR; Snyder, JT; Sondek, J; Harden, TK			Direct activation of phospholipase C-epsilon by Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-COUPLED RECEPTOR; ALPHA-SUBUNITS; P115 RHOGEF; STIMULATION; RAS; EFFECTOR; BINDING; IDENTIFICATION	Unique among the phospholipase C isozymes, the recently identified phospholipase C-epsilon (PLC-epsilon) contains an amino-terminal CDC25 domain capable of catalyzing nucleotide exchange on Ras family GTPases as well as a tandem array of Ras-associating ( RA) domains near its carboxyl terminus that are effector binding sites for activated H-Ras and Rap. To determine whether other small GTPases activate PLC-epsilon, we measured inositol phosphate accumulation in COS-7 cells expressing a broad range of GTPase-deficient mutants of Ras superfamily proteins. RhoA, RhoB, and RhoC all markedly stimulated inositol phosphate accumulation in PLC-epsilon-expressing cells. This stimulation matched or exceeded phospholipase activation promoted by co-expression of PLC-epsilon with the known regulators Ras, Galpha(12/13), or Gbeta(1)gamma(2). In contrast, little effect was observed with the other Rho family members Rac1, Rac2, Rac3, and Cdc42. Truncation of the two carboxyl-terminal RA domains caused loss of responsiveness to H-Ras but not to Rho. Truncation of PLC-epsilon to remove the CDC25 and pleckstrin homology (PH) domains also did not cause loss of responsiveness to Rho, Galpha(12/13), or Gbeta(1)gamma(2). Comparative sequence analysis of mammalian phospholipase C isozymes revealed a unique similar to65 amino acid insert within the catalytic core of PLC-epsilon not present in PLC-beta, gamma, delta, or zeta. A PLC-epsilon construct lacking this region was no longer activated by Rho or Galpha(12/13) but retained regulation by Gbetagamma and H-Ras. GTP-dependent interaction of Rho with PLC-epsilon was illustrated in pull-down experiments with GST-Rho, and this interaction was retained in the PLC-epsilon construct lacking the unique insert within the catalytic core. These results are consistent with the conclusion that Rho family GTPases directly interact with PLC-epsilon by a mechanism independent of the CDC25 or RA domains. A unique insert within the catalytic core of PLC-epsilon imparts responsiveness to Rho, which may signal downstream of Galpha(12/13) in the regulation of PLC-epsilon, because activation by both Rho and Galpha(12/13) is lost in the absence of this sequence.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Neurobiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Harden, TK (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.			Sondek, John/0000-0002-1127-8310	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM065533, R01GM057391] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65533, GM57391, GM29316] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Blake BL, 2001, J BIOL CHEM, V276, P49267, DOI 10.1074/jbc.M106565200; BLANK JL, 1992, J BIOL CHEM, V267, P23069; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BROWN HA, 1991, MOL PHARMACOL, V40, P648; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MEISENHELDER J, 1989, CELL, V57, P1099; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALDO GL, 1991, J BIOL CHEM, V266, P14217; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; WU DQ, 1992, J BIOL CHEM, V267, P1811; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	39	80	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41253	41258		10.1074/jbc.M306904200	http://dx.doi.org/10.1074/jbc.M306904200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900402	hybrid			2022-12-25	WOS:000185847200104
J	Yanow, SK; Gold, DA; Yoo, HY; Dunphy, WG				Yanow, SK; Gold, DA; Yoo, HY; Dunphy, WG			Xenopus Drf1, a regulator of Cdc7, displays checkpoint-dependent accumulation on chromatin during an S-phase arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE REGULATION; HUMAN CDC7-RELATED KINASE; PROTEIN-KINASE; REPLICATION ORIGINS; EGG EXTRACTS; FISSION YEAST; CDC7P-DBF4P KINASE; HELICASE ACTIVITY; POLYMERASE-ALPHA	We have cloned a Xenopus Dbf4-related factor named Drf1 and characterized this protein by using Xenopus egg extracts. Drf1 forms an active complex with the kinase Cdc7. However, most of the Cdc7 in egg extracts is not associated with Drf1, which raises the possibility that some or all of the remaining Cdc7 is bound to another Dbf4-related protein. Immunodepletion of Drf1 does not prevent DNA replication in egg extracts. Consistent with this observation, Cdc45 can still associate with chromatin in Drf1-depleted extracts, albeit at significantly reduced levels. Nonetheless, Drf1 displays highly regulated binding to replicating chromatin. Treatment of egg extracts with aphidicolin results in a substantial accumulation of Drf1 on chromatin. This accumulation is blocked by addition of caffeine and by immunodepletion of either ATR or Claspin. These observations suggest that the increased binding of Drf1 to aphidicolin-treated chromatin is an active process that is mediated by a caffeine-sensitive checkpoint pathway containing ATR and Claspin. Abrogation of this pathway also leads to a large increase in the binding of Cdc45 to chromatin. This increase is substantially reduced in the absence of Drf1, which suggests that regulation of Drf1 might be involved in the suppression of Cdc45 loading during replication arrest. We also provide evidence that elimination of this checkpoint causes resumed initiation of DNA replication in both Xenopus tissue culture cells and egg extracts. Taken together, these observations argue that Drf1 is regulated by an intra-S-phase checkpoint mechanism that down-regulates the loading of Cdc45 onto chromatin containing DNA replication blocks.	CALTECH, Howard Hughes Med Inst, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Dunphy, WG (corresponding author), CALTECH, Howard Hughes Med Inst, Div Biol, 216-76, Pasadena, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043974, R01GM070891] Funding Source: NIH RePORTER; PHS HHS [AY32889] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Geraghty DS, 2000, J BIOL CHEM, V275, P18011, DOI 10.1074/jbc.M909787199; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liu QH, 2000, GENE DEV, V14, P1448; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Masai H, 2000, BIOCHEM BIOPH RES CO, V275, P228, DOI 10.1006/bbrc.2000.3281; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakamura T, 2002, MOL CELL BIOL, V22, P309, DOI 10.1128/MCB.22.1.309-320.2002; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Ogino K, 2001, J BIOL CHEM, V276, P31376, DOI 10.1074/jbc.M102197200; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	56	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41083	41092		10.1074/jbc.M307144200	http://dx.doi.org/10.1074/jbc.M307144200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12897072	hybrid, Green Accepted			2022-12-25	WOS:000185847200083
J	Henderson, JN; Zhang, JY; Evans, BW; Redding, K				Henderson, JN; Zhang, JY; Evans, BW; Redding, K			Disassembly and degradation of photosystem I in an in vitro system are multievent, metal-dependent processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; CHLAMYDOMONAS-REINHARDTII; THYLAKOID MEMBRANES; CARBOXYPEPTIDASE-A; ESCHERICHIA-COLI; SERINE-PROTEASE; FTSH PROTEASE; CHLOROPLAST; IDENTIFICATION; CHLOROPHYLL	An in vitro system was created to study the process of membrane protein degradation by using photosystem I (PS1) as a model membrane protein. Purified chloroplast membranes were incubated at 30degreesC in a defined buffer along with various extracts or reagents to reconstitute the disassembly and degradation of PS1, which was monitored by a variety of techniques that probe the integrity of the PS1 complex: photo-biochemical assays, semi-native gel electrophoresis, low temperature fluorescence spectroscopy, and immunoblots using antibodies against different PS1 subunits. During a typical time course, degradation of PS1 appeared to be a multievent process, with disassembly of the complex preceding proteolysis of the subunits. The first change seen was a rapid (<5 min) decrease in PS1 photochemical activity. This was followed by a diminution of far-red fluorescence emission from the core antenna of PS1 and a slower disassembly of the PS1 chlorophyll-protein core complex, as visualized by semi-native gel electrophoresis. Surprisingly, the latter was not accompanied by a similar rate of proteolysis of the PsaA core subunit. In contrast, addition of soluble proteases caused rapid loss of immuno-detectable PS1 polypeptides and cleavage of the major PS1 polypeptides in interhelical loops. The in vitro degradation process was time- and temperature-dependent but did not require ATP, GTP, or soluble chloroplast proteins. Chelation of divalent cations by EDTA inhibited the later steps of disassembly and proteolysis, and this effect could be reversed by addition of micromolar Zn2+, with Co2+ and Ca2+ providing somewhat lower activity.	Univ Alabama, Dept Chem, Tuscaloosa, AL 35487 USA; Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA	University of Alabama System; University of Alabama Tuscaloosa; University of Alabama System; University of Alabama Tuscaloosa	Redding, K (corresponding author), Univ Alabama, Dept Chem, 120 Lloyd Hall,6th Ave, Tuscaloosa, AL 35487 USA.			Redding, Kevin/0000-0003-2819-4022	NIGMS NIH HHS [GM66345-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM066345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; ANGLETON EL, 1988, BIOCHEMISTRY-US, V27, P7413, DOI 10.1021/bi00419a036; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; Boudreaux B, 2001, J BIOL CHEM, V276, P37299, DOI 10.1074/jbc.M102327200; BREDDAM K, 1979, BIOCHEMISTRY-US, V18, P1563, DOI 10.1021/bi00575a028; BUNNING P, 1985, J INORG BIOCHEM, V24, P183, DOI 10.1016/0162-0134(85)85002-9; Caspi V, 2000, PHOTOCHEM PHOTOBIOL, V71, P441, DOI 10.1562/0031-8655(2000)071&lt;0441:OUPBDC&gt;2.0.CO;2; Choquet Y, 2000, BIOCHIMIE, V82, P615, DOI 10.1016/S0300-9084(00)00609-X; Cook M, 1997, PLANT PHYSIOL BIOCH, V35, P163; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GomezOrtiz M, 1997, FEBS LETT, V400, P336, DOI 10.1016/S0014-5793(96)01412-3; HALL DO, 1994, PHOTOSYNTHESIS, P10; Halperin T, 2001, PLANTA, V213, P614, DOI 10.1007/s004250100527; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Itzhaki H, 1998, J BIOL CHEM, V273, P7094, DOI 10.1074/jbc.273.12.7094; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LARSEN KS, 1991, BIOCHEMISTRY-US, V30, P2613, DOI 10.1021/bi00224a007; Lensch M, 2001, J BIOL CHEM, V276, P33645, DOI 10.1074/jbc.M100506200; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; Majeran W, 2000, PLANT CELL, V12, P137; Majeran W, 2001, PLANT PHYSIOL, V126, P421, DOI 10.1104/pp.126.1.421; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Murakami A, 1997, PHOTOSYNTH RES, V53, P141, DOI 10.1023/A:1005818317797; Ostersetzer O, 1997, PLANT CELL, V9, P957, DOI 10.1105/tpc.9.6.957; Ostersetzer O, 1996, EUR J BIOCHEM, V236, P932, DOI 10.1111/j.1432-1033.1996.00932.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; Rivett AJ, 1990, CURR OPIN CELL BIOL, V2, P1143, DOI 10.1016/0955-0674(90)90168-E; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; ROCHE RS, 1978, CRC CR REV BIOCH MOL, V5, P1; Rufenacht A, 2000, PHOTOSYNTH RES, V63, P249, DOI 10.1023/A:1006472325830; Spetea C, 1999, P NATL ACAD SCI USA, V96, P6547, DOI 10.1073/pnas.96.11.6547; STOECKER W, 1988, Biochemistry, V27, P5026, DOI 10.1021/bi00414a012; THORNBER JP, 1967, BIOCHEMISTRY-US, V6, P391, DOI 10.1021/bi00854a004; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; Vekrellis K, 2000, J NEUROSCI, V20, P1657; WARREN PV, 1990, BIOCHEMISTRY-US, V29, P6545, DOI 10.1021/bi00480a001; WILEY HS, 1985, CURR TOP MEMBR TRANS, V24, P369; ZISAPEL N, 1973, BIOCHEM BIOPH RES CO, V53, P722, DOI 10.1016/0006-291X(73)90153-8	45	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39978	39986		10.1074/jbc.M304299200	http://dx.doi.org/10.1074/jbc.M304299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885783	hybrid			2022-12-25	WOS:000185713800086
J	Koni, PA; Khanna, R; Chang, MC; Tang, MD; Kaczmarek, LK; Schlichter, LC; Flavell, RA				Koni, PA; Khanna, R; Chang, MC; Tang, MD; Kaczmarek, LK; Schlichter, LC; Flavell, RA			Compensatory anion currents in Kv1.3 channel-deficient thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LYMPHOCYTES-T; FLOW-CYTOMETRIC DETECTION; GATED K+ CHANNELS; POTASSIUM CHANNELS; CHLORIDE CHANNEL; PHOSPHATIDYLSERINE EXPRESSION; TYROSINE PHOSPHORYLATION; SMALL-CONDUCTANCE; VOLUME REGULATION; CELL DEVELOPMENT	Kv1.3 is a voltage-gated potassium channel with roles in human T cell activation/proliferation, cell-mediated cytotoxicity, and volume regulation and is thus a target for therapeutic control of T cell responses. Kv1.3 is also present in some mouse thymocyte subsets and splenocytes, but its role in the mouse is less well understood. We report the generation and characterization of Kv1.3-deficient (Kv1.3(-/-)) mice. In contrast to wild-type cells, the majority of Kv1.3(-/-) thymocytes had no detectable voltage-dependent potassium current, although RNA and protein for several potassium channel subunits were found in the thymocyte population. Surprisingly, the level of chloride current in the Kv1.3(-/-) thymocytes was increased approximately 50-fold over that in wildtype cells. There were no abnormalities in lymphocyte types or absolute numbers in thymus, spleen, and lymph nodes and no obvious defect in thymocyte apoptosis or T cell proliferation in the Kv1.3(-/-) animals. The compensatory effects of the enhanced chloride current may account for the apparent lack of immune system defects in Kv1.3(-/-) mice.	Univ Toronto, Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; RIKEN, Res Ctr Allergy & Immunol, Kanagawa 2300045, Japan; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; RIKEN; University of Toronto	Flavell, RA (corresponding author), Univ Toronto, Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada.	richard.flavell@yale.edu	Chang, Martin/J-2329-2016; Koni, Pandelakis/A-3349-2008	Khanna, Rajesh/0000-0002-9066-2969; Koni, Pandelakis/0000-0002-0892-4764	NIDCD NIH HHS [DC-01919] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001919] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298; Castedo M, 1996, J IMMUNOL, V157, P512; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; Chung I, 1997, AM J PHYSIOL-CELL PH, V273, pC622, DOI 10.1152/ajpcell.1997.273.2.C622; Chung I, 1997, J MEMBRANE BIOL, V156, P73, DOI 10.1007/s002329900189; Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296; Deas O, 1998, J IMMUNOL, V161, P3375; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P379, DOI 10.1085/jgp.89.3.379; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DECOURSEY TE, 1999, INFLAMMATION BASIC P, P639; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; FREEDMAN BD, 1995, J BIOL CHEM, V270, P22406, DOI 10.1074/jbc.270.38.22406; Furst J, 2000, CELL PHYSIOL BIOCHEM, V10, P329, DOI 10.1159/000016374; Garcia M L, 1997, Adv Pharmacol, V39, P425, DOI 10.1016/S1054-3589(08)60078-2; GRISSMER S, 1990, J IMMUNOL, V145, P2105; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Koo GC, 1997, J IMMUNOL, V158, P5120; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; KUES WA, 1992, EUR J NEUROSCI, V4, P1296, DOI 10.1111/j.1460-9568.1992.tb00155.x; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEWIS RS, 1988, SCIENCE, V239, P771, DOI 10.1126/science.2448877; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; MCKINNON D, 1986, J EXP MED, V164, P1846, DOI 10.1084/jem.164.6.1846; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; PAHAPILL PA, 1992, J MEMBRANE BIOL, V125, P171; PAHAPILL PA, 1992, J PHYSIOL-LONDON, V445, P407, DOI 10.1113/jphysiol.1992.sp018931; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; SCHLICHTER L, 1986, P NATL ACAD SCI USA, V83, P451, DOI 10.1073/pnas.83.2.451; SCHLICHTER L, 1986, P NATL ACAD SCI USA, V83, P5625, DOI 10.1073/pnas.83.15.5625; Schlichter LC, 1996, GLIA, V17, P225, DOI 10.1002/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#; SCHLICHTER LC, 1994, EXP CELL RES, V215, P211, DOI 10.1006/excr.1994.1334; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SCHUMACHER PA, 1995, J MEMBRANE BIOL, V145, P217; SIDELL N, 1986, J IMMUNOL, V137, P1650; Strange K, 1998, J GEN PHYSIOL, V111, P617, DOI 10.1085/jgp.111.5.617; Szabo I, 1997, PFLUG ARCH EUR J PHY, V433, P626, DOI 10.1007/s004240050323; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Verheugen JAH, 1997, CELL CALCIUM, V21, P1, DOI 10.1016/S0143-4160(97)90092-0; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Wickenden AD, 1999, CELL PHYSIOL BIOCHEM, V9, P11, DOI 10.1159/000016299; Xiong H, 1999, J MEMBRANE BIOL, V167, P215, DOI 10.1007/s002329900485; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	60	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39443	39451		10.1074/jbc.M304879200	http://dx.doi.org/10.1074/jbc.M304879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878608	hybrid			2022-12-25	WOS:000185713800022
J	Allen, S; Lu, H; Thornton, D; Tokatlidis, K				Allen, S; Lu, H; Thornton, D; Tokatlidis, K			Juxtaposition of the two distal CX3C motifs via intrachain disulfide bonding is essential for the folding of Tim10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; DEAFNESS DYSTONIA SYNDROME; YEAST ADP/ATP CARRIER; ADP ATP CARRIER; PROTEIN IMPORT; INTERMEMBRANE SPACE; CYSTEINE RESIDUES; TOM COMPLEX; TRANSLOCATION; COMPONENT	The TIM10 complex, composed of the homologous proteins Tim10 and Tim9, chaperones hydrophobic proteins inserted at the mitochondrial inner membrane. A salient feature of the TIM10 complex subunits is their conserved "twin CX3C" motif. Systematic mutational analysis of all cysteines of Tim10 showed that their underlying molecular defect is impaired folding (demonstrated by circular dichroism, aberrant homo-oligomer formation, and thiol trapping assays). As a result of defective folding, clear functional consequences were manifested in (i) complex formation with Tim9, (ii) chaperone activity, and (iii) import into tim9ts mitochondria lacking both endogenous Tim9 and Tim10. The organization of the four cysteines in intrachain disulfides was determined by trypsin digestion and mass spectrometry. The two distal CX3C motifs are juxtaposed in the folded structure and disulfide-bonded to each other rather than within each other, with an inner cysteine pair connecting Cys(44) with Cys(61) and an outer pair between Cys(40) and Cys(65). These cysteine pairs are not equally important for folding and assembly; mutations of the inner Cys are severely affected and form wrong, non-native disulfides, in contrast to mutations of the outer Cys that can still maintain the native inner disulfide pair and display weaker functional defects. Taken together these data reveal this specific intramolecular disulfide bonding as the crucial mechanism for Tim10 folding and show that the inner cysteine pair has a more prominent role in this process.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Crete, Dept Chem, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	University of Manchester; University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Tokatlidis, K (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Lu, Hui/AAB-5476-2021	Thornton, David/0000-0001-7148-1970; Lu, Hui/0000-0002-7029-2681; Tokatlidis, Kostas/0000-0001-6295-8183; Allen, Scott/0000-0003-4418-7375	MRC [G0000153] Funding Source: UKRI; Medical Research Council [G0000153] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Bauer MF, 2002, INT REV NEUROBIOL, V53, P57; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Carugo O, 2001, PROTEIN ENG, V14, P639, DOI 10.1093/protein/14.9.639; Cemazar M, 2003, P NATL ACAD SCI USA, V100, P5754, DOI 10.1073/pnas.2225470100; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Dyall SD, 2003, J BIOL CHEM, V278, P26757, DOI 10.1074/jbc.M302700200; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1987, J BIOL CHEM, V262, P14851; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Ryan KR, 1998, MOL CELL BIOL, V18, P178, DOI 10.1128/MCB.18.1.178; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; Tokatlidis K, 2000, BIOCHEM SOC T, V28, P495, DOI 10.1042/0300-5127:0280495; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951	40	74	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38505	38513		10.1074/jbc.M306027200	http://dx.doi.org/10.1074/jbc.M306027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882976	hybrid			2022-12-25	WOS:000185575100052
J	Filippin, L; Magalhaes, PJ; Di Benedetto, G; Colella, M; Pozzan, T				Filippin, L; Magalhaes, PJ; Di Benedetto, G; Colella, M; Pozzan, T			Stable interactions between mitochondria and endoplasmic reticulum allow rapid accumulation of calcium in a subpopulation of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEINS; RAT-LIVER; LIVING CELLS; REDOX STATE; CA2+; OSCILLATIONS; TRANSIENTS; SECRETION; RESPONSES; AEQUORIN	To better understand the functional role of the mitochondrial network in shaping the Ca2+ signals in living cells, we took advantage both of the newest genetically engineered green fluorescent protein-based Ca2+ sensors ("Cameleons," "Camgaroos," and "Pericams") and of the classical Ca2+-sensitive photoprotein aequorin, all targeted to the mitochondrial matrix. The properties of the green fluorescent protein-based probes in terms of subcellular localization, photosensitivity, and Ca2+ affinity have been analyzed in detail. It is concluded that the ratiometric pericam is, at present, the most reliable mitochondrial Ca2+ probe for single cell studies, although this probe too is not devoid of problems. The results obtained with ratiometric pericam in single cells, combined with those obtained at the population level with aequorin, provide strong evidence demonstrating that the close vicinity of mitochondria to the Ca2+ release channels (and thus responsible for the fast uptake of Ca2+ by mitochondria upon receptor activation) are highly stable in time, suggesting the existence of specific interactions between mitochondria and the endoplasmic reticulum.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Univ Bari, Dept Gen & Environm Physiol, I-70165 Bari, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Universita degli Studi di Bari Aldo Moro; Veneto Institute Molecular Medicine	Filippin, L (corresponding author), Univ Padua, Dept Biomed Sci, Viale G Colombo 3, I-35121 Padua, Italy.		Colella, Matilde/G-9246-2011; Di Benedetto, Giulietta/L-9842-2019	Colella, Matilde/0000-0002-9584-7030; Di Benedetto, Giulietta/0000-0002-1489-3896; Filippin, Luisa/0000-0001-7690-9147	Telethon [1226] Funding Source: Medline	Telethon(Fondazione Telethon)		ANGERMULLER S, 1983, J HISTOCHEM CYTOCHEM, V31, P230, DOI 10.1177/31.1A_Suppl.6186726; Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; BECKER PL, 1987, AM J PHYSIOL, V253, pC613, DOI 10.1152/ajpcell.1987.253.4.C613; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; DUNN KW, 1994, FASEB J, V8, P573, DOI 10.1096/fasebj.8.9.8005385; FLAKS B, 1976, CANCER RES, V36, P2194; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; KIMBERG DV, 1968, J CELL BIOL, V37, P63, DOI 10.1083/jcb.37.1.63; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; MORRE DJ, 1971, PROTOPLASMA, V73, P43, DOI 10.1007/BF01286410; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Pitter JG, 2002, CELL CALCIUM, V31, P97, DOI 10.1054/ceca.2001.0264; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robert V, 2001, EMBO J, V20, P4998, DOI 10.1093/emboj/20.17.4998; Scheenen WJJM, 1996, CHEM BIOL, V3, P765, DOI 10.1016/S1074-5521(96)90253-7; Szabadkai G, 2001, PFLUG ARCH EUR J PHY, V441, P678, DOI 10.1007/s004240000466; Trollinger DR, 2000, BIOPHYS J, V79, P39, DOI 10.1016/S0006-3495(00)76272-2; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	37	188	199	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39224	39234		10.1074/jbc.M302301200	http://dx.doi.org/10.1074/jbc.M302301200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874292	hybrid			2022-12-25	WOS:000185575100137
J	Rizhsky, L; Liang, HJ; Mittler, R				Rizhsky, L; Liang, HJ; Mittler, R			The water-water cycle is essential for chloroplast protection in the absence of stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ASCORBATE PEROXIDASE; CU/ZN-SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; GENE-EXPRESSION; PHOTOOXIDATIVE STRESS; HIGH LIGHT; LEAVES; ARABIDOPSIS; PLANTS	Maintaining electron flow through the photosynthetic apparatus, even in the absence of a sufficient amount of NADP(+) as an electron acceptor, is essential for chloroplast protection from photooxidative stress. At least two different pathways are thought to participate in this process, i.e. cyclic electron flow and the water-water cycle. Although the function of the water-water cycle was inferred from a number of biochemical and physiological studies, genetic evidence for the function of this cycle is very limited. Here we show that knockdown Arabidopsis plants with suppressed expression of the key water-water cycle enzyme, thylakoid-attached copper/zinc superoxide dismutase (KD-SOD), are suppressed in their growth and development. Chloroplast size, chlorophyll content, and photosynthetic activity were also reduced in KD-SOD plants. Microarray analysis of KD-SOD plants, grown under controlled conditions, revealed changes in transcript expression consistent with an acclimation response to light stress. Although a number of transcripts involved in the defense of plants from oxidative stress were induced in KD-SOD plants, and seedlings of KD-SOD plants were more tolerant to oxidative stress, these mechanisms were unable to compensate for the suppression of the water-water cycle in mature leaves. Thus, the localization of copper/zinc superoxide dismutase at the vicinity of photosystem I may be essential for its function. Our studies provide genetic evidence for the importance of the water-water cycle in protecting the photosynthetic apparatus of higher plants from photooxidative damage.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Iowa State Univ, Inst Plant Sci, Dept Bot, Ames, IA 50011 USA	Technion Israel Institute of Technology; Iowa State University	Mittler, R (corresponding author), Univ Nevada, Dept Biochem, Reno, NV 89557 USA.		Rizshsky, Ludmila/D-3133-2011; Mittler, Ron/ABE-6496-2020	Rizhsky, Ludmila/0000-0003-2323-8225				Aluru MR, 2001, PLANT PHYSIOL, V127, P67, DOI 10.1104/pp.127.1.67; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Bariola PA, 1999, PLANT PHYSIOL, V119, P331, DOI 10.1104/pp.119.1.331; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Choi SM, 2002, PLANTA, V216, P315, DOI 10.1007/s00425-002-0852-z; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Fryer MJ, 2002, J EXP BOT, V53, P1249, DOI 10.1093/jexbot/53.372.1249; GUPTA AS, 1993, P NATL ACAD SCI USA, V90, P1629, DOI 10.1073/pnas.90.4.1629; Heber U, 2001, J EXP BOT, V52, P1999, DOI 10.1093/jexbot/52.363.1999; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V33, P65, DOI 10.1016/0003-9861(51)90082-3; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962; Mittler R, 1997, J CELL SCI, V110, P1333; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Mullineaux P, 2002, CURR OPIN PLANT BIOL, V5, P43, DOI 10.1016/S1369-5266(01)00226-6; Pnueli L, 2003, PLANT J, V34, P187, DOI 10.1046/j.1365-313X.2003.01715.x; Rodriguez AA, 2002, PLANT PHYSIOL, V129, P1627, DOI 10.1104/pp.001222; Rossel JB, 2002, PLANT PHYSIOL, V130, P1109, DOI 10.1104/pp.005595; Vranova E, 2002, P NATL ACAD SCI USA, V99, P10870, DOI 10.1073/pnas.152337999; Yabuta Y, 2002, PLANT J, V32, P915, DOI 10.1046/j.1365-313X.2002.01476.x	24	175	196	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38921	38925		10.1074/jbc.M304987200	http://dx.doi.org/10.1074/jbc.M304987200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885779	hybrid, Green Published			2022-12-25	WOS:000185575100101
J	Frank, C; Gonzalez, MM; Oinonen, C; Dunlop, TW; Carlberg, C				Frank, C; Gonzalez, MM; Oinonen, C; Dunlop, TW; Carlberg, C			Characterization of DNA complexes formed by the nuclear receptor constitutive androstane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; RESPONSIVE ENHANCER MODULE; THYROID-HORMONE; VITAMIN-D-3 RECEPTOR; ACTIVATION; MONOMERS; GENE; IDENTIFICATION; RECOGNITION; SUPERFAMILY	The nuclear receptor constitutive androstane receptor (CAR) acts as a xenobiotic sensor and regulates the expression of enzymes, such as several cytochromes P450s and the UDP-glucuronosyltransferase (UGT) type 1A1. CAR binds as a heterodimer with the retinoid X receptor (RXR) to specific DNA sites, called response elements (REs). Clusters of CAR REs, referred to as phenobarbital response enhancer modules (PBREMs), have been identified in several CAR target genes. In this study we confirm that REs formed by direct repeats of two AGTTCA hexamers with 4 spacing nucleotides are optimal for the binding of CAR-RXR heterodimers. In addition, we found that the heterodimers also form complexes on everted repeat-type arrangements with 8 spacing nucleotides. We also observed that CAR is able to bind DNA as a monomer and to interact in this form with different coregulators even in the presence of RXR. Systematic variation of the nucleotides 5'-flanking to both AGTTCA hexamers showed that the dinucleotide sequence modulates the DNA complex formation of CAR monomers and CAR-RXR heterodimer by a factor of up to 20. The highest preference was found for the sequence AG and lowest for CC. The increased DNA affinity of CAR is mediated by the positively charged arginines 90 and 91 located in the carboxyl-terminal extension of the DNA-binding domain of the receptor. Furthermore, we show that one of the three CAR REs of the human UGT1A1 PBREM is exclusively bound by CAR monomers and this is regulated by ligands that bind to this nuclear receptor. This points to a physiological role for CAR monomers. Therefore, both CAR-RXR heterodimers and CAR monomers can contribute to the gene activating function of PBREMs in CAR target genes.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				Auwerx J, 1999, CELL, V97, P161; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Carlberg C, 1999, BIOFACTORS, V10, P91, DOI 10.1002/biof.5520100202; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRONEMEYER H, 1995, NATURE, V375, P190, DOI 10.1038/375190a0; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Quack M, 2002, J CELL BIOCHEM, V86, P601, DOI 10.1002/jcb.10247; Quack M, 2001, BIOCHEM J, V360, P387, DOI 10.1042/0264-6021:3600387; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; Sierk ML, 2001, BIOCHEMISTRY-US, V40, P12833, DOI 10.1021/bi011086r; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2	42	51	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43299	43310		10.1074/jbc.M305186200	http://dx.doi.org/10.1074/jbc.M305186200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12896978	hybrid			2022-12-25	WOS:000186157000073
J	Huang, FT; Jiang, XJ; Sorkin, A				Huang, FT; Jiang, XJ; Sorkin, A			Tyrosine phosphorylation of the beta 2 subunit of clathrin adaptor complex AP-2 reveals the role of a di-leucine motif in the epidermal growth factor receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED ENDOCYTOSIS; SORTING SIGNALS; STRUCTURAL EXPLANATION; EGF RECEPTORS; MU-2 SUBUNIT; BINDING; INTERNALIZATION; IDENTIFICATION; RECOGNITION; RESIDUES	Tyrosine phosphorylation of the beta2 subunit of clathrin adaptor complex AP-2 was detected in three types of cells treated with epidermal growth factor (EGF). The tyrosine phosphorylation was observed during recruitment of EGF receptors into coated pits at 4 degreesC and reached maximum at 37 degreesC at post-recruitment stages of endocytosis. An inhibitor of EGF receptor kinase completely abolished this phosphorylation in all cell types, whereas the inhibitor of Src family kinases partially inhibited beta2 phosphorylation in A-431 cells but not in HeLa cells. By using beta2 subunit tagged with yellow fluorescent protein that is effectively assembled into AP-2 complex, the major phosphorylation site of beta2 was mapped to Tyr-6. Analysis of cells expressing dominant-interfering mutant beta2 subunit of AP-2 suggested that beta2 phosphorylation is partially mediated by the receptor interaction with the mu2 subunit. Mutation of leucine residues 1010 and 1011 motif in the EGF receptor resulted in the severe inhibition of beta2 tyrosine phosphorylation. From these data, we propose that interactions of the EGF receptor with AP-2 mediated by the receptor (974)YRAL and di-leucine motifs may contribute to beta2 tyrosine phosphorylation. Surprisingly, mutation of the Leu-1010/Leu-1011 motif resulted in impaired degradation of EGF receptors, suggesting the role of this motif in lysosomal targeting of the receptor.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.	alexander.sorkin@uchsc.edu		Sorkin, Alexander/0000-0002-4446-1920	NCI NIH HHS [CA089151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLE S, 1989, J BIOL CHEM, V264, P20089; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Morrison P, 1996, BIOCHEMISTRY-US, V35, P14618, DOI 10.1021/bi961630+; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; Sorkina T, 1999, J CELL SCI, V112, P317; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635	37	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43411	43417		10.1074/jbc.M306072200	http://dx.doi.org/10.1074/jbc.M306072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12900408	hybrid			2022-12-25	WOS:000186157000085
J	Nyabi, O; Bentahir, M; Horre, K; Herreman, A; Gottardi-Littell, N; Van Broeckhoven, C; Merchiers, P; Spittaels, K; Annaert, W; De Strooper, B				Nyabi, O; Bentahir, M; Horre, K; Herreman, A; Gottardi-Littell, N; Van Broeckhoven, C; Merchiers, P; Spittaels, K; Annaert, W; De Strooper, B			Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and nicastrin glycosylation but remain catalytically inactive in the absence of wild type presenilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; FAMILIAL ALZHEIMERS-DISEASE; BETA-PEPTIDE PRODUCTION; INTRACELLULAR DOMAIN; A-BETA; INTRAMEMBRANE PROTEOLYSIS; TRANSMEMBRANE ASPARTATES; MUTANT PRESENILIN-1; CELL-SURFACE	The Presenilins are part of the gamma-secretase complex that is involved in the regulated intramembrane proteolysis of amyloid precursor protein and other type I integral membrane proteins. Nicastrin, Pen-2, and Aph1 are the other proteins of this complex. The Presenilins probably contribute the catalytic activity to the protease complex. However, several investigators reported normal Abeta-peptide generation in cells expressing Presenilins mutated at the putative catalytic site residue Asp-257, contradicting this hypothesis. Because endogenously expressed wild type Presenilin could contribute to residual gamma-secretase activity in these experiments, we have reinvestigated the problem by expressing mutated Presenilins in a Presenilin-negative cell line. We confirm that Presenilins with mutated Asp residues are catalytically inactive. Unexpectedly, these mutated Presenilins are still partially processed into amino-and carboxyl-terminal fragments by a "Presenilinase"-like activity. They are also able to rescue Pen-2 expression and Nicastrin glycosylation in Presenilin-negative cells and become incorporated into large similar to 440-kDa complexes as assessed by blue native gel electrophoresis. Our study demonstrates that the catalytic activity of Presenilin and its other functions in the generation, stabilization, and transport of the gamma-secretase complex can be separated and extends the concept that Presenilins are multifunctional proteins.	Flanders Interuniv Inst Biotechnol VIB4, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium; Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60135 USA; Flanders Interuniv Inst Biotechnol VIB, Dept Mol Genet, B-2610 Antwerp, Belgium; Univ Antwerp, UIA, B-2610 Antwerp, Belgium; Galapagos Genom NV, B-2800 Mechelen, Belgium	KU Leuven; Northwestern University; Feinberg School of Medicine; Flanders Institute for Biotechnology (VIB); University of Antwerp; Galapagos NV	De Strooper, B (corresponding author), Herestr 49, B-3000 Louvain, Belgium.	Bart.destrooper@med.kuleuven.ac.be	de+Strooper, Bart/Z-1638-2019; Van Broeckhoven, Christine/M-7853-2019; Van Broeckhoven, Christine/G-8362-2017; De Strooper, Bart/F-6507-2012	Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665; De Strooper, Bart/0000-0001-5455-5819; Horre, Katrien/0000-0002-6801-3137				Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Campbell WA, 2002, BIOCHEMISTRY-US, V41, P3372, DOI 10.1021/bi015810h; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Jonghe C, 1999, HUM MOL GENET, V8, P1529, DOI 10.1093/hmg/8.8.1529; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Michiels F, 2002, NAT BIOTECHNOL, V20, P1154, DOI 10.1038/nbt746; Morihara T, 2000, MOL BRAIN RES, V85, P85, DOI 10.1016/S0169-328X(00)00229-1; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nyabi O, 2002, NAT CELL BIOL, V4, pE164, DOI 10.1038/ncb0702-e164a; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yuan H, 1999, J NEUROSCI METH, V88, P45, DOI 10.1016/S0165-0270(99)00011-4	73	92	93	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43430	43436		10.1074/jbc.M306957200	http://dx.doi.org/10.1074/jbc.M306957200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12885769	hybrid			2022-12-25	WOS:000186157000087
J	Egawa, T; Yoshioka, S; Takahashi, S; Hori, H; Nagano, S; Shimada, H; Ishimori, K; Morishima, I; Suematsu, M; Ishimura, Y				Egawa, T; Yoshioka, S; Takahashi, S; Hori, H; Nagano, S; Shimada, H; Ishimori, K; Morishima, I; Suematsu, M; Ishimura, Y			Kinetic and spectroscopic characterization of a hydroperoxy compound in the reaction of native myoglobin with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HORSERADISH-PEROXIDASE; CATALASE-PEROXIDASE; I FORMATION; MYCOBACTERIUM-TUBERCULOSIS; GEMINATE RECOMBINATION; LIGNIN PEROXIDASE; CRYSTAL-STRUCTURE; DISTAL HISTIDINE; LOW-TEMPERATURE	The reaction of metmyoglobin with H2O2 was investigated in a pH range between 8.5 and 6.0 with the aid of stopped flow-rapid scan and rapid freezing-EPR techniques. Singular value decomposition analyses of the stopped flow data at pH 8.5 revealed that a spectral species previously unknown accumulated during the reaction and exhibited a Soret absorption maximum at greater than or equal to423 nm. In the EPR experiments, the new species exhibited a set of g values at 2.32, 2.19, and 1.94, indicating that the species was assignable to a ferric hydroperoxy (Fe(III)[O-O-H](-)) compound. In contrast, the hydroperoxy compound scarcely accumulated in the reaction at pH 6.0, and the dominant intermediate species accumulated was compound I, which was derived from the oxygen-oxygen bond cleavage of the hydroperoxy compound. The accumulated amount of the hydroperoxy compound relative to compound I showed a pH dependence with an apparent pK(a) (pK(a)(app)) from 6.95 to 7.27 depending on the metmyoglobins examined. This variation in pK(a)(app) paralleled that in pK(a) of the acid-alkaline transition (pK(a)(AB)) of metmyoglobins, suggesting that the accumulation of hydroperoxy compound is controlled by the distal histidine. We propose that the H2O2 activation by metmyoglobin is promoted at the acidic condition due to the imidazolium form of the distal histidine, and we further propose that the controlled protonation state of the distal histidine is important for the facile O-O bond cleavage in heme peroxidases.	Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Osaka 5608531, Japan	Keio University; Kyoto University; Osaka University	Egawa, T (corresponding author), Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Ishimori, Koichiro/S-1247-2016; Suematsu, Makoto/I-8135-2013; Suematsu, Makoto/O-5762-2018; Ishimori, Koichiro/AAQ-4434-2021	Ishimori, Koichiro/0000-0002-5868-0462; Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336; Ishimori, Koichiro/0000-0002-5868-0462				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; Agner K., 1941, ACTA PHYSIOL SCAND, V2, P1; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, V21, P40; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, V21, P55; BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BLEE E, 1990, J BIOL CHEM, V265, P12887; Brittain T, 1997, BIOCHEM J, V326, P109, DOI 10.1042/bj3260109; CUTNELL JD, 1981, J AM CHEM SOC, V103, P3567, DOI 10.1021/ja00402a053; Davydov R, 1999, J AM CHEM SOC, V121, P10654, DOI 10.1021/ja9918829; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; Denisov IG, 2002, J BIOL CHEM, V277, P42706, DOI 10.1074/jbc.M207949200; DEROPP JS, 1991, J BIOL CHEM, V266, P15001; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; ERMAN JE, 1992, J AM CHEM SOC, V114, P6592, DOI 10.1021/ja00042a068; Filizola M, 2000, J AM CHEM SOC, V122, P18, DOI 10.1021/ja992793z; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GASYNA Z, 1979, FEBS LETT, V106, P213, DOI 10.1016/0014-5793(79)80730-9; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; Golub G., 1965, SIAM J NUMER ANAL, V2, P205, DOI DOI 10.1137/0702016; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HEWSON WD, 1979, PORPHYRINS, V7, P295; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; HUG SJ, 1990, BIOCHEMISTRY-US, V29, P1475, DOI 10.1021/bi00458a019; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; LAMBRIGHT DG, 1993, BIOCHEMISTRY-US, V32, P10116, DOI 10.1021/bi00089a030; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; Matsui T, 1997, J BIOL CHEM, V272, P32735, DOI 10.1074/jbc.272.52.32735; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; NAGANO S, 1985, THESIS KYOTO U KYOTO; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; Ozaki S, 1998, J AM CHEM SOC, V120, P8020, DOI 10.1021/ja9714696; Palamakumbura AH, 1999, BIOCHEMISTRY-US, V38, P15647, DOI 10.1021/bi991497w; Palamakumbura AH, 1999, BIOCHEMISTRY-US, V38, P15653, DOI 10.1021/bi991498o; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; SATTERLEE JD, 1991, BIOCHEMISTRY-US, V30, P4398, DOI 10.1021/bi00232a005; Savenkova MI, 1996, J BIOL CHEM, V271, P24598, DOI 10.1074/jbc.271.40.24598; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SYMONS MCR, 1978, BIOCHIM BIOPHYS ACTA, V535, P241, DOI 10.1016/0005-2795(78)90090-9; Szabo Z. G., 1969, COMPREHENSIVE CHEM K, P1; TAJIMA K, 1989, INORG CHIM ACTA, V163, P115, DOI 10.1016/S0020-1693(00)87150-9; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9791, DOI 10.1021/bi9706172; Tanaka M, 2003, BIOPHYS J, V84, P1998, DOI 10.1016/S0006-3495(03)75008-5; THANABAL V, 1987, J AM CHEM SOC, V109, P7516, DOI 10.1021/ja00258a043; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; WALDA KN, 1994, BIOCHEMISTRY-US, V33, P2198, DOI 10.1021/bi00174a029; Wirstam M, 1999, J AM CHEM SOC, V121, P10178, DOI 10.1021/ja991997c; Woon DE, 1998, J PHYS CHEM A, V102, P10380, DOI 10.1021/jp9829896; YONETANI T, 1967, J BIOL CHEM, V242, P1974; Yonetani T., 1976, ENZYMES, P345	61	36	36	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41597	41606		10.1074/jbc.M210383200	http://dx.doi.org/10.1074/jbc.M210383200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902339	hybrid			2022-12-25	WOS:000185989500007
J	Fuglsang, AT; Borch, J; Bych, K; Jahn, TP; Roepstorff, P; Palmgren, MG				Fuglsang, AT; Borch, J; Bych, K; Jahn, TP; Roepstorff, P; Palmgren, MG			The binding site for regulatory 14-3-3 protein in plant plasma membrane H+-ATPase - Involvement of a region promoting phosphorylation-independent interaction in addition to the phosphorylation-dependent C-terminal end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3 PROTEINS; EXOENZYME-S; PSEUDOMONAS-AERUGINOSA; NITRATE REDUCTASE; BLUE-LIGHT; FUSICOCCIN; YEAST; COMPLEX; COMPLEMENTATION; RESIDUES	14-3-3 proteins constitute a family of well conserved proteins interacting with a large number of phosphorylated binding partners in eukaryotic cells. The plant plasma membrane H+-ATPase is an unusual target in that a unique phosphothreonine motif ((946)YpTV, where pT represents phosphothreonine) in the extreme C-terminal end of the H+-ATPase interacts with the binding cleft of 14-3-3 protein (Wurtele, M., Jelich-Ottmann, C., Wittinghofer, A., and Oecking, C. (2003) EMBO J. 22, 987-994). We report binding of 14-3-3 protein to a non-phosphorylated peptide representing the 34 C-terminal residues of the Arabidopsis plasma membrane H+-ATPase isoform 2 (AHA2). Following site-directed mutagenesis within the 45 C-terminal residues of AHA2, we conclude that, in addition to the 946YpTV motif, a number of residues located further upstream are required for phosphorylation-independent binding of 14-3-3. Among these, Thr-924 is important for interaction with 14-3-3 protein even when Thr-947 is phosphorylated. We suggest that the role of phosphorylation, which is accentuated by fusicoccin, is to stabilize protein-protein interaction between 14-3-3 protein and several residues of the H+-ATPase C-terminal domain.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Physiol & Anat Lab, DK-1871 Frederiksberg C, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; Royal Vet & Agr Univ, Plant Nutr Lab, Dept Agr Sci, DK-1871 Frederiksberg C, Denmark; Univ Paris 06, CNRS, F-75252 Paris, France	University of Copenhagen; University of Southern Denmark; University of Copenhagen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Palmgren, MG (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Physiol & Anat Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.		Palmgren, Michael/A-9808-2013; fuglsang, anja thoe t/E-1683-2012; Fuglsang, Anja Thoe/A-6733-2015	Palmgren, Michael/0000-0002-9982-6114; fuglsang, anja thoe t/0000-0003-1153-8394; Fuglsang, Anja Thoe/0000-0003-1153-8394				Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Bachmann M, 1996, FEBS LETT, V398, P26, DOI 10.1016/S0014-5793(96)01188-X; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; Henriksson ML, 2000, BIOCHEM J, V349, P697, DOI 10.1042/bj3490697; Henriksson ML, 2002, EUR J BIOCHEM, V269, P4921, DOI 10.1046/j.1432-1033.2002.03191.x; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; Jahn TP, 2002, J BIOL CHEM, V277, P6353, DOI 10.1074/jbc.M109637200; Jelich-Ottmann C, 2001, J BIOL CHEM, V276, P39852, DOI 10.1074/jbc.M106746200; Kinoshita T, 1999, EMBO J, V18, P5548, DOI 10.1093/emboj/18.20.5548; Kinoshita T, 2002, PLANT CELL PHYSIOL, V43, P1359, DOI 10.1093/pcp/pcf167; Kinoshita T, 2001, PLANT CELL PHYSIOL, V42, P424, DOI 10.1093/pcp/pce055; MARRE E, 1979, ANNU REV PLANT PHYS, V30, P273, DOI 10.1146/annurev.pp.30.060179.001421; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Oecking C, 1999, PLANTA, V207, P480, DOI 10.1007/s004250050507; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; PALMGREN MG, 1993, FEBS LETT, V317, P216, DOI 10.1016/0014-5793(93)81279-9; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Piotrowski M, 1998, J BIOL CHEM, V273, P30018, DOI 10.1074/jbc.273.45.30018; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Roberts MR, 2003, TRENDS PLANT SCI, V8, P218, DOI 10.1016/S1360-1385(03)00056-6; Sehnke PC, 2002, PLANT CELL, V14, pS339, DOI 10.1105/tpc.010430; Svennelid F, 1999, PLANT CELL, V11, P2379, DOI 10.1105/tpc.11.12.2379; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l	41	77	80	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42266	42272		10.1074/jbc.M306707200	http://dx.doi.org/10.1074/jbc.M306707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888557	hybrid			2022-12-25	WOS:000185989500086
J	Hemish, J; Nakaya, N; Mittal, V; Enikolopov, G				Hemish, J; Nakaya, N; Mittal, V; Enikolopov, G			Nitric oxide activates diverse signaling pathways to regulate gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; P53; PROLIFERATION; FIBROBLASTS; INHIBITION; MICROARRAY; RESPONSES; ALPHA	Nitric oxide signaling is crucial for effecting long lasting changes in cells, including gene expression, cell cycle arrest, apoptosis, and differentiation. We have determined the temporal order of gene activation induced by NO in mammalian cells and have examined the signaling pathways that mediate the action of NO. Using microarrays to study the kinetics of gene activation by NO, we have determined that NO induces three distinct waves of gene activity. The first wave is induced within 30 min of exposure to NO and represents the primary gene targets of NO. It is followed by subsequent waves of gene activity that may reflect further cascades of NO-induced gene expression. We verified our results using quantitative real time PCR and further validated our conclusions about the effects of NO by using cytokines to induce endogenous NO production. We next applied pharmacological and genetic approaches to determine the signaling pathways that are used by NO to regulate gene expression. We used inhibitors of particular signaling pathways, as well as cells from animals with a deleted p53 gene, to define groups of genes that require phosphatidylinositol 3-kinase, protein kinase C, NF-kappaB, p53, or combinations thereof for activation by NO. Our results demonstrate that NO utilizes several independent signaling pathways to induce gene expression.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Enikolopov, G (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.		Enikolopov, Grigori N/B-7771-2009; Enikolopov, Grigori/P-5731-2019	Enikolopov, Grigori N/0000-0001-8178-8917; Enikolopov, Grigori/0000-0001-8178-8917				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bandman O, 2002, ANN NY ACAD SCI, V975, P77, DOI 10.1111/j.1749-6632.2002.tb05943.x; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Cappola TP, 2003, PHYSIOL GENOMICS, V14, P25, DOI 10.1152/physiolgenomics.00156.2002; Cardozo AK, 2001, J BIOL CHEM, V276, P48879, DOI 10.1074/jbc.M108658200; Demple B, 2002, MOL CELL BIOCHEM, V234, P11, DOI 10.1023/A:1015933216079; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GARG UC, 1990, BIOCHEM BIOPH RES CO, V171, P474, DOI 10.1016/0006-291X(90)91417-Q; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Nathan C, 2003, J CLIN INVEST, V111, P769, DOI 10.1172/JCI200318174; NESBITT JA, 1976, J BIOL CHEM, V251, P2344; Peunova N, 2001, J NEUROSCI, V21, P8809, DOI 10.1523/JNEUROSCI.21-22-08809.2001; Wang PG, 2002, CHEM REV, V102, P1091, DOI 10.1021/cr000040l; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Zamora R, 2002, NITRIC OXIDE-BIOL CH, V7, P165, DOI 10.1016/S1089-8603(02)00104-0; Zhao BT, 2003, AM J PHYSIOL-CELL PH, V284, pC1577, DOI 10.1152/ajpcell.00243.2002; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	30	125	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42321	42329		10.1074/jbc.M308192200	http://dx.doi.org/10.1074/jbc.M308192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907672	hybrid			2022-12-25	WOS:000185989500093
J	Breitkreuz, KE; Allan, WL; Van Cauwenberghe, OR; Jakobs, C; Talibi, D; Andre, B; Shelp, BJ				Breitkreuz, KE; Allan, WL; Van Cauwenberghe, OR; Jakobs, C; Talibi, D; Andre, B; Shelp, BJ			A novel gamma-hydroxybutyrate dehydrogenase - Identification and expression of an Arabidopsis cDNA and potential role under oxygen deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINIC-SEMIALDEHYDE DEHYDROGENASE; ISOTOPE-DILUTION ANALYSIS; SACCHAROMYCES-CEREVISIAE; AMINOBUTYRIC-ACID; ESCHERICHIA-COLI; OXIDATIVE STRESS; RAT-BRAIN; METABOLISM; CLONING; GABA	In plants, gamma-aminobutyrate (GABA), a non-protein amino acid, accumulates rapidly in response to a variety of abiotic stresses such as oxygen deficiency. Under normoxia, GABA is catabolized to succinic semialdehyde and then to succinate with the latter reaction being catalyzed by succinic semialdehyde dehydrogenase (SSADH). Complementation of an SSADH-deficient yeast mutant with an Arabidopsis cDNA library enabled the identification of a novel cDNA ( designated as AtGH-BDH for Arabidopsis thaliana gamma-hydroxybutyrate dehydrogenase), which encodes a 289-amino acid polypeptide containing an NADP-binding domain. Constitutive expression of AtGHBDH in the mutant yeast enabled growth on 20 mM GABA and significantly enhanced the cellular concentrations of gamma-hydroxybutyrate, the product of the GHDBH reaction. These data confirm that the cDNA encodes a polypeptide with GHBDH activity. Arabidopsis plants subjected to flooding-induced oxygen deficiency for up to 4 h possessed elevated concentrations of gamma-hydroxybutyrate as well as GABA and alanine. RNA expression analysis revealed that GHBDH transcription was not up-regulated by oxygen deficiency. These findings suggest that GHBDH activity is regulated by the supply of succinic semialdehyde or by redox balance. It is proposed that GHBDH and SSADH activities in plants are regulated in a complementary fashion and that GHBDH and gamma-hydroxybutyrate function in oxidative stress tolerance.	Univ Guelph, Dept Plant Agr, Div Biotechnol, Guelph, ON N1G 2W1, Canada; Vrije Univ Med Ctr, Dept Clin Chem & Pediat, NL-1081 HV Amsterdam, Netherlands; Free Univ Brussels, Lab Physiol Cellulaire & Genet Levures, B-1050 Brussels, Belgium	University of Guelph; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Shelp, BJ (corresponding author), Univ Guelph, Dept Plant Agr, Div Biotechnol, Bovey Bldg, Guelph, ON N1G 2W1, Canada.		André, Bruno/D-1725-2010					ALLAN WL, 2003, IN PRESS CAN J PLANT; ALLAN WL, 2003, APPL B AGILENT TECHN, P4; Andriamampandry C, 1998, BIOCHEM J, V334, P43, DOI 10.1042/bj3340043; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; Bouche N, 2003, P NATL ACAD SCI USA, V100, P6843, DOI 10.1073/pnas.1037532100; Bown A., 1989, BIOCH LIFE SCI ADV, V8, P21; Bown AW, 1997, PLANT PHYSIOL, V115, P1, DOI 10.1104/pp.115.1.1; Buckel W, 2001, APPL MICROBIOL BIOT, V57, P263, DOI 10.1007/s002530100773; Busch K, 2000, BIOCHEMISTRY-US, V39, P10110, DOI 10.1021/bi000589e; Busch KB, 1999, PLANT PHYSIOL, V121, P589, DOI 10.1104/pp.121.2.589; CASH CD, 1994, NEUROSCI BIOBEHAV R, V18, P291, DOI 10.1016/0149-7634(94)90031-0; Coleman ST, 2001, J BIOL CHEM, V276, P244, DOI 10.1074/jbc.M007103200; DOHLMEN RJ, 1991, YEAST, V7, P691; Drew MC, 1997, ANNU REV PLANT PHYS, V48, P223, DOI 10.1146/annurev.arplant.48.1.223; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; GIBSON KM, 1990, BIOMED ENVIRON MASS, V19, P89, DOI 10.1002/bms.1200190207; GOOD AG, 1992, PLANT PHYSIOL, V99, P1520, DOI 10.1104/pp.99.4.1520; Harding SA, 1997, EMBO J, V16, P1137, DOI 10.1093/emboj/16.6.1137; HARDMAN JK, 1963, J BIOL CHEM, V238, P2088; Hawes JW, 1996, FEBS LETT, V389, P263, DOI 10.1016/0014-5793(96)00597-2; Hechler V, 1997, J PHARMACOL EXP THER, V281, P753; Henderson Jr J. W., 2000, 59801193E AG TECHN I; Kinnersley AM, 2000, CRIT REV PLANT SCI, V19, P479, DOI 10.1016/S0735-2689(01)80006-X; KOK RM, 1993, J INHERIT METAB DIS, V16, P508, DOI 10.1007/BF00711667; Lee SH, 1997, J BIOL CHEM, V272, P9252, DOI 10.1074/jbc.272.14.9252; Madden TE, 1998, J PHARMACOL EXP THER, V287, P261; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; MAMELAK M, 1989, NEUROSCI BIOBEHAV R, V13, P187, DOI 10.1016/S0149-7634(89)80053-3; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marwick C, 1997, JAMA-J AM MED ASSOC, V277, P1505, DOI 10.1001/jama.277.19.1505; METZER E, 1990, J BACTERIOL, V172, P3250, DOI 10.1128/jb.172.6.3250-3256.1990; MINET M, 1992, PLANT J, V2, P417; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; RAMOS F, 1985, EUR J BIOCHEM, V149, P401, DOI 10.1111/j.1432-1033.1985.tb08939.x; ROSEN MD, 1990, METHODS YEAST GENETI; RUMIGNY JF, 1980, FEBS LETT, V117, P111, DOI 10.1016/0014-5793(80)80924-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schaller M, 1999, EUR J BIOCHEM, V265, P1056, DOI 10.1046/j.1432-1327.1999.00826.x; Shelp BJ, 1999, TRENDS PLANT SCI, V4, P446, DOI 10.1016/S1360-1385(99)01486-7; SHELP BJ, 1992, CAN J PLANT SCI, V72, P883, DOI 10.4141/cjps92-111; VALENTIN HE, 1995, EUR J BIOCHEM, V227, P43, DOI 10.1111/j.1432-1033.1995.tb20358.x; Valentin HE, 2000, BIOTECHNOL BIOENG, V67, P291, DOI 10.1002/(SICI)1097-0290(20000205)67:3<291::AID-BIT5>3.0.CO;2-J; Van Cauwenberghe OR, 1999, PHYTOCHEMISTRY, V52, P575, DOI 10.1016/S0031-9422(99)00301-5; Van Cauwenberghe OR, 2002, CAN J BOT, V80, P933, DOI [10.1139/B02-087, 10.1139/b02-087]; WOLFF RA, 1993, APPL ENVIRON MICROB, V59, P1876, DOI 10.1128/AEM.59.6.1876-1882.1993	46	88	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41552	41556		10.1074/jbc.M305717200	http://dx.doi.org/10.1074/jbc.M305717200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882961	Green Submitted, hybrid			2022-12-25	WOS:000185847200136
J	Charest, PG; Bouvier, M				Charest, PG; Bouvier, M			Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; RESONANCE ENERGY-TRANSFER; CONFORMATIONAL REQUIREMENTS; BETA-2-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL; INTERNALIZATION; KINASE; DESENSITIZATION	A large number of G protein-coupled receptors are palmitoylated on cysteine residues located in their carboxyl tail, but the general role of this post-translational modification remains poorly understood. Here we show that preventing palmitoylation of the V2 vasopressin receptor, by site-directed mutagenesis of cysteines 341 and 342, significantly delayed and decreased both agonist-promoted receptor endocytosis and mitogen-activated protein kinase activation. Pharmacological blockade of receptor endocytosis is without effect on the vasopressin-stimulated mitogen-activated protein kinase activity, excluding the possibility that the reduced kinase activation mediated by the palmitoylation-less mutant could result from altered receptor endocytosis. In contrast, two dominant negative mutants of beta-arrestin which inhibit receptor endocytosis also attenuated vasopressin-stimulated mitogen-activated protein kinase activity, suggesting that the scaffolding protein, beta-arrestin, represents the common link among receptor palmitoylation, endocytosis, and kinase activation. Coimmunoprecipitation and bioluminescence resonance energy transfer experiments confirmed that inhibiting receptor palmitoylation considerably reduced the vasopressin-stimulated recruitment of beta-arrestin to the receptor. Interestingly, the changes in beta-arrestin recruitment kinetics were similar to those observed for vasopressin-stimulated receptor endocytosis and mitogen-activated protein kinase activation. Taken together the results indicate that palmitoylation enhances the recruitment of beta-arrestin to the activated V2 vasopressin receptor thus facilitating processes requiring the scaffolding action of beta-arrestin.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Bouvier, M (corresponding author), Univ Montreal, Dept Biochim, CP 6128 Succursale Centreville, Montreal, PQ H3C 3J7, Canada.		Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; Cramer H, 2001, EUR J BIOCHEM, V268, P5449, DOI 10.1046/j.0014-2956.2001.02486.x; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Groarke DA, 2001, MOL PHARMACOL, V59, P375, DOI 10.1124/mol.59.2.375; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2002, J CELL SCI, V115, P455; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; PATTERSON SI, 1994, J CELL BIOL, V124, P521, DOI 10.1083/jcb.124.4.521; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pizard A, 2001, BIOCHEMISTRY-US, V40, P15743, DOI 10.1021/bi011600t; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Saouaf SJ, 1997, BIOCHEM BIOPH RES CO, V234, P325, DOI 10.1006/bbrc.1997.6638; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Thibonnier M, 1998, ADV EXP MED BIOL, V449, P251; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200	56	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41541	41551		10.1074/jbc.M306589200	http://dx.doi.org/10.1074/jbc.M306589200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900404	hybrid			2022-12-25	WOS:000185847200135
J	Endo, K; Takino, T; Miyamori, H; Kinsen, H; Yoshizaki, T; Furukawa, M; Sato, H				Endo, K; Takino, T; Miyamori, H; Kinsen, H; Yoshizaki, T; Furukawa, M; Sato, H			Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH-FACTOR; 1-MATRIX METALLOPROTEINASE; MOLECULAR-INTERACTIONS; PROMOTES ACTIVATION; POOR-PROGNOSIS; EXPRESSION; SURFACE; DIFFERENTIATION; MESOTHELIOMA	The transmembrane heparan sulfate proteoglycan syndecan-1 was identified from a human placenta cDNA library by the expression cloning method as a gene product that interacts with membrane type matrix metalloproteinase-1 (MT1-MMP). Co-expression of MT1-MMP with syndecan-1 in HEK293T cells promoted syndecan-1 shedding, and concentration of cell-associated syndecan-1 was reduced. Treatment of cells with MMP inhibitor BB-94 or tissue inhibitor of MMP (TIMP)-2 but not TIMP-1 interfered with the syndecan-1 shedding promoted by MT1-MMP expression. In contrast, syndecan-1 shedding induced by 12-O-tetradecanoylphorbol-13-acetate treatment was inhibited by BB-94 but not by either TIMP-1 or TIMP-2. Shedding of syndecan-1 was also induced by MT3-MMP but not by other MT-MMPs. Recombinant syndecan-1 core protein was shown to be cleaved by recombinant MT1-MMP or MT3-MMP preferentially at the Gly(245)-Leu(246) peptide bond. HT1080 fibrosarcoma cells stably transfected with the syndecan-1 cDNA (HT1080/SDC), which express endogenous MT1-MMP, spontaneously shed syndecan-1. Migration of HT1080/ SDC cells on collagen-coated dishes was significantly slower than that of control HT1080 cells. Treatment of HT1080/ SDC cells with BB-94 or TIMP-2 induced accumulation of syndecan-1 on the cell surface, concomitant with further retardation of cell migration. Substitution of Gly(245) of syndecan-1 with Leu significantly reduced shedding from HT1080/ SDC cells and cell migration. These results suggest that the shedding of syndecan-1 promoted by MT1-MMP through the preferential cleavage of Gly(245)-Leu(246) peptide bond stimulates cell migration.	Kanazawa Univ, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Otolaryngol, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University; Kanazawa University; Kanazawa University	Sato, H (corresponding author), Kanazawa Univ, Dept Mol Oncol & Virol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	vhsato@kenroku.kanazawa-u.ac.jp	SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015					Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; Anttonen A, 2001, LUNG CANCER, V32, P297, DOI 10.1016/S0169-5002(00)00230-0; Bayer-Garner IB, 2000, AM J DERMATOPATH, V22, P119, DOI 10.1097/00000372-200004000-00005; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; Gattei V, 1999, BRIT J HAEMATOL, V104, P152, DOI 10.1046/j.1365-2141.1999.01132.x; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Hiller O, 2000, J BIOL CHEM, V275, P33008, DOI 10.1074/jbc.M001836200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Joensuu H, 2002, CANCER RES, V62, P5210; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kiessling LL, 1998, CHEM BIOL, V5, pR49, DOI 10.1016/S1074-5521(98)90056-4; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Kumar-Singh S, 1998, J PATHOL, V186, P300, DOI 10.1002/(SICI)1096-9896(1998110)186:3<300::AID-PATH180>3.0.CO;2-Q; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Matsumoto A, 1997, INT J CANCER, V74, P482, DOI 10.1002/(SICI)1097-0215(19971021)74:5<482::AID-IJC2>3.0.CO;2-#; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Merlos-Suarez A, 1999, BIOCHEM SOC T, V27, P243, DOI 10.1042/bst0270243; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 2001, CANCER RES, V61, P8896; NOMURA H, 1995, CANCER RES, V55, P3263; NUMA F, 1995, CANCER RES, V55, P4676; Ohashi K, 2000, CANCER-AM CANCER SOC, V88, P2201, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2201::AID-CNCR2>3.3.CO;2-E; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Perrimon N, 2001, SEMIN CELL DEV BIOL, V12, P65, DOI 10.1006/scdb.2000.0237; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Pulkkinen JO, 1997, ACTA OTO-LARYNGOL, V117, P312, DOI 10.3109/00016489709117794; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Takino T, 2003, ONCOGENE, V22, P4617, DOI 10.1038/sj.onc.1206542; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; Ueno H, 1997, CANCER RES, V57, P2055; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Woods A, 2001, J CLIN INVEST, V107, P935, DOI 10.1172/JCI12802; Yamamoto H, 1999, CANCER RES, V59, P3313; Yamamoto H, 2001, CANCER-AM CANCER SOC, V91, P1324, DOI 10.1002/1097-0142(20010401)91:7<1324::AID-CNCR1135>3.0.CO;2-2; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	60	302	314	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40764	40770		10.1074/jbc.M306736200	http://dx.doi.org/10.1074/jbc.M306736200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904296	hybrid, Green Submitted			2022-12-25	WOS:000185847200044
J	Gross, C; Koelch, W; DeMaio, A; Arispe, N; Multhoff, G				Gross, C; Koelch, W; DeMaio, A; Arispe, N; Multhoff, G			Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TUMOR-CELLS; IN-VITRO; RECEPTOR; PEPTIDE; PATHWAY; HSC70; CHAPERONES; EXPRESSION; LIGAND	Cell surface-bound heat shock protein 70 (Hsp70) renders tumor cells more sensitive to the cytolytic attack mediated by natural killer (NK) cells. A 14-amino acid Hsp70 sequence, termed TKD (TKDNNLLGRFELSG, aa(450-463)) could be identified as the extracellular localized recognition site for NK cells. Here, we show by affinity chromatography that both, full-length Hsp70-protein and Hsp70-peptide TKD, specifically bind a 32-kDa protein derived from NK cell lysates. The serine protease granzyme B was uncovered as the 32-kDa Hsp70-interacting protein using matrix-assisted laser desorption ionization time-of-flight mass peptide fingerprinting. Incubation of tumor cells with increasing concentrations of perforin-free, isolated granzyme B shows specific binding and uptake in a dose-dependent manner and results in initiation of apoptosis selectively in tumor cells presenting Hsp70 on the cell surface. Remarkably, Hsp70 cation channel activity was also determined selectively in purified phospholipid membranes of Hsp70 membrane-positive but not in membrane-negative tumor cells. The physiological role of our findings was demonstrated in primary NK cells showing elevated cytoplasmic granzyme B levels following contact with TKD. Furthermore, an increased lytic activity of Hsp70 membrane-positive tumor cells could be associated with granzyme B release by NK cells. Taken together we propose a novel perforin-independent, granzyme B-mediated apoptosis pathway for Hsp70 membrane-positive tumor cells.	Univ Hosp Regensburg, Dept Hematol, D-93053 Regensburg, Germany; Univ Glasgow, CRC, Beatson Labs, Inst Biomed & Life Sci, Glasgow G61 1BD, Lanark, Scotland; Johns Hopkins Univ, Sch Med, Div Pediat Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA	University of Regensburg; Beatson Institute; University of Glasgow; Johns Hopkins University; Johns Hopkins University; Uniformed Services University of the Health Sciences - USA	Multhoff, G (corresponding author), Univ Hosp Regensburg, Dept Hematol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	gabriele.multhoff@klinik.uni-regensburg.de	Multhoff, Gabriele/AAW-9796-2021	Multhoff, Gabriele/0000-0002-2616-3137; Gross, Catharina/0000-0002-4872-9189				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Arispe N, 2000, J BIOL CHEM, V275, P30839, DOI 10.1074/jbc.M005226200; Arispe N, 2002, CELL STRESS CHAPERON, V7, P330, DOI 10.1379/1466-1268(2002)007<0330:LIDTCA>2.0.CO;2; Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, CELL STRESS CHAPERON, V5, P425, DOI 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Beresford PJ, 1998, J IMMUNOL, V161, P161; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; Botzler C, 1999, EXP HEMATOL, V27, P470, DOI 10.1016/S0301-472X(98)00055-1; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Drexler HG, 2000, LEUKEMIA, V14, P777, DOI 10.1038/sj.leu.2401778; Feng HP, 2001, BLOOD, V97, P3505, DOI 10.1182/blood.V97.11.3505; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Gross C, 2003, BIOL CHEM, V384, P267, DOI 10.1515/BC.2003.030; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; MACDONALD HR, 1974, J EXP MED, V140, P718, DOI 10.1084/jem.140.3.718; Mamelak D, 1997, GLYCOCONJUGATE J, V14, P715, DOI 10.1023/A:1018569417218; MULTHOFF G, 1995, BLOOD, V86, P1374, DOI 10.1182/blood.V86.4.1374.bloodjournal8641374; Multhoff G, 1997, J IMMUNOL, V158, P4341; Multhoff G, 2001, CELL STRESS CHAPERON, V6, P337, DOI 10.1379/1466-1268(2001)006<0337:AMHPSN>2.0.CO;2; Multhoff G, 1999, EXP HEMATOL, V27, P1627, DOI 10.1016/S0301-472X(99)00104-6; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Pinkoski MJ, 2002, CURR OPIN HEMATOL, V9, P43, DOI 10.1097/00062752-200201000-00008; Pinkoski MJ, 1998, BLOOD, V92, P1044; Rabinovich BA, 2000, J IMMUNOL, V165, P2390, DOI 10.4049/jimmunol.165.5.2390; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Schild H, 1999, CURR OPIN IMMUNOL, V11, P109, DOI 10.1016/S0952-7915(99)80019-3; Shi LF, 2000, METHOD ENZYMOL, V322, P125; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; Sondermann H, 2000, BIOL CHEM, V381, P1165, DOI 10.1515/BC.2000.144; Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279	44	147	157	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41173	41181		10.1074/jbc.M302644200	http://dx.doi.org/10.1074/jbc.M302644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12874291	hybrid			2022-12-25	WOS:000185847200094
J	Yeo, SJ; Yoon, JG; Yi, AK				Yeo, SJ; Yoon, JG; Yi, AK			Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA - Tumor necrosis factor-alpha receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA STABILITY; NF-KAPPA-B; P38 SIGNALING CASCADE; BACTERIAL-DNA; CELL-ACTIVATION; DENDRITIC CELLS; GENE-EXPRESSION; TRANSLATIONAL EFFICIENCY; 3'-UNTRANSLATED REGION	The immune stimulatory unmethylated CpG motifs present in bacterial DNA ( CpG DNA) induce expression of cyclooxygenase-2 (cox-2). The present study demonstrates that CpG DNA can up-regulate cox-2 expression by post-transcriptional mechanisms in RAW264.7 cells. To determine the CpG DNA-mediated signaling pathway that post-transcriptionally regulates cox-2 expression, a cox-2 translational reporter (COX2-3'-UTR-luciferase) was generated by inserting sequences within the 3'-untranslated region (UTR) of cox-2 to the 3' end of the luciferase gene under control of the SV40 promoter. CpG DNA-induced COX2-3'-UTR-luciferase activity was completely inhibited by an endosomal acidification inhibitor chloroquine, a Toll-like receptor 9 antagonist inhibitory CpG DNA, or overexpression of a dominant negative (DN) form of MyD88. However, overexpression of DN-IRAK-1 or DN-TRAF6 resulted in substantial, but not complete, inhibition of the CpG DNA-induced COX2-3'- UTR-luciferase activity. Activation of all three MAPKs (ERK, p38, and JNK) was required for optimal COX2-3'- UTR-luciferase activity induced by CpG DNA. Overexpression of DN-TRAF6 suppressed CpG DNA-mediated activation of p38 and JNK, but not ERK, explaining the partial inhibitory effects of DN-TRAF6 on CpG DNA-induced COX2-3'- UTR-luciferase activity. Co-expression of DN-TRAF6 and N17Ras completely inhibited CpG DNA-induced COX2-3'- UTR-luciferase activity, indicating the involvement of Ras in CpG DNA-mediated ERK and COX2-3'- UTR regulation. Collectively, our results suggest that MyD88 and MAPKs play a key regulatory role in CpG DNA-mediated cox-2 expression at the post-transcriptional level and that TRAF6 is a diverging point in the Toll-like receptor 9-signaling pathway for CpG DNA-mediated MAPK activation.	Univ Tennessee, Hlth Sci Ctr, Le Bonheur Childrens Med Ctr, Childrens Fdn Res Ctr,Dept Pediat, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Yi, AK (corresponding author), Univ Tennessee, Hlth Sci Ctr, Le Bonheur Childrens Med Ctr, Childrens Fdn Res Ctr,Dept Pediat, 50 N Dunlap St,WPT 315, Memphis, TN 38103 USA.				NIAMS NIH HHS [1R03AR47757, AR-47379] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047757, P30AR047379] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Chen CY, 2000, GENE DEV, V14, P1236; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Cowdery J, 1996, J IMMUNOL, V156, P4570; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Fitzgerald GA, 2002, AM J CARDIOL, V89, p26D; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Gay E, 2000, BIOCHEM BIOPH RES CO, V267, P509, DOI 10.1006/bbrc.1999.2000; Ghosh DK, 2001, INFECT IMMUN, V69, P7703, DOI 10.1128/IAI.69.12.7703-7710.2001; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; Jakob T, 1998, J IMMUNOL, V161, P3042; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lenert P, 2001, ANTISENSE NUCLEIC A, V11, P247, DOI 10.1089/108729001317022241; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Milas L, 2001, SEMIN RADIAT ONCOL, V11, P290, DOI 10.1053/srao.2001.26018; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; SANO H, 1995, CANCER RES, V55, P3785; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Stunz LL, 2002, EUR J IMMUNOL, V32, P1212, DOI 10.1002/1521-4141(200205)32:5<1212::AID-IMMU1212>3.0.CO;2-D; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeshita S, 2000, CELL IMMUNOL, V206, P101, DOI 10.1006/cimm.2000.1735; Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3263, DOI 10.1210/jc.87.7.3263; Tanji K, 2001, BBA-MOL CELL BIOL L, V1530, P227, DOI 10.1016/S1388-1981(01)00089-0; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Warren T L, 2000, Clin Lymphoma, V1, P57, DOI 10.3816/CLM.2000.n.005; Warren TL, 2000, J IMMUNOL, V165, P6244, DOI 10.4049/jimmunol.165.11.6244; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xu HM, 2003, J BIOL CHEM, V278, P36334, DOI 10.1074/jbc.M305698200; Yeo SJ, 2003, J BIOL CHEM, V278, P22563, DOI 10.1074/jbc.M302076200; Yi AK, 1999, INT IMMUNOL, V11, P2015, DOI 10.1093/intimm/11.12.2015; Yi AK, 1996, J IMMUNOL, V157, P5394; Yi AK, 1996, J IMMUNOL, V157, P4918; Yi AK, 1998, J IMMUNOL, V160, P1240; Yi AK, 2003, INT IMMUNOL, V15, P577, DOI 10.1093/intimm/dxg058; Yi AK, 1998, J IMMUNOL, V160, P5898; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1998, J IMMUNOL, V160, P4755; Yi AK, 1996, J IMMUNOL, V156, P558; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117	75	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40590	40600		10.1074/jbc.M306280200	http://dx.doi.org/10.1074/jbc.M306280200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902324	hybrid			2022-12-25	WOS:000185847200022
J	Zhang, GF; Dai, JY; Lu, ZB; Dunaway-Mariano, D				Zhang, GF; Dai, JY; Lu, ZB; Dunaway-Mariano, D			The phosphonopyruvate decarboxylase from Bacteroides fragilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-PHOSPHORUS BOND; ENZYME PYRUVATE DECARBOXYLASE; C-P BOND; THIAMIN DIPHOSPHATE; CRYSTAL-STRUCTURE; CAPSULAR POLYSACCHARIDES; PHOSPHOENOLPYRUVATE MUTASE; PYROPHOSPHATE-BINDING; ANGSTROM RESOLUTION; TRYPANOSOMA-CRUZI	The Bacteroides fragilis capsular polysaccharide complex is the major virulence factor for abscess formation in human hosts. Polysaccharide B of this complex contains a 2-aminoethylphosphonate functional group. This functional group is synthesized in three steps, one of which is catalyzed by phosphonopyruvate decarboxylase. In this paper, we report the cloning and overexpression of the B. fragilis phosphonopyruvate decarboxylase gene (aepY), purification of the phosphonopyruvate decarboxylase recombinant protein, and the extensive characterization of the reaction that it catalyzes. The homotrimeric ( 41,184-Da subunit) phosphonopyruvate decarboxylase catalyzes (k(cat) = 10.2 +/- 0.3 s(-1)) the decarboxylation of phosphonopyruvate (K-m = 3.2 +/- 0.2 muM) to phosphonoacetaldehyde (K-i = 15 +/- 2 muM) and carbon dioxide at an optimal pH range of 7.0-7.5. Thiamine pyrophosphate (K-m = 13 +/- 2 muM) and certain divalent metal ions (Mg(II) K-m = 82 +/- 8 muM; Mn(II) K-m = 13 +/- 1 muM; Ca(II) K-m = 78 +/- 6 muM) serve as cofactors. Phosphonopyruvate decarboxylase is a member of the alpha-ketodecarboxylase family that includes sulfopyruvate decarboxylase, acetohydroxy acid synthase/acetolactate synthase, benzoylformate decarboxylase, glyoxylate carboligase, indole pyruvate decarboxylase, pyruvate decarboxylase, the acetyl phosphate-producing pyruvate oxidase, and the acetate-producing pyruvate oxidase. The Mg( II) binding residue Asp-260, which is located within the thiamine pyrophosphate binding motif of the alpha-ketodecarboxylase family, was shown by site-directed mutagenesis to play an important role in catalysis. Pyruvate (k(cat) = 0.05 s(-1), K-m = 25 mM) and sulfopyruvate (k(cat) similar to 0.05 s(-1); K-i = 200 +/- 20 muM) are slow substrates for the phosphonopyruvate decarboxylase, indicating that this enzyme is promiscuous.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of New Mexico	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	dd39@unm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688, R01GM061099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 61099, GM 28688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON VE, 1984, BIOCHEMISTRY-US, V23, P2779, DOI 10.1021/bi00307a038; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Baker AS, 1998, BIOCHEMISTRY-US, V37, P9305, DOI 10.1021/bi972677d; BARRY RJ, 1988, BIOCHEM BIOPH RES CO, V153, P177, DOI 10.1016/S0006-291X(88)81205-1; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSAIGNE A, 1976, CR ACAD SCI D NAT, V282, P1637; Chipman D, 1998, BBA-PROTEIN STRUCT M, V1385, P401, DOI 10.1016/S0167-4838(98)00083-1; Coyne MJ, 2000, INFECT IMMUN, V68, P6176, DOI 10.1128/IAI.68.11.6176-6181.2000; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; Graupner M, 2000, J BACTERIOL, V182, P4862, DOI 10.1128/JB.182.17.4862-4867.2000; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; Jia Y, 1999, BIOCHEMISTRY-US, V38, P14165, DOI 10.1021/bi990771j; JIANG WH, 1995, J BACTERIOL, V177, P6411, DOI 10.1128/jb.177.22.6411-6421.1995; JUNG EH, 1988, INT J BIOCHEM, V20, P1255, DOI 10.1016/0020-711X(88)90228-5; Kalka-Moll WM, 2001, INFECT IMMUN, V69, P2339, DOI 10.1128/IAI.69.4.2339-2344.2001; KENNEDY KE, 1970, SCIENCE, V168, P989, DOI 10.1126/science.168.3934.989; Kim A, 1998, J BIOL CHEM, V273, P4443, DOI 10.1074/jbc.273.8.4443; Kim AD, 2002, J BACTERIOL, V184, P4134, DOI 10.1128/JB.184.15.4134-4140.2002; KIM JB, 1994, THESIS U MARYLAND CO; LANAUZE JM, 1970, BIOCHIM BIOPHYS ACTA, V212, P332, DOI 10.1016/0005-2744(70)90214-7; LIANG CR, 1968, BIOCHIM BIOPHYS ACTA, V156, P437, DOI 10.1016/0304-4165(68)90283-3; Liu SJ, 2002, BIOCHEMISTRY-US, V41, P10270, DOI 10.1021/bi026024v; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; Nakashita H, 1997, J ANTIBIOT, V50, P212, DOI 10.7164/antibiotics.50.212; Nakashita H, 2000, BBA-GENE STRUCT EXPR, V1490, P159, DOI 10.1016/S0167-4781(99)00249-3; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; Parker GF, 1999, J BACTERIOL, V181, P389, DOI 10.1128/JB.181.2.389-395.1999; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; Schwartz D, 1998, FEMS MICROBIOL LETT, V163, P149, DOI 10.1016/S0378-1097(98)00165-7; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Seto H, 1999, NAT PROD REP, V16, P589, DOI 10.1039/a809398i; Shin JEN, 1997, CARBOHYD RES, V305, P223; STEINER S, 1973, J BACTERIOL, V116, P1199, DOI 10.1128/JB.116.3.1199-1211.1973; TATE JR, 1987, ANAL BIOCHEM, V160, P78, DOI 10.1016/0003-2697(87)90616-6; Ternan NG, 1998, SYST APPL MICROBIOL, V21, P346, DOI 10.1016/S0723-2020(98)80043-X; Thompson C J, 1995, Biotechnology, V28, P197; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; TZIANABOS AO, 1992, J BIOL CHEM, V267, P18230; Tzianabos AO, 2000, INFECT IMMUN, V68, P6650, DOI 10.1128/IAI.68.12.6650-6655.2000; Wang Y, 2000, P NATL ACAD SCI USA, V97, P13478, DOI 10.1073/pnas.97.25.13478; WARREN WA, 1968, BIOCHIM BIOPHYS ACTA, V156, P340, DOI 10.1016/0304-4165(68)90263-8; WASSEF MK, 1977, BIOCHIM BIOPHYS ACTA, V486, P172, DOI 10.1016/0005-2760(77)90081-9; WHITE RH, 1986, BIOCHEMISTRY-US, V25, P5304, DOI 10.1021/bi00366a047	50	34	36	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41302	41308		10.1074/jbc.M305976200	http://dx.doi.org/10.1074/jbc.M305976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904299	hybrid			2022-12-25	WOS:000185847200109
J	Hassel, B; Schreff, M; Stube, EM; Blaich, U; Schumacher, S				Hassel, B; Schreff, M; Stube, EM; Blaich, U; Schumacher, S			CALEB/NGC interacts with the Golgi-associated protein PIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; NEUROGLYCAN-C; GLUTAMATE-RECEPTOR; PROTGF-ALPHA; PDZ DOMAINS; BREFELDIN-A; EGF FAMILY; MEMBRANE; SYNTENIN; COMPLEX	CALEB/NGC is a neural member of the epidermal growth factor protein family expressed in axon and synapse-rich areas of the nervous system and shown to be important for neurite formation. It can bind to the extracellular matrix proteins tenascin-R and tenascin-C. Here we show that CALEB/NGC interacts with the Golgi-associated protein PIST. PIST was originally described as an interaction partner of the small GTPase TC10 and was then found to be Golgi-associated by binding to syntaxin-6 and to be important for the transport of frizzled proteins and the cystic fibrosis transmembrane conductance regulator to the plasma membrane. In addition, PIST was demonstrated to be involved in autophagy and linked to processes of neurodegeneration. CALEB/NGC interacts with PIST in the yeast two-hybrid system. This interaction can be confirmed by co-immunoprecipitations and co-localization studies. The juxtamembrane cytoplasmic peptide segment of CALEB/NGC, highly conserved during evolution, mediates the binding to PIST. CALEB/NGC co-localizes with PIST in the Golgi apparatus of transfected COS7 cells and in Golgi-derived vesicles after brefeldin A or nocodazole treatment. Co-localization studies in primary hippocampal cells and analysis of Purkinje cells of colchicine-treated rats, serving as an in vivo model system to block microtubule-dependent transport processes, support the view that PIST is an interaction partner of CALEB/NGC and implicate that this interaction may play a role in the intracellular transport of CALEB/NGC.	Univ Hamburg, Klinikum Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg	Schumacher, S (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	sschumac@uke.uni-hamburg.de						Aono S, 2000, J BIOL CHEM, V275, P337, DOI 10.1074/jbc.275.1.337; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; BRUMMENDORF T, 1993, NEURON, V10, P711; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CONNER JM, 1992, J COMP NEUROL, V326, P347, DOI 10.1002/cne.903260304; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Goslin K., 1998, CULTURING NERVE CELL, P339; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P4338; Iuliano R, 2001, FEBS LETT, V500, P41, DOI 10.1016/S0014-5793(01)02580-7; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Urena JM, 1999, J CELL SCI, V112, P773; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Woods R. A., 2001, METH MOL B, V177, P85; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9	41	18	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40136	40143		10.1074/jbc.M305577200	http://dx.doi.org/10.1074/jbc.M305577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885772	hybrid			2022-12-25	WOS:000185713800106
J	Ishaq, M; DeGray, G; Natarajan, V				Ishaq, M; DeGray, G; Natarajan, V			Protein kinase C0 modulates nuclear receptor-corepressor interaction during T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; THYROID-HORMONE RECEPTORS; SMALL INTERFERING RNAS; RETINOID-X-RECEPTOR; PKC-THETA; MAMMALIAN-CELLS; IL-2 PROMOTER; LYMPHOCYTES; CALCINEURIN; TCR	Transcriptional repression by nuclear receptor corepressors plays a critical role in T cell development. However, the role of these corepressors in T cell activation is poorly understood. We report that T cell activation silenced transcription driven by nuclear receptors retinoic acid receptor, retinoid X receptor, and thyroid hormone receptor and induced silencing mediator of retinoic acid and thyroid hormone receptors (SMRT)-receptor interaction. Whereas the expression of a dominant active mutant of protein kinase Ctheta (PKCtheta) induced strong SMRT-receptor interaction in the absence of T cell activation, a dominant negative mutant of PKCtheta decreased the interaction. Loss of PKCtheta expression by induction of "RNA interference" resulted in the attenuation of basal and activation-induced SMRT-receptor interaction. We suggest that T cell activation silences nuclear receptor-dependent transactivation in part through PKCtheta-dependent enhancement of SMRT-receptor interaction.	NCI, Mol Cell Biol Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Ishaq, M (corresponding author), NCI, Mol Cell Biol Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA.				NCI NIH HHS [N0-CO12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Arendt CW, 2002, CURR OPIN IMMUNOL, V14, P323, DOI 10.1016/S0952-7915(02)00346-1; BAIER G, 1993, J BIOL CHEM, V268, P4997; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hudson DF, 2002, TRENDS CELL BIOL, V12, P281, DOI 10.1016/S0962-8924(02)02281-X; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Ishaq M, 2002, J IMMUNOL, V169, P732, DOI 10.4049/jimmunol.169.2.732; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jepsen K, 2002, J CELL SCI, V115, P689; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lin J, 2001, J CELL SCI, V114, P243; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Scherr M, 2003, CURR MED CHEM, V10, P245, DOI 10.2174/0929867033368493; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Villalba M, 1999, J IMMUNOL, V163, P5813; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	47	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39296	39302		10.1074/jbc.M302767200	http://dx.doi.org/10.1074/jbc.M302767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890684	hybrid			2022-12-25	WOS:000185713800006
J	Liu, MF; Gupte, G; Roy, S; Bandwar, RP; Patel, SS; Garges, S				Liu, MF; Gupte, G; Roy, S; Bandwar, RP; Patel, SS; Garges, S			Kinetics of transcription initiation at lacP1 - Multiple roles of cyclic AMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; RNA-POLYMERASE; PROMOTER DNA; BASE; FLUORESCENCE; ACTIVATION; MECHANISM; CAMP; 2-AMINOPURINE; DYNAMICS	The cyclic AMP receptor protein (CRP) acts as a transcription activator at many promoters of Escherichia coli. We have examined the kinetics of open complex formation at the lacP1 promoter using tryptophan fluorescence of RNA polymerase and DNA fragments with 2-aminopurine substituted at specific positions. Apart from the closed complex formation and promoter clearance, we were able to detect three steps. The first step after the closed complex formation leads to a rapid increase of 2-aminopurine fluorescence. This was followed by another rapid step in which quenching of tryptophan fluorescence of RNA polymerase was observed. The slowest step detected by 2-aminopurine fluorescence increase is assigned to the final open complex formation. We have found that CRP not only enhances RNA polymerase binding at the promoter, but also enhances the slowest isomerization step by about 2-fold. Furthermore, potassium permanganate probing shows that the conformation of the open complex in the presence of CRP appears qualitatively and quantitatively different from that in the absence of CRP, suggesting that contact with RNA polymerase is maintained throughout the transcription initiation.	NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Bose Inst, Dept Biophys, Kolkata 700054, W Bengal, India; Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Department of Science & Technology (India); Bose Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, MF (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Rm 5138, Bethesda, MD 20892 USA.	liumo@pop.nci.nih.gov		Bandwar, Rajiv/0000-0002-8081-8958; liu, mo fang/0000-0003-1800-466X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051966, R37GM051966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DONNELLY CE, 1987, J BACTERIOL, V169, P1812, DOI 10.1128/jb.169.5.1812-1817.1987; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lim HM, 2001, P NATL ACAD SCI USA, V98, P14849, DOI 10.1073/pnas.261517398; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCLAUGHLIN LW, 1987, BIOCHEMISTRY-US, V26, P7238, DOI 10.1021/bi00397a007; NORDLUND TM, 1989, BIOCHEMISTRY-US, V28, P9095, DOI 10.1021/bi00449a021; RECORD TM, 1996, ESCHERICHIA COLI SAL, P792; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; Sullivan JJ, 1997, BIOCHEMISTRY-US, V36, P8005, DOI 10.1021/bi970363k; Tsujikawa L, 2002, BIOCHEMISTRY-US, V41, P15334, DOI 10.1021/bi026539m; WU PG, 1990, BIOCHEMISTRY-US, V29, P6508, DOI 10.1021/bi00479a024; XU DG, 1994, BIOCHEMISTRY-US, V33, P9592, DOI 10.1021/bi00198a027	25	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39755	39761		10.1074/jbc.M305995200	http://dx.doi.org/10.1074/jbc.M305995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881519	hybrid			2022-12-25	WOS:000185713800061
J	Wegele, H; Muschler, P; Bunck, M; Reinstein, J; Buchner, J				Wegele, H; Muschler, P; Bunck, M; Reinstein, J; Buchner, J			Dissection of the contribution of individual domains to the ATPase mechanism of Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; TERMINAL DOMAINS; IN-VIVO; BINDING; HYDROLYSIS; CYCLE; HEAT-SHOCK-PROTEIN-90; RECEPTOR	Hsp90 is a dimeric, ATP-regulated molecular chaperone. Its ATPase cycle involves the N-terminal ATP binding domain (amino acids (aa) 1-272) and, in addition, to some extent the middle domain (aa 273-528) and the C-terminal dimerization domain (aa 529-709). To analyze the contribution of the different domains and the oligomeric state on the progression of the ATPase cycle of yeast Hsp90, we created deletion constructs lacking either the C-terminal or both the C-terminal and the middle domain. To test the effect of dimerization on the ATPase activity of the different constructs, we introduced a Cys residue at the C-terminal ends of the constructs, which allowed covalent dimerization. We show that all monomeric constructs tested exhibit reduced ATPase activity and a decreased affinity for ATP in comparison with wild type Hsp90. The covalently linked dimers lacking only the C-terminal domain hydrolyze ATP as efficiently as the wild type protein. Furthermore, this construct is able to trap the ATP molecule similar to the full-length protein. This demonstrates that in the ATPase cycle, the C-terminal domain can be replaced by a cystine bridge. In contrast, the ATPase activity of the artificially linked N-terminal domains remains very low and bound ATP is not trapped. Taken together, we show that both the dimerization of the N-terminal domains and the association of the N-terminal with the middle domain are important for the efficiency of the ATPase cycle. These reactions are synergistic and require Hsp90 to be in the dimeric state.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Max Planck Inst Med Res, Abt Biomol Mech, D-69120 Heidelberg, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Fersht A., 1999, STRUCTURE MECH PROTE, P103; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; GUTFREUND H, 1995, KINETICS LIFE SCI, P59; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheibel T, 1999, MOL MICROBIOL, V34, P701, DOI 10.1046/j.1365-2958.1999.01632.x; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	36	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39303	39310		10.1074/jbc.M305751200	http://dx.doi.org/10.1074/jbc.M305751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890674	hybrid			2022-12-25	WOS:000185713800007
J	Yada, T; Sato, T; Kaseyama, H; Gotoh, M; Iwasaki, H; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Watanabe, H; Narimatsu, H; Kimata, K				Yada, T; Sato, T; Kaseyama, H; Gotoh, M; Iwasaki, H; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Watanabe, H; Narimatsu, H; Kimata, K			Chondroitin sulfate synthase-3 - Molecular cloning and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; TUMOR SUPPRESSORS EXT1; N-ACETYLGALACTOSAMINYLTRANSFERASE; GLUCURONIC-ACID; HIGH-AFFINITY; EXPRESSION; GLUCURONOSYLTRANSFERASE; BIOSYNTHESIS; PROTEOGLYCAN; ENZYME	Recently, it has become evident that chondroitin sulfate (CS) glycosyltransferases, which transfer glucuronic acid and/or N-acetylgalactosamine residues from each UDP-sugar to the nonreducing terminus of the CS chain, form a gene family. We report here a novel human gene (GenBank(TM) accession number AB086062) that possesses a sequence homologous with the human chondroitin sulfate synthase-1 (CSS1) gene, formerly known as chondroitin synthase. The full-length open reading frame consists of 882 amino acids and encodes a typical type II membrane protein. This enzyme contains a beta3-glycosyltransferase motif and a beta4-glycosyltransferase motif similar to that found in CSS1. Both the enzymes were expressed in COS-7 cells as soluble proteins, and their enzymatic natures were characterized. Both glucuronyltransferase and N-acetylgalactosaminyltransferase activities were observed when chondroitin, CS polymer, and their corresponding oligosaccharides were used as the acceptor substrates, but no polymerization reaction was observed as in the case of CSS1. The new enzyme was thus designated chondroitin sulfate synthase-3 (CSS3). However, the specific activity of CSS3 was much lower than that of CSS1. The reaction products were shown to have a GlcUAbeta1-3GalNAc linkage and a GalNAcbeta1-4GlcUA linkage in the nonreducing terminus of chondroitin resulting from glucuronyltransferase activity and N-acetylgalactosaminyltransferase activity, respectively. Quantitative real time PCR analysis revealed that the transcript level of CSS3 was much lower than that of CSS1, although it was ubiquitously expressed in various human tissues. These results indicate that CSS3 is a glycosyltransferase having both glucuronyltransferase and N-acetylgalactosaminyltransferase activities. It may make a contribution to CS biosynthesis that differs from that of CSS1.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Seikagaku Corp, Tokyo 2070021, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mol & Cell Biol, Lab Gene Funct Anal, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648555, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan	Aichi Medical University; Seikagaku Corporation; National Institute of Advanced Industrial Science & Technology (AIST)	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@aichi-med-u.ac.jp	Togayachi, Akira/M-4144-2018; Sato, Takashi/M-2577-2018; Narimatsu, Hisashi/M-4757-2018	Togayachi, Akira/0000-0003-3600-9149; Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X; Watanabe, Hideto/0000-0001-5291-0696				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Kudo T, 2002, J BIOL CHEM, V277, P47724, DOI 10.1074/jbc.M205839200; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RAZIN E, 1982, J BIOL CHEM, V257, P7229; Sasai K, 2001, J BIOL CHEM, V276, P759, DOI 10.1074/jbc.M004972200; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; Wei G, 2000, J BIOL CHEM, V275, P27733; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	41	63	67	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39711	39725		10.1074/jbc.M304421200	http://dx.doi.org/10.1074/jbc.M304421200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12907687	hybrid			2022-12-25	WOS:000185713800057
J	Baran, CP; Tridandapani, S; Helgason, CD; Humphries, RK; Krystal, G; Marsh, CB				Baran, CP; Tridandapani, S; Helgason, CD; Humphries, RK; Krystal, G; Marsh, CB			The inositol 5 '-phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH APOPTOSIS; M-CSF RECEPTOR; PROTEIN-KINASE; FACTOR-I; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHATASE; ACTIVATION; MURINE	Upon encountering macrophage colony-stimulating factor (M-CSF), human monocytes undergo a series of cellular signaling events leading to an increase in Akt activity. However, the regulation of these events is not completely understood. Because the inositol 5'-phosphatase SHIP-1 is an important regulator of intracellular levels of phosphatidylinositol 3,4,5-trisphosphate, an important second messenger necessary for Akt activation, we hypothesized that SHIP-1 was involved in the regulation of M-CSF receptor (M-CSF-R)-induced Akt activation. In the human monocytic cell line, THP-1, SHIP-1 became tyrosine-phosphorylated following M-CSF activation in a Src family kinase-dependent manner. Transfection of 3T3-Fms cells, which express the human M-CSF-R, with wild-type SHIP-1 showed that SHIP-1 was necessary for the negative regulation of M-CSF-induced Akt activation. In THP-1 cells, SHIP-1 bound Lyn, independent of the kinase activity of Lyn, following M-CSF activation. Utilizing a glutathione S-transferase fusion protein, we found that SHIP-1 bound to Lyn via the SHIP-1 Src homology 2 domain. Furthermore, transfection of THP-1 cells with a wild-type SHIP-1 construct reduced NF-kappaB-dependent transcriptional activation of a reporter gene, whereas a SHIP-1 Src homology 2 domain construct resulted in an increase in NF-kappaB activation. Additionally, in 3T3-Fms cells, Lyn enhanced the ability of SHIP-1 to regulate Akt activation by stabilizing SHIP-1 at the cellular membrane. Finally, macrophages isolated from both SHIP-1- and Lyn-deficient mice exhibited enhanced Akt phosphorylation following M-CSF stimulation. These data provide the first evidence of the involvement of both SHIP-1 and Lyn in the negative regulation of M-CSF-R-induced Akt activation.	Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; British Columbia Cancer Agency	Marsh, CB (corresponding author), Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Rm 201,473 W 12th Ave, Columbus, OH 43210 USA.	marsh.2@osu.edu	Tridandapani, Susheela/E-4209-2011	Krystal, Gerald/0000-0002-1961-6281; Humphries, Richard/0000-0003-0540-7005	NHLBI NIH HHS [R01HL63800, P01HL70294, R01HL66108, R01HL67176] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066108, R01HL063800, R01HL067176, P01HL070294] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78; Cornall RJ, 1999, CURR TOP MICROBIOL, V244, P57; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Csar XF, 2001, J BIOL CHEM, V276, P26211, DOI 10.1074/jbc.M100213200; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Damen JE, 1998, BLOOD, V92, P1199, DOI 10.1182/blood.V92.4.1199.416k16_1199_1205; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Gresham HD, 2000, J EXP MED, V191, P515, DOI 10.1084/jem.191.3.515; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; INABA T, 1992, J BIOL CHEM, V267, P5693; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lucas DM, 1999, BLOOD, V93, P1922, DOI 10.1182/blood.V93.6.1922.406k21_1922_1933; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MANGAN DF, 1991, J IMMUNOL, V146, P1541; Marsh CB, 1999, J IMMUNOL, V162, P6217; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Novak U, 1996, ONCOGENE, V13, P2607; Ozes ON, 1999, NATURE, V401, P82; Pengal RA, 2003, J BIOL CHEM, V278, P22657, DOI 10.1074/jbc.M302907200; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tridandapani S, 2002, J IMMUNOL, V169, P4370, DOI 10.4049/jimmunol.169.8.4370; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720	51	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38628	38636		10.1074/jbc.M305021200	http://dx.doi.org/10.1074/jbc.M305021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882960	hybrid			2022-12-25	WOS:000185575100067
J	Gonzalez, EM; Mongiat, M; Slater, SJ; Baffa, R; Iozzo, RV				Gonzalez, EM; Mongiat, M; Slater, SJ; Baffa, R; Iozzo, RV			A novel interaction between perlecan protein core and progranulin - Potential effects on tumor growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; EPITHELIAL-CELL GROWTH; BASEMENT-MEMBRANES; STABLE EXPRESSION; GENE-EXPRESSION; ANTISENSE CDNA; IN-VIVO; PRECURSOR; ANGIOGENESIS; GLYCOPROTEIN	In an in vivo search of novel partners for perlecan, a major heparan sulfate proteoglycan of basement membranes and cell surfaces, we identified progranulin, a secreted growth factor, as a strong interacting protein. Unambiguous interaction, first observed with the yeast two-hybrid system, was corroborated by co-immunoprecipitation studies using cell-free transcription/translation and transient cell transfection assays. The interaction of progranulin with perlecan domain V involved the first two laminin- and epidermal growth factor-like repeats. Within progranulin, the subdomains interacting most with perlecan harbored granulins F and B. Kinetics analysis of the interaction using surface plasmon resonance showed a saturable binding of relative low affinity (K-D similar to 1 muM). These results were supported by significant expression overlap of these two proteins in a series of ovarian tumor tissue microarrays. Progranulin was present within proliferating blood vessels of ovarian carcinomas and perivascular matrices, with a distribution similar to perlecan. Notably, both progranulin and domain V stimulated the growth of adrenal carcinoma cells. However, when used together in equimolar amounts, the two proteins counteracted each other's activity. Thus, progranulin/perlecan interaction could contribute to a fine regulation of tumor angiogenesis and could ultimately affect cancer growth.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020; Mongiat, Maurizio/H-8297-2018	Mongiat, Maurizio/0000-0001-6509-0068; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adatia R, 1997, ANN ONCOL, V8, P1257, DOI 10.1023/A:1008243115385; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; COHEN IR, 1994, CANCER RES, V54, P5771; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; He ZH, 1999, CANCER RES, V59, P3222; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jones MB, 2003, GYNECOL ONCOL, V88, pS136, DOI 10.1006/gyno.2002.6704; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	32	107	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38113	38116		10.1074/jbc.C300310200	http://dx.doi.org/10.1074/jbc.C300310200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12900424	hybrid			2022-12-25	WOS:000185575100003
J	Loiseau, L; Ollagnier-de-Choudens, S; Nachin, L; Fontecave, M; Barras, F				Loiseau, L; Ollagnier-de-Choudens, S; Nachin, L; Fontecave, M; Barras, F			Biogenesis of Fe-S cluster by the bacterial SUF system - SufS and SufE form a new type of cysteine desulfurase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; NIFS-LIKE PROTEIN; ESCHERICHIA-COLI; SELENOCYSTEINE LYASE; MITOCHONDRIAL PROTEINS; CRYSTAL-STRUCTURE; GENE CLONING; ISCS; PERSULFIDE; CSDB	Biosynthesis of iron-sulfur clusters (Fe-S) depends on multiprotein systems. Recently, we described the SUF system of Escherichia coli and Erwinia chrysanthemi as being important for Fe-S biogenesis under stressful conditions. The SUF system is made of six proteins: SufC is an atypical cytoplasmic ABC-ATPase, which forms a complex with SufB and SufD; SufA plays the role of a scaffold protein for assembly of iron-sulfur clusters and delivery to target proteins; SufS is a cysteine desulfurase which mobilizes the sulfur atom from cysteine and provides it to the cluster; SufE has no associated function yet. Here we demonstrate that: (i) SufE and SufS are both cystosolic as all members of the SUF system; (ii) SufE is a homodimeric protein; (iii) SufE forms a complex with SufS as shown by the yeast two-hybrid system and by affinity chromatography; (iv) binding of SufE to SufS is responsible for a 50-fold stimulation of the cysteine desulfurase activity of SufS. This is the first example of a two-component cysteine desulfurase enzyme.	Univ Grenoble 1, Ctr Redox Biol, Lab Chim & Biochim, DBMS CB,CEA,CNRS,UMR 5047, F-38054 Grenoble 09, France; IBSM, CNRS, LCB, F-13402 Marseille 20, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Fontecave, M (corresponding author), Univ Grenoble 1, Ctr Redox Biol, Lab Chim & Biochim, DBMS CB,CEA,CNRS,UMR 5047, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr; barras@ibsm.cnrs-mrs.fr		Ollagnier de Choudens, Sandrine/0000-0002-0080-6659; Barras, Frederic/0000-0003-3458-2574				BORTOLIGERMAN I, 1994, MOL MICROBIOL, V11, P545, DOI 10.1111/j.1365-2958.1994.tb00335.x; Bouley J, 2001, J MOL BIOL, V308, P205, DOI 10.1006/jmbi.2001.4594; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clausen T, 2000, P NATL ACAD SCI USA, V97, P3856, DOI 10.1073/pnas.97.8.3856; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Fontecave M, 2003, CHEM REV, V103, P2149, DOI 10.1021/cr020427j; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hantke K, 2002, J MOL MICROB BIOTECH, V4, P217; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Lang T, 1999, J BIOL CHEM, V274, P189, DOI 10.1074/jbc.274.1.189; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lima CD, 2002, J MOL BIOL, V315, P1199, DOI 10.1006/jmbi.2001.5308; LUNDBLAD V, 1993, CURRENT PROTOCOLS MO; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Marquet A, 2001, CURR OPIN CHEM BIOL, V5, P541, DOI 10.1016/S1367-5931(00)00249-0; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 2002, J BIOCHEM, V131, P679, DOI 10.1093/oxfordjournals.jbchem.a003151; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Parry R. J., 1999, COMPREHENSIVE NATURA, V1, P825; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	44	162	172	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38352	38359		10.1074/jbc.M305953200	http://dx.doi.org/10.1074/jbc.M305953200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876288	hybrid			2022-12-25	WOS:000185575100034
J	Tang, ED; Inohara, N; Wang, CY; Nunez, G; Guan, KL				Tang, ED; Inohara, N; Wang, CY; Nunez, G; Guan, KL			Roles for homotypic interactions and transautophosphorylation in I kappa B kinase (IKK beta) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; PHOSPHORYLATION; ALPHA; RIP; COMPLEX; GAMMA; STIMULATION; SUBUNIT	The nuclear factor kappaB (NF-kappaB)/Rel family of transcription factors participates in a wide range of biological activities including inflammation, immunity, and apoptosis. NF-kappaB is kept inactive in the cytoplasm in unstimulated cells by virtue of the masking of its nuclear localization sequence by bound IkappaB protein. Cellular stimuli trigger the destruction of IkappaB proteins and the liberation of NF-kappaB to enter the nucleus and activate gene expression. A multisubunit IkappaB kinase complex (IKK) phosphorylates IkappaB proteins and mediates the activation of NF-kappaB by proinflammatory stimuli such as tumor necrosis factor alpha. Phosphorylation of IkappaB proteins triggers their polyubiquitination and their subsequent recognition and degradation by the proteasome. The IKK complex contains two catalytic subunits, IKKalpha and IKKbeta, and a noncatalytic subunit, NF-kappaB essential modifier/IKKgamma. IKK activation depends upon the phosphorylation of residues in the activation loop of IKKbeta and the subsequent activation of IKKbeta kinase activity. However, the events contributing to IKKbeta phosphorylation are not well understood. Here, we present evidence that the activation of IKKbeta depends on its ability to form homotypic interactions and to transautophosphorylate. We find that an intact leucine zipper in IKKbeta is necessary for homotypic interactions, kinase activation, and phosphorylation on its activation loop. Enforced oligomerization of an IKKbeta mutant defective in forming homotypic interactions restores kinase activation. Homotypic interactions allow IKKbeta molecules to transautophosphorylate one another on their activation loops. Finally, the oligomerization of IKKbeta is stimulated by tumor necrosis factor alpha in cultured cells. Our findings support a model whereby ligand-induced homotypic interactions between IKKbeta molecules result in IKKbeta phosphorylation and consequently IKK activation.	Univ Michigan, Dept Biol Chem, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Tang, ED (corresponding author), Univ Michigan, Dept Biol Chem, Sch Dent, Ann Arbor, MI 48109 USA.							Carter RS, 2003, J BIOL CHEM, V278, P19642, DOI 10.1074/jbc.M301705200; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Inohara N, 2000, J BIOL CHEM, V275, P27823; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; TANG ED, 2003, J BIOL CHEM; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	22	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38566	38570		10.1074/jbc.M304374200	http://dx.doi.org/10.1074/jbc.M304374200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12890679	hybrid			2022-12-25	WOS:000185575100059
J	Gao, HM; Liu, B; Zhang, WQ; Hong, JS				Gao, HM; Liu, B; Zhang, WQ; Hong, JS			Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease	FASEB JOURNAL			English	Article						microglia; microgliosis; neurodegeneration; reactive oxygen species; astroglia	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; NIGRAL DOPAMINERGIC-NEURONS; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; NEURODEGENERATIVE DISEASES; ACTIVATED MICROGLIA; INTRANIGRAL INJECTION; GLIAL-CELLS; BRAIN; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damages dopaminergic neurons as seen in Parkinson's disease. Although increasing evidence suggests an involvement of glia in MPTP neurotoxicity, the nature of this involvement remains unclear. Exploiting the advantage of cell culture systems, we demonstrated that microglia, but not astroglia, significantly enhanced the progression of MPTP-induced dopaminergic neurodegeneration. Characterization of the temporal relationship between neurodegeneration and microglial activation demonstrates that reactive microgliosis resulting from MPTP-initiated neuronal injury, but not direct activation, underlies the microglia-enhanced MPTP neurotoxicity. Mechanistically, through the release of NADPH oxidase-derived reactive oxygen species, microglia contribute to the progressive neuronal damage. Among the factors measured, the production of extracellular superoxide was the most prominent. NADPH oxidase inhibitor, apocynin, attenuated MPTP-induced dopaminergic neurodegeneration only in the presence of glia. More importantly, dopaminergic neurons from mice lacking NADPH oxidase, a key enzyme for superoxide production in immune cells, are significantly more resistant to MPTP neurotoxicity than those from wild-type controls, and microglia dictate the resistance. This study demonstrates that reactive microgliosis triggered by MPTP-induced neuronal injury and NADPH oxidase-mediated superoxide production in microglia constitute an integral component of MPTP neurotoxicity. This study also suggests that NADPH oxidase may be a promising target for therapeutic interventions in Parkinson's disease.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Liu, B (corresponding author), Univ Florida, Coll Pharm, Dept Pharmacodynam, POB 100487 HSC, Gainesville, FL 32610 USA.	liu@cop.ufl.edu	gao, huiming/C-8454-2012; Hong, Jau-shyong/F-1920-2019; liu, Bin/A-7695-2009	Hong, Jau-shyong/0000-0002-3056-8401; 				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Castano A, 1998, J NEUROCHEM, V70, P1584; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; CHAO CC, 1992, J IMMUNOL, V149, P2736; DAWSON TM, 1994, J NEUROSCI, V14, P5147; de Yebenes J G, 1988, J Neural Transm Suppl, V27, P141; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Fleckenstein AE, 1997, EUR J PHARMACOL, V334, P111, DOI 10.1016/S0014-2999(97)01175-8; FUKUI T, 1995, BBA-BIOENERGETICS, V1231, P215, DOI 10.1016/0005-2728(95)00098-4; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Hanson GR, 1998, ANN NY ACAD SCI, V844, P103, DOI 10.1111/j.1749-6632.1998.tb08225.x; Hao AJ, 2002, NEUROSCIENCE, V112, P889, DOI 10.1016/S0306-4522(02)00144-6; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055-8330(95)90015-2; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kay JN, 2000, DEV NEUROSCI-BASEL, V22, P56, DOI 10.1159/000017427; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Klegeris A, 2002, NEUROBIOL AGING, V23, P787, DOI 10.1016/S0197-4580(02)00021-0; KOSTIC V, 1991, NEUROLOGY, V41, P202, DOI 10.1212/WNL.41.2_Part_1.202; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Liberatore GT, 1999, NAT MED, V5, P1403; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.t01-1-00216.x; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MYTILINEOU C, 1984, SCIENCE, V225, P529, DOI 10.1126/science.6610939; NAGATSU T, 2000, J NEURAL TRANSM-SUPP, P77290; Noh KM, 2000, J NEUROSCI, V20; PARESHERBUTE N, 1988, DEV BRAIN RES, V40, P89, DOI 10.1016/0165-3806(88)90011-9; Park SU, 2002, J NEUROSCI, V22, P4399, DOI 10.1523/JNEUROSCI.22-11-04399.2002; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Quinn NP, 1998, NEUROLOGY, V51, pS25, DOI 10.1212/WNL.51.2_Suppl_2.S25; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Tammariello SP, 2000, J NEUROSCI, V20; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002	54	241	252	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11								10.1096/fj.03-0109fje	http://dx.doi.org/10.1096/fj.03-0109fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897068				2022-12-25	WOS:000185345100026
J	Gong, LJ; Li, YW; Nedeljkovic-Kurepa, A; Sarkar, FH				Gong, LJ; Li, YW; Nedeljkovic-Kurepa, A; Sarkar, FH			Inactivation of NF-kappa B by genistein is mediated via Akt signaling pathway in breast cancer cells	ONCOGENE			English	Article						genistein; NF-kappa B; Akt; breast cancer cells	INDUCED APOPTOSIS; LEUKEMIA-CELLS; UP-REGULATION; CYCLE ARREST; BETA-CATENIN; IN-VITRO; KINASE; ACTIVATION; INHIBITION; INDUCTION	Genistein, a natural isoflavonoid found in soybean products, has been proposed to be associated with a lower rate of breast cancer in Asian women. Studies from our laboratory and others have shown that genistein can induce apoptosis by regulating the expression of apoptosis-related genes in breast cancer cells. However, the precise molecular mechanism(s) by which genistein induces apoptotic cell death is not clear. In order to investigate such mechanism, we tested the role of Akt and NF-kappaB in genistein-treated MDA-MB-231 breast cancer cells. We found that inhibition of cell growth and induction of apoptosis by genistein are partly mediated through the downregulation of Akt and NF-kappaB pathways. Gel shift assay showed that NF-kappaB DNA-binding activity in MDA-MB-231 cells transfected with Akt cDNA was induced, suggesting that there is a cross-talk between NF-kappaB and Akt signaling pathway. Moreover, we found that genistein could abrogate EGF and Akt induced NF-kappaB activation. From these results, we conclude that the inactivation of NF-kappaB by genistein in MDA-MB-231 breast cancer cells is partly mediated via Akt pathway, which could be useful for rational design of strategies for the prevention and/or treatment of breast cancer.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Hudson Webber Canc Res Ctr 715,Dept Pathol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Hudson Webber Canc Res Ctr 715,Dept Pathol, 110 E Warren, Detroit, MI 48201 USA.	fsarkar@med.wayne.edu			NCI NIH HHS [CA83695-O1A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083695] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alhasan SA, 1999, NUTR CANCER, V34, P12, DOI 10.1207/S15327914NC340102; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bradlow HL, 2002, ANN NY ACAD SCI, V963, P247; Brownson DM, 2002, J NUTR, V132, p3482S, DOI 10.1093/jn/132.11.3482S; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; Chen M, 2000, Biostatistics, V1, P293, DOI 10.1093/biostatistics/1.3.293; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; Dale TC, 1998, BIOCHEM J, V329, P209; Davis JN, 1998, NUTR CANCER, V32, P123, DOI 10.1080/01635589809514730; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Fotsis T, 1997, CANCER RES, V57, P2916; GRAY GE, 1979, BRIT J CANCER, V39, P1, DOI 10.1038/bjc.1979.1; GRILLI M, 1993, INT REV CYTOL, V143, P1; HIRAYAMA T, 1978, PREV MED, V7, P173, DOI 10.1016/0091-7435(78)90244-X; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650; Li YW, 1999, INT J ONCOL, V15, P525; Li YW, 2002, CLIN CANCER RES, V8, P2369; Lian FR, 1998, NUTR CANCER, V31, P184, DOI 10.1080/01635589809514701; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; MILLER AB, 1977, CANCER-AM CANCER SOC, V39, P2704, DOI 10.1002/1097-0142(197706)39:6<2704::AID-CNCR2820390657>3.0.CO;2-G; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Ozes ON, 1999, NATURE, V401, P82; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Santibanez JF, 2000, NUTR CANCER, V37, P49, DOI 10.1207/S15327914NC3701_6; Shao ZM, 1998, CANCER RES, V58, P4851; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; VAN AD, 1996, SCIENCE, V274, P787; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WEI HC, 1993, NUTR CANCER, V20, P1, DOI 10.1080/01635589309514265; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	49	199	207	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4702	4709		10.1038/sj.onc.1206583	http://dx.doi.org/10.1038/sj.onc.1206583			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879015				2022-12-25	WOS:000184157000011
J	Bruns, K; Fossen, T; Wray, V; Henklein, P; Tessmer, U; Schubert, U				Bruns, K; Fossen, T; Wray, V; Henklein, P; Tessmer, U; Schubert, U			Structural characterization of the HIV-1 Vpr N terminus - Evidence of cis/trans-proline isomerism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL PROTEIN-R; NUCLEAR-LOCALIZATION SIGNAL; CELL-CYCLE; SECONDARY STRUCTURE; NMR STRUCTURE; CIRCULAR-DICHROISM; PEPTIDE-FRAGMENTS; MATRIX PROTEIN; AMINO-ACIDS	The 96-residue human immunodeficiency virus (HIV) accessory protein Vpr serves manifold functions in the retroviral life cycle including augmentation of viral replication in non-dividing host cells, induction of G(2) cell cycle arrest, and modulation of HIV-induced apoptosis. Using a combination of dynamic light scattering, circular dichroism, and NMR spectroscopy the N terminus of Vpr is shown to be a unique domain of the molecule that behaves differently from the C-terminal domain in terms of self-association and secondary structure folding. Interestingly, the four highly conserved proline residues in the N terminus are predicted to have a high propensity for cis/trans isomerism. Thus the high resolution structure and folding of a synthetic N-terminal peptide (Vpr(1-40)) and smaller fragments thereof have been investigated. H-1 NMR data indicate Vpr(1-40) possesses helical structure between residues 17-32, and for the first time, this helix, which is bound by proline residues, was observed even in aqueous solution devoid of any detergent supplements. In addition, NMR data revealed that all of the proline residues undergo a cis/trans isomerism to such an extent that similar to40% of all Vpr molecules possess at least one proline in a cis conformation. This phenomenon of cis/trans isomerism, which is unprecedented for HIV-1 Vpr, not only provides an explanation for the molecular heterogeneity observed in the full-length molecule but also indicates that in vivo the folding and function of Vpr should depend on a cis/trans-proline isomerase activity, particularly as two of the proline residues in positions 14 and 35 show considerable amounts of cis isomers. This prediction correlates well with our recent observation (Zander, K., Sherman, M. P., Tessmer, U., Bruns, K., Wray, V., Prechtel, A. T., Schubert, E., Henklein, P., Luban, J., Neidleman, J., Greene, W. C., and Schubert, U. (2003) J. Biol. Chem. 278, 43170-43181) of a functional interaction between the major cellular isomerase cyclophilin A and Vpr, both of which are incorporated into HIV-1 virions.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Gesell Biotechnol Forsch mbH, Dept Biol Struct, D-38124 Braunschweig, Germany; Univ Hamburg, Heinrich Pette Inst, D-20251 Hamburg, Germany; Univ Bergen, Dept Chem, N-5007 Bergen, Norway; Humboldt Univ, Inst Biochem, D-10115 Berlin, Germany; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	University of Erlangen Nuremberg; Gesellschaft fur Biotechnologische Forschung mbH; Heinrich Pette Institute; University of Hamburg; University of Bergen; Humboldt University of Berlin; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schubert, U (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	ulrich.schubert@viro.med.uni-erlangen			NIDDK NIH HHS [DK59537-1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059537] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Agostini I, 1999, FEBS LETT, V450, P235, DOI 10.1016/S0014-5793(99)00501-3; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1999, FRONT BIOSCI, V4, P772; Chang DK, 1999, J STRUCT BIOL, V128, P270, DOI 10.1006/jsbi.1999.4182; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Cornille F, 1999, J PEPT RES, V54, P427, DOI 10.1034/j.1399-3011.1999.00129.x; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; HIV Sequence Database, HIV SEQ DAT; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jenkins Y, 2001, J VIROL, V75, P10537, DOI 10.1128/JVI.75.21.10537-10542.2001; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; Livingstone CD, 1996, METHOD ENZYMOL, V266, P497; Luban J, 1996, CELL, V87, P1157, DOI 10.1016/S0092-8674(00)81811-5; Luo ZW, 1998, BIOCHEM BIOPH RES CO, V244, P732, DOI 10.1006/bbrc.1998.8330; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; Muller B, 2000, J VIROL, V74, P9727, DOI 10.1128/JVI.74.20.9727-9731.2000; Nardi F, 2000, J BIOMOL NMR, V17, P63, DOI 10.1023/A:1008380807603; NEIDIG KP, 1990, J MAGN RESON, V88, P155, DOI 10.1016/0022-2364(90)90119-T; ONeal KD, 1996, BIOCHEM J, V315, P833, DOI 10.1042/bj3150833; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Piller SC, 1999, J VIROL, V73, P4230, DOI 10.1128/JVI.73.5.4230-4238.1999; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; Poon B, 1998, SCIENCE, V281, P266, DOI 10.1126/science.281.5374.266; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; Rizzardi GP, 2002, J CLIN INVEST, V109, P681, DOI 10.1172/JCI200214522; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Roques BP, 1997, BIOCHIMIE, V79, P673, DOI 10.1016/S0300-9084(97)83501-8; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Sherman MP, 2000, J VIROL, V74, P8159, DOI 10.1128/JVI.74.17.8159-8165.2000; Singh SP, 2000, J VIROL, V74, P10650, DOI 10.1128/JVI.74.22.10650-10657.2000; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zander K, 2003, J BIOL CHEM, V278, P43202, DOI 10.1074/jbc.M305414200; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	79	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43188	43201		10.1074/jbc.M305413200	http://dx.doi.org/10.1074/jbc.M305413200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12881523	hybrid			2022-12-25	WOS:000186157000060
J	Chang, JH; Mellon, E; Schanen, NC; Twiss, JL				Chang, JH; Mellon, E; Schanen, NC; Twiss, JL			Persistent TrkA activity is necessary to maintain transcription in neuronally differentiated PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; HIGH-AFFINITY RECEPTORS; NUCLEAR-PROTEIN CBP; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; SENSORY NEURONS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; FACTOR CREB	Neurotrophins are required for the differentiation and survival of several different neuronal subpopulations in the developing nervous system. The PC12 cell line responds to nerve growth factor (NGF) by withdrawing from the cell cycle and acquiring a sympathetic neuron-like phenotype. Previous studies have shown that the activation kinetics of the NGF receptor, TrkA, and downstream protein kinases appear rapid and seemingly transient after NGF treatment of naive PC12 cells. However, maintenance of the neuronal phenotype and survival of differentiated PC12 cells under serum-free conditions require constant NGF exposure. In this study we have addressed the mechanisms that NGF uses to maintain neuronal PC12 cells. We show that TrkA remains phosphorylated at a basal level throughout differentiation of the PC12 cells. The phospho-TrkA levels in the differentiated PC12 cells were diminished by both complete NGF withdrawal and pharmacological inhibition of Trk kinase activity. Intracellular sequestration of the majority of TrkA molecules ( both phosphorylated and nonphosphorylated TrkA) and persistent dephosphorylation of the small pool of cell surface TrkA renders the persistent phospho-TrkA signal in the differentiated PC12 cells resistant to partial NGF withdrawal as well as exposure to additional NGF. NGF regulated both extracellular-regulated kinases 1/2 and Akt activity in the differentiated PC12 cells via sustained TrkA activity. Moreover, analysis of transcription using activating protein 1-, serum response element-, and cyclic AMP response element- Luc reporter constructs showed that NGF regulated these promoters through TrkA activity in differentiated PC12 cells. Interestingly, the initial response of the cyclic AMP response element promoter to NGF was delayed, becoming Trk-dependent well beyond the peaks in TrkA and downstream protein kinase signal transduction.	Alfred I DuPont Hosp Children, Nemours Biomed Res, Neurosci Res Lab, Wilmington, DE 19803 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Cellular & Mol Pathol Grad Program, Los Angeles, CA 90095 USA	Nemours Alfred I. duPont Hospital for Children; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Twiss, JL (corresponding author), Alfred I DuPont Hosp Children, Nemours Biomed Res, Neurosci Res Lab, 1600 Rockland Rd, Wilmington, DE 19803 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK059752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041596] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 37874] Funding Source: Medline; NIDDK NIH HHS [DK 59752] Funding Source: Medline; NINDS NIH HHS [NS 41596] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Beattie EC, 2000, J NEUROSCI, V20, P7325; BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; BERG MM, 1992, J BIOL CHEM, V267, P13; BERND P, 1984, J BIOL CHEM, V259, P5509; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Canossa M, 1996, EMBO J, V15, P3369, DOI 10.1002/j.1460-2075.1996.tb00702.x; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes ML, 1996, J NEUROSCI, V16, P7950; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; Jiang H, 1997, J BIOL CHEM, V272, P6835, DOI 10.1074/jbc.272.11.6835; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Malcangio M, 1997, J NEUROSCI, V17, P8459; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Minneman KP, 2000, J NEUROCHEM, V74, P2392, DOI 10.1046/j.1471-4159.2000.0742392.x; MOHIUDDIN L, 1995, NEUROSCI LETT, V185, P20, DOI 10.1016/0304-3940(94)11215-5; MOLLIVER DC, 1995, J COMP NEUROL, V361, P404, DOI 10.1002/cne.903610305; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Senger DL, 1997, J CELL BIOL, V138, P411, DOI 10.1083/jcb.138.2.411; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH DS, 1989, J NEUROCHEM, V53, P800, DOI 10.1111/j.1471-4159.1989.tb11776.x; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAPLEY P, 1992, ONCOGENE, V7, P371; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsui-Pierchala BA, 1999, J NEUROSCI, V19, P8207; TWISS JL, 1995, J NEUROCHEM, V64, P550; Twiss JL, 1998, J NEUROSCI RES, V51, P442, DOI 10.1002/(SICI)1097-4547(19980215)51:4<442::AID-JNR4>3.0.CO;2-C; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Ye HH, 2003, NEURON, V39, P57, DOI 10.1016/S0896-6273(03)00266-6; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU J, 1995, J NEUROCHEM, V65, P1146	71	39	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42877	42885		10.1074/jbc.M308155200	http://dx.doi.org/10.1074/jbc.M308155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12909622	hybrid			2022-12-25	WOS:000186157000019
J	Balasubramanian, S; Kuppuswamy, D				Balasubramanian, S; Kuppuswamy, D			RGD-containing peptides activate S6K1 through beta(3) integrin in adult cardiac muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SIGNALING PATHWAY; FOCAL COMPLEX-FORMATION; MATRIX METALLOPROTEINASES; MONOCLONAL-ANTIBODIES; PROTEIN-SYNTHESIS; HEART-FAILURE; IN-VIVO; C-SRC; P70; PHOSPHORYLATION	The enzyme p70S6 kinase (S6K1) is critical for cell growth, and we have reported its activation during cardiac hypertrophy. Because cardiac hypertrophy also involves integrin activation, we analyzed whether integrins could contribute to S6K1 activation. Using adult feline cardiomyocytes, here we report that integrin-interacting Arg-Gly-Asp (RGD) peptides activate S6K1 as observed by band shifting, kinase activity and phosphorylation at Thr-389 and Thr-421/Ser-424 of S6K1, and S6 protein phosphorylation. Perturbation of specific integrin function with blocking antibodies and by overexpressing the beta(1A) cytoplasmic tail revealed that beta(3) but not beta(1) integrin mediates the RGD-induced S6K1 activation. This activation is focal adhesion complex-independent and is accompanied by the activation of extracellular signal-regulated kinases 1/2 (ERK) and mammalian target of rapamycin (mTOR). Studies using specific inhibitors and dominant negative c-Raf expression in cardiomyocytes indicate that the S6K1 activation involves mTOR, MEK/ERK, and phosphatidylinositol 3-kinase pathways and is independent of protein kinase C and c-Raf. Finally, addition of fluorescent-labeled RGD peptide to cardiomyocytes exhibits its internalization and localization to the endocytic vesicles, and pretreatment of cardiomyocytes with endocytic inhibitors reduced the S6K1 activation. These data suggest that RGD interaction with beta(3) integrin and its subsequent endocytosis trigger specific signaling pathway(s) for S6K1 activation in cardiomyocytes and that this process may contribute to hypertrophic growth and remodeling of myocardium.	Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kuppuswamy, D (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 114 Doughty St, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL 48788] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Blystone SD, 2002, J BIOL CHEM, V277, P46886, DOI 10.1074/jbc.M209506200; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Castel S, 2001, LAB INVEST, V81, P1615, DOI 10.1038/labinvest.3780375; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Erbacher P, 1999, GENE THER, V6, P138, DOI 10.1038/sj.gt.3300783; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; GARFIELD RE, 1975, LAB INVEST, V33, P418; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Goto M, 1999, J AM SOC NEPHROL, V10, P1640; Hein TW, 2001, AM J PHYSIOL-HEART C, V281, pH2378, DOI 10.1152/ajpheart.2001.281.6.H2378; HELFRICH MH, 1992, J BONE MINER RES, V7, P345; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Hoshijima M, 2002, J CLIN INVEST, V109, P849, DOI 10.1172/JCI15380; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200; Li YY, 2000, CARDIOVASC RES, V46, P214, DOI 10.1016/S0008-6363(00)00003-1; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lindemann S, 2001, J BIOL CHEM, V276, P33947, DOI 10.1074/jbc.M104281200; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MANN DL, 1991, CIRC RES, V68, P402, DOI 10.1161/01.RES.68.2.402; MARINO TA, 1983, ANAT REC, V207, P417, DOI 10.1002/ar.1092070304; Mde N. Soeiro, 2002, CELL STRUCT FUNCT, V27, P469; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nagai T, 1999, AM J CARDIOL, V83, p38H; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Pabla R, 1999, J CELL BIOL, V144, P175, DOI 10.1083/jcb.144.1.175; PAGE E, 1994, CIRC RES, V75, P335, DOI 10.1161/01.RES.75.2.335; PAGE E, 1993, AM J PHYSIOL, V365, pC986; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Perlot RL, 2002, J BONE MINER RES, V17, P66, DOI 10.1359/jbmr.2002.17.1.66; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Ross RS, 2001, CIRC RES, V88, P1112, DOI 10.1161/hh1101.091862; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Shai SY, 2002, CIRC RES, V90, P458, DOI 10.1161/hh0402.105790; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; TERADA N, 1993, J BIOL CHEM, V268, P12062; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; TRANQUI L, 1993, J CELL SCI, V106, P377; Triantafilou K, 2001, CRIT REV IMMUNOL, V21, P311; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Whittard JD, 2001, J CELL SCI, V114, P3265; WILDENTHAL K, 1980, FED PROC, V39, P37; Willey CD, 2003, J MOL CELL CARDIOL, V35, P671, DOI 10.1016/S0022-2828(03)00112-3; Wilson EM, 2001, ANN MED, V33, P623, DOI 10.3109/07853890109002108; Zhao MW, 1999, INVEST OPHTH VIS SCI, V40, P2713	65	40	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42214	42224		10.1074/jbc.M303428200	http://dx.doi.org/10.1074/jbc.M303428200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909616	hybrid			2022-12-25	WOS:000185989500080
J	Hartlieb, B; Modrof, J; Muhlberger, E; Klenk, HD; Becker, S				Hartlieb, B; Modrof, J; Muhlberger, E; Klenk, HD; Becker, S			Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; PROTEIN OLIGOMERIZATION; SECONDARY STRUCTURE; MARBURG-VIRUS; DOMAIN; PROMOTER; TRANSACTIVATION; PHOSPHORYLATION; REPLICATION; EXPRESSION	Transcription of Ebola virus ( EBOV)-specific mRNA is driven by the nucleocapsid proteins NP, VP35, and L. This process is further dependent on VP30, an essential EBOV-specific transcription factor. The present study addresses the self-assembly of VP30 and the functional significance of this process for viral transcription and propagation. Essential for oligomerization of VP30 is a region spanning amino acids 94 - 112. Within this region a cluster of four leucine residues is of critical importance. Mutation of only one of these leucine residues resulted in oligomerization-deficient VP30 molecules that were no longer able to support EBOV-specific transcription. The essential role of homo-oligomerization for the function of VP30 was further corroborated by the finding that mixed VP30 oligomers consisting of VP30 and transcriptionally inactive VP30 mutants were impaired in their ability to support EBOV transcription. The dominant negative effect of these VP30 mutants was dependent on their ability to bind to VP30. The oligomerization of VP30 could be dose dependently inhibited by a 25-mer peptide (E30(pep)-wt) derived from the presumed oligomerization domain (IC50, 1 muM). A control peptide (E30(pep)-3LA), in which three leucines were changed to alanine, had no inhibitory effect. Thus, E30(pep)-wt seemed to bind efficiently to VP30 and consequently blocked the oligomerization of the protein. When E30(pep)-wt was transfected into EBOV-infected cells, the peptide inhibited viral replication suggesting that inhibition of VP30 oligomerization represents a target for EBOV antiviral drugs.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Becker, S (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.		Modrof, Jens/AAU-4681-2020; Muhlberger, Elke/AAD-6924-2019; Modrof, Jens/AAQ-8751-2020	Modrof, Jens/0000-0001-8416-7681; Muhlberger, Elke/0000-0003-3547-9376				[Anonymous], 2001, Wkly Epidemiol Rec, V76, P41; Ashmole I, 1998, VIROLOGY, V240, P221, DOI 10.1006/viro.1997.8909; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; BECKER S, 1992, MED MICROBIOL IMMUN, V181, P43, DOI 10.1007/BF00193395; BOWEN ETW, 1977, LANCET, V1, P571; Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Choudhary SK, 2002, VIROLOGY, V302, P373, DOI 10.1006/viro.2002.1668; Conzelmann KK, 1998, ANNU REV GENET, V32, P123, DOI 10.1146/annurev.genet.32.1.123; CURRAN J, 1995, VIROLOGY, V214, P139, DOI 10.1006/viro.1995.9946; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; ELLIOTT LH, 1985, VIROLOGY, V147, P169, DOI 10.1016/0042-6822(85)90236-3; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003; Lium EK, 1998, J VIROL, V72, P7785, DOI 10.1128/JVI.72.10.7785-7795.1998; Lutzke RAP, 1998, J VIROL, V72, P4841, DOI 10.1128/JVI.72.6.4841-4848.1998; Maroun RG, 2001, BIOCHEMISTRY-US, V40, P13840, DOI 10.1021/bi011328n; Modrof J, 2003, J VIROL, V77, P3334, DOI 10.1128/JVI.77.5.3334-3338.2003; Modrof J, 2002, J BIOL CHEM, V277, P33099, DOI 10.1074/jbc.M203775200; Modrof J, 2001, VIROLOGY, V287, P171, DOI 10.1006/viro.2001.1027; Muhlberger E, 1999, J VIROL, V73, P2333; Noda T, 2002, J VIROL, V76, P4855, DOI 10.1128/JVI.76.10.4855-4865.2002; Olson VA, 2001, J VIROL, V75, P6042, DOI 10.1128/JVI.75.13.6042-6051.2001; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SANCHEZ A, 1989, VIROLOGY, V170, P81, DOI 10.1016/0042-6822(89)90354-1; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Thomas SL, 1998, J VIROL, V72, P2935, DOI 10.1128/JVI.72.4.2935-2944.1998; Timmins J, 2003, J MOL BIOL, V326, P493, DOI 10.1016/S0022-2836(02)01406-7; Volchkov VE, 2001, SCIENCE, V291, P1965, DOI 10.1126/science.1057269; Weik M, 2002, J VIROL, V76, P8532, DOI 10.1128/JVI.76.17.8532-8539.2002; *WHO, 1995, EPIDEMIOL B, V16, P16; *WHO, 1999, WKLY EPIDEMIOL REC, V74, P145	37	56	61	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41830	41836		10.1074/jbc.M307036200	http://dx.doi.org/10.1074/jbc.M307036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912982	hybrid			2022-12-25	WOS:000185989500035
J	Steinbacher, S; Schiffmann, S; Richter, G; Huber, R; Bacher, A; Fischer, M				Steinbacher, S; Schiffmann, S; Richter, G; Huber, R; Bacher, A; Fischer, M			Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase from Methanococcus jannaschii in complex with divalent metal ions and the substrate ribulose 5-phosphate - Implications for the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; D-XYLOSE ISOMERASE; ESCHERICHIA-COLI; CYCLOHYDROLASE-II; CRYSTAL-STRUCTURE; RIBOFLAVIN; BIOSYNTHESIS; PURIFICATION; DEAMINASE; REDUCTASE	Skeletal rearrangements of carbohydrates are crucial for many biosynthetic pathways. In riboflavin biosynthesis ribulose 5-phosphate is converted into 3,4-dihydroxy-2-butanone 4-phosphate while its C4 atom is released as formate in a sequence of metal-dependent reactions. Here, we present the crystal structure of Methanococcus jannaschii 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with the substrate ribulose 5-phosphate at a dimetal center presumably consisting of non-catalytic zinc and calcium ions at 1.7-Angstrom resolution. The carbonyl group (O2) and two out of three free hydroxyl groups (OH3 and OH4) of the substrate are metal-coordinated. We correlate previous mutational studies on this enzyme with the present structural results. Residues of the first coordination sphere involved in metal binding are indispensable for catalytic activity. Only Glu-185 of the second coordination sphere cannot be replaced without complete loss of activity. It contacts the C3 hydrogen atom directly and probably initiates enediol formation in concert with both metal ions to start the reaction sequence. Mechanistic similarities to Rubisco acting on the similar substrate ribulose 1,5-diphosphate in carbon dioxide fixation as well as other carbohydrate (reducto-) isomerases are discussed.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Max Planck Society; Technical University of Munich	Steinbacher, S (corresponding author), CALTECH, Div Chem & Chem Engn, Mail Code 114-96, Pasadena, CA 91125 USA.	steinbac@caltech.edu	Fischer, Markus/AFT-1856-2022; Fischer, Markus J./G-9477-2012; Richter, Gerald/F-3642-2011	Fischer, Markus/0000-0001-7243-4199; Schiffmann, Susanne/0000-0001-5035-2504				ANDREWS TJ, 1991, J BIOL CHEM, V266, P9447; Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; Bacher A., 1996, ESCHERICHIA COLI SAL, V1, P657; BACHER A, 2001, BIOSYNTHESIS RIBOFLA, P61; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer S, 2003, J MOL BIOL, V326, P1463, DOI 10.1016/S0022-2836(03)00059-7; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Bornemann S, 2002, NAT PROD REP, V19, P761, DOI 10.1039/b108916c; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURROWS RB, 1978, J BACTERIOL, V136, P657, DOI 10.1128/JB.136.2.657-667.1978; CALLENS M, 1988, BIOCHEM J, V250, P285, DOI 10.1042/bj2500285; CALVIN M, 1954, Fed Proc, V13, P697; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; COLLYER CA, 1990, J MOL BIOL, V212, P211, DOI 10.1016/0022-2836(90)90316-E; Dumas R, 2001, ACCOUNTS CHEM RES, V34, P399, DOI 10.1021/ar000082w; Feierberg I, 2002, THEOR CHEM ACC, V108, P71, DOI 10.1007/s00214-002-0365-7; Fischer M, 2003, J MOL BIOL, V326, P783, DOI 10.1016/S0022-2836(02)01473-0; Fischer M, 2002, J BIOL CHEM, V277, P41410, DOI 10.1074/jbc.M206863200; FOOR F, 1975, J BIOL CHEM, V250, P3545; Garcia-Viloca M, 2002, J AM CHEM SOC, V124, P7268, DOI 10.1021/ja026383d; HARZER G, 1978, BIOCHIM BIOPHYS ACTA, V540, P48, DOI 10.1016/0304-4165(78)90433-6; HOLLANDER I, 1979, BIOCHEM BIOPH RES CO, V89, P759, DOI 10.1016/0006-291X(79)90694-6; JONES TA, 1992, MOL REPLACEMENT, P91; Kelly MJS, 2001, P NATL ACAD SCI USA, V98, P13025, DOI 10.1073/pnas.231323598; LARIMER FW, 1994, J BIOL CHEM, V269, P11114; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee J., 1985, CHEM BIOLUMINESCENCE, P401; Liao DI, 2002, BIOCHEMISTRY-US, V41, P1795, DOI 10.1021/bi015652u; Liao DI, 2001, STRUCTURE, V9, P11, DOI 10.1016/S0969-2126(00)00550-5; MEIGHEN EA, 1993, FASEB J, V7, P1016, DOI 10.1096/fasebj.7.11.8370470; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MERRILL AH, 1980, J BIOL CHEM, V255, P1335; Morell MK, 1997, J BIOL CHEM, V272, P5445, DOI 10.1074/jbc.272.9.5445; MULLER F, 1992, CHEM BIOCH FLAVOENZY, V3; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V139, P1111, DOI 10.1016/S0006-291X(86)80292-3; NIELSEN P, 1981, BIOCHIM BIOPHYS ACTA, V662, P312, DOI 10.1016/0005-2744(81)90044-9; OKANE DJ, 1992, MOL MICROBIOL, V6, P443, DOI 10.1111/j.1365-2958.1992.tb01488.x; Olson LP, 1996, BIOCHEMISTRY-US, V35, P9782, DOI 10.1021/bi952020x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peach C., 1978, BIOCHEM BIOPH RES CO, V83, P1084; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PIERCE J, 1986, J BIOL CHEM, V261, P248; PLAUT GWE, 1960, J BIOL CHEM, V235, pPC41; PLAUT GWE, 1974, ANNU REV BIOCHEM, V43, P899, DOI 10.1146/annurev.bi.43.070174.004343; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RICHARD JP, 1984, J AM CHEM SOC, V106, P4926, DOI 10.1021/ja00329a050; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Scheuring J, 2001, J ORG CHEM, V66, P3811, DOI 10.1021/jo001739u; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Steinbacher S, 2003, J BIOL CHEM, V278, P18401, DOI 10.1074/jbc.M300993200; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; TURK D, 1992, THESIS TU MUNCHEN MU; VOLK R, 1990, J BIOL CHEM, V265, P19479; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; VOLK R, 1991, J BIOL CHEM, V266, P20610; WACKER H, 1964, J BIOL CHEM, V239, P3493; Wagner T, 2000, J MOL BIOL, V301, P389, DOI 10.1006/jmbi.2000.3957; YOUNG DW, 1986, NAT PROD REP, V3, P395, DOI 10.1039/np9860300395	65	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42256	42265		10.1074/jbc.M307301200	http://dx.doi.org/10.1074/jbc.M307301200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12904291	hybrid, Green Accepted			2022-12-25	WOS:000185989500085
J	Aguilera, B; Ghauharali-van der Vlugt, K; Helmond, MTJ; Out, JMM; Donker-Koopman, WE; Groener, JEM; Boot, RG; Renkema, GH; van der Marel, GA; van Boom, JH; Overkleeft, HS; Aerts, JMFG				Aguilera, B; Ghauharali-van der Vlugt, K; Helmond, MTJ; Out, JMM; Donker-Koopman, WE; Groener, JEM; Boot, RG; Renkema, GH; van der Marel, GA; van Boom, JH; Overkleeft, HS; Aerts, JMFG			Transglycosidase activity of chitotriosidase - Improved enzymatic assay for the human macrophage chitinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHERS-DISEASE; PLASMA; OLIGOSACCHARIDES; LYSOZYME; EMBRYOGENESIS; SUBSTRATE; DISTINCT; PLANT	Chitotriosidase is a chitinase that is massively expressed by lipid-laden tissue macrophages in man. Its enzymatic activity is markedly elevated in serum of patients suffering from lysosomal lipid storage disorders, sarcoidosis, thalassemia, and visceral Leishmaniasis. Monitoring of serum chitotriosidase activity in Gaucher disease patients during progression and therapeutic correction of their disease is useful to obtain insight in changes in body burden on pathological macrophages. However, accurate quantification of chitotriosidase levels by enzyme assay is complicated by apparent substrate inhibition, which prohibits the use of saturating substrate concentrations. We have therefore studied the catalytic features of chitotriosidase in more detail. It is demonstrated that the inhibition of enzyme activity at excess substrate concentration can be fully explained by transglycosylation of substrate molecules. The potential physiological consequences of the ability of chitotriosidase to hydrolyze as well as transglycosylate are discussed. The novel insight in transglycosidase activity of chitotriosidase has led to the design of a new substrate molecule, 4-methylumbelliferyl-(4-deoxy) chitobiose. With this substrate, which is no acceptor for transglycosylation, chitotriosidase shows normal Michaelis-Menten kinetics, resulting in major improvements in sensitivity and reproducibility of enzymatic activity measurements. The novel convenient chitotriosidase enzyme assay should facilitate the accurate monitoring of Gaucher disease patients receiving costly enzyme replacement therapy.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Tampere University	Aerts, JMFG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.		Aerts, Johannes/A-1028-2009; Renkema, Herma/L-1489-2015	Aerts, Johannes/0000-0001-8168-2565; Renkema, Herma/0000-0002-8174-6538; Overkleeft, Herman/0000-0001-6976-7005; Boot, Rolf/0000-0002-7031-3390				Aerts JMFG, 1997, BAILLIERE CLIN HAEM, V10, P691, DOI 10.1016/S0950-3536(97)80034-0; Bakkers J, 1999, EXS, V87, P71; Bakkers J, 1997, P NATL ACAD SCI USA, V94, P7982, DOI 10.1073/pnas.94.15.7982; Barone R, 1999, BLOOD CELL MOL DIS, V25, P1, DOI 10.1006/bcmd.1999.0221; BARTON DHR, 1975, J CHEM SOC PERK T 1, P1574, DOI 10.1039/p19750001574; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Choi EH, 2001, GENES IMMUN, V2, P248, DOI 10.1038/sj.gene.6363767; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; DELMOTTE FM, 1975, CARBOHYD RES, V40, P353, DOI 10.1016/S0008-6215(00)82616-6; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; INABA T, 1984, CHEM PHARM BULL, V32, P1597; KIM S, 1985, J ORG CHEM, V50, P1751, DOI 10.1021/jo00210a036; Mistry PK, 1997, BAILLIERE CLIN HAEM, V10, P817, DOI 10.1016/S0950-3536(97)80042-X; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Semino CE, 2000, INT J DEV BIOL, V44, P183; SHABAN M, 1971, CARBOHYD RES, V19, P311, DOI 10.1016/S0008-6215(00)86161-3; SHAHABUDDIN M, 1993, PARASITOL TODAY, V9, P252, DOI 10.1016/0169-4758(93)90069-R; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003	25	126	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40911	40916		10.1074/jbc.M301804200	http://dx.doi.org/10.1074/jbc.M301804200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890686	hybrid, Green Published			2022-12-25	WOS:000185847200062
J	Broedl, UC; Maugeais, C; Marchadier, D; Glick, JM; Rader, DJ				Broedl, UC; Maugeais, C; Marchadier, D; Glick, JM; Rader, DJ			Effects of nonlipolytic ligand function of endothelial lipase on high density lipoprotein metabolism in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC LIPASE; TRANSGENIC MICE; DEFICIENT MICE; HDL CHOLESTEROL; OVEREXPRESSION; DETERMINANT; EXPRESSION; BINDING; PLASMA	Endothelial lipase (EL) influences high density lipoprotein (HDL) metabolism in vivo and mediates bridging and uptake of HDL particles independent of its lipolytic activity in vitro. To determine whether EL has a nonlipolytic ligand function in HDL metabolism in vivo, 1 x 10(11) particles of a recombinant adenovirus encoding human EL (AdEL), catalytically inactive human EL (AdEL(S149A)), or control (Adnull) were injected into wildtype, apoA-I transgenic, and hepatic lipase knockout mice. ELS149A protein was expressed at higher levels than wild-type EL. EL and ELS149A protein were both substantially increased in the postheparin plasma compared with preheparin, indicating that both the wildtype and mutant EL were bound to cell-surface heparan sulfate proteoglycans. Overexpression of wild-type EL was associated with a significantly increased postheparin-plasma phospholipase activity and dramatically decreased levels of total cholesterol, HDL cholesterol, phospholipids, and apoA-I. Injection of AdEL(S149A) did not result in increased phospholipase activity confirming that ELS149A was catalytically inactive. Expression of ELS149A did not decrease lipid or apoA-I levels in wild-type and apoA-I transgenic mice yet led to an intermediate reduction of total cholesterol, HDL cholesterol, and phospholipids in hepatic lipase-deficient mice compared with control and EL-expressing mice. Our study demonstrates for the first time that EL has both a lipolytic and nonlipolytic function in HDL metabolism in vivo. Lipolytic activity of EL, however, seems to be most important for its effects on systemic HDL metabolism.	Univ Penn, Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania	Rader, DJ (corresponding author), Univ Penn, Med Ctr, 654 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL55323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055323, R37HL055323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; BELFRAGE P, 1969, J LIPID RES, V10, P341; BLADES B, 1993, ARTERIOSCLER THROMB, V13, P1227, DOI 10.1161/01.ATV.13.8.1227; Dichek HL, 2001, J LIPID RES, V42, P201; Dichek HL, 1998, J BIOL CHEM, V273, P1896, DOI 10.1074/jbc.273.4.1896; Dugi KA, 1997, J LIPID RES, V38, P1822; Dugi KA, 2000, ARTERIOSCL THROM VAS, V20, P793, DOI 10.1161/01.ATV.20.3.793; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; Ma K, 2003, P NATL ACAD SCI USA, V100, P2748, DOI 10.1073/pnas.0438039100; MAUGEAIS C, 2003, IN PRESS CIRCULATION; McCoy MG, 2002, J LIPID RES, V43, P921; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Merkel M, 2002, J BIOL CHEM, V277, P7405, DOI 10.1074/jbc.M107914200; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; Strauss JG, 2002, BIOCHEM J, V368, P69, DOI 10.1042/BJ20020306; Ye XH, 1996, J BIOL CHEM, V271, P3639	21	54	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40688	40693		10.1074/jbc.M304367200	http://dx.doi.org/10.1074/jbc.M304367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909635	hybrid			2022-12-25	WOS:000185847200033
J	Min, JK; Kim, YM; Kim, YM; Kim, EC; Gho, YS; Kang, IJ; Lee, SY; Kong, YY; Kwon, YG				Min, JK; Kim, YM; Kim, YM; Kim, EC; Gho, YS; Kang, IJ; Lee, SY; Kong, YY; Kwon, YG			Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells - Concomitant increase of angiogenic responses to RANK ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF FAMILY-MEMBER; OSTEOCLAST DIFFERENTIATION; INDUCED CYTOKINE; NITRIC-OXIDE; FACTOR VEGF; T-CELLS; BONE; KINASE; TRANCE	Vascular endothelial growth factor ( VEGF) is known as a key regulator of angiogenesis during endochondral bone formation. Recently, we demonstrated that TNF-related activation-induced cytokine ( TRANCE or RANKL), which is essential for bone remodeling, also had an angiogenic activity. Here we report that VEGF up-regulates expression of receptor activator of NF-kappa B ( RANK) and increases angiogenic responses of endothelial cells to TRANCE. Treatment of human umbilical vein endothelial cells (HUVECs) with VEGF increased both RANK mRNA and surface protein expression. Although placenta growth factor specific to VEGF receptor-1 had no significant effect on RANK expression, inhibition of downstream signaling molecules of the VEGF receptor-2 (Flk-1/KDR) such as Src, phospholipase C, protein kinase C, and phosphatidylinositol 3'-kinase suppressed VEGF-stimulated RANK expression in HUVECs. Moreover, the MEK inhibitor PD98059 or expression of dominant negative MEK1 inhibited induction of RANK by VEGF but not the Ca2+ chelator 1,2-bis( 2-aminophenoxy) ethane-N, N, N', N'-tetraacetic acid-acetoxymethyl ester (BAPTA-AM). VEGF potentiated TRANCE-induced ERK activation and tube formation via RANK up-regulation in HUVECs. Together, these results show that VEGF enhances RANK expression in endothelial cells through Flk-1/KDR-protein kinase C-ERK signaling pathway, suggesting that VEGF plays an important role in modulating the angiogenic action of TRANCE under physiological or pathological conditions.	Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Kyung Hee Univ, Grad Sch E W Med Sci, Dept Oncol, Yongin 449701, South Korea; Hallym Univ, Div Life Sci, Chunchon 200702, Kangwon Do, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea	Kangwon National University; Kangwon National University; Kyung Hee University; Hallym University; Ewha Womans University; Ewha Womans University; Pohang University of Science & Technology (POSTECH)	Kwon, YG (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea.	ygkwon@kangwon.ac.kr		Min, Jeong-Ki/0000-0003-4924-8739				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Blum S, 2001, J BIOL CHEM, V276, P33428, DOI 10.1074/jbc.M105474200; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Carlevaro MF, 2000, J CELL SCI, V113, P59; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harper J, 1999, NAT MED, V5, P617, DOI 10.1038/9460; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HONER A, 1999, J ANAT, V194, P519; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014-5793(00)01520-9; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yan T, 2001, J CELL BIOCHEM, V83, P320, DOI 10.1002/jcb.1200	47	94	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39548	39557		10.1074/jbc.M300539200	http://dx.doi.org/10.1074/jbc.M300539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893832	hybrid			2022-12-25	WOS:000185713800036
J	Pan, YX; Chen, H; Siu, F; Kilberg, MS				Pan, YX; Chen, H; Siu, F; Kilberg, MS			Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; GENE-EXPRESSION; REPRESSOR ATF3; NF-Y; ELEMENT; PATHWAY; GADD153/CHOP10; IDENTIFICATION; MEDIATOR; SITE	Transcription from the ASNS (asparagine synthetase) gene is increased in response to either amino acid (amino acid response) or glucose (endoplasmic reticulum stress response) deprivation. These two independent pathways converge on the same set of genomic cis-elements within the ASNS promoter, referred to as nutrient-sensing response element-1 and -2. Chromatin immunoprecipitation analysis provides the first in vivo evidence for activating transcription factor (ATF)-3 binding to the proximal ASNS promoter containing the nutrient-sensing response element-1 sequence. Overexpression of the full-length ATF3 protein caused a concentration-dependent biphasic response in ASNS promoter-driven transcription. Both amino acid limitation and activation of the endoplasmic reticulum stress response by glucose deprivation caused an increase in ATF3 mRNA content. However, reverse transcriptase-PCR analysis revealed that the increase in the ATF3 mRNA species detected by Northern analysis actually encoded both full-length ATF3 and two predicted truncated ATF3 isoforms (ATF3DeltaZip2c and ATF3DeltaZip3). Based on sequence analysis, one of the predicted truncated proteins (ATF3DeltaZip3) is likely incapable of binding DNA; and yet, exogenous expression of the cDNA enhanced starvation-induced or ATF4-activated ASNS transcription, possibly by sequestering corepressor proteins. Collectively, the results provide evidence for a potential role of multiple predicted ATF3 isoforms in the transcriptional regulation of the ASNS gene in response to nutrient deprivation.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Nutr Sci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, POB 100245, Gainesville, FL 32610 USA.		Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367	NIDDK NIH HHS [DK-52064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; HUTSON RG, 1994, BIOCHEM J, V303, P745; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; Kilberg M, 2002, J NUTR, V132, P1801, DOI 10.1093/jn/132.7.1801; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076	27	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38402	38412		10.1074/jbc.M304574200	http://dx.doi.org/10.1074/jbc.M304574200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12881527	hybrid			2022-12-25	WOS:000185575100040
J	Rawal, N; Pangburn, MK				Rawal, N; Pangburn, MK			Formation of high affinity C5 convertase of the classical pathway of complement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE-PATHWAY; 3RD COMPONENT; COVALENT BINDING; C3-C5 CONVERTASE; C3B; C4B; PROPERDIN; FRAGMENT; ENZYME; PURIFICATION	C3/C5 convertase is a serine protease that cleaves C3 and C5. In the present study we examined the C5 cleaving properties of classical pathway C3/C5 convertase either bound to the surface of sheep erythrocytes or in its free soluble form. Kinetic parameters revealed that the soluble form of the enzyme (C4b, C2a) cleaved C5 at a catalytic rate similar to that of the surface-bound form (EAC1, C4b, C2a). However, both forms of the enzyme exhibited a poor affinity for the substrate, C5, as indicated by a high K-m (6-9 muM). Increasing the density of C4b on the cell surface from 8,000 to 172,000 C4b/cell did not influence the K-m. Very high affinity C5 convertases were generated only when the low affinity C3/C5 convertases ( EAC1, C4b, C2a) were allowed to deposit C3b by cleaving native C3. These C3b-containing C3/C5 convertases exhibited K-m (0.0051 muM) well below the normal concentration of C5 in blood (0.37 muM). The data suggest that C3/C5 convertase assembled with either monomeric C4b or C4b-C4b complexes are inefficient in capturing C5 but cleave C3 opsonizing the cell surface with C3b for phagocytosis. Deposition of C3b converts the enzymes to high affinity C5 convertases, which cleave C5 in blood at catalytic rates approaching V-max, thereby switching from C3 to C5 cleavage. Comparison of the kinetic parameters with those of the alternative pathway convertase indicates that the 6-9-fold greater catalytic rate of the classical pathway C5 convertase may compensate for the fewer numbers of C5 convertase sites generated upon activation of this pathway.	Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75708 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Rawal, N (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 11937 US Highway 271, Tyler, TX 75708 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35081] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhatia M, 2000, J PATHOL, V190, P117; CHRISTOPHERSON RI, 1983, METHOD ENZYMOL, V91, P278; DAHA MR, 1976, J IMMUNOL, V117, P630; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1981, BIOCHEM J, V199, P497, DOI 10.1042/bj1990497; DODDS AW, 1993, METHOD ENZYMOL, V223, P46; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HARBECK RJ, 1991, DIAGN IMMUNOL, P49; HONG KS, 1991, J IMMUNOL, V146, P1868; ISENMAN DE, 1986, J IMMUNOL, V136, P2542; ISENMAN DE, 1980, J IMMUNOL, V124, P326; Jelezarova E, 1999, MOL IMMUNOL, V36, P837, DOI 10.1016/S0161-5890(99)00104-2; KERR MA, 1978, BIOCHEM J, V171, P99, DOI 10.1042/bj1710099; KIM YU, 1992, J BIOL CHEM, V267, P4171; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; KOLB WP, 1982, BIOCHEMISTRY-US, V21, P294, DOI 10.1021/bi00531a015; KOZONO H, 1990, J BIOL CHEM, V265, P14444; MASAKI T, 1991, J IMMUNOL, V147, P927; MASAKI T, 1995, MOL IMMUNOL, V32, P21, DOI 10.1016/0161-5890(94)00137-P; MEDICUS RG, 1976, P NATL ACAD SCI USA, V73, P612, DOI 10.1073/pnas.73.2.612; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; Pangburn MK, 2002, BIOCHEM SOC T, V30, P1006, DOI 10.1042/bst0301006; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PANGBURN MK, 1998, COMPLEMENT SYSTEM, P93; Rawal N, 1998, J BIOL CHEM, V273, P16828, DOI 10.1074/jbc.273.27.16828; Rawal N, 2001, INT IMMUNOPHARMACOL, V1, P415, DOI 10.1016/S1567-5769(00)00039-4; Rawal N, 2001, J IMMUNOL, V166, P2635, DOI 10.4049/jimmunol.166.4.2635; Rawal N, 2000, J IMMUNOL, V164, P1379, DOI 10.4049/jimmunol.164.3.1379; REID KBM, 1998, COMPLEMENT SYSTEM, P68; Sandoval A, 2000, J IMMUNOL, V165, P1066, DOI 10.4049/jimmunol.165.2.1066; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SCHUPF N, 1989, Brain Behavior and Immunity, V3, P28, DOI 10.1016/0889-1591(89)90003-2; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; VOGT W, 1978, IMMUNOLOGY, V34, P29; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X	41	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38476	38483		10.1074/jbc.M307017200	http://dx.doi.org/10.1074/jbc.M307017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878586	hybrid			2022-12-25	WOS:000185575100049
J	Garton, KJ; Gough, PJ; Philalay, J; Wille, PT; Blobel, CP; Whitehead, RH; Dempsey, PJ; Raines, EW				Garton, KJ; Gough, PJ; Philalay, J; Wille, PT; Blobel, CP; Whitehead, RH; Dempsey, PJ; Raines, EW			Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISINTEGRIN; EXPRESSION; CLEAVAGE; MIGRATION; PROTEASES; COLON; CD44	A variety of cell surface adhesion molecules can exist as both transmembrane proteins and soluble circulating forms. Increases in the levels of soluble adhesion molecules have been correlated with a variety of inflammatory diseases, suggesting a pathological role. Although soluble forms are thought to result from proteolytic cleavage from the cell surface, relatively little is known about the proteases responsible for their release. In this report we demonstrate that under normal culture conditions, cells expressing vascular cell adhesion molecule 1 (VCAM-1) release a soluble form of the extracellular domain that is generated by metalloproteinase-mediated cleavage. VCAM-1 release can be rapidly simulated by phorbol 12-myristate 13-acetate (PMA), and this induced VCAM-1 shedding is mediated by metalloproteinase cleavage of VCAM-1 near the transmembrane domain. PMA-induced VCAM-1 shedding occurs as the result of activation of a specific pathway, as the generation of soluble forms of three other adhesion molecules, E-selectin, platelet-endothelial cell adhesion molecule 1, and intercellular adhesion molecule 1, are not altered by PMA stimulation. Using cells derived from genetically deficient mice, we identify tumor necrosis factor-alpha-converting enzyme ( TACE or ADAM 17) as the protease responsible for PMA-induced VCAM-1 release, including shedding of endogenously expressed VCAM-1 by murine endothelial cells. Therefore, TACE-mediated shedding of VCAM-1 may be important for the regulation of VCAM-1 function at the cell surface.	Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Pacific NW Res Inst, Seattle, WA 98122 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University	Raines, EW (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pathol, 325 9th Ave,Box 359675, Seattle, WA 98104 USA.	ewraines@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645, R01HL067267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059778, R01DK063363] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645, HL67267] Funding Source: Medline; NIDDK NIH HHS [DK63363, DK59778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; Faveeuw C, 2001, BLOOD, V98, P688, DOI 10.1182/blood.V98.3.688; Garton KJ, 2002, BIOTECHNIQUES, V32, P830, DOI 10.2144/02324rr01; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Lidington EA, 2002, AM J PHYSIOL-CELL PH, V282, pC67, DOI 10.1152/ajpcell.2002.282.1.C67; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; SHINGU M, 1994, INFLAMMATION, V18, P23, DOI 10.1007/BF01534595; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587	27	209	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37459	37464		10.1074/jbc.M305877200	http://dx.doi.org/10.1074/jbc.M305877200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12878595	hybrid			2022-12-25	WOS:000185437200058
J	Luo, W; Ng, WW; Jin, LH; Ye, ZY; Han, JH; Lin, SC				Luo, W; Ng, WW; Jin, LH; Ye, ZY; Han, JH; Lin, SC			Axin utilizes distinct regions for competitive MEKK1 and MEKK4 binding and JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; CASEIN KINASE-I; MIXED-LINEAGE KINASE; PROTEIN-KINASE; BETA-CATENIN; NEGATIVE REGULATOR; RNA INTERFERENCE; GENE DISRUPTION; MAMMALIAN-CELLS; EXPRESSION	Axin is a multidomain protein that plays a critical role in Wnt signaling, serving as a scaffold for down-regulation of beta-catenin. It also activates the JNK mitogen-activated protein kinase by binding to MEKK1. However, it is intriguing that Axin requires several additional elements for JNK activation, including a requirement for homodimerization, sumoylation at the extreme C-terminal sites, and a region in the protein phosphatase 2A-binding domain. In our present study, we have shown that another MEKK family member, MEKK4, also binds to Axin in vivo and mediates Axin-induced JNK activation. Surprisingly MEKK4 binds to a region distinct from the MEKK1-binding site. Dominant negative mutant of MEKK4 attenuates the JNK activation by Axin. Activation of JNK by Axin in MEKK1(-/-) mouse embryonic fibroblast cells supports the idea that another MEKK can mediate Axin-induced JNK activation. Expression of specific small interfering RNA against MEKK4 effectively attenuates JNK activation by the MEKK1 binding-defective Axin mutant in 293T cells and inhibits JNK activation by wild-type Axin in MEKK1(-/-) cells, confirming that MEKK4 is indeed another mitogen-activated protein kinase kinase kinase that is specifically involved in Axin-mediated JNK activation independently of MEKK1. We have also identified an additional domain between MEKK1- and MEKK4-binding sites as being required for JNK activation by Axin. MEKK1 and MEKK4 compete for Axin binding even though they bind to sites far apart, suggesting that Axin may selectively bind to MEKK1 or MEKK4 depending on distinct signals or cellular context. Our findings will provide new insights into how scaffold proteins mediate ultimate activation of different mitogen-activated protein kinase kinase kinases.	Xiamen Univ, Dept Biol, Xiamen 361005, Fujian, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Scripps Res Inst, Dept Immunol, La Jolla, CA USA	Xiamen University; Hong Kong University of Science & Technology; Scripps Research Institute	Lin, SC (corresponding author), Xiamen Univ, Dept Biol, Xiamen 361005, Fujian, Peoples R China.		Han, J/G-4671-2010; Lin, SC/G-4666-2010; Jin, Lihua/AAN-5177-2020	Jin, Lihua/0000-0002-2685-6048				Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LIU C, 2002, CELL, V108, P1; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Povelones M, 2002, NAT CELL BIOL, V4, pE249, DOI 10.1038/ncb1102-e249; ROMOND TS, 2002, GENE DEV, V16, P2073; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Wang HY, 2002, J BIOL CHEM, V277, P3530, DOI 10.1074/jbc.M107031200; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	49	53	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37451	37458		10.1074/jbc.M305277200	http://dx.doi.org/10.1074/jbc.M305277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12878610	hybrid			2022-12-25	WOS:000185437200057
J	Guerra, B; Issinger, OG; Wang, JYJ				Guerra, B; Issinger, OG; Wang, JYJ			Modulation of human checkpoint kinase Chk1 by the regulatory beta-subunit of protein kinase CK2	ONCOGENE			English	Article						protein kinase CK2; Chk1; protein phosphorylation	DNA-DAMAGE CHECKPOINT; KAPPA-B-ALPHA; CRYSTAL-STRUCTURE; CASEIN KINASE-2; CELL-CYCLE; CK2-BETA SUBUNIT; FISSION YEAST; PHOSPHORYLATION; PROLIFERATION; ADAPTATION	Protein kinase CK2 is a serine/threonine protein kinase involved in various aspects of cellular regulation. The regulatory beta-subunit of CK2 exerts a central role not only in mediating formation of tetrameric CK2 complexes but also as a docking partner for several protein kinases. In this study, CK2beta is found to interact with the human cell cycle checkpoint kinase Chk1. The Chk1-interacting region of CK2beta is localized at the C-terminus and the complex between CK2beta and Chk1 is devoid of the catalytic CK2alpha-subunit. The interaction between CK2beta and Chk1 leads to an increase in the Cdc25C phosphorylation activity of Chk1. The screening of several cell lines has revealed that the association between CK2beta and Chk1 also occurs in vivo at a different degree. Collectively, these studies confirm the implication of the regulatory beta-subunit of protein kinase CK2 in cell cycle regulation and identify a novel mechanism for the activation of Chk1 protein kinase.	Univ Calif San Diego, Div Biol Sci 0322, La Jolla, CA 92093 USA; Univ So Denmark, Inst Biochem & Mol Biol, DK-5230 Odense, Denmark	University of California System; University of California San Diego; University of Southern Denmark	Guerra, B (corresponding author), Univ Calif San Diego, Div Biol Sci 0322, La Jolla, CA 92093 USA.			Guerra, Barbara/0000-0003-1136-2413	NCI NIH HHS [R01 CA043054, CA43054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; Bren GD, 2000, J MOL BIOL, V297, P1245, DOI 10.1006/jmbi.2000.3630; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Liu QH, 2000, GENE DEV, V14, P1448; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Takai H, 2000, GENE DEV, V14, P1439; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Zhang CJ, 2002, ONCOGENE, V21, P3754, DOI 10.1038/sj.onc.1205467; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	28	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4933	4942		10.1038/sj.onc.1206721	http://dx.doi.org/10.1038/sj.onc.1206721			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902976				2022-12-25	WOS:000184578900001
J	Lindstrom, MS; Wiman, KG				Lindstrom, MS; Wiman, KG			Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts	ONCOGENE			English	Article						p14ARF; p53; Myc; E2F1; phosphorylation; apoptosis; caffeine; RNA interference	CELL-CYCLE ARREST; C-MYC; DNA-DAMAGE; TUMOR SUPPRESSION; P53-DEPENDENT APOPTOSIS; RADIOSENSITIZING AGENT; TRANSCRIPTION FACTOR; INDUCED SENESCENCE; ONCOGENIC STRESS; NUCLEAR EXPORT	p19ARF is induced in response to oncogene activation or during cellular senescence in mouse embryo fibroblasts, triggering p53-dependent and p53-independent cell cycle arrest and apoptosis. We have studied the involvement of human p14ARF as a regulator of p53 activity in normal human skin fibroblasts (NHFs) or WI38 lung embryonic fibroblasts expressing conditional Myc or E2F1 estrogen receptor fusion proteins. Both Myc and E2F1 activation rapidly induced p53 phosphorylation at Ser-15, p53 protein accumulation, and upregulation of the p53 target genes MDM2 and p21. Activation of E2F1 induced p14ARF mRNA and protein levels. In contrast, Myc activation did not induce any significant increase in p14ARF mRNA or protein levels in neither NHFs nor WI38 fibroblasts within 48 h. Myc and E2F1 induced p53 and cell cycle arrest even after silencing of p14ARF using short-interfering RNA. Treatment with the ATM/ATR kinase inhibitor caffeine prevented p53 accumulation upon activation of Myc or E2F1. Our results indicate that p53 phosphorylation, but not p14ARF, plays a major role for the induction of p53 in response to Myc and E2F1 activation in normal human fibroblasts.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden	Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8-04, SE-17176 Stockholm, Sweden.	Klas.Wiman@mtc.ki.se	Wiman, Klas/AAB-8399-2021; Lindström, Mikael S/AAA-1451-2019	Wiman, Klas/0000-0002-7113-524X; Lindström, Mikael S/0000-0003-1148-8497				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deplanque G, 2000, BRIT J CANCER, V83, P346, DOI 10.1054/bjoc.2000.1259; Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hashemi J, 2002, CANCER LETT, V180, P211, DOI 10.1016/S0304-3835(02)00027-7; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lee C, 2000, CLIN CHIM ACTA, V295, P141, DOI 10.1016/S0009-8981(00)00201-1; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	91	64	65	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4993	5005		10.1038/sj.onc.1206659	http://dx.doi.org/10.1038/sj.onc.1206659			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902982				2022-12-25	WOS:000184578900007
J	Jansson, PA; Pellme, F; Hammarstedt, A; Sandqvist, M; Brekke, H; Caidahl, K; Forsberg, M; Volkmann, R; Carvalho, E; Funahashi, T; Matsuzawa, Y; Wiklund, O; Yang, XL; Taskinen, MR; Smith, U				Jansson, PA; Pellme, F; Hammarstedt, A; Sandqvist, M; Brekke, H; Caidahl, K; Forsberg, M; Volkmann, R; Carvalho, E; Funahashi, T; Matsuzawa, Y; Wiklund, O; Yang, XL; Taskinen, MR; Smith, U			A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin	FASEB JOURNAL			English	Article						type 2 diabetes; insulin signaling; adipose tissue; macroangiopathy; insulin	DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; COMPLEMENT-RELATED PROTEIN; INTIMA-MEDIA THICKNESS; METABOLIC SYNDROME; ARTERY DISEASE; PROINSULIN; SENSITIVITY; EXPRESSION; MICE	The epidemic increase in type 2 diabetes can be prevented only if markers of risk can be identified and used for early intervention. We examined the clinical phenotype of individuals characterized by normal or low IRS-1 protein expression in fat cells as well as the potential molecular mechanisms related to the adipose tissue. Twenty-five non-obese individuals with low or normal IRS-1 expression in subcutaneous abdominal fat cells were extensively characterized and the results compared with 71 carefully matched subjects with or without a known genetic predisposition for type 2 diabetes. In contrast to the commonly used risk marker, known heredity for diabetes, low cellular IRS-1 identified individuals who were markedly insulin resistant, had high proinsulin and insulin levels, and exhibited evidence of early atherosclerosis measured as increased intima media thickness in the carotid artery bulb. Circulating levels of adiponectin were also significantly reduced. Gene analyses of fat cells in a parallel study showed attenuated expression of several genes related to fat cell differentiation ( adiponectin, aP2, PPARgamma, and lipoprotein lipase) in the group of individuals characterized by a low IRS-1 expression and insulin resistance. A low IRS-1 expression in fat cells is a marker of insulin resistance and risk for type 2 diabetes and is associated with evidence of early vascular complications. Impaired adipocyte differentiation, including low gene expression and circulating levels of adiponectin, can provide a link between the cellular marker and the in vivo phenotype.	Univ Gothenburg, Sahlgrenska Acad, Lundberg Lab Diabet Res, Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Clin Nutr, Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Clin Physiol, Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Wallenberg Lab Cardiovasc Res, Gothenburg, Sweden; Univ Helsinki, Dept Med, FIN-00014 Helsinki, Finland; Osaka Univ, Dept Internal Med & Mol Sci, Suita, Osaka 565, Japan	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Helsinki; Osaka University	Smith, U (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Sahlgrenska Acad, Dept Internal Med,Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden.	ulf.smith@medic.gu.se	Taskinen, Marja-Riitta/AAN-5432-2020; Carvalho, Eugenia/AAV-6868-2021	Taskinen, Marja-Riitta/0000-0002-6229-3588; Carvalho, Eugenia/0000-0001-6264-3632				ADAMS MR, 1995, CIRCULATION, V92, P2127, DOI 10.1161/01.CIR.92.8.2127; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Axelsen M, 1999, ANN INTERN MED, V131, P27, DOI 10.7326/0003-4819-131-1-199907060-00006; BAVENHOLM P, 1995, CIRCULATION, V92, P1422, DOI 10.1161/01.CIR.92.6.1422; BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; Haffner SM, 1998, STROKE, V29, P1498, DOI 10.1161/01.STR.29.8.1498; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hammarstedt A, 2003, BIOCHEM BIOPH RES CO, V301, P578, DOI 10.1016/S0006-291X(03)00014-7; Hanley AJG, 2002, DIABETES, V51, P1263, DOI 10.2337/diabetes.51.4.1263; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Howard G, 1996, CIRCULATION, V93, P1809, DOI 10.1161/01.CIR.93.10.1809; Hulthe J, 1997, STROKE, V28, P1189, DOI 10.1161/01.STR.28.6.1189; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Laakso M, 2001, J INTERN MED, V249, P225, DOI 10.1046/j.1365-2796.2001.00789.x; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Reaven GM, 1996, CIRCULATION, V93, P1780, DOI 10.1161/01.CIR.93.10.1780; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; SMITH U, 1972, J LIPID RES, V13, P822; STEIL GM, 1993, DIABETES, V42, P250, DOI 10.2337/diabetes.42.2.250; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Wendelhag I, 1997, STROKE, V28, P2195, DOI 10.1161/01.STR.28.11.2195; WIKSTRAND J, 1992, ARTERIOSCLER THROMB, V12, P114, DOI 10.1161/01.ATV.12.1.114; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zethelius B, 2002, CIRCULATION, V105, P2153, DOI 10.1161/01.CIR.0000015855.04844.E7; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	40	91	95	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1434	1440		10.1096/fj.02-1132com	http://dx.doi.org/10.1096/fj.02-1132com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890697				2022-12-25	WOS:000185345100036
J	Xin, H; Pramanik, R; Choubey, D				Xin, H; Pramanik, R; Choubey, D			Retinoblastoma (Rb) protein upregulates expression of the Ifi202 gene encoding an interferon-inducible negative regulator of cell growth	ONCOGENE			English	Article						interferon-inducible p202; cell cycle; cell survival; Rb; JunD/AP-1	NIH 3T3 CELLS; C-JUN; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REPRESSION; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; INDUCED APOPTOSIS; P202; DIFFERENTIATION; INHIBITION	Studies have indicated that ectopic expression of p202, an interferon (IFN)-inducible retinoblastoma (Rb)-binding protein, in cultured cells retards cell proliferation and modulates cell survival. Consistent with a role of p202 in cell cycle regulation, levels of p202 increase in cells arrested in the G(0)/G(1) phase of cell cycle after withdrawal of serum growth factors. However, a role for p202 in cell growth arrest remains to be defined. Moreover, it remains unclear how levels of p202 are upregulated during the cell growth arrest. Here, we report that Rb upregulates expression of Ifi202 gene. We found that basal as well as IFN-induced levels of p202 were significantly higher in wild-type (Rb+/+) mouse embryonic fibroblasts (MEFs) than isogenic Rb-/- MEFs. Consistent with the regulation of Ifi202 gene by Rb, expression of functional Rb, but not a pocket mutant of it, stimulated the activity of a reporter whose expression was driven by the 5'-regulatory region of Ifi202 gene. Importantly, the stimulation by Rb was dependent, in part, on a JunD/AP-1 DNA-binding site present in the 5-regulatory region of the Ifi202 gene. Moreover, basal levels of p202 were significantly higher in wild-type (JunD(+/+)) than isogenic JunD(-/-) MEFs. Additionally, we found that increased expression of p202 potentiated the Rb-mediated inhibition of cell growth and mutations in the Rb-binding motif (LxCxE) of p202 significantly reduced cell survival. Together, our observations support the idea that the transcriptional activation of Ifi202 gene by Rb/JunD may be important for the regulation of cell growth and survival.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA	Loyola University Chicago	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1,Mail Code 114B, Maywood, IL 60153 USA.		Choubey, Divaker/A-4771-2008		NCI NIH HHS [CA69031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Berry DE, 1996, ONCOGENE, V12, P1809; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Geng YB, 2000, CELL GROWTH DIFFER, V11, P475; Grander D, 1997, EUR J HAEMATOL, V59, P129; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HAMEL PA, 1992, ONCOGENE, V7, P693; HAPUT Y, 1995, ONCOGENE, V10, P1563; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KRATZKE RA, 1994, ONCOGENE, V9, P1321; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Li H, 2001, ARCH BIOCHEM BIOPHYS, V394, P1, DOI 10.1006/abbi.2001.2518; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Min W, 1996, MOL CELL BIOL, V16, P359; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; Sen GC, 2000, SEMIN CANCER BIOL, V10, P93, DOI 10.1006/scbi.2000.0312; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang J, 1997, CANCER RES, V57, P351; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Xin H, 2003, J CELL BIOCHEM, V88, P191, DOI 10.1002/jcb.10372; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	59	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4775	4785		10.1038/sj.onc.1206780	http://dx.doi.org/10.1038/sj.onc.1206780			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894219				2022-12-25	WOS:000184344600001
J	Boisson, B; Giglione, C; Meinnel, T				Boisson, B; Giglione, C; Meinnel, T			Unexpected protein families including cell defense components feature in the N-myristoylome of a higher eukaryote	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; MYRISTIC ACID AUXOTROPHY; GENOME-WIDE ANALYSIS; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; ENDOPLASMIC-RETICULUM; PSEUDOMONAS-SYRINGAE; PEPTIDE DEFORMYLASES; PLASMA-MEMBRANE; CRYPTOCOCCUS-NEOFORMANS	N-Myristoylation is an irreversible modification that affects the membrane binding properties of crucial cytoplasmic proteins from signal transduction cascades. We characterized the two putative N-myristoyltransferases of Arabidopsis thaliana as a means of investigating the entire N-myristoylation proteome (N-myristoylome) in a higher eukaryote. AtNMT1 compensated for the nmt1 defect in yeast, whereas AtNMT2 and chimeras of the two genes did not. Only AtNMT1 modified known N-myristoylated proteins in vitro. AtNMT1 is therefore responsible for the A. thaliana N-myristoylome, whereas AtNMT2 does not seem to have usual myristoylation activity. We began with the whole set of N-myristoylated G proteins in the A. thaliana proteome. We then used a reiterative approach, based on the in vitro N-myristoylation of more than 60 different polypeptides, to determine the substrate specificity of AtNMT1. We found that the positive charge on residue 7 of the substrate was particularly important in substrate recognition. The A. thaliana N-myristoylome consists of 437 proteins, accounting for 1.7% of the complete proteome. We demonstrated the N-myristoylation of several unexpected protein families, including innate immunity proteins, thioredoxins, components of the protein degradation pathway, transcription factors, and a crucial regulatory enzyme of glycolysis. The role of N-myristoylation is discussed in each case; in particular, this process may underlie the "guard" hypothesis of innate immunity.	CNRS, UPR2355, Inst Sci Vegetal, Prot Maturat Grp, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Meinnel, T (corresponding author), CNRS, UPR2355, Inst Sci Vegetal, Prot Maturat Grp, Batiment 23,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	meinnel@isv.cnrs-gif.fr	Boisson, Bertrand/I-2485-2017; Boisson, Bertrand/AAC-6058-2019; Meinnel, Thierry/B-9813-2016	Boisson, Bertrand/0000-0001-5240-3555; Boisson, Bertrand/0000-0001-5240-3555; Meinnel, Thierry/0000-0001-5642-8637; Giglione, Carmela/0000-0002-7475-1558				Axtell MJ, 2003, CELL, V112, P369, DOI 10.1016/S0092-8674(03)00036-9; Bhatnagar R. S., 2001, ENZYMES, VXXI, P241; Boisson B, 2003, ANAL BIOCHEM, V322, P116, DOI 10.1016/j.ab.2003.07.007; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chico JM, 2002, PLANT PHYSIOL, V128, P256, DOI 10.1104/pp.010649; COCKWELL KY, 1989, COMPUT APPL BIOSCI, V5, P227; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; DEJONGE HR, 2000, SCI STKE; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; Eberle HB, 2002, J CELL SCI, V115, P827; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Farazi TA, 2001, BIOCHEMISTRY-US, V40, P6335, DOI 10.1021/bi0101401; Frommer WB, 2003, SCIENCE, V300, P261, DOI 10.1126/science.1084120; Furumoto T, 2001, PLANT CELL PHYSIOL, V42, P1044, DOI 10.1093/pcp/pce161; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; GIGLIONE C, 1999, THESIS PARIS SUD U O; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gupta R, 2002, PLANT CELL, V14, P2495, DOI 10.1105/tpc.005702; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Ishitani M, 2000, PLANT CELL, V12, P1667, DOI 10.1105/tpc.12.9.1667; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; Joshi CP, 1997, PLANT MOL BIOL, V35, P993, DOI 10.1023/A:1005816823636; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Keddie JS, 1998, PLANT CELL, V10, P877, DOI 10.1105/tpc.10.6.877; Kim SY, 2002, PLANT PHYSIOL, V130, P688, DOI 10.1104/pp.003566; Kimura Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P341, DOI 10.1016/S0003-9861(02)00639-2; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; KISS F, 1991, ARCH BIOCHEM BIOPHYS, V287, P337, DOI 10.1016/0003-9861(91)90487-4; Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624; Lin CY, 2000, J BIOL CHEM, V275, P37815, DOI 10.1074/jbc.M002470200; Lin CY, 2002, J CELL SCI, V115, P4433, DOI 10.1242/jcs.00123; Lin SS, 2003, J BIOL CHEM, V278, P13390, DOI 10.1074/jbc.M212818200; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; Lu SX, 2002, PLANT PHYSIOL, V128, P1008, DOI 10.1104/pp.010770; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Markham JE, 2002, EUR J BIOCHEM, V269, P1267, DOI 10.1046/j.1432-1033.2002.02771.x; Maurer-Stroh S, 2002, J MOL BIOL, V317, P541, DOI 10.1006/jmbi.2002.5426; Maurer-Stroh S, 2002, J MOL BIOL, V317, P523, DOI 10.1006/jmbi.2002.5425; McElver J, 2000, PLANT CELL, V12, P1379, DOI 10.1105/tpc.12.8.1379; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; Meyer Y, 2002, METHOD ENZYMOL, V347, P394; Meyers BC, 2003, PLANT CELL, V15, P809, DOI 10.1105/tpc.009308; Mudgett MB, 1999, MOL MICROBIOL, V32, P927, DOI 10.1046/j.1365-2958.1999.01403.x; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Price HP, 2003, J BIOL CHEM, V278, P7206, DOI 10.1074/jbc.M211391200; Puri N, 1997, MOL PLANT MICROBE IN, V10, P247, DOI 10.1094/MPMI.1997.10.2.247; Qi QG, 2000, J BIOL CHEM, V275, P9673, DOI 10.1074/jbc.275.13.9673; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; Romeis T, 2001, EMBO J, V20, P5556, DOI 10.1093/emboj/20.20.5556; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; Rutherford S, 2002, CURR OPIN PLANT BIOL, V5, P518, DOI 10.1016/S1369-5266(02)00307-2; Sahrawy M, 1996, J MOL EVOL, V42, P422; Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175; Shan LB, 2000, PLANT CELL, V12, P2323, DOI 10.1105/tpc.12.12.2323; Takeuchi M, 2002, PLANT J, V31, P499, DOI 10.1046/j.1365-313X.2002.01372.x; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; Travis AJ, 1999, J BIOL CHEM, V274, P34467, DOI 10.1074/jbc.274.48.34467; Ueda T, 2001, EMBO J, V20, P4730, DOI 10.1093/emboj/20.17.4730; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040; Utsumi T, 2001, J BIOL CHEM, V276, P10505, DOI 10.1074/jbc.M006134200; Vandepoele K, 2002, PLANT CELL, V14, P903, DOI 10.1105/tpc.010445; Vernoud V, 2003, PLANT PHYSIOL, V131, P1191, DOI 10.1104/pp.013052; Villadsen D, 2001, BIOCHEM J, V359, P591, DOI 10.1042/0264-6021:3590591; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; Wilkins MR, 1999, J MOL BIOL, V289, P645, DOI 10.1006/jmbi.1999.2794; Yu YS, 2003, SCIENCE, V300, P1566, DOI 10.1126/science.1083523; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	84	117	146	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43418	43429		10.1074/jbc.M307321200	http://dx.doi.org/10.1074/jbc.M307321200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12912986	hybrid			2022-12-25	WOS:000186157000086
J	Magnifico, A; Ettenberg, S; Yang, CH; Mariano, J; Tiwari, S; Fang, SY; Lipkowitz, S; Weissman, AM				Magnifico, A; Ettenberg, S; Yang, CH; Mariano, J; Tiwari, S; Fang, SY; Lipkowitz, S; Weissman, AM			WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; UBIQUITIN-PROTEIN LIGASE; EPITHELIAL NA+ CHANNEL; ROUS-SARCOMA VIRUS; C-CBL; DOWN-REGULATION; TYROSINE KINASES; IN-VIVO; NEDD4; FAMILY	Cbl proteins have RING finger-dependent ubiquitin ligase (E3) activity that is essential for down-regulation of tyrosine kinases. Here we establish that two WW domain HECT E3s, Nedd4 and Itch, bind Cbl proteins and target them for proteasomal degradation. This is dependent on the E3 activity of the HECT E3s but not on that of Cbl. Consistent with these observations, in cells expressing the epidermal growth factor receptor, Nedd4 reverses Cbl-b effects on receptor down-regulation, ubiquitylation, and proximal events in signaling. Cbl-b also targets active Src for degradation in cells, and Nedd4 similarly reverses Cbl-mediated Src degradation. These findings establish that RING finger E3s can be substrates, not only for autoubiquitylation but also for ubiquitylation by HECT E3s and suggest an additional level of regulation for Cbl substrates including protein-tyrosine kinases.	NCI, Regulat Prot Funct Lab, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20817 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Weissman, AM (corresponding author), NCI, Regulat Prot Funct Lab, Ctr Canc Res, Bldg 560,Rm 22-102, Frederick, MD 21702 USA.		Fang, Shengyun/H-3802-2011	Fang, Shengyun/0000-0001-7280-5463	NATIONAL CANCER INSTITUTE [ZIASC007263, Z01BC009392, ZIABC009392, Z01SC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 2002, TRENDS IMMUNOL, V23, P140, DOI 10.1016/S1471-4906(01)02157-3; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Patnaik A, 2002, J VIROL, V76, P2789, DOI 10.1128/JVI.76.6.2789-2795.2002; PATTERSON C, 2002, SCI STKE; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sanjay A., 2001, SCI STKE; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	59	141	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43169	43177		10.1074/jbc.M308009200	http://dx.doi.org/10.1074/jbc.M308009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12907674	hybrid			2022-12-25	WOS:000186157000058
J	Perestenko, PV; Henley, JM				Perestenko, PV; Henley, JM			Characterization of the intracellular transport of GluR1 and GluR2 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; AMPA RECEPTORS; GLUTAMATE RECEPTORS; SURFACE EXPRESSION; SYNAPTIC-TRANSMISSION; SYNAPSES; MEMBRANE; LOCALIZATION; ACTIVATION; PROTEINS	Little is known about the dynamics of the dendritic transport of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) to synapses. Here, using virally expressed green fluorescent protein (GFP)GluR1 and GFP-GluR2 and confocal photobleach techniques we show near real-time movement of these subunits in living cultured hippocampal neurons. GFP-GluR1 fluorescence was widely distributed throughout the extranuclear compartment with no evidence for discrete intracellular stores. GFP-GluR1 transport was predominantly proximal to distal at rates of 0.2 - 0.4 mum.s(-1). GFP-GluR2 fluorescence was more punctate and localized at or close to the plasma membrane. Overall, GFP-GluR2 movement was less dynamic with distinct mobile and immobile pools. Neither activation nor inhibition of surface-expressed N-methyl-D-aspartate receptors or AMPARs had any significant effect on the rates of GFP-GluR1 or GFP-GluR2 dendritic transport. These results demonstrate that GluR1 is constitutively and rapidly transported throughout the neuron. GluR2, on the other hand, is less mobile, with a majority retained in relatively immobile membrane-associated clusters, with similar to 40% showing synaptic co-localization. Furthermore, the transport of both subunits is activity-independent, suggesting that the regulated delivery of AMPARs to the vicinity of synapses is not a mechanism that is involved in processes such as synaptic plasticity.	Univ Bristol, Sch Med Sci, Dept Anat, MRC,Ctr Synapt Plast, Bristol BS8 1TD, Avon, England	University of Bristol	Henley, JM (corresponding author), Univ Bristol, Sch Med Sci, Dept Anat, MRC,Ctr Synapt Plast, Univ Walk, Bristol BS8 1TD, Avon, England.		Henley, Jeremy M/A-2776-2009	Henley, Jeremy/0000-0003-3589-8335	MRC [G9629038] Funding Source: UKRI; Medical Research Council [G9629038(61600), G9629038] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Archibald K, 1998, NEUROPHARMACOLOGY, V37, P1345, DOI 10.1016/S0028-3908(98)00135-X; BAUDE A, 1994, J NEUROSCI, V14, P2830; BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; Cottrell JR, 2000, J NEUROPHYSIOL, V84, P1573, DOI 10.1152/jn.2000.84.3.1573; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dingledine R, 1999, PHARMACOL REV, V51, P7; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Hall RA, 1997, J NEUROCHEM, V68, P625; HAMPSON DR, 1992, NEUROSCIENCE, V50, P11, DOI 10.1016/0306-4522(92)90378-F; HUH KH, 1997, SOC NEUR ABSTR, V23, P371; Kim CH, 2001, P NATL ACAD SCI USA, V98, P11725, DOI 10.1073/pnas.211132798; Kim CH, 2001, J NEUROSCI, V21, P4188, DOI 10.1523/JNEUROSCI.21-12-04188.2001; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kohrmann M, 1999, J NEUROSCI RES, V58, P831; Lochner JE, 1998, MOL BIOL CELL, V9, P2463, DOI 10.1091/mbc.9.9.2463; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Luthi A, 1999, NEURON, V24, P389, DOI 10.1016/S0896-6273(00)80852-1; Mammen AL, 1997, J NEUROSCI, V17, P7351; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; Nusser Z, 1998, NEURON, V21, P545, DOI 10.1016/S0896-6273(00)80565-6; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; Pickard L, 2000, J NEUROSCI, V20, P7922; Rao A, 1998, J NEUROSCI, V18, P1217; Richmond SA, 1996, NEUROSCIENCE, V75, P69, DOI 10.1016/0306-4522(96)00217-5; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Silverman MA, 2001, P NATL ACAD SCI USA, V98, P7051, DOI 10.1073/pnas.111146198; Takumi Y, 1999, ANN NY ACAD SCI, V868, P474, DOI 10.1111/j.1749-6632.1999.tb11316.x; Toomre D, 1999, J CELL SCI, V112, P21	41	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43525	43532		10.1074/jbc.M306206200	http://dx.doi.org/10.1074/jbc.M306206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12909632	Green Accepted, hybrid			2022-12-25	WOS:000186157000098
J	Liang, FB; Huang, ZH; Lee, SY; Liang, J; Ivanov, MI; Alonso, A; Bliska, JB; Lawrence, DS; Mustelin, T; Zhang, ZY				Liang, FB; Huang, ZH; Lee, SY; Liang, J; Ivanov, MI; Alonso, A; Bliska, JB; Lawrence, DS; Mustelin, T; Zhang, ZY			Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; OUTER-MEMBRANE PROTEINS; SUBSTRATE-SPECIFICITY; TRANSFERABLE PLASMID; STRUCTURAL BASIS; FOCAL ADHESIONS; IMMUNE-RESPONSE; PC12 CELLS; INHIBITOR; ENTEROCOLITICA	Yersinia are causative agents in human diseases ranging from gastrointestinal syndromes to Bubonic Plague. There is increasing risk of misuse of infectious agents, such as Yersinia pestis, as weapons of terror as well as instruments of warfare for mass destruction. YopH is an essential virulence factor whose protein-tyrosine phosphatase (PTP) activity is required for Yersinia pathogenicity. Consequently, there is considerable interest in developing potent and selective YopH inhibitors as novel anti-plague agents. We have screened a library of 720 structurally diverse commercially available carboxylic acids and identified 26 YopH inhibitors with IC50 values below 100 muM. The most potent and specific YopH inhibitor is aurintricarboxylic acid (ATA), which exhibits a K-i value of 5 nM for YopH and displays 6-120-fold selectivity in favor of YopH against a panel of mammalian PTPs. To determine whether ATA can block the activity of YopH in a cellular context, we have examined the effect of ATA on T-cell signaling in human Jurkat cells transfected with YopH. We show that YopH severely decreases the T-cell receptor-induced cellular tyrosine phosphorylation, ERK1/2 activity, and interleukin-2 transcriptional activity. We demonstrate that ATA can effectively block the inhibitory activity of YopH and restore normal T-cell function. These results provide a proof-of-concept for the hypothesis that small molecule inhibitors that selectively target YopH may be therapeutically useful. In addition, it is expected that potent and selective YopH inhibitors, such as ATA, should be useful reagents to delineate YopH's cellular targets in plague and other pathogenic conditions caused by Yersinia infection.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Infect Dis, Stony Brook, NY 11794 USA; Burnham Inst, La Jolla, CA 92037 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Sanford Burnham Prebys Medical Discovery Institute	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu	Alonso, Andrés/L-7523-2014	Alonso, Andrés/0000-0001-8674-9378; Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI 43389, AI 48506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043389, R56AI043389, R01AI048506] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson K, 1996, MOL MICROBIOL, V20, P1057, DOI 10.1111/j.1365-2958.1996.tb02546.x; Autenrieth IB, 1996, J MED MICROBIOL, V44, P285, DOI 10.1099/00222615-44-4-285; AUTENRIETH IB, 1993, INFECT IMMUN, V61, P2585, DOI 10.1128/IAI.61.6.2585-2595.1993; AUTENRIETH IB, 1993, IMMUNOBIOLOGY, V187, P1; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; Beery R, 2001, ENDOCRINOLOGY, V142, P3098, DOI 10.1210/en.142.7.3098; Black DS, 2000, CELL MICROBIOL, V2, P401, DOI 10.1046/j.1462-5822.2000.00061.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Black DS, 1998, MOL MICROBIOL, V29, P1263, DOI 10.1046/j.1365-2958.1998.01014.x; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; BULTER T, 1985, TXB MED, P1600; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chen YT, 2002, J MED CHEM, V45, P3946, DOI 10.1021/jm020093q; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Cornelis GR, 1998, FOLIA MICROBIOL, V43, P253, DOI 10.1007/BF02818610; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Guiyoule A, 2001, EMERG INFECT DIS, V7, P43, DOI 10.3201/eid0701.010106; Haimsohn M, 2002, ENDOCRINOLOGY, V143, P837, DOI 10.1210/en.143.3.837; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; HARTLAND EL, 1994, INFECT IMMUN, V62, P4445, DOI 10.1128/IAI.62.10.4445-4453.1994; Hawley RJ, 2001, ANNU REV MICROBIOL, V55, P235, DOI 10.1146/annurev.micro.55.1.235; Ibrahimi OA, 2000, BIOORG MED CHEM LETT, V10, P457, DOI 10.1016/S0960-894X(00)00019-6; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; Iversen LF, 2002, J BIOL CHEM, V277, P19982, DOI 10.1074/jbc.M200567200; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; KOLE HK, 1995, BIOCHEM J, V311, P1025, DOI 10.1042/bj3111025; Lee K, 2003, BIOORG MED CHEM LETT, V13, P2577, DOI 10.1016/S0960-894X(03)00481-5; McGovern TW, 1999, ARCH DERMATOL, V135, P311, DOI 10.1001/archderm.135.3.311; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; Mustelin T, 2003, IMMUNOL REV, V191, P139, DOI 10.1034/j.1600-065X.2003.00014.x; Okada N, 1997, BIOCHEM BIOPH RES CO, V230, P266, DOI 10.1006/bbrc.1996.5934; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PORTNOY DA, 1984, INFECT IMMUN, V43, P108, DOI 10.1128/IAI.43.1.108-114.1984; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; Ruckdeschel K, 1996, INFECT IMMUN, V64, P724, DOI 10.1128/IAI.64.3.724-733.1996; SARMA MH, 1976, BIOCHIM BIOPHYS ACTA, V418, P29, DOI 10.1016/0005-2787(76)90324-5; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 2000, J MED CHEM, V43, P146, DOI 10.1021/jm990329z; Sauvonnet N, 2002, MOL MICROBIOL, V45, P805, DOI 10.1046/j.1365-2958.2002.03053.x; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; STRALEY SC, 1986, INFECT IMMUN, V51, P445, DOI 10.1128/IAI.51.2.445-454.1986; Sun JP, 2003, J BIOL CHEM, V278, P33392, DOI 10.1074/jbc.M304693200; Yao T, 1999, J EXP MED, V190, P1343, DOI 10.1084/jem.190.9.1343; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang Z-Y, 2003, HDB CELLULAR SIGNALI, P677; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200	64	75	79	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41734	41741		10.1074/jbc.M307152200	http://dx.doi.org/10.1074/jbc.M307152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888560	hybrid			2022-12-25	WOS:000185989500024
J	Gross, I; Morrison, DJ; Hyink, DP; Georgas, K; English, MA; Mericskay, M; Hosono, S; Sasson, D; Wilson, PD; Little, M; Licht, JD				Gross, I; Morrison, DJ; Hyink, DP; Georgas, K; English, MA; Mericskay, M; Hosono, S; Sasson, D; Wilson, PD; Little, M; Licht, JD			The receptor tyrosine kinase regulator sprouty1 is a target of the tumor suppressor WT1 and important for kidney development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; WILMS-TUMOR; DROSOPHILA-SPROUTY; CNS DEVELOPMENT; RNA EXPRESSION; MESSENGER-RNA; DNA-BINDING; GENE WT1; PROTEIN; DIFFERENTIATION	WT1 encodes a transcription factor involved in kidney development and tumorigenesis. Using representational difference analysis, we identified a new set of WT1 targets, including a homologue of the Drosophila receptor tyrosine kinase regulator, sprouty. Sprouty1 was up-regulated in cell lines expressing wild-type but not mutant WT1. WT1 bound to the endogenous sprouty1 promoter in vivo and directly regulated sprouty1 through an early growth response gene-1 binding site. Expression of Sprouty1 and WT1 overlapped in the developing metanephric mesenchyme, and Sprouty1, like WT1, plays a key role in the early steps of glomerulus formation. Disruption of Sprouty1 expression in embryonic kidney explants by antisense oligonucleotides reduced condensation of the metanephric mesenchyme, leading to a decreased number of glomeruli. In addition, sprouty1 was expressed in the ureteric tree and antisense-treated ureteric trees had cystic lumens. Therefore, sprouty1 represents a physiologically relevant target gene of WT1 during kidney development.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Mt Sinai Sch Med, Dept Mol Cellular & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; University of Queensland; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), Mt Sinai Sch Med, Dept Med, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Hyink, Deborah/AAT-6821-2021; Gross, Isabelle/P-9859-2019; Little, Melissa H/A-6170-2010; Licht, Jonathan/L-4239-2019; Gross, Isabelle/I-4972-2016; MERICSKAY, Mathias/M-3477-2018	Hyink, Deborah/0000-0001-5820-4995; Gross, Isabelle/0000-0002-2783-8773; Little, Melissa H/0000-0003-0380-2263; Gross, Isabelle/0000-0002-2783-8773; Licht, Jonathan/0000-0002-3942-1369; Morrison, Debra/0000-0002-8265-5910; MERICSKAY, Mathias/0000-0002-6779-092X; Sassoon, David/0000-0001-6074-048X	NCI NIH HHS [CA95823, CA59998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095823, R01CA059998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Awqati Q, 1998, KIDNEY INT, V54, P1832, DOI 10.1046/j.1523-1755.1998.00196.x; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; AVNER ED, 1990, PEDIATR NEPHROL, V4, P372, DOI 10.1007/BF00862522; AVNER ED, 1985, IN VITRO CELL DEV B, V21, P297; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; Davidson BP, 2000, DEV BIOL, V221, P41, DOI 10.1006/dbio.2000.9663; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guo JK, 2002, HUM MOL GENET, V11, P651, DOI 10.1093/hmg/11.6.651; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kolle G, 2000, MECH DEVELOP, V90, P181, DOI 10.1016/S0925-4773(99)00248-8; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kuure S, 2000, MECH DEVELOP, V92, P31, DOI 10.1016/S0925-4773(99)00323-8; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; LUO XN, 1995, ONCOGENE, V11, P743; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; Minowada G, 1999, DEVELOPMENT, V126, P4465; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	58	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41420	41430		10.1074/jbc.M306425200	http://dx.doi.org/10.1074/jbc.M306425200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882970	hybrid			2022-12-25	WOS:000185847200122
J	Xu, M; Welling, A; Paparisto, S; Hofmann, F; Klugbauer, N				Xu, M; Welling, A; Paparisto, S; Hofmann, F; Klugbauer, N			Enhanced expression of L-type Ca(v)1.3 calcium channels in murine embryonic hearts from Ca(v)1.2-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; MOUSE HEART; DEVELOPMENTAL-CHANGES; SINOATRIAL NODE; MESSENGER-RNA; RAT-HEART; GENE; MODULATION; SUBUNIT; CARDIOMYOCYTES	Voltage-gated calcium (Ca2+) channels play a key role in the control of heart contraction and are essential for normal heart development. The Ca(v)1.2 L-type calcium channel is the predominant isoform in cardiomyocytes and is essential for excitation-contraction coupling. Although the inactivation of the Ca(v)1.2 gene caused embryonic lethality before embryonic day E14.5, hearts were contracting before E14 depending on a dihydropyridine-sensitive calcium influx. We analyzed the consequences of the deletion of the Ca(v)1.2 channel on the expression level of other voltage-gated calcium channels in the embryonic mouse heart and isolated cardiomyocytes. A strong compensatory up-regulation of the Ca(v)1.3 calcium channel was observed on the mRNA as well as on the protein level. Reverse transcriptase PCR indicated that the recently identified new Ca(v)1.3(1b) isoform was strongly up-regulated, whereas a more moderate increase was found for the Ca(v)1.3(1a) variant. Heterologous expression of Ca(v)1.3( 1b) in HEK293 cells induced Ba2+ currents with properties similar to those found in Ca(v)1.2 (-/-) cardiomyocytes, suggesting that this isoform constitutes a major component of the residual L-type calcium current in Ca(v)1.2 (-/-) cardiomyocytes. In summary, our results imply that calcium channel expression is dynamically regulated during heart development and that the Ca(v)1.3 channel may substitute for Ca(v)1.2 during early embryogenesis.	Tech Univ Munich, Dept Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Klugbauer, N (corresponding author), Tech Univ Munich, Dept Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.		Welling, Andrea/K-6674-2017	Welling, Andrea/0000-0002-5364-4980				An RH, 1996, CIRC RES, V78, P371, DOI 10.1161/01.RES.78.3.371; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Bohn G, 2000, FEBS LETT, V481, P73, DOI 10.1016/S0014-5793(00)01979-7; Campbell DB, 1999, MOL PHARMACOL, V55, P23, DOI 10.1124/mol.55.1.23; Cribbs LL, 2001, CIRC RES, V88, P403; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Ferron L, 2002, J MOL CELL CARDIOL, V34, P533, DOI 10.1006/jmcc.2002.1535; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Huang BY, 2000, CARDIOVASC RES, V46, P442, DOI 10.1016/S0008-6363(00)00017-1; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; Klugbauer N, 2002, EUR J PHARMACOL, V447, P279, DOI 10.1016/S0014-2999(02)01850-2; Koschak A, 2001, J BIOL CHEM, V276, P22100, DOI 10.1074/jbc.M101469200; Larsen JK, 2002, J MOL CELL CARDIOL, V34, P519, DOI 10.1006/jmcc.2001.1534; Lipscombe D, 2002, CIRC RES, V90, P933, DOI 10.1161/01.RES.0000019740.52306.92; Liu W, 1999, AM J PHYSIOL-HEART C, V276, pH608, DOI 10.1152/ajpheart.1999.276.2.H608; Mangoni ME, 2003, P NATL ACAD SCI USA, V100, P5543, DOI 10.1073/pnas.0935295100; Menard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Namkung Y, 2001, J CLIN INVEST, V108, P1015, DOI 10.1172/JCI13310; Nattel S, 1999, CIRC RES, V85, P473, DOI 10.1161/01.RES.85.5.473; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Protas L, 2001, AM J PHYSIOL-HEART C, V281, pH1252, DOI 10.1152/ajpheart.2001.281.3.H1252; Seisenberger C, 2000, J BIOL CHEM, V275, P39193, DOI 10.1074/jbc.M006467200; Takimoto K, 1997, J MOL CELL CARDIOL, V29, P3035, DOI 10.1006/jmcc.1997.0532; Viatchenko-Karpinski S, 1999, P NATL ACAD SCI USA, V96, P8259, DOI 10.1073/pnas.96.14.8259; Weissgerber P, 2003, N-S ARCH PHARMACOL, V367, pR92; Yasui K, 2001, CIRC RES, V88, P536, DOI 10.1161/01.RES.88.5.536; Zhang Z, 2002, CIRC RES, V90, P981, DOI 10.1161/01.RES.0000018003.14304.E2	32	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40837	40841		10.1074/jbc.M307598200	http://dx.doi.org/10.1074/jbc.M307598200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900400	hybrid			2022-12-25	WOS:000185847200052
J	Lee, YC; Tang, YC; Chen, YH; Wong, CM; Tsou, AP				Lee, YC; Tang, YC; Chen, YH; Wong, CM; Tsou, AP			Selenite-induced survival of HuH7 hepatoma cells involves activation of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt pathway and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL DNA LOOPS; HEPATITIS-B VIRUS; SERUM-FREE MEDIUM; NF-KAPPA-B; GLUTATHIONE-PEROXIDASE; CANCER MORTALITY; THIOREDOXIN REDUCTASE; REDOX MECHANISM; SELENOPROTEIN-P; TRANSGENIC MICE	Selenium has been shown to sustain the growth of selected human hepatocellular carcinoma cell lines under serum-free conditions, but the detailed mechanism remained undetermined. In the present study, the molecular mechanism(s) involving sodium selenite (Na2SO3, Se) as a survival agent were determined. Selenite not only protects HuH7 cells from serum deprivation-induced apoptosis, it also supports its long-term growth in sodium selenite ( 10(-7) M) supplemented serum-free medium. The anti-apoptotic effect correlates with activation of focal adhesion kinase and the phosphatidylinositol 3-kinase (PI3K)-Akt kinase pathway. Using HuH7 cells stably transfected with a constitutively active Akt kinase and PI3K inhibitor LY294002, selenite-induced cell survival was shown to be PI3K-Akt-dependent. Parallel changes included a significant reduction in the intracellular reactive oxygen species content, the reversal of DNA fragmentation, and the suppression of caspase and apoptosis signal-regulating kinase 1 activities. HuH7 cells stably expressing a Rac1 mutant N17 (Rac1(N17)-HuH7) are refractory to selenite treatment. In these cells selenite supplement neither triggers Akt activation nor supports cell proliferation. Participation of Rac1 activation in this event is supported by the fact that selenite treatment drastically enhanced activation of Rac1. The exact link between selenite treatment, Rac1 activation, and activation of the focal adhesion kinase-PI 3-kinase, however, remains to be characterized. The mitogenic signaling mediated by selenite may involve unconventional growth stimuli including higher glutathione peroxidase 1 activity and higher transcription levels of selenoprotein P. The selenium-HuH7 system we have established thus provides a unique tool that will allow the biological role of selenite in growth regulation of hepatocytes to be studied in detail.	Natl Yang Ming Univ, Inst Biotechnol Med, Sch Med Technol & Engn, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Inst Genet, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Tsou, AP (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Sch Med Technol & Engn, Taipei 112, Taiwan.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Baker A, 1997, CANCER RES, V57, P5162; BARNES D, 1979, NATURE, V281, P388, DOI 10.1038/281388a0; Bergsland EK, 2001, SEMIN ONCOL, V28, P521, DOI 10.1053/sonc.2001.26955; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; BURK RF, 1983, ANNU REV NUTR, V3, P53, DOI 10.1146/annurev.nu.03.070183.000413; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; CLARK LC, 1991, ARCH ENVIRON HEALTH, V46, P37, DOI 10.1080/00039896.1991.9937427; Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ESWORTHY RS, 1995, CANCER RES, V55, P957; Fiala ES, 1998, CARCINOGENESIS, V19, P597, DOI 10.1093/carcin/19.4.597; Frydman B, 1997, CANCER RES, V57, P620; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; LAGARKOVA MA, 1995, J BIOL CHEM, V270, P20239, DOI 10.1074/jbc.270.35.20239; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Lu YP, 1997, CANCER RES, V57, P1468; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; Mostert V, 2000, ARCH BIOCHEM BIOPHYS, V376, P433, DOI 10.1006/abbi.2000.1735; MURAKAMI H, 1980, P NATL ACAD SCI-BIOL, V77, P3464, DOI 10.1073/pnas.77.6.3464; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; NIWA A, 1979, J CELL PHYSIOL, V98, P177, DOI 10.1002/jcp.1040980119; OYAMA Y, 1994, BRAIN RES, V635, P113, DOI 10.1016/0006-8993(94)91429-X; Park HS, 2000, J BIOL CHEM, V275, P8487, DOI 10.1074/jbc.275.12.8487; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHRAUZER GN, 1977, BIOINORG CHEM, V7, P35, DOI 10.1016/S0006-3061(00)80127-1; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; STADTMAN TC, 1991, J BIOL CHEM, V266, P16257; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Stapleton SR, 1997, BBA-MOL CELL RES, V1355, P259, DOI 10.1016/S0167-4889(96)00140-1; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUNDE RA, 1990, ANNU REV NUTR, V10, P451, DOI 10.1146/annurev.nu.10.070190.002315; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang HM, 2001, BIOCHEMISTRY-US, V40, P3316, DOI 10.1021/bi002786j; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; WEBBER RJ, 1988, J ORTHOP RES, V6, P13, DOI 10.1002/jor.1100060103; WU L, 1995, CARCINOGENESIS, V16, P1579, DOI 10.1093/carcin/16.7.1579; Yan J, 1998, J NEUROSCI, V18, P8682; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Yu SY, 1997, BIOL TRACE ELEM RES, V56, P117, DOI 10.1007/BF02778987; YU SY, 1988, BIOL TRACE ELEM RES, V15, P243, DOI 10.1007/BF02990141; YU SY, 1985, BIOL TRACE ELEM RES, V7, P21, DOI 10.1007/BF02916544	54	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39615	39624		10.1074/jbc.M304095200	http://dx.doi.org/10.1074/jbc.M304095200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12896980	hybrid			2022-12-25	WOS:000185713800045
J	Nemoto, T; Tanida, I; Tanida-Miyake, E; Minematsu-Ikeguchi, N; Yokota, M; Ohsumi, M; Ueno, T; Kominami, E				Nemoto, T; Tanida, I; Tanida-Miyake, E; Minematsu-Ikeguchi, N; Yokota, M; Ohsumi, M; Ueno, T; Kominami, E			The mouse APG10 homologue, an E2-like enzyme for Apg12p conjugation, facilitates MAP-LC3 modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; VACUOLE TARGETING PATHWAY; SACCHAROMYCES-CEREVISIAE; ACTIVATING ENZYME; ERYTHROID-CELLS; AUTOPHAGY; YEAST; UBIQUITIN; SYSTEM; DISEASE	Autophagy is a process for the bulk degradation of cytosolic compartments by lysosomes/vacuoles. The formation of autophagosomes involves a dynamic rearrangement of the membrane for which two ubiquitinlike modifications ( the conjugation of Apg12p and the modification of a soluble form of MAP-LC3 to a membrane-bound form) are essential. In yeast, Apg10p is an E2-like enzyme essential for Apg12p conjugation. The isolated mouse APG10 gene product interacts with mammalian Apg12p dependent on mammalian Apg7p ( E1-like enzyme), and facilitates Apg12p conjugation. The interaction of Apg10p with Apg12p is dependent on the carboxyl-terminal glycine of Apg12p. Mutational analysis of the predicted active site cysteine (Cys(161)) within mouse Apg10p shows that mutant Apg10pC161S, which can form a stable intermediate with Apg12p, inhibits Apg12p conjugation even in the presence of Apg7p, while overexpression of Apg7p facilitates formation of an Apg12p-Apg5p conjugate. Furthermore, the coexpression of Apg10p with Apg7p facilitates the modification of a soluble form of MAP-LC3 to a membrane-bound form, a second modification essential for autophagy. Mouse Apg10p interacts with MAP-LC3 in HEK293 cells, while no mutant Apg10pC161S forms any intermediate with MAP-LC3. Direct interaction between Apg10p and MAP-LC3 is also demonstrated by yeast two-hybrid analysis. The inability of mutant Apg10pC161S to form any intermediate with MAP-LC3 has ruled out the possibility that MAP-LC3 interacts with Apg10p as a substrate.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan; Teikyo Univ Sci & Technol, Dept Biosci, Yamanashi 4090193, Japan	Juntendo University	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.		Kominami, Eiki/D-3802-2009; Tanida, Isei/C-8277-2009	Tanida, Isei/0000-0001-8999-3990				Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; HEYNEN MJ, 1985, CELL TISSUE RES, V239, P235, DOI 10.1007/BF00214924; HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2002, FEBS LETT, V532, P450, DOI 10.1016/S0014-5793(02)03739-0; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; OHSHITA T, 1986, J BIOCHEM-TOKYO, V100, P623, DOI 10.1093/oxfordjournals.jbchem.a121754; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; SULLIVAN ML, 1993, J BIOL CHEM, V268, P8777; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Takano-Ohmuro H, 2000, EUR J CELL BIOL, V79, P759, DOI 10.1078/0171-9335-00096; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, BIOCHEM BIOPH RES CO, V292, P256, DOI 10.1006/bbrc.2002.6645; Tanida I, 2002, BIOCHEM BIOPH RES CO, V296, P1164, DOI 10.1016/S0006-291X(02)02057-0; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	38	71	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39517	39526		10.1074/jbc.M300550200	http://dx.doi.org/10.1074/jbc.M300550200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890687	hybrid			2022-12-25	WOS:000185713800032
J	de Graaf, P; Little, NA; Ramos, YFM; Meulmeester, E; Letteboer, SJF; Jochemsen, AG				de Graaf, P; Little, NA; Ramos, YFM; Meulmeester, E; Letteboer, SJF; Jochemsen, AG			Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC LETHALITY; DNA-DAMAGE; MDM2-DEFICIENT MICE; MALIGNANT GLIOMAS; ACIDIC DOMAIN; P53 STABILITY; CELL-GROWTH; DEGRADATION; EXPRESSION; TRANSACTIVATION	The stability of the p53 tumor suppressor protein is critically regulated by the Hdm2 and Hdmx proteins. Hdm2 protein levels are auto-regulated by the self-ubiquitination activity of Hdm2 and on the transcriptional level by p53-activated transcription of the hdm2 gene. Little is known about the regulation of Hdmx expression levels, apart from the observation that the Mdmx protein can be cleaved by caspase-3 in a p53-inducible manner. In the functional analysis of two mutant Hdmx proteins, products of two alternatively spliced mRNAs, it was found that Hdmx proteins are targets for ubiquitination by Mdm2. The stability of the Hdmx protein is partly dependent on the presence of its internal acidic domain. Mdm2 appears only to require an intact RING domain to be able to ubiquitinate Hdmx and target it for proteasomal degradation. These findings highlight the intricate functional relationships between p53, Mdm2, and Hdmx.	Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Dept Mol & Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.		Ramos, Yolande F. M./C-3774-2018; Letteboer, Stef JF/P-8272-2015	Ramos, Yolande F. M./0000-0003-1459-413X; de Graaf, Petra/0000-0002-3183-8901				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Ghosh M, 2003, BIOCHEMISTRY-US, V42, P2291, DOI 10.1021/bi0271291; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; LUNA RMD, 1995, NATURE, V378, P203; Maniatis T., 1982, MOL CLONING LAB MANU; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Parant JM, 2001, GENE, V270, P277, DOI 10.1016/S0378-1119(01)00432-2; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 2003, INT J CANCER, V104, P752, DOI 10.1002/ijc.11023; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; van der Eb A J, 1980, Methods Enzymol, V65, P826; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	51	117	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38315	38324		10.1074/jbc.M213034200	http://dx.doi.org/10.1074/jbc.M213034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874296	hybrid			2022-12-25	WOS:000185575100030
J	Sekoguchi, E; Sato, N; Yasui, A; Fukada, S; Nimura, Y; Aburatani, H; Ikeda, K; Matsuura, A				Sekoguchi, E; Sato, N; Yasui, A; Fukada, S; Nimura, Y; Aburatani, H; Ikeda, K; Matsuura, A			A novel mitochondrial carnitine-acylcarnitine translocase induced by partial hepatectomy and fasting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; LIVER-REGENERATION; FATTY-ACIDS; ACETYL-COA; RAT-HEART; PROTEIN; CARRIER; DEFICIENCY; METABOLISM	The carnitine-dependent transport of long-chain fatty acids is essential for fatty acid catabolism. In this system, the fatty acid moiety of acyl-CoA is transferred enzymatically to carnitine, and the resultant product, acylcarnitine, is imported into the mitochondrial matrix through a transporter named carnitine-acylcarnitine translocase (CACT). Here we report a novel mammalian protein homologous to CACT. The protein, designated as CACL (CACT-like), is localized to the mitochondria and has palmitoylcarnitine transporting activity. The tissue distribution of CACL is similar to that of CACT; both are expressed at a higher level in tissues using fatty acids as fuels, except in the brain, where only CACL is expressed. In addition, CACL is induced by partial hepatectomy or fasting. Thus, CACL may play an important role cooperatively with its homologue CACT in a stress-induced change of lipid metabolism, and may be specialized for the metabolism of a distinct class of fatty acids involved in brain function.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Chubu Natl Hosp, Aichi 4748522, Japan; Nagoya Univ, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Tokyo Univ Pharm & Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan	Nagoya University; Tokyo University of Pharmacy & Life Sciences; University of Tokyo	Matsuura, A (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan.		Matsuura, Akira/AAO-1572-2021; Matsuura, Akira/J-3864-2017	Matsuura, Akira/0000-0002-2300-7227; Matsuura, Akira/0000-0002-2300-7227				ADAMS MG, 1981, J PATHOL, V135, P111, DOI 10.1002/path.1711350203; ASINS G, 1994, BIOCHEM J, V299, P65, DOI 10.1042/bj2990065; De Lucas JR, 1999, ARCH MICROBIOL, V171, P386, DOI 10.1007/s002030050725; DENTON RM, 1967, BIOCHEM J, V104, P416, DOI 10.1042/bj1040416; Eraly SA, 2002, BIOCHEM BIOPH RES CO, V297, P1159, DOI 10.1016/S0006-291X(02)02343-4; Fraser F, 1999, FEBS LETT, V445, P41, DOI 10.1016/S0014-5793(99)00095-2; HALE DE, 1992, J PEDIATR-US, V121, P1, DOI 10.1016/S0022-3476(05)82532-6; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOLECEK M, 1989, PHYSIOL BOHEMOSLOV, V38, P503; Huizing M, 1997, AM J HUM GENET, V61, P1239, DOI 10.1086/301628; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; Inoue Y, 2002, HEPATOLOGY, V36, P336, DOI 10.1053/jhep.2002.34942; Knoll A, 1999, MOL BRAIN RES, V74, P217, DOI 10.1016/S0169-328X(99)00252-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lai HS, 1998, WORLD J SURG, V22, P42, DOI 10.1007/s002689900347; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MITCHELL GA, 1995, CLIN INVEST MED, V18, P193; MURTHY MSR, 1984, J BIOL CHEM, V259, P9082; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; Onishi M, 1996, EXP HEMATOL, V24, P324; PANDE SV, 1975, P NATL ACAD SCI USA, V72, P883, DOI 10.1073/pnas.72.3.883; PANDE SV, 1993, J CLIN INVEST, V91, P1247, DOI 10.1172/JCI116288; Pande SV, 1999, AM J MED SCI, V318, P22, DOI 10.1097/00000441-199907000-00004; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SIKORSKI RS, 1989, GENETICS, V122, P19; STANLEY CA, 1992, NEW ENGL J MED, V327, P19, DOI 10.1056/NEJM199207023270104; Su AI, 2002, P NATL ACAD SCI USA, V99, P11181, DOI 10.1073/pnas.122359899; Suzuki J, 2002, AM J PHYSIOL-ENDOC M, V283, pE94, DOI 10.1152/ajpendo.00017.2002; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Wallis JG, 2002, TRENDS BIOCHEM SCI, V27, P467, DOI 10.1016/S0968-0004(02)02168-0	35	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38796	38802		10.1074/jbc.M306372200	http://dx.doi.org/10.1074/jbc.M306372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882971	hybrid			2022-12-25	WOS:000185575100087
J	Wu-Baer, F; Lagrazon, K; Yuan, W; Baer, R				Wu-Baer, F; Lagrazon, K; Yuan, W; Baer, R			The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN CHAIN; TUMOR-SUPPRESSOR; LIGASE ACTIVITY; CONJUGATING ENZYME; PROTEIN LIGASE; RING DOMAIN; IN-VIVO; BRCA1; COMPLEX; BARD1	The BRCA1 tumor suppressor forms a heterodimer with the BARD1 protein, and the resulting complex functions as an E3 ubiquitin ligase that catalyzes the synthesis of polyubiquitin chains. In theory, polyubiquitination can occur by isopeptide bond formation at any of the seven lysine residues of ubiquitin. The isopeptide linkage of a polyubiquitin chain is a particularly important determinant of its cellular function, such that K48-linked chains commonly target proteins for proteasomal degradation, while K63 chains serve non-proteolytic roles in various signaling pathways. To determine the isopeptide linkage formed by BRCA1/BARD1-dependent polyubiquitination, we purified a full-length heterodimeric complex and compared its linkage specificity with that of E6-AP, an E3 ligase known to induce proteolysis of its cellular substrates. Using a comprehensive mutation analysis, we found that E6-AP catalyzes the synthesis of K48-linked polyubiquitin chains. In contrast, however, the BRCA1/BARD1 heterodimer directs polymerization of ubiquitin primarily through an unconventional linkage involving lysine residue K6. Although heterologous substrates of BRCA1/BARD1 are not known, BRCA1 autoubiquitination occurs principally by conjugation with K6-linked polymers. The ability of BRCA1/BARD1 to form K6-linked polyubiquitin chains suggests that it may impart unique cellular properties to its natural enzymatic substrates.	Columbia Univ, Inst Canc Genet, Dept Pathol, New York, NY 10032 USA	Columbia University	Baer, R (corresponding author), Columbia Univ, Inst Canc Genet, Dept Pathol, 1150 St Nicholas Ave, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [CA97403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199	28	219	229	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34743	34746		10.1074/jbc.C300249200	http://dx.doi.org/10.1074/jbc.C300249200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12890688	hybrid			2022-12-25	WOS:000185164400003
J	Shao, CL; Furusawa, Y; Kobayashi, Y; Funayama, T; Wada, S				Shao, CL; Furusawa, Y; Kobayashi, Y; Funayama, T; Wada, S			Bystander effect induced by counted high-LET particles in confluent human fibroblasts: a mechanistic study	FASEB JOURNAL			English	Article						microbeam; micronucleus; gap junction; reactive oxygen species	TISSUE-CULTURE MODEL; ALPHA-PARTICLES; MAMMALIAN-CELLS; INTERCELLULAR COMMUNICATION; LOW FLUENCES; IONIZING-RADIATION; GAMMA-IRRADIATION; MICROBEAM; SINGLE; INDUCTION	The possible mechanism of a radiation-induced bystander response was investigated by using a high-LET heavy particle microbeam, which allows selected cells to be individually hit with precise numbered particles. Even when only a single cell within the confluent culture was hit by one particle of Ar-40 (similar to1260 keV/mum) or Ne-20 (similar to380 keV/mum), a 1.4-fold increase of micronuclei (MN) was detected demonstrating a bystander response. When the number of targeted cells increased, the number of MN biphasically increased; however, the efficiency of MN induction per targeted cell markedly decreased. When 49 cells in the culture were individually hit by 1 to 4 particles, the production of MN in the irradiated cultures were similar to2-fold higher than control levels but independent of the number and LET of the particles. MN induction in the irradiated-culture was partly reduced by treatment with DMSO, a scavenger of reactive oxygen species (ROS), and was almost fully suppressed by the mixture of DMSO and PMA, an inhibitor of gap junctional intercellular communication (GJIC). Accordingly, both ROS and GJIC contribute to the above-mentioned bystander response and GJIC may play an essential role by mediating the release of soluble biochemical factors from targeted cells.	Natl Inst Radiol Sci, Heavy Ion Radiobiol Res Grp, Chiba 2638555, Japan; Japan Atom Energy Res Inst, Takasaki Radiat Chem Res Estab, Biotechnol Lab, Takasaki, Gumma 3701201, Japan	National Institutes for Quantum Science & Technology; Japan Atomic Energy Agency	Furusawa, Y (corresponding author), Natl Inst Radiol Sci, Heavy Ion Radiobiol Res Grp, 4-9-1 Anagawa, Chiba 2638555, Japan.	Shao@gci.ac.uk; Furusawa@nirs.go.jp	Furusawa, Yoshiya/A-4487-2012	Furusawa, Yoshiya/0000-0003-4213-7331; Shao, Chunlin/0000-0001-9336-9912; /0000-0003-4250-4269				Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Azzam EI, 2000, CANCER RES, V60, P2623; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; Bishayee A, 2001, RADIAT RES, V155, P335, DOI 10.1667/0033-7587(2001)155[0335:FRIAGJ]2.0.CO;2; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; EWING D, 1991, RADIAT RES, V126, P187, DOI 10.2307/3577817; FENECH M, 1986, MUTAT RES, V161, P193, DOI 10.1016/0027-5107(86)90010-2; FENECH M, 1993, ENVIRON HEALTH PERSP, V101, P101, DOI 10.2307/3431708; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 2001, RADIAT RES, V156, P796, DOI 10.1667/0033-7587(2001)156[0796:AFUXRM]2.0.CO;2; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; Furusawa Y, 2000, RADIAT RES, V154, P485, DOI 10.1667/0033-7587(2000)154[0485:IOAAHC]2.0.CO;2; Hei TK, 1997, P NATL ACAD SCI USA, V94, P3765, DOI 10.1073/pnas.94.8.3765; *ICRP, 1994, ANN ICRP, V24, P1; Iyer R, 2000, CANCER RES, V60, P1290; Iyer R, 2000, ARCH BIOCHEM BIOPHYS, V376, P14, DOI 10.1006/abbi.1999.1684; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; Shao CL, 1999, RADIAT ENVIRON BIOPH, V38, P105, DOI 10.1007/s004110050145; Shao CL, 2001, J RADIAT RES, V42, P305, DOI 10.1269/jrr.42.305; Sonveaux P, 2002, FASEB J, V16, P1979, DOI 10.1096/fj.02-0487fje; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2001, P NATL ACAD SCI USA, V98, P14410, DOI 10.1073/pnas.251524798	38	111	126	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1422	1427		10.1096/fj.02-1115com	http://dx.doi.org/10.1096/fj.02-1115com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890695				2022-12-25	WOS:000185345100034
J	Casteran, N; De Sepulveda, P; Beslu, N; Aoubala, M; Letard, S; Lecocq, E; Rottapel, R; Dubreuil, P				Casteran, N; De Sepulveda, P; Beslu, N; Aoubala, M; Letard, S; Lecocq, E; Rottapel, R; Dubreuil, P			Signal transduction by several KIT juxtamembrane domain mutations	ONCOGENE			English	Article						receptor; mutation; STI571; GIST	RECEPTOR TYROSINE KINASE; ACUTE MYELOID-LEUKEMIA; PROTOONCOGENE C-KIT; CELL LUNG-CANCER; CONSTITUTIVELY ACTIVATING MUTATIONS; GASTROINTESTINAL STROMAL TUMORS; LIGAND-INDEPENDENT ACTIVATION; MAST-CELLS; CATALYTIC DOMAIN; POINT MUTATION	Mutations of KIT receptor tyrosine kinase are found in the majority of patients with mastocytosis and in most gastrointestinal stromal tumors. Oncogenic KIT mutations in GISTs are located in the KIT juxtamembrane domain (JMD), while codon 816 in the KIT kinase domain is mutated in systemic mastocytosis. We describe and characterize a mutation in the KIT-JMD named KDelta27. We show that KDelta27 mutant is constitutively dimerized and phosphorylated. KDelta27 ectopic expression renders both the Ba/F3 cell line and primary cultures of bone marrow mast cells independent of cytokines for proliferation and cell survival. The classical signaling pathways activated by wild-type KIT upon ligand stimulation are constitutively activated by KDelta27 and other JMD mutations. However, a side-to-side comparison revealed differences between the wild-type and JMD mutations. First, in vitro kinase assays reveal a change in peptide substrate specificity. Second, STAT proteins are preferentially phosphorylated by KIT mutants. Third, inhibitors of KIT kinase are more efficient on JMD mutations than on WT KIT. We conclude that KDelta27 is a new oncogenic KIT mutation showing constitutive activation of downstream signaling pathways, and suggest that specific pathways are activated by oncogenic KIT.	INSERM, U119, Mol & Funct Hematopoiesis Lab, F-13009 Marseille, France; Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; University Health Network Toronto	De Sepulveda, P (corresponding author), INSERM, U119, Mol & Funct Hematopoiesis Lab, 27 Bd Lei Roure, F-13009 Marseille, France.		De sepulveda, paulo/K-6043-2015; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	De sepulveda, paulo/0000-0001-8295-5414; Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; LETARD, Sebastien/0000-0002-6508-7376; Rottapel, Robert/0000-0002-6024-5558				Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beghini A, 1998, BLOOD CELL MOL DIS, V24, P262, DOI 10.1006/bcmd.1998.0191; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Casteran N, 1998, LEUKEMIA, V12, P1089, DOI 10.1038/sj.leu.2401057; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; DASTYCH J, 1994, J IMMUNOL, V152, P213; Frost MJ, 2002, MOL CANCER THER, V1, P1115; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HERBST R, 1995, ONCOGENE, V10, P369; HIBI K, 1991, ONCOGENE, V6, P2291; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; KINASHI T, 1994, BLOOD, V83, P1033; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kitayama H, 1996, BLOOD, V88, P995; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Krystal GW, 1997, CANCER RES, V57, P2203; Leslie NR, 1998, BLOOD, V92, P4798, DOI 10.1182/blood.V92.12.4798.424k12_4798_4807; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; London CA, 1999, EXP HEMATOL, V27, P689, DOI 10.1016/S0301-472X(98)00075-7; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Ma YS, 1999, J INVEST DERMATOL, V112, P165, DOI 10.1046/j.1523-1747.1999.00488.x; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakao M, 1996, LEUKEMIA, V10, P1911; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Sperr WR, 1998, BRIT J HAEMATOL, V103, P740; Taniguchi M, 1999, CANCER RES, V59, P4297; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; TSUJIMURA T, 1994, BLOOD, V83, P2619; Tsujimura T, 1996, BLOOD, V87, P273; Tsujimura Tohru, 1997, Leukemia (Basingstoke), V11, P396; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	53	61	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4710	4722		10.1038/sj.onc.1206587	http://dx.doi.org/10.1038/sj.onc.1206587			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879016				2022-12-25	WOS:000184157000012
J	Jansson, AK; Emterling, AM; Arbman, G; Sun, XF				Jansson, AK; Emterling, AM; Arbman, G; Sun, XF			Noxa in colorectal cancer: a study on DNA, mRNA and protein expression	ONCOGENE			English	Article						Noxa; colorectal cancer; DNA sequencing; real-time PCR; immunohistochemistry	P53-DEPENDENT APOPTOSIS; BAX; P53; TRANSFORMATION; MUTATIONS; MEDIATOR; DEATH; CELLS; TUMOR; PUMA	Noxa is a BH3-only member of the Bcl-2 family, upregulated by p53 as a response to DNA damage. Mutations in the BH3-only region of other BH3-only members lead to an inactive protein. We have investigated the mRNA expression of Noxa with real-time PCR in 94 unselected colorectal adenocarcinomas and the corresponding normal mucosa. Among them, Noxa protein expression was investigated with immunohistochemistry in 16 tumors and six corresponding normal mucosa samples. Further, we searched for Noxa mutations in all the cases using single-stranded conformation polymorphism and DNA sequencing. The mRNA expression of Noxa was weak in 9% and strong in 2% of the tumors, and decreased in 9% and increased in 16% of the tumors compared with the normal mucosa; however, these changes did not have any clinical or pathological significance. The protein level in most of the cases investigated was correlated with the mRNA level. We did not find any mutations in the Noxa gene. Thus, we suggest that Noxa may not be of importance in the development of colorectal cancer.	Linkoping Univ, Dept Biomed & Surg, Div Oncol, S-58185 Linkoping, Sweden; Vrinnevi Hosp, Dept Surg, Norrkoping, Sweden	Linkoping University	Jansson, AK (corresponding author), Linkoping Univ, Dept Biomed & Surg, Div Oncol, S-58185 Linkoping, Sweden.	agnja@ibk.liu.se						Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jansson A, 2002, J CLIN ONCOL, V20, P811, DOI 10.1200/JCO.20.3.811; Jansson A, 2001, INT J CANCER, V92, P338, DOI 10.1002/ijc.1189; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Wei MC, 2000, GENE DEV, V14, P2060; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	18	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4675	4678		10.1038/sj.onc.1206655	http://dx.doi.org/10.1038/sj.onc.1206655			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879012				2022-12-25	WOS:000184157000008
J	Takino, T; Koshikawa, N; Miyamori, H; Tanaka, M; Sasaki, T; Okada, Y; Seiki, M; Sato, H				Takino, T; Koshikawa, N; Miyamori, H; Tanaka, M; Sasaki, T; Okada, Y; Seiki, M; Sato, H			Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases	ONCOGENE			English	Article						MMP; KiSS-1; cleavage	PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR; PROMOTES ACTIVATION; EXPRESSION; IDENTIFICATION; INVASION; BINDING; PEPTIDE; CELLS; ALPHA	A human placenta cDNA library was screened by the expression cloning method for gene products that interact with matrix metalloproteinases (MMPs), and we isolated a cDNA whose product formed a stable complex with pro-MMP-2 and pro-MMP-9. The cDNA encoded the metastasis suppressor gene KiSS-1. KiSS-1 protein was shown to form a complex with pro-MMP. KiSS-1 protein is known to be processed to peptide ligand of a G-protein-coupled receptor (hOT7T175) named metastin, and suppresses metastasis of tumors expressing the receptor. Active MMP-2, MMP-9, MT1-MMP, MT3-MMP and MT5-MMP cleaved the Gly(118)-Leu(119) peptide bond of not only full-length KiSS-1 protein but also metastin decapeptide. Metastin decapeptide induced formation of focal adhesion and actin stress fibers in cells expressing the receptor, and digestion of metastin decapeptide by MMP abolished its ligand activity. Migration of HT1080 cells expressing hOT7T175 that harbor a high-level MMP activity was only slightly suppressed by either metastin decapeptide or MMP inhibitor BB-94 alone, but the combination of metastin decapeptide and BB-94 showed a synergistic effect in blocking cell migration. We propose that metastin could be used as an antimetastatic agent in combination with MMP inhibitor, or MMP-resistant forms of metastin could be developed and may also be efficacious.	Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Tokyo 1088639, Japan; Kanazawa Univ, Canc Res Inst, Dept Chemotherapy, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Keio Univ, Sch Med, Dept Pathol, Tokyo 1608582, Japan	Kanazawa University; University of Tokyo; Kanazawa University; Kanazawa University; Keio University	Sato, H (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	vhsato@kenroku.kanazawa-u.ac.jp	SATO, Hiroshi/D-8454-2015; Seiki, Motoharu/K-9443-2015; TAKINO, Takahisa/D-8460-2015; Koshikawa, Naohiko/S-7306-2017; Okada, Yasunori/B-5550-2014	Koshikawa, Naohiko/0000-0002-4539-888X; Okada, Yasunori/0000-0001-9208-4755				BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Hiller O, 2000, J BIOL CHEM, V275, P33008, DOI 10.1074/jbc.M001836200; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Jaworski DM, 2000, BRAIN RES, V860, P174, DOI 10.1016/S0006-8993(00)02035-7; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Llano E, 1999, CANCER RES, V59, P2570; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Murray MJ, 1999, SEMIN REPROD ENDOCR, V17, P275, DOI 10.1055/s-2007-1016235; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 2001, CANCER RES, V61, P8896; NOMURA H, 1995, CANCER RES, V55, P3263; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shirasaki F, 2001, CANCER RES, V61, P7422; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Ueno H, 1997, CANCER RES, V57, P2055; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Velasco G, 2000, CANCER RES, V60, P877; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200	38	122	140	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4617	4626		10.1038/sj.onc.1206542	http://dx.doi.org/10.1038/sj.onc.1206542			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879005	Green Submitted			2022-12-25	WOS:000184157000001
J	Pei, Y; Shuman, S				Pei, Y; Shuman, S			Characterization of the Schizosaccharomyces pombe Cdk9/Pch1 protein kinase - Spt5 phosphorylation, autophosphorylation, and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CYCLIN-DEPENDENT KINASE; CARBOXY-TERMINAL DOMAIN; TRANSCRIPTION ELONGATION-FACTOR; T-LOOP PHOSPHORYLATION; PRE-MESSENGER-RNA; VIRUS TYPE-1 TAT; P-TEFB; CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE	Schizosaccharomyces pombe Cdk9/Pch1 protein kinase is a functional ortholog of the essential Saccharomyces cerevisiae Bur1/Bur2 kinase and a putative ortholog of metazoan P-TEFb (Cdk9/cyclin T). SpCdk9/Pch1 phosphorylates of the carboxyl-terminal domain (CTD) of the S. pombe transcription elongation factor Spt5, which consists of 18 tandem repeats of a nonapeptide of consensus sequence (1)TPAWNSGSK(9). We document the divalent cation dependence and specificity of SpCdk9/Pch1, its NTP dependence and specificity, the dependence of Spt5-CTD phosphorylation on the number of tandem nonamer repeats, and the specificity for phosphorylation of the Spt5-CTD on threonine at position 1 within the nonamer element. SpCdk9/Pch1 also phosphorylates the CTD heptaptide repeat array of the largest subunit of S. pombe RNA polymerase II (consensus sequence YSPTSPS) and does so exclusively on serine. SpCdk9/Pch1 catalyzes autophosphorylation of the kinase and cyclin subunits of the kinase complex. The distribution of phosphorylation sites on SpCdk9 (86% Ser(P), 11% Thr(P), 3% Tyr(P)) is distinct from that on Pch1 (2% Ser(P), 98% Thr(P)). We conducted a structure-guided mutational analysis of SpCdk9, whereby a total of 29 new mutations of 12 conserved residues were tested for in vivo function by complementation of a yeast bur1Delta mutant. We identified many lethal and conditional mutations of side chains implicated in binding ATP and the divalent cation cofactor, phosphoacceptor substrate recognition, and T-loop dynamics. We surmise that the lethality of the of T212A mutation in the T-loop reflects an essential phosphorylation event, insofar as the conservative T212S change rescued wild-type growth; the phosphomimetic T212E change rescued growth at 30degreesC; and the effects of mutating the T-loop threonine were phenocopied by mutations in the three conserved arginines predicted to chelate the phosphate on the T-loop threonine.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.		Pei, Yi/D-8998-2011	Pei, Yi/0000-0002-3466-760X	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Chen JY, 2000, MOL CELL BIOL, V20, P8696, DOI 10.1128/MCB.20.23.8696-8708.2000; Chiu YL, 2002, MOL CELL, V10, P585, DOI 10.1016/S1097-2765(02)00630-5; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cross FR, 1998, MOL CELL BIOL, V18, P2923, DOI 10.1128/MCB.18.5.2923; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Furnari BA, 1997, J BIOL CHEM, V272, P12100, DOI 10.1074/jbc.272.18.12100; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guo S, 2000, NATURE, V408, P366, DOI 10.1038/35042590; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Lavoie SB, 2001, J MOL BIOL, V312, P675, DOI 10.1006/jmbi.2001.4991; Levine K, 1998, MOL CELL BIOL, V18, P290, DOI 10.1128/MCB.18.1.290; Lindstrom DL, 2003, MOL CELL BIOL, V23, P1368, DOI 10.1128/MCB.23.4.1368-1378.2003; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Pei Y, 2003, J BIOL CHEM, V278, P7180, DOI 10.1074/jbc.M211713200; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 1999, J VIROL, V73, P5448, DOI 10.1128/JVI.73.7.5448-5458.1999; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANTOS RC, 1995, MOL CELL BIOL, V15, P5482; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yao S, 2000, MOL CELL BIOL, V20, P7080, DOI 10.1128/MCB.20.19.7080-7087.2000; Yao S, 2002, MOL CELL BIOL, V22, P6750, DOI 10.1128/MCB.22.19.6750-6758.2002; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	49	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43346	43356		10.1074/jbc.M307319200	http://dx.doi.org/10.1074/jbc.M307319200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12904290	hybrid			2022-12-25	WOS:000186157000078
J	Holmes, A; Abraham, DJ; Chen, YJ; Denton, C; Xu, SW; Black, CM; Leask, A				Holmes, A; Abraham, DJ; Chen, YJ; Denton, C; Xu, SW; Black, CM; Leask, A			Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; COLLAGEN GENE-EXPRESSION; TRANSCRIPTION FACTOR SP1; FACTOR-BETA; SYSTEMIC-SCLEROSIS; SKIN SCLEROSIS; TGF-BETA; IN-VITRO; FIBROSIS; CELLS	Fibrotic diseases such as scleroderma (systemic sclerosis, SSc) are characterized by an excessive production of extracellular matrix and profibrotic proteins such as connective tissue growth factor (CTGF). In normal dermal fibroblasts, CTGF is not expressed unless induced by proteins such as tumor growth factor-beta (TGFbeta). Conversely, in fibroblasts cultured from fibrotic lesions CTGF mRNA and protein are constitutively expressed, even in the absence of exogenously added TGFbeta. Thus, studying the mechanism underlying CTGF overexpression in SSc fibroblasts is likely to yield valuable insights into the basis of the fibrotic phenotype of SSc and possibly other scarring disease. CTGF overexpression is mediated primarily by sequences in the CTGF promoter. In this report, we identify the minimal promoter element involved with the overexpression of CTGF in SSc fibroblasts. This element is distinct from the element necessary and sufficient for the induction of CTGF expression by TGFbeta in normal fibroblasts. Within this region is a functional Sp1 binding site. Blocking Sp1 activity reduces the elevated, constitutive levels of CTGF promoter activity and protein expression observed in SSc fibroblasts. Relative to those prepared from normal dermal fibroblasts, nuclear extracts prepared from SSc fibroblasts possess increased Sp1 binding activity. Removal of phosphate groups from nuclear extracts enhanced Sp1 binding activity, suggesting that phosphorylation of Sp1 normally reduces Sp1 binding to DNA. Thus, the constitutive overexpression of CTGF in SSc fibroblasts seems to be independent of TGFbeta signaling but dependent at least in part on Sp1.	UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, Dept Med, London NW3 2PF, England; FibroGen Inc, San Francisco, CA 94080 USA	University of London; University College London; UCL Medical School; FibroGen	Leask, A (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, Dept Med, Rowland Hill St, London NW3 2PF, England.	a.leask@rfc.ucl.ac.uk	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045879] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 45879] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; Cotton SA, 1998, J PATHOL, V184, P4, DOI 10.1002/(SICI)1096-9896(199801)184:1<4::AID-PATH968>3.0.CO;2-0; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GRUSCHWITZ M, 1990, J INVEST DERMATOL, V94, P197, DOI 10.1111/1523-1747.ep12874503; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Ihn H, 2000, ARTHRITIS RHEUM, V43, P2240, DOI 10.1002/1529-0131(200010)43:10<2240::AID-ANR11>3.0.CO;2-2; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KIKUCHI K, 1992, BIOCHEM BIOPH RES CO, V187, P45, DOI 10.1016/S0006-291X(05)81456-1; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; MCWHIRTER A, 1994, LAB INVEST, V71, P885; MORELAND LW, 1992, AM J MED, V93, P628, DOI 10.1016/0002-9343(92)90195-H; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; Querfeld C, 1999, J DERMATOL SCI, V21, P13, DOI 10.1016/S0923-1811(99)00008-0; Sato S, 2000, J RHEUMATOL, V27, P149; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2001, J INVEST DERMATOL, V116, P755, DOI 10.1046/j.1523-1747.2001.01326.x; Watkin RD, 2003, TOXICOLOGY, V184, P157, DOI 10.1016/S0300-483X(02)00577-2; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	42	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41728	41733		10.1074/jbc.M305019200	http://dx.doi.org/10.1074/jbc.M305019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888575	hybrid			2022-12-25	WOS:000185989500023
J	Russell, DL; Doyle, KMH; Ochsner, SA; Sandy, JD; Richards, JS				Russell, DL; Doyle, KMH; Ochsner, SA; Sandy, JD; Richards, JS			Processing and localization of ADAMTS-1 and proteolytic cleavage of versican during cumulus matrix expansion and ovulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-DIFFERENTIATION FACTOR-9; FACTOR-STIMULATED GENE-6; EXTRACELLULAR-MATRIX; GRANULOSA-CELLS; HYALURONIC-ACID; MICE LACKING; FOLLICULAR DEVELOPMENT; THROMBOSPONDIN MOTIFS; REGULATED EXPRESSION; PERICELLULAR MATRIX	ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin motifs-1) is a member of the ADAMTS family of metalloproteases which, together with ADAMTS-4 and ADAMTS-5, has been shown to degrade members of the lectican family of proteoglycans. ADAMTS-1 mRNA is induced in granulosa cells of periovulatory follicles by the luteinizing hormone surge through a progesterone receptor-dependent mechanism. Female progesterone receptor knockout (PRKO) mice are infertile primarily due to ovulatory failure and lack the normal periovulatory induction of ADAMTS-1 mRNA. We therefore investigated the protein localization and function of ADAMTS-1 in ovulating ovaries. Antibodies against two specific peptide regions, the pro-domain and the metalloprotease domain of ADAMTS-1, were generated. Pro-ADAMTS-1 of 110 kDa was identified in mural granulosa cells and appears localized to cytoplasmic secretory vesicles. The mature (85-kDa pro-domain truncated) form accumulated in the extracellular matrix of the cumulus oocyte complex (COC) during the process of matrix expansion. Each form of ADAMTS-1 protein increased >10-fold after the ovulatory luteinizing hormone surge in wild-type but not PRKO mice. Versican is also localized selectively to the ovulating COC matrix and was found to be cleaved yielding a 70-kDaN-terminal fragment immunopositive for the neoepitope DPEAAE generated by ADAMTS-1 and ADAMTS-4 protease activity. This extracellular processing of versican was reduced in ADAMTS-1-deficient PRKO mouse ovaries. These observations suggest that one function of ADAMTS-1 in ovulation is to cleave versican in the expanded COC matrix and that the anovulatory phenotype of PRKO mice is at least partially due to loss of this function.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Shriners Hosp Children, Tampa, FL 33612 USA	Baylor College of Medicine; State University System of Florida; University of South Florida	Richards, JS (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Russell, Darryl L/I-6654-2012	Russell, Darryl L/0000-0002-4930-7658; Ochsner, Scott/0000-0003-1099-7863				Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Camaioni A, 1996, ARCH BIOCHEM BIOPHYS, V325, P190, DOI 10.1006/abbi.1996.0024; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; Curry TE, 2001, BIOL REPROD, V65, P855, DOI 10.1095/biolreprod65.3.855; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Elvin JA, 2000, P NATL ACAD SCI USA, V97, P10288, DOI 10.1073/pnas.180295197; EPPIG JJ, 1979, NATURE, V281, P483, DOI 10.1038/281483a0; Espey LL, 2000, BIOL REPROD, V62, P1090, DOI 10.1095/biolreprod62.4.1090; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gensberg K, 1998, SEMIN CELL DEV BIOL, V9, P11, DOI 10.1006/scdb.1997.0196; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Hsieh M, 2002, ENDOCRINOLOGY, V143, P898, DOI 10.1210/en.143.3.898; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lebaron RG, 1996, PERSPECT DEV NEUROBI, V3, P261; LEE GM, 1993, J CELL BIOL, V123, P1899, DOI 10.1083/jcb.123.6.1899; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Lydon JP, 1996, J STEROID BIOCHEM, V56, P67, DOI 10.1016/0960-0760(95)00254-5; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P1008, DOI 10.1210/en.2002-220435; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Richards JS, 2002, RECENT PROG HORM RES, V57, P195, DOI 10.1210/rp.57.1.195; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Robker RL, 2000, P NATL ACAD SCI USA, V97, P4689, DOI 10.1073/pnas.080073497; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; ROZEN S, 1998, PRIMER3 SOFTWARE DIS; Russell DL, 2003, ENDOCRINOLOGY, V144, P1020, DOI 10.1210/en.2002-220434; Salustri A, 1999, HUM REPROD UPDATE, V5, P293, DOI 10.1093/humupd/5.4.293; SALUSTRI A, 1992, DEV BIOL, V151, P541, DOI 10.1016/0012-1606(92)90192-J; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Talbot P, 2003, BIOL REPROD, V68, P1, DOI 10.1095/biolreprod.102.007856; Tirone E, 1997, J BIOL CHEM, V272, P4787, DOI 10.1074/jbc.272.8.4787; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; UJITA M, 1994, J BIOL CHEM, V269, P27603; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Wight TN, 2002, CURR OPIN CELL BIOL, V14, P617, DOI 10.1016/S0955-0674(02)00375-7; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Yoshioka S, 2000, ENDOCRINOLOGY, V141, P4114, DOI 10.1210/en.141.11.4114; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	59	210	221	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42330	42339		10.1074/jbc.M300519200	http://dx.doi.org/10.1074/jbc.M300519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907688	hybrid			2022-12-25	WOS:000185989500094
J	Castillo, EA; Vivancos, AP; Jones, N; Ayte, J; Hidalgo, E				Castillo, EA; Vivancos, AP; Jones, N; Ayte, J; Hidalgo, E			Schizosaccharomyces pombe cells lacking the Ran-binding protein Hba1 show a multidrug resistance phenotype due to constitutive nuclear accumulation of Pap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PAP1; STRESS-ACTIVATED KINASE; BREFELDIN-A RESISTANCE; FISSION YEAST; OXIDATIVE STRESS; NUCLEOCYTOPLASMIC TRANSPORT; CAFFEINE-RESISTANCE; ESCHERICHIA-COLI; EXPORT SIGNAL; GENE	In Schizosaccharomyces pombe, the transcription factor Pap1, and the mitogen-activated protein kinase Sty1 are excluded from the nucleus in a Crm1-dependent manner under non-stressed conditions. Upon oxidant treatment, both Sty1 and Pap1 concentrate into the nucleus, due to an enhanced import or an impaired export. Hba1, a protein that when overexpressed confers brefeldin A resistance, contains a Ran binding domain. The purpose of this project was to understand at the molecular level the role of Hba1 in the S. pombe oxidative stress response. Fluorescent and confocal microscopy studies demonstrate that Hba1 is located at the nucleoplasm and not at the nuclear envelope. We also demonstrate that either multiple copies or deletion of the hba1 gene induces nuclear accumulation of Pap1 and Sty1. We propose that Hba1 assists Crm1 to export some nuclear export signal-containing proteins. Pap1 nuclear accumulation is sufficient for constitutive activation of its specific antioxidant response. On the contrary, constitutive nuclear localization of Sty1 in the Deltahba1 strain does not trigger the Sty1-specific, Atf1-dependent antioxidant response in the absence of stress. We conclude that the increased multidrug resistance of strains lacking or overexpressing Hba1 is due to the accumulation of Pap1 in the nucleus under non-stressed conditions.	Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, Barcelona 08003, Spain; Christie Hosp NHS Trust, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England	Pompeu Fabra University; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Hidalgo, E (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, C Dr Aiguader 80, Barcelona 08003, Spain.	elena.hidalgo@upf.edu	Vivancos, Ana/AAG-8331-2019; Hidalgo, Elena/K-2919-2014; Ayte, Jose/L-5217-2014	Vivancos, Ana/0000-0003-2888-6512; Hidalgo, Elena/0000-0002-3768-6785; Ayte, Jose/0000-0002-6354-0536				Alfa C, 1993, EXPT FISSION YEAST L; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Benko Z, 1997, CURR GENET, V31, P481, DOI 10.1007/s002940050233; Benko Z, 1998, MOL GEN GENET, V260, P434, DOI 10.1007/s004380050914; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Castillo EA, 2002, MOL MICROBIOL, V45, P243, DOI 10.1046/j.1365-2958.2002.03020.x; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Degols G, 1996, MOL CELL BIOL, V16, P2870; Englmeier L, 2001, EMBO REP, V2, P926, DOI 10.1093/embo-reports/kve200; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Lindsay ME, 2001, J CELL BIOL, V153, P1391, DOI 10.1083/jcb.153.7.1391; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mueller L, 1998, FEBS LETT, V427, P330, DOI 10.1016/S0014-5793(98)00459-1; Nemergut ME, 2002, J BIOL CHEM, V277, P17385, DOI 10.1074/jbc.c100620200; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Nguyen AN, 2002, MOL BIOL CELL, V13, P2651, DOI 10.1091/mbc.02-03-0043; NISHI K, 1992, MOL MICROBIOL, V6, P761, DOI 10.1111/j.1365-2958.1992.tb01526.x; Noguchi E, 1999, J BIOCHEM-TOKYO, V125, P574, DOI 10.1093/oxfordjournals.jbchem.a022323; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Sies H., 1991, OXIDATIVE STRESS OXI; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Taura T, 1997, J BIOL CHEM, V272, P31877, DOI 10.1074/jbc.272.50.31877; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Turi TG, 1996, J BIOL CHEM, V271, P9166, DOI 10.1074/jbc.271.15.9166; TURI TG, 1995, BIOCHEM BIOPH RES CO, V213, P410, DOI 10.1006/bbrc.1995.2147; TURI TG, 1994, J BIOL CHEM, V269, P24229; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	48	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40565	40572		10.1074/jbc.M305859200	http://dx.doi.org/10.1074/jbc.M305859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896976	hybrid			2022-12-25	WOS:000185847200019
J	Dunne, A; Ejdeback, M; Ludidi, PL; O'Neill, LAJ; Gay, NJ				Dunne, A; Ejdeback, M; Ludidi, PL; O'Neill, LAJ; Gay, NJ			Structural complementarity of Toll/interleukin-1 receptor domains in toll-like receptors and the adaptors Mal and MyD88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AB-INITIO CONSTRUCTION; SIGNALING PATHWAY; DROSOPHILA TOLL; MOLECULAR CHARACTERIZATION; POLYPEPTIDE FRAGMENTS; IL-1 RECEPTOR; RECOGNITION; TRANSDUCTION; SURFACES; PROTEINS	The Toll/interleukin 1 receptor (TIR) domain is a region found in the cytoplasmic tails of members of the Toll-like receptor/interleukin-1 receptor superfamily. The domain is essential for signaling and is also found in the adaptor proteins Mal (MyD88 adaptor-like) and MyD88, which function to couple activation of the receptor to downstream signaling components. Experimental structures of two Toll/interleukin 1 receptor domains reveal a alpha-beta-fold similar to that of the bacterial chemotaxis protein CheY, and other evidence suggests that the adaptors can make heterotypic interactions with both the receptors and themselves. Here we show that the purified TIR domains of Mal and MyD88 can form stable heterodimers and also that Mal homodimers and oligomers are dissociated in the presence of ATP. To identify structural features that may contribute to the formation of signaling complexes, we produced models of the TIR domains from human Toll-like receptor 4 (TLR4), Mal, and MyD88. We found that although the overall fold is conserved the electrostatic surface potentials are quite distinct. Docking studies of the models suggest that Mal and MyD88 bind to different regions in TLRs 2 and 4, a finding consistent with a cooperative role of the two adaptors in signaling. Mal and MyD88 are predicted to interact at a third non-overlapping site, suggesting that the receptor and adaptors may form heterotetrameric complexes. The theoretical model of the interactions is supported by experimental data from glutathione S-transferase pull-downs and co-immunoprecipitations. Neither theoretical nor experimental data suggest a direct role for the conserved proline in the BB-loop in the association of TLR4, Mal, and MyD88. Finally we show a sequence relationship between the Drosophila protein Tube and Mal that may indicate a functional equivalence of these two adaptors in the Drosophila and vertebrate Toll pathways.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Dublin Trinity Coll, Inst Biochem & Biotechnol, Dublin 2, Ireland	University of Cambridge; Trinity College Dublin	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England.		Ejdebäck, Mikael/H-5796-2012	Ejdebäck, Mikael/0000-0002-3053-4543; dunne, aisling/0000-0002-2342-9518; O'Neill, Luke/0000-0002-4333-2748				Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Burke DF, 1999, PROTEINS, P55; de Bakker PIW, 2003, PROTEINS, V51, P21, DOI 10.1002/prot.10235; DePristo MA, 2003, PROTEINS, V51, P41, DOI 10.1002/prot.10285; DUNNE A, 2003, SCI STKE; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Hardiman G, 1996, ONCOGENE, V13, P2467; HOPP TP, 1995, PROTEIN SCI, V4, P1851, DOI 10.1002/pro.5560040920; Horng T, 2001, P NATL ACAD SCI USA, V98, P12654, DOI 10.1073/pnas.231471798; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Kambris Z, 2003, EMBO REP, V4, P64, DOI 10.1038/sj.embor.embor714; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Ronni T, 2003, MOL CELL BIOL, V23, P2543, DOI 10.1128/MCB.23.7.2543-2555.2003; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Simonovic M, 2001, J BIOL CHEM, V276, P28637, DOI 10.1074/jbc.C100295200; Tao X, 2002, BIOCHEM BIOPH RES CO, V299, P216, DOI 10.1016/S0006-291X(02)02581-0; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; Tovchigrechko A, 2002, PROTEIN SCI, V11, P1888, DOI 10.1110/ps.4730102; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; VAKSER IA, 1995, PROTEIN ENG, V8, P371, DOI 10.1093/protein/8.4.371; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Zhu XY, 1997, J BIOL CHEM, V272, P23758, DOI 10.1074/jbc.272.38.23758	36	159	169	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41443	41451		10.1074/jbc.M301742200	http://dx.doi.org/10.1074/jbc.M301742200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888566	hybrid, Green Published			2022-12-25	WOS:000185847200124
J	Foster, JS; Fernando, RI; Ishida, N; Nakayama, KI; Wimalasena, J				Foster, JS; Fernando, RI; Ishida, N; Nakayama, KI; Wimalasena, J			Estrogens down-regulate p27(Kip1) in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR; CDK INHIBITORS; MCF-7 CELLS; S-PHASE; CYTOPLASMIC LOCALIZATION; E-CDK2 ACTIVATION; DIRECT BINDING	The cyclin-dependent kinase (CDK) inhibitor p27(Kip1) plays a key role in growth and development of the mammary epithelium and in breast cancer. p27(Kip1) levels are regulated through ubiquitin/proteasome-mediated proteolysis, promoted by CDK2 and the F box protein Skp2 at the G(1)/S transition, and independent of Skp2 in mid-G(1). We investigated the respective roles of Skp2 and subcellular localization of p27(Kip1) in down-regulation of p27(Kip1) induced in MCF-7 cells by estrogens. 17beta-Estradiol treatment increased Skp2 expression in MCF-7 cells; however, this increase was prevented by G(1) blockade mediated by p16(Ink4a) or the CDK inhibitor roscovitine, whereas down-regulation of p27(Kip1) was maintained. Exogenous Skp2 prevented growth arrest of MCF-7 cells by antiestrogen, coinciding with decreased p27(Kip1) expression. Under conditions of G1 blockade, p27(Kip1) was stabilized by inhibition of CRM1-dependent nuclear export with leptomycin B or by mutation of p27(Kip1) (Ser(10) --> Ala; S10A) interfering with CRM1/ p27(Kip1) interaction. Antisense Skp2 oligonucleotides and a dominant-interfering Cul-1(1-452) mutant prevented down-regulation of p27(Kip1)S10A, whereas Skp2 overexpression elicited its destruction in mitogen- deprived cells. Active mediators of the extracellular signal-regulated kinase (ERK) pathway including Raf-1(caax) induced cytoplasmic localization of p27(Kip1) in antiestrogen-treated cells and prevented accumulation of p27(Kip1) in these cells independent of Skp2 expression and coinciding with ERK activation. Genetic or chemical blockade of the ERK pathway prevented down-regulation and cytoplasmic localization of p27(Kip1) in response to estrogen. Our studies indicate that estrogens elicit down-regulation of p27(Kip1) in MCF-7 cells through Skp2-dependent and -independent mechanisms that depend upon subcellular localization of p27(Kip1) and require the participation of mediators of the Ras/Raf-1/ERK signaling pathway.	Univ Tennessee, Med Ctr, Program Comparat & Expt Med, Grad Sch Med,Dept Obstet & Gynecol, Knoxville, TN 37920 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan	University of Tennessee System; University of Tennessee Health Science Center; Kyushu University	Wimalasena, J (corresponding author), Univ Tennessee, Med Ctr, Program Comparat & Expt Med, Grad Sch Med,Dept Obstet & Gynecol, 1924 Alcoa Highway, Knoxville, TN 37920 USA.				NCI NIH HHS [CA84048] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084048] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Ahamed S, 2002, MOL CARCINOGEN, V34, P45, DOI 10.1002/mc.10048; Ahamed S, 2001, MOL CARCINOGEN, V30, P88, DOI 10.1002/1098-2744(200102)30:2&lt;88::AID-MC1017&gt;3.0.CO;2-E; Bilodeau M, 1999, FEBS LETT, V452, P247, DOI 10.1016/S0014-5793(99)00629-8; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; DUBIK D, 1988, J BIOL CHEM, V263, P12705; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lenferink AEG, 2001, CANCER RES, V61, P6583; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moeller SJ, 2003, MOL CELL BIOL, V23, P3735, DOI 10.1128/MCB.23.11.3735-3752.2003; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Prall OWJ, 2001, J BIOL CHEM, V276, P45433, DOI 10.1074/jbc.M104752200; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sugiyama Y, 2001, J BIOL CHEM, V276, P12084, DOI 10.1074/jbc.M010811200; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tan P, 1997, CANCER RES, V57, P1259; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	84	87	92	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41355	41366		10.1074/jbc.M302830200	http://dx.doi.org/10.1074/jbc.M302830200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12904306	hybrid			2022-12-25	WOS:000185847200116
J	Selmi, B; Deval, J; Alvarez, K; Boretto, J; Sarfati, S; Guerreiro, C; Canard, B				Selmi, B; Deval, J; Alvarez, K; Boretto, J; Sarfati, S; Guerreiro, C; Canard, B			The Y181C substitution in 3 '-azido-3 '-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3 '-azido-3 '-deoxythymidine 5 '-monophosphate-terminated primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORANOPHOSPHATE NUCLEOTIDE ANALOGS; IN-VITRO SELECTION; RESISTANCE MUTATIONS; NUCLEOSIDE ANALOG; DNA-SYNTHESIS; ZIDOVUDINE RESISTANCE; HIV-1 REPLICATION; DRUG-RESISTANCE; AZT RESISTANCE; M184V MUTATION	Resistance to zidovudine (3'- azido-3'-deoxythymidine, AZT) by the human immunodeficiency virus, type 1, requires multiple amino acid substitutions such as D67N/ K70R/T215F/K219Q in the viral reverse transcriptase (RT). In this background of AZT resistance, additional "suppressive" substitutions such as Y181C restore sensitivity to AZT. In order to characterize the mechanism of this AZT resistance suppression, the Y181C substitution was introduced into both wild-type and AZT-resistant reverse transcriptase. The introduction of the Y181C substitution suppresses the increased repair ( or unblocking) of the AZTMP-terminated primer provided by the AZT resistance substitutions in RT using either DNA or RNA templates, independently from the RT RNase H activity. Contrary to wild-type RT, the low level of unblocking activity is not due to inhibition by the next correct nucleotide binding to the RT/AZTMP-terminated primer complex. When Y181C is added to the AZT resistance substitutions, ATP binds with less affinity to the AZTMP-terminated primer-RT binary complex. These results provide an insight into one possible molecular mechanism of re-sensitization of AZT-resistant viruses by suppressive substitutions.	CNRS, F-13288 Marseille 09, France; Univ Aix Marseille 1, UMR 6098, F-13288 Marseille, France; Univ Aix Marseille 2, UMR 6098, F-13288 Marseille 09, France; Inst Pasteur, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Canard, B (corresponding author), CNRS, ESIL Case 925,163 Ave Luminy, F-13288 Marseille 09, France.		ALVAREZ, Karine/T-6326-2017	Canard, Bruno/0000-0003-4924-1991				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arion D, 2000, J BIOL CHEM, V275, P9251, DOI 10.1074/jbc.275.13.9251; Balzarini J, 1999, BIOCHEM PHARMACOL, V58, P1; Bazmi HZ, 2000, ANTIMICROB AGENTS CH, V44, P1783, DOI 10.1128/AAC.44.7.1783-1788.2000; Boretto J, 2001, ANAL BIOCHEM, V292, P139, DOI 10.1006/abio.2001.5045; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; Boyer PL, 2002, J VIROL, V76, P9143, DOI 10.1128/JVI.76.18.9143-9151.2002; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; Deval J, 2002, J BIOL CHEM, V277, P42097, DOI 10.1074/jbc.M206725200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Isel C, 2001, J BIOL CHEM, V276, P48725, DOI 10.1074/jbc.M108352200; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; Mas A, 2002, J MOL BIOL, V323, P181, DOI 10.1016/S0022-2836(02)00911-7; Mas A, 2000, EMBO J, V19, P5752, DOI 10.1093/emboj/19.21.5752; MELLORS JW, 1995, ANTIMICROB AGENTS CH, V39, P1087, DOI 10.1128/AAC.39.5.1087; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; Ren JS, 1998, P NATL ACAD SCI USA, V95, P9518, DOI 10.1073/pnas.95.16.9518; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; Rigourd M, 2000, J BIOL CHEM, V275, P26944; SCHATZ O, 1989, FEBS LETT, V257, P279; Schinazi R.F., 2000, INT ANTIVIRAL NEWS, V8, P65; Selmi B, 2001, J BIOL CHEM, V276, P13965, DOI 10.1074/jbc.M009837200; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; Tachedjian G, 1998, ANTIMICROB AGENTS CH, V42, P3038, DOI 10.1128/AAC.42.11.3038; TACHEDJIAN G, 1995, VIROLOGY, V212, P58, DOI 10.1006/viro.1995.1453; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	60	44	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40464	40472		10.1074/jbc.M302928200	http://dx.doi.org/10.1074/jbc.M302928200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902345	hybrid			2022-12-25	WOS:000185847200007
J	Friedman, YE; O'Brian, MR				Friedman, YE; O'Brian, MR			A novel DNA-binding site for the ferric uptake regulator (Fur) protein from Bradyrhizobium japonicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON RESPONSE REGULATOR; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; IDENTIFICATION; REGULON; HEME; GENE; IRR; METABOLISM	The Fur protein is a global regulator of iron metabolism and other processes in many bacterial species. A key feature of the model of Fur function is the recognition of a DNA element within target promoters with similarity to a 19-bp AT-rich palindromic sequence called a Fur box. The irr gene from Bradyrhizobium japonicum is under the control of Fur. Here, we provide evidence that B. japonicum Fur (BjFur) binds to the irr gene promoter with high affinity despite the absence of DNA sequence similarity to the Fur box consensus. Both Escherichia coli Fur and BjFur bound a synthetic Fur box consensus DNA element in electrophoretic gel mobility shift assays, but only BjFur bound the irr promoter. BjFur maximally protected a 30-bp region in DNase I footprinting analysis that includes three imperfect direct repeat hexamers. BjFur formed a high mobility complex and a low mobility complex with DNA in electrophoretic gel mobility shift assays corresponding to occupancy by a single dimer and two dimers or a tetramer, respectively. A mutation in the downstream direct repeat DNA sequence allowed high mobility complex formation only. In vitro transcription from the wild type irr promoter or from a mutated promoter that allowed only dimer occupancy was repressed by Fur, indicating that the dimer can be a functional repressor unit. Our findings identify a novel DNA-binding element for Fur and suggest that the Fur box consensus may not completely represent the target sequences for bacterial Fur proteins as a whole. In addition, Fur binding to a target promoter is sufficient to repress transcription in vitro.	SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	O'Brian, MR (corresponding author), SUNY Buffalo, Dept Biochem, 140 Farber Hall, Buffalo, NY 14214 USA.	mrobrian@buffalo.edu						Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; Baichoo N, 2002, J BACTERIOL, V184, P5826, DOI 10.1128/JB.184.21.5826-5832.2002; Baichoo N, 2002, MOL MICROBIOL, V45, P1613, DOI 10.1046/j.1365-2958.2002.03113.x; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; COY M, 1991, BIOCHEMISTRY-US, V30, P8201, DOI 10.1021/bi00247a016; DELORENZO V, 1988, J MOL BIOL, V203, P875, DOI 10.1016/0022-2836(88)90113-1; Escolar L, 1998, J MOL BIOL, V283, P537, DOI 10.1006/jmbi.1998.2119; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Hall HK, 1996, J BACTERIOL, V178, P5683, DOI 10.1128/jb.178.19.5683-5691.1996; Hamza I, 1999, J BACTERIOL, V181, P5843, DOI 10.1128/JB.181.18.5843-5846.1999; Hamza I, 1998, J BIOL CHEM, V273, P21669, DOI 10.1074/jbc.273.34.21669; Hamza I, 2000, MICROBIOL-SGM, V146, P669, DOI 10.1099/00221287-146-3-669; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; Maxam A M, 1980, Methods Enzymol, V65, P499; MichaudSoret I, 1997, FEBS LETT, V413, P473, DOI 10.1016/S0014-5793(97)00963-0; OCHSNER UA, 1995, J BACTERIOL, V177, P7194, DOI 10.1128/jb.177.24.7194-7201.1995; Ochsner UA, 1996, P NATL ACAD SCI USA, V93, P4409, DOI 10.1073/pnas.93.9.4409; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Qi ZH, 1999, P NATL ACAD SCI USA, V96, P13056, DOI 10.1073/pnas.96.23.13056; Qi ZH, 2002, MOL CELL, V9, P155, DOI 10.1016/S1097-2765(01)00431-2; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; Thompson DK, 2002, APPL ENVIRON MICROB, V68, P881, DOI 10.1128/AEM.68.2.881-892.2002; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V83, P1608; Wexler M, 2003, MICROBIOL-SGM, V149, P1357, DOI 10.1099/mic.0.26130-0	30	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38395	38401		10.1074/jbc.M306710200	http://dx.doi.org/10.1074/jbc.M306710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12881516	hybrid			2022-12-25	WOS:000185575100039
J	Kulinski, T; Olejniczak, M; Huthoff, H; Bielecki, L; Pachulska-Wieczorek, K; Das, AT; Berkhout, B; Adamiak, RW				Kulinski, T; Olejniczak, M; Huthoff, H; Bielecki, L; Pachulska-Wieczorek, K; Das, AT; Berkhout, B; Adamiak, RW			The apical loop of the HIV-1 TAR RNA hairpin is stabilized by a cross-loop base pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANSACTIVATING REGION RNA; TRANS-ACTIVATION; BINDING-PROTEIN; CRYSTAL-STRUCTURE; CYCLIN T1; IN-VITRO; MOLECULAR-DYNAMICS; NMR-SPECTROSCOPY	The TAR hairpin of the HIV-1 RNA genome is indispensable for trans-activation of the viral promoter and virus replication. The TAR structure has been studied extensively, but most attention has been directed at the three-nucleotide bulge that constitutes the binding site of the viral Tat protein. In contrast, the conformational properties of the apical loop have remained elusive. We performed biochemical studies and molecular dynamics simulations, which indicate that the TAR loop is structured and stabilized by a cross-loop base pair between residues C-30 and G(34). Mutational disruption of the cross-loop base pair results in reduced Tat response of the LTR promoter, which can be rescued by compensatory mutations that restore the base pair. Thus, Tat-mediated transcriptional activation depends on the structure of the TAR apical loop. The C-30-G(34) cross-loop base pair classes TAR in a growing family of hairpins with a structured loop that was recently identified in ribosomal RNA, tRNA, and several viral and cellular mRNAs.	Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; University of Amsterdam; Academic Medical Center Amsterdam	Adamiak, RW (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Noskowskiego 12-14, PL-61704 Poznan, Poland.		Adamiak, Ryszard W/W-5089-2018; Pachulska-Wieczorek, Katarzyna/X-1533-2018	Adamiak, Ryszard W/0000-0001-8914-9618; Pachulska-Wieczorek, Katarzyna/0000-0002-5723-6204; Olejniczak, Mikolaj/0000-0001-5949-3944				AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CIESIOLKA J, 1989, EUR J BIOCHEM, V182, P445, DOI 10.1111/j.1432-1033.1989.tb14851.x; COLVIN RA, 1992, J VIROL, V66, P930, DOI 10.1128/JVI.66.2.930-935.1992; CRITCHLEY AD, 1993, J MOL GRAPHICS, V11, P92, DOI 10.1016/0263-7855(93)87002-M; Das AT, 1999, J VIROL, V73, P81, DOI 10.1128/JVI.73.1.81-91.1999; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; Dorin D, 2003, J BIOL CHEM, V278, P4440, DOI 10.1074/jbc.M208954200; Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Flodell S, 2002, NUCLEIC ACIDS RES, V30, P4803, DOI 10.1093/nar/gkf603; Foloppe N, 2000, J COMPUT CHEM, V21, P86, DOI 10.1002/(SICI)1096-987X(20000130)21:2<86::AID-JCC2>3.0.CO;2-G; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; FRISCH MJ, 1996, GAUSSIAN 94; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gdaniec Z, 1998, BIOCHEMISTRY-US, V37, P1505, DOI 10.1021/bi9719814; Haasnoot PCJ, 2000, RNA, V6, P708, DOI 10.1017/S1355838200992471; Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548; HAN XM, 1992, J VIROL, V66, P4065, DOI 10.1128/JVI.66.7.4065-4072.1992; HARPER JW, 1991, BIOCHEMISTRY-US, V30, P8060, DOI 10.1021/bi00246a026; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819; JAEGER JA, 1993, BIOCHEMISTRY-US, V32, P12522, DOI 10.1021/bi00097a032; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KACZMARSKI W, 1993, BIOCHEM BIOPH RES CO, V196, P935, DOI 10.1006/bbrc.1993.2339; King GC, 1995, METHOD ENZYMOL, V261, P436; Klinck R, 2000, RNA, V6, P1423, DOI 10.1017/S1355838200000935; Kulinski T, 1999, COLL SYMPOS SERIES, V2, P191; Laing LG, 1996, BIOCHEMISTRY-US, V35, P13586, DOI 10.1021/bi961310q; Lee JC, 2003, J MOL BIOL, V325, P65, DOI 10.1016/S0022-2836(02)01106-3; Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y; Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h; Lukavsky PJ, 2000, NAT STRUCT BIOL, V7, P1105; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MICHNICKA MJ, 1993, BIOCHEMISTRY-US, V32, P395, DOI 10.1021/bi00053a002; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; Nagaswamy U, 2002, RNA, V8, P1112, DOI 10.1017/S135583820202006X; Nifosi R, 2000, NUCLEIC ACIDS RES, V28, P4944, DOI 10.1093/nar/28.24.4944; Olejniczak M, 2002, NUCLEIC ACIDS RES, V30, P4241, DOI 10.1093/nar/gkf541; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V74, P1; Puglisi EV, 1998, NAT STRUCT BIOL, V5, P1033, DOI 10.1038/4141; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Reyes CM, 2001, BIOPHYS J, V80, P2833, DOI 10.1016/S0006-3495(01)76250-9; Richter S, 2002, P NATL ACAD SCI USA, V99, P7928, DOI 10.1073/pnas.122119999; Richter S, 2002, BIOCHEMISTRY-US, V41, P6391, DOI 10.1021/bi0159579; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SANTALUCIA J, 1992, SCIENCE, V256, P217, DOI 10.1126/science.1373521; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; SUMNERSMITH M, 1991, J VIROL, V65, P5196, DOI 10.1128/JVI.65.10.5196-5202.1991; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; Verhoef K, 1997, VIROLOGY, V237, P228, DOI 10.1006/viro.1997.8786; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128; WUBAER F, 1995, P NATL ACAD SCI USA, V92, P7153, DOI 10.1073/pnas.92.16.7153; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200; YORK DM, 1993, J CHEM PHYS, V99, P8345, DOI 10.1063/1.465608; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200	72	38	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38892	38901		10.1074/jbc.M301939200	http://dx.doi.org/10.1074/jbc.M301939200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882959	hybrid			2022-12-25	WOS:000185575100098
J	Lin, VY; Resnick, EM; Shupnik, MA				Lin, VY; Resnick, EM; Shupnik, MA			Truncated estrogen receptor product-1 stimulates estrogen receptor alpha transcriptional activity by titration of repressor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; MESSENGER-RNA ISOFORMS; ER-ALPHA; RAT PITUITARY; NUCLEAR RECEPTORS; HORMONE RECEPTORS; BETA; EXPRESSION; COACTIVATOR; COREPRESSOR	The truncated estrogen receptor product-1 (TERP-1, or TERP) is a pituitary-specific isoform of estrogen receptor alpha (ERalpha), and its expression is regulated by estrogen. TERP modulates the transcriptional activity of ERalpha but has no independent effect on transcription of estrogen-response element-containing promoters. At low concentrations, TERP stimulates ERalpha transcriptional activity in transient transfection assays. At TERP concentrations equal to or greater than full-length ERalpha, TERP forms dimers with ERalpha and reduces both ligand-dependent and -independent transcription. A dimerization mutant of TERP, TERP L509R, stimulated ERalpha transcription at all concentrations. We hypothesized that TERP stimulates ERalpha transcriptional activity by titrating suppressors of ERalpha activity. We found that repressor of estrogen receptor activity (REA), originally isolated from human breast cancer cells, is present in mouse pituitary gonadotrope cell lines. Levels of REA vary slightly throughout the rat reproductive cycle, but TERP mRNA and protein vary much more dramatically. In transfection experiments, REA suppressed ERalpha transcriptional activity, and TERP L509R was able to alleviate transcriptional suppression by REA. In glutathione S-transferase pull-down assays, TERP bound to REA more efficiently than did ERalpha at equivalent concentrations, suggesting that REA will preferentially bind to TERP. Our findings suggest that the stimulation of pituitary ERalpha activity by low concentrations of TERP can occur by titration of corepressors such as REA.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Internal Med, Div Endocrinol & Metab, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Shupnik, MA (corresponding author), Univ Virginia, Dept Med Endocrinol, POB 800578 HSC, Charlottesville, VA 22908 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057082] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD28934] Funding Source: Medline; NIDDK NIH HHS [R01-DK57082] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Friend KE, 1997, MOL CELL ENDOCRINOL, V131, P147, DOI 10.1016/S0303-7207(97)00098-1; FRIEND KE, 1995, P NATL ACAD SCI USA, V92, P4367, DOI 10.1073/pnas.92.10.4367; Gay F, 2000, MOL ENDOCRINOL, V14, P1627, DOI 10.1210/me.14.10.1627; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Laflamme N, 1998, J NEUROBIOL, V36, P357, DOI 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V; Loven MA, 2003, MOL ENDOCRINOL, V17, P67, DOI 10.1210/me.2002-0280; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Mitchner NA, 1999, ENDOCRINOLOGY, V140, P2651, DOI 10.1210/en.140.6.2651; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Murphy LC, 2000, CANCER RES, V60, P6266; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; Resnick EM, 2000, J BIOL CHEM, V275, P7158, DOI 10.1074/jbc.275.10.7158; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Schaufele F, 1999, MOL ENDOCRINOL, V13, P935, DOI 10.1210/me.13.6.935; Schreihofer DA, 1999, MOL ENDOCRINOL, V13, P320, DOI 10.1210/me.13.2.320; Schreihofer DA, 2000, ENDOCRINOLOGY, V141, P2174, DOI 10.1210/en.141.6.2174; Schreihofer DA, 2002, ENDOCRINOLOGY, V143, P4196, DOI 10.1210/en.2002-220353; Schreihofer DA, 2001, ENDOCRINOLOGY, V142, P3361, DOI 10.1210/en.142.8.3361; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shupnik MA, 2002, J NEUROENDOCRINOL, V14, P85, DOI 10.1046/j.0007-1331.2001.00744.x; Simon SLR, 2000, CANCER RES, V60, P2796; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Tiffoche C, 2001, ENDOCRINOLOGY, V142, P4106, DOI 10.1210/en.142.9.4106; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vaillant C, 2002, ENDOCRINOLOGY, V143, P4249, DOI 10.1210/en.2002-220193; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	47	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38125	38131		10.1074/jbc.M303882200	http://dx.doi.org/10.1074/jbc.M303882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878603	hybrid			2022-12-25	WOS:000185575100006
J	Augenlicht, L; Shi, L; Mariadason, J; Laboisse, C; Velcich, A				Augenlicht, L; Shi, L; Mariadason, J; Laboisse, C; Velcich, A			Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation	ONCOGENE			English	Article						human MUC2 gene; MUC2 expression; sodium butyrate and differentiation; goblet cell lineage	CHAIN FATTY-ACIDS; COLON-CARCINOMA-CELLS; SODIUM-BUTYRATE; CARCINOEMBRYONIC ANTIGEN; HISTONE ACETYLATION; PROTEIN PHOSPHATASE; TRICHOSTATIN-A; MESSENGER-RNA; DIFFERENTIATION; APOPTOSIS	Sodium butyrate (NaB) inhibits proliferation, stimulates apoptosis, and promotes differentiation of human colon cancer cells along the absorptive phenotype. In vitro, butyrate induces a switch from cells with a secretory to an absorptive phenotype. Here, we report that NaB specifically represses the expression of the MUC2 gene, a differentiation marker of the secretory goblet cell lineage, in forskolin- and 12-O-tetradecanoylphorbol 13-acetate-induced HT29 cells, and Cl.16E cells, a clonal derivative of HT29 cells that spontaneously differentiates into goblet cells. Thus, NaB repression is independent of the nature of the stimulus that triggers MUC2 expression. Further, repression was independent of new protein synthesis. Our results suggest that inhibition of MUC2 is linked to the ability of butyrate to repress histone deacetylase activity, since trichostatin A, another inhibitor of histone deacetylases, also inhibited MUC2 expression in induced HT29 cells. Finally, we demonstrate that the NaB effect is specific for this marker of the secretory cell lineage, since carcinoembryonic antigen, which is expressed in both the secretory and absorptive cells, is induced by NaB. Thus, the NaB repression of a definitive function of the secretory cell lineage is a further mechanism, in addition to the effects on proliferation and apoptotic pathways, through which butyrate can regulate intestinal homeostasis.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Fac Med, INSERM, U539, F-44035 Nantes, France	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm)	Velcich, A (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.		Mariadason, John/N-2003-2013	Mariadason, John/0000-0001-9123-7684	NATIONAL CANCER INSTITUTE [R01CA090808, R01CA068965, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA-13330, CA-68965, CA-90808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen A, 1998, INT J BIOCHEM CELL B, V30, P797, DOI 10.1016/S1357-2725(98)00028-4; AUGENLICHT LH, 1987, CANCER RES, V47, P3763; Augenlicht LH, 1999, CANCER RES, V59, P6005; AUGERON C, 1984, CANCER RES, V44, P3961; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; Csordas A., 1995, ROLE GUT BACTERIA HU, P105; Cuisset L, 1998, BIOCHEM BIOPH RES CO, V246, P760, DOI 10.1006/bbrc.1998.8698; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; DeRubertis F, 1996, NATURE, V384, P589; Espinos E, 1999, MOL CELL BIOL, V19, P3474; GUM JR, 1987, J BIOL CHEM, V262, P1092; Hague A, 1997, GASTROENTEROLOGY, V112, P1036, DOI 10.1053/gast.1997.v112.agast971036; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; HEERDT BG, 1994, CANCER RES, V54, P3288; HILL MJ, 1995, EUR J CANCER PREV, V4, P353, DOI 10.1097/00008469-199510000-00004; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Ilantzis C, 1997, LAB INVEST, V76, P703; JARRY A, 1994, EUR J PHARM-MOLEC PH, V267, P95, DOI 10.1016/0922-4106(94)90229-1; Laboisse C. L., 1989, CELL MOL BIOL COLON, P27; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Mariadason JM, 2000, CANCER RES, V60, P4561; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; NAP M, 1988, TUMOR BIOL, V9, P145, DOI 10.1159/000217555; PAULUS U, 1993, J CELL SCI, V106, P473; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; ROWE WA, 1992, GASTROENTEROLOGY, V103, P336, DOI 10.1016/0016-5085(92)91133-O; SCHEPPACH W, 1994, GUT, V35, pS35, DOI 10.1136/gut.35.1_Suppl.S35; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7; TRAN C, 1998, AM J PHYSIOL, pG85; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Velcich A, 1997, J BIOL CHEM, V272, P7968, DOI 10.1074/jbc.272.12.7968; VELCICH A, 1993, J BIOL CHEM, V268, P13956; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Weiss AA, 1996, J HISTOCHEM CYTOCHEM, V44, P1161, DOI 10.1177/44.10.8813081; Wu JT, 2001, AM J PHYSIOL-GASTR L, V280, pG482, DOI 10.1152/ajpgi.2001.280.3.G482; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	44	53	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					4983	4992		10.1038/sj.onc.1206521	http://dx.doi.org/10.1038/sj.onc.1206521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902981				2022-12-25	WOS:000184578900006
J	Simon, MT; Pauloin, A; Normand, G; Lieu, HT; Mouly, H; Pivert, G; Carnot, F; Tralhao, JG; Brechot, C; Christa, L				Simon, MT; Pauloin, A; Normand, G; Lieu, HT; Mouly, H; Pivert, G; Carnot, F; Tralhao, JG; Brechot, C; Christa, L			HIP/PAP stimulates liver regeneration after partial hepatectomy and combines mitogenic and anti-apoptotic functions through the PKA signaling pathway	FASEB JOURNAL			English	Article						HIP/PAP/Reg-2; c-type lectin; TNF-alpha; PKA	PANCREATITIS-ASSOCIATED PROTEIN; HEPATIC PROGENITOR CELLS; PRIMARY HEPATOCYTES; TRANSGENIC MICE; MOUSE-LIVER; OVAL CELLS; PAP-I; EXPRESSION; ACTIVATION; INTESTINE	The HIP/PAP (=human Reg-2) C-type lectin encoding gene is activated in primary liver cancers. In normal liver, the protein is undetectable in normal mature hepatocytes and found only in some ductular cells, representing potential hepatic progenitor cells. The aim of this study was to examine the consequences of human HIP/PAP expression in the liver of transgenic mice. We demonstrated that HIP/PAP stimulated liver regeneration after partial hepatectomy. To further investigate the enhanced liver regeneration observed in vivo, primary cultures of hepatocytes were used to evaluate the mitogenic and anti-apoptotic properties of HIP/PAP. HIP/PAP increased hepatocyte DNA synthesis and protected hepatocytes against TNF-alpha plus actinomycin-D-induced apoptosis. HIP/PAP anti-apoptotic effects against TNF-alpha were clearly demonstrated when protein kinase A activity was specifically inhibited by KT5720, and HIP/PAP stimulated PKA-dependent phosphorylation of the proapoptotic Bad protein at Ser-112, suggesting that HIP/PAP may compete with cAMP to stimulate PKA activity. Overall, our results led us to propose a new role for a C-type lectin, HIP/PAP, as a hepatic cytokine that combines mitogenic and anti-apoptotic functions regarding hepatocytes, and consequently acts as a growth factor in vivo to enhance liver regeneration.	Univ Paris 05, Necker pasteur Inst, INSERM, U370, F-75742 Paris 15, France; INRA, Jouy En Josas, France; Hop Necker Enfants Malad, Serv Anatomopathol, Paris, France; Hop Europeen Georges Pompidou, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Christa, L (corresponding author), Univ Paris 05, Necker pasteur Inst, INSERM, U370, 156 Rue Vaugirard, F-75742 Paris 15, France.	christa@necker.fr	Normand, Guillaume/A-1975-2010	Normand, Guillaume/0000-0003-1228-3813; Tralhao, Jose/0000-0002-5641-6975				Abergel C, 1999, ACTA CRYSTALLOGR D, V55, P1487, DOI 10.1107/S0907444999007969; Akahani S, 1997, CANCER RES, V57, P5272; Akhurst B, 2001, HEPATOLOGY, V34, P519, DOI 10.1053/jhep.2001.26751; Alison M, 1998, J HEPATOL, V29, P676, DOI 10.1016/S0168-8278(98)80165-7; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Christa L, 1996, AM J PHYSIOL-GASTR L, V271, pG993, DOI 10.1152/ajpgi.1996.271.6.G993; Christa L, 1999, AM J PATHOL, V155, P1525, DOI 10.1016/S0002-9440(10)65468-5; Christa L, 2000, EUR J BIOCHEM, V267, P1665, DOI 10.1046/j.1432-1327.2000.01159.x; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; FACTOR VM, 1994, AM J PATHOL, V145, P409; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto Nelson, 1994, P1501; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hatano E., 2002, AM J PHYSIOL-GASTR L, V282, pG1357; Higgins GM, 1931, ARCH PATHOL, V12, P186; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LASSERRE C, 1992, CANCER RES, V52, P5089; Lasserre C, 1999, AM J PATHOL, V154, P1601, DOI 10.1016/S0002-9440(10)65413-2; LEIST M, 1994, J IMMUNOL, V153, P1778; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Libbrecht L, 2001, AM J SURG PATHOL, V25, P1388, DOI 10.1097/00000478-200111000-00006; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; Malka D, 2000, GASTROENTEROLOGY, V119, P816, DOI 10.1053/gast.2000.16491; Montalto G, 1998, ONCOLOGY-BASEL, V55, P421, DOI 10.1159/000011889; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Petersen BE, 1998, HEPATOLOGY, V27, P1030, DOI 10.1002/hep.510270419; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RENTON KW, 1978, MOL PHARMACOL, V14, P672; Roskams T, 1998, J HEPATOL, V29, P455, DOI 10.1016/S0168-8278(98)80065-2; Sell S, 1998, HEPATOLOGY, V27, P317, DOI 10.1002/hep.510270202; Sirica A. E., 1997, BILIARY PANCREATIC D, P229; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	41	71	76	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1441	1450		10.1096/fj.02-1013com	http://dx.doi.org/10.1096/fj.02-1013com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890698				2022-12-25	WOS:000185345100037
J	Gutmann, DH; Winkeler, E; Kabbarah, O; Hedrick, N; Dudley, S; Goodfellow, PJ; Liskay, RM				Gutmann, DH; Winkeler, E; Kabbarah, O; Hedrick, N; Dudley, S; Goodfellow, PJ; Liskay, RM			Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice	ONCOGENE			English	Article						tumor suppressor gene; mismatch repair; leukemia; neurofibromin	DNA MISMATCH REPAIR; JUVENILE MYELOMONOCYTIC LEUKEMIA; ENDOMETRIAL TUMORIGENESIS; HEMATOLOGICAL MALIGNANCY; BONE-MARROW; GENE; TYPE-1; CHILDREN; CELL; MUTATION	Defects in DNA mismatch repair (MMR) have been implicated in the genesis of a diverse set of human cancers. Recent studies have suggested that one of the targets of MMR is the neurofibromatosis 1 (NF1) gene. To evaluate the contribution of Mlh1 MMR deficiency to Nf1 tumorigenesis, Mlh1 - / -; Nfl + / - mice were generated. All Mlh1 - / -; Nfl +/- mice (n = 21) were dead by 260 days compared to none of the Nf1 + / - mice. In all, 50% of the Mlh1 - / -; Nfl +/- mice were dead at 150 days compared to 252 days for Mlh1 - / - mice. Nine of the Mlh1 - / -; Nf1 + / - mice were found to harbor intrathoracic NOS2-immunoreactive myeloid leukemias similar to the hematopoietic malignancies observed in older Nfl + / - mice. As expected, significant microsatellite instability was observed in six of six tumors and neurofibromin expression was lost in all tumors analysed. These results suggest that MMR deficiency can accelerate myeloid leukemogenesis in Nfl + / - mice, presumably by inactivating Nf1 gene expression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Washington University (WUSTL); Washington University (WUSTL); Oregon Health & Science University	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Dudley, Samuel C/A-7085-2009	Gutmann, David/0000-0002-3127-5045	NIGMS NIH HHS [R37 GM32741] Funding Source: Medline; NINDS NIH HHS [NS36996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036996] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Birnbaum RA, 2000, MOL CELL, V5, P189, DOI 10.1016/S1097-2765(00)80415-3; Boland CR, 1998, CANCER RES, V58, P5248; Buermeyer AB, 1999, CANCER RES, V59, P538; Cohn DE, 2001, GENE CHROMOSOME CANC, V32, P295, DOI 10.1002/gcc.1194; Cooper LJN, 2000, BLOOD, V96, P2310; Edelmann W, 1999, CANCER RES, V59, P1301; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Gutmann DH, 2000, NEUROPATH APPL NEURO, V26, P361, DOI 10.1046/j.1365-2990.2000.00258.x; Heinen CD, 2002, CANCER BIOL THER, V1, P477, DOI 10.4161/cbt.1.5.160; Ingram DA, 2002, BLOOD, V100, P3656, DOI 10.1182/blood-2002-03-0734; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kim TJ, 2002, MOL IMMUNOL, V38, P701, DOI 10.1016/S0161-5890(01)00101-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; Li Y, 1996, CANCER RES, V56, P2872; Mahgoub N, 1999, BLOOD, V93, P3617, DOI 10.1182/blood.V93.11.3617.411a49_3617_3623; Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.3.CO;2-A; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Ricciardone MD, 1999, CANCER RES, V59, P290; Shannon KM, 2001, SEMIN CANCER BIOL, V11, P191, DOI 10.1006/scbi.2001.0372; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Side LE, 1998, BLOOD, V92, P267, DOI 10.1182/blood.V92.1.267.413a31_267_272; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Wang H, 2002, AM J PATHOL, V160, P1481, DOI 10.1016/S0002-9440(10)62573-4; Wang Q, 1999, CANCER RES, V59, P294; Wang Q, 2003, HUM GENET, V112, P117, DOI 10.1007/s00439-002-0858-4; Whiteside D, 2002, CANCER RES, V62, P359; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	31	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4581	4585		10.1038/sj.onc.1206768	http://dx.doi.org/10.1038/sj.onc.1206768			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881715				2022-12-25	WOS:000184054700014
J	Arunkumar, AI; Stauffer, ME; Bochkareva, E; Bochkarev, A; Chazin, WJ				Arunkumar, AI; Stauffer, ME; Bochkareva, E; Bochkarev, A; Chazin, WJ			Independent and coordinated functions of replication protein a tandem high affinity single-stranded DNA binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SSDNA BINDING; RPA; MECHANISM; POLARITY; SUBUNITS; SUGGESTS; REVEALS; REPAIR; SSB	The initial high affinity binding of single-stranded DNA (ssDNA) by replication protein A (RPA) is involved in the tandem domains in the central region of the RPA70 subunit (RPA70AB). However, it was not clear whether the two domains, RPA70A and RPA70B, bind DNA simultaneously or sequentially. Here, using primarily heteronuclear NMR complemented by fluorescence spectroscopy, we have analyzed the binding characteristics of the individual RPA70A and RPA70B domains and compared them with the intact RPA70AB. NMR chemical shift comparisons confirmed that RPA70A and RPA70B tumble independently in solution in the absence of ssDNA. NMR chemical shift perturbations showed that all ssDNA oligomers bind to the same sites as observed in the x-ray crystal structure of RPA70AB complexed to d(C)(8). Titrations using a variety of 5'-mer ssDNA oligomers showed that RPA70A has a 5-10-fold higher affinity for ssDNA than RPA70B. Detailed analysis of ssDNA binding to RPA70A revealed that all DNA sequences interact in a similar mode. Fluorescence binding measurements with a variety of 8-10'-mer DNA sequences showed that RPA70AB interacts with DNA with similar to 100-fold higher affinity than the isolated domains. Calculation of the theoretical "linkage effect" from the structure of RPA70AB suggests that the high overall affinity for ssDNA is a byproduct of the covalent attachment of the two domains via a short flexible tether, which increases the effective local concentration. Taken together, our data are consistent with a sequential model of DNA binding by RPA according to which RPA70A binds the majority of DNA first and subsequent loading of RPA70B domain is facilitated by the linkage effect.	Vanderbilt Univ, Ctr Struct Biol, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Dept Phys, Nashville, TN 37232 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Vanderbilt University; Vanderbilt University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Chazin, WJ (corresponding author), Vanderbilt Univ, Ctr Struct Biol, Dept Biochem, 5140 BIOSCI,MRB3, Nashville, TN 37232 USA.			Alphonse Ignatius, Arun/0000-0002-7342-044X	NCI NIH HHS [T32 CA009582, P30 CA68485] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [R01 GM65484, R01 GM61192, R01 GM065484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065484, R01GM061192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bastin-Shanower SA, 2001, J BIOL CHEM, V276, P36446, DOI 10.1074/jbc.M104386200; Bhattacharya S, 2002, PROTEIN SCI, V11, P2316, DOI 10.1110/ps.0209202; BHATTACHARYA S, 2003, IN PRESS J BIOMOL NM; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 2001, EMBO J, V20, P612, DOI 10.1093/emboj/20.3.612; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Daughdrill GW, 2001, NUCLEIC ACIDS RES, V29, P3270, DOI 10.1093/nar/29.15.3270; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; Hall DA, 2001, P NATL ACAD SCI USA, V98, P9521, DOI 10.1073/pnas.171168898; Iftode C, 2000, BIOCHEMISTRY-US, V39, P11970, DOI 10.1021/bi0005761; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kolpashchikov DM, 2001, NUCLEIC ACIDS RES, V29, P373, DOI 10.1093/nar/29.2.373; Lavrik OI, 1999, NUCLEIC ACIDS RES, V27, P4235, DOI 10.1093/nar/27.21.4235; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Mer G, 2000, COLD SPRING HARB SYM, V65, P193, DOI 10.1101/sqb.2000.65.193; Palmer A. G., 1996, PROTEIN NMR SPECTROS; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhou HX, 2001, BIOCHEMISTRY-US, V40, P15069, DOI 10.1021/bi015795g	26	93	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41077	41082		10.1074/jbc.M305871200	http://dx.doi.org/10.1074/jbc.M305871200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12881520	hybrid			2022-12-25	WOS:000185847200082
J	Gladue, RP; Tylaska, LA; Brissette, WH; Lira, PD; Kath, JC; Poss, CS; Brown, MF; Paradis, TJ; Conklyn, MJ; Ogborne, KT; McGlynn, MA; Lillie, BM; DiRico, AP; Mairs, EN; McElroy, EB; Martin, WH; Stock, IA; Shepard, RM; Showell, HJ; Neote, K				Gladue, RP; Tylaska, LA; Brissette, WH; Lira, PD; Kath, JC; Poss, CS; Brown, MF; Paradis, TJ; Conklyn, MJ; Ogborne, KT; McGlynn, MA; Lillie, BM; DiRico, AP; Mairs, EN; McElroy, EB; Martin, WH; Stock, IA; Shepard, RM; Showell, HJ; Neote, K			CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CCR1; RHEUMATOID-ARTHRITIS; SYNOVIAL TISSUE; CUTANEOUS INJECTION; UP-REGULATION; RANTES; EXPRESSION; RECRUITMENT; TNF; CELLS	The chemokines CCL3 and CCL5, as well as their shared receptor CCR1, are believed to play a role in the pathogenesis of several inflammatory diseases including rheumatoid arthritis, multiple sclerosis, and transplant rejection. In this study we describe the pharmacological properties of a novel small molecular weight CCR1 antagonist, CP-481,715 (quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3-fluorobenzyl)-2(S), 7-dihydroxy7- methyloctyl] amide). Radiolabeled binding studies indicate that CP-481,715 binds to human CCR1 with a K-d of 9.2 nM and displaces I-125-labeled CCL3 from CCR1-transfected cells with an IC50 of 74 nM. CP-481,715 lacks intrinsic agonist activity but fully blocks the ability of CCL3 and CCL5 to stimulate receptor signaling (guanosine 5'-O-(thiotriphosphate) incorporation; IC50 = 210 nM), calcium mobilization (IC50 = 71 nM), monocyte chemotaxis (IC50 = 55 nM), and matrix metalloproteinase 9 release (IC50 = 54 nM). CP- 481,715 retains activity in human whole blood, inhibiting CCL3-induced CD11b up-regulation and actin polymerization (IC50 = 165 and 57 nM, respectively) on monocytes. Furthermore, it behaves as a competitive and reversible antagonist. CP- 481,715 is > 100-fold selective for CCR1 as compared with a panel of G-protein-coupled receptors including related chemokine receptors. Evidence for its potential use in human disease is suggested by its ability to inhibit 90% of the monocyte chemotactic activity present in 11/15 rheumatoid arthritis synovial fluid samples. These data illustrate that CP- 481,715 is a potent and selective antagonist for CCR1 with therapeutic potential for rheumatoid arthritis and other inflammatory diseases.	Pfizer Inc, Global Res & Dev, Dept Immunol, Groton, CT 06340 USA	Pfizer	Gladue, RP (corresponding author), Pfizer Inc, Global Res & Dev, Dept Immunol, MS 8220-2410,Eastern Point Rd, Groton, CT 06340 USA.	Ronald_P_Gladue@Groton.Pfizer.com						AlMughales J, 1996, CLIN EXP IMMUNOL, V106, P230, DOI 10.1046/j.1365-2249.1996.d01-836.x; Barnes DA, 1998, J CLIN INVEST, V101, P2910, DOI 10.1172/JCI2172; Barr AJ, 1997, J BIOL CHEM, V272, P32979, DOI 10.1074/jbc.272.52.32979; Beck LA, 1997, J IMMUNOL, V159, P2962; Colantonio L, 1999, BLOOD, V94, P2981, DOI 10.1182/blood.V94.9.2981.421k27_2981_2989; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Conklyn MJ, 1996, CYTOKINE, V8, P762, DOI 10.1006/cyto.1996.0101; CUTOLO M, 1993, CLIN EXP RHEUMATOL, V11, P331; Dayer JM, 2002, JOINT BONE SPINE, V69, P123, DOI 10.1016/S1297-319X(02)00363-9; Dunne JL, 2002, BLOOD, V99, P336, DOI 10.1182/blood.V99.1.336; Ellingsen T, 2000, SCAND J RHEUMATOL, V29, P216; FAHEY TJ, 1992, J IMMUNOL, V148, P2764; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; Gao W, 2000, J CLIN INVEST, V105, P35, DOI 10.1172/JCI8126; Horuk R, 2000, MED RES REV, V20, P155, DOI 10.1002/(SICI)1098-1128(200003)20:2<155::AID-MED3>3.0.CO;2-G; Jenkins JK, 2002, AM J MED SCI, V323, P171, DOI 10.1097/00000441-200204000-00002; KASAMA T, 1995, J CLIN INVEST, V95, P2868, DOI 10.1172/JCI117993; Katrib A, 2001, RHEUMATOLOGY, V40, P988, DOI 10.1093/rheumatology/40.9.988; Katschke KJ, 2001, ARTHRITIS RHEUM, V44, P1022, DOI 10.1002/1529-0131(200105)44:5<1022::AID-ANR181>3.3.CO;2-E; Klier CM, 2001, BIOL CHEM, V382, P1405, DOI 10.1515/BC.2001.173; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; Lee SC, 2000, J IMMUNOL, V164, P3392, DOI 10.4049/jimmunol.164.6.3392; Liang M, 2000, J BIOL CHEM, V275, P19000, DOI 10.1074/jbc.M001222200; Luttichau H R, 2000, Curr Opin Drug Discov Devel, V3, P610; Makki RF, 2000, CLIN EXP RHEUMATOL, V18, P391; Meyer O, 2000, PRESSE MED, V29, P463; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; ROBINSON E, 1995, CLIN EXP IMMUNOL, V101, P398; Robinson SC, 2002, EUR J IMMUNOL, V32, P404, DOI 10.1002/1521-4141(200202)32:2<404::AID-IMMU404>3.0.CO;2-X; Rottman JB, 2000, EUR J IMMUNOL, V30, P2372, DOI 10.1002/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO;2-D; SCHILD HO, 1949, BRIT J PHARM CHEMOTH, V4, P277, DOI 10.1111/j.1476-5381.1949.tb00548.x; Tak PP, 1997, ARTHRITIS RHEUM, V40, P217, DOI 10.1002/art.1780400206; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; Volin MV, 1998, CLIN IMMUNOL IMMUNOP, V89, P44, DOI 10.1006/clin.1998.4590; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; Weber C, 2001, BLOOD, V97, P1144, DOI 10.1182/blood.V97.4.1144	41	74	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40473	40480		10.1074/jbc.M306875200	http://dx.doi.org/10.1074/jbc.M306875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909630	hybrid			2022-12-25	WOS:000185847200008
J	Haston, JL; Engelsen, SB; Roessle, M; Clarkson, J; Blanch, EW; Baldock, C; Kielty, CM; Wess, TJ				Haston, JL; Engelsen, SB; Roessle, M; Clarkson, J; Blanch, EW; Baldock, C; Kielty, CM; Wess, TJ			Raman Microscopy and X-ray diffraction, a combined study of fibrillin-rich microfibrillar elasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAMOLECULAR ORGANIZATION; MECHANICAL-PROPERTIES; SECONDARY STRUCTURE; ALPHA-HELIX; SPECTROSCOPY; FD; DETERMINES; PROTEINS; DOMAINS	Fibrillin-rich microfibrils are essential elastic structures contained within the extracellular matrix of a wide variety of connective tissues. Microfibrils are characterized as beaded filamentous structures with a variable axial periodicity ( average 56 nm in the untensioned state); however, the basis of their elasticity remains unknown. This study used a combination of small angle x-ray scattering and Raman microscopy to investigate further the packing of microfibrils within the intact tissue and to determine the role of molecular reorganization in the elasticity of these microfibrils. The application of relatively small strains produced no overall change in either molecular or macromolecular microfibrillar structure. In contrast, the application of larger tissue extensions (up to 150%) resulted in a markedly different structure, as observed by both Raman microscopy and small angle x-ray scattering. These changes occurred at different levels of architecture and are interpreted as ranging from alterations in peptide bond conformation to domain rearrangement. This study demonstrates the importance of molecular elasticity in the mechanical properties of fibrillin-rich microfibrils in the intact tissue.	Univ Stirling, Dept Biol Sci, Ctr Extracellular Matrix Biol, Stirling FK9 4LA, Scotland; Royal Vet & Agr Univ, Food Technol Ctr Adv Food Studies, DK-1958 Frederiksberg C, Denmark; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Med, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Stirling; University of Copenhagen; European Synchrotron Radiation Facility (ESRF); University of Glasgow; University of Manchester; University of Manchester; University of Manchester	Haston, JL (corresponding author), Univ Stirling, Dept Biol Sci, Ctr Extracellular Matrix Biol, Stirling FK9 4LA, Scotland.	j.l.haston@stir.ac.uk	Engelsen, Søren/D-7911-2011	Engelsen, Søren/0000-0003-4124-4338; Baldock, Clair/0000-0003-3497-1959; Blanch, Ewan/0000-0002-0781-4926; Rossle, Manfred/0000-0003-4196-0430				Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Barron LD, 2000, PROG BIOPHYS MOL BIO, V73, P1, DOI 10.1016/S0079-6107(99)00017-6; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Eriksen TA, 2001, PROTEINS, V45, P90, DOI 10.1002/prot.1127; HAMMERSLEY AO, 1993, EXPAH9302 ESRF INF O; Kielty CM, 2002, J MUSCLE RES CELL M, V23, P581, DOI 10.1023/A:1023479010889; Kielty CM, 2002, PHILOS T R SOC B, V357, P207, DOI 10.1098/rstb.2001.1029; Kielty CM, 2002, J CELL SCI, V115, P2817; LIPPERT JL, 1976, J AM CHEM SOC, V98, P7075, DOI 10.1021/ja00438a057; McConnell CJ, 1997, J PHYSIOL-LONDON, V499, P513, DOI 10.1113/jphysiol.1997.sp021945; Miura T, 1995, Subcell Biochem, V24, P55; Nielsen AS, 2002, POLYMER, V43, P2671, DOI 10.1016/S0032-3861(02)00053-8; Overman SA, 1998, BIOCHEMISTRY-US, V37, P5654, DOI 10.1021/bi972339c; Overman SA, 1999, BIOCHEMISTRY-US, V38, P4018, DOI 10.1021/bi982901e; OVERMAN SA, 1995, BIOCHEMISTRY-US, V34, P5440, DOI 10.1021/bi00016a015; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Robb BW, 1999, MOL BIOL CELL, V10, P3595, DOI 10.1091/mbc.10.11.3595; Thurmond FA, 1996, J EXP BIOL, V199, P1817; Trask TM, 1999, BIOCHEM J, V340, P693, DOI 10.1042/0264-6021:3400693; Wess TJ, 1997, FEBS LETT, V413, P424, DOI 10.1016/S0014-5793(97)00950-2; Wess TJ, 1998, J CELL BIOL, V141, P829, DOI 10.1083/jcb.141.3.829; Wess TJ, 1998, J STRUCT BIOL, V122, P123, DOI 10.1006/jsbi.1998.3992; Wright DM, 1999, J EXP BIOL, V202, P3011; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659	26	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41189	41197		10.1074/jbc.M212854200	http://dx.doi.org/10.1074/jbc.M212854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12876292	hybrid, Green Published			2022-12-25	WOS:000185847200096
J	Stanasila, L; Perez, JB; Vogel, H; Cotecchia, S				Stanasila, L; Perez, JB; Vogel, H; Cotecchia, S			Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes - Potential implications in receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED-RECEPTOR; RESONANCE ENERGY-TRANSFER; DELTA-OPIOID RECEPTOR; ALPHA(1B)-ADRENERGIC RECEPTOR; EXTRACELLULAR DOMAIN; ADRENERGIC-RECEPTOR; HORMONE RECEPTOR; CROSS-TALK; DIMERIZATION; HETERODIMERIZATION	We combined biophysical, biochemical, and pharmacological approaches to investigate the ability of the alpha(1a)- and alpha(1b)-adrenergic receptor (AR) subtypes to form homo- and hetero-oligomers. Receptors tagged with different epitopes (hemagglutinin and Myc) or fluorescent proteins (cyan and green fluorescent proteins) were transiently expressed in HEK-293 cells either individually or in different combinations. Fluorescence resonance energy transfer measurements provided evidence that both the alpha(1a)- and alpha(1b)-AR can form homo-oligomers with similar transfer efficiency of similar to0.10. Hetero-oligomers could also be observed between the alpha(1b)- and the alpha(1a)-AR subtypes but not between the alpha(1b)-AR and the beta(2)-AR, the NK1 tachykinin, or the CCR5 chemokine receptors. Oligomerization of the alpha(1b)-AR did not require the integrity of its C-tail, of two glycophorin motifs, or of the N-linked glycosylation sites at its N terminus. In contrast, helix I and, to a lesser extent, helix VII were found to play a role in the alpha(1b)-AR homo-oligomerization. Receptor oligomerization was not influenced by the agonist epinephrine or by the inverse agonist prazosin. A constitutively active (A293E) as well as a signaling-deficient (R143E) mutant displayed oligomerization features similar to those of the wild type alpha(1b)-AR. Confocal imaging revealed that oligomerization of the alpha(1)-AR subtypes correlated with their ability to co-internalize upon exposure to the agonist. The alpha(1a)-selective agonist oxymetazoline induced the co-internalization of the alpha(1a)- and alpha(1b)-AR, whereas the alpha(1b)-AR could not co-internalize with the NK1 tachykinin or CCR5 chemokine receptors. Oligomerization might therefore represent an additional mechanism regulating the physiological responses mediated by the alpha(1a)- and alpha(1b)-AR subtypes.	Ecole Polytech Fed Lausanne, Lab Chim Phys Polymeres & Membranes, CH-1015 Ecublens, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne	Vogel, H (corresponding author), Ecole Polytech Fed Lausanne, Lab Chim Phys Polymeres & Membranes, CH-1015 Ecublens, Switzerland.		Vogel, Horst/AAJ-5490-2021					AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2001, LIFE SCI, V68, P2243, DOI 10.1016/S0024-3205(01)01012-8; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bjorklof K, 2002, BIOCHEMISTRY-US, V41, P4281, DOI 10.1021/bi015790j; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Filizola M, 2002, BIOPOLYMERS, V66, P317, DOI 10.1002/bip.10311; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; Hur EM, 2002, CELL SIGNAL, V14, P397, DOI 10.1016/S0898-6568(01)00258-3; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Patel RC, 2002, P NATL ACAD SCI USA, V99, P3294, DOI 10.1073/pnas.042705099; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Scheer A, 2000, MOL PHARMACOL, V57, P219; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Watson C, 2000, MOL PHARMACOL, V58, P1230, DOI 10.1124/mol.58.6.1230; Yoshioka K, 2001, P NATL ACAD SCI USA, V98, P7617, DOI 10.1073/pnas.121587098; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	50	140	143	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40239	40251		10.1074/jbc.M306085200	http://dx.doi.org/10.1074/jbc.M306085200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888550	hybrid			2022-12-25	WOS:000185713800117
J	Waki, H; Yamauchi, T; Kamon, J; Ito, Y; Uchida, S; Kita, S; Hara, K; Hada, Y; Vasseur, F; Froguel, P; Kimura, S; Nagai, R; Kadowaki, T				Waki, H; Yamauchi, T; Kamon, J; Ito, Y; Uchida, S; Kita, S; Hara, K; Hada, Y; Vasseur, F; Froguel, P; Kimura, S; Nagai, R; Kadowaki, T			Impaired multimerization of human adiponectin mutants associated with diabetes - Molecular structure and multimer formation of adiponectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-RELATED PROTEIN; ADIPOSE-SPECIFIC GENE; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; METAPHYSEAL CHONDRODYSPLASIA; ADIPOCYTE DIFFERENTIATION; SUSCEPTIBILITY GENES; X COLLAGEN; MUTATIONS; DOMAIN	Adiponectin is an adipocyte-derived hormone, which has been shown to play important roles in the regulation of glucose and lipid metabolism. Eight mutations in human adiponectin have been reported, some of which were significantly related to diabetes and hypoadiponectinemia, but the molecular mechanisms of decreased plasma levels and impaired action of adiponectin mutants were not clarified. Adiponectin structurally belongs to the complement 1q family and is known to form a characteristic homomultimer. Herein, we demonstrated that simple SDS-PAGE under non-reducing and non-heat-denaturing conditions clearly separates multimer species of adiponectin. Adiponectin in human or mouse serum and adiponectin expressed in NIH-3T3 or Escherichia coli formed a wide range of multimers from trimers to high molecular weight (HMW) multimers. A disulfide bond through an amino-terminal cysteine was required for the formation of multimers larger than a trimer. An amino-terminal Cys-Ser mutation, which could not form multimers larger than a trimer, abrogated the effect of adiponectin on the AMP-activated protein kinase pathway in hepatocytes. Among human adiponectin mutations, G84R and G90S mutants, which are associated with diabetes and hypoadiponectinemia, did not form HMW multimers. R112C and I164T mutants, which are associated with hypoadiponectinemia, did not assemble into trimers, resulting in impaired secretion from the cell. These data suggested impaired multimerization and/or the consequent impaired secretion to be among the causes of a diabetic phenotype or hypoadiponectinemia in subjects having these mutations. In conclusion, not only total concentrations, but also multimer distribution should always be considered in the interpretation of plasma adiponectin levels in health as well as various disease states.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Tokyo 3320012, Japan; Inst Pasteur, Inst Biol Lille, CNRS 8090, F-59000 Lille, France; CHU Lille, F-59000 Lille, France	University of Tokyo; Japan Science & Technology Agency (JST); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		FROGUEL, Philippe/O-6799-2017; Waki, Hironori/AAE-3942-2020	FROGUEL, Philippe/0000-0003-2972-0784; Waki, Hironori/0000-0002-5302-9793	MRC [G0000477] Funding Source: UKRI; Medical Research Council [G0000477] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Hickling TP, 1998, MOL MED, V4, P266, DOI 10.1007/BF03401923; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kondo H, 2002, DIABETES, V51, P2325, DOI 10.2337/diabetes.51.7.2325; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Mori Y, 2002, DIABETES, V51, P1247, DOI 10.2337/diabetes.51.4.1247; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Takahashi M, 2000, INT J OBESITY, V24, P861, DOI 10.1038/sj.ijo.0801244; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Vasseur F, 2002, HUM MOL GENET, V11, P2607, DOI 10.1093/hmg/11.21.2607; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; Wallis R, 1999, J IMMUNOL, V163, P4953; Wilson R, 2002, J BIOL CHEM, V277, P12516, DOI 10.1074/jbc.M112044200; Xie LJ, 2000, THROMB HAEMOSTASIS, V84, P506; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	37	784	837	0	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40352	40363		10.1074/jbc.M300365200	http://dx.doi.org/10.1074/jbc.M300365200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878598	hybrid			2022-12-25	WOS:000185713800129
J	Chen, DS; Lucey, MJ; Phoenix, F; Lopez-Garcia, J; Hart, SM; Losson, R; Buluwela, L; Coombes, RC; Chambon, P; Schar, P; Ali, S				Chen, DS; Lucey, MJ; Phoenix, F; Lopez-Garcia, J; Hart, SM; Losson, R; Buluwela, L; Coombes, RC; Chambon, P; Schar, P; Ali, S			T : G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTORS; RETINOIC ACID RECEPTORS; COACTIVATOR COMPLEX; ANDROGEN RECEPTOR; SIGNALING PATHWAYS; MOLECULAR-BIOLOGY; BRCA1 INHIBITION; STRUCTURAL BASIS; LIGAND-BINDING; BREAST-CANCER	Nuclear receptors (NR) classically regulate gene expression by stimulating transcription upon binding to their cognate ligands. It is now well established that NR-mediated transcriptional activation requires the recruitment of coregulator complexes, which facilitate recruitment of the basal transcription machinery through direct interactions with the basal transcription machinery and/or through chromatin remodeling. However, a number of recently described NR coactivators have been implicated in cross-talk with other nuclear processes including RNA splicing and DNA repair. T: G mismatch-specific thymine DNA glycosylase (TDG) is required for base excision repair of deaminated methylcytosine. Here we show that TDG is a coactivator for estrogen receptor alpha(ERalpha). We demonstrate that TDG interacts with ERalpha in vitro and in vivo and suggest a separate role for TDG to its established role in DNA repair. We show that this involves helix 12 of ERalpha. The region of interaction in TDG is mapped to a putative alpha-helical motif containing a motif distinct from but similar to the LXXLL motif that mediates interaction with NR. Together with recent reports linking TFIIH in regulating NR function, our findings provide new data to further support an important link between DNA repair proteins and nuclear receptor function.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,Coll France, F-67404 Illkirch Graffenstaden, France; Univ Zurich, Inst Mol Canc Res, CH-8008 Zurich, Switzerland	Imperial College London; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Zurich	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Du Cane Rd, London W12 0NN, England.		Schär, Primo/G-5967-2012; Ali, Simak/M-6912-2018	Schär, Primo/0000-0003-1843-6147; Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; Glass CK, 2000, GENE DEV, V14, P121; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; KRAUS WL, 1994, MOL ENDOCRINOL, V8, P952, DOI 10.1210/me.8.8.952; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Park JJ, 2000, CANCER RES, V60, P5946; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; VOM BE, 1996, EMBO J, V15, P110; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897	75	96	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38586	38592		10.1074/jbc.M304286200	http://dx.doi.org/10.1074/jbc.M304286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874288	hybrid			2022-12-25	WOS:000185575100062
J	Jiang, AX; Pei, DQ				Jiang, AX; Pei, DQ			Distinct roles of catalytic and pexin-like domains in membrane-type matrix metalloproteinase (MMP)-mediated pro-MMP-2 activation and collagenolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA(V) SUBUNIT; BREAST-CARCINOMA CELLS; C-TERMINAL DOMAIN; SUBSTRATE-SPECIFICITY; MMP INHIBITION; A ACTIVATION; CDNA LIBRARY; TUMOR-CELLS; MT-MMPS; IDENTIFICATION	Members of the membrane-type matrix metalloproteinase (MT-MMPs) family are dual regulators of extracellular matrix remodeling through direct degradation of extracellular matrix components and activation of other latent MMPs. However, the structural basis of this functional diversity remains poorly understood. In an attempt to dissect the structural determinants for MT-MMP function, we performed domain exchange experiments between MT1-MMP and its close relative MT3-MMP and analyzed the exchange chimeras for pro-MMP-2 activation and collagen degradation at the cellular level. Our results indicate that catalytic domains determine the pattern of pro-MMP-2 activation, whereas pexin-like domains modulate the level of activation. On the other hand, both the catalytic and pexin-like domains of MT1-MMP are required for strong collagenolysis because exchanging either domain with that of MT3-MMP yielded significantly lower activity, and the introduction of the MT1-MMP catalytic or pexin-like domain into MT3-MMP failed to generate any significant enhancement of collagenolytic activity compared with wild-type MT3-MMP. Interestingly, the cytoplasmic domain of MT1-MMP behaves as a negative regulator not only for MT1-MMP itself, but also for MT3-MMP in both pro-MMP-2 activation and collagenolysis, consistent with and extending our recent findings (Jiang, A., Lehti, K., Wang, X., Weiss, S. J., Keski-Oja, J., and Pei, D. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13693-13698). Taken together, these results demonstrate that domains in MT-MMPs function differently toward a given substrate and thus should be targeted differentially for future therapeutic development.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Jiang, Aixiang/0000-0002-6153-7595	NATIONAL CANCER INSTITUTE [R29CA076308, R01CA076308] Funding Source: NIH RePORTER; NCI NIH HHS [CA76308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jackson C, 2001, INFLAMM RES, V50, P183, DOI 10.1007/s000110050743; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; Llano E, 1999, CANCER RES, V59, P2570; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shofuda K, 1998, LAB INVEST, V78, P915; Spinale FG, 2000, CARDIOVASC RES, V46, P225, DOI 10.1016/S0008-6363(99)00431-9; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	43	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38765	38771		10.1074/jbc.M306618200	http://dx.doi.org/10.1074/jbc.M306618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878590	hybrid			2022-12-25	WOS:000185575100083
J	Kim, CH; Xiong, WC; Mei, L				Kim, CH; Xiong, WC; Mei, L			Regulation of MuSK expression by a novel signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE-EXPRESSION; EPSILON-SUBUNIT GENE; NEUROMUSCULAR-JUNCTION; GAMMA-SUBUNIT; BETA-SUBUNIT; MAP KINASE; CRD DOMAIN; MUSCLE; PROTEIN; IDENTIFICATION	MuSK is a receptor tyrosine kinase essential for neuromuscular junction formation. Expression of the MuSK gene is tightly regulated during development and at the neuromuscular junction. However, little is known about molecular mechanisms regulating its gene expression. Here we report a characterization of the promoter of the mouse MuSK gene. The transcription of MuSK starts at multiple sites with a major site 51 nt upstream of the translation start site. We have identified an E-box-like cis-element that is both required and sufficient for differentiation-dependent transcription. Interestingly, the promoter activity of the MuSK gene did not respond to neuregulin, a factor believed to mediate the synapse-specific transcription of acetylcholine receptor subunit genes. Rather, MuSK expression is increased in muscle cells stimulated with Wnt or at conditions when the Wnt signaling was activated. These results suggest a novel mechanism for the MuSK synapse-specific expression.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Civitan Int Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Mei, L (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.	lmei@nrc.uab.edu	Mei, Lin/G-8755-2012		NIAMS NIH HHS [AR48120] Funding Source: Medline; NICHD NIH HHS [P30 HD38985-0] Funding Source: Medline; NIGMS NIH HHS [GM63861] Funding Source: Medline; NINDS NIH HHS [NS45710, NS44521, NS40480] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD038985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044521, R01NS045710, R01NS040480] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; d'Exaerde AD, 2002, EMBO REP, V3, P1075, DOI 10.1093/embo-reports/kvf220; Dale TC, 1998, BIOCHEM J, V329, P209; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Duclert A, 1996, J BIOL CHEM, V271, P17433, DOI 10.1074/jbc.271.29.17433; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; Herbst R, 2000, EMBO J, V19, P67, DOI 10.1038/sj.emboj.7592228b; Hopf C, 1996, J BIOL CHEM, V271, P5231; Ip FCF, 2000, MOL CELL NEUROSCI, V16, P661, DOI 10.1006/mcne.2000.0892; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; Jones G, 1996, P NATL ACAD SCI USA, V93, P5985, DOI 10.1073/pnas.93.12.5985; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Luo ZG, 2002, NEURON, V35, P489, DOI 10.1016/S0896-6273(02)00783-3; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; Packard M, 2003, NAT REV NEUROSCI, V4, P113, DOI 10.1038/nrn1036; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sapru MK, 1998, P NATL ACAD SCI USA, V95, P1289, DOI 10.1073/pnas.95.3.1289; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1997, J BIOL CHEM, V272, P10367; Si JT, 1999, MOL BRAIN RES, V67, P18, DOI 10.1016/S0169-328X(99)00028-5; Si JT, 1999, J NEUROSCI, V19, P8498; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; THEISEN H, 1994, DEVELOPMENT, V120, P347; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Xie MH, 1997, NAT BIOTECHNOL, V15, P768, DOI 10.1038/nbt0897-768; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	49	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38522	38527		10.1074/jbc.M305058200	http://dx.doi.org/10.1074/jbc.M305058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885777	hybrid			2022-12-25	WOS:000185575100054
J	Dhandapani, KM; Hadman, M; De Sevilla, L; Wade, MF; Mahesh, VB; Brann, DW				Dhandapani, KM; Hadman, M; De Sevilla, L; Wade, MF; Mahesh, VB; Brann, DW			Astrocyte protection of neurons - Role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; HORMONE-RELEASING-HORMONE; RAT HIPPOCAMPAL-NEURONS; C-JUN; TGF-BETA; CEREBRAL-ISCHEMIA; TRANSCRIPTION FACTORS; REACTIVE OXYGEN; GENE-EXPRESSION; IN-VITRO	Astrocytes have become a focal point for research in neurobiology, especially regarding their purported ability to regulate neuronal communication and survival. The present study addressed a poorly understood but important focus in this area, the mechanism(s) underlying astrocyte-induced survival of neurons. The results of the study show that soluble factors in astrocyte-conditioned media (ACM) protect murine GT1-7 neurons from serum deprivation-induced cell death and that this neuroprotection is correlated with enhanced activation/phosphorylation of the AP-1 transcription factor, c-Jun(Ser-63). A parallel and correlated activation of the upstream kinases, c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase kinase-4 (MKK4) was also demonstrated. Furthermore, co-administration of JNK inhibitors, but not a MEK inhibitor, significantly attenuated ACM-induced phosphorylation of c-Jun(Ser-63) and blocked its neuroprotective action. Gel shift analysis demonstrated that ACM enhanced AP-1 binding, an effect that appears functionally important, since an AP-1 binding inhibitor significantly attenuated the neuroprotective action of ACM. Further studies implicated transforming growth factor (TGF)-beta1 and TGF-beta2 as critical active soluble factors released by astrocytes, since both were demonstrated in ACM, and immunoneutralization of the conditioned media with a panspecific TGF-beta antibody significantly attenuated the enhanced AP-1 binding and neuroprotective action of the ACM. Furthermore, exogenous application of TGF-beta1 and TGF-beta2 was found to enhance c-Jun(Ser-63) phosphorylation and to be neuroprotective, and co-administration of JNK inhibitors or an AP-1 binding inhibitor blocked TGF-beta-induced neuroprotection. Taken together, these studies suggest that astrocytes can protect neurons from serum deprivation-induced cell death, at least in part, by release of TGF-beta and activation of a c-Jun/AP-1 protective pathway.	Med Coll Georgia, Sch Med, Inst Mol Med & Genet, Program Neurobiol, Augusta, GA 30912 USA; Med Coll Georgia, Sch Med, Dept Neurol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Brann, DW (corresponding author), Med Coll Georgia, Sch Med, Inst Mol Med & Genet, Program Neurobiol, 1120 15th St, Augusta, GA 30912 USA.	dbrann@mail.mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117				AUSUBEL FM, 2003, CURRENT PROTOCOLS MO, V2; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Bruno V, 1998, J NEUROSCI, V18, P9594; Buchanan CD, 2000, BIOL REPROD, V62, P1710, DOI 10.1095/biolreprod62.6.1710; Butterworth NJ, 1996, MOL BRAIN RES, V43, P1, DOI 10.1016/S0169-328X(96)00143-X; Cho SH, 2001, J CEREBR BLOOD F MET, V21, P550, DOI 10.1097/00004647-200105000-00009; Chuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399-5618.2002.01179.x; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Dhandapani KM, 2003, EXP BIOL MED, V228, P253, DOI 10.1177/153537020322800303; Dhandapani KM, 2003, CELL BIOCHEM BIOPHYS, V39, P13, DOI 10.1385/CBB:39:1:13; Dhandapani KM, 2003, ENDOCRINE, V21, P59, DOI 10.1385/ENDO:21:1:59; Dragunow M, 2000, MOL BRAIN RES, V83, P20, DOI 10.1016/S0169-328X(00)00191-1; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Gomes FCA, 2001, BRAZ J MED BIOL RES, V34, P611, DOI 10.1590/S0100-879X2001000500008; HADMAN M, 1993, ONCOGENE, V8, P1895; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; HUGHES P, 1995, PHARMACOL REV, V47, P133; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kapinya K, 2000, BRAIN RES, V872, P282, DOI 10.1016/S0006-8993(00)02503-8; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; Largo C, 1996, NEUROL RES, V18, P445; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; Mena MA, 1996, NEUROREPORT, V7, P441, DOI 10.1097/00001756-199601310-00016; Messi E, 1999, NEUROSCI LETT, V270, P165, DOI 10.1016/S0304-3940(99)00501-7; Mizuno H, 1998, MOL BRAIN RES, V60, P28, DOI 10.1016/S0169-328X(98)00163-6; Nawashiro H, 2000, J CEREBR BLOOD F MET, V20, P1040, DOI 10.1097/00004647-200007000-00003; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; Palcy S, 2000, J BONE MINER RES, V15, P2352, DOI 10.1359/jbmr.2000.15.12.2352; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pennypacker KR, 2000, NEUROSCI LETT, V289, P1, DOI 10.1016/S0304-3940(00)01250-7; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Ren RF, 1996, BRAIN RES, V732, P16, DOI 10.1016/0006-8993(96)00458-1; Ren RF, 1997, MOL BRAIN RES, V48, P315, DOI 10.1016/S0169-328X(97)00108-3; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Shashoua VE, 2003, BRAIN RES, V963, P214, DOI 10.1016/S0006-8993(02)04058-1; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; Shklyaev SS, 2001, THYROID, V11, P629, DOI 10.1089/105072501750362691; SOMMER C, 1995, BRAIN PATHOL, V5, P135, DOI 10.1111/j.1750-3639.1995.tb00587.x; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Sortino MA, 1999, ENDOCRINOLOGY, V140, P4841, DOI 10.1210/en.140.10.4841; Sortino MA, 1996, ENDOCRINOLOGY, V137, P1418, DOI 10.1210/en.137.4.1418; TAKEMOTO O, 1995, STROKE, V26, P1639, DOI 10.1161/01.STR.26.9.1639; TAKESHITA A, 1995, J IMMUNOL, V155, P419; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Truettner J, 2002, MOL BRAIN RES, V103, P106, DOI 10.1016/S0169-328X(02)00191-2; Van den Pol AN, 2000, NEUROSCIENCE, V95, P603; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; Walton M, 1998, J NEUROSCI RES, V53, P330, DOI 10.1002/(SICI)1097-4547(19980801)53:3<330::AID-JNR7>3.0.CO;2-B; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; Yoneda Y, 1998, J NEUROSCI RES, V51, P574, DOI 10.1002/(SICI)1097-4547(19980301)51:5<574::AID-JNR4>3.0.CO;2-C; Yuan PX, 1999, J NEUROCHEM, V73, P2299, DOI 10.1046/j.1471-4159.1999.0732299.x; Zhu Y, 2001, NEUROCHEM INT, V38, P227, DOI 10.1016/S0197-0186(00)00084-X	68	112	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43329	43339		10.1074/jbc.M305835200	http://dx.doi.org/10.1074/jbc.M305835200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12888549	hybrid			2022-12-25	WOS:000186157000076
J	Angelaccio, S; Chiaraluce, R; Consalvi, V; Buchenau, B; Giangiacomo, L; Bossa, F; Contestabile, R				Angelaccio, S; Chiaraluce, R; Consalvi, V; Buchenau, B; Giangiacomo, L; Bossa, F; Contestabile, R			Catalytic and thermodynamic properties of tetrahydromethanopterindependent serine hydroxymethyltransferase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SECONDARY STRUCTURE; ANGSTROM RESOLUTION; NEURAL-NETWORK; D-ALANINE; PURIFICATION; TRANSHYDROXYMETHYLASE; BINDING	The reaction catalyzed by serine hydroxymethyltransferase (SHMT), the transfer of Cbeta of serine to tetrahydropteroylglutamate, represents in Eucarya and Eubacteria a major source of one-carbon (C-1) units for several essential biosynthetic processes. In many Archaea, C-1 units are carried by modified pterin-containing compounds, which, although structurally related to tetrahydropteroylglutamate, play a distinct functional role. Tetrahydromethanopterin, and a few variants of this compound, are the modified folates of methanogenic and sulfate-reducing Archaea. Little information on SHMT from Archaea is available, and the metabolic role of the enzyme in these organisms is not clear. This contribution reports on the purification and characterization of recombinant SHMT from the hyperthermophilic methanogen Methanococcus jannaschii. The enzyme was characterized with respect to its catalytic, spectroscopic, and thermodynamic properties. Tetrahydromethanopterin was found to be the preferential pteridine substrate. Tetrahydropteroylglutamate could also take part in the hydroxymethyltransferase reaction, although with a much lower efficiency. The catalytic features of the enzyme with substrate analogues and in the absence of a pteridine substrate were also very similar to those of SHMT isolated from Eucarya or Eubacteria. On the other hand, the M. jannaschii enzyme showed increased thermoactivity and resistance to denaturating agents with respect to the enzyme purified from mesophilic sources. The results reported suggest that the active site structure and the mechanism of SHMT are conserved in the enzyme from M. jannaschii, which appear to differ only in its ability to bind and use a modified folate as substrate and increased thermal stability.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, Ctr Eccellenza Biol & Med Mol, I-00185 Rome, Italy; Univ Marburg, Max Planck Inst Terr Mikrobiol, D-35043 Marburg, Germany; Univ Marburg, Fachbereich Biol, Mikrobiol Lab, D-35043 Marburg, Germany	Sapienza University Rome; Sapienza University Rome; Max Planck Society; Philipps University Marburg; Philipps University Marburg	Contestabile, R (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Angelaccio, Sebastiana/D-2842-2011; Contestabile, Roberto/J-3467-2019; consalvi, valerio/F-1918-2011; Chiaraluce, Roberta/F-1920-2011	Contestabile, Roberto/0000-0002-5235-9993; 				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; [Anonymous], 1998, COMPREHENSIVE BIOL C; ARRIODUPONT M, 1971, BIOCHEM BIOPH RES CO, V44, P653, DOI 10.1016/S0006-291X(71)80133-X; Bertoldi M, 2002, BIOCHEMISTRY-US, V41, P9153, DOI 10.1021/bi025649q; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; CHEN MS, 1973, J BIOL CHEM, V248, P7979; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DelleFratte S, 1997, J BACTERIOL, V179, P7456, DOI 10.1128/jb.179.23.7456-7461.1997; Fu TF, 2003, J BIOL CHEM, V278, P2645, DOI 10.1074/jbc.M210649200; Fu TF, 2001, ANAL BIOCHEM, V290, P359, DOI 10.1006/abio.2001.4994; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HOYT JC, 1986, ARCH MICROBIOL, V145, P153, DOI 10.1007/BF00446773; Ionescu RM, 2000, BIOCHEMISTRY-US, V39, P9540, DOI 10.1021/bi000511y; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON WC, 1992, METHOD ENZYMOL, V210, P426; Lin ZS, 1998, CAN J MICROBIOL, V44, P652, DOI 10.1139/cjm-44-7-652; MADEN BE, 2000, BIOCHEM J, V350, P509; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Paiardini A, 2003, PROTEINS, V50, P122, DOI 10.1002/prot.10268; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; Rost B, 1996, METHOD ENZYMOL, V266, P525; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Scarsdale JN, 2000, J MOL BIOL, V296, P155, DOI 10.1006/jmbi.1999.3453; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH L, 1964, J BIOL CHEM, V239, P3801; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; SHALTIEL S, 1970, BIOCHEM BIOPH RES CO, V41, P594, DOI 10.1016/0006-291X(70)90054-9; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; Szebenyi DME, 2000, BIOCHEMISTRY-US, V39, P13313, DOI 10.1021/bi000635a; Trivedi V, 2002, J BIOL CHEM, V277, P17161, DOI 10.1074/jbc.M111976200; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; Vorholt JA, 1998, J BACTERIOL, V180, P5351, DOI 10.1128/JB.180.20.5351-5356.1998; Wasserfallen A, 2000, INT J SYST EVOL MICR, V50, P43, DOI 10.1099/00207713-50-1-43; WHITE RH, 1991, J BACTERIOL, V173, P1987, DOI 10.1128/jb.173.6.1987-1991.1991; Wyman J, 1943, J BIOL CHEM, V147, P297	42	23	25	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41789	41797		10.1074/jbc.M306747200	http://dx.doi.org/10.1074/jbc.M306747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902326	hybrid			2022-12-25	WOS:000185989500030
J	Kim, SJ; Hwang, SG; Kim, IC; Chun, JS				Kim, SJ; Hwang, SG; Kim, IC; Chun, JS			Actin cytoskeletal architecture regulates nitric oxide-induced apoptosis, dedifferentiation, and cyclooxygenase-2 expression in articular chondrocytes via mitogen-activated protein kinase and protein kinase C pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROSTAGLANDIN E-2; RETINOIC ACID; GROWTH-FACTOR; MESSENGER-RNA; IN-VITRO; F-ACTIN; DISRUPTION; ALPHA; PHENOTYPE	Nitric oxide (NO) in articular chondrocytes regulates differentiation, survival, and inflammatory responses by modulating ERK-1 and -2, p38 kinase, and protein kinase C (PKC) alpha and zeta. In this study, we investigated the effects of the actin cytoskeletal architecture on NO-induced dedifferentiation, apoptosis, cyclooxygenase (COX)-2 expression, and prostaglandin E-2 production in articular chondrocytes, with a focus on ERK-1/-2, p38 kinase, and PKC signaling. Disruption of the actin cytoskeleton by cytochalasin D (CD) inhibited NO-induced apoptosis, dedifferentiation, COX-2 expression, and prostaglandin E-2 production in chondrocytes cultured on plastic or during cartilage explants culture. CD treatment did not affect ERK-1/-2 activation but blocked the signaling events necessary for NO-induced dedifferentiation, apoptosis, and COX-2 expression such as activation of p38 kinase and inhibition of PKCalpha and -zeta. CD also suppressed activation of downstream signaling of p38 kinase and PKC, such as NF-kappaB activation, p53 accumulation, and caspase-3 activation, which are necessary for NO-induced apoptosis. NO production in articular chondrocytes caused down-regulation of phosphatidylinositol (PI) 3-kinase and Akt activities. The down-regulation of PI 3-kinase and Akt was blocked by CD treatment, and the CD effects on apoptosis, p38 kinase, and PKCalpha and -zeta were abolished by the inhibition of PI 3-kinase with LY294002. Our results collectively indicate that the actin cytoskeleton mediates NO-induced regulatory effects in chondrocytes by modulating down-regulation of PI 3-kinase and Akt, activation of p38 kinase, and inhibition of PKCalpha and -zeta.	Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea; Kongju Natl Univ, Dept Biol Sci, Gongju 314701, Chungnam, South Korea	Gwangju Institute of Science & Technology (GIST); Kongju National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea.	jschun@kjist.ac.kr						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281-199905000-00009; Bando M, 2002, BIOCHEM BIOPH RES CO, V290, P268, DOI 10.1006/bbrc.2001.6199; BENYA PD, 1988, J CELL BIOL, V106, P161, DOI 10.1083/jcb.106.1.161; BENYA PD, 1993, EXP CELL RES, V204, P268, DOI 10.1006/excr.1993.1033; BROWN PD, 1988, J CELL BIOL, V106, P171, DOI 10.1083/jcb.106.1.171; Cash DE, 1997, J CELL BIOL, V136, P445, DOI 10.1083/jcb.136.2.445; Clancy R, 1999, OSTEOARTHR CARTILAGE, V7, P399, DOI 10.1053/joca.1998.0223; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Demoor-Fossard M, 1998, BBA-GENE STRUCT EXPR, V1398, P179, DOI 10.1016/S0167-4781(98)00044-X; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Huh YH, 2003, J BIOL CHEM, V278, P9691, DOI 10.1074/jbc.M211360200; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Karino A, 1996, FEBS LETT, V398, P317, DOI 10.1016/S0014-5793(96)01266-5; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kim JA, 2002, NEUROPHARMACOLOGY, V42, P1109, DOI 10.1016/S0028-3908(02)00052-7; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Korichneva I, 1999, J CELL SCI, V112, P2521; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1051, P266, DOI 10.1016/0167-4889(90)90132-W; Lim YB, 2000, BIOCHEM BIOPH RES CO, V273, P609, DOI 10.1006/bbrc.2000.2987; Lim YB, 2003, J CELL BIOCHEM, V88, P713, DOI 10.1002/jcb.10389; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LOTY S, 1995, BIOL CELL, V83, P149, DOI 10.1016/0248-4900(96)81303-7; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Melamed I, 1999, CELL IMMUNOL, V194, P136, DOI 10.1006/cimm.1999.1506; Oh CD, 2003, J BIOL CHEM, V278, P36563, DOI 10.1074/jbc.M304857200; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sawyer SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1038, DOI 10.1152/ajpcell.2001.281.3.C1038; Schwartz Z, 1998, ENDOCRINOLOGY, V139, P1825, DOI 10.1210/en.139.4.1825; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Suria H, 1999, LIFE SCI, V65, P2697, DOI 10.1016/S0024-3205(99)00538-X; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; Vinall RL, 2002, EXP CELL RES, V272, P32, DOI 10.1006/excr.2001.5395; Weston AD, 2000, J CELL BIOL, V148, P679, DOI 10.1083/jcb.148.4.679; White SR, 2001, AM J RESP CELL MOL, V24, P282, DOI 10.1165/ajrcmb.24.3.3995; Yamazaki Y, 2000, EXP CELL RES, V259, P64, DOI 10.1006/excr.2000.4970; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115	53	66	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42448	42456		10.1074/jbc.M304887200	http://dx.doi.org/10.1074/jbc.M304887200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907684	hybrid			2022-12-25	WOS:000185989500109
J	Onuma, M; Bub, JD; Rummel, TL; Iwamoto, Y				Onuma, M; Bub, JD; Rummel, TL; Iwamoto, Y			Prostate cancer cell-adipocyte interaction - Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; NECROSIS-FACTOR-ALPHA; N-TERMINAL KINASE; PROTEIN-KINASE; INSULIN-RESISTANCE; ACTIVATION DOMAIN; RECEPTOR ISOFORMS; BODY-WEIGHT; OB/OB MICE; OBESE GENE	Prostate cancer is one of the leading causes of death among men in the United States, and acquisition of hormone resistance (androgen independence) by cancer cells is a fatal event during the natural history of prostate cancer. Obesity is another serious health problem and has been shown to be associated with prostate cancer. However, little is known about the molecular basis of this association. Here we show that factor(s) secreted from adipocytes stimulate prostate cancer cell proliferation. Leptin is one of the major adipose cytokines, and it controls body weight homeostasis through food intake and energy expenditure. We identify leptin as a novel growth factor in androgen-independent prostate cancer cell growth. Strikingly, leptin stimulates cell proliferation specifically in androgen-independent DU145 and PC-3 prostate cancer cells but not in androgen-dependent LNCaP-FGC cells, although both cell types express functional leptin receptor isoforms. c-Jun NH2-terminal kinase (JNK) has been shown recently to play a crucial role in obesity and insulin resistance. Intriguingly, leptin induces JNK activation in androgen-independent prostate cancer cells, and the pharmacological inhibition of JNK blocked the leptin stimulation of androgen-independent prostate cancer cell proliferation. This suggests that JNK activation is required for leptin-mediated, androgen-independent prostate cancer cell proliferation. Furthermore, other cytokines produced by adipocytes and critical for body weight homeostasis cooperate with leptin in androgen-independent prostate cancer cell proliferation: interleukin-6 and insulin-like growth factor I demonstrate additive and synergistic effects on the leptin stimulation of androgen-independent prostate cancer cell proliferation, respectively. Therefore, adipose cytokines, as well as JNK, are key mediators between obesity and hormone-resistant prostate cancer and could be therapeutic targets.	Med Coll Wisconsin, Dept Urol, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Iwamoto, Y (corresponding author), Med Coll Wisconsin, Dept Urol, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA.	yiwamoto@mcw.edu						Amling CL, 2001, UROLOGY, V58, P723, DOI 10.1016/S0090-4295(01)01373-5; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chung TDK, 1999, PROSTATE, V38, P199; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Frank S, 2000, J CLIN INVEST, V106, P501, DOI 10.1172/JCI9148; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Furuya Y, 1998, Int J Urol, V5, P134, DOI 10.1111/j.1442-2042.1998.tb00261.x; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hsing AW, 2000, CANCER EPIDEM BIOMAR, V9, P1335; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; Kaicer E, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104819; KEY T, 1995, CANCER SURV, V23, P63; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Mix H, 2000, GUT, V47, P481, DOI 10.1136/gut.47.4.481; Mizokami A, 2000, J UROLOGY, V164, P800, DOI 10.1016/S0022-5347(05)67318-1; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Mori S, 1999, BIOCHEM BIOPH RES CO, V257, P609, DOI 10.1006/bbrc.1999.0515; Okamoto M, 1997, CANCER RES, V57, P141; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Platz EA, 2002, J NUTR, V132, p3471S, DOI 10.1093/jn/132.11.3471S; Potapova O, 2002, CANCER RES, V62, P3257; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ring BD, 2000, ENDOCRINOLOGY, V141, P446, DOI 10.1210/en.141.1.446; Rodriguez C, 2001, CANCER EPIDEM BIOMAR, V10, P345; Schnabl B, 2001, HEPATOLOGY, V34, P953, DOI 10.1053/jhep.2001.28790; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimizu H, 1997, PEPTIDES, V18, P1263, DOI 10.1016/S0196-9781(97)00137-X; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Stattin P, 2001, J CLIN ENDOCR METAB, V86, P1341, DOI 10.1210/jc.86.3.1341; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Zachow RJ, 1997, ENDOCRINOLOGY, V138, P847, DOI 10.1210/en.138.2.847; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	146	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42660	42667		10.1074/jbc.M304984200	http://dx.doi.org/10.1074/jbc.M304984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12902351	hybrid			2022-12-25	WOS:000185989500132
J	Miller, MT; Gerratana, B; Stapon, A; Townsend, CA; Rosenzweig, AC				Miller, MT; Gerratana, B; Stapon, A; Townsend, CA; Rosenzweig, AC			Crystal structure of carbapenam synthetase (CarA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM SYNTHETASE; KINETIC MECHANISM; BIOSYNTHESIS; PROGRAM; SUBSTRATE; SYNTHASE; SERRATIA; REVEALS; GENES	Carbapenam synthetase (CarA) is an ATP/Mg2+-dependent enzyme that catalyzes formation of the beta-lactam ring in (5R)-carbapenem-3-carboxylic acid biosynthesis. CarA is homologous to beta-lactam synthetase (beta-LS), which is involved in clavulanic acid biosynthesis. The catalytic cycles of CarA and beta-LS mediate substrate adenylation followed by beta-lactamization via a tetrahedral intermediate or transition state. Another member of this family of ATP/Mg2+-dependent enzymes, asparagine synthetase (AS-B), catalyzes intermolecular, rather than intramolecular, amide bond formation in asparagine biosynthesis. The crystal structures of apo-CarA and CarA complexed with the substrate (2S,5S)-5-carboxymethylproline (CMPr), ATP analog alpha,beta-methyleneadenosine 5'-triphosphate (AMP-CPP), and a single Mg2+ ion have been determined. CarA forms a tetramer. Each monomer resembles beta-LS and AS-B in overall fold, but key differences are observed. The N-terminal domain lacks the glutaminase active site found in AS-B, and an extended loop region not observed in beta-LS or AS-B is present. Comparison of the C-terminal synthetase active site to that in beta-LS reveals that the ATP binding site is highly conserved. By contrast, variations in the substrate binding pocket reflect the different substrates of the two enzymes. The Mg2+ coordination is also different. Several key residues in the active site are conserved between CarA and beta-LS, supporting proposed roles in beta-lactam formation. These data provide further insight into the structures of this class of enzymes and suggest that CarA might be a versatile target for protein engineering experiments aimed at developing improved production methods and new carbapenem antibiotics.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	Northwestern University; Northwestern University; Johns Hopkins University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	amyr@northwestern.edu	Gerratana, Barbara/B-7448-2009	Stapon, Anthony/0000-0002-7858-1613	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014937, R37AI014937] Funding Source: NIH RePORTER; NIAID NIH HHS [AI14937] Funding Source: Medline; NIGMS NIH HHS [GM008061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann BO, 2000, BIOCHEMISTRY-US, V39, P11187, DOI 10.1021/bi000709i; Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boehlein SK, 1998, BIOCHEMISTRY-US, V37, P13230, DOI 10.1021/bi981058h; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clifton IJ, 2003, J BIOL CHEM, V278, P20843, DOI 10.1074/jbc.M213054200; Coulton S, 1996, Prog Med Chem, V33, P99, DOI 10.1016/S0079-6468(08)70304-7; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Gerratana B, 2003, BIOCHEMISTRY-US, V42, P7836, DOI 10.1021/bi034361d; HAYNIE DT, 2001, BIOL THERMODYNAMICS, P127; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li RF, 2000, J AM CHEM SOC, V122, P9296, DOI 10.1021/ja001723l; McGowan SJ, 1999, ANTON LEEUW INT J G, V75, P135, DOI 10.1023/A:1001768428383; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; McGowan SJ, 1997, MOL MICROBIOL, V26, P545, DOI 10.1046/j.1365-2958.1997.6001974.x; McGowan SJ, 1998, TRENDS MICROBIOL, V6, P203, DOI 10.1016/S0966-842X(98)01251-7; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller MT, 2002, P NATL ACAD SCI USA, V99, P14752, DOI 10.1073/pnas.232361199; Miller MT, 2001, NAT STRUCT BIOL, V8, P684, DOI 10.1038/90394; NEU HC, 1994, CURR OPIN INFECT DIS, V7, pS3; PARKER WL, 1982, J ANTIBIOT, V35, P653, DOI 10.7164/antibiotics.35.653; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; SALOWE SP, 1990, BIOCHEMISTRY-US, V29, P6499, DOI 10.1021/bi00479a023; Stapon A, 2003, J AM CHEM SOC, V125, P8486, DOI 10.1021/ja034248a; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thomson NR, 2000, MOL MICROBIOL, V36, P539, DOI 10.1046/j.1365-2958.2000.01872.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	36	34	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40996	41002		10.1074/jbc.M307901200	http://dx.doi.org/10.1074/jbc.M307901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890666	hybrid			2022-12-25	WOS:000185847200073
J	Zhao, XX; Carnevale, KA; Cathcart, MK				Zhao, XX; Carnevale, KA; Cathcart, MK			Human monocytes use Rac1, not Rac2, in the NADPH oxidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; COMPONENTS P47(PHOX); HUMAN NEUTROPHILS; P67(PHOX); ACTIVATION; BINDING; TRANSLOCATION; GTP; PHOSPHORYLATION; DISSOCIATION	Phagocyte NADPH oxidase is critical for defense against pathogens and contributes to inflammatory tissue injury. One component of the NADPH oxidase complex is the small GTP-binding protein Rac. There are two isoforms of Rac, and Rac2 is the predominant isoform in neutrophils and has been shown to be essential for NADPH oxidase activity. In primary human monocytes we report that in contrast to neutrophils, Rac1 is the predominantly expressed isoform. Upon monocyte activation by a variety of agents, we found that Rac1 dissociates from Rho GDP dissociation inhibitor ( RhoGDI) and translocates to the membrane. We also found that Rac1 interacts with two other NADPH oxidase components, p67phox and p47phox, upon monocyte activation. These data indicate that Rac1, and not Rac2, is a component of the activated NADPH oxidase in monocytes. This finding suggests that it may be possible to selectively interfere with either monocyte or neutrophil NADPH oxidase activity, thereby selectively targeting chronic versus acute inflammatory processes.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cathcart, MK (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL61971, HL51068] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051068, R01HL061971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; DUSI S, 1995, BIOCHEM J, V308, P991, DOI 10.1042/bj3080991; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; Forbes LV, 1999, FEBS LETT, V449, P225, DOI 10.1016/S0014-5793(99)00444-5; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JOHNSTON RB, 1981, METHODS STUDYING MON, P489; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matos P, 2000, BIOCHEM BIOPH RES CO, V277, P741, DOI 10.1006/bbrc.2000.3743; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	29	82	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40788	40792		10.1074/jbc.M302208200	http://dx.doi.org/10.1074/jbc.M302208200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12912997	hybrid			2022-12-25	WOS:000185847200047
J	Brouillard, F; Cremisi, CE				Brouillard, F; Cremisi, CE			Concomitant increase of histone acetyltransferase activity and degradation of p300 during retinoic acid-induced differentiation of F9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-MEDIATED DEGRADATION; DEPENDENT PROTEIN-KINASE; CREB-BINDING PROTEIN; COACTIVATORS P300; HORMONE-RECEPTOR; DISTINCT ROLES; CBP; PHOSPHORYLATION; INHIBITION; ACTIVATION	The p300 and closely related CBP histone acetyltransferases (HAT) function as global transcriptional co-activators that play roles in many cell differentiation and signal transduction pathways. Despite their similarities, p300 and CBP have distinct functions during retinoic acid-induced differentiation of mouse F9 embryonal carcinoma cells. F9 cells constitute a well established model system for investigating the first steps of early development and retinoic acid signaling ex vivo. p300, but not CBP, was shown to be essential for F9 differentiation. In this study we have investigated the regulation of p300 during F9 differentiation. We report a dramatic decrease of p300, but not CBP protein levels, after 48 h of retinoic acid treatment. p300 is degraded via the ubiquitin-proteasome pathway. Although the large majority of p300 is degraded, its global HAT activity stays constant during F9 differentiation, which means that its specific HAT activity increases considerably. p300 is strongly phosphorylated in both undifferentiated and differentiated F9 cells; its HAT activity, however, is independent of phosphorylation before differentiation and becomes dependent on phosphorylation during differentiation. Furthermore, we show that protein kinase A affects p300 HAT activity both in vivo and in vitro as well as p300 phosphorylation in differentiated cells. Thus, we show that p300 is differentially phosphorylated in undifferentiated versus differentiated cells and that the changes in phosphorylation affect its HAT activity. Moreover, our study suggests an explanation for the functional switch of p300-mediated repression versus activation during F9 differentiation.	CNRS, UPR 9079, Ligue Natl Contre Canc, Inst Andre Lwoff, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Cremisi, CE (corresponding author), CNRS, UPR 9079, Ligue Natl Contre Canc, Inst Andre Lwoff, 7 Rue Guy Moquet, F-94800 Villejuif, France.	cremisi@vjf.cnrs.fr						Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goodman RH, 2000, GENE DEV, V14, P1553; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Li Q, 2002, MOL ENDOCRINOL, V16, P2819, DOI 10.1210/me.2002-0154; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; Muniz M, 1996, J BIOL CHEM, V271, P30935, DOI 10.1074/jbc.271.48.30935; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ota M, 1998, CELL GROWTH DIFFER, V9, P989; Perletti L, 2001, BMC Mol Biol, V2, P4, DOI 10.1186/1471-2199-2-4; PLET A, 1985, DIFFERENTIATION, V30, P159, DOI 10.1111/j.1432-0436.1985.tb00527.x; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	36	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39509	39516		10.1074/jbc.M307123200	http://dx.doi.org/10.1074/jbc.M307123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888559	hybrid			2022-12-25	WOS:000185713800031
J	Hanson, ES; Rawlins, ML; Leibold, EA				Hanson, ES; Rawlins, ML; Leibold, EA			Oxygen and iron regulation of iron regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; ELEMENT-BINDING PROTEIN; PROLYL 4-HYDROXYLASES; ACONITASE ACTIVITY; MOLECULAR CONTROL; HIF-ALPHA; DEGRADATION; HYDROXYLATION/; INHIBITION; FAMILY	Iron regulatory protein 2 (IRP2) is a central regulator of cellular iron homeostasis due to its regulation of specific mRNAs encoding proteins of iron uptake and storage. Iron regulates IRP2 by mediating its rapid proteasomal degradation, where hypoxia and the hypoxia mimetics CoCl2 and desferrioxamine (DFO) stabilize it. Previous studies showed that iron-mediated degradation of IRP2 requires the presence of critical cysteines that reside within a 73-amino acid unique region. Here we show that a mutant IRP2 protein lacking this 73-amino acid region degraded at a rate similar to that of wild-type IRP2. In addition, DFO and hypoxia blocked the degradation of both the wild- type and mutant IRP2 proteins. Recently, members of the 2-oxoglutarate (2-OG)- dependent dioxygenase family have been shown to hydroxylate hypoxia-inducible factor-1alpha (HIF-1alpha), a modification required for its ubiquitination and proteasomal degradation. Since 2-OG-dependent dioxygenases require iron and oxygen, in addition to 2-OG, for substrate hydroxylation, we hypothesized that this activity may be involved in the regulation of IRP2 stability. To test this we used the 2-OG-dependent dioxygenase inhibitor dimethyloxalylglycine (DMOG) and showed that it blocked iron-mediated IRP2 degradation. In addition, hypoxia, DFO and DMOG blocked IRP2 ubiquitination. These data indicate that the region of IRP2 that is involved in IRP2 iron-mediated degradation lies outside of the 73-amino acid unique region and suggest a model whereby 2-OG-dependent dioxygenase activity may be involved in the oxygen and iron regulation of IRP2 protein stability.	Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Div Hematol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Hanson, ES (corresponding author), Univ Utah, Eccles Program Human Mol Biol & Genet, 15 N 2030 E Rm 4200, Salt Lake City, UT 84112 USA.				NIDDK NIH HHS [DK02960] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CUNLIFFE CJ, 1992, J MED CHEM, V35, P2652, DOI 10.1021/jm00092a016; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	32	128	133	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40337	40342		10.1074/jbc.M302798200	http://dx.doi.org/10.1074/jbc.M302798200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888568	hybrid			2022-12-25	WOS:000185713800127
J	Hewetson, A; Chilton, BS				Hewetson, A; Chilton, BS			An Sp1-NF-Y/progesterone receptor DNA binding-dependent mechanism regulates progesterone-induced transcriptional activation of the rabbit RUSH/SMARCA3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWNSTREAM PROMOTER ELEMENT; NEGATIVE AUTOREGULATION; UTEROGLOBIN PROMOTER; INHIBITOR-1 GENE; NF-Y; EXPRESSION; PROLACTIN; CLONING; SP1; PROTEINS	Steroids regulate alternative splicing of rabbit RUSH/SMARCA3, an SWI/SNF-related transcription factor. Transactivation was evaluated in 2057 bp of genomic sequence. Truncation analysis identified a minimal 252-bp region with strong basal promoter activity in transient transfection assays. The size of the 5'-untranslated region (233 bp) and the transcription start site were determined by primer extension analysis. The transcription start site mapped to a consensus initiator (Inr) element in a TATA-less region with a downstream promoter element (+29). These elements were authenticated by mutation/deletion analysis. The Inr/downstream promoter element combination is conserved in the putative core promoter (-35/+35) of the human ortholog, suggesting that transcription initiation is similarly conserved. Two Sp1 sites that are also conserved in the putative promoter of human SMARCA3 and a RUSH binding site (-616/-611) that is unique to the rabbit promoter repress basal transcription. These sites were variously authenticated by gel shift and chromatin immunoprecipitation assays. Analysis of the proximal promoter showed the -162/+90 region was required for progesterone responsiveness in transient transfection assays. Subsequent mutation/deletion analysis revealed a progesterone receptor half-site mediated induction by progesterone. An overlapping Y-box (in the reverse AT-TGG orientation) repressed basal transcription and progesterone-induced transcriptional activation in the presence of the Sp1 sites. The specificity of progesterone receptor and transcription factor NF-Y binding were authenticated by gel shift assays. Chromatin immunoprecipitation assays confirmed the Y-box effects were mediated in a DNA binding-dependent fashion. This represents a unique regulatory scenario in which ligand-dependent transactivation by the progesterone receptor is subject to Sp1/NF-Y repression.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Chilton, BS (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, 3601 4th St,Mail Stop 6540, Lubbock, TX 79430 USA.			Chilton, Beverly/0000-0002-8066-8697	NICHD NIH HHS [HD29457] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029457] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; AVIA H, 1972, P NATL ACAD SCI USA, V69, P1408; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CHILTON BS, 1988, MOL ENDOCRINOL, V2, P1169, DOI 10.1210/mend-2-12-1169; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Croager EJ, 2000, AM J PATHOL, V156, P1723, DOI 10.1016/S0002-9440(10)65043-2; Devine JH, 1999, MOL CELL ENDOCRINOL, V151, P49, DOI 10.1016/S0303-7207(99)00013-1; Ding H, 1998, HUM MOL GENET, V7, P1681, DOI 10.1093/hmg/7.11.1681; Ding H, 1996, DNA CELL BIOL, V15, P429, DOI 10.1089/dna.1996.15.429; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Farsetti A, 2001, ENDOCRINOLOGY, V142, P3380, DOI 10.1210/en.142.8.3380; FLISS AE, 1991, ENDOCRINOLOGY, V129, P697, DOI 10.1210/endo-129-2-697; Gong XH, 1997, DEV BIOL, V183, P166, DOI 10.1006/dbio.1996.8486; HAMMINK M, 1990, ONCOGENE, V5, P1843; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HaywardLester A, 1996, MOL ENDOCRINOL, V10, P1335, DOI 10.1210/me.10.11.1335; Hewetson A, 1997, MOL CELL ENDOCRINOL, V136, P1, DOI 10.1016/S0303-7207(97)00203-7; Hewetson A, 2002, MOL ENDOCRINOL, V16, P2101, DOI 10.1210/me.2002-0064; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; KLEISSANFRANCISCO S, 1993, MOL ENDOCRINOL, V7, P214, DOI 10.1210/me.7.2.214; Krikun G, 2002, J SOC GYNECOL INVEST, V9, P329, DOI 10.1016/S1071-5576(02)00168-5; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; LI WI, 1989, ENDOCRINOLOGY, V125, P2862, DOI 10.1210/endo-125-6-2862; Mahajan MC, 2002, BLOOD, V99, P348, DOI 10.1182/blood.V99.1.348; Mallick S, 1997, DNA CELL BIOL, V16, P807, DOI 10.1089/dna.1997.16.807; Mansharamani M, 2001, J BIOL CHEM, V276, P3641, DOI 10.1074/jbc.M004231200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MUKHERJEE AB, 1993, MOL CELL ENDOCRINOL, V94, P15; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; SHERIDAN PL, 1995, J BIOL CHEM, V270, P4575, DOI 10.1074/jbc.270.9.4575; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Zhang Q, 1997, GENE, V202, P31, DOI 10.1016/S0378-1119(97)00446-0; Zhou TY, 2001, J BIOL CHEM, V276, P25503, DOI 10.1074/jbc.M102875200	41	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40177	40185		10.1074/jbc.M303921200	http://dx.doi.org/10.1074/jbc.M303921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890680	hybrid			2022-12-25	WOS:000185713800111
J	Ortega, A; Ferrer, P; Carretero, J; Obrador, E; Asensi, M; Pellicer, JA; Estrela, JM				Ortega, A; Ferrer, P; Carretero, J; Obrador, E; Asensi, M; Pellicer, JA; Estrela, JM			Down-regulation of glutathione and Bcl-2 synthesis in mouse B16 melanoma cells avoids their survival during interaction with the vascular endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; HEPATIC SINUSOIDAL ENDOTHELIUM; CANCER-CELLS; IN-VITRO; ANTISENSE OLIGONUCLEOTIDES; HEMATOGENOUS METASTASIS; MITOCHONDRIAL-FUNCTION; INDUCED APOPTOSIS; REDOX REGULATION; SCID MICE	B16 melanoma (B16M) cells with high GSH content show high metastatic activity. However, the molecular mechanisms linking GSH to metastatic cell survival are unclear. The possible relationship between GSH and the ability of Bcl-2 to prevent cell death was studied in B16M cells with high (F10) and low (F1) metastatic potential. Analysis of a Bcl-2 family of genes revealed that B16M-F10 cells, as compared with B16M-F1 cells, overexpressed preferentially Bcl-2 ( similar to 5.7-fold). Hepatic sinusoidal endothelium-induced B16M-F10 cytotoxicity in vitro increased from similar to 19% ( controls) to similar to 97% in GSH-depleted B16M-F10 cells treated with an antisense Bcl-2 oligodeoxynucleotide (Bcl-2-AS). L-Buthionine (S,R)-sulfoximine-induced GSH depletion or Bcl-2-AS decreased the metastatic growth of B16M-F10 cells in the liver. However, the combination of L-buthionine (S,R)-sulfoximine and Bcl-2-AS abolished metastatic invasion. Bcl-2-overexpressing B16M-F1/Tet-Bcl-2 and B16M-F10/Tet-Bcl-2 cells, as compared with controls, showed an increase in GSH content, no change in the rate of GSH synthesis, and a decrease in GSH efflux. Thus, Bcl-2 overexpression may increase metastatic cell resistance against oxidative/nitrosative stress by inhibiting release of GSH. In addition, Bcl-2 availability regulates the mitochondrial GSH (mtGSH)-dependent opening of the permeability transition pore complex. Death in B16M-F10 cells was sharply activated at mtGSH levels below 30% of controls values. However, this critical threshold increased to similar to60% of control values in Bcl-2-AS-treated B16M-F10 cells. GSH ester-induced replenishment of mtGSH levels ( even under conditions of cytosolic GSH depletion) prevented cell death. Our results indicate that survival of B16M cells with high metastatic potential can be challenged by inhibiting their GSH and Bcl-2 synthesis.	Univ Valencia, Dept Physiol, Valencia 46010, Spain	University of Valencia	Estrela, JM (corresponding author), Univ Valencia, Dept Physiol, Av Blasco Ibanez 17, Valencia 46010, Spain.	jose.m.estrela@uv.es	Carretero, Julian/N-5214-2014; Miralles, Miguel A Asensi/I-2756-2015; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Estrela, Jose/H-4449-2015; OBRADOR, ELENA/H-4069-2015; Ortega, Angel L./A-4113-2014	Carretero, Julian/0000-0001-7269-8506; Miralles, Miguel A Asensi/0000-0003-1922-7777; Estrela, Jose/0000-0002-2540-9190; OBRADOR, ELENA/0000-0002-5934-5543; Ortega, Angel L./0000-0002-9901-3383				Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Baliga BC, 2002, HEMATOL ONCOL, V20, P63, DOI 10.1002/hon.685; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; BOUWENS L, 1988, CANCER IMMUNOL IMMUN, V27, P137; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carretero J, 2001, J BIOL CHEM, V276, P25775, DOI 10.1074/jbc.M101148200; Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; de Menezes DEL, 2000, CLIN CANCER RES, V6, P2891; Dias N, 2002, EUR J PHARM BIOPHARM, V54, P263, DOI 10.1016/S0939-6411(02)00060-7; Eissa S, 1998, CLIN CHEM, V44, P1423; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gross A, 2001, IUBMB LIFE, V52, P231, DOI 10.1080/15216540152846046; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hickman JA, 2002, CURR OPIN GENET DEV, V12, P67, DOI 10.1016/S0959-437X(01)00266-0; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jansen B, 2002, LANCET ONCOL, V3, P672, DOI 10.1016/S1470-2045(02)00903-8; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kaplowitz N, 1996, BIOL CHEM H-S, V377, P267; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P471, DOI 10.1073/pnas.86.2.471; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Miyake H, 1999, CANCER RES, V59, P4030; *NIH, 1985, GUID CAR US LAB AN; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; Obrador E, 2001, FREE RADICAL BIO MED, V31, P642, DOI 10.1016/S0891-5849(01)00622-0; Ogretmen B, 1996, INT J CANCER, V67, P608, DOI 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y; Ortega AL, 2003, J BIOL CHEM, V278, P13888, DOI 10.1074/jbc.M207140200; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Petrovic AS, 1998, BLOOD, V91, P3952, DOI 10.1182/blood.V91.10.3952.3952_3952_3961; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Rudin CM, 2003, CANCER RES, V63, P312; Rui M, 2002, LIFE SCI, V71, P1771, DOI 10.1016/S0024-3205(02)01943-4; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takeda K, 2001, CELL IMMUNOL, V214, P194, DOI 10.1006/cimm.2001.1896; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; VANDENBREKEL AJS, 1995, J CLIN ONCOL, V13, P2600, DOI 10.1200/JCO.1995.13.10.2600; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; WEISS L, 1992, CANCER METAST REV, V11, P227, DOI 10.1007/BF01307179; Weiss L, 1990, Adv Cancer Res, V54, P159, DOI 10.1016/S0065-230X(08)60811-8; WEISS L, 1992, INT J CANCER, V50, P103, DOI 10.1002/ijc.2910500121; Wong CW, 2001, CANCER RES, V61, P333; Yaziji H, 2003, INT J SURG PATHOL, V11, P11, DOI 10.1177/106689690301100103; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	64	43	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39591	39599		10.1074/jbc.M303753200	http://dx.doi.org/10.1074/jbc.M303753200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881529	hybrid			2022-12-25	WOS:000185713800042
J	Rhie, A; Kirby, L; Sayer, N; Wellesley, R; Disterer, P; Sylvester, I; Gill, A; Hope, J; James, W; Tahiri-Alaoui, A				Rhie, A; Kirby, L; Sayer, N; Wellesley, R; Disterer, P; Sylvester, I; Gill, A; Hope, J; James, W; Tahiri-Alaoui, A			Characterization of 2 '-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; NMR STRUCTURE; NUCLEOCAPSID PROTEIN; SPONGIFORM ENCEPHALOPATHIES; PEPTIDE PRP106-126; SCRAPIE ISOFORM; N-TERMINUS; PRP; RNA; AGGREGATION	We have isolated artificial ligands or aptamers for infectious prions in order to investigate conformational aspects of prion pathogenesis. The aptamers are 2'-fluoro-modified RNA produced by in vitro selection from a large, randomized library. One of these ligands (aptamer SAF-93) had more than 10-fold higher affinity for PrPSc than for recombinant PrPC and inhibited the accumulation of PrPres in near physiological cell-free conversion assay. To understand the molecular basis of these properties and to distinguish specific from nonspecific aptamer-PrP interactions, we studied deletion mutants of bovine PrP in denatured, alpha-helix-rich and beta-sheet-rich forms. We provide evidence that, like scrapie-associated fibrils (SAF), the beta-oligomer of PrP bound to SAF-93 with at least 10-fold higher affinity than did the alpha-form. This differential affinity could be explained by the existence of two binding sites within the PrP molecule. Site 1 lies within residues 23-110 in the unstructured N terminus and is a nonspecific RNA binding site found in all forms of PrP. The region between residue 90 and 110 forms a hinge region that is occluded in the alpha-rich form of PrP but becomes exposed in the denatured form of PrP. Site 2 lies in the region C-terminal of residue 110. This site is beta-sheet conformation-specific and is not recognized by control RNAs. Taken together, these data provide for the first time a specific ligand for a disease conformation-associated site in a region of PrP critical for conformational conversion. This aptamer could provide tools for the further analysis of the processes of PrP misfolding during prion disease and leads for the development of diagnostic and therapeutic approaches to TSEs.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Inst Anim Hlth, Newbury RG20 7NN, Berks, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Tahiri-Alaoui, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		james, william/H-4289-2013; Hope, James/C-4966-2011; Gill, Andrew C/A-5219-2009; Gill, ANdrew/GRO-1248-2022; Disterer, Petra/C-9709-2014	james, william/0000-0002-2506-1198; Gill, Andrew C/0000-0001-5201-9473; Disterer, Petra/0000-0001-9702-9974	Biotechnology and Biological Sciences Research Council [BBS/E/I/00000973, BBS/E/I/00000877] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ADAMS TE, 1992, GENE, V122, P371, DOI 10.1016/0378-1119(92)90229-I; AKOWITZ A, 1994, NUCLEIC ACIDS RES, V22, P1101, DOI 10.1093/nar/22.6.1101; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 2000, BIOCHEM J, V346, P785, DOI 10.1042/0264-6021:3460785; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; HEIDENREICH O, 1995, NUCLEIC ACIDS RES, V23, P2223, DOI 10.1093/nar/23.12.2223; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; Kirby L, 2003, J GEN VIROL, V84, P1013, DOI 10.1099/vir.0.18903-0; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X; Nandi PK, 1998, ARCH VIROL, V143, P1251, DOI 10.1007/s007050050373; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; Singh N, 2002, FRONT BIOSCI-LANDMRK, V7, pA60, DOI 10.2741/singh; SKLAVIADIS T, 1993, P NATL ACAD SCI USA, V90, P5713, DOI 10.1073/pnas.90.12.5713; Steitz TA, 1999, RNA WORLD, P427; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Tahiri-Alaoui A, 2003, PROTEIN SCI, V12, P600, DOI 10.1110/ps.0236703; Tahiri-Alaoui A, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e45; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuerk C, 1997, Methods Mol Biol, V67, P219; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	58	151	168	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39697	39705		10.1074/jbc.M305297200	http://dx.doi.org/10.1074/jbc.M305297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12902353	hybrid, Green Accepted			2022-12-25	WOS:000185713800055
J	Yahata, Y; Shirakata, Y; Tokumaru, S; Yamasaki, K; Sayama, K; Hanakawa, Y; Detmar, M; Hashimoto, K				Yahata, Y; Shirakata, Y; Tokumaru, S; Yamasaki, K; Sayama, K; Hanakawa, Y; Detmar, M; Hashimoto, K			Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SIGNAL-TRANSDUCTION; EMBRYONIC LETHALITY; FACTOR VEGF; MAP KINASE; VASCULOGENESIS; ANGIOGENESIS; ACTIVATION; GENE; IDENTIFICATION	Vascular endothelial growth factor (VEGF) is a potent, multifunctional, endothelial-cell-specific growth factor. It stimulates proliferation and migration of endothelial cells. Characterization of intracellular signal transduction after VEGF and VEGF receptor (VEGFR) interaction has demonstrated the involvement of the mitogen-activated protein kinase pathway. However, several studies indicated that signal transducers and activators of transcription (STAT) is another important pathway downstream of VEGF/VEGFR interaction. Therefore, we studied the role of STAT3 in the migration and tube formation of the human dermal microvascular endothelial cells (HDMEC). HDMEC expressed phosphorylated forms of STAT1, STAT3, and STAT5, and a marked increase of phosphorylated STAT3 in the nuclear fraction after addition of VEGF was observed by Western blot and immunohistochemical staining. To verify the functional implication of STAT3 phosphorylation in HDMEC migration, we introduced a dominant-negative STAT3 using adenovirus vector system. Dominant-negative STAT3 abolished the VEGF-induced nuclear translocation of phosphorylated STAT3 and inhibited HDMEC migration completely. Dominant-negative STAT3 also suppressed VEGF-induced HDMEC tube formation on Matrigel and on collagen gel. These data demonstrate that STAT3 and its phosphorylation are involved in the downstream pathway of VEGF/VEGFR interaction and regulate VEGF-induced HDMEC migration and tube formation.	Ehime Univ, Sch Med, Dept Dermatol, Onsen, Ehime 7910295, Japan; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Ehime University; Harvard University; Massachusetts General Hospital; Harvard University	Shirakata, Y (corresponding author), Ehime Univ, Sch Med, Dept Dermatol, Onsen, Ehime 7910295, Japan.		Yamasaki, Kenshi/C-8905-2018	Yamasaki, Kenshi/0000-0002-5495-4956				Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Blair RJ, 1997, J CLIN INVEST, V99, P2691, DOI 10.1172/JCI119458; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; ORTEGA N, 1999, FRONT BIOSCI, V4, P141; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SIMORREPINATEL V, 1994, INVEST OPHTH VIS SCI, V35, P3393; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566	43	143	162	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40026	40031		10.1074/jbc.M301866200	http://dx.doi.org/10.1074/jbc.M301866200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874294	hybrid			2022-12-25	WOS:000185713800092
J	Pappalardo, L; Janausch, IG; Vijayan, V; Zientz, E; Junker, J; Peti, W; Zweckstetter, M; Unden, G; Griesinger, C				Pappalardo, L; Janausch, IG; Vijayan, V; Zientz, E; Junker, J; Peti, W; Zweckstetter, M; Unden, G; Griesinger, C			The NMR structure of the sensory domain of the membranous two-component fumarate sensor (histidine protein kinase) DcuS of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; DIPOLAR COUPLINGS; GENE-EXPRESSION; RECEPTOR; SYSTEM; ALIGNMENT	The structure of the water-soluble, periplasmic domain of the fumarate sensor DcuS (DcuS-pd) has been determined by NMR spectroscopy in solution. DcuS is a prototype for a sensory histidine kinase with transmembrane signal transfer. DcuS belongs to the CitA family of sensors that are specific for sensing di- and tricarboxylates. The periplasmic domain is folded autonomously and shows helices at the N and the C terminus, suggesting direct linking or connection to helices in the two transmembrane regions. The structure constitutes a novel fold. The nearest structural neighbor is the Per-Arnt-Sim domain of the photoactive yellow protein that binds small molecules covalently. Residues Arg(107), His(110), and Arg(147) are essential for fumarate sensing and are found clustered together. The structure constitutes the first periplasmic domain of a two component sensory system and is distinctly different from the aspartate sensory domain of the Tar chemotaxis sensor.	Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Mainz, Inst Mikrobiol & Weinforsch, D-55099 Mainz, Germany	Max Planck Society; Johannes Gutenberg University of Mainz	Griesinger, C (corresponding author), Max Planck Inst Biophys Chem, Fassberg 11, D-37077 Gottingen, Germany.		Junker, Jochen/B-4487-2009; Pappalardo, Lucia/ABA-9311-2020; Peti, Wolfgang/L-3492-2014	Junker, Jochen/0000-0003-4002-4405; Pappalardo, Lucia/0000-0002-4491-2082; vijayan, vinesh/0000-0001-5483-1860; Zweckstetter, Markus/0000-0002-2536-6581				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863; Chou JJ, 2001, J AM CHEM SOC, V123, P3844, DOI 10.1021/ja015660y; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Golby P, 1999, J BACTERIOL, V181, P1238, DOI 10.1128/JB.181.4.1238-1248.1999; Hansen MR, 1998, J AM CHEM SOC, V120, P11210, DOI 10.1021/ja9829665; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Janausch IG, 2002, J BIOL CHEM, V277, P39809, DOI 10.1074/jbc.M204482200; Janausch IG, 2002, BBA-BIOENERGETICS, V1553, P39, DOI 10.1016/S0005-2728(01)00233-X; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Koradi R, 1996, J MOL GRAPHICS, V14, P29; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Parac TN, 2001, J BIOMOL NMR, V19, P91, DOI 10.1023/A:1008301425100; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; VUISTER GW, 1992, J AM CHEM SOC, V114, P9674, DOI 10.1021/ja00050a066; YEH JI, 1993, J BIOL CHEM, V268, P9787; Zientz E, 1998, J BACTERIOL, V180, P5421, DOI 10.1128/JB.180.20.5421-5425.1998; Zweckstetter M, 2001, J BIOMOL NMR, V20, P365, DOI 10.1023/A:1011263920003	22	87	89	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39185	39188		10.1074/jbc.C300344200	http://dx.doi.org/10.1074/jbc.C300344200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12907689	Green Published, hybrid			2022-12-25	WOS:000185575100132
J	Wood, A; Schneider, J; Dover, J; Johnston, M; Shilatifard, A				Wood, A; Schneider, J; Dover, J; Johnston, M; Shilatifard, A			The Paf1 complex is essential for histone monoubiquitination by the Rad6-Bre1 complex, which signals for histone methylation by COMPASS and Dot1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ELONGATION; GENE-EXPRESSION; H3 METHYLATION; ACTIVE GENES; SET DOMAIN; IN-VIVO; YEAST; UBIQUITINATION	Monoubiquitination of histone H2B, catalyzed by Rad6-Bre1, is required for methylation of histone H3 on lysines 4 and 79, catalyzed by the Set1-containing complex COMPASS and Dot1p, respectively. The Paf1 protein complex, which associates with RNA polymerase II, is known to be required for these histone H3 methylation events. During the early elongation stage of transcription, the Paf1 complex is required for association of COMPASS with RNA polymerase II, but the role the Paf1 complex plays at the promoter has not been clear. We present evidence that the Paf1 complex is required for monoubiquitination of histone H2B at promoters. Strains deleted for several components of the Paf1 complex are defective in monoubiquitination of histone H2B, which results in the loss of methylation of lysines 4 and 79 of histone H3. We also show that Paf1 complex is required for the interaction of Rad6 and COMPASS with RNA polymerase II. Finally, we show that the Paf1 complex is required for Rad6-Bre1 catalytic activity but not for the recruitment of Rad6-Bre1 to promoters. Thus, in addition to its role during the elongation phase of transcription, the Paf1 complex appears to activate the function but not the placement of the Rad6-Bre1 ubiquitin-protein ligase at the promoters of active genes.	St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Ctr Canc, St Louis, MO 63104 USA	Saint Louis University; Washington University (WUSTL); Saint Louis University	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; 	NATIONAL CANCER INSTITUTE [R01CA089455] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA089455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Porter SE, 2002, EUKARYOT CELL, V1, P830, DOI 10.1128/EC.1.5.830-842.2002; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schaft D, 2003, NUCLEIC ACIDS RES, V31, P2475, DOI 10.1093/nar/gkg372; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X	33	281	288	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34739	34742		10.1074/jbc.C300269200	http://dx.doi.org/10.1074/jbc.C300269200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12876294	hybrid			2022-12-25	WOS:000185164400002
J	Fieger, CB; Sassetti, CM; Rosen, SD				Fieger, CB; Sassetti, CM; Rosen, SD			Endoglycan, a member of the CD34 family, functions as an L-selectin ligand through modification with tyrosine sulfation and sialyl Lewis x	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; P-SELECTIN; GLYCOPROTEIN LIGAND; LEUKOCYTE ACCUMULATION; VASCULAR ADDRESSIN; EXPRESSION CLONING; HUMAN NEUTROPHILS; O-GLYCANS; IDENTIFICATION; DISTINCT	During lymphocyte homing to secondary lymphoid organs and instances of inflammatory trafficking, the rolling of leukocytes on vascular endothelium is mediated by transient interactions between L-selectin on leukocytes and several carbohydrate-modified ligands on the endothelium. Most L-selectin ligands such as CD34 and podocalyxin present sulfated carbohydrate structures (6-sulfated sialyl Lewis x or 6-sulfo-sLex) as a recognition determinant within their heavily glycosylated mucin domains. We recently identified endoglycan as a new member of the CD34 family. We report here that endoglycan, like the two other members of this family (CD34 and podocalyxin) can function as a L-selectin ligand. However, endoglycan employs a different binding mechanism, interacting with L-selectin through sulfation on two tyrosine residues and O-linked sLex structures that are presented within its highly acidic amino-terminal region. Our analysis establishes striking parallels with PSGL-1, a leukocyte ligand that interacts with all three selectins, mediating leukocyte-endothelial, leukocyte-leukocyte, and platelet-leukocyte interactions. Since the distribution of endoglycan includes hematopoietic precursors and leukocyte subpopulations, in addition to endothelial cells, our findings suggest several potential settings for endoglycan-mediated adhesion events.	Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, Program Immunol, Box 0452,513 Parnasus Ave, San Francisco, CA 94143 USA.	sdr@itsa.ucsf.edu		Rosen, Steven/0000-0002-6245-701X	NIGMS NIH HHS [R37GM23547, GM57411] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057411, R37GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, J BIOL CHEM, V266, P14869; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; Doyonnas R, 2001, J EXP MED, V194, P13, DOI 10.1084/jem.194.1.13; Eriksson EE, 2001, J EXP MED, V194, P205, DOI 10.1084/jem.194.2.205; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; Galustian C, 2002, IMMUNOLOGY, V105, P350, DOI 10.1046/j.1365-2567.2002.01369.x; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hirata T, 2002, J IMMUNOL, V169, P4307, DOI 10.4049/jimmunol.169.8.4307; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; Kanamori A, 2002, J BIOL CHEM, V277, P32578, DOI 10.1074/jbc.M204400200; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LEY K, 1993, BLOOD, V82, P1632; McEver RP, 1997, J CLIN INVEST, V100, pS97; McNagny KM, 1997, J CELL BIOL, V138, P1395, DOI 10.1083/jcb.138.6.1395; MITOMA J, 2003, J BIOL CHEM; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramos CL, 1998, BLOOD, V91, P1067, DOI 10.1182/blood.V91.3.1067.1067_1067_1075; Rodgers SD, 2001, BIOPHYS J, V81, P2001, DOI 10.1016/S0006-3495(01)75850-X; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Samulowitz U, 2002, AM J PATHOL, V160, P1669, DOI 10.1016/S0002-9440(10)61114-5; Sassetti C, 2000, J BIOL CHEM, V275, P9001, DOI 10.1074/jbc.275.12.9001; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SASSETTI C, 1999, THESIS U CALIFORNIA; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; Xia LJ, 2002, J CLIN INVEST, V109, P939; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	53	55	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27390	27398		10.1074/jbc.M304204200	http://dx.doi.org/10.1074/jbc.M304204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12889478	hybrid			2022-12-25	WOS:000184242700009
J	de Bruin, A; Maiti, B; Jakoi, L; Timmers, C; Buerki, R; Leone, G				de Bruin, A; Maiti, B; Jakoi, L; Timmers, C; Buerki, R; Leone, G			Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; ARABIDOPSIS; PROTEINS; COMPLEX; GENE; RB	The mammalian E2F family of transcription factors plays a crucial role in the regulation of cellular proliferation, apoptosis, and differentiation. Consistent with its biological role in a number of important cellular processes, E2F regulates the expression of genes involved in cell cycle, DNA replication, DNA repair, and mitosis. It has proven difficult, however, to determine the specific roles played by the various known family members in these cellular processes. The work presented here now extends the complexity of this family even further by the identification of a novel E2F family member, which we now term E2F7. Like the expression of the known E2F activators, E2F1, E2F2, and E2F3, the expression of E2F7 is growth-regulated, at least in part, through E2F binding elements on its promoter, and its protein product is localized to the nucleus and associates with DNA E2F recognition sites with high affinity. A number of salient features, however, make this member unique among the E2F family. First, the E2F7 gene encodes a protein that possesses two distinct DNA-binding domains and that lacks a dimerization domain as well as a transcriptional activation and a retinoblastoma-binding domain. In contrast to the E2F activators, E2F7 can block the E2F-dependent activation of a subset of E2F target genes as well as mitigate cellular proliferation of mouse embryo fibroblasts. These findings identify E2F7 as a novel member of the mammalian E2F transcription factor family that has properties of a transcriptional repressor capable of negatively influencing cellular proliferation.	Ohio State Univ, Dept Mol Virol Immunol & Med genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Mol Genet, Columbus, OH 43210 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Genet, Durham, NC 27710 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Duke University; Howard Hughes Medical Institute	Leone, G (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med genet, Human Canc Genet Program, Columbus, OH 43210 USA.		de Bruin, Alain/AAL-9195-2020	de Bruin, Alain/0000-0001-8579-2649				Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Mariconti L, 2002, J BIOL CHEM, V277, P9911, DOI 10.1074/jbc.M110616200; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	18	161	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42041	42049		10.1074/jbc.M308105200	http://dx.doi.org/10.1074/jbc.M308105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12893818	hybrid			2022-12-25	WOS:000185989500060
J	Takahashi, T; Yamashita, H; Nagano, Y; Nakamura, T; Ohmori, H; Avraham, H; Avraham, S; Yasuda, M; Matsumoto, M				Takahashi, T; Yamashita, H; Nagano, Y; Nakamura, T; Ohmori, H; Avraham, H; Avraham, S; Yasuda, M; Matsumoto, M			Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-synuclein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PARKINSONS-DISEASE; BINDING-PROTEIN; LEWY BODIES; HUMAN BRAIN; SRC-FAMILY; PYK2; EXPRESSION; SYSTEM; STRESS	alpha-Synuclein is a presynaptic protein involved in the pathogenesis of several neurodegenerative diseases, such as Parkinson's disease. Pyk2/related adhesion focal tyrosine kinase (RAFTK) tyrosine kinase is an upstream regulator of Src family kinases in the central nervous system that is involved in alpha-synuclein phosphorylation. The present study reports the cloning and characterization of a novel adaptor protein, Pyk2/RAFTK-associated protein (PRAP), that specifically binds to Pyk2/RAFTK and inhibits alpha-synuclein tyrosine phosphorylation. PRAP contains a coiled-coil domain, a pleckstrin homology domain, and a SH3 domain; the SH3 domain binds to the proline-rich domain of Pyk2/RAFTK. PRAP was observed to be present throughout the brain, including substantia nigra dopaminergic neurons, in which it localized to the cytoplasm. PRAP was found to function as a substrate for Src family kinases, such as c-Src or Fyn, but not for Pyk2/RAFTK. Hyperosmotic stress induced phosphorylation of tyrosine 125 of alpha-synuclein via Pyk2/RAFTK, which acted through Src family kinases. Such phosphorylation was inhibited by PRAP expression, suggesting that PRAP negatively regulates alpha-synuclein phosphorylation following cell stress. In conclusion, PRAP functions as a downstream target for Pyk2/RAFTK and plays a role in alpha-synuclein phosphorylation.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, Hiroshima 7348551, Japan; Hiroshima Int Univ, Fac Hlth Sci, Dept Clin Engn, Hiroshima 7290695, Japan; Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Hiroshima University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Yamashita, H (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			Avraham, Hava/0000-0002-7545-3640; NAGANO, YOSHITO/0000-0002-7974-4824				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Andreev J, 1999, MOL CELL BIOL, V19, P2338; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Kouroku Y, 1998, BIOCHEM BIOPH RES CO, V252, P738, DOI 10.1006/bbrc.1998.9637; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; Menegon A, 1999, EUR J NEUROSCI, V11, P3777, DOI 10.1046/j.1460-9568.1999.00798.x; Nagano Y, 2001, NEUROSCI LETT, V316, P103, DOI 10.1016/S0304-3940(01)02330-8; Nakamura T, 2002, FEBS LETT, V521, P190, DOI 10.1016/S0014-5793(02)02861-2; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Ohmori H, 1999, J NEUROCHEM, V72, P1497, DOI 10.1046/j.1471-4159.1999.721497.x; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Verney C, 2001, J COMP NEUROL, V429, P45, DOI 10.1002/1096-9861(20000101)429:1<45::AID-CNE4>3.0.CO;2-J; Yamashita H, 1999, J BIOL CHEM, V274, P29897, DOI 10.1074/jbc.274.42.29897; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	35	25	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42225	42233		10.1074/jbc.M213217200	http://dx.doi.org/10.1074/jbc.M213217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12893833	hybrid			2022-12-25	WOS:000185989500081
J	Busse, M; Kusche-Gullberg, M				Busse, M; Kusche-Gullberg, M			In vitro polymerization of heparan sulfate backbone by the EXT proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; D-GLUCOSAMINYLTRANSFERASE REACTIONS; TUMOR SUPPRESSORS EXT1; GENE FAMILY; GOLGI-APPARATUS; BIOSYNTHESIS; GLYCOSAMINOGLYCANS; GLUCURONOSYLTRANSFERASE; IDENTIFICATION; PROTEOGLYCANS	Multiple exosotoses is a dominantly inherited bone disorder caused by defects in EXT1 and EXT2, genes encoding glycosyltransferases involved in heparan sulfate chain elongation. Heparan sulfate polymerization occurs by the alternating addition of glucuronic acid and N-acetylglucosamine units to the nonreducing end of the polysaccharide. EXT1 and EXT2 are suggested to be dual glucuronyl/N-acetylglucosaminyltransferases, and a heterooligomeric complex of EXT1 and EXT2 (EXT1/2) is considered to be the biological functional polymerization unit. Here, we have investigated the in vitro polymerization capacities of recombinant soluble EXT1, EXT2, and EXT1/2 complex on exogenous oligosaccharide acceptors derived from Escherichia coli K5 capsular polysaccharide. Incubations of recombinant EXT1 or EXT1/2 complex with H-3-labeled oligosaccharide acceptors and the appropriate nucleotide sugars resulted in conversion of the acceptors to higher molecular weight compounds but with different efficacies for EXT1 and EXT1/2. In contrast, incubations with recombinant EXT2 resulted in the addition of a single glucuronic acid but no further polymerization. These results indicate that EXT1 alone and the EXT1/2 heterocomplex can act as heparan sulfate polymerases in vitro without the addition of additional auxiliary proteins.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Uppsala University	Kusche-Gullberg, M (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, Box 582, S-75123 Uppsala, Sweden.	Marion.Kusche@imbim.uu.se	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V268, P860, DOI 10.1006/bbrc.2000.2219; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; LIND T, 1993, J BIOL CHEM, V268, P20705; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Wei G, 2000, J BIOL CHEM, V275, P27733; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; Wuyts W, 1996, HUM MOL GENET, V5, P1547, DOI 10.1093/hmg/5.10.1547; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	30	52	53	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41333	41337		10.1074/jbc.M308314200	http://dx.doi.org/10.1074/jbc.M308314200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12907669	hybrid			2022-12-25	WOS:000185847200113
J	Susan-Resiga, D; Nowak, T				Susan-Resiga, D; Nowak, T			Monitoring active site alterations upon mutation of yeast pyruvate kinase using Tl-205(+) NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; MONO-VALENT; ACTIVATION	The interaction of the monovalent cation with wild type (WT) yeast pyruvate kinase (YPK) and with the T298S, T298C, and T298A mutants was investigated by Tl-205(+) NMR to monitor possible structural alterations at the active site by Thr-298 mutation. TlNO3 activates WT YPK with a k(cat) value similar to that obtained with KCl and an apparent K-a of 0.96 +/- 0.07 mM in the presence of Mn2+ and fructose 1,6-bisphosphate. With the three mutants, Tl+ is a better activator than is K+ based on k(cat) values. Tl+ activation and inhibition of YPK is affected by mutation of the active site Thr-298. The effect of Mn2+ on the 1/T-1 value of Tl-205(+) in the presence of the WT and mutant YPK complexes was determined at 173 MHz (300 MHz, H-1) and 346 MHz (600 MHz, H-1). For each complex studied, 1/pT(2p) >> 1/pT(1p) and 1/pT(1p) is frequency-dependent suggesting fast exchange conditions. The values of 1/pT(1p) differ for each mutant. A correlation time of 0.65 +/- 0.35 ns was estimated for the Mn2+-Tl-205(+) interaction. The Tl+-Mn2+ distances at the active site of YPK were calculated from the paramagnetic contribution of Mn2+ to 1/T-1M of YPK- bound Tl-205(+). The calculated Tl+-Mn2+ distance for the Thr-298 mutants is decreased by about 1 Angstrom from 6.0 +/- 0.2 Angstrom observed with WT. The results suggest conformational alterations at the active site of YPK where phosphoryl transfer occurs upon mutation of Thr-298. These conformational changes may, in part, explain the alteration in k(cat) and k(cat)/K-m,K-PEP observed with the Thr-298 mutants.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Nowak, T (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.		Susan-Resiga@ircm.qc.ca, Delia/O-2548-2017	Susan-Resiga@ircm.qc.ca, Delia/0000-0002-4856-090X	NIDDK NIH HHS [DK 17049] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017049] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLERHAND A, 1971, J CHEM PHYS, V55, P189, DOI 10.1063/1.1675508; BLOEMBERGEN N, 1957, J CHEM PHYS, V27, P572, DOI 10.1063/1.1743771; BOLLENBACH TJ, 1999, THESIS U NOTRE DAME; Boyer Paul D., 1942, JOUR BIOL CHEM, V146, P673; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; DWEK RA, 1973, MONOGRAPHS PHYSICAL, P174; HINTON JF, 1987, MAGN RESON CHEM, V25, P659, DOI 10.1002/mrc.1260250802; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KAYNE FJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P232, DOI 10.1016/0003-9861(71)90204-9; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; LORD KA, 1987, INORG CHEM, V26, P1464, DOI 10.1021/ic00256a032; Loria JP, 1998, BIOCHEMISTRY-US, V37, P6967, DOI 10.1021/bi972454n; MARKHAM GD, 1986, J BIOL CHEM, V261, P1507; MCNALLY T, 1989, FEBS LETT, V247, P312, DOI 10.1016/0014-5793(89)81359-6; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6803, DOI 10.1021/bi962870s; MILDVAN AS, 1970, ADV ENZYMOL REL S BI, V33, P1; NOWAK T, 1972, BIOCHEMISTRY-US, V11, P2819, DOI 10.1021/bi00765a014; NOWAK T, 1981, MOL CELL BIOCHEM, V35, P65, DOI 10.1007/BF02354821; NOWAK T, 1981, SPECTROSCOPY BIOCH, V2, P109; Pauling L, 1935, P NATL ACAD SCI USA, V21, P186, DOI 10.1073/pnas.21.4.186; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P5481, DOI 10.1021/bi00565a003; REUBEN J, 1971, J BIOL CHEM, V246, P6227; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; STENGLE TR, 1967, COORDIN CHEM REV, V2, P349; Susan-Resiga D, 2003, J BIOL CHEM, V278, P12660, DOI 10.1074/jbc.M300257200	25	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40943	40952		10.1074/jbc.M306068200	http://dx.doi.org/10.1074/jbc.M306068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882975	hybrid			2022-12-25	WOS:000185847200066
J	Hol, EM; van Dijk, R; Gerez, L; Sluijs, JA; Hobo, B; Tonk, MT; de Haan, A; Kamphorst, W; Fischer, DF; Benne, R; van Leeuwen, FW				Hol, EM; van Dijk, R; Gerez, L; Sluijs, JA; Hobo, B; Tonk, MT; de Haan, A; Kamphorst, W; Fischer, DF; Benne, R; van Leeuwen, FW			Frameshifted beta-amyloid precursor protein (APP(+1)) is a secretory protein, and the level of APP(+1) in cerebrospinal fluid is linked to Alzheimer pathology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MILD COGNITIVE IMPAIRMENT; BIOCHEMICAL MARKERS; DISEASE PATIENTS; ALPHA-SECRETASE; HUMAN-BRAIN; TAU; DEMENTIA; CULTURES; CELLS	Molecular misreading of the beta-amyloid precursor protein (APP) gene generates mRNA with dinucleotide deletions in GAGAG motifs. The resulting truncated and partly frameshifted APP protein ( APP(+1)) accumulates in the dystrophic neurites and the neurofibrillary tangles in the cortex and hippocampus of Alzheimer patients. In contrast, we show here that neuronal cells transfected with APP(+1) proficiently secreted APP(+1). Because various secretory APP isoforms are present in cerebrospinal fluid (CSF), this study aimed to determine whether APP(+1) is also a secretory protein that can be detected in CSF. Post-mortem CSF was obtained at autopsy from 50 non-demented controls and 122 Alzheimer patients; all subjects were staged for neuropathology (Braak score). Unexpectedly, we found that the APP(+1) level in the CSF of non-demented controls was much higher (1.75 ng/ml) than in the CSF of Alzheimer patients (0.51 ng/ml) ( p < 0.001), and the level of APP(+1) in CSF was inversely correlated with the severity of the neuropathology. Moreover the earliest neuropathological changes are already reflected in a significant decrease of the APP(+1) level in CSF. These data show that APP(+1) is normally secreted by neurons, preventing intraneuronal accumulation of APP(+1) in brains of nondemented controls without neurofibrillary pathology.	Netherlands Inst Brain Res, Grad Sch Neurosci, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Pathol, NL-1081 HV Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Hol, EM (corresponding author), Netherlands Inst Brain Res, Grad Sch Neurosci, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.		Hol, Elly/J-2025-2019; Hol, Elly M/F-1891-2013	Hol, Elly/0000-0001-5604-2603; Hol, Elly M/0000-0001-5604-2603; Fischer, David/0000-0002-6690-0197				Alafuzoff I, 1993, J Neural Transm Suppl, V39, P235; Andreasen N, 2002, PEPTIDES, V23, P1205, DOI 10.1016/S0196-9781(02)00056-6; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conover WJ, 1980, PRACTICAL NONPARAMET, P229; Cummings JL, 2002, JAMA-J AM MED ASSOC, V287, P2335, DOI 10.1001/jama.287.18.2335; de Leon MJ, 2002, NEUROSCI LETT, V333, P183, DOI 10.1016/S0304-3940(02)01038-8; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hersberger M, 2001, J NEUROCHEM, V76, P1308, DOI 10.1046/j.1471-4159.2001.00122.x; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Hol EM, 1998, PROG BRAIN RES, V117, P379; Hook VYH, 2002, J NEUROCHEM, V81, P237; Khachaturian ZS, 2002, NEUROBIOL AGING, V23, P509, DOI 10.1016/S0197-4580(01)00350-5; Klunk WE, 2002, NEUROBIOL AGING, V23, P517, DOI 10.1016/S0197-4580(01)00349-9; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; MAY C, 1990, NEUROLOGY, V40, P500, DOI 10.1212/WNL.40.3_Part_1.500; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; Papassotiropoulos A, 2002, NEUROBIOL AGING, V23, P513, DOI 10.1016/S0197-4580(01)00348-7; Peraus GC, 1997, J NEUROSCI, V17, P7714; RAVID R, 1992, PROG BRAIN RES, V93, P83; Riemenschneider M, 2002, ARCH NEUROL-CHICAGO, V59, P1729, DOI 10.1001/archneur.59.11.1729; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sennvik K, 2000, NEUROSCI LETT, V278, P169, DOI 10.1016/S0304-3940(99)00929-5; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Sjogren M, 2001, J NEUROL NEUROSUR PS, V70, P624, DOI 10.1136/jnnp.70.5.624; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Storey E, 1999, EUR J NEUROSCI, V11, P1779, DOI 10.1046/j.1460-9568.1999.00599.x; TANNA NK, 1991, RADIOLOGY, V178, P123, DOI 10.1148/radiology.178.1.1984290; Teunissen CE, 2002, NEUROBIOL AGING, V23, P485, DOI 10.1016/S0197-4580(01)00328-1; van den Hurk WH, 2001, J BIOL CHEM, V276, P11496, DOI 10.1074/jbc.M011040200; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Zhou JN, 2003, J PINEAL RES, V35, P125, DOI 10.1034/j.1600-079X.2003.00065.x	38	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39637	39643		10.1074/jbc.M302295200	http://dx.doi.org/10.1074/jbc.M302295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900421	hybrid			2022-12-25	WOS:000185713800048
J	Zhang, L; Joshi, AK; Smith, S				Zhang, L; Joshi, AK; Smith, S			Cloning, expression, characterization, and interaction of two components of a human mitochondrial fatty acid synthase - Malonyltransferase and acyl carrier protein.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA DECARBOXYLASE; ESCHERICHIA-COLI; LIPOIC ACID; SACCHAROMYCES-CEREVISIAE; ACETYL-COA; COENZYME-A; RAT-LIVER; SUBSTRATE-SPECIFICITY; HEART-MITOCHONDRIA; MOLECULAR-CLONING	The possibility that human cells contain, in addition to the cytosolic type I fatty acid synthase complex, a mitochondrial type II malonyl-CoA-dependent system for the biosynthesis of fatty acids has been examined by cloning, expressing, and characterizing two putative components. Candidate coding sequences for a malonyl-CoA: acyl carrier protein transacylase (malonyltransferase) and its acyl carrier protein substrate, identified by BLAST searches of the human sequence data base, were located on nuclear chromosomes 22 and 16, respectively. The encoded proteins localized exclusively in mitochondria only when the putative N-terminal mitochondrial targeting sequences were present as revealed by confocal microscopy of HeLa cells infected with appropriate green fluorescent protein fusion constructs. The mature, processed forms of the mitochondrial proteins were expressed in Sf9 cells and purified, the acyl carrier protein was converted to the holoform in vitro using purified human phosphopantetheinyltransferase, and the functional interaction of the two proteins was studied. Compared with the dual specificity malonyl/acetyltransferase component of the cytosolic type I fatty acid synthase, the type II mitochondrial counterpart exhibits a relatively narrow substrate specificity for both the acyl donor and acyl carrier protein acceptor. Thus, it forms a covalent acyl-enzyme complex only when incubated with malonyl-CoA and transfers exclusively malonyl moieties to the mitochondrial holoacyl carrier protein. The type II acyl carrier protein from Bacillus subtilis, but not the acyl carrier protein derived from the human cytosolic type I fatty acid synthase, can also function as an acceptor for the mitochondrial transferase. These data provide compelling evidence that human mitochondria contain a malonyl-CoA/acyl carrier protein-dependent fatty acid synthase system, distinct from the type I cytosolic fatty acid synthase, that resembles the type II system present in prokaryotes and plastids. The final products of this system, yet to be identified, may play an important role in mitochondrial function.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Smith, S (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; CHRIST EJV, 1968, BIOCHIM BIOPHYS ACTA, V152, P50, DOI 10.1016/0005-2760(68)90007-6; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Dyck JRB, 2000, BIOCHEM J, V350, P599, DOI 10.1042/0264-6021:3500599; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; HARINGTON A, 1993, MOL MICROBIOL, V9, P545, DOI 10.1111/j.1365-2958.1993.tb01715.x; JANG SH, 1989, J BIOL CHEM, V264, P3500; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; Joshi AK, 2003, J BIOL CHEM, V278, P33142, DOI 10.1074/jbc.M305459200; JOSHI AK, 1993, BIOCHEM J, V296, P143, DOI 10.1042/bj2960143; JOSHI VC, 1971, ARCH BIOCHEM BIOPHYS, V143, P493, DOI 10.1016/0003-9861(71)90234-7; Jung JW, 2000, PROTEIN SCI, V9, P1294, DOI 10.1110/ps.9.7.1294; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; MCCARTHY AD, 1983, FEBS LETT, V160, P296, DOI 10.1016/0014-5793(83)80986-7; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; Morikawa T, 2001, FEBS LETT, V498, P16, DOI 10.1016/S0014-5793(01)02469-3; PODACK ER, 1972, BIOCHIM BIOPHYS ACTA, V280, P235, DOI 10.1016/0005-2760(72)90090-2; QUAGLIARIELLO E, 1968, BIOCHIM BIOPHYS ACTA, V164, P12, DOI 10.1016/0005-2760(68)90066-0; Rangan V., 2003, BIOCH LIPIDS LIPOPRO, P151; Rangan VS, 1996, J BIOL CHEM, V271, P31749, DOI 10.1074/jbc.271.49.31749; Rangan VS, 1997, PROTEIN ENG, V10, P561, DOI 10.1093/protein/10.5.561; Rangan VS, 1997, J BIOL CHEM, V272, P11975, DOI 10.1074/jbc.272.18.11975; Reed MAC, 2003, ORG BIOMOL CHEM, V1, P463, DOI 10.1039/b208941f; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; SEUBERT W, 1973, MOL CELL BIOCHEM, V1, P29, DOI 10.1007/BF01659936; SEUBERT W, 1959, ANGEW CHEM, V69, P359; STAACK H, 1980, LIPIDS, V15, P175, DOI 10.1007/BF02540965; STERN A, 1982, J BIOL CHEM, V257, P799; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; SWOFFORD DL, 2000, PAUP PHYLOGENETIC AN; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Triepels R, 1999, J INHERIT METAB DIS, V22, P163, DOI 10.1023/A:1005402020569; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; WAKIL SJ, 1961, J LIPID RES, V2, P1; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; WHEREAT AF, 1967, J BIOL CHEM, V242, P4013; WHEREAT AF, 1969, J BIOL CHEM, V244, P6498; Widmer J, 1996, BIOCHEM J, V316, P915, DOI 10.1042/bj3160915	47	70	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40067	40074		10.1074/jbc.M306121200	http://dx.doi.org/10.1074/jbc.M306121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882974	hybrid			2022-12-25	WOS:000185713800097
J	Wen, L; Zhuang, L; Luo, X; Wei, P				Wen, L; Zhuang, L; Luo, X; Wei, P			TL1A-induced NF-kappa B activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING RECEPTOR; TNF-LIKE LIGAND; DEATH-DOMAIN; SIGNAL-TRANSDUCTION; IN-VITRO; T-CELL; INHIBITOR; DR3; CASPASE-8	We recently identified TL1A, an endothelium-derived T cell costimulator and a ligand for tumor necrosis factor receptor superfamily members DR3 and decoy receptor 3 (1). To elucidate the signaling events triggered by TL1A-DR3 interaction and to understand the molecular mechanisms regulating DR3-mediated apoptosis, we have studied the effect of TL1A and an agonistic DR3 monoclonal antibody in human erythroleukemic TF-1 cells, which express DR3 endogenously. TL1A induced the formation of a DR3 signaling complex containing TRADD, TRAF2, and RIP and activated the NF-kappaB and the ERK, JNK, and p38 mitogen-activated protein kinase pathways. However, TL1A or an agonistic DR3 monoclonal antibody did not induce apoptosis in these cells nor were there detectable levels of FADD or pro-caspase-8 seen in the signaling complex. Interestingly, DR3-mediated apoptosis was induced in TF-1 cells in the presence of a NF-kappaB pathway-specific inhibitor but not in the presence of mitogen-activated protein kinase inhibitors, either alone or in combination, suggesting that DR3-induced NF-kappaB activation was responsible for resistance to apoptosis in these cells. Consistent with this, we found that TL1A significantly increased the production of c-IAP2, a known NF-kappaB-dependent anti-apoptotic protein, and that the NF-kappaB inhibitor or cycloheximide prevented its synthesis. Furthermore, inhibition of c-IAP2 production by RNA interference significantly sensitized TF-1 cells to TL1A-induced apoptosis. Our study identifies a molecular mechanism by which TL1A and DR3 regulate cell fate in TF-1 cells.	Human Genome Sci Inc, Dept Antibody Dev, Rockville, MD 20833 USA	GlaxoSmithKline; Human Genome Sciences Inc	Wei, P (corresponding author), Human Genome Sci Inc, Dept Antibody Dev, Rockville, MD 20833 USA.	pingwei001@yahoo.com						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1996, SCIENCE, V274, P272; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gupta S., 2001, Current Molecular Medicine (Hilversum), V1, P317, DOI 10.2174/1566524013363780; Harlow E., 1988, ANTIBODIES LAB MANUA; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Richter BW, 2000, SCI STKE, V44, pPE1, DOI DOI 10.1126/STKE.2000.44.PE1; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Shi Y, 1999, BIOCHEM BIOPH RES CO, V262, P132, DOI 10.1006/bbrc.1999.1181; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ECY, 2001, MOL CELL BIOL, V21, P3451, DOI 10.1128/MCB.21.10.3451-3461.2001; Ware Carl F., 1998, P549; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	42	102	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39251	39258		10.1074/jbc.M305833200	http://dx.doi.org/10.1074/jbc.M305833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882979	hybrid			2022-12-25	WOS:000185575100140
J	Hertig, A; Berrou, J; Allory, Y; Breton, L; Commo, F; De Beauregard, MAC; Carmeliet, P; Rondeau, E				Hertig, A; Berrou, J; Allory, Y; Breton, L; Commo, F; De Beauregard, MAC; Carmeliet, P; Rondeau, E			Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta	FASEB JOURNAL			English	Article						antiglomerular basement membrane disease; thrombin; fibrinolysis; serpins; Th1 cells	INDUCED PULMONARY-FIBROSIS; CRESCENTIC GLOMERULONEPHRITIS; MICE; NEPHRITIS; SYSTEM; GENE; GENERATION; PREVENTS; PROTECTS; RECEPTOR	Type 1 plasminogen activator inhibitor (PAI-1) is the primary inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Whereas PAI-1 is not expressed in normal kidneys, it is strongly induced in glomerular diseases and thus could promote the local accumulation of fibrin. To study the role of PAI-1 in the development of inflammatory glomerular injury, passive antiglomerular basement membrane (GBM) glomerulonephritis (GN) was induced in PAI-1 knockout mice and in wild-type mice of the same genetic background. Unexpectedly, PAI-1 deficiency was associated with an early and severe exacerbation of glomerular injury: Infiltration by CD4 T cells, proportion of fibrinous crescents, and renal function impairment were significantly more pronounced in PAI-1 -/- mice. Interestingly, activation of transforming growth factor (TGF)-beta, which is known to be dependent on the PA/plasmin system in vitro, was dramatically enhanced in the kidneys in the absence of PAI-1. Moreover, administration of neutralizing antibodies against TGF-beta significantly attenuated the disease in PAI-1 -/- mice. This suggests that the poor outcome of GN in PAI-1 -/- mice is consecutive to an uncontrolled activation of TGF-beta and confers PAI-1 with a new, immunomodulatory role.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Hop Tenon, Assoc Claude Bernard, F-75020 Paris, France; Hop Tenon, Dept Pathol, F-75020 Paris, France; Hop Tenon, Dept Nephrol A, F-75020 Paris, France; Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Rondeau, E (corresponding author), INSERM, U489, 4 Rue Chine, F-75020 Paris, France.	eric.rondeau@tnn.ap-hop-paris.fr	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821				CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; Dewerchin M, 2001, THROMB HAEMOSTASIS, V86, P640; Drew AF, 2001, AM J PHYSIOL-RENAL, V281, pF1157, DOI 10.1152/ajprenal.0002.2001; Eddy AA, 2002, AM J PHYSIOL-RENAL, V283, pF209, DOI 10.1152/ajprenal.00032.2002; Eitzman DT, 2000, BLOOD, V96, P4212; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; FENG LL, 1993, J AM SOC NEPHROL, V3, P1753; FOUQUERAY B, 1996, J AM SOC NEPHROL, V7, P1968; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Haraguchi M, 2001, KIDNEY INT, V59, P2146, DOI 10.1046/j.1523-1755.2001.00729.x; Hattori N, 2000, J CLIN INVEST, V106, P1341, DOI 10.1172/JCI10531; Kanamaru Y, 2001, J IMMUNOL, V166, P2818, DOI 10.4049/jimmunol.166.4.2818; Kitching AR, 2000, HISTOL HISTOPATHOL, V15, P993, DOI 10.14670/HH-15.993; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793; Luttun A, 2002, ARTERIOSCL THROM VAS, V22, P499, DOI 10.1161/hq0302.104529; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MAKINO H, 1988, KIDNEY INT, V34, P195, DOI 10.1038/ki.1988.165; Marty I, 2001, J CLIN INVEST, V107, P631, DOI 10.1172/JCI11064; McCormick LL, 1999, J IMMUNOL, V163, P5693; NEALE TJ, 1988, LANCET, V2, P421; Oda T, 2001, KIDNEY INT, V60, P587, DOI 10.1046/j.1523-1755.2001.030002587.x; Rerolle JP, 2000, KIDNEY INT, V58, P1841, DOI 10.1046/j.1523-1755.2000.00355.x; RIFKIN DB, 1990, CELL DIFFER DEV, V32, P313, DOI 10.1016/0922-3371(90)90045-X; RONDEAU E, 1990, CLIN NEPHROL, V33, P55; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VILLAMEDIANA LM, 1990, KIDNEY INT, V38, P956, DOI 10.1038/ki.1990.297; Xu YC, 1996, KIDNEY INT, V50, P2011, DOI 10.1038/ki.1996.523; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; ZOJA C, 1990, LAB INVEST, V62, P34	32	51	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1904	+		10.1096/fj.03-0084fje	http://dx.doi.org/10.1096/fj.03-0084fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897066				2022-12-25	WOS:000185345100024
J	Neale, EJ; Elliott, DJS; Hunter, M; Sivaprasadarao, A				Neale, EJ; Elliott, DJS; Hunter, M; Sivaprasadarao, A			Evidence for intersubunit interactions between S4 and S5 transmembrane segments of the Shaker potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-SENSING DOMAINS; K+ CHANNEL; SLOW INACTIVATION; ACTIVATION GATE; PORE DOMAIN; MOVEMENT; SENSOR; COORDINATION; ORIENTATION; RESIDUES	Voltage-gated potassium channels are transmembrane proteins made up of four subunits, each comprising six transmembrane (S1-S6) segments. S1-S4 form the voltage-sensing domain and S5-S6 the pore domain with its central pore. The sensor domain detects membrane depolarization and transmits the signal to the activation gates situated in the pore domain, thereby leading to channel opening. An understanding of the mechanism by which the sensor communicates the signal to the pore requires knowledge of the structure of the interface between the voltage-sensing and pore domains. Toward this end, we have introduced single cysteine mutations into the extracellular end of S4 (positions 356 and 357) in conjunction with a cysteine in S5 (position 418) of the Shaker channel and expressed the mutants in Xenopus oocytes. We then examined the propensity of each pair of engineered cysteines to form a metal bridge or a disulfide bridge, respectively, by examining the effect of Cd2+ ions and copper phenanthroline on the K+ conductance of a whole oocyte. Both reagents reduced currents through the S357C,E418C double mutant channel, presumably by restricting the movements necessary for coupling the voltage-sensing function to pore opening. This inhibitory effect was seen in the closed state of the channel and with heteromers composed of S357C and E418C single mutant subunits; no effect was seen with homomers of any of the single mutant channels. These data indicate that the extracellular end of S4 lies in close proximity to the extracellular end of the S5 of the neighboring subunit in closed channels.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Sivaprasadarao, A (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.	a.sivaprasadarao@leeds.ac.uk		Sivaprasadarao, Asipu/0000-0002-6755-3502	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000704] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aziz QH, 2002, J BIOL CHEM, V277, P42719, DOI 10.1074/jbc.M207258200; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Blaustein RO, 2000, NAT STRUCT BIOL, V7, P309; CAREAGA CL, 1992, BIOPHYS J, V62, P209, DOI 10.1016/S0006-3495(92)81806-4; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Elinder F, 2001, J GEN PHYSIOL, V118, P1, DOI 10.1085/jgp.118.1.1; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Flynn GE, 2001, NEURON, V30, P689, DOI 10.1016/S0896-6273(01)00324-5; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kiss L, 1998, BIOPHYS J, V74, P1840, DOI 10.1016/S0006-3495(98)77894-4; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; Larsson HP, 2000, NEURON, V27, P573, DOI 10.1016/S0896-6273(00)00067-2; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Loots E, 2000, J GEN PHYSIOL, V116, P623, DOI 10.1085/jgp.116.5.623; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; Olcese R, 1997, J GEN PHYSIOL, V110, P579, DOI 10.1085/jgp.110.5.579; OSULLIVAN WJ, 1969, DATA BIOCH RES; Roux B, 2002, NOVART FDN SYMP, V245, P84; Ruegg U T, 1977, Methods Enzymol, V47, P111; Rulisek L, 1998, J INORG BIOCHEM, V71, P115, DOI 10.1016/S0162-0134(98)10042-9; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SINGH R, 1995, METHOD ENZYMOL, V251, P167, DOI 10.1016/0076-6879(95)51119-9; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Starace DM, 2001, J GEN PHYSIOL, V117, P469, DOI 10.1085/jgp.117.5.469; Tapper AR, 2001, J BIOL CHEM, V276, P38249; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; Wang MH, 1999, J PHYSIOL-LONDON, V521, P315, DOI 10.1111/j.1469-7793.1999.00315.x; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	48	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29079	29085		10.1074/jbc.M301991200/6493	http://dx.doi.org/10.1074/jbc.M301991200/6493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12883074	Bronze			2022-12-25	WOS:000184421100091
J	Spicer, J; Rayter, S; Young, N; Elliott, R; Ashworth, A; Smith, D				Spicer, J; Rayter, S; Young, N; Elliott, R; Ashworth, A; Smith, D			Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1	ONCOGENE			English	Article						cancer susceptibility; Peutz-Jeghers syndrome; Wnt signalling; colorectal cancer; protein kinase	PROTEIN-KINASES; KNOCKOUT MICE; BETA-CATENIN; CARCINOMA; POLARITY; ENCODES; INACTIVATION; POLYPOSIS; ASYMMETRY; PAR-1	Loss-of-function mutations in the LKB1 (STK11) serine-threonine kinase gene cause Peutz-Jeghers syndrome, which is associated with inherited susceptibility to colorectal and other cancers. No downstream targets of LKB1 kinase activity have been identified. Here we show that LKB1 can direct the phosphorylation of the serine-threonine kinase PAR1A. The amino-acid residues phosphorylated as a result of LKB1 activity have been identified and phosphorylation at these residues is required for PAR1A kinase activity. PAR1A has previously been implicated as a positive regulator of the Wnt-betacatenin signalling pathway. We show here that LKB1 can modify transcription driven by the Wnt-regulated TCF response element, implicating LKB1 in a pathway known to play a key role in human colorectal tumorigenesis.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, Canc Res UK Gene Funct & Regulat Grp, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Canc Res UK Gene Funct & Regulat Grp, Fulham Rd, London SW3 6JB, England.			Spicer, James/0000-0003-3732-8491				Back W, 1999, J CLIN PATHOL, V52, P345, DOI 10.1136/jcp.52.5.345; Bosman FT, 1999, J PATHOL, V188, P1, DOI 10.1002/(SICI)1096-9896(199905)188:1<1::AID-PATH327>3.0.CO;2-J; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Jan YN, 2000, CELL, V100, P599, DOI 10.1016/S0092-8674(00)80695-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; PARSA I, 1988, CANCER RES, V48, P2265; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; Watts JL, 2000, DEVELOPMENT, V127, P1467; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	26	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4752	4756		10.1038/sj.onc.1206669	http://dx.doi.org/10.1038/sj.onc.1206669			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879020				2022-12-25	WOS:000184157000016
J	Shcherbakova, PV; Pavlov, YI; Chilkova, O; Rogozin, IB; Johansson, E; Kunkel, TA				Shcherbakova, PV; Pavlov, YI; Chilkova, O; Rogozin, IB; Johansson, E; Kunkel, TA			Unique error signature of the four-subunit yeast DNA polymerase epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; REPLICATION ERRORS; MUTATIONAL SPECTRA; ENZYMOLOGICAL CHARACTERIZATION; EXONUCLEASE ACTIVITY; ACCESSORY PROTEINS; BASE SUBSTITUTION; CONSERVED REGION; CHROMOSOMAL DNA	We have purified wild type and exonuclease-deficient four-subunit DNA polymerase epsilon (Pol epsilon) complex from Saccharomyces cerevisiae and analyzed the fidelity of DNA synthesis by the two enzymes. Wild type Pol epsilon synthesizes DNA accurately, generating single-base substitutions and deletions at average error rates of less than or equal to 2 x 10(-5) and less than or equal to 5 x 10(-7), respectively. Pol epsilon lacking 3' --> 5' exonuclease activity is less accurate to a degree suggesting that wild type Pol epsilon proofreads at least 92% of base substitution errors and at least 99% of frameshift errors made by the polymerase. Surprisingly the base substitution fidelity of exonuclease-deficient Pol epsilon is severalfold lower than that of proofreading-deficient forms of other replicative polymerases. Moreover the spectrum of errors shows a feature not seen with other A, B, C, or X family polymerases: a high proportion of transversions resulting from T . dTTP, T . dCTP, and C . dTTP mispairs. This unique error specificity and amino acid sequence alignments suggest that the structure of the polymerase active site of Pol epsilon differs from those of other B family members. We observed both similarities and differences between the spectrum of substitutions generated by proofreading-deficient Pol epsilon in vitro and substitutions occurring in vivo in a yeast strain defective in Pol epsilon proofreading and DNA mismatch repair. We discuss the implications of these findings for the role of Pol epsilon polymerase activity in DNA replication.	NIEHS, Lab Struct Biol, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; NIEHS, Genet Mol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Dept Hlth & Human Serv, Bethesda, MD 20894 USA; Russian Acad Sci, Inst Cytol & Genet, Novosibirsk 630090, Russia	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Umea University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS	Kunkel, TA (corresponding author), NIEHS, Lab Struct Biol, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.		Kunkel, Thomas A./D-5088-2019; Pavlov, Youri/T-7532-2017	Kunkel, Thomas A./0000-0002-9900-1788; Johansson, Erik/0000-0002-8526-6224; Rogozin, Igor/0000-0003-0802-4851; Pavlov, Youri/0000-0003-1179-5796				ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Babenko VN, 1999, BIOFIZIKA+, V44, P632; Bebenek A, 2002, GENETICS, V162, P1003; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Chilkova O, 2003, J BIOL CHEM, V278, P14082, DOI 10.1074/jbc.M211818200; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; DONG Q, 1993, J BIOL CHEM, V268, P24175; Dua R, 1998, J BIOL CHEM, V273, P30046, DOI 10.1074/jbc.273.45.30046; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; FISHER PA, 1979, J BIOL CHEM, V254, P6128; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Glazko GB, 1998, J THEOR BIOL, V192, P475, DOI 10.1006/jtbi.1998.0668; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; Johansson E, 2001, J BIOL CHEM, V276, P43824, DOI 10.1074/jbc.M108842200; Kadyrov FA, 2002, NUCLEIC ACIDS RES, V30, P4387, DOI 10.1093/nar/gkf576; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Khromov-Borisov NN, 1999, MUTAT RES-FUND MOL M, V430, P55, DOI 10.1016/S0027-5107(99)00148-7; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Maki S, 1998, J BIOL CHEM, V273, P21332, DOI 10.1074/jbc.273.33.21332; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohya T, 2002, J BIOL CHEM, V277, P28099, DOI 10.1074/jbc.M111573200; Pavlov YI, 2001, GENETICS, V159, P47; Pavlov YI, 2003, CURR BIOL, V13, P744, DOI 10.1016/S0960-9822(03)00284-7; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; PIEGORSCH WW, 1994, GENETICS, V136, P403; Poloumienko A, 2001, MOL BIOL CELL, V12, P3317, DOI 10.1091/mbc.12.11.3317; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Rogozin IB, 2001, HUM MUTAT, V17, P83, DOI 10.1002/1098-1004(200102)17:2<83::AID-HUMU1>3.0.CO;2-E; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Shcherbakova PV, 1996, MUTAT RES-GENET TOX, V369, P33, DOI 10.1016/S0165-1218(96)90045-2; Shcherbakova PV, 1996, GENETICS, V142, P717; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; SHCHERBAKOVA PV, 2003, SCI SAGE KE; Shimizu K, 2002, J BIOL CHEM, V277, P37422, DOI 10.1074/jbc.M204476200; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Viguera E, 2001, EMBO J, V20, P2587, DOI 10.1093/emboj/20.10.2587; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	73	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43770	43780		10.1074/jbc.M306893200	http://dx.doi.org/10.1074/jbc.M306893200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12882968	hybrid			2022-12-25	WOS:000186157000127
J	Alic, N; Higgins, VJ; Pichova, A; Breitenbach, M; Dawes, IW				Alic, N; Higgins, VJ; Pichova, A; Breitenbach, M; Dawes, IW			Lipid hydroperoxides activate the mitogen-activated protein kinase Mpk1p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINOLEIC-ACID HYDROPEROXIDE; SIGNAL-TRANSDUCTION PATHWAY; OXIDATIVE STRESS-RESPONSE; POLARIZED CELL-GROWTH; MAP KINASE; TRANSCRIPTION FACTOR; BIOLOGICAL-SYSTEMS; GENE-EXPRESSION; ELEMENT STRE; CYCLE ARREST	Saccharomyces cerevisiae is capable of responding to oxidants, including lipid peroxidation products. We investigate here the role of the mitogen-activated protein kinase Mpk1p in protection against linoleic acid hydroperoxide (LoaOOH), a product of radical attack on an unsaturated lipid. MPK1 was found to be required for resistance to LoaOOH. Furthermore, Mpk1p was rapidly and transiently phosphorylated in response to LoaOOH. This phosphorylation was dose-dependent and stimulated by sublethal concentrations as low as 1 muM in the external medium. Such low doses have been shown to result in resistance to subsequent challenge with a higher dose through the process of adaptation. However MPK1 was not essential for this adaptive response. MPK1 was also not involved in cell cycle modulation and acted independently of the cell cycle-regulating Oca1p. Transcriptional profiling of the mpk1Delta cells during LoaOOH stress indicated that Mpk1p may be important in effecting changes to the cell surface and metabolism during LoaOOH exposure. Furthermore, it revealed that Mpk1p is required for the regulation of 97 LoaOOH-responsive transcripts. Evidence is presented that the activation of Mpk1p may be caused by the activation of protein kinase C by LoaOOH.	Univ New S Wales, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia; Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia; Salzburg Univ, Dept Genet, A-5020 Salzburg, Austria; Acad Sci Czech Republ, Inst Microbiol, Prague, Czech Republic	University of New South Wales Sydney; University of New South Wales Sydney; Salzburg University; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Dawes, IW (corresponding author), Univ New S Wales, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia.		Alic, Nazif/B-4665-2009	Alic, Nazif/0000-0003-0356-6600				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Alic N, 2001, MOL BIOL CELL, V12, P1801, DOI 10.1091/mbc.12.6.1801; Binley KM, 1999, YEAST, V15, P1459, DOI 10.1002/(SICI)1097-0061(199910)15:14<1459::AID-YEA472>3.0.CO;2-A; Brachmann CB, 1998, YEAST, V14, P115; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Charizanis C, 1999, MOL GEN GENET, V262, P437, DOI 10.1007/s004380051103; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Degols G, 1996, MOL CELL BIOL, V16, P2870; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; Evans MV, 1998, J BACTERIOL, V180, P483, DOI 10.1128/JB.180.3.483-490.1998; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; Girotti AW, 1998, J LIPID RES, V39, P1529; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Higgins VJ, 2002, YEAST, V19, P203, DOI 10.1002/yea.811; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jung US, 2002, MOL MICROBIOL, V46, P781, DOI 10.1046/j.1365-2958.2002.03198.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Kaul N, 1998, ARCH BIOCHEM BIOPHYS, V350, P79, DOI 10.1006/abbi.1997.0487; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Singh KK, 2000, FREE RADICAL BIO MED, V29, P1043, DOI 10.1016/S0891-5849(00)00432-9; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; SWEETMAN LL, 1995, ARCH BIOCHEM BIOPHYS, V323, P97, DOI 10.1006/abbi.1995.0014; Winkler A, 2002, EUKARYOT CELL, V1, P163, DOI 10.1128/EC.1.2.163-173.2002; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	47	35	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41849	41855		10.1074/jbc.M307760200	http://dx.doi.org/10.1074/jbc.M307760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912987	hybrid			2022-12-25	WOS:000185989500037
J	Duringer, C; Hamiche, A; Gustafsson, L; Kimura, H; Svanborg, C				Duringer, C; Hamiche, A; Gustafsson, L; Kimura, H; Svanborg, C			HAMLET interacts with histones and chromatin in tumor cell nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; ALPHA-LACTALBUMIN; CORE HISTONES; APOPTOSIS; PROTEIN; PARTICLE; FEATURES; KINETICS; H2B	HAMLET is a folding variant of human alpha-lactalbumin in an active complex with oleic acid. HAMLET selectively enters tumor cells, accumulates in their nuclei and induces apoptosis-like cell death. This study examined the interactions of HAMLET with nuclear constituents and identified histones as targets. HAMLET was found to bind histone H3 strongly and to lesser extent histones H4 and H2B. The specificity of these interactions was confirmed using BIAcore technology and chromatin assembly assays. In vivo in tumor cells, HAMLET co-localized with histones and perturbed the chromatin structure; HAMLET was found associated with chromatin in an insoluble nuclear fraction resistant to salt extraction. In vitro, HAMLET bound strongly to histones and impaired their deposition on DNA. We conclude that HAMLET interacts with histones and chromatin in tumor cell nuclei and propose that this interaction locks the cells into the death pathway by irreversibly disrupting chromatin organization.	Lund Univ, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, S-22362 Lund, Sweden; Inst Andre Lwoff, CNRS, UPR 9079, Equipe Fonct & Dynam Chromatine, F-94800 Villejuif, France; Tokyo Med & Dent Univ, Inst Med Res, Dept Funct Genom, Bunkyo Ku, Tokyo 1138510, Japan	Lund University; Centre National de la Recherche Scientifique (CNRS); Tokyo Medical & Dental University (TMDU)	Svanborg, C (corresponding author), Lund Univ, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, Solvegatan 23, S-22362 Lund, Sweden.		Kimura, Hiroshi/B-9524-2015	Kimura, Hiroshi/0000-0003-0854-083X; Gustafsson, Lotta/0000-0002-9826-9133				AUSUBEL FH, 1993, CURRENT PROTOCOLS MO, V2, P12; BATES DL, 1981, EUR J BIOCHEM, V119, P469, DOI 10.1111/j.1432-1033.1981.tb05631.x; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hakansson A, 1999, EXP CELL RES, V246, P451, DOI 10.1006/excr.1998.4265; Hamiche A, 1998, J BIOL CHEM, V273, P9261, DOI 10.1074/jbc.273.15.9261; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; Svensson M, 1999, J BIOL CHEM, V274, P6388, DOI 10.1074/jbc.274.10.6388; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yamaki M, 2001, GENES CELLS, V6, P1043, DOI 10.1046/j.1365-2443.2001.00487.x	19	98	103	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42131	42135		10.1074/jbc.M306462200	http://dx.doi.org/10.1074/jbc.M306462200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888554	hybrid			2022-12-25	WOS:000185989500071
J	Kuge, O; Hasegawa, K; Ohsawa, T; Saito, K; Nishijima, M				Kuge, O; Hasegawa, K; Ohsawa, T; Saito, K; Nishijima, M			Purification and characterization of Chinese hamster phosphatidylserine synthase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OVARY CELLS; RAT-BRAIN; MAMMALIAN-CELLS; GENETIC-EVIDENCE; ANNEXIN-V; PHOSPHOLIPIDS; MEMBRANE; BIOSYNTHESIS; ACTIVATION	Phosphatidylserine (PtdSer) in mammalian cells is synthesized through the action of PtdSer synthase (PSS) 1 and 2, which catalyze the conversion of phosphatidylcholine and phosphatidylethanolamine, respectively, to PtdSer. The PtdSer synthesis in intact cells and an isolated membrane fraction is inhibited by exogenous PtdSer, indicating that inhibition of PtdSer synthases by PtdSer is important for the regulation of PtdSer biosynthesis. In this study, to examine whether the inhibition occurs through the direct interaction of PtdSer with the synthases or is mediated by unidentified factor(s), we purified a FLAG and HA peptide-tagged form of Chinese hamster PSS 2 to near homogeneity. The purified enzyme, as well as the crude enzyme in a membrane fraction, was inhibited on the addition of PtdSer to the enzyme assay mixture. In contrast to PtdSer, phosphatidylcholine and phosphatidylethanolamine did not significantly inhibit the purified enzyme. Furthermore, PtdSer-resistant PtdSer synthesis was observed on cell-free assaying of the membrane fraction prepared from a Chinese hamster ovary cell strain whose PtdSer synthesis in vivo is not inhibited by exogenous PtdSer. These results suggested that the interaction of PtdSer with PSS 2 or a very minor protein co-purified with PSS 2 was critical for the regulation of PSS 2 activity in intact cells.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Kyowa Hakko Co Ltd, Tokyo Res Labs, Machida, Tokyo 1940023, Japan	National Institute of Infectious Diseases (NIID); Kyowa Kirin Ltd	Kuge, O (corresponding author), Kyushu Univ, Fac & Grad Sch Sci, Dept Chem, Higashi Ku, Hakozaki 6-10-1, Fukuoka 8128581, Japan.			Kuge, Osamu/0000-0003-4962-3519				BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; CALDERON C, 1994, J EXP MED, V180, P945, DOI 10.1084/jem.180.3.945; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HASEGAWA K, 1989, J BIOL CHEM, V264, P19887; KATO M, 1990, J BIOL CHEM, V265, P794; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; Kuge O, 1999, J BIOL CHEM, V274, P23844, DOI 10.1074/jbc.274.34.23844; Kuge O, 1997, BBA-LIPID LIPID MET, V1348, P151, DOI 10.1016/S0005-2760(97)00137-9; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; Saito K, 1998, J BIOL CHEM, V273, P17199, DOI 10.1074/jbc.273.27.17199; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P304, DOI 10.1016/0003-9861(75)90345-8; SATTA N, 1994, J IMMUNOL, V153, P3245; SUZUKI TT, 1985, J BIOL CHEM, V260, P1394; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TUMA PL, 1993, J BIOL CHEM, V268, P17240; YADA Y, 1990, J BIOL CHEM, V265, P19237; ZWAAL RFA, 1989, MOL CELL BIOCHEM, V91, P23, DOI 10.1007/BF00228075	31	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42692	42698		10.1074/jbc.M307270200	http://dx.doi.org/10.1074/jbc.M307270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12912985	hybrid			2022-12-25	WOS:000185989500136
J	Booth, RE; Tong, QS; Medina, J; Snyder, PM; Patel, P; Stockand, JD				Booth, RE; Tong, QS; Medina, J; Snyder, PM; Patel, P; Stockand, JD			A region directly following the second transmembrane domain in gamma ENaC is required for normal channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; SENSITIVE NA+ CHANNEL; ALPHA-SUBUNIT; LIDDLES-SYNDROME; PLASMA-MEMBRANE; APICAL MEMBRANE; EXPRESSION; TERMINUS; KINASE; CELLS	We used a yeast one-hybrid complementation screen to identify regions within the cytosolic tails of the mouse alpha, beta, and gamma epithelial Na+ channel (ENaC) important to protein-protein and/or protein-lipid interactions at the plasma membrane. The cytosolic COOH terminus of alphaENaC contained a strongly interactive domain just distal to the second transmembrane region (TM2) between Met(610) and Val(632). Likewise, gammaENaC contained such a domain just distal to TM2 spanning Gln(573)-Pro(600). Interactive domains were also localized within Met(1)-Gln(54) and the last 17 residues of alpha- and betaENaC, respectively. Confocal images of Chinese hamster ovary cells transfected with enhanced green fluorescent fusion proteins of the cytosolic tails of mENaC subunits were consistent with results in yeast. Fusion proteins of the NH2 terminus of alphaENaC and the COOH termini of all three subunits co-localized with a plasma membrane marker. The functional importance of the membrane interactive domain in the COOH terminus of gammaENaC was established with whole-cell patch clamp experiments of wild type (alpha, beta, and gamma) and mutant (alpha, beta, and gamma(DeltaQ573-P600)) mENaC reconstituted in Chinese hamster ovary cells. Mutant channels had about 13% of the activity of wild type channels with 0.33 +/- 0.14 versus 2.5 +/- 0.80 nA of amiloride-sensitive inward current at - 80 mV. Single channel analysis of recombinant channels demonstrated that mutant channels had a decrease in P-o with 0.16 +/- 0.03 versus 0.67 +/- 0.07 for wild type. Mutant gammaENaC associated normally with the other two subunits in co-immunoprecipitation studies and localized to the plasma membrane in membrane labeling experiments and when visualized with evanescent-field fluorescence microscopy. Similar to deletion of Gln(573)-Pro(600), deletion of Gln(573)-Arg(583) but not Thr(584)-Pro(600) decreased ENaC activity. The current results demonstrate that residues within Gln(573)-Arg(583) of gammaENaC are necessary for normal channel gating.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Texas System; University of Texas Health San Antonio; University of Iowa; University of Iowa	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Stockand, James/0000-0002-3817-4319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK59594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Berdiev BK, 1998, BIOPHYS J, V75, P2292, DOI 10.1016/S0006-3495(98)77673-8; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Dinudom A, 2001, J BIOL CHEM, V276, P13744, DOI 10.1074/jbc.M011273200; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Gamper N, 2003, J NEUROSCI, V23, P84; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Gupta SS, 2000, FEBS LETT, V481, P77, DOI 10.1016/S0014-5793(00)01977-3; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; Heda GD, 2000, BIOCHEM BIOPH RES CO, V271, P659, DOI 10.1006/bbrc.2000.2684; Hendron E, 2002, J BIOL CHEM, V277, P34480, DOI 10.1074/jbc.M204615200; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ji HL, 1999, J BIOL CHEM, V274, P37693, DOI 10.1074/jbc.274.53.37693; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Munn AL, 2000, MICROSC RES TECHNIQ, V51, P547, DOI 10.1002/1097-0029(20001215)51:6<547::AID-JEMT5>3.0.CO;2-D; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 1999, J BIOL CHEM, V274, P26912, DOI 10.1074/jbc.274.38.26912; Stockand JD, 2001, AM J PHYSIOL-CELL PH, V281, pC773, DOI 10.1152/ajpcell.2001.281.3.C773; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Thomas CP, 1998, AM J PHYSIOL-CELL PH, V274, pC1312, DOI 10.1152/ajpcell.1998.274.5.C1312; Volk KA, 2001, J BIOL CHEM, V276, P43887, DOI 10.1074/jbc.M108714200; Volk KA, 2000, AM J PHYSIOL-CELL PH, V278, pC1047, DOI 10.1152/ajpcell.2000.278.5.C1047; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	52	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41367	41379		10.1074/jbc.M305400200	http://dx.doi.org/10.1074/jbc.M305400200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12897071	hybrid			2022-12-25	WOS:000185847200117
J	Rosell, A; Valencia, E; Ochoa, WF; Fita, I; Pares, X; Farres, J				Rosell, A; Valencia, E; Ochoa, WF; Fita, I; Pares, X; Farres, J			Complete reversal of coenzyme specificity by concerted mutation of three consecutive residues in alcohol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID SUBSTITUTIONS; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; CATALYTIC EFFICIENCY; DINUCLEOTIDE BINDING; COFACTOR SPECIFICITY; HUMAN BETA-1-BETA-1; RANA-PEREZI; PROTEIN	Gastric tissues from amphibian Rana perezi express the only vertebrate alcohol dehydrogenase (ADH8) that is specific for NADP( H) instead of NAD(H). In the crystallographic ADH8-NADP(+) complex, a binding pocket for the extra phosphate group of coenzyme is formed by ADH8-specific residues Gly(223)-Thr(224)-His(225), and the highly conserved Leu(200) and Lys(228). To investigate the minimal structural determinants for coenzyme specificity, several ADH8 mutants involving residues 223 to 225 were engineered and kinetically characterized. Computer-assisted modeling of the docked coenzymes was also performed with the mutant enzymes and compared with the wild-type crystallographic binary complex. The G223D mutant, having a negative charge in the phosphate-binding site, still preferred NADP( H) over NAD( H), as did the T224I and H225N mutants. Catalytic efficiency with NADP( H) dropped dramatically in the double mutants, G223D/T224I and T224I/H225N, and in the triple mutant, G223D/T224I/ H225N (k(cat)/K(m)NADPH = 760 mM(-1) min(-1)), as compared with the wild-type enzyme (k(cat)/K(m)NADPH = 133,330 mM(-1) min(-1)). This was associated with a lower binding affinity for NADP(+) and a change in the rate-limiting step. Conversely, in the triple mutant, catalytic efficiency with NAD( H) increased, reaching values (k(cat)/K(m)NADH = 155,000 mM(-1) min(-1)) similar to those of the wild-type enzyme with NADP( H). The complete reversal of ADH8 coenzyme specificity was therefore attained by the substitution of only three consecutive residues in the phosphate-binding site, an unprecedented achievement within the ADH family.	Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain; Consejo Super Invest Cient, IBMB, E-08034 Barcelona, Spain	Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Farres, J (corresponding author), Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain.		Farrés, Jaume/F-8648-2016; Pares, Xavier/K-8228-2017	Farrés, Jaume/0000-0001-9069-3987; Pares, Xavier/0000-0002-5071-9465				BACKER PJ, 1992, J MOL BIOL, V228, P662; Banfield MJ, 2001, J MOL BIOL, V306, P239, DOI 10.1006/jmbi.2000.4381; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; BOSRON WF, 1979, BIOCHEMISTRY-US, V18, P1101, DOI 10.1021/bi00573a026; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C I, 1980, Experientia Suppl, V36, P40; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burdette DS, 1996, BIOCHEM J, V316, P115, DOI 10.1042/bj3160115; Burnell JC, 1989, HUMAN METABOLISM ALC, V2, P65; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; CEDERLUND E, 1991, BIOCHEMISTRY-US, V30, P2811, DOI 10.1021/bi00225a011; CHEN Z, 1991, EUR J BIOCHEM, V202, P263, DOI 10.1111/j.1432-1033.1991.tb16371.x; Cleland W W, 1979, Methods Enzymol, V63, P103; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; Fan F, 1999, ARCH BIOCHEM BIOPHYS, V367, P240, DOI 10.1006/abbi.1999.1242; FAN F, 1991, BIOCHEMISTRY-US, V30, P6397, DOI 10.1021/bi00240a008; FAN F, 1995, BIOCHEMISTRY-US, V34, P4709, DOI 10.1021/bi00014a027; FARRES J, 1994, EUR J BIOCHEM, V224, P549, DOI 10.1111/j.1432-1033.1994.00549.x; FEENEY R, 1990, BIOCHEM BIOPH RES CO, V166, P667, DOI 10.1016/0006-291X(90)90861-G; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Korkhin Y, 1998, J MOL BIOL, V278, P967, DOI 10.1006/jmbi.1998.1750; KUMAR A, 1992, P NATL ACAD SCI USA, V89, P10188, DOI 10.1073/pnas.89.21.10188; LAUVERGEAT V, 1995, BIOCHEMISTRY-US, V34, P12426, DOI 10.1021/bi00038a041; Lee SL, 2003, FEBS LETT, V544, P143, DOI 10.1016/S0014-5793(03)00492-7; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; METZGER MH, 1995, EUR J BIOCHEM, V228, P50, DOI 10.1111/j.1432-1033.1995.tb20227.x; MITTL PRE, 1994, PROTEIN SCI, V3, P1504, DOI 10.1002/pro.5560030916; MITTL PRE, 1993, J MOL BIOL, V231, P191, DOI 10.1006/jmbi.1993.1274; NELSON M, 1992, METHOD ENZYMOL, V216, P279; OHLSSON I, 1974, J MOL BIOL, V89, P339, DOI 10.1016/0022-2836(74)90523-3; Peralba JM, 1999, ADV EXP MED BIOL, V463, P343; Peralba JM, 1999, J BIOL CHEM, V274, P26021, DOI 10.1074/jbc.274.37.26021; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; Rosell A, 2003, J MOL BIOL, V330, P75, DOI 10.1016/S0022-2836(03)00431-5; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; STONE CL, 1993, J BIOL CHEM, V268, P892; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; Svensson S, 2000, J MOL BIOL, V302, P441, DOI 10.1006/jmbi.2000.4039; Valencia E, 2003, ACTA CRYSTALLOGR D, V59, P334, DOI 10.1107/S090744490201661X; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558	46	43	47	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40573	40580		10.1074/jbc.M307384200	http://dx.doi.org/10.1074/jbc.M307384200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902331	hybrid			2022-12-25	WOS:000185847200020
J	Wang, GL; Wei, LN; Loh, HH				Wang, GL; Wei, LN; Loh, HH			Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation - Involvement of Sp3 and A methyl-CpG-binding protein, MBD2, in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; CYTOSINE METHYLATION; PROMOTER; EXPRESSION; ACTIVATION; FAMILY; IDENTIFICATION; SITE	Opioid receptors are expressed in a cell type-specific manner. Here we show that the mouse delta-opioid receptor (mDOR) gene is regulated by promoter region CpG methylation. The mDOR promoter containing a putative CpG island is highly methylated in Neuro2A cells, correlating with the repression of this gene in these cells. This is in contrast with the unmethylated state of the mDOR promoter in NS20Y cells, which express a high level of mDOR. Repression of mDOR transcription in Neuro2A cells could be partially relieved by chemically induced demethylation with 5-aza-2'-deoxycytidine. In addition, in vitro methylation of the luciferase reporter gene driven by the mDOR promoter resulted in an inhibition of transcription in NS20Y cells. Methyl-CpG-binding protein complex 1 (MeCP1) has been implicated in methylation-mediated transcriptional repression of several genes. Electrophoretic mobility shift assays showed that fully methylated, but not unmethylated, mDOR promoter fragment formed a MeCP1-like protein complex that contained methyl-CpG-binding domain protein 2 (MBD2) and Sp3. Furthermore, the expression level of Sp3 was decreased when Neuro2A cells were demethylated with 5-aza-2'-deoxycytidine, and increasing Sp3 levels in Schneider's Drosophila line 2 cells led to the repression of mDOR promoter activity when the promoter was methylated. These results demonstrate that Sp3 and MBD2 are involved in the transcriptional repression of mDOR in Neuro2A cells through binding to the methylated CpG sites in the promoter region and may play a role in the cell type-specific expression of mDOR.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wang, GL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [K05DA070554, K02DA013926, R01DA001583, R37DA001583, P50DA011806] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00546, K02-DA13926, K05-DA-70554, DA-11806, DA-01583] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Feng Q, 2001, GENE DEV, V15, P827; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu HC, 1999, J BIOL CHEM, V274, P23617, DOI 10.1074/jbc.274.33.23617; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Smirnov D, 2001, MOL PHARMACOL, V60, P331, DOI 10.1124/mol.60.2.331; Sun P, 2001, J BIOL CHEM, V276, P45462, DOI 10.1074/jbc.M104793200; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200	32	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40550	40556		10.1074/jbc.M302879200	http://dx.doi.org/10.1074/jbc.M302879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12890683	hybrid			2022-12-25	WOS:000185847200017
J	Chen, YH; Layne, MD; Chung, SW; Ejima, K; Baron, RM; Yet, SF; Perrella, MA				Chen, YH; Layne, MD; Chung, SW; Ejima, K; Baron, RM; Yet, SF; Perrella, MA			Elk-3 is a transcriptional repressor of nitric-oxide synthase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; TRANSFORMING GROWTH-FACTOR-BETA-1; ETS FAMILY; SEPTIC SHOCK; DISEASE; RAS; INHIBITION	The inducible isoform of nitric-oxide synthase (NOS2), a key enzyme catalyzing the dramatic increase in nitric oxide by lipopolysaccharide (LPS), plays an important role in the pathophysiology of endotoxemia and sepsis. Recent evidence suggests that Ets transcription factors may contribute to NOS2 induction by inflammatory stimuli. In this study, we investigated the role of Ets transcription factors in the regulation of NOS2 by LPS and transforming growth factor (TGF)-beta1. Transient transfection assays in macrophages showed that Ets-2 produced an increase in NOS2 promoter activity, whereas the induction by Ets-1 was modest and NERF2 had no effect. Elk-3 (Net/Erp/Sap-2a) markedly repressed NOS2 promoter activity in a dose-dependent fashion, and overexpression of Elk-3 blunted the induction of endogenous NOS2 message. Mutation of the Net inhibitory domain of Elk-3, but not the C-terminal-binding protein interaction domain, partially alleviated this repressive effect. We also found that deletion of the Ets domain of Elk-3 completely abolished its repressive effect on the NOS2 promoter. LPS administration to macrophages led to a dose-dependent decrease in endogenous Elk-3 mRNA levels, and this decrease in Elk-3 preceded the induction of NOS2 mRNA. In a mouse model of endotoxemia, the expression of Elk-3 in kidney, lung, and heart was significantly down-regulated after systemic administration of LPS, and this down-regulation also preceded NOS2 induction. Moreover, TGF-beta1 significantly increased endogenous Elk-3 mRNA levels that had been down-regulated by LPS in macrophages. This increase in Elk-3 correlated with a TGF-beta1-induced down-regulation of NOS2. Taken together, our data suggest that Elk-3 is a strong repressor of NOS2 promoter activity and mRNA levels and that endogenous expression of Elk-3 inversely correlates with NOS2. Thus, Elk-3 may serve as an important mediator of NOS2 gene expression.	Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Kaohsiung Med Univ, Dept Internal Med, Div Infect Dis, Kaohsiung 807, Taiwan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kaohsiung Medical University	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St,TH-1327A, Boston, MA 02115 USA.		Yet, Shaw-Fang/B-1067-2010; Chen, Yen-Hsu/D-5484-2009; Yet, Shaw-Fang/O-8583-2019	Chen, Yen-hsu/0000-0002-8667-4844; Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60788] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Ejima K, 2002, ANTIOXID REDOX SIGN, V4, P569, DOI 10.1089/15230860260220067; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pellacani A, 2001, J BIOL CHEM, V276, P1653, DOI 10.1074/jbc.M008170200; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1996, P NATL ACAD SCI USA, V93, P2054, DOI 10.1073/pnas.93.5.2054; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Rees DD, 1998, BRIT J PHARMACOL, V124, P540, DOI 10.1038/sj.bjp.0701815; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	32	35	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39572	39577		10.1074/jbc.M308179200	http://dx.doi.org/10.1074/jbc.M308179200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12896968	hybrid			2022-12-25	WOS:000185713800039
J	Ferrari, A; Hoerndli, F; Baechi, T; Nitsch, RM; Gotz, J				Ferrari, A; Hoerndli, F; Baechi, T; Nitsch, RM; Gotz, J			beta-amyloid induces paired helical filament-like tau filaments in tissue culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; P301L TAU; NEUROFIBRILLARY DEGENERATION; ALZHEIMERS-DISEASE; PROTEIN; CELLS; PHOSPHORYLATION; MUTATIONS; DEMENTIA; AMYOTROPHY	Paired helical filaments (PHF) are the principal pathologic components of neurofibrillary tangles in Alzheimer's disease (AD). To reproduce the formation of PHF in tissue culture, we stably expressed human tau with and without pathogenic mutations in human SH-SY5Y cells and exposed them for 5 days to aggregated synthetic beta-amyloid peptide (Abeta(42)). This caused a decreased solubility of tau along with the generation of PHF-like tau-containing filaments. These were 20 nm wide and had periodicities of 130-140 nm in the presence of P301L mutant tau or 150-160 nm in the presence of wild-type tau. Mutagenesis of the phosphoepitope serine 422 of tau prevented both the Abeta(42)-mediated decrease in solubility and the generation of PHF-like filaments, suggesting a role of serine 422 or its phosphorylation in tau filament formation. Together, our data underscore a role of Abeta(42) in the formation of PHF-like filaments. Our culture system will be useful to map phosphoepitopes of tau involved in PHF formation and to identify and characterize modifiers of the tau pathology. Further adaptation of the system may allow the screening and validation of compounds designed to prevent PHF formation.	Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland; Univ Zurich, Cent Lab Electron Microscopy, CH-8028 Zurich, Switzerland	University of Zurich; University of Zurich	Gotz, J (corresponding author), Univ Zurich, Div Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.		Götz, Jürgen/C-2448-2014	Götz, Jürgen/0000-0001-8501-7896; Hoerndli, Frederic/0000-0001-6838-0386				Abraha A, 2000, J CELL SCI, V113, P3737; Berry RW, 2003, BIOCHEMISTRY-US, V42, P8325, DOI 10.1021/bi027348m; Bussiere T, 1999, ACTA NEUROPATHOL, V97, P221, DOI 10.1007/s004010050978; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Gotz J, 2001, BRAIN RES REV, V35, P266, DOI 10.1016/S0165-0173(01)00055-8; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Haque N, 1999, BRAIN RES, V838, P69, DOI 10.1016/S0006-8993(99)01622-4; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Ishihara T, 2001, AM J PATHOL, V158, P555, DOI 10.1016/S0002-9440(10)63997-1; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Perez M, 2002, EUR J BIOCHEM, V269, P1484, DOI 10.1046/j.1432-1033.2002.02794.x; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Uberti D, 1997, NEUROSCI LETT, V235, P149, DOI 10.1016/S0304-3940(97)00715-5; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	28	149	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40162	40168		10.1074/jbc.M308243200	http://dx.doi.org/10.1074/jbc.M308243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893817	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000185713800109
J	Kaplan-Albuquerque, N; Garat, C; Desseva, C; Jones, PL; Nemenoff, RA				Kaplan-Albuquerque, N; Garat, C; Desseva, C; Jones, PL; Nemenoff, RA			Platelet-derived growth factor-BB-mediated activation of akt suppresses smooth muscle-specific gene expression through inhibition of mitogen-activated protein kinase and redistribution of serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN EXPRESSION; SIGNAL-TRANSDUCTION PATHWAYS; PHOSPHOINOSITIDE 3-KINASE; NUCLEAR-LOCALIZATION; ARGININE-VASOPRESSIN; C-JUN; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; TYROSINE KINASES; ANGIOTENSIN-II	Platelet-derived growth factor (PDGF) inhibits expression of smooth muscle (SM) genes in vascular smooth muscle cells and blocks induction by arginine vasopressin (AVP). We have previously demonstrated that suppression of SM-alpha-actin by PDGF-BB is mediated in part through a Ras-dependent pathway. This study examined the role of phosphatidylinositol 3-kinase (PI3K)y and its downstream effector, Akt, in regulating SM gene expression. PDGF caused a rapid sustained activation of Akt, whereas AVP caused only a small transient increase. PDGF selectively caused a sustained stimulation of p85/p110alpha PI3K. In contrast, p85/110beta PI3K activity was not altered by either PDGF or AVP, whereas both agents caused a delayed activation of Class IB p101/110gamma PI3K. Expression of a gain-of-function PI3K or myristoylated Akt (myr-Akt) mimicked the inhibitory effect of PDGF on SM-alpha-actin and SM22alpha expression. Pretreatment with LY 294002 reversed the inhibitory effect of PDGF. Expression of myr-Akt selectively inhibited AVP-induced activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinases, which we have shown are critical for induction of these genes. Nuclear extracts from PDGF-stimulated or myr-Akt expressing cells showed reduced serum response factor binding to SM-specific CArG elements. This was associated with appearance of serum response factor in the cytoplasm. These data indicate that activation of p85/p110alpha/Akt mediates suppression of SM gene expression by PDGF.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Box C-281,4200 E 9th Ave, Denver, CO 80262 USA.			Jones, Peter Lloyd/0000-0003-1445-4081	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039902, P01DK019928] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62824] Funding Source: Medline; NIDDK NIH HHS [DK19928, DK39902] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Camoretti-Mercado B, 2000, J BIOL CHEM, V275, P30387, DOI 10.1074/jbc.M000840200; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FATIGATI V, 1984, J BIOL CHEM, V259, P4383; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fu YP, 2000, J APPL PHYSIOL, V89, P1985, DOI 10.1152/jappl.2000.89.5.1985; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Jung F, 2000, CARDIOVASC RES, V48, P148, DOI 10.1016/S0008-6363(00)00152-8; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KEMP PR, 1995, BIOCHEM J, V310, P1037, DOI 10.1042/bj3101037; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, DIFFERENTIATION, V32, P245, DOI 10.1111/j.1432-0436.1986.tb00580.x; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Levresse V, 2000, J NEUROSCI RES, V62, P799; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; LI XM, 1994, J BIOL CHEM, V269, P19653; Li XM, 1997, BIOCHEM J, V327, P709, DOI 10.1042/bj3270709; Liu HW, 2003, AM J RESP CELL MOL, V29, P39, DOI 10.1165/rcmb.2002-0206OC; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 1999, CIRC RES, V84, P852; Macrez N, 2001, CIRC RES, V89, P692, DOI 10.1161/hh2001.097864; Northcott CA, 2002, CIRC RES, V91, P360, DOI 10.1161/01.RES.0000030861.13850.F1; OWENS GK, 1995, PHYSIOL REV, V75, P487; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200; RECH J, 1994, J CELL SCI, V107, P3029; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sata M, 2002, CIRC RES, V91, P273, DOI 10.1161/01.RES.0000031956.29928.62; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tock J, 2003, BIOCHEM BIOPH RES CO, V301, P1116, DOI 10.1016/S0006-291X(03)00087-1; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VANPUTTEN V, 1994, CIRC RES, V75, P1126, DOI 10.1161/01.RES.75.6.1126	53	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39830	39838		10.1074/jbc.M305991200	http://dx.doi.org/10.1074/jbc.M305991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882977	hybrid			2022-12-25	WOS:000185713800069
J	D'Angelo, G; Duplan, E; Boyer, N; Vigne, P; Frelin, C				D'Angelo, G; Duplan, E; Boyer, N; Vigne, P; Frelin, C			Hypoxia up-regulates prolyl hydroxylase activity - A feedback mechansim that limits HIF-1 responses during reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; INDUCIBLE FACTOR; TRANSCRIPTIONAL ACTIVITY; PROLINE HYDROXYLATION; FACTOR 1-ALPHA; FACTOR-1-ALPHA; ALPHA; DEGRADATION; HIF-1-ALPHA; DESTRUCTION	The mechanism by which hypoxia induces gene transcription is now well established. Hypoxia reduces activity of prolyl hydroxylases (PHD) that hydroxylate specific proline residues in the oxygen-dependent degradation domain (ODD) of hypoxia-inducible factor-1alpha (HIF-1alpha). As a consequence, HIF-1alpha accumulates and promotes hypoxic tolerance by activating gene transcription. This paper identifies the three forms of PHDs in rats and shows that a period of hypoxia selectively increases expression of PHD-2 mRNAs levels. We developed assays for PHD activity that used (i) the peptide-specific conversion of labeled 2-oxoglutarate into succinate and (ii) the binding of the von Hippel-Lindau protein to a glutathione S-transferase-ODD fusion protein. The two assays indicated a low enzymatic activity in normoxic and hypoxic cells and a rapid increase during reoxygenation. We also developed hydroxyproline-specific antibodies that recognized hydroxylated forms of a fusion protein (ODD-green fluorescent protein) that combined the ODD domain of HIF-1alpha and the green fluorescent protein. Using this antibody, we demonstrated that reoxygenation induced a rapid hydroxylation of Pro-564, which was followed by a massive degradation of the proteins. The results suggest that a hypoxic up-regulation of PHD (presumably PHD-2) acts as a feedback mechanism to stop hypoxic responses in reoxygenated cells. We propose that proline hydroxylation might play a role in hypoxic preconditioning.	Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	D'Angelo, G (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.		Duplan, Eric/AAK-8224-2020	Duplan, Eric/0000-0002-1348-1507; D'ANGELO, Gisela/0000-0003-3150-2241				BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Baxter GF, 2002, CARDIOVASC RES, V55, P483, DOI 10.1016/S0008-6363(02)00280-8; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'Angelo G, 2003, J BIOL CHEM, V278, P15406, DOI 10.1074/jbc.M211293200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; O'Rourke B, 2000, CIRC RES, V87, P845, DOI 10.1161/01.RES.87.10.845; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304	20	233	239	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38183	38187		10.1074/jbc.M302244200	http://dx.doi.org/10.1074/jbc.M302244200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876291	Green Published, hybrid			2022-12-25	WOS:000185575100013
J	Duan, RD; Bergman, T; Xu, N; Wu, J; Cheng, Y; Duan, JX; Nelander, S; Palmberg, C; Nilsson, A				Duan, RD; Bergman, T; Xu, N; Wu, J; Cheng, Y; Duan, JX; Nelander, S; Palmberg, C; Nilsson, A			Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL ABSORPTION; ACID SPHINGOMYELINASE; LYSOPHOSPHOLIPASE-D; BILE-SALTS; AUTOTAXIN; EXPRESSION; PURIFICATION; HYDROLYSIS; PHOSPHATIDYLCHOLINE; SUPPRESSION	Alkaline sphingomyelinase (alk-SMase) hydrolyzes dietary sphingomyelin and generates sphingolipid messengers in the gut. In the present study, we purified the enzyme, identified a part of the amino acid sequence, and found a cDNA in the GenBank(TM) coding for the protein. The cDNA contains 1841 bp, and the open reading frame encodes 458 amino acids. Transient expression of the cDNA linked to a Myc tag in COS-7 cells increased alk-SMase activity in the cell extract by 689-fold and in the medium by 27-fold. High activity was also identified in the anti-Myc immunoprecipitated proteins and the proteins cross-reacted with anti-human alk-SMase. Northern blotting of human intestinal tissues found high levels of alk-SMase mRNA in the intestine and liver. The amino acid sequence shared no similarity with acid and neutral SMases but was related to the ecto-nucleotide phosphodiesterase (NPP) family with 30 - 36% identity to human NPPs. Alk-SMase has a predicted signal peptide domain at the N terminus and a signal anchor domain at the C terminus. The ion-binding sites and the catalytic residue of NPPs were conserved, but the substrate specificity domain was modified. Alk-SMase had no detectable nucleotidase activity, but its activity against sphingomyelin could be inhibited by orthovanadate, imidazole, and ATP. In contrast to NPPs, alk-SMase activity was not stimulated by divalent metal ions but inhibited by Zn2+. Differing from NPP2, the alk-SMase cleaved phosphocholine but not choline from lysophosphatidylcholine. Phylogenetic tree indicated that the enzyme is a new branch derived from the NPP family. Two cDNA sequences of mouse and rat that shared 83% identity to human alk-SMase were identified in the GenBank(TM). In conclusion, we identified the amino acid and cDNA sequences of human intestinal alk-SMase, and found that it is a novel ectoenzyme related to the NPP family with specific features essential for its SMase activity.	Lund Univ, Gastroenterol Lab, Ctr Biomed, S-22184 Lund, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden; Karolinska Inst, Novum, Dept Biosci, Struct Biochem Ctr, S-14157 Huddinge, Sweden; Univ Gothenburg, Dept Biochem Med, S-40530 Gothenburg, Sweden	Lund University; Karolinska Institutet; Lund University; Skane University Hospital; Karolinska Institutet; University of Gothenburg	Duan, RD (corresponding author), Lund Univ, Gastroenterol Lab, Ctr Biomed, B11, S-22184 Lund, Sweden.	Rui-dong.duan@med.lu.se	duan, rui/AAK-8037-2020	Nelander, Sven/0000-0003-1758-1262; Wu, Jun/0000-0002-5288-8473				Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Benson DA, 2002, NUCLEIC ACIDS RES, V30, P17, DOI 10.1093/nar/30.1.17; Bergman AC, 2000, PROTEOME AND PROTEIN ANALYSIS, P81; BLANK ML, 1992, J NUTR, V122, P1656, DOI 10.1093/jn/122.8.1656; Chatterjee S, 1999, J BIOL CHEM, V274, P37407, DOI 10.1074/jbc.274.52.37407; CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771; Cheng YJ, 2002, J LIPID RES, V43, P316; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; DILLEHAY DL, 1994, J NUTR, V124, P615, DOI 10.1093/jn/124.5.615; Duan RD, 1998, DIGEST DIS SCI, V43, P26, DOI 10.1023/A:1018807600683; Duan RD, 1996, DIGEST DIS SCI, V41, P1801, DOI 10.1007/BF02088748; Duan RD, 1998, SCAND J GASTROENTERO, V33, P673, DOI 10.1080/00365529850171594; Duan RD, 2000, METHOD ENZYMOL, V311, P276; Duan RD, 2003, J LIPID RES, V44, P1241, DOI 10.1194/jlr.M300037-JLR200; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; Duan RD, 1997, HEPATOLOGY, V26, P823, DOI 10.1053/jhep.1997.v26.pm0009328299; Eckhardt ERM, 2002, GASTROENTEROLOGY, V122, P948, DOI 10.1053/gast.2002.32539; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; Hertervig E, 1997, CANCER, V79, P448, DOI 10.1002/(SICI)1097-0142(19970201)79:3<448::AID-CNCR4>3.0.CO;2-E; Hertervig E, 1999, BRIT J CANCER, V81, P232, DOI 10.1038/sj.bjc.6690682; LANDT M, 1978, BIOCHEMISTRY-US, V17, P915, DOI 10.1021/bi00598a027; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MOE OA, 1983, J BIOL CHEM, V258, P6941; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339, DOI 10.1016/0005-2760(69)90192-1; Nyberg L, 2000, J NUTR BIOCHEM, V11, P244, DOI 10.1016/S0955-2863(00)00069-3; Nyberg L, 1996, BBA-LIPID LIPID MET, V1300, P42, DOI 10.1016/0005-2760(95)00245-6; Oppermann M, 2000, EUR J BIOCHEM, V267, P4713, DOI 10.1046/j.1432-1327.2000.01524.x; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Schmelz EM, 1997, NUTR CANCER, V28, P81, DOI 10.1080/01635589709514556; Schmelz EM, 1999, CANCER RES, V59, P5768; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Sjoqvist U, 2002, INFLAMM BOWEL DIS, V8, P258; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Stoffel W, 1975, Methods Enzymol, V35, P533; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; TOMITA M, 1982, BIOCHIM BIOPHYS ACTA, V704, P90, DOI 10.1016/0167-4838(82)90135-2; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; ZEISEL SH, 1986, J NUTR, V116, P50, DOI 10.1093/jn/116.1.50	49	115	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38528	38536		10.1074/jbc.M305437200	http://dx.doi.org/10.1074/jbc.M305437200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885774	hybrid			2022-12-25	WOS:000185575100055
J	Li, Y; Wu, LJ; Legendre, P; Xu, TL				Li, Y; Wu, LJ; Legendre, P; Xu, TL			Asymmetric cross-inhibition between GABA(A) and glycine receptors in rat spinal dorsal horn neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-STEM MOTONEURONS; HIPPOCAMPAL-NEURONS; GUINEA-PIG; IONOTROPIC RECEPTORS; COMMISSURAL NEURONS; CORD NEURONS; CALCINEURIN; RESPONSES; SYNAPSES; CHANNELS	Presynaptic nerve terminals of inhibitory synapses in the dorsal horn of the spinal cord and brain stem can release both GABA and glycine, leading to coactivation of postsynaptic GABA(A) and glycine receptors. In the present study we have analyzed functional interactions between GABA(A) and glycine receptors in acutely dissociated neurons from rat sacral dorsal commissural nucleus. Although the application of GABA and glycine activates pharmacologically distinct receptors, the current induced by a simultaneous application of these two transmitters was less than the sum of currents induced by applying two transmitters separately. Sequential application of glycine and GABA revealed that the GABA-evoked current is more affected by glycine than glycine-evoked responses by GABA. Activation of glycine receptors decreased the amplitude and accelerated the rate of desensitization of GABA-induced currents. This asymmetric cross-inhibition is reversible, dependent on the agonist concentration applied, but independent of both membrane potential and intracellular calcium concentration or changes in the chloride equilibrium potential. During sequential applications, the asymmetric cross-inhibition was prevented by selective GABA(A) or glycine receptor antagonists, suggesting that occupation of binding sites did not suffice to induce glycine and GABA(A) receptors functional interaction, and receptor channel activation is required. Furthermore, inhibition of phosphatase 2B, but not phosphatase 1 or 2A, prevented GABA(A) receptor inhibition by glycine receptor activation, whereas inhibition of phosphorylation pathways rendered cross-talk irreversible. Taken together, our results demonstrated that there is an asymmetric cross-inhibition between glycine and GABA(A) receptors and that a selective modulation of the state of phosphorylation of GABA(A) receptor and/or mediator proteins underlies the asymmetry in the cross-inhibition.	Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Univ Sci & Technol China, Dept Neurobiol & Biophys, Hefei 230027, Peoples R China; Univ Paris 06, CNRS, UMR 7102, F-75252 Paris 05, France	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Xu, TL (corresponding author), Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	tlxu@ion.ac.cn	Wu, Long-Jun/AAK-7113-2020; Wu, Long-Jun/E-2684-2012; Li, Yong/ABB-5588-2021	Wu, Long-Jun/0000-0001-8019-3380; 				AKAIKE N, 1987, J PHYSIOL-LONDON, V391, P219, DOI 10.1113/jphysiol.1987.sp016735; ARIENS EJ, 1964, J PHARM PHARMACOL, V16, P289, DOI 10.1111/j.2042-7158.1964.tb07461.x; BAEV KV, 1992, NEUROSCIENCE, V46, P931, DOI 10.1016/0306-4522(92)90195-8; Barajas-Lopez C, 1998, J PHYSIOL-LONDON, V513, P671, DOI 10.1111/j.1469-7793.1998.671ba.x; BARKER JL, 1979, NATURE, V277, P234, DOI 10.1038/277234a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CHEN QX, 1995, J PHYSIOL-LONDON, V482, P353, DOI 10.1113/jphysiol.1995.sp020522; Dumoulin A, 2001, J NEUROSCI, V21, P6045, DOI 10.1523/JNEUROSCI.21-16-06045.2001; Dumoulin A, 2000, EUR J NEUROSCI, V12, P3883, DOI 10.1046/j.1460-9568.2000.00271.x; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Fucile S, 1999, J PHYSIOL-LONDON, V517, P369, DOI 10.1111/j.1469-7793.1999.0369t.x; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; GRASSI F, 1992, BRAIN RES, V594, P115, DOI 10.1016/0006-8993(92)91035-D; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; Jones MV, 1997, J NEUROSCI, V17, P7626; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Kirsch J, 1998, NATURE, V392, P717, DOI 10.1038/33694; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; LEWIS CA, 1993, NEUROSCIENCE, V52, P83, DOI 10.1016/0306-4522(93)90184-H; Li Y, 2002, NEUROREPORT, V13, P223, DOI 10.1097/00001756-200202110-00010; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Lu YM, 2000, NEURON, V26, P197, DOI 10.1016/S0896-6273(00)81150-2; MA W, 1993, J COMP NEUROL, V338, P337, DOI 10.1002/cne.903380303; Martina M, 1996, NEUROSCI LETT, V215, P95, DOI 10.1016/S0304-3940(96)12957-8; NAKAZAWA K, 1994, J NEUROSCI, V14, P740; O'Brien JA, 1999, J NEUROPHYSIOL, V82, P1638, DOI 10.1152/jn.1999.82.3.1638; Russier M, 2002, J PHYSIOL-LONDON, V541, P123, DOI 10.1113/jphysiol.2001.016063; Saint Jan DD, 2001, J PHYSIOL-LONDON, V535, P741; Sokolova E, 2001, J NEUROSCI, V21, P4958, DOI 10.1523/JNEUROSCI.21-14-04958.2001; STELZER A, 1994, NEUROSCIENCE, V62, P813, DOI 10.1016/0306-4522(94)90479-0; Todd AJ, 1996, J NEUROSCI, V16, P974; Trombley PQ, 1999, J NEUROPHYSIOL, V82, P3417, DOI 10.1152/jn.1999.82.6.3417; Wang J, 2003, J NEUROSCI, V23, P826; Wu LJ, 2002, NEUROREPORT, V13, P977, DOI 10.1097/00001756-200205240-00016; Xu TL, 2000, EUR J NEUROSCI, V12, P1647; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; Zhou XP, 1998, J PHYSIOL-LONDON, V513, P685, DOI 10.1111/j.1469-7793.1998.685ba.x	42	50	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38637	38645		10.1074/jbc.M303735200	http://dx.doi.org/10.1074/jbc.M303735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885784	hybrid			2022-12-25	WOS:000185575100068
J	Muller, EM; Mackin, NA; Erdman, SE; Cunningham, KW				Muller, EM; Mackin, NA; Erdman, SE; Cunningham, KW			Fig1p facilitates Ca2+ influx and cell fusion during mating of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; GENE-EXPRESSION; NEUROTRANSMITTER RELEASE; ACTIN CYTOSKELETON; CALCIUM CHANNELS; MEMBRANE-PROTEIN; INVASIVE GROWTH; S-CEREVISIAE; YEAST-CELLS	During the mating process of yeast cells, two Ca2+ influx pathways become activated. The resulting elevation of cytosolic free Ca2+ activates downstream signaling factors that promote long term survival of unmated cells, but the roles of Ca2+ in conjugation have not been described. The high affinity Ca2+ influx system is composed of Cch1p and Mid1p and sensitive to feedback inhibition by calcineurin, a Ca2+/calmodulin-dependent protein phosphatase. To identify components and regulators of the low affinity Ca2+ influx system (LACS), we screened a collection of pheromone-responsive genes that when deleted lead to defects in LACS activity but not high affinity Ca2+ influx system activity. Numerous factors implicated in polarized morphogenesis and cell fusion (Fus1p, Fus2p, Rvs161p, Bni1p, Spa2p, and Pea2p) were found to be necessary for LACS activity. Each of these factors was also required for activation of the cell integrity mitogen-activated protein kinase cascade during the response to alpha-factor. Interestingly a polytopic plasma membrane protein, Fig1p, was required for LACS activity but not required for activation of Mpk1p mitogen-activated protein kinase. Mpk1p was not required for LACS activity, suggesting Mpk1p and Fig1p define two independent branches in the pheromone response pathways. Fig1p-deficient mutants exhibit defects in the cell-cell fusion step of mating, but unlike other fus1 and fus2 mutants the fusion defect of fig1 mutants can be largely suppressed by high Ca2+ conditions, which bypass the requirement for LACS. These findings suggest Fig1p is an important component or regulator of LACS and provide the first evidence for a role of Ca2+ signals in the cell fusion step of mating.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	Johns Hopkins University; Syracuse University	Cunningham, KW (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	kwc@jhu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053082] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM053082] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atlas D, 2001, CELL MOL NEUROBIOL, V21, P717, DOI 10.1023/A:1015104105262; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Bidlingmaier Scott, 2002, Functional and Integrative Genomics, V1, P345, DOI 10.1007/s10142-001-0043-1; Blondel M, 1999, GENE DEV, V13, P2284, DOI 10.1101/gad.13.17.2284; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; BONILLA M, 2003, IN PRESS MOL BIOL CE; Brachmann CB, 1998, YEAST, V14, P115; Brizzio V, 1998, J CELL BIOL, V141, P567, DOI 10.1083/jcb.141.3.567; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; BURNS N, 1994, GENE DEV, P1077; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHENEVERT J, 1994, GENETICS, V136, P1287; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dorer R, 1997, GENETICS, V146, P39; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1995, J CELL BIOL, V130, P1283, DOI 10.1083/jcb.130.6.1283; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; Gammie AE, 1998, MOL BIOL CELL, V9, P1395, DOI 10.1091/mbc.9.6.1395; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Heiman MG, 2000, J CELL BIOL, V151, P719, DOI 10.1083/jcb.151.3.719; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; Kawasaki R, 2003, GENES CELLS, V8, P235, DOI 10.1046/j.1365-2443.2003.00629.x; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Lord M, 2002, CURR BIOL, V12, P1347, DOI 10.1016/S0960-9822(02)01042-4; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Miller RK, 1999, J CELL BIOL, V144, P963, DOI 10.1083/jcb.144.5.963; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; Muller EM, 2001, GENETICS, V159, P1527; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; OHSUMI Y, 1985, J BIOL CHEM, V260, P482; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; Philips J, 1998, J CELL BIOL, V143, P375, DOI 10.1083/jcb.143.2.375; Philips J, 1997, J CELL BIOL, V138, P961, DOI 10.1083/jcb.138.5.961; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Sherman F., 1986, METHODS YEAST GENETI; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; SIKORSKI RS, 1989, GENETICS, V122, P19; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Stamboulian SV, 2002, DEV BIOL, V252, P72, DOI 10.1006/dbio.2002.0844; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Valtz N, 1996, J CELL BIOL, V135, P725, DOI 10.1083/jcb.135.3.725; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; Yanez-Mo M, 2001, MICROCIRCULATION, V8, P153; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	77	85	92	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38461	38469		10.1074/jbc.M304089200	http://dx.doi.org/10.1074/jbc.M304089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878605	hybrid			2022-12-25	WOS:000185575100047
J	Liu, SG; Guo, R; Simpson, LG; Xiao, ZS; Burnham, CE; Quarles, LD				Liu, SG; Guo, R; Simpson, LG; Xiao, ZS; Burnham, CE; Quarles, LD			Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED HYPOPHOSPHATEMIA; FIBROBLAST GROWTH FACTOR-23; PEX GENE; PHOSPHATE-TRANSPORT; SUBCELLULAR-LOCALIZATION; ONCOGENIC OSTEOMALACIA; PROTEOLYTIC CLEAVAGE; HYP MICE; ENDOPEPTIDASE; RICKETS	Inactivating mutations of Phex cause X-linked hypophosphatemia (XLH) by increasing levels of a circulating phosphaturic factor. FGF23 is a candidate for this phosphaturic factor. Elevated serum FGF23 levels correlate with the degree of hypophosphatemia in XLH, suggesting that loss of Phex function in this disorder results in either diminished degradation and/or increased biosynthesis of FGF23. To establish the mechanisms whereby Phex regulates FGF23, we assessed Phex-dependent hydrolysis of recombinant FGF23 in vitro and measured fgf23 message levels in the Hyp mouse homologue of XLH. In COS-7 cells, overexpression of FGF23 resulted in its degradation into N- and C-terminal fragments by an endogenous decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone-sensitive furin-type convertase. Phex-dependent hydrolysis of full-length FGF23 or its N- and C-terminal fragments could not be demonstrated in the presence or absence of decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone in COS-7 cells expressing Phex and FGF23. In a reticulolysate system, apparent cleavage of FGF23 occurred with wild-type Phex, the inactive Phex-3'M mutant, and vector controls, indicating nonspecific metabolism of FGF23 by contaminating enzymes. These findings suggest that FGF23 is not a direct Phex substrate. In contrast, by real-time reverse transcriptase PCR, the levels of fgf23 transcripts were highest in bone, the predominant site of Phex expression. In addition, Hyp mice displayed a bone-restricted increase in fgf23 transcripts in association with inactivating Phex mutations. Increased expression of fgf23 was also observed in Hyp-derived osteoblasts in culture. These findings suggest that Phex, possibly through the actions of unidentified Phex substrates or other downstream effectors, regulates fgf23 expression as part of a potential hormonal axis between bone and kidney that controls systemic phosphate homeostasis and mineralization.	Duke Univ, Med Ctr, Dept Med, Ctr Bone & Mineral Disorders, Durham, NC 27710 USA	Duke University	Quarles, LD (corresponding author), Duke Univ, Med Ctr, Dept Med, Ctr Bone & Mineral Disorders, Box 3036, Durham, NC 27710 USA.	quar1001@mc.duke.edu		Quarles, L. Darryl/0000-0002-5082-7896	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045955] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR-45955] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Argiro L, 2001, GENOMICS, V74, P342, DOI 10.1006/geno.2001.6553; Bai XY, 2003, J BIOL CHEM, V278, P9843, DOI 10.1074/jbc.M210490200; Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276; Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; Campos M, 2003, BIOCHEM J, V373, P271, DOI 10.1042/BJ20030287; Carpinelli MR, 2002, AM J PATHOL, V161, P1925, DOI 10.1016/S0002-9440(10)64468-9; De Beur SMJ, 2002, J BONE MINER RES, V17, P1102, DOI 10.1359/jbmr.2002.17.6.1102; Du L, 1996, GENOMICS, V36, P22, DOI 10.1006/geno.1996.0421; ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Grieff M, 1997, BIOCHEM BIOPH RES CO, V231, P635, DOI 10.1006/bbrc.1997.6153; Guo R, 1997, J BONE MINER RES, V12, P1009, DOI 10.1359/jbmr.1997.12.7.1009; Guo R, 2002, BIOCHEM BIOPH RES CO, V297, P38, DOI 10.1016/S0006-291X(02)02125-3; Guo R, 2001, AM J PHYSIOL-ENDOC M, V281, pE837, DOI 10.1152/ajpendo.2001.281.4.E837; Holm IA, 1997, AM J HUM GENET, V60, P790; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Lee S, 2001, J BIOL CHEM, V276, P27281, DOI 10.1074/jbc.M103433200; Leitlein J, 2001, J IMMUNOL, V166, P7238, DOI 10.4049/jimmunol.166.12.7238; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; Meyer RA, 1998, GENOMICS, V48, P289, DOI 10.1006/geno.1997.5169; MEYER RA, 1989, J BONE MINER RES, V4, P493; MEYER RA, 1989, J BONE MINER RES, V4, P523; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NESBITT T, 1992, J CLIN INVEST, V89, P1453, DOI 10.1172/JCI115735; Nesbitt T, 1999, J BONE MINER RES, V14, P2027, DOI 10.1359/jbmr.1999.14.12.2027; Ntayi C, 2001, EXP CELL RES, V270, P110, DOI 10.1006/excr.2001.5306; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; QIN C, 2003, IN PRESS J BIOL CHEM; Quarles LD, 2002, J AM SOC NEPHROL, V13, p572A; QUARLES LD, 2000, J AM SOC NEPHROL, V11, pA3002; RASMUSSEN H, 1983, FAMILIAL HYPOPHOSPHA, P1743; RIMINUCCI M, 2003, IN PRESS J CLIN INVE; Ruchon AF, 1998, J HISTOCHEM CYTOCHEM, V46, P459; Ruchon AF, 2000, J BONE MINER RES, V15, P1440, DOI 10.1359/jbmr.2000.15.8.1440; Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Strewler GJ, 2001, P NATL ACAD SCI USA, V98, P5945, DOI 10.1073/pnas.11154898; Strom TM, 1997, HUM MOL GENET, V6, P165, DOI 10.1093/hmg/6.2.165; Thompson DL, 2002, J BONE MINER RES, V17, P311, DOI 10.1359/jbmr.2002.17.2.311; Turner AJ, 2000, ADV EXP MED BIOL, V477, P229; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227; White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Xiao ZS, 1998, AM J PHYSIOL-ENDOC M, V275, pE700, DOI 10.1152/ajpendo.1998.275.4.E700; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002-021105	51	365	379	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37419	37426		10.1074/jbc.M304544200	http://dx.doi.org/10.1074/jbc.M304544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12874285	hybrid			2022-12-25	WOS:000185437200054
J	Murata, CE; Goldberg, DE				Murata, CE; Goldberg, DE			Plasmodium falciparum falcilysin - A metalloprotease with dual specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; HEMOGLOBIN DEGRADATION; FOOD VACUOLE; CLEAVAGE; PARASITE; PROTEASE; IDENTIFICATION; PLASMEPSINS; VIEW	The malaria parasite Plasmodium falciparum degrades host cell hemoglobin within an acidic food vacuole. The metalloprotease falcilysin has previously been identified as an important component of this catabolic process. Using random peptide substrate analysis, we confirm that recombinant falcilysin is highly active at acidic pH, consistent with its role in hemoglobin degradation. Unexpectedly, the enzyme is also robustly active at neutral pH, but with a substantially different substrate specificity. Imaging studies confirm the location of falcilysin in the food vacuole and reveal association with vesicular structures elsewhere within the parasite. These data suggest that falcilysin may have an expanded role beyond globin catabolism and may function as two different proteases in its two locations.	Washington Univ, Dept Mol Microbiol, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Dept Internal Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Dept Mol Microbiol, Sch Med, Howard Hughes Med Inst, Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	goldberg@borcim.wustl.edu			NIAID NIH HHS [AI-47798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; Banerjee R, 2001, INFEC DIS S, P43; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; BOHNI P, 1980, ORG EXPRESSION MITOC, P423; deDominguez NDG, 1996, BLOOD, V87, P4448, DOI 10.1182/blood.V87.10.4448.bloodjournal87104448; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Foley M, 1998, INT J PARASITOL, V28, P1671, DOI 10.1016/S0020-7519(98)00132-5; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; Francis SE, 1997, J BIOL CHEM, V272, P14961, DOI 10.1074/jbc.272.23.14961; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198; Kojima K, 2001, J BIOL CHEM, V276, P2115, DOI 10.1074/jbc.M003111200; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Murata CE, 2003, MOL BIOCHEM PARASIT, V129, P123, DOI 10.1016/S0166-6851(03)00098-7; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; RAWLINGS ND, 1998, HDB PROTEOLYTIC ENZY, P1360; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; SCHMIDT GW, 1979, J CELL BIOL, V83, P615, DOI 10.1083/jcb.83.3.615; SHAHABUDDIN M, 1992, EXP PARASITOL, V74, P11, DOI 10.1016/0014-4894(92)90134-V; Sherman I. W., 1998, MALARIA PARASITE BIO; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x	35	58	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38022	38028		10.1074/jbc.M306842200	http://dx.doi.org/10.1074/jbc.M306842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12876284	hybrid			2022-12-25	WOS:000185437200124
J	Harvey, AJ; Crompton, MR				Harvey, AJ; Crompton, MR			Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation	ONCOGENE			English	Article						protein-tyrosine kinase; breast cancer; RNA interference; small interfering RNA; proliferation	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; EPIDERMAL-GROWTH-FACTOR; GASTROINTESTINAL-TRACT; EXPRESSION; 3-KINASE; PROTEIN; FAMILY; TUMORS; SIK	Brk (PTK6) is a nonreceptor protein tyrosine kinase, which is expressed in over 60% of breast carcinoma tissue samples and breast tumour cell lines, but not normal mammary tissue or benign lesions. Since experimental Brk expression in nontransformed mammary epithelial cells enhances their mitogenic response to epidermal growth factor, it was important to determine the role Brk plays in the proliferation of breast carcinoma cells and validate it as a therapeutic target. We have used RNA interference to efficiently and specifically downregulate Brk protein levels in breast carcinoma cells, and determined that this results in a significant suppression of their proliferation. Additionally, through the expression of a kinase-inactive mutant, we have determined that Brk can mediate promotion of proliferation via a kinase-independent mechanism, potentially functioning as an 'adapter'. These data identify Brk as a novel target for antiproliferative therapy in the majority of breast cancers, and illustrate the power of RNA interference for rapidly validating candidate therapeutic targets.	Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of London; Royal Holloway University London	Crompton, MR (corresponding author), Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England.							Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Lee HY, 1998, MOL CELLS, V8, P401; Llor X, 1999, CLIN CANCER RES, V5, P1767; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; QUI H, 2002, J BIOL CHEM, V277, P34634; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	21	64	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5006	5010		10.1038/sj.onc.1206577	http://dx.doi.org/10.1038/sj.onc.1206577			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902983				2022-12-25	WOS:000184578900008
J	Jin, BF; He, K; Wang, HX; Wang, J; Zhou, T; Lan, Y; Hu, MR; Wei, KH; Yang, SC; Shen, BF; Zhang, XM				Jin, BF; He, K; Wang, HX; Wang, J; Zhou, T; Lan, Y; Hu, MR; Wei, KH; Yang, SC; Shen, BF; Zhang, XM			Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A	ONCOGENE			English	Article						proteomics; ubiquitin-proteasome; matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; apoptosis; leukemic cell	HYPUSINE MODIFICATION; CELL-PROLIFERATION; APOPTOSIS; PROTEINS; EIF-5A; PHOSPHORYLATION; PATHWAY; RNA; DEOXYHYPUSINE; LOCALIZATION	The global effect of ubiquitin-proteasome (UP) inhibitors on leukemic cell proteome was analysed. A total of 39 protein spots, affected by UP inhibitors, were identified, including 11 new apoptosis-associated proteins. They are involved in different cellular functions and four were associated with caspase-3 activation. Eukaryotic initiation factor 5A (eIF-5A) was identified in two spots; however, the peptide mass-fingerprinting for the accumulated one included a peptide with lysine(50), indicating that hypusine formation was suppressed during UP inhibitor-induced apoptosis. Hypusine modification ensues immediately following translation of eIF-5A precursor, unless cells are treated with the modification inhibitors diaminoheptane. However, UP inhibitors induced a much stronger accumulation of unmodified eIF-5A compared to the effect of diaminoheptane. We further showed the unmodified eIF-5A was regulated in a proteasome-dependent manner. Inhibition of hypusine formation by diaminoheptane triggered apoptosis, but of particular interest is the finding that eIF-5A expression inhibition by antisense oligodeoxynucleotides significantly enhanced the stimulating effect of GM-CSF on cell growth. Therefore, the eIF-5A accumulation played important roles in the apoptosis induced by UP inhibitors. Moreover, hypusine inhibition in apoptosis was further revealed to be associated with the subcellular localization of eIF-5A. Our data pave the way to a better understanding of the mechanisms by which UP system has been linked to apoptosis.	Natl Ctr Biomed Anal, Inst Basic Med Sci, Beijing 100850, Peoples R China		Zhang, XM (corresponding author), Natl Ctr Biomed Anal, Inst Basic Med Sci, 27 Tai Ping Rd, Beijing 100850, Peoples R China.		Lan, Yu/AAV-2236-2021	Lan, Yu/0000-0002-4731-5945				Caraglia M, 2001, AMINO ACIDS, V20, P91, DOI 10.1007/s007260170050; Chen KY, 1999, J CHIN CHEM SOC-TAIP, V46, P727, DOI 10.1002/jccs.199900100; Chen KY, 1997, BIOL SIGNAL, V6, P105; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Gamble SC, 2000, CANCER RES, V60, P2146; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; HERSHEY JWB, 1990, BIOCHIM BIOPHYS ACTA, V1050, P160, DOI 10.1016/0167-4781(90)90159-Y; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ito H, 2002, J BIOCHEM, V131, P593, DOI 10.1093/oxfordjournals.jbchem.a003139; JAKUS J, 1993, J BIOL CHEM, V268, P13131; Jao DLE, 2002, J CELL BIOCHEM, V86, P590, DOI 10.1002/jcb.10235; KANG HA, 1994, J BIOL CHEM, V269, P3934; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Liu YP, 1997, BIOL SIGNAL, V6, P166; Lovric J, 1998, J BIOL CHEM, V273, P22848; Melhem R, 1997, LEUKEMIA, V11, P1690, DOI 10.1038/sj.leu.2400792; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1991, J BIOL CHEM, V266, P7988; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rosorius O, 1999, J CELL SCI, V112, P2369; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Shen EC, 2000, J BIOL CHEM, V275, P23718, DOI 10.1074/jbc.M002312200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi XP, 1996, EXP CELL RES, V225, P348, DOI 10.1006/excr.1996.0185; Soldes OS, 1999, BRIT J CANCER, V79, P595, DOI 10.1038/sj.bjc.6690094; Tome ME, 1997, BIOCHEM J, V328, P847; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Verlaet M, 2001, BIOCHEM BIOPH RES CO, V283, P12, DOI 10.1006/bbrc.2001.4731; Wang HX, 2002, ACTA BIOCH BIOPH SIN, V34, P630; Witke W, 2001, P NATL ACAD SCI USA, V98, P3832, DOI 10.1073/pnas.051515498; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6; Zhang XM, 1999, BIOCHEM J, V340, P127, DOI 10.1042/0264-6021:3400127	36	66	70	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4819	4830		10.1038/sj.onc.1206738	http://dx.doi.org/10.1038/sj.onc.1206738			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894223				2022-12-25	WOS:000184344600005
J	Rose-Hellekant, TA; Arendt, LM; Schroeder, MD; Gilchrist, K; Sandgren, EP; Schuler, LA				Rose-Hellekant, TA; Arendt, LM; Schroeder, MD; Gilchrist, K; Sandgren, EP; Schuler, LA			Prolactin induces ER alpha-positive and ER alpha-negative mammary cancer in transgenic mice	ONCOGENE			English	Article						mammary cancer; prolactin; ER alpha; transgenic mice	ESTROGEN-RECEPTOR-ALPHA; GLAND DEVELOPMENT; GROWTH-HORMONE; PROGESTERONE-RECEPTOR; CELL-PROLIFERATION; BREAST-CANCER; EPITHELIAL-CELLS; EXPRESSION; TUMORS; DISRUPTION	The role of prolactin in human breast cancer has been controversial. However, it is now apparent that human mammary epithelial cells can synthesize prolactin endogenously, permitting autocrine/paracrine actions within the mammary gland that are independent of pituitary prolactin. To model this local mammary production of prolactin (PRL), we have generated mice that overexpress prolactin within mammary epithelial cells under the control of a hormonally nonresponsive promoter, neurelated lipocalin (NRL). In each of the two examined NRL-PRL transgenic mouse lineages, female virgin mice display mammary developmental abnormalities, mammary intraepithelial neoplasias, and invasive neoplasms. Prolactin increases proliferation in morphologically normal alveoli and ducts, as well as in lesions. The tumors are of varied histotype, but papillary adenocarcinomas and adenosquamous neoplasms predominate. Neoplasms can be separated into two populations: one is estrogen receptor alpha (ERalpha) positive (greater than 15% of the cells stain for ERalpha), and the other is ERalpha- ( < 3%). ER alpha expression does not correlate with tumor histotype, or proliferative or apoptotic indices. These studies provide a mouse model of hormonally dependent breast cancer, and, perhaps most strikingly, a model in which some neoplasms retain ERa, as occurs in the human disease.	Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu		Arendt, Lisa/0000-0002-7954-3635	NATIONAL CANCER INSTITUTE [R01CA064843, R01CA078312] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000265] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078312, R01-CA64843, R01 CA78312] Funding Source: Medline; NCRR NIH HHS [K01 RR00145] Funding Source: Medline; NIA NIH HHS [T32 AG000265, T32-AG00265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Beck MT, 2002, ONCOGENE, V21, P5047, DOI 10.1038/sj.onc.1205637; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; BERA TK, 1994, MOL CELL BIOCHEM, V132, P145, DOI 10.1007/BF00926923; BOOT LM, 1962, GEN COMP ENDOCR, V2, P601; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Camarillo IG, 2001, J ENDOCRINOL, V171, P85, DOI 10.1677/joe.0.1710085; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; Christov KT, 1996, CARCINOGENESIS, V17, P1741, DOI 10.1093/carcin/17.8.1741; Clarke RB, 1997, CANCER RES, V57, P4987; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; DEOME KB, 1959, CANCER RES, V19, P515; EDERY M, 1985, ENDOCRINOLOGY, V116, P105, DOI 10.1210/endo-116-1-105; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; GOUT PW, 1980, CANCER RES, V40, P2433; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Hu ZZ, 2001, J BIOL CHEM, V276, P41086, DOI 10.1074/jbc.M102109200; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; HUSEBY RA, 1985, ENDOCRINOLOGY, V116, P1440, DOI 10.1210/endo-116-4-1440; Imagawa W, 2002, J STEROID BIOCHEM, V80, P213, DOI 10.1016/S0960-0760(01)00188-1; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Medina D, 2002, BBA-REV CANCER, V1603, P1, DOI 10.1016/S0304-419X(02)00053-7; Mertani HC, 1998, INT J CANCER, V79, P202; MULDOON TG, 1987, ENDOCRINOLOGY, V121, P141, DOI 10.1210/endo-121-1-141; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Qin W, 1999, J VIROL, V73, P368, DOI 10.1128/JVI.73.1.368-376.1999; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Rose-Hellekant TA, 2002, AM J PATHOL, V161, P1439, DOI 10.1016/S0002-9440(10)64419-7; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Schroeder MD, 2001, MOL CELL ENDOCRINOL, V175, P173, DOI 10.1016/S0303-7207(01)00385-9; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; SHAFIE S, 1977, CANCER RES, V37, P792; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Shyamala G, 2002, J STEROID BIOCHEM, V80, P137, DOI 10.1016/S0960-0760(01)00182-0; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Stoesz SP, 1995, ONCOGENE, V11, P2233; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tseng YH, 1997, MOL CELL ENDOCRINOL, V128, P117, DOI 10.1016/S0303-7207(97)04028-8; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 2000, CONT ENDOCRINOL, P101; WELSCH CW, 1977, CANCER RES, V37, P951; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Yarus S, 1996, Genet Eng (N Y), V18, P57; Yoshidome K, 2000, CANCER RES, V60, P6901; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x	66	148	148	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4664	4674		10.1038/sj.onc.1206619	http://dx.doi.org/10.1038/sj.onc.1206619			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879011	Green Accepted			2022-12-25	WOS:000184157000007
J	Ceni, C; Muller-Steffner, H; Lund, F; Pochon, N; Schweitzer, A; De Waard, M; Schuber, F; Villaz, M; Moutin, MJ				Ceni, C; Muller-Steffner, H; Lund, F; Pochon, N; Schweitzer, A; De Waard, M; Schuber, F; Villaz, M; Moutin, MJ			Evidence for an intracellular ADP-ribosyl cyclase/NAD(+)-glycohydrolase in brain from CD38-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; RAT CARDIAC MYOCYTES; SURFACE-MOLECULE; CYCLASE ACTIVITY; NEUROTRANSMITTER RELEASE; FUNCTIONAL EXPRESSION; RYANODINE RECEPTOR; ANTIGEN CD38; CA2+ RELEASE; CELLS	Cyclic ADP-ribose, a metabolite of NAD(+), is known to modulate intracellular calcium levels and signaling in various cell types, including neural cells. The enzymes responsible for producing cyclic ADP-ribose in the cytoplasm of mammalian cells remain unknown; however, two mammalian enzymes that are capable of producing cyclic ADP-ribose extracellularly have been identified, CD38 and CD157. The present study investigated whether an ADP-ribosyl cyclase/NAD(+)-glycohydrolase independent of CD38 is present in brain tissue. To address this question, NAD(+) metabolizing activities were accurately examined in developing and adult Cd38(-/-) mouse brain protein extracts and cells. Low ADP-ribosyl cyclase and NAD(+)-glycohydrolase activities ( in the range of pmol of product formed/mg of protein/min) were detected in Cd38(-/-) brain at all developmental stages studied. Both activities were found to be associated with cell membranes. The activities were significantly higher in Triton X-100-treated neural cells compared with intact cells, suggesting an intracellular location of the novel cyclase. The cyclase and glycohydrolase activities were optimal at pH 6.0 and were inhibited by zinc, properties which are distinct from those of CD157. Both activities were enhanced by guanosine 5'-O-(3-thiotriphosphate), a result suggesting that the novel enzyme may be regulated by a G protein-dependent mechanism. Altogether our results indicate the presence of an intracellular membrane-bound ADP-ribosyl cyclase/NAD(+)-glycohydrolase distinct from CD38 and from CD157 in mouse brain. This novel enzyme, which is more active in the developing brain than in the adult tissue, may play an important role in cyclic ADP-ribose-mediated calcium signaling during brain development as well as in adult tissue.	CEA, DRDC, INSERM, EMI 9931,Lab Canaux Ion & Signalisat, F-38051 Grenoble 9, France; Univ Strasbourg, Fac Pharm, CNRS, UMR 7514,Lab Chim Bioorgan, F-67400 Strasbourg, France; CEA, DRDC, INSERM, U366,Lab Cytosquelette, F-38051 Grenoble, France; Trudeau Inst Inc, Saranac Lake, NY 12983 USA	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Trudeau Institute	Moutin, MJ (corresponding author), CEA, DRDC, INSERM, EMI 9931,Lab Canaux Ion & Signalisat, 17 Ave Martyrs, F-38051 Grenoble 9, France.	moutin@dsvgre.cea.fr	De Waard, Michel/G-7406-2014; Moutin, Marie-Jo/P-7518-2017	De Waard, Michel/0000-0002-2782-9615; Moutin, Marie-Jo/0000-0003-2681-9818	NIAID NIH HHS [AI43929] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI043929] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Augustin A, 2000, BIOCHEM J, V345, P43, DOI 10.1042/0264-6021:3450043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budde T, 2000, NEURON, V26, P483, DOI 10.1016/S0896-6273(00)81180-0; Cakir-Kiefer C, 2000, BIOCHEM J, V349, P203, DOI 10.1042/0264-6021:3490203; Ceni C, 2003, BIOCHEM J, V370, P175, DOI 10.1042/BJ20020604; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; Graeff RM, 1998, J BIOL CHEM, V273, P118, DOI 10.1074/jbc.273.1.118; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Higashida H, 1997, J BIOL CHEM, V272, P31272, DOI 10.1074/jbc.272.50.31272; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Hussain AMM, 1998, PROTEIN EXPRES PURIF, V12, P133, DOI 10.1006/prep.1997.0811; ITOH M, 1994, BIOCHEM BIOPH RES CO, V203, P1309, DOI 10.1006/bbrc.1994.2325; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; Kajimoto Y, 1996, BIOCHEM BIOPH RES CO, V219, P941, DOI 10.1006/bbrc.1996.0327; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; Lee Hon Cheung, 1998, Cell Biochemistry and Biophysics, V28, P1, DOI 10.1007/BF02738306; LI Q, 1994, BIOCHEM BIOPH RES CO, V202, P629, DOI 10.1006/bbrc.1994.1974; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; Missiaen L, 1998, BIOCHEM J, V329, P489, DOI 10.1042/bj3290489; MIZUGUCHI M, 1995, BRAIN RES, V697, P235, DOI 10.1016/0006-8993(95)00885-T; Morikawa H, 2003, J NEUROSCI, V23, P149; Mothet JP, 1998, J PHYSIOL-LONDON, V507, P405, DOI 10.1111/j.1469-7793.1998.405bt.x; Noda M, 2003, J NEUROCHEM, V84, P222, DOI 10.1046/j.1471-4159.2003.01518.x; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Pollock J, 1999, CELL CALCIUM, V26, P139, DOI 10.1054/ceca.1999.0064; Reyes-Harde M, 1999, P NATL ACAD SCI USA, V96, P4061, DOI 10.1073/pnas.96.7.4061; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TWU JS, 1977, ARCH BIOCHEM BIOPHYS, V184, P249, DOI 10.1016/0003-9861(77)90348-4; Vanlingen S, 2001, BIOCHEM PHARMACOL, V61, P803, DOI 10.1016/S0006-2952(01)00540-8; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; Walseth TF, 1997, METHOD ENZYMOL, V280, P287; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; Yamamoto-Katayama S, 2002, J MOL BIOL, V316, P711, DOI 10.1006/jmbi.2001.5386	43	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40670	40678		10.1074/jbc.M301196200	http://dx.doi.org/10.1074/jbc.M301196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12909645	hybrid			2022-12-25	WOS:000185847200031
J	Lopez, RG; Carron, C; Ghysdael, J				Lopez, RG; Carron, C; Ghysdael, J			v-SRC specifically regulates the nucleo-cytoplasmic delocalization of the major isoform of TEL (ETV6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTIONAL REPRESSOR ACTIVITY; PUTATIVE TUMOR-SUPPRESSOR; RAS-TRANSFORMED-CELLS; ETS DOMAIN PROTEIN; NUCLEAR EXPORT; DNA-BINDING; HISTONE DEACETYLASE-3; STAT3 ACTIVATION; FUSION PROTEIN	TEL is a frequent target of chromosomal translocations in human cancer and an alleged tumor suppressor gene. TEL encodes two isoforms: a major TEL-M1 isoform as well as TEL-M43, which lacks the first 42 amino acid residues of TEL-M1. Both isoforms are potent transcriptional repressors that can inhibit RAS-induced transformation. Here we show that the v-SRC protein-tyrosine kinase relieves the repressive activity of TEL-M1, an activity that is associated with the v-SRC-induced delocalization of TEL-M1 from the nucleus to the cytoplasm. TEL-M1 delocalization requires the kinase activity of v-SRC and is not induced by oncogenic RAS or AKT. Cytoplasmic delocalization of TEL-M1 in response to v-SRC critically depends upon its unique aminoterminal domain (SRCD domain) because (i) v-SRC did not inhibit the repressive properties of TEL-M43, nor affected TEL-M43 nuclear localization; (ii) fusion of the first 52 amino acid residues of TEL-M1 to FLI-1, an ETS protein insensitive to v-SRC-induced delocalization, is sufficient to confer v-SRC-induced delocalization to this TEL/FLI-1 chimeric protein. The v-SRC-induced nucleo-cytoplasmic delocalization of TEL-M1 does not involve phosphorylation of the SRCD and does not require TEL self-association and repressive domains. Finally, enforced expression of the v-SRC-insensitive TEL-M43, but not of TEL-M1, inhibits v-SRC-induced transformation of NIH3T3 fibroblasts. These results identify a regulatory domain in TEL that specifically impinges on the subcellular localization of its major TEL-M1 isoform. They, furthermore, indicate that inhibition of TEL-M1 nuclear function is required for v-SRC to induce cellular transformation.	Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Ghysdael, J (corresponding author), Inst Curie, CNRS, UMR 146, Ctr Univ,Bat 110, F-91405 Orsay, France.	Jacques.Ghysdael@curie.u-psud.fr	Carron, Clémence/AAG-6304-2021; GHYSDAEL, Jacques/F-3377-2013	Carron, Clemence/0000-0002-8776-7380				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Boccuni P, 2003, J BIOL CHEM, V278, P15412, DOI 10.1074/jbc.M300592200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Ducret C, 1999, MOL CELL BIOL, V19, P7076; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Griesinger F, 2002, BRIT J HAEMATOL, V119, P454, DOI 10.1046/j.1365-2141.2002.03850.x; Guidez F, 2000, BLOOD, V96, P2557; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Montpetit A, 2001, ONCOGENE, V20, P3437, DOI 10.1038/sj.onc.1204444; Nordentoft I, 2003, BIOCHEM J, V374, P165, DOI 10.1042/BJ20030087; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Peeters P, 1997, CANCER RES, V57, P564; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Van Rompaey L, 2002, BIOCHEM BIOPH RES CO, V291, P820, DOI 10.1006/bbrc.2002.6513; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100	56	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41316	41325		10.1074/jbc.M306435200	http://dx.doi.org/10.1074/jbc.M306435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12893822	hybrid			2022-12-25	WOS:000185847200111
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DISULFIDE CROSS-LINKING; CYSTEINE-SCANNING MUTAGENESIS; TRANSMEMBRANE SEGMENTS; COVALENT MODIFICATION; MEMBRANE TOPOLOGY; DOMAIN; SITE; TRANSPORTER; NUCLEOTIDE	The human multidrug resistance P-glycoprotein (P-gp, ABCB1) transports a wide variety of structurally diverse compounds out of the cell. The drug-binding pocket of P-gp is located in the transmembrane domains. Although occupation of the drug-binding pocket by one molecule is sufficient to activate the ATPase activity of P-gp, the drug-binding pocket may be large enough to accommodate two different substrates at the same time. In this study, we used cysteine-scanning mutagenesis to test whether P-gp could simultaneously interact with the thiol-reactive drug substrate, Tris-(2-maleimidoethyl)amine (TMEA) and a second drug substrate. TMEA is a cross-linker substrate of P-gp that allowed us to test for stimulation of cross-linking by a second substrate such as calcein-acetoxymethyl ester, colchicine, demecolcine, cyclosporin A, rhodamine B, progesterone, and verapamil. We report that verapamil induced TMEA cross-linking of mutant F343C(TM6)/V982C(TM12). By contrast, no cross-linked product was detected in mutants F343C(TM6), V982C(TM12), or F343C(TM6)/V982C(TM12) in the presence of TMEA alone. The verapamil-stimulated ATPase activity of mutant F343C(TM6)/V982C(TM12) in the presence of TMEA decreased with increased cross-linking of the mutant protein. These results show that binding of verapamil must induce changes in the drug-binding pocket (induced-fit mechanism) resulting in exposure of residues F343C(TM6)/V982C(TM12) to TMEA. The results also indicate that the common drug-binding pocket in P-gp is large enough to accommodate both verapamil and TMEA simultaneously and suggests that the substrates must occupy different regions in the common drug-binding pocket.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED M, 1994, J BIOL CHEM, V269, P28506; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Brooun A, 1999, J BACTERIOL, V181, P5131, DOI 10.1128/JB.181.16.5131-5133.1999; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Garrigos M, 1997, EUR J BIOCHEM, V244, P664, DOI 10.1111/j.1432-1033.1997.00664.x; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kenyon G L, 1977, Methods Enzymol, V47, P407; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Thomas Hilary, 2003, Cancer Control, V10, P159; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200	47	155	159	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39706	39710		10.1074/jbc.M308559200	http://dx.doi.org/10.1074/jbc.M308559200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12909621	hybrid			2022-12-25	WOS:000185713800056
J	Luo, B; Prescott, SM; Topham, MK				Luo, B; Prescott, SM; Topham, MK			Protein kinase C alpha phosphorylates and negatively regulates diacylglycerol kinase zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; CELL-CYCLE; ASSOCIATION; RELEASE; BINDING; CLONING; FAMILY	Diacylglycerol kinase (DGK) terminates diacylglycerol (DAG) signaling by phosphorylating DAG to produce phosphatidic acid, which also has signaling properties. Thus, precise control of DGK activity is essential for proper signal transduction. We demonstrated previously that a peptide corresponding to the myristoylated alanine-rich C kinase substrate ( MARCKS) phosphorylation site domain (PSD) in DGKzeta was phosphorylated in vitro by an active fragment of protein kinase C (PKC). In the present study, we tested full-length DGKzeta and found that PKCalpha phosphorylated DGKzeta on serines within the MARCKS PSD in vitro and in vivo. DGKzeta also coimmunoprecipitated with PKCalpha, suggesting that they reside in a regulated signaling complex. We then tested whether phosphorylation affected DAG kinase activity. We found that a mutant ( DGKzeta S/D) in which serines within the MARCKS PSD were altered to aspartates ( to mimic phosphorylation) had lower activity compared with wild-type DGKzeta or a control mutant (DGKzeta S/N) in which the same serines were changed to asparagines. Furthermore, activation of PKCalpha by phorbol 12-myristate 13-acetate inhibited the activity of wild-type DGKzeta, but not DGKzeta S/D, in human embryonic kidney 293 cells. These results suggest that by phosphorylating the MARCKS PSD, PKCalpha attenuates DGKzeta activity. Supporting this, we found that cells expressing DGKzeta S/D had higher DAG levels and grew more rapidly compared with cells expressing DGKzeta S/N that could not be phosphorylated. Taken together, these results indicate that PKCalpha phosphorylates DGKzeta in cells, and this phosphorylation inhibits its kinase activity to remove cellular DAG, thereby affecting cell growth.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Topham, MK (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84132 USA.	matt.topham@hci.utah.edu						Balciunaite E, 2000, CURR BIOL, V10, P261, DOI 10.1016/S0960-9822(00)00358-4; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; Divecha N, 1997, BIOCHEM SOC T, V25, P571, DOI 10.1042/bst0250571; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KEIZER J, 1995, MOL BIOL CELL, V6, P945, DOI 10.1091/mbc.6.8.945; Luo B, 2003, J CELL BIOL, V160, P929, DOI 10.1083/jcb.200208120; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pawson T, 2000, GENE DEV, V14, P1027; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rojnuckarin P, 2001, BLOOD, V97, P154, DOI 10.1182/blood.V97.1.154; Santos T, 2002, J BIOL CHEM, V277, P30300, DOI 10.1074/jbc.M200999200; Smith PJ, 2002, SIGHT SOUND, V12, P32; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130	39	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39542	39547		10.1074/jbc.M307153200	http://dx.doi.org/10.1074/jbc.M307153200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12890670	hybrid			2022-12-25	WOS:000185713800035
J	Perez, CF; Mukherjee, S; Allen, PD				Perez, CF; Mukherjee, S; Allen, PD			Amino acids 1-1,680 of ryanodine receptor type 1 hold critical determinants of skeletal type for excitation-contraction coupling - Role of divergence domain D2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIHYDROPYRIDINE RECEPTOR; CENTRAL CORE DISEASE; II-III LOOP; CALCIUM-RELEASE UNITS; CA2+ RELEASE; RYR1; REGIONS; IDENTIFICATION; LOCALIZATION; SEQUENCE	To identify domains of the ryanodine receptor (RyR1) that are functionally relevant for excitation-contraction (EC) coupling in vivo, we have studied the ability of RyR1/RyR3 chimera to rescue skeletal EC coupling in dyspedic myotubes. In this work we show that chimeric receptors containing amino acids 1 - 1,680 of RyR1 were able to render depolarization-induced Ca2+ release to RyR3. Within this region, residues 1,272 - 1,455, containing divergent domain D2 of RyR1, proved to be a critical element because the absence of this region selectively abolished depolarization-evoked Ca2+ transients without affecting chemically induced activation. Although the D2 domain by itself failed to restore skeletal EC coupling to RyR3, the addition of the D2 region resulted in a dramatic enhancement of EC coupling restored by an RyR3 chimera containing amino acids 1,681 - 3,770 of RyR1. These results suggest that although the D2 domain of RyR1 plays a key role during EC coupling, additional region(s) from the N-terminal end of RyR1 as well as previously identified regions of the central portion of the receptor are needed in order to allow normal EC coupling.	Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Perez, CF (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol, 75 Francis St, Boston, MA 02115 USA.				FIC NIH HHS [F05TW05455] Funding Source: Medline; NIAMS NIH HHS [P01AR47605] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW005455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047605] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIREY JA, 1990, J BIOL CHEM, V265, P14187; Avila G, 2003, J GEN PHYSIOL, V121, P277, DOI 10.1085/jgp.200308791; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Buck ED, 1997, J BIOL CHEM, V272, P7360, DOI 10.1074/jbc.272.11.7360; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Dirksen RT, 2002, TRENDS CARDIOVAS MED, V12, P189, DOI 10.1016/S1050-1738(02)00163-9; Dulhunty AF, 2002, PROG BIOPHYS MOL BIO, V79, P45, DOI 10.1016/S0079-6107(02)00013-5; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; Mouton J, 2001, BIOCHEM J, V354, P597, DOI 10.1042/0264-6021:3540597; Murray BE, 1997, BIOCHEM J, V324, P689, DOI 10.1042/bj3240689; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; Perez CF, 2003, BIOPHYS J, V84, P2655, DOI 10.1016/S0006-3495(03)75071-1; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161	33	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39644	39652		10.1074/jbc.M305160200	http://dx.doi.org/10.1074/jbc.M305160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12900411	hybrid			2022-12-25	WOS:000185713800049
J	Richter, S; Lamppa, GK				Richter, S; Lamppa, GK			Structural properties of the chloroplast stromal processing peptidase required for its function in transit peptide removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; INSULIN-DEGRADING ENZYME; PROTEIN IMPORT; BETA-SUBUNIT; ACTIVE-SITE; CATALYTIC-ACTIVITY; ESCHERICHIA-COLI; CYSTEINE SWITCH; SIGNAL PEPTIDE; RAT-LIVER	The stromal processing peptidase (SPP) catalyzes removal of transit peptides from a diversity of precursor proteins imported into chloroplasts. SPP contains an HXXEH zinc-binding motif characteristic of members of the metallopeptidase family M16. We previously found that the three steps of precursor processing by SPP (i.e. transit peptide binding, removal, and conversion to a degradable subfragment) are mediated by features that reside in the C-terminal 10 - 15 residues of the transit peptide. In this study, we performed a mutational analysis of SPP to identify structural elements that determine its function. SPP loses the ability to proteolytically remove the transit peptide when residues of the HXXEH motif, found in an N-terminal region, are mutated. Deletion of 240 amino acids from its C terminus also abolishes activity. Interestingly, however, SPP can still carry out the initial binding step, recognizing the C-terminal residues of the transit peptide. Hence, transit peptide binding and removal are two separable steps of the overall processing reaction. Transit peptide conversion to a subfragment also depends on the HXXEH motif. The precursor of SPP, containing an unusually long transit peptide itself, is not proteolytically active. Thus, the SPP precursor is synthesized as a latent form of the metallopeptidase.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Lamppa, GK (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.	gklamppa@midway.uchicago.edu						ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Chen K, 2000, BIOCHEM SOC T, V28, P485, DOI 10.1042/0300-5127:0280485; CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; deChateau M, 1996, P NATL ACAD SCI USA, V93, P8490, DOI 10.1073/pnas.93.16.8490; GEHM BD, 1993, J BIOL CHEM, V268, P7943; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kojima K, 1998, J BIOL CHEM, V273, P32542, DOI 10.1074/jbc.273.49.32542; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer U, 1996, MOL MICROBIOL, V21, P301, DOI 10.1046/j.1365-2958.1996.6481362.x; Makarova KS, 1999, PROTEIN SCI, V8, P2537; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Richter S, 1999, J CELL BIOL, V147, P33, DOI 10.1083/jcb.147.1.33; Richter S, 1998, MOL GEN GENET, V257, P534, DOI 10.1007/s004380050679; Richter S, 2002, J BIOL CHEM, V277, P43888, DOI 10.1074/jbc.M206020200; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Stahl A, 2002, J BIOL CHEM, V277, P41931, DOI 10.1074/jbc.M205500200; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vothknecht UC, 2000, BIOL CHEM, V381, P887, DOI 10.1515/BC.2000.110; Wan JX, 1998, PLANT J, V15, P459, DOI 10.1046/j.1365-313X.1998.00224.x; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; Zhong R, 2003, PLANT J, V34, P802, DOI 10.1046/j.1365-313X.2003.01772.x	48	43	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39497	39502		10.1074/jbc.M305729200	http://dx.doi.org/10.1074/jbc.M305729200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888578	hybrid			2022-12-25	WOS:000185713800029
J	Kim, W; Moon, SO; Sung, MJ; Kim, SH; Lee, S; So, JN; Park, SK				Kim, W; Moon, SO; Sung, MJ; Kim, SH; Lee, S; So, JN; Park, SK			Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; ERK	SMOOTH-MUSCLE CELLS; HUMAN ENDOMETRIUM; SURVIVAL FACTOR; GROWTH-FACTOR; EXPRESSION; SECRETION; RECEPTOR; PEPTIDE; ANGIOPOIETIN-1; MECHANISMS	Adrenomedullin ( AM) is a multifunctional peptide in human pheochromocytoma. To evaluate whether AM could be an angiogenic factor, we examined its effect on kinases and angiogenic processes. AM induced tyrosine phosphorylation of Akt and mitogen-activated protein kinase ( MAPK)/extracellular signal-regulated kinase1/2 (ERK1/2) by using distinct signaling pathways in human umbilical vein endothelial cells (HUVECs). AM also phosphorylated focal adhesion kinase, and phosphatidylinositol 3'-kinase inhibitor inhibited AM-induced focal adhesion kinase phosphorylation. Pretreatment with high concentrations of AM(22-52), a putative AM receptor antagonist, partially suppressed AM-induced phosphorylation of Akt, ERK1/2, and focal adhesion kinase. AM and vascular endothelial growth factor produced increases in DNA synthesis and migration in HUVECs. AM induced tube formation in HUVECs, and its effect was inhibited by pretreatment with phosphatidylinositol 3'-kinase inhibitor or ERK1/2 inhibitor. AM induced sprouting in porcine pulmonary arterial endothelial cells and promoted neovessel formation in a mouse Matrigel plug assay. Inhibitors of phosphatidylinositol 3'- kinase and ERK1/2 inhibited AM-induced endothelial sprouting in vitro and angiogenesis in vivo. AM exerts angiogenic activity through activation of Akt, MAPK, and focal adhesion kinase in endothelial cells.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Inst Clin Med, Chonju 560180, South Korea; Woosuk Univ, Dept Biotechnol, Chonju, South Korea	Jeonbuk National University; Woosuk University	Park, SK (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Inst Clin Med, 634-1 Keum Am Dong, Chonju 560180, South Korea.	parksk@moak.chonbuk.ac.kr	Kim, Won/F-1643-2018	Kim, Won/0000-0003-1068-1455				Abe K, 2000, FERTIL STERIL, V74, P141, DOI 10.1016/S0015-0282(00)00585-9; ABEDI H, 1995, CARDIOVASC RES, V30, P544, DOI 10.1016/0008-6363(95)00092-5; BEAN AJ, 1994, FASEB J, V8, P630, DOI 10.1096/fasebj.8.9.8005390; Cameron VA, 2002, AM J PHYSIOL-ENDOC M, V282, pE139, DOI 10.1152/ajpendo.2002.282.1.E139; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Cuttitta F, 2002, MICROSC RES TECHNIQ, V57, P110, DOI 10.1002/jemt.10059; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FREDERICK J, 1998, MATRIX METALLOPROTEI, P1; Fujita Y, 2002, INT J UROL, V9, P285, DOI 10.1046/j.1442-2042.2002.00469.x; Grant D S, 1997, EXS, V79, P317; Hay D L, 2001, Trends Pharmacol Sci, V22, P57, DOI 10.1016/S0165-6147(00)01617-5; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; HORIO T, 1995, CIRC RES, V77, P660, DOI 10.1161/01.RES.77.4.660; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; Kano H, 1996, J HYPERTENS, V14, P209, DOI 10.1097/00004872-199602000-00009; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim W, 2002, APOPTOSIS, V7, P527, DOI 10.1023/A:1020695110648; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kitamura K, 2002, MICROSC RES TECHNIQ, V57, P3, DOI 10.1002/jemt.10052; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Lee MS, 2001, CANCER RES, V61, P3290; Lee S, 2003, FASEB J, V17, pA326, DOI 10.1096/fj.02-0570fje; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Minamino N, 2002, MICROSC RES TECHNIQ, V57, P28, DOI 10.1002/jemt.10048; Nikitenko LL, 2000, MOL HUM REPROD, V6, P811, DOI 10.1093/molehr/6.9.811; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; SUGO S, 1994, BIOCHEM BIOPH RES CO, V203, P719, DOI 10.1006/bbrc.1994.2241; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	40	109	112	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1937	+		10.1096/fj.02-1209fje	http://dx.doi.org/10.1096/fj.02-1209fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897063				2022-12-25	WOS:000185345100021
J	Petit, MA; Jolivet-Reynaud, C; Peronnet, E; Michal, Y; Trepo, C				Petit, MA; Jolivet-Reynaud, C; Peronnet, E; Michal, Y; Trepo, C			Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN COMPLEXES; RECOMBINANT VACCINIA; B VIRUS; HCV; LOCALIZATION; PARTICLES; SEQUENCE; REGION; GLYCOSYLATION; ANTIBODIES	Monoclonal antibody D32.10 produced by immunizing mice with a hepatitis C virus (HCV)-enriched pellet obtained from plasmapheresis of a chronically HCV1b-infected patient binds HCV particles derived from serum of different HCV1a- and HCV1b-infected patients. Moreover, this monoclonal has been shown to recognize both HCV envelope proteins E1 and E2. In an attempt to provide novel insight into the membrane topology of HCV envelope glycoproteins E1 and E2, we localized the epitope recognized by D32.10 on the E1 and/or E2 sequence using Ph.D.-12(TM) phage display peptide library technology. Mimotopes selected from the phage display dodecapeptide library by D32.10 shared partial similarities with (297)RHWTTQGCNC(306) of the HCV E1 glycoprotein and with both (YRLWHYPCT621)-Y-613 and (480)PDQRPYCWHYPPKPC(494) of the HCV E2 glycoprotein. Immunoreactivity of D32.10 with overlapping peptides corresponding to these three HCV regions confirmed these localizations and suggested that the three regions identified are likely closely juxtaposed on the surface of serum-derived particles as predicted by the secondary model structure of HCV E2 derived from the tick-borne encephalitis virus E protein. This assertion was supported by the detection of specific antibodies directed against these three E1E2 regions in sera from HCV-infected patients.	INSERM, U271, F-69424 Lyon 03, France; CNRS BioMerieux, Unite Mixte Rech 2142, Ctr Etud Rech Virol & Immunol, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	Petit, MA (corresponding author), INSERM, U271, 151 Cours Albert Thomas, F-69424 Lyon 03, France.							[Anonymous], 1982, MOL CLONING LAB MANU; Baumert TF, 2000, HEPATOLOGY, V32, P610, DOI 10.1053/jhep.2000.9876; Bukh J, 1997, VIROLOGY, V229, P429, DOI 10.1006/viro.1997.8461; Buttin G, 1978, Curr Top Microbiol Immunol, V81, P27; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Dubuisson J, 2000, J BIOL CHEM, V275, P30605, DOI 10.1074/jbc.M004326200; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Jolivet-Reynaud C, 1998, J MED VIROL, V56, P300, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;300::AID-JMV3&gt;3.0.CO;2-8; Meunier JC, 1999, J GEN VIROL, V80, P887, DOI 10.1099/0022-1317-80-4-887; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; Patel J, 1999, J GEN VIROL, V80, P1681, DOI 10.1099/0022-1317-80-7-1681; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETIT MA, 1989, MOL IMMUNOL, V26, P531, DOI 10.1016/0161-5890(89)90004-7; PETIT MA, 1987, J GEN VIROL, V68, P2759, DOI 10.1099/0022-1317-68-11-2759; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; RICE CM, 1996, FIELDS VIROLOGY, P931; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1993, VIROLOGY, V196, P354, DOI 10.1006/viro.1993.1488; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; SPAETE RR, 1992, VIROLOGY, V188, P819, DOI 10.1016/0042-6822(92)90537-Y; Trepo C, 1998, ANN ONCOL, V9, P469, DOI 10.1023/A:1008298228620; Wellnitz S, 2002, J VIROL, V76, P1181, DOI 10.1128/JVI.76.3.1181-1193.2002; Yagnik AT, 2000, PROTEINS, V40, P355, DOI 10.1002/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K	33	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44385	44392		10.1074/jbc.M304047200	http://dx.doi.org/10.1074/jbc.M304047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12882983	hybrid			2022-12-25	WOS:000186306700063
J	Koch, M; Laub, F; Zhou, PH; Hahn, RA; Tanaka, S; Burgeson, RE; Gerecke, DR; Ramirez, F; Gordon, MK				Koch, M; Laub, F; Zhou, PH; Hahn, RA; Tanaka, S; Burgeson, RE; Gerecke, DR; Ramirez, F; Gordon, MK			Collagen XXIV, a vertebrate fibrillar collagen with structural features of invertebrate collagens - Selective expression in developing cornea and bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; ARGININE-RICH PROTEIN; V COLLAGEN; PRO-ALPHA-1(XI) COLLAGEN; NH2-TERMINAL DOMAIN; MESSENGER-RNA; DEVELOPMENTAL EXPRESSION; GENE; CHAIN; MATRIX	Tissue-specific assembly of fibers composed of the major collagen types I and II depends in part on the formation of heterotypic fibrils, using the quantitatively minor collagens V and XI. Here we report the identification of a new fibrillar-like collagen chain that is related to the fibrillar alpha1(V), alpha1(XI), and alpha2(XI) collagen polypeptides and which is coexpressed with type I collagen in the developing bone and eye. The new collagen was designated the alpha1(XXIV) chain and consists of a long triple helical domain flanked by typical propeptide-like sequences. The carboxyl propeptide is classic, with 8 conserved cysteine residues. The amino-terminal peptide contains a thrombospodin-N-terminal-like (TSP) motif and a highly charged segment interspersed with several tyrosine residues, like the fibril diameter-regulating collagen chains alpha1(V) and alpha1(XI). However, a short imperfection in the triple helix makes alpha1(XXIV) unique from other chains of the vertebrate fibrillar collagen family. The triple helical interruption and additional select features in both terminal peptides are common to the fibrillar chains of invertebrate organisms. Based on these data, we propose that collagen XXIV is an ancient molecule that may contribute to the regulation of type I collagen fibrillogenesis at specific anatomical locations during fetal development.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Univ Cologne, Inst Biochem 2, D-50931 Cologne, Germany; Cornell Univ, Weill Med Coll, Hosp Special Surg, Lab Genet & Organogenesis, New York, NY 10021 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Rutgers State University New Brunswick; University of Cologne; Cornell University; Rutgers State University New Brunswick; Harvard University	Gordon, MK (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	magordon@eohsi.rutgers.edu	Koch, Manuel/AAG-9914-2021	Koch, Manuel/0000-0002-2962-7814	NEI NIH HHS [EY09056] Funding Source: Medline; NHLBI NIH HHS [HL67708] Funding Source: Medline; NIAMS NIH HHS [AR-38648] Funding Source: Medline; NIEHS NIH HHS [ES05022] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL067708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; BIRK DE, 1990, J CELL SCI, V95, P649; Blaschke UK, 2000, J BIOL CHEM, V275, P10370, DOI 10.1074/jbc.275.14.10370; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; Burrows NP, 1998, AM J HUM GENET, V63, P390, DOI 10.1086/301948; Chou MY, 2002, GENOMICS, V79, P395, DOI 10.1006/geno.2002.6712; CLUZEL C, 2000, J BIOCHEM-TOKYO, V28, P957; DePaepe A, 1997, AM J HUM GENET, V60, P547; Deutzmann R, 2000, DEVELOPMENT, V127, P4669; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; Gordon MK, 2000, INVEST OPHTH VIS SCI, V41, pS752; Gordon MK, 2002, FASEB J, V16, pA359; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Laub F, 2001, DEV BIOL, V233, P305, DOI 10.1006/dbio.2001.0243; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MALLEINGERIN F, 1995, EXP CELL RES, V219, P257, DOI 10.1006/excr.1995.1226; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; Meirowitz NB, 2002, AM J OBSTET GYNECOL, V187, P1679, DOI 10.1067/mob.2002.127595; Michalickova K, 1998, HUM MOL GENET, V7, P249, DOI 10.1093/hmg/7.2.249; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; Morio LA, 2001, TOXICOL APPL PHARM, V172, P44, DOI 10.1006/taap.2000.9133; MYERS JC, 1994, J BIOL CHEM, V269, P18549; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; Peltonen S, 1999, J INVEST DERMATOL, V113, P635, DOI 10.1046/j.1523-1747.1999.00736.x; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; Sato K, 2002, J BIOL CHEM, V277, P37678, DOI 10.1074/jbc.M205347200; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; Sicot FX, 2000, J MOL BIOL, V302, P811, DOI 10.1006/jmbi.2000.4505; Sicot FX, 1997, EUR J BIOCHEM, V246, P50, DOI 10.1111/j.1432-1033.1997.00050.x; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TSENG SCG, 1982, J BIOL CHEM, V257, P2627; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; Tuckwell D, 2002, MATRIX BIOL, V21, P63, DOI 10.1016/S0945-053X(01)00176-7; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Yoneda C, 1999, EUR J BIOCHEM, V261, P714, DOI 10.1046/j.1432-1327.1999.00313.x; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	60	81	88	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43236	43244		10.1074/jbc.M302112200	http://dx.doi.org/10.1074/jbc.M302112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12874293	hybrid			2022-12-25	WOS:000186157000065
J	Oberley, MJ; Inman, DR; Farnham, PJ				Oberley, MJ; Inman, DR; Farnham, PJ			E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; CHROMATIN IMMUNOPRECIPITATION; DIHYDROFOLATE-REDUCTASE; TARGETED DELETION; DNA-REPAIR; IDENTIFICATION; PROMOTER; MYC; FAMILY	E2F6 contains a DNA binding domain that is very similar to that of the other members of the E2F family of transcriptional regulators. However, E2F6 cannot bind to all promoters that contain consensus E2F-binding sites. Therefore, we used a combination of chromatin immunoprecipitation and genomic microarrays to identify promoters bound by E2F6 in human cells. Although most of the identified promoters were bound by multiple E2F family members, one promoter was bound only by E2F6. To determine which of the newly identified promoters were regulated by E2F6, we reduced the level of E2F6 by using RNA interference technology. We found that mRNA transcribed from promoters bound by E2F6 was increased after reduction of the amount of E2F6 protein in the cell. Interestingly, many of the E2F6-regulated genes encoded functions involved in tumor suppression and the maintenance of chromatin structure. Specifically, our results suggest that E2F6 represses transcription of the brca1, ctip, art27, hp1alpha, and the rbap48 genes. E2F6 has been postulated to mediate transcriptional repression by recruiting a histone H3 methyltransferase to the DNA. However, we found that the E2F6-regulated promoters did not contain histone H3 methylated at lysine 9. To determine the mechanism by which E2F6 regulates transcription, we performed chromatin immunoprecipitation before and after the introduction of small inhibitory ribonucleic acids specific to E2F6. We found that depletion of E2F6 resulted in the recruitment of E2F1 to the target promoters. In summary, we have identified 48 endogenous target genes of E2F6 and have shown that E2F6 can repress target promoters in a manner that does not require histone H3 methylation at lysine 9.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu	Oberley, Matthew/I-8107-2019; Oberley, Matthew/L-4326-2019	Oberley, Matthew/0000-0001-6419-2513; Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA 09135, CA 45240, CA 14520] Funding Source: Medline; NIEHS NIH HHS [ES 07015-24] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014520, R01CA045240, R29CA045240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kennedy RD, 2002, LANCET, V360, P1007, DOI 10.1016/S0140-6736(02)11087-7; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Kirschmann DA, 2000, CANCER RES, V60, P3359; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lavia P, 1999, BIOESSAYS, V21, P221; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Markus SM, 2002, MOL BIOL CELL, V13, P670, DOI 10.1091/mbc.01-10-0513; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Moriuchi M, 1999, J IMMUNOL, V162, P5986; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; OBERLEY MJ, 2003, IN PRESS METHODS ENZ; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pearson A, 1997, ONCOGENE, V15, P2643, DOI 10.1038/sj.onc.1201451; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Schroer A, 1999, GENOMICS, V56, P340, DOI 10.1006/geno.1998.5712; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379; Yan PS, 2001, CANCER RES, V61, P8375	49	69	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42466	42476		10.1074/jbc.M307733200	http://dx.doi.org/10.1074/jbc.M307733200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12909625	hybrid			2022-12-25	WOS:000185989500111
J	Tremblay, JJ; Viger, RS				Tremblay, JJ; Viger, RS			A mutated form of steroidogenic factor 1 (SF-1 G35E) that causes sex reversal in humans fails to synergize with transcription factor GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULLERIAN-INHIBITING SUBSTANCE; NUCLEAR RECEPTOR SF-1; VENTROMEDIAL HYPOTHALAMIC NUCLEUS; MULTIPLE GONADAL PROMOTERS; FACTOR-I; WILMS-TUMOR; ADRENAL DEVELOPMENT; GENE-TRANSCRIPTION; BINDING-PROTEINS; SERTOLI-CELLS	Steroidogenic factor 1 (SF-1) is a transcription factor belonging to the nuclear receptor superfamily. SF-1 regulates the expression of many genes involved in reproduction, steroidogenesis, and sexual differentiation. An important SF-1 target for male sexual differentiation is the gene encoding the Mullerian-inhibiting substance hormone that induces regression of the Mullerian ducts in the developing male embryo. Not long ago, a mutation (G35E) in the human SF-1 gene was identified as the cause of sex reversal and adrenal failure in a phenotypically female but genotypically XY individual. This suggested that the mutated SF-1 protein might interfere with the expression of SF-1 target gene(s) involved in the male sexual differentiation pathway, such as MIS. Surprisingly, the initial biochemical characterization of the SF-1 G35E mutant revealed that it could bind and activate the MIS promoter as efficiently as wild-type SF-1. MIS expression, however, does not rely solely on SF-1 but rather requires the concerted action of several transcription factors including GATA-4. We have previously reported that GATA-4 and SF-1 transcriptionally cooperate to synergistically activate the MIS promoter. Thus, we hypothesized that the phenotype observed with the SF-1 G35E mutation could be explained, at least in part, by a failure and/or a disruption of GATA-4/SF-1 synergism. We found that the SF-1 G35E mutant failed to synergize with GATA-4 despite a direct physical interaction between the two proteins. Interestingly, the SF-1 G35E mutant also disrupted transcriptional synergism between wild-type SF-1 and GATA-4, indicating that it could act as a dominant negative competitor. Thus, our results strengthen the importance of a GATA-4/SF-1 cooperation for MIS transcription and reveal that disruption of this synergism might be responsible for some cases of abnormal sex differentiation in humans.	CHU Laval, Ctr Rech, Ontogeny Reprod Res Unit, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Obstet & Gynecol, Ctr Rech Biol Reprod, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Viger, RS (corresponding author), CHU Laval, Ctr Rech, Ontogeny Reprod Res Unit, Rm T1-49,2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	Robert.Viger@crchul.ulaval.ca	Tremblay, Jacques J./AAO-2491-2021	Tremblay, Jacques J./0000-0002-4738-6284				Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; Achermann JC, 2002, J CLIN ENDOCR METAB, V87, P1829, DOI 10.1210/jc.87.4.1829; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; BEHRINGER RR, 1994, CURR TOP DEV BIOL, V29, P171, DOI 10.1016/S0070-2153(08)60550-5; Bland ML, 2000, P NATL ACAD SCI USA, V97, P14488, DOI 10.1073/pnas.97.26.14488; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORREA RV, 2001, PEDIATR RES, V49, P55; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; de Santa Barbara P, 2000, DEV DYNAM, V217, P293, DOI 10.1002/(SICI)1097-0177(200003)217:3<293::AID-DVDY7>3.0.CO;2-P; Giuili G, 1997, DEVELOPMENT, V124, P1799; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 2000, J BIOL CHEM, V275, P31708, DOI 10.1074/jbc.M002892200; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lu JR, 1999, MOL CELL BIOL, V19, P4495; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Rajpert-De Meyts E, 1999, J CLIN ENDOCR METAB, V84, P3836, DOI 10.1210/jc.84.10.3836; Robert NM, 2002, ENDOCRINOLOGY, V143, P3963, DOI 10.1210/en.2002-220280; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; Teixeira J, 2001, ENDOCR REV, V22, P657, DOI 10.1210/er.22.5.657; Tremblay AJ, 2001, BIOL REPROD, V64, P1191, DOI 10.1095/biolreprod64.4.1191; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; Tremblay JJ, 2001, ENDOCRINOLOGY, V142, P977, DOI 10.1210/en.142.3.977; Tremblay JJ, 2001, MOL ENDOCRINOL, V15, P1636, DOI 10.1210/me.15.9.1636; Viger RS, 1998, DEVELOPMENT, V125, P2665; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Watanabe K, 2000, P NATL ACAD SCI USA, V97, P1624, DOI 10.1073/pnas.97.4.1624; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794	41	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42637	42642		10.1074/jbc.M305485200	http://dx.doi.org/10.1074/jbc.M305485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12907682	hybrid			2022-12-25	WOS:000185989500129
J	Blanc, V; Kennedy, S; Davidson, NO				Blanc, V; Kennedy, S; Davidson, NO			A novel nuclear localization signal in the auxiliary domain of apobec-1 complementation factor regulates nucleocytoplasmic import and shuttling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; MOLECULAR-CLONING; BINDING PROTEIN; EXPORT SIGNAL; CATALYTIC SUBUNIT; LEPTOMYCIN B; IDENTIFICATION; TRANSPORT; CYTIDINE; MODULATE	C to U editing of the nuclear apolipoprotein B ( apoB) transcript is mediated by a core enzyme containing a catalytic deaminase, apobec-1, and an RNA binding subunit, apobec-1 complementation factor (ACF). ACF expression is predominantly nuclear, including mutant proteins with deletions of a putative nuclear localization signal. We have now identified a novel 41-residue motif (ANS) in the auxiliary domain of ACF that functions as an authentic nuclear localization signal. ANS-green fluorescence protein and ANS-beta-galactosidase chimeras were both expressed exclusively in the nucleus, whereas wild-type chimeras or an ACF deletion mutant lacking the ANS were cytoplasmic. Nuclear accumulation of ACF is transcription-dependent, temperature-sensitive, and reversible, features reminiscent of a shuttling protein. ACF relocates to the cytoplasm after actinomycin D treatment, an effect blocked by the CRM1 inhibitor leptomycin B. Heterokaryon assays confirmed directly that ACF shuttles in vivo. ACF binds to the protein carrier, transportin 2 in vivo, and colocalizes to the nucleus as determined by confocal microscopy. Coimmunoprecipitation experiments revealed that transportin 2 binds directly to the ANS motif. These data suggest that directed nuclear localization and compartmentalization of the core complex of the apoB RNA editing enzyme is regulated through a dominant targeting sequence ( ANS) contained within ACF.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.	nod@im.wustl.edu			NHLBI NIH HHS [HL-38180] Funding Source: Medline; NIDDK NIH HHS [DK-56260, DK-52574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, R01DK056260] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Blanc V, 2001, J BIOL CHEM, V276, P46386, DOI 10.1074/jbc.M107654200; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 2002, RNA, V8, P69, DOI 10.1017/S1355838202015649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Moore MJ, 2001, SCIENCE, V294, P1841, DOI 10.1126/science.1067676; Mukhopadhyay D, 2003, ENDOCRINOLOGY, V144, P711, DOI 10.1210/en.2002-220741; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Sowden MP, 2002, J CELL SCI, V115, P1027; Sowden MP, 2001, BIOCHEM J, V359, P697, DOI 10.1042/0264-6021:3590697; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang Y, 1997, P NATL ACAD SCI USA, V94, P13075, DOI 10.1073/pnas.94.24.13075; Yang Y, 2001, EXP CELL RES, V267, P153, DOI 10.1006/excr.2001.5255	37	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41198	41204		10.1074/jbc.M302951200	http://dx.doi.org/10.1074/jbc.M302951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12896982	hybrid			2022-12-25	WOS:000185847200097
J	D'Aguanno, S; Gonzales, IN; Simmaco, M; Contestabile, R; John, RA				D'Aguanno, S; Gonzales, IN; Simmaco, M; Contestabile, R; John, RA			Stereochemistry of the reactions of glutamate-1-semialdehyde aminomutase with 4,5-diaminovalerate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE 1-SEMIALDEHYDE AMINOTRANSFERASE; AMINO-ACID DECARBOXYLASE; STATE KINETIC-ANALYSIS; SEMIALDEHYDE AMINOTRANSFERASE; ASPARTATE-AMINOTRANSFERASE; DELTA-AMINOLEVULINATE; SUBSTRATE; SYNECHOCOCCUS; BIOSYNTHESIS; MECHANISM	Conversion of glutamate 1-semialdehyde to the tetrapyrrole precursor, 5-aminolevulinate, takes place in an aminomutase-catalyzed reaction involving transformations at both the non-chiral C5 and the chiral C4 of the intermediate 4,5-diaminovalerate. Presented with racemic diaminovalerate and an excess of succinic semialdehyde, the enzyme catalyzes a transamination in which only the L-enantiomer is consumed. Simultaneously, equimolar 4-aminobutyrate and aminolevulinate are formed. The enzyme is also shown to transaminate aminolevulinate and 4-aminohexenoate to L-diaminovalerate as the exclusive amino product. The interaction of the enzyme with pure D- and L-enantiomers of diaminovalerate prepared by these reactions is described. Transamination of L-diaminovalerate yielded aminolevulinate quantitatively showing that reaction at the C5 amine does not occur significantly. A much slower transamination reaction was catalyzed with D- diaminovalerate as substrate. One product of this reaction, 4-aminobutyrate, was formed in the amount equal to that of the diaminovalerate consumed. Glutamate semialdehyde was deduced to be the other primary product and was also measured in significant amounts when a high concentration of the enzyme in its pyridoxal form was reacted with D- diaminovalerate in a single turnover. Single turnover reactions showed that both enantiomers of diaminovalerate converted the enzyme from its 420-nm absorbing pyridoxaldimine form to the 330-nm absorbing pyridoxamine via rapidly formed intermediates with different absorption spectra. The intermediate formed with L-DAVA (lambda(max) = 420 nm) was deduced to be the protonated external aldimine with the 4-amino group. The intermediate formed with D- DAVA (lambda(max) = 390 nm) was deduced to be the unprotonated external aldimine with the 5-amino group.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Rome, Italy; Univ Roma La Sapienza, Azienda Osped SantAndrea Lab DiMA, Rome, Italy; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF23 6QU, S Glam, Wales	Sapienza University Rome; Sapienza University Rome; Cardiff University	John, RA (corresponding author), Univ Wales Coll Cardiff, Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.		Contestabile, Roberto/J-3467-2019; Simmaco, Maurizio/AAC-2870-2019; Nogues, Isabel/AAA-7499-2019; Gonzalez, Isabel Nogues/K-2118-2012; D'Aguanno, Simona/H-2179-2016	Contestabile, Roberto/0000-0002-5235-9993; Simmaco, Maurizio/0000-0003-4164-1472; Gonzalez, Isabel Nogues/0000-0002-7475-2411; D'Aguanno, Simona/0000-0002-1224-4454				Contestabile R, 2000, J BIOL CHEM, V275, P3879, DOI 10.1074/jbc.275.6.3879; DIXON HBF, 1968, BIOCHEM J, V110, pP18, DOI 10.1042/bj1100018P; FRIEDMANN HC, 1992, BIOCHEM BIOPH RES CO, V185, P60, DOI 10.1016/S0006-291X(05)80955-6; GOLDBERG JM, 1991, BIOCHEMISTRY-US, V30, P305, DOI 10.1021/bi00215a041; GRIMM B, 1991, J BIOL CHEM, V266, P12495; Hayashi H, 1999, BIOCHEMISTRY-US, V38, P15615, DOI 10.1021/bi9909795; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P812, DOI 10.1021/bi00054a011; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P11, DOI 10.1007/BF02908411; JOHNSON R. J., 1970, Methods in Enzymology, V18A, P433, DOI 10.1016/0076-6879(71)18345-0; KANNANGARA CG, 1988, TRENDS BIOCHEM SCI, V13, P139; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MINELLI A, 1979, BIOCHEM J, V183, P361, DOI 10.1042/bj1830361; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; PUGH CE, 1992, J BIOL CHEM, V267, P1584; PUGH CE, 1991, ANAL BIOCHEM, V198, P43, DOI 10.1016/0003-2697(91)90503-L; Scaloni Andrea, 2003, Methods Mol Biol, V211, P169; SMITH MA, 1991, EUR J BIOCHEM, V202, P749, DOI 10.1111/j.1432-1033.1991.tb16429.x; Smith MA, 1998, BIOCHEMISTRY-US, V37, P319, DOI 10.1021/bi9717587; TYACKE RJ, 1995, BIOCHEM J, V309, P307, DOI 10.1042/bj3090307	20	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40521	40526		10.1074/jbc.M306223200	http://dx.doi.org/10.1074/jbc.M306223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12878592	hybrid			2022-12-25	WOS:000185847200013
J	Porcellini, A; Messina, S; De Gregorio, G; Feliciello, A; Carlucci, A; Barone, M; Picascia, A; De Blasi, A; Avvedimento, EV				Porcellini, A; Messina, S; De Gregorio, G; Feliciello, A; Carlucci, A; Barone, M; Picascia, A; De Blasi, A; Avvedimento, EV			The expression of the thyroid-stimulating hormone (TSH) receptor and the cAMP-dependent protein kinase RII beta regulatory subunit confers TSH-cAMP-dependent growth to mouse fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN RECEPTOR; CELL-GROWTH; MESSENGER-RNA; PC12 CELLS; PHOSPHORYLATION; PATHWAY; PROLIFERATION; LOCALIZATION; INHIBITION; ACTIVATION	TSH activates its specific receptor in thyroid cells and induces cAMP, a robust stimulator of thyroid cell proliferation. Conversely, cAMP is a potent inhibitor of growth in mouse fibroblasts. To dissect the signals mediating cAMP-dependent growth, we have expressed in mouse fibroblasts the human thyrotropin receptor (TSHR) or a constitutively active mutant, under the control of the tetracyclin promoter. Both TSHR and cAMP levels were modulated by tetracyclin. In the presence of serum, activation of TSHR by TSH induced growth arrest. In the absence of serum, cells expressing TSHR stimulated with TSH, replicated their DNA, but underwent apoptosis. Co-expression of cAMP-dependent protein kinase (PKA) regulatory subunit type II ( RIIbeta) inhibited apoptosis and stimulated the growth of cells only in the presence of TSH. Expression of RIIbeta-PKA, in the absence of TSHR, induced apoptosis, which was reversed by cAMP. Growth, stimulated by TSHR-RIIbeta-PKA in mouse fibroblasts, was also dependent on Rap1 activity, indicating cAMP-dependent growth in thyroid cells. As for the molecular mechanism underlying these effects, we found that in normal fibroblasts, TSH induced AKT and ERK1/2 only in cells expressing TSHR and RII. Similarly, activation of TSHR increased cAMP levels greatly, but was unable to stimulate CREB phosphorylation and transcription of cAMP-induced genes in the absence of RII. These data provide a simple explanation for the anti-proliferative and proliferative effects of cAMP in different cell types and indicate that RII-PKAII complements TSHR action by stably propagating robust cAMP signals in cell compartments.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; IRCCS, Ist Neurol Mediterraneo Neuromed, Dipartimento Patol Mol, I-86077 Pozzilli, Italy; IRCCS, Ist Neurol Mediterraneo Neuromed, Dipartimento Neurobiol Cellulare & Mol, I-86077 Pozzilli, Italy; Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Mol & Cellulare L Calif, I-80131 Naples, Italy; Univ Naples Federico II, Consiglio Nazl Ric, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	Sapienza University Rome; IRCCS Neuromed; IRCCS Neuromed; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Porcellini, A (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy.		Porcellini, Antonio/E-1900-2011; Porcellini, Antonio/AAC-6097-2019	Porcellini, Antonio/0000-0001-6882-9518; Feliciello, Antonio/0000-0002-7932-2170; BARONE, Maria Vittoria/0000-0001-6190-4917				Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; Cassano S, 1999, J BIOL CHEM, V274, P32574, DOI 10.1074/jbc.274.46.32574; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Costanzo V, 1999, CURR BIOL, V9, P903, DOI 10.1016/S0960-9822(99)80395-9; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Du Villard J, 2000, ONCOGENE, V19, P4896, DOI 10.1038/sj.onc.1203852; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; GUIZOUARN H, 1993, J BIOL CHEM, V268, P8632; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; PERSANI L, 1993, J ENDOCRINOL INVEST, V16, P511, DOI 10.1007/BF03348894; Porcellini A, 1997, ONCOGENE, V15, P781, DOI 10.1038/sj.onc.1201240; PORCELLINI A, 1995, ONCOGENE, V11, P1089; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Suh JM, 2003, J BIOL CHEM, V278, P21960, DOI 10.1074/jbc.M300805200; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TORTORA G, 1994, CELL GROWTH DIFFER, V5, P753; van Oirschot BA, 2001, J BIOL CHEM, V276, P33854, DOI 10.1074/jbc.M104395200; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	44	21	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40621	40630		10.1074/jbc.M307501200	http://dx.doi.org/10.1074/jbc.M307501200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902333	hybrid			2022-12-25	WOS:000185847200026
J	Ralton, JE; Naderer, T; Piraino, HL; Bashtannyk, TA; Callaghan, JM; McConville, MJ				Ralton, JE; Naderer, T; Piraino, HL; Bashtannyk, TA; Callaghan, JM; McConville, MJ			Evidence that intracellular beta 1-2 mannan is a virulence factor in Leishmania parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEXICANA; LIPOPHOSPHOGLYCAN; MANNOSE; BIOSYNTHESIS; AMASTIGOTES; MACROPHAGES; DISRUPTION; DONOVANI; PATHWAY; GENE	The protozoan parasite Leishmania mexicana proliferates within macrophage phagolysosomes in the mammalian host. In this study we provide evidence that a novel class of intracellular beta1-2 mannan oligosaccharides is important for parasite survival in host macrophages. Mannan ( degree of polymerization 4 - 40) is expressed at low levels in non-pathogenic promastigote stages but constitutes 80 and 90% of the cellular carbohydrate in the two developmental stages that infect macrophages, non-dividing promastigotes, and lesion-derived amastigotes, respectively. Mannan is catabolized when parasites are starved of glucose, suggesting a reserve function, and developmental stages having low mannan levels or L. mexicana GDPMP mutants lacking all mannose molecules are highly sensitive to glucose starvation. Environmental stresses, such as mild heat shock or the heat shock protein-90 inhibitor, geldanamycin, that trigger the differentiation of promastigotes to amastigotes, result in a 10-25-fold increase in mannan levels. Developmental stages with low mannan levels or L. mexicana mutants lacking mannan do not survive heat shock and are unable to differentiate to amastigotes or infect macrophages in vitro. In contrast, a L. mexicana mutant deficient only in components of the mannose-rich surface glycocalyx differentiates normally and infects macrophages in vitro. Collectively, these data provide strong evidence that mannan accumulation is important for parasite differentiation and survival in macrophages.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	University of Melbourne	McConville, MJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	malcolmm@unimelb.edu.au		Naderer, Thomas/0000-0003-2691-0283				Barrett MP, 1997, PARASITOL TODAY, V13, P11, DOI 10.1016/S0169-4758(96)10075-2; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; Burchmore RJS, 2001, INT J PARASITOL, V31, P1311, DOI 10.1016/S0020-7519(01)00259-4; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1111/j.1574-6976.2001.tb00574.x; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; GORIN PAJ, 1979, J PROTOZOOL, V26, P473, DOI 10.1111/j.1550-7408.1979.tb04656.x; Hilley JD, 2000, MOL BIOL CELL, V11, P1183, DOI 10.1091/mbc.11.4.1183; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; KEEGAN FP, 1993, J EUKARYOT MICROBIOL, V40, P730, DOI 10.1111/j.1550-7408.1993.tb04467.x; KEEGAN FP, 1992, MOL BIOCHEM PARASIT, V53, P193, DOI 10.1016/0166-6851(92)90021-B; MALLINSON DJ, 1989, PARASITOLOGY, V98, P7, DOI 10.1017/S0031182000059631; MANNERS DJ, 1982, ENCY PLANT PHYSL A, V13; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MENDONCAPREVIATO L, 1979, BIOCHEMISTRY-US, V18, P149, DOI 10.1021/bi00568a023; MOTTRAM JC, 1985, EXP PARASITOL, V59, P265, DOI 10.1016/0014-4894(85)90081-5; Naderer T, 2002, MOL BIOCHEM PARASIT, V125, P147, DOI 10.1016/S0166-6851(02)00236-0; Nitz M, 2002, J BIOL CHEM, V277, P3440, DOI 10.1074/jbc.M109274200; Opperdoes FR, 2001, INT J PARASITOL, V31, P482, DOI 10.1016/S0020-7519(01)00155-2; PREVIATO JO, 1982, EXP PARASITOL, V53, P170, DOI 10.1016/0014-4894(82)90058-3; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; Ralton JE, 2002, BIOCHEM J, V363, P365, DOI 10.1042/0264-6021:3630365; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; SCHLEIN Y, 1986, Parasitology Today, V2, P175, DOI 10.1016/0169-4758(86)90150-X; Schluepmann H, 2003, P NATL ACAD SCI USA, V100, P6849, DOI 10.1073/pnas.1132018100; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; VanHellemond JJ, 1997, MOL BIOCHEM PARASIT, V85, P135, DOI 10.1016/S0166-6851(97)02828-4; Wiesgigl M, 2001, MOL BIOL CELL, V12, P3307, DOI 10.1091/mbc.12.11.3307; WINTER G, 1994, J CELL SCI, V107, P2471	37	82	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40757	40763		10.1074/jbc.M307660200	http://dx.doi.org/10.1074/jbc.M307660200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12902334	hybrid			2022-12-25	WOS:000185847200043
J	Tateno, H; Goldstein, IJ				Tateno, H; Goldstein, IJ			Molecular cloning, expression, and characterization of novel hemolytic lectins from the mushroom Laetiporus sulphureus, which show homology to bacterial toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERTEBRATE CUCUMARIA-ECHINATA; SEPTICUM ALPHA-TOXIN; MARASMIUS-OREADES; HIGH-AFFINITY; CEL-III; BINDING; PROTEINS; GAL-ALPHA-1,3GAL; AEROLYSIN; MEMBRANE	We describe herein the cDNA cloning, expression, and characterization of a hemolytic lectin and its related species from the parasitic mushroom Laetiporus sulphureus. The lectin designated LSL ( L. sulphureus lectin), is a tetramer composed of subunits of similar to 35 kDa associated by non-covalent bonds. From a cDNA library, three similar full-length cDNAs, termed LSLa, LSLb, and LSLc, were generated, each of which had an open reading frame of 945 bp encoding 315 amino acid residues. These proteins share 80 - 90% sequence identity and showed structural similarity to bacterial toxins: mosquitocidal toxin (MTX2) from Bacillus sphaericus and alpha toxin from Clostridium septicum. Native and recombinant forms of LSL showed hemagglutination and hemolytic activity and both activities were inhibited by N-acetyllactosamine, whereas a C-terminal deletion mutant of LSLa (LSLa-D1) retained hemagglutination, but not hemolytic activity, indicating the N-terminal domain is a carbohydrate recognition domain and the C-terminal domain functions as an oligomerization domain. The LSL-mediated hemolysis was protected osmotically by polyethylene glycol 4000 and maltohexaose. Inhibition studies showed that lacto-N-neotetraose (Galbeta1-4GlcNAcbeta1-3Gal beta1-4Glc) was the best inhibitor for LSL. These results indicate that LSL is a novel pore-forming lectin homologous to bacterial toxins.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Goldstein, IJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Tateno, Hiroaki/M-2706-2018	Tateno, Hiroaki/0000-0003-3006-1659	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLARD J, 1995, INFECT IMMUN, V63, P340, DOI 10.1128/IAI.63.1.340-344.1995; BUCKLEY JT, 1999, COMPREHENSIVE SOURCE, P362; Chan SW, 1996, J BIOL CHEM, V271, P14183, DOI 10.1074/jbc.271.24.14183; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; HATAKEYAMA T, 1995, J BIOL CHEM, V270, P3560, DOI 10.1074/jbc.270.8.3560; Hatakeyama T, 1996, J BIOL CHEM, V271, P16915, DOI 10.1074/jbc.271.28.16915; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; KONSKA G, 1994, J BIOCHEM-TOKYO, V116, P519, DOI 10.1093/oxfordjournals.jbchem.a124555; Kruger RP, 2002, J BIOL CHEM, V277, P15002, DOI 10.1074/jbc.M200165200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mo HQ, 2000, J BIOL CHEM, V275, P10623, DOI 10.1074/jbc.275.14.10623; Mo HQ, 2001, EUR J BIOCHEM, V268, P2609, DOI 10.1046/j.1432-1327.2001.02148.x; Novak T.P., 1975, BIOCHIM BIOPHYS ACTA, V393, P115; Olsnes S, 2001, TOXICON, V39, P1723, DOI 10.1016/S0041-0101(01)00158-1; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Thanabalu T, 1996, GENE, V170, P85, DOI 10.1016/0378-1119(95)00836-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; WARREN L, 1959, J BIOL CHEM, V234, P1971; Winter HC, 2002, J BIOL CHEM, V277, P14996, DOI 10.1074/jbc.M200161200; YANG JT, 1986, METHOD ENZYMOL, V130, P208	27	56	64	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40455	40463		10.1074/jbc.M306836200	http://dx.doi.org/10.1074/jbc.M306836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12900403	hybrid			2022-12-25	WOS:000185847200006
J	Cao, C; Leng, YM; Huang, W; Liu, X; Kufe, D				Cao, C; Leng, YM; Huang, W; Liu, X; Kufe, D			Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; DEPENDENT PROTEIN-KINASE; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; CELLULAR-RESPONSE; ACTIVATION; CELLS; MICE; SUSCEPTIBILITY; SENSITIVITY	The c-Abl and Arg tyrosine kinases are activated in the cellular response to oxidative stress. The present studies demonstrate that c-Abl and Arg associate with glutathione peroxidase 1 (GPx1) and that this interaction is regulated by intracellular oxidant levels. The c-Abl and Arg SH3 domains bind directly to a proline-rich site in GPx1 at amino acids 132 - 145. GPx1 also functions as a substrate for c-Abl- and Arg-mediated phosphorylation on Tyr-96. The results further show that c-Abl and Arg stimulate GPx activity and that these kinases contribute to GPx-mediated protection of cells against oxidative stress. Our findings provide the first evidence that GPx1 is regulated by a signaling pathway that is activated in the oxidative stress response.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Beijing Inst Technol, Beijing 100850, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Beijing Institute of Technology	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA98626, CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA098626, R56CA098626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Duval C, 2002, BIOCHEM J, V367, P889, DOI 10.1042/BJ20020625; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Kim-Han JS, 1998, FREE RADICAL BIO MED, V25, P512, DOI 10.1016/S0891-5849(98)00076-8; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KOLESNICHENKO LS, 1986, DOKL AKAD NAUK SSSR+, V287, P735; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Miller S, 2002, BBA-MOL BASIS DIS, V1588, P85, DOI 10.1016/S0925-4439(02)00143-6; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P237, DOI 10.1159/000013847; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Schnurr K, 2000, PROTEIN EXPRES PURIF, V19, P403, DOI 10.1006/prep.2000.1262; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998	23	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39609	39614		10.1074/jbc.M305770200	http://dx.doi.org/10.1074/jbc.M305770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12893824	hybrid			2022-12-25	WOS:000185713800044
J	Mateo, J; Kreda, S; Henry, CE; Harden, TK; Boyer, JL				Mateo, J; Kreda, S; Henry, CE; Harden, TK; Boyer, JL			Requirement of Cys(399) for processing of the human ecto-ATPase (NTPDase2) and its implications for determination of the activities of splice variants of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; QUATERNARY STRUCTURE; PHOSPHODIESTERASE-I; MOLECULAR-CLONING; SECRETORY PATHWAY; CD39; APYRASE; PROTEIN	Ecto-ATPase (CD39L1) corresponds to the type 2 enzyme of the ecto-nucleoside triphosphate diphosphohydrolase family (E-NTPDase). We have isolated from human ECV304 cells three cDNAs with high homology with members of the E-NTPDase family that encode predicted proteins of 495, 472, and 450 amino acids. Sequencing of a genomic DNA clone confirmed that these three sequences correspond to splice variants of the human ecto-ATPase (NTPDase2alpha, -2beta, and -2gamma). Although all three enzyme forms were expressed heterologously to similar levels in Chinese hamster ovary cells clone K-1 (CHO-K1) cells, only the 495-amino acid protein (NTPDase2alpha exhibited ecto-ATPase activity. Immunolocalization studies demonstrated that NTPDase2alpha is fully processed and trafficked to the plasma membrane, whereas the NTPDase2beta and -2gamma splice variants were retained in not fully glycosylated forms in the endoplasmic reticulum. The potential roles of two highly conserved residues, Cys(399) and Asn(443), in the activity and cellular trafficking of the ecto-ATPase were examined. Mutation of Cys(399), which is absent in NTPDase2beta and -2gamma, produced a protein completely devoid of nucleotidase activity, while mutation of Asn(443) to Asp resulted in substantial loss of activity. Neither the Cys(399) nor Asn(443) mutants were fully glycosylated, and both were retained in the endoplasmic reticulum. These results indicate that the lack of ecto-nucleotidase activity exhibited by NTPDase2beta and -2gamma and the (CS)-S-399 mutant, as well as the large reduction of activity in the N443D mutant are due to alterations in the folding/maturation of these proteins.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Harden, TK (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365,Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.		de Castro, Jesus Mateo/N-4434-2014	de Castro, Jesus Mateo/0000-0003-4459-7083	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054889, R01HL054889, P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54889, HL34322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Boyer JL, 1997, MOL PHARMACOL, V52, P928, DOI 10.1124/mol.52.6.928; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruess Michael, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology, V362, P392; Burnstock G, 1996, LANCET, V347, P1604, DOI 10.1016/S0140-6736(96)91082-X; Chadwick BP, 1997, MAMM GENOME, V8, P668, DOI 10.1007/s003359900534; CHE MX, 1992, J BIOL CHEM, V267, P9684; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Failer BU, 2003, EUR J BIOCHEM, V270, P1802, DOI 10.1046/j.1432-1033.2003.03542.x; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fuss B, 1997, J NEUROSCI, V17, P9095; Gao L, 1998, J BIOL CHEM, V273, P15358, DOI 10.1074/jbc.273.25.15358; Grinthal A, 2000, BIOCHEMISTRY-US, V39, P9, DOI 10.1021/bi991751k; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Heine P, 2001, EUR J BIOCHEM, V268, P364, DOI 10.1046/j.1432-1327.2001.01896.x; Hicks-Berger CA, 2000, IUBMB LIFE, V50, P43; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KANSAS GS, 1991, J IMMUNOL, V146, P2235; KAWAGOE H, 1995, GENOMICS, V30, P380, DOI 10.1006/geno.1995.0036; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Mateo J, 1999, BRIT J PHARMACOL, V128, P396, DOI 10.1038/sj.bjp.0702805; Milgram SL, 1997, J CELL SCI, V110, P695; Mulero JJ, 2000, BIOCHEMISTRY-US, V39, P12924, DOI 10.1021/bi000960y; MURATA J, 1994, J BIOL CHEM, V269, P30479; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PLESNER L, 1995, INT REV CYTOL, V158, P141; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTE EJ, 1999, BIOCHEMISTRY-US, V38, P2248; Smith TM, 1999, BIOCHEMISTRY-US, V38, P1509, DOI 10.1021/bi9821768; Stout JG, 1996, BIOCHEMISTRY-US, V35, P8289, DOI 10.1021/bi960563g; Vasconcelos EG, 1996, J BIOL CHEM, V271, P22139, DOI 10.1074/jbc.271.36.22139; Vlajkovic SM, 1999, MOL BRAIN RES, V73, P85, DOI 10.1016/S0169-328X(99)00244-2; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WARD CL, 1994, J BIOL CHEM, V269, P25710; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; [No title captured]	44	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39960	39968		10.1074/jbc.M307854200	http://dx.doi.org/10.1074/jbc.M307854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888562	hybrid, Green Published			2022-12-25	WOS:000185713800084
J	Sobol, RW; Kartalou, M; Almeida, KH; Joyce, DF; Engelward, BP; Horton, JK; Prasad, R; Samson, LD; Wilson, SH				Sobol, RW; Kartalou, M; Almeida, KH; Joyce, DF; Engelward, BP; Horton, JK; Prasad, R; Samson, LD; Wilson, SH			Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; MISMATCH REPAIR; PHOSPHATE LYASE; MICE DEFICIENT; N-GLYCOSYLASE; P53; PROTEIN; DAMAGE; CELLS; MUTATIONS	DNA alkylation damage is primarily repaired by the base excision repair (BER) machinery in mammalian cells. In repair of the N-alkylated purine base lesion, for example, alkyl adenine DNA glycosylase (Aag) recognizes and removes the base, and DNA polymerase beta (beta-pol) contributes the gap tailoring and DNA synthesis steps. It is the loss of beta-pol-mediated 5'-deoxyribose phosphate removal that renders mouse fibroblasts alkylation-hypersensitive. Here we report that the hypersensitivity of beta-pol-deficient cells after methyl methanesulfonate-induced alkylation damage is wholly dependent upon glycosylase-mediated initiation of repair, indicating that alkylated base lesions themselves are tolerated in these cells and demonstrate that beta-pol protects against accumulation of toxic BER intermediates. Further, we find that these intermediates are initially tolerated in vivo by a second repair pathway, homologous recombination, inducing an increase in sister chromatid exchange events. If left unresolved, these BER intermediates trigger a rapid block in DNA synthesis and cytotoxicity. Surprisingly, both the cytotoxic and genotoxic signals are independent of both the p53 response and mismatch DNA repair pathways, demonstrating that p53 is not required for a functional BER pathway, that the observed damage response is not part of the p53 response network, and that the BER intermediate-induced cytotoxic and genotoxic effects are distinct from the mechanism engaged in response to mismatch repair signaling. These studies demonstrate that, although base damage is repaired by the BER pathway, incomplete BER intermediates are shuttled into the homologous recombination pathway, suggesting possible coordination between BER and the recombination machinery.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Massachusetts Institute of Technology (MIT)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Classen, Scott/AAY-8176-2020; Sobol, Robert W./E-4125-2013	Wilson, Samuel H/0000-0002-1702-5293; Sobol, Robert W./0000-0001-7385-3563	NCI NIH HHS [R01 CA079827, R21 CA084740, CA92584, CA55042, CA84740, R01 CA055042, P01 CA092584, CA79287] Funding Source: Medline; NIEHS NIH HHS [ES02109, P30 ES002109, 5 T32 ES07020] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055042, R21CA084740, P01CA092584, R01CA079827, R33CA084740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007020, Z01ES050159, P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERTS B, 1994, MOL BIOL CELL, P1284; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Carr AM, 2002, SCIENCE, V297, P557, DOI 10.1126/science.1075456; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; Esposito G, 2000, P NATL ACAD SCI USA, V97, P1166, DOI 10.1073/pnas.97.3.1166; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hasan S, 2002, MOL CELL, V10, P1213, DOI 10.1016/S1097-2765(02)00745-1; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kartalou M, 2000, BIOCHEMISTRY-US, V39, P8032, DOI 10.1021/bi000417h; KASTAN MB, 1991, CANCER RES, V51, P6304; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LOEB LA, 1991, CANCER RES, V51, P3075; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Plosky B, 2002, DNA REPAIR, V1, P683, DOI 10.1016/S1568-7864(02)00075-7; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Roth RB, 2002, CANCER RES, V62, P656; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Smith SA, 2000, NUCLEIC ACIDS RES, V28, P3294, DOI 10.1093/nar/28.17.3294; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 2002, P NATL ACAD SCI USA, V99, P6860, DOI 10.1073/pnas.092662499; Sobol RW, 2001, PROG NUCLEIC ACID RE, V68, P57; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Wilson SH, 2000, COLD SPRING HARB SYM, V65, P143, DOI 10.1101/sqb.2000.65.143; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	49	150	156	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39951	39959		10.1074/jbc.M306592200	http://dx.doi.org/10.1074/jbc.M306592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882965	hybrid			2022-12-25	WOS:000185713800083
J	Matsuda, S; Matsuda, Y; D'Adamio, L				Matsuda, S; Matsuda, Y; D'Adamio, L			Amyloid beta protein precursor (A beta PP), but not A beta PP-like protein 2, is bridged to the kinesin light chain by the scaffold protein JNK-interacting protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL-TRANSPORT; SECRETASE; FRAGMENT; COMPLEX; DOMAIN; CARGO; BINDS; NOTCH	Proteolytic processing of amyloid beta protein precursor (AbetaPP) generates peptides that regulate normal cell signaling and are implicated in Alzheimer's disease pathogenesis. AbetaPP processing also occurs in nerve processes where AbetaPP is transported from the cell body by kinesin-I, a microtubule motor composed of two kinesin heavy chain and two kinesin light chain (Klc) subunits. AbetaPP transport is supposedly mediated by the direct AbetaPP-Klc1 interaction. Here we demonstrate that the AbetaPP-Klc1 interaction is not direct but is mediated by JNK-interacting protein 1 (JIP1). The phosphotyrosine binding domain of JIP1 binds the cytoplasmic tail of AbetaPP, whereas the JIP1 C-terminal region interacts with the tetratrico-peptide repeats of Klc1. We also show that JIP1 does not bridge the AbetaPP gene family member AbetaPP-like protein 2, APLP2, to Klc1. These results support a model where JIP1 mediates the interaction of AbetaPP to the motor protein kinesin-I and that this JIP1 function is unique for AbetaPP relative to its family member APLP2. Our data suggest that kinesin-I-dependent neuronal AbetaPP transport, which controls AbetaPP processing, may be regulated by JIP1.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	D'Adamio, L (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu		D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882	NIA NIH HHS [R01 AG22024-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG022024] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; D'Adamio L, 2002, RES PER ALZ, P101; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Matsuda S, 2001, J NEUROSCI, V21, P6597; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sisodia SS, 2002, SCIENCE, V295, P805, DOI 10.1126/science.1069661; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	22	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38601	38606		10.1074/jbc.M304379200	http://dx.doi.org/10.1074/jbc.M304379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12893827	hybrid			2022-12-25	WOS:000185575100064
J	Bertoldi, M; Cellini, B; D'Aguanno, S; Voltattorni, CB				Bertoldi, M; Cellini, B; D'Aguanno, S; Voltattorni, CB			Lysine 238 is an essential residue for alpha,beta-elimination catalyzed by Treponema denticola cystalysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE LYSYL RESIDUE; PYRIDOXAL-PHOSPHATE; ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; ACTIVE-SITE; INTERNAL ALDIMINE; EXOGENOUS AMINES; PRODUCT RELEASE; DECARBOXYLASE; 5'-PHOSPHATE	Treponema denticola cystalysin is a pyridoxal 5'-phosphate (PLP) enzyme that catalyzes the alpha,beta-elimination of L-cysteine to pyruvate, ammonia, and H2S. Similar to other PLP enzymes, an active site Lys residue (Lys-238) forms an internal Schiff base with PLP. The mechanistic role of this residue has been studied by an analysis of the mutant enzymes in which Lys-238 has been replaced by Ala (K238A) and Arg (K238R). Both apomutants reconstituted with PLP bind noncovalently similar to 50% of the normal complement of the cofactor and have a lower affinity for the coenzyme than that of wild-type. Kinetic analyses of the reactions of K238A and K238R mutants with glycine compared with that of wild-type demonstrate the decrease of the rate of Schiff base formation by 10(3)- and 7.5 x 10(4)-fold, respectively, and, to a lesser extent, a decrease of the rate of Schiff base hydrolysis. Thus, a role of Lys-238 is to facilitate formation of external aldimine by transimination. Kinetic data reveal that the K238A mutant is inactive in the alpha,beta-elimination of L-cysteine and beta- chloro-L-alanine, whereas K238R retains 0.3% of the wild-type activity. These data, together with those derived from a spectral analysis of the reaction of Lys-238 mutants with unproductive substrate analogues, indicate that Lys-238 is an essential catalytic residue, possibly participating as a general base abstracting the Calpha-proton from the substrate and possibly as a general acid protonating the beta-leaving group.	Univ Verona, Fac Med & Chirurg, Sezione Chim Biol, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy	University of Verona; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Voltattorni, CB (corresponding author), Univ Verona, Fac Med & Chirurg, Sezione Chim Biol, Dipartimento Sci Neurol & Vis, Strada Grazie 8, I-37134 Verona, Italy.		Cellini, Barbara/AAC-6401-2019; D'Aguanno, Simona/H-2179-2016; Bertoldi, Mariarita/F-1154-2010	Cellini, Barbara/0000-0002-5221-9288; D'Aguanno, Simona/0000-0002-1224-4454; Bertoldi, Mariarita/0000-0002-2337-9928				Bertoldi M, 2002, BIOCHEMISTRY-US, V41, P9153, DOI 10.1021/bi025649q; Bertoldi M, 2000, BIOCHEM J, V352, P533, DOI 10.1042/0264-6021:3520533; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; CHU L, 1995, INFECT IMMUN, V63, P4448, DOI 10.1128/IAI.63.11.4448-4455.1995; CORDES EH, 1962, BIOCHEMISTRY-US, V1, P773, DOI 10.1021/bi00911a007; FERREIRA GC, 1993, PROTEIN SCI, V2, P1959, DOI 10.1002/pro.5560021117; FERREIRA GC, 1995, PROTEIN SCI, V4, P1001; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GREGERMAN RI, 1956, J BIOL CHEM, V220, P765; HARRIS CM, 1976, BIOCHIM BIOPHYS ACTA, V421, P181, DOI 10.1016/0304-4165(76)90284-1; INOUE Y, 1989, J BIOL CHEM, V264, P9673; KIRSCH JF, 1990, ENZYMES DEPENDENT PY, P161; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; KURAMITSU S, 1987, BIOCHEM BIOPH RES CO, V146, P416, DOI 10.1016/0006-291X(87)90545-6; LANE CF, 1975, SYNTHESIS-STUTTGART, P135; LONGENECKER JB, 1957, J BIOL CHEM, V225, P409; LU ZC, 1993, J BIOL CHEM, V268, P8727; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; Osterman AL, 1999, BIOCHEMISTRY-US, V38, P11814, DOI 10.1021/bi9906221; Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j; ROBERTS WJ, 1988, J BIOL CHEM, V263, P7196; SCHIRCH D, 1993, J BIOL CHEM, V268, P23132; SLEBE JC, 1976, J BIOL CHEM, V251, P5663; TATSUMOTO K, 1981, J AM CHEM SOC, V103, P6197, DOI 10.1021/ja00410a036; TATSUMOTO K, 1977, J AM CHEM SOC, V99, P6080; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; Tramonti A, 2002, EUR J BIOCHEM, V269, P4913, DOI 10.1046/j.1432-1033.2002.03149.x; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; Watababe A, 1999, J BIOL CHEM, V274, P4189, DOI 10.1074/jbc.274.7.4189	30	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37336	37343		10.1074/jbc.M305967200	http://dx.doi.org/10.1074/jbc.M305967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12882978	hybrid			2022-12-25	WOS:000185437200043
J	Clancy, JL; Henderson, MJ; Russell, AJ; Anderson, DW; Bova, RJ; Campbell, IG; Choong, DYH; Macdonald, GA; Mann, GJ; Nolan, T; Brady, G; Olopade, OI; Woollatt, E; Davies, MJ; Segara, D; Hacker, NF; Henshall, SM; Sutherland, RL; Watts, CKW				Clancy, JL; Henderson, MJ; Russell, AJ; Anderson, DW; Bova, RJ; Campbell, IG; Choong, DYH; Macdonald, GA; Mann, GJ; Nolan, T; Brady, G; Olopade, OI; Woollatt, E; Davies, MJ; Segara, D; Hacker, NF; Henshall, SM; Sutherland, RL; Watts, CKW			EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer	ONCOGENE			English	Article						allelic imbalance; amplification; human neoplasms; gene expression; mutation	COMPARATIVE-GENOMIC-HYBRIDIZATION; POSTERIOR UVEAL MELANOMA; SQUAMOUS-CELL CARCINOMA; DNA-DAMAGE RESPONSE; HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; OVARIAN-TUMORS; COPY NUMBER; FREQUENT MULTIPLICATION; CYTOGENETIC ANALYSIS	EDD (E3 isolated by differential display), located at chromosome 8q22.3, is the human orthologue of the Drosophila melanogaster tumour suppressor gene 'hyperplastic discs' and encodes a HECT domain E3 ubiquitin protein-ligase. To investigate the possible involvement of EDD in human cancer, several cancers from diverse tissue sites were analysed for allelic gain or loss (allelic imbalance, AI) at the EDD locus using an EDD-specific microsatellite, CEDD, and other polymorphic microsatellites mapped in the vicinity of the 8q22.3 locus. Of 143 cancers studied, 38 had AI at CEDD (42% of 90 informative cases). In 14 of these cases, discrete regions of imbalance encompassing 8q22.3 were present, while the remainder had more extensive 8q aberrations. AI of CEDD was most frequent in ovarian cancer (22/47 informative cases, 47%), particularly in the serous subtype (16/22, 73%), but was rare in benign and borderline ovarian tumours. AI was also common in breast cancer (31%), hepatocellular carcinoma (46%), squamous cell carcinoma of the tongue (50%) and metastatic melanoma (18%). AI is likely to represent amplification of the EDD gene locus rather than loss of heterozygosity, as quantitative RT-PCR and immunohistochemistry showed that EDD mRNA and protein are frequently overexpressed in breast and ovarian cancers, while among breast cancer cell lines EDD overexpression and increased gene copy number were correlated. These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; NIDCD, Mol Genet Lab, NIH, Rockville, MD USA; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia; Univ Queensland, Populat & Clin Sci Div, Queensland Inst Med Res, Brisbane, Qld, Australia; Univ Queensland, Dept Med, Brisbane, Qld, Australia; Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; Univ Chicago, Med Ctr, Ctr Med Genet, Chicago, IL 60637 USA; Womens & Childrens Hosp, Ctr Med Genet, Adelaide, SA, Australia; Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Peter Maccallum Cancer Center; QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; University of Sydney; Westmead Institute for Medical Research; University of Manchester; University of Chicago; University of Chicago Medical Center; Womens & Childrens Hospital Australia	Watts, CKW (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		campbell, Ian G/F-6006-2011; Sutherland, Robert L/A-8378-2008; henderson, Michelle/G-6657-2012; Mann, Graham J/G-4758-2014; Macdonald, Graeme A/K-4167-2013	Mann, Graham J/0000-0003-1301-405X; Macdonald, Graeme A/0000-0003-0929-110X; Campbell, Ian/0000-0002-7773-4155; Hacker, Neville/0000-0002-1445-2302				Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Al-Taher A, 2000, YEAST, V17, P201, DOI 10.1002/1097-0061(20000930)17:3<201::AID-YEA30>3.0.CO;2-R; Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O; Bova RJ, 1999, CLIN CANCER RES, V5, P2810; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Dahiya R, 1998, INT J ONCOL, V12, P811; Diebold J, 1996, LAB INVEST, V75, P473; ElNaggar AK, 1997, AM J SURG PATHOL, V21, P691, DOI 10.1097/00000478-199706000-00009; Fejzo MS, 1998, GENE CHROMOSOME CANC, V22, P105; Forozan F, 2000, CANCER RES, V60, P4519; FUJIWARA Y, 1993, CANCER RES, V53, P857; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Hermsen MAJA, 1997, ORAL ONCOL, V33, P414, DOI 10.1016/S0964-1955(97)00031-6; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Indsto JO, 1998, CANCER GENET CYTOGEN, V100, P68, DOI 10.1016/S0165-4608(97)00016-2; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Knuutila S, 1998, AM J PATHOL, V152, P1107; Lee JD, 2002, DEVELOPMENT, V129, P5697, DOI 10.1242/dev.00159; Macdonald GA, 1998, HEPATOLOGY, V28, P90, DOI 10.1002/hep.510280114; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Mark HFL, 1997, PATHOBIOLOGY, V65, P184, DOI 10.1159/000164121; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; Mori Y, 2002, CANCER RES, V62, P3641; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NAWROZ H, 1994, CANCER RES, V54, P1152; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nogradi A, 1998, AM J PATHOL, V153, P1, DOI 10.1016/S0002-9440(10)65537-X; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Obata K, 1998, CANCER RES, V58, P2095; Orntoft TF, 2002, MOL CELL PROTEOMICS, V1, P37, DOI 10.1074/mcp.M100019-MCP200; Parrella P, 1999, CANCER RES, V59, P3032; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Pieretti M, 1995, INT J CANCER, V64, P434, DOI 10.1002/ijc.2910640614; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Seute A, 2001, INT J CANCER, V93, P80, DOI 10.1002/ijc.1296; Sisley K, 1997, GENE CHROMOSOME CANC, V19, P22, DOI 10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2; Sutherland R.L., 1999, HUMAN CELL CULTURE, P79; Tsuneizumi M, 2001, CLIN CANCER RES, V7, P3526; vanDekken H, 1997, HISTOCHEM CELL BIOL, V108, P419, DOI 10.1007/s004180050182; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yokota T, 1999, CANCER LETT, V139, P7, DOI 10.1016/S0304-3835(98)00329-2	53	79	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5070	5081		10.1038/sj.onc.1206775	http://dx.doi.org/10.1038/sj.onc.1206775			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902990				2022-12-25	WOS:000184578900015
J	Kothari, S; Cizeau, J; McMillan-Ward, E; Israels, SJ; Bailes, M; Ens, K; Kirshenbaum, LA; Gibson, SB				Kothari, S; Cizeau, J; McMillan-Ward, E; Israels, SJ; Bailes, M; Ens, K; Kirshenbaum, LA; Gibson, SB			BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF	ONCOGENE			English	Article						hypoxia; cell death; tumor; BNIP3; EGF; IGF	MITOCHONDRIAL PERMEABILITY TRANSITION; ADVANCED BREAST-CANCER; TUMOR ANGIOGENESIS; INDUCED APOPTOSIS; PROTEIN BNIP3; BH3 DOMAIN; FACTOR-I; EXPRESSION; NIP3; HERCEPTIN	Hypoxic regions within solid tumors are often resistant to chemotherapy and radiation. BNIP3 (Bcl-2/E1B 19 kDa interacting protein) is a proapoptotic member of the Bcl-2 family that is expressed in hypoxic regions of tumors. During hypoxia, BNIP3 expression is increased in many cell types and upon forced overexpression BNIP3 induces cell death. Herein, we have demonstrated that blockage of hypoxia-induced BNIP3 expression using antisense oligonucleotides against BNIP3 or blockage of BNIP3 function through expression of a mutant form of BNIP3 inhibits hypoxia-induced cell death in human embryonic kidney 293 cells. We have also determined that hypoxia-mediated BNIP3 expression is regulated by the transcription factor, hypoxia-inducible factor-1alpha (HIF-1alpha) in human epithelial cell lines. Furthermore, HIF-1alpha directly binds to a consensus HIF-1alpha-responsive element (HRE) in the human BNIP3 promoter that upon mutation of this HRE site eliminates the hypoxic responsiveness of the promoter. Since BNIP3 is expressed in hypoxic regions of tumors but fails to induce cell death, we determined whether growth factors block BNIP3-induced cell death. Treatment of the breast cancer cell line MCF-7 cells with epidermal growth factor (EGF) or insulin-like growth factor effectively protected these cells from BNIP3-induced cell death. Furthermore, inhibiting EGF receptor signaling using antibodies against ErbB2 (Herceptin) resulted in increased hypoxia-induced cell death in MCF-7 cells. Taken together, BNIP3 plays a role in hypoxia-induced cell death in human epithelial cells that could be circumvented by growth factor signaling.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada; St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Biochem & Med Genet, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB, Canada.		Kirshenbaum, Lorrie A./F-5742-2014; Israels, Sara/ABC-3684-2021	Israels, Sara/0000-0002-1849-4825; Ryplanski, Kairee/0000-0002-3737-7181; Gibson, Spencer/0000-0003-0119-732X				Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burris HA, 2000, SEMIN ONCOL, V27, P19; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Clawson TF, 1999, BIOL SIGNAL RECEPT, V8, P281; Farooq M, 2001, EXP MOL MED, V33, P169, DOI 10.1038/emm.2001.29; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Giatromanolaki A, 2001, ANTICANCER RES, V21, P4317; Gibson EM, 2002, CANCER RES, V62, P488; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Goonewardene TI, 2002, MICROSC RES TECHNIQ, V59, P41, DOI 10.1002/jemt.10175; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellermann JP, 2002, AM J MED, V113, P324, DOI 10.1016/S0002-9343(02)01185-3; Hochachka PW, 2002, BIOESSAYS, V24, P749, DOI 10.1002/bies.10131; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hung MC, 1999, SEMIN ONCOL, V26, P51; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; Knowles HJ, 2001, BREAST CANCER RES, V3, P318, DOI 10.1186/bcr314; Koukourakis MI, 2001, ANTICANCER RES, V21, P4285; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leek RD, 2002, CANCER RES, V62, P1326; Miura M, 2000, METHOD ENZYMOL, V322, P480; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Mrsic M, 2001, ANN ONCOL, V12, P95, DOI 10.1023/A:1011116224931; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Seigel G, 2000, MOL VIS, V6, P157; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Sowter HM, 2001, CANCER RES, V61, P6669; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	45	168	179	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4734	4744		10.1038/sj.onc.1206666	http://dx.doi.org/10.1038/sj.onc.1206666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879018				2022-12-25	WOS:000184157000014
J	Peller, S; Frenkel, J; Lapidot, T; Kahn, J; Rahimi-Levene, N; Yona, R; Nissim, L; Goldfinger, N; Sherman, DJ; Rotter, V				Peller, S; Frenkel, J; Lapidot, T; Kahn, J; Rahimi-Levene, N; Yona, R; Nissim, L; Goldfinger, N; Sherman, DJ; Rotter, V			The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts	ONCOGENE			English	Article						p53; erythropoiesis; differentiation; apoptosis	WILD-TYPE P53; ERYTHROID PRECURSORS; CASPASE ACTIVATION; DNA-DAMAGE; PROTEIN; EXPRESSION; CELLS; ERYTHROPOIETIN; DEATH; GENE	The p53 tumor suppressor gene was found to play a role in the differentiation of several tissue types. We report here that p53-dependent apoptosis plays a role in the final stages of physiological differentiation of normoblasts, resulting in nuclear condensation and expulsion without cell death. Blood samples of healthy newborns, cord blood as well as bone marrow, were analysed for apoptosis by TUNEL and p53 expression by immunostaining. While some samples exhibited simultaneously several distinct patterns of apoptosis, such as perinuclear, diffused nuclear or nuclear apoptotic bodies, others presented a single defined pattern. Overexpression of p53 protein was detected in normoblasts exhibiting either perinuclear or diffused nuclear p53, corresponding to the nuclear apoptotic pattern in the same sample. Similar results were also evident with colonies cultivated for 12-14 days in culture. Differentiated erythroid colonies exhibited overexpression of p53 and positive TUNEL staining only in the normoblasts. We further examined the state of caspase 3/7 and observed a decrease of this activated enzyme during erythroid differentiation in culture. This study suggests a novel role for apoptosis in normoblast differentiation where nuclear degradation occurs with a delay in the actual cell death. A pivotal role for the p53-dependent apoptosis in the erythroid lineage development is implied. However, this apoptotic process is not fully executed because of the exhaustion in caspase 3/7 and thus cells are diverted towards final stages of differentiation.	Assaf Harofeh Med Ctr, Dept Hematol, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Dept Obstet & Gynecol, IL-70300 Zerifin, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Weizmann Institute of Science; Weizmann Institute of Science	Peller, S (corresponding author), Assaf Harofeh Med Ctr, Dept Hematol, IL-70300 Zerifin, Israel.	SPELLER@asaf.health.gov.il	Lapidot, Tsvee/A-1812-2010	Nissim, Lior/0000-0001-6495-4741				Aljurf M, 1996, BLOOD, V87, P2049; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; BETKE K, 1967, NATURE, V214, P188, DOI 10.1038/214188a0; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KASTAN MB, 1991, CANCER RES, V51, P4279; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; KELLEY LL, 1993, BLOOD, V82, P2340; KELLY RM, 1994, WOMEN POLIT, V14, P3; Kollet O, 1999, BLOOD, V94, P923, DOI 10.1182/blood.V94.3.923.415k08_923_931; Koury MJ, 1997, BLOOD, V89, P4617, DOI 10.1182/blood.V89.12.4617; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; Mahdi T, 1996, EXP HEMATOL, V24, P702; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rehberger PA, 1997, CELL GROWTH DIFFER, V8, P851; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1998, NEW ENGL J MED, V338, P564, DOI 10.1056/NEJM199802263380902; WINTROBE, 1999, WINTROBES CLIN HEMAT; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN J, 1993, BLOOD, V82, P374, DOI 10.1182/blood.V82.2.374.bloodjournal822374; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	37	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4648	4655		10.1038/sj.onc.1206541	http://dx.doi.org/10.1038/sj.onc.1206541			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879009				2022-12-25	WOS:000184157000005
